<SEC-DOCUMENT>0000885590-22-000061.txt : 20221103
<SEC-HEADER>0000885590-22-000061.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103165045
ACCESSION NUMBER:		0000885590-22-000061
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		120
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		221358792

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bhc-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:7672b0ed-3503-4562-bc82-7a3368936983,g:725d4d73-5fd8-4cb1-b65a-aa245208ce29,d:0269b61f01054b6698b35799c21833bd--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:bhc="http://www.bauschhealth.com/20220930" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV8zLTEtMS0xLTE0MzA2MQ_ad1debf5-f6d6-4f33-b6c9-19aeb36eafe1">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV80LTEtMS0xLTE0MzA2MQ_4900a47c-062e-44b1-bba1-5cfa3a34e7e2">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV81LTEtMS0xLTE0MzA2MQ_4099ea4b-8460-4ba0-925a-4569eab3e5b5">2022</ix:nonNumeric><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV82LTEtMS0xLTE0MzA2MQ_bab46bc0-b1af-4b75-ade5-b683877710b6">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV83LTEtMS0xLTE0MzA2MQ_d657b874-b1d8-445c-9606-4225b74e4896">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i2717f1d183464ab1be432c601c1e94f8_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83MC9mcmFnOmI1Y2E2OWY5ODFhYzQ3NzA4YzAyYzNmMDAyOTEzMjRhL3RhYmxlOmE3NWZhNjc2ZjE1NTRkNzU5MmFjMWFkZmYxNWJjODAwL3RhYmxlcmFuZ2U6YTc1ZmE2NzZmMTU1NGQ3NTkyYWMxYWRmZjE1YmM4MDBfMC0xLTEtMS0xNDMwNjE_98af9c80-b158-4ccd-8997-a5cd3c1317fd">0.5</ix:nonFraction><ix:nonNumeric contextRef="iee6e1b627daa4dd5ab985eaf3d792732_D20220905-20220905" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTA5OTUxMTYzODk0Ng_fd0ab737-0f9e-4702-b219-264d2a3842ea">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ia324b82ecfe4472a8eec915831a5f250_D20220701-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5Mjg4MQ_d3858cff-cf89-4b94-8aea-b1ba58bb78da">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i8fac2a0db25144f7bc4d94691e6afeaa_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwMDEy_e97cd2b1-3d30-484e-913a-aa54ff2af89e">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i68315b257d6e4c95b8a3e5c0005d0240_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwMDIx_bc9436ff-de88-4331-91d8-a9df8b7736b9">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i206a35173cac452e80a9011a351123e0_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwMDMw_30562d2b-c006-404e-812d-781fda3c08a9">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib0a224dcb25e4aa8bc91a4cef4a39b4d_D20220701-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwNjc5_a46ac787-f630-4eca-a546-55d19a548b75">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id428743f89e44793bea4c8584a67335c_D20220701-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwNjg3_a09f85e8-e9d5-479e-94f3-6c540031b33c">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i677c4838f7c64a0fa4133f133bfaf2ce_D20220701-20220930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwNjk1_a39c23fa-c1bb-430a-976e-6abd42ad57f8">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c4dbce9e34463bbe2a00df8262767d_I20221028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib630580e79374684b3bc209e9e4a1fc3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if69ff7ae606c425c94a4c448e089a08c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d79d42128d480b82421ffda65ff432_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b121d7e567435ea3af71bf428e3992_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd2719ffeb04494b5ee89c5d6c0a3a0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d19e9379e0b46ff90d34e1fad8d4f3d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e24bce6ec5b4cebbd4550c104f4e7a0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd02a55811c46a28847d139aeb65d5d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd1fe160b76486586dea1195d3717a4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4616ed6436e429cb0594228303a7f15_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i491b8b5f831e4808948911e15a6b2a0f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07559fd94f9e408894b9f0c6aada463c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76eac81be66b465e8aba6b3b5a572b56_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4460f5d13fa347f896eef94a4a28cf12_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40be409bfc0e4dc099944810f89c820c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id510a93f2b0d4cf69f18a984bca524b0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided2e9f46db04fda99ec75cd3415d325_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1740e6c15b4fbc806318e1936a2721_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf017ab13df548e2924759ee558786bd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39bc9daea7904ebe939e366457a5979b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd550841fc7c45b8af6c60f3fa0f8a34_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd39be4430f7409d935946ee25e5a791_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59016e9a1d5d48dea6c8c26d31dd6af0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8095b42f3c3d46cfb8bfdef54101a414_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie97645899e0b4e1d91b3cd525dccb36d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c1da51dbab44e64942a8f1d0b64b893_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9cc0087df7423bace5af792d04a89b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d26e27e7eb4667bc1c7dfa8dc72756_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36852dd15708409995b804b93901ddf2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59c4371c6a064973ac5404a53c264be7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a588955016a4859baf6ff4894efc919_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cffb35711eb46d0a03ca5bfcf9b95b1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e25b288b94b4d6bba1d74ff8d01f12f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab855eaea194ef4a3d9af3afceb50c7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb174302e02b47c68127faa1d72aa6f2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ab05c36a284bfd9324f1075433acc0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a385d9c0e3419ca8a25109e4234007_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3313fdc6f1694bb296ecbac5328fdb95_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2b530ece41403e8f0fdbb413bee88f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id43076b85ac44e909d1c513b58c40e62_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97b7fc5f8df45e9bcc906e84ddf8c0d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfaf80fdae174541957b5feb3aae627a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifda2519ceb7a4fc5ad1fcf6edc583672_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79d8ec7d74b44b3a63979eaf5bdd09b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8819f6bc6184106ba285e6415d9d42a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i988f46577a7a4454b3957c277d8b04fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15e3ddf01146436a8b3c8b5d3de2420d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52176978c3e649dea74aeb5b1def24dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6be7f41bbca44db88e2eea447f357ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f46d75206b485682e1e2267be9e2df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025bf4b7665f402cbde028bef48f281f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb866bb408947579450eca5b5dfd24a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba83711893564f9c8987daf355043fdb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdf4f32143d24f1fa87f639690b700e3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a46937aff434e73aae5f0ed8b35218f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5d21251ba2e4156877ad94aed58ea65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e021ab77684430873b508aa3f19f9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b28c3de4db4949bc89001e98278b7b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d5398ad231d43158c6f75706adfe6f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbe2379453e44861a0ed685834555c93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8fc54ee0cd4b3e9e5451b181dc7a62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia798b021a554457c89afa7d9f4e59bf9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9acba15c5791474e88c007d6018e0579_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i488484ed6b0d4a8eb2d7c63599be0468_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i645aadc8462e4f0bb9c3992e508abc6d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d1b61008f54b72978ed1b60c02dd15_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:context id="i029ce1f6669d4d13bf48542871624ff7_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ecb2729d3c48b5a5174645d3aea6b0_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7976654304fe4df0800004afdc2d26a2_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24bd8f4d8504fd09de88aa4e16a7666_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a1d308f9414a5fa9f55e2a191cc9dc_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400457a1387e48eaa2cf072d6caa4556_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9385fd4916c644dcaffe698618f5a572_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie66b2900222448dca6ffb1983135533a_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bhc:IPOAndOverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75431739df4487280446af7b19c22ac_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13e6d60640d4848933c41324b30da24_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b64397f3134ccc856057d7d06cac18_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55bc36e507494e61b200544c3360e3d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7bba4a0408e47b6904cb9363a54d0c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d25a700a694dd0bb04c6e978004998_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588fb4f24bc44da9b20f9ba64cdce034_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5023261686ca407a90455d9077dc3871_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a74aed9df0544728bda592f48dc4d5c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12459cee3f4646d2966fb895ab93f2eb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a39f472d42a4f5ebd126b085b5fe9e1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09603225e8f46f9adf432aff5307061_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5cafad91a7439a8ee4e91276eddf07_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e2c1d055a04b8ca3b8229415cd198d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54b70832a484dda991eba0bea3d37ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id913d7fd4ae340d99bf84a67735c6296_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37dc4d41d03d46f296e6c60b958dba8d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf53ff30035f4469b7bf0b121a32dffd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7419cf53c79e45e3a1c6ffa5120da79d_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id369b423b8504df5bb95a335c257add6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c705f4ebe8f4e9caa8290ee18d7fa8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2600d93b104798b8817d0bd816b754_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5b868d47f54d2daecf77fbde9240da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67586450d7a94efeb4d4b4e98a992f51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i383189ddaae4494a9ead4886d08862ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c5d4750d6b4c8ab87893cf4856f81b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33ad1c289f4d477c9fa5a51190c9e7cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ed4784134a476cac4779215bef619d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b06a8025f5c4eb68a5b3de937057a18_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa59c5c6d2574133b660040dfd6f39d7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae15cba69f554a19879bbd577f98cbc2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf7ec2397c1c476d83c06887b07a46d3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i264f439282794b6795807f3ae1bb71b6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2965757201c94320abadce3840340f63_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24db5cc85723404fb1251cfa00551475_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6131be55d52f42009c7700e15ebe45e7_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4245062a7b418a90b5c3eb455b38c7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i687a6d97c876442da5f14198d88e14b1_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0c9cf75bab4540be7e213a897e311f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f67a143f58b4616851d1f79883c3ce8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83dd54e76be14e2b8cddedd0ad775700_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc7df085735496995eedc6a00cacc90_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c15779e38db4d9f960b2dbcddd1f4c7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98ff32b9f66642d49d99b62aac6963ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iede60bc2c8b94524b78454391fd1f286_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b8d98ba0764e17812507d2898812ea_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6bf4d2916304721b590b0e9b170762c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i189881ec0c284dfcbb328b608d14d436_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6f4ef12df34897a610582fba7a5ca1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddfccdfa38764f7ab26413e57457105b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib11917dc946040bfa50a896265fc544d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3856df3c34054e50b83aafeb6a21dfa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59def28407a7463daf61067d0788531e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55579786a38243319015619aafa89fd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7cb0e3db56a4ea981bbab9943aa32d0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdfbccb558174a2c8c0c09b05b34c8ef_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c63ea1cea814379bfb6c3678f5a4b33_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec1e524d22a438c9c456e1b9c501f25_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i560fd028d7474fdd985f6a52302094c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b7c343d445f4dcc9a19e5d1ba15e4af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3102bdd26ddc4acc85720c1d44031b39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f25ff584194105b7bc29f5d77efe7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ad6947f6374ac48f3ac1e7694627ce_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80389df867444889b10bc292d83780a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cb7a659ca664b599f9e404ffbd842e7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97ffb0132d5844cbb9a45d214fa9b29a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d83aa84f0be438bac5f8d689a31f364_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02290af2908a48d9818fdaed17915266_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80540287663d42bebe1ebb76c28b9e75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb8cfd06a6a49f8879cde7f8a7d98ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ef55f3a8f4410b942a22f1c9b01c26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3064f6af45484839a5e9e28044f57d64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="appeal"><xbrli:measure>bhc:appeal</xbrli:measure></xbrli:unit><xbrli:context id="i259cd2e6dab94c2ba09224dea2beb7c7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i172f1137c8f54eb5aee6b0e56da822a2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i664840dc517c429f8d7027d6465fdf0d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1e5a6363fc74a07884d25a0f2217af6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658a48e24ddb46329d8726eb2248580e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib700cf771af14037994bc18bd56d1eac_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5c6d1837094f3da3275340aac12543_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c32f9e20d74e7ab62844bacfe8a06d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ae5d31784454d4f9c64507a80288ac4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f6d573695f9479a899bfc1140a6a312_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ebd628dcc84efa96e5a3f56fbb029b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9a33dade7514111bc4b73c39a7e80d8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39777750e2f64ea99b3afe8746b25115_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04b46684430b436b80adda1d481b4307_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c5a5a87413f4813b60dc909501166c4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d13600b4ae84400ad2d966a20e8cc67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5f7fd33a30e4a169c5464ee3e62b2cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic008afd14a8e42b1b866d63b770b5fa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0491752f49af4e53b382633de1597dca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c556fd4fe44909bc9174e88819eb06_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba36257072b246d29fda1803494bc0af_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed75df41237422bacb5217c299a7a89_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c71f42a1544418b4d10d3fc382ee03_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>bhc:rate</xbrli:measure></xbrli:unit><xbrli:context id="i75b032ae3e214a648b569459dbab455d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae4a5ad398947318b5198492ce65b04_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260c0d75915a4ca3ad834d641fa75343_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f2915dbf2941e5b52e80096e27bf1a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae79b3262d842b1af103d3792958795_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb7aaa35ab964b01b84dfe94e256903f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a5e3f00efb48b2b18db41abfecd3de_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e359c95d524712918710296eeeae37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11472c1bcca3473484bcfadfc7e303e1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18a1afc3dcb4214ad64a89920a42e55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9613fcb5ca34578a0abf1ab147f9208_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e063d61f8c44899a3f8978861d16697_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602595f1880446f59ec15696e1d75c4a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e873c909a3144db9339746a1a94254f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia86e90503a154ca4bb57d7823f5d7f75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec524df231434a33b3b75a1f327b3a14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88feb25df1514be1b2bf7b05d2488070_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a1ed1bc1784b8db2b2d22151163626_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3d864a514bb45dca143ed3ab32eedb7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397b0577878d4f30830c80e5e23ba904_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ea1f91a3ce42f0acfbb45e515ff2fe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940f002456e444718203e05f909f5845_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f554645c0484ce0ae9425488ca631d5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a2ccee5a034061b928c4d52b49efe2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0129268431144c2283e8e4acc5441d56_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbd566effed4fadb5896bab8a971143_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b8feee0c59f4701a4312e6c630644df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ef4daf91aa4f8281c317fad068c66c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee578c670ae4dc29125f5982e51a5c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ee081f26b684d829a12ac1265d3053c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b49bc1d6794cc7856a6269ce445917_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3da8eb119b435bbd381609ad532677_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c7425072c141219aa1cdd573bd405a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184f88c56dd24fc0a24d578d3cec1912_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i524914c3e77a431bb6e23bf2b8d68654_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c2a1f6e1e67469ca7b69557b895dc8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i054e43fb12054855a665b8a78721656b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e156c972764457f83682644cc5296a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0655cf22cd44bd085e0dfc3bd855124_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041eda0c99c84e58bc1f197756109245_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4586553989374f86b0151f9e1dc47d44_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28a9044c2815433dadfb6a1fbc0fc718_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e30d8a0b70472da327a5cd5d504e40_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb7d5760de84dbba93d5758373f7df3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3f217039214cc99ebb1a3146d44e2c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf04300c0b04203930e4017146b0a29_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i171290f4c16143278fe977553e53a298_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361b8355ced14036903137406c65acd3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie32f67a7dcdc4304965f785c3401a61c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e12bdaebcc45a1b8c0c18938e51e4e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734ba9baeab74604b0c7c558dc66e5be_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c43778cbdf409ca15ed80687c13da5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec85868873634d7aaec5771a953c7224_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee0f7dd3ca94d9a813c20822f42b12e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75d309fb9e24efe806b94be702f2683_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0b557c0f5743d4853cda063a55d5a1_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64029e7dfd364587a73eb03edb488c6c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7be821d39f844c7c9e6f5db374b2d390_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icebcda21eb184f5596ae20266fcd05c5_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i807f651e453049d280b13aa13946098b_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e572145d9a7467baa36216af20a4a17_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad592bdffaae43e9a655afeab7d37965_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bhc:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i9520dcf4eed94040af3402086c331516_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaabe709841d4ab5a8f48593d73a6236_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29fa46a2016a4d6fbd35835aab2e7733_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d23798ee6944435964f0ae2a74b0053_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7cbe70ccd6a46a295e6b86c6ca5e603_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06aa410016b4d3d9736289f10b1b949_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabdffbd57d864d79afae07b110981771_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8161c31ec1444e4282b76d79a09434c1_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34d55f72c27c47f6afb001ca411f5fa2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4339e12a380546a9b2b74237a9f3cff2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1130a33c0fde483fa1bae8711549f82b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibefdea46ac904b858f0d89701cc31d09_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203a22f1210340a79695abcf5e8cbc84_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a8a8be34dc47ba912bb7fad91b59d1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e21f5810f55489593ecaa960423f5ab_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf38a4e092a6474e82b48723b723f43e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bad238d099849c8bbcf419abb996956_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b8f0ab2fbb4bb7b6a75eb4df909667_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58467a391034c9cb187019aeffd9731_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59c61192e231431db2b0a3faccf31084_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e23e6b1602e45c69f5e0263e4e91c1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e0efdc5bd2442e86a6a489bf72fa7a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e089be5eb041cf9cce81981f011be7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f39bda64df4253bfb97df28400bd07_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4825754c7324c8182558e6ae17503ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4424b9ece149c8ae2652648e9479fe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60f32e20efe40bdafd03b20dcc4ea54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2719dec24cd48aea9d17bcf664f412b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658fec0dcb034795a01b1f1d2734dfe7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id923a0c7821d408eab60e2d1ebbdbec9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c72157e725454bae3d98331b48e1b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c8689541c04f66b5293904f3094a90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9736f916a62479d8d54ac9b1251c9c4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id34ba1093cad49c292458d52b08c823e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65627fa9869f456389b3882ce8b37654_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847b6dcc9bf747ab946d8f1b08b3d71e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2824f9dc84c40c396db9edca43574e5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb6c1c4d20b44c3a7dd173a66fc96d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ead96a008c4245b48958509368a215_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6770f439f6854fdf80d5b734c92a4554_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0837135263d44f058fe95a28f43c5e2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd7119954044616a3233f093428ce2e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4849d9106bec4ca28083d112da7d7ad9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a060f4700c410dbf92bd4bbab91133_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d20de201c0e49b49c27d368b4cb4cb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67496121616e45d98e1c3a401c8ad3e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ea118f8acc428ca2545966a39f9e19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6125e68618df43ada745dc4ed96c0b44_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f48cc3094e8425dbf7cb547b1775c69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624988cc531340da8809b18541e3ae0c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb7f0a78f9524510a26d87340b762969_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec3a4af6ebd741b697f1f5228fc4b251_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46824116217340c19c4097a996b6f0f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffaec666689a4abf87b5f4f4e20a8005_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed6c73971e144729fd723b401f24f72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i736c5fc93f2242fe9da805a6c5e69418_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7da4ab69e9549eaa9e8488eb34481b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ad837f07b304b389bac2395b7bb644c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e0e09e5ca542869e0a304640beb346_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3431ac7fda8140f496bbf1281db492f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2386767ef8494039a45eedf4276380c7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b58cc7f53b24512935c9762a50cc8ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28a31a3954134e40bc913cd1fb66abf3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice079f38e9d1403daa063c880dace2d2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a12b5112bb435791910303cfa182e6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8728c63be96941459a588f3116991b8d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6053ee47e754dcc8601ba99403a76b5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cae089600e94389bc02d059bc908b54_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79f3bd1f9bc4330bfa744f8b69c453d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if878061e7e8a4d5b87624e62ac22aa3a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie761f67bcaf44003906b0b905ba5b263_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a9533f0c874026af3f2ce11e610087_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f288fb4475b42e396cfd814e2d07cb9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8044c0008d4224a9252821ed90cab1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2c41e745e94aaca242b47db1e9da3a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f1e467a3104724bf0814979c3d7b24_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64b46934a374f298609c8f8d6de0962_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie88308ccb55545679dce2acf47006522_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideda0b3afeb94283b8b7495bc71f5cfa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58945eb4f42545a2a975fa287df7030b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f887978c4a542b19634fbdbca4dbd97_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i278988850934419e80acc9d963dac666_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00732fc9ff374b49b979455466cc8f7e_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfc7e6315fd42efbda70b4c17cce33d_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6365ee6027ab48f0a916168124555cb4_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia532a9f771954ea39e670e6607d20d41_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie52f1d3dd7b44370875bfbf01edce092_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff4ef5de85bb4627a12cb69700bd7abe_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i829327ff659443278a6e3108a31e2416_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafb7519d3db4ba79da9149156c9be5b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c63af1038a498d97b0707660dbeca4_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie319941a51a34294bbdb2ae3718dec8e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20cd5f0493f2487bbde5f2221db59a0c_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3eed0b285dc42a99845525f57bc2eaf_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a03fb030a0040cebef22c0f5654ea66_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e53d6553f64b7eae83fca240d210f8_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15dd8f000b9941858060dedaf7e029d0_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id330da73af3e4586bf7d8a9ae96e9b1f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb86b03b3ac24b4e82d95decf997f3b8_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b38bcf16e54859a0dde3ac0bd30c5c_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3944f858836c472bb400b25d49c9a870_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id154aa3590224033afe021d4daefc439_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02856360ad9c4499aa8ee226526b1aa5_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36893810d2ab469aaa9b5e3e8bd9c2e4_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b91f50e40904c03b83e3484fe6eee31_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be6df6cb851454f9afb224870173486_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f125d7ae474da9a0a4942295b43c0c_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i726749b95a30497288303bb51019c959_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e638cdad174145acfe1cb7ca9c3b06_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f9310875d34c5aab769c2612112be4_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b599cb18c944ee87759c867f11b854_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8e5c5dac3f4de3a568fb4b1dc17504_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15ff81720f140728bd400ed17b1d660_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3070a693a5854af3a22dfe66f3655e85_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943999c56fff450aa77e708b60d39def_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16b8fead453422ab2aa9fbbbcccf83c_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i297866a68ce24747b81d40a30c023bb4_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13632d9de3844a9cbd798441522b1bc7_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4c681d58b24f99b498d9e6a296937c_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b5207c38da4c0c9112b7da48cb7ce7_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f700a1b8cb457dbc050366a46232f1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia63c47b1828f4ae0b6b1dbab0bb42d98_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa17fd0da484c67bc48038c0747623b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53fbf53285954caeb0e7f050632c7597_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d49f58bd8e741069f996a82897124ce_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifebc6076ad5441fe9acf2610a82c6104_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f904c39c824f0cbed6373fc8027458_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61dd05e0e56948b8bcb9f052101aeaf6_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9189a38171dd4ebaa45559422267b0ab_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i797254cc60b049dcb744c873a7a119bb_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35465fe55b7945e3b6f24aa54344fa38_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a503b3152c24a3aae993d9cca166b10_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7cb7ba0199a427782c6e11d979cc908_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i463a1df44c5e447c95a44b5652a58c27_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic986ed29a4b54c67b340f512dca91b23_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb285fdcf7346e4931be632a5d32554_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d9f7c4a1b54b0893e8a5c93f2b8b41_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1870e555a1fd4b21a7e5585f4d019a9f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31cc3cc5d3ca41eaaeacd771a686a45e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7356824e0b3446aeb0703cbdc0f9101f_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4804f7e82ed3464d857db9b9aadf33f1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f730e3004c4467e93c8beedc0748d7b_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4afef88c6a4140829ef856906a21c44c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id98c05c2a0a14ddb8c06bf78beb4aad8_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042059a75e2442fd999e415f9c25591a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2717f1d183464ab1be432c601c1e94f8_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93eb31e461ac4db5ba4c0df1c70c52c7_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9c7cf1e63843dd9922d9993278a56a_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d0f02ef63b4948ba4e261acdbbbfc2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6e1b627daa4dd5ab985eaf3d792732_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23da95982875422e85842884cfcf3c78_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cc1e4c1e0e45c088cf0da8d3478561_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i879c2fd226954205b21a10810b667c13_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40e0ab954b9546489a9ef90bab33b427_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e20cb0b43649a1a6d77f2a05f00d92_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba04e7a5f74b447488bf33d1bba8d3d1_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4638c5e4165448498eae9d03caa89485_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3179052a5e4e44b4b9793cfa4650a3_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i125d23605450450a9432058cc84577ab_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ae116d5b71442d8c602ff3e0ff2420_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8dc48d6ec2b4113ad14034a1c76b675_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87da6b4d8544d5dade0efad5191c5c3_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7042d4e6e0d42a092deb71733fc7627_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5a843db9464057940288007937dd58_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i838762aec48a48bfaae871f10aa12c35_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c04f97f5c714af7a5e387b0d156bc8d_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia324b82ecfe4472a8eec915831a5f250_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae9beb58b9b44bcbb18d4e6cd9e9fbb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f371d3c6a04f48a82246f042826add_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b5c2e6a48345c0b538f3138c5ab5b2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a9ae3100a74f7ebf2929870b5083e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6a3ac703f94d4e8ba3718b45516087_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c67b322920745f8ba3080e92c213cff_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf2bc07e5c9d48648d447ff5d3dfcfc8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c782729eb2a4eaeae9a5f19119db3ef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2464c5727ff448ddb5ad8146c4b17152_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4675f7627ec5490496e997650085e455_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d2d86b33a741058fda2e20bf9a30d4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8cb01e461c43f0ba0ff2f3565c5ef5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31113824bcf41b3885c724ca05e5ed5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c39c0bbcb54df291baffd09082d1d1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fae9ccc16447a4bb6ce23208cd688c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e8f2a27e6664bf9aca3e322fc1aa7ea_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b865ebec004e23aa361ef3a12e65ac_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if73278e7a6654cec90d56f5d9e86109f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ce14ad9dd241979ec43ff28ed9826c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18c983dff3c34ced9a702d90c64a861a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65cd64412b1044dca3d7df190d03e1c1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ff9b7bc0a6b4740af09323c44145b47_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5726cb791047928df873284ca85f71_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i788020833e76460b8e095fa176b6d7ce_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781d955207d8472f97604932ca86559d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67229cf570e341819da1a0f863e8fcb8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fac2a0db25144f7bc4d94691e6afeaa_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68315b257d6e4c95b8a3e5c0005d0240_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i206a35173cac452e80a9011a351123e0_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a224dcb25e4aa8bc91a4cef4a39b4d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id428743f89e44793bea4c8584a67335c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i677c4838f7c64a0fa4133f133bfaf2ce_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c67458cddf440fae3e9d2616d2822e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb87d76e2584480b8c68e4b07d46150a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib82c90dfcfed4b258e3dfca87b481343_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93570e5abb6e4069bba204d6409b97aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39bbe98ba2634efa8a0ac3f26b52da3d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17555885c6b4ec5b2e98860a7c4cf48_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3c57844e57475ab663a9bb253a2e8e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda04c31ebe54292bc90ace1f755d969_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e9cb5876bfd4fbeb27c0c8d2d1847d7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4a35e3c4d845dea31eb0b4afb0fab0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b3fef19b7a044478c661e599645a697_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i177e13e488324255b69c74c8f05e9364_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia499047b1cbd4a05a81ffaa7a7ac8912_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib221baeee1504b62a9a00fd4bafa821d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed370dc33214c95b38faa3097c8e671_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3cf936e9a74f7ebf11fb503c9b7c72_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="i5e3f5299561c4eebbd5248dec3a4060e_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="idcb2e316fec14bdc856e971726c9f87e_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ebe24a04454b4091861650ed6bacb1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="i4fd9f0cc91de49dcb8c8cb33d395da0d_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i29e2849b192f4aaba1d8952c944b6789_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="iaab8fb8a87cb4b22aebbfd8cc4b85230_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd7324df4a84a149605aa327631d7ab_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia481a4b7a6514b33bd76b28c5e86f915_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="i048227f1aea14eb384517a325981bff1_I20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insured"><xbrli:measure>bhc:insured</xbrli:measure></xbrli:unit><xbrli:context id="i871383296da145e486609cb4113359a6_D20210720-20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6de1e6ea024ddbaff325eb35a50f24_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49d2de7c0d8f4004960c2d05a237a525_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a53e2265c4140e89771283e17cbb465_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3c58e3d67e4e9cad64210e49062a44_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5f207d7cdc4819ab32038b7d6fb0c6_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dbd8d94f94a4b9b9032e8124939d763_D20200326-20200326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-26</xbrli:startDate><xbrli:endDate>2020-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c90fbc7cb942fcad2237f660bb4d3b_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6951d2873de43869ddbd5c757e327b2_D20220721-20220721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-21</xbrli:startDate><xbrli:endDate>2022-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ea1630078d4e05a6bca37ee09dc60f_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie22ec902753448c8a53dab3d0449fdc3_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53724202d602400c9250252097901776_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>bhc:defendant</xbrli:measure></xbrli:unit><xbrli:unit id="proceeding"><xbrli:measure>bhc:proceeding</xbrli:measure></xbrli:unit><xbrli:context id="i845628c47166456bb97e0565f2c1bdc9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if47547b12409405d8d9c9257fea4a4ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc621b0fe4dd43248d552d9e078f0955_D20221103-20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33c91c7c2a624d73a2b21e6f04607fd7_D20210910-20210910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea0bb7c52aa4fc2b812e3b4ce2644ba_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5916243ff944d46aa17d2219e926c0e_D20180801-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PatentInfringementLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332ac3fd809849fd83751e1cc812e29a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>bhc:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i4136072a63394788a51d3aa4149f4df9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d82fa052dd1452883203a200bf1217f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e10e59808e4d0092702cbb02aea06a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb508c450eed40579b6ee442cc2907b7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184af1e8e9cc401f9c92a4612adf20cc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f33cd61e80f44d8b6fec68312c48113_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e33ca886304a7f8736aba94ba18b95_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc41fcffae24dafb443704717376dce_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05dba365c7149048c6b1a7245d1b247_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b4c08132f844779089399f6327cc37_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b3dcad39c345c5ac603e17ed95fc3a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a48564554644fbf91499853e1132e1d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb4504aa6bf41d1a6be48aa2c1f175d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d031dd6d0d24cffa3eb903bb856d240_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5656b3707db4122895e60ea240cf646_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib141aa7ca51144b7b474e3fc89019f7d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f6422ec5e814d71921b4040a843846b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d22d39c1ee04a7787dc2f60be8d5f7a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86d17424aa5a4db5a07016d40a84d937_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f9b74c57634e8c912801d8ecd437ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6378396c4e9a47e1bf78d4f23861e774_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870c4afe29af49f3a2a7f8542ee2ccfb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7789d8fa68d94ab1832565529cc7b6dd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961d5c068e19458eba50a317f05a809d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d87fac315ac4359b4ba48ecf9d3800a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc4fa0ce3094043b06c419d4f2739db_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f4d42dc1e84b6ebb78a7f56a821a8e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6abdfe5c4694514950ade150231952d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2f85a36c4542b38c592e0acf6f1180_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee32157246540168ca54485ea8c5d71_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2502f43413f4cd480e2a0246b792a52_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84aaf53830b474e8b82377c387fa23c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib58454b50b234f0cae6d889781bf1c3f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1bff2464e6492f978876c9c6825fc3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d876376e54400484f8385cdeda205d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd45d6d098e940cea4a1d9a05d7a84d1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a9da148f254cccbc56ead023ff8e94_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id018a592918a4c7d92d36586e30b8b25_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0df6736f2847b197e7b8bed8c689ca_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e24b87e5d8f49d18b41d6f564417334_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21fbd1b5e5b446a289edffe298fe2beb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9903b8834174c129ab4fc958937b81c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1abefd1a9ec41a0a822f596885e4972_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eede7fabe3a4f2ba57b19bd82733d3d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i567d22541928427db55a03ad179a4ad1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aae3e10a71b4f6a98a38090820fa000_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53e184c5e4e4ea79e2591ec3164d59f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50af148aa25b49fbbfe10ca60b5ceceb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i947a6e91ffdc4fbe89b4ecb87866d600_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6813706915f4ea589187e4729d7e82d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88458031f6ac47b59b944bfddbce8e54_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa45dacdd3d94b9da782f49919c50c7c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5529206dd0354add818ec8ebc745ea99_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b101667c39b43339df8dca9eb8a5c17_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i195b71e75a26477289ed617294657ed5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586500eaabcf48daa510aef12cb36e94_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4547bdb61bec469cb232355667f60334_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d5528e4e03c4951891b8333a4918812_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1da9ab6b49674688a517da02ff148635_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8677733f10724b908cb5fa12e547a9cd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d18eaf8a344deabfb39b5d1d2f5244_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c7c1f563024eb885219d1cc73e2c03_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e529afb54794cf0a4114a5202965a4d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888846f7a8a24e6cac9459c35c333be9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfcbd7bd0541403ba70a5c4a488abfad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2366ec826494978b8848268dbd37f56_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5abfa18a5c8641a1819cda416997710d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79e84fc1b29410e8ce4e71df86aa5b6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5421c9b35b4516a49077974d2e5949_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if27fc1e4a91e4d25a238da7b45796c0b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4a4f9d43f164c9b99692b1912045740_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66b3252a18104908b5a55f890c213286_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425034548a5c4d40b9c2c34552bd6d3d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34bd3f79386a444ea669a83657bf3167_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1418ca7566eb4be890fe201a00997650_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60598e761b44eaaaceb643fb0d3f737_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib91c304c54df4d51a17ad1319b6cefd2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8153aeaa29c14cf78898a3e0430db0b3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3155b234cd454dcda100820d79b828e3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2478dd9d311e41849390cfdcaf83acb0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b297ee44b024a5a84ce38bae85846c2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22473c0e99cb43b1bd4931030815e25a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56c6ec263244270a0635f1fc010b8d1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c3b644d34948be9d9c18866f4a5d9a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f341155d9df46758157a2f5d967fcf5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c0d01651fa42ddb2726f307d78e1b1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e6f8d534264d698d9daaefe158ba7b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43251ca627784927b25da791c21f44b4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3037fa5f424f4fcd91ed8575d90726cd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic136910890c64c788ae7b465e4125b6c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3ff051184a4834850b051a7d4eb1df_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c9b728ace2464d8f96d58ae572ebbc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6567a2441b6f405199585a4b83fe5bc8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if77a4befe17f484688509cd99dc3b12e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aca7ca963b44994a71d3617c064d6fe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422af7d7e455458c85d983e22cdac59a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944bf2eea27245dfa96a85b44b8afebb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44102882489d45b8a65cbe80612eb503_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629f1d9bd1a2455f855f4061c4ce4dfe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib508b0f79c104da081f95ec2beaff2c1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e8b341226e741e6a61a9d17cbae03d0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1c2ec3c04143fc919380f19acc7cd5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90dad0cb3874aca84524b1022581f5a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa8cafb0fc44a99b36bcfc0892304b6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda4a6e048d64e4c8a7245ff0c6385df_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23473ab81eaf45d8a36b3bf461716a8a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48494750e70944a6a8fe08c72a157c9d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a743c0619b545b2b9851ee1735cece3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26aec855e3534a57b91887cca0df636c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b64fc9195a481b99d8eba5eba2c499_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2020a325cfd844aeae55587fb97a9bde_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc165abe9fd94612a2e9711f068afaa2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b7b11900d04f5ab4a91815dc85a13f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d594998be2c466a8ae3f74769b467f1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id14c76797d024f8a850f17d12da55d9b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d945399f7fb410484aeea7fa1086e9c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19757afbfd8c45fa860915adcb1688d8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib120955476934bcab3cfc8a57258b2df_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54edda7460544fea9cde5c3172db7617_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb54743e79e418c8eeba61c5c9441e3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755e8ef589a6417c85697fb2489e0997_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e344425e326404fa4c3a5ceeb0a33ad_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie27be4668ecb485da4269a39bfa27526_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfc2d283efe4a7e834029578338109a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599ad95889f140dd856c86816a0647de_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75dbc41746a6477da43e97ab5cdea898_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4464cc778bb74ce498dcb23fed88c066_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583e1c626b03403f87d3f3663e850328_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e34d06d4c144ab84ed676f2b1e7904_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e97965210ba400a8aa5affa4e5e8dda_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9713e38b2cbc4a72bf04b0dea907a1e3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579951261424471ebfa617bcad167deb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4241952b1e174e2b865fc979ca30a592_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50980e0088f041399e5e72f5cff6248c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2de33d45cf94f6b9d2f33a3c2bba1cc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc88c3d81b1c4955992d1247bfba1b8e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2811781ce7f642ca89c86c7f0de518bd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i791a2916a2aa4ab395ca981e61e7daf2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9826556f6d8947a69d81d512d9468782_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2f39db7b954476bf2c8bb5f8ad798f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54bd462ed1446b096e8f3df008338e2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f9d93817ce485782bbbade2c8f8fab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ea63fc42464411a719b65e9cea618a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12376a48681c46099f3a4e9ecbf34c5f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb127d7bf284643bc5c01a24c9fc5b0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58982e1d6ef14225a9ab3729ceaa6948_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i301b2caac8d446778085cc79b589a737_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fe2a425b9245fca2bb47d15a250d6b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dae99d75ed24ba5b1b8b1f3747dda78_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c493f1eaa24d36a5056a2ca842a812_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad50b284a5ed4c6d86183cb2fe3fdb97_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f87201482142909a01e5261b00e554_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i905ce8cfd82b4f538a2dc187e9546dbf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id81d14aa32074f3ab7f08a1036ee0b8f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id20223e746334d6f82eca42140a4c935_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5755175f3f06430ab66277abd6454600_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia191f4ea8c4945b4906ab7f70a93deed_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec8559c1ec940ef809744ef427103e5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214a5e16df454787bd61853a8fb3b9f4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib03306f36d12454ab64e7ac8cdae92a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f14675214e546ad9d45a02682113cf2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cbf185e217c4dc9a7593467145c745b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc95d6d82edd44fe9ed4f8dc335f7e42_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe643b692e4449fadb261eff5314a8a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ecc27feb094b618ce6496fa054bc12_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0115418e894ab6b82b70dc6e6d9531_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia407433f62b843baa034edc40f2c05c3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86d57f75bc2442e29fe1c7f8fa969c3b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0e8eb0aeed843fba31c70ada9493305_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i072aaec2db174878954cb70bf860e758_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0814d1f5f404ef9b9ce2c33efbb9cf5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46f1158b96e7498b8bfdd8ccc5ad9827_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24af9b92680b4f0694745bf435e5472a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="i2d52656bf37d43cdb7e063c81480fb0d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed64d739418416f87bf91f8425ea391_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c17a5874a9e4075aaf8c4ce5d1a4e12_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e326ea2d1834500a5932fa3f6d1b28f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a7b27f028d4f1b8e3316964ae4b6ed_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8acc98b4a99485f8de664a8f1b2574b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7593d4411424499ea8071b2b1744ee40_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81cef13fb1fe4cff88b12247a3647d2f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a1547713f2b44918264056f12b2d4a2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cee586c236841fc9a104c883eb25025_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1a9b9786b845c6826efe7b5650b900_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94f8fad7b19469aa645f46052c57c3b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00ad1728e8924998803b5744ae677c7c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbe3c58b4ffa463c91e47a7cb28199b4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id150c24526bc4303af49c01163da23dd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38317d58388c4fdebeaa753429b54d9e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib445c562897042bdbd49b80e1286d65a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e344dce62744d278e0b20e50c3fb0e3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0143ed82024e4ba05f759a4321dc0f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0197306db91e4812a3d4fa3b19135985_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75298065a5bb4d7abc0cd5a872c8c23a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ed176248a7493d8af99f37e6e639a8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9253db1500949fe906fc9a1f4fa1b38_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b96a64aab504e74910b39ceb4520476_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30d18d2c61649808a5f0ae632b41c66_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5dc9560462546608eaecbaa48330ebf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f4818ab24d4eef82fd27de079b7973_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f81890fdf044bcb330e157d04a97a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eff41ef021547c6bd85e06df906d0fe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac7d036a10b44a9b80aec045229f3086_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic155d49fa70f4c1198d083cf8239e270_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc467b3d64744017a93680acfc732aa9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefbd58fa6bd147a482305292a074c257_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0d0748800694d148893ade42e236442_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c124d21acf42ce85f54a6eac7f7ba9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c7a4309c6b4558b2d3e9160a31980b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8dbcf8ffc494fab8b9df1864aaf00a5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d0c319938f45b0a9419a9e53c66df5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3959030e4f5c4df99cf6dcf1ebede4d4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e5e8321bd646448a93cf036eae8e2b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc35d5603e0942dda30e190b9deb1627_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11911151b9f54dabb034a5f6b1fe8839_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a95d34d1ea24fd586a885cd6b872083_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89bbb02a54d240ef8ea4afba712e86a2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52bf2297ad3d49449422ea1e9823e61f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f8127e8b0141fb9d4372bf3c182783_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ada8553598f446f8ad09650f86726aa_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbaea260f0344e5b94077f35b76e27eb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd4d24d726d04432a277be2e908a6abc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f382705cad4a4b84c68be25fa55777_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec9bea2ce13443798c0a6d868c068d6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c5dedac9f749aa9c8913ab247f1fdc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29b7b8ee29a431598793c1ba4520dc0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee531f5d0b64027bae00dc04e77f297_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21fc561bc8064837bb579d9d55ae3b5a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea6d886b69f47798e958d42e3654c2a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e2a5680cfc4b46b7891fc6f9830006_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8595d458c34e018a63a7863b77580f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d246b81e15499094a367cbe1d8db6d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54794b3420624c9fb619461becb59f8f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0d411b81984c788cc81aa73ab8f449_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a332bbaec540e481ed114e383e4dd0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a84613cff7f4368a54a708f8ba0ff04_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bbda526e0454dffafc588718e72bdbf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0269b61f01054b6698b35799c21833bd_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTg0_7f38060f-e9a3-435e-871b-a0f48cf0352f">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NDVhN2EyMDBlODAyNGI0NjgyNzc4M2E2ZWY2OGMyYjkvdGFibGVyYW5nZTo0NWE3YTIwMGU4MDI0YjQ2ODI3NzgzYTZlZjY4YzJiOV8wLTAtMS0xLTE0MzA2MQ_5d7f7bb5-97cd-4b40-8705-639c601fd42c">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:right;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Quarterly Period Ended</span></div></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NDVhN2EyMDBlODAyNGI0NjgyNzc4M2E2ZWY2OGMyYjkvdGFibGVyYW5nZTo0NWE3YTIwMGU4MDI0YjQ2ODI3NzgzYTZlZjY4YzJiOV8xLTItMS0xLTE0MzA2MQ_11521d02-7009-49ae-b243-4ae7390852d0">September 30, 2022</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NDVhN2EyMDBlODAyNGI0NjgyNzc4M2E2ZWY2OGMyYjkvdGFibGVyYW5nZTo0NWE3YTIwMGU4MDI0YjQ2ODI3NzgzYTZlZjY4YzJiOV8zLTAtMS0xLTE0MzA2MQ_636972bf-b8be-4a61-8e81-e6c1e4b3bc28">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the transition period from&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTg1_896c6609-6019-4088-b107-e6f49b6136a2">001-14956</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTg2_0bf463d4-ae34-4aa5-acdb-373c1f8c5ccc">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6MTI2YmNjYzAwODYxNDk5ZjhiZDljYTIxYzZlNTZjZDYvdGFibGVyYW5nZToxMjZiY2NjMDA4NjE0OTlmOGJkOWNhMjFjNmU1NmNkNl8wLTAtMS0xLTE0MzA2MQ_d2a6c7bf-c19f-4a77-8c55-155185087a40">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6MTI2YmNjYzAwODYxNDk5ZjhiZDljYTIxYzZlNTZjZDYvdGFibGVyYW5nZToxMjZiY2NjMDA4NjE0OTlmOGJkOWNhMjFjNmU1NmNkNl8wLTQtMS0xLTE0MzA2MQ_2cd7d047-8e44-4288-a19e-c1e492e27e9b">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6MTI2YmNjYzAwODYxNDk5ZjhiZDljYTIxYzZlNTZjZDYvdGFibGVyYW5nZToxMjZiY2NjMDA4NjE0OTlmOGJkOWNhMjFjNmU1NmNkNl8wLTctMS0xLTE0MzA2MQ_04a5bc82-7177-4815-bb13-4c038e4c2c78">98-0448205</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgw_c9446c84-c107-401a-a53f-1bbf36a46918">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgx_56abe654-f128-4123-ada1-f696939572e8">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgy_32122d9d-3690-46d0-a71b-e8e90aa48bdb">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc3_61090692-ae16-4319-ad2d-e8a6afe37e30">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc4_ab37f43f-9cb0-4e58-800b-837cbf21ba80">H7L 4A8</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc5_be748414-7cb2-45a4-bf0f-2b8bb57ad330">514</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc2_14b130c9-6992-471d-ab8b-e552a5710e0f">744-6792</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.522%"><tr><td style="width:1.0%"></td><td style="width:29.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NmNmNDAzOGU3MjM4NGVmOGI0NTQwYWEwMzBhZWZiMjgvdGFibGVyYW5nZTo2Y2Y0MDM4ZTcyMzg0ZWY4YjQ1NDBhYTAzMGFlZmIyOF8xLTAtMS0xLTE0MzA2MQ_890f1185-77c2-42de-8bb8-1a7aafeda72a">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NmNmNDAzOGU3MjM4NGVmOGI0NTQwYWEwMzBhZWZiMjgvdGFibGVyYW5nZTo2Y2Y0MDM4ZTcyMzg0ZWY4YjQ1NDBhYTAzMGFlZmIyOF8xLTEtMS0xLTE0MzA2MQ_b5ca43f1-d0c1-4350-9f7f-1b35c8a9abed">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NmNmNDAzOGU3MjM4NGVmOGI0NTQwYWEwMzBhZWZiMjgvdGFibGVyYW5nZTo2Y2Y0MDM4ZTcyMzg0ZWY4YjQ1NDBhYTAzMGFlZmIyOF8xLTItMS0xLTE0MzA2MQ_8d7ae362-fa2c-4d56-aa05-3591975879de">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc0_66c46762-1c59-478c-9823-bc497e1238b5">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTcz_c45f7cfb-6993-4100-a14c-f44808e5270c">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6YmFhMDA1OTIzN2U1NDczODkwMjliZjljODA4OTZiYTMvdGFibGVyYW5nZTpiYWEwMDU5MjM3ZTU0NzM4OTAyOWJmOWM4MDg5NmJhM18wLTAtMS0xLTE0MzA2MQ_e3d71db3-1a2b-40f2-b748-11431f47ef9a">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6YmFhMDA1OTIzN2U1NDczODkwMjliZjljODA4OTZiYTMvdGFibGVyYW5nZTpiYWEwMDU5MjM3ZTU0NzM4OTAyOWJmOWM4MDg5NmJhM18wLTctMS0xLTE0MzA2MQ_64908284-e7bd-4107-9a56-b25b4617cd17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6YmFhMDA1OTIzN2U1NDczODkwMjliZjljODA4OTZiYTMvdGFibGVyYW5nZTpiYWEwMDU5MjM3ZTU0NzM4OTAyOWJmOWM4MDg5NmJhM18wLTktMS0xLTE0MzA2MQ_db341cde-4c1c-41d5-b969-b7f627f19540">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as&#160;defined in Rule&#160;12b-2 of the Exchange Act). Yes &#9744; No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgz_4b6684f2-090a-44ed-9abf-9adfeb412078">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable&#160;date.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares, no par value&#160;&#8212; <ix:nonFraction unitRef="shares" contextRef="i57c4dbce9e34463bbe2a00df8262767d_I20221028" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTI5_738a12a3-7420-4c2a-862d-00b673022946">361,868,131</ix:nonFraction> shares outstanding as of October 28, 2022.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER&#160;30, 2022 </span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;I.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_22">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_22"> 30, 2022 and December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_25">Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_25"> 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_28">Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_31">Consolidated Statements of Shareholders&#8217; Equity (Deficit) for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_31">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_31"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_31"> 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_34">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_34">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_34"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_34">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_34"> 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_37">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_37">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_103">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_217">Quantitative and&#160;Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:right;text-indent:-27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_217">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_220">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_220">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_229">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_229">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_232">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_232">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_235">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt;text-align:right;text-indent:-40.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_235">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_238">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_238">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_241">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_241">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_244">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_244">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_247">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_247">103</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i0269b61f01054b6698b35799c21833bd_250">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0269b61f01054b6698b35799c21833bd_250">105</a></span></div></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER&#160;30, 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introductory Note</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Quarterly Report on Form&#160;10-Q for the quarterly period ended September&#160;30, 2022 (this &#8220;Form&#160;10-Q&#8221;) to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies&#160;Inc. and its subsidiaries, taken together. In this Form&#160;10-Q, references to&#160;&#8220;$&#8221; are to United&#160;States (&#8220;U.S.&#8221;) dollars, references to &#8220;&#8364;&#8221; are to euros and references to &#8220;CAD&#8221; are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form&#160;10-Q are presented as of September&#160;30, 2022.</span></div><div id="i0269b61f01054b6698b35799c21833bd_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning of applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;), as described in more detail under the heading &#8220;Forward-Looking Statements&#8221; in Item 2 of Part I of this Form 10-Q. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in (i) our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, under Item&#160;1A. &#8220;Risk Factors&#8221;; (ii) under Item 1A. Risk Factors in Part II of this Form 10-Q; and (iii) in the Company&#8217;s other filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;). When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i0269b61f01054b6698b35799c21833bd_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i0269b61f01054b6698b35799c21833bd_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:70.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:36pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMy0xLTEtMS0xNDMwNjE_34a0178d-6d3b-4b63-b816-8454cb107404">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMy0zLTEtMS0xNDMwNjE_13816750-86fe-4313-9cf3-4fd3ca721db3">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNC0xLTEtMS0xNDMwNjE_2c7d9fba-8e7e-4b2a-b88c-328a4ec9e3a7">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNC0zLTEtMS0xNDMwNjE_66246cba-c41b-47db-864a-7047dba821fa">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNS0xLTEtMS0xNDMwNjE_ac0c9f28-1abd-4768-b630-e372b78ff151">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNS0zLTEtMS0xNDMwNjE_a920a054-7db0-4731-a6cc-2e2424c82cdf">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNi0xLTEtMS0xNDMwNjE_c95c80a1-bfd7-4631-a062-0af941019a49">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNi0zLTEtMS0xNDMwNjE_dfd98fb4-7cad-4b77-a569-5a978b221ec5">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNy0xLTEtMS0xNDMwNjE_550aa195-91ff-440d-9770-21ae6cc140bc">718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNy0zLTEtMS0xNDMwNjE_faf6a28a-b9f9-43bd-9376-0a7c451fdb28">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOC0xLTEtMS0xNDMwNjE_c14a7ba4-7461-4a64-b042-46b722e2b449">4,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOC0zLTEtMS0xNDMwNjE_72a82245-594b-468e-995f-26744c110cb0">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOS0xLTEtMS0xNDMwNjE_652755e0-c495-43f7-8352-100a79af49cd">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOS0zLTEtMS0xNDMwNjE_9bf58513-6850-4c50-b9d9-a528e8dfc7fe">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTAtMS0xLTEtMTQzMDYx_f27f5263-7eb1-4104-812b-ec1636d2ce85">6,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTAtMy0xLTEtMTQzMDYx_052a7fd2-896b-43de-a930-2534dd0b5ad0">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTEtMS0xLTEtMTQzMDYx_243b4eda-6384-42db-ba04-230746dc8c76">12,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTEtMy0xLTEtMTQzMDYx_f3817632-2cbb-4fd1-b639-cf752649766b">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTItMS0xLTEtMTQzMDYx_54538867-7565-4218-b676-0eef7facc7b8">2,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTItMy0xLTEtMTQzMDYx_0544ef01-cee2-4cd6-86ad-b002f6754b81">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTMtMS0xLTEtMTQzMDYx_e052e142-e5eb-485b-bec2-13f6fa1cf9e9">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTMtMy0xLTEtMTQzMDYx_1347d26a-d43b-4e32-ae7e-eb2347af73d6">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTQtMS0xLTEtMTQzMDYx_cd455c78-7241-4ecd-834e-abb679eef6ca">26,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTQtMy0xLTEtMTQzMDYx_2c2d3ed7-03c1-48b4-91f0-03351ca6bb0e">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTctMS0xLTEtMTQzMDYx_3434b80e-647f-4aaa-b5ca-05b2935c2982">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTctMy0xLTEtMTQzMDYx_40a41124-2d59-4c7a-be7a-ad18500bef2e">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTgtMS0xLTEtMTQzMDYx_2d38df92-2695-4bca-ab56-cb6bece937d0">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTgtMy0xLTEtMTQzMDYx_d6daac51-3b61-4b0e-863c-918d850dcfe4">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTktMS0xLTEtMTQzMDYx_a5c7896a-bd57-4faa-96ed-266f5abddfe2">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTktMy0xLTEtMTQzMDYx_d56221b8-3833-4a14-a402-d2a525d187f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjAtMS0xLTEtMTQzMDYx_42bf85a6-51f2-4031-8ed9-ccbee1ecc794">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjAtMy0xLTEtMTQzMDYx_d0ddf8bf-765e-4be4-b8c0-d3138077fbac">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjEtMS0xLTEtMTQzMDYx_6e82ead0-4ffe-4f54-8f1b-8182108e7d14">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjEtMy0xLTEtMTQzMDYx_697a223e-6abe-4c8d-b962-ae34b675db9d">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjItMS0xLTEtMTQzMDYx_321154bc-e993-45e5-94e3-893a114f1a3a">20,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjItMy0xLTEtMTQzMDYx_6d05c7c9-5d77-4a84-a217-64dddaf4a0b9">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjMtMS0xLTEtMTQzMDYx_fb6ca9b0-d333-4ce0-9bd3-4574550b6867">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjMtMy0xLTEtMTQzMDYx_200d35f5-0333-4cf7-97dc-f9d773b876c4">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjQtMS0xLTEtMTQzMDYx_07dbda16-d55a-4e5a-81fa-1aeb7d14bff9">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjQtMy0xLTEtMTQzMDYx_58d28982-2739-4c90-a072-c08e19f2ccb4">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjUtMS0xLTEtMTQzMDYx_8b869365-4647-4c0b-9e36-583c4ee96adb">25,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjUtMy0xLTEtMTQzMDYx_eadd84cf-42ec-4007-8832-ada8c83d866a">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjYtMS0xLTEtMTQzMDYx_3574f597-1e50-452e-b40b-4ff3fbb1045a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjYtMy0xLTEtMTQzMDYx_11478fb4-8ff8-475c-93fe-e3807cc2b777"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjI_3627a8a4-db6c-4bc2-820f-df46ccdbc530"><ix:nonFraction unitRef="shares" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjI_f95d1ca6-3b69-4e35-82a6-988662fd41f7">361,781,292</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjk_5eb1d84d-715d-4e3f-98e6-1992152d6cd1"><ix:nonFraction unitRef="shares" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjk_6cb04e06-02fe-47c0-8048-c26b19aa6f41">359,405,748</ix:nonFraction></ix:nonFraction> issued and outstanding at September 30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMS0xLTEtMTQzMDYx_c568eec6-8efb-4a2e-837a-5abc69ced4c3">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMy0xLTEtMTQzMDYx_78af924b-4623-427d-a508-6e8600d2e82a">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjktMS0xLTEtMTQzMDYx_208c1e03-132b-45ae-ae81-810341fc05f9">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjktMy0xLTEtMTQzMDYx_fe17c273-eb92-4534-9eb1-81b3f649f7d7">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzAtMS0xLTEtMTQzMDYx_f9bd4acb-7022-49bc-8a8b-309243a0d502">8,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzAtMy0xLTEtMTQzMDYx_903a86ef-4628-434c-bc23-883aa5f76d1a">8,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzEtMS0xLTEtMTQzMDYx_a7f3ea5b-b26c-4b8a-82c7-4a873b70ad2d">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzEtMy0xLTEtMTQzMDYx_9470794f-332c-4215-84f8-1fe00e61f062">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzItMS0xLTEtMTQzMDYx_b3e7bc49-f306-4acc-8b6d-eb7bc9c8b7b6">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzItMy0xLTEtMTQzMDYx_d73e062b-49be-432b-8fe0-c06af3531568">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzMtMS0xLTEtMTQzMDYx_882ee015-8aa4-434f-936b-3f784e455c0c">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzMtMy0xLTEtMTQzMDYx_93a852dd-091b-438c-808a-f9c1d70a5f97">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzQtMS0xLTEtMTQzMDYx_f23c1da9-7363-4060-bf83-7954619669f6">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzQtMy0xLTEtMTQzMDYx_e690ce12-328f-40f0-bcd9-2b78e256c4bf">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzUtMS0xLTEtMTQzMDYx_922e64a2-72f4-4ff0-b2cf-f9c0e9ae8fbd">26,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzUtMy0xLTEtMTQzMDYx_61d81d8a-b10e-4ca1-858f-f5a37ca3dd8a">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:60.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.849%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d79d42128d480b82421ffda65ff432_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy0xLTEtMS0xNDMwNjE_1aee8974-3563-4b80-80cd-7a6573662f89">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b121d7e567435ea3af71bf428e3992_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy0zLTEtMS0xNDMwNjE_d5925af0-d58c-4038-9173-8c488f27c2c3">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd2719ffeb04494b5ee89c5d6c0a3a0_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy01LTEtMS0xNDMwNjE_3c61b20d-602a-477d-bbb6-02e749f8ae34">5,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d19e9379e0b46ff90d34e1fad8d4f3d_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy03LTEtMS0xNDMwNjE_30908725-f513-4718-aefd-c60caaeacff2">6,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e24bce6ec5b4cebbd4550c104f4e7a0_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC0xLTEtMS0xNDMwNjE_7efac629-8075-4687-8102-2ca66cf6840c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd02a55811c46a28847d139aeb65d5d_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC0zLTEtMS0xNDMwNjE_4476da3a-8a85-4d74-bef7-ab40e7847168">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd1fe160b76486586dea1195d3717a4_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC01LTEtMS0xNDMwNjE_c1926737-0d89-4b75-ab2c-e5c2c217de97">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4616ed6436e429cb0594228303a7f15_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC03LTEtMS0xNDMwNjE_958c2742-d5a1-4ce5-a960-32ed9ee2db98">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS0xLTEtMS0xNDMwNjE_6e9da6ac-4eb2-4990-b114-8167bda65c0d">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS0zLTEtMS0xNDMwNjE_de4eeb30-4a57-41a3-8a29-0cb9f2b900ed">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS01LTEtMS0xNDMwNjE_1bcefd04-f8f1-45b8-9019-cc4308ad0cbb">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS03LTEtMS0xNDMwNjE_fa140726-da3b-42e3-adbf-667c5f9f67cc">6,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(excluding amortization and impairments of intangible assets)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d79d42128d480b82421ffda65ff432_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy0xLTEtMS0xNDMwNjE_1536519a-ad68-46da-9dff-16f1d3a4035d">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b121d7e567435ea3af71bf428e3992_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy0zLTEtMS0xNDMwNjE_64117549-1776-4d29-ba1c-ba5e288fb716">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd2719ffeb04494b5ee89c5d6c0a3a0_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy01LTEtMS0xNDMwNjE_fc17d89f-7a8b-40dc-8119-1e4f75d08f0a">1,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d19e9379e0b46ff90d34e1fad8d4f3d_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy03LTEtMS0xNDMwNjE_41a4fa05-f98b-49ed-965a-566572c97ba0">1,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e24bce6ec5b4cebbd4550c104f4e7a0_D20220701-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC0xLTEtMS0xNDMwNjE_7a8e196c-4b68-48e6-a2dd-ebd420af1abd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd02a55811c46a28847d139aeb65d5d_D20210701-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC0zLTEtMS0xNDMwNjE_418ab3db-70b2-4cf7-b127-0c8668637d02">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd1fe160b76486586dea1195d3717a4_D20220101-20220930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC01LTEtMS0xNDMwNjE_6f9c3b0d-7896-421a-b034-692f0a4d6a77">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4616ed6436e429cb0594228303a7f15_D20210101-20210930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC03LTEtMS0xNDMwNjE_e20404d1-2caa-4268-b9aa-3c763fbb687d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS0xLTEtMS0xNDMwNjE_b9ef45ff-1de6-48b1-a69d-797565a548df">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS0zLTEtMS0xNDMwNjE_3cca0754-dce6-420b-9fae-4ad30cb11016">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS01LTEtMS0xNDMwNjE_9d378969-b461-4133-abcf-6190b9e2326b">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS03LTEtMS0xNDMwNjE_338edf76-c4b1-4739-aeb6-6b23e706fce3">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtMS0xLTEtMTQzMDYx_e2469cb8-6509-4d61-a273-d49312d37ebd">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtMy0xLTEtMTQzMDYx_9d11b81d-ecde-4016-a58d-625e2113993a">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtNS0xLTEtMTQzMDYx_e9bcf1d6-f927-44fb-a0d1-b1266d4e6692">387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtNy0xLTEtMTQzMDYx_d3b754cb-c4ce-4b07-b6b7-f5d9218c9e71">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtMS0xLTEtMTQzMDYx_a4e81901-d4f7-43fe-8855-fe80cd5a6cd3">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtMy0xLTEtMTQzMDYx_e58b8188-f517-42e1-a3f3-d0cdbdd76200">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtNS0xLTEtMTQzMDYx_6a56e1fc-53ab-4410-ad7d-efd1b4a05126">902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtNy0xLTEtMTQzMDYx_051943e3-4b3c-4fcb-985d-48494e2e32b3">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItMS0xLTEtMTQzMDYx_7db686ff-4b03-4222-992d-17188ae55e15">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItMy0xLTEtMTQzMDYx_47f7f12e-6128-4015-aa82-135db32db2f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItNS0xLTEtMTQzMDYx_54aeb270-6113-4d1f-885d-f39eaefef274">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItNy0xLTEtMTQzMDYx_d5fbaf97-0fab-4c15-9586-ca64cd2d6a3e">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtMS0xLTEtMTQzMDYx_b011880c-3157-48e7-8fa6-de3abf3015b7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtMy0xLTEtMTQzMDYx_3fb1f731-20ad-49af-9088-deadde64682d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtNS0xLTEtMTQzMDYx_53576144-f858-4587-9f84-f2380bee12a1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtNy0xLTEtMTQzMDYx_dabca78c-e0a5-44d4-937d-7dc57ad0ae3f">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtMS0xLTEtMTQzMDYx_aa92231d-8bcb-438f-bb18-8151dae512f9">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtMy0xLTEtMTQzMDYx_97f4518d-eb65-4e92-ac45-c858a0c77863">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtNS0xLTEtMTQzMDYx_b480e1e6-ee4f-45ed-ac10-afb2a2dd456d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtNy0xLTEtMTQzMDYx_ed6bf435-0d91-4950-8491-abae387f70ca">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtMS0xLTEtMTQzMDYx_5d3fc0cc-1b15-4371-a0e7-6412775e612a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtMy0xLTEtMTQzMDYx_7d79482a-931a-4f7a-92a6-3936ee7013d9">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtNS0xLTEtMTQzMDYx_a795633f-4438-43ee-8633-f6f59003b1f8">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtNy0xLTEtMTQzMDYx_fb0527c4-9828-4f0c-8863-41dfe00be639">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtMS0xLTEtMTQzMDYx_4cbd206e-f299-47f5-ae8a-b5e0ea54b81c">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtMy0xLTEtMTQzMDYx_22bd2834-7f3f-41a1-afc8-957069501ae1">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtNS0xLTEtMTQzMDYx_0806ca5d-2a9e-45b8-b9fb-ff0d98ad9d22">5,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtNy0xLTEtMTQzMDYx_5d8ae629-32e6-43a0-9428-67818c3d2f43">6,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctMS0xLTEtMTQzMDYx_c652b240-cc1a-4b61-a96e-840d734ded81">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctMy0xLTEtMTQzMDYx_a1a52138-2aba-46ff-8fca-73407124bbb9">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctNS0xLTEtMTQzMDYx_98a24026-805b-44c4-a737-2032a1c63bdb">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctNy0xLTEtMTQzMDYx_87e4dff5-99af-44bd-bcf8-c555cd3568ed">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtMS0xLTEtMTQzMDYx_7c14e528-82b9-46e1-b3b5-7aab7204e525">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtMy0xLTEtMTQzMDYx_9b7d5462-7a78-4d76-a86e-d5759a169c65">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtNS0xLTEtMTQzMDYx_44cc43e1-8168-4541-a481-325e2a9f11e5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtNy0xLTEtMTQzMDYx_cc514f33-6dbb-464c-b580-63e954da75ea">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktMS0xLTEtMTQzMDYx_a35b9a37-6267-4df5-8f21-713b2177c80f">385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktMy0xLTEtMTQzMDYx_962c0837-44e3-4cfd-904a-4f9022aa52e8">351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktNS0xLTEtMTQzMDYx_ee234b8d-a1cc-4515-a52e-82e98ae17008">1,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktNy0xLTEtMTQzMDYx_34356990-91a7-4875-abca-6a04c1eebb7a">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtMS0xLTEtMTQzMDYx_3322aa28-d4c9-4bcb-af54-3bee85bfd2ca">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtMy0xLTEtMTQzMDYx_6014ee8d-f338-4ee4-95af-34c69ec798c5">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtNS0xLTEtMTQzMDYx_284af2fc-2603-45de-adb1-02b34e306e5d">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtNy0xLTEtMTQzMDYx_e50eccaa-e46f-4aa7-af27-44408860dcbc">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtMS0xLTEtMTQzMDYx_6a6b205b-83b6-42c1-a4a3-5b2cddddadaa">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtMy0xLTEtMTQzMDYx_1d6ecf2c-c8c5-40fb-a623-bb82fd2c9220">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtNS0xLTEtMTQzMDYx_9353523f-6392-4108-9877-78a45fc38961">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtNy0xLTEtMTQzMDYx_f8fb37c1-0e8d-4be5-b7bf-9496af5ecfda">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItMS0xLTEtMTQzMDYx_eb23c674-7e2b-458e-a5a3-80776bb33bef">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItMy0xLTEtMTQzMDYx_4070fa03-b91c-47ee-a6ea-a211dbfcc870">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItNS0xLTEtMTQzMDYx_8b44bea0-a89c-4141-ab5b-d4f3c1b338dc">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItNy0xLTEtMTQzMDYx_42302d2f-c5c3-4f3b-9b90-d01747d0fe97">1,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtMS0xLTEtMTQzMDYx_f273fad4-7593-40ae-b596-fb7d0dc3eec1">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtMy0xLTEtMTQzMDYx_785d6de3-3337-4383-a679-f52a7ebd8764">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtNS0xLTEtMTQzMDYx_de081cd2-35b4-4ddd-aced-95b33cbe6ccd">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtNy0xLTEtMTQzMDYx_97135b66-87c4-4caa-b357-9fb6f4044fcc">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtMS0xLTEtMTQzMDYx_4d2b06f8-42a8-407c-a967-dd70af5c476f">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtMy0xLTEtMTQzMDYx_0ff7f9ef-a241-40b4-90e6-66025087f17d">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtNS0xLTEtMTQzMDYx_e2970937-48a1-4e1d-92bb-e06659edcb65">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtNy0xLTEtMTQzMDYx_578a9dcb-97ce-468e-ba3d-bc5e44ba6fe5">1,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtMS0xLTEtMTQzMDYx_f61a9283-556c-4ede-b958-325c6cc19d5d">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtMy0xLTEtMTQzMDYx_4bcbd5d6-a3bb-48d4-9413-479d8d2a6574">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtNS0xLTEtMTQzMDYx_415ffba8-2917-4806-8ebe-193c824cfb27">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtNy0xLTEtMTQzMDYx_13aaf1b0-e2c2-47b2-abd9-80a31cc80e24">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtMS0xLTEtMTQzMDYx_1d6e841e-c79a-4e1b-8424-c0317b41e58b">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtMy0xLTEtMTQzMDYx_df65d569-281c-4a1c-b67c-121dac226f6b">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtNS0xLTEtMTQzMDYx_18754181-cc86-472f-8695-dd41c3859721">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtNy0xLTEtMTQzMDYx_7d9b6870-a1a7-47f6-b1b5-274b5f275f51">1,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMS0xLTEtMTQ3MjM0_2e7a496a-b7e8-44f6-b921-0ac06951c873">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMy0xLTEtMTQ3MjQ0_49fa1996-5163-4e1f-a08d-28eaf5bff4cf">0.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNS0xLTEtMTQ3MjQ5_2cc35c29-fdbb-4e6b-8eb2-8cfb7a303d35">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNy0xLTEtMTQ3MjQ5_d1a311c7-6533-43bb-b815-0dae4967d478">2.84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMS0xLTEtMTQzMDYx_5b9e8b4e-21ea-4cb7-a193-bb336639113f">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMy0xLTEtMTQzMDYx_317947e2-949c-48ec-b172-61c8df62bfd6">0.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNS0xLTEtMTQzMDYx_59078555-809d-4d4f-8170-2fdbf9894b40">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNy0xLTEtMTQzMDYx_198d8b0c-4bd6-47df-aba8-ee3772aed201">2.84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtMS0xLTEtMTQ3MjI1_1544ce08-714a-4087-976e-a6e552df2516">362.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtMy0xLTEtMTQ3MjAw_74ee50c5-84a6-4050-8765-bd7facb33012">359.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtNS0xLTEtMTQ3MjEx_b29561b1-2230-4dcb-bd60-553a1b105aaa">361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtNy0xLTEtMTQ3MjAz_662a735e-800d-4f56-9524-02f290a13eec">358.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtMS0xLTEtMTQzMDYx_c1874835-bc0b-47b3-9bee-6201f79daf72">363.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtMy0xLTEtMTQzMDYx_b2f9aff0-fae2-4f87-af1f-883d65fda68a">364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtNS0xLTEtMTQzMDYx_9f556423-26c1-49bf-8057-e0bfe63b4a01">363.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtNy0xLTEtMTQzMDYx_5470d419-cf15-4f07-ad2f-de02d39a3f72">358.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi0xLTEtMS0xNDMwNjE_e43481fb-7748-4ece-b66f-7b5b3ca749ed">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi0zLTEtMS0xNDMwNjE_074d1996-99c4-4398-a2ff-f21fcb2ffbf6">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi01LTEtMS0xNDMwNjE_35422856-d03a-42c8-8780-63bcd6022eaa">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi03LTEtMS0xNDMwNjE_296421d9-7ac3-459f-90dc-2334f5a922ee">1,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC0xLTEtMS0xNDMwNjE_dabb653a-0267-420c-af15-f5342364bf41">243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC0zLTEtMS0xNDMwNjE_8c897e43-15a3-4986-aecf-1cf04d290ed4">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC01LTEtMS0xNDMwNjE_460684af-d3f1-4905-b972-f2c409ac1223">465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC03LTEtMS0xNDMwNjE_9035d1fe-1ea4-4b96-866b-92284fcd890f">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS0xLTEtMS0xNDMwNjE_4e0d86ac-1073-4e1a-af3b-1941ad1cea79">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS0zLTEtMS0xNDMwNjE_8a54412c-6196-4e65-8d1c-cc7cd1b8a81a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS01LTEtMS0xNDMwNjE_e64e4314-12f5-497e-a229-779b256c4199">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS03LTEtMS0xNDMwNjE_69be4ea4-1693-484e-a691-6f08c8e0c398">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi0xLTEtMS0xNDMwNjE_410daa47-e3a6-4ab9-9166-663b87c5b11c">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi0zLTEtMS0xNDMwNjE_f8024abe-9e0e-4306-ab77-c6998ddecb81">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi01LTEtMS0xNDMwNjE_63e12231-c79a-4a72-81dc-a43c809ae62f">459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi03LTEtMS0xNDMwNjE_4ff32b5e-083d-4a93-bbf0-801f7dd35a5f">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy0xLTEtMS0xNDMwNjE_bf6d90af-fb22-4828-8f19-b2070fff0c3a">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy0zLTEtMS0xNDMwNjE_342afb5e-8308-4663-9767-2851410ed14d">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy01LTEtMS0xNDMwNjE_02cec7fb-ae2c-498a-bb73-81cddee3a9b9">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy03LTEtMS0xNDMwNjE_cdca795a-ffe4-44b9-a2ed-35cfcd1f0a54">1,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC0xLTEtMS0xNDMwNjE_1587875c-f8ba-4449-bcbf-95acaef5b170">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC0zLTEtMS0xNDMwNjE_fcfe6516-7287-47bc-bfa9-4afdd46209cb">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC01LTEtMS0xNDMwNjE_82a5e59f-24a3-4026-9fed-8d6f9e00ebaf">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC03LTEtMS0xNDMwNjE_00149f90-530b-422f-859e-9aa7707538c8">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS0xLTEtMS0xNDMwNjE_afd2ee5e-b13f-4824-bbfe-e3fe6b93323f">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS0zLTEtMS0xNDMwNjE_a6edecca-5f8f-4702-8c9f-dfdb87535136">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS01LTEtMS0xNDMwNjE_3ed9638e-168d-4252-a09e-8ceff05302a9">293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS03LTEtMS0xNDMwNjE_729b5df6-7b4e-4892-8a7d-070a91b02b1f">1,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders&#8217;<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Equity<br/>(Deficit)</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, July 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i491b8b5f831e4808948911e15a6b2a0f_I20220630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0yLTEtMS0xNDMwNjE_9a2afb54-d475-4db1-9ca3-38da59bce168">361.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491b8b5f831e4808948911e15a6b2a0f_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC00LTEtMS0xNDMwNjE_5c7adc67-85bb-4c43-9cf5-6f9e94648cff">10,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07559fd94f9e408894b9f0c6aada463c_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC02LTEtMS0xNDMwNjE_8c5b032d-17aa-4796-9ad8-8a87b83e1eab">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76eac81be66b465e8aba6b3b5a572b56_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC04LTEtMS0xNDMwNjE_7c57a50b-b96c-47f0-bcb6-0421ed6abae6">9,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4460f5d13fa347f896eef94a4a28cf12_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xMC0xLTEtMTQzMDYx_8b0aad78-ce23-4781-bfbc-0125ab03a4d6">2,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40be409bfc0e4dc099944810f89c820c_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xMi0xLTEtMTQzMDYx_1f954f08-f2b7-4d6f-9fac-7ec7d9a15b23">693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id510a93f2b0d4cf69f18a984bca524b0_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xNC0xLTEtMTQzMDYx_98f7c6f7-2487-4a9e-8ea1-30430cb108ac">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2e9f46db04fda99ec75cd3415d325_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xNi0xLTEtMTQzMDYx_38655b02-da22-4d57-a4d0-2c999a22235d">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d1740e6c15b4fbc806318e1936a2721_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi0yLTEtMS0xNDMwNjE_8224913c-72e7-44d1-b5f3-03d4051a1d73">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1740e6c15b4fbc806318e1936a2721_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi00LTEtMS0xNDMwNjE_cae7686d-246a-49ed-83c9-80161c607469">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi02LTEtMS0xNDMwNjE_290be743-52d4-461d-840c-ffabed7c443c">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi0xMi0xLTEtMTQzMDYx_a358e277-f212-4a92-a1e0-74caec37f368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi0xNi0xLTEtMTQzMDYx_12ca1712-80ad-49e0-965e-0f4e44d18edc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNy02LTEtMS0xNDMwNjE_bf02f1ca-60aa-4fa2-a1d9-269a825c2111">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNy0xMi0xLTEtMTQzMDYx_4091374f-88cd-4eae-8df9-a1a43a40575d">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNy0xNi0xLTEtMTQzMDYx_404d1e3f-c73c-4463-b0d1-19d044ed4914">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfOC02LTEtMS0xNDMwNjE_90bbe1df-5b74-4dcb-ad3a-0c85b1d43fd2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfOC0xMi0xLTEtMTQzMDYx_73504058-7050-433f-a316-cb0e13795c9f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfOC0xNi0xLTEtMTQzMDYx_7ec69e2d-8700-43e5-9e3f-984da28cc5c4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf017ab13df548e2924759ee558786bd_D20220701-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTAtMTQtMS0xLTE0MzA2MQ_637b4aa5-6e4f-4cfd-b0f8-f905837487c6">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTAtMTYtMS0xLTE0MzA2MQ_4e5b3256-9a50-4b53-b2b6-8f0730af3805">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39bc9daea7904ebe939e366457a5979b_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItOC0xLTEtMTQzMDYx_3f0b24a6-43ab-43f3-8731-7dba0af2555b">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItMTItMS0xLTE0MzA2MQ_8b1a6258-f57c-4988-a4e6-48e2dc1a9dbb">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf017ab13df548e2924759ee558786bd_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItMTQtMS0xLTE0MzA2MQ_b4b7f407-3685-4c0b-9750-270b912b1c56">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItMTYtMS0xLTE0MzA2MQ_76d90ec0-fef6-4bca-b8a8-4a9cdbd210b7">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive (loss) income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd550841fc7c45b8af6c60f3fa0f8a34_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTAtMS0xLTE0MzA2MQ_a3398503-9d11-4536-85c6-4d124cddc4cf">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTItMS0xLTE0MzA2MQ_d7f12ca8-3b9d-4294-93cf-88aa79081bed">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf017ab13df548e2924759ee558786bd_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTQtMS0xLTE2MzAzNA_732e3a64-c03f-4b95-9b4b-61ed5a8edb06">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTYtMS0xLTE0MzA2MQ_e27a171b-336d-4bcc-81e8-5f208480f728">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMi0xLTEtMTQzMDYx_4f6e082d-e221-47dd-8516-f08e8d7774e5">361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtNC0xLTEtMTQzMDYx_716afc85-3bb4-4144-8bf4-84e297d42215">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59016e9a1d5d48dea6c8c26d31dd6af0_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtNi0xLTEtMTQzMDYx_32140b04-a03f-4d0f-b88a-4d518ceddbcf">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8095b42f3c3d46cfb8bfdef54101a414_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtOC0xLTEtMTQzMDYx_aa0f9748-4028-4fa4-81ea-c2ce194bee3b">8,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie97645899e0b4e1d91b3cd525dccb36d_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTAtMS0xLTE0MzA2MQ_3b598cec-1468-43ae-82b8-c6476d4dda4c">2,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c1da51dbab44e64942a8f1d0b64b893_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTItMS0xLTE0MzA2MQ_060567d9-e6e8-4268-8cc3-606a65ebbb8e">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9cc0087df7423bace5af792d04a89b_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTQtMS0xLTE0MzA2MQ_10ad975d-1e67-4b33-968b-7c1d18d5bbd5">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTYtMS0xLTE0MzA2MQ_3bf6dd6c-ae45-4786-9903-90934ff2afdd">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, July 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70d26e27e7eb4667bc1c7dfa8dc72756_I20210630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMi0xLTEtMTQzMDYx_3f8b7ef5-5c87-477b-8158-1638ae7fff7f">358.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d26e27e7eb4667bc1c7dfa8dc72756_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctNC0xLTEtMTQzMDYx_15c9d711-dd58-4669-97bd-ec1b569e1ba1">10,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36852dd15708409995b804b93901ddf2_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctNi0xLTEtMTQzMDYx_4fe119d7-2e88-4b6d-a14d-5f32a49cb15c">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59c4371c6a064973ac5404a53c264be7_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctOC0xLTEtMTQzMDYx_7c9b8877-150b-4044-bd65-266531106a23">9,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a588955016a4859baf6ff4894efc919_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTAtMS0xLTE0MzA2MQ_049866e3-147b-4158-b03b-729d595fcbf0">2,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cffb35711eb46d0a03ca5bfcf9b95b1_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTItMS0xLTE0MzA2MQ_bc47e962-87d1-4fec-b6b9-31c2557dca9a">687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e25b288b94b4d6bba1d74ff8d01f12f_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTQtMS0xLTE0MzA2MQ_4ac0a7bc-da5b-4311-93a2-1b5a91f5f0ab">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaab855eaea194ef4a3d9af3afceb50c7_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTYtMS0xLTE0MzA2MQ_3a17cbd4-7bea-4f91-aaff-cdf1f9b4737e">611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb174302e02b47c68127faa1d72aa6f2_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtMi0xLTEtMTQzMDYx_a0b14037-9e8c-4d59-a91b-882c29a35ec5">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb174302e02b47c68127faa1d72aa6f2_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtNC0xLTEtMTQzMDYx_92d71fff-c5dc-4d0f-bf98-5db6bf8d622a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtNi0xLTEtMTQzMDYx_8eef0632-a182-4ea0-aec7-c6cc646a2e83">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtMTItMS0xLTE0MzA2MQ_f68af68b-d843-440d-b28c-ed08a9ed8113">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtMTYtMS0xLTE0MzA2MQ_1d1d59bb-1764-4aa2-8abd-3fa17c780fa2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTktNi0xLTEtMTQzMDYx_0d5ed254-610e-4264-980e-59c336dcea2c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTktMTItMS0xLTE0MzA2MQ_29eee240-32de-4f41-9a51-293846407271">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTktMTYtMS0xLTE0MzA2MQ_c361b85d-0230-466c-b7de-84fa483c4fa8">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjAtNi0xLTEtMTQzMDYx_3a4dbbba-03c6-46d5-a74b-9ee1521a6cae">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjAtMTItMS0xLTE0MzA2MQ_830bdd7b-5912-4aa3-8b0e-911eec6dea3e">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjAtMTYtMS0xLTE0MzA2MQ_80611a6a-2b99-454a-b424-b2769a910819">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Release of foreign currency translation losses upon disposal of assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ab05c36a284bfd9324f1075433acc0_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTAtMS0xLTE0NzM5Nw_6e37cba2-3d3d-45d8-a69c-837b1eedff66">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTItMS0xLTE0NzM5Nw_fd4e0dda-6cbb-4e12-976a-dca0bbc413b0">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTYtMS0xLTE0NzM5Nw_1834fa5f-c622-4a6d-85c3-094537822054">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a385d9c0e3419ca8a25109e4234007_D20210701-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTQtMS0xLTE0MzA2MQ_1359a1c8-5653-4f82-98f3-78f8ceedfd86">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTYtMS0xLTE0MzA2MQ_de7fed96-aab0-4eaa-819c-5f5f3f23f1cd">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3313fdc6f1694bb296ecbac5328fdb95_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItOC0xLTEtMTQzMDYx_e759e1ed-cde2-4818-b965-aada2854f717">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItMTItMS0xLTE0MzA2MQ_c56fe246-45e3-4dd6-bd4f-523147a67ad7">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a385d9c0e3419ca8a25109e4234007_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItMTQtMS0xLTE0MzA2MQ_8ed51dc4-6bf7-4469-894a-5cad7483b774">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItMTYtMS0xLTE0MzA2MQ_7b5ae678-8622-448c-b4ba-daa3fe84fd08">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52ab05c36a284bfd9324f1075433acc0_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjMtMTAtMS0xLTE0MzA2MQ_9ec5f866-d184-41a2-8866-7792665d5a86">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjMtMTItMS0xLTE0MzA2MQ_50f14369-8d4c-4375-b1fd-407b7f8a67d7">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjMtMTYtMS0xLTE0MzA2MQ_bfc7aa78-da33-41e1-aba2-92d4339888c8">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMi0xLTEtMTQzMDYx_c84c4e95-b723-4238-b408-56c143552494">359.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtNC0xLTEtMTQzMDYx_505dca01-bf9c-4fd3-8613-8524e46ab444">10,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43076b85ac44e909d1c513b58c40e62_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtNi0xLTEtMTQzMDYx_8ce8685c-71e6-4144-993c-519eb38498af">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id97b7fc5f8df45e9bcc906e84ddf8c0d_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtOC0xLTEtMTQzMDYx_84171c59-07b7-43c2-9379-2ca30eaabef7">9,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaf80fdae174541957b5feb3aae627a_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTAtMS0xLTE0MzA2MQ_967c439e-b9b6-44f1-9a1f-2db58d197e5e">1,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifda2519ceb7a4fc5ad1fcf6edc583672_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTItMS0xLTE0MzA2MQ_ff9943f1-d6d4-45a9-92fb-7c8f3ad8733e">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d8ec7d74b44b3a63979eaf5bdd09b_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTQtMS0xLTE0MzA2MQ_14ef84bf-10e5-419b-9201-fb0af3538a19">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTYtMS0xLTE0MzA2MQ_17b19557-67af-4f73-8f2d-9d11437cacdf">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i988f46577a7a4454b3957c277d8b04fe_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMi0xLTEtMTQzMDYx_4901836f-edf9-48be-b2e8-587d339c5f9c">359.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i988f46577a7a4454b3957c277d8b04fe_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctNC0xLTEtMTQzMDYx_c17d492c-569b-482f-ab0c-83618609c050">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3ddf01146436a8b3c8b5d3de2420d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctNi0xLTEtMTQzMDYx_63084b6f-cf5f-4831-95ff-4509102efbdf">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52176978c3e649dea74aeb5b1def24dc_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctOC0xLTEtMTQzMDYx_c3332639-d126-411d-8e70-f78f83ecfc6f">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6be7f41bbca44db88e2eea447f357ac_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTAtMS0xLTE0MzA2MQ_684e3be5-3e93-46f2-9117-b4bc72ac0e3f">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95f46d75206b485682e1e2267be9e2df_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTItMS0xLTE0MzA2MQ_e78aa44a-4ecb-45cd-b7fa-b5939bdb28ae">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i025bf4b7665f402cbde028bef48f281f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTQtMS0xLTE0MzA2MQ_006995fe-084c-4a30-b27e-d1d54c1ac6d1">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTYtMS0xLTE0MzA2MQ_5e5c7954-b2aa-474a-a8ca-ea1188365b37">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from B+L initial public offering, net of costs (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtNi0xLTEtMTQzMDYx_6b761b49-d100-4beb-aa5a-9feaf6a79503">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb866bb408947579450eca5b5dfd24a_D20220101-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTAtMS0xLTE0MzA2MQ_b9d75b8b-a7c4-46c4-b9c5-95cccef1c70e">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTItMS0xLTE0MzA2MQ_4104d726-64f3-4a8f-a4fa-1981d97f6567">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTQtMS0xLTE0MzA2MQ_f6322f8e-bf4e-4799-bc53-30e22911ceba">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTYtMS0xLTE0MzA2MQ_09ee6806-81ce-4474-891f-846f9f69d017">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdf4f32143d24f1fa87f639690b700e3_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktMi0xLTEtMTQzMDYx_ffda2870-9aba-4578-ba07-ab4342773ad2">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf4f32143d24f1fa87f639690b700e3_D20220101-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktNC0xLTEtMTQzMDYx_e37a804c-fca2-4b9a-aad7-49b5e095bc4a">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktNi0xLTEtMTQzMDYx_92955f80-d6e6-47a2-9133-384546a1caa7">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktMTItMS0xLTE0MzA2MQ_f28d44c9-e252-491c-8bc1-e549970b5ffd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktMTYtMS0xLTE0MzA2MQ_caef58a8-f991-4190-9599-eab3ec678bd4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzAtNi0xLTEtMTQzMDYx_a301f257-2c6a-4f0d-a3ea-c76659aab023">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzAtMTItMS0xLTE0MzA2MQ_d1f85021-92bb-4b0c-bb46-e523aaf70b17">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzAtMTYtMS0xLTE0MzA2MQ_26f45bf9-393b-4db2-9731-2c556faf9d17">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzEtNi0xLTEtMTQzMDYx_8ec0fcbe-4958-426c-9d59-7ff83385f0f4">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzEtMTItMS0xLTE0MzA2MQ_4ab72182-77e2-4906-b1e6-2a90878fae0d">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzEtMTYtMS0xLTE0MzA2MQ_59d9a25e-86ec-4226-bac6-dc1a7b384b7f">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzItMTQtMS0xLTE0MzA2MQ_7a6d793c-c226-4c92-8d70-622afd71f525">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzItMTYtMS0xLTE0MzA2MQ_c040b27a-df2d-4312-8546-8b41b5d68719">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a46937aff434e73aae5f0ed8b35218f_D20220101-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtOC0xLTEtMTQzMDYx_c2b28d4f-3c1b-4f46-a64b-c4b47e6f3e50">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtMTItMS0xLTE0MzA2MQ_95cfefa7-41e3-426d-b4f6-9278e53a719f">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtMTQtMS0xLTE0MzA2MQ_fca9b3ab-032b-4dff-bdfd-fe177a36495e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtMTYtMS0xLTE0MzA2MQ_8477a188-0530-4ac0-b658-4858cdeda680">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceb866bb408947579450eca5b5dfd24a_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzQtMTAtMS0xLTE0MzA2MQ_e620daa2-b9bb-4459-b472-e37753cb9abd">478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzQtMTItMS0xLTE0MzA2MQ_b752d9f4-0feb-415f-adb1-1e9718497a5f">478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTQtMS0xLTE2MzA0Mg_189f3298-7cd7-4d6f-bca1-fec167536c3b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzQtMTYtMS0xLTE0MzA2MQ_606d738d-9c80-4479-b1b9-7f315829b051">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMi0xLTEtMTQzMDYx_43a297d9-d3f6-447d-8d7d-b8408fc7a477">361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtNC0xLTEtMTQzMDYx_e2806944-490e-4ad6-beee-c427944ad304">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59016e9a1d5d48dea6c8c26d31dd6af0_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtNi0xLTEtMTQzMDYx_8167a52e-8b7c-416c-983f-34ae539c130b">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8095b42f3c3d46cfb8bfdef54101a414_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtOC0xLTEtMTQzMDYx_4c62c150-9aac-438c-b388-baa573d636a9">8,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie97645899e0b4e1d91b3cd525dccb36d_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTAtMS0xLTE0MzA2MQ_48a2f797-4164-4c52-b608-ec193efe6bfd">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c1da51dbab44e64942a8f1d0b64b893_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTItMS0xLTE0MzA2MQ_33867f58-53b8-4b25-8d58-aa3329510382">525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9cc0087df7423bace5af792d04a89b_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTQtMS0xLTE0MzA2MQ_d7b60386-2e0d-4033-bc89-ee6a9940aeb8">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTYtMS0xLTE0MzA2MQ_24faa1ae-714f-4060-96e8-52f04982dba3">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5d21251ba2e4156877ad94aed58ea65_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMi0xLTEtMTQzMDYx_4427d7bb-a242-4fd5-9555-95cc8ef94507">355.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d21251ba2e4156877ad94aed58ea65_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtNC0xLTEtMTQzMDYx_7a92ae32-3c3f-4985-b24e-9582302b403a">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e021ab77684430873b508aa3f19f9a_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtNi0xLTEtMTQzMDYx_33aae100-ddc3-478a-afeb-40a51b79532e">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6b28c3de4db4949bc89001e98278b7b_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtOC0xLTEtMTQzMDYx_30a0f9bf-0a06-404f-a80b-110d10e6e362">8,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d5398ad231d43158c6f75706adfe6f2_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTAtMS0xLTE0MzA2MQ_2a70fe01-bb8e-48d3-9f01-c6fdd27a3341">2,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe2379453e44861a0ed685834555c93_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTItMS0xLTE0MzA2MQ_c1f9d5d1-fc94-48e3-9b57-96e631014217">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8fc54ee0cd4b3e9e5451b181dc7a62_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTQtMS0xLTE0MzA2MQ_986c289d-f189-490a-a01c-6ee67635aa58">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTYtMS0xLTE0MzA2MQ_4a27fa72-eab6-4c8c-b385-c125d906bada">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9acba15c5791474e88c007d6018e0579_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktMi0xLTEtMTQzMDYx_ae4f761d-296b-45f1-a689-2f08b692fe5b">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9acba15c5791474e88c007d6018e0579_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktNC0xLTEtMTQzMDYx_d203006f-29e7-4277-8281-51697feb6fb7">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktNi0xLTEtMTQzMDYx_c03753a3-9d7c-4e4f-998b-7cfc2b9b5147">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktMTItMS0xLTE0MzA2MQ_be0ff916-852d-4088-89a7-28dcdb3fc173">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktMTYtMS0xLTE0MzA2MQ_2144a246-0624-4ac3-98e4-b8095f31a587">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDAtNi0xLTEtMTQzMDYx_eada50df-8b17-4fb6-b085-b0280c84598e">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDAtMTItMS0xLTE0MzA2MQ_f4d1af59-1349-46b2-a00c-0cbd4fa0933b">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDAtMTYtMS0xLTE0MzA2MQ_9765c0d9-5896-4bb8-b724-f2718fd3d2ec">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDEtNi0xLTEtMTQzMDYx_4f9bfd86-392e-4b3c-bb56-78ef963c4097">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDEtMTItMS0xLTE0MzA2MQ_f0713fe5-5e05-4ba5-a99f-d37648e7a8a1">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDEtMTYtMS0xLTE0MzA2MQ_1d53ac12-9b16-4292-a482-552cc889e631">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Release of foreign currency translation losses upon disposal of assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488484ed6b0d4a8eb2d7c63599be0468_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTAtMS0xLTE0NzM5NQ_db1290b6-d5ab-4d6b-925e-4646926cb7ab">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTItMS0xLTE0NzM5NQ_d29d3ab2-c889-45c5-8fd8-93a85d75393d">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTYtMS0xLTE0NzM5NQ_883a04d7-797b-4d60-a5a8-8ca2021ee12f">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTQtMS0xLTE0NzM5Mw_6de4885e-1a3d-473f-a743-92704b93561c">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTYtMS0xLTE0NzM5MQ_2b86592a-233e-4640-bab6-01c314c9a6c9">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i645aadc8462e4f0bb9c3992e508abc6d_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItOC0xLTEtMTQzMDYx_13ed6761-22a8-4143-aeb6-eefc8165f384"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItOC0xLTEtMTQzMDYx_39a1679d-3c77-49ad-ac3f-c71053ccd212">1,017</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItMTItMS0xLTE0MzA2MQ_45bf546f-bdc0-47ad-ab90-2237fd7352da">1,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItMTQtMS0xLTE0MzA2MQ_2ebcacbe-cb6a-440e-9e94-bf4ed3402776">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItMTYtMS0xLTE0MzA2MQ_e3fdf8ec-bac1-4ad8-8bbf-39003eea0185">1,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i488484ed6b0d4a8eb2d7c63599be0468_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTAtMS0xLTE0MzA2MQ_229445af-57af-4f0e-8a99-1a51c9bf75c1">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTItMS0xLTE0MzA2MQ_faa8782a-7f60-4c71-ab7b-0ff8ffb15745">130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTQtMS0xLTE0MzA2MQ_1acc90ac-ddc5-405e-b110-445168d38ca9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTYtMS0xLTE0MzA2MQ_32898338-cc2a-4f34-bb9b-5e42d89b5230">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMi0xLTEtMTQzMDYx_b421657d-2f20-45f8-8b38-5ba5c8f263d8">359.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtNC0xLTEtMTQzMDYx_5e0e7243-cc2d-4cbd-993e-3392ad6ea979">10,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43076b85ac44e909d1c513b58c40e62_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtNi0xLTEtMTQzMDYx_35c15fa8-b6a7-4d7c-8e1b-0433fec2af3a">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id97b7fc5f8df45e9bcc906e84ddf8c0d_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtOC0xLTEtMTQzMDYx_acfb74a1-8319-4699-89f4-2ea52adb3ebc">9,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfaf80fdae174541957b5feb3aae627a_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTAtMS0xLTE0MzA2MQ_7fdde931-a006-4c36-9f72-7edf4e2bed1e">1,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifda2519ceb7a4fc5ad1fcf6edc583672_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTItMS0xLTE0MzA2MQ_5b947cba-d768-4699-8343-ed6d2843c939">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d8ec7d74b44b3a63979eaf5bdd09b_I20210930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTQtMS0xLTE0MzA2MQ_5ddfd9fc-6bca-4062-b603-5f62d9301b7a">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTYtMS0xLTE0MzA2MQ_9809072c-4530-4fa8-8b4e-3ef96a6485cd">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 22.50pt 54.00pt"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:81.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMy0xLTEtMS0xNDMwNjE_35422856-d03a-42c8-8780-63bcd6022eaa">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMy0zLTEtMS0xNDMwNjE_296421d9-7ac3-459f-90dc-2334f5a922ee">1,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNS0xLTEtMS0xNDMwNjE_48604e6a-6800-4a1a-ad7a-d0ae343f82e9">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNS0zLTEtMS0xNDMwNjE_e47bc27f-74b0-4135-b0bd-168424653167">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and write-off of debt premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNi0xLTEtMS0xNDMwNjE_0c94560b-ed25-4e31-bb9d-4d5ca6e09ec5">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNi0zLTEtMS0xNDMwNjE_2b19ec32-d11f-4264-bd9f-9f570cacfbd2">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNy0xLTEtMS0xNDMwNjE_53576144-f858-4587-9f84-f2380bee12a1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNy0zLTEtMS0xNDMwNjE_dabca78c-e0a5-44d4-937d-7dc57ad0ae3f">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOC0xLTEtMS0xNDMwNjE_54aeb270-6113-4d1f-885d-f39eaefef274">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOC0zLTEtMS0xNDMwNjE_d5fbaf97-0fab-4c15-9586-ca64cd2d6a3e">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOS0xLTEtMS0xNDMwNjE_82ea33f3-2d09-4af5-8789-299fcb02fd99">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOS0zLTEtMS0xNDMwNjE_ccc3f4e1-0c62-40a4-9934-3004bd6a7ac8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowances for losses on trade receivable and inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTAtMS0xLTEtMTQzMDYx_41d9df97-51a1-41a8-9297-4840fa70c086">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTAtMy0xLTEtMTQzMDYx_a6335d9f-8a49-4f11-8a5a-dfc52c3cc909">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTEtMS0xLTEtMTQzMDYx_1d18680d-762e-44f7-a9d8-b034da03a788">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTEtMy0xLTEtMTQzMDYx_ef44d94c-14b1-4443-9ef1-28eaa1cb1db9">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTItMS0xLTEtMTQzMDYx_8ccc7d29-4558-4ac4-bb82-c9ff541360d0">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTItMy0xLTEtMTQzMDYx_c0408b58-a72b-42d5-a92b-36683f36efdf">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to accrued legal settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTMtMS0xLTEtMTQzMDYx_5bec94af-6ff8-4775-b82d-158d6ee6c0ea">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTMtMy0xLTEtMTQzMDYx_1b56421e-5118-42ed-84cd-bc1ddb1580e6">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTQtMS0xLTEtMTQzMDYx_5481c0fc-64f5-412d-8402-428e1524c709">1,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTQtMy0xLTEtMTQzMDYx_6f9301ae-70e2-4775-b3e0-99a4068f6ac2">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTUtMS0xLTEtMTQzMDYx_a77926be-b3e4-4e8d-bf87-c379ff8fe770">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTUtMy0xLTEtMTQzMDYx_7463e76b-1f66-4f1c-87ab-a88282e4d3a3">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTYtMS0xLTEtMTQzMDYx_128b0c71-7825-45e7-98a6-9ada4a92a4b5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTYtMy0xLTEtMTQzMDYx_ed34aade-9658-41ef-a45a-6187dd549d81">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTctMS0xLTEtMTQzMDYx_300d9336-69ef-48f1-9159-471ae3891026">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTctMy0xLTEtMTQzMDYx_a469a13c-451f-4dfe-b7bc-b3f335792f61">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTgtMS0xLTEtMTQzMDYx_c23ac869-3e11-42bd-89fd-a5df0bc1785c">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTgtMy0xLTEtMTQzMDYx_ad5ad934-9a89-455e-a038-db7550a1614c">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third party fees paid in connection with the Exchange Offer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMS0xLTEtMTY1NjMz_06da84a4-c859-4b8d-82a2-e4987fc4bf3b">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMy0xLTEtMTY1NjM1_13b40197-8cd4-4766-a24a-e0e29467711a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of contingent consideration adjustments, including accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMS0xLTEtMTQzMDYx_335ebee3-6d09-4eef-aaa6-c825c3ce691b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMy0xLTEtMTQzMDYx_09b929ef-d887-4dd4-9386-4ad61d172112">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjAtMS0xLTEtMTQzMDYx_17b65f35-6cf6-486e-9052-905abd4e4ced">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjAtMy0xLTEtMTQzMDYx_bab2bc1c-6e52-4f34-a92f-5fc392f78524">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjItMS0xLTEtMTQzMDYx_44e9a9e4-c63e-4186-b957-da8209fe8562">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjItMy0xLTEtMTQzMDYx_b7278372-df80-4c27-b312-3229a137479f">177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjMtMS0xLTEtMTQzMDYx_dc461697-e422-4aa0-8ca3-d0f23ebaf3bc">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjMtMy0xLTEtMTQzMDYx_7f4ba631-f3f7-4098-814d-4852590f5788">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjQtMS0xLTEtMTQzMDYx_67b46f64-c1f3-4a1a-bf2b-445fc424ad67">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjQtMy0xLTEtMTQzMDYx_4da1dfea-07b0-4ac5-b00f-689b35b87408">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjUtMS0xLTEtMTQzMDYx_a1b48b93-854d-4c47-9d67-65cd14744521">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjUtMy0xLTEtMTQzMDYx_1c5ab316-2c69-41b1-96b3-bc9d347d85c1">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjYtMS0xLTEtMTQzMDYx_09cb4e7e-2220-4698-9169-d2c8b96a2ab9">1,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjYtMy0xLTEtMTQzMDYx_0f916f48-0e40-43f3-a0e4-9797996a6c9f">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjgtMS0xLTEtMTQzMDYx_c3aa8dc9-8724-4594-9e0c-b8966717514b">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjgtMy0xLTEtMTQzMDYx_44664b67-04fc-4402-a47f-ed87eaad097c">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for intangible and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjktMS0xLTEtMTQzMDYx_716005b9-196b-4092-8338-cb28182589c3">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjktMy0xLTEtMTQzMDYx_200c4e31-5848-4b62-afe8-4b60f6367d3f">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzAtMS0xLTEtMTQzMDYx_2380941b-0a70-47c6-8e24-8da997b1cee2">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzAtMy0xLTEtMTQzMDYx_10b7955a-e28d-4773-ac8b-1daab5babd06">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzEtMS0xLTEtMTQzMDYx_bf976ba4-65e5-4df9-86df-515740174f4c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzEtMy0xLTEtMTQzMDYx_334575f9-666a-4204-a677-030f70e5581b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of assets and businesses, net of costs to sell</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzItMS0xLTEtMTQzMDYx_14d9ebdc-117f-4a33-928a-496396684a57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzItMy0xLTEtMTQzMDYx_030031e1-8ab4-49e8-907e-f48896a20888">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest settlements from cross-currency swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzMtMS0xLTEtMTQzMDYx_77b23f4e-ec77-4ca5-b8cb-ce24b14eb9fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzMtMy0xLTEtMTQzMDYx_0ac5e3da-75cc-41d1-9f9f-4fd034c21eb5">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzQtMS0xLTEtMTQzMDYx_b7516dde-e8fd-44a3-b6e1-b221686818b4">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzQtMy0xLTEtMTQzMDYx_37fe0d6e-1eb7-4d09-a1e4-df7b8e5278fa">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzYtMS0xLTEtMTQzMDYx_741219c2-38a2-47bb-8d9a-7a60a43e77d9">6,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzYtMy0xLTEtMTQzMDYx_3f44d946-a6b0-46e7-b7c5-d3ba01b37106">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzctMS0xLTEtMTQzMDYx_fbd95540-2503-4832-b67d-bf8baaa7657a">7,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzctMy0xLTEtMTQzMDYx_d1c9f135-f5b9-4860-bbf9-6e70330ae8a8">3,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from B+L initial public offering, net of costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDAtMS0xLTEtMTQzMDYx_a3af3ed6-8642-4c20-b005-d4ed55feea6d">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDAtMy0xLTEtMTQzMDYx_144adb08-5b8c-4140-be79-2918be284dc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of employee withholding taxes related to share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDEtMS0xLTEtMTQzMDYx_22812969-309d-4e8a-86b2-062153b2ea14">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDEtMy0xLTEtMTQzMDYx_3c4f833f-4a8f-4682-a4d4-cd3563a6a81c">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDItMS0xLTEtMTQzMDYx_1acbdefb-2475-46e5-b83e-e3f9691f67bd">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDItMy0xLTEtMTQzMDYx_2b8d6bba-6033-4433-8290-6446ee3301f5">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDMtMS0xLTEtMTQzMDYx_75ba6e52-feb0-4a6e-aa79-08b461aa9b19">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDMtMy0xLTEtMTQzMDYx_0a9e67c0-164f-45db-a974-a854877c00d9">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDQtMS0xLTEtMTQzMDYx_d2435bf5-aab4-4ab7-a13c-a350c0d60287">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDQtMy0xLTEtMTQzMDYx_1bb5f13d-8cd9-44c4-94de-1a782c9351e5">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDUtMS0xLTEtMTQzMDYx_81d4f8a3-8689-4774-ad32-a1f19b64b72c">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDUtMy0xLTEtMTQzMDYx_5c0f923a-81a6-41b8-99a7-b2e3abeab6b9">1,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDYtMS0xLTEtMTQzMDYx_a82b3e9b-9669-42ff-b2fb-6d4b679f74f6">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDYtMy0xLTEtMTQzMDYx_6b1cc7db-b5c1-4261-b7d6-0cfede33418d">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDctMS0xLTEtMTQzMDYx_6875ed3f-76a3-494e-905d-82cae03844fc">1,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDctMy0xLTEtMTQzMDYx_ce20655d-9b44-4540-85d5-9025a6211f69">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDgtMS0xLTEtMTQzMDYx_26c976b7-e6f9-4b05-a5c6-c66565344b44">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDgtMy0xLTEtMTQzMDYx_27a79cfe-ca86-432b-92ed-71f54d65f248">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDktMS0xLTEtMTQzMDYx_cded048f-a2a0-4315-9c3c-bfba1a631a3e">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDktMy0xLTEtMTQzMDYx_544e07d3-5839-4693-80ed-d244d0d7a57b">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTAtMS0xLTEtMTQzMDYx_303e0163-3166-4c1e-aee3-a3773822944b">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTAtMy0xLTEtMTQzMDYx_2577d89f-46b9-4db5-a3b4-f88a25603f4d">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTEtMS0xLTEtMTQzMDYx_6bbcf930-67f1-48dd-b74b-c9d19983eb05">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTEtMy0xLTEtMTQzMDYx_fa1d8b9c-55d4-4ddc-bbec-8391a309e7e6">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTMtMS0xLTEtMTQzMDYx_21744c2d-43ce-417b-9849-8ee378336806">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTMtMy0xLTEtMTQzMDYx_81f1faec-2670-4427-aabe-89c09190d9d2">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i0269b61f01054b6698b35799c21833bd_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80MC9mcmFnOjMyYTI4YjNjN2Q5ODQwMTdhMjUyZTE5MWI0OWE3MDc0L3RleHRyZWdpb246MzJhMjhiM2M3ZDk4NDAxN2EyNTJlMTkxYjQ5YTcwNzRfNzg5_48ca1d71-b024-4460-8472-690cdf9dcee5" continuedAt="ic4bed852274645dfad193a6175f1ca04" escape="true">DESCRIPTION OF BUSINESS </ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4bed852274645dfad193a6175f1ca04">Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its approximately <ix:nonFraction unitRef="number" contextRef="ib6d1b61008f54b72978ed1b60c02dd15_I20220930" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80MC9mcmFnOjMyYTI4YjNjN2Q5ODQwMTdhMjUyZTE5MWI0OWE3MDc0L3RleHRyZWdpb246MzJhMjhiM2M3ZDk4NDAxN2EyNTJlMTkxYjQ5YTcwNzRfMTA5OTUxMTYyODU3Mw_b4119140-e597-4467-bba5-42cd22f534d3">89</ix:nonFraction>% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-2" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80MC9mcmFnOjMyYTI4YjNjN2Q5ODQwMTdhMjUyZTE5MWI0OWE3MDc0L3RleHRyZWdpb246MzJhMjhiM2M3ZDk4NDAxN2EyNTJlMTkxYjQ5YTcwNzRfNzc2_48d9d1fd-7a45-439f-b4d0-da4de24aac0d">100</ix:nonFraction> countries.</ix:continuation></span></div><div id="i0269b61f01054b6698b35799c21833bd_43"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTEyMQ_8a013838-1d33-4e6c-b63a-86398203883c" continuedAt="ifd3ccb8b646b48e482904553671d3370" escape="true">SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="ifd3ccb8b646b48e482904553671d3370" continuedAt="ic8db97b242144c97adf66a3422a8c234"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTEwNg_25011561-2e94-463a-b7d8-8c9cc5ca71f7" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health (the &#8220;B+L Separation&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold <ix:nonFraction unitRef="shares" contextRef="i029ce1f6669d4d13bf48542871624ff7_D20220510-20220510" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjM2MA_9e8f4294-5447-4205-919b-4657efec1796">35,000,000</ix:nonFraction> common shares of Bausch + Lomb, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie4ecb2729d3c48b5a5174645d3aea6b0_I20220510" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjQxOQ_de0416c3-362b-4d22-8e3a-f0cb7f7df762">18.00</ix:nonFraction> per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of <ix:nonNumeric contextRef="i7976654304fe4df0800004afdc2d26a2_D20220510-20220510" name="bhc:SaleOfStockOverAllotmentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjU0Ng_e0870265-4b25-4742-8dfe-a279ea6668c9">30</ix:nonNumeric> days from the date of the B+L IPO to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="i7976654304fe4df0800004afdc2d26a2_D20220510-20220510" decimals="INF" name="bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjYxMA_5c4842f0-3855-4294-a24d-e38671e2e20f">5,250,000</ix:nonFraction> common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional <ix:nonFraction unitRef="shares" contextRef="id24bd8f4d8504fd09de88aa4e16a7666_D20220601-20220601" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjg4MA_4976f7a3-296d-46ec-8e5c-bfe45579fbd5">4,550,357</ix:nonFraction> common shares of Bausch + Lomb at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if7a1d308f9414a5fa9f55e2a191cc9dc_I20220601" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjkzOA_7ff8a8d4-7cce-45f5-8049-2baf4f769b8a">18.00</ix:nonFraction> per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health indirectly holds <ix:nonFraction unitRef="shares" contextRef="i400457a1387e48eaa2cf072d6caa4556_I20220601" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMzIyNQ_0f4f64b6-0f3c-4eb5-8329-6af748742c16">310,449,643</ix:nonFraction> Bausch + Lomb common shares, which represent approximately <ix:nonFraction unitRef="number" contextRef="i9385fd4916c644dcaffe698618f5a572_D20220601-20220601" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMzI4Nw_11f8726a-5d96-4bda-8f65-224e79086aa5">89</ix:nonFraction>% of Bausch + Lomb&#8217;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $<ix:nonFraction unitRef="usd" contextRef="ie66b2900222448dca6ffb1983135533a_D20220601-20220601" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMzUxNQ_3e63daf3-c182-4e15-9e6b-2560d490b539">675</ix:nonFraction>&#160;million. The Company continues to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company which includes the Company&#8217;s Salix, International (formerly International Rx), Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical) products, and Solta aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ic8db97b242144c97adf66a3422a8c234" continuedAt="i70fd7f19322e4a2cb47ce0ac96fa9b87"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than the effects of the B+L IPO described above, these unaudited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has had, and continues to have, an adverse impact on the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#8220;Solta&#8221; or &#8220;Solta Medical&#8221;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business.</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTA5Mw_b7f3ffcc-d5cc-4375-91a2-7895104a79cd" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTA4OQ_8fa33b87-468a-4ede-b4e0-637d22ddc206" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTExNg_1df640c1-fd82-4c2e-8765-ab352bd86e77" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Salix, (ii) International Rx, (iii) Ortho </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i70fd7f19322e4a2cb47ce0ac96fa9b87">Dermatologics, (iv) Diversified Products and (v) Bausch + Lomb. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</ix:continuation></span></div><div id="i0269b61f01054b6698b35799c21833bd_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTY5NA_756ce900-e2ac-42cd-b529-9f8715da9970" continuedAt="i2f225c588a0842a0be0a918eeb3201e8" escape="true"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTcyMA_8897fe79-70bf-408d-b699-1385992a5072" continuedAt="i95f8f654a6294d9287f470684bb7c754" escape="true">REVENUE RECOGNITION </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i2f225c588a0842a0be0a918eeb3201e8"><ix:continuation id="i95f8f654a6294d9287f470684bb7c754" continuedAt="ia1b7b0e3e2cd47bc82f89b46e98f8a91"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="ia75431739df4487280446af7b19c22ac_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfMzg0ODI5MDcwNTY0MA_cadd8561-a02f-4317-be4a-2e7f329e64bb">84</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTQ5NzU1ODIxMjQ4_43d44e02-da31-4cde-b5fc-357c7919734d">94</ix:nonFraction>&#160;million, respectively, and include reductions in variable consideration for sales return provisions related to past sales of approximately $<ix:nonFraction unitRef="usd" contextRef="id13e6d60640d4848933c41324b30da24_D20220701-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTQ5NzU1ODIyMTYx_2305e3e7-16cf-44af-acfa-571f597da38c">21</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia2b64397f3134ccc856057d7d06cac18_D20210701-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTQ5NzU1ODIxMjYx_0938ac8c-e4c8-4298-b4a0-c6302cdd5a27">28</ix:nonFraction>&#160;million for the three months ended September 30, 2022 and 2021, respectively.</span></div></ix:continuation></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia1b7b0e3e2cd47bc82f89b46e98f8a91"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTcxOA_3c7e6673-07ba-48d8-92ad-06ca17ab57c9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the nine months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55bc36e507494e61b200544c3360e3d4_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi0yLTEtMS0xNDMwNjE_22468879-c940-47fa-9da6-30e104f1ebec">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7bba4a0408e47b6904cb9363a54d0c6_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi00LTEtMS0xNDMwNjE_3ef87621-d37c-4258-984d-dc1dcdc057c4">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64d25a700a694dd0bb04c6e978004998_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi02LTEtMS0xNDMwNjE_61273537-c8d9-4497-9b05-70ee1378db18">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588fb4f24bc44da9b20f9ba64cdce034_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi04LTEtMS0xNDMwNjE_bfc4fabd-a128-4cf0-840e-fb6d57cc8e5d">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5023261686ca407a90455d9077dc3871_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi0xMC0xLTEtMTQzMDYx_4c259f23-f13d-4296-ac75-d9e674cdd3c7">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi0xMi0xLTEtMTQzMDYx_34baad09-1c23-486a-aa47-61d588b682b0">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a74aed9df0544728bda592f48dc4d5c_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy0yLTEtMS0xNDMwNjE_d0cea854-6265-499b-af89-a3e9ae19ff71">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75431739df4487280446af7b19c22ac_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy00LTEtMS0xNDMwNjE_8a17f6e4-bf10-4762-b133-aee0806e57f4">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12459cee3f4646d2966fb895ab93f2eb_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy02LTEtMS0xNDMwNjE_f2bcca6c-28cd-4594-be25-8cd3ebf2682d">1,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a39f472d42a4f5ebd126b085b5fe9e1_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy04LTEtMS0xNDMwNjE_1a91dbb4-5f6e-4000-95c0-ba30a4c32710">1,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09603225e8f46f9adf432aff5307061_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy0xMC0xLTEtMTQzMDYx_6f47bab8-b7f6-43b3-a3f9-c951f9de725f">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy0xMi0xLTEtMTQzMDYx_3aa7154f-1d35-440b-af21-284e83915ec6">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a74aed9df0544728bda592f48dc4d5c_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC0yLTEtMS0xNDMwNjE_d35908be-fccf-4e7d-80d8-68fc41a564b0">452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia75431739df4487280446af7b19c22ac_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC00LTEtMS0xNDMwNjE_03c4e681-b710-4409-b00a-cd0dcd5b322a">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12459cee3f4646d2966fb895ab93f2eb_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC02LTEtMS0xNDMwNjE_69937037-e69e-4ff5-8a30-59959c92dbe5">1,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a39f472d42a4f5ebd126b085b5fe9e1_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC04LTEtMS0xNDMwNjE_567a3f6f-4ede-4400-9c1c-96d778b397d7">1,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia09603225e8f46f9adf432aff5307061_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC0xMC0xLTEtMTQzMDYx_fa9b027e-ad9f-406b-a370-de9d1ae18196">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC0xMi0xLTEtMTQzMDYx_c08ca8ed-c950-435c-892d-379de20eb8c6">4,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5cafad91a7439a8ee4e91276eddf07_I20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS0yLTEtMS0xNDMwNjE_d1843a86-17c1-43e4-9996-b594a4ad6ad5">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e2c1d055a04b8ca3b8229415cd198d_I20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS00LTEtMS0xNDMwNjE_44480c1b-1165-4db3-ad8f-2653fe15b023">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54b70832a484dda991eba0bea3d37ba_I20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS02LTEtMS0xNDMwNjE_2d0a477a-6ea8-4274-b550-f83fb358e725">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id913d7fd4ae340d99bf84a67735c6296_I20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS04LTEtMS0xNDMwNjE_b2dddb0f-2971-4837-b209-6aa81b09e4c7">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37dc4d41d03d46f296e6c60b958dba8d_I20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS0xMC0xLTEtMTQzMDYx_1c2fcf5b-5f9c-416a-952d-2470cbece27e">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS0xMi0xLTEtMTQzMDYx_afdca43c-6fd1-4077-b684-61014e34fa0b">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="ibf53ff30035f4469b7bf0b121a32dffd_I20220930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDEwOA_bcde2efe-1331-48ba-a29c-88720cd28346">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7419cf53c79e45e3a1c6ffa5120da79d_I20220101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDExNQ_efbbcf43-41e2-412f-897f-e06f4c42035d">36</ix:nonFraction>&#160;million as of September 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were <ix:nonFraction unitRef="usd" contextRef="id369b423b8504df5bb95a335c257add6_D20220101-20220930" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDI2NA_3c653040-e6e5-4984-bc9e-e30181f9a89f">no</ix:nonFraction> price appreciation credits during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c705f4ebe8f4e9caa8290ee18d7fa8c_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi0yLTEtMS0xNDMwNjE_31897c38-ea52-43ed-b2fd-c26df6a0dcf8">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2600d93b104798b8817d0bd816b754_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi00LTEtMS0xNDMwNjE_09f8e64f-10df-445b-ac45-4f348bcd45dc">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b868d47f54d2daecf77fbde9240da_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi02LTEtMS0xNDMwNjE_79133b6f-6afc-45a1-bf8d-bfede30f8594">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67586450d7a94efeb4d4b4e98a992f51_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi04LTEtMS0xNDMwNjE_055f4c14-ea8c-4e7f-838a-3252f603a0eb">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383189ddaae4494a9ead4886d08862ca_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi0xMC0xLTEtMTQzMDYx_8d4a163e-9edf-466b-831b-a3b2336c846d">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi0xMi0xLTEtMTQzMDYx_3457fb82-fc79-4a9c-8a6e-069b9a6d0521">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54c5d4750d6b4c8ab87893cf4856f81b_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy0yLTEtMS0xNDMwNjE_828f619f-4eab-46a9-bf5d-f4e2e12f6a4d">472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy00LTEtMS0xNDMwNjE_1948c4c6-46ae-486c-9448-c2131d68bac4">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ad1c289f4d477c9fa5a51190c9e7cb_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy02LTEtMS0xNDMwNjE_00267a57-9ad7-4777-a6b4-61cb6a8c304a">1,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ed4784134a476cac4779215bef619d_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy04LTEtMS0xNDMwNjE_d5e51cc1-a678-4cfb-ae31-fc8b10225afb">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b06a8025f5c4eb68a5b3de937057a18_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy0xMC0xLTEtMTQzMDYx_89ab61c2-5c6f-4cda-9179-8b76366a4cf8">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy0xMi0xLTEtMTQzMDYx_39f61079-f7c8-415f-ba63-a189c078a58d">4,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54c5d4750d6b4c8ab87893cf4856f81b_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC0yLTEtMS0xNDMwNjE_387fd979-c00b-4f8a-af58-0043a99ce5fc">448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC00LTEtMS0xNDMwNjE_0b2cb2e2-1dfd-435f-b8fc-7aaaf7e03e4b">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33ad1c289f4d477c9fa5a51190c9e7cb_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC02LTEtMS0xNDMwNjE_51fd1cb8-6b96-48a0-b0d5-017bdc6dae3f">1,619</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87ed4784134a476cac4779215bef619d_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC04LTEtMS0xNDMwNjE_85977555-988f-4180-8b92-b0f827de1699">1,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b06a8025f5c4eb68a5b3de937057a18_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC0xMC0xLTEtMTQzMDYx_361c3e32-efe3-455f-9cf8-fed8257a2d80">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC0xMi0xLTEtMTQzMDYx_feeab653-52b3-4bf3-8ed8-d86b67c03d2a">3,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa59c5c6d2574133b660040dfd6f39d7_I20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS0yLTEtMS0xNDMwNjE_19bb8f1e-2215-439d-a53b-79efaa3e098b">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae15cba69f554a19879bbd577f98cbc2_I20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS00LTEtMS0xNDMwNjE_f3b85513-78d6-401a-8f21-a40ab58b6f71">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7ec2397c1c476d83c06887b07a46d3_I20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS02LTEtMS0xNDMwNjE_c6ad771a-e1fd-4864-b83c-634ed1fc16b2">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i264f439282794b6795807f3ae1bb71b6_I20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS04LTEtMS0xNDMwNjE_c234be4b-3b9e-490c-85db-66c81e0c0282">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2965757201c94320abadce3840340f63_I20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS0xMC0xLTEtMTQzMDYx_73f561b4-3b73-4b27-815e-6237a25193a0">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS0xMi0xLTEtMTQzMDYx_d28ae144-6ee4-4355-b41d-82a18d5d447d">1,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i24db5cc85723404fb1251cfa00551475_I20210930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDQyMA_4e4b144f-d8a3-44ff-9297-ae4b3db95a58">38</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6131be55d52f42009c7700e15ebe45e7_I20210101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDQyNw_5598d81f-c91e-44fd-90cd-9435f60393b8">32</ix:nonFraction>&#160;million as of September 30, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $<ix:nonFraction unitRef="usd" contextRef="icf4245062a7b418a90b5c3eb455b38c7_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDU4MA_e32d99f6-7673-4c49-a46d-fb533b27a963">1</ix:nonFraction>&#160;million during the nine months ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTcxMw_bcf95550-643b-4a5a-b856-5177265be791" continuedAt="i2fdb5f589ea74f18bbf36c1286e0bcb3" escape="true">The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2022 and 2021 is as follows.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><ix:continuation id="i2fdb5f589ea74f18bbf36c1286e0bcb3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMS0xLTEtMS0xNDMwNjE_db269abb-fe41-434f-ad29-c15d5382025d">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMS0zLTEtMS0xNDMwNjE_b81d3435-95df-4119-85ab-6545b9bd1d51">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMi0xLTEtMS0xNDMwNjE_57db6dbf-002c-44a9-85d1-302abbaa4b5e">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMi0zLTEtMS0xNDMwNjE_afb86df4-8e34-4b3d-a83c-1666e0b3b403">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMy0xLTEtMS0xNDMwNjE_99576590-7b12-4edd-8ce5-f57745b0428f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMy0zLTEtMS0xNDMwNjE_0ea6b793-b522-4c5e-b0d4-7b71d9f5baa5">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNC0xLTEtMS0xNDMwNjE_78e93c68-5a50-44eb-92ba-d76240f17a8a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNC0zLTEtMS0xNDMwNjE_7e7502ad-25eb-4e1e-82e9-f070f8816ec9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNS0xLTEtMS0xNDMwNjE_99263c9f-4735-4269-964f-e3cdf91d0e2d">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNS0zLTEtMS0xNDMwNjE_ecfaa2eb-e1f4-4a05-a635-15fda743ee29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNi0xLTEtMS0xNDMwNjE_7ca3e068-263b-4393-904f-5c0e4a542ccf">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNi0zLTEtMS0xNDMwNjE_7008fcb8-1d47-4df1-934b-0575926d29ce">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjUwMA_e7a928ca-5eaf-486a-b98c-0a9b1bb78f4f" continuedAt="if140523ad348435b946472eb9b892d68" escape="true">LICENSING AGREEMENTS AND DIVESTITURE</ix:nonNumeric></span></div><ix:continuation id="if140523ad348435b946472eb9b892d68" continuedAt="ic8bf424aed93434392980bf707b3e2ad"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ic8bf424aed93434392980bf707b3e2ad"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i687a6d97c876442da5f14198d88e14b1_D20210331-20210331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMTI0OQ_32a84388-ea3b-49b8-a29c-eb15b0b60b58">740</ix:nonFraction>&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International Rx segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i2c0c9cf75bab4540be7e213a897e311f_D20210101-20210930" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjIwMA_b392da48-6937-4e09-882a-436462c4ff2c">88</ix:nonFraction>&#160;million during the nine months ended September 30, 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $<ix:nonFraction unitRef="usd" contextRef="i0f67a143f58b4616851d1f79883c3ce8_D20210701-20210930" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMTA5OTUxMTYzMDYxOA_cfc4f074-cb10-41b5-8304-4ffbb8e907d9">26</ix:nonFraction>&#160;million during the three months ended September 30, 2021, included within Other (income) expense, net in the Combined Statements of Operations. Revenues associated with Amoun were $<ix:nonFraction unitRef="usd" contextRef="i83dd54e76be14e2b8cddedd0ad775700_D20210701-20210930" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjQyNg_93e7f51a-e675-4609-afd4-60c65d25e4ac">20</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4bc7df085735496995eedc6a00cacc90_D20210101-20210930" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjc0ODc3OTA3MjMzOQ_0652c010-5db2-43bb-b315-78163bdd7517">157</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2021, respectively.</span></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_52"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMjczMQ_0980ee2c-ac9e-48e3-bf43-2ff62c98682d" continuedAt="i04630ae9557b4146bbd946095d838229" escape="true">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS </ix:nonNumeric></span></div><ix:continuation id="i04630ae9557b4146bbd946095d838229"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of September 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i5c15779e38db4d9f960b2dbcddd1f4c7_I20220930" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfNzA4_eb5fc6fa-fdad-42ab-8c8e-d213894d63b3">13</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i98ff32b9f66642d49d99b62aac6963ff_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfNzMz_ff57779e-ac23-47d5-b5b0-054a09d01796">28</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iede60bc2c8b94524b78454391fd1f286_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfNzQw_7f390438-2bcb-4f17-964b-3d3c21357612">9</ix:nonFraction>&#160;million of restructuring and integration costs and made payments of $<ix:nonFraction unitRef="usd" contextRef="i98ff32b9f66642d49d99b62aac6963ff_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfODAz_9492096d-cd0e-4eba-a029-e9776bd3467f">37</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iede60bc2c8b94524b78454391fd1f286_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfODEw_a1548621-af63-45e0-bdd1-70c1bc3d2270">13</ix:nonFraction>&#160;million during the nine months ended September 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities relating to the B+L Separation. The Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the nine months ended September 30, 2022 and 2021 are separation and IPO costs of $<ix:nonFraction unitRef="usd" contextRef="ib1b8d98ba0764e17812507d2898812ea_D20220101-20220930" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMTkzMQ_b1c63252-d3a1-410f-9842-debca74f32fc">30</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id6bf4d2916304721b590b0e9b170762c_D20210101-20210930" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMTkzOA_0c891e6a-d097-4901-a073-c6cce00b865d">20</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and expects to continue to incur with respect to the B+L Separation, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO including, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the nine months ended September 30, 2022 and 2021 are separation-related and IPO-related costs of $<ix:nonFraction unitRef="usd" contextRef="ib1b8d98ba0764e17812507d2898812ea_D20220101-20220930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMjU0Mg_84db55c5-8a4b-4c7f-baf2-fda2c7b18f5b">84</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id6bf4d2916304721b590b0e9b170762c_D20210101-20210930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMjU0OQ_ddff2195-6098-4340-9119-675638ce048a">91</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_55"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAxOQ_516cbc17-5c0a-4c68-8582-4f05d9394495" continuedAt="i82bcdcc1cbab46de91e8a309724d37bb" escape="true">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i82bcdcc1cbab46de91e8a309724d37bb" continuedAt="iea514a699a74415783ea0b9f9ac202cb"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis </span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAyMg_4bbc918a-b612-4f4e-957d-7f43127894ad" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189881ec0c284dfcbb328b608d14d436_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0yLTEtMS0xNDMwNjE_271e9333-ac9c-4bf1-a87d-55efbab2c5a8">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6f4ef12df34897a610582fba7a5ca1_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy00LTEtMS0xNDMwNjE_15e053da-5f2f-4d88-8791-e752673e0d4e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy02LTEtMS0xNDMwNjE_35ee2cb8-551a-4ac7-9393-c0538afe07fe">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfccdfa38764f7ab26413e57457105b_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy04LTEtMS0xNDMwNjE_f8c1f7ed-8ee5-4276-b131-5f4bf7cf3bd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11917dc946040bfa50a896265fc544d_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xMC0xLTEtMTQzMDYx_02d38be8-9605-490b-96a3-1465014b8cd5">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3856df3c34054e50b83aafeb6a21dfa8_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xMi0xLTEtMTQzMDYx_6617c031-0116-4dc1-a740-2c00b34ea3ef">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59def28407a7463daf61067d0788531e_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xNC0xLTEtMTQzMDYx_d38ef7ad-4a8f-402d-8998-f0be810fc402">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55579786a38243319015619aafa89fd5_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xNi0xLTEtMTQzMDYx_2af09d06-3c53-4de0-84ae-b9857ba38ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189881ec0c284dfcbb328b608d14d436_I20220930" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0yLTEtMS0xNDMwNjE_f29ef554-ed6e-473d-a390-7e0fb02068a7">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6f4ef12df34897a610582fba7a5ca1_I20220930" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC00LTEtMS0xNDMwNjE_ea2adeee-5c3a-406e-a565-59dbb8b80fe8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC02LTEtMS0xNDMwNjE_3c8b04a0-9162-4e8b-8c76-4ecd71fd2045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfccdfa38764f7ab26413e57457105b_I20220930" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC04LTEtMS0xNDMwNjE_cab8ed32-e8ee-4e00-9346-b013bb09c0d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11917dc946040bfa50a896265fc544d_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xMC0xLTEtMTQzMDYx_02bcd4ae-999c-4726-9147-292ac0a60be7">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3856df3c34054e50b83aafeb6a21dfa8_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xMi0xLTEtMTQzMDYx_3bd1321d-87b4-4e16-9581-7f8850339276">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59def28407a7463daf61067d0788531e_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xNC0xLTEtMTQzMDYx_0a78d637-58c0-436c-8ed0-1000672b4bf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55579786a38243319015619aafa89fd5_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xNi0xLTEtMTQzMDYx_7cb5270f-184e-4f7b-8586-60859497fa76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7cb0e3db56a4ea981bbab9943aa32d0_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0yLTEtMS0xNDMwNjE_72ec095a-dc37-4bbe-a6c9-1556fbc74081">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdfbccb558174a2c8c0c09b05b34c8ef_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS00LTEtMS0xNDMwNjE_e542a916-6bcc-476e-8031-efa0cafceaeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c63ea1cea814379bfb6c3678f5a4b33_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS02LTEtMS0xNDMwNjE_786253ac-0477-4f55-8101-976a092330d9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec1e524d22a438c9c456e1b9c501f25_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS04LTEtMS0xNDMwNjE_946f9702-fc14-422c-8f12-b2bd294118b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i560fd028d7474fdd985f6a52302094c1_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xMC0xLTEtMTQzMDYx_5f71557a-3367-44b4-9d4e-3a812bb74f77">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7c343d445f4dcc9a19e5d1ba15e4af_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xMi0xLTEtMTQzMDYx_8de5d699-2918-4bba-b222-60b6633e9fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3102bdd26ddc4acc85720c1d44031b39_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xNC0xLTEtMTQzMDYx_38c9baff-559b-47ab-b96a-9a23a5c63bbb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f25ff584194105b7bc29f5d77efe7f_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xNi0xLTEtMTQzMDYx_fd33f3de-6343-47f0-9f5f-6ca5b97afa7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ad6947f6374ac48f3ac1e7694627ce_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0yLTEtMS0xNDc1MTY_29dd0b29-d6f3-4c05-9e7a-7ad4ab69e501">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80389df867444889b10bc292d83780a_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi00LTEtMS0xNDc1MTY_5f6e38b1-ba7b-467c-a78f-801a841b4dbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb7a659ca664b599f9e404ffbd842e7_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi02LTEtMS0xNDc1MTY_1bc2c794-f6a5-4e34-9f53-1770d1a08c96">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97ffb0132d5844cbb9a45d214fa9b29a_I20220930" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi04LTEtMS0xNDc1MTY_7909a100-1e39-4ded-8bb8-2e8e89d5a5b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d83aa84f0be438bac5f8d689a31f364_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xMC0xLTEtMTQ3NTE2_f0199044-ce51-4311-9ab1-e06623396ec5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02290af2908a48d9818fdaed17915266_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xMi0xLTEtMTQ3NTE2_aea1cdf5-6bff-4052-b0d0-811e4987e0c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80540287663d42bebe1ebb76c28b9e75_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xNC0xLTEtMTQ3NTE2_ce9c69c1-8a05-42f2-b9f1-90ae6ebcc8dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb8cfd06a6a49f8879cde7f8a7d98ee_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xNi0xLTEtMTQ3NTE2_7eb5646f-a49c-47c0-a6aa-ad7f43c2cde6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i189881ec0c284dfcbb328b608d14d436_I20220930" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0yLTEtMS0xNDMwNjE_f259206a-1f2d-4928-b6b9-845bad02d786">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6f4ef12df34897a610582fba7a5ca1_I20220930" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy00LTEtMS0xNDMwNjE_7b71f75f-46bf-4365-b992-ef395fa4dfd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy02LTEtMS0xNDMwNjE_841acfc2-55c9-4e72-b5d7-6c0a3828fd0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfccdfa38764f7ab26413e57457105b_I20220930" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy04LTEtMS0xNDMwNjE_3e5fe08b-e902-4323-9a01-39bbff553b33">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib11917dc946040bfa50a896265fc544d_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xMC0xLTEtMTQzMDYx_2bf25644-431d-4668-b40c-3bcb9f506707">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3856df3c34054e50b83aafeb6a21dfa8_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xMi0xLTEtMTQzMDYx_21e8c4cb-3907-4ef4-8534-8984cc19b2d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59def28407a7463daf61067d0788531e_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xNC0xLTEtMTQzMDYx_f6d61fad-320d-4915-9d13-9ebbc9f2e0da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55579786a38243319015619aafa89fd5_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xNi0xLTEtMTQzMDYx_3bfe8131-c82f-4017-b6f2-6f229b7f7bb2">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7cb0e3db56a4ea981bbab9943aa32d0_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0yLTEtMS0xNDMwNjE_38a3098c-1252-4f9d-a8ec-a18f9eec081a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdfbccb558174a2c8c0c09b05b34c8ef_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC00LTEtMS0xNDMwNjE_569e8f16-2689-48a0-b9c5-05b6383342df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c63ea1cea814379bfb6c3678f5a4b33_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC02LTEtMS0xNDMwNjE_625e2700-b57c-4fc4-af56-434f0d185a0e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec1e524d22a438c9c456e1b9c501f25_I20220930" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC04LTEtMS0xNDMwNjE_e44ff201-e744-47d6-a189-8c0187e69a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i560fd028d7474fdd985f6a52302094c1_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xMC0xLTEtMTQzMDYx_bd02469a-bc85-402a-be2c-16c99df6d3eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b7c343d445f4dcc9a19e5d1ba15e4af_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xMi0xLTEtMTQzMDYx_ed4d35a6-ed2c-4250-b520-535c3ebdd066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3102bdd26ddc4acc85720c1d44031b39_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xNC0xLTEtMTQzMDYx_ac687f53-4b58-4840-9637-14f5167506e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f25ff584194105b7bc29f5d77efe7f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xNi0xLTEtMTQzMDYx_b6f53747-bc9b-4295-b8fb-1d11caf8105b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMTQyOA_24d038a1-b487-4eaf-8edd-47508afdb945">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of September 30, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMTczMA_dbadd6b0-eba4-4f52-bb5a-b992994eba7d">297</ix:nonFraction>&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Restricted cash and other settlement deposits included $<ix:nonFraction unitRef="usd" contextRef="ic0ef55f3a8f4410b942a22f1c9b01c26_D20210101-20211231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjU0MA_92fc8385-bb65-4db8-bfce-203ad1eebf41">1,210</ix:nonFraction>&#160;million of payments into an escrow fund under the terms of the Securities Class Action Settlement (as defined in Note 18, &#8220;LEGAL PROCEEDINGS&#8221;), which was subject to <ix:nonFraction unitRef="appeal" contextRef="i3064f6af45484839a5e9e28044f57d64_I20211231" decimals="INF" name="bhc:LitigationSettlementNumberOfObjectorsAppeals" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjcwNA_9a8057e1-0ec6-4de0-b48e-015a4f394c60">one</ix:nonFraction> objector&#8217;s appeal of the final court approval of the agreement. The period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the Securities Class Action Settlement has become &#8220;final&#8221;, as no more appeals can be filed. As a result, the Company's rights to the funds in escrow were extinguished and the Company reduced Restricted cash and other settlement deposits with a corresponding reduction to liabilities for legal settlements, included in Accrued and other current liabilities on the Company's Consolidated Balance Sheets, by $<ix:nonFraction unitRef="usd" contextRef="i259cd2e6dab94c2ba09224dea2beb7c7_D20220701-20220930" decimals="-6" sign="-" name="bhc:IncreaseDecreaseInAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjc0ODc3OTA4MTk0OA_7f2b8c6c-b57b-471d-90fd-f0c374664664"><ix:nonFraction unitRef="usd" contextRef="i259cd2e6dab94c2ba09224dea2beb7c7_D20220701-20220930" decimals="-6" sign="-" name="bhc:IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjc0ODc3OTA4MTk0OA_ad1df5c8-d6c8-4087-a0af-6607862f87ba">1,210</ix:nonFraction></ix:nonFraction>&#160;million in the three months ended September 30, 2022. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;U.S. Securities Litigation - Opt -Out Litigation&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for additional details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 assets or liabilities during the nine months ended September 30, 2022.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="iea514a699a74415783ea0b9f9ac202cb" continuedAt="i74b9e0546dab48f4b818d0fa424f4c8a"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i172f1137c8f54eb5aee6b0e56da822a2_I20220930" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMTA5OTUxMTYzODE1OQ_948dab73-f25e-408a-aabe-b6048bf28169">1,000</ix:nonFraction>&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s cross-currency swaps qualify for and have been designated as a hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the periods presented. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjc0ODc3OTA4MDIzMQ_68b4bde9-3816-4e4a-a79d-b2a13307a03a" continuedAt="i13324004922a4db2971488b324fc8de6" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with Bausch + Lomb&#8217;s cross-currency swaps as included in the Consolidated Balance Sheet as of September&#160;30, 2022 are as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i664840dc517c429f8d7027d6465fdf0d_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmEyMmNiMTkyZGZkZTQxYzc5NjQ1OTE3Y2NkZjM1Zjg2L3RhYmxlcmFuZ2U6YTIyY2IxOTJkZmRlNDFjNzk2NDU5MTdjY2RmMzVmODZfMS0yLTEtMS0xNDc1Mzc_bdef57bb-aa03-4558-9e3a-e84a50ebad50">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1e5a6363fc74a07884d25a0f2217af6_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmEyMmNiMTkyZGZkZTQxYzc5NjQ1OTE3Y2NkZjM1Zjg2L3RhYmxlcmFuZ2U6YTIyY2IxOTJkZmRlNDFjNzk2NDU5MTdjY2RmMzVmODZfMi0yLTEtMS0xNDc1Mzc_3621ec9e-1bee-40ad-bf1a-b75a3c78abab">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172f1137c8f54eb5aee6b0e56da822a2_I20220930" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmEyMmNiMTkyZGZkZTQxYzc5NjQ1OTE3Y2NkZjM1Zjg2L3RhYmxlcmFuZ2U6YTIyY2IxOTJkZmRlNDFjNzk2NDU5MTdjY2RmMzVmODZfMy0yLTEtMS0xNDc1Mzc_2ebb9ba6-1799-455f-9dc9-cb5ab0344e4d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i658a48e24ddb46329d8726eb2248580e_I20191231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMzIyNg_7d39239d-3b8a-4362-a846-0ef9a107335e">1,250</ix:nonFraction> million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021. As a result, there were no assets or liabilities related to the cross-currency swaps included in the Consolidated Balance Sheets as of December 31, 2021.</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAyNA_cb221e9b-9f8a-4def-8a36-71593d55b27f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib700cf771af14037994bc18bd56d1eac_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi0yLTEtMS0xNDMwNjE_7af03ed5-98b2-4ce8-b5e1-6c064fd069da">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5c6d1837094f3da3275340aac12543_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi00LTEtMS0xNDMwNjE_6b4f7712-cdfb-4fb8-a793-783c98205208">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c32f9e20d74e7ab62844bacfe8a06d_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi01LTEtMS0xNDMwNjE_2de95f30-0a91-4201-b802-a2ff114f4ff4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae5d31784454d4f9c64507a80288ac4_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi03LTEtMS0xNDMwNjE_6bcba301-3a7c-440e-a1e8-810f6938ea1b">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6d573695f9479a899bfc1140a6a312_D20220701-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy0yLTEtMS0xNDMwNjE_b954365e-5497-4809-ab3b-989740727ef4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82ebd628dcc84efa96e5a3f56fbb029b_D20210701-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy00LTEtMS0xNDMwNjE_3cb7e069-3a65-4e01-a626-411382c1bd52">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a33dade7514111bc4b73c39a7e80d8_D20220101-20220930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy01LTEtMS0xNDMwNjE_007c7124-f827-45f9-97d3-0a0b6d24e587">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39777750e2f64ea99b3afe8746b25115_D20210101-20210930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy03LTEtMS0xNDMwNjE_eee68cce-65bc-4107-9a61-3c29fc8f60c5">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest settlement of the 2022 cross-currency swaps occurs in January and July each year, with the first settlement in January 2023. Future settlements of the 2022 cross-currency swaps will be reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="ie2c32f9e20d74e7ab62844bacfe8a06d_D20220101-20220930" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNDA0Nw_4872ffd9-bd05-4343-99f2-cfbaef438270">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6ae5d31784454d4f9c64507a80288ac4_D20210101-20210930" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNDA1NA_5cbf7e92-d4a0-4364-9aa9-1a7bea784cc4">23</ix:nonFraction>&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i74b9e0546dab48f4b818d0fa424f4c8a" continuedAt="if14a91b6181940af94b794f651e1bae0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company's outstanding foreign currency exchange contracts had an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i04b46684430b436b80adda1d481b4307_I20220930" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNDM3Mw_b16d766f-c45b-43a8-9dc8-bc317e47ef9b">394</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. </span></div><ix:continuation id="i13324004922a4db2971488b324fc8de6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c5a5a87413f4813b60dc909501166c4_I20220930" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMS0xLTEtMS0xNDMwNjE_d663d5a3-cae4-4898-9d16-1eac09654183">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d13600b4ae84400ad2d966a20e8cc67_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMS0zLTEtMS0xNDMwNjE_db629e9a-c270-4cfe-b4bb-3a5ce85ae399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f7fd33a30e4a169c5464ee3e62b2cb_I20220930" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMi0xLTEtMS0xNDMwNjE_c7a5395e-f95b-4395-8b28-8e6d94ddb77f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic008afd14a8e42b1b866d63b770b5fa0_I20211231" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMi0zLTEtMS0xNDMwNjE_2c72222a-d2ab-412d-a5c4-84b306135cea">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04b46684430b436b80adda1d481b4307_I20220930" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMy0xLTEtMS0xNDMwNjE_27a007a9-e6f9-4aa3-95b8-18026d075f50">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0491752f49af4e53b382633de1597dca_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMy0zLTEtMS0xNDMwNjE_5028d612-969b-4d4e-88d0-8b4b036607c7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAxMw_fa1606f1-1077-4fa6-9f97-d1a533df67ef" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi0xLTEtMS0xNDMwNjE_69d69049-1907-4dd0-b687-8d4e16b43480">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c556fd4fe44909bc9174e88819eb06_D20210701-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi0zLTEtMS0xNDMwNjE_7445cbbe-eed1-4de6-a0ec-32f2a4d4f904">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba36257072b246d29fda1803494bc0af_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi01LTEtMS0xNDMwNjE_f382dcdf-0a09-4836-aec1-b3e97df52043">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ed75df41237422bacb5217c299a7a89_D20210101-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi03LTEtMS0xNDMwNjE_54d59b60-462d-4a8f-a8fd-8b4ccd52e628">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy0xLTEtMS0xNDMwNjE_c56d30b8-dfff-490b-900e-2a170391a11e">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7c556fd4fe44909bc9174e88819eb06_D20210701-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy0zLTEtMS0xNDMwNjE_a4f3bf76-8794-4348-bb61-8e863d0ec21e">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba36257072b246d29fda1803494bc0af_D20220101-20220930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy01LTEtMS0xNDMwNjE_69b74c84-346b-41ec-924b-bf52a4fa99ac">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ed75df41237422bacb5217c299a7a89_D20210101-20210930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy03LTEtMS0xNDMwNjE_51d7cb25-4583-4fe0-bdf7-6a4e54524ade">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At September&#160;30, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="rate" contextRef="i07c71f42a1544418b4d10d3fc382ee03_I20220930" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjQzMQ_10a7d873-2b41-48ae-8e64-295503ab27dd">6</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="i75b032ae3e214a648b569459dbab455d_I20220930" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjQzNw_1ca51df9-03b1-4167-8581-18913c3805af">18</ix:nonFraction>%, and a weighted average risk-adjusted discount rate of <ix:nonFraction unitRef="rate" contextRef="i9ae4a5ad398947318b5198492ce65b04_I20220930" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjQ5NQ_24b39baa-894a-4558-928f-6fb49e795906">7</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at September&#160;30, 2022.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="if14a91b6181940af94b794f651e1bae0"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAyNw_af2b69ae-1e60-4d05-913f-972c0433d0d6" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:70.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMS00LTEtMS0xNDMwNjE_07d0df5e-c039-46f8-bf20-5099f1b9e384">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMS04LTEtMS0xNDMwNjE_abea0037-2df8-42aa-9819-29d2ef6e168a">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260c0d75915a4ca3ad834d641fa75343_D20220101-20220930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMy0yLTEtMS0xNDMwNjE_ebb4faa3-4fc5-4380-8ec8-b7291f6f79c6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f2915dbf2941e5b52e80096e27bf1a_D20210101-20210930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMy02LTEtMS0xNDMwNjE_c1786361-71fc-4dcd-99e8-04388ba82112">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ae79b3262d842b1af103d3792958795_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNC0yLTEtMS0xNDMwNjE_5e0d5073-9e97-429a-89c9-501091c19b7e">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb7aaa35ab964b01b84dfe94e256903f_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNC02LTEtMS0xNDMwNjE_8e785d40-33a2-4949-bcbb-a74471542692">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNS00LTEtMS0xNDMwNjE_21b2a73b-634a-445b-8ef7-8771b1f0b8f0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNS04LTEtMS0xNDMwNjE_ea097f52-a039-446f-8edf-ac6498c82489">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNi00LTEtMS0xNDMwNjE_2e615764-325b-4a35-b152-49c9c29269a3">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNi04LTEtMS0xNDMwNjE_2934f5b1-82ec-41f5-bf99-3896f6b8ba52">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNy00LTEtMS0xNDMwNjE_54f5a5fb-8ed6-41b0-9ca2-f05eaa7b7467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNy04LTEtMS0xNDMwNjE_b3efc8fd-6a0e-4b84-b59e-1890a71130a1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfOS00LTEtMS0xNDMwNjE_a6d4524e-ec84-499e-95a3-37aa8ead2889">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfOS04LTEtMS0xNDMwNjE_aec3c327-37b2-40de-b1ca-32675960431b">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTAtNC0xLTEtMTQzMDYx_54c61132-111e-40c7-bc64-12454e1522df">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTAtOC0xLTEtMTQzMDYx_2e32c4b4-31af-49e4-b732-129e2580508f">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTEtNC0xLTEtMTQzMDYx_9a6d61a4-15d8-49c7-afd8-c9e880f62c86">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTEtOC0xLTEtMTQzMDYx_8290049c-1fbf-4186-939c-d4633e156593">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of September&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i63a5e3f00efb48b2b18db41abfecd3de_I20220930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjg4MA_fa21f526-8db6-4883-bfab-c0052b83dfd2">13,450</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i71e359c95d524712918710296eeeae37_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjg4Nw_13237079-af11-460a-ab94-92de1d31a971">22,689</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_58"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RleHRyZWdpb246MTk3N2VlNDk3YzEyNDRiYWI4MmY3NDMwYmYwYTBkMjdfNTk_2dc1291e-1382-4bb0-b0af-a528bb62cb39" continuedAt="ia12a1c0b4dc54238a0ed73cfc3d77d98" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="ia12a1c0b4dc54238a0ed73cfc3d77d98"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RleHRyZWdpb246MTk3N2VlNDk3YzEyNDRiYWI4MmY3NDMwYmYwYTBkMjdfNTU_633ab699-8d9d-4a02-bab5-8734728c8a0e" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMS0yLTEtMS0xNDMwNjE_f8a5092f-1188-47b3-a6c5-0ee4128e8b1d">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMS00LTEtMS0xNDMwNjE_45103006-8c88-45f4-b2b1-cf6f3ece5557">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMi0yLTEtMS0xNDMwNjE_d2f0b45e-0cd6-4178-a072-21872d904bc0">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMi00LTEtMS0xNDMwNjE_c88012b4-002a-45f7-8851-b5e051bf4ce3">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMy0yLTEtMS0xNDMwNjE_c3c54576-d220-4081-957c-63a03271438f">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMy00LTEtMS0xNDMwNjE_55473472-7107-4dee-943f-8d05ef95b8b2">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfNC0yLTEtMS0xNDMwNjE_91ac43e3-f91b-42b2-8ad0-55e720e1e9b1">1,056</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfNC00LTEtMS0xNDMwNjE_47c17942-830a-41fb-8157-1ad45178c3e9">993</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5NjI_39f0d0c3-2e97-469a-9f8e-ad45045fd38a" continuedAt="iab477fc7e4634183a8f04d2f32cc1047" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="iab477fc7e4634183a8f04d2f32cc1047" continuedAt="id8c37f16d25c4938b973da91eb1f39eb"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5NjQ_ff948247-4539-4392-a5b7-a79666a419ca" escape="true"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5OTY_6a5662f1-0217-47d6-8a1b-3d229cb08e05" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11472c1bcca3473484bcfadfc7e303e1_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy0yLTEtMS0xNDMwNjE_d46774ab-8480-488b-894f-183bbd59563b">20,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11472c1bcca3473484bcfadfc7e303e1_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy00LTEtMS0xNDMwNjE_1d29082c-a95c-4960-9394-bf2ff9aa3d3e">16,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11472c1bcca3473484bcfadfc7e303e1_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy02LTEtMS0xNDMwNjE_fa8afd22-0094-4140-afc8-5c820799e529">3,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18a1afc3dcb4214ad64a89920a42e55_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy04LTEtMS0xNDMwNjE_1aef4626-5cbd-43f9-bf25-f6c0ee5c1363">20,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id18a1afc3dcb4214ad64a89920a42e55_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy0xMC0xLTEtMTQzMDYx_29839fb3-af00-4d7e-9c28-df4cab71c45c">16,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18a1afc3dcb4214ad64a89920a42e55_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy0xMi0xLTEtMTQzMDYx_23e27a10-2e36-4f3c-ae2e-f8d86bb46021">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9613fcb5ca34578a0abf1ab147f9208_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC0yLTEtMS0xNDMwNjE_71413593-0c8d-485c-b4fd-aca5c334baeb">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9613fcb5ca34578a0abf1ab147f9208_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC00LTEtMS0xNDMwNjE_5b87d61e-1f42-4f23-ada6-5d25715ba0c3">520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9613fcb5ca34578a0abf1ab147f9208_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC02LTEtMS0xNDMwNjE_f022ebcf-5640-4f9f-a4aa-5f65e8708dd7">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e063d61f8c44899a3f8978861d16697_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC04LTEtMS0xNDMwNjE_1932abf1-d38f-4b18-a633-7ca1e9d22c81">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e063d61f8c44899a3f8978861d16697_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC0xMC0xLTEtMTQzMDYx_3d7e3278-7177-4908-a51a-6d4e1136b09f">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e063d61f8c44899a3f8978861d16697_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC0xMi0xLTEtMTQzMDYx_de27f238-b396-4d8d-9283-cd8f052a760f">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602595f1880446f59ec15696e1d75c4a_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS0yLTEtMS0xNDMwNjE_d5984271-2eab-4eb2-90ed-01796f5fc414">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i602595f1880446f59ec15696e1d75c4a_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS00LTEtMS0xNDMwNjE_5b00e597-8e38-4901-998d-d60fe71b3d16">3,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602595f1880446f59ec15696e1d75c4a_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS02LTEtMS0xNDMwNjE_dc82a742-918e-46b1-b150-7bd5252e3e99">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e873c909a3144db9339746a1a94254f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS04LTEtMS0xNDMwNjE_9b242258-4b78-480d-a048-803aadf32fae">3,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e873c909a3144db9339746a1a94254f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS0xMC0xLTEtMTQzMDYx_fb3b1814-0659-43d7-9638-385e411740b2">3,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e873c909a3144db9339746a1a94254f_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS0xMi0xLTEtMTQzMDYx_24ae3f32-40a3-4afd-840b-6f6fcd386895">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi0yLTEtMS0xNDMwNjE_46503b47-0fe6-4e3f-8d21-931292bbe401">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi00LTEtMS0xNDMwNjE_3d7e548e-a7e8-4b3a-9e92-316b85f44447">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi02LTEtMS0xNDMwNjE_32f654ec-c261-41ac-8ebc-2d2e1d7a0959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86e90503a154ca4bb57d7823f5d7f75_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi04LTEtMS0xNDMwNjE_626c0b81-e59e-49af-9897-dbcbdf49edeb">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia86e90503a154ca4bb57d7823f5d7f75_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi0xMC0xLTEtMTQzMDYx_986bf0e4-adb1-481a-ab00-225eaa296072">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86e90503a154ca4bb57d7823f5d7f75_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi0xMi0xLTEtMTQzMDYx_dbab492e-fef5-4470-a321-87e57a328077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy0yLTEtMS0xNDMwNjE_58ab0085-3bfe-4687-b33f-4f35b1a3e652">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy00LTEtMS0xNDMwNjE_5d7dea9d-6f55-4acf-8652-001a7c3099d3">191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy02LTEtMS0xNDMwNjE_d9dbda62-38b4-45d1-9d3f-3bfbc4dff827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec524df231434a33b3b75a1f327b3a14_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy04LTEtMS0xNDMwNjE_8c277b59-0321-4346-a095-7d38dd78735d">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec524df231434a33b3b75a1f327b3a14_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy0xMC0xLTEtMTQzMDYx_75475671-88b1-4344-a26a-7fc403aac5aa">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec524df231434a33b3b75a1f327b3a14_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy0xMi0xLTEtMTQzMDYx_f38401b8-c9b3-4f63-8d49-3ecdc519dcf2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC0yLTEtMS0xNDMwNjE_9596e5f3-6cd5-4b8e-b708-1ff5489f92c8">25,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC00LTEtMS0xNDMwNjE_4450b5c7-a908-40a3-89a3-a3a905971f09">20,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC02LTEtMS0xNDMwNjE_8e72f995-f0e5-48d9-aa8c-2277202de5dd">4,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC04LTEtMS0xNDMwNjE_28df14b8-c113-4630-be6c-a6ced4804e3d">25,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC0xMC0xLTEtMTQzMDYx_f5339114-349d-47f1-958f-09267cd407cb">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC0xMi0xLTEtMTQzMDYx_638ebbec-44a6-429b-b3f1-a7fa9dc8ff4d">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88feb25df1514be1b2bf7b05d2488070_I20220930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS0yLTEtMS0xNDMwNjE_b429093b-03bf-4769-9720-b88d1f670b04">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88feb25df1514be1b2bf7b05d2488070_I20220930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS02LTEtMS0xNDMwNjE_61ebc2e2-9e50-4b17-838c-1fb904b9b8bc">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a1ed1bc1784b8db2b2d22151163626_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS04LTEtMS0xNDMwNjE_3b6a5525-a8d0-4003-a2d6-6833d847503e">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a1ed1bc1784b8db2b2d22151163626_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS0xMi0xLTEtMTQzMDYx_1cc5de08-5e45-45fa-8faf-642d387c0c1d">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtMi0xLTEtMTQzMDYx_3ad6e52e-433d-4a5d-a9df-0b37ebb451b7">26,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtNC0xLTEtMTQzMDYx_3dc083df-6802-487e-8e1d-3d05d02fbc59">20,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtNi0xLTEtMTQzMDYx_e1978be1-d42f-4a6d-8b06-e0fffe0b1d23">6,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtOC0xLTEtMTQzMDYx_c3c48259-678a-4237-99ad-f1d7a0a298ad">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtMTAtMS0xLTE0MzA2MQ_370e4176-b130-48ab-a209-25a5c39882c5">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtMTItMS0xLTE0MzA2MQ_84936794-756e-4bd1-a6c6-7560bf51c744">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="id8c37f16d25c4938b973da91eb1f39eb" continuedAt="i31001109fba64f489904e1d0f3e3216f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the nine months ended September 30, 2022 were $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODkwNjY4_53576144-f858-4587-9f84-f2380bee12a1">15</ix:nonFraction>&#160;million and include: (i) impairments of $<ix:nonFraction unitRef="usd" contextRef="ib3d864a514bb45dca143ed3ab32eedb7_D20220101-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzA0_31611b36-f383-406e-bb8a-5b718814c7d5">10</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i397b0577878d4f30830c80e5e23ba904_D20220101-20220930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODA4_98c70142-c193-4611-ad7b-9562837cfaf1">5</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets included in the unaudited Consolidated Balance Sheets had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="ia8ea1f91a3ce42f0acfbb45e515ff2fe_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2MzExNQ_33fd9752-3724-4d5c-a2e4-299cefd85777">2,828</ix:nonFraction>&#160;million and an estimated remaining useful life of <ix:nonNumeric contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2MzE0MA_138ec543-1d61-4cda-8f77-2463c9074cfe">63</ix:nonNumeric> months as of September 30, 2022. On August 10, 2022, a court held, that among other findings, that certain U.S. patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) were invalid (the &#8220;Norwich Legal Decision&#8221;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $<ix:nonFraction unitRef="usd" contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODg2MTY1_ba1ec995-fb9f-4d9a-828f-bbd588b21a3b">1,216</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4f554645c0484ce0ae9425488ca631d5_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODg2MTgz_f60ad7b7-88a0-4906-a7cb-2d9782ea6cc4">1,194</ix:nonFraction>&#160;million for the nine months ended September 30, 2022 and 2021, respectively. As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets for potential impairment. The Company performed this assessment using a probability-weighted undiscounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. This assessment resulted in <ix:nonFraction unitRef="usd" contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2NzIyMw_d9308d91-8e1f-40a0-93d5-2aad6308f034">no</ix:nonFraction> impairment of the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets as of September&#160;30, 2022. The Company also determined that no change to the remaining useful lives of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets was required as of September&#160;30, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be material to the results of operations of the Company in the period or periods in which they were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the nine months ended September 30, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfOTU3_1ad201cf-5dbc-4f27-8d6b-064334853e9e">213</ix:nonFraction>&#160;million and include: (i) $<ix:nonFraction unitRef="usd" contextRef="i69a2ccee5a034061b928c4d52b49efe2_D20210101-20210930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfOTc3_25a827e5-16a7-46f7-b724-60b250788ecb">105</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an adjustment of $<ix:nonFraction unitRef="usd" contextRef="i4bc7df085735496995eedc6a00cacc90_D20210101-20210930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA4MA_cb894826-f98a-4a6f-bfa7-f060f5b2ebc6">88</ix:nonFraction>&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i0129268431144c2283e8e4acc5441d56_D20210101-20210930" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTE4Mg_0445adac-802b-4ff8-b0e7-823607e212f9">20</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines. </span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5OTc_ab3c2e2c-67f7-41e8-9263-6ecafa9263de" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0yLTEtMS0xNDMwNjE_8f0c6042-4e1c-4e1c-972a-ad22d81a00f8">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS00LTEtMS0xNDMwNjE_a7adb653-453a-4325-8ef3-7d35a553fa91">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS02LTEtMS0xNDMwNjE_aff9cf30-bc98-4fd4-83ce-d3199e1943ad">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS04LTEtMS0xNDMwNjE_dbc04233-961a-44c5-8dea-37991a075500">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xMC0xLTEtMTQzMDYx_bcf94400-b360-4ca9-a24d-4cd96684b0b0">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xMi0xLTEtMTQzMDYx_6f4f6087-3cb9-4bfb-92f5-8369a53cf89f">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xNC0xLTEtMTQzMDYx_d583201a-d496-451e-9e48-ea5d830ddf9a">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xNi0xLTEtMTQzMDYx_9a2b2b35-00d0-45aa-a9b3-43d4ceff1f3c">4,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets amounts to approximately $<ix:nonFraction unitRef="usd" contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930" decimals="-6" name="bhc:AnnualAmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2MzY0Mg_e1c685d3-8d89-493a-9237-e5e45816d18e">539</ix:nonFraction>&#160;million annually through 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5Njg_129cb3b8-80f5-4f9a-9bbf-76a5055f3c5f" continuedAt="if2d90fa244d4490fbcbe9ca9f1ca7131" escape="true">The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 and the year ended December&#160;31, 2021 were as follows:</ix:nonNumeric></span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i31001109fba64f489904e1d0f3e3216f" continuedAt="iae8fb651f75a42fdadb53e440cc2e08f"><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="if2d90fa244d4490fbcbe9ca9f1ca7131"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbd566effed4fadb5896bab8a971143_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0yLTEtMS0xNDMwNjE_b7fb324d-d6ab-4cdf-830a-3d3b6202c8f6">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b8feee0c59f4701a4312e6c630644df_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS00LTEtMS0xNDMwNjE_ccaaa89c-20b4-4a27-b268-3e5d03e2ee70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ef4daf91aa4f8281c317fad068c66c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS02LTEtMS0xNDMwNjE_262ad717-4eea-4598-b642-d6a0755c64c7">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee578c670ae4dc29125f5982e51a5c9_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS04LTEtMS0xNDMwNjE_9beabc63-5413-4aba-9547-5eadc58eeaff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee081f26b684d829a12ac1265d3053c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xMC0xLTEtMTQzMDYx_eb1d4d63-2106-47a1-b558-b8778b4f0673">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b49bc1d6794cc7856a6269ce445917_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xMi0xLTEtMTQzMDYx_c9636b96-1a77-4fed-84f3-93de12229f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3da8eb119b435bbd381609ad532677_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xNC0xLTEtMTQzMDYx_5871de61-f7a4-4e44-8b6e-518d5ae76ded">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xNi0xLTEtMTQzMDYx_71d5db4b-1202-48ab-92b9-7941b8892134">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0yLTEtMS0xNDMwNjE_fbef9ba5-14c8-4157-8c94-8e7466297e55">5,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi00LTEtMS0xNDMwNjE_30b53fe8-1e6d-48d3-b05a-cfc1afa37521">5,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi02LTEtMS0xNDMwNjE_44d49ae3-f032-4dc7-a9a8-7e805f933cea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi04LTEtMS0xNDMwNjE_c7fa3a04-7893-4e5d-8382-a6a03acbb655">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xMC0xLTEtMTQzMDYx_ffc7d027-1f6b-4669-b298-68d1e2396220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xMi0xLTEtMTQzMDYx_7bddffac-b297-452b-a000-0f36d7e1846a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xNC0xLTEtMTQzMDYx_361c45f6-d766-4ba6-bab2-9ddf6549ea23">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xNi0xLTEtMTQzMDYx_71e9c2af-51b8-4018-9320-ecbb00a9014d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0yLTEtMS0xNDMwNjE_af5b03eb-e701-42e3-bb1a-482000d8004d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy00LTEtMS0xNDMwNjE_846c6fee-ff3f-4916-ab71-8674356b4be6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy02LTEtMS0xNDMwNjE_4a04ddb4-e2ed-4be8-b9bd-a6952d6319ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy04LTEtMS0xNDMwNjE_fc19827e-875d-4990-a900-11bec60a75e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xMC0xLTEtMTQzMDYx_57966609-3551-4c6e-87e8-56e7fec0f4be">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xMi0xLTEtMTQzMDYx_9ea7ec0a-5270-4fcf-a49c-014eaf3ab7d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xNC0xLTEtMTQzMDYx_f8a2154d-37ec-493a-8939-1f37bbd3b9f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xNi0xLTEtMTQzMDYx_7637ab82-5470-4044-b0af-7f83f863c509">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0yLTEtMS0xNDMwNjE_69542c61-e4e4-443a-81e1-eba1812a6005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC00LTEtMS0xNDMwNjE_339fd1e8-6090-4022-9b3c-821c05eed1c9">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC02LTEtMS0xNDMwNjE_c37e917f-6c4f-4d5e-87a1-120e3a06a087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC04LTEtMS0xNDMwNjE_5b89bc0b-f2ab-4257-b274-1ffc1ee6bb5b">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xMC0xLTEtMTQzMDYx_a9cfd1be-a8d2-41a7-91c2-17cfa32c3929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xMi0xLTEtMTQzMDYx_dc9e5eeb-29aa-4fb0-bc32-76ef06a89a40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xNC0xLTEtMTQzMDYx_e2d0ee40-f476-49a0-bd02-d97ad8593d92">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xNi0xLTEtMTQzMDYx_6f7bdeb1-34db-43c2-92c9-dc740432d5bc">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c7425072c141219aa1cdd573bd405a_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0yLTEtMS0xNDMwNjE_889d3290-42ff-4d66-988c-6e898ec9bab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184f88c56dd24fc0a24d578d3cec1912_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS00LTEtMS0xNDMwNjE_ef937ef7-73ed-478e-8902-b0193c3eeaf3">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524914c3e77a431bb6e23bf2b8d68654_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS02LTEtMS0xNDMwNjE_cc390d7b-d15f-462f-92d3-93ad53813181">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c2a1f6e1e67469ca7b69557b895dc8b_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS04LTEtMS0xNDMwNjE_614eb1e3-bca7-4a89-8b0e-bafbb6af6f22">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054e43fb12054855a665b8a78721656b_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xMC0xLTEtMTQzMDYx_1f7a3fe4-3167-4ced-936a-9bbf1c20b978">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e156c972764457f83682644cc5296a4_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xMi0xLTEtMTQzMDYx_08a74d10-0205-4ef8-b4bb-0824eebfff2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0655cf22cd44bd085e0dfc3bd855124_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xNC0xLTEtMTQzMDYx_e7542ecb-ef01-42ff-8680-3ec1252bfc26">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xNi0xLTEtMTQzMDYx_d7cac102-39b8-491f-b226-1cce1b5512e0">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0yLTEtMS0xNDMwNjE_b8597f76-6fa0-4af3-82a5-c8b57a57d335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi00LTEtMS0xNDMwNjE_6777d22d-f019-4dea-afca-6dada7070f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi02LTEtMS0xNDMwNjE_73a78fce-25f0-4259-939c-0e8152504d24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi04LTEtMS0xNDMwNjE_96404b5f-1fc5-4e2a-bdcb-8e510ac4bbd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xMC0xLTEtMTQzMDYx_f24079af-e78a-49cd-8f1c-0ccf26f91c93">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xMi0xLTEtMTQzMDYx_2f172447-e494-49e0-be64-d2adccd1e7bb">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xNC0xLTEtMTQzMDYx_d680251f-feb9-432c-be4c-c0d88868be6c">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xNi0xLTEtMTQzMDYx_28dd2565-c205-41c6-99cd-d7ffed625613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0yLTEtMS0xNDMwNjE_4f5fc81b-9403-48e2-9611-bb8d6599cd7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy00LTEtMS0xNDMwNjE_16b3b3fb-7087-423a-8dbd-a56c70479bff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy02LTEtMS0xNDMwNjE_f70d8138-0976-4614-8f7a-0e9594c0c537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy04LTEtMS0xNDMwNjE_46e4dc92-5263-4ad8-bc4c-e7abb6bb0940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xMC0xLTEtMTQzMDYx_1e367968-8010-4f1e-8ee8-974a686a889b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xMi0xLTEtMTQzMDYx_0a4936c0-3331-408d-b5d2-71b3707aec4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xNC0xLTEtMTQzMDYx_4baf43b5-54da-4434-a089-b89546b0efe6">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xNi0xLTEtMTQzMDYx_61075e65-4f22-41c5-bc78-9e0062f73b92">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0yLTEtMS0xNDMwNjE_a9ea3cc4-8866-43d0-a0dd-8038ab25e87e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC00LTEtMS0xNDMwNjE_4f469167-665e-49a5-ae6f-cfe516c58160">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC02LTEtMS0xNDMwNjE_88e785dc-65ab-4f17-98d2-9ca5cc03bf9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC04LTEtMS0xNDMwNjE_a32f6e83-2c21-49b4-a12a-8e248ccd8884">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xMC0xLTEtMTQzMDYx_757bee70-60a6-4fd7-af84-638a11145850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xMi0xLTEtMTQzMDYx_2e17aae7-8b73-4619-8f24-137ed0f5e805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xNC0xLTEtMTQzMDYx_d18893a3-05d0-49d5-a249-cf1d2def4144">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xNi0xLTEtMTQzMDYx_fbe88739-145a-4ffb-b2d4-13eef1cedace">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4586553989374f86b0151f9e1dc47d44_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0yLTEtMS0xNDMwNjE_7fc7263f-f4fa-4aee-ab0e-981536cdb89b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a9044c2815433dadfb6a1fbc0fc718_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS00LTEtMS0xNDMwNjE_27f4e8f3-8f71-481a-a824-459272b32c5c">5,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e30d8a0b70472da327a5cd5d504e40_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS02LTEtMS0xNDMwNjE_81c1d981-9eb5-4d8a-8ba1-36321787ad19">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eb7d5760de84dbba93d5758373f7df3_I20220930" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS04LTEtMS0xNDMwNjE_275f5884-c351-4466-8366-2412903b3975">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3f217039214cc99ebb1a3146d44e2c_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xMC0xLTEtMTQzMDYx_6f5a58f7-c9c1-4752-84c5-1a8edbe99ad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf04300c0b04203930e4017146b0a29_I20220930" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xMi0xLTEtMTQzMDYx_2f79529e-e208-4e7c-af00-f699aa3c944a">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171290f4c16143278fe977553e53a298_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xNC0xLTEtMTQzMDYx_c2e720a0-a4f6-4410-8570-f0241dc5eda3">2,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xNi0xLTEtMTQzMDYx_d136499b-31ea-4040-8232-6bf601ee3030">12,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="iae8fb651f75a42fdadb53e440cc2e08f" continuedAt="ia38d837330eb42a0b5896c5f8678dd20"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i361b8355ced14036903137406c65acd3_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzc4MA_7f86be98-9984-4189-bbaa-988c186b5ea8">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie32f67a7dcdc4304965f785c3401a61c_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzc4Ng_248192d6-4443-4772-a098-eeca58913842">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i361b8355ced14036903137406c65acd3_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzgyNw_6914d4ea-be05-48d5-969f-4a8bf7a18716">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie32f67a7dcdc4304965f785c3401a61c_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzgzNA_95bb6826-70fc-4d1f-9fe9-aa3956ae2ce6">12.25</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="ia6e12bdaebcc45a1b8c0c18938e51e4e_I20210331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODAxMw_1b41f052-6484-4200-8a6f-68d6d678f2f0">40</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i734ba9baeab74604b0c7c558dc66e5be_D20210331-20210331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODA0Mw_e2486b88-10f7-41bf-b820-024b16fad090">no</ix:nonFraction> impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="if0c43778cbdf409ca15ed80687c13da5_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODk2Ng_c8711b0e-0cf4-4231-a959-67e1be1b1859">no</ix:nonFraction> impairments were recorded.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="iec85868873634d7aaec5771a953c7224_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA1ODQ_92166582-492b-4a6e-b00c-68d978aa5d71">1.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i9ee0f7dd3ca94d9a813c20822f42b12e_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA2MjU_857cb2c0-ade8-4a75-8b1c-08eab66ffd5b">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia75d309fb9e24efe806b94be702f2683_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA2MzI_942853ac-10d8-4b8e-bd4e-031d87e00168">10.0</ix:nonFraction>%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="icf0b557c0f5743d4853cda063a55d5a1_D20210331-20210331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA4MzU_d5940295-cbad-414e-8463-90a39554bb0d">469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i64029e7dfd364587a73eb03edb488c6c_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI4ODI_2284189d-a30f-472a-944e-23d89fe489e8">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7be821d39f844c7c9e6f5db374b2d390_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI4ODk_e7c47439-215e-4dc0-b709-7b9224f49010">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i64029e7dfd364587a73eb03edb488c6c_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5MzA_58b290a0-b949-4a7e-8018-4c7256cfa783"><ix:nonFraction unitRef="number" contextRef="i64029e7dfd364587a73eb03edb488c6c_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5MzA_93f0d3c0-0a23-4387-80ca-465a3ad9e2a0">7.0</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7be821d39f844c7c9e6f5db374b2d390_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5Mzc_1901ddc8-e2d0-4976-8209-7ffcb1f6c1bd"><ix:nonFraction unitRef="number" contextRef="i7be821d39f844c7c9e6f5db374b2d390_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5Mzc_77e11b24-d122-49ce-afbf-29debfa5d799">10.0</ix:nonFraction></ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="iaab855eaea194ef4a3d9af3afceb50c7_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTMxMTY_7fa5473d-ffbb-4995-b5d9-7bb1e5fe5699"><ix:nonFraction unitRef="number" contextRef="iaab855eaea194ef4a3d9af3afceb50c7_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTMxMTY_bda18d06-d8ee-4d2d-907c-b6f64fff771a">45</ix:nonFraction></ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="icebcda21eb184f5596ae20266fcd05c5_D20210630-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTMxNDY_e3b95092-cb2a-43a3-9743-dd75b86678f6">no</ix:nonFraction> impairment to goodwill.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia38d837330eb42a0b5896c5f8678dd20" continuedAt="id27cd44d84b54184a2ec0b3795f59e38"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i807f651e453049d280b13aa13946098b_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ2MDA_ad3318f8-bab6-4baf-9c44-39bea9a75ffd">1.0</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i807f651e453049d280b13aa13946098b_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ2MjY_a0a1f2be-9131-4ea6-b624-ca9c59cbef7c">9.0</ix:nonFraction>%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="i807f651e453049d280b13aa13946098b_I20211001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ4MDQ_33a58c98-70a4-45b1-91a4-6019a8011910">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i7e572145d9a7467baa36216af20a4a17_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ4NjU_aaf536f2-a15c-4018-9505-6cfa69ba8d48">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="iad592bdffaae43e9a655afeab7d37965_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTU3ODQ_d0fe07c8-5aa0-4a4a-8cba-f967df385d0f">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i9520dcf4eed94040af3402086c331516_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTY4NzU_1dff4f26-245c-4e14-ac94-a377e97d730f">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i9520dcf4eed94040af3402086c331516_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTY5MDE_5ab490f8-7028-4341-8722-1fdc2446c5f3">9</ix:nonFraction>%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than <ix:nonFraction unitRef="number" contextRef="i9520dcf4eed94040af3402086c331516_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTcyOTI_1b883fd4-5d28-459f-a335-72f063f65f0f">2</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="ieaabe709841d4ab5a8f48593d73a6236_D20220101-20220331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTczNTM_fa901669-7d39-4581-9cc9-dff611247bbf">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment of Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s latest discounted cash flow model for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTg4NzY_5810e0b2-2a1f-40d0-bd6e-e98198a60df0">1</ix:nonFraction>% and a discount </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="id27cd44d84b54184a2ec0b3795f59e38" continuedAt="i1299c43ca24a4a33b51c6df5e8176afe"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate of <ix:nonFraction unitRef="number" contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTg5MDI_6a536fb4-5fbf-4235-9b98-51fa12c849b4">10</ix:nonFraction>%. The discount rate had increased <ix:nonFraction unitRef="number" contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTg5Mzg_466756da-0ce7-42ee-8993-81618f872da0">1</ix:nonFraction>% since the assessment performed at March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="i29fa46a2016a4d6fbd35835aab2e7733_D20220401-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTkzMzg_9af4c7b6-933b-42b8-ba28-0015a30e328a">83</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the time Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The decline in the equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which at June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the <ix:nonFraction unitRef="reporting_unit" contextRef="i0d23798ee6944435964f0ae2a74b0053_D20220506-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjAwMzk_15574e27-f365-442c-8b70-881e6ee1a7ba">three</ix:nonFraction> reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized Bausch + Lomb&#8217;s most recent cash flow projections for each of the reporting units and utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="ib7cbe70ccd6a46a295e6b86c6ca5e603_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA0NjE_5736e1e5-f32f-4e6b-9d09-a9c7d71388dc">2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if06aa410016b4d3d9736289f10b1b949_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA0Njg_68616f0b-8658-45eb-b09f-0f07208b6a51">3</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="ib7cbe70ccd6a46a295e6b86c6ca5e603_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA0OTM_4a558cfa-47cd-4f69-a70c-388f04e222b3">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if06aa410016b4d3d9736289f10b1b949_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA1MDA_aeb2e925-f0de-44c2-9e8f-84cf6a57f874">11.5</ix:nonFraction>%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than <ix:nonFraction unitRef="number" contextRef="iabdffbd57d864d79afae07b110981771_I20220630" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA2Mzc_d1877980-f666-43b2-aacb-9c4c8a63c711">25</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i8161c31ec1444e4282b76d79a09434c1_D20220506-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA2Njc_582e81e3-517f-428d-92dd-b645f533b24b">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, with the exception of the Ortho Dermatologics reporting unit and the reporting units of the Bausch + Lomb segment, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="i34d55f72c27c47f6afb001ca411f5fa2_D20220401-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjEwMDc_8fcb2217-0de2-4946-aa51-be04e0fd1df2">no</ix:nonFraction> impairment to those reporting units was recorded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 30, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Based on the impairment of goodwill recognized in the second quarter of 2022 for the Ortho Dermatologics reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections which reflect current market conditions and current trends in business performance. The Company&#8217;s latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i4339e12a380546a9b2b74237a9f3cff2_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTA5NjIwOQ_efacf78b-ba47-4c45-87df-aa47089d643b">1</ix:nonFraction>% and the discount rate increased from <ix:nonFraction unitRef="number" contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTA5NjIxMw_41ce841d-63d1-4af3-a321-5210fee211c3">10.0</ix:nonFraction>% at June 30, 2022 to <ix:nonFraction unitRef="number" contextRef="i4339e12a380546a9b2b74237a9f3cff2_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTA5NjIyMA_6fbf815b-c5f3-414d-8f1d-703c48cb7238">10.5</ix:nonFraction>% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="i1130a33c0fde483fa1bae8711549f82b_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA5OTUxMTcwNDk3Ng_8ebb5360-6b22-4983-abd6-7d7f2d72f08f">119</ix:nonFraction>&#160;million for the three months ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues represent approximately <ix:nonFraction unitRef="number" contextRef="ibefdea46ac904b858f0d89701cc31d09_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODkwNjQ4_55bddcd0-22e3-43d0-8247-5ae7e288b8bd"><ix:nonFraction unitRef="number" contextRef="i203a22f1210340a79695abcf5e8cbc84_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODkwNjQ4_fd5b7fd8-c824-4511-bf98-6fadce5b2205">80</ix:nonFraction></ix:nonFraction>% of the Salix reporting unit&#8217;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i1299c43ca24a4a33b51c6df5e8176afe"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="ic7a8a8be34dc47ba912bb7fad91b59d1_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0NjYxMw_c87939fb-5567-4bef-a252-3008acb294d4">2.5</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="i6e21f5810f55489593ecaa960423f5ab_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0NjYxOQ_1309f3a6-28f4-40d0-b9bd-65c6779f83b7">9.75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iaf38a4e092a6474e82b48723b723f43e_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0NjYyNg_80277a99-8d71-4dea-a4ab-a987c4b54803">10.0</ix:nonFraction>%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore <ix:nonFraction unitRef="usd" contextRef="i4bad238d099849c8bbcf419abb996956_D20220701-20220930" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0ODkzNQ_e1af756c-c873-4a4a-a4ee-49421aa7371c">no</ix:nonFraction> impairment was recorded as of September 30, 2022. However, as the Company&#8217;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than <ix:nonFraction unitRef="number" contextRef="ic7a8a8be34dc47ba912bb7fad91b59d1_I20220930" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0ODk0NA_b11ee74d-95df-4571-b1d5-407dc21253e2">5</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix segment in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period of October 1, 2021 (the last time goodwill was tested for all other reporting units) through September&#160;30, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics and Salix reporting units and the reporting units of the Bausch + Lomb segment, might be below its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through September&#160;30, 2022 were $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjExMTc_3234dd2a-877a-410a-b745-38914c2dcfd6">4,382</ix:nonFraction> million.</span></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RleHRyZWdpb246ZGFjMWVlMjUwNjhlNDdlNWE2NmMwZmZkZGJmZDI5NDBfMTAw_a430af61-aef5-419b-a246-17f0facdaf56" continuedAt="i16c765c94dfd4d90a2192ae7257962e6" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i16c765c94dfd4d90a2192ae7257962e6"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RleHRyZWdpb246ZGFjMWVlMjUwNjhlNDdlNWE2NmMwZmZkZGJmZDI5NDBfOTk_a17eb9a7-71ca-4b4f-b226-1e58c83ab08b" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMS0yLTEtMS0xNDMwNjE_a9174373-fa3c-44d3-b029-7c977eda74ed">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMS00LTEtMS0xNDMwNjE_02f44f04-c297-4953-b328-36460f1e7795">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMi0yLTEtMS0xNDMwNjE_2e25370b-0b70-4447-82dd-862bb661996d">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMi00LTEtMS0xNDMwNjE_e85b85e2-0c9e-4e3f-b1be-0b75cc35f6dc">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMy0yLTEtMS0xNDMwNjE_fabd5283-c0c0-4889-b645-769c00097714">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMy00LTEtMS0xNDMwNjE_7710a605-f20f-4120-aabe-cb5ec7dbf92c">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNC0yLTEtMS0xNDMwNjE_633dbf2e-2461-4a3b-bd31-ccb73d3d00c0">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNC00LTEtMS0xNDMwNjE_e48f6ff5-0e60-4032-b119-5e291aa58b78">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNS0yLTEtMS0xNDMwNjE_08893894-2f63-4790-a580-4f3f2e6e3004">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNS00LTEtMS0xNDMwNjE_4c65bdab-c093-4965-a9c0-a9e57310ce84">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNi0yLTEtMS0xNDMwNjE_026aa796-449f-43f3-b52a-0106a1d1b341">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNi00LTEtMS0xNDMwNjE_160a7bcd-eede-4242-aa8b-57aff49c6e98">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNy0yLTEtMS0xNDMwNjE_c2f7a305-9a1c-4bc2-b99d-376a701aa055">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNy00LTEtMS0xNDMwNjE_67af27fc-c348-4aaf-b482-2c996bba8855">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfOC0yLTEtMS0xNDMwNjE_1af8e54c-58a6-443b-8825-0779a529e157">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfOC00LTEtMS0xNDMwNjE_24ae09db-3adf-460c-8501-28200e798889">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_67"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg4OTY_10c8247f-2f4d-4702-bb56-f2df1fe39220" continuedAt="iba621c823f6b4cfa99798013566ee088" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="iba621c823f6b4cfa99798013566ee088" continuedAt="ia1d662eded1a4f179e37b6bbd8e9735d"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg5MDU_2a30bf46-e112-4be7-9a47-12d5e9c40a69" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b8f0ab2fbb4bb7b6a75eb4df909667_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC00LTEtMS0xNDMwNjE_e89cc100-d9aa-4c65-a23e-0c91dd069804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b8f0ab2fbb4bb7b6a75eb4df909667_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC02LTEtMS0xNDMwNjE_b0a5bcdb-1a35-44ac-8f86-14ae98b42f1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58467a391034c9cb187019aeffd9731_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC04LTEtMS0xNDMwNjE_9b7e24a0-6643-4e96-9a90-776c608b5a46">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie58467a391034c9cb187019aeffd9731_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC0xMC0xLTEtMTQzMDYx_0453e577-6d5b-4405-abcb-7b2c820017d3">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c61192e231431db2b0a3faccf31084_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS00LTEtMS0xNDMwNjE_dccffd04-7cd5-43f4-945b-5e4f8afef1df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c61192e231431db2b0a3faccf31084_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS02LTEtMS0xNDMwNjE_281799fe-655b-4ae1-998c-3079f1ef73cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e23e6b1602e45c69f5e0263e4e91c1f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS04LTEtMS0xNDMwNjE_ba5db6f9-8a86-4124-a3dd-e8073abd0128">2,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e23e6b1602e45c69f5e0263e4e91c1f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS0xMC0xLTEtMTQzMDYx_bf1b3d0c-bb7d-49b7-a696-f5ce99d03426">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e0efdc5bd2442e86a6a489bf72fa7a_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi00LTEtMS0xNDMwNjE_30d66993-b5ea-45a9-8613-2524c166b148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e0efdc5bd2442e86a6a489bf72fa7a_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi02LTEtMS0xNDMwNjE_f7c1c064-be61-4685-85e5-da9ec26ff994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e089be5eb041cf9cce81981f011be7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi04LTEtMS0xNDMwNjE_cbcc4f28-734c-4e1b-b521-4fd90ee0c202">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e089be5eb041cf9cce81981f011be7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi0xMC0xLTEtMTQzMDYx_3566a632-af78-4bf5-a8cf-076ccd311181">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f39bda64df4253bfb97df28400bd07_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC00LTEtMS0xNDMwNjE_6340978a-a85d-4912-a7a2-b396b7f65501">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96f39bda64df4253bfb97df28400bd07_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC02LTEtMS0xNDMwNjE_94b7045d-250d-42d4-9315-c847c9228975">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4825754c7324c8182558e6ae17503ef_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC04LTEtMS0xNDMwNjE_5ad10557-892f-45a4-812d-4b6afc293b40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4825754c7324c8182558e6ae17503ef_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC0xMC0xLTEtMTQzMDYx_57ac6314-f7f9-4a5e-90d2-f8f371433b58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4424b9ece149c8ae2652648e9479fe_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS00LTEtMS0xNDMwNjE_e0ed11c7-fc7d-4978-82f0-cb2d793e2edb">2,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4424b9ece149c8ae2652648e9479fe_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS02LTEtMS0xNDMwNjE_715bbd13-6f8a-4091-ae23-88f4d05b1170">2,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60f32e20efe40bdafd03b20dcc4ea54_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS04LTEtMS0xNDMwNjE_54fd6584-830d-45d3-bc55-3d2569697796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60f32e20efe40bdafd03b20dcc4ea54_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS0xMC0xLTEtMTQzMDYx_bf057957-143c-4957-a219-25d80d872061">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2719dec24cd48aea9d17bcf664f412b_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtNC0xLTEtMTQzMDYx_2d86744a-d52f-4bcb-8574-ef25fac6e189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2719dec24cd48aea9d17bcf664f412b_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtNi0xLTEtMTQzMDYx_da9c5729-05b1-4b85-8975-4857a4fd51bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658fec0dcb034795a01b1f1d2734dfe7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtOC0xLTEtMTQzMDYx_d16e0761-0a3c-4410-bd54-498a8138d4e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658fec0dcb034795a01b1f1d2734dfe7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtMTAtMS0xLTE0MzA2MQ_07926b3d-a5d4-4109-82e5-0fc1527c6c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItNC0xLTEtMTQzMDYx_e958c7e6-8474-4e80-a63a-a2cd6d860f20">2,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItNi0xLTEtMTQzMDYx_1e6bf392-d5fd-41a5-9643-08cc3d98aa0d">2,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c72157e725454bae3d98331b48e1b8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItOC0xLTEtMTQzMDYx_542343da-748f-4e27-aff3-bb4338d94bf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c72157e725454bae3d98331b48e1b8_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItMTAtMS0xLTE0MzA2MQ_3795ad6a-babe-48fb-bdf9-5d64395d216e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NWU4MTNjN2ZjOWI1NDI2ZGFiNzc0OWUyOWQyNGIyZDBfNA_41f62df0-c592-4edf-8710-07ee72c68647">5.50</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtNC0xLTEtMTQzMDYx_3f728565-3b44-48a9-a8ef-266d23f3216f">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtNi0xLTEtMTQzMDYx_f1cb2696-dc55-46b6-9481-e037d05a0cd2">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c8689541c04f66b5293904f3094a90_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtOC0xLTEtMTQzMDYx_bbd020c4-84db-49d4-aeb2-217711e0b9ad">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c8689541c04f66b5293904f3094a90_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtMTAtMS0xLTE0MzA2MQ_80ad0a8b-adae-41ce-95c2-00ba04d724c9">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic9736f916a62479d8d54ac9b1251c9c4_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NWVjZDZhOTAxMDJiNDVkYjlhZTY5NzYxNDVlZDIyMTdfNA_888513ac-6e16-438b-8136-7593eb813a86">6.125</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9736f916a62479d8d54ac9b1251c9c4_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtNC0xLTEtMTQzMDYx_bf561fba-25d2-4990-b63c-27b3dbde52af">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9736f916a62479d8d54ac9b1251c9c4_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtNi0xLTEtMTQzMDYx_18e114aa-3f0f-418f-9d9b-620add493ae5">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34ba1093cad49c292458d52b08c823e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtOC0xLTEtMTQzMDYx_24897fa8-cd79-4a7f-9f24-57d739ac4e64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34ba1093cad49c292458d52b08c823e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtMTAtMS0xLTE0MzA2MQ_0ef06ef6-d462-45f9-910c-3683c778a38c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65627fa9869f456389b3882ce8b37654_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjAwMTE3ZjU2ZDQ3NDRhNGE0MWE0NjQyZjY5MDRmYWJfNA_cb47dd77-0f91-45d9-93fa-f25430a4681e">5.75</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65627fa9869f456389b3882ce8b37654_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtNC0xLTEtMTQzMDYx_20d99bec-888f-442e-a7b7-15cf9fdca442">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65627fa9869f456389b3882ce8b37654_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtNi0xLTEtMTQzMDYx_75df2572-ee1a-4dae-99b1-d56a3a6a87b2">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847b6dcc9bf747ab946d8f1b08b3d71e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtOC0xLTEtMTQzMDYx_22eccc90-d7de-43b5-8e65-6f70a2ec7ba1">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i847b6dcc9bf747ab946d8f1b08b3d71e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtMTAtMS0xLTE0MzA2MQ_26f6f798-8ae2-411c-9a71-1ca44b9a27ee">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2824f9dc84c40c396db9edca43574e5_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctMC0xLTEtMTQzMDYxL3RleHRyZWdpb246OWQ0MDBkOWFjM2NmNDM5MmI4YTNiNDc0NTg5NzViOGNfNA_e89bac14-5a61-4092-9ef9-51315bf02e73">4.875</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2824f9dc84c40c396db9edca43574e5_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctNC0xLTEtMTQzMDYx_ce713418-489b-436f-9301-24c32ee8eea9">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2824f9dc84c40c396db9edca43574e5_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctNi0xLTEtMTQzMDYx_67839575-5c0f-4e3d-a3cf-fdb17f9d4773">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb6c1c4d20b44c3a7dd173a66fc96d4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctOC0xLTEtMTQzMDYx_0b2e42fd-385f-4aa4-b2cd-7adec61888ce">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb6c1c4d20b44c3a7dd173a66fc96d4_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctMTAtMS0xLTE0MzA2MQ_c29cb46b-925e-4e06-9d6f-1cf992fffffb">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMC0xLTEtMTQ5NTE4L3RleHRyZWdpb246OTM2ZjliOThhMTQzNDUwZTg5NzAyNTY0N2Q2ZjQwZDlfNTQ5NzU1ODEzOTI5_9dcc4884-e42b-4418-90e5-b436386c1941">11.00</ix:nonFraction>% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNC0xLTEtMTQ5NTI1_be5334f6-ebd2-433b-8f62-54a8cb30cca3">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNi0xLTEtMTQ5NTI1_0b1ba91f-930a-4eba-a042-ca443b912126">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ead96a008c4245b48958509368a215_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktOC0xLTEtMTQ5NTI1_371404df-c509-411a-9b71-a31441ca8bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ead96a008c4245b48958509368a215_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMTAtMS0xLTE0OTUyNQ_4453e455-8060-4882-a96b-8d60011ec2d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMC0xLTEtMTQ5NTE4L3RleHRyZWdpb246NDY4YjUzODJkNzg1NGJlNjhmNmZhZWNkOTdmNWQyMDNfNTQ5NzU1ODEzOTMw_51f3eb8c-b7d5-4b1e-9ef4-676861a7da93">14.00</ix:nonFraction>% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNC0xLTEtMTQ5NTI1_f17d78da-50bf-46b1-8677-7e7ba46473cc">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNi0xLTEtMTQ5NTI1_fa911e80-6a27-4688-bc77-1b00be21ee6e">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0837135263d44f058fe95a28f43c5e2c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtOC0xLTEtMTQ5NTI1_d9ccde47-a763-42c8-95c5-57f1a55cfd2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0837135263d44f058fe95a28f43c5e2c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMTAtMS0xLTE0OTUyNQ_dd6b9f28-e27f-47b0-9356-f684407e0e7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMC0xLTEtMTUxMjM4L3RleHRyZWdpb246MjZmM2RjYmJmZDU0NGY1MjhjNzM3Zjg0ZmJhZjhhOTlfNTQ5NzU1ODEzOTM2_1ac71bb1-ce37-4e1f-bcac-73cab2354eef">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNC0xLTEtMTUxMjM4_54e86c50-c110-41a4-b433-459869ac7cff">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNi0xLTEtMTUxMjM4_88b7e0c1-aeab-43c3-a3dd-7a5a6981d841">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4849d9106bec4ca28083d112da7d7ad9_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItOC0xLTEtMTUxMjM4_ae145d9b-c9e9-484d-bfe5-21f98c33d131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4849d9106bec4ca28083d112da7d7ad9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMTAtMS0xLTE1MTIzOA_ea65b95f-5416-4fed-a902-a876f39cbd3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMC0xLTEtMTQzMDYxL3RleHRyZWdpb246ZjRlN2YyNzg1NTEwNGI0MDgxNDJlMTkxNzVkNTgxNDVfNA_0e827e85-f3cc-4c94-a203-c9b75ffb8122">6.125</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNC0xLTEtMTQzMDYx_cd66fbf8-a61b-4470-a8ce-d459fe9bbebc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNi0xLTEtMTQzMDYx_36f4b6d4-efa0-457a-8d2e-2de2bda643d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d20de201c0e49b49c27d368b4cb4cb3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktOC0xLTEtMTQzMDYx_76de95ae-fa8f-4d0c-8091-b08fdce44512">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d20de201c0e49b49c27d368b4cb4cb3_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMTAtMS0xLTE0MzA2MQ_25d56557-d095-49cf-acd5-980939fe1629">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246N2I1ZWZjYmU3YzQ3NGQ3YzgzMTU1MGJjZmMxY2Y5ZjVfNA_a99e52ac-5dcf-44c9-b916-86f26939094f">9.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNC0xLTEtMTQzMDYx_6e992740-9208-4c68-8190-b3f155f0c06c">959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNi0xLTEtMTQzMDYx_420f3d98-c658-413f-bdba-9c844ef7fa33">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67496121616e45d98e1c3a401c8ad3e6_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtOC0xLTEtMTQzMDYx_2589fb37-56d5-482a-b90f-40084ca0b1fd">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67496121616e45d98e1c3a401c8ad3e6_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMTAtMS0xLTE0MzA2MQ_203de56b-d5d7-41ae-b437-5d024c2f2c1b">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NGZkZDY2MTJkYmEwNGJlNWIyNjYwNTk5NzU0YWYyZDBfNA_f96683da-a87f-48a8-8945-6021db7374a7">9.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtNC0xLTEtMTQzMDYx_e198c077-bed5-4d07-aead-f7847e52b8a6">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtNi0xLTEtMTQzMDYx_718c82c5-a5cb-499a-948c-4d33fa3755bb">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ea118f8acc428ca2545966a39f9e19_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtOC0xLTEtMTQzMDYx_06209e61-8176-46da-89ea-06712f04923c">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ea118f8acc428ca2545966a39f9e19_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtMTAtMS0xLTE0MzA2MQ_acd0accd-575e-4359-90b3-66c5109f54cf">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6125e68618df43ada745dc4ed96c0b44_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MDRmZWE3ZjZjMDYyNGRlYWIyNTYyOGE2ZTQwODYwZTlfNA_279a66f0-4a37-4681-8e34-1bc59809f956">8.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6125e68618df43ada745dc4ed96c0b44_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNC0xLTEtMTQzMDYx_9eefdf49-54f3-4374-9f66-8e0a44efc54f">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6125e68618df43ada745dc4ed96c0b44_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNi0xLTEtMTQzMDYx_2619b6e5-cd28-4701-b145-15c927e6ddb3">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f48cc3094e8425dbf7cb547b1775c69_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItOC0xLTEtMTQzMDYx_ee1cc719-d01b-4ae3-bc6b-7baa8421dfc4">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f48cc3094e8425dbf7cb547b1775c69_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMTAtMS0xLTE0MzA2MQ_66d175c8-0d28-4c66-9e16-8e69396656b4">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i624988cc531340da8809b18541e3ae0c_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NjczYjNjNDE5MzNhNDhjZTk5OTUwN2I3NTUzNmZlMTVfNA_ed44f234-b5f9-4ffc-b1c3-4cb11fea98d0">7.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624988cc531340da8809b18541e3ae0c_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtNC0xLTEtMTQzMDYx_6a7d1aae-b7b2-4141-8373-b0c8e6fe2ae6">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624988cc531340da8809b18541e3ae0c_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtNi0xLTEtMTQzMDYx_b02412bc-3492-4e43-a703-61a34710284a">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7f0a78f9524510a26d87340b762969_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtOC0xLTEtMTQzMDYx_289b58a3-a554-4404-9fc5-c2adca799e87">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb7f0a78f9524510a26d87340b762969_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtMTAtMS0xLTE0MzA2MQ_af115aaa-045f-46fb-8935-1463ac4f32eb">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec3a4af6ebd741b697f1f5228fc4b251_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NDU0YmMxNmEyMTZjNDliMGI4ZTc3ZDAzYTQ5MmVlN2VfNA_8c65228b-f129-4250-98e1-a1288d4aa844">5.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3a4af6ebd741b697f1f5228fc4b251_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtNC0xLTEtMTQzMDYx_1d288116-167f-4928-a997-99c687b6cdc9">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec3a4af6ebd741b697f1f5228fc4b251_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtNi0xLTEtMTQzMDYx_e6e66c82-2f6c-4340-ba6c-d82a44b9fb1c">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46824116217340c19c4097a996b6f0f6_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtOC0xLTEtMTQzMDYx_07e40298-2293-4f41-a404-ae9bf23d6efb">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46824116217340c19c4097a996b6f0f6_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtMTAtMS0xLTE0MzA2MQ_97086d13-1992-400b-947c-81e6dc5ec20c">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NzAxMTQzMjRlZGQ1NGJlNTgwYmUxODQwZDE4NGVhNmNfNA_2256c272-ec3c-447b-8970-8af95dc80453">6.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtNC0xLTEtMTQzMDYx_2ad5133c-511f-4253-ba24-ba601bb53ba7">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtNi0xLTEtMTQzMDYx_84c1b632-1086-41a8-b1c1-2345423fc600">857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffaec666689a4abf87b5f4f4e20a8005_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtOC0xLTEtMTQzMDYx_18b4a37a-0644-4dd8-9681-51fd3420344b">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffaec666689a4abf87b5f4f4e20a8005_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtMTAtMS0xLTE0MzA2MQ_056ae5d0-ca53-4693-8c07-606a006de39d">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtMC0xLTEtMTQzMDYx_761edc8c-3320-4de5-abcd-47822a23f25a">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtNC0xLTEtMTQzMDYx_c8fc643f-5b53-46b7-b115-0e618ea61807">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtNi0xLTEtMTQzMDYx_f22dc069-09b6-429d-9bbc-0f73c1d67f31">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed6c73971e144729fd723b401f24f72_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtOC0xLTEtMTQzMDYx_46778c1d-40e1-43bf-8c6e-866bbc5e553a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed6c73971e144729fd723b401f24f72_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtMTAtMS0xLTE0MzA2MQ_2afa0c5d-4e6e-4b10-9f0d-2e525eb6ef1d">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i736c5fc93f2242fe9da805a6c5e69418_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctMC0xLTEtMTQzMDYxL3RleHRyZWdpb246ZjBjYTI5Zjk3YmEwNGQ1Y2E4ZDFhOTU2OWRhNjc5MTlfNA_262367d2-e649-40a2-af46-1828f0b51ccf">7.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736c5fc93f2242fe9da805a6c5e69418_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctNC0xLTEtMTQzMDYx_d3b516dd-8901-454d-ad2b-958620aef6dd">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736c5fc93f2242fe9da805a6c5e69418_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctNi0xLTEtMTQzMDYx_eb3a1f18-cb0c-47be-b6c2-a1b299d607ea">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7da4ab69e9549eaa9e8488eb34481b2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctOC0xLTEtMTQzMDYx_6b13f328-bc24-48f0-8f0e-cfe2cbbfc794">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7da4ab69e9549eaa9e8488eb34481b2_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctMTAtMS0xLTE0MzA2MQ_da2c679d-904a-4f3f-8dd3-796f68a9c7af">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ad837f07b304b389bac2395b7bb644c_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246Njc5ZjVjMmVhYTI2NDI1ZTg1YjlmN2Y2ZTY5MzIxNWRfNA_2c7be1e9-44e3-4128-9583-f03902f8b349">5.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad837f07b304b389bac2395b7bb644c_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtNC0xLTEtMTQzMDYx_59a92555-1ec7-4314-ac07-fd8c1891cc47">869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad837f07b304b389bac2395b7bb644c_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtNi0xLTEtMTQzMDYx_b0966cb1-a5c8-4ea6-8998-c6f443e80c48">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e0e09e5ca542869e0a304640beb346_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtOC0xLTEtMTQzMDYx_f6444f5d-4e8f-45fb-a90f-8d28db6d5ebd">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e0e09e5ca542869e0a304640beb346_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtMTAtMS0xLTE0MzA2MQ_d95d2b92-b448-4ee1-9c4d-e39155864f66">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktMC0xLTEtMTQzMDYx_a015c81a-286e-49db-9225-484f7986e8c3">5.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktNC0xLTEtMTQzMDYx_11322ee9-d414-40b9-815f-79f5adc4405f">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktNi0xLTEtMTQzMDYx_908d0cfe-bec5-43ee-b6a1-867d39de0a96">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3431ac7fda8140f496bbf1281db492f8_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktOC0xLTEtMTQzMDYx_f87e5ac7-3ccd-4c51-a667-dbb316e935a0">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3431ac7fda8140f496bbf1281db492f8_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktMTAtMS0xLTE0MzA2MQ_3a63b8fe-8dbb-4968-a1b0-33167415f076">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2386767ef8494039a45eedf4276380c7_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtNC0xLTEtMTQzMDYx_d2b0afb1-cb6a-4a80-ab42-c6fd0eb21abf">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2386767ef8494039a45eedf4276380c7_I20220930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtNi0xLTEtMTQzMDYx_9e86a08d-b4e8-4e1e-9fe5-d8503dee57c8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b58cc7f53b24512935c9762a50cc8ef_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtOC0xLTEtMTQzMDYx_dfef9f6b-6ef2-4cc6-9fd1-8dd5ccf26e21">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b58cc7f53b24512935c9762a50cc8ef_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtMTAtMS0xLTE0MzA2MQ_c38aff11-ca18-47cf-9c2b-655dfda8ffec">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtNC0xLTEtMTQzMDYx_3c6c3729-b1ac-48f3-951b-595bd0f0c3db"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtNC0xLTEtMTQzMDYx_d1b50fe3-d39b-4fec-bf7e-ca8ae8d73507">19,574</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtNi0xLTEtMTQzMDYx_89f44626-7384-455a-bd71-77dd229151d8">21,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtOC0xLTEtMTQzMDYx_5e1e0a05-70d7-4d8b-9613-241a150f630f">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtMTAtMS0xLTE0MzA2MQ_bded3c9c-1c36-41cf-95ab-dc5ad9ac6ec0">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzItNi0xLTEtMTQzMDYx_a5c7896a-bd57-4faa-96ed-266f5abddfe2">411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzItMTAtMS0xLTE0MzA2MQ_d56221b8-3833-4a14-a402-d2a525d187f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzMtNi0xLTEtMTQzMDYx_1359b7ea-5125-47e7-a066-f5b374f14115">20,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzMtMTAtMS0xLTE0MzA2MQ_e29c07a5-df51-44c2-b016-9e32546688bb">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTYwMQ_a51a7a44-bf8f-4b71-b38d-265a78a29344">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia1d662eded1a4f179e37b6bbd8e9735d" continuedAt="i0bd14d443d0640a29dd06a5e59ef4fdf"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of September&#160;30, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="i28a31a3954134e40bc913cd1fb66abf3_I20220930" decimals="-6" name="bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTMzOQ_6cd1e034-ce04-454d-9052-2f973a22bc66">12,000</ix:nonFraction>&#160;million (although such availability is subject to the Company&#8217;s compliance with a <ix:nonFraction unitRef="number" contextRef="ice079f38e9d1403daa063c880dace2d2_I20220930" decimals="INF" name="bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQxNg_a4e43ecc-e4c0-4fc1-8342-9d0ec08a72f7">2.00</ix:nonFraction>:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="ice079f38e9d1403daa063c880dace2d2_I20220930" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTY0Ng_f1cd59a0-0045-4888-985a-fb824192b500">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to seek to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#8220;Exchange Offer&#8221;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="i74a12b5112bb435791910303cfa182e6_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2Njk2MA_5d5be041-2ca4-420e-9db3-e0c5c7fe1d7b">5,594</ix:nonFraction>&#160;million as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTcyNjMzNA_50f8dd17-9155-4262-a1f8-6d7398c3212a">3,125</ix:nonFraction>&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $<ix:nonFraction unitRef="usd" contextRef="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930" decimals="INF" name="bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTk0Nw_c96b5d05-fb14-4645-a389-2d6496257909">2,469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $<ix:nonFraction unitRef="usd" contextRef="i8728c63be96941459a588f3116991b8d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2Njk3Ng_33b0535d-008e-485c-bf5f-e2b5572993c6">1,774</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="i8728c63be96941459a588f3116991b8d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2Njk5Mg_39775e25-d5df-425f-9901-a45d303ed861">11.00</ix:nonFraction>% First Lien Secured Notes due 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i8728c63be96941459a588f3116991b8d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAwMA_f7f26343-53fc-4dd7-af68-f53941b5c16f">11.00</ix:nonFraction>% First Lien Secured Notes&#8221;) issued by the Company, (ii) $<ix:nonFraction unitRef="usd" contextRef="ia6053ee47e754dcc8601ba99403a76b5_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAwOA_02e988cc-ad2e-4030-8e02-5996a3522270">352</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="ia6053ee47e754dcc8601ba99403a76b5_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAyMg_3d6d604d-1bb0-43f3-9215-178b62cc2dfc">14.00</ix:nonFraction>% Second Lien Secured Notes due 2030 (the &#8220;<ix:nonFraction unitRef="number" contextRef="ia6053ee47e754dcc8601ba99403a76b5_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAzMA_ed857ad6-be07-4a0b-89f4-d5f00e5817c7">14.00</ix:nonFraction>% Second Lien Secured Notes&#8221; and, together with the <ix:nonFraction unitRef="number" contextRef="i8728c63be96941459a588f3116991b8d_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAzOA_c3599c20-4906-440b-8962-426ff7a8bb82">11.00</ix:nonFraction>% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $<ix:nonFraction unitRef="usd" contextRef="i0cae089600e94389bc02d059bc908b54_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA0Ng_68d610c5-f7b2-4725-a892-548d31103e27">999</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="i0cae089600e94389bc02d059bc908b54_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA2MA_15f025b2-4f0f-4bb5-bde7-e30883e0805f">9.00</ix:nonFraction>% Senior Secured Notes due 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i0cae089600e94389bc02d059bc908b54_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA2Nw_06bbc837-d6fa-47ef-8cd0-37d191f3cb22">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes&#8221; and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds <ix:nonFraction unitRef="number" contextRef="ie79f3bd1f9bc4330bfa744f8b69c453d_I20220930" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA3NA_edd66f23-56be-4b66-98cb-ced92fc0c6b2">38.6</ix:nonFraction>% of the issued and outstanding common shares of Bausch + Lomb.</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE0OTI3MQ_963a11f2-0fc8-489b-b8ab-5bf84ecdfa3a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:88.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if878061e7e8a4d5b87624e62ac22aa3a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMS0wLTEtMS0xNDgxNTQvdGV4dHJlZ2lvbjplZDY3OWVlYTQwYTM0YmEwYjgwNmY0NzYxNjdjNzZkM181NDk3NTU4MTM4OTE2_ff0888a9-253d-4806-aaa8-3babfd7370ca">9.00</ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if878061e7e8a4d5b87624e62ac22aa3a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMS0yLTEtMS0xNTI3Mzg_595d47d5-586e-418d-9b6e-7e58e0bf8f34">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie761f67bcaf44003906b0b905ba5b263_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMi0wLTEtMS0xNTI4NDAvdGV4dHJlZ2lvbjoxNzcxYTU5NWRjNTA0OTQ5OTMwY2M0OGMxZDdiYjVkM181NDk3NTU4MTM4OTE2_f281094f-e385-4f85-af2e-09aafe3d9f44">9.25</ix:nonFraction>% Senior Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie761f67bcaf44003906b0b905ba5b263_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMi0yLTEtMS0xNTI3Mzg_9ac18b87-03e9-41a2-a9d4-d147c6dfe68e">752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66a9533f0c874026af3f2ce11e610087_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMy0wLTEtMS0xNTI4NDIvdGV4dHJlZ2lvbjphNjA1MTk5Y2IzOTA0OTczYjE3NWFmNWZjOGVjM2ExMl81NDk3NTU4MTM4OTE2_ce911d19-dab0-4e42-9932-baa8e290b064">8.50</ix:nonFraction>% Senior Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a9533f0c874026af3f2ce11e610087_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMy0yLTEtMS0xNTI3Mzg_9e740247-ae22-4be2-8741-b229d22fda64">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f288fb4475b42e396cfd814e2d07cb9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNC0wLTEtMS0xNTI4NDQvdGV4dHJlZ2lvbjowZjI1MmU1MjcxYTM0MWI2OGY3YTMzMmU3MjEyNmI2MF81NDk3NTU4MTM4OTE2_92a4e2a0-bdd1-4f3d-8572-3327c845abc4">7.00</ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f288fb4475b42e396cfd814e2d07cb9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNC0yLTEtMS0xNTI3Mzg_bb07f1d4-9fed-4919-aebc-f2fbe3461446">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a8044c0008d4224a9252821ed90cab1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNS0wLTEtMS0xNTI4NDYvdGV4dHJlZ2lvbjowOGY0NGI4MjQzNjE0NDliODM5OGRjNmNhMmM3OTZmNl81NDk3NTU4MTM4OTE3_e67eeb03-bdf3-4b60-a78b-6b34cfa0b764">5.00</ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8044c0008d4224a9252821ed90cab1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNS0yLTEtMS0xNTI3Mzg_a891bf29-11df-4da4-820d-04c657fa0840">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e2c41e745e94aaca242b47db1e9da3a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNi0wLTEtMS0xNTI4NDgvdGV4dHJlZ2lvbjpiMDRkMGE1ZTZlY2Y0OTc4YWYyYWMwYzFiYWM4Nzg3Ml81NDk3NTU4MTM4OTE2_fde20288-d5ba-42c7-bc0b-a2a381cd9769">7.25</ix:nonFraction>% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2c41e745e94aaca242b47db1e9da3a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNi0yLTEtMS0xNTI3Mzg_b52987a4-ecca-4fce-898c-83dd8a576a61">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22f1e467a3104724bf0814979c3d7b24_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNy0wLTEtMS0xNTI4NTAvdGV4dHJlZ2lvbjo5YTI0NDkxYjI3ZGQ0YzZiOWUyMmFjZWE1NGEzNWU1NV81NDk3NTU4MTM4OTE2_15fe57bf-8f9a-44b0-8871-5e25e4784226">6.25</ix:nonFraction>% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22f1e467a3104724bf0814979c3d7b24_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNy0yLTEtMS0xNTI3Mzg_422f9a4e-2bd6-42b1-ae5b-6211d7c5777c">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib64b46934a374f298609c8f8d6de0962_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOC0wLTEtMS0xNTI4MzYvdGV4dHJlZ2lvbjozNmE5OGZjZDQ4MmY0Y2FiOTRkZjQ4MWI1ODU0MDBkMV81NDk3NTU4MTM4OTE2_d45abf8c-2be3-4acc-be3e-09776b60b68a">5.00</ix:nonFraction>% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64b46934a374f298609c8f8d6de0962_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOC0yLTEtMS0xNTI3Mzg_df7d8e1f-bc23-4a2a-9fb9-b4bf55b3a1c4">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie88308ccb55545679dce2acf47006522_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOS0wLTEtMS0xNTI4MzQvdGV4dHJlZ2lvbjo4OTRkMzcyOGExZTk0NGU0OTUzOGNkNzc0NjYwM2I3MF81NDk3NTU4MTM4OTE2_121e9edd-d4a6-4e45-a308-b66070552875">5.25</ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie88308ccb55545679dce2acf47006522_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOS0yLTEtMS0xNTI3Mzg_0062246f-46be-49bb-8b81-75cf500c6a08">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ideda0b3afeb94283b8b7495bc71f5cfa_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMTAtMC0xLTEtMTUyODMyL3RleHRyZWdpb246ZmM0YTI0NTY3ZjY0NDI5ZWE0MzMwZjNjYTQwODBiNjBfNTQ5NzU1ODEzODkxNg_00318007-4a3a-4857-b45e-432c2a4d31d4">5.25</ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideda0b3afeb94283b8b7495bc71f5cfa_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMTAtMi0xLTEtMTUyNzM4_0fa37f81-e876-4535-a0b5-c3b591fbd318">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74a12b5112bb435791910303cfa182e6_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMTEtMi0xLTEtMTUyNzM4_2e7f9a04-38bf-4699-94e1-3b32ba44c1bf">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer and following receipt of the requisite number of consents from noteholders, the Company and the applicable notes trustee, executed supplemental indentures to amend each of the indentures governing the <ix:nonFraction unitRef="number" contextRef="ie761f67bcaf44003906b0b905ba5b263_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4Nzg5OA_704bc108-a098-4e28-8595-082efedd113e">9.25</ix:nonFraction>% Senior Notes due 2026, <ix:nonFraction unitRef="number" contextRef="i66a9533f0c874026af3f2ce11e610087_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkwNQ_8d4b8b98-0731-4398-81a6-5cd1f91729ef">8.50</ix:nonFraction>% Senior Notes due 2027, <ix:nonFraction unitRef="number" contextRef="i9a8044c0008d4224a9252821ed90cab1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkxMg_e2aada53-f571-4a0d-8802-c1b6c1429888">5.00</ix:nonFraction>% Senior Notes due 2028, <ix:nonFraction unitRef="number" contextRef="i8f288fb4475b42e396cfd814e2d07cb9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkxOQ_bbc2f005-e184-4228-b90e-a11e9a8706a1">7.00</ix:nonFraction>% Senior Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="i7e2c41e745e94aaca242b47db1e9da3a_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkyNg_193d05b7-1b30-49f5-90ba-469c824c823d">7.25</ix:nonFraction>% Senior Notes due 2029, which amendments eliminate substantially all of the restrictive covenants as well as certain events of default and related provisions applicable to such series of notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i0bd14d443d0640a29dd06a5e59ef4fdf" continuedAt="i38f6ef9f3bf140f28239c1af989ca182"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the principal amount of the New Secured Notes and their carrying value as calculated above has been recorded as a premium and is included in long-term debt on the Company&#8217;s Consolidated Balance Sheet, which will be reduced as the Company makes stated interest payments on the New Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, the Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="i58945eb4f42545a2a975fa287df7030b_D20220701-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTkwNA_b030b7cb-fb38-4f08-a1ea-c05503879260">570</ix:nonFraction>&#160;million, net of third party fees of $<ix:nonFraction unitRef="usd" contextRef="i58945eb4f42545a2a975fa287df7030b_D20220701-20220930" decimals="-6" name="bhc:ExtinguishmentOfDebtThirdPartyFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTkxOA_cd2dfc5f-630a-4af7-9a9e-0f8a8ca88a77">25</ix:nonFraction>&#160;million, in connection with the Exchange Offer. As of September 30, 2022, the premium recorded on the New Secured Notes was $<ix:nonFraction unitRef="usd" contextRef="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTkzMQ_b6e6c90e-82cf-4e26-a2aa-b683b6d4a955">1,835</ix:nonFraction>&#160;million, which will be reduced as stated interest payments are made on the New Secured Notes. Further details of the New Secured Notes are discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i0f887978c4a542b19634fbdbca4dbd97_I20180601" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzIzOQ_617610f4-678e-4893-9025-98386ca7fa96">1,225</ix:nonFraction> million, maturing on the earlier of June 1, 2023 and the date that is <ix:nonNumeric contextRef="i278988850934419e80acc9d963dac666_D20180601-20180601" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzMwNA_2274dd2e-4246-484b-9bb5-4af526dfd41f">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="i0f887978c4a542b19634fbdbca4dbd97_I20180601" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzQ5MA_338c189d-5a5d-4d52-93b6-8d00bb570ff9">1,000</ix:nonFraction> million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $<ix:nonFraction unitRef="usd" contextRef="i00732fc9ff374b49b979455466cc8f7e_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzU5MA_30237722-ba63-492a-9087-e88308859398">4,565</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icdfc7e6315fd42efbda70b4c17cce33d_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzU5Nw_05a73282-a424-4cbc-9dae-62b10d632bde">1,500</ix:nonFraction> million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i6365ee6027ab48f0a916168124555cb4_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDE5NA_15a74b8e-3679-4d9a-ba12-905b7a03608f">2,500</ix:nonFraction>&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDI5OQ_ec5bae8d-e880-4c18-a7e9-136f644991c5">975</ix:nonFraction>&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is <ix:nonNumeric contextRef="ie52f1d3dd7b44370875bfbf01edce092_D20220510-20220510" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDQxNA_5ea35fbf-5c13-42e9-bf18-1b4d8ff5c818">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDU2Nw_2752cfd3-1c1d-49c7-988d-98d725c8c4bb">1,000</ix:nonFraction>&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of September&#160;30, 2022, the Company had drawn $<ix:nonFraction unitRef="usd" contextRef="i96f39bda64df4253bfb97df28400bd07_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTE2Ng_2ee413ce-0f36-4675-be60-1e27d4119494">450</ix:nonFraction>&#160;million on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus <ix:nonFraction unitRef="number" contextRef="iff4ef5de85bb4627a12cb69700bd7abe_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTgwOQ_43ff6199-4033-483b-abc6-a8b53c67c1d4">1.00</ix:nonFraction>% (or if such rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i829327ff659443278a6e3108a31e2416_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTg1Nw_103b194f-5ccb-438b-b2f2-b3142d4207fb">1.50</ix:nonFraction>%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="ifafb7519d3db4ba79da9149156c9be5b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTk4MQ_f003b4c9-671d-4803-8f39-fb1a0f363e77">0.50</ix:nonFraction>% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of <ix:nonFraction unitRef="number" contextRef="ie2c63af1038a498d97b0707660dbeca4_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNjMzNQ_26dc7c20-0a2a-4959-8859-9b9fedb9b06e">0.00</ix:nonFraction>% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i38f6ef9f3bf140f28239c1af989ca182" continuedAt="i92f181d048af4943b8cf812b1cd99d2d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of <ix:nonFraction unitRef="number" contextRef="ie319941a51a34294bbdb2ae3718dec8e_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzY0OQ_46d69282-ec6c-4288-8106-8c5be9ab4d8e">0.00</ix:nonFraction>% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from <ix:nonFraction unitRef="number" contextRef="ie2c63af1038a498d97b0707660dbeca4_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzc4MA_81486f5a-1f70-4ea8-81b7-858a8f64cb5e">0.10</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i20cd5f0493f2487bbde5f2221db59a0c_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzc4Mw_975caa4f-df87-4dcf-8c98-da0fea84ee55">0.25</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="i829327ff659443278a6e3108a31e2416_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzg3Nw_1cb07f7f-2157-4217-a56f-d93f160671b9">5.25</ix:nonFraction>% for term SOFR rate loans and <ix:nonFraction unitRef="number" contextRef="id3eed0b285dc42a99845525f57bc2eaf_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzkwOQ_6fe6a68d-a50a-47af-8e43-0b23ce4aeef7">4.25</ix:nonFraction>% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from <ix:nonFraction unitRef="number" contextRef="i8a03fb030a0040cebef22c0f5654ea66_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODA0OQ_7c0fbd5f-f721-449a-9a2b-2646e86226f3">4.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id3e53d6553f64b7eae83fca240d210f8_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODA1NQ_36d32131-b0db-4cdd-b3ea-9fe05c76ac4f">5.25</ix:nonFraction>% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i15dd8f000b9941858060dedaf7e029d0_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODEyMA_7a67d167-95bd-4482-9d0e-903e8f6c5b1e">3.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id330da73af3e4586bf7d8a9ae96e9b1f_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODEyNg_7ebcbd8b-6ea8-4ec5-8270-e438651d3124">4.25</ix:nonFraction>% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="ifb86b03b3ac24b4e82d95decf997f3b8_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODI1NQ_4665f200-612b-478b-ac7d-879d9cc27a0f">0.25</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i06b38bcf16e54859a0dde3ac0bd30c5c_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODI1OA_e6240b5a-c0e1-4038-b874-57875c21032a">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTA0OA_75361f2d-9ce6-4ced-8334-e51f44770954">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) <ix:nonFraction unitRef="number" contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTIxMg_278b94bc-0321-4a57-8b4b-c1faec499d2b">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTM1Mw_b161e7fb-442f-4c32-af7d-a8ea42f7d3a9">50</ix:nonFraction>% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTUxNA_b37172d7-99f4-437b-b4bc-e14a23d4c37e">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="i6365ee6027ab48f0a916168124555cb4_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTc1MA_3f4c3e57-a61c-4ca0-97f5-1e84c8636d81">5.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="i3944f858836c472bb400b25d49c9a870_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTc2Nw_13c6b640-04be-4fba-aaf9-c30c7090acd9">125</ix:nonFraction>&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September&#160;30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $<ix:nonFraction unitRef="usd" contextRef="id154aa3590224033afe021d4daefc439_D20220630-20220630" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTAwNTc_1810bca9-da73-40bf-939d-b2bf2ccff5a3">531</ix:nonFraction>&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $<ix:nonFraction unitRef="usd" contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTAyMDM_d9fda4ae-cdb0-4aee-b32e-c6be83de339d">1,000</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="ie52f1d3dd7b44370875bfbf01edce092_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTAyMTA_52a7c554-4f50-44e5-b729-ff94c1a296ee">40</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i02856360ad9c4499aa8ee226526b1aa5_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA1MTU_e519fcb8-484f-41df-8d52-6cd002c4ab5d">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i36893810d2ab469aaa9b5e3e8bd9c2e4_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA2MTA_a638f431-0a79-4255-add9-903c88e1543b">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA2NjU_26408ecc-d991-427f-9967-cf911386d33b">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than <ix:nonFraction unitRef="number" contextRef="i3b91f50e40904c03b83e3484fe6eee31_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTEzNzI_f75ca1ca-896b-418c-bae6-27e5318d74aa">7.60</ix:nonFraction>:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $<ix:nonFraction unitRef="usd" contextRef="i1be6df6cb851454f9afb224870173486_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTE3NDk_bc5633ef-ccbe-44c8-b6cc-219e260f80f4">2,500</ix:nonFraction>&#160;million with a <ix:nonNumeric contextRef="i93f125d7ae474da9a0a4942295b43c0c_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg5MDc_a68d2b34-4dd2-407f-8007-693197b903ba">five-year</ix:nonNumeric> term to maturity (the &#8220;B+L Term Facility&#8221;) and a <ix:nonNumeric contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg5MTA_0ea4e220-daba-4548-9c9e-44dbd5f9bc00">five-year</ix:nonNumeric> revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i726749b95a30497288303bb51019c959_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTE4NTM_2fb7e1e9-292b-480d-8bc3-9bb4809c4193">500</ix:nonFraction>&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of September&#160;30, 2022, the principal amount outstanding under the B+L Term Facility was $<ix:nonFraction unitRef="usd" contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODQ5MDU2_20a5b292-de72-4f5f-ac42-61d924fbce90">2,494</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODQ5MTUz_0852705a-030e-4e70-a05f-736e4ce6b796">2,442</ix:nonFraction>&#160;million net of issuance costs. The B+L Revolving Credit Facility remained undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i92f181d048af4943b8cf812b1cd99d2d" continuedAt="i5d613ee70b324a41a66f7b67fd112082"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than <ix:nonFraction unitRef="number" contextRef="i22e638cdad174145acfe1cb7ca9c3b06_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTEwNDE3MA_08dad638-ffe1-463f-a726-a5fed9329d18">0.00</ix:nonFraction>% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than <ix:nonFraction unitRef="number" contextRef="i85f9310875d34c5aab769c2612112be4_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY1OTMzMA_cb2c897f-8ed9-455f-bdf9-f57ad5a3b5be">1.00</ix:nonFraction>% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i14b599cb18c944ee87759c867f11b854_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY1OTMzOA_2ef2122f-d844-4cd7-b9d0-73819c1ba335">0.10</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between <ix:nonFraction unitRef="number" contextRef="i2b8e5c5dac3f4de3a568fb4b1dc17504_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ4Nzk_7b609be8-60d8-4021-9e95-d99508078ee4">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic15ff81720f140728bd400ed17b1d660_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ4ODU_6ebf9b3b-232d-4804-8c8e-27c0ba2c7010">1.75</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i3070a693a5854af3a22dfe66f3655e85_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ5Nzk_72efb4be-be86-4466-90cc-a9719417578b">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i943999c56fff450aa77e708b60d39def_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ5ODU_8aab4805-6968-4ea8-b3d9-4ec1bfc090ac">2.75</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between <ix:nonFraction unitRef="number" contextRef="ic16b8fead453422ab2aa9fbbbcccf83c_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTUzOTc_0893e939-37ee-4682-9919-15f7b4cbcf61">0.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i297866a68ce24747b81d40a30c023bb4_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU0MDM_eed7d323-bd8b-420c-a64d-e403a46fa358">0.475</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i13632d9de3844a9cbd798441522b1bc7_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU0OTc_38b43446-e2ca-44cd-8d2e-06d6c19c1e3e">1.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i4d4c681d58b24f99b498d9e6a296937c_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU1MDM_0bd7d985-b3b6-412b-9024-af5e034e600f">1.475</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU2Nzg_368d3880-4bd5-42b8-ba1a-360b2a1576a9">0.25</ix:nonFraction>% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between <ix:nonFraction unitRef="number" contextRef="ic4b5207c38da4c0c9112b7da48cb7ce7_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU4NTA_b085fdb4-8a54-4705-835f-0d73238b0b69">0.110</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i80f700a1b8cb457dbc050366a46232f1_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU4NTY_682e2429-6e21-4e02-ae29-c2409fde7cef">0.275</ix:nonFraction>% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="ia63c47b1828f4ae0b6b1dbab0bb42d98_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU2MA_7abb4b9e-fe5f-4567-9063-6ba9d716725a">3.25</ix:nonFraction>% or (ii) a U.S. dollar base rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="ifaa17fd0da484c67bc48038c0747623b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU2Mg_5b1ef72c-65ab-44f3-a3b5-ae28d5bc1812">2.25</ix:nonFraction>% (provided, however, that the term SOFR-based rate shall be no less than <ix:nonFraction unitRef="number" contextRef="i53fbf53285954caeb0e7f050632c7597_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU3MA_f6cec17e-aad1-497f-b550-778fc940e657">0.50</ix:nonFraction>% per annum at any time and the U.S. dollar base rate shall not be lower than <ix:nonFraction unitRef="number" contextRef="i8d49f58bd8e741069f996a82897124ce_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU4NQ_3510fcaf-98fe-4773-8f22-c3de28f48731">1.50</ix:nonFraction>% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="ia63c47b1828f4ae0b6b1dbab0bb42d98_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU5Mg_7a0dab72-3c97-4efb-b5cf-de021480fade">0.10</ix:nonFraction>%. The stated rate of interest under the Term Facility at September&#160;30, 2022 was <ix:nonFraction unitRef="number" contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU3Nw_84b31bb6-6d35-4f22-9091-eef471f15ffb">6.10</ix:nonFraction>% per annum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc0OTI_b30f3150-1ac3-40ea-bceb-452e2fc37f77">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) <ix:nonFraction unitRef="number" contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc2ODk_5f25226a-e99b-4ca5-970e-117275f662ee">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc4MjE_f6cefbc7-9ca8-46f8-a576-2dae99bef35d">50</ix:nonFraction>% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc5NzM_156c44f2-29b1-4b76-bd8c-7db39f56a27a">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is <ix:nonFraction unitRef="number" contextRef="i1be6df6cb851454f9afb224870173486_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTgyMzM_91a45858-07a9-4bf0-bc80-6d07939979a9">1.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="i93f125d7ae474da9a0a4942295b43c0c_D20220510-20220510" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTgyNTA_b0ee8f11-92ee-4dbf-b728-892329b5bb8e">25</ix:nonFraction>&#160;million, payable in quarterly installments. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of September&#160;30, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $<ix:nonFraction unitRef="usd" contextRef="ifebc6076ad5441fe9acf2610a82c6104_D20220101-20220930" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTg1MzQ_0ad466fd-6e04-4923-8c40-a2d9644a3093">113</ix:nonFraction>&#160;million through March 2027, with the remaining term loan balance being due in May 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTg4Njc_9ccdf8ce-33fd-4423-8312-77016de33703">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture, the &#8220;April 2025 Unsecured Notes Indenture&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i5d613ee70b324a41a66f7b67fd112082" continuedAt="ideb4a14e93644df4bdfa588701585e64"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjEwMTE_5cccd8f1-29c6-4a3f-ad3b-189d1246ec31">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ic1f904c39c824f0cbed6373fc8027458_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjEwODA_431dca51-9728-4436-b033-6893c46b4820">4.875</ix:nonFraction>% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ic1f904c39c824f0cbed6373fc8027458_I20210608" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjExODY_38a1f11d-d287-436f-b187-12362abd42df">1,600</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ic1f904c39c824f0cbed6373fc8027458_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjEyMTk_431dca51-9728-4436-b033-6893c46b4820">4.875</ix:nonFraction>% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $<ix:nonFraction unitRef="usd" contextRef="i61dd05e0e56948b8bcb9f052101aeaf6_D20210608-20210608" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjE0MTA_7cf63adf-be4a-47f3-93be-a86ffbccf532">1,600</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="i9189a38171dd4ebaa45559422267b0ab_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjE0MTY_c3d9de7e-a60d-4e83-9c4b-d7aed3d6704b">7.00</ix:nonFraction>% Senior Secured Notes due 2024 (the &#8220;March 2024 Secured Notes&#8221;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i797254cc60b049dcb744c873a7a119bb_D20210608-20210608" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjE4NDg_a816b21c-dff9-403c-80a0-f9caf25836a1">38</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i35465fe55b7945e3b6f24aa54344fa38_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI0MDM_72109c5a-9c1f-478e-99ac-649fba09c82c">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i2a503b3152c24a3aae993d9cca166b10_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI2Mjg_70133c16-33a4-42a7-b2ba-e054ba1c4ece">40</ix:nonFraction>% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI4MjM_6880c1aa-898d-4807-bf52-75d635a5fc1f">6.125</ix:nonFraction>% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI5MjM_398cedb9-1a32-48de-965e-c5439b040d1a">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI5NTY_7adb45e8-0104-4670-8240-d9426f7a2dc5">6.125</ix:nonFraction>% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjMzNTg_7adb45e8-0104-4670-8240-d9426f7a2dc5">6.125</ix:nonFraction>% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="ic7cb7ba0199a427782c6e11d979cc908_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjM3Mzc_b9b70f99-22cc-4676-855d-9ed3051b9c64">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i463a1df44c5e447c95a44b5652a58c27_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjM4NTQ_fb7337ef-9107-4523-8bcc-2f4b92dab2ed">40</ix:nonFraction>% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzI4_53f19781-169e-45b6-bf7b-0fb7d722d7e6">11.00</ix:nonFraction>% First Lien Secured Notes mature on September 30, 2028, and accrue interest at <ix:nonFraction unitRef="number" contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzM4_08129b26-faef-4113-bf54-6cc2e2ef9353">11.00</ix:nonFraction>% per year, payable semi-annually in arrears on each March 30 and September 30. The <ix:nonFraction unitRef="number" contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzg0_9f582f25-2e29-41f6-9152-5a06d4ec34e0">11.00</ix:nonFraction>% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to <ix:nonFraction unitRef="number" contextRef="ic986ed29a4b54c67b340f512dca91b23_D20220101-20220930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDA1_7c0d91a7-7537-4f23-b9a6-7e791aa96b26">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the <ix:nonFraction unitRef="number" contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzU0_029caf7d-9947-4d7c-b479-fb616d0496cb">11.00</ix:nonFraction>% First Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzMz_fc6ba770-e1de-480d-aad3-8de40db5678c">14.00</ix:nonFraction>% Second Lien Secured Notes mature on October 15, 2030, and accrue interest at <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzQ2_8e7bc046-6b4e-4fa2-ac9d-f75459490f64">14.00</ix:nonFraction>% per year, payable semi-annually in arrears on each April 15 and October 15. The <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzY5_7f343c68-25d1-49e6-b144-f94f259e8033">14.00</ix:nonFraction>% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDAw_e54e2e57-b14e-4382-8ddc-8c0ecb483247">14.00</ix:nonFraction>% Second Lien Secured Notes indenture. In addition, some or all of the <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzc0_5c674a1d-f6ef-4686-b92d-1693c411a239">14.00</ix:nonFraction>% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to <ix:nonFraction unitRef="number" contextRef="i3cb285fdcf7346e4931be632a5d32554_D20220101-20220930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzg5_6dba2095-be54-43ed-ac6f-7858b01fb315">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzU5_d76647a4-ceea-4fc6-a44b-1d614cd114d7">14.00</ix:nonFraction>% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to <ix:nonFraction unitRef="number" contextRef="i08d9f7c4a1b54b0893e8a5c93f2b8b41_D20220101-20220930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzk1_1d96f9af-55e6-4630-b27f-ea20eb0f7e8f">40</ix:nonFraction>% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzY0_147a706d-b739-43e8-9bcc-c5c099dfe52f">14.00</ix:nonFraction>% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzc5_37f843bc-2f49-4cb8-b4f9-d511568310ba">14.00</ix:nonFraction>% Second Lien Secured Notes indenture.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ideb4a14e93644df4bdfa588701585e64" continuedAt="iafec3834fe4f4c2198f7fbad315841a6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDEx_0b697979-f7b3-496a-a9c7-e606051f2a14">9.00</ix:nonFraction>% Intermediate Holdco Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDE1_afd4e92a-b83a-4f37-a438-9109f4197bfe">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes mature on January 30, 2028, and accrue interest at <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDE5_f5d2f5ca-23b3-4d9f-8588-5d1c57016e6b">9.00</ix:nonFraction>% per year, payable semi-annually in arrears on each January 30 and July 30. The <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDIz_bc419a9d-42be-4aba-9f87-ff93183dc84e">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDI3_e4d9adba-8c03-493c-8b69-9df7f8289dee">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDMx_4c0fb4f9-9de8-406a-8ee1-2ea86e30c95a">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of September 30, 2022 were comprised of <ix:nonFraction unitRef="number" contextRef="i1870e555a1fd4b21a7e5585f4d019a9f_I20220930" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NjE1OQ_f5cc6232-4954-4b48-9b24-079852c52062">38.6</ix:nonFraction>% of the issued and outstanding common shares of Bausch + Lomb Corporation. The <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDM1_49b3c8f6-8c3d-4321-a97d-288af82a0259">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzg0ODI5MDgxMzA2OQ_4c0fb4f9-9de8-406a-8ee1-2ea86e30c95a">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes under the <ix:nonFraction unitRef="number" contextRef="iabd7119954044616a3233f093428ce2e_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzg0ODI5MDgxMzEyMg_4c0fb4f9-9de8-406a-8ee1-2ea86e30c95a">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee certain of the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i31cc3cc5d3ca41eaaeacd771a686a45e_D20220101-20220930" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjUyMjA_e543ab50-d0c8-48d6-ae72-6eafa354275a">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $<ix:nonFraction unitRef="usd" contextRef="i7356824e0b3446aeb0703cbdc0f9101f_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjU1Nzk_7b8991c1-5506-440c-9f45-d7bd3cc6d885">370</ix:nonFraction>&#160;million in aggregate principal amount of the Company&#8217;s outstanding <ix:nonFraction unitRef="number" contextRef="i7356824e0b3446aeb0703cbdc0f9101f_I20220118" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjU2NDE_418303fb-4775-4be1-a78d-ed40cb951490">9.00</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) conditioned upon the receipt of aggregate proceeds of at least $<ix:nonFraction unitRef="usd" contextRef="i7356824e0b3446aeb0703cbdc0f9101f_I20220118" decimals="INF" name="bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjU3Nzc_8f8a09fc-da0b-4768-be05-03671b338db9">7,000</ix:nonFraction>&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of <ix:nonFraction unitRef="number" contextRef="i4804f7e82ed3464d857db9b9aadf33f1_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjY0Nzk_cba4dc97-afd2-4e90-8bc8-58472548d2a9">101.021</ix:nonFraction>% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of September&#160;30, 2022 and December&#160;31, 2021 was <ix:nonFraction unitRef="number" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc1ODk_f612d778-16af-470f-af15-77dcc68b0320">7.24</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc1OTY_9ab9e655-4057-4b65-8863-64c5f4579d67">5.88</ix:nonFraction>%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements in future periods will not be representative of the weighted average stated rate of interest.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="iafec3834fe4f4c2198f7fbad315841a6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company completed the Exchange Offer and recorded a net gain of $<ix:nonFraction unitRef="usd" contextRef="i7f730e3004c4467e93c8beedc0748d7b_D20220901-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA4Mg_c7177483-07c1-47dd-9f5f-591074c05d8d">570</ix:nonFraction>&#160;million as described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company repurchased and retired certain outstanding Senior Unsecured Notes with an aggregate par value of $<ix:nonFraction unitRef="usd" contextRef="i4afef88c6a4140829ef856906a21c44c_I20220630" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc4MDA_3055e2a2-8582-441c-ae35-cf8c7c1bc576">481</ix:nonFraction>&#160;million in the open market, for an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="id98c05c2a0a14ddb8c06bf78beb4aad8_D20220601-20220630" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc4NDg_c2b15d21-2a8e-4b4c-9e7f-e9aa9d1a12aa">300</ix:nonFraction>&#160;million. In connection with these repurchases, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="id98c05c2a0a14ddb8c06bf78beb4aad8_D20220601-20220630" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc5MjM_a820e6ec-8975-4e5d-825a-ea6adb70164c">176</ix:nonFraction>&#160;million on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with (i) the repayment of the June 2025 Term Loan B Facility, November 2025 Term Loan B Facility and 2023 Revolving Credit Facility and (ii) the redemption of April 2025 Unsecured Notes, the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i042059a75e2442fd999e415f9c25591a_D20220510-20220510" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjgzMjU_b8d89087-bfa1-474c-943d-a52d2bbaf845">63</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg4OTQ_33748b9e-3687-48e8-9f2b-bc33f224bf1e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMS0xLTEtMS0xNDMwNjE_a16695a5-fe64-4e79-8985-f4503831aecd">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMi0xLTEtMS0xNDMwNjE_8a1cee05-0f43-4add-ab85-29d6c8c8f87e">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMy0xLTEtMS0xNDMwNjE_817dcbd2-36e1-40d6-9baa-6f26209b2f90">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNC0xLTEtMS0xNDMwNjE_02e48968-e27e-4de4-9c73-40614c54a2fd">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNS0xLTEtMS0xNDMwNjE_6dc6694e-6fc1-404a-bf54-f49feb3cef48">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNi0xLTEtMS0xNDMwNjE_0da4201b-c36f-4e48-814b-71533370c8dc">6,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNy0xLTEtMS0xNDMwNjE_566c398d-cfa4-4544-8f78-0f914cacd3bf">8,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfOC0xLTEtMS0xNDMwNjE_26f52e99-5a25-426a-9eba-5bc274b1f73a">19,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfOS0xLTEtMS0xNDMwNjE_677bb556-2f95-44ff-b4fe-be2729f65720">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMTAtMS0xLTEtMTQzMDYx_7ee7bb7f-0175-4684-a3b8-c3e7cc109b9c">21,215</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RleHRyZWdpb246ODk2Mjc1OTY1MjcxNDE2ZGI4ZjU3NDExMWY5NDYwZjNfNDAx_eefd187a-41a8-4f0e-bc8c-dc7b9bdfaf9e" continuedAt="i0acdb03951ba40efa6f31bfbe22c1a9b" escape="true">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i0acdb03951ba40efa6f31bfbe22c1a9b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RleHRyZWdpb246ODk2Mjc1OTY1MjcxNDE2ZGI4ZjU3NDExMWY5NDYwZjNfMzk3_d61bdbfb-80e9-4713-a2ae-a6d35ac5c983" continuedAt="i56df2eb2b2a748e6be8e8dd9560bfb15" escape="true">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2022 and 2021 consists of: </ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><ix:continuation id="i56df2eb2b2a748e6be8e8dd9560bfb15"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.980%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy0yLTEtMS0xNDMwNjE_2f46b296-8940-45b5-9420-a4bb2c435f02">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy00LTEtMS0xNDMwNjE_8037585e-2821-44a8-bb8d-1b1105026e0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy02LTEtMS0xNDMwNjE_f238fc75-52ac-4f28-ae3d-03ad511ea1bb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy04LTEtMS0xNDMwNjE_7bcb9d43-c8ad-4e03-abb1-a684ad521328">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy0xMC0xLTEtMTQzMDYx_6811e4e8-83d2-49ac-aec6-bc389f2de9e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy0xMi0xLTEtMTQzMDYx_828297cc-2805-446f-8fe5-78ac32b69ef6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC0yLTEtMS0xNDMwNjE_89c961a3-7e75-4287-b58e-ebf1cd6ffd9d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC00LTEtMS0xNDMwNjE_6bcf092c-6847-4981-8cb7-25433ac4f790">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC02LTEtMS0xNDMwNjE_55cf03d8-d311-4f01-9457-0887b9c4562d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC04LTEtMS0xNDMwNjE_717b9823-5516-45d7-98d6-1216e935ccf0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC0xMC0xLTEtMTQzMDYx_d8bd8106-d0f2-465a-ab25-9655aab91aa6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC0xMi0xLTEtMTQzMDYx_c61fb3b2-8079-4eff-be82-3057c0037695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS0yLTEtMS0xNDMwNjE_251f518d-1697-4417-8279-777299695d31">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS00LTEtMS0xNDMwNjE_df057853-8a5e-4658-af07-be7ec8bfe060">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS02LTEtMS0xNDMwNjE_db2989d1-72e4-4de9-8520-fc4328b14576">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS04LTEtMS0xNDMwNjE_dd97a1b0-e1a9-4782-8ade-86f3f33cd6a1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS0xMC0xLTEtMTQzMDYx_02ba54a8-7486-4f82-9381-2c4da6b2cef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS0xMi0xLTEtMTQzMDYx_98200266-5dc7-4caf-9fd0-aa88eebf9500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi0yLTEtMS0xNDMwNjE_8e2c08d4-7fdc-4196-962f-67482d6df7cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi00LTEtMS0xNDMwNjE_f2e6d7b7-1189-44c9-848a-6622505042f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi02LTEtMS0xNDMwNjE_b76cf389-20ea-4f15-b107-46753cc2b66e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi04LTEtMS0xNDMwNjE_469321f8-b190-482d-ba7c-4f89d3d64468">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi0xMC0xLTEtMTQzMDYx_1d5a5e60-1d6f-4ff4-9452-2bd06f7cab49">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi0xMi0xLTEtMTQzMDYx_8d95a826-c8d1-4980-975d-7365069981d8">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy0yLTEtMS0xNDMwNjE_76db2ffe-27c1-4432-990b-d60fd1e623c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy00LTEtMS0xNDMwNjE_d479caf0-88f5-4ca4-baef-167033dc39a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy02LTEtMS0xNDMwNjE_fbb0389f-5273-420a-a140-e0ac6d1b8694">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy04LTEtMS0xNDMwNjE_4a850ffb-3658-424b-85ee-4291d3853d09">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy0xMC0xLTEtMTQzMDYx_06fd92e2-a1c1-4abf-805a-7d74480ad0b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy0xMi0xLTEtMTQzMDYx_8b20e282-c01d-4cdd-8a02-73316c33dc1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC0yLTEtMS0xNDMwNjE_0734d40e-d10c-40ae-91e1-f509fb1c8db3">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC00LTEtMS0xNDMwNjE_985e249d-5681-4e78-b2c4-532a36de407f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC02LTEtMS0xNDMwNjE_dedefe5e-204d-47a5-8a5e-e1822c1b4a4f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC04LTEtMS0xNDMwNjE_8857f2b1-d7ca-42f6-aa09-c6ac9504634f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC0xMC0xLTEtMTQzMDYx_20321e7b-596d-417b-bc9b-b9a95b7e79a2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC0xMi0xLTEtMTQzMDYx_57cb3668-cab0-4990-9756-b10693d6c544">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMg_e81cc71e-42c0-4572-9134-0030d020705c" continuedAt="i274240ed9ddd446995d149a40b99c065" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i274240ed9ddd446995d149a40b99c065" continuedAt="id6401080f71a4848a97e22641b7dc676"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved Bausch Health&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced Bausch Health&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="id6401080f71a4848a97e22641b7dc676" continuedAt="i5d41c9e5c805482e8b9f4e78446904c4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to <ix:nonFraction unitRef="shares" contextRef="i93eb31e461ac4db5ba4c0df1c70c52c7_I20140531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDg1_f6a62d10-6683-4c0f-995a-7dbf72d055a7">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="i93eb31e461ac4db5ba4c0df1c70c52c7_I20140531" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfODQ1_72c60f1c-5db9-481c-9093-c8151392665f">20,000,000</ix:nonFraction> common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional <ix:nonFraction unitRef="shares" contextRef="i7e9c7cf1e63843dd9922d9993278a56a_D20180430-20180430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTM5NQ_e9121c57-eb3a-4958-85d6-1e4ec128ef9f">11,500,000</ix:nonFraction> common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="ic1d0f02ef63b4948ba4e261acdbbbfc2_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTQ0Nw_d09735cd-6851-46ae-850e-01f9a3d0cb84">18,328,000</ix:nonFraction> common shares were available for future grants under the Amended and Restated 2014 Plan as of September&#160;30, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to retain and incentivize certain members of the Company&#8217;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#8220;Retention RSU Grant&#8221;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTA5OTUxMTYzODk0Ng_fd0ab737-0f9e-4702-b219-264d2a3842ea">three</span> anniversaries of the grant date based on continuous employment with Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to May 5, 2022, Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb participated in Bausch Health&#8217;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of <ix:nonFraction unitRef="shares" contextRef="i23da95982875422e85842884cfcf3c78_I20220505" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjg2Mg_fecc6a05-64bc-430a-bfb6-386e5343a26f">28,000,000</ix:nonFraction> common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of <ix:nonNumeric contextRef="id7cc1e4c1e0e45c088cf0da8d3478561_D20220505-20220505" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzI4NA_a34b260e-cdbe-4fff-833d-3b7b5735f70d">ten years</ix:nonNumeric> and a <ix:nonNumeric contextRef="id7cc1e4c1e0e45c088cf0da8d3478561_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMw_ef1ff35d-1a83-4850-8390-2fb8db673f89">three-year</ix:nonNumeric> vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, in connection with the B+L IPO, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted certain awards to certain eligible recipients (the &#8220;IPO Founder Grants&#8221;). Eligible recipients are individuals employed by </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb or employed by an affiliate of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb. Approximately <ix:nonFraction unitRef="shares" contextRef="i879c2fd226954205b21a10810b667c13_D20220505-20220505" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzYxNA_220286e3-16e3-47e2-a343-323335edbfc4">3,900,000</ix:nonFraction> IPO Founder Grants were issued to </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb executive officers and were awarded <ix:nonFraction unitRef="number" contextRef="i40e0ab954b9546489a9ef90bab33b427_I20220505" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzcwMQ_cd4de13e-f943-439c-a993-92a809a4b301">50</ix:nonFraction>% in the form of stock options and <ix:nonFraction unitRef="number" contextRef="i12e20cb0b43649a1a6d77f2a05f00d92_I20220505" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzczNw_e2ab4e29-7a78-4984-b7b6-8f75c096fdb5">50</ix:nonFraction>% in the form of RSUs. Additionally, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted approximately <ix:nonFraction unitRef="shares" contextRef="iba04e7a5f74b447488bf33d1bba8d3d1_D20220505-20220505" decimals="-5" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzgxMQ_973d2ac3-c544-4964-a664-e4031ebe6987">5,700,000</ix:nonFraction> stock options and RSUs to non-executive eligible recipients, of which approximately <ix:nonFraction unitRef="shares" contextRef="i4638c5e4165448498eae9d03caa89485_D20220505-20220505" decimals="-5" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzg5OA_04ae0860-07b8-4f32-a433-d62ee89f3538">4,300,000</ix:nonFraction> were B+L IPO Founder Grants. The IPO Founder options have a <ix:nonNumeric contextRef="i9e3179052a5e4e44b4b9793cfa4650a3_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIwNQ_2a299e91-c5d9-48b9-aa19-1c97555746d9">three-year</ix:nonNumeric> graded vesting period and the IPO Founder RSUs vest <ix:nonFraction unitRef="number" contextRef="i125d23605450450a9432058cc84577ab_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzk5Mw_55b21155-f9ad-45e2-bc4c-89bdc9c940bc">50</ix:nonFraction>% in the second year and <ix:nonFraction unitRef="number" contextRef="if3ae116d5b71442d8c602ff3e0ff2420_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDAxOQ_393bfb3e-0df4-42be-af56-a1e53ddc7bc9">50</ix:nonFraction>% in the third year after the grant. With the exception of the separation agreement and retention program, as discussed below, vesting of the IPO Founder Grants are linked to the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb entered into a separation agreement in connection with the departure of its Chief Executive Officer (&#8220;CEO&#8221;). Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of RSUs will vest upon his termination of service date (pro rated based on his period of service relative to the original <ix:nonNumeric contextRef="ie8dc48d6ec2b4113ad14034a1c76b675_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzYxMg_03b2c250-504e-48c7-997b-df70889d00ef">three-year</ix:nonNumeric> vesting period associated with such grants), but the shares received upon settlement will remain fully restricted and nontransferable until the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer pursue a distribution, and the <ix:nonNumeric contextRef="ib87da6b4d8544d5dade0efad5191c5c3_D20220719-20220719" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzYyMg_fe65804b-8f18-463e-83bd-0468d6c7d4dc">two-year</ix:nonNumeric> anniversary of the CEO&#8217;s termination of service date. Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of stock options will vest and become exercisable (pro-rated based on his period of service relative to the original <ix:nonNumeric contextRef="id7042d4e6e0d42a092deb71733fc7627_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzYzMw_e56734c6-76c3-42e0-afac-9610fb117cc6">three-year</ix:nonNumeric> vesting period associated with such grants) upon the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i5d41c9e5c805482e8b9f4e78446904c4" continuedAt="ia518961957104fc39ef31bad9c1dcb7f"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursue a distribution, and the <ix:nonNumeric contextRef="i7e5a843db9464057940288007937dd58_D20220719-20220719" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzY0Mw_4a8470cd-d378-4607-ba3a-6f59432215df">two-year</ix:nonNumeric> anniversary of the CEO&#8217;s termination of service date and remain exercisable for <ix:nonNumeric contextRef="i7e5a843db9464057940288007937dd58_D20220719-20220719" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzY0NA_481f4f05-392c-4d42-895c-c0d88adb4126">two years</ix:nonNumeric> following this date. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Talent and Compensation Committee of the Bausch + Lomb Board of Directors approved a retention program that includes </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s named executive officers (other than the CEO) and certain other employees. This program provides the Executive Officers (other than the CEO), among other benefits, pro-rata vesting of the IPO Founder Grants previously issued to these named executives, subject to certain restrictions, in the event of an involuntary termination of employment by </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb without &#8220;cause&#8221; or the executive&#8217;s resignation for &#8220;good reason&#8221;, in each case through the <ix:nonNumeric contextRef="i838762aec48a48bfaae871f10aa12c35_D20220701-20220930" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA3Njk3NQ_2417b719-5d29-49c2-a146-5e310819f53b">one-year</ix:nonNumeric> anniversary of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s appointment of the successor to the CEO (pro-rated based on the period of service relative to the original <ix:nonNumeric contextRef="i9c04f97f5c714af7a5e387b0d156bc8d_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA3Njk5Nw_1a4b0d6c-6dd3-4082-9a75-97aa09da5d10">three-year</ix:nonNumeric> vesting period associated with such grants). Additionally, these named executive officers (other than the CEO) and certain other employees were granted a one-time award of approximately <ix:nonFraction unitRef="shares" contextRef="ia324b82ecfe4472a8eec915831a5f250_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5Mjg3Mw_05656e03-b6a6-46d3-9598-710c86c81b40">850,000</ix:nonFraction> RSUs under the retention program pursuant to </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s 2022 Omnibus Incentive Plan. The retention grant will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5Mjg4MQ_d3858cff-cf89-4b94-8aea-b1ba58bb78da">three</span> anniversaries of the grant date based on continuous employment with </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDIzMg_481a2064-b8d9-4617-8bfe-dd80e3828e6a">17,500,000</ix:nonFraction> Bausch + Lomb common shares were available for future grants as of September&#160;30, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMA_d167bbb3-83e2-45d9-9a6d-b52b355476f5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company's share-based compensation expenses related to stock options and RSUs for the three and nine months ended September 30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae9beb58b9b44bcbb18d4e6cd9e9fbb_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi0yLTEtMS0xNDMwNjE_cfc2299d-8094-449b-8fc7-54aba323dd3e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f371d3c6a04f48a82246f042826add_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi00LTEtMS0xNDMwNjE_bab6fe75-f38e-4cbc-9c05-52e937a9ff4a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi02LTEtMS0xNDMwNjE_e478b6f9-6600-49eb-b824-70b75c9c4db2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi04LTEtMS0xNDMwNjE_689731c4-1ebb-400a-a812-c5bc164dc62f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b5c2e6a48345c0b538f3138c5ab5b2_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy0yLTEtMS0xNDMwNjE_6b93ef4d-c647-4e8c-83ae-d0f45f4e14a8">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a9ae3100a74f7ebf2929870b5083e9_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy00LTEtMS0xNDMwNjE_4bb378ba-739f-4f0f-9875-1f504d750fde">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6a3ac703f94d4e8ba3718b45516087_D20220101-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy02LTEtMS0xNDMwNjE_7bdf60bd-8739-4786-b63a-908cd898eb17">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c67b322920745f8ba3080e92c213cff_D20210101-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy04LTEtMS0xNDMwNjE_0114b6a7-bfb1-47fa-8faa-2a0a6deb323e">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC0yLTEtMS0xNDMwNjE_b816eadd-1c6f-4115-8aef-242473d24f9a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC00LTEtMS0xNDMwNjE_ecef509d-631e-43d1-8e7e-49c8eda5aeaf">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC02LTEtMS0xNDMwNjE_3dc67b52-90b7-48e6-bbf0-05e316cefc1d">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC04LTEtMS0xNDMwNjE_9a3b0fd7-32dd-43d9-9f86-c6c47d0437b9">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2bc07e5c9d48648d447ff5d3dfcfc8_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi0yLTEtMS0xNDMwNjE_45bce321-d70a-492c-9cbc-ec792f5e711e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c782729eb2a4eaeae9a5f19119db3ef_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi00LTEtMS0xNDMwNjE_697f2285-b281-46c8-8156-47119febb4a1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2464c5727ff448ddb5ad8146c4b17152_D20220101-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi02LTEtMS0xNDMwNjE_75a69aca-6dba-4b97-ad57-eb3e6e984f1e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4675f7627ec5490496e997650085e455_D20210101-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi04LTEtMS0xNDMwNjE_a97e760b-ba01-4aa4-925b-4329128765e9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d2d86b33a741058fda2e20bf9a30d4_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy0yLTEtMS0xNDMwNjE_0552d146-2c63-4cdf-a935-e7058953035b">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8cb01e461c43f0ba0ff2f3565c5ef5_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy00LTEtMS0xNDMwNjE_d42dae95-10cf-4c29-9a71-9f103b3c9d1f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31113824bcf41b3885c724ca05e5ed5_D20220101-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy02LTEtMS0xNDMwNjE_7564e350-738d-45af-98f2-a5c29724ae14">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c39c0bbcb54df291baffd09082d1d1_D20210101-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy04LTEtMS0xNDMwNjE_81024a32-4e7d-49d5-b942-bbb877e4e4b5">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC0yLTEtMS0xNDMwNjE_aa3b202a-39d1-4d03-a267-eee15b415092">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC00LTEtMS0xNDMwNjE_f42206ac-8a2a-4a46-9328-b83556c9ec5c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC02LTEtMS0xNDMwNjE_ae5280be-9827-4713-9c19-9299297332b7">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC04LTEtMS0xNDMwNjE_8e6d611a-cd47-43eb-ba0d-945861787aef">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia518961957104fc39ef31bad9c1dcb7f"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMQ_6c248912-e6a3-47df-b1f7-f93e8dda3e7f" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the nine months ended September 30, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMy0xLTEtMS0xNDMwNjE_d5d321c6-7084-4351-bf52-19712b557e14">2,570,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMy0zLTEtMS0xNDMwNjE_cf591f1b-1119-4168-a771-ca82bd2d8e9c">1,497,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNC0xLTEtMS0xNDMwNjE_e0e17cd7-5b6a-4980-895b-bbb5802acc15">23.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNC0zLTEtMS0xNDMwNjE_71921fa5-b51c-4688-8410-1878af73e9cc">32.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNS0xLTEtMS0xNDMwNjE_598d8174-f750-4e97-bea7-f6da689e2c8d">6.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNS0zLTEtMS0xNDMwNjE_cedf8731-f312-4b41-8ee2-263a64cde79c">11.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60fae9ccc16447a4bb6ce23208cd688c_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNy0xLTEtMS0xNDMwNjE_941d4512-cc06-4590-ad14-fee949f9a41d">6,151,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e8f2a27e6664bf9aca3e322fc1aa7ea_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNy0zLTEtMS0xNDMwNjE_986060ab-148d-4267-950a-c1ee46f498f0">3,119,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60fae9ccc16447a4bb6ce23208cd688c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfOC0xLTEtMS0xNDMwNjE_fcb65796-0442-4874-9154-e485830d0630">11.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e8f2a27e6664bf9aca3e322fc1aa7ea_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfOC0zLTEtMS0xNDMwNjE_0333acb8-841c-43cd-a1da-49dfdefb09b7">31.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2b865ebec004e23aa361ef3a12e65ac_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTAtMS0xLTEtMTQzMDYx_28d6c26f-0cf9-4d59-bee8-a37f7d080edb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if73278e7a6654cec90d56f5d9e86109f_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTAtMy0xLTEtMTQzMDYx_1ff00dbb-4e87-4b38-878b-0d077b586f45">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2b865ebec004e23aa361ef3a12e65ac_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTEtMS0xLTEtMTQzMDYx_637c3012-b66e-4c6a-bf98-2ab13407efb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if73278e7a6654cec90d56f5d9e86109f_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTEtMy0xLTEtMTQzMDYx_6b142dff-4ca4-4562-8b4d-2b2073ca5ceb">56.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8ce14ad9dd241979ec43ff28ed9826c_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTMtMS0xLTEtMTQzMDYx_9646f748-a7ce-4b26-9176-8d9a93da126e">369,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18c983dff3c34ced9a702d90c64a861a_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTMtMy0xLTEtMTQzMDYx_bf1ce5d6-1d73-4070-a546-b7717aedb9f5">413,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8ce14ad9dd241979ec43ff28ed9826c_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTQtMS0xLTEtMTQzMDYx_0728d811-ca0f-4ad5-bd89-f45be4d269d8">9.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18c983dff3c34ced9a702d90c64a861a_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTQtMy0xLTEtMTQzMDYx_2994e750-784e-4638-9228-d0a3e4ba3a5c">31.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65cd64412b1044dca3d7df190d03e1c1_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTYtMS0xLTEtMTQzMDYx_648a186c-64ad-4b15-a667-9573822cc2af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ff9b7bc0a6b4740af09323c44145b47_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTYtMy0xLTEtMTQzMDYx_6453b81c-7080-4d74-a382-b91f19d4fcc1">222,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65cd64412b1044dca3d7df190d03e1c1_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTctMS0xLTEtMTQzMDYx_57222237-6a7c-472d-9de4-068f82dd7ff7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ff9b7bc0a6b4740af09323c44145b47_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTctMy0xLTEtMTQzMDYx_241d459e-7dd1-4793-954d-d968f8bd7551">28.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa5726cb791047928df873284ca85f71_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjAtMS0xLTEtMTQzMDYx_a00f4b88-1e48-4cb3-ae3b-6bce750e0395">6,455,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjAtMy0xLTEtMTQzMDYx_74dfef3b-b923-4871-9c5f-2f509bc5c632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa5726cb791047928df873284ca85f71_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjEtMS0xLTEtMTQzMDYx_49c7228c-a4d2-43b8-ab19-d291c6cede68">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjEtMy0xLTEtMTQzMDYx_6b91bbbd-0dde-44c2-ab9c-daadffae17d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa5726cb791047928df873284ca85f71_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjItMS0xLTEtMTQzMDYx_94759f25-c841-45c4-b7c8-6ecf020b21f5">4.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjItMy0xLTEtMTQzMDYx_fd95ec5f-54a0-44de-b658-2f16c6180d1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i788020833e76460b8e095fa176b6d7ce_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjQtMS0xLTEtMTQzMDYx_90c1edfd-225c-457f-b582-66a3e838c988">4,205,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i781d955207d8472f97604932ca86559d_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjQtMy0xLTEtMTQzMDYx_4c5ec8c7-4731-4ebe-b907-beeeb02b4ead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i788020833e76460b8e095fa176b6d7ce_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjUtMS0xLTEtMTQzMDYx_dcbdd885-67d1-4ea7-9b98-2af1da322a59">17.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i781d955207d8472f97604932ca86559d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjUtMy0xLTEtMTQzMDYx_494f1b41-41c3-49c9-8fc1-2bcb452ba8b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDg3NA_54015417-5f71-470b-8d90-df073f82eb5e">152</ix:nonFraction> million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDkzNg_1745aa2e-6861-4388-b6d9-f1616d20d958">1.77</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $<ix:nonFraction unitRef="usd" contextRef="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTEzMg_12749228-556f-42c6-928e-7563e61c6163">72</ix:nonFraction>&#160;million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i67229cf570e341819da1a0f863e8fcb8_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTE5NA_2adfffd9-4387-450e-90c3-0d362f9f8ca5">1.64</ix:nonNumeric> years.</span></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RleHRyZWdpb246MWE3ZDk3YjNlNjNiNDRhYWFjMDAwYjJiN2ZlODUzYWNfNzcy_94840f08-0cde-4b45-894f-b0e5a3a74744" continuedAt="i8b01bfa8367c4d6381f723e5248e0ff5" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i8b01bfa8367c4d6381f723e5248e0ff5"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RleHRyZWdpb246MWE3ZDk3YjNlNjNiNDRhYWFjMDAwYjJiN2ZlODUzYWNfNzYz_4a184c52-1ef6-4346-957d-bedd763ce0c1" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71c67458cddf440fae3e9d2616d2822e_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMS0yLTEtMS0xNDMwNjE_7969a93f-cb45-4da9-bcad-472ae3634037">2,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb87d76e2584480b8c68e4b07d46150a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMS00LTEtMS0xNDMwNjE_519043ca-2f67-401d-8682-520e2a79e50c">1,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib82c90dfcfed4b258e3dfca87b481343_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMy0yLTEtMS0xNDMwNjE_e4cfce8d-786c-4615-8ff8-7a0726552644">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93570e5abb6e4069bba204d6409b97aa_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMy00LTEtMS0xNDMwNjE_4ff19f08-dc7a-44aa-b122-186932bdccba">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie97645899e0b4e1d91b3cd525dccb36d_I20220930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfNC0yLTEtMS0xNDMwNjE_d7e1f1ac-b29c-4bd6-8dad-493b54ab8d98">2,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6be7f41bbca44db88e2eea447f357ac_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfNC00LTEtMS0xNDMwNjE_5b1a3c3f-37c3-4d01-8f1f-6e94c4f92931">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $<ix:nonFraction unitRef="usd" contextRef="idd550841fc7c45b8af6c60f3fa0f8a34_D20220701-20220930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RleHRyZWdpb246MWE3ZDk3YjNlNjNiNDRhYWFjMDAwYjJiN2ZlODUzYWNfNzIz_7cc5ade2-8b44-4095-b189-b0376d7bde77">137</ix:nonFraction>&#160;million to equity attributable to the Company.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RleHRyZWdpb246MGZkMWU4MmZjZGMyNDNmM2JmMDc0NDc5NjdkNGUzNTdfMjM4_c72cd873-3dcb-493f-a54c-1690749fc6e5" continuedAt="if59e754115cf45c3a560114c314f07ba" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="if59e754115cf45c3a560114c314f07ba"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RleHRyZWdpb246MGZkMWU4MmZjZGMyNDNmM2JmMDc0NDc5NjdkNGUzNTdfMjM3_04dddc88-5a62-4bd5-a9ce-c17cc8f4dfcc" continuedAt="ic8fc9891f6b443148c84a6dd851e7ea3" escape="true">Research and development costs consist of:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="ic8fc9891f6b443148c84a6dd851e7ea3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi0yLTEtMS0xNDMwNjE_f948a297-a478-40ef-8e5a-ec2735618b23">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi00LTEtMS0xNDMwNjE_ee55b204-4d90-4460-9b7a-1ff869281e12">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi02LTEtMS0xNDMwNjE_30fbb371-66b1-4eaa-92fe-40ee20e06799">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi04LTEtMS0xNDMwNjE_6c9dfca1-91c7-46c9-ad59-1ceabff9811f">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy0yLTEtMS0xNDMwNjE_05cac056-96e2-44b3-964b-09b49be4d79f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy00LTEtMS0xNDMwNjE_cc3dab25-67e7-4f4e-ac97-a0e2cbc2a4f5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy02LTEtMS0xNDMwNjE_a8fea922-08fe-40c0-a15a-4aaa4400f8d6">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy04LTEtMS0xNDMwNjE_e78fc6a2-5b64-41d4-aaec-66bc6cb1cc74">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC0yLTEtMS0xNDMwNjE_94f0a7c6-3440-45c9-bb2a-85153763f989">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC00LTEtMS0xNDMwNjE_44c86581-00e6-4423-a9a2-6a1ee7d2e8b7">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC02LTEtMS0xNDMwNjE_2586bc46-0525-4ab4-a1b1-69d65c84c512">387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC04LTEtMS0xNDMwNjE_2111beff-3197-48a3-a891-3d69701a04f3">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfMTg3_5f0aed97-3acf-48ad-ae7e-93b7e4cd45d6" continuedAt="id1390bdc482745e9bd23654337dbe7d0" escape="true">OTHER EXPENSE (INCOME), NET</ix:nonNumeric></span></div><ix:continuation id="id1390bdc482745e9bd23654337dbe7d0"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfMTkw_c9f40383-602a-431d-a981-ed346a18e088" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi0yLTEtMS0xNDMwNjE_cb057985-0fb7-42b1-ba82-4f6043a0283a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi00LTEtMS0xNDMwNjE_d4e143ea-8f23-4aa8-b290-723230a0d957">212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi02LTEtMS0xNDMwNjE_b9b82b19-8c10-4b0b-8dac-18b7b50de253">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi04LTEtMS0xNDMwNjE_d11b2d7c-2d33-452a-9d0b-7a0e0c4ba173">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy0yLTEtMS0xNDMwNjE_c5b381f8-813e-417e-8eae-9815de79f30b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy00LTEtMS0xNDMwNjE_7eea5012-d13e-46fe-84c0-a29fb3c11745">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy02LTEtMS0xNDMwNjE_2fccd0b0-109b-4c65-a548-6fd1ab1acd85">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy04LTEtMS0xNDMwNjE_24743bb8-698f-4959-88cc-430fef71e394">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC0yLTEtMS0xNDMwNjE_34bffbf7-41bc-401d-87bb-788ec27747e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC00LTEtMS0xNDMwNjE_83db9f38-8649-450b-9719-a0c41218045b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC02LTEtMS0xNDMwNjE_20546e94-c35f-42d9-b5fc-4fd935a83007">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC04LTEtMS0xNDMwNjE_41902a11-014f-45aa-875b-b67019cabacf">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS0yLTEtMS0xNDMwNjE_95f36a22-5a88-46d1-a34b-f422e090a936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS00LTEtMS0xNDMwNjE_6be2f193-c116-4557-9a3a-84b19e77943d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS02LTEtMS0xNDMwNjE_9911885d-9576-405a-8999-d4ee560e0880">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS04LTEtMS0xNDMwNjE_69616e87-6685-4e47-b9c8-ba4a2c475b25">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi0yLTEtMS0xNDMwNjE_00a0da3c-da85-4281-934a-8799c5a2facd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi00LTEtMS0xNDMwNjE_b65e6c27-c543-4dd0-8378-d3939abb8088">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi02LTEtMS0xNDMwNjE_23299581-6222-4d8c-b224-5b6e80afd11f">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi04LTEtMS0xNDMwNjE_b6f49d95-abbd-4bfc-980f-a98580dd9d26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy0yLTEtMS0xNDMwNjE_c08558dc-71fd-4e52-86c8-788fc5e5b2cf">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy00LTEtMS0xNDMwNjE_c26b4a87-5fb7-46a4-8f5e-b3a29f601e86">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy02LTEtMS0xNDMwNjE_fc96aa62-0e27-4e47-8eb3-35c805077a65">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy04LTEtMS0xNDMwNjE_c3fc1efe-20e5-4165-afef-2983f7e1cb27">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Gain) loss on sale of assets, net for the nine months ended September 30, 2021, includes $<ix:nonFraction unitRef="usd" contextRef="i39bbe98ba2634efa8a0ac3f26b52da3d_D20210101-20210930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfMTEx_4514c622-499c-4d5a-a425-4b547a887f8d">25</ix:nonFraction>&#160;million related to the achievement of a milestone related to a certain product and a $<ix:nonFraction unitRef="usd" contextRef="i83dd54e76be14e2b8cddedd0ad775700_D20210701-20210930" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfNTQ5NzU1ODE0Mjk1_7ba25497-aa62-46b0-9362-6aebb1a0ff73">26</ix:nonFraction>&#160;million loss upon completion of the Amoun Sale during the three months ended September 30, 2021.</span></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNzQyNA_a8a5d4a4-098b-4e32-a9af-e9c787a5e678" continuedAt="i454a371537914b0da1dbd0fe7af9ad7f" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i454a371537914b0da1dbd0fe7af9ad7f" continuedAt="i47fa35fb77154e309767f9837d947cb5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes for the nine months ended September 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNzA3_de081cd2-35b4-4ddd-aced-95b33cbe6ccd">30</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNzI4_a880b04e-c68e-4f03-94dd-deac69a54055">42</ix:nonFraction>&#160;million of income tax expense for the Company&#8217;s ordinary income for the nine months ended September 30, 2022 and (ii) $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfODA1_70a2006b-0b76-49f6-84ee-ae9f85c4b44d">9</ix:nonFraction> million of net income tax benefit for discrete items, which includes: (a) $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfODc0_1e9eee3a-be4d-4196-97ea-d11264ef5e63">37</ix:nonFraction>&#160;million of net income tax benefit recognized for changes in uncertain tax positions, (b) a $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfOTYz_cb8976a4-e0b6-439e-83b6-e4d037910828">22</ix:nonFraction>&#160;million tax provision associated with filing certain tax returns and (c) a $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNTQ5NzU1ODI3MDc3_9764e9ae-92d6-4235-a0f0-f057bd3e18a6">5</ix:nonFraction>&#160;million tax provision associated with stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the nine months ended September 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTA1NQ_97135b66-87c4-4caa-b357-9fb6f4044fcc">36</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTA3Ng_da87282e-ab56-44c2-ab5d-2c1d9268b310">34</ix:nonFraction> million of income tax benefit for the Company&#8217;s ordinary loss for the nine months ended September 30, 2021 and (ii) $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTE4MQ_e1f9fcf5-f63e-4cb2-8f92-f5151f56d9c7">2</ix:nonFraction>&#160;million of net income tax provision for discrete items, which includes: (a) a $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTI1NA_f1dca7c8-3947-47a3-a6da-224acaf08024">54</ix:nonFraction>&#160;million of net income tax benefit associated with certain legal settlements, (b) a $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTMzMg_84c2f286-8f47-4393-8493-e9d579819be3">46</ix:nonFraction>&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (c) an $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTQzNA_99b75660-7498-45e0-a099-cc2909429d9a">11</ix:nonFraction>&#160;million tax provision recognized for changes in uncertain tax provisions, (d) an $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNTQ5NzU1ODIxNjY0_951e76ef-13c7-4891-b5a9-6e61ccfe49d8">8</ix:nonFraction>&#160;million tax benefit related to a deduction for stock compensation and (e) a $<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTUwNQ_da7e5b67-e974-43b6-b0ba-8273d87c6ccb">3</ix:nonFraction>&#160;million tax provision associated with the filing of certain tax returns. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMjAxOA_92d40822-6bf7-4775-9e07-84617323e9ef">1,931</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMjAyNQ_d0f4e97f-13b9-4df5-b37b-523c5cdab8e8">2,222</ix:nonFraction> million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The decrease was primarily due to the utilization of net operating losses against debt </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i47fa35fb77154e309767f9837d947cb5" continuedAt="id54ec15aa7404057b019cc6ac4188451"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forgiveness income in Canada associated with the Exchange Offer. The Company will continue to assess the need for a valuation allowance on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Some further guidance on the plan and rules has been published, with additional guidance expected to be published in 2023. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which it operates. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#8217;s liability for corporate taxes and the Company&#8217;s consolidated effective tax rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, President Biden signed the Inflation Reduction Act into law, which includes implementation of a new alternative minimum tax, an excise tax on stock buybacks, and significant tax incentives for energy and climate initiatives, among other provisions. The corporate alternative minimum tax (&#8220;CAMT&#8221;) imposes a minimum tax on the adjusted financial statement income (&#8220;AFSI&#8221;) for &#8220;applicable corporations&#8221; with average annual AFSI over a three-year period in excess of $1 billion. A corporation that is a member of a foreign-parented multinational group, as defined, must include the AFSI (with certain modifications) of all members of the group in applying the $1 billion test, but would only be subject to CAMT if the three-year average AFSI of its U.S. members, US trades or business of foreign group members that are not subsidiaries of U.S. members, and foreign subsidiaries of U.S. members exceeds $100 million. The Company currently does not believe this will have a significant impact on its tax results, but will continue to evaluate the law and its provisions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221;, during the three months ended September 30, 2022, the Company undertook a restructuring of its third-party debt resulting in extinguishment of debt income in the US and Canada for tax purposes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDIyMg_94f7008a-9d51-43bc-ae75-f753fae29a3b">937</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDIyOQ_cdee07bd-2014-4c97-8724-63248a4b18c7">927</ix:nonFraction> million, respectively, of unrecognized tax benefits, which included $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDI3Nw_e42ab867-618a-45ff-a793-cc8f3585d586">45</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDI4NA_01fcd8e0-f645-4657-9cb2-24e2d5d4a483">41</ix:nonFraction> million of interest and penalties, respectively. Of the total unrecognized tax benefits as of September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDM3Nw_abc93fae-25a0-4c32-a4b9-e62d70f22476">164</ix:nonFraction> million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at September&#160;30, 2022 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDU4Mw_be68e96c-1979-40ad-94dd-6727a05082a8">13</ix:nonFraction> million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of September&#160;30, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 capital loss&#8221;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#8220;IRS&#8221;) is continuing its examination of the Company&#8217;s annual tax filings for 2015 and 2016 and the Company&#8217;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017. In 2021, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNjE3Nw_5c9ab5f0-35e7-4325-9f8f-149051288437">2,100</ix:nonFraction>&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. The Company has been accepted into the IRS's fast track mediation program and mediation meetings are scheduled for early 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2021.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="id54ec15aa7404057b019cc6ac4188451"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settled its audit with the Australian Taxation Office for various years beginning in 2011 through 2017 with no material adjustments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div></ix:continuation><div id="i0269b61f01054b6698b35799c21833bd_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTM5NA_03688a22-8fac-4dfb-b375-9760fa1ab9b2" continuedAt="i52eaa37a8f8d42c7b88ba96e045c327d" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i52eaa37a8f8d42c7b88ba96e045c327d" continuedAt="i3011a6ecddaa49c7ba2fb6bb65310519"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTQwMQ_ca4f8125-2f47-4922-9fb5-86ae2ad10329" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi0xLTEtMS0xNDMwNjE_edf23bb6-5281-4429-a02d-09119e3a2ab0">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi0zLTEtMS0xNDMwNjE_d07d8088-ab6d-422b-b929-debab82fced9">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi01LTEtMS0xNDMwNjE_03fb66b7-4164-4592-abb2-77a1cff3f280">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi03LTEtMS0xNDMwNjE_ea02ae06-b451-4e7c-b5ce-5bf22f5d1c23">1,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy0xLTEtMS0xNDMwNjE_1544ce08-714a-4087-976e-a6e552df2516">362.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy0zLTEtMS0xNDMwNjE_74ee50c5-84a6-4050-8765-bd7facb33012">359.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy01LTEtMS0xNDMwNjE_b29561b1-2230-4dcb-bd60-553a1b105aaa">361.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy03LTEtMS0xNDMwNjE_662a735e-800d-4f56-9524-02f290a13eec">358.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted effect of stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC0xLTEtMS0xNDMwNjE_b7dd587c-7c5b-4446-83df-5209a62e20b9">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC0zLTEtMS0xNDMwNjE_5892456a-f41f-4156-bb33-086c521da95b">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC01LTEtMS0xNDMwNjE_aa367248-5722-4199-ab7f-114d3a7ab214">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC03LTEtMS0xNDMwNjE_f123fe96-fea7-492c-9f77-6707c99982a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS0xLTEtMS0xNDMwNjE_987ae857-fbf8-4553-bbaf-c0ec999c99b7">363.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS0zLTEtMS0xNDMwNjE_83c7fe85-4ea1-409f-b9ee-10c9e9bd454f">364.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS01LTEtMS0xNDMwNjE_6f20019a-f994-46df-b539-18a6ace7172e">363.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS03LTEtMS0xNDMwNjE_a318103d-ea1c-454d-b488-b737c37dc0bb">358.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0xLTEtMS0xNDcyOTI_2e7a496a-b7e8-44f6-b921-0ac06951c873">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0zLTEtMS0xNDcyOTI_49fa1996-5163-4e1f-a08d-28eaf5bff4cf">0.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy01LTEtMS0xNDcyOTI_2cc35c29-fdbb-4e6b-8eb2-8cfb7a303d35">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy03LTEtMS0xNDcyOTI_d1a311c7-6533-43bb-b815-0dae4967d478">2.84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0xLTEtMS0xNDMwNjE_5b9e8b4e-21ea-4cb7-a193-bb336639113f">1.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0zLTEtMS0xNDMwNjE_317947e2-949c-48ec-b172-61c8df62bfd6">0.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy01LTEtMS0xNDMwNjE_59078555-809d-4d4f-8170-2fdbf9894b40">0.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy03LTEtMS0xNDMwNjE_198d8b0c-4bd6-47df-aba8-ee3772aed201">2.84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="id17555885c6b4ec5b2e98860a7c4cf48_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNTA5_f57260a4-0ea3-4032-8f45-cd0c24ef9bb8">1,906,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7b3c57844e57475ab663a9bb253a2e8e_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNTE2_5730e8d9-a27d-47a2-999b-18b62387e29c">5,221,000</ix:nonFraction> common shares for the nine months ended September 30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3011a6ecddaa49c7ba2fb6bb65310519">During the three and nine months ended September 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="icda04c31ebe54292bc90ace1f755d969_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNjk2_69d04318-89ce-45de-8784-98e7b8256d2a">16,008,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3e9cb5876bfd4fbeb27c0c8d2d1847d7_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNzAz_8291b74d-55de-43ce-bd15-aa707d3522b1">15,392,000</ix:nonFraction> common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="iae4a35e3c4d845dea31eb0b4afb0fab0_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTAyMQ_44ec8df7-584c-4883-84ff-d740c4106722">3,103,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i8b3fef19b7a044478c661e599645a697_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTAyOA_c1ea4de2-b622-4e2e-bdc5-38178e1f8094">3,453,000</ix:nonFraction> common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2022 and 2021, an additional <ix:nonFraction unitRef="shares" contextRef="i177e13e488324255b69c74c8f05e9364_D20210101-20210930" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_27eefd50-5114-4bbb-be5b-0224d6fcd5e8"><ix:nonFraction unitRef="shares" contextRef="ia499047b1cbd4a05a81ffaa7a7ac8912_D20220701-20220930" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_b998454b-9498-4761-a0b8-b07a207d7e0a"><ix:nonFraction unitRef="shares" contextRef="ib221baeee1504b62a9a00fd4bafa821d_D20210701-20210930" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_bc54a751-cb44-4b0d-865c-7f41b5723eef"><ix:nonFraction unitRef="shares" contextRef="i2ed370dc33214c95b38faa3097c8e671_D20220101-20220930" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_cbdb3a2f-76a8-4df3-9f14-a4d2718fac67">156,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</ix:continuation> </span></div><div id="i0269b61f01054b6698b35799c21833bd_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNjE2MDA_d7211030-88de-45fa-9c7f-ea56e017370d" continuedAt="i055c2f9493244837a7c91d78a42d289b" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i055c2f9493244837a7c91d78a42d289b" continuedAt="i0125585e15c14f1fa4e82d8e516797fd">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the nine months ended September 30, 2022.</ix:continuation></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i0125585e15c14f1fa4e82d8e516797fd" continuedAt="i8ea7322d55fc42bebb7b82b46f3b2b33"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of September 30, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTM2Ng_bda77d35-24ae-4f7a-9aab-da36fce6ebef">323</ix:nonFraction> million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts (Department of Justice), requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. In October 2022, the Company and the Department of Justice reached an agreement in principle to resolve the investigation as to the Company for an immaterial settlement payment plus payment of applicable interest and other related costs. Any final resolution would be subject to certain material contingencies, including, without limitation, the parties negotiating mutually satisfactory civil settlement documents and final approvals by the Department of Justice and the Company. While the Company has reached an agreement in principle with the Department of Justice, there can be no assurance that a settlement will be agreed to and finalized, nor the timing of any such potential resolution.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#8220;Securities Class Action Settlement&#8221;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, <ix:nonFraction unitRef="case" contextRef="ieb3cf936e9a74f7ebf11fb503c9b7c72_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQzNg_f1cc61af-23d2-4b96-80de-aa74d24a17c2">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="ieb3cf936e9a74f7ebf11fb503c9b7c72_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNTAwNw_d2822bd8-d70c-4908-a5f2-12fe023003fa">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="i5e3f5299561c4eebbd5248dec3a4060e_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNTMwNw_b2e1bc3f-8e0f-42d6-aaaf-efc91771adfa">1,210</ix:nonFraction> million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i8ea7322d55fc42bebb7b82b46f3b2b33" continuedAt="i7178b8c747a64caf8841b9976b928845"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the settlement agreement. The Company's rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNzgyNA_e7424e47-94cf-4fa7-aeb5-fe09ac27d315">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. <ix:nonFraction unitRef="case" contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfODI3Nw_1ae34cba-2765-48ea-9d7e-eeb02ee5d9a1">Sixteen</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfODI4Nw_e7424e47-94cf-4fa7-aeb5-fe09ac27d315">thirty-seven</ix:nonFraction> opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfODQxOA_26921de2-634a-4ce6-9258-5cf7b653ed3b">twenty-one</ix:nonFraction> actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="idcb2e316fec14bdc856e971726c9f87e_D20150101-20151231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTExMzM_eeb60f76-c5bc-41eb-8161-41de715660a2">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of <ix:nonFraction unitRef="action" contextRef="i99ebe24a04454b4091861650ed6bacb1_D20220101-20220930" decimals="INF" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTEzNTE_d41c4f91-0973-4638-970e-86ce2aeea902">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i7178b8c747a64caf8841b9976b928845" continuedAt="i60935aa916dd4552aa03fe791fa23c7e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="i4fd9f0cc91de49dcb8c8cb33d395da0d_D20200804-20200804" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTI5MTQ_825fa4ff-9be8-4810-9cef-42666843972c">94,000,000</ix:nonFraction> plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="i29e2849b192f4aaba1d8952c944b6789_I20190215" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTQzMzg_915588e2-13ce-4a89-ad57-bd841a0fdd28">one</ix:nonFraction> of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, <ix:nonFraction unitRef="entity" contextRef="iaab8fb8a87cb4b22aebbfd8cc4b85230_I20210317" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTYzMjQ_3817af16-8e7d-4a82-8e46-d20fa3a84dd5">four</ix:nonFraction> additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i60935aa916dd4552aa03fe791fa23c7e" continuedAt="if6b062948d7841be8bc033a09dbcb0c7"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="iafd7324df4a84a149605aa327631d7ab_D20160527-20160916" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTc2MzA_87d33821-4634-43d1-94cb-68c4703f771f">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="ia481a4b7a6514b33bd76b28c5e86f915_D20171207-20171207" decimals="INF" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTk2MjI_d30e6dd8-3ec5-46c1-af9d-0080e69803b4">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with <ix:nonFraction unitRef="insured" contextRef="i048227f1aea14eb384517a325981bff1_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjE1OTI_7d46a21f-cf57-42f5-8def-952b684bd762">two</ix:nonFraction> of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those <ix:nonFraction unitRef="insured" contextRef="i048227f1aea14eb384517a325981bff1_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjE3MDg_4ae0f607-2bb4-42de-abf0-c016fa3d028d">two</ix:nonFraction> insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="i871383296da145e486609cb4113359a6_D20210720-20210720" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjE5NDU_d39065c7-7688-4de2-aacd-15d2b540e78b">213</ix:nonFraction>&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="if6b062948d7841be8bc033a09dbcb0c7" continuedAt="i96754d185fae48618a9c8f2e9bd0b547"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, <ix:nonFraction unitRef="case" contextRef="i0c6de1e6ea024ddbaff325eb35a50f24_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjI2Njk_08926a0d-f77d-412e-b58f-06a22624ce02">eight</ix:nonFraction> (8) putative antitrust class actions and <ix:nonFraction unitRef="case" contextRef="i49d2de7c0d8f4004960c2d05a237a525_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjI3MTM_ca4f72aa-e301-46a2-96de-dd90ee8872c2">four</ix:nonFraction> (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. <ix:nonFraction unitRef="case" contextRef="i8a53e2265c4140e89771283e17cbb465_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjI5OTI_07091453-e78c-48ab-84f3-80c334c959ab">Three</ix:nonFraction> (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. <ix:nonFraction unitRef="case" contextRef="i2c3c58e3d67e4e9cad64210e49062a44_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjM0MDE_97181fdf-c9ac-4aef-a3e1-58da639bbb4d">Three</ix:nonFraction> (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $<ix:nonFraction unitRef="usd" contextRef="i1d5f207d7cdc4819ab32038b7d6fb0c6_D20210726-20210726" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjUxNTA_fcfa3461-ff01-4ae1-8efc-28224aaf6ecf">300</ix:nonFraction>&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i96754d185fae48618a9c8f2e9bd0b547" continuedAt="ifd9cc64331b34a98ba34495d9d34af6c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above), Humana Inc. (&#8220;Humana&#8221;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. Trial is scheduled to begin on August 25, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022. On October 4, 2022, Defendants filed a motion to consolidate this action with the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Colazal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i6dbd8d94f94a4b9b9032e8124939d763_D20200326-20200326" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzMxNzg_b5c118b6-36a9-47b7-9aeb-f1706215bee5">30</ix:nonNumeric>-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued the Norwich Legal Decision on August 10, 2022, finding that the U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D invalid. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ifd9cc64331b34a98ba34495d9d34af6c" continuedAt="i6d5e5402530342ada55775987d7b87c3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal Circuit on August 16, 2022. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i99c90fbc7cb942fcad2237f660bb4d3b_D20200828-20200828" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzQ4MDg_14823161-5c84-48c2-bdbb-83b625909af0">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. A three-day trial commenced on October 4, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a <ix:nonNumeric contextRef="ie6951d2873de43869ddbd5c757e327b2_D20220721-20220721" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzU3NzA_f4e4c526-e162-491b-98c1-efed26a3617f">30</ix:nonNumeric>-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a <ix:nonNumeric contextRef="i74ea1630078d4e05a6bca37ee09dc60f_D20200501-20200501" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzY2MjI_ba2a9397-a59e-49dd-98ec-2209ccab7497">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion. A three-day trial commenced on October 4, 2022. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a <ix:nonNumeric contextRef="ie22ec902753448c8a53dab3d0449fdc3_D20210401-20210430" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzc4NjA_f82d7958-818b-4c89-8380-b8b9114233fd">30</ix:nonNumeric>-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against <ix:nonFraction unitRef="defendant" contextRef="i53724202d602400c9250252097901776_D20210301-20210331" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjc0ODc3OTE1NjQ5NQ_9de20cf2-3856-4a25-89ab-2a0088dd9072">19</ix:nonFraction> named defendants in <ix:nonFraction unitRef="proceeding" contextRef="i53724202d602400c9250252097901776_D20210301-20210331" decimals="INF" name="bhc:GainContingencyNumberOfProceedings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjc0ODc3OTE1NjQ5OQ_5911ec75-7c65-494b-a85d-38a28bc698cb">16</ix:nonFraction> proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. <ix:nonFraction unitRef="defendant" contextRef="i845628c47166456bb97e0565f2c1bdc9_D20220101-20220930" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzg2ODE_c4c9e1ba-e392-4d43-9c98-e4a646c5ef00">Twelve</ix:nonFraction> of these proceedings were subsequently settled; <ix:nonFraction unitRef="defendant" contextRef="if47547b12409405d8d9c9257fea4a4ff_D20220101-20220930" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzg3MzI_021c6b61-8197-4ba6-96a0-bd073313f744">two</ix:nonFraction> resulted in a default. As of the date of this filing, there are <ix:nonFraction unitRef="defendant" contextRef="ibc621b0fe4dd43248d552d9e078f0955_D20221103-20221103" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzg5OTM_7547e4be-9bed-482f-b768-58493b5fb618">two</ix:nonFraction> ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i6d5e5402530342ada55775987d7b87c3" continuedAt="ibdc0cbe57d6644739310433f3af64990"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="i33c91c7c2a624d73a2b21e6f04607fd7_D20210910-20210910" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDEzMDA_367c3b74-8dfc-4030-a68e-04dbd6b639d5">30</ix:nonNumeric>-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="i3ea0bb7c52aa4fc2b812e3b4ce2644ba_D20220202-20220202" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDIwODQ_5500b176-49f9-470a-8f34-ff9db0270c27">30</ix:nonNumeric>-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes Review Proceedings at the U.S. Patent and Trademark Office</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against <ix:nonFraction unitRef="defendant" contextRef="ie5916243ff944d46aa17d2219e926c0e_D20180801-20180930" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQwMDY_ead12dd2-af8d-46a0-9477-dbf879121a62">four</ix:nonFraction> separate defendants. All cases in U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, <ix:nonFraction unitRef="lawsuit" contextRef="i332ac3fd809849fd83751e1cc812e29a_D20220101-20220930" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQwOTY_0163ee5a-d1a3-407e-8939-bd50dfd472ec">two</ix:nonFraction> lawsuits remain pending against Apotex Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. On October 12, 2022, MSN filed a petition for IPR of U.S. Patent No. 7,041,786. The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ibdc0cbe57d6644739310433f3af64990" continuedAt="i4fe7500f10884eb095ced26300a05e21"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-six (<ix:nonFraction unitRef="case" contextRef="i4136072a63394788a51d3aa4149f4df9_I20220930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQ4NTk_5b74786e-18ed-48ac-b158-3be066d97b6c">26</ix:nonFraction>) of such product liability suits currently remain pending. In <ix:nonFraction unitRef="case" contextRef="i5d82fa052dd1452883203a200bf1217f_I20220930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjc0ODc3OTE1NDE0Nw_3013dddc-0344-4a76-96c6-0de7ef998cfe">three</ix:nonFraction> cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-five (<ix:nonFraction unitRef="case" contextRef="ie3e10e59808e4d0092702cbb02aea06a_I20220930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDU0MDE_863e6c8b-13b4-44f7-820f-a8235af90fea">25</ix:nonFraction>) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, <ix:nonFraction unitRef="case" contextRef="idb508c450eed40579b6ee442cc2907b7_I20220930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDYyNDg_965aaf49-a295-49f6-85e2-d7809d1f1320">two</ix:nonFraction> proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (<ix:nonFraction unitRef="case" contextRef="i184af1e8e9cc401f9c92a4612adf20cc_I20220930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDYzNjA_95a12951-72d8-4411-9cc0-cf32a28cc3db">one</ix:nonFraction> in the Supreme Court of British Columbia and <ix:nonFraction unitRef="case" contextRef="i4f33cd61e80f44d8b6fec68312c48113_I20220930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDY0MDg_0bddd973-29fe-488f-b451-d5446e59a1bf">one</ix:nonFraction> in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (<ix:nonNumeric contextRef="i92e33ca886304a7f8736aba94ba18b95_D20211101-20211130" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDgwOTM_67347915-ca8c-4eb9-88af-e1dcf605c3cf">60</ix:nonNumeric>) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the <ix:nonNumeric contextRef="iafc41fcffae24dafb443704717376dce_D20211201-20211231" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDg4NzI_d55edf51-b813-4263-beb6-c69fc32a5f0c">60</ix:nonNumeric>-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022, and a decision is pending. Further, pursuant to a court order dated March 18, 2022, the Bankruptcy Court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also ordered separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. The Bankruptcy Court extended LTL&#8217;s exclusive period to file a chapter 11 plan until November 17, 2022, and the talc claimants filed a motion to terminate LTL&#8217;s exclusivity. The parties have since consensually agreed to extend LTL&#8217;s exclusive period to December 13, 2022. On July 26, 2022, the Bankruptcy Court held a hearing to consider alternative paths to case resolution, and on July 28, 2022, authorized an abbreviated estimation process designed to determine the extent of LTL&#8217;s aggregate liability. Additionally, the Bankruptcy Court appointed an independent expert who will issue a report forecasting and estimating the volume and value of claims. The Bankruptcy Court has scheduled November 16, 2022 for a status update on the expert report and to discuss scheduling further formal mediation sessions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Bankruptcy Court also ruled that it would leave in place the stay and injunction enjoining talc product liability cases from proceeding until at least the completion of the estimation process. To the extent that any cases proceed </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i4fe7500f10884eb095ced26300a05e21" continuedAt="i32ad3e99e3554a238c6d03dbb98eae74"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the pendency of the bankruptcy case, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. As a result, the New Jersey Superior Court action is closed and the case is now pending in the District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion is fully briefed and pending. Other proceedings are in abeyance pending resolution of Plaintiffs&#8217; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the current stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and accordingly, asked the Ninth Circuit if Johnson &amp; Johnson could have until December 19, 2022, to provide the next status report while the stay remains in place in this action. They also indicated they will inform the court if the status of the bankruptcy stay changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i32ad3e99e3554a238c6d03dbb98eae74"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on May 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the State of New Mexico from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction and noting it would be revisited during the December 2022 omnibus hearing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="ic05dba365c7149048c6b1a7245d1b247_D20180401-20180430" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNTk5NDU_f934cb8f-2869-47b2-b9e6-b8934106e123">23</ix:nonFraction> million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $<ix:nonFraction unitRef="usd" contextRef="i88b4c08132f844779089399f6327cc37_D20190128-20190128" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNjA4NzQ_37a04844-af68-4e47-ad7d-3526c079c1fd">30</ix:nonFraction> million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_97"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY3Mg_b9c8025f-9364-407a-b144-2eb382644264" continuedAt="i6fbf0990cb5f47528b413fbfc7952fd8" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i6fbf0990cb5f47528b413fbfc7952fd8" continuedAt="i9b9f9bcf64a8483987025087044f8897"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s previously announced plan to separate its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company had begun managing its operations in a manner which was consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s CEO, who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. The new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfMTMwMg_8480efee-e389-422e-bd1a-b3f6a144a5c1">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, the Company announced it was suspending plans for the Solta IPO; however, the Company is continuing to manage and operate the business in its current reportable segment structure. See Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately <ix:nonFraction unitRef="number" contextRef="ibefdea46ac904b858f0d89701cc31d09_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfMjEyNw_55bddcd0-22e3-43d0-8247-5ae7e288b8bd"><ix:nonFraction unitRef="number" contextRef="i203a22f1210340a79695abcf5e8cbc84_D20220701-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfMjEyNw_fd5b7fd8-c824-4511-bf98-6fadce5b2205">80</ix:nonFraction></ix:nonFraction>% of the Salix segment&#8217;s revenues for each of the three and nine month periods ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i9b9f9bcf64a8483987025087044f8897" continuedAt="i0da4a27b349b4ea695c16db0c81271a5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY1MQ_c225e2de-d0ea-4af6-994f-0712fc77fa9d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b3dcad39c345c5ac603e17ed95fc3a_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy0xLTEtMS0xNDMwNjE_430532be-6734-4098-8a41-b93368f233f2">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a48564554644fbf91499853e1132e1d_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy0zLTEtMS0xNDMwNjE_6b5eb4ca-b9f3-4895-af3e-c4965a0fecbc">527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb4504aa6bf41d1a6be48aa2c1f175d_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy01LTEtMS0xNDMwNjE_a4155c4f-ffcd-4fb2-bb2e-08ed9d66a178">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d031dd6d0d24cffa3eb903bb856d240_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy03LTEtMS0xNDMwNjE_f4eebb77-8380-4677-85b6-32de5e061c00">1,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5656b3707db4122895e60ea240cf646_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC0xLTEtMS0xNDMwNjE_85ade8db-757f-41dd-9f04-54d8e286fdf8">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib141aa7ca51144b7b474e3fc89019f7d_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC0zLTEtMS0xNDMwNjE_ba2a83c1-47b6-4679-9a8d-72bf3a433db3">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6422ec5e814d71921b4040a843846b_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC01LTEtMS0xNDMwNjE_ecbdd68f-c7be-4ce5-a7be-29fffca2f2b2">727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d22d39c1ee04a7787dc2f60be8d5f7a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC03LTEtMS0xNDMwNjE_f675e869-6ede-4625-b093-89af779855a6">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d17424aa5a4db5a07016d40a84d937_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0xLTEtMS0xNjc5NDY_e8a42e82-44d5-4b14-8cfd-1f351a2da4ea">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f9b74c57634e8c912801d8ecd437ff_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0zLTEtMS0xNjc5NDY_6c3974ca-a86c-456f-8669-bf7159a892b3">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6378396c4e9a47e1bf78d4f23861e774_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS01LTEtMS0xNjc5NDY_cd2f56fe-15dc-44e6-aff1-321c02584464">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870c4afe29af49f3a2a7f8542ee2ccfb_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS03LTEtMS0xNjc5NDY_e4d60e50-96aa-48e4-8082-d1303c66aa88">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7789d8fa68d94ab1832565529cc7b6dd_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0xLTEtMS0xNDMwNjE_c59a736b-a6f6-4e33-8c27-be337f5130d0">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961d5c068e19458eba50a317f05a809d_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0zLTEtMS0xNDMwNjE_a28d05a0-66fc-4036-b2df-fb3bb6ce3f4c">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d87fac315ac4359b4ba48ecf9d3800a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS01LTEtMS0xNDMwNjE_3aa8ad50-2c98-4e5b-a005-2f455ccebe70">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc4fa0ce3094043b06c419d4f2739db_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS03LTEtMS0xNDMwNjE_9ef2189c-4550-4e0d-9b57-8fdfddb048cc">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f4d42dc1e84b6ebb78a7f56a821a8e_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy0xLTEtMS0xNDMwNjE_2ec516fc-7f62-4c04-a671-9b1fda13fb71">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6abdfe5c4694514950ade150231952d_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy0zLTEtMS0xNDMwNjE_73fc35ce-73b1-43bf-842e-aac18f6d3402">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f85a36c4542b38c592e0acf6f1180_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy01LTEtMS0xNDMwNjE_1032cae8-a89d-4f87-bc80-6dc63a1a3359">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee32157246540168ca54485ea8c5d71_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy03LTEtMS0xNDMwNjE_898209ce-9a3b-4484-ad59-5b8ada01527b">2,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2502f43413f4cd480e2a0246b792a52_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC0xLTEtMS0xNDMwNjE_47a05a51-940d-4c8c-99ca-fe7eb56f09ab">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84aaf53830b474e8b82377c387fa23c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC0zLTEtMS0xNDMwNjE_e94b35ba-c6a6-4417-bf29-68d4648e2cc0">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58454b50b234f0cae6d889781bf1c3f_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC01LTEtMS0xNDMwNjE_45b38a6a-2afb-409c-8a63-d36f9c2bc927">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1bff2464e6492f978876c9c6825fc3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC03LTEtMS0xNDMwNjE_912c4b1f-2d41-4a75-8470-99d7eeda37dd">6,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b3dcad39c345c5ac603e17ed95fc3a_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtMS0xLTEtMTQzMDYx_74ea4f5b-a15f-4f5f-adfa-c2c7b32a61a2">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a48564554644fbf91499853e1132e1d_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtMy0xLTEtMTQzMDYx_0b3e89a2-ed8c-4229-9741-712e9e87d456">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb4504aa6bf41d1a6be48aa2c1f175d_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtNS0xLTEtMTQzMDYx_fa3b40fa-0baf-4bf4-a87f-09a81f0b6be5">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d031dd6d0d24cffa3eb903bb856d240_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtNy0xLTEtMTQzMDYx_6817d61b-34c7-49b4-b200-ea86139b4ee9">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5656b3707db4122895e60ea240cf646_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtMS0xLTEtMTQzMDYx_500a39f5-6d69-4f58-b2ed-56eccef8911d">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib141aa7ca51144b7b474e3fc89019f7d_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtMy0xLTEtMTQzMDYx_f3889194-bfb9-449d-8a57-b236bdedfdd5">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f6422ec5e814d71921b4040a843846b_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtNS0xLTEtMTQzMDYx_eb79cef0-bd0d-4df8-a4c4-dfb3db7f130b">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d22d39c1ee04a7787dc2f60be8d5f7a_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtNy0xLTEtMTQzMDYx_7a58d165-26ad-4d11-bc04-d367f39b5ee4">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d17424aa5a4db5a07016d40a84d937_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMS0xLTEtMTY3OTYx_1fca8bc6-a57f-418b-a457-fe907d929b3c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f9b74c57634e8c912801d8ecd437ff_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMy0xLTEtMTY3OTYx_d4865963-b221-4a3f-b6fe-19b10a39ad21">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6378396c4e9a47e1bf78d4f23861e774_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNS0xLTEtMTY3OTYx_32f9b508-ff21-49c8-8b35-49247834b473">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870c4afe29af49f3a2a7f8542ee2ccfb_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNy0xLTEtMTY3OTYx_558766e5-b65c-4308-9e27-1774e00120c5">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7789d8fa68d94ab1832565529cc7b6dd_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMS0xLTEtMTQzMDYx_48824f87-fccb-473b-a66c-83443c088d39">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961d5c068e19458eba50a317f05a809d_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMy0xLTEtMTQzMDYx_14556271-b5ad-41e6-acda-b889213037b6">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d87fac315ac4359b4ba48ecf9d3800a_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNS0xLTEtMTQzMDYx_8b3cadcc-31f9-49b3-a3b4-25bed206d19f">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc4fa0ce3094043b06c419d4f2739db_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNy0xLTEtMTQzMDYx_457eab78-8258-42e7-b4e1-d9ba515cd14c">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f4d42dc1e84b6ebb78a7f56a821a8e_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtMS0xLTEtMTQzMDYx_18112fb7-3d07-41c8-ab5f-9590ba920dfd">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6abdfe5c4694514950ade150231952d_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtMy0xLTEtMTQzMDYx_c14a8908-330b-4fc9-8902-9747eee1346e">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb2f85a36c4542b38c592e0acf6f1180_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtNS0xLTEtMTQzMDYx_90dd772f-4f97-4f0a-9096-09d2419e4db1">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee32157246540168ca54485ea8c5d71_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtNy0xLTEtMTQzMDYx_532357e0-82ac-4b49-a6cf-e1e9a56734a5">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2502f43413f4cd480e2a0246b792a52_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtMS0xLTEtMTQzMDYx_5fa7cfb4-8a7d-415f-8422-3a8b681dae2b">886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84aaf53830b474e8b82377c387fa23c_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtMy0xLTEtMTQzMDYx_4bd90882-ee64-4969-b8dc-1f772b3f2755">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib58454b50b234f0cae6d889781bf1c3f_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtNS0xLTEtMTQzMDYx_55c52ba9-8151-4950-8d41-7bb6a355b09d">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1bff2464e6492f978876c9c6825fc3_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtNy0xLTEtMTQzMDYx_c86e4ecf-668f-4288-bf28-abb2e9fed543">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d876376e54400484f8385cdeda205d_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtMS0xLTEtMTQzMDYx_b019b7d2-c9c9-409f-8ef7-01d170a054d5">218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd45d6d098e940cea4a1d9a05d7a84d1_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtMy0xLTEtMTQzMDYx_cd8dace4-2904-4756-9e22-2da0f2989e96">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4a9da148f254cccbc56ead023ff8e94_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtNS0xLTEtMTQzMDYx_256b399b-60b7-401a-bf7e-8a6d0b20ac4c">614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id018a592918a4c7d92d36586e30b8b25_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtNy0xLTEtMTQzMDYx_68a55808-1947-4e4c-a80a-c064e8e2101d">566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctMS0xLTEtMTQzMDYx_3dd47d6d-1868-48a4-9f2b-8aafd8d7c761">290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctMy0xLTEtMTQzMDYx_71df02dc-bd64-4932-90c4-6aefb84597f3">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctNS0xLTEtMTQzMDYx_ba1c286e-4283-433f-9c5a-e37756ce7532">902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctNy0xLTEtMTQzMDYx_6c1ef00f-c8fe-46a5-9c36-5bc9f48b355e">1,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtMS0xLTEtMTQzMDYx_5e328c17-7afc-4f1a-8b89-820e11357532">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtMy0xLTEtMTQzMDYx_a376b834-af7b-4df3-a9db-36800cb11741">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtNS0xLTEtMTQzMDYx_8a398dec-fe1a-4e3a-a6a5-e4285f64cf46">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtNy0xLTEtMTQzMDYx_061bce0a-1e74-4a1e-8afd-8dea4889497e">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktMS0xLTEtMTQzMDYx_78228e0a-181f-45e0-b0a2-516b4086dce0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktMy0xLTEtMTQzMDYx_a3f2ec8d-341c-435f-8b11-49fdce462ac7">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktNS0xLTEtMTQzMDYx_2d54f675-0631-4e95-98f1-7e7ff4235e94">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktNy0xLTEtMTQzMDYx_c7e1cbca-0e03-4703-9c5e-edb56a3cdd1b">213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtMS0xLTEtMTQzMDYx_05ea8fb3-d884-49c0-8290-e9a1e27bf33d">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtMy0xLTEtMTQzMDYx_c63db402-b48f-4082-9f46-085c88e9d38e">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtNS0xLTEtMTQzMDYx_aab0bf52-e4be-45a8-aa4b-d99d2d8157a8">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtNy0xLTEtMTQzMDYx_50d218d4-0b1e-4d37-a154-6f2c724e8b6a">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtMS0xLTEtMTQzMDYx_8f37e401-e506-42de-ad02-21642f239f76">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtMy0xLTEtMTQzMDYx_8c394ef7-d256-43c2-b5ea-b9050f3af075">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtNS0xLTEtMTQzMDYx_1cd821c8-8802-482a-9234-40d9c5b4fe97">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtNy0xLTEtMTQzMDYx_c44bbe15-f19f-40d4-95e8-0f7c8fa37494">329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItMS0xLTEtMTQzMDYx_99045aa2-6bf5-4bb5-8627-2c6bddae4d45">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItMy0xLTEtMTQzMDYx_b7cebfbb-e079-4954-87eb-9fc9a633d58a">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItNS0xLTEtMTQzMDYx_ccb8596b-8314-40fa-ba8e-07201c6707f5">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItNy0xLTEtMTQzMDYx_8eeb0f76-0b70-469d-b07c-f315459e15e0">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtMS0xLTEtMTQzMDYx_146c1892-b53a-47bc-be29-db2b7935e1e9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtMy0xLTEtMTQzMDYx_21f9a4b5-b970-44a8-8ca5-f22c18178516">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtNS0xLTEtMTQzMDYx_78bfcc1a-a74c-49c8-bee4-27b8bdcfeff7">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtNy0xLTEtMTQzMDYx_7d7a1cdc-20bc-4308-a6f4-b4a12ceca7b4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtMS0xLTEtMTQzMDYx_0ec7c617-9a38-44e7-9b67-179efdd432df">385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtMy0xLTEtMTQzMDYx_f2a67a54-77fe-4961-a80e-3cdd0e95ce5c">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtNS0xLTEtMTQzMDYx_b9b9b62e-8b73-47f5-968e-8e5c45dc93f1">1,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtNy0xLTEtMTQzMDYx_ac4cf34c-8667-4575-b25d-c15213cfdf5c">1,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtMS0xLTEtMTQzMDYx_fa3c062b-a0da-4fe1-8a0a-412e637facc6">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtMy0xLTEtMTQzMDYx_a8ff5c07-e33a-4436-bd67-bf6853249596">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtNS0xLTEtMTQzMDYx_27527a54-9e8e-45ca-9743-80f595f829da">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtNy0xLTEtMTQzMDYx_163a52c3-41e1-4778-9b74-81df0f1a0b87">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtMS0xLTEtMTQzMDYx_0c225ad0-0fdc-4394-b747-5ad10f58d78f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtMy0xLTEtMTQzMDYx_9a5cd991-470b-448d-9a89-13bf061b1eae">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtNS0xLTEtMTQzMDYx_ca73fc32-2913-45b4-891c-3a90cbf0cd1e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtNy0xLTEtMTQzMDYx_33c21daa-e591-4129-a739-a7b1e397efd2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctMS0xLTEtMTQzMDYx_365f7c72-d87f-4eb6-b0c7-245b36fdde5b">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctMy0xLTEtMTQzMDYx_2344df24-99ae-42fd-8f5b-078bba3271d6">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctNS0xLTEtMTQzMDYx_8a945bc7-da1f-4f7d-aed7-c5f190f91708">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctNy0xLTEtMTQzMDYx_b33d3fd4-3f7f-4728-b84a-3169c8cc4e8e">1,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i0da4a27b349b4ea695c16db0c81271a5" continuedAt="icd8c4b11199342a29056a75e03dd1600"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY1Mg_8b4d8f2d-4faa-4ef1-a0cd-b60bfb1825ee" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:29.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0df6736f2847b197e7b8bed8c689ca_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi0xLTEtMS0xNDMwNjE_f6ae3e3f-6d1b-468a-af23-61952ff7f228">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e24b87e5d8f49d18b41d6f564417334_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi0zLTEtMS0xNDMwNjE_061e963f-f3cb-4e1a-92e1-74732127b46e">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21fbd1b5e5b446a289edffe298fe2beb_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi01LTEtMS0xNjc5ODM_2d4824b8-33f4-4604-a698-ee48cd5aa03b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9903b8834174c129ab4fc958937b81c_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi03LTEtMS0xNDMwNjE_75f36d33-6a74-42ff-8eb6-1dd6116213b6">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1abefd1a9ec41a0a822f596885e4972_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi05LTEtMS0xNDMwNjE_4d628386-34d5-49fa-a1aa-75af8b40fe33">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eede7fabe3a4f2ba57b19bd82733d3d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi0xMS0xLTEtMTQzMDYx_4e8e59e2-ae7e-4617-ab88-4cac9b0c9130">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i567d22541928427db55a03ad179a4ad1_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy0xLTEtMS0xNDMwNjE_b89da1ef-1c90-40dd-8137-c4d439eaba58">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aae3e10a71b4f6a98a38090820fa000_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy0zLTEtMS0xNDMwNjE_5e3a195b-3802-4709-84dd-cb9ab9d95782">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie53e184c5e4e4ea79e2591ec3164d59f_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy01LTEtMS0xNjc5ODM_554eff9f-efb2-444c-bf57-35e47ae0855a">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50af148aa25b49fbbfe10ca60b5ceceb_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy03LTEtMS0xNDMwNjE_b4571ca2-90e0-41fe-81d5-c1b728cd40a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947a6e91ffdc4fbe89b4ecb87866d600_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy05LTEtMS0xNDMwNjE_cf7f0a88-02f9-4db9-8680-879a9d437f24">390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6813706915f4ea589187e4729d7e82d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy0xMS0xLTEtMTQzMDYx_06729d9a-f52d-4f3c-9697-1cef6df2fa7e">462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88458031f6ac47b59b944bfddbce8e54_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC0xLTEtMS0xNDMwNjE_869ffe61-4188-4691-bf2f-3ad6c6ec33cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa45dacdd3d94b9da782f49919c50c7c_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC0zLTEtMS0xNDMwNjE_0c5f5a1c-a48c-43d8-a7e8-76c6a5aa6914">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5529206dd0354add818ec8ebc745ea99_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC01LTEtMS0xNjc5ODM_d88ba5ec-b651-474a-9181-97ea5b3917fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b101667c39b43339df8dca9eb8a5c17_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC03LTEtMS0xNDMwNjE_cf0f12a2-0dd9-4b6d-a350-37e844c742d8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195b71e75a26477289ed617294657ed5_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC05LTEtMS0xNDMwNjE_999bc769-9e92-4a11-b0d3-d1fea086418e">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586500eaabcf48daa510aef12cb36e94_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC0xMS0xLTEtMTQzMDYx_a9c9c6f2-8876-4601-9dbe-51eb1c77158a">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4547bdb61bec469cb232355667f60334_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS0xLTEtMS0xNDMwNjE_cbd8b1a0-b44b-4464-876b-86c47fcdab9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5528e4e03c4951891b8333a4918812_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS0zLTEtMS0xNDMwNjE_abbed9d9-a6c5-4a27-89d5-6cdb0c37b194">131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1da9ab6b49674688a517da02ff148635_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS01LTEtMS0xNjc5ODM_62c5645a-324f-4a9a-b16c-5f6082127e28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8677733f10724b908cb5fa12e547a9cd_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS03LTEtMS0xNDMwNjE_6bcd572b-681e-41e3-89f6-48cde3c3f974">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d18eaf8a344deabfb39b5d1d2f5244_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS05LTEtMS0xNDMwNjE_10d21907-f7bf-411d-8d92-3a21951aefc7">65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c7c1f563024eb885219d1cc73e2c03_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS0xMS0xLTEtMTQzMDYx_8f1f28aa-d7e0-4ed3-a304-b8413d564f64">220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e529afb54794cf0a4114a5202965a4d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi0xLTEtMS0xNDMwNjE_0ef7dd13-5583-4d4b-b691-b888438afe2b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888846f7a8a24e6cac9459c35c333be9_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi0zLTEtMS0xNDMwNjE_da203cac-9107-4a78-8c2e-af8632e686a5">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcbd7bd0541403ba70a5c4a488abfad_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi01LTEtMS0xNjc5ODM_eed6350f-b29c-463c-ad34-fb0d6519db96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2366ec826494978b8848268dbd37f56_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi03LTEtMS0xNDMwNjE_1c4aaa59-4195-45f4-bbf6-a857c292b3ec">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5abfa18a5c8641a1819cda416997710d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi05LTEtMS0xNDMwNjE_eed25414-62ce-49dd-a3ce-8e7b79592d34">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79e84fc1b29410e8ce4e71df86aa5b6_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi0xMS0xLTEtMTQzMDYx_8749de7e-19fb-4532-81cb-a9611af4b049">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5421c9b35b4516a49077974d2e5949_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy0xLTEtMS0xNDMwNjE_31dc81c6-62cc-4212-b674-9fff49a1f4ed">544</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27fc1e4a91e4d25a238da7b45796c0b_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy0zLTEtMS0xNDMwNjE_fca294d3-bbb8-45c8-ae85-ef93fcf06c61">250</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a4f9d43f164c9b99692b1912045740_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy01LTEtMS0xNjc5ODM_2ea22d66-11a9-4e73-b449-b8c900358949">72</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b3252a18104908b5a55f890c213286_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy03LTEtMS0xNDMwNjE_328f5eb4-c25c-4e61-b5fe-7d926a77d240">238</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425034548a5c4d40b9c2c34552bd6d3d_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy05LTEtMS0xNDMwNjE_3b2530ed-69c2-4399-b534-bd0d9b809c49">942</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy0xMS0xLTEtMTQzMDYx_6e97eea2-9d08-49df-b78e-2a49e49917e5">2,046</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bd3f79386a444ea669a83657bf3167_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtMS0xLTEtMTQzMDYx_00566f34-5f05-4d2a-890f-f3b40fab42a9">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1418ca7566eb4be890fe201a00997650_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtMy0xLTEtMTQzMDYx_f856fc41-ebaa-4ada-9051-c08bcb0dd57d">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60598e761b44eaaaceb643fb0d3f737_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtNS0xLTEtMTY3OTgz_48b95b4b-8f9d-4b74-b770-db2506a44f3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91c304c54df4d51a17ad1319b6cefd2_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtNy0xLTEtMTQzMDYx_6ae71e58-04c5-430f-aebe-baf39f09af04">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8153aeaa29c14cf78898a3e0430db0b3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtOS0xLTEtMTQzMDYx_fa4f57b1-bbaa-4cd6-8c93-71d55167180a">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3155b234cd454dcda100820d79b828e3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtMTEtMS0xLTE0MzA2MQ_64019404-7d11-4f07-8e8c-1343446bcf03">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2478dd9d311e41849390cfdcaf83acb0_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtMS0xLTEtMTQzMDYx_0e53e830-498b-4c3d-a11f-e14b08eb85cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b297ee44b024a5a84ce38bae85846c2_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtMy0xLTEtMTQzMDYx_2287b3da-9d70-4f6e-8415-43cda08ae05d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22473c0e99cb43b1bd4931030815e25a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtNS0xLTEtMTY3OTgz_2a02e432-8c5f-4a99-b2ec-8231e4ea2b8e">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic56c6ec263244270a0635f1fc010b8d1_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtNy0xLTEtMTQzMDYx_983301a9-78b6-44b9-ad6a-2b1b8878409c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c3b644d34948be9d9c18866f4a5d9a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtOS0xLTEtMTQzMDYx_1acfa27b-0338-44e2-aae5-6ea5b0eee644">395</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f341155d9df46758157a2f5d967fcf5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtMTEtMS0xLTE0MzA2MQ_b1ea01db-4c95-4c61-8a5d-31823ebc8952">469</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c0d01651fa42ddb2726f307d78e1b1_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItMS0xLTEtMTQzMDYx_c5585d12-d9b3-4f26-8cff-141af8d32737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e6f8d534264d698d9daaefe158ba7b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItMy0xLTEtMTQzMDYx_eaef294e-f4ce-4a35-89de-f6bd532a421e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43251ca627784927b25da791c21f44b4_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItNS0xLTEtMTY3OTgz_63a07426-0269-4441-9a17-496cf545426a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3037fa5f424f4fcd91ed8575d90726cd_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItNy0xLTEtMTQzMDYx_3e3c3996-3010-4b74-a32e-53948c872a6d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic136910890c64c788ae7b465e4125b6c_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItOS0xLTEtMTQzMDYx_60e99367-c766-4c51-a1a9-0ae7988107a9">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3ff051184a4834850b051a7d4eb1df_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItMTEtMS0xLTE0MzA2MQ_3a0f7d44-e95d-42da-9ab3-28fd7bc70340">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40c9b728ace2464d8f96d58ae572ebbc_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtMS0xLTEtMTQzMDYx_4d67cbe1-e819-4f5b-bb40-2a1bc2d49080">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6567a2441b6f405199585a4b83fe5bc8_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtMy0xLTEtMTQzMDYx_bb13e48e-3597-4ccc-884a-ec88492a6bf8">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77a4befe17f484688509cd99dc3b12e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtNS0xLTEtMTY3OTgz_96453d38-f714-4833-854d-4a5eb2c52534">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aca7ca963b44994a71d3617c064d6fe_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtNy0xLTEtMTQzMDYx_dbb7920c-820e-401a-90c2-e970583dd994">47</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422af7d7e455458c85d983e22cdac59a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtOS0xLTEtMTQzMDYx_f57001d2-90b1-4ea1-b411-be4c540331e9">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944bf2eea27245dfa96a85b44b8afebb_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtMTEtMS0xLTE0MzA2MQ_c6725d79-afef-436a-af1d-49a70e7869df">269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44102882489d45b8a65cbe80612eb503_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtMS0xLTEtMTQzMDYx_128df98d-3431-448f-8301-f2b869f84812">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629f1d9bd1a2455f855f4061c4ce4dfe_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtMy0xLTEtMTQzMDYx_7feb0283-8af1-4082-ba3a-b5e4842cfa19">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib508b0f79c104da081f95ec2beaff2c1_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtNS0xLTEtMTY3OTgz_f81a3035-add9-4683-a248-ce70ef9f644c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e8b341226e741e6a61a9d17cbae03d0_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtNy0xLTEtMTQzMDYx_62ef6778-67cb-4e15-b6d5-26e490ca3f38">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1c2ec3c04143fc919380f19acc7cd5_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtOS0xLTEtMTQzMDYx_d090b31e-8ab2-4c2b-a071-fe252ef709df">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90dad0cb3874aca84524b1022581f5a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtMTEtMS0xLTE0MzA2MQ_cf064f37-ed45-4084-be73-fce20e3c471f">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa8cafb0fc44a99b36bcfc0892304b6_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtMS0xLTEtMTQzMDYx_9eddb412-c17b-4d2b-ac6c-8b2f5dd41eb1">527</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda4a6e048d64e4c8a7245ff0c6385df_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtMy0xLTEtMTQzMDYx_e7fbac54-190d-4cd5-a728-7d3d213b92f4">271</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23473ab81eaf45d8a36b3bf461716a8a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtNS0xLTEtMTY3OTgz_7bd59405-b99b-4796-af8d-afbf06bf933b">74</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48494750e70944a6a8fe08c72a157c9d_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtNy0xLTEtMTQzMDYx_faf9dda4-45b4-4cb7-a439-53c5aca132e9">290</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a743c0619b545b2b9851ee1735cece3_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtOS0xLTEtMTQzMDYx_8ea9f441-7747-494a-9ccd-7bc66f1ccfbc">949</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtMTEtMS0xLTE0MzA2MQ_b05cdf07-fe72-4cb4-8a19-2f89bf823971">2,111</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26aec855e3534a57b91887cca0df636c_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtMS0xLTEtMTQzMDYx_0cde31be-7370-4cec-ab71-18b8f074924a">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8b64fc9195a481b99d8eba5eba2c499_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtMy0xLTEtMTQzMDYx_860927db-3507-40ea-ab06-02b58aca51fc">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2020a325cfd844aeae55587fb97a9bde_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtNS0xLTEtMTY3OTgz_9e0d0a9c-541f-462f-ac81-c0c797b29fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc165abe9fd94612a2e9711f068afaa2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtNy0xLTEtMTQzMDYx_78320feb-2f5e-40db-b6bc-05c2a65336ab">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67b7b11900d04f5ab4a91815dc85a13f_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtOS0xLTEtMTQzMDYx_0c3c3772-0010-4bcd-b430-03b0295bfb3c">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d594998be2c466a8ae3f74769b467f1_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtMTEtMS0xLTE0MzA2MQ_d2fbc5b1-1585-4d14-abb3-885531b2dac9">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id14c76797d024f8a850f17d12da55d9b_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktMS0xLTEtMTQzMDYx_c014e12a-b30a-4bcc-98ed-15e18ec354d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d945399f7fb410484aeea7fa1086e9c_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktMy0xLTEtMTQzMDYx_fc1d1db5-4a88-4089-967d-0d56450718ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19757afbfd8c45fa860915adcb1688d8_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktNS0xLTEtMTY3OTgz_8b36edf7-a59d-474c-8ced-fd023a67c659">201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib120955476934bcab3cfc8a57258b2df_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktNy0xLTEtMTQzMDYx_d031db20-b1a4-469b-936d-1b6a956eb16a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54edda7460544fea9cde5c3172db7617_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktOS0xLTEtMTQzMDYx_34b2c5e8-5f70-4ba9-bec2-962962d19f9e">1,168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb54743e79e418c8eeba61c5c9441e3_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktMTEtMS0xLTE0MzA2MQ_1b608c9c-d3ea-431a-9572-b6a4b00925b0">1,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755e8ef589a6417c85697fb2489e0997_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtMS0xLTEtMTQzMDYx_a3bed599-dd02-48c2-9339-0478cc273278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e344425e326404fa4c3a5ceeb0a33ad_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtMy0xLTEtMTQzMDYx_31a5b618-5510-4683-90a7-efa1b0aa07f2">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie27be4668ecb485da4269a39bfa27526_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtNS0xLTEtMTY3OTgz_1b2d3517-b0c7-4094-a7ec-b76e78a2eb97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfc2d283efe4a7e834029578338109a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtNy0xLTEtMTQzMDYx_cc4eef19-b531-4133-a875-2840555aac5c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599ad95889f140dd856c86816a0647de_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtOS0xLTEtMTQzMDYx_88d94db7-eb55-4ed2-a341-120c5cc9a43e">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75dbc41746a6477da43e97ab5cdea898_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtMTEtMS0xLTE0MzA2MQ_6fda2693-bb41-4e2c-ba91-7230bc3b1ec2">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4464cc778bb74ce498dcb23fed88c066_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtMS0xLTEtMTQzMDYx_4155e26e-b038-40ec-828e-5a3d356f0cf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i583e1c626b03403f87d3f3663e850328_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtMy0xLTEtMTQzMDYx_1a4181aa-6bde-4544-b850-9a1ff501514b">386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34d06d4c144ab84ed676f2b1e7904_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtNS0xLTEtMTY3OTgz_aceb7af7-2444-456c-bc55-bb8d8cafaf43">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e97965210ba400a8aa5affa4e5e8dda_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtNy0xLTEtMTQzMDYx_5dc604f0-d800-4185-9bd2-77ebc0da4209">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9713e38b2cbc4a72bf04b0dea907a1e3_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtOS0xLTEtMTQzMDYx_fe82dff1-0a0f-4aaa-b6bd-51b217852c7a">178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579951261424471ebfa617bcad167deb_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtMTEtMS0xLTE0MzA2MQ_17b1841a-d74b-4086-966d-ebad1aa875f6">655</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4241952b1e174e2b865fc979ca30a592_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItMS0xLTEtMTQzMDYx_2bf2e605-d7f5-4fcf-9648-af4bb15c2a71">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50980e0088f041399e5e72f5cff6248c_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItMy0xLTEtMTQzMDYx_7720ae27-8ad6-43ef-af26-65ac5ddb2c5e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib2de33d45cf94f6b9d2f33a3c2bba1cc_D20220101-20220930" xsi:nil="true" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItNS0xLTEtMTY3OTgz_85d6db5f-cf57-445d-97c5-df8e54d1909c"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc88c3d81b1c4955992d1247bfba1b8e_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItNy0xLTEtMTQzMDYx_d82d0c30-7905-4bd2-8718-5bba0b7378ed">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2811781ce7f642ca89c86c7f0de518bd_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItOS0xLTEtMTQzMDYx_7d972b20-5c29-44a2-be6d-69bcaf0a0675">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791a2916a2aa4ab395ca981e61e7daf2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItMTEtMS0xLTE0MzA2MQ_03d5e446-6d38-440e-b970-690a5b1cf1bf">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtMS0xLTEtMTQzMDYx_ba2862f3-221b-40fc-86f2-a006d3263897">1,509</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtMy0xLTEtMTQzMDYx_1a894e0b-7380-43fb-92b4-d1c55932ce0f">727</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtNS0xLTEtMTY3OTgz_2a786c38-25b2-4552-ada6-a40ddd5f135c">201</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtNy0xLTEtMTQzMDYx_5f869b5b-4499-4c6d-93a1-8a4364eaeba1">722</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtOS0xLTEtMTQzMDYx_ef23aa61-2683-4c23-8f63-43f689248945">2,772</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtMTEtMS0xLTE0MzA2MQ_906f87b5-398c-4a5e-863d-c4c7084ec24e">5,931</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9826556f6d8947a69d81d512d9468782_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtMS0xLTEtMTQzMDYx_c213757e-21ce-462a-a567-7ac4a24a809b">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2f39db7b954476bf2c8bb5f8ad798f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtMy0xLTEtMTQzMDYx_ba766093-52e6-4cd3-9b35-156d49975bc0">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54bd462ed1446b096e8f3df008338e2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtNS0xLTEtMTY3OTgz_caeeaf5e-99ae-4519-94e1-89f1bc653972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f9d93817ce485782bbbade2c8f8fab_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtNy0xLTEtMTQzMDYx_b67a7cd5-9c6c-44f0-86e1-5690b19e39f8">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ea63fc42464411a719b65e9cea618a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtOS0xLTEtMTQzMDYx_321ae192-d9d5-4e8f-a2f0-fe4a9c91e41b">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12376a48681c46099f3a4e9ecbf34c5f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtMTEtMS0xLTE0MzA2MQ_0330aa76-264e-40f9-9938-3686aaa6feec">2,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb127d7bf284643bc5c01a24c9fc5b0_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctMS0xLTEtMTQzMDYx_1e4d56ef-ada6-4153-aedc-90cdc59e4445">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58982e1d6ef14225a9ab3729ceaa6948_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctMy0xLTEtMTQzMDYx_dcd8477b-31e8-4492-a3eb-8bb88507cc61">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i301b2caac8d446778085cc79b589a737_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctNS0xLTEtMTY3OTgz_e5dcf530-6e74-4f35-b633-32b18dc9a7f3">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2fe2a425b9245fca2bb47d15a250d6b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctNy0xLTEtMTQzMDYx_2c17c9e3-f8e5-49a0-91d6-0cce9495f976">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dae99d75ed24ba5b1b8b1f3747dda78_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctOS0xLTEtMTQzMDYx_e5373ea7-640b-4ab8-a8ac-079db3aca7f0">1,174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c493f1eaa24d36a5056a2ca842a812_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctMTEtMS0xLTE0MzA2MQ_2a11e4bf-dec0-49f3-8fb8-1f8daffd99cc">1,393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad50b284a5ed4c6d86183cb2fe3fdb97_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtMS0xLTEtMTQzMDYx_aa6ac760-fc8a-446d-a892-080d9fb7f35c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f87201482142909a01e5261b00e554_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtMy0xLTEtMTQzMDYx_04281dc8-d577-4c4c-a202-8472027fadfd">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905ce8cfd82b4f538a2dc187e9546dbf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtNS0xLTEtMTY3OTgz_6708354b-9a2e-46f8-8a93-1b6571021948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81d14aa32074f3ab7f08a1036ee0b8f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtNy0xLTEtMTQzMDYx_65847d6e-914d-4c5c-98b4-af9c56824377">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20223e746334d6f82eca42140a4c935_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtOS0xLTEtMTQzMDYx_0366466b-46c7-4010-91f5-660c0ce9d71e">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5755175f3f06430ab66277abd6454600_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtMTEtMS0xLTE0MzA2MQ_3db2e087-3ab1-4b3d-9328-ff68b3de9159">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia191f4ea8c4945b4906ab7f70a93deed_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktMS0xLTEtMTQzMDYx_496f7001-c5e0-4c37-a333-2ad996c81941">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec8559c1ec940ef809744ef427103e5_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktMy0xLTEtMTQzMDYx_82844c05-3b3c-4e46-bbce-90371fd641ec">579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i214a5e16df454787bd61853a8fb3b9f4_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktNS0xLTEtMTY3OTgz_0b1e7bd6-f0ef-4214-b7b0-d46b3550251b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03306f36d12454ab64e7ac8cdae92a6_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktNy0xLTEtMTQzMDYx_70dc7876-783e-466e-86c4-f89f4be961a5">125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f14675214e546ad9d45a02682113cf2_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktOS0xLTEtMTQzMDYx_5803d258-7bf0-4cec-b703-3b7814b3c35f">180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cbf185e217c4dc9a7593467145c745b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktMTEtMS0xLTE0MzA2MQ_974ddcd0-66fd-4813-aede-57721226f10e">884</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc95d6d82edd44fe9ed4f8dc335f7e42_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtMS0xLTEtMTQzMDYx_efc8ef54-b681-432e-9d70-36db15afc022">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe643b692e4449fadb261eff5314a8a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtMy0xLTEtMTQzMDYx_9c5be941-c071-42df-a1ff-f24f104d85e6">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ecc27feb094b618ce6496fa054bc12_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtNS0xLTEtMTY3OTgz_c2b9c9b4-5a8c-4b48-8484-5bcf5c770f42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0115418e894ab6b82b70dc6e6d9531_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtNy0xLTEtMTQzMDYx_d898793c-42d3-40f7-9d21-5680fc4aa57c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia407433f62b843baa034edc40f2c05c3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtOS0xLTEtMTQzMDYx_b246e2f9-4a62-4de0-bc92-864cb9479de2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d57f75bc2442e29fe1c7f8fa969c3b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtMTEtMS0xLTE0MzA2MQ_b5442712-d3d9-4658-9c00-ddfa41057174">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e8eb0aeed843fba31c70ada9493305_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtMS0xLTEtMTQzMDYx_6b795e4d-b6e9-4f1d-8807-c9458ebb2e12">1,515</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072aaec2db174878954cb70bf860e758_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtMy0xLTEtMTQzMDYx_1ee3f6b8-2c16-4e75-a61d-2daea9b40e0c">890</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0814d1f5f404ef9b9ce2c33efbb9cf5_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtNS0xLTEtMTY3OTgz_03a727a1-420e-4dc6-ab64-2643e1478947">219</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46f1158b96e7498b8bfdd8ccc5ad9827_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtNy0xLTEtMTQzMDYx_7e9571d6-0447-4fa5-8d9f-c166060a65ae">850</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24af9b92680b4f0694745bf435e5472a_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtOS0xLTEtMTQzMDYx_ec0517ac-4c9c-414b-8fe8-ce124a6ebd14">2,764</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtMTEtMS0xLTE0MzA2MQ_530ebee7-2788-4338-9650-0f888bd6a4f1">6,238</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top <ix:nonFraction unitRef="product" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDIzNw_50d139a3-be39-4606-8391-abf02aceec5d"><ix:nonFraction unitRef="product" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDIzNw_87e8c58f-71fa-43e1-ad80-d089883ba428">ten</ix:nonFraction></ix:nonFraction> products for the nine months ended September 30, 2022 and 2021 represented <ix:nonFraction unitRef="number" contextRef="i2d52656bf37d43cdb7e063c81480fb0d_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDI3Mg_90085ee7-9402-405e-8cd6-cb4fc17e043e">48</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6ed64d739418416f87bf91f8425ea391_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDI3OQ_17c205ce-a618-494a-a256-21f838f74cc4">45</ix:nonFraction>% of total revenues for the nine months ended September 30, 2022 and 2021, respectively.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="icd8c4b11199342a29056a75e03dd1600"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY1OA_8269a742-f130-4535-8542-98a2609e53f7" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c17a5874a9e4075aaf8c4ce5d1a4e12_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi0xLTEtMS0xNDMwNjE_7b6fff45-b1c7-4ac4-ae39-abb1d7f1b8ca">1,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e326ea2d1834500a5932fa3f6d1b28f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi0zLTEtMS0xNDMwNjE_5c5402f0-61fb-4ec4-967e-0e473567b934">1,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7b27f028d4f1b8e3316964ae4b6ed_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi01LTEtMS0xNDMwNjE_ebe8e2ff-30b4-43ab-a5d5-66f6ad8adfa9">3,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8acc98b4a99485f8de664a8f1b2574b_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi03LTEtMS0xNDMwNjE_ef68291b-3bfb-4f0a-a4f3-87ae44e226c4">3,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7593d4411424499ea8071b2b1744ee40_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy0xLTEtMS0xNDMwNjE_6f30a9eb-4e7b-4dac-b1d0-fa76a610ff53">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81cef13fb1fe4cff88b12247a3647d2f_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy0zLTEtMS0xNDMwNjE_53d81ac7-dbd9-4004-9246-3596ed5a1639">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1547713f2b44918264056f12b2d4a2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy01LTEtMS0xNDMwNjE_fe51ca5d-619b-45b7-8473-e58059d68b81">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cee586c236841fc9a104c883eb25025_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy03LTEtMS0xNDMwNjE_6ca14ed9-d903-4c61-9863-ef70cab098a1">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1a9b9786b845c6826efe7b5650b900_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC0xLTEtMS0xNDMwNjE_9bc37c73-763a-4a61-9272-259f1b570bf5">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94f8fad7b19469aa645f46052c57c3b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC0zLTEtMS0xNDMwNjE_90586c8a-30fb-4876-b1a4-641ffe4a152a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00ad1728e8924998803b5744ae677c7c_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC01LTEtMS0xNDMwNjE_2b378557-21be-4fac-9dac-c5a9803b6933">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbe3c58b4ffa463c91e47a7cb28199b4_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC03LTEtMS0xNDMwNjE_ba804fa8-1066-42ac-8128-f64996dfa3f8">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id150c24526bc4303af49c01163da23dd_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS0xLTEtMS0xNDMwNjE_d29efab3-77ce-4fbf-a8c9-be3e91fa33df">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38317d58388c4fdebeaa753429b54d9e_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS0zLTEtMS0xNDMwNjE_d18c9cbc-11db-492b-919c-d2c51d934a4b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib445c562897042bdbd49b80e1286d65a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS01LTEtMS0xNDMwNjE_ebe2b6c1-ef9b-4137-a629-047e019c0b4b">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e344dce62744d278e0b20e50c3fb0e3_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS03LTEtMS0xNDMwNjE_6e742d67-04dd-42bc-8fe8-669afaac56b6">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0143ed82024e4ba05f759a4321dc0f_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi0xLTEtMS0xNDMwNjE_09f68e45-2aeb-4c8c-83ef-2b60d7e09db2">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0197306db91e4812a3d4fa3b19135985_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi0zLTEtMS0xNDMwNjE_65140fa1-c679-41de-b04d-c75daf7dd468">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75298065a5bb4d7abc0cd5a872c8c23a_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi01LTEtMS0xNDMwNjE_f106bd36-83bd-4e24-8057-1e0642376b5b">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ed176248a7493d8af99f37e6e639a8_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi03LTEtMS0xNDMwNjE_5fae71c5-1b0c-4bcb-bda2-d87d0ef79db9">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9253db1500949fe906fc9a1f4fa1b38_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy0xLTEtMS0xNDMwNjE_3c9b9f8e-212e-43bb-a97d-b3d6ce2fd05c">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b96a64aab504e74910b39ceb4520476_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy0zLTEtMS0xNDMwNjE_b2094d49-5079-4846-ae00-b6e2ef4ca802">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30d18d2c61649808a5f0ae632b41c66_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy01LTEtMS0xNDMwNjE_cbdd4a9f-d974-404c-9501-de7eefb1d9ba">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5dc9560462546608eaecbaa48330ebf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy03LTEtMS0xNDMwNjE_cf8dc1fe-cc08-44b9-9c8f-0f6166a1c059">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f4818ab24d4eef82fd27de079b7973_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC0xLTEtMS0xNDMwNjE_cf309f40-7c24-4ee5-b85d-2f73ea988d21">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f81890fdf044bcb330e157d04a97a0_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC0zLTEtMS0xNDMwNjE_90b2b515-8efb-440d-8e14-81d20361470c">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eff41ef021547c6bd85e06df906d0fe_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC01LTEtMS0xNDMwNjE_72d5ce26-164a-4d34-9789-3b4d8d57a321">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7d036a10b44a9b80aec045229f3086_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC03LTEtMS0xNDMwNjE_9cf6b42f-92fb-48ae-8fbf-c1912a0ba338">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic155d49fa70f4c1198d083cf8239e270_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS0xLTEtMS0xNDMwNjE_1f74c8f1-6bd3-47bd-a66b-0bdba5f985f7">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc467b3d64744017a93680acfc732aa9_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS0zLTEtMS0xNDMwNjE_739d086a-597a-44f9-b65e-bc0d051f665a">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbd58fa6bd147a482305292a074c257_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS01LTEtMS0xNDMwNjE_a9586a63-7f42-439c-a9ca-4dc7cfa76604">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0d0748800694d148893ade42e236442_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS03LTEtMS0xNDMwNjE_d4c64302-e3d2-4e85-abe6-f2d1c8ce8c50">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2c124d21acf42ce85f54a6eac7f7ba9_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtMS0xLTEtMTQzMDYx_9b76e0d6-d642-430f-ab14-14b47e5aa392">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c7a4309c6b4558b2d3e9160a31980b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtMy0xLTEtMTQzMDYx_4c37bce3-c6a1-4d64-8ddb-3dfdbc8656cd">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dbcf8ffc494fab8b9df1864aaf00a5_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtNS0xLTEtMTQzMDYx_f6573837-3bc3-45cf-bd7a-8672b46b8b5d">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d0c319938f45b0a9419a9e53c66df5_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtNy0xLTEtMTQzMDYx_f3d66b57-df5b-4d3e-9d5e-49abc9f39587">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3959030e4f5c4df99cf6dcf1ebede4d4_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtMS0xLTEtMTQzMDYx_530a0a1f-3205-4b9a-bfc3-14596d6fed74">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e5e8321bd646448a93cf036eae8e2b_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtMy0xLTEtMTQzMDYx_100299f3-c014-4e52-afed-891752f01c9f">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc35d5603e0942dda30e190b9deb1627_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtNS0xLTEtMTQzMDYx_5e1e75f9-7ff8-4594-bc4c-ec09fe03bed7">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11911151b9f54dabb034a5f6b1fe8839_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtNy0xLTEtMTQzMDYx_1f66fa47-b2b7-4835-acc7-2ac08e9cc0a9">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a95d34d1ea24fd586a885cd6b872083_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItMS0xLTEtMTQzMDYx_8f3cfd0c-33f0-47f0-bad3-655366cda396">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89bbb02a54d240ef8ea4afba712e86a2_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItMy0xLTEtMTQzMDYx_ff7419f3-f2df-4f11-909d-fb3fbd9e5909">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bf2297ad3d49449422ea1e9823e61f_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItNS0xLTEtMTQzMDYx_4b9bee2f-10b8-4597-bd23-1dbac1c10aa9">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f8127e8b0141fb9d4372bf3c182783_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItNy0xLTEtMTQzMDYx_85b94591-0b4d-4d66-ac2a-3bd4cb0d19b6">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ada8553598f446f8ad09650f86726aa_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtMS0xLTEtMTQzMDYx_891cd2b1-49a3-4cca-8612-b452e0bf463d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbaea260f0344e5b94077f35b76e27eb_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtMy0xLTEtMTQzMDYx_362fdcc2-fe61-4753-8332-1f6f1138df78">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4d24d726d04432a277be2e908a6abc_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtNS0xLTEtMTQzMDYx_e2769516-7b0a-4a8b-bd20-c8a59c3ea82c">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f382705cad4a4b84c68be25fa55777_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtNy0xLTEtMTQzMDYx_92767da5-23e5-42d0-a740-319ac37edd59">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ec9bea2ce13443798c0a6d868c068d6_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtMS0xLTEtMTQzMDYx_eee43507-95fe-4aff-b9ac-4072f092bd61">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c5dedac9f749aa9c8913ab247f1fdc_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtMy0xLTEtMTQzMDYx_0c547f40-65de-47cc-8e88-185f9823fa59">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29b7b8ee29a431598793c1ba4520dc0_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtNS0xLTEtMTQzMDYx_101a1003-5eea-445f-94f9-acdcb80d8165">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee531f5d0b64027bae00dc04e77f297_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtNy0xLTEtMTQzMDYx_746c454b-6264-4306-aa71-3c9ae3b47abd">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21fc561bc8064837bb579d9d55ae3b5a_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtMS0xLTEtMTQzMDYx_edbe8bab-dd42-48e5-89f7-f7dd9b261678">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieea6d886b69f47798e958d42e3654c2a_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtMy0xLTEtMTQzMDYx_ebc4bcc5-4c84-4430-9f49-89693154d599">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3e2a5680cfc4b46b7891fc6f9830006_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtNS0xLTEtMTQzMDYx_6da16d04-b6bf-4af4-9e37-ad73ae41759f">647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8595d458c34e018a63a7863b77580f_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtNy0xLTEtMTQzMDYx_aa76eac0-ca10-4e11-adf3-2e92a0257871">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtMS0xLTEtMTQzMDYx_96923222-7c05-46bb-9300-b4df5c758c1f">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtMy0xLTEtMTQzMDYx_f39534ff-9e93-4b7a-82ef-8e6c891533cc">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtNS0xLTEtMTQzMDYx_a6e97476-02ca-4e0f-b760-2aa9e3701af8">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtNy0xLTEtMTQzMDYx_4868d98d-ae70-4f1e-9b82-e2739750f12a">6,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY3MQ_2686087a-4c51-48f6-9418-cba93aa983bf" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72d246b81e15499094a367cbe1d8db6d_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMi0xLTEtMS0xNDMwNjE_a77d2a59-5355-42d4-b874-9b73c8b762e3">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54794b3420624c9fb619461becb59f8f_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMi0zLTEtMS0xNDMwNjE_dca2d213-cac9-45fe-b1a7-b08c84a5f01c">18</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd0d411b81984c788cc81aa73ab8f449_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMy0xLTEtMS0xNDMwNjE_7752dd92-514c-4486-853a-589b6c9eb216">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62a332bbaec540e481ed114e383e4dd0_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMy0zLTEtMS0xNDMwNjE_7074498d-408d-4c64-a6f9-4bd2d20f1dc9">16</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a84613cff7f4368a54a708f8ba0ff04_D20220101-20220930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfNC0xLTEtMS0xNDMwNjE_f0df8f33-7976-48ae-944b-9c55436f8d86">11</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bbda526e0454dffafc588718e72bdbf_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfNC0zLTEtMS0xNDMwNjE_833d0b9e-9641-4a3b-84f2-9c16a02ecb81">12</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_103"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of&#160;Operations</span></div><div id="i0269b61f01054b6698b35799c21833bd_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise indicates, as used in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; &#8220;Bausch Health,&#8221; and similar terms refer to Bausch Health Companies Inc. and its subsidiaries, taken together. This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should be read in conjunction with the unaudited interim Consolidated Financial Statements and the related notes (the &#8220;Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended September&#160;30, 2022 (this &#8220;Form 10-Q&#8221;). The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of The Securities Act of 1933, as amended, and Section 21E of The Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning of applicable Canadian securities laws (collectively &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our accompanying unaudited interim Consolidated Financial Statements as of September&#160;30, 2022 and for the three and nine months ended September 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements, and should be read in conjunction with our Consolidated Financial Statements for the year ended December&#160;31, 2021, which were included in our Annual Report on Form 10-K filed on February&#160;23, 2022. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations and cash flows for the periods indicated. Additional company information is available on SEDAR at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the SEC website at&#160;</span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted. Certain defined terms used herein have the meaning ascribed to them in the Financial Statements. </span></div><div id="i0269b61f01054b6698b35799c21833bd_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global company whose mission is to improve people&#8217;s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, and eye health, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (&#8220;OTC&#8221;) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five operating and reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. These segments are discussed in detail in Note 19, &#8220;SEGMENT INFORMATION&#8221; to our unaudited Consolidated Financial Statements. The following is a brief description of the Company&#8217;s segments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented 80% of the Salix segment&#8217;s revenues for each of the three and nine month periods ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, the Company changed its segment structure. The new segment structure resulted in a change to the Company&#8217;s former Ortho Dermatologics segment whereby its medical dermatology business (Ortho Dermatologics) is now managed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) as part of the Diversified Products segment and the Solta Medical business is now managed by the CODM as its own operating and reportable segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current reporting structure. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Focus on Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we implemented a multi-year plan designed to transform and bring out value in our Company. The multi-year plan increased our focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since that time, we have been executing and continue to execute on our commitments to transform the Company and generate value. As discussed below, under the multi-year plan, we have taken actions that among other things included: (i) divesting non-core assets, (ii) making strategic investments in our core businesses and (iii) making measurable progress in improving our capital structure. These measures gave us operating flexibility and put us in a strong position to unlock the additional value to be found in our specific businesses. We believe that these and other actions we have taken to transform our Company, have helped to focus our operations, and improve our capital structure. These positive actions also presented us with an opportunity to unlock potential value across our portfolio of assets by separating our pharmaceutical and eye health businesses. Although management believes the B+L Separation (as defined below) will bring out additional value, there can be no assurance that it will be successful in doing so.</span></div><div id="i0269b61f01054b6698b35799c21833bd_118"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye health business consisting of our Bausch + Lomb Global Vision Care (formerly Vision Care/Consumer Health), Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;) from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). During May 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold shares of Bausch + Lomb pursuant to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;). The underwriters partially exercised the over-allotment option granted by the Selling Shareholder. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company indirectly holds 310,449,643 common shares of Bausch + Lomb, which represents approximately 89% of Bausch + Lomb&#8217;s outstanding common shares. We continue to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. We continue to evaluate all factors and considerations related to the B+L Separation, including the effect of the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements) on the B+L Separation.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation, if consummated, will result in two separate, independent companies:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, hepatology, dermatology, neurology and international pharmaceuticals, and aesthetic medical devices. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International, dentistry, neurology, medical dermatology and generics, and aesthetic medical devices businesses; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated, &#8220;pure play&#8221; eye health company built on the iconic Bausch + Lomb brand and long history of innovation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the B+L Separation has created two highly attractive but dissimilar businesses. As independent entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs. Further, the B+L Separation will allow us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes the B+L Separation will unlock value, there can be no assurance that it will be successful in doing so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement of the B+L Separation, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, as such, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the B+L Separation, if consummated, provides us with an attractive opportunity for liquidity to support the appropriate capitalization and leverage of the Bausch + Lomb entity and the remainder of Bausch Health, which we refer to as &#8220;Bausch Pharma&#8221; and which will assume a new name upon completion of the B+L Separation. Management will continue to thoughtfully evaluate all factors in connection with the B+L Separation. For additional details on the B+L Separation, see &#8220;Separation of the Bausch + Lomb Eye Health Business&#8221; in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our unaudited interim Consolidated Financial Statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors &#8212; Risk Relating to the B+L Separation and the Solta IPO&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022, for additional risks relating to the B+L Separation.</span></div><div id="i0269b61f01054b6698b35799c21833bd_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Focus on Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To position ourselves to unlock the value we see in our individual businesses, we have sought to right-size our portfolio of assets and provide financial flexibility. In line with this focus on our core businesses, we have: (i) made measurable progress in effectively managing our capital structure, (ii) directed capital allocation to drive growth within these core businesses, (iii) divested assets to improve our capital structure and simplify our business, (iv) resolved certain of the Company's legacy litigation matters originating back to 2015 and prior, (v) increased our efforts to improve patient access and (vi) continued to invest in sustainable growth drivers to position us for long-term growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other actions we have taken to transform our Company, have helped focus our operations, unlocked value across our product portfolios, improved our capital structure and mitigated certain risks associated with legacy litigation matters. We believe that these measures, along with our continued commitment to improving people&#8217;s lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our eye health and pharmaceutical businesses. Although management believes the B+L Separation will unlock additional value, there can be no assurance that it will be successful in doing so.</span></div><div id="i0269b61f01054b6698b35799c21833bd_145"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we have emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these entities post-separation as a key to bringing out the maximum value across our portfolio of assets and, as such, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Managing Our Capital Structure 2016 through 2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, our executive team committed to improving our Company&#8217;s capital structure and, since that time, we have been executing and continue to execute on that commitment. As a result of a series of debt repayments and transactions since making that commitment, the Company positioned itself to execute on the B+L IPO, while at the same time progressing toward providing the appropriate capitalization and leverage of the Company to effect the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the $1,210 million financing of the Securities Class Action Settlement (as defined in Note 18, &#8220;LEGAL PROCEEDINGS&#8221; in the accompanying unaudited interim Consolidated Financial Statements), we repaid (net of additional borrowings) approximately $10,000&#160;million of long-term debt during the period January 1, 2016 through December 31, 2021 using the net cash proceeds from divestitures of non-core assets, cash on hand and cash from operations, including from our focus on working capital management. See &#8220;U.S. Securities Litigation - Opt -Out Litigation&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for additional details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Managing Our Capital Structure in 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we continue to effectively manage our capital structure by: (i) executing on our plan for the B+L Separation, including using the net proceeds from the B+L IPO which closed on May 10, 2022, to make repayments of debt, (ii) reducing our debt through open market repurchases, (iii) extending the maturities of debt through refinancing and (iv) completing an exchange offer which reduced the outstanding principal balance of our debt by $2,469 million by exchanging $5,594 million of aggregate principal value of existing unsecured senior notes (the &#8220;Existing Unsecured Senior Notes&#8221;) for newly issued secured notes with an aggregate principal balance of $3,125 million (the &#8220;Exchange Offer&#8221;). As a result of these actions, described in additional detail below, during the nine months ended September 30, 2022, we have reduced the aggregate principal amount of our debt obligations by approximately $3,300 million as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The B+L IPO, 2022 Notes Issuance and Credit Agreement Refinancing - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L IPO, we completed a series of transactions in support of our commitment to improve our liquidity, reduce our leverage and better capitalize the two business entities post-separation. These transactions included:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On February 10, 2022, the Company issued (the &#8220;2022 Notes Issuance&#8221;) $1,000 million aggregate principal amount of 6.125% Senior Secured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due February 2027 (the &#8220;February 2027 Secured Notes&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On May 10, 2022: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The B+L IPO closed, with aggregate net proceeds (including from the partial exercise of the over-allotment option by the underwriters), after deducting underwriting commissions, of approximately $675&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company entered into the 2022 Amended Credit Agreement as defined and discussed in further detail below, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;. The 2022 Amended Credit Agreement consists of new term loans of $2,500 million and a revolving credit facility of $975 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb entered into the B+L Credit Agreement, as defined and discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;. The B+L Credit Agreement provides for a five-year term loan facility in an initial principal amount of $2,500 million and also provides for a five-year revolving credit facility of $500 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from these transactions, along with cash on hand, allowed us to: (i) repay certain amounts outstanding under our then existing June 2025 Term Loan B Facility and November 2025 Term Loan B Facility (each as defined and discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;), (ii) replace our existing revolving credit facility which was due to mature in 2023, with revolving credit facilities that mature in 2027, (iii) redeem in full all of our then outstanding 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221;) and (iv) replace our then remaining amounts outstanding under our June 2025 Term Loan B Facility and November 2025 Term Loan B Facility with term loan facilities that expire in 2027. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishment of Debt - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During June 2022, through a series of transactions we repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $481 million in the open market for approximately $300 million using: (i) the net proceeds from the partial exercise of the over-allotment option in the B+L IPO by the underwriters, after deducting underwriting commissions, (ii) amounts available under our revolving credit facility and (iii) cash on hand. As a result of these transactions, we recognized a gain on the extinguishment of debt of approximately $176 million, net of write-offs of debt premiums, discounts and deferred issuance costs, representing the differences between the amounts paid to retire the senior unsecured notes and their carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Offer - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;, we made the strategic decision based on the fair value of our Senior Unsecured Notes to undertake the Exchange Offer in September 2022. We exchanged certain validly tendered existing senior unsecured notes, with an aggregate outstanding principal balance of approximately $5,594&#160;million with maturities of 2025 through 2031 for newly issued senior secured notes, with an aggregate principal balance of approximately $3,125 million with maturities of 2028 and 2030. After fees and expenses, the Exchange Offer reduced the principal balances of our outstanding debt obligations by $2,469 million and extended the maturities of approximately $2,400 million of principal balances coming due during the years 2025 through 2027 to the years 2028 and 2030. We also recorded a net gain of $570&#160;million as the future undiscounted cash flows of certain New Secured Notes were less than the net carrying value of the Existing Unsecured Senior Notes which were exchanged.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of: (i) the 2022 Notes Issuance and Credit Agreement Refinancing (as defined below under &#8220;&#8212;Senior Secured Credit Facilities under the 2022 Amended Credit Agreement&#8221;), (ii) the early extinguishment of debt, (iii) the Exchange Offer and (iv) other debt repayments (net of additional borrowings under our Revolving Credit Facility) we reduced the principal balances of our contractual debt obligations in 2022 by approximately $3,300 million. The contractual principal amount of our debt obligations as of September 30, 2022 and December 31, 2021 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan Facilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Term Loan Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other, net of premiums, discounts and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These transactions also had the effect of reducing our cash debt service requirements over the next five years thereby providing us with additional flexibility as it relates to liquidity to operate. Prior to these transactions, our aggregate principal contractual debt repayment requirements through the year 2026 were approximately $5,425 million. As a result of these transactions, as of September 30, 2022, we have reduced our estimated debt service requirements of principal and interest over the 12 months period ending September 30, 2023 by approximately $65 million and reduced our aggregate principal contractual debt repayment requirements through the year 2026 to approximately $4,100 million. Maturities of our principal balances of debt obligations as of September 30, 2022 and December 31, 2021, were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 - 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,574&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the contractual principal and interest payments of the New Secured Notes. Contractual interest payments will be allocated to the reduction of the recorded premium and interest expense as presented below. Additionally, the amount of interest which reduces the premium will be reported as a Financing activity in the Consolidated Statement of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal Payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Payments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments recorded as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium reduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these transactions improve our overall capitalization and leverage. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements and &#8220;Liquidity and Capital Resources: Long-term Debt&#8221; below for additional discussion of these matters. Cash requirements for future debt repayments including interest can be found in &#8220;Management&#8217;s Discussion and Analysis - Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Continue to Manage our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, to give us the ability to better focus on our core businesses and prepare us for post-separation. Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance, repurchase or exchange existing debt or issue additional debt, equity or equity-linked securities.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_130"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is driven by our long-term growth strategies. We have made strategic investments in our core businesses in order to support recent revenue growth and prepare for additional growth opportunities which we plan to capitalize on for our core businesses. We have been aggressively allocating resources to our core businesses globally through: (i) R&amp;D investment, (ii) strategic licensing agreements and (iii) strategic investments in our infrastructure. We believe that the outcome of this process will allow us to better drive value in our product portfolio and generate operational efficiencies.</span></div><div id="i0269b61f01054b6698b35799c21833bd_136"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We search for new product opportunities through internal development and strategic licensing agreements, that, if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal R&amp;D organization focuses on the development of products through clinical trials. As of December 31, 2021, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts internally. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had approximately 160 projects in our global pipeline. Certain core internal R&amp;D projects that have received a significant portion of our R&amp;D investment in current and prior periods are listed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gastrointestinal</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation (SSD IR) of rifaximin showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study and other clinical data of SSD in cirrhotic patients will help inform further research on potential new indications for rifaximin. A Phase 3 study has commenced (RED-C) with patients actively enrolling for the prevention of the first episode of Overt Hepatic Encephalopathy.</span></div><div style="text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Rifaximin recently received orphan drug designation for sickle cell disease. A phase 2 study with novel dosage formulation is currently enrolling patients for the treatment of sickle cell disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth, or &#8220;SIBO&#8221;, is continuing in 2022.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Rifaximin - We have entered into an agreement with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS-D. Two preclinical studies have been completed. A Clinical Proof of Concept study that was paused due to COVID-19 pandemic related factors, has recommenced and is fully enrolled. Based on recent FDA comments dated February 10, 2022, the program was being assessed and related timelines reviewed and upon further review of the applicable timelines, the Company expects to terminate this program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Envive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In October 2020, we launched, on a limited basis, a probiotic supplement that was developed to address gastrointestinal disturbances. In April 2021, we expanded the launch to additional territories in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Amiselimod (S1P modulator) - We commenced a Phase 2 study during the first half of 2021 to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% - In June 2020, we launched this acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Internal Development Project (&#8220;IDP&#8221;) 120 - An acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin. Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors, but resumed in June 2020. Both Phase 3 studies have been completed and have met their primary endpoints. A comparative bridging safety and efficacy study was delayed until 2021 due to COVID-19. The bridging study has completed enrollment in July 2022. We anticipate filing a New Drug Application (&#8220;NDA&#8221;) in the fourth quarter of 2022.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;laser that is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. This product was launched in the U.S. in March 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens. In the fourth quarter of 2020, SiHy Daily was launched in Australia, Hong Kong and Canada under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. SiHy Daily has also received regulatory approval in China, New Zealand, Japan, South Korea, Europe, Singapore and Malaysia, where it will be branded as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, and in the second quarter of 2021, we launched SiHy Daily in South Korea and Singapore as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">LUMIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. We launched this product in the U.S. in May 2018 and in Canada in June 2022. Currently, we have several new line formulations under development. The first Phase 3 study in support of these line extensions has initiated. Additional studies have commenced during October 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">New Ophthalmic Viscosurgical Device (&#8220;OVD&#8221;) product - A formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during IOL delivery. A clinical study report was completed for the cohesive OVD product (StableVisc&#8482;) during the second quarter of 2022. FDA approval is expected in the fourth quarter of 2022 and launch is expected in the first quarter of 2023. In addition, in March 2021, we received Premarket Approval from the FDA for Clearvisc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> dispersive OVD, which we launched in the U.S. in June 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb is expanding its portfolio of premium IOLs built on the enVista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with Monofocal Plus, EDOF and Trifocal optical designs for presbyopia correction. Bausch + Lomb expects that they will be commercialized together with a new preloaded inserter with two options: non-Toric, as well as Toric for astigmatism patients. Bausch + Lomb anticipates launching Monofocal Plus, Trifocal and EDOF optical designs for presbyopia in the U.S. in 2023, 2024 and 2025/2026, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Multi-Purpose Solution (&#8220;MPS&#8221;) - Contains a triple disinfectant system that kills 99.9% of germs tested, and has a dual surfactant system that provides up to 20 hours of moisture. Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfect, rinse and store soft contact lenses including those composed of silicone hydrogels. Prior to 2022, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in India, Mexico, Korea, Turkey and Greece and gained regulatory approvals in Indonesia, Malaysia, Singapore, the European Union, Belarus and China. In 2022, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in Taiwan, Czech Republic, Israel, Poland, Slovakia, China, Argentina, Columbia, Ecuador and Peru. We anticipate launches in Slovenia, other parts of Europe and the Nordic regions.</span></div><div id="i0269b61f01054b6698b35799c21833bd_139"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&amp;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA or other regulators, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. (&#8220;Clearside&#8221;) for the commercialization and development of Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and Canada. Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside&#8217;s proprietary SCS Microinjector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2021, the FDA approved Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for suprachoroidal use for the treatment of macular edema associated with uveitis. We launched Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. in the first quarter of 2022.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound. Topline results were positive and we commenced a Phase 2 study in the first half of 2021.</span></div><div id="i0269b61f01054b6698b35799c21833bd_124"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Divest Assets to Improve Our Capital Structure and Simplify Our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to better focus on our core businesses, we continue to evaluate opportunities to simplify our operations and improve our capital structure, including divesting non-core assets in order to narrow the Company&#8217;s activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. To date, we received approximately $4,100&#160;million in net proceeds from these divestitures, which includes the sale of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;) discussed below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, we completed the sale of Amoun for total gross consideration of approximately $740&#160;million, subject to certain adjustments (the &#8220;Amoun Sale&#8221;). Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International segment). Revenues associated with Amoun were $157&#160;million for the period of January 1, 2021 through July 26, 2021. On July 30, 2021 and August 3, 2021, the Company made aggregate payments of $600&#160;million, to repay $469&#160;million of its June 2025 Term Loan B Facility and $131&#160;million of its November 2025 Term Loan B Facility (each as defined below), using the proceeds from the Amoun Sale and cash on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to consider further dispositions of various assets in line with this strategy. While we anticipate that any future divestiture activities will be on non-core assets, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company. See Note 4, &#8220;LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our unaudited interim Consolidated Financial Statements for additional information.</span></div><div id="i0269b61f01054b6698b35799c21833bd_1898"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resolved Legacy Legal Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2021, we resolved certain of the Company's legacy legal matters originating back to 2015 and prior, including settling the U.S. Securities Litigation (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;U.S. Securities Litigation - Opt -Out Litigation&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;). The Securities Class Action Settlement resolves the most significant of the Company's remaining legacy legal matters and eliminates a material uncertainty regarding the Company. </span></div><div id="i0269b61f01054b6698b35799c21833bd_148"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our Patient Access and Pricing Committee is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies. The Patient Access and Pricing Committee considers new to market product pricing, price changes and their impact across channels on patient accessibility and affordability. Since its inception in 2016, the Patient Access and Pricing Committee has limited the average annual price increase for our branded prescription pharmaceutical products to single digits. Future pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our revenues and profits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Patient Assistance Program - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is essential that our patients continue their prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Patient Assistance Program. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who meet stated qualifications and have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products where their financial circumstances or insurance status would otherwise interfere with their ability to access such products. If approved, patients receive their Bausch Health prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. The cash-pay program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. (&#8220;Walgreens&#8221;). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies.</span></div><div id="i0269b61f01054b6698b35799c21833bd_151"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market. We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&amp;D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum. We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraging our Salix Infrastructure - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we have built around these products to extend our market share. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (&#8220;PCP&#8221;). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is well positioned to reach more patients in need of IBS-D treatment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales force has been successful in delivering consistent growth in demand for our GI products, demonstrated by our growth in Salix revenues of 32% when comparing 2021 to 2017. We continue to seek ways to bring out further value through leveraging our existing sales force including the following opportunities:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. (&#8220;Synergy&#8221;), whereby we acquired the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force. In order to drive growth of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, we have increased the number of sales force representatives for the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. We believe this has been successful as Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $77&#160;million and $74&#160;million for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing Arrangement - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in April 2019, we entered into a licensing agreement to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. This license presents a unique developmental opportunity to address unmet needs of individuals suffering with certain GI and liver diseases and, if developed and approval is obtained from the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Next Generation Formulations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line increased approximately 11%, 2% and 22% in 2021, 2020 and 2019, respectively. For the nine months ended September 30, 2022 and 2021, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product revenues were $1,216&#160;million and $1,194&#160;million, respectively, an increase of $22&#160;million or 2%. In order to extend growth in Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we continue to directly invest in next generation formulations of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the acquisition and licensing opportunities discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Our Solta Aesthetic Medical Device Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fourth-generation non-invasive treatment option using a radio frequency platform designed to optimize key functional characteristics and improve patient outcomes, has been on sale since 2017 in the U.S., Hong Kong, Japan, Korea, Taiwan, Philippines, </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe as part of our Solta aesthetic medical devices portfolio. We plan to continue to expand into other regions, paced by country-specific regulatory registrations. Next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $154&#160;million and $142&#160;million for the years 2021 and 2020, respectively. Consistent with our business strategy to continually update and improve our technology, in 2021, we launched, in the U.S., our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system which is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. The launch of our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S. is expected to serve as a foundation for future launches in Asia and Europe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reposition the Ortho Dermatologics Business to Generate Additional Value - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ortho Dermatologics business continues to work towards improving the treatment options for medical dermatology patients needing topical acne and psoriasis products. We continue to explore additional strategic e-commerce and partnership expansion opportunities which can enable increased accessibility for patients and we continue to invest in our on-market products and evaluate various opportunities for our key medical dermatology pipeline products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of the complete dermatology portfolio, we continue to take a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) building on our legacy brands to improve and meet today&#8217;s physician relevance and customer service, (ii) making key investments in our core medical device and dermatological products portfolios, (iii) optimizing our go to market strategy by building on our relationships with prescribers of our products to balance our sales portfolio with the business&#8217; profitability, (iv) refocusing our operational and promotional resources and (v) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed. In addition, we made significant investments to build out our psoriasis and acne portfolios as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Psoriasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In response to the increasing number of reported cases of psoriasis in the U.S., we launched Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June 2019 and launched Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November 2018, which align well with our topical portfolio of psoriasis treatments. Although we continue to support a diverse portfolio of topical and injectable biologics, in order to provide a diverse choice of psoriasis treatments to doctors and patients, we believe some patients prefer topical products as an alternative to injectable biologics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In support of our established acne product portfolio, we have developed and launched several products, which include Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tazarotene) Lotion (launched in the U.S. in June 2020), Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(launched in the U.S. in October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne, and Retin-A Micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.06% (launched in the U.S. in January 2018). As previously discussed, we also have a unique acne project in our pipeline (IDP-126) that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in our Bausch + Lomb Business - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a fully integrated eye health business with a legacy of over 165 years, Bausch + Lomb has an established line of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye health market. As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye health market to meet changing consumer/patient needs and identify areas for investment to extend our market share through new launches and effective pricing. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, there is an increasing rate of myopia, and importantly, myopia is a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65). To extend our market share in eye health, we continually seek to identify new products tailored to address these key trends for development internally with our own R&amp;D team to generate organic growth. Recent product launches include Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lenses, SiHy Daily contact lenses (branded as AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Japan, Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable in the U.S. and Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Australia, Hong Kong, Canada and South Korea and Singapore), Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an eye redness treatment), Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension), Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices) and SimplifEYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (preloaded intraocular lens injector platform for enVista intraocular lens). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license selective molecules or technology in leveraging our own R&amp;D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired a global exclusive license for a myopia control contact lens design developed by BHVI, which we plan to pair with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children, and exclusive licenses for the commercialization and development in the U.S. and Canada of: (i) a microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12; (ii) Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was approved by the FDA in October 2021 and launched in the first quarter of 2022, and is the first treatment available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis; and (iii) NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD which has demonstrated statistically significant topline data in two Phase 3 studies. We also acquired the U.S. rights to EM-100, which was launched in February 2021 as Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative-Free and is the first OTC preservative-free formulation eye drop for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children 3 years of age and older. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon our strong portfolio of integrated eye health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which were at our Waterford facility in Ireland to meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday lenses, our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lens and our Lynchburg facility in Virginia to be our main point of distribution for medical devices in the U.S. During late 2018, we began investing in additional expansion projects at the Waterford and Rochester facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses, which we launched in Japan in September 2018, under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, in the U.S. in August 2020, under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens, and in Australia, Hong Kong and Canada in the fourth quarter of 2020 and in South Korea and Singapore in the second quarter of 2021, under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recent product launches, licensing arrangements and the investments in our Waterford, Rochester and Lynchburg facilities demonstrate the growth potential we see in our Bausch + Lomb products and our eye health business and that these investments will position us to further extend our market share in the eye health market.</span></div><div id="i0269b61f01054b6698b35799c21833bd_154"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends. The matters discussed in this section contain forward-looking statements. Please see &#8220;Forward-Looking Statements&#8221; at the end of Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for additional information.</span></div><div id="i0269b61f01054b6698b35799c21833bd_157"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. As military activity and sanctions against Russia, Belarus and specific areas of Ukraine have continued, the war has increasingly affected economic and global financial markets and exacerbated ongoing economic challenges, including issues such as rising inflation and global supply-chain disruption. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues attributable to Russia for the nine months ended September 30, 2022 and 2021 were $122&#160;million and $106&#160;million, respectively. Our revenues attributable to Ukraine for the nine months ended September 30, 2022 and 2021 were $7 million and $9 million, respectively. Our revenues attributable to Belarus for the nine months ended September 30, 2022 and 2021 were $6 million in each period. As the geopolitical situation in Eastern Europe continues to intensify, political events and sanctions are continually changing, and we continue to assess the impact that the Russia-Ukraine war has had and will have on our businesses. These impacts may include but are not limited to: (i) interruptions or stoppage of production, (ii) damage or loss of inventories, (iii) supply-chain and product distribution disruptions in Eastern Europe, (iv) volatility in commodity prices and currencies, (v) disruption in banking systems and capital markets, (vi) reductions in sales and earnings of business in affected areas, (vii) increased costs and (viii) cyberattacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, these challenges have not yet had a material impact on our operations; however, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response will continue to hinder our ability to conduct business with customers and vendors in this region. For example, we expect to experience further disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We may also experience further decreased demand for our products in these countries as a result of the conflict and invasion. In addition, we expect to experience difficulties in collecting receivables from such customers. If we continue to be hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to or suspension of our business and operations in Russia, Belarus and Ukraine may have a material adverse impact on our business, financial condition, cash flows and results of operations. We will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on our businesses. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_160"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has had, and continues to have, an adverse impact on the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. Our revenues were most negatively impacted during our second quarter of 2020 by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. After the launch of effective vaccines in December 2020, infection rates began to decline, signaling the beginning of a recovery from the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues gradually returned to pre-pandemic levels for many of our businesses and geographies throughout 2021. However, in some regions, including China (as further described below), we continue to experience negative impacts of the COVID-19 pandemic on our business in those regions. The rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus and variant and subvariant strains thereof, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and, once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus or variant and subvariant strains thereof and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the omicron variant in China in 2022 resulted in government enforced lockdowns and other social restrictions, which impacted our ability to conduct business as usual in certain regions in China, particularly Shanghai. The lockdowns in China have impacted the demand for certain products, particularly our consumer, vision care and Solta products, as shelter in place orders limit the demand and need for the use of contact lenses and related products as well as for aesthetic medical treatments. Our revenues in China for the nine months ended September 30, 2022 and 2021 were $293&#160;million and $350&#160;million, respectively, a decrease of $57&#160;million and, in part, reflects the impact of the surge of the omicron variant in China. Additionally, government enforced lockdowns have caused certain businesses to suspend operations, creating distribution and other logistic issues for the distribution of our products and the sourcing for a limited number of raw materials. Through the date of this filing, we have dealt with these issues in China with only a minimal impact on our manufacturing and distribution processes. However, as the impacts of global reaction to the COVID-19 pandemic remains a fluid situation, we continue to monitor the impacts on our businesses of the COVID-19 virus and variant and subvariant strains thereof in order to timely address new issues if and when they arise.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other COVID-19 related risks, see Item 1A. &#8220;Risk Factors &#8212; Risk Relating to COVID-19&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div><div id="i0269b61f01054b6698b35799c21833bd_163"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Reduction Act</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, President Biden signed the Inflation Reduction Act into law, which includes implementation of a new alternative minimum tax, an excise tax on stock buybacks and significant tax incentives for energy and climate initiatives, among other provisions. The corporate alternative minimum tax (&#8220;CAMT&#8221;) imposes a minimum tax on the adjusted financial statement income (&#8220;AFSI&#8221;) for &#8220;applicable corporations&#8221; with average annual AFSI over a three-year period in excess of $1 billion. A corporation that is a member of a foreign-parented multinational group, as defined, must include the AFSI (with certain modifications) of all members of the group in applying the $1 billion test, but would only be subject to CAMT if the three-year average AFSI of its U.S. members, US trades or business of foreign group members that are not subsidiaries of U.S. members, and foreign subsidiaries of U.S. members exceeds $100 million. We currently do not believe this will have a significant impact on our tax results, but will continue to evaluate the law and its provisions.</span></div><div id="i0269b61f01054b6698b35799c21833bd_166"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Minimum Corporate Tax Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, a portion of the residual profits of multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will be allocated to market countries where such allocated profits would be taxed. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2024. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with the agreement reached by the Inclusive Framework in October 2021. Some further guidance on the plan and the related rules has been published, with additional guidance expected to be published in 2023. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, and it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</span></div><div id="i0269b61f01054b6698b35799c21833bd_169"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. In March&#160;2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was enacted in the U.S.&#160;The ACA contains several provisions that impact our business, including: (i) an increase in the minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2013, federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA&#8217;s private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion&#8217;s cost paid for by the federal government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 and 2020, we incurred costs of $13 million and $21 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S.&#160;government programs (e.g.,&#160;Medicare and Medicaid). For 2021 and 2020, we also incurred costs of $94 million and $131 million, respectively, on Medicare Part&#160;D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part&#160;D coverage gap (i.e.,&#160;the &#8220;donut&#160;hole&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the failure of the Senate&#8217;s multiple attempts to repeal various combinations of ACA provisions and the change in the U.S. Presidential administration. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Department of Health and Human Services announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the prior administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have a significant impact on our future cash flows, we cannot provide assurance as to the effect or impact of such a plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canada Gazette the new pricing regulation for patented drugs. These regulations were scheduled to become effective on July 1, 2021, but have been delayed until July 1, 2022. The new regulations will, among other things, change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019 and the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, former U.S. President Donald Trump signed four Executive Orders related to drug pricing, including orders addressing: (i) Part D rebate reform, (ii) the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, (iii) drug importation from Canada and (iv) most favored nation pricing for Medicare. In November 2020, former U.S. President Donald Trump announced the Most Favored Nation Model for Medicare Part B Payment which was to be implemented by the Centers for Medicare &amp; Medicaid Services Innovation on January 1, 2021; however, it has not been implemented, as it is currently being challenged in court. It is also uncertain whether the Biden administration intends to reverse these measures or adopt similar policy initiatives.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, as part of a series of drug pricing-related rules issued by the Trump Administration, the Center for Medicare &amp; Medicaid Services issued a Final Rule that makes significant modifications to the Medicaid Drug Rebate Program regulations in several areas, including with respect to the definition of key terms &#8220;line extension&#8221; and &#8220;new formulation&#8221; and best price reporting relating to certain value-based purchasing arrangements (which took effect on January 1, 2022) and the price reporting treatment of manufacturer-sponsored patient benefit programs (which take effect on January 1, 2023).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the U.S. Congress enacted the American Rescue Plan Act of 2021. One of the provisions included within the American Rescue Plan Act of 2021 eliminated the Maximum Rebate Amount for Single Source drugs and Innovator Multiple Source drugs in the Medicaid Drug Rebate Program. We are currently reviewing this legislation, the impact of which is uncertain at this time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products. Additionally, U.S. President Joseph Biden and several members of the current U.S. Congress have indicated that lowering drug prices is a legislative and political priority. Other legislative efforts relating to drug pricing have been enacted and others have been proposed at the U.S. federal and state levels. For instance, certain states have enacted legislation related to prescription drug pricing transparency. Several states have passed importation legislation and Florida is working with the U.S. government to implement an importation program from Canada. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system. We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rulemaking and guidance published by the Department of Health and Human Services and the FDA; however, at this time, it is unclear the effect these matters may have on our businesses.</span></div><div id="i0269b61f01054b6698b35799c21833bd_172"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2022 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2022 or in later years. Following a loss of exclusivity (&#8220;LOE&#8221;) of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic (&#8220;AG&#8221;) of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products already face generic competition. Prior to and during 2021, in the U.S., these products include, among others, Ammonul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Benzaclin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bupap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Demser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Edecrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Istalol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Locoid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension, Mephyton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MoviPrep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nitropress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Timoptic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Ocudose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet, Virazole</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin&#160;XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zegerid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream. In Canada, these products include, among others, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;XL and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ointment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Branded products that began facing generic competition in the U.S. during 2021 included Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products. These products accounted for less than 1% of our total revenues in 2020. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 through 2026 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential LOE and/or generic competition in the U.S. during the years 2022 through 2026. These products and year of expected LOE include, but are not limited to, Noritate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2022), Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel (2022), Xerese</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2022)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products that are subject to settlement agreements which could impact their exclusivity during the years 2022 through 2026.&#160;In aggregate, these products accounted for 2% of our total revenues in 2021. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 200mg and 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection in the U.S. and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Norwich) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On March 26, 2020, the Company and its licensor, Alfasigma, filed suit against Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), alleging infringement by Norwich of one or more claims of the 23 Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents by Norwich&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. On November 13, 2020, an additional three patents alleged to be infringed by Norwich were added to the suit. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued a final judgment on August 10, 2022 finding that the U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(rifaximin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D invalid (the &#8220;Norwich Legal Decision&#8221;). The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the Federal Circuit on August 16, 2022. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q, as well as Note 20, &#8220;LEGAL PROCEEDINGS&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022 for further details regarding certain infringement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending the Company&#8217;s patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company&#8217;s pipeline in order to identify innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future. We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A &#8220;Risk Factors&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on our competition risks.</span></div><div id="i0269b61f01054b6698b35799c21833bd_175"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matters</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. In August 2022, we received a non-compliant rating from Health Canada related to our pharmaceutical manufacturing facility in Laval, Quebec. This rating was received without any restrictive conditions on plant operations so the production of important treatments for Canadians and for export continues without interruption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_178"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL PERFORMANCE HIGHLIGHTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited financial information for the three and nine months ended September 30, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Three Months Ended September 30, 2022 Compared to the Three Months Ended September 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the three months ended September 30, 2022 and 2021 were $2,046 million and $2,111 million, respectively, a decrease of $65 million, or 3%. The decrease was primarily due to: (i) the unfavorable impact of foreign currencies, primarily in Europe and Asia, (ii) the impact of our divestiture related to Amoun on July 26, 2021, (iii) a decline in revenues in our Diversified Products segment partially offset by: (a) growth in revenue in Salix segment driven by improved net pricing and (b) an increase in net volumes and net pricing in our Bausch + Lomb and International segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended September 30, 2022 and 2021 was $244 million and $574&#160;million, respectively, a decrease in our operating results of $330 million and reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $66 million primarily due to: (i) the decrease in revenues as previously discussed and (ii) higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in selling, general and administrative (&#8220;SG&amp;A&#8221;) of $8 million primarily attributable to higher selling expenses related to freight and administrative expenses partially offset by the favorable impact of foreign currencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D expenses of $12 million primarily attributable to lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $48 million primarily attributable to fully amortized intangible assets no longer being amortized in 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Goodwill impairments of $119 million as during the three months ended September 30, 2022, we recognized a $119&#160;million impairment to the goodwill of the Ortho Dermatologics reporting unit;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments, including loss on assets held for sale of $17 million primarily attributable to higher impairments to certain products during the three months September 30, 2021; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an unfavorable change in Other expense (income), net of $187 million, primarily attributable to higher adjustments related to the insurance recoveries related to certain litigation matters partially offset by the loss on the completion of the Amoun sale during the three months ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended September 30, 2022 and 2021 was $244 million and $574&#160;million, and included non-cash charges for Depreciation and amortization of intangible assets of $335 million and $382 million, Goodwill impairments of $119 million and $0, Asset impairments, including loss on assets held for sale, of $1 million and $18 million and Share-based compensation of $33&#160;million and $33&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the three months ended September 30, 2022 and 2021 was $439 million and $216&#160;million, respectively, an increase of $223 million. The increase in our Income before income taxes is primarily attributable to the favorable change in Gain (loss) on extinguishment of debt of $582&#160;million driven by the impact of the </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Offer partially offset by: (i) the decrease in our operating results of $330 million, as previously discussed, and (ii) an increase in Interest expense of $34 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Bausch Health for the three months ended September 30, 2022 and 2021 was $399&#160;million and $188&#160;million, respectively, an increase in our results of $211 million. The increase in our results was primarily due to the increase in our Income before income taxes of $223 million, as previously discussed, partially offset by an unfavorable change in income taxes of $11 million.</span></div><div id="i0269b61f01054b6698b35799c21833bd_181"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Nine Months Ended September 30, 2022 Compared to the Nine Months Ended September 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the nine months ended September 30, 2022 and 2021 were $5,931 million and $6,238 million, respectively, a decrease of $307 million, or 5%. The decrease was primarily due to: (i) the unfavorable impact of foreign currencies, (ii) the impact of our divestiture of Amoun on July 26, 2021 and (iii) a decrease in volumes primarily attributable to our Diversified Products and Salix segments partially offset by an increase in volumes in our Bausch + Lomb and International segments. These decreases were partially offset by an increase in net realized pricing, primarily in our Salix, Bausch + Lomb and International segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the nine months ended September 30, 2022 and 2021 was $690 million and $83 million, respectively, an increase in our operating results of $607 million and reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution of $245 million primarily due to: (i) the decrease in revenues as previously discussed and (ii) higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in SG&amp;A of $15 million primarily attributable to: (i) higher advertising and promotion expenses, (ii) higher freight and administrative expenses and (iii) higher compensation expenses partially offset by: (i) the favorable impact of foreign currencies and (ii) the impact of our divestiture of Amoun on July 26, 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D of $39 million primarily attributable to lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $153 million primarily attributable to fully amortized intangible assets no longer being amortized in 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Goodwill impairments of $267 million as we recognized impairments associated with our Ortho Dermatologics reporting unit of $202 million and $469 million for the nine months ended September 30, 2022 and 2021, respectively;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments, including loss on assets held for sale of $198 million, primarily attributable to adjustments to the loss on assets held for sale in connection with the Amoun Sale during 2021; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Restructuring, integration, separation and IPO costs of $29 million primarily attributable to an increase in separation costs and IPO costs associated with the B+L Separation, the B+L IPO completed on May 10, 2022 and the Solta IPO which was suspended in June 2022; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a favorable change in Other expense (income), net of $323 million primarily attributable to: (i) to higher adjustments related to the settlements of certain litigation matters during the nine months ended September 30, 2021 and (ii) the loss on the completion of the Amoun Sale during the three months ended September 30, 2021, partially offset by insurance recoveries related to certain litigation matters during the three months ended September 30, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the nine months ended September 30, 2022 and 2021 was $690 million and $83 million, respectively, and included non-cash charges for Depreciation and amortization of intangible assets of $1,034 million and $1,189 million, Asset impairments, including loss on assets held for sale of $15 million and $213 million, Goodwill impairments of $202 million and $469 million and Share-based compensation of $91 million and $95&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the nine months ended September 30, 2022 was $228 million as compared to Loss before income taxes of $1,045&#160;million for the nine months ended September 30, 2021, an increase in our results of $1,273 million. The increase in our results is primarily attributable to: (i) the favorable change in Gain (loss) on extinguishment of debt of $745 million primarily driven by the Exchange Offer and (ii) the increase in our operating results of $607 million, as previously discussed, partially offset by: (i) an increase in Interest expense of $74 million and (ii) the unfavorable net change in Foreign exchange and other of $7 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Bausch Health for the nine months ended September 30, 2022 was $185&#160;million as compared to Net loss attributable to Bausch Health of $1,017 million for the nine months ended September 30, 2021, an increase in our results of $1,202 million. The increase in our results was primarily due to the increase in our Income before </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income taxes of $1,273 million, as previously discussed, partially offset by the unfavorable change in our provision for income taxes of $66 million.</span></div><div id="i0269b61f01054b6698b35799c21833bd_184"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited operating results for the three and nine months ended September 30, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:0.8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.030%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(330)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,009)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i0269b61f01054b6698b35799c21833bd_187"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended September 30, 2022 Compared to the Three Months Ended September 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $2,046 million and $2,111 million for the three months ended September 30, 2022 and 2021, respectively, a decrease of $65 million, or 3%. The decrease was due to: (i) the unfavorable impact of foreign currencies of $82 million, primarily in Europe and Asia, (ii) the impact of divestitures and discontinuations of $26 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (iii) a decrease in volumes of $5 million primarily due to decreases in our Diversified Products and Salix segments, partially offset by increases in volumes in our Bausch + Lomb and International segments. These decreases were partially offset by an increase in net realized pricing of $48&#160;million, primarily in our Salix and Bausch + Lomb segments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits for the three months ended September 30, 2022, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 3, &#8220;REVENUE RECOGNITION&#8221; to our unaudited interim Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available. Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate. Provisions recorded to reduce gross product sales to net product sales and revenues for the three months ended September 30, 2022 and 2021 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 41.4% and 39.2% for the three months ended September 30, 2022 and 2021, respectively, an increase of 2.2 percentage points and includes: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily driven by higher discounts in 2021 for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG partially offset by: (i) higher gross sales for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) the impact of higher gross product sales and discount rates for certain generics;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns were higher, however as a percentage of gross product sales remain below 1% primarily due to the Company&#8217;s continued focus on maximizing operational efficiencies and actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due to an increase in gross product sales and higher rebate rates for certain branded products such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales and lower rebate rates for certain branded products such as Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .06% and Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .08% and Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to lower gross sales;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due to higher gross product sales and chargeback rates for certain branded products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX and certain generic products such as Ofloxacin, Dorzolamide and Nifediac due to increased gross product sales and higher chargeback rates as a result of the impact of increased generic competition on pricing. These increases were partially offset by: (i) lower gross sales of certain generic products such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and (ii) lower gross product sales and lower chargeback rates for certain branded products such as Xifaxan 200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our neurology products Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Atavin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were unchanged. Price appreciation credits are offset against distribution service fees when due to wholesalers. There were no price appreciation credits for the three months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or market adjustments to inventories. Cost of goods sold typically vary between periods as a result of product mix, volume, royalties, changes in foreign currency and inflation. Cost of goods sold excludes the amortization and impairments of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $578 million and $574 million for the three months ended September 30, 2022 and 2021, respectively, an increase of $4 million, or 1%. The increase was primarily driven by: (i) the impact of the divestiture of Amoun on July 26, 2021, (ii) the decrease in volumes previously discussed and (iii) the favorable impact of foreign currencies. These increases were partially offset by higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue were 28.5% and 27.5% for the three months ended September 30, 2022 and 2021, respectively, an increase of 1.0 percentage points. Cost of goods sold as a percentage of product sales revenue was unfavorably impacted by higher manufacturing variances as previously discussed, partially offset by the increase in net realized pricing, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; and other general and administrative costs. The Company has also incurred, and expects to continue to incur with respect to the B+L Separation, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO including, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $661 million and $653 million for the three months ended September 30, 2022 and 2021, respectively, an increase of $8 million, or 1%. The increase was primarily attributable to higher selling expenses related to freight and administrative expenses partially offset by the favorable impact of foreign currencies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $133 million and $121 million for the three months ended September 30, 2022 and 2021, respectively, an increase of $12 million, or 10%. R&amp;D expenses as a percentage of Product sales were approximately 7% and 6% for the three months ended September 30, 2022 and 2021, respectively. The increase was primarily attributable to: (i) lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021, as discussed below, and (ii) higher spend on certain Solta and Bausch + Lomb projects. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, due to the COVID-19 pandemic, certain of our R&amp;D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused, as most trial sites were not able to accept new patients due to </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government-mandated shutdowns. During our third quarter of 2020, many of these trial sites began to reopen. During 2021, the pace of new patient enrollments and the increase in these activities and related R&amp;D spend gradually increased until they approached a normalized spend rate toward the end of 2021. As of the date of this filing, we have not had to make material changes to our development timelines and the pause in our clinical trials has not had a material impact on our operating results; however, a resurgence of COVID-19 could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays which could have a significant adverse effect on our future operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years. Management continually assesses the useful lives related to the Company&#8217;s long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $290 million and $338 million for the three months ended September 30, 2022 and 2021, respectively, a decrease of $48 million. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were $119 million and $0 for the three months ended September 30, 2022 and 2021, respectively, an increase of $119 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, we continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. As a result of an impairment to the goodwill of the Ortho Dermatologics reporting unit recognized in second quarter of 2022, the reporting unit had no headroom as calculated on June 30, 2022. We considered the increases in interest rates, higher than expected inflation in the U.S. and other macroeconomic factors which would impact the key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). We believed these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022 which reflect current market conditions and current trends in business performance. The Company updated revenue assumptions for a certain product and other products reaching LOE and updated its assumptions regarding selling, advertising and promotion investments. The Company also increased the discount rate used in the valuation of the reporting unit from 10.0% utilized in the June 30, 2022 testing to 10.5% utilized in the September 30, 2022 testing which reflects the increases in market interest rates. The Company has not changed its long-term growth rate assumption of 1%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and we recognized a goodwill impairment of $119&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued, that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed this decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $1,216&#160;million and $1,194&#160;million for the nine months ended September 30, 2022 and 2021, respectively, representing approximately 80% of the revenues of the Salix reporting unit. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of 2.5% and discount rates of 9.75% and 10.00%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore no impairment was recorded as of September 30, 2022. However, as the Company&#8217;s probability-weighted discount valuation includes scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix segment in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the three months ended September 30, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics and Salix reporting units, might be below its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our goodwill. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairments, Including Loss on Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $1 million and $18 million for the three months ended September 30, 2022 and 2021, respectively, a decrease of $17 million. Asset impairments, including loss on assets held for sale for the three months ended September 30, 2022 of $1 million was related to the discontinuance of a specific product. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale for the three months ended September 30, 2021 of $18 million include: (i) impairments of $9&#160;million due to decreases in forecasted sales of a certain product line in our Diversified Products segment and (ii) impairments of $9&#160;million, in aggregate, related to the discontinuance of certain product lines. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets included in the unaudited Consolidated Balance Sheets have a carrying value of $2,828&#160;million and an estimated remaining useful life of 63 months as of September 30, 2022. The Company determined that the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets for potential impairment. The Company performed this assessment using the same probability-weighted undiscounted cash flow analysis it used in assessing the goodwill of the Salix reporting unit for impairment discussed above. This assessment resulted in no impairment of the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets as of September&#160;30, 2022. The Company also determined </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that no change to the remaining useful lives of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets was required as of September&#160;30, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future related developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration, separation and IPO costs were $10 million and $8 million for the three months ended September 30, 2022 and 2021, respectively, an increase of $2 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $3&#160;million for the three months ended September 30, 2022 and 2021, in each period. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities relating to the B+L Separation. The Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Separation and IPO costs were $7 million and $5 million for the three months ended September 30, 2022 and 2021, respectively. The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our unaudited interim Consolidated Financial Statements for further details regarding these actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the three months ended September 30, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other matters for the three months ended September 30, 2021, included insurance recoveries of $213&#160;million related to a certain litigation. Loss on sale of assets for the three months ended September 30, 2021, included a loss of $26&#160;million upon completion of the Amoun Sale as discussed in Note 4, &#8220;LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our unaudited interim Consolidated Financial Statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization of debt premiums, discounts and deferred issuance costs on indebtedness under our credit facilities and notes and, during 2021, the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company&#8217;s cross-currency swaps. In November 2021, we entered into a transaction to unwind our cross-currency swaps. In July 2022, Bausch +Lomb entered into new cross-currency swaps with aggregate notional amounts of $1,000&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $385 million and $351 million, and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $22 million and $17 million, for the three months ended September 30, 2022 and 2021, respectively. Interest expense for the three months ended September 30, 2022 increased $34 million, or 10%, as compared to the three months ended September 30, 2021, primarily attributable to the higher interest rates partially offset by the impact of lower outstanding debt balances. The weighted average stated rate of interest as of September&#160;30, 2022 and 2021 was 7.24% and 5.91%, respectively. The increase in the weighted average stated rate of interest of 133 bps is primarily attributable to the New Secured Notes. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements and the section titled &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. The gain on extinguishment of debt was $570 million for the three months ended September 30, 2022 was attributable to the Exchange Offer, as compared to a loss on extinguishment of debt of $12 million for the three months ended September 30, 2021. The Exchange Offer is discussed in further detail under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; below. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to seek to improve its operating results to ensure continual compliance with its financial maintenance covenants and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common shares of Bausch + Lomb, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on extinguishment of debt of $12 million for the three months ended September 30, 2021 is primarily associated with debt repayments made during the three months ended September 30, 2021 and represents the differences between the amounts paid to settle the extinguished debt and its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other primarily includes: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts. Foreign exchange and other was a gain of $7&#160;million and $3&#160;million for the three months ended September 30, 2022 and 2021, respectively, a favorable net change of $4&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $36 million and $25 million for the three months ended September 30, 2022 and 2021, respectively, a unfavorable change of $11&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended September 30, 2022 differs from the statutory Canadian income tax rate primarily due to: (i) the tax provision generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowance on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of certain tax matters, primarily related to: (a) changes in uncertain tax positions, (b) adjustments for book to income tax return provisions and (c) changes to the tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended September 30, 2021 differs from the statutory Canadian income tax rate primarily due to: (i) the tax benefit generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowance on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain tax matters, primarily related to: (a) changes in uncertain tax positions, (b) adjustments for book to income tax return provisions and (c) tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, &#8220;INCOME TAXES&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div id="i0269b61f01054b6698b35799c21833bd_190"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.15pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues for the three and nine months ended September 30, 2022, in each period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 19, &#8220;SEGMENT INFORMATION&#8221; to our unaudited interim Consolidated Financial Statements for a reconciliation of segment profit to Income (loss) before income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the period-over-period changes in segment revenues for the three months ended September 30, 2022 and 2021. The following table also presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the three months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue and organic revenue change are non-GAAP measures. Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company&#8217;s financial statements and might not be comparable to similar financial measures disclosed by other issuers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue (non-GAAP) and change in organic revenue (non-GAAP), are defined as GAAP Revenue and change in GAAP revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess performance of its reportable segments, and the Company in total. The Company believes that providing these measures is useful to investors as they provide a supplemental period-to-period comparison.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adjustments to GAAP Revenue and changes in GAAP revenue to determine organic revenue (non-GAAP) and changes in organic revenue (non-GAAP) are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and organic growth/change exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and change in organic revenue exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. There were no acquisitions during the twelve month period ended September&#160;30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and the period-over-period changes in organic revenue (non-GAAP) for the three months ended September 30, 2022 and 2021 by segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.032%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.006%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Divestitures <br/>and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line accounted for approximately 80% of the Salix segment revenues for the three months ended September 30, 2022 and 2021, in each period. No other single product group represents 10% or more of the Salix segment product sales. Salix segment revenue for the three months ended September 30, 2022 and 2021 was $544 million and $527 million, respectively, an increase of $17 million, or 3%. The increase is primarily driven by an increase in net realized pricing of $29 million, primarily driven by Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by a decrease in volumes of $12 million primarily attributable to unfavorable inventory balancing of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by certain wholesalers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the three months ended September 30, 2022 and 2021 was $391&#160;million and $377&#160;million, respectively, an increase of $14&#160;million, or 4%. The increase was primarily driven by an increase in contribution primarily attributable to the increase in revenues, as previously discussed.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $250 million and $271 million for the three months ended September 30, 2022 and 2021, respectively, a decrease of $21 million, or 8%. The decrease was primarily attributable to: (i) the impact of divestitures and discontinuations of $23 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) the unfavorable impact of foreign currencies of $22 million, primarily in Europe. These decreases were partially offset by increases in: (i) volumes of $16 million and (ii) net realized pricing of $8 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for the three months ended September 30, 2022 and 2021 was $85 million and $92&#160;million, respectively, a decrease of $7 million, or 8%. The decrease was primarily attributable to: (i) our divestiture of Amoun on July 26, 2021 and (ii) lower contribution primarily attributable to the unfavorable impact of foreign currencies and by higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line, which accounted for approximately 81% of the Solta segment revenues for the three months ended September 30, 2022. No other single product group represents 10% or more of the Solta segment revenues. The Solta Medical segment revenue for the three months ended September 30, 2022 and 2021 was $72&#160;million and $74&#160;million, respectively, a decrease of $2&#160;million, or 3%. The decrease was primarily attributable to the unfavorable impact of foreign currencies of $5&#160;million partially offset by an increase in net realized pricing of $3&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit for the three months ended September 30, 2022 and 2021 was $33 million and $40&#160;million, respectively, a decrease of $7 million, or 18%. The decrease was attributable to: (i) the decrease in contribution primarily driven by higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs, (ii) an increase in R&amp;D and (iii) the unfavorable impact of foreign currencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue for the three months ended September 30, 2022 and 2021 was $238 million and $290 million, respectively, a decrease of $52 million, or 18%. The decrease was primarily driven by: (i) a decrease in volume of $34 million, primarily attributable to our Neurology and Generics businesses and (ii) a decrease in net realized pricing of $16 million, primarily in our Generics business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit for the three months ended September 30, 2022 and 2021 was $151 million and $185&#160;million, respectively, a decrease of $34 million, or 18%. The decrease was primarily driven by the decrease in contribution attributable to the net decrease in revenues, as previously discussed, partially offset by lower general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment has a diversified product line with no single product group representing 10% or more of its product sales. The Bausch + Lomb segment revenue was $942 million and $949 million for the three months ended September 30, 2022 and 2021, respectively, a decrease of $7 million, or 1%. The decrease was attributable to (i) the unfavorable impact of foreign currencies across the Bausch + Lomb international businesses of $55 million primarily in Europe and Asia and (ii) the impact of divestitures and discontinuations of $1 million, related to the discontinuation of certain products. These decreases were partially offset by increases in: (i) volumes of $25 million and (ii) net realized pricing of $24 million primarily within the Vision Care business. The increase in volume was due to: (i) new launches within the international contact lens business, (ii) increased demand of consumables and IOLs within the Surgical business and (iii) increased demand and new launches within the Ophthalmic Pharmaceuticals business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit for the three months ended September 30, 2022 and 2021 was $226&#160;million and $247&#160;million, respectively, a decrease of $21 million, or 9%. The decrease was primarily attributable to: (i) a decrease in contribution primarily driven by: (a) the decrease in revenues as previously discussed and (b) higher manufacturing variances, driven by inflationary pressures and higher manufacturing efficiency ramp-up costs of Daily SiHy lenses and (ii) higher R&amp;D expense.</span></div><div id="i0269b61f01054b6698b35799c21833bd_193"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine Months Ended September 30, 2022 Compared to the Nine Months Ended September 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue was $5,931 million and $6,238 million for the nine months ended September 30, 2022 and 2021, respectively, a decrease of $307 million, or 5%. The decrease was due to: (i) the unfavorable impact of foreign currencies of $186 million primarily in Europe and Asia, (ii) the impact of divestitures and discontinuations of $172&#160;million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (iii) a decrease in volumes of $79 million primarily in our Diversified, Salix and Solta segments partially offset by an increase in volumes in our Bausch + Lomb and International segments. These decreases were partially offset by an increase in net realized pricing of $130&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits for the nine months ended September 30, 2022, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions recorded to reduce gross product sales to net product sales and revenues for the nine months ended September 30, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 41.4% and 39.7% for the nine months ended September 30, 2022 and 2021, respectively, an increase of 1.7 percentage points and includes:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily due to lower gross product sales for certain generic products, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG, Timoptic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales were lower primarily due to: (i) the result of the Company&#8217;s improving return experience and (ii) the favorable year over year impact due to the recall of certain Bausch + Lomb consumer products as a result of a quality issue at a third-party supplier during the three months ended June 30, 2021, as discussed below. Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience primarily for certain of our branded products such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These factors driving our lower return experience were partially offset by charges in our International segment of approximately $11 million during the three months ended June 30, 2022, to reflect a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID-19 lockdown restrictions and a change of distributors;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due the impact of an increase in gross product sales of certain branded products with higher rebate rates, such as Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales and lower rebate rates for certain branded products such as Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .06% and Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .08% and the generic product Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due to higher chargeback rates for certain products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Ofloxacin and Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower chargeback rates and gross product sales for certain generic products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and certain branded products such as Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were unchanged. Price appreciation credits were $0 and $1&#160;million for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $1,691 million and $1,742 million for the nine months ended September 30, 2022 and 2021, respectively, a decrease of $51 million, or 3%. The decrease was primarily driven by: (i) the impact of the divestiture of Amoun on July 26, 2021, (ii) the net decrease in volumes, as previously discussed, and (iii) the favorable impact of foreign currencies. These decreases were partially offset by higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs, partially offset by the impact of manufacturing variances incurred in 2021 related to a quality issue at a third-party supplier, as discussed below.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Bausch + Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) was notified by a third-party supplier of sterilization services for its lens care solution bottles and caps at its Milan, Italy facility, of inconsistencies in the sterilization data versus certificates of conformance previously submitted to B&amp;L Inc. by that supplier. Based on B&amp;L Inc.&#8217;s internal Health and Safety Analysis, it was determined that this issue did not affect the safety or performance of any of its products and was limited to a specific number of lots for certain Consumer products within our Bausch + Lomb segment. However, out of an abundance of caution and working with the appropriate notified body and responsible health authorities, B&amp;L Inc. has contained and/or recalled down to the consumer level the limited number of affected lots of products resulting in $8&#160;million of manufacturing variances and $6&#160;million of returns during the nine months ended September 30, 2021. Further, although B&amp;L Inc.&#8217;s Greenville, South Carolina facility increased production to support some of the demand in the near term, due to the limited availability of qualified materials, production at the Milan facility could not keep up with demand which negatively impacted sales for the affected products in this region during the nine months ended September 30, 2021. During the third quarter of 2021, B&amp;L Inc. had removed this supplier from its Approved Supplier List and qualified another sterilization supplier, who, along with an existing secondary supplier, will provide bottle sterilization, thereby allowing the Milan facility to return to full production capacity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue was 28.8% and 28.2% for the nine months ended September 30, 2022 and 2021, respectively, an increase of 0.6 percentage points. Costs of goods sold as a percentage of Product sales revenue was unfavorably impacted by higher manufacturing variances as previously discussed, partially offset by the increase in net realized pricing, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $1,959 million and $1,944 million for the nine months ended September 30, 2022 and 2021, respectively, an increase of $15 million, or 1%. The increase was primarily attributable to higher selling expenses related to freight and administrative expenses partially offset by: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $387 million and $348 million for the nine months ended September 30, 2022 and 2021, respectively, an increase of $39 million, or 11%. R&amp;D expenses as a percentage of Product sales were approximately 7% and 6% for the nine months ended September 30, 2022 and 2021, respectively. The increase was primarily due to: (i) the result of lower R&amp;D spend in early 2021 as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021, as previously discussed, and (ii) higher spend on certain Solta and Bausch + Lomb projects.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $902 million and $1,055 million for the nine months ended September 30, 2022 and 2021, respectively, a decrease of $153 million, or 15%. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were $202 million for the nine months ended September 30, 2022, related to our Ortho Dermatologics unit as previously discussed, and for the nine months ended September 30, 2021 were $469 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, we believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and we recognized a goodwill impairment of $83&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, during the third quarter of 2022 we continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit and determined that facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and we recognized a goodwill impairment of $119 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, the ultimate outcome of the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response) and other potential future developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore no impairment was recorded. However, as the Company&#8217;s probability-weighted discount valuation includes scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix segment in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairments, Including Loss on Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $15 million and $213 million for the nine months ended September 30, 2022 and 2021, respectively, a decrease of $198 million. Asset impairments, including loss on assets held for sale for the nine months ended September 30, 2022 includes: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $5&#160;million, in aggregate, related to the discontinuance of certain product lines. Asset impairments, including loss on assets held for sale for the nine months ended September 30, 2021 include: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) adjustments of $88&#160;million to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $20&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration, separation and IPO costs were $58 million and $29 million for the nine months ended September 30, 2022 and 2021, respectively, an increase of $29 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $28 million and $9&#160;million for the nine months ended September 30, 2022 and 2021, respectively, an increase of $19 million. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation and IPO costs were $30&#160;million and $20&#160;million for the nine months ended September 30, 2022 and 2021, respectively. The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our unaudited interim Consolidated Financial Statements for further details regarding these actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense (Income), Net </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net for the nine months ended September 30, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other matters for the nine months ended September 30, 2021, included charges for adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries of $213&#160;million related to certain litigation matters. See Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $1,157 million and $1,083 million and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $86 million and $42 million for the nine months ended September 30, 2022 and 2021, respectively. Interest expense increased $74 million, or 7%, primarily due to higher interest rates partially offset by lower outstanding principal balances. The weighted average stated rate of interest as of September&#160;30, 2022 and 2021 was 7.24% and 5.91%, respectively. The increase in the weighted average stated rate of interest of 133 bps is primarily attributable to the New Secured Notes. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on extinguishment of debt was $683 million for the nine months ended September 30, 2022 as compared to a loss on extinguishment of debt of $62 million for the nine months ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on extinguishment of debt for the nine months ended September 30, 2022 includes: (i) the gain associated with the Exchange Offer of $570 million and (ii) the gains associated with the early retirement of certain senior unsecured notes of $176 million discussed below, partially offset by $63&#160;million of losses associated with the refinancing and modification to certain debt obligations completed in connection with the B+L IPO, as discussed in further detail below, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt&#8221; and represents the differences between the amounts paid to settle the extinguished debt and its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During June 2022, through a series of transactions we repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $481 million in the open market for approximately $300 million using: (i) the net proceeds from the partial exercise of the over-allotment option in the B+L IPO by the underwriters, after deducting underwriting commissions, (ii) amounts available under our revolving credit facility and (iii) cash on hand. The senior unsecured notes retired had maturities of January 2028 through February 2031 and had a weighted average interest rate of approximately 5.35%. As a result of these transactions, we recognized a gain on the extinguishment of debt of approximately $176 million, net of write offs of debt premiums, discounts and deferred issuance costs, representing the differences between the amounts paid to retire the senior unsecured notes and their carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on extinguishment of debt of $62 million for the nine months ended September 30, 2021 is primarily associated with refinancing transactions during the nine months ended September 30, 2021 and represents the differences between the amounts paid to settle the extinguished debt and its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other was a gain of $4 million and $11 million for the nine months ended September 30, 2022 and 2021, respectively, an unfavorable net change of $7 million primarily due to: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $30 million as compared to a Benefit from income taxes of $36 million for the nine months ended September 30, 2022 and 2021, respectively, an unfavorable change of $66 million. Our effective income tax rate for the nine months ended September 30, 2022 differs from the statutory Canadian income tax rate primarily due to: (i) the tax provision generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowance on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of certain tax matters, primarily related to: (a) a net income tax benefit associated with certain legal settlements, (b) changes in uncertain tax positions, (c) tax provision related to potential and recognized withholding tax on intercompany dividends, (d) adjustments to book to income tax provisions and (e) adjustments to the tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the nine months ended September 30, 2021 differs from the statutory Canadian income tax rate primarily due to: (i) the tax benefit generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowance on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of certain tax matters, primarily related to: (a) net income tax benefit associated with certain legal settlements, (b) tax provision </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to potential and recognized withholding tax on intercompany dividends, (c) changes in uncertain tax positions, (d) adjustments for book to income tax return provisions and (e) a tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, &#8220;INCOME TAXES&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div id="i0269b61f01054b6698b35799c21833bd_196"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the year-over-year changes in segment revenues for the nine months ended September 30, 2022 and 2021. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for the nine months ended September 30, 2022 and 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt; 1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents organic revenue (non-GAAP) and the year-over-year changes in organic revenue (non-GAAP) for the nine months ended September 30, 2022 and 2021 by segment. Organic revenues (non-GAAP) and organic growth (non-GAAP) rates are defined in the previous section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.006%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Divestitures <br/>and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,066&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line. Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line accounted for approximately 80% of the Salix segment revenues for the nine months ended September 30, 2022 and 2021, in each period. No other single product group represents 10% or more of the Salix segment product sales. The Salix segment revenue for the nine months ended September 30, 2022 and 2021 was $1,509 million and $1,515 million, respectively, a decrease of $6 million, or &lt; 1%. The decrease was primarily driven by decreases in volume of $85 million, primarily attributable to: (i) unfavorable inventory balancing of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by certain wholesalers and (ii) the impact of generic competition as certain </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which lost exclusivity, partially offset by an increase in net realized pricing of $79 million, primarily attributable to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the nine months ended September 30, 2022 and 2021 was $1,067 million and $1,074&#160;million, respectively, a decrease of $7 million, or &lt; 1%. The decrease was primarily driven by: (i) a decrease in contribution primarily attributable to the net decrease in revenues, as previously discussed, and (ii) higher selling, advertising and promotion expenses primarily associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower litigation costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $727 million and $890 million for the nine months ended September 30, 2022 and 2021, respectively, a decrease of $163 million, or 18%. The decrease was primarily attributable to: (i) the impact of divestitures and discontinuations of $163&#160;million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) the unfavorable impact of foreign currencies of $49 million, primarily in Europe. These decreases were partially offset by: (i) an increase in net realized pricing of $24 million and (ii) an increase in volumes of $25 million. The increase in volumes is primarily attributable to Europe and was partially offset by charges for approximately $13 million of returns in connection with a change in certain distribution agreements representing a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID-19 lockdown restrictions as well as a change of distributors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for the nine months ended September 30, 2022 and 2021 was $242 million and $304 million, respectively, a decrease of $62 million, or 20%. The decrease was primarily driven by the decrease in contribution primarily attributable to: (i) our divestiture of Amoun on July 26, 2021, (ii) the unfavorable impact of foreign currencies and (iii) higher manufacturing variances, driven by inflationary pressures related to certain manufacturing costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, which accounted for approximately 76% of the Solta segment revenues for the nine months ended September 30, 2022. No other single product group represents 10% or more of the Solta segment revenues. The Solta Medical segment revenue for the nine months ended September 30, 2022 and 2021 was $201 million and $219 million, respectively, a decrease of $18 million, or 8%. The decrease was primarily attributable to: (i) a decrease in volumes of $24 million, primarily driven by the impact of the COVID-19 pandemic related shutdowns in China and (ii) the unfavorable impact of foreign currencies of $7 million, partially offset by an increase in net realized pricing of $13 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit for the nine months ended September 30, 2022 and 2021 was $88 million and $120 million, respectively, a decrease of $32 million, or 27%. The decrease is attributable to lower contribution primarily driven by an increase in R&amp;D and the unfavorable impact of foreign currencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue for the nine months ended September 30, 2022 and 2021 was $722 million and $850&#160;million, respectively, a decrease of $128 million, or 15%. The decrease was primarily driven by: (i) a decrease in net realized pricing of $18 million and (ii) a decrease in volumes of $108 million. The decrease in volumes was primarily attributable to our Neurology and Generics businesses, including: (i) decreases in several products attributable to the non-recurring pandemic related government mail order programs in 2021 and (ii) the impacts of more generic competitors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit for the nine months ended September 30, 2022 and 2021 was $450 million and $547 million, respectively, a decrease of $97 million, or 18% and was primarily driven by the decrease in revenues, as previously discussed.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment revenue was $2,772 million and $2,764 million for the nine months ended September 30, 2022 and 2021, respectively, an increase of $8 million, or &lt; 1%. The increase was primarily attributable to: (i) an increase in volumes across each of the Bausch + Lomb businesses of $113 million and (ii) an increase in net realized pricing of $32 million. The increase in volumes was primarily driven by: (i) the consumer eye care business, driven by: (a) increased demand for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (b) the non-recurrence of a third-party supplier quality issue on the prior year revenues of certain consumer eye care products, as previously discussed, (ii) increased demand of consumables and intraocular lenses within the Surgical business and (iii) increased demand and new launches within the Ophthalmic Pharmaceuticals business. These increases in volumes were partially offset by the impact of the COVID-19 pandemic during the first half of the year on the contact lens business in China. The increases in revenue were partially offset by: (i) the unfavorable impact of foreign currencies across all international businesses of $130 million, primarily in Europe and Asia and (ii) the impact of divestitures and discontinuations of $7 million, related to the discontinuation of certain products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit for the nine months ended September 30, 2022 and 2021 was $640&#160;million and $699 million, respectively, a decrease of $59 million, or 8%. The decrease was primarily driven by: (i) higher selling expenses, primarily due to freight and (ii) higher manufacturing variances, driven by inflationary pressures and higher manufacturing efficiency ramp-up costs of Daily SiHy lenses and, partially offset by the non-recurrence of prior year charges related to a quality issue at a third-party supplier, as previously discussed. These decreases were partially offset by the increase in revenues, as previously discussed. </span></div><div id="i0269b61f01054b6698b35799c21833bd_199"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,009)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,027)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by operating activities before changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(829)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,142)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,605)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,622)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,407)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $1,203 million for the nine months ended September 30, 2022, as compared to net cash provided by operating activities of $1,402 million for the nine months ended September 30, 2021, a decrease of $2,605 million. The decrease was attributable to: (i) the decrease in Cash provided by operating activities before changes in operating assets and liabilities and (ii) Changes in operating assets and liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities before changes in operating assets and liabilities was $829 million for the nine months ended September 30, 2022 as compared to cash provided by operating activities before changes in operating assets and liabilities of $1,313 million for the nine months ended September 30, 2021, a decrease of $2,142 million. The decrease is primarily attributable to: (i) payments of accrued legal settlements related to the Securities Class Action Settlement, the Glumetza Antitrust Litigation and a RICO class action matter paid during 2022, (ii) changes in business performance, (iii) the impact of our divestiture of Amoun on July 26, 2021 and (iv) an increase in payments for separation-related costs and IPO-related costs in 2022 as compared to 2021. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Restricted cash and other settlement deposits included $1,210&#160;million of payments into an escrow fund under the terms of Securities Class Action Settlement, which was subject to one objector&#8217;s appeal of the final court approval of the agreement. The period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the Securities Class Action Settlement has become &#8220;final&#8221;, as no more appeals can be filed. As a result, the Company&#8217;s rights in the funds previously paid into the escrow account were extinguished in accordance with the terms of the Securities Class Action Settlement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net decrease in cash of $374 million for the nine months ended September 30, 2022, as compared to a net increase of $89 million for the nine months ended September 30, 2021, a decrease of $463 million. During the nine months ended September 30, 2022, Changes in operating assets and liabilities were negatively impacted by: (i) an increase in inventories of $194 million, (ii) the timing of other payments in the ordinary course of business of $154&#160;million, driven in part by the impact of the interest payments made on September 30, 2022 associated with the notes tendered in the Exchange Offer and (iii) increases in trade receivables of $26 million. During the nine months ended September 30, 2021, Changes in operating assets and liabilities was positively impacted by: (i) the timing of other payments in the ordinary course of business of $314&#160;million and (ii) an increase in accrued interest due to timing of payments of $14&#160;million and was partially offset by: (i) an increase in trade receivables of $177 million and (ii) an increase in inventories of $62 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $167 million for the nine months ended September 30, 2022 and was primarily driven by Purchases of property, plant and equipment of $152 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $489 million for the nine months ended September 30, 2021 and was primarily driven by partial: (i) Proceeds from sale of assets and businesses, net of costs to sell of $669 million, which was primarily attributable to the Amoun sale and (ii) Interest settlements from cross-currency swaps of $23 million partially offset by Purchases of property, plant and equipment of $191 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $198 million for the nine months ended September 30, 2022 and was primarily driven by: (i) the issuance of long-term debt, net of discounts, of $6,481 million related to the February 2027 Secured Notes, 2027 Term Loan B Facility, draws on the 2027 Revolving Credit Facility and the B+L Term Loan Facility and (ii) net proceeds from the B+L IPO of $675 million, partially offset by the repayment of long-term debt of $7,224 million related to: (i) the repayment of the outstanding balance under our 2023 Revolving Credit Facility, (ii) the repayment of the outstanding balance of our 6.125% Senior Unsecured Notes, (iii) the repayment of the outstanding balances under our 2025 Term Loan B Facilities and (iv) the repurchase and retirement of certain outstanding senior unsecured notes in the open market with an aggregate par value of $481 million for approximately $300 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $1,788 million for the nine months ended September 30, 2021 and was primarily driven by the repayments of debt of $3,200 million which consisted of: (i) $1,600 million of 7.00% Senior Secured Notes due 2024 as part of the 2021 Refinancing Transactions and (ii) the aggregate prepayments of $1,600 million using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale. Issuance of long-term debt, net of discounts of $1,576 million primarily includes the proceeds of $1,580 million from the issuance of $1,600 million in principal amount of 4.875% Senior Secured Notes due June 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for additional information regarding the financing activities described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least the twelve months following the issuance of this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance, repurchase or exchange existing debt or issue equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of September 30, 2022 includes $297&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $21,215 million and $22,654 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. Aggregate contractual principal amounts due under our debt obligations were $19,574 million and $22,870 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively, a decrease of $3,296 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we closed the Exchange Offer, pursuant to which existing unsecured senior notes as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) with an aggregate outstanding principal balance of $5,594&#160;million were exchanged for $3,125&#160;million in aggregate principal balance of New Secured Notes (as defined below). The Exchange Offer reduced our then aggregate outstanding principal debt balance by $2,469 million. In accordance with U.S. GAAP, we recognized a portion of this reduction as a gain of $570 million, net of third-party fees and the write-off of the unamortized debt discounts and issuance costs related to the Existing Unsecured Senior Notes. In accordance with U.S. GAAP, we were required to record the balance of the reduction in our debt balance, $1,835 million, as a premium on the New Secured Notes. This premium will be reduced as we make interest payments on the New Secured Notes in the amounts as presented in the previously provided table under the caption &#8220;Exchange Offer&#8221;. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements in future periods will not be representative of their stated rates of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details on the accounting for the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#8220;11.00% First Lien Secured Notes&#8221;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#8220;14.00% Second Lien Secured Notes&#8221;, and, together with the 11.00% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#8220;9.00% Intermediate Holdco Secured Notes&#8221;, and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Aggregate Principal Amount Validly Tendered</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Outstanding Existing Notes Validly Tendered</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00% Senior Notes due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25% Senior Notes due 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50% Senior Notes due 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00% Senior Notes due 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% Senior Notes due 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25% Senior Notes due 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exchange Offer reduced the principal balances of our outstanding debt obligations by $2,469 million. The Exchange Offer also had the effect of extending the maturities of approximately $2,400 million of aggregate principal balances of senior notes coming due during the years 2025 through 2027 out to the years 2028 and 2030. Additionally, we have reduced our estimated debt service requirements of principal and interest over the 12 months ending September 30, 2023 by approximately $65 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Exchange Offer, we made debt repayments and completed refinancing transactions during the nine months ended September 30, 2022 that reduced our outstanding debt obligations and extended certain maturities of our remaining debt obligations as previously discussed under &#8220;&#8212; Liquidity and Capital Resources &#8212; Cash Flows &#8212; Financing Activities&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of September&#160;30, 2022, the Company had drawn $450&#160;million on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and 3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September&#160;30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $531&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five-year revolving credit facility of $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of September&#160;30, 2022, the principal amount outstanding under the B+L Term Facility was $2,494&#160;million and $2,442&#160;million net of issuance costs. The B+L Revolving Credit Facility remained undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb's option, either: (a) Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to term SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate plus an applicable margin of 3.25% or (ii) a US dollar base rate plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum and the first installment is payable on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. Provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes (as defined in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements) are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 11.00% First Lien Secured Notes mature on September 30, 2028, and accrue interest at 11.00% per year, payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 11.00% First Lien Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 14.00% Second Lien Secured Notes mature on October 15, 2030, and accrue interest at 14.00% per year, payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">9.00% Intermediate Holdco Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and accrue interest at 9.00% per year, payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of September 30, 2022 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Secured Notes and 9.00% Intermediate Holdco Secured Notes as of September 30, 2022 and December 31, 2021 was $7,975&#160;million and $3,850&#160;million, respectively, an increase of $4,125&#160;million. The increase is attributable to: (i) the issuance of the New BHC Secured Notes and the issuance of the 9.00% Intermediate Holdco Secured Notes in connection with the Exchange Offer as previously discussed and (ii) the issuance of the February 2027 Secured Notes as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes (as defined in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements) issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release under the 2022 Amended Credit Agreement described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of $12,266&#160;million and total liabilities of $5,338&#160;million as of September&#160;30, 2022, and revenues of $3,044&#160;million and operating income of $50&#160;million for the nine months ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Unsecured Notes as of September 30, 2022 and December 31, 2021 was $6,175&#160;million and $14,900&#160;million, respectively, a decrease of $8,725&#160;million, attributable to: (i) Existing Unsecured Notes of $5,594&#160;million validly tendered and accepted in connection with the Exchange Offer, (ii) the redemption in full of $2,650 million of April 2025 Unsecured Notes and (iii) the repurchase and retirement of certain outstanding Senior Unsecured Notes in the open market with an aggregate par value of approximately $481&#160;million for $300&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Availability Under Revolving Credit Facilities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, November&#160;3, 2022, there were $510&#160;million of outstanding borrowings, $35&#160;million of issued and outstanding letters of credit and approximately $430&#160;million of remaining availability under the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, November&#160;3, 2022, there were no outstanding borrowings, $9 million of issued and outstanding letters of credit and $491 million remaining availability under the B+L Revolving Credit Facility. Absent the </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our 2022 Amended Credit Agreement, B+L Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our 2022 Amended Credit Agreement and B+L Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company was in compliance with its financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to seek to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common shares of Bausch + Lomb, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for the Exchange Offer results in the New Secured Notes being carried at a premium relative to their principal amount and will result in no interest expense to be recorded in our financial statements for a significant portion of the New Secured Notes. Therefore, interest expense recorded in our consolidated financial statements will differ significantly from the contractual interest rates of the New Secured Notes. The weighted average interest rate of our debt as reported in our financial statements and the weighted average stated interest rate was 5.67% and 7.24%, respectively, as of September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest of the Company&#8217;s outstanding debt as of December&#160;31, 2021 was 5.88%. The increase in the weighted average stated rate of interest of 136 bps is due to the issuance of the New Secured Notes in connection with the Exchange Offer. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we have emphasized that it is important that the post-separation entities be well-capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to bringing out the maximum value across our portfolio of assets and it continues to be a primary objective of our plan of separation.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Ratings </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November&#160;3, 2022, the credit ratings and outlook from Moody&#8217;s, Standard &amp; Poor&#8217;s (&#8220;S&amp;P&#8217;s&#8221;) and Fitch for certain outstanding obligations of the Company were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:15.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Positive</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No Outlook</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rating Watch Evolving</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Companies Inc. -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 30, 2022, Moody&#8217;s downgraded all ratings to: a corporate rating of Caa2, a senior secured rating of Caa1 and a senior unsecured rating of Ca. On October 4, 2022, S&amp;P lowered its senior secured rating to B-. On October 6, 2022, Fitch downgraded all ratings to: a corporate rating of CCC, a senior secured rating of B and a senior unsecured rating of CC. These downgrades were a result of the Exchange Offer (see Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Corporation - Bausch + Lomb is a restricted subsidiary under the 2022 Amended Credit Agreement and related indentures and will remain a restricted subsidiary until Bausch Health designates Bausch + Lomb as &#8220;unrestricted&#8221;, which is expected to occur at or prior to the distribution anticipated under the proposed B+L Separation. We expect Bausch + Lomb&#8217;s credit ratings could be capped to those of the Company, until we designate Bausch + Lomb as &#8220;unrestricted&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, S&amp;P changed its outlook assigned to Bausch + Lomb from developing to positive. In October 2022, Fitch lowered its rating two notches to a B- corporate rating as well as lowered the senior secured rating two notches to BB-. These downgrades were made simultaneously with the downgrades to the credit ratings of Bausch Health, Bausch + Lomb&#8217;s parent company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div><div id="i0269b61f01054b6698b35799c21833bd_202"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material effect on our results of operations, financial condition, capital expenditures, liquidity or capital resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our cash requirements for the remainder of 2022 are for debt service. Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring, integration and separation costs, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions. We regularly consider licensing and acquisition opportunities within our core therapeutic areas, some of which could be sizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of September&#160;30, 2022, we expect our primary cash requirements during the remainder of 2022 to include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt repayments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Based on our debt portfolio as of November&#160;3, 2022, we anticipate making mandatory amortization payments of approximately $38&#160;million and interest payments of approximately $284&#160;million during the period October 1, 2022 through December 31, 2022. As discussed below, we have and in the future may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay additional amounts under our credit facilities using cash on hand, cash from operations and cash provided from the sale of common stock and additional debt financings in connection with the B+L Separation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">IT Infrastructure Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $11&#160;million for licensing, maintenance and capitalizable costs associated with our IT infrastructure improvement projects during the period October 1, 2022 through December 31, 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $120 million for property, plant and equipment during the period October 1, 2022 through December 31, 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration and other development/approval/sales-based milestone payments of approximately $12&#160;million during the period October 1, 2022 through December 31, 2022;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring and integration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of $3&#160;million during the period October 1, 2022 through December 31, 2022 for employee separation costs and lease termination obligations associated with restructuring and integration actions we have taken through September&#160;30, 2022; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make aggregate payments under our pension and postretirement obligations of $5&#160;million during the period October 1, 2022 through December 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Costs of B+L Separation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred costs associated with activities to complete the B+L Separation and the suspended Solta IPO and will continue to incur costs associated with the B+L Separation. These activities include the costs of: (i) separating Bausch + Lomb and the Solta Medical businesses from the remainder of the Company and (ii) registering Bausch + Lomb as an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing new boards of directors and related board committees for Bausch + Lomb. The Company has also incurred, and will incur, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation. These costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings. During 2022, we made $1,572 million in payments of accrued legal settlements including payments related to the Securities Class Action Settlement, the Glumetza Antitrust Litigation and a RICO class action matter. As of September 30, 2022, the Company&#8217;s Consolidated Balance Sheet includes accrued loss contingencies of $323 million related to matters which are both probable and reasonably estimable, however, a reliable estimate of the period in which the remaining loss contingencies will be payable, if&#160;ever, cannot be made. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements for further details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 4, &#8220;LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our unaudited interim Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company had unrecognized tax benefits totaling $937 million, of which, $13&#160;million is expected to be realized during the remainder of 2022, however a reliable estimate of the period in which the remaining uncertain tax positions will be payable, if&#160;ever, cannot be made. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Repurchases of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, we may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the contractual obligations disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Off-Balance Sheet Arrangements and Contractual Obligations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_205"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares trade on the New&#160;York Stock Exchange and the Toronto Stock Exchange under the symbol &#8220;BHC&#8221;. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October&#160;28, 2022, we had 361,868,131 issued and outstanding common shares. In addition, as of October&#160;28, 2022, we had outstanding 10,742,236 stock options and 9,032,437 time-based restricted share units that each represent the right of a holder to receive one of the Company&#8217;s common shares, and 1,473,152 performance-based restricted share units that represent the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. A maximum of 1,103,782 common shares could be issued upon vesting of the performance-based restricted share units outstanding.</span></div><div id="i0269b61f01054b6698b35799c21833bd_208"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management&#8217;s most subjective and complex judgment due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. Management has reassessed the critical accounting policies and estimates as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Critical Accounting Policies and Estimates&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022, and determined that there were no significant changes in our critical accounting policies and estimates during the nine months ended September 30, 2022, except for: (i) estimates and assumptions regarding the nature, timing and extent that the COVID-19 pandemic had on the Company&#8217;s operations and cash flows as discussed in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our unaudited interim Consolidated Financial Statements, (ii) the impact that the current year segment and reporting unit realignments had on the Company&#8217;s allocation of goodwill, (iii) the assumptions utilized in the assessment of our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets and Salix goodwill for impairment, particularly those related to the range of possible outcomes of the Norwich Legal Decision and related developments, the potential timing of one or more generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being approved and introduced to the U.S. market, and the related estimated probability of each outcome, as discussed in Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements and (iv) the estimates associated with the fair value of Ortho Dermatologics reporting unit in testing goodwill for impairment as discussed in Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements.</span></div><div id="i0269b61f01054b6698b35799c21833bd_211"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0269b61f01054b6698b35799c21833bd_214"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development (&#8220;R&amp;D&#8221;) and marketing spend; our expected primary cash and working capital requirements for this fiscal year and beyond; the Company&#8217;s plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in the 2022 Amended Credit Agreement and senior notes indentures; the ability of our subsidiary, Bausch + Lomb, to comply with the financial and other covenants contained in the B+L Credit Agreement; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the anticipated impact from the ongoing conflict between Russia and Ukraine; and the Company&#8217;s plan to separate its eye health business, including the structure and timing of completing such separation transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. All of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, the resurgence of the COVID-19 virus and variant and subvariant strains thereof (including, but not limited to, the recent resurgence of COVID-19 cases) and any resulting reinstitution of lockdowns and other restrictions, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including, but not limited to, its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition, costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges the Company faces as a result of the closing of the B+L IPO, including the transitional services being provided by and to Bausch + Lomb, any potential, actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the Company's proposed B+L Separation, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the B+L Separation, the expected timing of completion of the B+L Separation and its terms, the Company&#8217;s ability to complete the B+L Separation considering the various conditions to the completion of the B+L Separation (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and applicable shareholder and stock exchange approvals), that market or other conditions are no longer favorable to completing the B+L Separation, that the previously announced planned Solta IPO has been suspended, that the Norwich Legal Decision (see &#8220;Xifaxan&#174; Paragraph IV Proceedings&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements) may affect the timing of, or our ability to complete the B+L Separation, that applicable shareholder, stock exchange, regulatory or other approvals are not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of, or following, the B+L Separation, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the B+L Separation (some of which are beyond their control), limitations on the Company&#8217;s ability to sell a portion of the Company&#8217;s interest in Bausch + Lomb in order to maintain the tax-free status of the B+L Separation (including due to dilution from B+L&#8217;s issuance of share-based compensation awards), other potential tax or other liabilities that may arise as a result of the B+L Separation, the potential dissynergy costs resulting from the B+L Separation, the impact of the B+L Separation on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance that any B+L Separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the B+L Separation and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action and certain opt-out actions in Canada relating to the previously settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take this fiscal year or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our senior notes indentures, the 2027 Revolving Credit Facility, the 2022 Amended Credit Agreement, the B+L Credit Agreement and other current or future credit and/or debt agreements, including the ability of Bausch + Lomb to comply with its covenants and obligations under the B+L Credit Agreement, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2027 Revolving Credit Facility, Bausch + Lomb&#8217;s ability to draw down under the revolving credit facility under the B+L Credit Agreement and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or the 2022 Amended Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for this fiscal year or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in the 2022 Amended Credit Agreement, senior notes indentures and/or the B+L Credit Agreement (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit directors, executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our 2022 Amended Credit Agreement, the B+L Credit Agreement, our senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; the impact of obtaining or maintaining such reimbursement on the price and sales of our products; and the launch and implementation of any new pharma-care or dental-care program or related spending by the Canadian federal government;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our eligibility for benefits under tax treaties and the availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development Inclusive Framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions, including rates of inflation, and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the U.S. and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the ongoing conflict between Russia and Ukraine and the export controls, sanctions and other restrictive actions that have been or may be imposed by the U.S., Canada and other countries against governmental and other entities in Russia, Belarus and parts of Ukraine;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith) and the impact of the Norwich Legal Decision on, among other things, our business results, financial results, and the B+L Separation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully appeal the decision of the U.S. District Court for the District of Delaware in the Company&#8217;s lawsuit against Norwich in connection with Norwich&#8217;s ANDA and challenge Norwich&#8217;s ability to achieve a modified ANDA that avoids the August 10, 2022 final judgement by the District Court and omits the Xifaxan&#174; hepatic encephalopathy (&#8220;HE&#8221;) indication and HE safety data;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">the fact that a substantial amount of our revenues are derived from the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, and that we may be materially impacted by the entry of a generic rifaximin product earlier than January 2028, including the risk of a competitor launching a generic rifaximin at risk prior to a final unappealable decision;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co., including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the current administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any plans for the Company's aesthetic medical business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and risks detailed from time to time in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;), as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, under Item&#160;1A. &#8220;Risk Factors&#8221;, under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div id="i0269b61f01054b6698b35799c21833bd_217"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;Quantitative and&#160;Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as indicated below under &#8220;&#8212; Interest Rate Risk&#8221; and &#8220;&#8212; Inflation Risk&#8221;, there have been no material changes to our exposures to market risks as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Quantitative and Qualitative Disclosures About Market Risks&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had $14,161&#160;million and $5,413&#160;million in outstanding aggregate principal amount of fixed rate debt and variable rate debt, respectively. The estimated fair value of our issued fixed rate debt as of September&#160;30, 2022 was $8,798&#160;million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $313&#160;million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $329&#160;million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-point increase in interest rates would have an annualized pre-tax effect of approximately $54&#160;million in our Consolidated Statements of Operations and Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some markets.</span></div><div id="i0269b61f01054b6698b35799c21833bd_220"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Controls and&#160;Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), has evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2022. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of September&#160;30, 2022. </span></div><div id="i0269b61f01054b6698b35799c21833bd_223"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the three months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_226"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i0269b61f01054b6698b35799c21833bd_229"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information concerning legal proceedings, reference is made to Note 18, &#8220;LEGAL PROCEEDINGS&#8221; of notes to&#160;the unaudited interim Consolidated Financial Statements included elsewhere in this Form&#160;10-Q.</span></div><div id="i0269b61f01054b6698b35799c21833bd_232"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below, there have been no material changes to the risk factors as disclosed in Item 1A. &#8220;Risk Factors&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022. The following additional and amended and restated</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risk factors set forth additional and/or amended risks affecting the Company from those originally presented in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a result of the current conflict between Russia and Ukraine, including the recent invasion of Ukraine by Russia, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we have begun to experience and may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, Russia launched a military invasion of Ukraine. The ongoing military conflict between Ukraine and Russia has provoked strong reactions from the United States, the UK, the EU, Canada and various other countries around the world, including the imposition of export controls and broad financial and economic sanctions against Russia, Belarus and specific areas of Ukraine. Additional sanctions or other measures may be imposed by the global community, and counteractive measures may be taken by the Russian government, other entities in Russia or governments or other entities outside of Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the full year ended December 31, 2021 and the nine months ended September 30, 2022, we derived approximately 2% of our revenues from sales of our products in Russia, less than 1% of our revenues from sales of our products in Ukraine and less than 1% of our revenues from sales of our products in Belarus. As of the date of this filing, the conflict between Ukraine and Russia has begun to impact our business in the region, and we are continuously monitoring developments to assess any potential future impact that may arise. Given the nature of our products, we do not believe that the current sanctions and other measures imposed by the United States and other countries preclude us from conducting business in the region. However, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response may continue to hinder our ability to conduct business with customers and vendors in this region. For example, we have experienced and may in the future experience disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We have experienced and may in the future also experience decreased demand for our products in these countries as a result of the conflict and invasion. In addition, we may experience difficulties in collecting receivables from such customers. If we are hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to, or suspension of, our business and operations in Russia, Belarus and Ukraine would adversely impact our business, financial condition, cash flows and results of operations in this region which may, in turn, materially adversely impact our overall business, financial condition, cash flows and results of operations, which impact could be material, and could cause the market value of our common shares to decline. Finally, we are also subject to risks if exchange controls were to be imposed that would limit the repatriation of profits from our operations in Russia. While we do not rely on profits or dividends from our Russian operations to fund our debt repayment or other business activities generally, as our operations from Russia primarily involve the sale of products purchased from our affiliates located outside of Russia, any exchange controls that would limit the purchase of or payment for products or goods from outside of Russia may have an adverse impact on our operations in Russia or the way we conduct business in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the precise effects of the ongoing military conflict and sanctions on the Russian and global economies remain uncertain, they have already resulted in significant volatility in financial markets and depreciation of the Russian ruble and the Ukrainian hryvnia against the U.S. dollar, as well as in an increase in energy and commodity prices globally. Should the conflict continue or escalate, there may be various economic and security consequences including, but not limited to, supply shortages of different kinds, further increases in prices of commodities, including piped gas, oil and agricultural goods, reduced consumer purchasing power, significant disruptions in logistics infrastructure, telecommunications services and risks </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relating to the unavailability of information technology systems and infrastructure. The resulting impacts to the global economy, financial markets, inflation, interest rates and unemployment, among others, could adversely impact economic and financial conditions, and may disrupt the global economy&#8217;s ongoing recovery following the COVID-19 pandemic. Other potential consequences include, but are not limited to, growth in the number of popular uprisings in the region, increased political discontent, especially in the regions most affected by the conflict or economic sanctions, increase in cyberterrorism activities and attacks, displacement of persons to regions close to the areas of conflict and an increase in the number of refugees fleeing across Europe, among other unforeseen social and humanitarian effects.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of the ongoing conflict between Russia and Ukraine, we may experience other risks, difficulties and challenges in the way we conduct our business and operations generally. For example, there may be an increased risk of cybersecurity attacks due to the current conflict between Russia and Ukraine, including cyber security attacks perpetrated by Russia or others at its direction in response to economic sanctions and other actions taken against Russia as a result of its invasion of Ukraine. Any increase in such attacks on us or our third-party providers or other systems could adversely affect our network systems or other operations. In order to address the risks associated with cybersecurity attacks from the region (including state-sponsored cybersecurity attacks), we have taken action to consolidate network traffic from Russia and Belarus through a single point, which is designed to allow us to more closely inspect that traffic. In addition, if required, this consolidation provides a single point to quickly and efficiently disconnect the region from our corporate network. At this time, to the best of our knowledge, we do not believe we have experienced any cyberattacks that are related to the conflict between Russia and Ukraine. Although we have taken steps to enhance our protections against such attacks, we may not be able to address these cybersecurity threats proactively or implement adequate preventative measures and there can be no assurance that we will promptly detect and address any such disruption or security breach, if at all. In addition, as a result of the risk of collectability of receivables from our customers in Russia, Belarus and Ukraine, we may be required to adjust our accounting practices relating to revenue recognition in this region, with the result that we may not be able to recognize revenue from these customers until collected. We may also suffer reputational harm as a result of our continued operations in Russia, which may adversely impact our sales and other businesses in other countries. Finally, we have one global clinical trial involving Russia, Ukraine and Belarus with patients enrolled. We continue to support the existing patients, but have no plans to enroll new patients at this time. Plans for any additional trials involving Russia, Ukraine and Belarus have been postponed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A protracted conflict between Ukraine and Russia, any escalation of that conflict, and the financial and economic sanctions and import and/or export controls imposed on Russia by the U.S., the UK, the EU, Canada and others, and the above-mentioned adverse effect on our operations (both in this region and generally) and on the wider global economy and market conditions could, in turn, have a material adverse impact on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The B+L Separation is subject to challenge and could be subject to further challenges in the future, any of which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation, including a distribution of all or a portion of our remaining equity interest in Bausch + Lomb to our shareholders, is subject to challenge, which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect. For example, in March 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division (which was subsequently removed to the U.S. District Court for the District of New Jersey), brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain of its current or former officers and directors. This newly filed action seeks a declaratory judgment that the transfer of assets from the Company to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. In addition, the Company could, in the future, face additional legal proceedings and investigations and inquiries by governmental agencies relating to these or similar matters. For more information regarding legal proceedings, see Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the outcome of any such proceedings, investigations and inquiries, but we may incur significant costs and diversion of management attention as a result of these matters, regardless of the outcome. Some or all of these proceedings, investigations and inquiries may lead to damages, settlement payments, fines, penalties, consent orders or other administrative sanctions against us. Furthermore, publicity surrounding these proceedings, investigations and inquiries or any enforcement action as a result thereof, even if ultimately resolved favorably for us could result in additional investigations and legal proceedings. As a result, these proceedings, investigations and inquiries could have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We recently announced that we are suspending our plan to pursue an IPO of our Solta Medical device aesthetics business. Accordingly, the Solta IPO will not be completed in accordance with the previously-anticipated timeline, and may not be completed at all, and if resumed will involve significant time, expense, and distraction, any of which could disrupt or have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, we announced that we intended to pursue an IPO of Solta Medical. The proposed Solta IPO would establish Solta Medical as a separate publicly traded company that consists of our medical aesthetics business. On June 16, 2022, as a result of challenging market conditions and other factors, we announced that we were suspending our plans for the Solta IPO, and that we will revisit alternative paths for Solta in the future. Such suspension could delay the completion of the Solta IPO for a significant period of time or prevent it from occurring at all.</span></div><div id="i0269b61f01054b6698b35799c21833bd_235"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of equity securities by the Company during the three months ended September 30, 2022.</span></div><div id="i0269b61f01054b6698b35799c21833bd_238"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0269b61f01054b6698b35799c21833bd_241"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0269b61f01054b6698b35799c21833bd_244"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i0269b61f01054b6698b35799c21833bd_247"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="-sec-extract:summary;margin-bottom:2pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;Exhibits </span></div><div style="margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex41.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex41.htm">Indenture, dated as of September 30, 2022, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto, originally filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex41.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex42.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex42.htm">Indenture, dated as of September 30, 2022, by and among Bausch Health Companies Inc., the guarantors party thereto, The Bank of New York Mellon, as trustee, and the notes collateral agents party thereto, originally filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex43.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/885590/000119312522257589/d397743dex43.htm">Indenture, dated as of September 30, 2022, by and among 1375209 B.C. Ltd., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, as notes collateral agent, originally filed as Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on October 4, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit104supplementalinde.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit104supplementalinde.htm">Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of March 26, 2018 relating to the BHA's 9.250% Senior Notes due 2026.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108supplementalinde.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit108supplementalinde.htm">Sixteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Americas, Inc. (&#8220;BHA&#8221;) and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of June 1, 2018 relating to the BHA&#8217;s 8.500% Senior Notes due 2027.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106supplementalinde.htm">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit106supplementalinde.htm">Fourteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of May 23, 2019 relating to the Company&#8217;s 7.000% Senior Notes due 2028.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107supplementalinde.htm">10.7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107supplementalinde.htm">Fourteenth Supplemental Indenture, dated as of September 14, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of December 30, 2019 relating to the Company&#8217;s 5.000% Senior Notes due 2028.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105supplementalinde.htm">10.8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105supplementalinde.htm">Fifteenth Supplemental Indenture, dated as of September 28, 2022, by and among Bausch Health Companies Inc. and the Bank of New York Mellon, as trustee, amending that certain Indenture dated as of May 23, 2019 relating to the Company&#8217;s 7.250% Senior Notes due 2029.</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q32022.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q32022.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q32022.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q32022.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q32022.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q32022.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q32022.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q32022.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*     Filed herewith.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i0269b61f01054b6698b35799c21833bd_250"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health Companies&#160;Inc.</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ THOMAS J. APPIO</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio<br/>Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ TOM VADAKETH</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom Vadaketh<br/>Executive Vice President, <br/>Chief Financial Officer <br/>(Principal Financial Officer)</span></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>exhibit104supplementalinde.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic56a1a0498044cfebf280095a0314eae_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.4</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SIXTEENTH SUPPLEMENTAL INDENTURE<br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Sixteenth Supplemental Indenture, dated as of September 14, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between Bausch Health Americas, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and The Bank of New York Mellon, as trustee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) under the Indenture referred to below.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WITNESSETH&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, each of the Company and the guarantors party thereto has heretofore executed and delivered to the Trustee that certain indenture, dated as of March 26, 2018 (as amended, supplemented, waived or otherwise modified prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), relating to the Company&#8217;s 9.250% Senior Notes due 2026 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to Section 9.2 of the Indenture, the Company and the Trustee are authorized to execute and deliver this Supplemental Indenture to supplement or waive certain provisions of the Indenture for the purposes set forth herein, with the consent of the Holders of a majority in principal amount of the outstanding Notes&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Exchange Offer and Consent Solicitation Statement, dated as of August 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consent Solicitation Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company has solicited consents from Holders of the Notes to amend the Indenture as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Holders of a majority in principal amount of the outstanding Notes have consented to the Amendments to the Indenture, as certified by D.F. King &#38; Co., Inc., on the date hereof&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, all things necessary to make this Supplemental Indenture a valid agreement and supplement to the Indenture have been done&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows&#58;</font></div><div style="margin-bottom:8pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><br>DEFINITIONS</font></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless otherwise defined in this Supplemental Indenture, terms defined in the Indenture are used herein as therein defined.</font></div><div style="margin-bottom:12pt;margin-top:8pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><br>AMENDMENTS TO INDENTURE</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Article II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:31.42pt">Article IV (&#8220;Covenants&#8221;) of the Indenture is hereby amended to delete each of the following sections in its entirety and, in the case of each such section so deleted, insert in lieu thereof the phrase &#8220;&#91;Intentionally Omitted&#93;&#8221;&#58;</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.3 &#8211; Reports</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.4 &#8211; Compliance Certificates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.5 &#8211; Further Instruments and Acts</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.8 &#8211; Restricted Payments</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.9 &#8211; Incurrence of Indebtedness and Issuance of Preferred Stock</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.11 &#8211; Liens</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.12 &#8211; Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.13 &#8211; Transaction with Affiliates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.14 &#8211; Asset Sales</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.15 &#8211; Additional Note Guarantees</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.17 &#8211; Business Activities</font></div><div style="margin-bottom:8pt;text-indent:13.5pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Article V (&#8220;Merger, Consolidation or Sale of Assets&#8221;) of the Indenture is hereby amended by deleting the stricken text (indicated in the same manner as the following example&#58; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">stricken text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and adding the inserted text (indicated in the same manner as the following example&#58; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">inserted text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger, Consolidation or Sale of Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) The Company shall not, directly or indirectly&#58; (1) consolidate, amalgamate or merge with or into another Person (whether or not the Company is the surviving corporation) or (2) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole, in one or more related transactions, to another Person, unless&#58; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) &#160;&#160;&#160;&#160;either (x) the Company is the surviving corporation&#59; or (y) the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made is organized and validly existing under the laws of the U.S., any state of the U.S. or the District of Columbia or under the laws of Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island or Switzerland (provided that if such entity is not a corporation, a co-obligor of the Notes is a corporation)&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or the Person to which such sale, assignment, transfer, conveyance or other disposition has been made expressly assumes all the obligations of the Company under the Notes and this Indenture pursuant to agreements reasonably satisfactory to the Trustee&#59; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;immediately after such transaction, no Default or Event of Default exists&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;either (a) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company), or to which such sale, assignment, transfer, conveyance or other disposition has been made shall, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, be permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth in Section 4.9(a) hereof or (b) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made would, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, have a Fixed Charge Coverage Ratio for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">such Person and its Restricted Subsidiaries that would be equal to or greater than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action&#59; and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">iii</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#160;&#160;&#160;&#160;the Company has delivered to the Trustee an Officers&#8217; Certificate stating that such consolidation, amalgamation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Article and that all conditions precedent herein provided for relating to such transaction have been complied with.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any provision contained in the Notes that relates to any provision of the Indenture as amended by this Article II shall likewise be amended so that any such provision contained in the Notes will conform to and be consistent with any provision of the Indenture as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any definitions used exclusively in the provisions of the Indenture that are deleted pursuant to this Article II, and any definitions used exclusively within such definitions, are hereby deleted in their entirety from the Indenture, and all references in the Indenture to any sections or clauses set forth in this Article II, and any and all obligations thereunder related solely to such sections and clauses, are hereby deleted throughout the Indenture. Any references in the Indenture to any sections or clauses that have been modified by virtue of this Article II are hereby modified throughout the Indenture to conform to the changes set forth in this Article II.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Governing Law, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ratification of Indenture&#59; Supplemental Indenture Part of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture for all purposes, and every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.  The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture. This Supplemental Indenture shall be effective as of the date first referenced above. This Supplemental Indenture shall become operative only upon the payment of the applicable consideration pursuant to the terms set forth in the Exchange Offer and Consent Solicitation Statement. This Supplemental Indenture shall not amend, modify or alter any provision of the Indenture that would require, pursuant to Section 9.2 of the Indenture, the consent of each affected holder or holders of at least 66 2&#47;3% in principal amount of the Notes in order to make such amendment, modification or alteration.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Duplicate and Counterpart Originals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The parties may sign any number of copies of this Supplemental Indenture.  One signed copy is enough to prove this Supplemental Indenture.  This </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be an original, but all of them together represent the same agreement. The exchange of copies of the Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of the Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.  The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; &#8220;delivery,&#8221; and words of like import in or relating to this Supplemental Indenture or any  document to be signed in connection with this Supplemental Indenture shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The headings of the Articles and Sections in this Supplemental Indenture have been inserted for convenience of reference only, are not intended to be considered as a part hereof and shall not modify or restrict any of the terms or provisions hereof.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the original Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of this Supplemental Indenture as fully and with like effect as if set forth herein in full.  The Trustee makes no representations or warranties as to the correctness of the recitals contained herein, which shall be taken as statements of the Company, or the validity or sufficiency of this Supplemental Indenture and the Trustee shall not be accountable or responsible for or with respect to nor shall the Trustee have any responsibility for provisions thereof.  The Trustee represents that it is duly authorized to execute and deliver this Supplemental Indenture and perform its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature pages follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="ic56a1a0498044cfebf280095a0314eae_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH AMERICAS, INC.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; William N. Woodfield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                       </font></div><div style="padding-left:274.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; William N. Woodfield</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President, Treasurer</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE BANK OF NEW YORK MELLON,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Trustee</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Francine Kincaid                   </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;  Francine Kincaid</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice President</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>exhibit105supplementalinde.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iadaec64ee386435b9cf7cb1c86b9a2a6_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.5</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FIFTEENTH SUPPLEMENTAL INDENTURE<br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Fifteenth Supplemental Indenture, dated as of September 28, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and The Bank of New York Mellon, as trustee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) under the Indenture referred to below.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WITNESSETH&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, each of the Company and the guarantors party thereto has heretofore executed and delivered to the Trustee that certain indenture, dated as of May 23, 2019 (as amended, supplemented, waived or otherwise modified prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), relating to the Company&#8217;s 7.250% Senior Notes due 2029 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to Section 9.2 of the Indenture, the Company and the Trustee are authorized to execute and deliver this Supplemental Indenture to supplement or waive certain provisions of the Indenture for the purposes set forth herein, with the consent of the Holders of a majority in principal amount of the outstanding Notes&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Exchange Offer and Consent Solicitation Statement, dated as of August 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consent Solicitation Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company has solicited consents from Holders of the Notes to amend the Indenture as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Holders of a majority in principal amount of the outstanding Notes have consented to the Amendments to the Indenture, as certified by D.F. King &#38; Co., Inc., on the date hereof&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, all things necessary to make this Supplemental Indenture a valid agreement and supplement to the Indenture have been done&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows&#58;</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless otherwise defined in this Supplemental Indenture, terms defined in the Indenture are used herein as therein defined.</font></div><div style="padding-right:-36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AMENDMENTS TO INDENTURE</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Article IV (&#8220;Covenants&#8221;) of the Indenture is hereby amended, solely with respect to the Notes, to delete each of the following sections in its entirety and, in the case of each such section so deleted, insert in lieu thereof the phrase &#8220;&#91;Intentionally Omitted&#93;&#8221;&#58;</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.3 &#8211; Reports</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.4 &#8211; Compliance Certificates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.5 &#8211; Further Instruments and Acts</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.8 &#8211; Restricted Payments</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.9 &#8211; Incurrence of Indebtedness and Issuance of Preferred Stock</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.11 &#8211; Liens</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.12 &#8211; Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.13 &#8211; Transaction with Affiliates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.14 &#8211; Asset Sales</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.15 &#8211; Additional Note Guarantees</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.17 &#8211; Business Activities</font></div><div style="margin-bottom:8pt;text-indent:13.5pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Article V (&#8220;Merger, Consolidation or Sale of Assets&#8221;) of the Indenture is hereby amended, solely with respect to the Notes, by deleting the stricken text (indicated in the same manner as the following example&#58; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">stricken text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and adding the inserted text (indicated in the same manner as the following example&#58; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">inserted text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger, Consolidation or Sale of Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) The Company shall not, directly or indirectly&#58; (1) consolidate, amalgamate or merge with or into another Person (whether or not the Company is the surviving corporation) or (2) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole, in one or more related transactions, to another Person, unless&#58; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) &#160;&#160;&#160;&#160;either (x) the Company is the surviving corporation&#59; or (y) the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made is organized and validly existing under the laws of the U.S., any state of the U.S. or the District of Columbia or under the laws of Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island or Switzerland (provided that if such entity is not a corporation, a co-obligor of the Notes is a corporation)&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or the Person to which such sale, assignment, transfer, conveyance or other disposition has been made expressly assumes all the obligations of the Company under the Notes and this Indenture pursuant to agreements reasonably satisfactory to the Trustee&#59; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;immediately after such transaction, no Default or Event of Default exists&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;either (a) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company), or to which such sale, assignment, transfer, conveyance or other disposition has been made shall, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, be permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth in Section 4.9(a) hereof or (b) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made would, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">beginning of the applicable four-quarter period, have a Fixed Charge Coverage Ratio for such Person and its Restricted Subsidiaries that would be equal to or greater than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action&#59; and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">iii</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#160;&#160;&#160;&#160;the Company has delivered to the Trustee an Officers&#8217; Certificate stating that such consolidation, amalgamation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Article and that all conditions precedent herein provided for relating to such transaction have been complied with.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any provision contained in the Notes that relates to any provision of the Indenture as amended by this Article II shall likewise be amended so that any such provision contained in the Notes will conform to and be consistent with any provision of the Indenture as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any definitions used exclusively in the provisions of the Indenture that are deleted pursuant to this Article II, and any definitions used exclusively within such definitions, are hereby deleted in their entirety from the Indenture, and all references in the Indenture to any sections or clauses set forth in this Article II, and any and all obligations thereunder related solely to such sections and clauses, are hereby deleted throughout the Indenture. Any references in the Indenture to any sections or clauses that have been modified by virtue of this Article II are hereby modified throughout the Indenture to conform to the changes set forth in this Article II.</font></div><div style="padding-right:-18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Governing Law, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ratification of Indenture&#59; Supplemental Indenture Part of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture, solely with respect to the Notes, for all purposes, and every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.  The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture. This Supplemental Indenture shall be effective, solely with respect to the Notes, as of the date first referenced above. This Supplemental Indenture shall become operative, solely with respect to the Notes, only upon the payment of the applicable consideration pursuant to the terms set forth in the Exchange Offer and Consent Solicitation Statement. This Supplemental Indenture shall not amend, modify or alter any provision of the Indenture that would require, pursuant to Section 9.2 of the Indenture, the consent of each affected holder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or holders of at least 66 2&#47;3% in principal amount of the Notes in order to make such amendment, modification or alteration.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Duplicate and Counterpart Originals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The parties may sign any number of copies of this Supplemental Indenture.  One signed copy is enough to prove this Supplemental Indenture.  This Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be an original, but all of them together represent the same agreement. The exchange of copies of the Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of the Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.  The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; &#8220;delivery,&#8221; and words of like import in or relating to this Supplemental Indenture or any  document to be signed in connection with this Supplemental Indenture shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The headings of the Articles and Sections in this Supplemental Indenture have been inserted for convenience of reference only, are not intended to be considered as a part hereof and shall not modify or restrict any of the terms or provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the original Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of this Supplemental Indenture as fully and with like effect as if set forth herein in full.  The Trustee makes no representations or warranties as to the correctness of the recitals contained herein, which shall be taken as statements of the Company, or the validity or sufficiency of this Supplemental Indenture and the Trustee shall not be accountable or responsible for or with respect to nor shall the Trustee have any responsibility for provisions thereof.  The Trustee represents that it is duly authorized to execute and deliver this Supplemental Indenture and perform its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature pages follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="iadaec64ee386435b9cf7cb1c86b9a2a6_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; William N. Woodfield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                       </font></div><div style="padding-left:274.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; William N. Woodfield</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President, Treasurer</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> to Supplemental Indenture - 2029 Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE BANK OF NEW YORK MELLON,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Trustee</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Stacey B. Poindexter           </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;  Stacey B. Poindexter</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice President</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> to Supplemental Indenture - 2029 Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>4
<FILENAME>exhibit106supplementalinde.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i91285e052efc423299e36838d5be7c06_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.6</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOURTEENTH SUPPLEMENTAL INDENTURE<br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Fourteenth Supplemental Indenture, dated as of September 14, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and The Bank of New York Mellon, as trustee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) under the Indenture referred to below.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WITNESSETH&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, each of the Company and the guarantors party thereto has heretofore executed and delivered to the Trustee that certain indenture, dated as of May 23, 2019 (as amended, supplemented, waived or otherwise modified prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), relating to the Company&#8217;s 7.000% Senior Notes due 2028 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to Section 9.2 of the Indenture, the Company and the Trustee are authorized to execute and deliver this Supplemental Indenture to supplement or waive certain provisions of the Indenture for the purposes set forth herein, with the consent of the Holders of a majority in principal amount of the outstanding Notes&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Exchange Offer and Consent Solicitation Statement, dated as of August 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consent Solicitation Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company has solicited consents from Holders of the Notes to amend the Indenture as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Holders of a majority in principal amount of the outstanding Notes have consented to the Amendments to the Indenture, as certified by D.F. King &#38; Co., Inc., on the date hereof&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, all things necessary to make this Supplemental Indenture a valid agreement and supplement to the Indenture have been done&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless otherwise defined in this Supplemental Indenture, terms defined in the Indenture are used herein as therein defined.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><br>AMENDMENTS TO INDENTURE</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:0.09pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Article IV (&#8220;Covenants&#8221;) of the Indenture is hereby amended, solely with respect to the Notes, to delete each of the following sections in its entirety and, in the case of each such section so deleted, insert in lieu thereof the phrase &#8220;&#91;Intentionally Omitted&#93;&#8221;&#58;</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.3 &#8211; Reports</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.4 &#8211; Compliance Certificates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.5 &#8211; Further Instruments and Acts</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.8 &#8211; Restricted Payments</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.9 &#8211; Incurrence of Indebtedness and Issuance of Preferred Stock</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.11 &#8211; Liens</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.12 &#8211; Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.13 &#8211; Transaction with Affiliates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.14 &#8211; Asset Sales</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.15 &#8211; Additional Note Guarantees</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.17 &#8211; Business Activities</font></div><div style="margin-bottom:8pt;text-indent:13.5pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Article V (&#8220;Merger, Consolidation or Sale of Assets&#8221;) of the Indenture is hereby amended, solely with respect to the Notes, by deleting the stricken text (indicated in the same manner as the following example&#58; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">stricken text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and adding the inserted text (indicated in the same manner as the following example&#58; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">inserted text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger, Consolidation or Sale of Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) The Company shall not, directly or indirectly&#58; (1) consolidate, amalgamate or merge with or into another Person (whether or not the Company is the surviving corporation) or (2) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole, in one or more related transactions, to another Person, unless&#58; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) &#160;&#160;&#160;&#160;either (x) the Company is the surviving corporation&#59; or (y) the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made is organized and validly existing under the laws of the U.S., any state of the U.S. or the District of Columbia or under the laws of Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island or Switzerland (provided that if such entity is not a corporation, a co-obligor of the Notes is a corporation)&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or the Person to which such sale, assignment, transfer, conveyance or other disposition has been made expressly assumes all the obligations of the Company under the Notes and this Indenture pursuant to agreements reasonably satisfactory to the Trustee&#59; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;immediately after such transaction, no Default or Event of Default exists&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;either (a) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company), or to which such sale, assignment, transfer, conveyance or other disposition has been made shall, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, be permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth in Section 4.9(a) hereof or (b) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made would, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">beginning of the applicable four-quarter period, have a Fixed Charge Coverage Ratio for such Person and its Restricted Subsidiaries that would be equal to or greater than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action&#59; and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">iii</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#160;&#160;&#160;&#160;the Company has delivered to the Trustee an Officers&#8217; Certificate stating that such consolidation, amalgamation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Article and that all conditions precedent herein provided for relating to such transaction have been complied with.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any provision contained in the Notes that relates to any provision of the Indenture as amended by this Article II shall likewise be amended so that any such provision contained in the Notes will conform to and be consistent with any provision of the Indenture as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any definitions used exclusively in the provisions of the Indenture that are deleted pursuant to this Article II, and any definitions used exclusively within such definitions, are hereby deleted in their entirety from the Indenture, and all references in the Indenture to any sections or clauses set forth in this Article II, and any and all obligations thereunder related solely to such sections and clauses, are hereby deleted throughout the Indenture. Any references in the Indenture to any sections or clauses that have been modified by virtue of this Article II are hereby modified throughout the Indenture to conform to the changes set forth in this Article II.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Governing Law, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.</font></div><div style="margin-bottom:0.09pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ratification of Indenture&#59; Supplemental Indenture Part of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture, solely with respect to the Notes, for all purposes, and every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.  The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture. This Supplemental Indenture shall be effective, solely with respect to the Notes, as of the date first referenced above. This Supplemental Indenture shall become operative, solely with respect to the Notes, only upon the payment of the applicable consideration pursuant to the terms set forth in the Exchange Offer and Consent Solicitation Statement. This Supplemental Indenture shall not amend, modify or alter any provision of the Indenture that would require, pursuant to Section 9.2 of the Indenture, the consent of each affected holder or holders of at least 66 2&#47;3% in principal amount of the Notes in order to make such amendment, modification or alteration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Duplicate and Counterpart Originals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The parties may sign any number of copies of this Supplemental Indenture.  One signed copy is enough to prove this Supplemental Indenture.  This Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be an original, but all of them together represent the same agreement. The exchange of copies of the Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of the Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.  The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; &#8220;delivery,&#8221; and words of like import in or relating to this Supplemental Indenture or any  document to be signed in connection with this Supplemental Indenture shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The headings of the Articles and Sections in this Supplemental Indenture have been inserted for convenience of reference only, are not intended to be considered as a part hereof and shall not modify or restrict any of the terms or provisions hereof.</font></div><div style="margin-bottom:0.09pt;text-align:justify;text-indent:0.72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the original Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of this Supplemental Indenture as fully and with like effect as if set forth herein in full.  The Trustee makes no representations or warranties as to the correctness of the recitals contained herein, which shall be taken as statements of the Company, or the validity or sufficiency of this Supplemental Indenture and the Trustee shall not be accountable or responsible for or with respect to nor shall the Trustee have any responsibility for provisions thereof.  The Trustee represents that it is duly authorized to execute and deliver this Supplemental Indenture and perform its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature pages follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i91285e052efc423299e36838d5be7c06_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; William N. Woodfield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                       </font></div><div style="padding-left:274.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; William N. Woodfield</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President, Treasurer</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE BANK OF NEW YORK MELLON,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Trustee</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Francine Kincaid                   </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;  Francine Kincaid</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice President</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>5
<FILENAME>exhibit107supplementalinde.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id5358258d5294614bb9448c5645f0238_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.7</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FOURTEENTH SUPPLEMENTAL INDENTURE<br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Fourteenth Supplemental Indenture, dated as of September 14, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and The Bank of New York Mellon, as trustee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) under the Indenture referred to below.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WITNESSETH&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, each of the Company and the guarantors party thereto has heretofore executed and delivered to the Trustee that certain indenture, dated as of December 30, 2019 (as amended, supplemented, waived or otherwise modified prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), relating to the Company&#8217;s 5.000% Senior Notes due 2028 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to Section 9.2 of the Indenture, the Company and the Trustee are authorized to execute and deliver this Supplemental Indenture to supplement or waive certain provisions of the Indenture for the purposes set forth herein, with the consent of the Holders of a majority in principal amount of the outstanding Notes&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Exchange Offer and Consent Solicitation Statement, dated as of August 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consent Solicitation Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company has solicited consents from Holders of the Notes to amend the Indenture as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Holders of a majority in principal amount of the outstanding Notes have consented to the Amendments to the Indenture, as certified by D.F. King &#38; Co., Inc., on the date hereof&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, all things necessary to make this Supplemental Indenture a valid agreement and supplement to the Indenture have been done&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows&#58;</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless otherwise defined in this Supplemental Indenture, terms defined in the Indenture are used herein as therein defined.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AMENDMENTS TO INDENTURE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Article IV (&#8220;Covenants&#8221;) of the Indenture is hereby amended, solely with respect to the Notes, to delete each of the following sections in its entirety and, in the case of each such section so deleted, insert in lieu thereof the phrase &#8220;&#91;Intentionally Omitted&#93;&#8221;&#58;</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.3 &#8211; Reports</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.4 &#8211; Compliance Certificates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.5 &#8211; Further Instruments and Acts</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.8 &#8211; Restricted Payments</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.9 &#8211; Incurrence of Indebtedness and Issuance of Preferred Stock</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.11 &#8211; Liens</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.12 &#8211; Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.13 &#8211; Transaction with Affiliates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.14 &#8211; Asset Sales</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.15 &#8211; Additional Note Guarantees</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.17 &#8211; Business Activities</font></div><div style="margin-bottom:8pt;text-indent:13.5pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Article V (&#8220;Merger, Consolidation or Sale of Assets&#8221;) of the Indenture is hereby amended, solely with respect to the Notes, by deleting the stricken text (indicated in the same manner as the following example&#58; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">stricken text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and adding the inserted text (indicated in the same manner as the following example&#58; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">inserted text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger, Consolidation or Sale of Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) The Company shall not, directly or indirectly&#58; (1) consolidate, amalgamate or merge with or into another Person (whether or not the Company is the surviving corporation) or (2) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole, in one or more related transactions, to another Person, unless&#58; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) &#160;&#160;&#160;&#160;either (x) the Company is the surviving corporation&#59; or (y) the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made is organized and validly existing under the laws of the U.S., any state of the U.S. or the District of Columbia or under the laws of Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island or Switzerland (provided that if such entity is not a corporation, a co-obligor of the Notes is a corporation)&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or the Person to which such sale, assignment, transfer, conveyance or other disposition has been made expressly assumes all the obligations of the Company under the Notes and this Indenture pursuant to agreements reasonably satisfactory to the Trustee&#59; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;immediately after such transaction, no Default or Event of Default exists&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;either (a) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company), or to which such sale, assignment, transfer, conveyance or other disposition has been made shall, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, be permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth in Section 4.9(a) hereof or (b) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made would, on the date of such transaction after giving pro forma </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, have a Fixed Charge Coverage Ratio for such Person and its Restricted Subsidiaries that would be equal to or greater than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action&#59; and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">iii</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#160;&#160;&#160;&#160;the Company has delivered to the Trustee an Officers&#8217; Certificate stating that such consolidation, amalgamation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Article and that all conditions precedent herein provided for relating to such transaction have been complied with.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any provision contained in the Notes that relates to any provision of the Indenture as amended by this Article II shall likewise be amended so that any such provision contained in the Notes will conform to and be consistent with any provision of the Indenture as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any definitions used exclusively in the provisions of the Indenture that are deleted pursuant to this Article II, and any definitions used exclusively within such definitions, are hereby deleted in their entirety from the Indenture, and all references in the Indenture to any sections or clauses set forth in this Article II, and any and all obligations thereunder related solely to such sections and clauses, are hereby deleted throughout the Indenture. Any references in the Indenture to any sections or clauses that have been modified by virtue of this Article II are hereby modified throughout the Indenture to conform to the changes set forth in this Article II.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Governing Law, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ratification of Indenture&#59; Supplemental Indenture Part of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture, solely with respect to the Notes, for all purposes, and every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.  The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture. This Supplemental Indenture shall be effective, solely with respect to the Notes, as of the date first referenced above. This Supplemental Indenture shall become operative, solely with respect to the Notes, only upon the payment of the applicable consideration pursuant to the terms set forth in the Exchange Offer and Consent Solicitation Statement. This Supplemental Indenture shall not amend, modify or alter any provision of the Indenture that would require, pursuant to Section 9.2 of the Indenture, the consent of each affected holder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or holders of at least 66 2&#47;3% in principal amount of the Notes in order to make such amendment, modification or alteration.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Duplicate and Counterpart Originals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The parties may sign any number of copies of this Supplemental Indenture.  One signed copy is enough to prove this Supplemental Indenture.  This Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be an original, but all of them together represent the same agreement. The exchange of copies of the Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of the Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.  The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; &#8220;delivery,&#8221; and words of like import in or relating to this Supplemental Indenture or any  document to be signed in connection with this Supplemental Indenture shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The headings of the Articles and Sections in this Supplemental Indenture have been inserted for convenience of reference only, are not intended to be considered as a part hereof and shall not modify or restrict any of the terms or provisions hereof.</font></div><div style="margin-bottom:0.12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the original Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of this Supplemental Indenture as fully and with like effect as if set forth herein in full.  The Trustee makes no representations or warranties as to the correctness of the recitals contained herein, which shall be taken as statements of the Company, or the validity or sufficiency of this Supplemental Indenture and the Trustee shall not be accountable or responsible for or with respect to nor shall the Trustee have any responsibility for provisions thereof.  The Trustee represents that it is duly authorized to execute and deliver this Supplemental Indenture and perform its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature pages follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="id5358258d5294614bb9448c5645f0238_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; William N. Woodfield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                       </font></div><div style="padding-left:274.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; William N. Woodfield</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President, Treasurer</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE BANK OF NEW YORK MELLON,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Trustee</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Francine Kincaid                   </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;  Francine Kincaid</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice President</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>6
<FILENAME>exhibit108supplementalinde.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5211e4643d334751a6c67e8341361b69_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.8</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SIXTEENTH SUPPLEMENTAL INDENTURE<br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Sixteenth Supplemental Indenture, dated as of September 14, 2022 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), by and between Bausch Health Americas, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and The Bank of New York Mellon, as trustee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) under the Indenture referred to below.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WITNESSETH&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, each of the Company and the guarantors party thereto has heretofore executed and delivered to the Trustee that certain indenture, dated as of June 1, 2018 (as amended, supplemented, waived or otherwise modified prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), relating to the Company&#8217;s 8.500% Senior Notes due 2027 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to Section 9.2 of the Indenture, the Company and the Trustee are authorized to execute and deliver this Supplemental Indenture to supplement or waive certain provisions of the Indenture for the purposes set forth herein, with the consent of the Holders of a majority in principal amount of the outstanding Notes&#59; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Exchange Offer and Consent Solicitation Statement, dated as of August 30, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consent Solicitation Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Company has solicited consents from Holders of the Notes to amend the Indenture as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Holders of a majority in principal amount of the outstanding Notes have consented to the Amendments to the Indenture, as certified by D.F. King &#38; Co., Inc., on the date hereof&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, all things necessary to make this Supplemental Indenture a valid agreement and supplement to the Indenture have been done&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows&#58;</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Unless otherwise defined in this Supplemental Indenture, terms defined in the Indenture are used herein as therein defined.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><br>AMENDMENTS TO INDENTURE</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Article IV (&#8220;Covenants&#8221;) of the Indenture is hereby amended to delete each of the following sections in its entirety and, in the case of each such section so deleted, insert in lieu thereof the phrase &#8220;&#91;Intentionally Omitted&#93;&#8221;&#58;</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.3 &#8211; Reports</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.4 &#8211; Compliance Certificates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.5 &#8211; Further Instruments and Acts</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.8 &#8211; Restricted Payments</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.9 &#8211; Incurrence of Indebtedness and Issuance of Preferred Stock</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.11 &#8211; Liens</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.12 &#8211; Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.13 &#8211; Transaction with Affiliates</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.14 &#8211; Asset Sales</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.15 &#8211; Additional Note Guarantees</font></div><div style="padding-left:72pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.65pt">Section 4.17 &#8211; Business Activities</font></div><div style="margin-bottom:8pt;text-indent:13.5pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Article V (&#8220;Merger, Consolidation or Sale of Assets&#8221;) of the Indenture is hereby amended by deleting the stricken text (indicated in the same manner as the following example&#58; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">stricken text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and adding the inserted text (indicated in the same manner as the following example&#58; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">inserted text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Merger, Consolidation or Sale of Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) The Company shall not, directly or indirectly&#58; (1) consolidate, amalgamate or merge with or into another Person (whether or not the Company is the surviving corporation) or (2) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole, in one or more related transactions, to another Person, unless&#58; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) &#160;&#160;&#160;&#160;either (x) the Company is the surviving corporation&#59; or (y) the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made is organized and validly existing under the laws of the U.S., any state of the U.S. or the District of Columbia or under the laws of Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island or Switzerland (provided that if such entity is not a corporation, a co-obligor of the Notes is a corporation)&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or the Person to which such sale, assignment, transfer, conveyance or other disposition has been made expressly assumes all the obligations of the Company under the Notes and this Indenture pursuant to agreements reasonably satisfactory to the Trustee&#59; </font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iii)&#160;&#160;&#160;&#160;immediately after such transaction, no Default or Event of Default exists&#59; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">(iv)&#160;&#160;&#160;&#160;either (a) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company), or to which such sale, assignment, transfer, conveyance or other disposition has been made shall, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, be permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth in Section 4.9(a) hereof or (b) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made would, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">beginning of the applicable four-quarter period, have a Fixed Charge Coverage Ratio for such Person and its Restricted Subsidiaries that would be equal to or greater than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action&#59; and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(</font><font style="color:#3b4deb;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">iii</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#160;&#160;&#160;&#160;the Company has delivered to the Trustee an Officers&#8217; Certificate stating that such consolidation, amalgamation, merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Article and that all conditions precedent herein provided for relating to such transaction have been complied with.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any provision contained in the Notes that relates to any provision of the Indenture as amended by this Article II shall likewise be amended so that any such provision contained in the Notes will conform to and be consistent with any provision of the Indenture as amended hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any definitions used exclusively in the provisions of the Indenture that are deleted pursuant to this Article II, and any definitions used exclusively within such definitions, are hereby deleted in their entirety from the Indenture, and all references in the Indenture to any sections or clauses set forth in this Article II, and any and all obligations thereunder related solely to such sections and clauses, are hereby deleted throughout the Indenture. Any references in the Indenture to any sections or clauses that have been modified by virtue of this Article II are hereby modified throughout the Indenture to conform to the changes set forth in this Article II.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing expressed or mentioned herein is intended or shall be construed to give any Person, firm or corporation, other than the Holders and the Trustee, any legal or equitable right, remedy or claim under or in respect of this Supplemental Indenture or the Indenture or any provision herein or therein contained.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Governing Law, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In case any provision in this Supplemental Indenture shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby and such provision shall be ineffective only to the extent of such invalidity, illegality or unenforceability.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ratification of Indenture&#59; Supplemental Indenture Part of Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect.  This Supplemental Indenture shall form a part of the Indenture for all purposes, and every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.  The Trustee makes no representation or warranty as to the validity or sufficiency of this Supplemental Indenture. This Supplemental Indenture shall be effective as of the date first referenced above. This Supplemental Indenture shall become operative only upon the payment of the applicable consideration pursuant to the terms set forth in the Exchange Offer and Consent Solicitation Statement. This Supplemental Indenture shall not amend, modify or alter any provision of the Indenture that would require, pursuant to Section 9.2 of the Indenture, the consent of each affected holder or holders of at least 66 2&#47;3% in principal amount of the Notes in order to make such amendment, modification or alteration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Duplicate and Counterpart Originals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The parties may sign any number of copies of this Supplemental Indenture.  One signed copy is enough to prove this Supplemental Indenture.  This Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be an original, but all of them together represent the same agreement. The exchange of copies of the Supplemental Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of the Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.  The words &#8220;execution,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; &#8220;delivery,&#8221; and words of like import in or relating to this Supplemental Indenture or any  document to be signed in connection with this Supplemental Indenture shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The headings of the Articles and Sections in this Supplemental Indenture have been inserted for convenience of reference only, are not intended to be considered as a part hereof and shall not modify or restrict any of the terms or provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">The Trustee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The recitals in this Supplemental Indenture are made by the Company only and not by the Trustee, and all of the provisions contained in the original Indenture in respect of the rights, privileges, immunities, powers and duties of the Trustee shall be applicable in respect of this Supplemental Indenture as fully and with like effect as if set forth herein in full.  The Trustee makes no representations or warranties as to the correctness of the recitals contained herein, which shall be taken as statements of the Company, or the validity or sufficiency of this Supplemental Indenture and the Trustee shall not be accountable or responsible for or with respect to nor shall the Trustee have any responsibility for provisions thereof.  The Trustee represents that it is duly authorized to execute and deliver this Supplemental Indenture and perform its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Signature pages follow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i5211e4643d334751a6c67e8341361b69_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH AMERICAS, INC.</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; William N. Woodfield        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">               </font></div><div style="padding-left:274.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; William N. Woodfield</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Senior Vice President, Treasurer</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THE BANK OF NEW YORK MELLON,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as Trustee</font></div><div style="margin-bottom:9pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Francine Kincaid                   </font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Name&#58;  Francine Kincaid</font></div><div style="margin-bottom:9pt;padding-left:274.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Vice President</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Supplemental Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exhibit311q32022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id5864b7aa4184e4383faa46558a664e6_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"><tr><td style="width:1.0%"></td><td style="width:5.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exhibit312q32022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i06b4c6736c0f4b9d8d52da02ff09823d_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom Vadaketh, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exhibit321q32022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i45703d0969e6414ca955efddb2c26586_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, Chief Executive Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended September&#160;30, 2022 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>exhibit322q32022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i40c584d41d594482ba97171ce8e8c44c_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom Vadaketh, Executive Vice-President, Chief Financial Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended September&#160;30, 2022 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>bhc-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7672b0ed-3503-4562-bc82-7a3368936983,g:725d4d73-5fd8-4cb1-b65a-aa245208ce29-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000008 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION">
        <link:definition>0000010 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDDIVESTITURE" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE">
        <link:definition>0000011 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS">
        <link:definition>0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS">
        <link:definition>0000013 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>0000014 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>0000016 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>0000017 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS">
        <link:definition>0000018 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>0000019 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>0000021 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET">
        <link:definition>0000022 - Disclosure - OTHER EXPENSE (INCOME), NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>0000023 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>0000024 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>0000025 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>0000026 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables">
        <link:definition>0000028 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables">
        <link:definition>0000029 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>0000030 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>0000031 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>0000032 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>0000033 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables">
        <link:definition>0000034 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>0000035 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>0000036 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>0000037 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables">
        <link:definition>0000038 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>0000040 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>0000041 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>0000042 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails">
        <link:definition>0000043 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
        <link:definition>0000044 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails">
        <link:definition>0000045 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
        <link:definition>0000046 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
        <link:definition>0000047 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000048 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
        <link:definition>0000049 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>0000050 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>0000051 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>0000052 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>0000053 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>0000054 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
        <link:definition>0000055 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
        <link:definition>0000056 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
        <link:definition>0000057 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
        <link:definition>0000058 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESComponentsofInventoriesDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails">
        <link:definition>0000059 - Disclosure - INVENTORIES - Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
        <link:definition>0000060 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>0000061 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>0000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
        <link:definition>0000063 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>0000064 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>0000065 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>0000066 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSExchangeOfferDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails">
        <link:definition>0000067 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails">
        <link:definition>0000068 - Disclosure - FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>0000069 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>0000070 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>0000071 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>0000072 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails">
        <link:definition>0000073 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails">
        <link:definition>0000074 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000075 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000076 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>0000077 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
        <link:definition>0000078 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000079 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
        <link:definition>0000080 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails">
        <link:definition>0000081 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails">
        <link:definition>0000082 - Disclosure - OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETNarrativeDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails">
        <link:definition>0000083 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000084 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails">
        <link:definition>0000085 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails">
        <link:definition>0000086 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails">
        <link:definition>0000087 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
        <link:definition>0000088 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSAntitrustDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails">
        <link:definition>0000089 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSIntellectualPropertyDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails">
        <link:definition>0000090 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSProductLiabilityDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails">
        <link:definition>0000091 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSGeneralCivilActionsDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails">
        <link:definition>0000092 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000093 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
        <link:definition>0000094 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONDisaggregationofRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails">
        <link:definition>0000095 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails_1" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1">
        <link:definition>0000096 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
        <link:definition>0000097 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>0000098 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_XifaxanBrandedProductsMember" abstract="true" name="XifaxanBrandedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherIncomeExpenseNet" abstract="false" name="OtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" abstract="true" name="SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsLupinANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" abstract="true" name="BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" abstract="true" name="OmnibusIncentivePlan2014RetentionRSUGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SOFRCDOREURIBORAndSONIARatesMember" abstract="true" name="SOFRCDOREURIBORAndSONIARatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IPOAndOverAllotmentOptionMember" abstract="true" name="IPOAndOverAllotmentOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" abstract="true" name="SeniorSecured1400NotesSecondLienDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes700DueMarch2024Member" abstract="true" name="SeniorNotes700DueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IPOFoundersGrantsMember" abstract="true" name="IPOFoundersGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" abstract="true" name="VisionCareSurgicalAndOphthalmicReportingUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantComplianceSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" abstract="true" name="PerrigoIsraelPharmaceuticalsLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" abstract="false" name="PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" abstract="true" name="AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" abstract="true" name="CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesLineItems" abstract="true" name="ScheduleOfOtherIncomeAndExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_Legalsettlementsandrelatedfees" abstract="false" name="Legalsettlementsandrelatedfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AmounPharmaceuticalCompanySAEMember" abstract="true" name="AmounPharmaceuticalCompanySAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LitigationSettlementNumberOfObjectorsAppeals" abstract="false" name="LitigationSettlementNumberOfObjectorsAppeals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" abstract="false" name="DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" abstract="false" name="SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorNotes525DueFebruary2031Member" abstract="true" name="SeniorNotes525DueFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" abstract="false" name="SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AssetImpairmentChargesMember" abstract="true" name="AssetImpairmentChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OrthoDermatologicsSegmentMember" abstract="true" name="OrthoDermatologicsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" abstract="false" name="ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" abstract="true" name="SeniorSecured1100NotesFirstLienDueSeptember2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A2022OmnibusIncentivePlanMember" abstract="true" name="A2022OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A9.00SeniorNotesdueDecember2025Member" abstract="true" name="A9.00SeniorNotesdueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueMay2027Member" abstract="true" name="RevolvingCreditFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueFebruary2027Member" abstract="true" name="RevolvingCreditFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="ROTCPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RICOClassActionsMember" abstract="true" name="RICOClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalPeriod" abstract="false" name="LossContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsSlaybackANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombInternationalMember" abstract="true" name="BauschLombInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NewRestatedCreditAgreementMember" abstract="true" name="NewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AnnualAmortizationOfIntangibleAssets" abstract="false" name="AnnualAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NonExecutiveEligibleRecipientsMember" abstract="true" name="NonExecutiveEligibleRecipientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ExtinguishmentOfDebtThirdPartyFees" abstract="false" name="ExtinguishmentOfDebtThirdPartyFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SaleOfStockOverAllotmentTerm" abstract="false" name="SaleOfStockOverAllotmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" abstract="true" name="USDollarBaseRateAndCanadianDollarPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiversifiedProductsSegmentMember" abstract="true" name="DiversifiedProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ExchangeOfferMember" abstract="true" name="ExchangeOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OrthoDermatologicsReportingUnitMember" abstract="true" name="OrthoDermatologicsReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefaultJudgementMember" abstract="true" name="DefaultJudgementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermFacilityDueMay2027Member" abstract="true" name="TermFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CanadianSecuritiesLitigationMember" abstract="true" name="CanadianSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainContingencyNumberOfDefendants" abstract="false" name="GainContingencyNumberOfDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_LossContingencySettlementAgreementsNumberOfInsurers" abstract="false" name="LossContingencySettlementAgreementsNumberOfInsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SoltaMedicalSegmentMember" abstract="true" name="SoltaMedicalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InternationalRxMember" abstract="true" name="InternationalRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" abstract="true" name="FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured6125NotesDueFebruary2027Member" abstract="true" name="SeniorSecured6125NotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" abstract="false" name="PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PreserVisionAREDSPatentLitigationMember" abstract="true" name="PreserVisionAREDSPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombMember" abstract="true" name="BauschLombMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CustomerTopTenProductsMember" abstract="true" name="CustomerTopTenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SOFRCDORAndEURIBORRatesMember" abstract="true" name="SOFRCDORAndEURIBORRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaroPharmaceuticalsIncLitigationMember" abstract="true" name="TaroPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" abstract="false" name="DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ReportingUnitsExcludingOrthoDermatologicsMember" abstract="true" name="ReportingUnitsExcludingOrthoDermatologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" abstract="true" name="PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" abstract="false" name="GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TroubledDebtRestructuringDebtorTypeDomain" abstract="true" name="TroubledDebtRestructuringDebtorTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeparationAndInitialPublicOfferingCostsMember" abstract="true" name="SeparationAndInitialPublicOfferingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TroubledDebtRestructuringDebtorTypeAxis" abstract="true" name="TroubledDebtRestructuringDebtorTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" abstract="false" name="AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ApotexIncLitigationMember" abstract="true" name="ApotexIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" abstract="false" name="RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes500DueFebruary2029Member" abstract="true" name="SeniorNotes500DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" abstract="false" name="DebtInstrumentCreditSpreadAdjustmentOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" abstract="true" name="ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="RestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A2022OmnibusIncentivePlanRetentionProgramMember" abstract="true" name="A2022OmnibusIncentivePlanRetentionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured4875NotesDueJune2028Member" abstract="true" name="SeniorSecured4875NotesDueJune2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" abstract="true" name="ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A1375209BCLtdMember" abstract="true" name="A1375209BCLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesTable" abstract="true" name="ScheduleOfOtherIncomeAndExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentCovenantAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GainContingencyNumberOfProceedings" abstract="false" name="GainContingencyNumberOfProceedings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SalixReportingUnitMember" abstract="true" name="SalixReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringChargesAndInitialPublicOfferingCosts" abstract="false" name="RestructuringChargesAndInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueFebruary2027Member" abstract="true" name="TermLoanBFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="SeparationPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EuropeInterbankOfferedRateEURIBORMember" abstract="true" name="EuropeInterbankOfferedRateEURIBORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilityMember" abstract="true" name="SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MilestonePaymentRelatedToCertainProductMember" abstract="true" name="MilestonePaymentRelatedToCertainProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PadagisLitigationMember" abstract="true" name="PadagisLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PatentInfringementLitigationMember" abstract="true" name="PatentInfringementLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_GainContingencyStayOfApprovalPeriod" abstract="false" name="GainContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" abstract="true" name="ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NorwichPharmaceuticalsIncLitigationMember" abstract="true" name="NorwichPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MSNLaboratoriesPrivateLtdLitigationMember" abstract="true" name="MSNLaboratoriesPrivateLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>bhc-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7672b0ed-3503-4562-bc82-7a3368936983,g:725d4d73-5fd8-4cb1-b65a-aa245208ce29-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_04c0d0c4-ddf2-44de-b3b2-69e1faca05e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e8078634-3763-4979-9216-56cdf50a3b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_04c0d0c4-ddf2-44de-b3b2-69e1faca05e3" xlink:to="loc_us-gaap_AccountsPayableCurrent_e8078634-3763-4979-9216-56cdf50a3b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cca68cbe-f147-423f-bc11-9dfae77d4c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_04c0d0c4-ddf2-44de-b3b2-69e1faca05e3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cca68cbe-f147-423f-bc11-9dfae77d4c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7f5ed1c8-a2d6-457d-956f-dd73d43a1df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_04c0d0c4-ddf2-44de-b3b2-69e1faca05e3" xlink:to="loc_us-gaap_LongTermDebtCurrent_7f5ed1c8-a2d6-457d-956f-dd73d43a1df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c012e372-1b2f-42b6-9cd9-f7d04a786a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f2fb4abd-8223-4525-b96a-8146303283a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c012e372-1b2f-42b6-9cd9-f7d04a786a4d" xlink:to="loc_us-gaap_AssetsCurrent_f2fb4abd-8223-4525-b96a-8146303283a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d1ac50e8-5e6b-40c7-a6a2-1239f5fb97cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c012e372-1b2f-42b6-9cd9-f7d04a786a4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d1ac50e8-5e6b-40c7-a6a2-1239f5fb97cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3321c46d-2535-4235-877e-a287d1f95579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c012e372-1b2f-42b6-9cd9-f7d04a786a4d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3321c46d-2535-4235-877e-a287d1f95579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5cc37aab-7847-4e32-90ea-997cd270315a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c012e372-1b2f-42b6-9cd9-f7d04a786a4d" xlink:to="loc_us-gaap_Goodwill_5cc37aab-7847-4e32-90ea-997cd270315a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_75468ed2-0e0b-49d5-a800-48e9daa19b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c012e372-1b2f-42b6-9cd9-f7d04a786a4d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_75468ed2-0e0b-49d5-a800-48e9daa19b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6b771ef4-8e8e-4d6f-9454-e50fe064b0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c012e372-1b2f-42b6-9cd9-f7d04a786a4d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6b771ef4-8e8e-4d6f-9454-e50fe064b0bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d3e14868-0938-4110-a3b2-52ce056c6014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_40d67145-7471-4394-8615-f113fd0ab6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d3e14868-0938-4110-a3b2-52ce056c6014" xlink:to="loc_us-gaap_CommonStockValue_40d67145-7471-4394-8615-f113fd0ab6f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_59bfbb46-418c-4f46-9868-3229466b72db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d3e14868-0938-4110-a3b2-52ce056c6014" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_59bfbb46-418c-4f46-9868-3229466b72db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94d9401a-7eb9-4234-828c-7d0041b9e3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d3e14868-0938-4110-a3b2-52ce056c6014" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_94d9401a-7eb9-4234-828c-7d0041b9e3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_924516c2-aa58-4981-a350-4a7165f377ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d3e14868-0938-4110-a3b2-52ce056c6014" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_924516c2-aa58-4981-a350-4a7165f377ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8c4b939f-27fd-4b66-ba43-5a914c31a920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a535553-94ae-4c6a-8691-e05a48450f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8c4b939f-27fd-4b66-ba43-5a914c31a920" xlink:to="loc_us-gaap_LiabilitiesCurrent_9a535553-94ae-4c6a-8691-e05a48450f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_c17da707-713f-4763-9221-bf411af27128" xlink:href="bhc-20220930.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8c4b939f-27fd-4b66-ba43-5a914c31a920" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_c17da707-713f-4763-9221-bf411af27128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_44861be4-78b2-4531-877f-56eef43c0e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8c4b939f-27fd-4b66-ba43-5a914c31a920" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_44861be4-78b2-4531-877f-56eef43c0e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6943ef9b-3d85-4537-8196-9871dbaa6297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8c4b939f-27fd-4b66-ba43-5a914c31a920" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6943ef9b-3d85-4537-8196-9871dbaa6297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d96fa3e6-6141-4cd3-8ab1-d668648efdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8c4b939f-27fd-4b66-ba43-5a914c31a920" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d96fa3e6-6141-4cd3-8ab1-d668648efdd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a7e1637-dd0c-4da6-a0a2-3788443cd66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3c08ef50-25b1-4bb7-a570-4f3320e865d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a7e1637-dd0c-4da6-a0a2-3788443cd66c" xlink:to="loc_us-gaap_Liabilities_3c08ef50-25b1-4bb7-a570-4f3320e865d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2550f250-4c0b-46ad-9c22-e1da72954b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a7e1637-dd0c-4da6-a0a2-3788443cd66c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2550f250-4c0b-46ad-9c22-e1da72954b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9dacbdb3-326c-4b6f-a05b-32f9d8dcd34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6a7e1637-dd0c-4da6-a0a2-3788443cd66c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9dacbdb3-326c-4b6f-a05b-32f9d8dcd34b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2b9e84cc-7fb7-4a8e-a564-9adbc6dde446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6c9f96a8-ef6b-4ba6-9afa-39603832f7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b9e84cc-7fb7-4a8e-a564-9adbc6dde446" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6c9f96a8-ef6b-4ba6-9afa-39603832f7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_92001c93-9376-404d-b66e-cf74e8dd2b8e" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b9e84cc-7fb7-4a8e-a564-9adbc6dde446" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_92001c93-9376-404d-b66e-cf74e8dd2b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c35639ed-2b4b-47ee-ab97-4719d33b4cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b9e84cc-7fb7-4a8e-a564-9adbc6dde446" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c35639ed-2b4b-47ee-ab97-4719d33b4cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_108e4f97-ac5f-4934-9e8d-5d6066fab2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b9e84cc-7fb7-4a8e-a564-9adbc6dde446" xlink:to="loc_us-gaap_InventoryNet_108e4f97-ac5f-4934-9e8d-5d6066fab2db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_719d4468-ef94-4b61-a296-19ba640bbc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2b9e84cc-7fb7-4a8e-a564-9adbc6dde446" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_719d4468-ef94-4b61-a296-19ba640bbc34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7966d2e-1f30-450a-abdc-6a0b5fbb7b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c28ac2d-6e3e-4bfd-9dd0-f412eed82f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7966d2e-1f30-450a-abdc-6a0b5fbb7b89" xlink:to="loc_us-gaap_StockholdersEquity_1c28ac2d-6e3e-4bfd-9dd0-f412eed82f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5570c6d4-dc0a-4a68-b306-7d4edebf1fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7966d2e-1f30-450a-abdc-6a0b5fbb7b89" xlink:to="loc_us-gaap_MinorityInterest_5570c6d4-dc0a-4a68-b306-7d4edebf1fd1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ce4f295-931f-4ae3-a143-ff7e295ce6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_02064f4c-c314-4a77-bdf3-2b67ed071ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ce4f295-931f-4ae3-a143-ff7e295ce6ef" xlink:to="loc_us-gaap_OperatingIncomeLoss_02064f4c-c314-4a77-bdf3-2b67ed071ffa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2e5da7b4-cd5a-413f-9539-69a88cd1d000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ce4f295-931f-4ae3-a143-ff7e295ce6ef" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2e5da7b4-cd5a-413f-9539-69a88cd1d000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_272fea02-21ae-484e-a805-f3280b5076a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ce4f295-931f-4ae3-a143-ff7e295ce6ef" xlink:to="loc_us-gaap_InterestExpenseDebt_272fea02-21ae-484e-a805-f3280b5076a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b553b8ff-026e-4f3b-8954-fcb04d9000b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ce4f295-931f-4ae3-a143-ff7e295ce6ef" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b553b8ff-026e-4f3b-8954-fcb04d9000b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7dafb168-6cf3-41c9-9869-c007ac006622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ce4f295-931f-4ae3-a143-ff7e295ce6ef" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7dafb168-6cf3-41c9-9869-c007ac006622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63172dac-8992-4926-867b-14c7933bf033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_abfdfae3-9b6a-4c7f-b1de-988584816be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_63172dac-8992-4926-867b-14c7933bf033" xlink:to="loc_us-gaap_ProfitLoss_abfdfae3-9b6a-4c7f-b1de-988584816be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a8e378fa-0878-447d-af92-6184ec03f7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_63172dac-8992-4926-867b-14c7933bf033" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a8e378fa-0878-447d-af92-6184ec03f7c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dcdb8038-e58e-4124-b7f1-0c898a8ed68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99e0d164-f6a7-420c-b7e9-2e8feeff53ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_dcdb8038-e58e-4124-b7f1-0c898a8ed68b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99e0d164-f6a7-420c-b7e9-2e8feeff53ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d5ccce0e-54b2-4dd8-83b4-b352e1a99688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_dcdb8038-e58e-4124-b7f1-0c898a8ed68b" xlink:to="loc_us-gaap_CostsAndExpenses_d5ccce0e-54b2-4dd8-83b4-b352e1a99688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e43bc528-2799-40b3-bf1d-e72aebc6dd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e43bc528-2799-40b3-bf1d-e72aebc6dd4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2949d19-e9ac-4ab9-a006-07246501bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2949d19-e9ac-4ab9-a006-07246501bcc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2bbd3514-33ed-4c42-869e-ef881714424f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2bbd3514-33ed-4c42-869e-ef881714424f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_b25ce8f7-d189-48e7-b04d-1256fda076ca" xlink:href="bhc-20220930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_b25ce8f7-d189-48e7-b04d-1256fda076ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_9f512012-6bd5-4cb8-a24d-3be37062f2f1" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_9f512012-6bd5-4cb8-a24d-3be37062f2f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e5a60fe3-23c8-49a9-b708-d1435dcec1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_us-gaap_AssetImpairmentCharges_e5a60fe3-23c8-49a9-b708-d1435dcec1b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_9dbc66f5-b4ce-4015-9c2f-a7a8590aea04" xlink:href="bhc-20220930.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_9dbc66f5-b4ce-4015-9c2f-a7a8590aea04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_f09f18ca-7813-4988-90e3-0a9ee7bbbabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_613e581f-12a9-4331-851c-a8cdf416062b" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_f09f18ca-7813-4988-90e3-0a9ee7bbbabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a49798a9-053e-4fba-a82c-2b29cbe40fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e23962d-e1e8-42c2-93ca-bdfecc25b8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a49798a9-053e-4fba-a82c-2b29cbe40fd6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e23962d-e1e8-42c2-93ca-bdfecc25b8c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_033f934a-dbc9-4373-87bf-d46f0d1f6ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a49798a9-053e-4fba-a82c-2b29cbe40fd6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_033f934a-dbc9-4373-87bf-d46f0d1f6ce6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0d74fba6-0843-442d-96cc-c9b51fc8a959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_71913444-6a4c-432d-946c-829700f3df6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0d74fba6-0843-442d-96cc-c9b51fc8a959" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_71913444-6a4c-432d-946c-829700f3df6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2448237f-81ee-4eeb-9a78-b60715a481e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0d74fba6-0843-442d-96cc-c9b51fc8a959" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2448237f-81ee-4eeb-9a78-b60715a481e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a260e6f6-35d2-4135-ab64-0b9cebbc4a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2308a031-4afe-4df8-8368-5168b7d1a8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a260e6f6-35d2-4135-ab64-0b9cebbc4a7e" xlink:to="loc_us-gaap_ProfitLoss_2308a031-4afe-4df8-8368-5168b7d1a8db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_055f7e9f-a97d-4e12-9afd-2524ef02ce35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a260e6f6-35d2-4135-ab64-0b9cebbc4a7e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_055f7e9f-a97d-4e12-9afd-2524ef02ce35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_52875ef7-23cf-46cd-8c84-a13c62a78e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b9f7303e-4ae8-44c0-9d0d-84ab7acfe17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_52875ef7-23cf-46cd-8c84-a13c62a78e50" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b9f7303e-4ae8-44c0-9d0d-84ab7acfe17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_06d3f6d9-e85e-4d87-b311-3b032cc7d91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_52875ef7-23cf-46cd-8c84-a13c62a78e50" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_06d3f6d9-e85e-4d87-b311-3b032cc7d91d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_434afd87-6bb0-454d-a9fe-c612adbbb43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_ProfitLoss_434afd87-6bb0-454d-a9fe-c612adbbb43f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5740e355-72d4-4630-b700-bb0e8a1b924e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_DepreciationAndAmortization_5740e355-72d4-4630-b700-bb0e8a1b924e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_82c5dcf3-3af9-4d5c-ab46-0f30ae6506cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_82c5dcf3-3af9-4d5c-ab46-0f30ae6506cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_595599c8-fd61-4321-8949-6a39bab8df7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_AssetImpairmentCharges_595599c8-fd61-4321-8949-6a39bab8df7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_27a24a41-9320-480d-8390-2ec223225282" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_27a24a41-9320-480d-8390-2ec223225282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_88e5779e-1df7-4925-bf54-eac1410f4aa4" xlink:href="bhc-20220930.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_88e5779e-1df7-4925-bf54-eac1410f4aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_4c280e14-aaaf-4af6-9024-17b2873423c8" xlink:href="bhc-20220930.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_4c280e14-aaaf-4af6-9024-17b2873423c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_916e4168-d849-4e59-ba76-4150205f437e" xlink:href="bhc-20220930.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_916e4168-d849-4e59-ba76-4150205f437e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_ba58cb3b-9096-47e1-a988-44044c4609bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_ba58cb3b-9096-47e1-a988-44044c4609bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_8557dc33-3323-4c76-86b6-df37a8684989" xlink:href="bhc-20220930.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_8557dc33-3323-4c76-86b6-df37a8684989" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_0cbf26f6-9ec9-458d-ad3f-8635007de804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_0cbf26f6-9ec9-458d-ad3f-8635007de804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1d6a8a5b-205b-4b75-96cb-fca7bda0e8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_ShareBasedCompensation_1d6a8a5b-205b-4b75-96cb-fca7bda0e8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_ffe0dd10-460b-49ba-a5d1-59bb9678557c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_ffe0dd10-460b-49ba-a5d1-59bb9678557c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_c303db73-9cbe-4599-8773-9de183770e42" xlink:href="bhc-20220930.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_DerivativeGainExcludedComponent_c303db73-9cbe-4599-8773-9de183770e42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_daefa625-0a15-45fe-8ff6-8cf84b9bac10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_daefa625-0a15-45fe-8ff6-8cf84b9bac10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_7bf8720c-58ae-4c1e-89f7-320dbc855a85" xlink:href="bhc-20220930.xsd#bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_7bf8720c-58ae-4c1e-89f7-320dbc855a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_d314dea6-ce80-4dc5-9184-a9b6ae66dbe3" xlink:href="bhc-20220930.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_d314dea6-ce80-4dc5-9184-a9b6ae66dbe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_1457f394-e86e-4190-baac-a383fd050f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_1457f394-e86e-4190-baac-a383fd050f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_281d26d3-c02f-4063-bcb3-691eadb61049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_281d26d3-c02f-4063-bcb3-691eadb61049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eefa02dd-cadf-462f-9e56-9b9aab8439ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eefa02dd-cadf-462f-9e56-9b9aab8439ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c9d07fcc-8c27-40c0-8d01-cf81fae3eb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c9d07fcc-8c27-40c0-8d01-cf81fae3eb9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_61735fcd-4e31-4893-9870-19899f7fa99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1a5511c-f744-4159-b1eb-df8eead6b0b2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_61735fcd-4e31-4893-9870-19899f7fa99c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c78d2fd-b993-4fda-af4c-6019360229ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1715020-4297-4815-9524-6140bcb6522d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c78d2fd-b993-4fda-af4c-6019360229ee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1715020-4297-4815-9524-6140bcb6522d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a966ac6d-57da-4a93-a19b-99a5dd06a225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c78d2fd-b993-4fda-af4c-6019360229ee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a966ac6d-57da-4a93-a19b-99a5dd06a225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b65fc5db-014e-4a9e-9750-cdf06c877f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c78d2fd-b993-4fda-af4c-6019360229ee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b65fc5db-014e-4a9e-9750-cdf06c877f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef5ab749-4723-4b77-bbd3-c20dba6bb213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c78d2fd-b993-4fda-af4c-6019360229ee" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef5ab749-4723-4b77-bbd3-c20dba6bb213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49530c8c-04f5-4017-b048-ea67820a6b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_867fbe6d-7d0c-4d96-94e9-7d7819b8e702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49530c8c-04f5-4017-b048-ea67820a6b13" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_867fbe6d-7d0c-4d96-94e9-7d7819b8e702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7d5058e7-0708-4be4-b818-6ca89c8d6389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49530c8c-04f5-4017-b048-ea67820a6b13" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7d5058e7-0708-4be4-b818-6ca89c8d6389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1cf8dd9d-1020-4433-9f88-024c096fa18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49530c8c-04f5-4017-b048-ea67820a6b13" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1cf8dd9d-1020-4433-9f88-024c096fa18f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_05440c82-b016-4a26-9c0f-38293cbdf033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49530c8c-04f5-4017-b048-ea67820a6b13" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_05440c82-b016-4a26-9c0f-38293cbdf033" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d28a8668-2ab7-4b7d-bc3d-0ddc11c70f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49530c8c-04f5-4017-b048-ea67820a6b13" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d28a8668-2ab7-4b7d-bc3d-0ddc11c70f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_bfda3403-87f0-4a80-b5dd-25ab8ab3ce9d" xlink:href="bhc-20220930.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49530c8c-04f5-4017-b048-ea67820a6b13" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_bfda3403-87f0-4a80-b5dd-25ab8ab3ce9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d622449a-692d-4485-865d-b7f5b0213bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d622449a-692d-4485-865d-b7f5b0213bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_febfdddd-7bbc-4214-8a4a-5ea9a784f7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_febfdddd-7bbc-4214-8a4a-5ea9a784f7ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_59d21d4f-5e15-438d-8c11-57ba04324626" xlink:href="bhc-20220930.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:to="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_59d21d4f-5e15-438d-8c11-57ba04324626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_66533eab-8e78-4468-9b34-26d33d000a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_66533eab-8e78-4468-9b34-26d33d000a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_530f2432-1421-4d5b-bd4c-4e78e12f2a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_530f2432-1421-4d5b-bd4c-4e78e12f2a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6e12e752-2a8f-4668-ae56-2e189f1a3ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6e12e752-2a8f-4668-ae56-2e189f1a3ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_efe965f5-06fb-4986-8ded-0ee2d5343faf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_556d0977-3a4d-4f1e-aacc-77ee6bb97db3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_efe965f5-06fb-4986-8ded-0ee2d5343faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17a30948-411f-4e6f-bb9b-fb56deb17f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_767800e9-38ad-4df1-b60a-f5782adece93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17a30948-411f-4e6f-bb9b-fb56deb17f1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_767800e9-38ad-4df1-b60a-f5782adece93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_765b6469-6bde-46e3-93c8-3910672b40e5" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17a30948-411f-4e6f-bb9b-fb56deb17f1d" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_765b6469-6bde-46e3-93c8-3910672b40e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cf992e08-96b3-476c-848f-b921c52eeed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_18551266-1ff9-461c-8370-81d97cc6a4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cf992e08-96b3-476c-848f-b921c52eeed9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_18551266-1ff9-461c-8370-81d97cc6a4bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_222d6c89-df52-4c11-8de3-5c51eabf7725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cf992e08-96b3-476c-848f-b921c52eeed9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_222d6c89-df52-4c11-8de3-5c51eabf7725" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7caac3ee-9f97-4a62-b9f5-95c822f66402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_19110437-5b6f-4629-bf4a-eb14955e626c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7caac3ee-9f97-4a62-b9f5-95c822f66402" xlink:to="loc_us-gaap_InventoryRawMaterials_19110437-5b6f-4629-bf4a-eb14955e626c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_61544aa6-ae1a-4271-bea2-f6ab49d06a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7caac3ee-9f97-4a62-b9f5-95c822f66402" xlink:to="loc_us-gaap_InventoryWorkInProcess_61544aa6-ae1a-4271-bea2-f6ab49d06a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_3dad8d5f-79e2-412e-9c4e-b6f0aecaa567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_7caac3ee-9f97-4a62-b9f5-95c822f66402" xlink:to="loc_us-gaap_InventoryFinishedGoods_3dad8d5f-79e2-412e-9c4e-b6f0aecaa567" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e74acdda-72a7-4fa3-af9f-fb13d45b19a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_83f9b92b-2d00-4f00-8c3e-da7170ee4aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e74acdda-72a7-4fa3-af9f-fb13d45b19a0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_83f9b92b-2d00-4f00-8c3e-da7170ee4aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9c257bf2-b84b-4d57-988f-8d2f577b30d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e74acdda-72a7-4fa3-af9f-fb13d45b19a0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9c257bf2-b84b-4d57-988f-8d2f577b30d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78506fdf-7be5-45b3-b029-00ca1e9be150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c8681c2e-0486-4ea3-9a9e-acba31152ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78506fdf-7be5-45b3-b029-00ca1e9be150" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c8681c2e-0486-4ea3-9a9e-acba31152ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed69c5fb-67a3-486e-97ac-d5e04b35e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78506fdf-7be5-45b3-b029-00ca1e9be150" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed69c5fb-67a3-486e-97ac-d5e04b35e42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7324ad29-2bec-4417-8d41-726035dc61f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_480c0a75-80f5-42e5-9274-20f6ccc1c278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7324ad29-2bec-4417-8d41-726035dc61f9" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_480c0a75-80f5-42e5-9274-20f6ccc1c278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a3571e2e-3bf1-41dd-bd5c-40ddb9c7147c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7324ad29-2bec-4417-8d41-726035dc61f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a3571e2e-3bf1-41dd-bd5c-40ddb9c7147c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d222d191-274f-439e-ad08-df5b8ed10c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d222d191-274f-439e-ad08-df5b8ed10c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bf225248-7df0-47e1-999d-4de036983220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bf225248-7df0-47e1-999d-4de036983220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d7d5f9e-d616-4378-9a3d-80ffe03171b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d7d5f9e-d616-4378-9a3d-80ffe03171b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c4907f38-b72f-4b02-8894-763936e92aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c4907f38-b72f-4b02-8894-763936e92aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47922023-7643-4d4e-b577-f1ce0164f726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47922023-7643-4d4e-b577-f1ce0164f726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_86884092-d367-4002-a1a9-3059c03b33b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_86884092-d367-4002-a1a9-3059c03b33b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2cbf8476-8352-4f40-a89a-5179e7dcc90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fbfdc9c0-4b0d-4d72-a6da-b6b6e5387651" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2cbf8476-8352-4f40-a89a-5179e7dcc90a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_f1f12cd2-753c-4d3f-9f38-1179479f1f35" xlink:href="bhc-20220930.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_f1f12cd2-753c-4d3f-9f38-1179479f1f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_1b65193d-47d7-457f-9d93-daf7f9107755" xlink:href="bhc-20220930.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:to="loc_bhc_AccruedProductRebateCurrent_1b65193d-47d7-457f-9d93-daf7f9107755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_182a220b-2f6c-43a9-9fb8-0e67654074ed" xlink:href="bhc-20220930.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:to="loc_bhc_AccruedProductReturnCurrent_182a220b-2f6c-43a9-9fb8-0e67654074ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_3696b50c-8870-455e-b13d-4d94cfa24eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:to="loc_us-gaap_InterestPayableCurrent_3696b50c-8870-455e-b13d-4d94cfa24eb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_71824f9e-aafb-49df-b982-473a06134e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_71824f9e-aafb-49df-b982-473a06134e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_9752d9de-d833-47ea-9837-a41ff97bc99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_9752d9de-d833-47ea-9837-a41ff97bc99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6115318d-b1f1-4b0e-bec7-d4014de6113a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8a5eb46a-2341-4d6d-b6d9-9f60ac6a44c6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6115318d-b1f1-4b0e-bec7-d4014de6113a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a7ebfcba-05e7-460c-a528-d8c23e1ae58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1f161990-b93b-41ff-911f-1096abc5dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7ebfcba-05e7-460c-a528-d8c23e1ae58b" xlink:to="loc_us-gaap_LongTermDebtCurrent_1f161990-b93b-41ff-911f-1096abc5dd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_95ff830b-da1c-4d3b-bfcc-5cfb8c3ba928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7ebfcba-05e7-460c-a528-d8c23e1ae58b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_95ff830b-da1c-4d3b-bfcc-5cfb8c3ba928" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8ff60e7d-cab8-439f-aca9-90d615773f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8ff60e7d-cab8-439f-aca9-90d615773f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b4551134-b964-4e68-92e1-b8877b83dc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b4551134-b964-4e68-92e1-b8877b83dc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_85e323aa-a72a-4bdb-a28f-690558f78ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_85e323aa-a72a-4bdb-a28f-690558f78ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_513be1aa-3ccf-41e6-a207-f2c22d5d0ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_513be1aa-3ccf-41e6-a207-f2c22d5d0ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f99aa53b-9dfe-46b7-889b-6737b2a59edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f99aa53b-9dfe-46b7-889b-6737b2a59edb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6cc9a34f-2b4f-4757-9c97-59e92c6bcf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_6cc9a34f-2b4f-4757-9c97-59e92c6bcf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2035994c-ce85-4529-acbe-cb4603b83be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_fd201d17-ed46-4390-bd08-badb5ea6d454" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2035994c-ce85-4529-acbe-cb4603b83be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d2e5b80f-fa82-49a2-be31-1d059b40f97c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f15af462-709f-4ad9-b4da-2bcb78087fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d2e5b80f-fa82-49a2-be31-1d059b40f97c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f15af462-709f-4ad9-b4da-2bcb78087fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_83365621-2a42-4bc6-bae9-33a8d64e0ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d2e5b80f-fa82-49a2-be31-1d059b40f97c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_83365621-2a42-4bc6-bae9-33a8d64e0ac3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e1af29e7-d0b5-43ca-aadd-1a1e767dcb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_c6f2fed9-ba78-4735-b7ce-93c17f3f7cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e1af29e7-d0b5-43ca-aadd-1a1e767dcb68" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_c6f2fed9-ba78-4735-b7ce-93c17f3f7cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_3a9152fc-2087-4c59-adb1-593aee548326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e1af29e7-d0b5-43ca-aadd-1a1e767dcb68" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_3a9152fc-2087-4c59-adb1-593aee548326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_4c7b23ec-63ed-45c0-a1a9-ef8643a044b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e1af29e7-d0b5-43ca-aadd-1a1e767dcb68" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_4c7b23ec-63ed-45c0-a1a9-ef8643a044b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_32799b78-5d91-4ff4-8b3f-d439628af686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e1af29e7-d0b5-43ca-aadd-1a1e767dcb68" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_32799b78-5d91-4ff4-8b3f-d439628af686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_80f568e7-bbaa-47ae-b4b1-aaa6521631dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e1af29e7-d0b5-43ca-aadd-1a1e767dcb68" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_80f568e7-bbaa-47ae-b4b1-aaa6521631dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_25cdc855-8e42-4591-8363-ca4745621003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_2a733232-440c-4f32-8835-fd40bc60568b" xlink:href="bhc-20220930.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_25cdc855-8e42-4591-8363-ca4745621003" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_2a733232-440c-4f32-8835-fd40bc60568b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_1a535da6-cb24-495e-9583-ab233990b113" xlink:href="bhc-20220930.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_25cdc855-8e42-4591-8363-ca4745621003" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_1a535da6-cb24-495e-9583-ab233990b113" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5f301682-9230-40a8-8d6f-872affdbd269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_509df3c3-e1e2-4096-99e7-9cedccc014a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5f301682-9230-40a8-8d6f-872affdbd269" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_509df3c3-e1e2-4096-99e7-9cedccc014a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5387b950-2141-4945-bda2-833c9c811046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5f301682-9230-40a8-8d6f-872affdbd269" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5387b950-2141-4945-bda2-833c9c811046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_c2262a21-95d5-437b-9ecd-f2980afee328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5f301682-9230-40a8-8d6f-872affdbd269" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_c2262a21-95d5-437b-9ecd-f2980afee328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_84b60e1a-45b3-4b1f-9a14-d6e9d1297a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5f301682-9230-40a8-8d6f-872affdbd269" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_84b60e1a-45b3-4b1f-9a14-d6e9d1297a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_af9c0093-b391-46b7-8623-66dbb59fdf5e" xlink:href="bhc-20220930.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_5f301682-9230-40a8-8d6f-872affdbd269" xlink:to="loc_bhc_OtherIncomeExpenseNet_af9c0093-b391-46b7-8623-66dbb59fdf5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_245d5dfa-5762-4ab2-b4a1-7721ab8803d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a23c4c0f-8861-4d41-b391-ff26e500fd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_245d5dfa-5762-4ab2-b4a1-7721ab8803d8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a23c4c0f-8861-4d41-b391-ff26e500fd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a9254deb-6123-45a6-9e47-4817ee4db732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_245d5dfa-5762-4ab2-b4a1-7721ab8803d8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a9254deb-6123-45a6-9e47-4817ee4db732" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>bhc-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7672b0ed-3503-4562-bc82-7a3368936983,g:725d4d73-5fd8-4cb1-b65a-aa245208ce29-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="id09b03e3a9c34c5a930eafe4d3cde2c5_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_88c6f5d5-43a8-4d66-8620-f619432aac51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_RevenuesAbstract_88c6f5d5-43a8-4d66-8620-f619432aac51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83bed02c-aeb5-44e6-9bf4-d4db3eb9d4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_88c6f5d5-43a8-4d66-8620-f619432aac51" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83bed02c-aeb5-44e6-9bf4-d4db3eb9d4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2dc3fbcb-c46b-428e-8a85-7d554f68583b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2dc3fbcb-c46b-428e-8a85-7d554f68583b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2190c34c-5552-4f59-8ef0-77de4b0a7ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2190c34c-5552-4f59-8ef0-77de4b0a7ed5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4763505f-f527-4c22-8434-083b7aeb46be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4763505f-f527-4c22-8434-083b7aeb46be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_6effa904-f97d-499e-a9c7-81a938e55885" xlink:href="bhc-20220930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_6effa904-f97d-499e-a9c7-81a938e55885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_208069df-f18e-4bd1-a63b-0b8b4cc57662" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_208069df-f18e-4bd1-a63b-0b8b4cc57662" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cb668814-f85f-43f0-ae74-a489bef810d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_AssetImpairmentCharges_cb668814-f85f-43f0-ae74-a489bef810d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_392cd646-637d-403e-8071-fcea523d786e" xlink:href="bhc-20220930.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_392cd646-637d-403e-8071-fcea523d786e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_d81be64f-6047-4bb6-b519-7da6b7865479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_d81be64f-6047-4bb6-b519-7da6b7865479" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f9453009-0065-47f5-8592-1e22b63da48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_CostsAndExpenses_f9453009-0065-47f5-8592-1e22b63da48c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1c811c66-4688-49c7-9bd8-48d5e8fb4d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_OperatingIncomeLoss_1c811c66-4688-49c7-9bd8-48d5e8fb4d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5597dfc3-e2e8-4206-bf4a-dd43006d6119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5597dfc3-e2e8-4206-bf4a-dd43006d6119" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7dd22c3b-27c6-4fa0-ad08-0c06cc90ec71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_InterestExpenseDebt_7dd22c3b-27c6-4fa0-ad08-0c06cc90ec71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eb2293af-8332-4d27-963a-e7c116f0dda9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eb2293af-8332-4d27-963a-e7c116f0dda9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8fc4bb3b-f621-43ea-b3ed-20267df13e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8fc4bb3b-f621-43ea-b3ed-20267df13e49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c2978a0c-9656-476a-a8fd-07467bac4fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c2978a0c-9656-476a-a8fd-07467bac4fa4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04d4fbb0-80b0-46f3-a579-47b82dc2fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04d4fbb0-80b0-46f3-a579-47b82dc2fefd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9dc2486a-3979-4474-a477-64acc2eff60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_ProfitLoss_9dc2486a-3979-4474-a477-64acc2eff60d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_01124876-ccb9-42ff-a894-f4ae41eb6330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_01124876-ccb9-42ff-a894-f4ae41eb6330" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17bca143-ff90-4272-994e-39cf21266f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_NetIncomeLoss_17bca143-ff90-4272-994e-39cf21266f7c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c9de3d25-cf71-4f2d-91b4-fb9db9305b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:to="loc_us-gaap_EarningsPerShareBasic_c9de3d25-cf71-4f2d-91b4-fb9db9305b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_47697120-a03b-4814-a851-0bce698d3ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_47697120-a03b-4814-a851-0bce698d3ba6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95093e0d-b2c6-4405-bccb-bf6e5bdf87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95093e0d-b2c6-4405-bccb-bf6e5bdf87ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_854c8f3b-9e41-4d88-93fa-e37734c6dffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_854c8f3b-9e41-4d88-93fa-e37734c6dffd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_66ce626c-a311-4419-820c-d0b4fd4369a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_StatementTable_66ce626c-a311-4419-820c-d0b4fd4369a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b9fe4fab-0a80-453e-b551-67399f72dc38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_66ce626c-a311-4419-820c-d0b4fd4369a4" xlink:to="loc_srt_ProductOrServiceAxis_b9fe4fab-0a80-453e-b551-67399f72dc38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b9fe4fab-0a80-453e-b551-67399f72dc38_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b9fe4fab-0a80-453e-b551-67399f72dc38" xlink:to="loc_srt_ProductsAndServicesDomain_b9fe4fab-0a80-453e-b551-67399f72dc38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b9fe4fab-0a80-453e-b551-67399f72dc38" xlink:to="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_658ef9b2-0b8b-4b5d-8cd2-49f978f572d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:to="loc_us-gaap_ProductMember_658ef9b2-0b8b-4b5d-8cd2-49f978f572d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d56b23bf-9c8f-45a9-8395-0570a72ef3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d56b23bf-9c8f-45a9-8395-0570a72ef3bf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i436b33c8c9464ec7b93cd97b0bb84fe9_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1c57472-fad5-4279-a037-b8f6e7245bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c1c57472-fad5-4279-a037-b8f6e7245bab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a20f7672-63e2-4d70-ac08-b34cccff5d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_CommonStockSharesIssued_a20f7672-63e2-4d70-ac08-b34cccff5d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70852b87-4a8a-4a67-9ce8-eb37b0cdf21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70852b87-4a8a-4a67-9ce8-eb37b0cdf21b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cb2dc637-91e3-407a-a3bd-7817d6674f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cb2dc637-91e3-407a-a3bd-7817d6674f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f9f459-23fb-406e-b24c-f4e5a607aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f9f459-23fb-406e-b24c-f4e5a607aa87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4a7fb5fc-b83a-4889-826e-496d0f1b5ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4a7fb5fc-b83a-4889-826e-496d0f1b5ed9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7332738-a684-4b8c-915d-fe1327b56bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7332738-a684-4b8c-915d-fe1327b56bbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_52ae8fb4-ec1f-4622-be95-2b280c5fbce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_52ae8fb4-ec1f-4622-be95-2b280c5fbce2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_faad2af9-b50f-4084-ac8f-a16a3c4d01a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_faad2af9-b50f-4084-ac8f-a16a3c4d01a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c57be3fc-c62c-48bb-bb5f-56ef46ab1337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c57be3fc-c62c-48bb-bb5f-56ef46ab1337" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3718a256-9799-4d68-8514-df5f50dfcf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_ProfitLoss_3718a256-9799-4d68-8514-df5f50dfcf55" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c41bab6-0ee5-4c0a-9b9b-c226c43012ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c41bab6-0ee5-4c0a-9b9b-c226c43012ef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bb8e18df-a9f3-4e6a-bc83-0912234b1f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1128c6d1-f5a3-4e04-a05e-ee6ed27026ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6be7cfb3-d9c8-4974-b069-de69135c34f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c1c57472-fad5-4279-a037-b8f6e7245bab" xlink:to="loc_us-gaap_StatementTable_6be7cfb3-d9c8-4974-b069-de69135c34f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7b67464d-0a8e-4260-b50e-cdf2e43695c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6be7cfb3-d9c8-4974-b069-de69135c34f1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7b67464d-0a8e-4260-b50e-cdf2e43695c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b67464d-0a8e-4260-b50e-cdf2e43695c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7b67464d-0a8e-4260-b50e-cdf2e43695c4" xlink:to="loc_us-gaap_EquityComponentDomain_7b67464d-0a8e-4260-b50e-cdf2e43695c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7b67464d-0a8e-4260-b50e-cdf2e43695c4" xlink:to="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:to="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f4fefba-3c39-44ac-a731-734f2f8cb311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_CommonStockMember_7f4fefba-3c39-44ac-a731-734f2f8cb311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e6a77d86-a60a-4e7e-b013-31fd7099afb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e6a77d86-a60a-4e7e-b013-31fd7099afb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dafb4ee1-c55d-419a-85f6-865ad3c00d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_RetainedEarningsMember_dafb4ee1-c55d-419a-85f6-865ad3c00d08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9638734f-1147-4945-9ec0-adfa49dbeda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9638734f-1147-4945-9ec0-adfa49dbeda1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f2c294ef-4cb8-4cc6-a254-199be1f678c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f2c294ef-4cb8-4cc6-a254-199be1f678c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended" id="ibac4fd26b4af4772a5e798303cb68b27_DESCRIPTIONOFBUSINESSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_ba7f638b-3706-4a7d-a2f3-eaf87dbd0612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b0dbba99-5561-40fe-aa56-25bd0b8d06bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_ba7f638b-3706-4a7d-a2f3-eaf87dbd0612" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b0dbba99-5561-40fe-aa56-25bd0b8d06bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d123fb9b-6420-4431-af95-b73b63ddfad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_ba7f638b-3706-4a7d-a2f3-eaf87dbd0612" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d123fb9b-6420-4431-af95-b73b63ddfad8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4e339aec-3191-4c68-a3a1-1bcd41a3c582" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d123fb9b-6420-4431-af95-b73b63ddfad8" xlink:to="loc_srt_OwnershipAxis_4e339aec-3191-4c68-a3a1-1bcd41a3c582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4e339aec-3191-4c68-a3a1-1bcd41a3c582_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4e339aec-3191-4c68-a3a1-1bcd41a3c582" xlink:to="loc_srt_OwnershipDomain_4e339aec-3191-4c68-a3a1-1bcd41a3c582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_53efdd4f-0978-4016-97ba-9fa46292db54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4e339aec-3191-4c68-a3a1-1bcd41a3c582" xlink:to="loc_srt_OwnershipDomain_53efdd4f-0978-4016-97ba-9fa46292db54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e59a2a00-5c37-41f7-a73d-28dbdbbbd2ba" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_53efdd4f-0978-4016-97ba-9fa46292db54" xlink:to="loc_bhc_BauschLombMember_e59a2a00-5c37-41f7-a73d-28dbdbbbd2ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="i51a5b52e43284a0980417c0cffaea787_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a497883d-18f2-4d6a-9170-d3e03b278e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a497883d-18f2-4d6a-9170-d3e03b278e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e5cb6d70-ef0f-484a-a490-2e1c22f8d929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e5cb6d70-ef0f-484a-a490-2e1c22f8d929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_20249c51-4e7d-4687-a758-29615dd8fa53" xlink:href="bhc-20220930.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_20249c51-4e7d-4687-a758-29615dd8fa53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_222572cc-e5fc-4e45-9614-ee68eef74212" xlink:href="bhc-20220930.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_222572cc-e5fc-4e45-9614-ee68eef74212" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_93244d33-d05b-4c90-a424-e36beb3f81ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_93244d33-d05b-4c90-a424-e36beb3f81ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_2a373128-267c-4115-844f-1117bc5b68fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_2a373128-267c-4115-844f-1117bc5b68fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99e78bae-2fb8-4b5f-bbe0-2630d4de314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99e78bae-2fb8-4b5f-bbe0-2630d4de314e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_57571f5d-fa61-4daa-a28d-d2b2b587a964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_57571f5d-fa61-4daa-a28d-d2b2b587a964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57571f5d-fa61-4daa-a28d-d2b2b587a964_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57571f5d-fa61-4daa-a28d-d2b2b587a964" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_57571f5d-fa61-4daa-a28d-d2b2b587a964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4add042e-fead-43fb-b2f1-86d7d488770b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57571f5d-fa61-4daa-a28d-d2b2b587a964" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4add042e-fead-43fb-b2f1-86d7d488770b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:href="bhc-20220930.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4add042e-fead-43fb-b2f1-86d7d488770b" xlink:to="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_231af541-7304-4cf0-a33d-0f0b013045c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:to="loc_us-gaap_IPOMember_231af541-7304-4cf0-a33d-0f0b013045c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a407249b-cdf8-4abf-9d44-e7086375232c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a407249b-cdf8-4abf-9d44-e7086375232c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:to="loc_srt_OwnershipAxis_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31" xlink:to="loc_srt_OwnershipDomain_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6d440d9c-79f3-4469-b5d9-4f669ab6ce74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31" xlink:to="loc_srt_OwnershipDomain_6d440d9c-79f3-4469-b5d9-4f669ab6ce74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_055184c4-8165-4811-89ee-239624fffd56" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6d440d9c-79f3-4469-b5d9-4f669ab6ce74" xlink:to="loc_bhc_BauschLombMember_055184c4-8165-4811-89ee-239624fffd56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended" id="i04063d1e95d742049df56533e1eba315_REVENUERECOGNITIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_47d992a9-db0e-4a64-9275-82fc24089321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_47d992a9-db0e-4a64-9275-82fc24089321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_cbf65ade-2e25-4690-b682-3161f81d48ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_cbf65ade-2e25-4690-b682-3161f81d48ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ab325755-5656-4f72-a544-780fb65a61f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ab325755-5656-4f72-a544-780fb65a61f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb71d793-bfc6-47d6-86f7-e2482067b768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb71d793-bfc6-47d6-86f7-e2482067b768" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_aa71679b-eeaf-40bc-a609-80af01c84f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_aa71679b-eeaf-40bc-a609-80af01c84f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_aa71679b-eeaf-40bc-a609-80af01c84f2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_aa71679b-eeaf-40bc-a609-80af01c84f2c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_aa71679b-eeaf-40bc-a609-80af01c84f2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_aa71679b-eeaf-40bc-a609-80af01c84f2c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_1a546206-d0ab-4fd9-9c69-a03549d75300" xlink:href="bhc-20220930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_1a546206-d0ab-4fd9-9c69-a03549d75300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_ce53b15b-9249-4905-bdf0-9a699eb70e1e" xlink:href="bhc-20220930.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_ce53b15b-9249-4905-bdf0-9a699eb70e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a8ba3913-d668-4d74-b885-6bdc26fcb1a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:to="loc_srt_ProductOrServiceAxis_a8ba3913-d668-4d74-b885-6bdc26fcb1a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8ba3913-d668-4d74-b885-6bdc26fcb1a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a8ba3913-d668-4d74-b885-6bdc26fcb1a6" xlink:to="loc_srt_ProductsAndServicesDomain_a8ba3913-d668-4d74-b885-6bdc26fcb1a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89103dcd-cce5-49bf-8193-861a9743b360" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a8ba3913-d668-4d74-b885-6bdc26fcb1a6" xlink:to="loc_srt_ProductsAndServicesDomain_89103dcd-cce5-49bf-8193-861a9743b360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_8d450dea-be23-43ca-bc40-a7178375439c" xlink:href="bhc-20220930.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89103dcd-cce5-49bf-8193-861a9743b360" xlink:to="loc_bhc_PriceAppreciationCreditMember_8d450dea-be23-43ca-bc40-a7178375439c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended" id="i9764a050450b49da92808653debd1b59_REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d76b923a-7fb6-40b5-9db9-4c7a67c72cc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d76b923a-7fb6-40b5-9db9-4c7a67c72cc1" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6eb3e926-809c-4a5a-9d41-390dda6c1f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6eb3e926-809c-4a5a-9d41-390dda6c1f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_243ce3a2-921e-4ab7-af04-4334cc36f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_243ce3a2-921e-4ab7-af04-4334cc36f1f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c39e9c86-50e8-4eba-a8d9-c38f2ec9d172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c39e9c86-50e8-4eba-a8d9-c38f2ec9d172" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_158790ed-9784-4fbd-9e0d-aab146d6b5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1d180f1c-bd3a-4fce-8077-01b0bac4b320" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d76b923a-7fb6-40b5-9db9-4c7a67c72cc1" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1d180f1c-bd3a-4fce-8077-01b0bac4b320" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_05dd4ba7-0dac-47c0-b517-92059f055cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1d180f1c-bd3a-4fce-8077-01b0bac4b320" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_05dd4ba7-0dac-47c0-b517-92059f055cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_05dd4ba7-0dac-47c0-b517-92059f055cf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_05dd4ba7-0dac-47c0-b517-92059f055cf1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_05dd4ba7-0dac-47c0-b517-92059f055cf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_05dd4ba7-0dac-47c0-b517-92059f055cf1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_2d99e5df-f459-4266-b6ef-5cc82c292fa8" xlink:href="bhc-20220930.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_2d99e5df-f459-4266-b6ef-5cc82c292fa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_d5b80c23-6b6a-4606-ade6-c6cdd3e68526" xlink:href="bhc-20220930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_d5b80c23-6b6a-4606-ade6-c6cdd3e68526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_2c3fcb0d-7e45-4782-9b13-d7920ac3c716" xlink:href="bhc-20220930.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForRebatesMember_2c3fcb0d-7e45-4782-9b13-d7920ac3c716" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_1d4038f6-f971-4e3f-b20f-4f9689eda610" xlink:href="bhc-20220930.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForChargebacksMember_1d4038f6-f971-4e3f-b20f-4f9689eda610" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_6266cad1-0318-46b0-878c-50295f5d53ae" xlink:href="bhc-20220930.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForDistributionFeesMember_6266cad1-0318-46b0-878c-50295f5d53ae" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended" id="i65e25e2a695940babf2661e8c1594bd2_LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ef1ecd0f-ec3a-492d-9f51-d02c2cade1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ef1ecd0f-ec3a-492d-9f51-d02c2cade1ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_75543381-0f95-4dbb-99b4-f4575db5b119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_75543381-0f95-4dbb-99b4-f4575db5b119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_6a78be57-3882-49fb-ac44-920adf4dcf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_6a78be57-3882-49fb-ac44-920adf4dcf46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_708c30a9-6625-4c01-a8fe-03a80f0e65ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_708c30a9-6625-4c01-a8fe-03a80f0e65ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_708c30a9-6625-4c01-a8fe-03a80f0e65ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_708c30a9-6625-4c01-a8fe-03a80f0e65ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_708c30a9-6625-4c01-a8fe-03a80f0e65ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c61d2f8e-0517-4702-a577-71064ea58a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_708c30a9-6625-4c01-a8fe-03a80f0e65ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c61d2f8e-0517-4702-a577-71064ea58a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_34300b0b-b821-4de9-ae25-f38a218bc767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c61d2f8e-0517-4702-a577-71064ea58a6d" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_34300b0b-b821-4de9-ae25-f38a218bc767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_564b716b-275a-4ce1-9d19-0e1e0a63586a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_564b716b-275a-4ce1-9d19-0e1e0a63586a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_564b716b-275a-4ce1-9d19-0e1e0a63586a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_564b716b-275a-4ce1-9d19-0e1e0a63586a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_564b716b-275a-4ce1-9d19-0e1e0a63586a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d1adb0f-bb65-4f7b-9819-27efcef0e8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_564b716b-275a-4ce1-9d19-0e1e0a63586a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d1adb0f-bb65-4f7b-9819-27efcef0e8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_d03b5a9d-fbd1-4235-be6e-45c655310c15" xlink:href="bhc-20220930.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d1adb0f-bb65-4f7b-9819-27efcef0e8a7" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_d03b5a9d-fbd1-4235-be6e-45c655310c15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_da8d5e82-d43e-45a6-8a0d-51fb2e980f9b" xlink:href="bhc-20220930.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:to="loc_bhc_AssetImpairmentChargesMember_da8d5e82-d43e-45a6-8a0d-51fb2e980f9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_973af61d-7b5c-44ad-ade9-785ac30ef32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_973af61d-7b5c-44ad-ade9-785ac30ef32d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended" id="i24262e50939c4731ac040e120e42c213_RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4c9f7d27-2ce2-405f-9f87-73492c86ffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_RestructuringReserve_4c9f7d27-2ce2-405f-9f87-73492c86ffd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8a8e0e07-cba1-481a-9fc6-9939605a3596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8a8e0e07-cba1-481a-9fc6-9939605a3596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_78ad2c37-2027-4aa4-8a4e-fd6a29b4a911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_PaymentsForRestructuring_78ad2c37-2027-4aa4-8a4e-fd6a29b4a911" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_54b32768-ce64-4634-b1bd-57f25ed5776d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_RestructuringCharges_54b32768-ce64-4634-b1bd-57f25ed5776d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f3595742-ac35-4d8b-92b9-1a38f4b44fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f3595742-ac35-4d8b-92b9-1a38f4b44fbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_80de7851-2725-4fe8-b204-81cc533ba934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_80de7851-2725-4fe8-b204-81cc533ba934" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_271b5583-330e-4bad-9007-d797a4f7979e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_80de7851-2725-4fe8-b204-81cc533ba934" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_271b5583-330e-4bad-9007-d797a4f7979e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_271b5583-330e-4bad-9007-d797a4f7979e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_271b5583-330e-4bad-9007-d797a4f7979e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_271b5583-330e-4bad-9007-d797a4f7979e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_271b5583-330e-4bad-9007-d797a4f7979e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_2ea6c531-28f1-4032-8327-6734d6229a5e" xlink:href="bhc-20220930.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_2ea6c531-28f1-4032-8327-6734d6229a5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_98e4a9c2-08fe-4984-a279-f9b82c704983" xlink:href="bhc-20220930.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_98e4a9c2-08fe-4984-a279-f9b82c704983" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i8fd2995d870a4fc6a78bd3a67c3f988f_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_06f77cf8-dbfe-4ec0-b962-8f7f652a7454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_06f77cf8-dbfe-4ec0-b962-8f7f652a7454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_f2b7aaca-a36e-4e90-88d0-68d25d693def" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_f2b7aaca-a36e-4e90-88d0-68d25d693def" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a144c863-2c0b-4ec3-bc7d-4fab22b3238c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:to="loc_us-gaap_DerivativeAssets_a144c863-2c0b-4ec3-bc7d-4fab22b3238c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_90d5311f-6d05-473a-a7d4-72575dc5e6e6" xlink:href="bhc-20220930.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_90d5311f-6d05-473a-a7d4-72575dc5e6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_950bf58b-6c17-4451-889b-a484d42debf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:to="loc_us-gaap_DerivativeLiabilities_950bf58b-6c17-4451-889b-a484d42debf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0197388-229e-42b6-bbf7-4f4800e1f4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0197388-229e-42b6-bbf7-4f4800e1f4cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f0197388-229e-42b6-bbf7-4f4800e1f4cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0197388-229e-42b6-bbf7-4f4800e1f4cd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f0197388-229e-42b6-bbf7-4f4800e1f4cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2c58353-ee16-4eee-a931-dc1b0323c7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0197388-229e-42b6-bbf7-4f4800e1f4cd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2c58353-ee16-4eee-a931-dc1b0323c7a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8ba03c56-0c03-40ce-ab48-1d159fc76785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2c58353-ee16-4eee-a931-dc1b0323c7a0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8ba03c56-0c03-40ce-ab48-1d159fc76785" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21e9cf07-9196-424b-9f60-05ff2f58677e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21e9cf07-9196-424b-9f60-05ff2f58677e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21e9cf07-9196-424b-9f60-05ff2f58677e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21e9cf07-9196-424b-9f60-05ff2f58677e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21e9cf07-9196-424b-9f60-05ff2f58677e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21e9cf07-9196-424b-9f60-05ff2f58677e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e8a8a784-6e20-4a45-88ad-c2ed5e0b8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e8a8a784-6e20-4a45-88ad-c2ed5e0b8e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55e230c1-a47f-483f-83ab-192f0567fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55e230c1-a47f-483f-83ab-192f0567fb0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_04da5792-d2c7-4f05-8554-a95e95b4f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_04da5792-d2c7-4f05-8554-a95e95b4f59a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5432b237-d2a8-478c-a10c-27d3635e46fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5432b237-d2a8-478c-a10c-27d3635e46fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5432b237-d2a8-478c-a10c-27d3635e46fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5432b237-d2a8-478c-a10c-27d3635e46fe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5432b237-d2a8-478c-a10c-27d3635e46fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5432b237-d2a8-478c-a10c-27d3635e46fe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a255c9a5-3d24-49d4-b9c3-fe9152ddebde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a255c9a5-3d24-49d4-b9c3-fe9152ddebde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_772f524b-5251-44cd-8faf-9600edcfe323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:to="loc_us-gaap_CurrencySwapMember_772f524b-5251-44cd-8faf-9600edcfe323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ef8fc964-aa30-4b1f-9224-d60d41bb4e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_HedgingDesignationAxis_ef8fc964-aa30-4b1f-9224-d60d41bb4e29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ef8fc964-aa30-4b1f-9224-d60d41bb4e29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ef8fc964-aa30-4b1f-9224-d60d41bb4e29" xlink:to="loc_us-gaap_HedgingDesignationDomain_ef8fc964-aa30-4b1f-9224-d60d41bb4e29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ef8fc964-aa30-4b1f-9224-d60d41bb4e29" xlink:to="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_d3870f7d-3a7d-4ea6-a5ba-b92eda164472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:to="loc_us-gaap_NondesignatedMember_d3870f7d-3a7d-4ea6-a5ba-b92eda164472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e40b65b7-2b34-483f-8969-fbedecab6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e40b65b7-2b34-483f-8969-fbedecab6fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d745417f-fd01-4b4a-933b-4eee153845e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d745417f-fd01-4b4a-933b-4eee153845e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d745417f-fd01-4b4a-933b-4eee153845e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d745417f-fd01-4b4a-933b-4eee153845e7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d745417f-fd01-4b4a-933b-4eee153845e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2de162ae-2296-4aa5-93dc-7179714929e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d745417f-fd01-4b4a-933b-4eee153845e7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2de162ae-2296-4aa5-93dc-7179714929e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d524a814-d749-43c0-9425-0dfc75f08dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2de162ae-2296-4aa5-93dc-7179714929e0" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d524a814-d749-43c0-9425-0dfc75f08dba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_88b402f6-13b4-4d57-b65d-e64b7a7a70b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_dei_LegalEntityAxis_88b402f6-13b4-4d57-b65d-e64b7a7a70b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_88b402f6-13b4-4d57-b65d-e64b7a7a70b6_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_88b402f6-13b4-4d57-b65d-e64b7a7a70b6" xlink:to="loc_dei_EntityDomain_88b402f6-13b4-4d57-b65d-e64b7a7a70b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_607f5864-03d5-469f-a370-a468325f5ce4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_88b402f6-13b4-4d57-b65d-e64b7a7a70b6" xlink:to="loc_dei_EntityDomain_607f5864-03d5-469f-a370-a468325f5ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3e196c8a-5ca3-4b3d-964f-b288744828e9" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_607f5864-03d5-469f-a370-a468325f5ce4" xlink:to="loc_bhc_BauschLombMember_3e196c8a-5ca3-4b3d-964f-b288744828e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended" id="i224d7d4e2ed4461eb6b2e66665218238_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_4a6e53b7-3899-4832-9f42-d1382b159456" xlink:href="bhc-20220930.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_4a6e53b7-3899-4832-9f42-d1382b159456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9a67940d-c278-4119-99ac-6ba7e26e63b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9a67940d-c278-4119-99ac-6ba7e26e63b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_36668ad0-79a6-4ebe-8a6f-3d1e9d4c9339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_36668ad0-79a6-4ebe-8a6f-3d1e9d4c9339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_42fb4783-de76-4fbc-9e13-4431b9204791" xlink:href="bhc-20220930.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_42fb4783-de76-4fbc-9e13-4431b9204791" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_af78a5e5-2bc0-4a5c-8f71-d92f183762da" xlink:href="bhc-20220930.xsd#bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_af78a5e5-2bc0-4a5c-8f71-d92f183762da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_926f7153-2087-4b44-b5dd-897039e9cbcf" xlink:href="bhc-20220930.xsd#bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_926f7153-2087-4b44-b5dd-897039e9cbcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_06ce0be0-cdca-4658-9a76-e1827d8c15f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_srt_LitigationCaseAxis_06ce0be0-cdca-4658-9a76-e1827d8c15f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_06ce0be0-cdca-4658-9a76-e1827d8c15f4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_06ce0be0-cdca-4658-9a76-e1827d8c15f4" xlink:to="loc_srt_LitigationCaseTypeDomain_06ce0be0-cdca-4658-9a76-e1827d8c15f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_10ddff63-e488-40db-a7af-94522ba2b675" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_06ce0be0-cdca-4658-9a76-e1827d8c15f4" xlink:to="loc_srt_LitigationCaseTypeDomain_10ddff63-e488-40db-a7af-94522ba2b675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_c402cc69-7b02-4b36-b2be-2a552d6e0756" xlink:href="bhc-20220930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_10ddff63-e488-40db-a7af-94522ba2b675" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_c402cc69-7b02-4b36-b2be-2a552d6e0756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_58284fab-3056-4973-a1a8-78ddfbbaa44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_us-gaap_LitigationStatusAxis_58284fab-3056-4973-a1a8-78ddfbbaa44c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_58284fab-3056-4973-a1a8-78ddfbbaa44c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_58284fab-3056-4973-a1a8-78ddfbbaa44c" xlink:to="loc_us-gaap_LitigationStatusDomain_58284fab-3056-4973-a1a8-78ddfbbaa44c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ffe34c3e-217e-4c26-98b2-1127a7fe83ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_58284fab-3056-4973-a1a8-78ddfbbaa44c" xlink:to="loc_us-gaap_LitigationStatusDomain_ffe34c3e-217e-4c26-98b2-1127a7fe83ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d7da6e0d-c2f4-476d-9df7-820483c226ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ffe34c3e-217e-4c26-98b2-1127a7fe83ad" xlink:to="loc_us-gaap_SettledLitigationMember_d7da6e0d-c2f4-476d-9df7-820483c226ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_12431768-8048-4962-ad0b-1f4719118997" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_srt_StatementGeographicalAxis_12431768-8048-4962-ad0b-1f4719118997" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_12431768-8048-4962-ad0b-1f4719118997_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_12431768-8048-4962-ad0b-1f4719118997" xlink:to="loc_srt_SegmentGeographicalDomain_12431768-8048-4962-ad0b-1f4719118997_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5074584-2749-4c1d-9eb1-3348137b3161" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_12431768-8048-4962-ad0b-1f4719118997" xlink:to="loc_srt_SegmentGeographicalDomain_f5074584-2749-4c1d-9eb1-3348137b3161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_641216af-3b8f-48f9-a01f-2b5eb7fef63c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f5074584-2749-4c1d-9eb1-3348137b3161" xlink:to="loc_stpr_NJ_641216af-3b8f-48f9-a01f-2b5eb7fef63c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f926e837-4833-4020-8700-d98adf7dfedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_dei_LegalEntityAxis_f926e837-4833-4020-8700-d98adf7dfedf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f926e837-4833-4020-8700-d98adf7dfedf_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f926e837-4833-4020-8700-d98adf7dfedf" xlink:to="loc_dei_EntityDomain_f926e837-4833-4020-8700-d98adf7dfedf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_80008db2-bc62-40c1-aa39-0c67f5116719" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f926e837-4833-4020-8700-d98adf7dfedf" xlink:to="loc_dei_EntityDomain_80008db2-bc62-40c1-aa39-0c67f5116719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_b8032ed4-33bf-455a-83fb-fda497d6e8ad" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_80008db2-bc62-40c1-aa39-0c67f5116719" xlink:to="loc_bhc_BauschLombMember_b8032ed4-33bf-455a-83fb-fda497d6e8ad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="ib3ad264cdb524a1e910c888ceddb283b_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7a689d1a-8783-46b4-b001-720cd008b2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7a689d1a-8783-46b4-b001-720cd008b2af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d004d730-8040-4b6e-9685-6caf9285f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d004d730-8040-4b6e-9685-6caf9285f3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_428c5747-9e9f-4caf-a329-72f9028cd02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_428c5747-9e9f-4caf-a329-72f9028cd02b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_428c5747-9e9f-4caf-a329-72f9028cd02b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_428c5747-9e9f-4caf-a329-72f9028cd02b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_428c5747-9e9f-4caf-a329-72f9028cd02b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_14a24f8a-f03d-4654-a19d-b3a6ad0f17ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_428c5747-9e9f-4caf-a329-72f9028cd02b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_14a24f8a-f03d-4654-a19d-b3a6ad0f17ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_77e845eb-02bd-42fa-8f80-b6e7e891a6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_14a24f8a-f03d-4654-a19d-b3a6ad0f17ca" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_77e845eb-02bd-42fa-8f80-b6e7e891a6de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_45684d1d-0491-45d7-949d-0f46bd9f7fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_45684d1d-0491-45d7-949d-0f46bd9f7fce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_45684d1d-0491-45d7-949d-0f46bd9f7fce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45684d1d-0491-45d7-949d-0f46bd9f7fce" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_45684d1d-0491-45d7-949d-0f46bd9f7fce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_797e3e0e-b31c-4464-829b-87bca53155f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45684d1d-0491-45d7-949d-0f46bd9f7fce" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_797e3e0e-b31c-4464-829b-87bca53155f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ae7beb09-8305-4c09-b25e-c5c72ae9863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_797e3e0e-b31c-4464-829b-87bca53155f4" xlink:to="loc_us-gaap_CurrencySwapMember_ae7beb09-8305-4c09-b25e-c5c72ae9863c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e7d42dce-367b-49da-8d02-c8d9207564b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_us-gaap_HedgingDesignationAxis_e7d42dce-367b-49da-8d02-c8d9207564b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e7d42dce-367b-49da-8d02-c8d9207564b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_e7d42dce-367b-49da-8d02-c8d9207564b0" xlink:to="loc_us-gaap_HedgingDesignationDomain_e7d42dce-367b-49da-8d02-c8d9207564b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_83881e97-f5da-431a-960d-754945aecdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_e7d42dce-367b-49da-8d02-c8d9207564b0" xlink:to="loc_us-gaap_HedgingDesignationDomain_83881e97-f5da-431a-960d-754945aecdf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5595e6cc-dd62-44a3-9ee3-9c341590f0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_83881e97-f5da-431a-960d-754945aecdf3" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5595e6cc-dd62-44a3-9ee3-9c341590f0f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d649d332-5c45-4b32-8776-142d74ee2f5b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_dei_LegalEntityAxis_d649d332-5c45-4b32-8776-142d74ee2f5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d649d332-5c45-4b32-8776-142d74ee2f5b_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d649d332-5c45-4b32-8776-142d74ee2f5b" xlink:to="loc_dei_EntityDomain_d649d332-5c45-4b32-8776-142d74ee2f5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6011fc05-69df-4b9b-9e76-d2f93f4f6b16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d649d332-5c45-4b32-8776-142d74ee2f5b" xlink:to="loc_dei_EntityDomain_6011fc05-69df-4b9b-9e76-d2f93f4f6b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_dbb2a718-4b19-4f99-a75a-c82084ff08b7" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6011fc05-69df-4b9b-9e76-d2f93f4f6b16" xlink:to="loc_bhc_BauschLombMember_dbb2a718-4b19-4f99-a75a-c82084ff08b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i39216c24f9fd44b7b97d12618dbf6410_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cba6d99d-4725-4dfc-a7bf-d65e663c6b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_e24595d2-57b0-411a-a34f-ec68e5fdf2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cba6d99d-4725-4dfc-a7bf-d65e663c6b59" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_e24595d2-57b0-411a-a34f-ec68e5fdf2ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cba6d99d-4725-4dfc-a7bf-d65e663c6b59" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_46579846-67e7-4cb5-a51b-bbc0e982b23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_46579846-67e7-4cb5-a51b-bbc0e982b23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_46579846-67e7-4cb5-a51b-bbc0e982b23d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_46579846-67e7-4cb5-a51b-bbc0e982b23d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_46579846-67e7-4cb5-a51b-bbc0e982b23d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_46579846-67e7-4cb5-a51b-bbc0e982b23d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4c2110ad-06c5-453c-a97c-8b9da6b42bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4c2110ad-06c5-453c-a97c-8b9da6b42bee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_da983371-5b05-466c-adce-b870e9736eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_da983371-5b05-466c-adce-b870e9736eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_72d8a829-e314-4e54-8109-a28c036db91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_72d8a829-e314-4e54-8109-a28c036db91e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_72d8a829-e314-4e54-8109-a28c036db91e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_72d8a829-e314-4e54-8109-a28c036db91e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_72d8a829-e314-4e54-8109-a28c036db91e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_05f9ece9-781d-4b63-9558-e52a0ef9a365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_72d8a829-e314-4e54-8109-a28c036db91e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_05f9ece9-781d-4b63-9558-e52a0ef9a365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_e0a54020-e0c6-46dd-9085-05c7b1cbba00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05f9ece9-781d-4b63-9558-e52a0ef9a365" xlink:to="loc_us-gaap_CurrencySwapMember_e0a54020-e0c6-46dd-9085-05c7b1cbba00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_26c31906-48ad-466a-863e-3f38d28b14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_26c31906-48ad-466a-863e-3f38d28b14bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_26c31906-48ad-466a-863e-3f38d28b14bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_26c31906-48ad-466a-863e-3f38d28b14bc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_26c31906-48ad-466a-863e-3f38d28b14bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b24b06d7-2207-4999-94f4-6ddeb46fd6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_26c31906-48ad-466a-863e-3f38d28b14bc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b24b06d7-2207-4999-94f4-6ddeb46fd6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_92c2df23-572f-4cdf-8553-42e754f50173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b24b06d7-2207-4999-94f4-6ddeb46fd6a9" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_92c2df23-572f-4cdf-8553-42e754f50173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c8f26cbb-a133-4f9f-b370-99d9d35dafa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_HedgingDesignationAxis_c8f26cbb-a133-4f9f-b370-99d9d35dafa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c8f26cbb-a133-4f9f-b370-99d9d35dafa7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c8f26cbb-a133-4f9f-b370-99d9d35dafa7" xlink:to="loc_us-gaap_HedgingDesignationDomain_c8f26cbb-a133-4f9f-b370-99d9d35dafa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_aebe1f8b-0724-4a56-a699-7b64ff8a93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c8f26cbb-a133-4f9f-b370-99d9d35dafa7" xlink:to="loc_us-gaap_HedgingDesignationDomain_aebe1f8b-0724-4a56-a699-7b64ff8a93b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f12db573-2279-4512-8404-4963c665173b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_aebe1f8b-0724-4a56-a699-7b64ff8a93b4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f12db573-2279-4512-8404-4963c665173b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1eada976-b493-41db-8440-afc8ce7b202d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_dei_LegalEntityAxis_1eada976-b493-41db-8440-afc8ce7b202d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1eada976-b493-41db-8440-afc8ce7b202d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1eada976-b493-41db-8440-afc8ce7b202d" xlink:to="loc_dei_EntityDomain_1eada976-b493-41db-8440-afc8ce7b202d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_77261e94-5a88-4a32-8123-3ee180146330" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1eada976-b493-41db-8440-afc8ce7b202d" xlink:to="loc_dei_EntityDomain_77261e94-5a88-4a32-8123-3ee180146330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f144e2d1-c9da-4b3b-ae52-d5faa0d7b44a" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_77261e94-5a88-4a32-8123-3ee180146330" xlink:to="loc_bhc_BauschLombMember_f144e2d1-c9da-4b3b-ae52-d5faa0d7b44a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="i3a7e30af41fb46658bb7b65cb9d5bc5d_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_becb911c-6093-44a3-898d-22f18ed4a551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_becb911c-6093-44a3-898d-22f18ed4a551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_6598c67e-41f2-4f9d-a6bb-5d989f6dc1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_6598c67e-41f2-4f9d-a6bb-5d989f6dc1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f6a1a878-127a-4f13-b277-a902a87ae72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f6a1a878-127a-4f13-b277-a902a87ae72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_4f907360-b111-4333-8465-eaee68e8d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6a1a878-127a-4f13-b277-a902a87ae72e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_4f907360-b111-4333-8465-eaee68e8d5cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f1c8c565-d6ad-4756-969f-dfb109ca4b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f1c8c565-d6ad-4756-969f-dfb109ca4b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_fcb13c71-bdb8-4839-ac94-9430a5792326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f1c8c565-d6ad-4756-969f-dfb109ca4b76" xlink:to="loc_us-gaap_CurrencySwapMember_fcb13c71-bdb8-4839-ac94-9430a5792326" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_HedgingDesignationAxis_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb" xlink:to="loc_us-gaap_HedgingDesignationDomain_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e0cba37e-1629-4493-b2ae-dd4fe2516577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb" xlink:to="loc_us-gaap_HedgingDesignationDomain_e0cba37e-1629-4493-b2ae-dd4fe2516577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_855d5a1d-4795-4d9d-9ea6-8f24b18c5ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e0cba37e-1629-4493-b2ae-dd4fe2516577" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_855d5a1d-4795-4d9d-9ea6-8f24b18c5ab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_54204c0f-9329-48c9-af9a-4184c18f5aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_54204c0f-9329-48c9-af9a-4184c18f5aac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54204c0f-9329-48c9-af9a-4184c18f5aac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54204c0f-9329-48c9-af9a-4184c18f5aac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54204c0f-9329-48c9-af9a-4184c18f5aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345099c7-b9a3-4d3a-a12f-27500cd4606b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54204c0f-9329-48c9-af9a-4184c18f5aac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345099c7-b9a3-4d3a-a12f-27500cd4606b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_763b0094-da64-40ec-93a1-00da37f0adf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345099c7-b9a3-4d3a-a12f-27500cd4606b" xlink:to="loc_us-gaap_InterestExpenseMember_763b0094-da64-40ec-93a1-00da37f0adf4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="idbefc7468fc7426e83aea1919266da4f_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c31de7c-43ac-4827-b762-521118dc7764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9ea82527-5bb8-405c-94f7-b8b56bb89245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c31de7c-43ac-4827-b762-521118dc7764" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9ea82527-5bb8-405c-94f7-b8b56bb89245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c31de7c-43ac-4827-b762-521118dc7764" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_afcff991-952f-410e-9c00-41d851b6041a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:to="loc_us-gaap_HedgingDesignationAxis_afcff991-952f-410e-9c00-41d851b6041a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_afcff991-952f-410e-9c00-41d851b6041a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_afcff991-952f-410e-9c00-41d851b6041a" xlink:to="loc_us-gaap_HedgingDesignationDomain_afcff991-952f-410e-9c00-41d851b6041a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_09e5fe23-6c0f-4810-9a97-e0665906325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_afcff991-952f-410e-9c00-41d851b6041a" xlink:to="loc_us-gaap_HedgingDesignationDomain_09e5fe23-6c0f-4810-9a97-e0665906325e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_625f05e3-ff67-4a65-85dc-37c52595ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_09e5fe23-6c0f-4810-9a97-e0665906325e" xlink:to="loc_us-gaap_NondesignatedMember_625f05e3-ff67-4a65-85dc-37c52595ff97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e081f74d-7f62-46c4-813d-4081028d536f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e081f74d-7f62-46c4-813d-4081028d536f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e081f74d-7f62-46c4-813d-4081028d536f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e081f74d-7f62-46c4-813d-4081028d536f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e081f74d-7f62-46c4-813d-4081028d536f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9007ee2f-199d-47fc-8137-fdc8e0cce045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e081f74d-7f62-46c4-813d-4081028d536f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9007ee2f-199d-47fc-8137-fdc8e0cce045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a86f0ebb-4190-42c1-8416-17f50e1b2074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9007ee2f-199d-47fc-8137-fdc8e0cce045" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a86f0ebb-4190-42c1-8416-17f50e1b2074" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i7c25568f7df2403ea2671e00bfe28dea_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c70d7caf-beab-4ea3-beec-bf65a0ce7f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_542c828d-7d5a-4a3f-9534-5ce9f10893ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c70d7caf-beab-4ea3-beec-bf65a0ce7f40" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_542c828d-7d5a-4a3f-9534-5ce9f10893ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c70d7caf-beab-4ea3-beec-bf65a0ce7f40" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fb713eb3-7910-4eb0-86a7-1d833a8f253e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fb713eb3-7910-4eb0-86a7-1d833a8f253e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fb713eb3-7910-4eb0-86a7-1d833a8f253e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fb713eb3-7910-4eb0-86a7-1d833a8f253e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fb713eb3-7910-4eb0-86a7-1d833a8f253e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fb713eb3-7910-4eb0-86a7-1d833a8f253e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_3f7a4c41-fc31-4a58-b839-2bf01ff6b415" xlink:href="bhc-20220930.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_3f7a4c41-fc31-4a58-b839-2bf01ff6b415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_3908447f-0ec2-44be-93fc-16747f8c1a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_3908447f-0ec2-44be-93fc-16747f8c1a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a56d0f29-61e8-4bc2-a2c0-022eea599517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a56d0f29-61e8-4bc2-a2c0-022eea599517" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a56d0f29-61e8-4bc2-a2c0-022eea599517_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a56d0f29-61e8-4bc2-a2c0-022eea599517" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a56d0f29-61e8-4bc2-a2c0-022eea599517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7adea3b9-9bbe-4d84-b888-5aece1691349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a56d0f29-61e8-4bc2-a2c0-022eea599517" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7adea3b9-9bbe-4d84-b888-5aece1691349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c4b19418-2c6c-4222-a238-41a7b059f98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7adea3b9-9bbe-4d84-b888-5aece1691349" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c4b19418-2c6c-4222-a238-41a7b059f98e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5d052a6e-647d-4f39-bc55-d8d877896530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:to="loc_us-gaap_HedgingDesignationAxis_5d052a6e-647d-4f39-bc55-d8d877896530" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5d052a6e-647d-4f39-bc55-d8d877896530_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5d052a6e-647d-4f39-bc55-d8d877896530" xlink:to="loc_us-gaap_HedgingDesignationDomain_5d052a6e-647d-4f39-bc55-d8d877896530_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_579318bc-87d0-46e9-86ec-8b6874942046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5d052a6e-647d-4f39-bc55-d8d877896530" xlink:to="loc_us-gaap_HedgingDesignationDomain_579318bc-87d0-46e9-86ec-8b6874942046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_31455c7e-2c55-417f-bedb-c87090794dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_579318bc-87d0-46e9-86ec-8b6874942046" xlink:to="loc_us-gaap_NondesignatedMember_31455c7e-2c55-417f-bedb-c87090794dbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended" id="i320db3971caf443faabce78b9c092c36_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fe8ae51a-b9c2-4702-90c6-477fdb151de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fe8ae51a-b9c2-4702-90c6-477fdb151de7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_a17c314b-baa7-4a5a-ba95-8ca124596522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_a17c314b-baa7-4a5a-ba95-8ca124596522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_98a80385-c227-45da-8b4f-ea36d792e443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_98a80385-c227-45da-8b4f-ea36d792e443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_98a80385-c227-45da-8b4f-ea36d792e443_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_98a80385-c227-45da-8b4f-ea36d792e443" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_98a80385-c227-45da-8b4f-ea36d792e443_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_91def94e-40f4-45dd-8dee-1ffd111dde53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_98a80385-c227-45da-8b4f-ea36d792e443" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_91def94e-40f4-45dd-8dee-1ffd111dde53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9e981111-7477-473b-ae65-f73b174d4178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91def94e-40f4-45dd-8dee-1ffd111dde53" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9e981111-7477-473b-ae65-f73b174d4178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_88580743-01c1-4bb0-b238-d8134a065cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:to="loc_us-gaap_HedgingDesignationAxis_88580743-01c1-4bb0-b238-d8134a065cbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_88580743-01c1-4bb0-b238-d8134a065cbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_88580743-01c1-4bb0-b238-d8134a065cbd" xlink:to="loc_us-gaap_HedgingDesignationDomain_88580743-01c1-4bb0-b238-d8134a065cbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7cdc0ca4-f149-436f-9d20-9b8f8ae82d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_88580743-01c1-4bb0-b238-d8134a065cbd" xlink:to="loc_us-gaap_HedgingDesignationDomain_7cdc0ca4-f149-436f-9d20-9b8f8ae82d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e5869d78-c6ed-4a65-afeb-47a0ba9608d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7cdc0ca4-f149-436f-9d20-9b8f8ae82d5f" xlink:to="loc_us-gaap_NondesignatedMember_e5869d78-c6ed-4a65-afeb-47a0ba9608d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended" id="i199b8276bf0c4e15aa3aae1a39623a73_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_def3c772-c2b4-43c0-9ef2-b631594ce8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fda6c94c-53b4-42fa-be30-c09a7592269b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_def3c772-c2b4-43c0-9ef2-b631594ce8c3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fda6c94c-53b4-42fa-be30-c09a7592269b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_def3c772-c2b4-43c0-9ef2-b631594ce8c3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32ecb701-2ebf-485f-b8eb-6065c0cff710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32ecb701-2ebf-485f-b8eb-6065c0cff710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_32ecb701-2ebf-485f-b8eb-6065c0cff710_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32ecb701-2ebf-485f-b8eb-6065c0cff710" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_32ecb701-2ebf-485f-b8eb-6065c0cff710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ec6c22b-7d94-4e35-a578-bb00e5d917b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32ecb701-2ebf-485f-b8eb-6065c0cff710" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ec6c22b-7d94-4e35-a578-bb00e5d917b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_462ef451-cabe-4eb9-a6ec-31c5334d1ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ec6c22b-7d94-4e35-a578-bb00e5d917b9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_462ef451-cabe-4eb9-a6ec-31c5334d1ac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5cd92045-a6d5-4b65-b92c-be8e962f5ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5cd92045-a6d5-4b65-b92c-be8e962f5ff0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5cd92045-a6d5-4b65-b92c-be8e962f5ff0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5cd92045-a6d5-4b65-b92c-be8e962f5ff0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5cd92045-a6d5-4b65-b92c-be8e962f5ff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5cd92045-a6d5-4b65-b92c-be8e962f5ff0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_efa08a2c-83c3-4889-8fd0-4667c2c94dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_efa08a2c-83c3-4889-8fd0-4667c2c94dcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_73dc5516-aafc-4f4c-9c85-9ad5977d6e9b" xlink:href="bhc-20220930.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_73dc5516-aafc-4f4c-9c85-9ad5977d6e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf37a2b9-a14d-4023-8d2e-a91ddd3bd50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf37a2b9-a14d-4023-8d2e-a91ddd3bd50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_eff943cb-c6a8-45b3-8923-c27c7b509884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf37a2b9-a14d-4023-8d2e-a91ddd3bd50f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_eff943cb-c6a8-45b3-8923-c27c7b509884" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_86aa63e2-b51b-44b0-9965-6eba8fe29e62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_srt_RangeAxis_86aa63e2-b51b-44b0-9965-6eba8fe29e62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86aa63e2-b51b-44b0-9965-6eba8fe29e62_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_86aa63e2-b51b-44b0-9965-6eba8fe29e62" xlink:to="loc_srt_RangeMember_86aa63e2-b51b-44b0-9965-6eba8fe29e62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_86aa63e2-b51b-44b0-9965-6eba8fe29e62" xlink:to="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6575b83-ec7d-40f4-b593-b751869cf2a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:to="loc_srt_MinimumMember_b6575b83-ec7d-40f4-b593-b751869cf2a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa4c27f6-dbca-4be7-82e1-ea74449fb564" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:to="loc_srt_MaximumMember_fa4c27f6-dbca-4be7-82e1-ea74449fb564" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended" id="i6d9e2c39e7be473296e9101e4f3903f4_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ed66cbbb-cea8-470a-89eb-f964ce76969b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ed66cbbb-cea8-470a-89eb-f964ce76969b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_45fa3c85-636e-4542-aad5-fae02a3db526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_45fa3c85-636e-4542-aad5-fae02a3db526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c6f562c-bb11-4c8e-9b7b-ead68ae74506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c6f562c-bb11-4c8e-9b7b-ead68ae74506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eec52755-0943-43d5-8c11-1c2ed7580e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eec52755-0943-43d5-8c11-1c2ed7580e70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_7c541979-0d43-4399-83b4-9c237677b407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_7c541979-0d43-4399-83b4-9c237677b407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3086a70b-d992-48ba-8327-f3ee4c81caf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7837f6c7-c995-4d06-a6c9-69625a71e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7837f6c7-c995-4d06-a6c9-69625a71e60b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9ca2806d-940d-4aac-8fb2-bf20e45602d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9ca2806d-940d-4aac-8fb2-bf20e45602d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_aa14ac8d-b620-44c6-97f3-bebe2266639b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ed66cbbb-cea8-470a-89eb-f964ce76969b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_aa14ac8d-b620-44c6-97f3-bebe2266639b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_aa14ac8d-b620-44c6-97f3-bebe2266639b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_371e4d8f-d7a7-45d8-a3a0-d22cf64912fc" xlink:href="bhc-20220930.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_371e4d8f-d7a7-45d8-a3a0-d22cf64912fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_a94f6623-852b-4d3e-8796-fc7deb97cca5" xlink:href="bhc-20220930.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_a94f6623-852b-4d3e-8796-fc7deb97cca5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended" id="i2efb0c3c6e8f40b6aa064bbdab155749_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d002d6a7-e48b-4f51-8d82-220149aee533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ccbe4036-c55b-414b-967d-7ef9a710fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d002d6a7-e48b-4f51-8d82-220149aee533" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ccbe4036-c55b-414b-967d-7ef9a710fd07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d002d6a7-e48b-4f51-8d82-220149aee533" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77362468-01c5-4f42-8790-38921146f6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77362468-01c5-4f42-8790-38921146f6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_77362468-01c5-4f42-8790-38921146f6e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77362468-01c5-4f42-8790-38921146f6e9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_77362468-01c5-4f42-8790-38921146f6e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d798d3b-ca9c-408d-86f9-74ed563d373c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77362468-01c5-4f42-8790-38921146f6e9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d798d3b-ca9c-408d-86f9-74ed563d373c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_2e04f531-a34c-4e91-a6d3-ba23793b7ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d798d3b-ca9c-408d-86f9-74ed563d373c" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_2e04f531-a34c-4e91-a6d3-ba23793b7ac9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8251394f-212f-47b2-89ae-efb9b7ce4dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8251394f-212f-47b2-89ae-efb9b7ce4dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25fd0c66-2627-409e-98a1-6c9045046cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8251394f-212f-47b2-89ae-efb9b7ce4dbc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25fd0c66-2627-409e-98a1-6c9045046cab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended" id="i3b238671925d4fbe8517b568403bf644_INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:href="bhc-20220930.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed8e8d5-0717-4d14-b1e2-bf84b3810977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed8e8d5-0717-4d14-b1e2-bf84b3810977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_53aa8fca-1c32-4756-9ff8-27bffd83b85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_53aa8fca-1c32-4756-9ff8-27bffd83b85c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6a0cfa45-c6fa-43aa-8999-05bfbb85a7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6a0cfa45-c6fa-43aa-8999-05bfbb85a7db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2a0830a5-a464-43f1-af93-69c18ec58dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2a0830a5-a464-43f1-af93-69c18ec58dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_563bdf7a-f018-42a7-9557-b38998e1d186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2a0830a5-a464-43f1-af93-69c18ec58dd8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_563bdf7a-f018-42a7-9557-b38998e1d186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ebd8fee-69e3-474f-852b-8bee7bd50698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ebd8fee-69e3-474f-852b-8bee7bd50698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500d4170-c171-4a6f-b4dc-6ab8288736f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500d4170-c171-4a6f-b4dc-6ab8288736f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6828ed77-071d-413c-81c7-eeb5f2a84348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6828ed77-071d-413c-81c7-eeb5f2a84348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6828ed77-071d-413c-81c7-eeb5f2a84348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6828ed77-071d-413c-81c7-eeb5f2a84348" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6828ed77-071d-413c-81c7-eeb5f2a84348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6828ed77-071d-413c-81c7-eeb5f2a84348" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_66569ff7-db4a-410a-a7f9-775b0c2829e4" xlink:href="bhc-20220930.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_bhc_ProductBrandsMember_66569ff7-db4a-410a-a7f9-775b0c2829e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b3ed0f83-42cd-4a03-9de5-e39773933d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_us-gaap_TradeNamesMember_b3ed0f83-42cd-4a03-9de5-e39773933d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_7acad2c5-6a2b-4b77-851b-ca3fcfb305bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_us-gaap_ContractualRightsMember_7acad2c5-6a2b-4b77-851b-ca3fcfb305bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_754a007c-cef8-47b4-ada4-3e50b9414763" xlink:href="bhc-20220930.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_bhc_PartnerRelationshipsMember_754a007c-cef8-47b4-ada4-3e50b9414763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_92c572d4-8ba5-4ac7-8514-6dd01f2ac9df" xlink:href="bhc-20220930.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_bhc_OutLicensedTechnologyMember_92c572d4-8ba5-4ac7-8514-6dd01f2ac9df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e34866b9-6d50-45cc-bafe-dd2021627be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e34866b9-6d50-45cc-bafe-dd2021627be3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e34866b9-6d50-45cc-bafe-dd2021627be3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e34866b9-6d50-45cc-bafe-dd2021627be3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e34866b9-6d50-45cc-bafe-dd2021627be3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cf48c6ef-f786-44d9-bd9d-c7733cf8641b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e34866b9-6d50-45cc-bafe-dd2021627be3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cf48c6ef-f786-44d9-bd9d-c7733cf8641b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_35d1852f-9142-4f93-8d66-6405994e8402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cf48c6ef-f786-44d9-bd9d-c7733cf8641b" xlink:to="loc_us-gaap_TrademarksMember_35d1852f-9142-4f93-8d66-6405994e8402" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="i94eebf3f56104de7a2ef07b4da1635d0_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d92ed3ed-52af-4059-9355-8fde4d82f654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_AssetImpairmentCharges_d92ed3ed-52af-4059-9355-8fde4d82f654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_38390aea-2374-46be-8f40-6a956c77fb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_38390aea-2374-46be-8f40-6a956c77fb77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f86073e3-c916-40c2-92f4-2b0712faf1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f86073e3-c916-40c2-92f4-2b0712faf1df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_850bd6e4-0ace-4d99-85f0-90a56717e2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_850bd6e4-0ace-4d99-85f0-90a56717e2bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2fafd0-f6ae-481f-ab3c-f6f469414adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2fafd0-f6ae-481f-ab3c-f6f469414adb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AnnualAmortizationOfIntangibleAssets_22d9c218-5d14-4d7e-b036-b32e34adcfbd" xlink:href="bhc-20220930.xsd#bhc_AnnualAmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_AnnualAmortizationOfIntangibleAssets_22d9c218-5d14-4d7e-b036-b32e34adcfbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_8742cceb-3792-4607-8f69-4ec7e4a3a65d" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_8742cceb-3792-4607-8f69-4ec7e4a3a65d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_5afddd1d-6ef5-47f2-b146-d02705f33b1f" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_5afddd1d-6ef5-47f2-b146-d02705f33b1f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ccad5d1-2160-4670-b10f-94eea5d84a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ccad5d1-2160-4670-b10f-94eea5d84a95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_dd720716-a150-45a8-99c0-7a3b3c186dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_dd720716-a150-45a8-99c0-7a3b3c186dd5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_46755441-a31e-4073-bf95-2b451ce05378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_NumberOfReportingUnits_46755441-a31e-4073-bf95-2b451ce05378" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_52ee0b7f-b276-4873-9718-f33c6c65db25" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_52ee0b7f-b276-4873-9718-f33c6c65db25" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c9e949af-b1d9-4b03-978d-82469d31835e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c9e949af-b1d9-4b03-978d-82469d31835e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f37691b1-0b0c-4f6f-bc79-53e94fbfebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f37691b1-0b0c-4f6f-bc79-53e94fbfebcd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17d493e5-9df4-49f2-8219-19541b025302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17d493e5-9df4-49f2-8219-19541b025302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17d493e5-9df4-49f2-8219-19541b025302_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17d493e5-9df4-49f2-8219-19541b025302" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_17d493e5-9df4-49f2-8219-19541b025302_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17d493e5-9df4-49f2-8219-19541b025302" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_132abdde-2efd-4e6c-bfc5-e5f4605116e0" xlink:href="bhc-20220930.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:to="loc_bhc_ProductBrandsMember_132abdde-2efd-4e6c-bfc5-e5f4605116e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_81ed1b73-01a2-4a56-8af8-8eb6976c7eb8" xlink:href="bhc-20220930.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:to="loc_bhc_DiscontinuedProductLinesMember_81ed1b73-01a2-4a56-8af8-8eb6976c7eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d13e431-1c98-4d5a-99e7-65aee05878b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_srt_ProductOrServiceAxis_3d13e431-1c98-4d5a-99e7-65aee05878b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d13e431-1c98-4d5a-99e7-65aee05878b1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3d13e431-1c98-4d5a-99e7-65aee05878b1" xlink:to="loc_srt_ProductsAndServicesDomain_3d13e431-1c98-4d5a-99e7-65aee05878b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_101588b5-87fa-40c2-b6d9-46e18da1384b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3d13e431-1c98-4d5a-99e7-65aee05878b1" xlink:to="loc_srt_ProductsAndServicesDomain_101588b5-87fa-40c2-b6d9-46e18da1384b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_47bb0416-95d4-4b0f-93c4-352664639283" xlink:href="bhc-20220930.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_101588b5-87fa-40c2-b6d9-46e18da1384b" xlink:to="loc_bhc_XifaxanBrandedProductsMember_47bb0416-95d4-4b0f-93c4-352664639283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_45824792-48f1-4faa-8faf-f91fb8865432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_45824792-48f1-4faa-8faf-f91fb8865432" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_45824792-48f1-4faa-8faf-f91fb8865432_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_45824792-48f1-4faa-8faf-f91fb8865432" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_45824792-48f1-4faa-8faf-f91fb8865432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_68bd5bda-1d57-4fb3-96e7-7f8e90f1111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_45824792-48f1-4faa-8faf-f91fb8865432" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_68bd5bda-1d57-4fb3-96e7-7f8e90f1111e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_320b81de-deaa-4326-b398-4059af2e8148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_68bd5bda-1d57-4fb3-96e7-7f8e90f1111e" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_320b81de-deaa-4326-b398-4059af2e8148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8db2a201-4edd-4234-ad37-03a2b0a6cf13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_srt_RangeAxis_8db2a201-4edd-4234-ad37-03a2b0a6cf13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8db2a201-4edd-4234-ad37-03a2b0a6cf13_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8db2a201-4edd-4234-ad37-03a2b0a6cf13" xlink:to="loc_srt_RangeMember_8db2a201-4edd-4234-ad37-03a2b0a6cf13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8db2a201-4edd-4234-ad37-03a2b0a6cf13" xlink:to="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0da42c19-f9de-45d6-9b77-5edd1a5afe85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:to="loc_srt_MinimumMember_0da42c19-f9de-45d6-9b77-5edd1a5afe85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_790d682d-1cf3-4c75-9f7d-d3c5bd66c7f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:to="loc_srt_MaximumMember_790d682d-1cf3-4c75-9f7d-d3c5bd66c7f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7ef568ae-9249-4338-92b8-5fe6814b7c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7ef568ae-9249-4338-92b8-5fe6814b7c45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ef568ae-9249-4338-92b8-5fe6814b7c45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7ef568ae-9249-4338-92b8-5fe6814b7c45" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_7ef568ae-9249-4338-92b8-5fe6814b7c45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cf2529f-4105-4b61-8902-bb8cd5278690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7ef568ae-9249-4338-92b8-5fe6814b7c45" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cf2529f-4105-4b61-8902-bb8cd5278690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_7cb1ffda-fa91-4d88-a665-5a6830960f6e" xlink:href="bhc-20220930.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cf2529f-4105-4b61-8902-bb8cd5278690" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_7cb1ffda-fa91-4d88-a665-5a6830960f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_edeea4e7-4db3-4ffe-8955-2b2a90487fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_ReportingUnitAxis_edeea4e7-4db3-4ffe-8955-2b2a90487fdc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_edeea4e7-4db3-4ffe-8955-2b2a90487fdc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_edeea4e7-4db3-4ffe-8955-2b2a90487fdc" xlink:to="loc_us-gaap_ReportingUnitDomain_edeea4e7-4db3-4ffe-8955-2b2a90487fdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_edeea4e7-4db3-4ffe-8955-2b2a90487fdc" xlink:to="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_ddc969aa-ed31-4b70-a1e9-361cd8e50970" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_ddc969aa-ed31-4b70-a1e9-361cd8e50970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_3d10127f-cc69-490d-94d7-597c2e4c8b6b" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_3d10127f-cc69-490d-94d7-597c2e4c8b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_9cac6e27-264d-4f26-8b57-e95f8043fb5e" xlink:href="bhc-20220930.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_9cac6e27-264d-4f26-8b57-e95f8043fb5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_4cd5afe1-885e-4452-9784-f73aec215099" xlink:href="bhc-20220930.xsd#bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_4cd5afe1-885e-4452-9784-f73aec215099" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember_9ac0107d-8da0-4df4-95bc-6b4c0972eba5" xlink:href="bhc-20220930.xsd#bhc_SalixReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_SalixReportingUnitMember_9ac0107d-8da0-4df4-95bc-6b4c0972eba5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f31102a7-c43e-4a16-bf62-7db541de0e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f31102a7-c43e-4a16-bf62-7db541de0e14" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f31102a7-c43e-4a16-bf62-7db541de0e14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f31102a7-c43e-4a16-bf62-7db541de0e14" xlink:to="loc_us-gaap_SegmentDomain_f31102a7-c43e-4a16-bf62-7db541de0e14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f31102a7-c43e-4a16-bf62-7db541de0e14" xlink:to="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_71e4511c-f459-472f-b79a-8a053e27133c" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_71e4511c-f459-472f-b79a-8a053e27133c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_3375fa76-6b5a-49b3-9ad6-244df1374b82" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:to="loc_bhc_SalixSegmentMember_3375fa76-6b5a-49b3-9ad6-244df1374b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7c144734-eb92-49c1-a0dc-3200457a5b32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_dei_LegalEntityAxis_7c144734-eb92-49c1-a0dc-3200457a5b32" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7c144734-eb92-49c1-a0dc-3200457a5b32_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7c144734-eb92-49c1-a0dc-3200457a5b32" xlink:to="loc_dei_EntityDomain_7c144734-eb92-49c1-a0dc-3200457a5b32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8b0375b0-e82d-4b65-ab93-488d55d4a648" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7c144734-eb92-49c1-a0dc-3200457a5b32" xlink:to="loc_dei_EntityDomain_8b0375b0-e82d-4b65-ab93-488d55d4a648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_a81a2a62-bef0-4ac8-8aca-a7a749689b39" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8b0375b0-e82d-4b65-ab93-488d55d4a648" xlink:to="loc_bhc_BauschLombMember_a81a2a62-bef0-4ac8-8aca-a7a749689b39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ac16e4c0-848c-46bc-ad66-8b729827c116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ac16e4c0-848c-46bc-ad66-8b729827c116" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ac16e4c0-848c-46bc-ad66-8b729827c116_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ac16e4c0-848c-46bc-ad66-8b729827c116" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ac16e4c0-848c-46bc-ad66-8b729827c116_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_48021c8f-4b0a-4a58-8f2c-8e364b863e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ac16e4c0-848c-46bc-ad66-8b729827c116" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_48021c8f-4b0a-4a58-8f2c-8e364b863e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_bc3fae2c-ff30-4bc4-9729-105fa6acf875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_48021c8f-4b0a-4a58-8f2c-8e364b863e75" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_bc3fae2c-ff30-4bc4-9729-105fa6acf875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e057dbd0-9b28-4efe-a0c2-f0e3769205cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e057dbd0-9b28-4efe-a0c2-f0e3769205cd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e057dbd0-9b28-4efe-a0c2-f0e3769205cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e057dbd0-9b28-4efe-a0c2-f0e3769205cd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e057dbd0-9b28-4efe-a0c2-f0e3769205cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_adb619b5-5770-4280-85cc-44e0d28f22fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e057dbd0-9b28-4efe-a0c2-f0e3769205cd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_adb619b5-5770-4280-85cc-44e0d28f22fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_1afd0125-4389-4afa-a55f-f72ca81cb1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_adb619b5-5770-4280-85cc-44e0d28f22fb" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_1afd0125-4389-4afa-a55f-f72ca81cb1cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended" id="ia3166c53db274470a3e2901a33380c6d_INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_abbc975a-3b9a-4dbc-8083-34ed12283af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_abbc975a-3b9a-4dbc-8083-34ed12283af4" xlink:to="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0310466c-f509-4d41-9ab2-b337a512297f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_Goodwill_0310466c-f509-4d41-9ab2-b337a512297f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_7c19bc7e-2a93-4d30-a296-9bce0e883794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_7c19bc7e-2a93-4d30-a296-9bce0e883794" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8002c3f5-fd10-4365-822b-c7862fa635b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8002c3f5-fd10-4365-822b-c7862fa635b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15eaa94b-d657-42c1-96e9-4d42af522aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15eaa94b-d657-42c1-96e9-4d42af522aa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05899d7e-cfb4-4314-bd57-c46e7a63003d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c2c3c022-7189-49a2-9cfc-863c090c4244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_abbc975a-3b9a-4dbc-8083-34ed12283af4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c2c3c022-7189-49a2-9cfc-863c090c4244" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bef64488-52e1-485f-9a19-f3ab6e1c8f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c2c3c022-7189-49a2-9cfc-863c090c4244" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bef64488-52e1-485f-9a19-f3ab6e1c8f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bef64488-52e1-485f-9a19-f3ab6e1c8f0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bef64488-52e1-485f-9a19-f3ab6e1c8f0e" xlink:to="loc_us-gaap_SegmentDomain_bef64488-52e1-485f-9a19-f3ab6e1c8f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bef64488-52e1-485f-9a19-f3ab6e1c8f0e" xlink:to="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_991ede27-427e-4816-9ea5-3fac68335fab" xlink:href="bhc-20220930.xsd#bhc_BauschLombInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_BauschLombInternationalMember_991ede27-427e-4816-9ea5-3fac68335fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f4017ea8-8a29-4da2-a8c6-08a9c9b6b162" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_BauschLombMember_f4017ea8-8a29-4da2-a8c6-08a9c9b6b162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_77c1a9b7-c12b-45e2-bfac-e24701c6ffb2" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_SalixSegmentMember_77c1a9b7-c12b-45e2-bfac-e24701c6ffb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_5b90206f-04f7-440e-85ff-e9fdcf943197" xlink:href="bhc-20220930.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_InternationalRxMember_5b90206f-04f7-440e-85ff-e9fdcf943197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_233ffbc4-961c-44c8-9674-0c8d82e87217" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_233ffbc4-961c-44c8-9674-0c8d82e87217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_4e701c37-88d3-4ecd-8de9-572458c42414" xlink:href="bhc-20220930.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_SoltaMedicalSegmentMember_4e701c37-88d3-4ecd-8de9-572458c42414" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_18f64587-85b8-4ac5-8bb6-c2907ee22b2c" xlink:href="bhc-20220930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_18f64587-85b8-4ac5-8bb6-c2907ee22b2c" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="i85f4e56dbb3945239875ee1ed33d3329_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00a4caab-f678-4e26-bcac-d2996ed4e182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00a4caab-f678-4e26-bcac-d2996ed4e182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5e34cd75-b1c3-4bc1-906a-85474a4e10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5e34cd75-b1c3-4bc1-906a-85474a4e10ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d851c4aa-8004-4421-b39c-03f2c6789f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_LongTermDebt_d851c4aa-8004-4421-b39c-03f2c6789f62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5b24ae43-5822-4695-8848-94f07855e29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_LongTermDebtCurrent_5b24ae43-5822-4695-8848-94f07855e29a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1f8a9733-b076-4351-90d6-401c18d7385f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1f8a9733-b076-4351-90d6-401c18d7385f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_483392ed-f6ce-4843-81b5-833e7f610516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_us-gaap_CreditFacilityAxis_483392ed-f6ce-4843-81b5-833e7f610516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_483392ed-f6ce-4843-81b5-833e7f610516_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_483392ed-f6ce-4843-81b5-833e7f610516" xlink:to="loc_us-gaap_CreditFacilityDomain_483392ed-f6ce-4843-81b5-833e7f610516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c43efa3b-660f-4afe-8b52-5e869c9c095d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_483392ed-f6ce-4843-81b5-833e7f610516" xlink:to="loc_us-gaap_CreditFacilityDomain_c43efa3b-660f-4afe-8b52-5e869c9c095d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e9780a89-49a7-4cc7-88ec-b806e7ce72c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c43efa3b-660f-4afe-8b52-5e869c9c095d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e9780a89-49a7-4cc7-88ec-b806e7ce72c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b60787c5-3fff-4307-97f5-a65a79db3c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b60787c5-3fff-4307-97f5-a65a79db3c84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b60787c5-3fff-4307-97f5-a65a79db3c84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b60787c5-3fff-4307-97f5-a65a79db3c84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b60787c5-3fff-4307-97f5-a65a79db3c84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b60787c5-3fff-4307-97f5-a65a79db3c84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e30d7ffb-42f3-4b6c-8fda-35a844fdccd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:to="loc_us-gaap_SecuredDebtMember_e30d7ffb-42f3-4b6c-8fda-35a844fdccd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0856448c-2b88-430c-b6f4-83c7e38fb727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:to="loc_us-gaap_UnsecuredDebtMember_0856448c-2b88-430c-b6f4-83c7e38fb727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a38bb6b6-0a3b-451f-aa69-76f160fa703c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_us-gaap_DebtInstrumentAxis_a38bb6b6-0a3b-451f-aa69-76f160fa703c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a38bb6b6-0a3b-451f-aa69-76f160fa703c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a38bb6b6-0a3b-451f-aa69-76f160fa703c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a38bb6b6-0a3b-451f-aa69-76f160fa703c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a38bb6b6-0a3b-451f-aa69-76f160fa703c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_06687b31-e8a6-4796-8e1c-c5bda54c42a9" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_06687b31-e8a6-4796-8e1c-c5bda54c42a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_75fa50bb-d510-40ec-a000-cf2b3fc3912a" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_75fa50bb-d510-40ec-a000-cf2b3fc3912a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_e35c7b6f-1c0a-4896-80d2-5faf111b5b83" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_e35c7b6f-1c0a-4896-80d2-5faf111b5b83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_d7511c29-f669-4e94-8b1b-cda13c1bb940" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_d7511c29-f669-4e94-8b1b-cda13c1bb940" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_fd353f82-c61b-47cc-a026-b3a86966c68a" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_fd353f82-c61b-47cc-a026-b3a86966c68a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_67f87181-3b2d-4f48-941a-13d6a01bfa04" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_67f87181-3b2d-4f48-941a-13d6a01bfa04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_82616eac-05bf-41f5-a00c-0c4da475fde6" xlink:href="bhc-20220930.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermFacilityDueMay2027Member_82616eac-05bf-41f5-a00c-0c4da475fde6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_bf92bfa0-c4d9-486c-a9b0-6b703d971eb0" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_bf92bfa0-c4d9-486c-a9b0-6b703d971eb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_45a4f6d2-6c0c-4477-8981-507ee1eb14fe" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_45a4f6d2-6c0c-4477-8981-507ee1eb14fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_3933b75a-f8b6-4a24-9037-2678d1fb0094" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_3933b75a-f8b6-4a24-9037-2678d1fb0094" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_07c1f449-b00d-49f7-9a95-b0f716c1a4b1" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_07c1f449-b00d-49f7-9a95-b0f716c1a4b1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_c8e633f8-ede4-49f7-a6db-9c4cd39953f1" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_c8e633f8-ede4-49f7-a6db-9c4cd39953f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_d53618e2-2b07-4a72-a5d2-52a319cbfcf1" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_d53618e2-2b07-4a72-a5d2-52a319cbfcf1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_0065803c-a959-427f-b9ad-ca97e76ab974" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_0065803c-a959-427f-b9ad-ca97e76ab974" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_7c2ee420-57cd-4513-8352-b4184215c669" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_7c2ee420-57cd-4513-8352-b4184215c669" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_eda4fe50-d136-40df-b7a8-d5780574af0e" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_eda4fe50-d136-40df-b7a8-d5780574af0e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_a6a89469-fedd-4be0-998b-d95c645d2752" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_a6a89469-fedd-4be0-998b-d95c645d2752" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_462e69ac-687a-450c-964c-dc336befe0c3" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_462e69ac-687a-450c-964c-dc336befe0c3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_3c43e263-c227-4ce8-974c-6bde8ac2bc07" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_3c43e263-c227-4ce8-974c-6bde8ac2bc07" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_aab41b49-a6b3-4f5e-9755-20e0a024e690" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_aab41b49-a6b3-4f5e-9755-20e0a024e690" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_59a5d32f-cfd0-42ca-9d67-bd7ffb2e4abb" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_59a5d32f-cfd0-42ca-9d67-bd7ffb2e4abb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_a2b8bd5b-fc56-4dfe-aaae-eab760e5db5b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_a2b8bd5b-fc56-4dfe-aaae-eab760e5db5b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_a435abc8-bf64-4141-ad6c-35fce41dc41f" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_a435abc8-bf64-4141-ad6c-35fce41dc41f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_1129fc97-7a09-4aeb-928d-101faea3dff2" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_1129fc97-7a09-4aeb-928d-101faea3dff2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_e21581e0-4c59-4968-8775-bf5a99913bb6" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_e21581e0-4c59-4968-8775-bf5a99913bb6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_297b7172-e627-4474-a507-21459bcc6a7b" xlink:href="bhc-20220930.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_OtherLongTermDebtMember_297b7172-e627-4474-a507-21459bcc6a7b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_dei_LegalEntityAxis_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85" xlink:to="loc_dei_EntityDomain_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9c9b25c3-f2f3-4762-a7d9-1810980bf352" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85" xlink:to="loc_dei_EntityDomain_9c9b25c3-f2f3-4762-a7d9-1810980bf352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_238965c7-82e0-4966-ba5f-20a4de12305d" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9c9b25c3-f2f3-4762-a7d9-1810980bf352" xlink:to="loc_bhc_BauschLombMember_238965c7-82e0-4966-ba5f-20a4de12305d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="i8997d7a6cd994ad0940b2fc1673ad749_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36075511-5dc9-4418-86c6-e4ab5611c91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36075511-5dc9-4418-86c6-e4ab5611c91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_5b213638-503d-4e8a-bb66-ee6767ed135d" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_5b213638-503d-4e8a-bb66-ee6767ed135d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_0c77fdd6-6d58-4352-81be-7a1e4423508b" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_0c77fdd6-6d58-4352-81be-7a1e4423508b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_b2428f86-04c4-4234-a487-b84893e9452a" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_b2428f86-04c4-4234-a487-b84893e9452a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:to="loc_us-gaap_CreditFacilityAxis_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896" xlink:to="loc_us-gaap_CreditFacilityDomain_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896" xlink:to="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_c952e41d-6562-48ba-8487-fb977b40113f" xlink:href="bhc-20220930.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_c952e41d-6562-48ba-8487-fb977b40113f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e217d967-e625-4069-9e18-34ab7bc709a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e217d967-e625-4069-9e18-34ab7bc709a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e868f5b8-fafd-4f56-8a62-f743decbd352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e868f5b8-fafd-4f56-8a62-f743decbd352" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e868f5b8-fafd-4f56-8a62-f743decbd352_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e868f5b8-fafd-4f56-8a62-f743decbd352" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e868f5b8-fafd-4f56-8a62-f743decbd352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be37668c-da20-477a-a101-0931bbf3baac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e868f5b8-fafd-4f56-8a62-f743decbd352" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be37668c-da20-477a-a101-0931bbf3baac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_01287012-e25f-4b91-a294-d395f6648002" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be37668c-da20-477a-a101-0931bbf3baac" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_01287012-e25f-4b91-a294-d395f6648002" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e813c975-7c4f-4e97-bdb5-63429a0d289d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e813c975-7c4f-4e97-bdb5-63429a0d289d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e813c975-7c4f-4e97-bdb5-63429a0d289d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e813c975-7c4f-4e97-bdb5-63429a0d289d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e813c975-7c4f-4e97-bdb5-63429a0d289d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e81f65a6-1102-4d19-8706-f72c351b45b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e813c975-7c4f-4e97-bdb5-63429a0d289d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e81f65a6-1102-4d19-8706-f72c351b45b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2167c098-c1a5-40e4-80e8-eef8eacaeebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e81f65a6-1102-4d19-8706-f72c351b45b0" xlink:to="loc_us-gaap_SecuredDebtMember_2167c098-c1a5-40e4-80e8-eef8eacaeebd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSExchangeOfferDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="extended" id="icda905e8f49e44d89c7445ff900d5c90_FINANCINGARRANGEMENTSExchangeOfferDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_de566d25-e056-4dd2-a941-279a3300e957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_de566d25-e056-4dd2-a941-279a3300e957" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_75483d81-2af2-4739-9f1d-027bcc3a98eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_75483d81-2af2-4739-9f1d-027bcc3a98eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_d6b6c36a-2c58-4760-a6ca-555116066f38" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_d6b6c36a-2c58-4760-a6ca-555116066f38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64f210b3-bf02-49bb-838f-c5db3f68e322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64f210b3-bf02-49bb-838f-c5db3f68e322" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f7572a08-ddb7-4276-8d13-1a2f5ba0e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f7572a08-ddb7-4276-8d13-1a2f5ba0e4a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1ae2e7d-a6dd-4a03-baf9-441a23768d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1ae2e7d-a6dd-4a03-baf9-441a23768d16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_b1b1aaf6-9bf9-4a71-a7f0-edd535bf6790" xlink:href="bhc-20220930.xsd#bhc_ExtinguishmentOfDebtThirdPartyFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_b1b1aaf6-9bf9-4a71-a7f0-edd535bf6790" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd4400ae-e9c4-404d-aa9b-13257e885ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd4400ae-e9c4-404d-aa9b-13257e885ff2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f38590f0-0314-4b26-ab19-70f60e480c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f38590f0-0314-4b26-ab19-70f60e480c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f38590f0-0314-4b26-ab19-70f60e480c34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f38590f0-0314-4b26-ab19-70f60e480c34" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f38590f0-0314-4b26-ab19-70f60e480c34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f38590f0-0314-4b26-ab19-70f60e480c34" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_46d7c638-c11a-4dc6-88c5-10d5de930755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:to="loc_us-gaap_UnsecuredDebtMember_46d7c638-c11a-4dc6-88c5-10d5de930755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_92f79317-9d97-4c31-a25c-a82b68e293cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:to="loc_us-gaap_SecuredDebtMember_92f79317-9d97-4c31-a25c-a82b68e293cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_83641b06-82eb-484a-a5dd-a330091e457b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_us-gaap_DebtInstrumentAxis_83641b06-82eb-484a-a5dd-a330091e457b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_83641b06-82eb-484a-a5dd-a330091e457b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_83641b06-82eb-484a-a5dd-a330091e457b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_83641b06-82eb-484a-a5dd-a330091e457b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_83641b06-82eb-484a-a5dd-a330091e457b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_b4555dfc-aee0-417d-a5c1-a7cce3c4b57d" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_b4555dfc-aee0-417d-a5c1-a7cce3c4b57d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_23a92704-79ad-465e-9165-ff477a106fc9" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_23a92704-79ad-465e-9165-ff477a106fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_efed1f16-d2cc-429f-a8df-ac38e2ed0706" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_efed1f16-d2cc-429f-a8df-ac38e2ed0706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_aa7c0472-8030-4e4c-aca2-d7e5ba149c6b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_aa7c0472-8030-4e4c-aca2-d7e5ba149c6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_f9fd2919-360a-4f4f-92ea-8595a3111f4b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_f9fd2919-360a-4f4f-92ea-8595a3111f4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_6284858c-7d06-4723-8544-5f3b2d69f802" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_6284858c-7d06-4723-8544-5f3b2d69f802" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_52f642d4-809e-4acb-966b-a68ec91e73b2" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_52f642d4-809e-4acb-966b-a68ec91e73b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_0793e32b-3b5d-4218-addc-fc12b31511d1" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_0793e32b-3b5d-4218-addc-fc12b31511d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f857cb64-eef2-42d7-96a6-af9f534fe0de" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f857cb64-eef2-42d7-96a6-af9f534fe0de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_f857cb64-eef2-42d7-96a6-af9f534fe0de_default" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f857cb64-eef2-42d7-96a6-af9f534fe0de" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_f857cb64-eef2-42d7-96a6-af9f534fe0de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_e0f4151c-26cc-466e-ac2f-962db1f314e8" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f857cb64-eef2-42d7-96a6-af9f534fe0de" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_e0f4151c-26cc-466e-ac2f-962db1f314e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_590d43e8-153e-427c-bff8-6f0f0acfb2d1" xlink:href="bhc-20220930.xsd#bhc_ExchangeOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_e0f4151c-26cc-466e-ac2f-962db1f314e8" xlink:to="loc_bhc_ExchangeOfferMember_590d43e8-153e-427c-bff8-6f0f0acfb2d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_55605f6d-942b-4308-b5b3-3bd9f9c8c667" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_srt_OwnershipAxis_55605f6d-942b-4308-b5b3-3bd9f9c8c667" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_55605f6d-942b-4308-b5b3-3bd9f9c8c667_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_55605f6d-942b-4308-b5b3-3bd9f9c8c667" xlink:to="loc_srt_OwnershipDomain_55605f6d-942b-4308-b5b3-3bd9f9c8c667_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_51450db7-75ed-4b02-a39f-e0d4f7b144a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_55605f6d-942b-4308-b5b3-3bd9f9c8c667" xlink:to="loc_srt_OwnershipDomain_51450db7-75ed-4b02-a39f-e0d4f7b144a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_dd37528b-5bbe-4ba8-92ce-b2f466ebf9e2" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_51450db7-75ed-4b02-a39f-e0d4f7b144a4" xlink:to="loc_bhc_BauschLombMember_dd37528b-5bbe-4ba8-92ce-b2f466ebf9e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_835340da-589c-4cd0-ad13-7948c50a4cdf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_dei_LegalEntityAxis_835340da-589c-4cd0-ad13-7948c50a4cdf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_835340da-589c-4cd0-ad13-7948c50a4cdf_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_835340da-589c-4cd0-ad13-7948c50a4cdf" xlink:to="loc_dei_EntityDomain_835340da-589c-4cd0-ad13-7948c50a4cdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d880bfa3-cebf-4bb4-a68c-3df937a81d79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_835340da-589c-4cd0-ad13-7948c50a4cdf" xlink:to="loc_dei_EntityDomain_d880bfa3-cebf-4bb4-a68c-3df937a81d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_e558ec52-963f-45a4-a5df-4afdad288b1c" xlink:href="bhc-20220930.xsd#bhc_A1375209BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d880bfa3-cebf-4bb4-a68c-3df937a81d79" xlink:to="loc_bhc_A1375209BCLtdMember_e558ec52-963f-45a4-a5df-4afdad288b1c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="extended" id="id6ffcac81d3b472ead1c5987dbcddb0a_FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_83f49629-c86c-4dd4-8a29-048ce6514134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_83f49629-c86c-4dd4-8a29-048ce6514134" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c6433048-b1ae-4531-a3fb-5498f7defe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c6433048-b1ae-4531-a3fb-5498f7defe1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ae31f4b5-dbab-4b66-83f1-191230a5d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:to="loc_us-gaap_DebtInstrumentAxis_ae31f4b5-dbab-4b66-83f1-191230a5d6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ae31f4b5-dbab-4b66-83f1-191230a5d6dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ae31f4b5-dbab-4b66-83f1-191230a5d6dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ae31f4b5-dbab-4b66-83f1-191230a5d6dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ae31f4b5-dbab-4b66-83f1-191230a5d6dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_6847d399-7d6d-44e1-9054-e643f6eeffd4" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_6847d399-7d6d-44e1-9054-e643f6eeffd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_2a672fb8-1cb2-4692-a61e-5bc4e0a0dbf8" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_2a672fb8-1cb2-4692-a61e-5bc4e0a0dbf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_30c692da-1242-45c6-a841-19c44ca18610" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_30c692da-1242-45c6-a841-19c44ca18610" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_5e55e937-7595-41d8-9b48-566067a174b2" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_5e55e937-7595-41d8-9b48-566067a174b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_81c570cb-95a2-4e4f-ab19-d744fd41d474" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_81c570cb-95a2-4e4f-ab19-d744fd41d474" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_f8433176-008d-4af2-ae2a-ec816da245d6" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_f8433176-008d-4af2-ae2a-ec816da245d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_9b30ae73-fde8-4f2d-8991-1f43bc18ae60" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_9b30ae73-fde8-4f2d-8991-1f43bc18ae60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_a5c29817-6380-415f-a852-d283e2bc7cfe" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_a5c29817-6380-415f-a852-d283e2bc7cfe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_73e7ccbd-4d00-44b4-9156-d7da55918ce5" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_73e7ccbd-4d00-44b4-9156-d7da55918ce5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_71652c21-eef2-4d5e-9335-66a2397afbe3" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_71652c21-eef2-4d5e-9335-66a2397afbe3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b7adcf38-f5f9-44a7-8c5d-9863cae879f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b7adcf38-f5f9-44a7-8c5d-9863cae879f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b7adcf38-f5f9-44a7-8c5d-9863cae879f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b7adcf38-f5f9-44a7-8c5d-9863cae879f8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b7adcf38-f5f9-44a7-8c5d-9863cae879f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cb6bb438-68a1-4a52-9167-517f7f33ecd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b7adcf38-f5f9-44a7-8c5d-9863cae879f8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cb6bb438-68a1-4a52-9167-517f7f33ecd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c3510109-7757-4a59-9709-c53f7faacb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cb6bb438-68a1-4a52-9167-517f7f33ecd4" xlink:to="loc_us-gaap_UnsecuredDebtMember_c3510109-7757-4a59-9709-c53f7faacb5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_96529cbe-0897-49d9-a65e-8b37f055c9e5" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_96529cbe-0897-49d9-a65e-8b37f055c9e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_96529cbe-0897-49d9-a65e-8b37f055c9e5_default" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_96529cbe-0897-49d9-a65e-8b37f055c9e5" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_96529cbe-0897-49d9-a65e-8b37f055c9e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_ad6587a1-3592-471f-9914-7415f003b926" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_96529cbe-0897-49d9-a65e-8b37f055c9e5" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_ad6587a1-3592-471f-9914-7415f003b926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_3361cbde-afb1-45f7-85fd-8ecd8a44f1f5" xlink:href="bhc-20220930.xsd#bhc_ExchangeOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_ad6587a1-3592-471f-9914-7415f003b926" xlink:to="loc_bhc_ExchangeOfferMember_3361cbde-afb1-45f7-85fd-8ecd8a44f1f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i1b84c433c6634fbdb10dd9e7bde891cf_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f3dfeef-165b-4792-9e77-64aba39b4012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f3dfeef-165b-4792-9e77-64aba39b4012" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_0c166efc-ae88-409a-b69a-2af48be2cc38" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_0c166efc-ae88-409a-b69a-2af48be2cc38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_2f15ecfa-52e6-491b-ab60-4cf4f50c9017" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_2f15ecfa-52e6-491b-ab60-4cf4f50c9017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d0db10a0-4b46-4e6e-a08e-5079cc09810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d0db10a0-4b46-4e6e-a08e-5079cc09810f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e52bcbb8-88ca-4592-8e76-2b21b17715de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LongTermDebt_e52bcbb8-88ca-4592-8e76-2b21b17715de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e4174abe-24d9-4ce7-8de3-6159e8ffca89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e4174abe-24d9-4ce7-8de3-6159e8ffca89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_03e1172e-60fc-44d5-af31-035817a7da96" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_03e1172e-60fc-44d5-af31-035817a7da96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_c6f05ff4-525e-453b-85ed-b73082cbc151" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_c6f05ff4-525e-453b-85ed-b73082cbc151" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9ca9b435-7deb-4e41-83a8-6986daa30e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9ca9b435-7deb-4e41-83a8-6986daa30e58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_32abd90e-ad88-4f74-83d0-0a405ec80303" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_32abd90e-ad88-4f74-83d0-0a405ec80303" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_e0b732a8-32d2-4b8a-a675-7586d9ee7f07" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_e0b732a8-32d2-4b8a-a675-7586d9ee7f07" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_9fa16efa-b32a-4725-88e2-d81705088702" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_9fa16efa-b32a-4725-88e2-d81705088702" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_20c2ea09-2580-4b9e-a41a-e9061bbca9e2" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_20c2ea09-2580-4b9e-a41a-e9061bbca9e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_dc4b77c6-626d-4cee-b0bc-6d7837274db9" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_dc4b77c6-626d-4cee-b0bc-6d7837274db9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_0acb7f56-1a35-46a0-805d-21b2637e20ad" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_0acb7f56-1a35-46a0-805d-21b2637e20ad" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_ebf42ba1-c0df-42c8-ace3-6d88d7274f33" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_ebf42ba1-c0df-42c8-ace3-6d88d7274f33" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_68605504-2e23-4afb-8bc8-9bb27644a39b" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_68605504-2e23-4afb-8bc8-9bb27644a39b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_75c9433e-b065-4b95-9403-e019d0793c2b" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_75c9433e-b065-4b95-9403-e019d0793c2b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_33b259c6-c99b-4af1-b0c8-600d49be4227" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_33b259c6-c99b-4af1-b0c8-600d49be4227" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_8795c018-af81-4206-9ed5-48b95f3c4158" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_8795c018-af81-4206-9ed5-48b95f3c4158" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_604745dc-ff85-49a9-a6b6-95023e0a2fe1" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_604745dc-ff85-49a9-a6b6-95023e0a2fe1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_bbe86291-b3fd-4467-8695-e83bb8911454" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_bbe86291-b3fd-4467-8695-e83bb8911454" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_aa97f0ff-c110-4bde-ae0e-b23d06e52dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentTerm_aa97f0ff-c110-4bde-ae0e-b23d06e52dec" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ecc38828-30e6-491d-95aa-f925961ce56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ecc38828-30e6-491d-95aa-f925961ce56a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_899ee8f1-9543-4a97-bd5d-7c66ad6a4c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_899ee8f1-9543-4a97-bd5d-7c66ad6a4c43" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_880c038e-f67d-48d4-af14-2ad1c635541f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_880c038e-f67d-48d4-af14-2ad1c635541f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7ff11591-4f68-4981-9599-6baba8e6541f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_VariableRateAxis_7ff11591-4f68-4981-9599-6baba8e6541f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7ff11591-4f68-4981-9599-6baba8e6541f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7ff11591-4f68-4981-9599-6baba8e6541f" xlink:to="loc_us-gaap_VariableRateDomain_7ff11591-4f68-4981-9599-6baba8e6541f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7ff11591-4f68-4981-9599-6baba8e6541f" xlink:to="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_65b81fd5-bc26-4d9f-a0e7-a4c2285c7c68" xlink:href="bhc-20220930.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_65b81fd5-bc26-4d9f-a0e7-a4c2285c7c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_fd8e11d2-842d-401d-98e5-0050adfbbb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_fd8e11d2-842d-401d-98e5-0050adfbbb89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_0a65beb4-68a9-42a0-9d3b-35536e6f0b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_0a65beb4-68a9-42a0-9d3b-35536e6f0b69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_a763ab86-d5d1-4cf4-b46a-72ef32ddd91d" xlink:href="bhc-20220930.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_a763ab86-d5d1-4cf4-b46a-72ef32ddd91d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_ae401b44-de08-41fd-bc0f-9ed4ebeeb0cd" xlink:href="bhc-20220930.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_ae401b44-de08-41fd-bc0f-9ed4ebeeb0cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_bbc33e20-8302-4cec-ac75-74e52c9f9881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_us-gaap_BaseRateMember_bbc33e20-8302-4cec-ac75-74e52c9f9881" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_449e2b45-9532-4ac7-92c7-c04c93170da2" xlink:href="bhc-20220930.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_449e2b45-9532-4ac7-92c7-c04c93170da2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_a8a93622-094a-4a4c-8b86-dfb43e2ce897" xlink:href="bhc-20220930.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_a8a93622-094a-4a4c-8b86-dfb43e2ce897" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db14097e-cc5a-41b6-8c5b-919c615ca0ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_srt_RangeAxis_db14097e-cc5a-41b6-8c5b-919c615ca0ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db14097e-cc5a-41b6-8c5b-919c615ca0ff_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_db14097e-cc5a-41b6-8c5b-919c615ca0ff" xlink:to="loc_srt_RangeMember_db14097e-cc5a-41b6-8c5b-919c615ca0ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_db14097e-cc5a-41b6-8c5b-919c615ca0ff" xlink:to="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4ce0d6b-da7c-4585-b341-8fe3df653bfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:to="loc_srt_MinimumMember_d4ce0d6b-da7c-4585-b341-8fe3df653bfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_02d72be1-a4f0-48a8-8eff-1a3152b0e91a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:to="loc_srt_MaximumMember_02d72be1-a4f0-48a8-8eff-1a3152b0e91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ae9edd1b-a14f-4b78-ac45-ce69c213f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:to="loc_us-gaap_SecuredDebtMember_ae9edd1b-a14f-4b78-ac45-ce69c213f1a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c8730f64-29c8-4103-9337-ed81cf0525ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:to="loc_us-gaap_UnsecuredDebtMember_c8730f64-29c8-4103-9337-ed81cf0525ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9a6480ef-7c14-4cff-84cf-818d8468c578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_DebtInstrumentAxis_9a6480ef-7c14-4cff-84cf-818d8468c578" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9a6480ef-7c14-4cff-84cf-818d8468c578_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a6480ef-7c14-4cff-84cf-818d8468c578" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9a6480ef-7c14-4cff-84cf-818d8468c578_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a6480ef-7c14-4cff-84cf-818d8468c578" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_8dcf25ec-d8b0-4ce6-ace2-4a9e970bf206" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_8dcf25ec-d8b0-4ce6-ace2-4a9e970bf206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_a863ebdf-0aea-4949-a72b-e03156d27c9b" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_a863ebdf-0aea-4949-a72b-e03156d27c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_c57c4eec-f343-4e20-9727-c7488b8c8a3b" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_c57c4eec-f343-4e20-9727-c7488b8c8a3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0dea830a-1ec7-44ec-ae72-c005d1463ae7" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0dea830a-1ec7-44ec-ae72-c005d1463ae7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_bc0ca2b7-d8c3-43bc-a5a6-11017cfab6a9" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_bc0ca2b7-d8c3-43bc-a5a6-11017cfab6a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_107a06b2-a523-411c-b566-6660e57f0ac8" xlink:href="bhc-20220930.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_107a06b2-a523-411c-b566-6660e57f0ac8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_daf4cb7d-9345-4314-8386-d84580d95b0a" xlink:href="bhc-20220930.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_daf4cb7d-9345-4314-8386-d84580d95b0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_86c3c8cd-4f95-41dd-9eb4-6e1eba489b5e" xlink:href="bhc-20220930.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermFacilityDueMay2027Member_86c3c8cd-4f95-41dd-9eb4-6e1eba489b5e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_4f9fb01c-f4bf-4ceb-86f9-68a90c4bf9a6" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_4f9fb01c-f4bf-4ceb-86f9-68a90c4bf9a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e38b43d2-1ac3-4785-80f9-178256dec35f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_dei_LegalEntityAxis_e38b43d2-1ac3-4785-80f9-178256dec35f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e38b43d2-1ac3-4785-80f9-178256dec35f_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e38b43d2-1ac3-4785-80f9-178256dec35f" xlink:to="loc_dei_EntityDomain_e38b43d2-1ac3-4785-80f9-178256dec35f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8b6cef66-5c19-468a-83b1-944424f6bee7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e38b43d2-1ac3-4785-80f9-178256dec35f" xlink:to="loc_dei_EntityDomain_8b6cef66-5c19-468a-83b1-944424f6bee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_cd583bba-df2b-4916-8788-078ace3be28b" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8b6cef66-5c19-468a-83b1-944424f6bee7" xlink:to="loc_bhc_BauschLombMember_cd583bba-df2b-4916-8788-078ace3be28b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_89758e76-c713-4572-8a50-7e540df59071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_CreditFacilityAxis_89758e76-c713-4572-8a50-7e540df59071" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_89758e76-c713-4572-8a50-7e540df59071_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_89758e76-c713-4572-8a50-7e540df59071" xlink:to="loc_us-gaap_CreditFacilityDomain_89758e76-c713-4572-8a50-7e540df59071_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_78c299f7-004f-4efb-90ff-90f80bc085f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_89758e76-c713-4572-8a50-7e540df59071" xlink:to="loc_us-gaap_CreditFacilityDomain_78c299f7-004f-4efb-90ff-90f80bc085f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_902f16cd-909d-4093-bd36-653d91c59d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_78c299f7-004f-4efb-90ff-90f80bc085f4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_902f16cd-909d-4093-bd36-653d91c59d4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="i22a2d8ad261046ada86efc2166d621bf_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faea80d1-8837-4c69-a8f5-d08a168f169f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faea80d1-8837-4c69-a8f5-d08a168f169f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6273a4c7-3827-4fc6-b423-ec3284d1ee32" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6273a4c7-3827-4fc6-b423-ec3284d1ee32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13e3fe64-8b69-4a65-888e-56dc7abd1b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13e3fe64-8b69-4a65-888e-56dc7abd1b96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8ff00909-f34c-40b1-b013-fc82e167ff9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8ff00909-f34c-40b1-b013-fc82e167ff9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a22392b7-42bc-4273-b777-cd6ec242c3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a22392b7-42bc-4273-b777-cd6ec242c3f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f2f4c0c-cb14-44f3-97ce-87a1b847b800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f2f4c0c-cb14-44f3-97ce-87a1b847b800" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b8ca2efa-524d-4430-b31d-b0da9a3993a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b8ca2efa-524d-4430-b31d-b0da9a3993a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e6346646-1596-48cf-b217-1d18ae505b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e6346646-1596-48cf-b217-1d18ae505b2a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4df2ca92-ef19-4106-bf9d-7878ff788b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_us-gaap_DebtInstrumentAxis_4df2ca92-ef19-4106-bf9d-7878ff788b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4df2ca92-ef19-4106-bf9d-7878ff788b44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4df2ca92-ef19-4106-bf9d-7878ff788b44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4df2ca92-ef19-4106-bf9d-7878ff788b44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4df2ca92-ef19-4106-bf9d-7878ff788b44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_3b76a2b8-e89e-4bf1-b3b8-0d3f525d7942" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_3b76a2b8-e89e-4bf1-b3b8-0d3f525d7942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_da575037-9cf2-4114-a84c-30a6db3686a9" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_da575037-9cf2-4114-a84c-30a6db3686a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_2bafc10b-0885-4028-9b66-a847da91e97b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_2bafc10b-0885-4028-9b66-a847da91e97b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_ff09edcc-bd5e-4e7f-b87d-5cc815e862a5" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_ff09edcc-bd5e-4e7f-b87d-5cc815e862a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_9f127232-3704-44a2-a8de-64a181f2d28d" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_9f127232-3704-44a2-a8de-64a181f2d28d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_54a3815b-0a75-44b2-8b24-f923c91d3243" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_54a3815b-0a75-44b2-8b24-f923c91d3243" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b6bf01cd-6143-43ef-817f-5b00881a04f2" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b6bf01cd-6143-43ef-817f-5b00881a04f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_6989ed50-4835-48ce-bb22-e4b1b0b270d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:to="loc_us-gaap_UnsecuredDebtMember_6989ed50-4835-48ce-bb22-e4b1b0b270d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a42bbaf6-ecd8-497a-a24d-3d65e3e00f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:to="loc_us-gaap_SecuredDebtMember_a42bbaf6-ecd8-497a-a24d-3d65e3e00f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c3b829ef-a3fa-4d68-8215-c4c05f9600f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c3b829ef-a3fa-4d68-8215-c4c05f9600f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c3b829ef-a3fa-4d68-8215-c4c05f9600f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c3b829ef-a3fa-4d68-8215-c4c05f9600f1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c3b829ef-a3fa-4d68-8215-c4c05f9600f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c3b829ef-a3fa-4d68-8215-c4c05f9600f1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_738224ba-ec7c-4f0d-983f-b140a336911b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_738224ba-ec7c-4f0d-983f-b140a336911b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e2aa40bb-55a1-4a8e-a96a-aea394499a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e2aa40bb-55a1-4a8e-a96a-aea394499a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_002658c6-2397-4981-b53e-376b136a1cc0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_srt_RangeAxis_002658c6-2397-4981-b53e-376b136a1cc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_002658c6-2397-4981-b53e-376b136a1cc0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_002658c6-2397-4981-b53e-376b136a1cc0" xlink:to="loc_srt_RangeMember_002658c6-2397-4981-b53e-376b136a1cc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45fbc3d3-b990-4194-a2dd-27e6ad4d7cd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_002658c6-2397-4981-b53e-376b136a1cc0" xlink:to="loc_srt_RangeMember_45fbc3d3-b990-4194-a2dd-27e6ad4d7cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3898f57b-45ce-42f4-ab19-bbed7d68faf7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45fbc3d3-b990-4194-a2dd-27e6ad4d7cd0" xlink:to="loc_srt_MaximumMember_3898f57b-45ce-42f4-ab19-bbed7d68faf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bd6e9082-46b6-4ded-82ab-b32d0f6c0315" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_srt_OwnershipAxis_bd6e9082-46b6-4ded-82ab-b32d0f6c0315" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bd6e9082-46b6-4ded-82ab-b32d0f6c0315_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_bd6e9082-46b6-4ded-82ab-b32d0f6c0315" xlink:to="loc_srt_OwnershipDomain_bd6e9082-46b6-4ded-82ab-b32d0f6c0315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e6afe18d-b6c9-4c76-bca8-4825bb797a0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_bd6e9082-46b6-4ded-82ab-b32d0f6c0315" xlink:to="loc_srt_OwnershipDomain_e6afe18d-b6c9-4c76-bca8-4825bb797a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_214d2532-6083-4d71-8d54-02bc09ad25cd" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e6afe18d-b6c9-4c76-bca8-4825bb797a0f" xlink:to="loc_bhc_BauschLombMember_214d2532-6083-4d71-8d54-02bc09ad25cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_69c9f189-8a56-48e0-835d-00414d0cfe3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_dei_LegalEntityAxis_69c9f189-8a56-48e0-835d-00414d0cfe3e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_69c9f189-8a56-48e0-835d-00414d0cfe3e_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_69c9f189-8a56-48e0-835d-00414d0cfe3e" xlink:to="loc_dei_EntityDomain_69c9f189-8a56-48e0-835d-00414d0cfe3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66caacbd-2ab3-47a9-a8fe-312d2e17aa05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_69c9f189-8a56-48e0-835d-00414d0cfe3e" xlink:to="loc_dei_EntityDomain_66caacbd-2ab3-47a9-a8fe-312d2e17aa05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_5fd17f00-b23c-4e11-8e6d-839abaa443ce" xlink:href="bhc-20220930.xsd#bhc_A1375209BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66caacbd-2ab3-47a9-a8fe-312d2e17aa05" xlink:to="loc_bhc_A1375209BCLtdMember_5fd17f00-b23c-4e11-8e6d-839abaa443ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="ibd1685c231794920b91868caf3aa3df1_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_8df743b1-b97f-4926-aaf2-4b60b9597eaf" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_8df743b1-b97f-4926-aaf2-4b60b9597eaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3756f9b5-538c-4552-8d04-411b98677bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3756f9b5-538c-4552-8d04-411b98677bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_620ef5e8-7ba9-4ec7-95cf-74488ede89e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_620ef5e8-7ba9-4ec7-95cf-74488ede89e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_c7355381-c0f2-428e-a054-9a06591e0cf5" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_c7355381-c0f2-428e-a054-9a06591e0cf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_023aeed0-b486-4e29-bdec-b9c67ec4b80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_023aeed0-b486-4e29-bdec-b9c67ec4b80f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a68abe8-b470-49f0-a7b6-188d8a0b04b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a68abe8-b470-49f0-a7b6-188d8a0b04b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2660ad1e-f66f-478a-abfc-e5441c0c6cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a68abe8-b470-49f0-a7b6-188d8a0b04b8" xlink:to="loc_us-gaap_UnsecuredDebtMember_2660ad1e-f66f-478a-abfc-e5441c0c6cca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e34cf8e2-b603-45ff-8174-6a8b7e9676f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:to="loc_us-gaap_DebtInstrumentAxis_e34cf8e2-b603-45ff-8174-6a8b7e9676f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e34cf8e2-b603-45ff-8174-6a8b7e9676f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e34cf8e2-b603-45ff-8174-6a8b7e9676f1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e34cf8e2-b603-45ff-8174-6a8b7e9676f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e34cf8e2-b603-45ff-8174-6a8b7e9676f1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_932bee3b-2588-4d55-850d-b7c9e0388b27" xlink:href="bhc-20220930.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_932bee3b-2588-4d55-850d-b7c9e0388b27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_d28020cc-b014-4980-bb36-c5d0c4402700" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_d28020cc-b014-4980-bb36-c5d0c4402700" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="extended" id="ied02e3da076d48138f40e44040670fab_FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a417611-9fb7-4358-b2df-c139e4d7b270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a417611-9fb7-4358-b2df-c139e4d7b270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3d334c6d-61fa-4b71-8a51-d00b4f9879d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3d334c6d-61fa-4b71-8a51-d00b4f9879d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_029362bf-3166-4fca-90eb-90020ef78e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_029362bf-3166-4fca-90eb-90020ef78e4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_91572ace-1e83-4f5d-9218-f79b6cc0cf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:to="loc_us-gaap_DebtInstrumentTable_91572ace-1e83-4f5d-9218-f79b6cc0cf34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_91572ace-1e83-4f5d-9218-f79b6cc0cf34" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df06c227-602a-4d6f-9f12-62f6a2559de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df06c227-602a-4d6f-9f12-62f6a2559de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_790dd032-adba-4a8b-924a-0c8fd42ea3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df06c227-602a-4d6f-9f12-62f6a2559de9" xlink:to="loc_us-gaap_UnsecuredDebtMember_790dd032-adba-4a8b-924a-0c8fd42ea3b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="if3268bfb2ac04ca38263a77d7ef0b9c6_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ee4bc80a-2208-4b20-b36f-8352231f84f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ee4bc80a-2208-4b20-b36f-8352231f84f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_eb15f7b6-aa89-4c7f-a01a-9f35c6de3d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_eb15f7b6-aa89-4c7f-a01a-9f35c6de3d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3ff274bd-6898-4fed-99d9-6b59db05c755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3ff274bd-6898-4fed-99d9-6b59db05c755" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5e8aab20-b929-4a0f-bde8-819a7c158f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5e8aab20-b929-4a0f-bde8-819a7c158f61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_4e34d583-a344-4e98-8477-9aafee032be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_4e34d583-a344-4e98-8477-9aafee032be8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f021631d-47c0-4895-be93-3bc103db8193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f021631d-47c0-4895-be93-3bc103db8193" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f4dff6c1-0a77-4b90-81c3-3d537424b7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f4dff6c1-0a77-4b90-81c3-3d537424b7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f4dff6c1-0a77-4b90-81c3-3d537424b7fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f4dff6c1-0a77-4b90-81c3-3d537424b7fe" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f4dff6c1-0a77-4b90-81c3-3d537424b7fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f4dff6c1-0a77-4b90-81c3-3d537424b7fe" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1d2242e3-4e46-41cc-be5d-fef5caf5fe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1d2242e3-4e46-41cc-be5d-fef5caf5fe4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_21e302b7-7d0d-494c-b48b-33e4861aa0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_21e302b7-7d0d-494c-b48b-33e4861aa0ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7bc069e2-8f16-4947-a08d-fad3e64a0a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7bc069e2-8f16-4947-a08d-fad3e64a0a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7bc069e2-8f16-4947-a08d-fad3e64a0a49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7bc069e2-8f16-4947-a08d-fad3e64a0a49" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7bc069e2-8f16-4947-a08d-fad3e64a0a49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7bc069e2-8f16-4947-a08d-fad3e64a0a49" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_56827f01-436a-4d44-b35c-c0d127805db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:to="loc_us-gaap_DomesticPlanMember_56827f01-436a-4d44-b35c-c0d127805db8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2e13c79e-494c-4aa8-8e5f-51c4e7da2a49" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_56827f01-436a-4d44-b35c-c0d127805db8" xlink:to="loc_country_US_2e13c79e-494c-4aa8-8e5f-51c4e7da2a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_c9cf9e51-7747-4b5d-943a-318f407b1ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:to="loc_us-gaap_ForeignPlanMember_c9cf9e51-7747-4b5d-943a-318f407b1ee1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i8b874dee61a94a0f8086bedbd7074f33_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cf831b-9eb5-4922-93f9-47cb5348a31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cf831b-9eb5-4922-93f9-47cb5348a31f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e39d922-9e2a-403b-844c-0afc0e13b293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e39d922-9e2a-403b-844c-0afc0e13b293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdfd3586-3c62-481f-9399-7de0a891e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdfd3586-3c62-481f-9399-7de0a891e6fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c8f2870-10e4-45f4-ae2c-e768473f3272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c8f2870-10e4-45f4-ae2c-e768473f3272" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_892a9450-c3aa-42b8-9621-4c408038f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_892a9450-c3aa-42b8-9621-4c408038f6ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6cf9b8f6-884e-49df-a093-2fc232328589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6cf9b8f6-884e-49df-a093-2fc232328589" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_783ff1b3-65b3-4bcd-9ceb-5aa68525962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_783ff1b3-65b3-4bcd-9ceb-5aa68525962c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_940ae232-e75c-4d06-b2be-6886f41cf015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_940ae232-e75c-4d06-b2be-6886f41cf015" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_4c7d40dd-83f3-4263-9f25-7bc1e4dfc576" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_4c7d40dd-83f3-4263-9f25-7bc1e4dfc576" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_49e3710a-6b48-4fa9-a374-dca8bf3bc143" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_49e3710a-6b48-4fa9-a374-dca8bf3bc143" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_24729f95-6884-4f40-844f-12860d6cef2e" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_24729f95-6884-4f40-844f-12860d6cef2e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_4b4911f0-138f-4960-a090-542d2d2803c7" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_4b4911f0-138f-4960-a090-542d2d2803c7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_74d1472c-e2af-4444-8ecd-a474efb949d9" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_74d1472c-e2af-4444-8ecd-a474efb949d9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_860c6f32-2dee-424c-a381-67df8063f76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_860c6f32-2dee-424c-a381-67df8063f76f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68f09b5b-be57-44c8-a69e-38530cf5a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68f09b5b-be57-44c8-a69e-38530cf5a4be" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3434ff01-d4ce-4809-856f-8911569ca7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_us-gaap_PlanNameAxis_3434ff01-d4ce-4809-856f-8911569ca7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3434ff01-d4ce-4809-856f-8911569ca7c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3434ff01-d4ce-4809-856f-8911569ca7c1" xlink:to="loc_us-gaap_PlanNameDomain_3434ff01-d4ce-4809-856f-8911569ca7c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3434ff01-d4ce-4809-856f-8911569ca7c1" xlink:to="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_2e831132-de29-4561-8eb2-c9803042823f" xlink:href="bhc-20220930.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_2e831132-de29-4561-8eb2-c9803042823f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_c16d161a-5ac4-44e9-b89b-f41a49fc367c" xlink:href="bhc-20220930.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member_2e831132-de29-4561-8eb2-c9803042823f" xlink:to="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_c16d161a-5ac4-44e9-b89b-f41a49fc367c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember_854ea228-021a-4d56-8845-1e9b0ca2d489" xlink:href="bhc-20220930.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:to="loc_bhc_IPOFoundersGrantsMember_854ea228-021a-4d56-8845-1e9b0ca2d489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_fecaf2cf-1e74-4d02-9337-69a1141306b2" xlink:href="bhc-20220930.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_fecaf2cf-1e74-4d02-9337-69a1141306b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_675fbab0-e501-4407-bf02-49b3d51da14a" xlink:href="bhc-20220930.xsd#bhc_A2022OmnibusIncentivePlanRetentionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_A2022OmnibusIncentivePlanMember_fecaf2cf-1e74-4d02-9337-69a1141306b2" xlink:to="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_675fbab0-e501-4407-bf02-49b3d51da14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_srt_TitleOfIndividualAxis_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:href="bhc-20220930.xsd#bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_eaeb405f-9f2e-44bf-85f4-7b9feb818618" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:to="loc_srt_ExecutiveOfficerMember_eaeb405f-9f2e-44bf-85f4-7b9feb818618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_69bcb910-19f0-4927-9bbe-28a0f00a3bb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:to="loc_srt_ChiefExecutiveOfficerMember_69bcb910-19f0-4927-9bbe-28a0f00a3bb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember_49ddc57f-c331-441c-a291-b4c3b54a818a" xlink:href="bhc-20220930.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_NonExecutiveEligibleRecipientsMember_49ddc57f-c331-441c-a291-b4c3b54a818a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_6b6269d0-4069-4d67-8a3f-77f004d3b6e5" xlink:href="bhc-20220930.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_6b6269d0-4069-4d67-8a3f-77f004d3b6e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_86554bfb-6ed3-434f-8d1b-c1180dd250ef" xlink:href="bhc-20220930.xsd#bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_86554bfb-6ed3-434f-8d1b-c1180dd250ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9667210a-983d-4ee2-bd3a-a617a5cbca0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_us-gaap_AwardTypeAxis_9667210a-983d-4ee2-bd3a-a617a5cbca0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9667210a-983d-4ee2-bd3a-a617a5cbca0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9667210a-983d-4ee2-bd3a-a617a5cbca0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9667210a-983d-4ee2-bd3a-a617a5cbca0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbd2bbb4-fa4d-48df-afa3-5bd76a1f3bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9667210a-983d-4ee2-bd3a-a617a5cbca0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbd2bbb4-fa4d-48df-afa3-5bd76a1f3bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:href="bhc-20220930.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbd2bbb4-fa4d-48df-afa3-5bd76a1f3bbf" xlink:to="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5228fc68-8e9f-45f9-9c74-bc07cdede4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5228fc68-8e9f-45f9-9c74-bc07cdede4d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f046a628-365a-40b4-b1b1-aa40e446592a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f046a628-365a-40b4-b1b1-aa40e446592a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_229d0e08-b3b6-46cb-a80b-a9d1bff3364a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_dei_LegalEntityAxis_229d0e08-b3b6-46cb-a80b-a9d1bff3364a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_229d0e08-b3b6-46cb-a80b-a9d1bff3364a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_229d0e08-b3b6-46cb-a80b-a9d1bff3364a" xlink:to="loc_dei_EntityDomain_229d0e08-b3b6-46cb-a80b-a9d1bff3364a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f9f0f0c6-faa7-4dc3-a8c4-a38725bc3c6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_229d0e08-b3b6-46cb-a80b-a9d1bff3364a" xlink:to="loc_dei_EntityDomain_f9f0f0c6-faa7-4dc3-a8c4-a38725bc3c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_333fa265-c58c-437d-886b-de857246e585" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f9f0f0c6-faa7-4dc3-a8c4-a38725bc3c6d" xlink:to="loc_bhc_BauschLombMember_333fa265-c58c-437d-886b-de857246e585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0af2d4ea-268d-4f31-af19-85143107d17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_us-gaap_VestingAxis_0af2d4ea-268d-4f31-af19-85143107d17d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_0af2d4ea-268d-4f31-af19-85143107d17d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_0af2d4ea-268d-4f31-af19-85143107d17d" xlink:to="loc_us-gaap_VestingDomain_0af2d4ea-268d-4f31-af19-85143107d17d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_0af2d4ea-268d-4f31-af19-85143107d17d" xlink:to="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_360577a5-b6c4-4b83-b019-887378bf0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_360577a5-b6c4-4b83-b019-887378bf0f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7e847e0-4090-4ecc-8f70-14573eff6143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7e847e0-4090-4ecc-8f70-14573eff6143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e680f984-db6d-4dd9-95d7-13f426acfb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e680f984-db6d-4dd9-95d7-13f426acfb33" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i36e51399adb64c6198d12510644557b7_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8fb58ae6-0e58-4d54-a183-192223e14271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_188c169b-5d3a-49f8-aa61-d866e9c3f535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8fb58ae6-0e58-4d54-a183-192223e14271" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_188c169b-5d3a-49f8-aa61-d866e9c3f535" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8fb58ae6-0e58-4d54-a183-192223e14271" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_44402c39-9d35-46c1-adbb-8f6aee3b97cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:to="loc_us-gaap_AwardTypeAxis_44402c39-9d35-46c1-adbb-8f6aee3b97cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44402c39-9d35-46c1-adbb-8f6aee3b97cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_44402c39-9d35-46c1-adbb-8f6aee3b97cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44402c39-9d35-46c1-adbb-8f6aee3b97cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_44402c39-9d35-46c1-adbb-8f6aee3b97cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80adf5b7-1f3e-4d81-a027-4741d3edfffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80adf5b7-1f3e-4d81-a027-4741d3edfffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aad87936-27f6-41cf-96f7-e6d683b4b8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aad87936-27f6-41cf-96f7-e6d683b4b8cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f31f5465-724e-43c6-ac1a-acb19774f6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f31f5465-724e-43c6-ac1a-acb19774f6d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f31f5465-724e-43c6-ac1a-acb19774f6d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f31f5465-724e-43c6-ac1a-acb19774f6d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f31f5465-724e-43c6-ac1a-acb19774f6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f31f5465-724e-43c6-ac1a-acb19774f6d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a1f62489-8f83-478d-8a7b-e758d88ebc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a1f62489-8f83-478d-8a7b-e758d88ebc9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d4e9d45-5f48-4a21-abc3-9edeffb15e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d4e9d45-5f48-4a21-abc3-9edeffb15e65" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended" id="ie696d7b8546a401fbcf450434e44aa29_SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68e0a973-ec7b-4021-b626-7320f6c10ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68e0a973-ec7b-4021-b626-7320f6c10ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_44c0568a-0ffd-4af0-aef3-1387869be404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_44c0568a-0ffd-4af0-aef3-1387869be404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_065acdb1-1028-4c5d-9148-09a5750b282a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_065acdb1-1028-4c5d-9148-09a5750b282a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c18b239e-cece-4079-8095-671e4abb4c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c18b239e-cece-4079-8095-671e4abb4c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a14c71e3-10e1-4180-ba81-0a73ecb0add1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a14c71e3-10e1-4180-ba81-0a73ecb0add1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ed38b6df-eade-4a78-a6d3-3ace220a977d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:to="loc_us-gaap_AwardTypeAxis_ed38b6df-eade-4a78-a6d3-3ace220a977d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed38b6df-eade-4a78-a6d3-3ace220a977d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ed38b6df-eade-4a78-a6d3-3ace220a977d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ed38b6df-eade-4a78-a6d3-3ace220a977d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ed38b6df-eade-4a78-a6d3-3ace220a977d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_418ed384-c1ae-4d15-8a19-61c6edd9acad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_418ed384-c1ae-4d15-8a19-61c6edd9acad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_c8914a64-3173-4699-83c4-aec9b3165806" xlink:href="bhc-20220930.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_TimeBasedRSUMember_c8914a64-3173-4699-83c4-aec9b3165806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5410ba07-b9a3-4b7b-861f-0c8ee0368838" xlink:href="bhc-20220930.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5410ba07-b9a3-4b7b-861f-0c8ee0368838" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_efd0986e-6820-4996-8433-9192a35d8178" xlink:href="bhc-20220930.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_efd0986e-6820-4996-8433-9192a35d8178" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_010a7fe6-6f2d-498f-8354-7951c3b12117" xlink:href="bhc-20220930.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_010a7fe6-6f2d-498f-8354-7951c3b12117" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:to="loc_dei_LegalEntityAxis_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca" xlink:to="loc_dei_EntityDomain_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_58be9335-7a8d-4cf0-a7d3-2a08fa92af5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca" xlink:to="loc_dei_EntityDomain_58be9335-7a8d-4cf0-a7d3-2a08fa92af5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3d2f1a2e-459a-4249-ac65-7f5e4dcf825c" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_58be9335-7a8d-4cf0-a7d3-2a08fa92af5f" xlink:to="loc_bhc_BauschLombMember_3d2f1a2e-459a-4249-ac65-7f5e4dcf825c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i1c317d8e30a5406b8d6a3581acd5fa82_ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d867af88-0a43-4947-82aa-8505a0fdc3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52663b99-3b78-4e03-8d09-197715e93982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d867af88-0a43-4947-82aa-8505a0fdc3d7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52663b99-3b78-4e03-8d09-197715e93982" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25894525-d31e-4261-bdf4-ecf27adbf71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d867af88-0a43-4947-82aa-8505a0fdc3d7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25894525-d31e-4261-bdf4-ecf27adbf71f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8ac6fbf-0fda-4494-82d9-4e6681444772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25894525-d31e-4261-bdf4-ecf27adbf71f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8ac6fbf-0fda-4494-82d9-4e6681444772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8ac6fbf-0fda-4494-82d9-4e6681444772_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8ac6fbf-0fda-4494-82d9-4e6681444772" xlink:to="loc_us-gaap_EquityComponentDomain_c8ac6fbf-0fda-4494-82d9-4e6681444772_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8ac6fbf-0fda-4494-82d9-4e6681444772" xlink:to="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_901b0eeb-c691-4a71-97e0-47fb13536adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_901b0eeb-c691-4a71-97e0-47fb13536adb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_059ba6d3-fd33-4cb0-9658-53cb356056e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_059ba6d3-fd33-4cb0-9658-53cb356056e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_502a7bb9-76ab-4b80-8484-6c43dade88d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_502a7bb9-76ab-4b80-8484-6c43dade88d2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended" id="ic1af1bea72f34b9d80cbc62e2f1bd078_ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5c30a765-a0c2-4d2b-9d97-9d0a189730f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc000e5b-a07d-4dfc-9f64-0f3eccc808b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5c30a765-a0c2-4d2b-9d97-9d0a189730f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc000e5b-a07d-4dfc-9f64-0f3eccc808b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192b4bc0-35fa-43b2-9593-0756d5008af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5c30a765-a0c2-4d2b-9d97-9d0a189730f6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192b4bc0-35fa-43b2-9593-0756d5008af1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_be40e5bf-1ad5-413a-ba6a-5718bb7780d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192b4bc0-35fa-43b2-9593-0756d5008af1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_be40e5bf-1ad5-413a-ba6a-5718bb7780d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_be40e5bf-1ad5-413a-ba6a-5718bb7780d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_be40e5bf-1ad5-413a-ba6a-5718bb7780d2" xlink:to="loc_us-gaap_EquityComponentDomain_be40e5bf-1ad5-413a-ba6a-5718bb7780d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a7cf9485-5d80-43f1-b4bd-fa1521b2effd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_be40e5bf-1ad5-413a-ba6a-5718bb7780d2" xlink:to="loc_us-gaap_EquityComponentDomain_a7cf9485-5d80-43f1-b4bd-fa1521b2effd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b086720b-c800-4bc3-b29f-731a378cb6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a7cf9485-5d80-43f1-b4bd-fa1521b2effd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b086720b-c800-4bc3-b29f-731a378cb6ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#OTHEREXPENSEINCOMENETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="extended" id="i412a8d422853489e8bdde6fa208232d1_OTHEREXPENSEINCOMENETNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_9a4f6831-03ba-4205-a484-544b0d6f4d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_9a4f6831-03ba-4205-a484-544b0d6f4d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_deca8663-7a57-4345-a7a4-0df05a42d5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_deca8663-7a57-4345-a7a4-0df05a42d5d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fd82e71a-7c8c-467f-b8ea-8991843632fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fd82e71a-7c8c-467f-b8ea-8991843632fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd82e71a-7c8c-467f-b8ea-8991843632fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fd82e71a-7c8c-467f-b8ea-8991843632fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd82e71a-7c8c-467f-b8ea-8991843632fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48d474b1-f3a5-428a-a003-4d288ded2d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fd82e71a-7c8c-467f-b8ea-8991843632fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48d474b1-f3a5-428a-a003-4d288ded2d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_5eacf379-bfc5-4928-95e1-18b458d37c34" xlink:href="bhc-20220930.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48d474b1-f3a5-428a-a003-4d288ded2d61" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_5eacf379-bfc5-4928-95e1-18b458d37c34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0874bf19-3ddc-4a88-8b76-1cafb76e50ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0874bf19-3ddc-4a88-8b76-1cafb76e50ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0874bf19-3ddc-4a88-8b76-1cafb76e50ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0874bf19-3ddc-4a88-8b76-1cafb76e50ab" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0874bf19-3ddc-4a88-8b76-1cafb76e50ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c4891ece-a22a-471e-ab83-2636b2edcc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0874bf19-3ddc-4a88-8b76-1cafb76e50ab" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c4891ece-a22a-471e-ab83-2636b2edcc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_debf10fe-07c2-4bd7-8f3b-3dddc98e2a3c" xlink:href="bhc-20220930.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c4891ece-a22a-471e-ab83-2636b2edcc50" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_debf10fe-07c2-4bd7-8f3b-3dddc98e2a3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0f018350-421a-414c-854d-654e8a40284d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0f018350-421a-414c-854d-654e8a40284d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0f018350-421a-414c-854d-654e8a40284d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0f018350-421a-414c-854d-654e8a40284d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0f018350-421a-414c-854d-654e8a40284d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f7fedfb4-14fe-46b3-8741-69ca90f509f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0f018350-421a-414c-854d-654e8a40284d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f7fedfb4-14fe-46b3-8741-69ca90f509f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b1d83acc-459d-4ee6-853f-d62d0e1b841e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f7fedfb4-14fe-46b3-8741-69ca90f509f0" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b1d83acc-459d-4ee6-853f-d62d0e1b841e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#EARNINGSLOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="extended" id="i42ffe65b145d429c9abfc5409c6021fd_EARNINGSLOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5186d28-f7cf-41a0-96c1-a837adc813a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5186d28-f7cf-41a0-96c1-a837adc813a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_b3e0a438-5e86-4df2-a326-097565d453f5" xlink:href="bhc-20220930.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_b3e0a438-5e86-4df2-a326-097565d453f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_43d38b80-6522-4ee7-91b9-1ad89bfca940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_43d38b80-6522-4ee7-91b9-1ad89bfca940" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15e3f0a1-c0d1-4947-97c8-737c686e07e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_43d38b80-6522-4ee7-91b9-1ad89bfca940" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15e3f0a1-c0d1-4947-97c8-737c686e07e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15e3f0a1-c0d1-4947-97c8-737c686e07e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15e3f0a1-c0d1-4947-97c8-737c686e07e1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_15e3f0a1-c0d1-4947-97c8-737c686e07e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15e3f0a1-c0d1-4947-97c8-737c686e07e1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_bdd9d5f8-e600-47ef-be36-b4642ef1dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:to="loc_us-gaap_StockCompensationPlanMember_bdd9d5f8-e600-47ef-be36-b4642ef1dd14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_2b216048-234b-4f88-9a8e-a65d900d56ee" xlink:href="bhc-20220930.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_2b216048-234b-4f88-9a8e-a65d900d56ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_dfaebdfa-b48c-411c-9ef8-acd8038404e2" xlink:href="bhc-20220930.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_dfaebdfa-b48c-411c-9ef8-acd8038404e2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended" id="i98266cf475764b81ae95910734081bc4_LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b3210501-431b-4fe2-b302-e21e99ee3ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b3210501-431b-4fe2-b302-e21e99ee3ac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_74383054-b875-4577-ad03-6605eb3ed817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_74383054-b875-4577-ad03-6605eb3ed817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_9d4f6339-4fd6-4ccd-a5c7-2b14b79e4d92" xlink:href="bhc-20220930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_9d4f6339-4fd6-4ccd-a5c7-2b14b79e4d92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_782c4342-94fd-4765-805b-b5b2941a8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_782c4342-94fd-4765-805b-b5b2941a8b8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_992a8cc1-6657-4987-bc42-3573e4395fff" xlink:href="bhc-20220930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_992a8cc1-6657-4987-bc42-3573e4395fff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_8f25ab3d-e512-484c-ac54-bba1dce28f9a" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_8f25ab3d-e512-484c-ac54-bba1dce28f9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_1b0631af-7d9c-4919-9c88-3415d11c45ec" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_1b0631af-7d9c-4919-9c88-3415d11c45ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_a97654db-ead9-432e-8c28-c8507728cf27" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_a97654db-ead9-432e-8c28-c8507728cf27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_50514555-8f9d-49b9-b882-e9d661923f88" xlink:href="bhc-20220930.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_50514555-8f9d-49b9-b882-e9d661923f88" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_54f14f9b-a74a-4346-9585-ec91e43313e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_54f14f9b-a74a-4346-9585-ec91e43313e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5cc20951-c91a-4b30-870a-2f0f4da9bced" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_srt_LitigationCaseAxis_5cc20951-c91a-4b30-870a-2f0f4da9bced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5cc20951-c91a-4b30-870a-2f0f4da9bced_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_5cc20951-c91a-4b30-870a-2f0f4da9bced" xlink:to="loc_srt_LitigationCaseTypeDomain_5cc20951-c91a-4b30-870a-2f0f4da9bced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_5cc20951-c91a-4b30-870a-2f0f4da9bced" xlink:to="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_de20d3dc-e720-4f2d-ae16-81792188b97c" xlink:href="bhc-20220930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_de20d3dc-e720-4f2d-ae16-81792188b97c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_90067e69-f59a-44f3-9ea7-a7e7b5c08639" xlink:href="bhc-20220930.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_90067e69-f59a-44f3-9ea7-a7e7b5c08639" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_6248978e-7618-425f-b218-cca4d3c32788" xlink:href="bhc-20220930.xsd#bhc_RICOClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_RICOClassActionsMember_6248978e-7618-425f-b218-cca4d3c32788" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_fc99278f-21f0-4954-bdc9-1f834af0b4e0" xlink:href="bhc-20220930.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_fc99278f-21f0-4954-bdc9-1f834af0b4e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_acb65f7c-b40b-40e2-814e-0c238feb96c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_us-gaap_LitigationStatusAxis_acb65f7c-b40b-40e2-814e-0c238feb96c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_acb65f7c-b40b-40e2-814e-0c238feb96c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_acb65f7c-b40b-40e2-814e-0c238feb96c3" xlink:to="loc_us-gaap_LitigationStatusDomain_acb65f7c-b40b-40e2-814e-0c238feb96c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_50a94d80-6d9f-4c4a-a1c7-14b3494b6d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_acb65f7c-b40b-40e2-814e-0c238feb96c3" xlink:to="loc_us-gaap_LitigationStatusDomain_50a94d80-6d9f-4c4a-a1c7-14b3494b6d15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5c41e014-79fb-4ccb-a144-d994e83f315c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_50a94d80-6d9f-4c4a-a1c7-14b3494b6d15" xlink:to="loc_us-gaap_SettledLitigationMember_5c41e014-79fb-4ccb-a144-d994e83f315c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9491703b-35b3-4ba4-8c2c-db6d0554a2e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_srt_StatementGeographicalAxis_9491703b-35b3-4ba4-8c2c-db6d0554a2e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9491703b-35b3-4ba4-8c2c-db6d0554a2e7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9491703b-35b3-4ba4-8c2c-db6d0554a2e7" xlink:to="loc_srt_SegmentGeographicalDomain_9491703b-35b3-4ba4-8c2c-db6d0554a2e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9491703b-35b3-4ba4-8c2c-db6d0554a2e7" xlink:to="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_1027eeb2-ab31-474c-8e59-90fc79533ef0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:to="loc_stpr_NJ_1027eeb2-ab31-474c-8e59-90fc79533ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_7375c8aa-a7af-4085-9f47-6434066f87b4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:to="loc_country_CA_7375c8aa-a7af-4085-9f47-6434066f87b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4e408215-f53b-4740-957e-725f8dcdb2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4e408215-f53b-4740-957e-725f8dcdb2d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_4e408215-f53b-4740-957e-725f8dcdb2d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4e408215-f53b-4740-957e-725f8dcdb2d5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_4e408215-f53b-4740-957e-725f8dcdb2d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4e408215-f53b-4740-957e-725f8dcdb2d5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_d6a1074c-602a-4447-b6a7-5562ced594a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_d6a1074c-602a-4447-b6a7-5562ced594a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_089b49aa-ac0f-41cd-902f-b5596a5b0eaf" xlink:href="bhc-20220930.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_089b49aa-ac0f-41cd-902f-b5596a5b0eaf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended" id="i567928e6f28c416a9269b0badbab0d97_LEGALPROCEEDINGSAntitrustDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f6498ffa-63a7-4008-a76d-8c2cbf511ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f6498ffa-63a7-4008-a76d-8c2cbf511ee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_132d109d-a6df-4c16-9c64-ac85d79a4121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_132d109d-a6df-4c16-9c64-ac85d79a4121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:to="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_25c4a852-f27d-4839-a870-a713561da969" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:to="loc_srt_LitigationCaseAxis_25c4a852-f27d-4839-a870-a713561da969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_25c4a852-f27d-4839-a870-a713561da969_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_25c4a852-f27d-4839-a870-a713561da969" xlink:to="loc_srt_LitigationCaseTypeDomain_25c4a852-f27d-4839-a870-a713561da969_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_25c4a852-f27d-4839-a870-a713561da969" xlink:to="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_0a355667-1851-4ec4-93dd-0b4c6bfb9e1b" xlink:href="bhc-20220930.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_0a355667-1851-4ec4-93dd-0b4c6bfb9e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_2ca06102-2ee8-42af-b467-7e9893ec217b" xlink:href="bhc-20220930.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_2ca06102-2ee8-42af-b467-7e9893ec217b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_38d99c62-9bad-40f5-9b32-e880b601bf55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:to="loc_srt_CounterpartyNameAxis_38d99c62-9bad-40f5-9b32-e880b601bf55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38d99c62-9bad-40f5-9b32-e880b601bf55_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_38d99c62-9bad-40f5-9b32-e880b601bf55" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_38d99c62-9bad-40f5-9b32-e880b601bf55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746e62e8-5691-4c23-85cb-54af454c2425" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_38d99c62-9bad-40f5-9b32-e880b601bf55" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746e62e8-5691-4c23-85cb-54af454c2425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_bdd105b1-5179-497a-b1a2-70288eee009a" xlink:href="bhc-20220930.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746e62e8-5691-4c23-85cb-54af454c2425" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_bdd105b1-5179-497a-b1a2-70288eee009a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a049209c-d34e-43fb-81f5-d97e429a3f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:to="loc_us-gaap_LitigationStatusAxis_a049209c-d34e-43fb-81f5-d97e429a3f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a049209c-d34e-43fb-81f5-d97e429a3f3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_a049209c-d34e-43fb-81f5-d97e429a3f3f" xlink:to="loc_us-gaap_LitigationStatusDomain_a049209c-d34e-43fb-81f5-d97e429a3f3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_27c9279d-6546-4cbf-a811-2aa46b946e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_a049209c-d34e-43fb-81f5-d97e429a3f3f" xlink:to="loc_us-gaap_LitigationStatusDomain_27c9279d-6546-4cbf-a811-2aa46b946e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4c1c3087-4cbb-4946-a845-685e0288275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_27c9279d-6546-4cbf-a811-2aa46b946e7e" xlink:to="loc_us-gaap_PendingLitigationMember_4c1c3087-4cbb-4946-a845-685e0288275b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended" id="if04b88f8c3ba4ccdb2e81ba28bbf1edd_LEGALPROCEEDINGSIntellectualPropertyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_0af6b4dc-89d5-40fc-a3a0-7314bbc8cafc" xlink:href="bhc-20220930.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_0af6b4dc-89d5-40fc-a3a0-7314bbc8cafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_e87dfc58-7a0a-4f60-ad4f-267c2d3bb6ed" xlink:href="bhc-20220930.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_e87dfc58-7a0a-4f60-ad4f-267c2d3bb6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings_6fa743c4-6ac6-4863-84ee-d737ac500af9" xlink:href="bhc-20220930.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_bhc_GainContingencyNumberOfProceedings_6fa743c4-6ac6-4863-84ee-d737ac500af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_323ddfc0-1b69-4937-8634-ada54a6f6145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_323ddfc0-1b69-4937-8634-ada54a6f6145" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_daf88d5a-4519-44ae-aa48-18ec514ca659" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_srt_LitigationCaseAxis_daf88d5a-4519-44ae-aa48-18ec514ca659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_daf88d5a-4519-44ae-aa48-18ec514ca659_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_daf88d5a-4519-44ae-aa48-18ec514ca659" xlink:to="loc_srt_LitigationCaseTypeDomain_daf88d5a-4519-44ae-aa48-18ec514ca659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_daf88d5a-4519-44ae-aa48-18ec514ca659" xlink:to="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_504ec8da-69ea-4093-81eb-0a3fc8dc62dd" xlink:href="bhc-20220930.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_504ec8da-69ea-4093-81eb-0a3fc8dc62dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_1ea92f5f-082e-414b-9665-ceafe3bfd12c" xlink:href="bhc-20220930.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_1ea92f5f-082e-414b-9665-ceafe3bfd12c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_72197a1d-3897-439f-9691-dd726a123d9f" xlink:href="bhc-20220930.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_72197a1d-3897-439f-9691-dd726a123d9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_a285dcfa-cb06-4e26-85d6-498fb7a534ad" xlink:href="bhc-20220930.xsd#bhc_PadagisLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PadagisLitigationMember_a285dcfa-cb06-4e26-85d6-498fb7a534ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_c8a88b5c-6f43-496b-9577-2a6a8175e782" xlink:href="bhc-20220930.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_c8a88b5c-6f43-496b-9577-2a6a8175e782" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_68eb091b-65e1-4bc2-80b2-448372b3ea61" xlink:href="bhc-20220930.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_68eb091b-65e1-4bc2-80b2-448372b3ea61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_b2bd2d60-1c45-423c-a412-72fd475f0a96" xlink:href="bhc-20220930.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_b2bd2d60-1c45-423c-a412-72fd475f0a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_7e425e31-f7e1-451a-b576-374a5a12f044" xlink:href="bhc-20220930.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_7e425e31-f7e1-451a-b576-374a5a12f044" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember_377be25b-0eef-4be0-9645-576970f091cb" xlink:href="bhc-20220930.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PatentInfringementLitigationMember_377be25b-0eef-4be0-9645-576970f091cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_90f13c2a-9dd8-4e0d-b258-9716e9ded47e" xlink:href="bhc-20220930.xsd#bhc_ApotexIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_ApotexIncLitigationMember_90f13c2a-9dd8-4e0d-b258-9716e9ded47e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e72f29b1-ae24-42d9-a800-95bd5468284f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_srt_StatementGeographicalAxis_e72f29b1-ae24-42d9-a800-95bd5468284f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e72f29b1-ae24-42d9-a800-95bd5468284f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e72f29b1-ae24-42d9-a800-95bd5468284f" xlink:to="loc_srt_SegmentGeographicalDomain_e72f29b1-ae24-42d9-a800-95bd5468284f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_868ed576-a9d0-47ef-9274-6d93d1f56e1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e72f29b1-ae24-42d9-a800-95bd5468284f" xlink:to="loc_srt_SegmentGeographicalDomain_868ed576-a9d0-47ef-9274-6d93d1f56e1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8dfdd5e3-e455-42a2-a5c7-4e4eb81ed3e7" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_868ed576-a9d0-47ef-9274-6d93d1f56e1c" xlink:to="loc_country_CA_8dfdd5e3-e455-42a2-a5c7-4e4eb81ed3e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_059fe05b-3958-4bd1-aaad-a864a95254be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_us-gaap_LitigationStatusAxis_059fe05b-3958-4bd1-aaad-a864a95254be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_059fe05b-3958-4bd1-aaad-a864a95254be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_059fe05b-3958-4bd1-aaad-a864a95254be" xlink:to="loc_us-gaap_LitigationStatusDomain_059fe05b-3958-4bd1-aaad-a864a95254be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_059fe05b-3958-4bd1-aaad-a864a95254be" xlink:to="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f1994913-726b-4de4-957c-9e7d64018d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:to="loc_us-gaap_PendingLitigationMember_f1994913-726b-4de4-957c-9e7d64018d96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_929dd660-1d63-4358-bee3-a29795bf2107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:to="loc_us-gaap_SettledLitigationMember_929dd660-1d63-4358-bee3-a29795bf2107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_acf126ca-ab96-4991-95af-1b600d9c8464" xlink:href="bhc-20220930.xsd#bhc_DefaultJudgementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:to="loc_bhc_DefaultJudgementMember_acf126ca-ab96-4991-95af-1b600d9c8464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ae0f5e11-b405-4b74-9df6-7af37eb77a9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_dei_LegalEntityAxis_ae0f5e11-b405-4b74-9df6-7af37eb77a9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ae0f5e11-b405-4b74-9df6-7af37eb77a9d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ae0f5e11-b405-4b74-9df6-7af37eb77a9d" xlink:to="loc_dei_EntityDomain_ae0f5e11-b405-4b74-9df6-7af37eb77a9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1e317357-11dc-451a-a768-ed3607494b0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ae0f5e11-b405-4b74-9df6-7af37eb77a9d" xlink:to="loc_dei_EntityDomain_1e317357-11dc-451a-a768-ed3607494b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_bd28c8cf-f53c-4b71-86e2-2d456126bb3c" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1e317357-11dc-451a-a768-ed3607494b0e" xlink:to="loc_bhc_BauschLombMember_bd28c8cf-f53c-4b71-86e2-2d456126bb3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_180d5ad0-dfb4-464d-a787-c5a78bf69931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_180d5ad0-dfb4-464d-a787-c5a78bf69931" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_180d5ad0-dfb4-464d-a787-c5a78bf69931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_180d5ad0-dfb4-464d-a787-c5a78bf69931" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_180d5ad0-dfb4-464d-a787-c5a78bf69931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4fb7cb31-18f4-48cc-86fe-ab7db2eb3abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_180d5ad0-dfb4-464d-a787-c5a78bf69931" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4fb7cb31-18f4-48cc-86fe-ab7db2eb3abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_59ebb296-95bc-45c7-85fb-d49396781bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4fb7cb31-18f4-48cc-86fe-ab7db2eb3abb" xlink:to="loc_us-gaap_SubsequentEventMember_59ebb296-95bc-45c7-85fb-d49396781bb2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended" id="ibbbfacaa2c6243d59df65a0305a2827a_LEGALPROCEEDINGSProductLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b3dde066-50ac-48a2-87e8-4d512d191ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b3dde066-50ac-48a2-87e8-4d512d191ddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_c1632b2b-c9cf-48b3-b9f2-a0001666bed7" xlink:href="bhc-20220930.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_c1632b2b-c9cf-48b3-b9f2-a0001666bed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_b21bd05b-d77d-4dc7-afdd-3e5e7acf6277" xlink:href="bhc-20220930.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_b21bd05b-d77d-4dc7-afdd-3e5e7acf6277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:to="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:to="loc_srt_LitigationCaseAxis_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10" xlink:to="loc_srt_LitigationCaseTypeDomain_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10" xlink:to="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_a776109e-3d3c-4a78-806b-efe5df97c6e2" xlink:href="bhc-20220930.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_a776109e-3d3c-4a78-806b-efe5df97c6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_096f296a-6323-47cb-aa40-5a8ff5b67c7b" xlink:href="bhc-20220930.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_a776109e-3d3c-4a78-806b-efe5df97c6e2" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_096f296a-6323-47cb-aa40-5a8ff5b67c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_b56db4ea-8346-4952-9929-782cc3487243" xlink:href="bhc-20220930.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_b56db4ea-8346-4952-9929-782cc3487243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f6250362-63d1-4d0f-9789-315da363e8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:to="loc_us-gaap_LitigationStatusAxis_f6250362-63d1-4d0f-9789-315da363e8d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f6250362-63d1-4d0f-9789-315da363e8d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_f6250362-63d1-4d0f-9789-315da363e8d1" xlink:to="loc_us-gaap_LitigationStatusDomain_f6250362-63d1-4d0f-9789-315da363e8d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_27097455-e01b-483e-b3c6-b52dbd630a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_f6250362-63d1-4d0f-9789-315da363e8d1" xlink:to="loc_us-gaap_LitigationStatusDomain_27097455-e01b-483e-b3c6-b52dbd630a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_30a583f3-ef15-4847-b979-c8be83aabdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_27097455-e01b-483e-b3c6-b52dbd630a95" xlink:to="loc_us-gaap_PendingLitigationMember_30a583f3-ef15-4847-b979-c8be83aabdb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_119d4fef-2ded-49c8-a76c-02ef7a0c5824" xlink:href="bhc-20220930.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PendingLitigationMember_30a583f3-ef15-4847-b979-c8be83aabdb2" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_119d4fef-2ded-49c8-a76c-02ef7a0c5824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4e40ecd8-aa17-43c9-b46b-09c160a9be25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:to="loc_srt_StatementGeographicalAxis_4e40ecd8-aa17-43c9-b46b-09c160a9be25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4e40ecd8-aa17-43c9-b46b-09c160a9be25_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4e40ecd8-aa17-43c9-b46b-09c160a9be25" xlink:to="loc_srt_SegmentGeographicalDomain_4e40ecd8-aa17-43c9-b46b-09c160a9be25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4e40ecd8-aa17-43c9-b46b-09c160a9be25" xlink:to="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e3960d3c-9b1b-48ad-a8f8-3e8351e8788a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:to="loc_country_CA_e3960d3c-9b1b-48ad-a8f8-3e8351e8788a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_e7443751-621f-4f66-934d-e809e3aa9395" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:to="loc_stpr_CA-BC_e7443751-621f-4f66-934d-e809e3aa9395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_fc8981b3-fcf9-486e-8611-34c62f119268" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:to="loc_stpr_CA-QC_fc8981b3-fcf9-486e-8611-34c62f119268" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended" id="i44e4e35452154466a00a83fe002d1330_LEGALPROCEEDINGSGeneralCivilActionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d909ba83-6646-4a55-a476-49cf054cb27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_c6ba9c59-6123-4f1e-bea1-372067da491b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d909ba83-6646-4a55-a476-49cf054cb27e" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_c6ba9c59-6123-4f1e-bea1-372067da491b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_88c5145e-8cfe-46a8-8b13-1f85a6888095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d909ba83-6646-4a55-a476-49cf054cb27e" xlink:to="loc_us-gaap_LossContingenciesTable_88c5145e-8cfe-46a8-8b13-1f85a6888095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b329c0e4-b24d-4105-96fe-de5486391479" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_88c5145e-8cfe-46a8-8b13-1f85a6888095" xlink:to="loc_srt_LitigationCaseAxis_b329c0e4-b24d-4105-96fe-de5486391479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b329c0e4-b24d-4105-96fe-de5486391479_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b329c0e4-b24d-4105-96fe-de5486391479" xlink:to="loc_srt_LitigationCaseTypeDomain_b329c0e4-b24d-4105-96fe-de5486391479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b329c0e4-b24d-4105-96fe-de5486391479" xlink:to="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_ad6f523a-f0e0-43a9-98f6-e45f196afe89" xlink:href="bhc-20220930.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_ad6f523a-f0e0-43a9-98f6-e45f196afe89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_e7217311-5fc1-4b64-b3ef-f5e7ddf0be1b" xlink:href="bhc-20220930.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_e7217311-5fc1-4b64-b3ef-f5e7ddf0be1b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="if2e947e33a0647d9821a855cffcec717_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_e2b026b3-c12e-4470-a89f-2a86be7c8f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:to="loc_us-gaap_NumberOfReportingUnits_e2b026b3-c12e-4470-a89f-2a86be7c8f70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_598f21f2-2abe-48ed-9e46-b344132d0b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_598f21f2-2abe-48ed-9e46-b344132d0b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96" xlink:to="loc_us-gaap_SegmentDomain_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96" xlink:to="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_1e0c0fc9-4ff3-408c-bf35-f820ef13ef36" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_1e0c0fc9-4ff3-408c-bf35-f820ef13ef36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_c9863faa-3eef-4151-8715-7de5a15e9b8b" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:to="loc_bhc_SalixSegmentMember_c9863faa-3eef-4151-8715-7de5a15e9b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df983ec2-e1ff-4459-aa8b-c5061971afbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_srt_ProductOrServiceAxis_df983ec2-e1ff-4459-aa8b-c5061971afbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df983ec2-e1ff-4459-aa8b-c5061971afbb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_df983ec2-e1ff-4459-aa8b-c5061971afbb" xlink:to="loc_srt_ProductsAndServicesDomain_df983ec2-e1ff-4459-aa8b-c5061971afbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d9c64158-8da2-4d7a-9942-b16581cd82bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_df983ec2-e1ff-4459-aa8b-c5061971afbb" xlink:to="loc_srt_ProductsAndServicesDomain_d9c64158-8da2-4d7a-9942-b16581cd82bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_dbfcd7b8-2b53-4757-a1e4-77b607c0111f" xlink:href="bhc-20220930.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9c64158-8da2-4d7a-9942-b16581cd82bd" xlink:to="loc_bhc_XifaxanBrandedProductsMember_dbfcd7b8-2b53-4757-a1e4-77b607c0111f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a483a246-994d-45ee-946d-0ca85ee86acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a483a246-994d-45ee-946d-0ca85ee86acb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a483a246-994d-45ee-946d-0ca85ee86acb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a483a246-994d-45ee-946d-0ca85ee86acb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a483a246-994d-45ee-946d-0ca85ee86acb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93201bad-b8df-4211-be71-142d9012d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a483a246-994d-45ee-946d-0ca85ee86acb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93201bad-b8df-4211-be71-142d9012d4b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_85d1488c-f9c8-43c8-b943-8aca240a66b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93201bad-b8df-4211-be71-142d9012d4b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_85d1488c-f9c8-43c8-b943-8aca240a66b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9524787b-5c75-4dc3-911f-138b690a79ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9524787b-5c75-4dc3-911f-138b690a79ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9524787b-5c75-4dc3-911f-138b690a79ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9524787b-5c75-4dc3-911f-138b690a79ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9524787b-5c75-4dc3-911f-138b690a79ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_155ab678-9d35-416f-ae1b-c1b44d178431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9524787b-5c75-4dc3-911f-138b690a79ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_155ab678-9d35-416f-ae1b-c1b44d178431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d11abd77-80e1-4d77-abf4-fbfaec336409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_155ab678-9d35-416f-ae1b-c1b44d178431" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d11abd77-80e1-4d77-abf4-fbfaec336409" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended" id="iac243d94913c4080ae8bd9a74336fe5c_SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fde1efce-e0fa-4876-9a50-d74c5694de69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fde1efce-e0fa-4876-9a50-d74c5694de69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_532fe166-27f0-4638-8972-ca7c3357b2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_OperatingIncomeLoss_532fe166-27f0-4638-8972-ca7c3357b2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_970dcfa6-a794-4d02-88e3-db0d37dd2e76" xlink:href="bhc-20220930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_970dcfa6-a794-4d02-88e3-db0d37dd2e76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0ff9aede-873e-460b-87f0-c1c932a1fde1" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0ff9aede-873e-460b-87f0-c1c932a1fde1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c26f0066-0c4f-4dc7-ace0-895eb13b73f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_AssetImpairmentCharges_c26f0066-0c4f-4dc7-ace0-895eb13b73f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_48dea98b-e058-41e6-9aa3-56b03dfdfe25" xlink:href="bhc-20220930.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_48dea98b-e058-41e6-9aa3-56b03dfdfe25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8387009f-591a-4920-b2bc-eaf8fb034337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8387009f-591a-4920-b2bc-eaf8fb034337" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_969ce13b-56ca-49ea-8c75-2ed61ad07cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_969ce13b-56ca-49ea-8c75-2ed61ad07cd1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3ccc7371-4a80-4cea-a3ad-f366b6ccbf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_InterestExpenseDebt_3ccc7371-4a80-4cea-a3ad-f366b6ccbf55" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_94658ede-58a7-46bf-b833-8658bfe2e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_94658ede-58a7-46bf-b833-8658bfe2e63f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e83550f0-0b8a-4d0c-a7e8-81e3ef6de6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e83550f0-0b8a-4d0c-a7e8-81e3ef6de6bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5e3d82f-28e7-4dd3-b49a-a265b2e4bb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5e3d82f-28e7-4dd3-b49a-a265b2e4bb19" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_bbbac6c1-8de8-4fa8-bb7e-2036b245b071" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:to="loc_srt_ConsolidationItemsAxis_bbbac6c1-8de8-4fa8-bb7e-2036b245b071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_bbbac6c1-8de8-4fa8-bb7e-2036b245b071_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_bbbac6c1-8de8-4fa8-bb7e-2036b245b071" xlink:to="loc_srt_ConsolidationItemsDomain_bbbac6c1-8de8-4fa8-bb7e-2036b245b071_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_bbbac6c1-8de8-4fa8-bb7e-2036b245b071" xlink:to="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_3159f94c-626c-4c86-ad00-8d3b7c980d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:to="loc_us-gaap_OperatingSegmentsMember_3159f94c-626c-4c86-ad00-8d3b7c980d56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_182ed762-c6ce-4809-9a5d-18ba13832b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:to="loc_us-gaap_CorporateNonSegmentMember_182ed762-c6ce-4809-9a5d-18ba13832b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3d61d34c-397a-4e10-ba87-c2e372c7ed94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3d61d34c-397a-4e10-ba87-c2e372c7ed94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3d61d34c-397a-4e10-ba87-c2e372c7ed94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d61d34c-397a-4e10-ba87-c2e372c7ed94" xlink:to="loc_us-gaap_SegmentDomain_3d61d34c-397a-4e10-ba87-c2e372c7ed94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d61d34c-397a-4e10-ba87-c2e372c7ed94" xlink:to="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_bf6d47cd-94a1-4574-9726-9d6ed1ffbd2c" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_SalixSegmentMember_bf6d47cd-94a1-4574-9726-9d6ed1ffbd2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_6d4f02b2-1b5a-435d-9ae4-cb876a74ed1d" xlink:href="bhc-20220930.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_InternationalRxMember_6d4f02b2-1b5a-435d-9ae4-cb876a74ed1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_33631fda-271e-4b41-b3c3-789712008e36" xlink:href="bhc-20220930.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_SoltaMedicalSegmentMember_33631fda-271e-4b41-b3c3-789712008e36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_7dc8ce20-b080-40d0-bcf9-f6ce12508c8a" xlink:href="bhc-20220930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_7dc8ce20-b080-40d0-bcf9-f6ce12508c8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_5c390a9c-5adc-4940-b654-b929a55cb31a" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_BauschLombMember_5c390a9c-5adc-4940-b654-b929a55cb31a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended" id="i9072d7d3f73d42a185c84f969208d016_SEGMENTINFORMATIONDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b0a12c3a-ef04-4e30-b9f3-7906aec922ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2aa71afd-acdf-4a87-a1b2-f9691dce332e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0a12c3a-ef04-4e30-b9f3-7906aec922ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2aa71afd-acdf-4a87-a1b2-f9691dce332e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0a12c3a-ef04-4e30-b9f3-7906aec922ef" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_46cffc93-ddde-4304-b2b9-a9806c33509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_46cffc93-ddde-4304-b2b9-a9806c33509a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_46cffc93-ddde-4304-b2b9-a9806c33509a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46cffc93-ddde-4304-b2b9-a9806c33509a" xlink:to="loc_us-gaap_SegmentDomain_46cffc93-ddde-4304-b2b9-a9806c33509a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46cffc93-ddde-4304-b2b9-a9806c33509a" xlink:to="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_2ba0b15d-35df-4f8e-a9c5-40c01f6e122b" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_SalixSegmentMember_2ba0b15d-35df-4f8e-a9c5-40c01f6e122b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_c3147002-ecf7-48d6-910e-d8bb428d858f" xlink:href="bhc-20220930.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_InternationalRxMember_c3147002-ecf7-48d6-910e-d8bb428d858f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_99099ae2-1583-4aaf-a276-90b6d74326a7" xlink:href="bhc-20220930.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_SoltaMedicalSegmentMember_99099ae2-1583-4aaf-a276-90b6d74326a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_9a2ca8fb-1580-450a-80ff-679a35179d95" xlink:href="bhc-20220930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_9a2ca8fb-1580-450a-80ff-679a35179d95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_47d10411-90ff-4d28-b47e-33bc4ca8ad23" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_BauschLombMember_47d10411-90ff-4d28-b47e-33bc4ca8ad23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_238c6557-eb14-4cf4-8ffb-6beeee281770" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:to="loc_srt_ProductOrServiceAxis_238c6557-eb14-4cf4-8ffb-6beeee281770" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_238c6557-eb14-4cf4-8ffb-6beeee281770_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_238c6557-eb14-4cf4-8ffb-6beeee281770" xlink:to="loc_srt_ProductsAndServicesDomain_238c6557-eb14-4cf4-8ffb-6beeee281770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_238c6557-eb14-4cf4-8ffb-6beeee281770" xlink:to="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_3474c4a2-498a-4f59-897a-d99f17b4d79a" xlink:href="bhc-20220930.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_PharmaceuticalProductsMember_3474c4a2-498a-4f59-897a-d99f17b4d79a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_83a7b00c-1db0-4792-84de-ebfd1b652f6c" xlink:href="bhc-20220930.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_DeviceProductsMember_83a7b00c-1db0-4792-84de-ebfd1b652f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_22bb0647-061d-4f06-9d72-ef0c35b416bd" xlink:href="bhc-20220930.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_OvertheCounterProductsMember_22bb0647-061d-4f06-9d72-ef0c35b416bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_c0b20668-7134-4a1e-b97a-679d019817ff" xlink:href="bhc-20220930.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_c0b20668-7134-4a1e-b97a-679d019817ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_ef41631c-d894-413b-82cd-4b4633e398f3" xlink:href="bhc-20220930.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_OtherRevenuesMember_ef41631c-d894-413b-82cd-4b4633e398f3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended" id="i6db0bf24e3c74e569675bb47839bf9ff_SEGMENTINFORMATIONNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_d8295fbf-c773-491a-abb8-ce5583937a7b" xlink:href="bhc-20220930.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_d8295fbf-c773-491a-abb8-ce5583937a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_204c5fc1-891d-4088-94b0-1054c7d89600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_204c5fc1-891d-4088-94b0-1054c7d89600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_df78a6e4-6fa9-4125-a55d-1b638d4bf539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_df78a6e4-6fa9-4125-a55d-1b638d4bf539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f843bcab-e4d7-4bd3-a15e-5496f3ab9f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_df78a6e4-6fa9-4125-a55d-1b638d4bf539" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f843bcab-e4d7-4bd3-a15e-5496f3ab9f9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333e69ae-5117-4590-a3c3-80c9412b2f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333e69ae-5117-4590-a3c3-80c9412b2f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_fdbb21eb-d785-41e4-b130-380eccefc215" xlink:href="bhc-20220930.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333e69ae-5117-4590-a3c3-80c9412b2f32" xlink:to="loc_bhc_RevenuesNetMember_fdbb21eb-d785-41e4-b130-380eccefc215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:to="loc_srt_MajorCustomersAxis_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de" xlink:to="loc_srt_NameOfMajorCustomerDomain_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_69a6bd0e-30f6-48b3-9c01-e4b29322b851" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de" xlink:to="loc_srt_NameOfMajorCustomerDomain_69a6bd0e-30f6-48b3-9c01-e4b29322b851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_59824f0d-b432-4ba9-ac21-c8cf96ff06eb" xlink:href="bhc-20220930.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_69a6bd0e-30f6-48b3-9c01-e4b29322b851" xlink:to="loc_bhc_CustomerTopTenProductsMember_59824f0d-b432-4ba9-ac21-c8cf96ff06eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended" id="i6074c9094234428690be410206c49f76_SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9b1f0e0-0b95-4526-b356-fb46ab571e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cf5c50b-f093-48b8-8e15-86cf1f83ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9b1f0e0-0b95-4526-b356-fb46ab571e1d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cf5c50b-f093-48b8-8e15-86cf1f83ddc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_975fa236-8227-4ef0-beaa-8ceb40d12a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9b1f0e0-0b95-4526-b356-fb46ab571e1d" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_975fa236-8227-4ef0-beaa-8ceb40d12a0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eff4938c-2db0-499d-9f1c-33a3036df14a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_975fa236-8227-4ef0-beaa-8ceb40d12a0a" xlink:to="loc_srt_StatementGeographicalAxis_eff4938c-2db0-499d-9f1c-33a3036df14a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eff4938c-2db0-499d-9f1c-33a3036df14a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_eff4938c-2db0-499d-9f1c-33a3036df14a" xlink:to="loc_srt_SegmentGeographicalDomain_eff4938c-2db0-499d-9f1c-33a3036df14a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_eff4938c-2db0-499d-9f1c-33a3036df14a" xlink:to="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_e6ad0c76-448f-4a42-b92c-8df62d8dde7c" xlink:href="bhc-20220930.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_e6ad0c76-448f-4a42-b92c-8df62d8dde7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_9376b69f-35fb-455d-977e-31a63d40d3cc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_CN_9376b69f-35fb-455d-977e-31a63d40d3cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_fd5dde9c-dfde-4c01-8c2b-fe8fda8ed429" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_CA_fd5dde9c-dfde-4c01-8c2b-fe8fda8ed429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_52e37276-b6c3-416e-9379-390a381deb3c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_PL_52e37276-b6c3-416e-9379-390a381deb3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_1abdddf5-28b2-4dde-9e92-3059625396cd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_MX_1abdddf5-28b2-4dde-9e92-3059625396cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_14a0dbc6-99fe-4432-9c46-4f54b42ac631" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_FR_14a0dbc6-99fe-4432-9c46-4f54b42ac631" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c6a86cc6-d08f-48f2-8a86-cb951f61d637" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_JP_c6a86cc6-d08f-48f2-8a86-cb951f61d637" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_bcacd1fd-8ad6-48da-a591-e628aec0facc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_DE_bcacd1fd-8ad6-48da-a591-e628aec0facc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_289e1320-f53d-4eb1-b636-618fc64ee356" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_GB_289e1320-f53d-4eb1-b636-618fc64ee356" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_ae96768b-5159-4552-8529-a9f9619bd3a4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_RU_ae96768b-5159-4552-8529-a9f9619bd3a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_15d81012-8c9f-4709-8fdb-acf5b341b327" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_ES_15d81012-8c9f-4709-8fdb-acf5b341b327" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_abf9b2ee-dd9a-46c6-9938-2c55d071a125" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_IT_abf9b2ee-dd9a-46c6-9938-2c55d071a125" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_624a0f27-bdc3-4876-9782-510c2ff59ac2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_KR_624a0f27-bdc3-4876-9782-510c2ff59ac2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_b28b81d5-0272-47f5-9073-fea01b2bd39a" xlink:href="bhc-20220930.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_bhc_OtherCountriesMember_b28b81d5-0272-47f5-9073-fea01b2bd39a" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="id744909292f34a1d8a943a838ced0e33_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ca58c8f0-a456-4694-85a3-151795b04f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_623e29b8-2637-4993-b932-2c075e3e1467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ca58c8f0-a456-4694-85a3-151795b04f16" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_623e29b8-2637-4993-b932-2c075e3e1467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ca58c8f0-a456-4694-85a3-151795b04f16" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d3e7b7c-68d4-4108-891d-7ace8d634f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d3e7b7c-68d4-4108-891d-7ace8d634f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d3e7b7c-68d4-4108-891d-7ace8d634f74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d3e7b7c-68d4-4108-891d-7ace8d634f74" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0d3e7b7c-68d4-4108-891d-7ace8d634f74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65eb7b52-dbb5-4447-bbe3-a0fee6f6d7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d3e7b7c-68d4-4108-891d-7ace8d634f74" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65eb7b52-dbb5-4447-bbe3-a0fee6f6d7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_824f929f-7e74-47ef-bb9b-6b8ba14bd7f2" xlink:href="bhc-20220930.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65eb7b52-dbb5-4447-bbe3-a0fee6f6d7cd" xlink:to="loc_bhc_RevenuesNetMember_824f929f-7e74-47ef-bb9b-6b8ba14bd7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dc9e41ea-cb0d-47be-a9ee-347f5781468e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dc9e41ea-cb0d-47be-a9ee-347f5781468e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_dc9e41ea-cb0d-47be-a9ee-347f5781468e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dc9e41ea-cb0d-47be-a9ee-347f5781468e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_dc9e41ea-cb0d-47be-a9ee-347f5781468e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_da8d5b6d-dda2-4875-9c2b-7735b9e85680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dc9e41ea-cb0d-47be-a9ee-347f5781468e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_da8d5b6d-dda2-4875-9c2b-7735b9e85680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4f088c54-24e4-4ffd-8dc4-e170d5661d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_da8d5b6d-dda2-4875-9c2b-7735b9e85680" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4f088c54-24e4-4ffd-8dc4-e170d5661d73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9b5ddf64-4e72-4f32-b618-c0add2984c8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:to="loc_srt_MajorCustomersAxis_9b5ddf64-4e72-4f32-b618-c0add2984c8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9b5ddf64-4e72-4f32-b618-c0add2984c8c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9b5ddf64-4e72-4f32-b618-c0add2984c8c" xlink:to="loc_srt_NameOfMajorCustomerDomain_9b5ddf64-4e72-4f32-b618-c0add2984c8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9b5ddf64-4e72-4f32-b618-c0add2984c8c" xlink:to="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_97ae50ee-d2d8-4d7e-b155-171cb1fe125c" xlink:href="bhc-20220930.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_97ae50ee-d2d8-4d7e-b155-171cb1fe125c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_f51e9329-9c34-4c36-83e7-54020e603fae" xlink:href="bhc-20220930.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:to="loc_bhc_McKessonCorporationMember_f51e9329-9c34-4c36-83e7-54020e603fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_45b7d23e-fa57-4af5-948e-aa670edf95e4" xlink:href="bhc-20220930.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:to="loc_bhc_CardinalHealthIncMember_45b7d23e-fa57-4af5-948e-aa670edf95e4" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>bhc-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7672b0ed-3503-4562-bc82-7a3368936983,g:725d4d73-5fd8-4cb1-b65a-aa245208ce29-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_9f820b1a-b85f-4576-9d82-3c1f6f66c50e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_ea68a228-5a4b-478d-b168-8b91a6b46d16_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for expected credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_4429c5f6-f2cb-4937-b115-139575ed9ea8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_624f37a1-1ec8-4e37-b142-5eb50dd9f2b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7d62dde6-2da3-4a67-beae-7fb39e925eb3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_07eb0261-a02f-48c3-ae17-be2c6120b2b2_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_06b5a85c-590c-4f1f-81b6-c1520a93792d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_17847c12-6e8f-4043-8aa8-41645666c4bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_3865214a-5730-4b24-bb56-9ae62afddcaf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-QC_336c6d2c-5c34-482a-bba5-449ac3b5e21b_terseLabel_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:label id="lab_stpr_CA-QC_label_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-QC" xlink:to="lab_stpr_CA-QC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_46f2edbb-8664-4531-bf05-b6e00719c09d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_39297f5a-ff81-483b-b403-e75b172e0137_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5907fc0e-e86d-4a52-b72d-630282c19834_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue associated with products for disposal</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_fa2e791c-3221-4aea-bf99-cdf16a59c122_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9bd3ac02-315d-4a57-b927-b132056ffdc9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_ec35dd2b-54a3-4820-8a31-122e8c2649e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue attributed to a geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_27c59f4a-8267-4576-b20b-0ab16514211e_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_53ad3eb0-d279-4bc3-baf6-a64314a1b171_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20220930.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_e7aba12d-110c-417d-a14b-a7c6822b4d14_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_8e6d014b-1da8-4ff2-b800-f5a277903062_negatedLabel_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration adjustments, including accretion</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_label_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_documentation_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:href="bhc-20220930.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:to="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_7703fc6a-50c9-4b77-890f-5b4cb161a94b_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d81f75c2-d2a3-4488-97c8-39c634ff217e_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_ab915e0d-e38b-4977-8f2e-9e4899e9502e_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_label_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics [Member]</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_documentation_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:to="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_df3b7715-bc3c-41a5-9259-fcabd8c9fb11_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f56a4dff-1b92-431f-a81a-b812475908c5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares not included in the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ee3c5475-af64-4788-ab0c-ccdbc8313cb5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_609855cc-6273-454a-8acf-f366a3f066e6_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_895b2e85-5b31-4396-956e-222bb7e96ff3_negatedLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20220930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8dac2f76-b37d-4e76-88f3-f0a44f0020eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_edab3cdf-4b6c-49cb-a62c-d6c3aa0f92a1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_cd6439fb-1882-48f9-8106-8cf4098c84f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_5f0ccb2d-ab8e-4de5-a145-2a5c476dfc93_terseLabel_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_label_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:href="bhc-20220930.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:to="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_725608cd-6029-445f-8dac-77403df35970_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_94fd6382-fa61-4438-a199-3e2c4cf28797_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_82722e12-faff-4644-9fc7-d66be776c736_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_3d754d62-753e-470e-9288-958f64065891_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_a0613f47-378f-49f4-b815-54bb158a02cf_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20220930.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_1288a64e-765c-4f3f-9b67-8b5801a8c607_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_59935534-96a4-4fb5-b75e-6a339a743969_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Notes due 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c3966a96-43aa-481c-9b58-bde73fe74fa0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_b9f10fac-beac-417f-9821-f1dd73a0395d_terseLabel_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_label_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet" xlink:href="bhc-20220930.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherIncomeExpenseNet" xlink:to="lab_bhc_OtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8b7ed5f8-6661-449e-b24b-df4f63277903_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_db819a9b-b59b-4c45-a329-4d9140b21ff2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_797e9e31-ee5d-49b6-9617-79b762221883_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_997fb016-b518-4689-ae8c-9382cb294ca8_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_6afb8eff-c09e-4960-a170-a3abe661c00b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from divestiture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6704b82c-d0bf-467e-b6ea-555912f29162_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_53fee4db-55a4-4d83-b152-bded3bb496c8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_903f3480-dbeb-4030-9918-17341f744fad_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20220930.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0243fb48-a8fa-403b-9cc6-e69e5e0e73bb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a145ed35-d52a-4b0e-afab-6bec1c0518c7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4fa0b777-2291-4d60-97e0-15b6f192678a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3b58b942-8c7c-4992-b312-81039715ed17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_441b2c6b-8b78-4aff-87b3-2e234b564f9a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_d8e37526-6e56-4fb8-a731-4d6d6d7b6e43_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments due to changes in estimates of other future payments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:href="bhc-20220930.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:to="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_77507e00-29ea-4195-bf5b-c3743436c86f_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Intermediate Holdco Senior Notes, Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:to="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_b5066235-8151-443d-9d73-97ed63d4f509_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:href="bhc-20220930.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fd9c6625-3dd8-4fd5-8515-ba0066438377_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f674fe37-9698-41ab-af41-9030201e1166_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_e38004f7-0cfd-4970-8ce1-32090e4143a2_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20220930.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_bf1bd2c9-a349-41ba-9e62-accb3b05acd7_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_27d45466-bd1e-4df7-9e08-2660db89dbe8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombMember_5e4b38cd-73d4-4444-88b9-56a740ec9027_terseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_label_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb [Member]</link:label>
    <link:label id="lab_bhc_BauschLombMember_documentation_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombMember" xlink:to="lab_bhc_BauschLombMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d5663976-834b-4765-b565-a3df769dbe86_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_882acab3-5ce9-4077-a580-3953451c714e_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_55ccc14f-b15d-4e55-b648-da9ecd58bdc2_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_82bff16e-afb3-4354-80db-72ddb87a4f52_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8069a756-1766-415d-baf0-d4ee58de778a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_4d087aca-4433-49b8-88ef-b32bd1b74f90_terseLabel_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="bhc-20220930.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_45a06033-53e0-46f8-99e8-b7046ebc0be8_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:href="bhc-20220930.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2421b2d4-2f07-49b7-b637-83f485beee6f_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1d42cfdd-f48c-4332-97f7-11bfac809632_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_1d9dbe2a-75ed-4878-9077-8a72cfd9d8fe_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit spread adjustment (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_label_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:to="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66f8aa24-047d-4101-85b3-ee7cbd3652dc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_7da33d27-8829-4c93-9091-cd187c396598_terseLabel_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_label_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products [Member]</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_documentation_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember" xlink:href="bhc-20220930.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CustomerTopTenProductsMember" xlink:to="lab_bhc_CustomerTopTenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_58a2bef4-94ea-40a4-9ee1-d862d93ed057_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs charged against the allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8a62e435-e2ce-4a67-bd11-a7c790685c2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_f6e9d7ec-e2cf-42a2-8e72-a676f9994f23_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_db422433-c1d1-4715-a9bc-17355d035f93_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_10488354-cbd4-4494-b8af-db6429eb5e63_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments or receipts in settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5b00f984-7bcb-4f0b-8fb6-01aaf5fddb99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_03d5fbc5-2425-4c4b-9b43-979d2e51b181_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8e5f1c33-3b81-4e04-9418-571d5869a73a_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_45387ab0-1be5-48d8-8186-2bbe622d9865_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_11f3d1a7-b77e-452c-85f3-75d8293cc46b_netLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Unsecured Senior Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_457a5492-e899-45d6-a23b-c1c32460c288_verboseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_31582007-e6eb-47fd-a897-a14ba4583985_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ac546723-6ca0-4247-aaf2-a224606ad76c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9af1c214-cdd0-48bf-ab4c-30eed8ecd095_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0b66e43e-0c48-447b-9be9-43552ec3d80c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_86a31155-6fbd-47ef-8ca1-0a79c01150e1_terseLabel_en-US" xlink:label="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer, Excluding The Chief Executive Officer</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer, Excluding The Chief Executive Officer [Member]</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer, Excluding The Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:href="bhc-20220930.xsd#bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:to="lab_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_bde72a43-9351-4b54-9192-85ca0ab40711_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_836d7997-ad95-4dc2-8d28-2e6853bfa25e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_f2fc7fc6-2b7e-46da-961c-c710171c9345_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3f9eb330-463a-40d1-87dd-c013bfd9a0ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_26eb8a2c-d324-42bc-98fd-2015d56afa46_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities, Current</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:href="bhc-20220930.xsd#bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:to="lab_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_181997b6-e402-47c2-a139-2434b3201bbc_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_b68c42e2-1d82-4853-ac3d-0d1b2ebfb885_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2eff5139-0b46-470e-b137-35b52a968a5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_7c7f12d9-d74e-432e-bcac-77eaa2404c2a_terseLabel_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO and Over-Allotment Option</link:label>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_label_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO And Over-Allotment Option [Member]</link:label>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_documentation_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO And Over-Allotment Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember" xlink:href="bhc-20220930.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember" xlink:to="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_f66bc146-1911-46f8-bc7f-8309a6e448de_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from incurrence of debt</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_5a2127ef-d267-4993-bf09-2794c1cbd7b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_164c4944-0e1a-40bd-aa2d-8df69b4bcb9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2094d5ab-061c-4831-a7ba-8a814e69ae0f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average service period over which compensation cost is expected to be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1f02e3aa-eacb-475c-9799-0f82c000a5ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a6ec4ccf-000d-44ef-97a4-090a426bed29_terseLabel_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived and Indefinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="bhc-20220930.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_c5380e05-cc92-46a4-a929-7cf211a6b64f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d497367f-6c43-45f8-b763-46b1e717eb68_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_cb3922b2-dac0-4e4e-9fa8-58ed465086fa_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of debt exchanged</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_7789960f-6397-4fb0-982f-6acf18c2aa80_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_a8099dc7-d637-4f57-a04d-ec60416d0eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased debt, aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_2f87a097-8a25-497d-8b28-6d903a5822c2_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:href="bhc-20220930.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_56b6b7dc-7ce5-4eaa-995c-52101246965c_terseLabel_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member" xlink:href="bhc-20220930.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermFacilityDueMay2027Member" xlink:to="lab_bhc_TermFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_3095549e-3a31-4ae5-98d2-ef7bf92321e6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment included in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_81ebe6c7-04d2-4ffa-8041-fd4c9cf3f548_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_7c251400-e44d-4509-b991-e716860ff5c7_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43c049b5-7103-4dde-ab06-66b2c8128901_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49001e8f-3950-44b3-b5e2-60c18afd2fa0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e28f929a-815e-4356-bea8-a7c5f0eaed83_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc0f1626-63d5-4914-a3b1-41d231d17d09_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_98747f09-71be-4d87-bab7-ebbee59d95cc_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_5c8a003a-ef60-4fe5-87ec-68d0cfdd2d5c_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a1e8e610-defa-406f-a94a-e87e758a5635_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1051451b-8955-4833-bbba-728337ab4b5d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_56ea2a6f-b2a8-48d1-bc75-a490ae88703b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a44ea70-5bf5-41a4-8278-a6c1f24014e6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a62bd985-8d25-4227-beda-a8303e3b212a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d1ed23a0-e3a6-4bcc-81b3-9b758b46fb4d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c11e32a8-8497-4b48-a130-b6b7801f35aa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_2c0ba944-4e03-4093-8f9d-8fa0c597a3fc_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20220930.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_36fc7468-6a76-44fb-a6b6-385f26581706_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_16f23c34-9ad4-4fa1-883b-22de94f3f00b_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220930.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c2ba7953-b180-4615-a6d3-a183b6ea2eef_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d5cf5dfc-127e-4fb4-919c-a93734becc8b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_487197c0-9d8c-4bfe-b654-21fdf9e71c53_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_ab73f37c-63b7-4683-aba3-4b9211daf39b_terseLabel_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_label_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E [Member]</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_documentation_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:href="bhc-20220930.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:to="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_97e57b35-cc09-4638-9f54-68d6c13d6bfc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares held</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6f3ccb18-67aa-4e27-8e72-a46f6cb8ff56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_fc55a88c-db89-42ac-813d-a62b03d88858_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b576ec2d-b30b-4a36-ab6a-932f40b3c002_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, one-time award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4ed04115-73e7-4ce4-927f-3e2bb759c7e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_87acc8fa-359c-4f9b-b35c-0954c87f1f3a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_88390b75-c7cd-4f03-8c6b-8bf84f36a843_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c4ef0868-5d48-48a7-8829-9c26c81c184b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_1f1a40c6-8900-4760-9b50-644e8c771511_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_be5fc767-e700-4844-a761-a4ee7641d5b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ba760057-90a8-418d-bc3f-c8b7231b935e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_67f5377b-d8f0-4bc8-814a-d9394090af84_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_23b4ab5a-4013-416e-8c88-b052f45d6b2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_122552e0-da4c-460e-92bd-23fde4639395_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_a3e2319f-149e-4aac-bb03-ed224ba86d0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d2f0bea9-b73e-48ae-a46a-2f7bba2b4784_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_d642592a-f746-4a7a-885f-4cf474485214_terseLabel_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers and Other Members of Leadership</link:label>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_label_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers And Other Members Of Leadership [Member]</link:label>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_documentation_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers And Other Members Of Leadership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:href="bhc-20220930.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:to="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_a492cd7c-cf26-4028-b163-9e2d61b3dd13_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20220930.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_54f7fa73-ab58-4f5e-81ee-67cbb20940ec_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, award type, percent</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b8638ef3-7d5f-49ff-92e5-46f0daa7b84a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f40ebb09-c7b9-4d36-822c-316e490ae5ea_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_df09612b-ee5c-41e9-ac0c-22a4897cf1ae_terseLabel_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations of Dismissal Submitted</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_label_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_documentation_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:href="bhc-20220930.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:to="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_54c1d872-cd27-4daa-9572-33a4183b45eb_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems" xlink:to="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c7d865b0-ca83-4f87-ba68-1312fbe350a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_a84f5c67-6ad2-400b-a1e3-61e22b5a04b6_terseLabel_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_label_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:href="bhc-20220930.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:to="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_a782e985-651c-44a1-b9aa-588de2cbd0ed_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_3f916844-0fd1-4bd8-a700-12d8a5fd2fbb_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_045b04e6-1fcd-4d13-b536-32f21b3146b7_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan, Retention RSU Grant</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014, Retention RSU Grant [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014, Retention RSU Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:href="bhc-20220930.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:to="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_2527a8f6-0dfb-4790-bfa2-af62e3549ec0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_13727cfb-4534-42d5-b262-1f8640b410ee_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_d72bc2ec-3a13-4385-9a30-69394ad2395a_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_25fd8016-3e68-43fa-a269-995d6ab631b2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cfe16421-2d14-46de-8141-e5316eed2237_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_d0fe31a4-30d8-43b2-bd1a-58b066d2ca0f_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_label_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_documentation_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants" xlink:href="bhc-20220930.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyNumberOfDefendants" xlink:to="lab_bhc_GainContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_5525ba62-7243-4084-b8cb-23ba74a1d087_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20220930.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_ce0ffe3b-3e3b-41d9-80d3-e745e4d1d405_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20220930.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_5dd66c47-25a2-4313-a33b-35ecfdab4941_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ea633d8-63a8-4f23-8ad1-a4cf13d72815_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_5bd71f3a-d03b-4f8a-849a-6325730d639d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_510cfb21-a651-43fa-b7bf-39c5ad526379_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes due 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_61354dbe-688b-423f-a8c6-74c2d04bfdd5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AnnualAmortizationOfIntangibleAssets_7833595e-e0a7-4fdb-80e1-7715a9efad74_terseLabel_en-US" xlink:label="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, annual amortization expense</link:label>
    <link:label id="lab_bhc_AnnualAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amortization Of Intangible Assets</link:label>
    <link:label id="lab_bhc_AnnualAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amortization Of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AnnualAmortizationOfIntangibleAssets" xlink:href="bhc-20220930.xsd#bhc_AnnualAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AnnualAmortizationOfIntangibleAssets" xlink:to="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_d7291612-6f97-4727-89a2-9ec8c3786796_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_eadfc2a0-58f3-4123-a9c0-f35141a5c3b9_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_09591903-f322-4fbd-a6de-fe62f0ddf0be_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d708d0fc-a443-461d-bb6e-bd187bb463e3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2b497324-eea1-4709-a982-7501a2539691_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_93c6b08e-f746-4fab-a1b5-7dd0109c8cde_terseLabel_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220930.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_42344b4c-7e32-49f9-93c7-ff57bfdff7df_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20220930.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_939a1271-372f-47a3-baf8-49e9b859090c_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20220930.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_0fed79a0-3fc2-49e8-82f0-900339800004_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f21f1183-d2de-4014-aa6b-4cdab8d7bfc2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_7ca4510f-5629-4f88-8418-ad9f0ff94ee8_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb Trademark</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1df1ea9c-f64b-42a2-8812-96800f8a1bcd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_7e26f140-bba6-438e-ac3c-0c4e2c329110_terseLabel_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:href="bhc-20220930.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_2be5bd9f-e912-4ab0-8c74-ada3ad05b17c_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3abe0789-f1bd-4399-9f20-afba846ff73e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_6393c2ed-7e4f-4054-9fd9-87d7835f9dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2eb98909-8579-4dd9-983d-a4551bc12b9b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e1a95c32-efe6-4d07-b91d-0f539d1400d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_8287b6bc-7522-46e2-93a6-3f25b993ce7d_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20220930.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_260b8cb0-f0ab-4fa9-b22b-73d5bfa436d2_terseLabel_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSING AGREEMENTS AND DIVESTITURE</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_label_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_documentation_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:href="bhc-20220930.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:to="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1fa1fd31-b780-473f-a630-26221b285901_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_eab8784e-f3c8-47c0-8884-0a13a48ef171_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_43d9c563-d849-46ff-983a-8fa7acaf3cf1_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:to="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_bdf33a59-cc61-497a-808a-a4f72509d628_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_adc30bbc-437d-4395-848b-579f31153b49_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_27147472-9fc3-4328-8c30-90d1ed532d9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3672680b-3c23-43b1-915e-49f6bf200382_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_49106e11-be2e-4099-93c2-348c5a8fe188_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_053045c2-9580-48a0-9408-ca0b4ed0eec3_terseLabel_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_label_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:href="bhc-20220930.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:to="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_9c44d24d-bf0f-44b3-98b9-6f0e700d2732_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_fb7f19fc-d196-4d33-8fc8-f9291413cbd4_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes due 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_5f13668f-4d1f-4778-b8ca-c9512ca227fe_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20220930.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_89f53d29-d1bc-4c73-84ff-1d5478770cc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_01beb6cc-f94b-48a0-8a0f-1b1a12e8e4a9_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1ec2220e-8ee5-4367-9f7b-aae1e16050fc_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_6f320e42-b387-43fc-9dec-0423481216eb_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_9871c4da-3f7b-4899-b28c-04ef678fafd1_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4732a35a-9833-4ea4-88db-6bb98b98f804_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_83f96b22-1da9-4dbc-bbf4-efa17203a28c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of contingent payment obligations measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_85f7cad7-3e05-4788-b679-9ae93cea94af_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_label_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_documentation_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:href="bhc-20220930.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:to="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8d100cb8-5f7d-4772-bd3c-4eebe8048581_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1837fae8-9c9d-4a9c-b90f-1509c72aa366_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_d3fdf2a2-38d6-4ed3-8b2c-f13daed979c2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_99de628e-fbfe-4a74-bd35-c47cd87469d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_f96418b0-f21a-4747-ab4d-8aa6a78b6740_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3d42da52-a17a-4aa9-bf2a-59178745f06d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_c4c31c13-23bd-450f-8b5b-ecd57e3e624c_terseLabel_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants</link:label>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_label_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants [Member]</link:label>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_documentation_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember" xlink:href="bhc-20220930.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IPOFoundersGrantsMember" xlink:to="lab_bhc_IPOFoundersGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_1890e15b-4eb5-44d0-83f3-13ca95e7ea48_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_77d5bda5-985a-48d3-b9af-24a6ea216fd5_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_0d037320-72f2-4e89-8665-e76e920fc495_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20220930.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_0364b34d-abfd-4468-b55a-e07dbb42e188_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_2a73eb30-5f2d-47b1-a5c6-913b6f8c4557_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20220930.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_83b38473-91fe-4af0-9aa2-9dffa88fda4a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_6f440bcd-72c9-4c30-b0af-ea1788e2b8b8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be2afba0-0c60-4dcc-8e29-b1333fb8636d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_81ea6260-6366-45ab-b014-d73349866fd7_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5c27dd89-d997-42b0-9341-75d06d6bf498_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20220930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_37c61dc1-0e6d-4b2b-a87c-989f1da532f4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_dc8b9255-8548-496b-9772-90232571692e_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_d95e71a7-6dcf-4ef2-87cf-5b86a5f940da_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes due 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_8aac6a7a-c9e0-4aa5-8c04-8c0b4b9b0e17_terseLabel_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_label_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units [Member]</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_documentation_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:href="bhc-20220930.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:to="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_895a86c0-8405-42b2-a51a-234df90eaacd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 361,781,292 and 359,405,748 issued and outstanding at September 30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_3ee1e408-9dbc-4f79-a6a7-360a78c24198_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20220930.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_97e62073-4dfb-408c-b25f-c113af3cd1aa_terseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs, Performance-based RSUs and Stock Options</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220930.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5d5385b5-1024-44bb-8436-1fb4d06dc826_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_0a83cf99-69ad-40ec-9bc9-2823f0dda629_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_19c25b5c-1e77-4a0b-aae5-81cc3b444c94_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_484daa2a-d3dd-4170-98c7-37120763c410_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_194a5348-541c-4d2b-9205-f73530714beb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_7cebf1fe-87a6-4bf5-8d5a-953e1fa4fb57_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_11c6b5c8-db37-49b2-9687-5effab1c7130_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0b968279-0ff4-44ed-a042-e65b958e1e3e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ba7e1b2-4239-4ac7-8cdb-73229bf2f469_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c14cf7a2-43e4-42b7-8528-3f8e4cf9b20b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5e2e328f-ec95-4202-8bd3-10ba847d1fe0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_81058755-be61-485a-9e0b-e29faafdddf1_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:href="bhc-20220930.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9cb3d6a3-eb4c-4bf0-9b6c-0d749164e45f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_415a90e8-c9a9-42c6-91d1-b0899826221e_terseLabel_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_label_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_documentation_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember" xlink:href="bhc-20220930.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A2022OmnibusIncentivePlanMember" xlink:to="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_77a7b363-6322-433a-afe2-87eade53eb18_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_2a5018f9-8e26-4947-a4cf-cdf4f78ea213_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9c7fdcc1-0c5d-4a36-82b0-d52340030f45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3718d189-8910-4980-9193-68099bf6c30f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_59d78b5b-e71f-43c2-8833-28a02e6e09ff_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_de97dbaa-df14-4c32-8e01-2e8e8f64de07_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e171a523-67de-4456-a65b-aa8984ab3974_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_1b13e280-0300-48b2-8706-6e8678474ac9_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4d85e290-c3fe-4735-bba5-fef7dbeb98df_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_99282c62-c967-493f-9b9c-1ef1385d5265_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_65b2cf37-64bf-4cf6-93db-1a1e907804c2_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20220930.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_8a49e875-5565-4027-97ad-81f59232b7d7_negatedLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20220930.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_4b01f3ee-c93b-47f8-9301-b756bdbdbb3d_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_b29b2415-ced5-4d18-a72c-151441db178a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_a64a087c-43cf-4007-a345-67815c03888e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefaultJudgementMember_e9e669fc-c27c-4ba3-a2c3-b8ee9f78802d_terseLabel_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_label_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement [Member]</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_documentation_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember" xlink:href="bhc-20220930.xsd#bhc_DefaultJudgementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefaultJudgementMember" xlink:to="lab_bhc_DefaultJudgementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_e5dc8c35-8488-4ffb-9e31-120f47096af8_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20220930.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_cd122e83-a3fe-4168-944a-b07ce886ca30_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_fcb60478-6c55-45e8-b0ab-20eeae1fca9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss, income tax examination (up to)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_b2c49574-ac24-4352-abec-945af0124bb9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income Loss [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0e36fd93-c4f0-4359-9cb6-c9596c3cd876_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_d4d0409c-c622-45e9-a5bf-e9a9b319b98e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_303f11f0-7bda-45a8-a71a-24bbe1a42a52_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_90b5aac3-ee4b-4864-be1b-350972d80f7e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_6a4d93d2-08e1-4f49-b0bc-13ed5e60ac9a_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to withholding tax, intercompany dividends</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_44d91353-edcd-40c2-ac6b-e68db87a1cb6_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_a5144725-2b7c-45a7-9f6b-ab2011731155_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5a059ee9-1954-434a-9a4d-30a3ec33c39e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_557f740b-f8fb-4f43-8df1-7f812a6945c5_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_fc378ae2-1b8d-476f-859d-e9c76e0d7b9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE (INCOME), NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_a5e629e0-4042-49ef-a079-7ed94d281244_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of proceedings</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_label_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Proceedings</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_documentation_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Proceedings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings" xlink:href="bhc-20220930.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyNumberOfProceedings" xlink:to="lab_bhc_GainContingencyNumberOfProceedings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_aed55f3d-1613-47e4-b890-7f08fae8b128_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f1022bf-5feb-40d2-929a-dbfe19a53ed4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_3c367a29-1144-4be3-a3a5-88fabb31cc6a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_026e4002-9b10-4674-b5e8-7abae2fcc456_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef4cbc9e-a00c-4979-9a74-79e49b3d6c47_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_3f85527a-28ae-4aa8-86a1-0073a1f0f433_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_fc68c8d9-9889-4ce4-afc4-0890ff00aa59_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_bb70b9da-586f-4d32-9cf8-d797ec835db3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_7711f388-d4bf-49df-8ccd-1fddee94cc63_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realignment of segment goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_12f52038-0870-4dd2-ba9a-c0cd79f1cd45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_873b4205-e588-4b23-bc2a-0e3db164a155_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_08dc704f-dcdd-4c06-8105-87296fd477a7_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:label id="lab_stpr_NJ_3dc03b19-1fd3-4d1f-a321-a70fa6fdfe81_verboseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_f18c379b-9bde-485a-8052-8220e34e4cdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_01c059f3-429e-48b3-b92f-23345b53f856_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_0f6847c1-2856-4a61-8086-8b0e49e35858_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20220930.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_6d427950-6905-4b45-a50d-e59057ada1f6_terseLabel_en-US" xlink:label="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical and Ophthalmic</link:label>
    <link:label id="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_label_en-US" xlink:label="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic [Member]</link:label>
    <link:label id="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_documentation_en-US" xlink:label="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:href="bhc-20220930.xsd#bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:to="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_64ec3d88-1424-46f4-9f54-fba8f6401057_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fd50bdb6-c096-460f-b7e8-2ba93daf0431_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8da23d2e-5539-4040-ae5d-16af50eb2bd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_6c1b37e6-83bb-42a7-9360-6931f1fe697b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_608b55a5-b232-4b90-a2e9-253fb3e0879c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bf2172d4-d4ab-47df-afb4-21668db30394_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_2d0f371d-7ad7-4423-ab7b-4b8d53d4e807_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_97979bb7-b33b-440b-ae64-77a9de830560_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision (benefit) related to stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f1013bfe-0f9c-44de-b7b0-81884cfe3612_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of foreign currency translation losses upon disposal of assets held for sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7bf9466d-2695-407c-a480-e66883764bdc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_06419dff-fa21-4352-8fd8-af5a3dc44177_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7d0d0872-0526-4c0d-a85e-ebc23bb95efe_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, agreed to pay</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ddea9e8d-221a-40d2-af86-f72cd2d94cd4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_aea194a1-cfd9-4e44-a0d9-8715477fdfa1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_72e8f350-6c5e-4f97-8a13-e7903e747696_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20220930.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_974ca7bc-c73a-41eb-9878-1f0909d91d66_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1765cac0-25a5-4dbc-ae56-60826b4c52fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_7e467904-020c-42ab-adae-bfa8e318e485_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7a2c704b-00c2-4d7d-a7d6-24f2f659959b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_77e83e8e-72f8-4aa3-aa3f-c0b24fb6b455_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_514c4ab4-33a7-4405-90b0-8fd27b69efb6_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of reporting value, greater than its carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5cb10b0a-99df-47f9-ae9a-9d96208e90f7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_6278ce77-5a17-4e78-89eb-6e7bf4ed59b6_terseLabel_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from B+L initial public offering, net of costs</link:label>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_label_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party</link:label>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_documentation_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:href="bhc-20220930.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:to="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombInternationalMember_8b4007d1-9f1b-4e89-8190-736a32314bba_terseLabel_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_label_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/International [Member]</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_documentation_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember" xlink:href="bhc-20220930.xsd#bhc_BauschLombInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombInternationalMember" xlink:to="lab_bhc_BauschLombInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_dc396625-1df9-4879-88dc-37e5fb370f3f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_4dc29f3c-7307-4f5a-aa5c-6151b4df1c94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on sale of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_1927bdc5-f073-4961-a5ac-bf1d839eae9c_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement, included in net (loss) gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_30efd6cb-1240-4aee-a682-34396e167d72_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20220930.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_7d21c7f4-cf3c-49a7-a7cb-446b18d130e3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_1de9e18d-3b15-4f6c-9513-b32034288951_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_9aff2609-7666-44cd-a84f-044993cd1ca3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_a9807104-5f2c-408a-9b55-502a81e7be02_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for incremental borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_5035f60e-fc24-4dc0-91b4-4addf1ae26c4_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20220930.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_64bd91c4-774b-4b90-8c05-c4048479563d_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_51d562b4-c003-4bd2-a2ff-550aa1eec92a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d8be7795-d88e-40d2-8555-77c1295b5783_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_30e91135-5008-4e58-889e-bc46aeb5c837_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_851a591e-b6bb-4534-bf3e-8f767f1d2d54_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_2d435259-c314-4052-906f-760e48b670cd_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of outstanding principal</link:label>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_label_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</link:label>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:to="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_7637aebf-1bc6-4201-a93d-b4fd4cc11be0_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_568fbf98-f3af-4cd3-95eb-e3dfb2f51583_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_36559b59-5f32-4f30-a71b-2e9a9329f62b_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_fd3c66f7-5687-4677-bca8-5d144865bc3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_13768884-cc33-44da-bdf7-61dc65ebb745_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_3c1b210a-6e49-4588-b31c-edb1cace5a89_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_17f2aeee-010f-48f8-8435-3cf5c5b6ceae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_93d221da-c17e-4387-94de-0083490ab1fa_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (gain) loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1d177ebd-ca79-4cea-b52c-d39d72236c98_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_343d6869-a112-41b3-bd2f-fb585a4c3602_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_c6d0ee2b-c7a5-47ea-9411-2c28c9d70857_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">14.00% Second Lien Senior Notes, Due October 2030</link:label>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_label_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 14.00% Notes, Second Lien, Due October 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 14.00% Notes, Second Lien, Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:to="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_370a96c7-03a1-48a8-b73d-d636e479dcc9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_eade5182-7abe-4724-b3a5-f3a188d04c90_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted effect of stock options and RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_b823182f-5945-4d9c-9cc9-fb103ac5937c_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_bf57fb3b-aba9-4fce-89f6-144c9055fa46_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45335e30-2383-47c9-b9b6-2fb158290e31_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1f155924-e0f7-4e47-8ab7-671ff7e9853d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bd346668-7da7-4af7-b6a4-769e1bd5a7e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_9c2df726-17fd-4208-b7db-342d6b4c9441_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_729a522f-da65-42cd-8f1c-e1650397b048_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_feb90e95-a703-47dd-b22c-871cb531745b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d78efefc-6704-430a-aa66-88e99476a0bc_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c78d808d-710a-4dd5-b002-b2458b67c86d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_01e85193-4b31-4a75-ac79-8b2f9feaa8e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_090878b0-c731-4b20-9e67-48c166a998e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3a23d159-6f04-43fd-b275-2c4c5c7692e4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_554d5ca2-a972-4652-9090-b769266c163a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_ee33de13-6a57-41c7-9928-41aedf23c0c4_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_beb5af06-4e54-492b-a31b-051d1136705f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_8210c2b0-c3d0-4885-89c9-afd1c5863aea_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20220930.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_32e9fa96-b586-4cf9-b7f6-5573f483ebbe_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_43032d5c-f557-4e9c-abdf-5bc40481e685_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20220930.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_1ce34705-0ccb-4042-af34-18127215cfb4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_01117b46-aa3c-4e7e-a2dc-7d2f02e19e8a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37c8d1d6-d6d6-46fd-8676-4536f6b4c4e5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_177e1524-5f2c-4b09-b24e-87e6e84e9b13_verboseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsSegmentMember" xlink:to="lab_bhc_OrthoDermatologicsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_e6dad56e-7863-47a4-8e94-61a857f963b9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_8959e334-4aaa-446a-abb1-bc81b656c117_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of customers that accounted for 10% or more of total revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_39f2f7f8-3a69-4b98-aaf4-f68c0a395243_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_9e53a189-36ca-45eb-8a05-54909276a7aa_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20220930.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_dbdd38f2-869a-4bd9-8f0a-40dafad313da_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7081c5f6-b537-4da1-a123-7ee33143cad0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_148b1d0e-1fd9-4451-9864-5f2d18476da2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_3064712f-423a-42c4-b21e-f8123363a928_terseLabel_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO Costs</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_label_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:href="bhc-20220930.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:to="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_9937a64a-8380-42be-ae8a-58fdeb427c6f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExtinguishmentOfDebtThirdPartyFees_8b43becc-eb63-444b-a772-d8e20880731f_terseLabel_en-US" xlink:label="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party fees</link:label>
    <link:label id="lab_bhc_ExtinguishmentOfDebtThirdPartyFees_label_en-US" xlink:label="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment Of Debt, Third Party Fees</link:label>
    <link:label id="lab_bhc_ExtinguishmentOfDebtThirdPartyFees_documentation_en-US" xlink:label="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment Of Debt, Third Party Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:href="bhc-20220930.xsd#bhc_ExtinguishmentOfDebtThirdPartyFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:to="lab_bhc_ExtinguishmentOfDebtThirdPartyFees" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_74b2bc18-a326-4b5a-910a-ef4474ee8522_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:href="bhc-20220930.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:to="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1bcb466c-a3f1-4d56-8b0e-9ce956aeb6e5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_75f923e2-2e4c-4feb-b9f2-ca7d93893c45_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1ba68cb0-1089-4dff-97e2-de0dd8845ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_30c53fd5-9ede-4f2d-920d-ce4dec9109a8_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_5a9c20df-dfb2-4e43-a556-6e2f0d1116db_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination, program criteria, if circumstances met, exercisable period following the anniversary period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1018af09-a917-4671-9262-05f8ba64b58c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_44af2e66-cb80-49cd-b8c6-faa595028105_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_4702f87c-10b8-4e9e-b48b-0039bdf10cdf_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in variable consideration provision, adjustment</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_83e00280-6de0-45de-9425-e3901208c6b0_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_260ae4d8-0949-4c42-a4aa-0eefebe7419c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d753b19c-d94a-4c57-a33d-3fb251a8829b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_377b8afe-d6ca-4914-963f-91ef2eda4151_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_dec60f50-a44a-4a12-954c-c2307b38c72a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_37a1188a-bb51-4e96-9c7a-d30d348452db_terseLabel_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_label_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:href="bhc-20220930.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:to="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3bafcfd1-4554-4de0-8224-6a238829476e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_21996a84-915b-4d15-b8b9-9051a8ae9375_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fd27c99b-fb1c-47d4-b33c-92668d4b0e95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5aaa7fa6-be69-439a-918b-09bdb5b707ee_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_50581082-c388-4b64-b778-a51979030b76_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9ac83ae6-4279-491b-a771-3f34585f379c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ecf0b99b-536d-4729-8c0a-720f16cf1f3a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9ffe8ba3-ab6c-4bdc-8b28-cc71c4b61cfb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_2b5ac9ec-849d-4690-a5f7-da6754bcd27b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ca43ddf2-3ceb-46e0-b0c4-f5fc3a191661_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0301e69b-6385-4c06-be86-bf8bed5167c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_21ce908f-475e-442a-b347-af2de8a6e3d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_f0da3b4f-5911-4db9-abc6-bbeb93530c0d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a1ffc23b-620a-4500-a16e-a1aac96ca808_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_bd863ce1-4bb8-439c-a152-c75f28683d3a_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_593230d2-a06a-407d-af76-31b40bcd47f2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PadagisLitigationMember_da338176-5a3b-4cf2-85e1-02bee89a8c5a_terseLabel_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_label_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation [Member]</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_documentation_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember" xlink:href="bhc-20220930.xsd#bhc_PadagisLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PadagisLitigationMember" xlink:to="lab_bhc_PadagisLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59172857-8882-4cd0-801a-bca3c5f74360_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4ad9a9ad-6b8b-4d73-b514-7c0076feaf54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_e7834755-a670-4c3f-aa89-263ff979bc8e_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20220930.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_b615afda-2ec8-4b0c-a391-71133f2ef790_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_854ad8c2-452f-44d8-8a4f-d0f1632bb58e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_c5aac35e-249b-472b-9af9-4fe08c40e359_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_152faa07-bc32-42d5-a973-dad0a2212fc5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8e9540da-fb8c-4c71-9cc4-e4add72f84c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_142ce94b-8760-49ed-8381-e0560a05f666_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_486dbb7e-7923-4e74-8819-ea20c05cde38_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e549cf5d-292e-4572-99da-4f42743345f6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_7e8dc0b2-a05f-476f-b486-1385b0906647_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision (benefit) for discrete items</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_38cbc120-645e-4ab8-bdd4-faa0cbeb54cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_4604dd30-7b85-43c4-8d4f-a9f2f6f78d7d_terseLabel_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash, number of objectors' appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_label_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_documentation_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:href="bhc-20220930.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:to="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_80442c30-a3ad-4639-8801-3c0b07b5e086_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_ce662106-4803-4251-b82a-613c34bc206f_terseLabel_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember" xlink:href="bhc-20220930.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianSecuritiesLitigationMember" xlink:to="lab_bhc_CanadianSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4111932e-3d77-4017-9b09-cda9222129b9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_4278aaca-2bc6-4ebb-b5fd-1d3749778fc4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_142d754f-86fb-4708-8164-6e304fe1dfad_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities associated with restructuring, integration and separation costs</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_d128e347-e151-42fc-84be-a0de64e91e55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_dd59892c-7909-4e80-a4bf-37d22bae5d0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_139df07a-ba62-4d3d-bf8f-1b61e9630e07_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20220930.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_714c7cdc-3862-44f7-8c78-9393c64ce320_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense (income), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a95264ad-f061-4342-8d09-c765d0b6674b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_45073bd2-03d7-45fb-b703-687b27305149_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9cfb78ec-cc68-47fa-8338-56ed4f9189c7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2c9f3ecc-7fc9-4983-ab17-771d00bd76e1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efd41cc5-6a76-432e-8f4e-bdfbd1103885_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_b9b5b517-56a3-45ef-9b8f-16b4eb1ea3bf_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_385514ac-7d79-4246-975e-7031453d700d_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20220930.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_3abe624d-3800-4423-8a46-9c5757e7caaf_terseLabel_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreements, number of insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_label_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_documentation_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:href="bhc-20220930.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:to="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9eb45936-fcca-442b-be7c-0a8e0cf776bb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_012da8b1-7c86-4da5-901b-79363a342c7c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_af86e199-c474-484f-a916-883c01214e01_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_4a403619-b391-4326-a6ec-3c8f79118a3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_20199334-d2f8-4e27-9009-94cdf2d1caab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_e4cfdcc3-6a4c-4f7e-8fa6-7126009b78d9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_ef83fe6c-915e-420f-8d54-f7d14a3fb8a9_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_fc343880-6c03-467e-9f22-6c81e65520bd_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination, program criteria, if circumstances met, anniversary period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_780af253-52b5-4d40-a28b-bc95d21f5623_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_fb5cb75a-2d32-4dd9-aa77-a98dbccc20b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_da580048-8e42-4f89-af88-521deb04e174_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2c17ae9c-6381-4136-a370-7753dcaa34a9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8a680f44-f541-40f7-848b-b63b183f2a38_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_bc25e3da-9296-4e21-b448-3a1e1c726956_terseLabel_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Axis]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_label_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Axis]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_documentation_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:to="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_16ad5a6d-49b4-4a07-a3c4-ce160885295d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_03500b9b-fcb1-41ab-8bd5-62c61f2c281a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_2dc3221b-dcbc-4717-a86c-db397b36b45e_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_266d9c6b-d9c3-40cb-9a79-6e96f35bab1b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_741b723d-fc05-47f3-9a14-2db35dcd3217_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20220930.xsd#bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_a7833663-5875-4a8c-966a-9a1dfb87bd24_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4ce305ed-55e6-4a93-b653-cca9c99a98ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4a8fcf22-4d31-438d-a8b0-66985e7d4567_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_968cea6a-dd27-480a-b04b-2e98f68e23e9_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_852c39fa-f317-4dba-9261-e35e9d0d63e0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_4eba7d0b-7280-43d8-a12e-a4c749cfe9da_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_a93e2730-0b89-44c8-8f76-004868040779_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_33b6e6ff-c0ac-48b6-a5a8-db82369b5f76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixReportingUnitMember_9cb2441c-469f-4543-b615-3dd6ff4581ab_terseLabel_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit</link:label>
    <link:label id="lab_bhc_SalixReportingUnitMember_label_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_SalixReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember" xlink:href="bhc-20220930.xsd#bhc_SalixReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixReportingUnitMember" xlink:to="lab_bhc_SalixReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_0b2f07b9-817a-4a08-9298-5239947ed471_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provisions (benefits) related to changes in uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_74e04904-62c1-4a0b-973f-6528488bb1d5_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:href="bhc-20220930.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_c586578d-8465-4e6a-9206-bcaa1f320c26_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries of amounts previously written off</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_fdbca11d-96e8-453c-a018-a2bd08d00c78_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_60e134b3-9630-40b7-89e0-321969a9f7c4_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:href="bhc-20220930.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:to="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_df7ab4ec-dc59-4f0b-a414-59cd52c8476d_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:to="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_2ee5b259-14f0-425e-8cc4-9e1a953551b6_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20220930.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_83fd5756-8a33-40a0-adc0-4be9bb92c808_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3d06859f-c026-49d7-a087-5b95988e8f14_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from B+L initial public offering, net of costs (Note 2)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e89591a0-4ddc-4bd3-9dd8-4486810e5d76_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reflect change in ownership interest in Bausch + Lomb</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_93510ccf-a865-4afa-9e0b-dae584acd1af_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InternationalRxMember_a18772d8-292d-428c-8c7e-33c290dc05ef_terseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_d77f44fd-1b98-4199-8418-f754283bbec5_verboseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_label_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx [Member]</link:label>
    <link:label id="lab_bhc_InternationalRxMember_documentation_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember" xlink:href="bhc-20220930.xsd#bhc_InternationalRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InternationalRxMember" xlink:to="lab_bhc_InternationalRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_107e1863-3efb-4a6c-9cf9-ad63bd3a5308_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_b46e2ef1-4e41-4233-acf4-65fdcc13b20c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_483b4c48-f7b5-460a-90c9-15a772483957_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_205401da-bcf9-400f-8afd-90787dee9a44_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20220930.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_30107e6d-fd54-4c71-8cb7-e6bc8a75ce80_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20220930.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9e9ffa14-6584-4a50-b4df-9ee8af1ba693_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a35e3e1d-7bc8-434d-ab36-5924553c3a19_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_88f1c0c0-8bfb-4818-9745-c5f1b63fa88e_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, grants in period (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a09e9b85-719d-437e-a882-7979d8b38d3c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_4572f5f1-e2e1-49c7-aef0-382cb0517f32_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_d5c9de63-5bf1-47c2-9fbf-1f0a41ec8286_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowings interest rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_f69d1dc1-54b1-43de-97e7-1b953d15cc71_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6f1810a8-711d-49d0-8737-64b1e921e0ac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ac87ae84-6e7c-4a40-913d-a7308a916e24_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_a0a967ea-269e-4779-9b5d-5a5ce29b26d3_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20220930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5c66937b-ecc7-48c6-a950-06e3078828a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_25da4b74-4372-4bdc-82f0-f6f42beee065_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_db53f83a-7a30-46f0-8463-ccad63c1c850_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_66770b25-0dc6-41c1-81f6-13ba5bf26b60_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount to be received</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_a7e65231-f128-469d-aaf7-744d98413137_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1577483b-bf33-4d56-83a8-726ade27734f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_689ffc1b-0840-4035-9620-a48bdacfac78_terseLabel_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:href="bhc-20220930.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c3b67cf7-abb0-42e5-962b-305e70aa3b63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_59e90ef7-b699-4050-b26d-f2fc37b7942d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_40a14dff-654d-48db-ac6f-46d6dd8121cf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_813d873c-b5dd-4a03-b4be-ed91747acf67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e381f2b1-45b5-4df3-8d68-be2c9c21306d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_708dabeb-3a04-461a-903c-ca3c9ae86363_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_996da3a0-7f3e-4cd3-ac55-acd980a0db7c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_b3ce5427-0c9e-4d56-ac15-967c721594b7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85511890-da84-4b7b-b69d-381a1f677f22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9bea762d-3a66-434d-8164-8dc78449243e_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_37dfb6f5-2016-412b-b673-7ce026fa2456_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_30766f7f-45fd-48de-8435-03af7ad09357_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_ee34a598-286e-4ff2-bd55-f2c443b169c4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_0a775b81-9620-41f4-b51b-2dfca8d7e42a_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% Senior Notes due 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_1e535ea0-037e-4da9-8e6f-c3f4805d60d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_5c1e7bb0-2160-4cea-9999-e753a0a08f38_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and RSUs</link:label>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs [Member]</link:label>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:href="bhc-20220930.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:to="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7c92ec23-2956-4b34-bcff-4e832cf7baaa_terseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_55ae88d8-334b-40e3-a2b9-595602c7911e_negatedTerseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_label_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:href="bhc-20220930.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:to="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_3110f4e4-baa0-480b-b39a-882337c665ef_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_94f4248a-8385-4ca7-a96f-61b07a4da891_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20220930.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_36685720-daee-43ce-893b-7ab3dbb6f70c_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20220930.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_3ec39bf8-3f89-4c77-b400-c84492530e34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_8c56c856-fe78-4cf8-a7a6-568313218e78_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_79f1a74d-ae58-43d6-92d3-0b381aee2660_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_c38977e7-6214-4ff0-bc34-3f86abd8807b_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed but not yet served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_816c0a92-3305-4a86-a80d-58e855579765_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_c24bebb9-7d79-430a-9bc3-6553133cd5a9_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20220930.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_149736f3-852d-4319-a310-6f607f9b2d7a_terseLabel_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option to purchase additional shares, term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_label_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_documentation_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:href="bhc-20220930.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:to="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_48c5015d-59d7-4b2d-9bce-bd548a681913_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_73d275b2-4cd0-46b4-9c1f-e9e9d8008c19_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_0ad46142-2647-4444-81ce-63006627b71a_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6968574a-0eca-45f7-9062-4007a0db66cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_19ee1e5f-c68d-4911-9d2d-df02bb1c90a1_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_387b5194-7222-45b8-a03d-e00110ce8813_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20220930.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_d6a983fa-8696-49b9-a1c6-a8ef6a31012a_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_90e35d6a-e774-4bdc-a88f-3cb0f41af5ee_terseLabel_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_label_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Additional Shares Available For Issuance</link:label>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Additional Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:href="bhc-20220930.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:to="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_4111176d-0b22-408b-9c0e-8377042d737e_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:to="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_67c24e8d-018f-48a6-a5f3-6d265499512e_terseLabel_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients</link:label>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_label_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients [Member]</link:label>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_documentation_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember" xlink:href="bhc-20220930.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonExecutiveEligibleRecipientsMember" xlink:to="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_83aec143-a8b2-4717-9068-7dca860df92e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_660c53b2-3aa9-4d2d-9025-29b2870c5028_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_bbdaa0a7-058b-4c26-a490-e5d857aa2d7f_terseLabel_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_label_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_documentation_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees" xlink:href="bhc-20220930.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_Legalsettlementsandrelatedfees" xlink:to="lab_bhc_Legalsettlementsandrelatedfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c0a2a17-984a-4c10-8921-a81d4e16ed8e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5c88662a-7a94-4105-9696-8e40a1b44b21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3abb907a-57a3-43c7-aa44-4d7a79852a85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_2a51d30c-0f53-4e06-9ee0-7f5a300911c5_terseLabel_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan, Retention Program</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_label_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan, Retention Program [Member]</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_documentation_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan, Retention Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:href="bhc-20220930.xsd#bhc_A2022OmnibusIncentivePlanRetentionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:to="lab_bhc_A2022OmnibusIncentivePlanRetentionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_518153c8-8d6a-4d4d-a253-ec377ce125dc_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_9e4282b8-b329-4a39-aecc-773cb60bc199_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_302fc269-52ab-46fe-beb0-507fb2a7496b_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual excess cash flow</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsMember_507d4181-34ff-4990-b7e7-175b9dab22c5_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember" xlink:href="bhc-20220930.xsd#bhc_RICOClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsMember" xlink:to="lab_bhc_RICOClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_cec55618-4569-491d-907d-2bcd828a20a2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_a55d4353-e82a-4a2f-8927-5040aa35d933_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20220930.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_d27de984-7e7f-4b50-bb40-69267a6e4b7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_1d2c4fef-c41a-4087-a75b-2c1bff824760_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Involuntary termination, program criteria, if circumstances met, anniversary period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_e923df75-3769-4d7a-ad3e-b290ddc63c39_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_04c42f93-6796-43a7-9588-b790f7d7e29b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8ccac2ba-85d6-4eed-bb69-18fc84ae5994_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_1d241cd9-9250-41f5-b674-06d54af201c4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_60ee788e-173c-4c6b-8625-c2fddf4a5888_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20220930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_955f7925-6a7f-4de4-831d-bb536cd69458_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to filing certain tax returns</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_29d549e3-ec8a-4607-b09e-8c5591803967_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b38e141d-005b-4a11-855c-bb8d2980f186_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_994a9af9-c91f-40e9-b5ed-86f30de14912_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_17656222-0f90-44b8-afb0-7147f895ea60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_17a2447e-a835-483f-b8f3-e867d913ce37_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_90489f23-7af7-4022-ba6c-8d2f5aa5f33b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_03bc379e-5702-4a34-8899-dbbb08a1afde_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_23019c26-73d7-4b5f-bf57-705366d76c8a_terseLabel_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_label_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_documentation_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:href="bhc-20220930.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:to="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_28b4a177-bf5d-4dca-8b1a-eca99fb580a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_049ce3de-c5a5-4d0b-9112-e8a0006a17de_terseLabel_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC performance-based RSUs</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220930.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ab1b6455-9b53-4196-a629-c461eb16d93a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_672b0afb-3b24-469a-ab77-1ad52a27aeca_terseLabel_en-US" xlink:label="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer [Member]</link:label>
    <link:label id="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:href="bhc-20220930.xsd#bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:to="lab_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_33565a1d-6c27-4db5-a7eb-627929f71159_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_ea570f69-1933-4dd6-bc6e-00fd7ca0c4e1_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes, Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:to="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_14e0396a-d8b3-413b-9f41-bb16b7afaaa6_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20220930.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f848120e-7f5e-4056-bce1-73ff1412c2e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_757616ef-ef19-4a7d-9e10-52b33a3ecf75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_262d4902-4dfa-45c0-a1b9-ac091803e1d7_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_58880058-f7e8-45ec-b7f3-dd30bb04ba76_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_791edf80-15f6-4503-8de4-87c52fe0f540_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_700dbffd-7318-46d8-a8fc-3430969a2dae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_0f1803f4-7c86-4078-bda6-0a48f2122866_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20220930.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ee1908c5-89de-4cea-9e70-bffd6353a371_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_013c471b-44d5-46ce-88b3-2c9f474a0669_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_f2f030cb-f4a9-4a27-b813-ad589133e811_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes Due June 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:to="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_fe433216-78de-4e07-915b-dd227d2cfddf_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_41503383-e214-414d-ad83-1e9233885f6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_54438b00-f229-4a45-8a88-794c1313a608_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20220930.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_50c46a29-41bf-482c-af07-89bc74881c47_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_f9c52487-8f8d-40bd-af61-b8aefe8f4f48_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_aaf061e3-e089-44a6-8afa-9f15bde1f77f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_01db70ed-c323-49c7-b53c-56b49cc07a45_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_32d5e0ac-95b1-487e-aeb7-42e21efafce0_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20220930.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_5f345159-d825-4b11-850f-00bc79d9afc7_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_6bda5011-1cfd-49b5-9704-969555a17f06_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_20a995d4-234a-4ca4-915a-7a7219694d3c_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes due 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_68d06f4c-a293-4bf2-a462-6ec8f310c1b4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_1b533095-6449-481c-a74f-db1eb2eb17af_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e0ca90dc-b288-451d-b095-4394a78526ca_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a99a598b-be7d-4405-bdf3-70390f7cd215_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO-related costs included in selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b1fb5b8c-cac1-4b48-9dae-fa12e060e016_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_674cf361-97af-4055-af34-959a96ba0d62_terseLabel_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_label_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_documentation_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:to="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d86aa9d6-a386-496e-8de7-4eb3dc0fe267_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_73e7f65b-f71c-4198-ac53-5999b652f208_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_cb73b7ae-3099-4d6f-a6ed-a649a540bab1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_cdaf1eb8-e686-4e2f-bdf8-0830a152f246_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_92d60404-5fc1-482b-be6b-067fcf81259d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_804e42db-3fde-4512-afc0-0acad3a4a4ab_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_56bd1cc4-268d-4836-b1e5-722bafb25574_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_cedcae22-cf84-4336-9e6a-ec29e9796a50_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17802abe-edf1-4f6b-85ba-dfd798d40304_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_cd4bcbd7-d833-498c-b9d6-0d7066143d47_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_6d6ddb43-3ca2-4f59-a428-2a176bfde9e4_verboseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_9c508ca3-6426-4787-888c-b1a29e238867_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:href="bhc-20220930.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6af403cb-7b91-4f38-88d9-4260e0b98e8b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_045515ba-162e-4980-a765-f1469af08155_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_49df7f3e-8b5a-4927-8907-c0353652e9a9_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20220930.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_65d62327-6371-4771-9bf1-dbfc3db70f28_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4b827b48-e84f-4510-8f9e-4b5dfae51382_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_a490a129-bd82-477b-a5b0-64896a94da27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_168ed706-ee2c-4cb4-bf41-e0aa34645d77_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a3d183a6-bd52-4a92-9d05-332cc257afc1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_675fbbe4-a17c-42bc-8fd4-13e40aba3cb2_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, redemption and discharge condition, amount, if circumstances met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_760c1148-a9f0-43d9-9101-bc3ae4812624_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_68fc7686-f1c9-4df3-a108-f3777e613702_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_055e454c-4c23-457b-bb57-51912014496c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_9f679527-63ad-4a28-89d3-92528265b94f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_bd9df61b-690d-4c13-bda8-0cc132db0678_terseLabel_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_label_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products [Member]</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_documentation_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember" xlink:href="bhc-20220930.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_XifaxanBrandedProductsMember" xlink:to="lab_bhc_XifaxanBrandedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a8c9871d-279e-45b7-b29b-e80001fca433_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_df2ca095-4ddd-44ab-83ce-a1b55e951cd9_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_54f6dcb2-2c74-4024-8f3b-0d2f14d06f9a_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_ae4e78a6-b2eb-4a02-a401-3709beae9664_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20220930.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec8fb5bd-b66c-49e8-a564-072cf0ff2f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_8d6a78f8-0a2e-43a8-b29c-b4c84236ce21_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_4d689c6c-fdf8-4094-bb9a-0a962693cdab_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, change in discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_aeebcc3e-8eeb-4854-926c-0cf6f4938342_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_8579a69e-27e6-4bfa-8839-8beb8a2d801f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d0aac8fd-e806-481a-913c-84ba1618f36e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A1375209BCLtdMember_6a33c0b1-8b8c-4445-8ffc-78e738583875_terseLabel_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intermediate Holdco</link:label>
    <link:label id="lab_bhc_A1375209BCLtdMember_label_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1375209 B.C. Ltd. [Member]</link:label>
    <link:label id="lab_bhc_A1375209BCLtdMember_documentation_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1375209 B.C. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember" xlink:href="bhc-20220930.xsd#bhc_A1375209BCLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A1375209BCLtdMember" xlink:to="lab_bhc_A1375209BCLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_041c34c5-f802-4082-9e77-043f732d78b6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_30b5ebe9-5f5e-4ec3-b26f-4b25721e4371_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_139b342b-7e2b-4c58-a737-6a227aefab7a_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit, amount possible to decrease in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_c8621d43-b97f-45c8-85fc-150c7f1cbe76_terseLabel_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_label_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_documentation_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember" xlink:href="bhc-20220930.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetImpairmentChargesMember" xlink:to="lab_bhc_AssetImpairmentChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_fa4a4630-c071-462b-8a1e-430ffc9bf450_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes due 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:to="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3f0be827-404c-418b-9d06-ea1fd60145aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_71208129-f2cb-4572-a696-6a5ece06f6a3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6ce221c9-8298-448c-aa39-22fdd2b7b437_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_010c3cb2-3e21-4739-a044-0b5ed5b739c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2b5f5424-ac0c-4e55-ac37-38583cf23bd8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cde46b16-f9f8-4095-b99b-40bf1eff40d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_86b25184-5537-4042-98af-2f3b627b4c67_terseLabel_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_label_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation [Member]</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_documentation_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:href="bhc-20220930.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:to="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_0ceca9af-a1b3-4d9c-b39a-081c2bb73562_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_9b4ef10a-ae45-43bb-a02f-204d03e4aef3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0d172bcb-49b0-490e-98b5-97d7446e79c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7965ea42-b8fb-45f4-b8e0-d2bbb5c80b34_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_37a8decf-2702-453a-9a83-06c0ab275742_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:href="bhc-20220930.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_956ed31c-2e02-4b68-a14a-c86666e3ca10_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate, if rate not ascertainable (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_label_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:to="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e0e3475e-d6e4-4bb7-b8f2-be95d53b9e63_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_5b303608-e9e3-4220-861a-67bcac2653cd_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_cb7edde3-842e-4304-a7b7-a45b8075d809_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_KR_8b7dfde4-c938-4fa0-9e8a-488d2b0f937c_terseLabel_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea</link:label>
    <link:label id="lab_country_KR_label_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KR" xlink:to="lab_country_KR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_5aa7f417-422b-45ad-807e-068a85819aec_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_62ac3cd5-f38a-45d0-9bf6-74230d686ca7_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of putative antitrust class actions filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_196b76f8-0c13-4562-b6bd-294777a7c90a_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_970e10e1-da3a-4f76-9edd-e53e1266a106_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_8f346b9a-c6b3-4179-a511-54d6eb47712d_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_254469f8-dbce-40c3-97a5-c4900a41d064_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_5d000c47-a4b6-49f6-9aff-fc9e7368b726_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_6a1a4181-52f9-4389-a238-a0cd297879e1_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_49885de8-9e54-4d74-9a7c-6a575687dac0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_b1e3812b-f89f-44a5-b0e4-3c682c239f50_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_148cbb9a-43bf-4bde-b4c6-b9a7fba015a3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets classified as held for sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_12e82335-d1f9-4869-8fe1-2c5d4dd970eb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_31e57420-dae8-419b-964f-cef3ff6256af_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_f9f5d05d-ab74-4b12-8075-b6915e6d42ce_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_c0bc44e2-8e57-4ad4-8486-aea43b5edf52_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_b7629f16-7c4d-49e6-a8fa-8c2cb6a58e65_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_78f61f18-6d08-46b1-aab9-844cfc923a0e_terseLabel_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L Separation performance-based RSUs</link:label>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220930.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_5f60f287-82db-4fa9-9874-0421617f7b89_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes due 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_82890d7a-f888-41b8-8709-8c183e55ab40_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued loss contingencies</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_07e60837-09ef-46b8-8b2b-8b49ffa20acb_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e8b2f6cc-7062-43b6-9cc1-445eaa3c6cb2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_83ab9323-ce26-4987-a4b0-3088d71c097d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and other</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_385e086c-6039-4333-a58c-f63b058b5599_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_fd6947ab-063f-4f13-a8c1-4e6b5e78a652_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExchangeOfferMember_cd60ae46-b683-4dac-8113-ed0fe35b80ae_terseLabel_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer</link:label>
    <link:label id="lab_bhc_ExchangeOfferMember_label_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer [Member]</link:label>
    <link:label id="lab_bhc_ExchangeOfferMember_documentation_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember" xlink:href="bhc-20220930.xsd#bhc_ExchangeOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExchangeOfferMember" xlink:to="lab_bhc_ExchangeOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1e4c69c9-ebbd-4e4f-b6e5-61ce47de23eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f9eff282-9948-4b8d-bc91-614576bb33a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_05c74389-802c-48d2-b4a5-2754be1f76ec_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_7fa89594-94e0-42a9-997d-49f7bbc8416b_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes due 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_1793a098-05d2-4a75-92da-e3313a3387d5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d8842ab5-6ac6-427b-b6e6-f3766a185f04_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1036745e-f9f2-46e7-af94-4d6779541c91_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_fb53da71-0c50-42cd-a063-1531ed130ca3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount drawn under credit facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8df78b0f-1578-44c2-9f4a-6a3c96006c1e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3c257267-4074-4c73-a743-fe8cbf67d70d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_52c6fdaf-763a-4254-a955-a404cb3d7230_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_3a53370f-5015-48c3-98cb-751eeeebda13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) related to changes in fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_63b77bc6-1391-42cd-9b79-77b147586778_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b9d4fc35-c489-4c90-bfac-bdadb61ca6cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_39910174-f38a-46b1-90a0-979cdda22353_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_2df1716e-3c03-4edf-97e2-5e313fbdd7c0_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20220930.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_d09b7472-2171-4f34-8b3d-3fa393e26061_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and RSUs</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a267b75d-91c0-4707-82a5-6ec5a0f41f28_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_8848e574-f2e4-4b82-ac00-602a9b59411b_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_950783d3-499c-4985-828f-28c2cd27d95d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_c9a78b19-92fe-482c-899a-29d6215bbeb0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_75e8b3ea-522c-4f5d-89a9-c8def0162f29_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4a4e512d-17e3-49e2-8594-c848bd392094_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_359b1be0-2f1d-4161-8a1d-039874adc82a_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_136b1788-c37d-4435-8cec-eb85e7d6d559_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_4032fd26-2479-42d3-ab29-b7b83da60d2f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_9fd39566-345f-44e8-a450-d8817e08360d_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20220930.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_cf812945-9f1a-4b5d-8f57-dd351e355612_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8135d0e9-f79b-4a2b-b89b-671eb5785623_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_b24a1dda-db6d-4c7f-9d66-a526d7f7b86a_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember" xlink:href="bhc-20220930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedProductsSegmentMember" xlink:to="lab_bhc_DiversifiedProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_27016d9e-125d-4633-8fb3-485c872b2fc5_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c93998b9-17d6-4b87-b001-e405a5e9766f_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_5dab8688-2d75-4059-9e0b-9cf9bb0a7a5a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_86a6cb80-5457-4986-8efa-c118067db297_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_98388d1a-e5c1-488e-bc32-d3d531ae5830_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_417d9d4d-d97c-4d74-b6e4-40a43818477f_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_aaa8e79e-bde1-4222-9472-f28a36929cb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7ea59c21-2b40-46b3-9695-8667b369bb2e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8b22337d-6a43-4684-bb98-e39c7c3790e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_7e9eae61-003e-4e61-88bc-39dc1f305345_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3d73a19e-a27f-422c-9a7b-20232f94dc0b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_65ae70f7-681b-4484-a938-afc2747e4f27_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_ab786a6d-5f6e-4071-b5e5-60e785eb4335_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation (including McKesson Specialty)</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20220930.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_3c64ccec-0bf9-49d2-92c8-40df2717633f_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20220930.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_21cbb722-5b25-4028-ba30-c7332fdf2cde_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit for legal settlements</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Legal Settlements, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Legal Settlements, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e6d4564d-c93c-4a39-bdd2-99ef07a8cc9b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_34780942-0238-44e9-9497-8596ff2176c0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_fef2d63d-6469-4ac2-8fea-60db353b2326_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_79573b6b-2184-4c60-a5d5-7da4a550aa48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_1b4a0b95-ebe3-4008-b806-f8f6c593ae61_terseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_a7a10e26-e15f-4823-bc93-1426ae5ca819_verboseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_eac82e1c-dfe6-4c20-a7ec-85e2c68c8563_negatedTerseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_label_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_documentation_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:to="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d16430f2-ce8c-4813-9fe3-08c44725d341_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_e6a17064-62d4-4cf6-9089-dde2316d5438_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for intangible and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0fc27676-f0e1-43c7-bd8f-66a30289f5a6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_24806d53-661b-4f60-a650-92687fda661a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation, and IPO costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_ab1d94a9-6e5d-4ddb-8e81-e9ffa2fc1103_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_46613702-4391-44fa-9902-42447b81a7d3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_82582293-56c7-409f-8ae7-b4eeb75a4e9c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_a084999e-8fce-4bf4-ab12-f4c0ac11f85c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_46f1b5cc-9b04-4a02-8e04-83d7cd59e569_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2d92855d-4be4-4a24-a758-fba2dd617999_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_6146438c-958a-4e00-b3a7-922d5faa106a_terseLabel_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_label_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment [Member]</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_documentation_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember" xlink:href="bhc-20220930.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SoltaMedicalSegmentMember" xlink:to="lab_bhc_SoltaMedicalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_48c931f2-7ff9-4b14-bc5e-7d625d026fa5_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20220930.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_1906d931-2cb5-41a2-bcaa-e7e103820d19_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Plan</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_600fc902-b4cf-470d-8cfc-6abe359632c1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_241aa9d9-34db-4d47-972f-c4034da2dbb7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_26c7c198-3a8d-45f0-8e46-feacde4c2dff_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c32dbc1b-7b4d-4da8-9a58-caa5b87fcfa2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_a87107d9-8583-40a4-b8b3-020d3bfdb09b_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_label_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:to="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_74204160-a4f8-400a-a4e2-cd07de076df0_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20220930.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45e13b75-013a-4c9d-9a27-ea0019dfb8b4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2913c22e-b0fd-408a-95c3-b73c80a6277d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price appreciation credits</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_b7e7e64c-1056-4bbb-9744-184fd8ac7439_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f1a648c0-69cd-4697-b50e-19487b25fb30_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_e32e6c70-d515-4eba-af94-072234d29a9e_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivable and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20220930.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5722dbc9-ea3c-466d-9dc6-8da51cf0f315_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b5f94aca-98b3-46c3-928e-39c74c8363d7_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_545a0080-1e45-45ba-8ea2-0e354adda774_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_5c169649-eef2-4fd5-b5d5-f28e09a09c0f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_c4927781-466b-4377-be1b-51d812058ee8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:to="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_3bd7e221-af51-44f5-9bd7-a75d8f335562_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_364b6fbc-217d-4d2e-aeb8-9fd6b087349b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ffd140e7-96ef-44ba-bedf-dffcf14bda8d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_f80fa675-2f99-4f02-91cf-b1192f20b3ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_64362d8b-6686-4024-bbdb-ff1812b56a8a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_77416a98-7741-4c82-b89c-0e0ba03ea2b9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_0e9d0cf4-f316-4649-83c7-f33cc1369033_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of aggregate principal amounts of debt validly tendered and subsequently accepted</link:label>
    <link:label id="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Troubled Debt Restructuring Note, Debtor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:to="lab_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ba2e9c23-e025-44ad-a24b-42056107a3ee_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_d1b43c0c-9c10-45a7-84a8-8ab55500ddb8_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:href="bhc-20220930.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_b00801e8-fc10-4047-9522-2f701b6eb72d_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_9b2fbb35-a678-41d0-b129-1e3c68905c3a_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_616ab55b-af45-4f86-919f-ce31ba22c39d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7e54cc80-cf9e-4018-9c3c-61321872a49b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits related to interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_d5b42bd0-e8d9-49cf-ac24-c4fda8a66c38_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4eae18d8-7931-4754-8426-49b958bac460_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d37b31fb-e797-4641-a993-644ecdec8d31_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_34c5e52b-c1ba-4835-8a6e-14d1938d5f34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_f515e962-af09-41b3-8e76-79997a525d81_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_8f5fe2f8-6984-4b16-a66d-3e3a8859c931_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_12a20e52-8694-45b9-99c9-02de337c7a49_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_3143747f-1b0d-4f2e-927c-a9cae7960367_terseLabel_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember" xlink:href="bhc-20220930.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NewRestatedCreditAgreementMember" xlink:to="lab_bhc_NewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_49c061b4-6672-4680-a724-e93f4dccc535_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_bdeb242e-1f39-4d67-b3a1-5a52bac52d15_terseLabel_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation</link:label>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_label_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation [Member]</link:label>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_documentation_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember" xlink:href="bhc-20220930.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PatentInfringementLitigationMember" xlink:to="lab_bhc_PatentInfringementLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_227b004f-1ba2-4a6f-9477-2b986cccd779_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_87e754a4-a795-4905-b9f7-1d9cfe3fa2f7_terseLabel_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EURIBOR</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_label_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR) [Member]</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_documentation_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:href="bhc-20220930.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:to="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_144d2766-b783-403a-a71c-8006997eada3_negatedTerseLabel_en-US" xlink:label="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party fees paid in connection with the Exchange Offer</link:label>
    <link:label id="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_label_en-US" xlink:label="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities</link:label>
    <link:label id="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_documentation_en-US" xlink:label="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:href="bhc-20220930.xsd#bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:to="lab_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_91f6f2df-797c-4f36-9f97-9aba43683bf7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0e14266b-b8e7-4081-a039-14bf57dda514_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_4d67c565-b4d9-4b9a-a6d2-99bd0931a566_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a98eadca-6d29-4830-8d69-4b34ed8fb27a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_429ae812-d5a6-413d-9ad7-de49f72ddc41_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_7ab3a5ed-5525-409a-a7be-4b43fdd30fc7_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_92dc4309-a1b0-47f7-b2a0-4e8f4634767e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_e0d72219-ce4e-492a-b65b-b9738399a4fc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_2cd68d08-7172-4d2d-b846-375cb1669090_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20220930.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_800b4e03-cc3c-4cde-b818-82a60c647124_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20220930.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_f0b3529f-4e42-424d-9144-ef4d6cee29c2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_fa647c33-e5e6-47dd-8ac5-5ab353980b0d_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_22620f35-8605-408e-a387-ff79c068dc46_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_23c65814-478e-46d6-ac40-efcb55c9d1a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_e64f435b-140a-417a-a1ff-1964e619bd83_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20220930.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_f73850b4-a208-4eed-b6e9-4ec734a1be68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_73c97788-4078-4db2-b99d-bb042831695a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_58d2bb27-70b4-47ec-974f-6b79eb5da9ae_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20220930.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_11792366-c050-4b1d-88c8-9693deb8326e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9815f461-d03e-42a1-a501-2465cce053b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ApotexIncLitigationMember_b02bc03b-1404-4bb7-b9ed-519893d1a13f_terseLabel_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_label_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember" xlink:href="bhc-20220930.xsd#bhc_ApotexIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ApotexIncLitigationMember" xlink:to="lab_bhc_ApotexIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8a919a3d-d858-43b5-80b3-a182abfe7373_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_6a4f5773-b41d-4da1-a4e3-9589e72d2644_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_f62e3845-35c8-40f9-bd04-2699bd1c209e_terseLabel_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluded from computation of earnings per share, performance conditions not met (in shares)</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_label_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_documentation_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:href="bhc-20220930.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:to="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_01a299ec-3759-43ad-ac7c-cbdbd7bf74c6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_a7be1cd0-df26-4c4b-a8a6-1ac268598736_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_89c3bb2e-9ebe-4f19-980f-db69241053bd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_bc7d63f9-b646-4c20-9915-c7a4d9ae47e2_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20220930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_22845a64-402a-4398-a809-b979c3e70c18_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_0d335827-7743-4621-91cd-f2b6de3dc9b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) on ordinary income (loss)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_9a2c6d2c-c624-44e0-ae9b-d3a6141a4463_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">11.00% First Lien Senior Notes, Due September 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 11.00% Notes, First Lien, Due September 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 11.00% Notes, First Lien, Due September 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:to="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fa472175-77c1-4d0c-91b3-efcb54e0bfed_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_d1221334-7ad4-4790-949e-7d2b91b4cfb8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_45be3cab-fca2-4ab2-a6a4-a8a455e5c454_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_3b275327-44fe-4ddf-92b2-f3a35ee15a8c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_3bb6daba-d164-4f37-9e05-d8c0e318e31a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_ec3658e0-ec1e-4ebb-8968-4198b279bb87_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_bdd4bbac-f192-469a-be7b-8e59790dc0f6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c27b4612-b742-4edc-8470-12914e1408ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_4ff59c65-5a02-4ca6-a5fb-3362c41da7f6_terseLabel_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, SOFR</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_label_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:href="bhc-20220930.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:to="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_8896b4d6-6233-47b6-baf5-54aad0c722f6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets and businesses, net of costs to sell</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>bhc-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7672b0ed-3503-4562-bc82-7a3368936983,g:725d4d73-5fd8-4cb1-b65a-aa245208ce29-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20220930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0ed49049-ec2d-43f2-bb58-db6aa8d318bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_DocumentType_0ed49049-ec2d-43f2-bb58-db6aa8d318bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a724451e-4440-43ef-b314-a5564f94bbd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_DocumentQuarterlyReport_a724451e-4440-43ef-b314-a5564f94bbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a7455857-163c-4fa2-bff7-d165f4083bd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_DocumentPeriodEndDate_a7455857-163c-4fa2-bff7-d165f4083bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f1042899-5f57-4f26-9e95-da7179d44c6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_DocumentTransitionReport_f1042899-5f57-4f26-9e95-da7179d44c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1783d71f-a617-4ca6-8d45-1bb23f3dba3f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityFileNumber_1783d71f-a617-4ca6-8d45-1bb23f3dba3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_82d5e547-bf57-4bc9-ba9e-2092049165b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityRegistrantName_82d5e547-bf57-4bc9-ba9e-2092049165b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8c2bc83d-1f84-44be-802c-8b5d147f0ff3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8c2bc83d-1f84-44be-802c-8b5d147f0ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_7a4d1f90-eb9c-4714-bf03-d47dfa4ef8c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityAddressCountry_7a4d1f90-eb9c-4714-bf03-d47dfa4ef8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_40cec4cb-1805-4ea4-b58b-ac5100a56374" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityTaxIdentificationNumber_40cec4cb-1805-4ea4-b58b-ac5100a56374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4f6f2af6-54c9-49d5-ba94-ca17008df9d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityAddressAddressLine1_4f6f2af6-54c9-49d5-ba94-ca17008df9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c91d9368-2b49-4cd7-b8f0-3f19acf8ecd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityAddressCityOrTown_c91d9368-2b49-4cd7-b8f0-3f19acf8ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_be9eaa21-80f5-4ac9-8f0a-20d766e85e75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityAddressStateOrProvince_be9eaa21-80f5-4ac9-8f0a-20d766e85e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_530c9d62-8208-46d1-9ad1-7c36e44cbb44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityAddressPostalZipCode_530c9d62-8208-46d1-9ad1-7c36e44cbb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_52826777-cb49-47d7-b332-34b3729cc71c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_CityAreaCode_52826777-cb49-47d7-b332-34b3729cc71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d4575df1-110b-47ec-aab3-b6504b388054" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_LocalPhoneNumber_d4575df1-110b-47ec-aab3-b6504b388054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a344ad8c-843e-4e68-9647-ff60048d5ae7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_Security12bTitle_a344ad8c-843e-4e68-9647-ff60048d5ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2834dc05-b75e-4b25-b613-66d5eda2eb79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_TradingSymbol_2834dc05-b75e-4b25-b613-66d5eda2eb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7f021a88-b733-411f-84ad-e0755755417a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_SecurityExchangeName_7f021a88-b733-411f-84ad-e0755755417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5a4e23b1-2b1a-4830-a108-ec5f97b869aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityCurrentReportingStatus_5a4e23b1-2b1a-4830-a108-ec5f97b869aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_85245188-60c2-4215-92de-68ee9ecf858e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityInteractiveDataCurrent_85245188-60c2-4215-92de-68ee9ecf858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_33e29d50-a1e6-47fe-a8c2-609fb58f5268" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityFilerCategory_33e29d50-a1e6-47fe-a8c2-609fb58f5268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d859fdca-54cd-48d0-93e5-21de29b56611" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntitySmallBusiness_d859fdca-54cd-48d0-93e5-21de29b56611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_55cf16d9-d4ad-445d-80b8-a35f5cc077de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityEmergingGrowthCompany_55cf16d9-d4ad-445d-80b8-a35f5cc077de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1cc164c0-2632-43fd-8fd4-01aeacb2dfbf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityShellCompany_1cc164c0-2632-43fd-8fd4-01aeacb2dfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_989b115c-d150-4bf4-8e5e-c111aed67978" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_989b115c-d150-4bf4-8e5e-c111aed67978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bc7da897-e93f-4d7e-aa7a-79ae0bef5814" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_EntityCentralIndexKey_bc7da897-e93f-4d7e-aa7a-79ae0bef5814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8bceebb0-f729-4928-83c1-4c0e362e67a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_CurrentFiscalYearEndDate_8bceebb0-f729-4928-83c1-4c0e362e67a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_33017639-bb5b-4be1-b08f-3afd254bf69d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_DocumentFiscalYearFocus_33017639-bb5b-4be1-b08f-3afd254bf69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2b11f840-8bb3-4b90-9cc2-ae1447acafc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2b11f840-8bb3-4b90-9cc2-ae1447acafc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9f63374f-49f1-4c80-942d-7a561c7e4286" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_53e38092-9d92-4e1f-8112-a4f2ace9faab" xlink:to="loc_dei_AmendmentFlag_9f63374f-49f1-4c80-942d-7a561c7e4286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cefdf53d-d9f5-4873-94dc-250f5a910e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cefdf53d-d9f5-4873-94dc-250f5a910e0a" xlink:to="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270d3f45-d569-4164-a591-30441f03a986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270d3f45-d569-4164-a591-30441f03a986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_e536fcb9-abdd-4be9-9b32-abe439f4408a" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_e536fcb9-abdd-4be9-9b32-abe439f4408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_534a2132-8e6c-4afb-818a-f8435c9a4c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_534a2132-8e6c-4afb-818a-f8435c9a4c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d2069605-a564-44ea-84af-91e1cf3f9190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:to="loc_us-gaap_InventoryNet_d2069605-a564-44ea-84af-91e1cf3f9190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_17dfa830-3927-4aa1-9030-30f2a79f8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_17dfa830-3927-4aa1-9030-30f2a79f8bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73fce6e4-7f06-49a2-9560-f2a7982c743d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84d9cc06-9de9-4fd1-97ad-4048d4ab901b" xlink:to="loc_us-gaap_AssetsCurrent_73fce6e4-7f06-49a2-9560-f2a7982c743d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b4d08d9d-da54-4ed7-9666-d11f7e96d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b4d08d9d-da54-4ed7-9666-d11f7e96d9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3634eb80-4992-49bf-a3fd-e44e93534dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3634eb80-4992-49bf-a3fd-e44e93534dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d966e758-14bc-405c-8e96-0b4aedefa32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:to="loc_us-gaap_Goodwill_d966e758-14bc-405c-8e96-0b4aedefa32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_75efb5a7-a105-46bb-be88-dcdbec3af00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_75efb5a7-a105-46bb-be88-dcdbec3af00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2b38b267-822c-4958-af98-06885ea5fe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2b38b267-822c-4958-af98-06885ea5fe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b701a95d-a79c-4ef8-8333-6397b7a4f5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f795c994-c08e-4734-91f9-b4445ec96cc5" xlink:to="loc_us-gaap_Assets_b701a95d-a79c-4ef8-8333-6397b7a4f5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cefdf53d-d9f5-4873-94dc-250f5a910e0a" xlink:to="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fe57cc21-30af-4792-9c21-b184b67bbccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fe57cc21-30af-4792-9c21-b184b67bbccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6e126f6b-13cc-4be0-a2c9-562c92660e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe57cc21-30af-4792-9c21-b184b67bbccc" xlink:to="loc_us-gaap_AccountsPayableCurrent_6e126f6b-13cc-4be0-a2c9-562c92660e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a6a473f6-a1c1-4307-843e-2306df4861b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe57cc21-30af-4792-9c21-b184b67bbccc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a6a473f6-a1c1-4307-843e-2306df4861b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9b51213b-4252-4d26-96fc-435224c8a769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe57cc21-30af-4792-9c21-b184b67bbccc" xlink:to="loc_us-gaap_LongTermDebtCurrent_9b51213b-4252-4d26-96fc-435224c8a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_46ce9fbf-b895-4843-b77a-d83ca98b6ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fe57cc21-30af-4792-9c21-b184b67bbccc" xlink:to="loc_us-gaap_LiabilitiesCurrent_46ce9fbf-b895-4843-b77a-d83ca98b6ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_11f72d5f-13ea-4c45-8469-2614764c7f57" xlink:href="bhc-20220930.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_11f72d5f-13ea-4c45-8469-2614764c7f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_46654e7c-68b7-4a12-8067-2265041e719a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_46654e7c-68b7-4a12-8067-2265041e719a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0f28db69-a836-4b38-95d4-01f0fbbdb8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_0f28db69-a836-4b38-95d4-01f0fbbdb8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9bf24dea-3a79-4937-8321-563e42bd04d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9bf24dea-3a79-4937-8321-563e42bd04d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_90cc8e7f-1a72-454b-80b8-93f6a0ab3d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_f43494cd-c4c6-41bf-98c1-f6fdd11eec17" xlink:to="loc_us-gaap_Liabilities_90cc8e7f-1a72-454b-80b8-93f6a0ab3d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7460164b-8c51-4791-94ed-575f4e59a678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cefdf53d-d9f5-4873-94dc-250f5a910e0a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7460164b-8c51-4791-94ed-575f4e59a678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cefdf53d-d9f5-4873-94dc-250f5a910e0a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fc1c6d35-4bd5-4190-9913-4c41672d2825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:to="loc_us-gaap_CommonStockValue_fc1c6d35-4bd5-4190-9913-4c41672d2825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e72f5ec5-dbf6-47d3-85e6-75fd787d0df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_e72f5ec5-dbf6-47d3-85e6-75fd787d0df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6eb18054-014d-47e7-800e-f9df0920d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6eb18054-014d-47e7-800e-f9df0920d7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a93dd0bb-8ace-488b-a1a1-3d0995edb095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a93dd0bb-8ace-488b-a1a1-3d0995edb095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5643f82e-06a2-4d79-8c20-503a16bd62b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:to="loc_us-gaap_StockholdersEquity_5643f82e-06a2-4d79-8c20-503a16bd62b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f01fc280-5f55-46aa-8083-714f6b0a5119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:to="loc_us-gaap_MinorityInterest_f01fc280-5f55-46aa-8083-714f6b0a5119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f526bae9-b83a-42a6-b475-5c9a7399985f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90a6926f-ba32-43d5-90fd-e0b6e30cf82d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f526bae9-b83a-42a6-b475-5c9a7399985f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e5b0116a-38c0-4f2d-86fd-5d49d26edcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cefdf53d-d9f5-4873-94dc-250f5a910e0a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e5b0116a-38c0-4f2d-86fd-5d49d26edcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4aa53c5e-f1ea-4d1e-b5e1-929f7808a305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_758b519b-bb4a-41b7-b117-85a2539eb45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4aa53c5e-f1ea-4d1e-b5e1-929f7808a305" xlink:to="loc_us-gaap_CommonStockSharesIssued_758b519b-bb4a-41b7-b117-85a2539eb45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eaf1b188-8d26-4c6b-9db7-5f0144cf4039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4aa53c5e-f1ea-4d1e-b5e1-929f7808a305" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eaf1b188-8d26-4c6b-9db7-5f0144cf4039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_70b7227f-9217-4c38-8868-9d352196a78f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_66ce626c-a311-4419-820c-d0b4fd4369a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70b7227f-9217-4c38-8868-9d352196a78f" xlink:to="loc_us-gaap_StatementTable_66ce626c-a311-4419-820c-d0b4fd4369a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b9fe4fab-0a80-453e-b551-67399f72dc38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66ce626c-a311-4419-820c-d0b4fd4369a4" xlink:to="loc_srt_ProductOrServiceAxis_b9fe4fab-0a80-453e-b551-67399f72dc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b9fe4fab-0a80-453e-b551-67399f72dc38" xlink:to="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_658ef9b2-0b8b-4b5d-8cd2-49f978f572d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:to="loc_us-gaap_ProductMember_658ef9b2-0b8b-4b5d-8cd2-49f978f572d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_d56b23bf-9c8f-45a9-8395-0570a72ef3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4892dae8-fa35-4bfe-9f0b-d7bf0d91e7dc" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_d56b23bf-9c8f-45a9-8395-0570a72ef3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_66ce626c-a311-4419-820c-d0b4fd4369a4" xlink:to="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_88c6f5d5-43a8-4d66-8620-f619432aac51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_RevenuesAbstract_88c6f5d5-43a8-4d66-8620-f619432aac51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83bed02c-aeb5-44e6-9bf4-d4db3eb9d4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_88c6f5d5-43a8-4d66-8620-f619432aac51" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83bed02c-aeb5-44e6-9bf4-d4db3eb9d4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2dc3fbcb-c46b-428e-8a85-7d554f68583b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2dc3fbcb-c46b-428e-8a85-7d554f68583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2190c34c-5552-4f59-8ef0-77de4b0a7ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2190c34c-5552-4f59-8ef0-77de4b0a7ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4763505f-f527-4c22-8434-083b7aeb46be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4763505f-f527-4c22-8434-083b7aeb46be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_6effa904-f97d-499e-a9c7-81a938e55885" xlink:href="bhc-20220930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_6effa904-f97d-499e-a9c7-81a938e55885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_208069df-f18e-4bd1-a63b-0b8b4cc57662" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_208069df-f18e-4bd1-a63b-0b8b4cc57662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cb668814-f85f-43f0-ae74-a489bef810d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_AssetImpairmentCharges_cb668814-f85f-43f0-ae74-a489bef810d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_392cd646-637d-403e-8071-fcea523d786e" xlink:href="bhc-20220930.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_392cd646-637d-403e-8071-fcea523d786e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_d81be64f-6047-4bb6-b519-7da6b7865479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_d81be64f-6047-4bb6-b519-7da6b7865479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f9453009-0065-47f5-8592-1e22b63da48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1b09f6de-54c5-41f6-91f8-1a3b834d8405" xlink:to="loc_us-gaap_CostsAndExpenses_f9453009-0065-47f5-8592-1e22b63da48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1c811c66-4688-49c7-9bd8-48d5e8fb4d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_OperatingIncomeLoss_1c811c66-4688-49c7-9bd8-48d5e8fb4d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5597dfc3-e2e8-4206-bf4a-dd43006d6119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5597dfc3-e2e8-4206-bf4a-dd43006d6119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7dd22c3b-27c6-4fa0-ad08-0c06cc90ec71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_InterestExpenseDebt_7dd22c3b-27c6-4fa0-ad08-0c06cc90ec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eb2293af-8332-4d27-963a-e7c116f0dda9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_eb2293af-8332-4d27-963a-e7c116f0dda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8fc4bb3b-f621-43ea-b3ed-20267df13e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8fc4bb3b-f621-43ea-b3ed-20267df13e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c2978a0c-9656-476a-a8fd-07467bac4fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c2978a0c-9656-476a-a8fd-07467bac4fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_04d4fbb0-80b0-46f3-a579-47b82dc2fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_04d4fbb0-80b0-46f3-a579-47b82dc2fefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9dc2486a-3979-4474-a477-64acc2eff60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_ProfitLoss_9dc2486a-3979-4474-a477-64acc2eff60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_01124876-ccb9-42ff-a894-f4ae41eb6330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_01124876-ccb9-42ff-a894-f4ae41eb6330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17bca143-ff90-4272-994e-39cf21266f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_NetIncomeLoss_17bca143-ff90-4272-994e-39cf21266f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c9de3d25-cf71-4f2d-91b4-fb9db9305b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:to="loc_us-gaap_EarningsPerShareBasic_c9de3d25-cf71-4f2d-91b4-fb9db9305b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_47697120-a03b-4814-a851-0bce698d3ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1b2982d8-ea53-4b6e-8a35-5e9e0cb2a27f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_47697120-a03b-4814-a851-0bce698d3ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6831a377-db40-4bb0-b591-dbaae5a2b3ea" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95093e0d-b2c6-4405-bccb-bf6e5bdf87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95093e0d-b2c6-4405-bccb-bf6e5bdf87ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_854c8f3b-9e41-4d88-93fa-e37734c6dffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_07574051-dfff-4709-bb83-7264159c11f7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_854c8f3b-9e41-4d88-93fa-e37734c6dffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8685a83-f466-4531-93e6-481d50b12e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d90d05f6-9d22-4840-b030-523e1086b84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8685a83-f466-4531-93e6-481d50b12e80" xlink:to="loc_us-gaap_ProfitLoss_d90d05f6-9d22-4840-b030-523e1086b84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2604d573-d424-418b-a82e-348b20b61dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8685a83-f466-4531-93e6-481d50b12e80" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2604d573-d424-418b-a82e-348b20b61dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ffb6cf13-df4d-40e0-85c3-358fad63aacf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2604d573-d424-418b-a82e-348b20b61dd2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ffb6cf13-df4d-40e0-85c3-358fad63aacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_24dbb4f7-214a-4341-8bb1-d5080f250017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2604d573-d424-418b-a82e-348b20b61dd2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_24dbb4f7-214a-4341-8bb1-d5080f250017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6e448d4d-d06c-468c-a6c8-52834b263c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2604d573-d424-418b-a82e-348b20b61dd2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6e448d4d-d06c-468c-a6c8-52834b263c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f0018cf7-883e-4bd9-9827-26fa263fdcda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8685a83-f466-4531-93e6-481d50b12e80" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f0018cf7-883e-4bd9-9827-26fa263fdcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2dc16cb6-960b-4fc8-9312-54572b3cf75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8685a83-f466-4531-93e6-481d50b12e80" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2dc16cb6-960b-4fc8-9312-54572b3cf75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_20c98211-5cfc-4d60-a102-3f650865c0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c8685a83-f466-4531-93e6-481d50b12e80" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_20c98211-5cfc-4d60-a102-3f650865c0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ae831fbd-1c9e-4a60-ac2c-fc16e8685295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6be7cfb3-d9c8-4974-b069-de69135c34f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ae831fbd-1c9e-4a60-ac2c-fc16e8685295" xlink:to="loc_us-gaap_StatementTable_6be7cfb3-d9c8-4974-b069-de69135c34f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7b67464d-0a8e-4260-b50e-cdf2e43695c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6be7cfb3-d9c8-4974-b069-de69135c34f1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7b67464d-0a8e-4260-b50e-cdf2e43695c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7b67464d-0a8e-4260-b50e-cdf2e43695c4" xlink:to="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:to="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f4fefba-3c39-44ac-a731-734f2f8cb311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_CommonStockMember_7f4fefba-3c39-44ac-a731-734f2f8cb311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e6a77d86-a60a-4e7e-b013-31fd7099afb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e6a77d86-a60a-4e7e-b013-31fd7099afb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dafb4ee1-c55d-419a-85f6-865ad3c00d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_RetainedEarningsMember_dafb4ee1-c55d-419a-85f6-865ad3c00d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9638734f-1147-4945-9ec0-adfa49dbeda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_7b62487a-a160-49d1-a298-a65d802f7b38" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9638734f-1147-4945-9ec0-adfa49dbeda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f2c294ef-4cb8-4cc6-a254-199be1f678c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c3fc03c3-ae8d-4a76-9dad-20c977803193" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f2c294ef-4cb8-4cc6-a254-199be1f678c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c1c57472-fad5-4279-a037-b8f6e7245bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6be7cfb3-d9c8-4974-b069-de69135c34f1" xlink:to="loc_us-gaap_StatementLineItems_c1c57472-fad5-4279-a037-b8f6e7245bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c1c57472-fad5-4279-a037-b8f6e7245bab" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a20f7672-63e2-4d70-ac08-b34cccff5d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_CommonStockSharesIssued_a20f7672-63e2-4d70-ac08-b34cccff5d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70852b87-4a8a-4a67-9ce8-eb37b0cdf21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70852b87-4a8a-4a67-9ce8-eb37b0cdf21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cb2dc637-91e3-407a-a3bd-7817d6674f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cb2dc637-91e3-407a-a3bd-7817d6674f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f9f459-23fb-406e-b24c-f4e5a607aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f9f459-23fb-406e-b24c-f4e5a607aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4a7fb5fc-b83a-4889-826e-496d0f1b5ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4a7fb5fc-b83a-4889-826e-496d0f1b5ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7332738-a684-4b8c-915d-fe1327b56bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b7332738-a684-4b8c-915d-fe1327b56bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_52ae8fb4-ec1f-4622-be95-2b280c5fbce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_52ae8fb4-ec1f-4622-be95-2b280c5fbce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_faad2af9-b50f-4084-ac8f-a16a3c4d01a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_faad2af9-b50f-4084-ac8f-a16a3c4d01a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c57be3fc-c62c-48bb-bb5f-56ef46ab1337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c57be3fc-c62c-48bb-bb5f-56ef46ab1337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3718a256-9799-4d68-8514-df5f50dfcf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_ProfitLoss_3718a256-9799-4d68-8514-df5f50dfcf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c41bab6-0ee5-4c0a-9b9b-c226c43012ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c41bab6-0ee5-4c0a-9b9b-c226c43012ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bb8e18df-a9f3-4e6a-bc83-0912234b1f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_CommonStockSharesIssued_bb8e18df-a9f3-4e6a-bc83-0912234b1f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1128c6d1-f5a3-4e04-a05e-ee6ed27026ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7f912b67-ffb8-4863-8c06-20d9ed386e46" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1128c6d1-f5a3-4e04-a05e-ee6ed27026ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3da12d08-06ff-4dc7-996a-23185246da1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3da12d08-06ff-4dc7-996a-23185246da1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_36d09838-f731-4c71-894c-0cb13f826b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3da12d08-06ff-4dc7-996a-23185246da1a" xlink:to="loc_us-gaap_ProfitLoss_36d09838-f731-4c71-894c-0cb13f826b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3da12d08-06ff-4dc7-996a-23185246da1a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_8fe6b33d-b8b2-42f4-b3c7-7e6c7381f3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_DepreciationAndAmortization_8fe6b33d-b8b2-42f4-b3c7-7e6c7381f3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_504d3a25-a175-48d7-9283-06b145c2a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_504d3a25-a175-48d7-9283-06b145c2a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3e7beeb4-3a0b-4312-9b3c-447ae3f917e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_AssetImpairmentCharges_3e7beeb4-3a0b-4312-9b3c-447ae3f917e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_faccae45-161d-41e3-a20a-320f62cb1331" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_faccae45-161d-41e3-a20a-320f62cb1331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_2ada1823-d0f2-4711-9bb9-726d03e19e6d" xlink:href="bhc-20220930.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_2ada1823-d0f2-4711-9bb9-726d03e19e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_95599fc9-7b2d-4339-8233-08e5a3127d04" xlink:href="bhc-20220930.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_95599fc9-7b2d-4339-8233-08e5a3127d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_23bf9e9e-c22e-4d4c-a9b2-1ff379a246c5" xlink:href="bhc-20220930.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_23bf9e9e-c22e-4d4c-a9b2-1ff379a246c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6868689f-5efe-49af-adc9-b9400d2e5647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6868689f-5efe-49af-adc9-b9400d2e5647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_45538564-0a6a-4ed7-aafb-24fc23148763" xlink:href="bhc-20220930.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_45538564-0a6a-4ed7-aafb-24fc23148763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_780e2fc7-3fee-47d9-a3c0-9a49f6b72dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_780e2fc7-3fee-47d9-a3c0-9a49f6b72dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9b37868a-e5d9-495b-ab92-1ffc3b2812d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_ShareBasedCompensation_9b37868a-e5d9-495b-ab92-1ffc3b2812d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_520c685f-d1f2-4c61-8692-dbb6c7d0b494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_520c685f-d1f2-4c61-8692-dbb6c7d0b494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_4a33d675-6fdd-43e4-abc9-db0cfff48fcf" xlink:href="bhc-20220930.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_DerivativeGainExcludedComponent_4a33d675-6fdd-43e4-abc9-db0cfff48fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e8ffb03a-6b4d-4ff6-95ba-64ce11fce3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e8ffb03a-6b4d-4ff6-95ba-64ce11fce3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_4b4eb6a3-f198-459b-8da3-8abc2ab5888d" xlink:href="bhc-20220930.xsd#bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities_4b4eb6a3-f198-459b-8da3-8abc2ab5888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_9ee0bde1-7679-4f4c-b5f6-71125744d0a9" xlink:href="bhc-20220930.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_9ee0bde1-7679-4f4c-b5f6-71125744d0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8b112d8a-0731-4fd5-8092-0a1d145579d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8b112d8a-0731-4fd5-8092-0a1d145579d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b31755cf-662a-41e3-8442-757a43926811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92419ad4-abc1-4061-b183-5990056c02be" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b31755cf-662a-41e3-8442-757a43926811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3a96db8c-0e1a-44f7-b6e5-b8eb4aee9b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b31755cf-662a-41e3-8442-757a43926811" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3a96db8c-0e1a-44f7-b6e5-b8eb4aee9b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_81139bd3-7ddd-419c-91ce-ba3a36c16af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b31755cf-662a-41e3-8442-757a43926811" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_81139bd3-7ddd-419c-91ce-ba3a36c16af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f4dc5081-b1ef-4b14-864c-1e5830a47ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b31755cf-662a-41e3-8442-757a43926811" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f4dc5081-b1ef-4b14-864c-1e5830a47ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_688049c7-ea60-4567-ba2c-a627922c72ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b31755cf-662a-41e3-8442-757a43926811" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_688049c7-ea60-4567-ba2c-a627922c72ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc3d6346-3181-49c1-92b0-fed3056a6516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3da12d08-06ff-4dc7-996a-23185246da1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc3d6346-3181-49c1-92b0-fed3056a6516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_751fee52-cae8-4a99-a41b-cbac76799098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_751fee52-cae8-4a99-a41b-cbac76799098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ae056a9f-afea-49b4-a7bd-5ad0c137740a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ae056a9f-afea-49b4-a7bd-5ad0c137740a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_cf15b32c-0b71-46f0-b105-590119d8d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_cf15b32c-0b71-46f0-b105-590119d8d2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5ac2206b-e68d-4e31-aed7-ed761c03979a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5ac2206b-e68d-4e31-aed7-ed761c03979a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_5e710209-e17a-4242-9e46-b394b8d16371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_5e710209-e17a-4242-9e46-b394b8d16371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_3dfbb9e1-9e91-4973-834f-c355d35d9d39" xlink:href="bhc-20220930.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_3dfbb9e1-9e91-4973-834f-c355d35d9d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8b17e6e-c988-4a0e-9238-996d18b6c5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_56646b87-74fd-49e4-8407-35bc11c81ac7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f8b17e6e-c988-4a0e-9238-996d18b6c5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4020a739-518d-4993-b567-40db673c8fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4020a739-518d-4993-b567-40db673c8fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5b7aa888-cf40-4338-b6e5-c0544f3eea80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5b7aa888-cf40-4338-b6e5-c0544f3eea80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_164e6304-8a95-4b20-91bd-3d2e31cf24e1" xlink:href="bhc-20220930.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_164e6304-8a95-4b20-91bd-3d2e31cf24e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_81a636c2-1e21-418c-a21e-43d8d3869f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_81a636c2-1e21-418c-a21e-43d8d3869f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_4629b244-32d9-411e-b146-3c92ddf7d758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_4629b244-32d9-411e-b146-3c92ddf7d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6ed80205-255b-4a36-8cdd-376edae9e72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6ed80205-255b-4a36-8cdd-376edae9e72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_222979a1-8132-448f-bb1a-6fef84494e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_222979a1-8132-448f-bb1a-6fef84494e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e04a6e43-bfda-4ff0-a37d-f45f700ab574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0d9b0607-c0ed-4399-8d94-4abdad56dd69" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e04a6e43-bfda-4ff0-a37d-f45f700ab574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c45639ea-4b05-4cd1-997e-f80d6c9181a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c45639ea-4b05-4cd1-997e-f80d6c9181a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78652eed-24e3-47cf-8588-012b0924b45e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78652eed-24e3-47cf-8588-012b0924b45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcef53c2-9ddf-4caa-b2b6-61e7025a9213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcef53c2-9ddf-4caa-b2b6-61e7025a9213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0d8c163-4ac8-4b9f-8830-ad2445830351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0d8c163-4ac8-4b9f-8830-ad2445830351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fe5a2e54-2f06-41c2-824a-e21929d57440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fe5a2e54-2f06-41c2-824a-e21929d57440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_ea099c70-8843-4885-91bb-df53c9c24607" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_ea099c70-8843-4885-91bb-df53c9c24607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51aaa57f-6fb3-43b0-8dd1-a6c533a74210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_95f1ea90-c7f9-489b-aeb1-49ba69ef5875" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51aaa57f-6fb3-43b0-8dd1-a6c533a74210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20220930.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ad88ed-7b72-4208-9ad1-bca26621937e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_0ba133c9-7e58-4c7c-b2ef-9163f9400916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7ad88ed-7b72-4208-9ad1-bca26621937e" xlink:to="loc_us-gaap_NatureOfOperations_0ba133c9-7e58-4c7c-b2ef-9163f9400916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20220930.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c6dabc93-8541-4163-8f49-88cc9807da0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7d084508-ed05-40bf-bacd-bdcb3536b074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6dabc93-8541-4163-8f49-88cc9807da0a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7d084508-ed05-40bf-bacd-bdcb3536b074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="bhc-20220930.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_155ab76f-cd53-46f6-820e-6af1c2654a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7dc3d474-2d7a-4d9d-83ea-4bcd9f2716d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_155ab76f-cd53-46f6-820e-6af1c2654a92" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7dc3d474-2d7a-4d9d-83ea-4bcd9f2716d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="simple" xlink:href="bhc-20220930.xsd#LICENSINGAGREEMENTSANDDIVESTITURE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ca86dbe-49af-478e-84b2-480bcb2b8502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_b2e40b0f-2f27-436a-9b18-ecd5008e14db" xlink:href="bhc-20220930.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ca86dbe-49af-478e-84b2-480bcb2b8502" xlink:to="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_b2e40b0f-2f27-436a-9b18-ecd5008e14db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="simple" xlink:href="bhc-20220930.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1634d307-4bec-4b57-91bd-fdc1d60b1f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_bd876ee8-218e-4da4-a93b-46f2997ee04a" xlink:href="bhc-20220930.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1634d307-4bec-4b57-91bd-fdc1d60b1f9d" xlink:to="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_bd876ee8-218e-4da4-a93b-46f2997ee04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6491eecc-afbd-4adf-998d-b86e55617251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_754ed9e2-bfa1-44f7-bcd8-4c7c8c3c6177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6491eecc-afbd-4adf-998d-b86e55617251" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_754ed9e2-bfa1-44f7-bcd8-4c7c8c3c6177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20220930.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6bfe46a3-b104-4d2c-8ed8-25c26cf9e836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_b6fb447b-9020-4f84-94e4-afcb13acf45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6bfe46a3-b104-4d2c-8ed8-25c26cf9e836" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_b6fb447b-9020-4f84-94e4-afcb13acf45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_644f079d-bdd4-4471-a1c9-05325732d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_43cd6fbe-6524-427f-9d81-eff82b24e81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_644f079d-bdd4-4471-a1c9-05325732d8f1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_43cd6fbe-6524-427f-9d81-eff82b24e81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3bf74ac7-e952-49ea-a01b-ed8ff57bb347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ed1d135d-9930-490a-a1f4-1ac8270c59ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3bf74ac7-e952-49ea-a01b-ed8ff57bb347" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ed1d135d-9930-490a-a1f4-1ac8270c59ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_646e05ed-2052-481d-a708-ba3408012ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fe070b9f-64d3-46ef-9d92-6c32d3795074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_646e05ed-2052-481d-a708-ba3408012ed1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fe070b9f-64d3-46ef-9d92-6c32d3795074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20220930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_10bec9b4-41eb-45fe-9737-bc6b134c5a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5436b3ca-a2a5-4f5a-96e5-85cfbf8f47ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_10bec9b4-41eb-45fe-9737-bc6b134c5a1a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5436b3ca-a2a5-4f5a-96e5-85cfbf8f47ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8d944a4-b8f2-4fa8-a456-90a220dcce7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5d6dfe43-102f-473d-8b6c-27c58ac80e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8d944a4-b8f2-4fa8-a456-90a220dcce7f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5d6dfe43-102f-473d-8b6c-27c58ac80e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_baa4d062-a366-47e4-8fc2-85bc374b60e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_b209d845-4061-4c07-af08-ec342afe1614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_baa4d062-a366-47e4-8fc2-85bc374b60e8" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_b209d845-4061-4c07-af08-ec342afe1614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20220930.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_95e9ceda-7da1-43f3-92cd-39707631517e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2443f0f8-489b-4f61-a178-473639ed9541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_95e9ceda-7da1-43f3-92cd-39707631517e" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2443f0f8-489b-4f61-a178-473639ed9541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET" xlink:type="simple" xlink:href="bhc-20220930.xsd#OTHEREXPENSEINCOMENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_31820faf-ef94-4c56-998d-5c02bcd40e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_90358c7a-6785-4ca1-b3ef-e1bbf262ac5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_31820faf-ef94-4c56-998d-5c02bcd40e57" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_90358c7a-6785-4ca1-b3ef-e1bbf262ac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20220930.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fc6fea19-3efa-4cfa-9b1b-2386279d41f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ec0026e6-56fd-4627-957f-87f518dd05ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fc6fea19-3efa-4cfa-9b1b-2386279d41f6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ec0026e6-56fd-4627-957f-87f518dd05ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20220930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b3d91bed-bb1e-419b-824d-e194abf3f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f6e1692c-0598-4d66-add4-2bd7df24e6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b3d91bed-bb1e-419b-824d-e194abf3f9e5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f6e1692c-0598-4d66-add4-2bd7df24e6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f04f9435-e385-436e-8484-087080c3e91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9c270e09-0754-433f-a3ed-c04c70f8fb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f04f9435-e385-436e-8484-087080c3e91e" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9c270e09-0754-433f-a3ed-c04c70f8fb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ff3b9167-9c97-41db-b898-fffd70cc5d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_185215b5-5add-4a70-84a1-8d7673fc79c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ff3b9167-9c97-41db-b898-fffd70cc5d59" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_185215b5-5add-4a70-84a1-8d7673fc79c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20220930.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_132b8753-6b90-4499-ab32-69938032e49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c931cebf-8c1a-40d3-8970-330c1e362ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_132b8753-6b90-4499-ab32-69938032e49a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c931cebf-8c1a-40d3-8970-330c1e362ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_3a7db5af-37ff-4ec7-8fb2-4ad6587e1cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_132b8753-6b90-4499-ab32-69938032e49a" xlink:to="loc_us-gaap_UseOfEstimates_3a7db5af-37ff-4ec7-8fb2-4ad6587e1cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_12787f1c-3412-4f82-ad77-18632a040cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_132b8753-6b90-4499-ab32-69938032e49a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_12787f1c-3412-4f82-ad77-18632a040cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_0aee5b18-fa0f-4f27-8e1a-b0218a7f6b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_132b8753-6b90-4499-ab32-69938032e49a" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_0aee5b18-fa0f-4f27-8e1a-b0218a7f6b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ac68e984-7c2e-41e5-b994-a058ce65704e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_132b8753-6b90-4499-ab32-69938032e49a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ac68e984-7c2e-41e5-b994-a058ce65704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7f819b46-0c74-4e06-b658-11646dd20b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_31c91fd8-9d88-4c6c-848d-2ddfc5de2b45" xlink:href="bhc-20220930.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7f819b46-0c74-4e06-b658-11646dd20b99" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_31c91fd8-9d88-4c6c-848d-2ddfc5de2b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_51c6144e-952c-4229-95db-4f8f09a45c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7f819b46-0c74-4e06-b658-11646dd20b99" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_51c6144e-952c-4229-95db-4f8f09a45c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dcfaeeb1-52d1-48de-9350-edd7ed37f818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_28f9fc85-115e-4cac-b5b5-d5af0bd40334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dcfaeeb1-52d1-48de-9350-edd7ed37f818" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_28f9fc85-115e-4cac-b5b5-d5af0bd40334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3bb3506a-eec7-4d40-a4af-1b0ce831ccad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dcfaeeb1-52d1-48de-9350-edd7ed37f818" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3bb3506a-eec7-4d40-a4af-1b0ce831ccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_36921cb7-1492-4461-98a7-7ca428fd4d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dcfaeeb1-52d1-48de-9350-edd7ed37f818" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_36921cb7-1492-4461-98a7-7ca428fd4d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_fc8cc8d6-5592-4d15-9066-51e4c3487ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dcfaeeb1-52d1-48de-9350-edd7ed37f818" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_fc8cc8d6-5592-4d15-9066-51e4c3487ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a6596915-bf82-4631-bc7f-7562b1397ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dcfaeeb1-52d1-48de-9350-edd7ed37f818" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a6596915-bf82-4631-bc7f-7562b1397ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_dc2e5cdd-0685-4bfa-afb3-2f4f06597cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_83078c2b-0906-4206-a043-3d50287530ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_dc2e5cdd-0685-4bfa-afb3-2f4f06597cdb" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_83078c2b-0906-4206-a043-3d50287530ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_47e87dfe-0186-46f3-bc99-0659c0a91a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_6800bad5-cfc2-4483-a191-af04e04fd1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_47e87dfe-0186-46f3-bc99-0659c0a91a58" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_6800bad5-cfc2-4483-a191-af04e04fd1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2d3d45fd-8e75-44fb-a004-3e52b3b783ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_47e87dfe-0186-46f3-bc99-0659c0a91a58" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2d3d45fd-8e75-44fb-a004-3e52b3b783ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4dc95523-e153-4c37-987f-d7709037562b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_47e87dfe-0186-46f3-bc99-0659c0a91a58" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4dc95523-e153-4c37-987f-d7709037562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_998d4fa3-d786-4896-a84f-ccab9abf6445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_47e87dfe-0186-46f3-bc99-0659c0a91a58" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_998d4fa3-d786-4896-a84f-ccab9abf6445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fb7eefc6-2114-48f2-be88-67e9b9a82d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6f34b1bb-44b4-452a-b9ca-b3f2ea2ab631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fb7eefc6-2114-48f2-be88-67e9b9a82d4e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6f34b1bb-44b4-452a-b9ca-b3f2ea2ab631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d4338906-3ea2-4cbb-90bf-33acdc3f9f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_e9551ec4-0490-491a-aa4a-45b938d1ca09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4338906-3ea2-4cbb-90bf-33acdc3f9f89" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_e9551ec4-0490-491a-aa4a-45b938d1ca09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_fb5a00ca-4872-420f-9675-681fd4261d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4338906-3ea2-4cbb-90bf-33acdc3f9f89" xlink:to="loc_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock_fb5a00ca-4872-420f-9675-681fd4261d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8fbf7f4c-6651-4bef-9616-e85147992689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d4338906-3ea2-4cbb-90bf-33acdc3f9f89" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8fbf7f4c-6651-4bef-9616-e85147992689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1bbe30eb-24bf-40e3-8444-d88f2ce98b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8a0227a6-d7cc-4fd7-a546-9825d7cd4e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1bbe30eb-24bf-40e3-8444-d88f2ce98b5e" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8a0227a6-d7cc-4fd7-a546-9825d7cd4e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d58ec50-9a81-424a-a5f5-9d676c0ac984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74b47f53-82df-4ace-9993-6d7e50434b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d58ec50-9a81-424a-a5f5-9d676c0ac984" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_74b47f53-82df-4ace-9993-6d7e50434b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_ed55aaa2-f2c3-48b1-9aae-47af1548ef78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d58ec50-9a81-424a-a5f5-9d676c0ac984" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_ed55aaa2-f2c3-48b1-9aae-47af1548ef78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d26ba321-4ab1-4359-b8d7-dd2f902d2ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6600b255-260e-4ce6-92f5-574eb4cb2e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d26ba321-4ab1-4359-b8d7-dd2f902d2ccd" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6600b255-260e-4ce6-92f5-574eb4cb2e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_3e1d2150-01fb-4bf2-a936-67163b276040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_ccd6a0f1-5401-4c2b-846d-cd037fb4b578" xlink:href="bhc-20220930.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_3e1d2150-01fb-4bf2-a936-67163b276040" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_ccd6a0f1-5401-4c2b-846d-cd037fb4b578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#OTHEREXPENSEINCOMENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_7d9b5b88-2976-4b07-abc2-eff1e77ae33d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_f66622c5-425c-4ea3-a3df-22423f29afbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7d9b5b88-2976-4b07-abc2-eff1e77ae33d" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_f66622c5-425c-4ea3-a3df-22423f29afbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20220930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84bdc3b2-26b5-4e73-bdee-2f9897a3cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_229d47e5-a782-4705-ad09-7dab83917d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84bdc3b2-26b5-4e73-bdee-2f9897a3cc97" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_229d47e5-a782-4705-ad09-7dab83917d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c5fff5e7-fcb3-48ba-835b-0a71b61187cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7f3555c3-17a3-4751-b8d1-9e90dd269a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c5fff5e7-fcb3-48ba-835b-0a71b61187cd" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7f3555c3-17a3-4751-b8d1-9e90dd269a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6e0807ed-9d72-4d57-8f07-8a3c155b8817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c5fff5e7-fcb3-48ba-835b-0a71b61187cd" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6e0807ed-9d72-4d57-8f07-8a3c155b8817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_469b98af-f99e-4e97-8c33-10d2094dbcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c5fff5e7-fcb3-48ba-835b-0a71b61187cd" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_469b98af-f99e-4e97-8c33-10d2094dbcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_b6e66b6b-4d7e-49de-bed8-7ea89de326ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c5fff5e7-fcb3-48ba-835b-0a71b61187cd" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_b6e66b6b-4d7e-49de-bed8-7ea89de326ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f095a545-dd62-48f3-abea-00faa2e9d273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_7e7f3264-3edf-40f4-b076-a03b42daf58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f095a545-dd62-48f3-abea-00faa2e9d273" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_7e7f3264-3edf-40f4-b076-a03b42daf58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d123fb9b-6420-4431-af95-b73b63ddfad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f095a545-dd62-48f3-abea-00faa2e9d273" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d123fb9b-6420-4431-af95-b73b63ddfad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4e339aec-3191-4c68-a3a1-1bcd41a3c582" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d123fb9b-6420-4431-af95-b73b63ddfad8" xlink:to="loc_srt_OwnershipAxis_4e339aec-3191-4c68-a3a1-1bcd41a3c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_53efdd4f-0978-4016-97ba-9fa46292db54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4e339aec-3191-4c68-a3a1-1bcd41a3c582" xlink:to="loc_srt_OwnershipDomain_53efdd4f-0978-4016-97ba-9fa46292db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e59a2a00-5c37-41f7-a73d-28dbdbbbd2ba" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_53efdd4f-0978-4016-97ba-9fa46292db54" xlink:to="loc_bhc_BauschLombMember_e59a2a00-5c37-41f7-a73d-28dbdbbbd2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_ba7f638b-3706-4a7d-a2f3-eaf87dbd0612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_d123fb9b-6420-4431-af95-b73b63ddfad8" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_ba7f638b-3706-4a7d-a2f3-eaf87dbd0612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b0dbba99-5561-40fe-aa56-25bd0b8d06bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_ba7f638b-3706-4a7d-a2f3-eaf87dbd0612" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_b0dbba99-5561-40fe-aa56-25bd0b8d06bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4eaa84f7-5e8a-407c-a4ef-b465a0fbc664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4eaa84f7-5e8a-407c-a4ef-b465a0fbc664" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_57571f5d-fa61-4daa-a28d-d2b2b587a964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_57571f5d-fa61-4daa-a28d-d2b2b587a964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4add042e-fead-43fb-b2f1-86d7d488770b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_57571f5d-fa61-4daa-a28d-d2b2b587a964" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4add042e-fead-43fb-b2f1-86d7d488770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:href="bhc-20220930.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4add042e-fead-43fb-b2f1-86d7d488770b" xlink:to="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_231af541-7304-4cf0-a33d-0f0b013045c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:to="loc_us-gaap_IPOMember_231af541-7304-4cf0-a33d-0f0b013045c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a407249b-cdf8-4abf-9d44-e7086375232c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_4cbc5890-791c-4fee-a4a9-cf9fb24f9567" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a407249b-cdf8-4abf-9d44-e7086375232c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:to="loc_srt_OwnershipAxis_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6d440d9c-79f3-4469-b5d9-4f669ab6ce74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_dbe8a7fb-9bfe-488f-8b37-7120d9b52a31" xlink:to="loc_srt_OwnershipDomain_6d440d9c-79f3-4469-b5d9-4f669ab6ce74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_055184c4-8165-4811-89ee-239624fffd56" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6d440d9c-79f3-4469-b5d9-4f669ab6ce74" xlink:to="loc_bhc_BauschLombMember_055184c4-8165-4811-89ee-239624fffd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_080bf903-7c2f-4159-9058-944449c2a697" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a497883d-18f2-4d6a-9170-d3e03b278e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a497883d-18f2-4d6a-9170-d3e03b278e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e5cb6d70-ef0f-484a-a490-2e1c22f8d929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e5cb6d70-ef0f-484a-a490-2e1c22f8d929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_20249c51-4e7d-4687-a758-29615dd8fa53" xlink:href="bhc-20220930.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_20249c51-4e7d-4687-a758-29615dd8fa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_222572cc-e5fc-4e45-9614-ee68eef74212" xlink:href="bhc-20220930.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_222572cc-e5fc-4e45-9614-ee68eef74212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_93244d33-d05b-4c90-a424-e36beb3f81ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_93244d33-d05b-4c90-a424-e36beb3f81ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_2a373128-267c-4115-844f-1117bc5b68fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_2a373128-267c-4115-844f-1117bc5b68fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99e78bae-2fb8-4b5f-bbe0-2630d4de314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_d92efe2b-ecbc-4dbd-bfe9-1e1a56f0b7a0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_99e78bae-2fb8-4b5f-bbe0-2630d4de314e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_601c383f-40d5-4d74-b96e-eb4bb40de936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_601c383f-40d5-4d74-b96e-eb4bb40de936" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_aa71679b-eeaf-40bc-a609-80af01c84f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_aa71679b-eeaf-40bc-a609-80af01c84f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_aa71679b-eeaf-40bc-a609-80af01c84f2c" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_1a546206-d0ab-4fd9-9c69-a03549d75300" xlink:href="bhc-20220930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_1a546206-d0ab-4fd9-9c69-a03549d75300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_ce53b15b-9249-4905-bdf0-9a699eb70e1e" xlink:href="bhc-20220930.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e72e9fd2-d52b-4267-b900-b42694923319" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_ce53b15b-9249-4905-bdf0-9a699eb70e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a8ba3913-d668-4d74-b885-6bdc26fcb1a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:to="loc_srt_ProductOrServiceAxis_a8ba3913-d668-4d74-b885-6bdc26fcb1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89103dcd-cce5-49bf-8193-861a9743b360" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a8ba3913-d668-4d74-b885-6bdc26fcb1a6" xlink:to="loc_srt_ProductsAndServicesDomain_89103dcd-cce5-49bf-8193-861a9743b360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_8d450dea-be23-43ca-bc40-a7178375439c" xlink:href="bhc-20220930.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89103dcd-cce5-49bf-8193-861a9743b360" xlink:to="loc_bhc_PriceAppreciationCreditMember_8d450dea-be23-43ca-bc40-a7178375439c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_bcb24322-cb59-49ea-bf79-5d0c689a72e7" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_47d992a9-db0e-4a64-9275-82fc24089321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_47d992a9-db0e-4a64-9275-82fc24089321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_cbf65ade-2e25-4690-b682-3161f81d48ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_cbf65ade-2e25-4690-b682-3161f81d48ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ab325755-5656-4f72-a544-780fb65a61f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ab325755-5656-4f72-a544-780fb65a61f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb71d793-bfc6-47d6-86f7-e2482067b768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_db807e33-9a76-4de2-9cf0-ba88edf371a2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb71d793-bfc6-47d6-86f7-e2482067b768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_62a51da1-3073-4456-804d-1eb0067ac2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1d180f1c-bd3a-4fce-8077-01b0bac4b320" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_62a51da1-3073-4456-804d-1eb0067ac2cf" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1d180f1c-bd3a-4fce-8077-01b0bac4b320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_05dd4ba7-0dac-47c0-b517-92059f055cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1d180f1c-bd3a-4fce-8077-01b0bac4b320" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_05dd4ba7-0dac-47c0-b517-92059f055cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_05dd4ba7-0dac-47c0-b517-92059f055cf1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_2d99e5df-f459-4266-b6ef-5cc82c292fa8" xlink:href="bhc-20220930.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_2d99e5df-f459-4266-b6ef-5cc82c292fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_d5b80c23-6b6a-4606-ade6-c6cdd3e68526" xlink:href="bhc-20220930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_d5b80c23-6b6a-4606-ade6-c6cdd3e68526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_2c3fcb0d-7e45-4782-9b13-d7920ac3c716" xlink:href="bhc-20220930.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForRebatesMember_2c3fcb0d-7e45-4782-9b13-d7920ac3c716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_1d4038f6-f971-4e3f-b20f-4f9689eda610" xlink:href="bhc-20220930.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForChargebacksMember_1d4038f6-f971-4e3f-b20f-4f9689eda610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_6266cad1-0318-46b0-878c-50295f5d53ae" xlink:href="bhc-20220930.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5b07028b-ff14-4592-a270-8871095decbf" xlink:to="loc_bhc_ReserveForDistributionFeesMember_6266cad1-0318-46b0-878c-50295f5d53ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d76b923a-7fb6-40b5-9db9-4c7a67c72cc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1d180f1c-bd3a-4fce-8077-01b0bac4b320" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d76b923a-7fb6-40b5-9db9-4c7a67c72cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d76b923a-7fb6-40b5-9db9-4c7a67c72cc1" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6eb3e926-809c-4a5a-9d41-390dda6c1f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6eb3e926-809c-4a5a-9d41-390dda6c1f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_243ce3a2-921e-4ab7-af04-4334cc36f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_243ce3a2-921e-4ab7-af04-4334cc36f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c39e9c86-50e8-4eba-a8d9-c38f2ec9d172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c39e9c86-50e8-4eba-a8d9-c38f2ec9d172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_158790ed-9784-4fbd-9e0d-aab146d6b5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_934f1f6a-2964-4aba-801f-656213bf0810" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_158790ed-9784-4fbd-9e0d-aab146d6b5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d3cdee6a-fa64-4242-804b-a6b7479896e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d3cdee6a-fa64-4242-804b-a6b7479896e4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3fd571bf-9d05-4d2b-8f37-aeeb8d784787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3fd571bf-9d05-4d2b-8f37-aeeb8d784787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fccb1078-998b-4a9c-9658-419d94d18836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fccb1078-998b-4a9c-9658-419d94d18836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_e8c3f7f0-c021-450f-a3d0-982da4da12b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_e8c3f7f0-c021-450f-a3d0-982da4da12b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_5c4a5468-e23f-4ee1-b731-d3180ec137ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_5c4a5468-e23f-4ee1-b731-d3180ec137ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_edff6594-6fdc-4867-8870-b579c9627b2d" xlink:href="bhc-20220930.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_edff6594-6fdc-4867-8870-b579c9627b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_6626f5d3-e69e-4657-a80f-15a6a5a22aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_c3ca4d25-a507-4ee5-934e-cedf765b45e2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_6626f5d3-e69e-4657-a80f-15a6a5a22aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6d799e8f-339f-4171-b419-52efc223bda7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6d799e8f-339f-4171-b419-52efc223bda7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_708c30a9-6625-4c01-a8fe-03a80f0e65ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_708c30a9-6625-4c01-a8fe-03a80f0e65ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c61d2f8e-0517-4702-a577-71064ea58a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_708c30a9-6625-4c01-a8fe-03a80f0e65ad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c61d2f8e-0517-4702-a577-71064ea58a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_34300b0b-b821-4de9-ae25-f38a218bc767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c61d2f8e-0517-4702-a577-71064ea58a6d" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_34300b0b-b821-4de9-ae25-f38a218bc767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_564b716b-275a-4ce1-9d19-0e1e0a63586a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_564b716b-275a-4ce1-9d19-0e1e0a63586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d1adb0f-bb65-4f7b-9819-27efcef0e8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_564b716b-275a-4ce1-9d19-0e1e0a63586a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d1adb0f-bb65-4f7b-9819-27efcef0e8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_d03b5a9d-fbd1-4235-be6e-45c655310c15" xlink:href="bhc-20220930.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9d1adb0f-bb65-4f7b-9819-27efcef0e8a7" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_d03b5a9d-fbd1-4235-be6e-45c655310c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cdfceae0-c51c-4fbe-8fd1-01b68a91a3eb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_da8d5e82-d43e-45a6-8a0d-51fb2e980f9b" xlink:href="bhc-20220930.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:to="loc_bhc_AssetImpairmentChargesMember_da8d5e82-d43e-45a6-8a0d-51fb2e980f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_973af61d-7b5c-44ad-ade9-785ac30ef32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5e609419-fa98-4b12-b8ee-e6174f7d2647" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_973af61d-7b5c-44ad-ade9-785ac30ef32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6500fac9-8277-4dda-aadb-bd762205b422" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ef1ecd0f-ec3a-492d-9f51-d02c2cade1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_ef1ecd0f-ec3a-492d-9f51-d02c2cade1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_75543381-0f95-4dbb-99b4-f4575db5b119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_75543381-0f95-4dbb-99b4-f4575db5b119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_6a78be57-3882-49fb-ac44-920adf4dcf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fbfc77d9-ba4f-49b3-b7f1-0a42d9b08660" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_6a78be57-3882-49fb-ac44-920adf4dcf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f52b4fd9-02d2-4b3d-9de2-3fb24e70dc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_80de7851-2725-4fe8-b204-81cc533ba934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f52b4fd9-02d2-4b3d-9de2-3fb24e70dc6f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_80de7851-2725-4fe8-b204-81cc533ba934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_271b5583-330e-4bad-9007-d797a4f7979e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_80de7851-2725-4fe8-b204-81cc533ba934" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_271b5583-330e-4bad-9007-d797a4f7979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_271b5583-330e-4bad-9007-d797a4f7979e" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_2ea6c531-28f1-4032-8327-6734d6229a5e" xlink:href="bhc-20220930.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_2ea6c531-28f1-4032-8327-6734d6229a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_98e4a9c2-08fe-4984-a279-f9b82c704983" xlink:href="bhc-20220930.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ae8f468-61dd-447f-b7b0-9094346c4b9a" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_98e4a9c2-08fe-4984-a279-f9b82c704983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_80de7851-2725-4fe8-b204-81cc533ba934" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4c9f7d27-2ce2-405f-9f87-73492c86ffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_RestructuringReserve_4c9f7d27-2ce2-405f-9f87-73492c86ffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8a8e0e07-cba1-481a-9fc6-9939605a3596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_8a8e0e07-cba1-481a-9fc6-9939605a3596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_78ad2c37-2027-4aa4-8a4e-fd6a29b4a911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_PaymentsForRestructuring_78ad2c37-2027-4aa4-8a4e-fd6a29b4a911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_54b32768-ce64-4634-b1bd-57f25ed5776d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_RestructuringCharges_54b32768-ce64-4634-b1bd-57f25ed5776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f3595742-ac35-4d8b-92b9-1a38f4b44fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d85f99e7-131c-4977-ac56-77b4e1b46c64" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f3595742-ac35-4d8b-92b9-1a38f4b44fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cd56c369-e098-4717-bff2-171b5394ccd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cd56c369-e098-4717-bff2-171b5394ccd9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0197388-229e-42b6-bbf7-4f4800e1f4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0197388-229e-42b6-bbf7-4f4800e1f4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2c58353-ee16-4eee-a931-dc1b0323c7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f0197388-229e-42b6-bbf7-4f4800e1f4cd" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2c58353-ee16-4eee-a931-dc1b0323c7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8ba03c56-0c03-40ce-ab48-1d159fc76785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2c58353-ee16-4eee-a931-dc1b0323c7a0" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8ba03c56-0c03-40ce-ab48-1d159fc76785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21e9cf07-9196-424b-9f60-05ff2f58677e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21e9cf07-9196-424b-9f60-05ff2f58677e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21e9cf07-9196-424b-9f60-05ff2f58677e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e8a8a784-6e20-4a45-88ad-c2ed5e0b8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e8a8a784-6e20-4a45-88ad-c2ed5e0b8e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55e230c1-a47f-483f-83ab-192f0567fb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55e230c1-a47f-483f-83ab-192f0567fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_04da5792-d2c7-4f05-8554-a95e95b4f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b87e39bc-ec8d-4aa9-8183-6bb0cbd904c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_04da5792-d2c7-4f05-8554-a95e95b4f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5432b237-d2a8-478c-a10c-27d3635e46fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5432b237-d2a8-478c-a10c-27d3635e46fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5432b237-d2a8-478c-a10c-27d3635e46fe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a255c9a5-3d24-49d4-b9c3-fe9152ddebde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a255c9a5-3d24-49d4-b9c3-fe9152ddebde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_772f524b-5251-44cd-8faf-9600edcfe323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f6fdf17c-1ea9-469a-9c34-11e3d3120a2b" xlink:to="loc_us-gaap_CurrencySwapMember_772f524b-5251-44cd-8faf-9600edcfe323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ef8fc964-aa30-4b1f-9224-d60d41bb4e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_HedgingDesignationAxis_ef8fc964-aa30-4b1f-9224-d60d41bb4e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ef8fc964-aa30-4b1f-9224-d60d41bb4e29" xlink:to="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_d3870f7d-3a7d-4ea6-a5ba-b92eda164472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:to="loc_us-gaap_NondesignatedMember_d3870f7d-3a7d-4ea6-a5ba-b92eda164472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e40b65b7-2b34-483f-8969-fbedecab6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c246b4bb-babc-4c1e-bbcd-b0e0a48a526e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e40b65b7-2b34-483f-8969-fbedecab6fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d745417f-fd01-4b4a-933b-4eee153845e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d745417f-fd01-4b4a-933b-4eee153845e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_2de162ae-2296-4aa5-93dc-7179714929e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d745417f-fd01-4b4a-933b-4eee153845e7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_2de162ae-2296-4aa5-93dc-7179714929e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d524a814-d749-43c0-9425-0dfc75f08dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_2de162ae-2296-4aa5-93dc-7179714929e0" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d524a814-d749-43c0-9425-0dfc75f08dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_88b402f6-13b4-4d57-b65d-e64b7a7a70b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_dei_LegalEntityAxis_88b402f6-13b4-4d57-b65d-e64b7a7a70b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_607f5864-03d5-469f-a370-a468325f5ce4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_88b402f6-13b4-4d57-b65d-e64b7a7a70b6" xlink:to="loc_dei_EntityDomain_607f5864-03d5-469f-a370-a468325f5ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3e196c8a-5ca3-4b3d-964f-b288744828e9" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_607f5864-03d5-469f-a370-a468325f5ce4" xlink:to="loc_bhc_BauschLombMember_3e196c8a-5ca3-4b3d-964f-b288744828e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e85ff869-e13a-47c8-a2d5-13e25e14f2f7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_06f77cf8-dbfe-4ec0-b962-8f7f652a7454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_06f77cf8-dbfe-4ec0-b962-8f7f652a7454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_f2b7aaca-a36e-4e90-88d0-68d25d693def" xlink:href="bhc-20220930.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_f2b7aaca-a36e-4e90-88d0-68d25d693def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a144c863-2c0b-4ec3-bc7d-4fab22b3238c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_60e18a16-6026-4e0c-8548-b5aae40869dc" xlink:to="loc_us-gaap_DerivativeAssets_a144c863-2c0b-4ec3-bc7d-4fab22b3238c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9d0a55fc-33db-4fb4-9fd6-e0c29cd0a280" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_90d5311f-6d05-473a-a7d4-72575dc5e6e6" xlink:href="bhc-20220930.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_90d5311f-6d05-473a-a7d4-72575dc5e6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_950bf58b-6c17-4451-889b-a484d42debf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_df27bd20-4902-471e-a180-0526b6dbd341" xlink:to="loc_us-gaap_DerivativeLiabilities_950bf58b-6c17-4451-889b-a484d42debf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7dd76a95-0751-4378-a566-4dbe1d7f876c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7dd76a95-0751-4378-a566-4dbe1d7f876c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_06ce0be0-cdca-4658-9a76-e1827d8c15f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_srt_LitigationCaseAxis_06ce0be0-cdca-4658-9a76-e1827d8c15f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_10ddff63-e488-40db-a7af-94522ba2b675" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_06ce0be0-cdca-4658-9a76-e1827d8c15f4" xlink:to="loc_srt_LitigationCaseTypeDomain_10ddff63-e488-40db-a7af-94522ba2b675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_c402cc69-7b02-4b36-b2be-2a552d6e0756" xlink:href="bhc-20220930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_10ddff63-e488-40db-a7af-94522ba2b675" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_c402cc69-7b02-4b36-b2be-2a552d6e0756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_58284fab-3056-4973-a1a8-78ddfbbaa44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_us-gaap_LitigationStatusAxis_58284fab-3056-4973-a1a8-78ddfbbaa44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ffe34c3e-217e-4c26-98b2-1127a7fe83ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_58284fab-3056-4973-a1a8-78ddfbbaa44c" xlink:to="loc_us-gaap_LitigationStatusDomain_ffe34c3e-217e-4c26-98b2-1127a7fe83ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d7da6e0d-c2f4-476d-9df7-820483c226ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ffe34c3e-217e-4c26-98b2-1127a7fe83ad" xlink:to="loc_us-gaap_SettledLitigationMember_d7da6e0d-c2f4-476d-9df7-820483c226ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_12431768-8048-4962-ad0b-1f4719118997" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_srt_StatementGeographicalAxis_12431768-8048-4962-ad0b-1f4719118997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5074584-2749-4c1d-9eb1-3348137b3161" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_12431768-8048-4962-ad0b-1f4719118997" xlink:to="loc_srt_SegmentGeographicalDomain_f5074584-2749-4c1d-9eb1-3348137b3161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_641216af-3b8f-48f9-a01f-2b5eb7fef63c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f5074584-2749-4c1d-9eb1-3348137b3161" xlink:to="loc_stpr_NJ_641216af-3b8f-48f9-a01f-2b5eb7fef63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f926e837-4833-4020-8700-d98adf7dfedf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_dei_LegalEntityAxis_f926e837-4833-4020-8700-d98adf7dfedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_80008db2-bc62-40c1-aa39-0c67f5116719" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f926e837-4833-4020-8700-d98adf7dfedf" xlink:to="loc_dei_EntityDomain_80008db2-bc62-40c1-aa39-0c67f5116719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_b8032ed4-33bf-455a-83fb-fda497d6e8ad" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_80008db2-bc62-40c1-aa39-0c67f5116719" xlink:to="loc_bhc_BauschLombMember_b8032ed4-33bf-455a-83fb-fda497d6e8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fa379b3-dcb2-4892-9727-f586e885e6c3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_4a6e53b7-3899-4832-9f42-d1382b159456" xlink:href="bhc-20220930.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_4a6e53b7-3899-4832-9f42-d1382b159456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9a67940d-c278-4119-99ac-6ba7e26e63b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9a67940d-c278-4119-99ac-6ba7e26e63b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_36668ad0-79a6-4ebe-8a6f-3d1e9d4c9339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_36668ad0-79a6-4ebe-8a6f-3d1e9d4c9339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_42fb4783-de76-4fbc-9e13-4431b9204791" xlink:href="bhc-20220930.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_42fb4783-de76-4fbc-9e13-4431b9204791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_af78a5e5-2bc0-4a5c-8f71-d92f183762da" xlink:href="bhc-20220930.xsd#bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent_af78a5e5-2bc0-4a5c-8f71-d92f183762da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_926f7153-2087-4b44-b5dd-897039e9cbcf" xlink:href="bhc-20220930.xsd#bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c7d1f5a-ceae-4118-8116-c132a83e1c2f" xlink:to="loc_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent_926f7153-2087-4b44-b5dd-897039e9cbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_faa121a9-938a-45ea-8df8-43c5b3727729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_faa121a9-938a-45ea-8df8-43c5b3727729" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_428c5747-9e9f-4caf-a329-72f9028cd02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_428c5747-9e9f-4caf-a329-72f9028cd02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_14a24f8a-f03d-4654-a19d-b3a6ad0f17ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_428c5747-9e9f-4caf-a329-72f9028cd02b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_14a24f8a-f03d-4654-a19d-b3a6ad0f17ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_77e845eb-02bd-42fa-8f80-b6e7e891a6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_14a24f8a-f03d-4654-a19d-b3a6ad0f17ca" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_77e845eb-02bd-42fa-8f80-b6e7e891a6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_45684d1d-0491-45d7-949d-0f46bd9f7fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_45684d1d-0491-45d7-949d-0f46bd9f7fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_797e3e0e-b31c-4464-829b-87bca53155f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_45684d1d-0491-45d7-949d-0f46bd9f7fce" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_797e3e0e-b31c-4464-829b-87bca53155f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_ae7beb09-8305-4c09-b25e-c5c72ae9863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_797e3e0e-b31c-4464-829b-87bca53155f4" xlink:to="loc_us-gaap_CurrencySwapMember_ae7beb09-8305-4c09-b25e-c5c72ae9863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_e7d42dce-367b-49da-8d02-c8d9207564b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_us-gaap_HedgingDesignationAxis_e7d42dce-367b-49da-8d02-c8d9207564b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_83881e97-f5da-431a-960d-754945aecdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_e7d42dce-367b-49da-8d02-c8d9207564b0" xlink:to="loc_us-gaap_HedgingDesignationDomain_83881e97-f5da-431a-960d-754945aecdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5595e6cc-dd62-44a3-9ee3-9c341590f0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_83881e97-f5da-431a-960d-754945aecdf3" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5595e6cc-dd62-44a3-9ee3-9c341590f0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d649d332-5c45-4b32-8776-142d74ee2f5b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_dei_LegalEntityAxis_d649d332-5c45-4b32-8776-142d74ee2f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6011fc05-69df-4b9b-9e76-d2f93f4f6b16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d649d332-5c45-4b32-8776-142d74ee2f5b" xlink:to="loc_dei_EntityDomain_6011fc05-69df-4b9b-9e76-d2f93f4f6b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_dbb2a718-4b19-4f99-a75a-c82084ff08b7" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6011fc05-69df-4b9b-9e76-d2f93f4f6b16" xlink:to="loc_bhc_BauschLombMember_dbb2a718-4b19-4f99-a75a-c82084ff08b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_052ae1c6-dbb3-4bbd-8806-eeeb3035e946" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7a689d1a-8783-46b4-b001-720cd008b2af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7a689d1a-8783-46b4-b001-720cd008b2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d004d730-8040-4b6e-9685-6caf9285f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56184b02-bb9d-42bd-b3ac-b5e590cba51f" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d004d730-8040-4b6e-9685-6caf9285f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fa73f15e-3fb2-4d15-9efc-a1bd65ab1ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fa73f15e-3fb2-4d15-9efc-a1bd65ab1ef8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_46579846-67e7-4cb5-a51b-bbc0e982b23d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_46579846-67e7-4cb5-a51b-bbc0e982b23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_46579846-67e7-4cb5-a51b-bbc0e982b23d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4c2110ad-06c5-453c-a97c-8b9da6b42bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_4c2110ad-06c5-453c-a97c-8b9da6b42bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_da983371-5b05-466c-adce-b870e9736eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9a9258cd-08e7-4262-a64c-19b330cf6fec" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_da983371-5b05-466c-adce-b870e9736eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_72d8a829-e314-4e54-8109-a28c036db91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_72d8a829-e314-4e54-8109-a28c036db91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_05f9ece9-781d-4b63-9558-e52a0ef9a365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_72d8a829-e314-4e54-8109-a28c036db91e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_05f9ece9-781d-4b63-9558-e52a0ef9a365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_e0a54020-e0c6-46dd-9085-05c7b1cbba00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_05f9ece9-781d-4b63-9558-e52a0ef9a365" xlink:to="loc_us-gaap_CurrencySwapMember_e0a54020-e0c6-46dd-9085-05c7b1cbba00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_26c31906-48ad-466a-863e-3f38d28b14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_26c31906-48ad-466a-863e-3f38d28b14bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b24b06d7-2207-4999-94f4-6ddeb46fd6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_26c31906-48ad-466a-863e-3f38d28b14bc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b24b06d7-2207-4999-94f4-6ddeb46fd6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_92c2df23-572f-4cdf-8553-42e754f50173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b24b06d7-2207-4999-94f4-6ddeb46fd6a9" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_92c2df23-572f-4cdf-8553-42e754f50173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c8f26cbb-a133-4f9f-b370-99d9d35dafa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_HedgingDesignationAxis_c8f26cbb-a133-4f9f-b370-99d9d35dafa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_aebe1f8b-0724-4a56-a699-7b64ff8a93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c8f26cbb-a133-4f9f-b370-99d9d35dafa7" xlink:to="loc_us-gaap_HedgingDesignationDomain_aebe1f8b-0724-4a56-a699-7b64ff8a93b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f12db573-2279-4512-8404-4963c665173b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_aebe1f8b-0724-4a56-a699-7b64ff8a93b4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f12db573-2279-4512-8404-4963c665173b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1eada976-b493-41db-8440-afc8ce7b202d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_dei_LegalEntityAxis_1eada976-b493-41db-8440-afc8ce7b202d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_77261e94-5a88-4a32-8123-3ee180146330" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1eada976-b493-41db-8440-afc8ce7b202d" xlink:to="loc_dei_EntityDomain_77261e94-5a88-4a32-8123-3ee180146330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f144e2d1-c9da-4b3b-ae52-d5faa0d7b44a" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_77261e94-5a88-4a32-8123-3ee180146330" xlink:to="loc_bhc_BauschLombMember_f144e2d1-c9da-4b3b-ae52-d5faa0d7b44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cba6d99d-4725-4dfc-a7bf-d65e663c6b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e8ef82f-1e2e-4844-a477-9004ac6d08d7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cba6d99d-4725-4dfc-a7bf-d65e663c6b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_e24595d2-57b0-411a-a34f-ec68e5fdf2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cba6d99d-4725-4dfc-a7bf-d65e663c6b59" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_e24595d2-57b0-411a-a34f-ec68e5fdf2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b3f60245-519d-4b82-9e02-84d8164f9a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b3f60245-519d-4b82-9e02-84d8164f9a47" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f6a1a878-127a-4f13-b277-a902a87ae72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2dccdcc9-2dfd-4ff8-81e1-ae69706ab34b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f6a1a878-127a-4f13-b277-a902a87ae72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_4f907360-b111-4333-8465-eaee68e8d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f6a1a878-127a-4f13-b277-a902a87ae72e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_4f907360-b111-4333-8465-eaee68e8d5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f1c8c565-d6ad-4756-969f-dfb109ca4b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ac78b03e-c03a-4cf8-a633-c7a87f8b8c4e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f1c8c565-d6ad-4756-969f-dfb109ca4b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_fcb13c71-bdb8-4839-ac94-9430a5792326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f1c8c565-d6ad-4756-969f-dfb109ca4b76" xlink:to="loc_us-gaap_CurrencySwapMember_fcb13c71-bdb8-4839-ac94-9430a5792326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_HedgingDesignationAxis_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e0cba37e-1629-4493-b2ae-dd4fe2516577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_3ea1e5e8-dd57-4784-a1cf-2eac26daebfb" xlink:to="loc_us-gaap_HedgingDesignationDomain_e0cba37e-1629-4493-b2ae-dd4fe2516577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_855d5a1d-4795-4d9d-9ea6-8f24b18c5ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e0cba37e-1629-4493-b2ae-dd4fe2516577" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_855d5a1d-4795-4d9d-9ea6-8f24b18c5ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_54204c0f-9329-48c9-af9a-4184c18f5aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_54204c0f-9329-48c9-af9a-4184c18f5aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_345099c7-b9a3-4d3a-a12f-27500cd4606b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54204c0f-9329-48c9-af9a-4184c18f5aac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_345099c7-b9a3-4d3a-a12f-27500cd4606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_763b0094-da64-40ec-93a1-00da37f0adf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_345099c7-b9a3-4d3a-a12f-27500cd4606b" xlink:to="loc_us-gaap_InterestExpenseMember_763b0094-da64-40ec-93a1-00da37f0adf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_eae955e2-0b40-49c8-95fb-4ff46773538a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_becb911c-6093-44a3-898d-22f18ed4a551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_becb911c-6093-44a3-898d-22f18ed4a551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_6598c67e-41f2-4f9d-a6bb-5d989f6dc1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_9a43258a-581e-41e9-a339-1d7b32151d05" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_6598c67e-41f2-4f9d-a6bb-5d989f6dc1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_769cef6a-c5bc-4732-954a-ab87e35bc6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_769cef6a-c5bc-4732-954a-ab87e35bc6c6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_afcff991-952f-410e-9c00-41d851b6041a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:to="loc_us-gaap_HedgingDesignationAxis_afcff991-952f-410e-9c00-41d851b6041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_09e5fe23-6c0f-4810-9a97-e0665906325e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_afcff991-952f-410e-9c00-41d851b6041a" xlink:to="loc_us-gaap_HedgingDesignationDomain_09e5fe23-6c0f-4810-9a97-e0665906325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_625f05e3-ff67-4a65-85dc-37c52595ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_09e5fe23-6c0f-4810-9a97-e0665906325e" xlink:to="loc_us-gaap_NondesignatedMember_625f05e3-ff67-4a65-85dc-37c52595ff97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e081f74d-7f62-46c4-813d-4081028d536f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e081f74d-7f62-46c4-813d-4081028d536f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9007ee2f-199d-47fc-8137-fdc8e0cce045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e081f74d-7f62-46c4-813d-4081028d536f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9007ee2f-199d-47fc-8137-fdc8e0cce045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a86f0ebb-4190-42c1-8416-17f50e1b2074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9007ee2f-199d-47fc-8137-fdc8e0cce045" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a86f0ebb-4190-42c1-8416-17f50e1b2074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c31de7c-43ac-4827-b762-521118dc7764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29a5c254-3d04-4c78-aaca-c7efbe0ec8ef" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c31de7c-43ac-4827-b762-521118dc7764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9ea82527-5bb8-405c-94f7-b8b56bb89245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7c31de7c-43ac-4827-b762-521118dc7764" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9ea82527-5bb8-405c-94f7-b8b56bb89245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_43ad3309-dc1d-42e6-b01a-aab58bc3502b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_43ad3309-dc1d-42e6-b01a-aab58bc3502b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fb713eb3-7910-4eb0-86a7-1d833a8f253e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fb713eb3-7910-4eb0-86a7-1d833a8f253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fb713eb3-7910-4eb0-86a7-1d833a8f253e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_3f7a4c41-fc31-4a58-b839-2bf01ff6b415" xlink:href="bhc-20220930.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_3f7a4c41-fc31-4a58-b839-2bf01ff6b415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_3908447f-0ec2-44be-93fc-16747f8c1a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7d5a962c-a9e0-4a20-9cd6-36dd129dbcbd" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_3908447f-0ec2-44be-93fc-16747f8c1a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a56d0f29-61e8-4bc2-a2c0-022eea599517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a56d0f29-61e8-4bc2-a2c0-022eea599517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7adea3b9-9bbe-4d84-b888-5aece1691349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a56d0f29-61e8-4bc2-a2c0-022eea599517" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7adea3b9-9bbe-4d84-b888-5aece1691349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c4b19418-2c6c-4222-a238-41a7b059f98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7adea3b9-9bbe-4d84-b888-5aece1691349" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c4b19418-2c6c-4222-a238-41a7b059f98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5d052a6e-647d-4f39-bc55-d8d877896530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:to="loc_us-gaap_HedgingDesignationAxis_5d052a6e-647d-4f39-bc55-d8d877896530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_579318bc-87d0-46e9-86ec-8b6874942046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5d052a6e-647d-4f39-bc55-d8d877896530" xlink:to="loc_us-gaap_HedgingDesignationDomain_579318bc-87d0-46e9-86ec-8b6874942046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_31455c7e-2c55-417f-bedb-c87090794dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_579318bc-87d0-46e9-86ec-8b6874942046" xlink:to="loc_us-gaap_NondesignatedMember_31455c7e-2c55-417f-bedb-c87090794dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c70d7caf-beab-4ea3-beec-bf65a0ce7f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f1ea890a-7697-4c6f-a151-efd001f904f8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c70d7caf-beab-4ea3-beec-bf65a0ce7f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_542c828d-7d5a-4a3f-9534-5ce9f10893ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c70d7caf-beab-4ea3-beec-bf65a0ce7f40" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_542c828d-7d5a-4a3f-9534-5ce9f10893ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2ada8874-450d-42c9-99cf-3ce8ea1888e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2ada8874-450d-42c9-99cf-3ce8ea1888e1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_98a80385-c227-45da-8b4f-ea36d792e443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_98a80385-c227-45da-8b4f-ea36d792e443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_91def94e-40f4-45dd-8dee-1ffd111dde53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_98a80385-c227-45da-8b4f-ea36d792e443" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_91def94e-40f4-45dd-8dee-1ffd111dde53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9e981111-7477-473b-ae65-f73b174d4178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_91def94e-40f4-45dd-8dee-1ffd111dde53" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9e981111-7477-473b-ae65-f73b174d4178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_88580743-01c1-4bb0-b238-d8134a065cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:to="loc_us-gaap_HedgingDesignationAxis_88580743-01c1-4bb0-b238-d8134a065cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7cdc0ca4-f149-436f-9d20-9b8f8ae82d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_88580743-01c1-4bb0-b238-d8134a065cbd" xlink:to="loc_us-gaap_HedgingDesignationDomain_7cdc0ca4-f149-436f-9d20-9b8f8ae82d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e5869d78-c6ed-4a65-afeb-47a0ba9608d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7cdc0ca4-f149-436f-9d20-9b8f8ae82d5f" xlink:to="loc_us-gaap_NondesignatedMember_e5869d78-c6ed-4a65-afeb-47a0ba9608d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_921ac02b-02c4-4c33-b405-3950924b7cc1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fe8ae51a-b9c2-4702-90c6-477fdb151de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fe8ae51a-b9c2-4702-90c6-477fdb151de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_a17c314b-baa7-4a5a-ba95-8ca124596522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5590fe19-42f2-4ba8-a8b2-c274caf92d1c" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_a17c314b-baa7-4a5a-ba95-8ca124596522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a5eaa909-49ea-47f9-9163-4cad12f4788b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a5eaa909-49ea-47f9-9163-4cad12f4788b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32ecb701-2ebf-485f-b8eb-6065c0cff710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32ecb701-2ebf-485f-b8eb-6065c0cff710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ec6c22b-7d94-4e35-a578-bb00e5d917b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32ecb701-2ebf-485f-b8eb-6065c0cff710" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ec6c22b-7d94-4e35-a578-bb00e5d917b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_462ef451-cabe-4eb9-a6ec-31c5334d1ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ec6c22b-7d94-4e35-a578-bb00e5d917b9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_462ef451-cabe-4eb9-a6ec-31c5334d1ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5cd92045-a6d5-4b65-b92c-be8e962f5ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5cd92045-a6d5-4b65-b92c-be8e962f5ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5cd92045-a6d5-4b65-b92c-be8e962f5ff0" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_efa08a2c-83c3-4889-8fd0-4667c2c94dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_efa08a2c-83c3-4889-8fd0-4667c2c94dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_73dc5516-aafc-4f4c-9c85-9ad5977d6e9b" xlink:href="bhc-20220930.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_63d82566-f251-4b79-856f-0be2e7ceeab2" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_73dc5516-aafc-4f4c-9c85-9ad5977d6e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf37a2b9-a14d-4023-8d2e-a91ddd3bd50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3a55c99e-7c4a-4f67-8beb-43c6b52a7b6f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf37a2b9-a14d-4023-8d2e-a91ddd3bd50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_eff943cb-c6a8-45b3-8923-c27c7b509884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf37a2b9-a14d-4023-8d2e-a91ddd3bd50f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_eff943cb-c6a8-45b3-8923-c27c7b509884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_86aa63e2-b51b-44b0-9965-6eba8fe29e62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_srt_RangeAxis_86aa63e2-b51b-44b0-9965-6eba8fe29e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_86aa63e2-b51b-44b0-9965-6eba8fe29e62" xlink:to="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b6575b83-ec7d-40f4-b593-b751869cf2a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:to="loc_srt_MinimumMember_b6575b83-ec7d-40f4-b593-b751869cf2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa4c27f6-dbca-4be7-82e1-ea74449fb564" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2bf5f9c8-60e0-44d8-910d-c2d40a544539" xlink:to="loc_srt_MaximumMember_fa4c27f6-dbca-4be7-82e1-ea74449fb564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_def3c772-c2b4-43c0-9ef2-b631594ce8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_7e0ac559-a47f-4035-b983-aa6f1d7a88d4" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_def3c772-c2b4-43c0-9ef2-b631594ce8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fda6c94c-53b4-42fa-be30-c09a7592269b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_def3c772-c2b4-43c0-9ef2-b631594ce8c3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_fda6c94c-53b4-42fa-be30-c09a7592269b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbac3100-7a9f-4f7b-a5d9-9aa2c2c68bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_aa14ac8d-b620-44c6-97f3-bebe2266639b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbac3100-7a9f-4f7b-a5d9-9aa2c2c68bde" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_aa14ac8d-b620-44c6-97f3-bebe2266639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_aa14ac8d-b620-44c6-97f3-bebe2266639b" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_d0a3d7aa-13d1-4a1c-84c8-2c0fffa69c28" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_371e4d8f-d7a7-45d8-a3a0-d22cf64912fc" xlink:href="bhc-20220930.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_371e4d8f-d7a7-45d8-a3a0-d22cf64912fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_a94f6623-852b-4d3e-8796-fc7deb97cca5" xlink:href="bhc-20220930.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_f47d501d-4f3d-485f-9b13-1955d3c23e9c" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_a94f6623-852b-4d3e-8796-fc7deb97cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ed66cbbb-cea8-470a-89eb-f964ce76969b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_aa14ac8d-b620-44c6-97f3-bebe2266639b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ed66cbbb-cea8-470a-89eb-f964ce76969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ed66cbbb-cea8-470a-89eb-f964ce76969b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_45fa3c85-636e-4542-aad5-fae02a3db526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_45fa3c85-636e-4542-aad5-fae02a3db526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c6f562c-bb11-4c8e-9b7b-ead68ae74506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c6f562c-bb11-4c8e-9b7b-ead68ae74506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eec52755-0943-43d5-8c11-1c2ed7580e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eec52755-0943-43d5-8c11-1c2ed7580e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_7c541979-0d43-4399-83b4-9c237677b407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_7c541979-0d43-4399-83b4-9c237677b407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3086a70b-d992-48ba-8327-f3ee4c81caf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3086a70b-d992-48ba-8327-f3ee4c81caf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7837f6c7-c995-4d06-a6c9-69625a71e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7837f6c7-c995-4d06-a6c9-69625a71e60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9ca2806d-940d-4aac-8fb2-bf20e45602d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6cb699a0-8eb2-4001-8e6d-79a55449ff4a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9ca2806d-940d-4aac-8fb2-bf20e45602d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d63e97a1-4ee6-4a5b-8771-35f58c7a1b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d63e97a1-4ee6-4a5b-8771-35f58c7a1b79" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77362468-01c5-4f42-8790-38921146f6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77362468-01c5-4f42-8790-38921146f6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d798d3b-ca9c-408d-86f9-74ed563d373c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_77362468-01c5-4f42-8790-38921146f6e9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d798d3b-ca9c-408d-86f9-74ed563d373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_2e04f531-a34c-4e91-a6d3-ba23793b7ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3d798d3b-ca9c-408d-86f9-74ed563d373c" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_2e04f531-a34c-4e91-a6d3-ba23793b7ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8251394f-212f-47b2-89ae-efb9b7ce4dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d269aa97-0f7d-4ce3-a9f5-53b74ec086cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8251394f-212f-47b2-89ae-efb9b7ce4dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_25fd0c66-2627-409e-98a1-6c9045046cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8251394f-212f-47b2-89ae-efb9b7ce4dbc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_25fd0c66-2627-409e-98a1-6c9045046cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d002d6a7-e48b-4f51-8d82-220149aee533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_97c1902e-8623-48dd-b27e-0c293914f803" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d002d6a7-e48b-4f51-8d82-220149aee533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ccbe4036-c55b-414b-967d-7ef9a710fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d002d6a7-e48b-4f51-8d82-220149aee533" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ccbe4036-c55b-414b-967d-7ef9a710fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5c6bb61d-6fcc-45e2-a888-646791a907ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_9c3f32bf-a8f3-488b-8e0b-10205fe0dced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5c6bb61d-6fcc-45e2-a888-646791a907ec" xlink:to="loc_us-gaap_InventoryRawMaterials_9c3f32bf-a8f3-488b-8e0b-10205fe0dced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_0476cc14-1e6d-4789-9e6d-204b13a3085c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5c6bb61d-6fcc-45e2-a888-646791a907ec" xlink:to="loc_us-gaap_InventoryWorkInProcess_0476cc14-1e6d-4789-9e6d-204b13a3085c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_c0340ab3-46c4-4724-8cc0-e6bf349a98d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5c6bb61d-6fcc-45e2-a888-646791a907ec" xlink:to="loc_us-gaap_InventoryFinishedGoods_c0340ab3-46c4-4724-8cc0-e6bf349a98d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_42d5fabf-64d5-4c76-8672-b8e62cafb05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5c6bb61d-6fcc-45e2-a888-646791a907ec" xlink:to="loc_us-gaap_InventoryGross_42d5fabf-64d5-4c76-8672-b8e62cafb05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_89640434-24e9-4b21-b8d3-a572dcce4873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_89640434-24e9-4b21-b8d3-a572dcce4873" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6828ed77-071d-413c-81c7-eeb5f2a84348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6828ed77-071d-413c-81c7-eeb5f2a84348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6828ed77-071d-413c-81c7-eeb5f2a84348" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_66569ff7-db4a-410a-a7f9-775b0c2829e4" xlink:href="bhc-20220930.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_bhc_ProductBrandsMember_66569ff7-db4a-410a-a7f9-775b0c2829e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b3ed0f83-42cd-4a03-9de5-e39773933d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_us-gaap_TradeNamesMember_b3ed0f83-42cd-4a03-9de5-e39773933d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_7acad2c5-6a2b-4b77-851b-ca3fcfb305bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_us-gaap_ContractualRightsMember_7acad2c5-6a2b-4b77-851b-ca3fcfb305bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_754a007c-cef8-47b4-ada4-3e50b9414763" xlink:href="bhc-20220930.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_bhc_PartnerRelationshipsMember_754a007c-cef8-47b4-ada4-3e50b9414763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_92c572d4-8ba5-4ac7-8514-6dd01f2ac9df" xlink:href="bhc-20220930.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e8808bde-5706-43f1-944e-10cb01508925" xlink:to="loc_bhc_OutLicensedTechnologyMember_92c572d4-8ba5-4ac7-8514-6dd01f2ac9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e34866b9-6d50-45cc-bafe-dd2021627be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e34866b9-6d50-45cc-bafe-dd2021627be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cf48c6ef-f786-44d9-bd9d-c7733cf8641b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e34866b9-6d50-45cc-bafe-dd2021627be3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cf48c6ef-f786-44d9-bd9d-c7733cf8641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_35d1852f-9142-4f93-8d66-6405994e8402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_cf48c6ef-f786-44d9-bd9d-c7733cf8641b" xlink:to="loc_us-gaap_TrademarksMember_35d1852f-9142-4f93-8d66-6405994e8402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:href="bhc-20220930.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c3885d36-ffba-4647-a7d8-35aee669fe81" xlink:to="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed8e8d5-0717-4d14-b1e2-bf84b3810977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5ed8e8d5-0717-4d14-b1e2-bf84b3810977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_53aa8fca-1c32-4756-9ff8-27bffd83b85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_53aa8fca-1c32-4756-9ff8-27bffd83b85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6a0cfa45-c6fa-43aa-8999-05bfbb85a7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2c2fac91-2a11-478d-b358-9a197b8bc128" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6a0cfa45-c6fa-43aa-8999-05bfbb85a7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2a0830a5-a464-43f1-af93-69c18ec58dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2a0830a5-a464-43f1-af93-69c18ec58dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_563bdf7a-f018-42a7-9557-b38998e1d186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2a0830a5-a464-43f1-af93-69c18ec58dd8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_563bdf7a-f018-42a7-9557-b38998e1d186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e997b7e9-b400-4374-b976-db2a6cfc817a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ebd8fee-69e3-474f-852b-8bee7bd50698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0ebd8fee-69e3-474f-852b-8bee7bd50698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500d4170-c171-4a6f-b4dc-6ab8288736f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_e0b3568b-9c18-492f-97e5-beb7d2212a28" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500d4170-c171-4a6f-b4dc-6ab8288736f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1574c823-89e9-485e-92da-74195343aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1574c823-89e9-485e-92da-74195343aa12" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17d493e5-9df4-49f2-8219-19541b025302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17d493e5-9df4-49f2-8219-19541b025302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17d493e5-9df4-49f2-8219-19541b025302" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_132abdde-2efd-4e6c-bfc5-e5f4605116e0" xlink:href="bhc-20220930.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:to="loc_bhc_ProductBrandsMember_132abdde-2efd-4e6c-bfc5-e5f4605116e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_81ed1b73-01a2-4a56-8af8-8eb6976c7eb8" xlink:href="bhc-20220930.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ac735a68-8adc-45fb-a9dd-bea07ab317d6" xlink:to="loc_bhc_DiscontinuedProductLinesMember_81ed1b73-01a2-4a56-8af8-8eb6976c7eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d13e431-1c98-4d5a-99e7-65aee05878b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_srt_ProductOrServiceAxis_3d13e431-1c98-4d5a-99e7-65aee05878b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_101588b5-87fa-40c2-b6d9-46e18da1384b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3d13e431-1c98-4d5a-99e7-65aee05878b1" xlink:to="loc_srt_ProductsAndServicesDomain_101588b5-87fa-40c2-b6d9-46e18da1384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_47bb0416-95d4-4b0f-93c4-352664639283" xlink:href="bhc-20220930.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_101588b5-87fa-40c2-b6d9-46e18da1384b" xlink:to="loc_bhc_XifaxanBrandedProductsMember_47bb0416-95d4-4b0f-93c4-352664639283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_45824792-48f1-4faa-8faf-f91fb8865432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_45824792-48f1-4faa-8faf-f91fb8865432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_68bd5bda-1d57-4fb3-96e7-7f8e90f1111e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_45824792-48f1-4faa-8faf-f91fb8865432" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_68bd5bda-1d57-4fb3-96e7-7f8e90f1111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_320b81de-deaa-4326-b398-4059af2e8148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_68bd5bda-1d57-4fb3-96e7-7f8e90f1111e" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_320b81de-deaa-4326-b398-4059af2e8148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8db2a201-4edd-4234-ad37-03a2b0a6cf13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_srt_RangeAxis_8db2a201-4edd-4234-ad37-03a2b0a6cf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8db2a201-4edd-4234-ad37-03a2b0a6cf13" xlink:to="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0da42c19-f9de-45d6-9b77-5edd1a5afe85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:to="loc_srt_MinimumMember_0da42c19-f9de-45d6-9b77-5edd1a5afe85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_790d682d-1cf3-4c75-9f7d-d3c5bd66c7f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_568beabe-12b9-4e42-b17a-e058cf402e96" xlink:to="loc_srt_MaximumMember_790d682d-1cf3-4c75-9f7d-d3c5bd66c7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7ef568ae-9249-4338-92b8-5fe6814b7c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7ef568ae-9249-4338-92b8-5fe6814b7c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cf2529f-4105-4b61-8902-bb8cd5278690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7ef568ae-9249-4338-92b8-5fe6814b7c45" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cf2529f-4105-4b61-8902-bb8cd5278690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_7cb1ffda-fa91-4d88-a665-5a6830960f6e" xlink:href="bhc-20220930.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cf2529f-4105-4b61-8902-bb8cd5278690" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_7cb1ffda-fa91-4d88-a665-5a6830960f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_edeea4e7-4db3-4ffe-8955-2b2a90487fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_ReportingUnitAxis_edeea4e7-4db3-4ffe-8955-2b2a90487fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_edeea4e7-4db3-4ffe-8955-2b2a90487fdc" xlink:to="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_ddc969aa-ed31-4b70-a1e9-361cd8e50970" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_ddc969aa-ed31-4b70-a1e9-361cd8e50970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_3d10127f-cc69-490d-94d7-597c2e4c8b6b" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_3d10127f-cc69-490d-94d7-597c2e4c8b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_9cac6e27-264d-4f26-8b57-e95f8043fb5e" xlink:href="bhc-20220930.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_9cac6e27-264d-4f26-8b57-e95f8043fb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_4cd5afe1-885e-4452-9784-f73aec215099" xlink:href="bhc-20220930.xsd#bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_4cd5afe1-885e-4452-9784-f73aec215099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember_9ac0107d-8da0-4df4-95bc-6b4c0972eba5" xlink:href="bhc-20220930.xsd#bhc_SalixReportingUnitMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_d3ffa801-e143-415b-a8bb-7ad539d0beec" xlink:to="loc_bhc_SalixReportingUnitMember_9ac0107d-8da0-4df4-95bc-6b4c0972eba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f31102a7-c43e-4a16-bf62-7db541de0e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f31102a7-c43e-4a16-bf62-7db541de0e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f31102a7-c43e-4a16-bf62-7db541de0e14" xlink:to="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_71e4511c-f459-472f-b79a-8a053e27133c" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_71e4511c-f459-472f-b79a-8a053e27133c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_3375fa76-6b5a-49b3-9ad6-244df1374b82" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_17e8f78f-986f-4547-b4fe-7bf99c866df5" xlink:to="loc_bhc_SalixSegmentMember_3375fa76-6b5a-49b3-9ad6-244df1374b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7c144734-eb92-49c1-a0dc-3200457a5b32" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_dei_LegalEntityAxis_7c144734-eb92-49c1-a0dc-3200457a5b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8b0375b0-e82d-4b65-ab93-488d55d4a648" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7c144734-eb92-49c1-a0dc-3200457a5b32" xlink:to="loc_dei_EntityDomain_8b0375b0-e82d-4b65-ab93-488d55d4a648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_a81a2a62-bef0-4ac8-8aca-a7a749689b39" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8b0375b0-e82d-4b65-ab93-488d55d4a648" xlink:to="loc_bhc_BauschLombMember_a81a2a62-bef0-4ac8-8aca-a7a749689b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ac16e4c0-848c-46bc-ad66-8b729827c116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ac16e4c0-848c-46bc-ad66-8b729827c116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_48021c8f-4b0a-4a58-8f2c-8e364b863e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ac16e4c0-848c-46bc-ad66-8b729827c116" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_48021c8f-4b0a-4a58-8f2c-8e364b863e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_bc3fae2c-ff30-4bc4-9729-105fa6acf875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_48021c8f-4b0a-4a58-8f2c-8e364b863e75" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_bc3fae2c-ff30-4bc4-9729-105fa6acf875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e057dbd0-9b28-4efe-a0c2-f0e3769205cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e057dbd0-9b28-4efe-a0c2-f0e3769205cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_adb619b5-5770-4280-85cc-44e0d28f22fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e057dbd0-9b28-4efe-a0c2-f0e3769205cd" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_adb619b5-5770-4280-85cc-44e0d28f22fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_1afd0125-4389-4afa-a55f-f72ca81cb1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_adb619b5-5770-4280-85cc-44e0d28f22fb" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_1afd0125-4389-4afa-a55f-f72ca81cb1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_72ac347c-710a-4ba5-a977-8a5208aa1507" xlink:to="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d92ed3ed-52af-4059-9355-8fde4d82f654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_AssetImpairmentCharges_d92ed3ed-52af-4059-9355-8fde4d82f654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_38390aea-2374-46be-8f40-6a956c77fb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_38390aea-2374-46be-8f40-6a956c77fb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f86073e3-c916-40c2-92f4-2b0712faf1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f86073e3-c916-40c2-92f4-2b0712faf1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_850bd6e4-0ace-4d99-85f0-90a56717e2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_850bd6e4-0ace-4d99-85f0-90a56717e2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2fafd0-f6ae-481f-ab3c-f6f469414adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2fafd0-f6ae-481f-ab3c-f6f469414adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AnnualAmortizationOfIntangibleAssets_22d9c218-5d14-4d7e-b036-b32e34adcfbd" xlink:href="bhc-20220930.xsd#bhc_AnnualAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_AnnualAmortizationOfIntangibleAssets_22d9c218-5d14-4d7e-b036-b32e34adcfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_8742cceb-3792-4607-8f69-4ec7e4a3a65d" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_8742cceb-3792-4607-8f69-4ec7e4a3a65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_5afddd1d-6ef5-47f2-b146-d02705f33b1f" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_5afddd1d-6ef5-47f2-b146-d02705f33b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ccad5d1-2160-4670-b10f-94eea5d84a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ccad5d1-2160-4670-b10f-94eea5d84a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_dd720716-a150-45a8-99c0-7a3b3c186dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_dd720716-a150-45a8-99c0-7a3b3c186dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_46755441-a31e-4073-bf95-2b451ce05378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_NumberOfReportingUnits_46755441-a31e-4073-bf95-2b451ce05378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_52ee0b7f-b276-4873-9718-f33c6c65db25" xlink:href="bhc-20220930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_52ee0b7f-b276-4873-9718-f33c6c65db25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c9e949af-b1d9-4b03-978d-82469d31835e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c9e949af-b1d9-4b03-978d-82469d31835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f37691b1-0b0c-4f6f-bc79-53e94fbfebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ddb50a55-b382-4873-bae1-7ae786adf00d" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f37691b1-0b0c-4f6f-bc79-53e94fbfebcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_72a815fa-e72b-4541-843f-5b08ba54a41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_72a815fa-e72b-4541-843f-5b08ba54a41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c95ffba2-fd9f-4c83-b09d-c92e1d9e4dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c95ffba2-fd9f-4c83-b09d-c92e1d9e4dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8bc3fb8e-e05e-4c8b-95d8-a323f6539355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8bc3fb8e-e05e-4c8b-95d8-a323f6539355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fcffe409-87dc-4b5c-854c-7c41fe7b6637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_fcffe409-87dc-4b5c-854c-7c41fe7b6637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0bc8c814-e8f3-498d-8be3-0ed1651121c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0bc8c814-e8f3-498d-8be3-0ed1651121c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4d9f4d0a-2230-4718-96d5-7f0d900782d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4d9f4d0a-2230-4718-96d5-7f0d900782d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_970bac33-f49c-429c-bfdd-31b88b359c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_970bac33-f49c-429c-bfdd-31b88b359c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8714da94-2eae-4aed-932a-1032692c9921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bf1a122-aa7e-4595-920a-b0d2487f68b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8714da94-2eae-4aed-932a-1032692c9921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b65f6a3-52db-47c7-a836-6057e8944851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c2c3c022-7189-49a2-9cfc-863c090c4244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b65f6a3-52db-47c7-a836-6057e8944851" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c2c3c022-7189-49a2-9cfc-863c090c4244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bef64488-52e1-485f-9a19-f3ab6e1c8f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c2c3c022-7189-49a2-9cfc-863c090c4244" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bef64488-52e1-485f-9a19-f3ab6e1c8f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bef64488-52e1-485f-9a19-f3ab6e1c8f0e" xlink:to="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_991ede27-427e-4816-9ea5-3fac68335fab" xlink:href="bhc-20220930.xsd#bhc_BauschLombInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_BauschLombInternationalMember_991ede27-427e-4816-9ea5-3fac68335fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f4017ea8-8a29-4da2-a8c6-08a9c9b6b162" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_BauschLombMember_f4017ea8-8a29-4da2-a8c6-08a9c9b6b162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_77c1a9b7-c12b-45e2-bfac-e24701c6ffb2" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_SalixSegmentMember_77c1a9b7-c12b-45e2-bfac-e24701c6ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_5b90206f-04f7-440e-85ff-e9fdcf943197" xlink:href="bhc-20220930.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_InternationalRxMember_5b90206f-04f7-440e-85ff-e9fdcf943197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_233ffbc4-961c-44c8-9674-0c8d82e87217" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_233ffbc4-961c-44c8-9674-0c8d82e87217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_4e701c37-88d3-4ecd-8de9-572458c42414" xlink:href="bhc-20220930.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_SoltaMedicalSegmentMember_4e701c37-88d3-4ecd-8de9-572458c42414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_18f64587-85b8-4ac5-8bb6-c2907ee22b2c" xlink:href="bhc-20220930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_30bf48d7-95b7-4916-b8a7-acb8f1265ae2" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_18f64587-85b8-4ac5-8bb6-c2907ee22b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_abbc975a-3b9a-4dbc-8083-34ed12283af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c2c3c022-7189-49a2-9cfc-863c090c4244" xlink:to="loc_us-gaap_GoodwillLineItems_abbc975a-3b9a-4dbc-8083-34ed12283af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_abbc975a-3b9a-4dbc-8083-34ed12283af4" xlink:to="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0310466c-f509-4d41-9ab2-b337a512297f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_Goodwill_0310466c-f509-4d41-9ab2-b337a512297f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_7c19bc7e-2a93-4d30-a296-9bce0e883794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_7c19bc7e-2a93-4d30-a296-9bce0e883794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8002c3f5-fd10-4365-822b-c7862fa635b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8002c3f5-fd10-4365-822b-c7862fa635b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15eaa94b-d657-42c1-96e9-4d42af522aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15eaa94b-d657-42c1-96e9-4d42af522aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05899d7e-cfb4-4314-bd57-c46e7a63003d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7fe480be-f4b6-497b-a8f9-a55d0988b5a4" xlink:to="loc_us-gaap_Goodwill_05899d7e-cfb4-4314-bd57-c46e7a63003d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_f0977092-8f82-42f1-9edf-977a674d2535" xlink:href="bhc-20220930.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_f0977092-8f82-42f1-9edf-977a674d2535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_16792ffe-4499-4de5-8cf8-26b4b1413c21" xlink:href="bhc-20220930.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_bhc_AccruedProductRebateCurrent_16792ffe-4499-4de5-8cf8-26b4b1413c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_5fbea201-991d-470b-8294-6ec0367be917" xlink:href="bhc-20220930.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_bhc_AccruedProductReturnCurrent_5fbea201-991d-470b-8294-6ec0367be917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_14efbc83-cc42-45af-aacd-357bd4229730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_us-gaap_InterestPayableCurrent_14efbc83-cc42-45af-aacd-357bd4229730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_13ad969c-7d09-44ae-bbf6-c9bf845514f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_13ad969c-7d09-44ae-bbf6-c9bf845514f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_190e13bf-ae18-4f9f-a949-49797d3e4316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_190e13bf-ae18-4f9f-a949-49797d3e4316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ff5ced3-70c1-4baf-b434-e34948986d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ff5ced3-70c1-4baf-b434-e34948986d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c5b6373a-704e-4ea3-815c-7509326b23de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_383aacdc-d3f4-45fd-a8e9-1525558b379c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c5b6373a-704e-4ea3-815c-7509326b23de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bb457e5c-eab4-4ae4-9375-9671ca10c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bb457e5c-eab4-4ae4-9375-9671ca10c62c" xlink:to="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_483392ed-f6ce-4843-81b5-833e7f610516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_us-gaap_CreditFacilityAxis_483392ed-f6ce-4843-81b5-833e7f610516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c43efa3b-660f-4afe-8b52-5e869c9c095d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_483392ed-f6ce-4843-81b5-833e7f610516" xlink:to="loc_us-gaap_CreditFacilityDomain_c43efa3b-660f-4afe-8b52-5e869c9c095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e9780a89-49a7-4cc7-88ec-b806e7ce72c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c43efa3b-660f-4afe-8b52-5e869c9c095d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e9780a89-49a7-4cc7-88ec-b806e7ce72c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b60787c5-3fff-4307-97f5-a65a79db3c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b60787c5-3fff-4307-97f5-a65a79db3c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b60787c5-3fff-4307-97f5-a65a79db3c84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e30d7ffb-42f3-4b6c-8fda-35a844fdccd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:to="loc_us-gaap_SecuredDebtMember_e30d7ffb-42f3-4b6c-8fda-35a844fdccd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0856448c-2b88-430c-b6f4-83c7e38fb727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a3f9fdd2-bf89-47ee-859d-2d4fb604797c" xlink:to="loc_us-gaap_UnsecuredDebtMember_0856448c-2b88-430c-b6f4-83c7e38fb727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a38bb6b6-0a3b-451f-aa69-76f160fa703c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_us-gaap_DebtInstrumentAxis_a38bb6b6-0a3b-451f-aa69-76f160fa703c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a38bb6b6-0a3b-451f-aa69-76f160fa703c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_06687b31-e8a6-4796-8e1c-c5bda54c42a9" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_06687b31-e8a6-4796-8e1c-c5bda54c42a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_75fa50bb-d510-40ec-a000-cf2b3fc3912a" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_75fa50bb-d510-40ec-a000-cf2b3fc3912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_e35c7b6f-1c0a-4896-80d2-5faf111b5b83" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_e35c7b6f-1c0a-4896-80d2-5faf111b5b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_d7511c29-f669-4e94-8b1b-cda13c1bb940" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_d7511c29-f669-4e94-8b1b-cda13c1bb940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_fd353f82-c61b-47cc-a026-b3a86966c68a" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_fd353f82-c61b-47cc-a026-b3a86966c68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_67f87181-3b2d-4f48-941a-13d6a01bfa04" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_67f87181-3b2d-4f48-941a-13d6a01bfa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_82616eac-05bf-41f5-a00c-0c4da475fde6" xlink:href="bhc-20220930.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_TermFacilityDueMay2027Member_82616eac-05bf-41f5-a00c-0c4da475fde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_bf92bfa0-c4d9-486c-a9b0-6b703d971eb0" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_bf92bfa0-c4d9-486c-a9b0-6b703d971eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_45a4f6d2-6c0c-4477-8981-507ee1eb14fe" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_45a4f6d2-6c0c-4477-8981-507ee1eb14fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_3933b75a-f8b6-4a24-9037-2678d1fb0094" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_3933b75a-f8b6-4a24-9037-2678d1fb0094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_07c1f449-b00d-49f7-9a95-b0f716c1a4b1" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_07c1f449-b00d-49f7-9a95-b0f716c1a4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_c8e633f8-ede4-49f7-a6db-9c4cd39953f1" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_c8e633f8-ede4-49f7-a6db-9c4cd39953f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_d53618e2-2b07-4a72-a5d2-52a319cbfcf1" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_d53618e2-2b07-4a72-a5d2-52a319cbfcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_0065803c-a959-427f-b9ad-ca97e76ab974" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_0065803c-a959-427f-b9ad-ca97e76ab974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_7c2ee420-57cd-4513-8352-b4184215c669" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_7c2ee420-57cd-4513-8352-b4184215c669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_eda4fe50-d136-40df-b7a8-d5780574af0e" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_eda4fe50-d136-40df-b7a8-d5780574af0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_a6a89469-fedd-4be0-998b-d95c645d2752" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_a6a89469-fedd-4be0-998b-d95c645d2752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_462e69ac-687a-450c-964c-dc336befe0c3" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_462e69ac-687a-450c-964c-dc336befe0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_3c43e263-c227-4ce8-974c-6bde8ac2bc07" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_3c43e263-c227-4ce8-974c-6bde8ac2bc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_aab41b49-a6b3-4f5e-9755-20e0a024e690" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_aab41b49-a6b3-4f5e-9755-20e0a024e690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_59a5d32f-cfd0-42ca-9d67-bd7ffb2e4abb" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_59a5d32f-cfd0-42ca-9d67-bd7ffb2e4abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_a2b8bd5b-fc56-4dfe-aaae-eab760e5db5b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_a2b8bd5b-fc56-4dfe-aaae-eab760e5db5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_a435abc8-bf64-4141-ad6c-35fce41dc41f" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_a435abc8-bf64-4141-ad6c-35fce41dc41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_1129fc97-7a09-4aeb-928d-101faea3dff2" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_1129fc97-7a09-4aeb-928d-101faea3dff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_e21581e0-4c59-4968-8775-bf5a99913bb6" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_e21581e0-4c59-4968-8775-bf5a99913bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_297b7172-e627-4474-a507-21459bcc6a7b" xlink:href="bhc-20220930.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0223b51b-fe70-45cd-b234-dfa1a6375313" xlink:to="loc_bhc_OtherLongTermDebtMember_297b7172-e627-4474-a507-21459bcc6a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_dei_LegalEntityAxis_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9c9b25c3-f2f3-4762-a7d9-1810980bf352" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cfdc9db6-dcfd-43dc-b12d-2c25e3015e85" xlink:to="loc_dei_EntityDomain_9c9b25c3-f2f3-4762-a7d9-1810980bf352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_238965c7-82e0-4966-ba5f-20a4de12305d" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9c9b25c3-f2f3-4762-a7d9-1810980bf352" xlink:to="loc_bhc_BauschLombMember_238965c7-82e0-4966-ba5f-20a4de12305d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0a2c0b0-5264-42e8-a602-3f44e2a72c76" xlink:to="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00a4caab-f678-4e26-bcac-d2996ed4e182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_00a4caab-f678-4e26-bcac-d2996ed4e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5e34cd75-b1c3-4bc1-906a-85474a4e10ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5e34cd75-b1c3-4bc1-906a-85474a4e10ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d851c4aa-8004-4421-b39c-03f2c6789f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_LongTermDebt_d851c4aa-8004-4421-b39c-03f2c6789f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5b24ae43-5822-4695-8848-94f07855e29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_LongTermDebtCurrent_5b24ae43-5822-4695-8848-94f07855e29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1f8a9733-b076-4351-90d6-401c18d7385f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_441bbac7-7204-4b8a-9423-3499e52e913e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1f8a9733-b076-4351-90d6-401c18d7385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5c6c45b1-3d39-4240-89ad-316a56a1c62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5c6c45b1-3d39-4240-89ad-316a56a1c62b" xlink:to="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:to="loc_us-gaap_CreditFacilityAxis_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_cb6bb036-fbe3-4ae3-ba18-9bbd1a7f5896" xlink:to="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_c952e41d-6562-48ba-8487-fb977b40113f" xlink:href="bhc-20220930.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_c952e41d-6562-48ba-8487-fb977b40113f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e217d967-e625-4069-9e18-34ab7bc709a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_136a1edd-6f9a-4c21-8d44-ded7284c1f93" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e217d967-e625-4069-9e18-34ab7bc709a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e868f5b8-fafd-4f56-8a62-f743decbd352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:to="loc_us-gaap_DebtInstrumentAxis_e868f5b8-fafd-4f56-8a62-f743decbd352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_be37668c-da20-477a-a101-0931bbf3baac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e868f5b8-fafd-4f56-8a62-f743decbd352" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_be37668c-da20-477a-a101-0931bbf3baac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_01287012-e25f-4b91-a294-d395f6648002" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_be37668c-da20-477a-a101-0931bbf3baac" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_01287012-e25f-4b91-a294-d395f6648002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e813c975-7c4f-4e97-bdb5-63429a0d289d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e813c975-7c4f-4e97-bdb5-63429a0d289d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e81f65a6-1102-4d19-8706-f72c351b45b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e813c975-7c4f-4e97-bdb5-63429a0d289d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e81f65a6-1102-4d19-8706-f72c351b45b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2167c098-c1a5-40e4-80e8-eef8eacaeebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e81f65a6-1102-4d19-8706-f72c351b45b0" xlink:to="loc_us-gaap_SecuredDebtMember_2167c098-c1a5-40e4-80e8-eef8eacaeebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_036b40dd-fe67-4787-8b33-3c035f7de9e1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36075511-5dc9-4418-86c6-e4ab5611c91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36075511-5dc9-4418-86c6-e4ab5611c91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_5b213638-503d-4e8a-bb66-ee6767ed135d" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_5b213638-503d-4e8a-bb66-ee6767ed135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_0c77fdd6-6d58-4352-81be-7a1e4423508b" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_0c77fdd6-6d58-4352-81be-7a1e4423508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_b2428f86-04c4-4234-a487-b84893e9452a" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c57f17ea-a24b-4265-8bf8-dbf11a9efd94" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_b2428f86-04c4-4234-a487-b84893e9452a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSExchangeOfferDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0cfa3e45-5a6d-46bd-bb1b-02f6b5372ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0cfa3e45-5a6d-46bd-bb1b-02f6b5372ddc" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f38590f0-0314-4b26-ab19-70f60e480c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f38590f0-0314-4b26-ab19-70f60e480c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f38590f0-0314-4b26-ab19-70f60e480c34" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_46d7c638-c11a-4dc6-88c5-10d5de930755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:to="loc_us-gaap_UnsecuredDebtMember_46d7c638-c11a-4dc6-88c5-10d5de930755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_92f79317-9d97-4c31-a25c-a82b68e293cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bdb1086d-cf64-4ad9-bc0a-742cd4490b90" xlink:to="loc_us-gaap_SecuredDebtMember_92f79317-9d97-4c31-a25c-a82b68e293cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_83641b06-82eb-484a-a5dd-a330091e457b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_us-gaap_DebtInstrumentAxis_83641b06-82eb-484a-a5dd-a330091e457b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_83641b06-82eb-484a-a5dd-a330091e457b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_b4555dfc-aee0-417d-a5c1-a7cce3c4b57d" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_b4555dfc-aee0-417d-a5c1-a7cce3c4b57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_23a92704-79ad-465e-9165-ff477a106fc9" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_23a92704-79ad-465e-9165-ff477a106fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_efed1f16-d2cc-429f-a8df-ac38e2ed0706" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_efed1f16-d2cc-429f-a8df-ac38e2ed0706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_aa7c0472-8030-4e4c-aca2-d7e5ba149c6b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_aa7c0472-8030-4e4c-aca2-d7e5ba149c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_f9fd2919-360a-4f4f-92ea-8595a3111f4b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_f9fd2919-360a-4f4f-92ea-8595a3111f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_6284858c-7d06-4723-8544-5f3b2d69f802" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_6284858c-7d06-4723-8544-5f3b2d69f802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_52f642d4-809e-4acb-966b-a68ec91e73b2" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_52f642d4-809e-4acb-966b-a68ec91e73b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_0793e32b-3b5d-4218-addc-fc12b31511d1" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_668b149f-e655-4536-abc4-2088cfbbd9fe" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_0793e32b-3b5d-4218-addc-fc12b31511d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f857cb64-eef2-42d7-96a6-af9f534fe0de" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f857cb64-eef2-42d7-96a6-af9f534fe0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_e0f4151c-26cc-466e-ac2f-962db1f314e8" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_f857cb64-eef2-42d7-96a6-af9f534fe0de" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_e0f4151c-26cc-466e-ac2f-962db1f314e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_590d43e8-153e-427c-bff8-6f0f0acfb2d1" xlink:href="bhc-20220930.xsd#bhc_ExchangeOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_e0f4151c-26cc-466e-ac2f-962db1f314e8" xlink:to="loc_bhc_ExchangeOfferMember_590d43e8-153e-427c-bff8-6f0f0acfb2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_55605f6d-942b-4308-b5b3-3bd9f9c8c667" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_srt_OwnershipAxis_55605f6d-942b-4308-b5b3-3bd9f9c8c667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_51450db7-75ed-4b02-a39f-e0d4f7b144a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_55605f6d-942b-4308-b5b3-3bd9f9c8c667" xlink:to="loc_srt_OwnershipDomain_51450db7-75ed-4b02-a39f-e0d4f7b144a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_dd37528b-5bbe-4ba8-92ce-b2f466ebf9e2" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_51450db7-75ed-4b02-a39f-e0d4f7b144a4" xlink:to="loc_bhc_BauschLombMember_dd37528b-5bbe-4ba8-92ce-b2f466ebf9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_835340da-589c-4cd0-ad13-7948c50a4cdf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_dei_LegalEntityAxis_835340da-589c-4cd0-ad13-7948c50a4cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d880bfa3-cebf-4bb4-a68c-3df937a81d79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_835340da-589c-4cd0-ad13-7948c50a4cdf" xlink:to="loc_dei_EntityDomain_d880bfa3-cebf-4bb4-a68c-3df937a81d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_e558ec52-963f-45a4-a5df-4afdad288b1c" xlink:href="bhc-20220930.xsd#bhc_A1375209BCLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d880bfa3-cebf-4bb4-a68c-3df937a81d79" xlink:to="loc_bhc_A1375209BCLtdMember_e558ec52-963f-45a4-a5df-4afdad288b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_5ff7fa39-d388-4650-8939-c0a28a61a215" xlink:to="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_de566d25-e056-4dd2-a941-279a3300e957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_de566d25-e056-4dd2-a941-279a3300e957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_75483d81-2af2-4739-9f1d-027bcc3a98eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_75483d81-2af2-4739-9f1d-027bcc3a98eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_d6b6c36a-2c58-4760-a6ca-555116066f38" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_d6b6c36a-2c58-4760-a6ca-555116066f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64f210b3-bf02-49bb-838f-c5db3f68e322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_64f210b3-bf02-49bb-838f-c5db3f68e322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f7572a08-ddb7-4276-8d13-1a2f5ba0e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f7572a08-ddb7-4276-8d13-1a2f5ba0e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1ae2e7d-a6dd-4a03-baf9-441a23768d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1ae2e7d-a6dd-4a03-baf9-441a23768d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_b1b1aaf6-9bf9-4a71-a7f0-edd535bf6790" xlink:href="bhc-20220930.xsd#bhc_ExtinguishmentOfDebtThirdPartyFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_bhc_ExtinguishmentOfDebtThirdPartyFees_b1b1aaf6-9bf9-4a71-a7f0-edd535bf6790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd4400ae-e9c4-404d-aa9b-13257e885ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_42d9bf58-514d-44d4-983d-154cf81cfb8e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_dd4400ae-e9c4-404d-aa9b-13257e885ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b2e2f4cd-89d4-444a-a3be-ec0a662dba59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b2e2f4cd-89d4-444a-a3be-ec0a662dba59" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ae31f4b5-dbab-4b66-83f1-191230a5d6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:to="loc_us-gaap_DebtInstrumentAxis_ae31f4b5-dbab-4b66-83f1-191230a5d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ae31f4b5-dbab-4b66-83f1-191230a5d6dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_6847d399-7d6d-44e1-9054-e643f6eeffd4" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_6847d399-7d6d-44e1-9054-e643f6eeffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_2a672fb8-1cb2-4692-a61e-5bc4e0a0dbf8" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_2a672fb8-1cb2-4692-a61e-5bc4e0a0dbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_30c692da-1242-45c6-a841-19c44ca18610" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_30c692da-1242-45c6-a841-19c44ca18610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_5e55e937-7595-41d8-9b48-566067a174b2" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_5e55e937-7595-41d8-9b48-566067a174b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_81c570cb-95a2-4e4f-ab19-d744fd41d474" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_81c570cb-95a2-4e4f-ab19-d744fd41d474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_f8433176-008d-4af2-ae2a-ec816da245d6" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_f8433176-008d-4af2-ae2a-ec816da245d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_9b30ae73-fde8-4f2d-8991-1f43bc18ae60" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_9b30ae73-fde8-4f2d-8991-1f43bc18ae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_a5c29817-6380-415f-a852-d283e2bc7cfe" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_a5c29817-6380-415f-a852-d283e2bc7cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_73e7ccbd-4d00-44b4-9156-d7da55918ce5" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_73e7ccbd-4d00-44b4-9156-d7da55918ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_71652c21-eef2-4d5e-9335-66a2397afbe3" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dc02a0b6-13a8-4de6-a199-b5ffe5c94903" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_71652c21-eef2-4d5e-9335-66a2397afbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b7adcf38-f5f9-44a7-8c5d-9863cae879f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b7adcf38-f5f9-44a7-8c5d-9863cae879f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cb6bb438-68a1-4a52-9167-517f7f33ecd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b7adcf38-f5f9-44a7-8c5d-9863cae879f8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cb6bb438-68a1-4a52-9167-517f7f33ecd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c3510109-7757-4a59-9709-c53f7faacb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cb6bb438-68a1-4a52-9167-517f7f33ecd4" xlink:to="loc_us-gaap_UnsecuredDebtMember_c3510109-7757-4a59-9709-c53f7faacb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_96529cbe-0897-49d9-a65e-8b37f055c9e5" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_96529cbe-0897-49d9-a65e-8b37f055c9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_ad6587a1-3592-471f-9914-7415f003b926" xlink:href="bhc-20220930.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_96529cbe-0897-49d9-a65e-8b37f055c9e5" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_ad6587a1-3592-471f-9914-7415f003b926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_3361cbde-afb1-45f7-85fd-8ecd8a44f1f5" xlink:href="bhc-20220930.xsd#bhc_ExchangeOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_ad6587a1-3592-471f-9914-7415f003b926" xlink:to="loc_bhc_ExchangeOfferMember_3361cbde-afb1-45f7-85fd-8ecd8a44f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_4cff8ac0-e926-4002-a6d2-4dd57b6d7354" xlink:to="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_83f49629-c86c-4dd4-8a29-048ce6514134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_83f49629-c86c-4dd4-8a29-048ce6514134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c6433048-b1ae-4531-a3fb-5498f7defe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_01763240-1276-4346-9c58-f6da1888b20d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c6433048-b1ae-4531-a3fb-5498f7defe1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_69210f57-c9e1-4223-95d7-50ca0637e175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_69210f57-c9e1-4223-95d7-50ca0637e175" xlink:to="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7ff11591-4f68-4981-9599-6baba8e6541f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_VariableRateAxis_7ff11591-4f68-4981-9599-6baba8e6541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7ff11591-4f68-4981-9599-6baba8e6541f" xlink:to="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_65b81fd5-bc26-4d9f-a0e7-a4c2285c7c68" xlink:href="bhc-20220930.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_65b81fd5-bc26-4d9f-a0e7-a4c2285c7c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_fd8e11d2-842d-401d-98e5-0050adfbbb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_fd8e11d2-842d-401d-98e5-0050adfbbb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_0a65beb4-68a9-42a0-9d3b-35536e6f0b69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_0a65beb4-68a9-42a0-9d3b-35536e6f0b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_a763ab86-d5d1-4cf4-b46a-72ef32ddd91d" xlink:href="bhc-20220930.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_a763ab86-d5d1-4cf4-b46a-72ef32ddd91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_ae401b44-de08-41fd-bc0f-9ed4ebeeb0cd" xlink:href="bhc-20220930.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_ae401b44-de08-41fd-bc0f-9ed4ebeeb0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_bbc33e20-8302-4cec-ac75-74e52c9f9881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_us-gaap_BaseRateMember_bbc33e20-8302-4cec-ac75-74e52c9f9881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_449e2b45-9532-4ac7-92c7-c04c93170da2" xlink:href="bhc-20220930.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_449e2b45-9532-4ac7-92c7-c04c93170da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_a8a93622-094a-4a4c-8b86-dfb43e2ce897" xlink:href="bhc-20220930.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_01092a77-22e4-4bfe-aea2-f5a52f66e839" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_a8a93622-094a-4a4c-8b86-dfb43e2ce897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db14097e-cc5a-41b6-8c5b-919c615ca0ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_srt_RangeAxis_db14097e-cc5a-41b6-8c5b-919c615ca0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_db14097e-cc5a-41b6-8c5b-919c615ca0ff" xlink:to="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4ce0d6b-da7c-4585-b341-8fe3df653bfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:to="loc_srt_MinimumMember_d4ce0d6b-da7c-4585-b341-8fe3df653bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_02d72be1-a4f0-48a8-8eff-1a3152b0e91a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bf24444f-216c-4ef4-8017-5ea6ab289014" xlink:to="loc_srt_MaximumMember_02d72be1-a4f0-48a8-8eff-1a3152b0e91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ace4cf23-755b-4c8b-8db4-de6fd7d1b60b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ae9edd1b-a14f-4b78-ac45-ce69c213f1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:to="loc_us-gaap_SecuredDebtMember_ae9edd1b-a14f-4b78-ac45-ce69c213f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c8730f64-29c8-4103-9337-ed81cf0525ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8b80e670-84f3-4bbd-85e9-712330a15dfa" xlink:to="loc_us-gaap_UnsecuredDebtMember_c8730f64-29c8-4103-9337-ed81cf0525ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9a6480ef-7c14-4cff-84cf-818d8468c578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_DebtInstrumentAxis_9a6480ef-7c14-4cff-84cf-818d8468c578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9a6480ef-7c14-4cff-84cf-818d8468c578" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_8dcf25ec-d8b0-4ce6-ace2-4a9e970bf206" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_8dcf25ec-d8b0-4ce6-ace2-4a9e970bf206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_a863ebdf-0aea-4949-a72b-e03156d27c9b" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_a863ebdf-0aea-4949-a72b-e03156d27c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_c57c4eec-f343-4e20-9727-c7488b8c8a3b" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_c57c4eec-f343-4e20-9727-c7488b8c8a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0dea830a-1ec7-44ec-ae72-c005d1463ae7" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0dea830a-1ec7-44ec-ae72-c005d1463ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_bc0ca2b7-d8c3-43bc-a5a6-11017cfab6a9" xlink:href="bhc-20220930.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_bc0ca2b7-d8c3-43bc-a5a6-11017cfab6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_107a06b2-a523-411c-b566-6660e57f0ac8" xlink:href="bhc-20220930.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_107a06b2-a523-411c-b566-6660e57f0ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_daf4cb7d-9345-4314-8386-d84580d95b0a" xlink:href="bhc-20220930.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_daf4cb7d-9345-4314-8386-d84580d95b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_86c3c8cd-4f95-41dd-9eb4-6e1eba489b5e" xlink:href="bhc-20220930.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_TermFacilityDueMay2027Member_86c3c8cd-4f95-41dd-9eb4-6e1eba489b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_4f9fb01c-f4bf-4ceb-86f9-68a90c4bf9a6" xlink:href="bhc-20220930.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dbb6532a-6c5f-4d1d-8a73-5d291d3155db" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_4f9fb01c-f4bf-4ceb-86f9-68a90c4bf9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e38b43d2-1ac3-4785-80f9-178256dec35f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_dei_LegalEntityAxis_e38b43d2-1ac3-4785-80f9-178256dec35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8b6cef66-5c19-468a-83b1-944424f6bee7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e38b43d2-1ac3-4785-80f9-178256dec35f" xlink:to="loc_dei_EntityDomain_8b6cef66-5c19-468a-83b1-944424f6bee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_cd583bba-df2b-4916-8788-078ace3be28b" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8b6cef66-5c19-468a-83b1-944424f6bee7" xlink:to="loc_bhc_BauschLombMember_cd583bba-df2b-4916-8788-078ace3be28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_89758e76-c713-4572-8a50-7e540df59071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_CreditFacilityAxis_89758e76-c713-4572-8a50-7e540df59071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_78c299f7-004f-4efb-90ff-90f80bc085f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_89758e76-c713-4572-8a50-7e540df59071" xlink:to="loc_us-gaap_CreditFacilityDomain_78c299f7-004f-4efb-90ff-90f80bc085f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_902f16cd-909d-4093-bd36-653d91c59d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_78c299f7-004f-4efb-90ff-90f80bc085f4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_902f16cd-909d-4093-bd36-653d91c59d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7dce5028-55df-4b6c-adb4-38ae62e187ac" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f3dfeef-165b-4792-9e77-64aba39b4012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8f3dfeef-165b-4792-9e77-64aba39b4012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_0c166efc-ae88-409a-b69a-2af48be2cc38" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_0c166efc-ae88-409a-b69a-2af48be2cc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_2f15ecfa-52e6-491b-ab60-4cf4f50c9017" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_2f15ecfa-52e6-491b-ab60-4cf4f50c9017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d0db10a0-4b46-4e6e-a08e-5079cc09810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d0db10a0-4b46-4e6e-a08e-5079cc09810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e52bcbb8-88ca-4592-8e76-2b21b17715de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LongTermDebt_e52bcbb8-88ca-4592-8e76-2b21b17715de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e4174abe-24d9-4ce7-8de3-6159e8ffca89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e4174abe-24d9-4ce7-8de3-6159e8ffca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_03e1172e-60fc-44d5-af31-035817a7da96" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_03e1172e-60fc-44d5-af31-035817a7da96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_c6f05ff4-525e-453b-85ed-b73082cbc151" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_c6f05ff4-525e-453b-85ed-b73082cbc151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9ca9b435-7deb-4e41-83a8-6986daa30e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_9ca9b435-7deb-4e41-83a8-6986daa30e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_32abd90e-ad88-4f74-83d0-0a405ec80303" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_32abd90e-ad88-4f74-83d0-0a405ec80303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_e0b732a8-32d2-4b8a-a675-7586d9ee7f07" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_e0b732a8-32d2-4b8a-a675-7586d9ee7f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_9fa16efa-b32a-4725-88e2-d81705088702" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_9fa16efa-b32a-4725-88e2-d81705088702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_20c2ea09-2580-4b9e-a41a-e9061bbca9e2" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_20c2ea09-2580-4b9e-a41a-e9061bbca9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_dc4b77c6-626d-4cee-b0bc-6d7837274db9" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_dc4b77c6-626d-4cee-b0bc-6d7837274db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_0acb7f56-1a35-46a0-805d-21b2637e20ad" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_0acb7f56-1a35-46a0-805d-21b2637e20ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_ebf42ba1-c0df-42c8-ace3-6d88d7274f33" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_ebf42ba1-c0df-42c8-ace3-6d88d7274f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_68605504-2e23-4afb-8bc8-9bb27644a39b" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_68605504-2e23-4afb-8bc8-9bb27644a39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_75c9433e-b065-4b95-9403-e019d0793c2b" xlink:href="bhc-20220930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_75c9433e-b065-4b95-9403-e019d0793c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_33b259c6-c99b-4af1-b0c8-600d49be4227" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_33b259c6-c99b-4af1-b0c8-600d49be4227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_8795c018-af81-4206-9ed5-48b95f3c4158" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_8795c018-af81-4206-9ed5-48b95f3c4158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_604745dc-ff85-49a9-a6b6-95023e0a2fe1" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_604745dc-ff85-49a9-a6b6-95023e0a2fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_bbe86291-b3fd-4467-8695-e83bb8911454" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_bbe86291-b3fd-4467-8695-e83bb8911454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_aa97f0ff-c110-4bde-ae0e-b23d06e52dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentTerm_aa97f0ff-c110-4bde-ae0e-b23d06e52dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ecc38828-30e6-491d-95aa-f925961ce56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ecc38828-30e6-491d-95aa-f925961ce56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_899ee8f1-9543-4a97-bd5d-7c66ad6a4c43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_899ee8f1-9543-4a97-bd5d-7c66ad6a4c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_880c038e-f67d-48d4-af14-2ad1c635541f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c95e5864-df6a-4145-b36e-4be7a724aaf3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_880c038e-f67d-48d4-af14-2ad1c635541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c110d6ce-5d94-48cb-85b7-6c27db248a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c110d6ce-5d94-48cb-85b7-6c27db248a68" xlink:to="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4df2ca92-ef19-4106-bf9d-7878ff788b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_us-gaap_DebtInstrumentAxis_4df2ca92-ef19-4106-bf9d-7878ff788b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4df2ca92-ef19-4106-bf9d-7878ff788b44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_3b76a2b8-e89e-4bf1-b3b8-0d3f525d7942" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_3b76a2b8-e89e-4bf1-b3b8-0d3f525d7942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_da575037-9cf2-4114-a84c-30a6db3686a9" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_da575037-9cf2-4114-a84c-30a6db3686a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_2bafc10b-0885-4028-9b66-a847da91e97b" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_2bafc10b-0885-4028-9b66-a847da91e97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_ff09edcc-bd5e-4e7f-b87d-5cc815e862a5" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_ff09edcc-bd5e-4e7f-b87d-5cc815e862a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_9f127232-3704-44a2-a8de-64a181f2d28d" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_9f127232-3704-44a2-a8de-64a181f2d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_54a3815b-0a75-44b2-8b24-f923c91d3243" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_54a3815b-0a75-44b2-8b24-f923c91d3243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b6bf01cd-6143-43ef-817f-5b00881a04f2" xlink:href="bhc-20220930.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0014a01-f628-4ed2-84a5-350f02e605b1" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b6bf01cd-6143-43ef-817f-5b00881a04f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15ed61b7-d8e0-4e0b-9ca1-a4ae9fc52d4a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_6989ed50-4835-48ce-bb22-e4b1b0b270d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:to="loc_us-gaap_UnsecuredDebtMember_6989ed50-4835-48ce-bb22-e4b1b0b270d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_a42bbaf6-ecd8-497a-a24d-3d65e3e00f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_634afa2a-8a6f-4b21-b677-e09170d5f55d" xlink:to="loc_us-gaap_SecuredDebtMember_a42bbaf6-ecd8-497a-a24d-3d65e3e00f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c3b829ef-a3fa-4d68-8215-c4c05f9600f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c3b829ef-a3fa-4d68-8215-c4c05f9600f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c3b829ef-a3fa-4d68-8215-c4c05f9600f1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_738224ba-ec7c-4f0d-983f-b140a336911b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_738224ba-ec7c-4f0d-983f-b140a336911b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e2aa40bb-55a1-4a8e-a96a-aea394499a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_58cf5a39-b902-40a3-9c87-52e0b9e354ca" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e2aa40bb-55a1-4a8e-a96a-aea394499a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_002658c6-2397-4981-b53e-376b136a1cc0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_srt_RangeAxis_002658c6-2397-4981-b53e-376b136a1cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45fbc3d3-b990-4194-a2dd-27e6ad4d7cd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_002658c6-2397-4981-b53e-376b136a1cc0" xlink:to="loc_srt_RangeMember_45fbc3d3-b990-4194-a2dd-27e6ad4d7cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3898f57b-45ce-42f4-ab19-bbed7d68faf7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45fbc3d3-b990-4194-a2dd-27e6ad4d7cd0" xlink:to="loc_srt_MaximumMember_3898f57b-45ce-42f4-ab19-bbed7d68faf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bd6e9082-46b6-4ded-82ab-b32d0f6c0315" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_srt_OwnershipAxis_bd6e9082-46b6-4ded-82ab-b32d0f6c0315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e6afe18d-b6c9-4c76-bca8-4825bb797a0f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_bd6e9082-46b6-4ded-82ab-b32d0f6c0315" xlink:to="loc_srt_OwnershipDomain_e6afe18d-b6c9-4c76-bca8-4825bb797a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_214d2532-6083-4d71-8d54-02bc09ad25cd" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e6afe18d-b6c9-4c76-bca8-4825bb797a0f" xlink:to="loc_bhc_BauschLombMember_214d2532-6083-4d71-8d54-02bc09ad25cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_69c9f189-8a56-48e0-835d-00414d0cfe3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_dei_LegalEntityAxis_69c9f189-8a56-48e0-835d-00414d0cfe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66caacbd-2ab3-47a9-a8fe-312d2e17aa05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_69c9f189-8a56-48e0-835d-00414d0cfe3e" xlink:to="loc_dei_EntityDomain_66caacbd-2ab3-47a9-a8fe-312d2e17aa05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_5fd17f00-b23c-4e11-8e6d-839abaa443ce" xlink:href="bhc-20220930.xsd#bhc_A1375209BCLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66caacbd-2ab3-47a9-a8fe-312d2e17aa05" xlink:to="loc_bhc_A1375209BCLtdMember_5fd17f00-b23c-4e11-8e6d-839abaa443ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9c31bad8-9856-4303-8a8b-add04536c318" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faea80d1-8837-4c69-a8f5-d08a168f169f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_faea80d1-8837-4c69-a8f5-d08a168f169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6273a4c7-3827-4fc6-b423-ec3284d1ee32" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6273a4c7-3827-4fc6-b423-ec3284d1ee32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13e3fe64-8b69-4a65-888e-56dc7abd1b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13e3fe64-8b69-4a65-888e-56dc7abd1b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8ff00909-f34c-40b1-b013-fc82e167ff9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8ff00909-f34c-40b1-b013-fc82e167ff9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a22392b7-42bc-4273-b777-cd6ec242c3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a22392b7-42bc-4273-b777-cd6ec242c3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f2f4c0c-cb14-44f3-97ce-87a1b847b800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f2f4c0c-cb14-44f3-97ce-87a1b847b800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b8ca2efa-524d-4430-b31d-b0da9a3993a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_b8ca2efa-524d-4430-b31d-b0da9a3993a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e6346646-1596-48cf-b217-1d18ae505b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d39d9d50-c5b6-4acc-be78-5f905387a3f5" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_e6346646-1596-48cf-b217-1d18ae505b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f6777c61-463a-46f9-ad2f-d012921894e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f6777c61-463a-46f9-ad2f-d012921894e7" xlink:to="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a68abe8-b470-49f0-a7b6-188d8a0b04b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4276ed4d-3e9c-4b63-ac3d-c5d7446516ac" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a68abe8-b470-49f0-a7b6-188d8a0b04b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2660ad1e-f66f-478a-abfc-e5441c0c6cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a68abe8-b470-49f0-a7b6-188d8a0b04b8" xlink:to="loc_us-gaap_UnsecuredDebtMember_2660ad1e-f66f-478a-abfc-e5441c0c6cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e34cf8e2-b603-45ff-8174-6a8b7e9676f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:to="loc_us-gaap_DebtInstrumentAxis_e34cf8e2-b603-45ff-8174-6a8b7e9676f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e34cf8e2-b603-45ff-8174-6a8b7e9676f1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_932bee3b-2588-4d55-850d-b7c9e0388b27" xlink:href="bhc-20220930.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_932bee3b-2588-4d55-850d-b7c9e0388b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_d28020cc-b014-4980-bb36-c5d0c4402700" xlink:href="bhc-20220930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5f20540f-0c30-48c8-99a1-9ba01dcb0fed" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_d28020cc-b014-4980-bb36-c5d0c4402700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa20c986-0b69-4f7e-afb7-7c6538950a09" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_8df743b1-b97f-4926-aaf2-4b60b9597eaf" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_8df743b1-b97f-4926-aaf2-4b60b9597eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3756f9b5-538c-4552-8d04-411b98677bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3756f9b5-538c-4552-8d04-411b98677bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_620ef5e8-7ba9-4ec7-95cf-74488ede89e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_620ef5e8-7ba9-4ec7-95cf-74488ede89e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_c7355381-c0f2-428e-a054-9a06591e0cf5" xlink:href="bhc-20220930.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_c7355381-c0f2-428e-a054-9a06591e0cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_023aeed0-b486-4e29-bdec-b9c67ec4b80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9679d9d7-2759-4a8b-8ee9-863085e51922" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_023aeed0-b486-4e29-bdec-b9c67ec4b80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_30e83884-65b3-4e7b-bb0f-5615956fe86c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_93016882-2cf9-4bcc-90c1-2d32b4dbfbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_30e83884-65b3-4e7b-bb0f-5615956fe86c" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_93016882-2cf9-4bcc-90c1-2d32b4dbfbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4dd32e1b-c2eb-43db-9654-471dc109d4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_91572ace-1e83-4f5d-9218-f79b6cc0cf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4dd32e1b-c2eb-43db-9654-471dc109d4a7" xlink:to="loc_us-gaap_DebtInstrumentTable_91572ace-1e83-4f5d-9218-f79b6cc0cf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_91572ace-1e83-4f5d-9218-f79b6cc0cf34" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df06c227-602a-4d6f-9f12-62f6a2559de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ed1e48a8-a2cf-4dab-9af6-7b11a9d5eb65" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df06c227-602a-4d6f-9f12-62f6a2559de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_790dd032-adba-4a8b-924a-0c8fd42ea3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df06c227-602a-4d6f-9f12-62f6a2559de9" xlink:to="loc_us-gaap_UnsecuredDebtMember_790dd032-adba-4a8b-924a-0c8fd42ea3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_91572ace-1e83-4f5d-9218-f79b6cc0cf34" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a417611-9fb7-4358-b2df-c139e4d7b270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a417611-9fb7-4358-b2df-c139e4d7b270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3d334c6d-61fa-4b71-8a51-d00b4f9879d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_3d334c6d-61fa-4b71-8a51-d00b4f9879d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_029362bf-3166-4fca-90eb-90020ef78e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7a43d140-90c0-4340-a52a-1da3a1c819c2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_029362bf-3166-4fca-90eb-90020ef78e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2929c4e6-3828-4956-a76e-38f776b7db1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2929c4e6-3828-4956-a76e-38f776b7db1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0e744884-f283-4838-aefc-2b3dac85fa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0e744884-f283-4838-aefc-2b3dac85fa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15f35a0d-cfbc-4fc2-b0b8-e5a504d2eec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_15f35a0d-cfbc-4fc2-b0b8-e5a504d2eec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba10a05f-db6b-4ed0-903f-5126db925ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba10a05f-db6b-4ed0-903f-5126db925ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8598d43b-3a5d-4e05-b535-8b7cb958e179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8598d43b-3a5d-4e05-b535-8b7cb958e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b41cca54-b809-4e57-9f22-fe40b5fcb391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b41cca54-b809-4e57-9f22-fe40b5fcb391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e7a73967-b007-4640-8a4f-37434dae49a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e7a73967-b007-4640-8a4f-37434dae49a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0e91dd44-1e66-4452-9420-87c553a55ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0e91dd44-1e66-4452-9420-87c553a55ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1fbd3898-4dc2-4348-9fe9-ddaf57adad78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1fbd3898-4dc2-4348-9fe9-ddaf57adad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_eb0cbeda-8aa9-4897-a2db-9bfdd0c600a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10f2ab22-63ad-40ca-b15c-693a2fdef972" xlink:to="loc_us-gaap_LongTermDebt_eb0cbeda-8aa9-4897-a2db-9bfdd0c600a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6d8b3621-9257-4379-a7a7-a47466fbfbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6d8b3621-9257-4379-a7a7-a47466fbfbd5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f4dff6c1-0a77-4b90-81c3-3d537424b7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f4dff6c1-0a77-4b90-81c3-3d537424b7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f4dff6c1-0a77-4b90-81c3-3d537424b7fe" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_1d2242e3-4e46-41cc-be5d-fef5caf5fe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_1d2242e3-4e46-41cc-be5d-fef5caf5fe4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_21e302b7-7d0d-494c-b48b-33e4861aa0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_09715269-fb9b-4d97-8716-b52c5904dcb9" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_21e302b7-7d0d-494c-b48b-33e4861aa0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_7bc069e2-8f16-4947-a08d-fad3e64a0a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_7bc069e2-8f16-4947-a08d-fad3e64a0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_7bc069e2-8f16-4947-a08d-fad3e64a0a49" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_56827f01-436a-4d44-b35c-c0d127805db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:to="loc_us-gaap_DomesticPlanMember_56827f01-436a-4d44-b35c-c0d127805db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2e13c79e-494c-4aa8-8e5f-51c4e7da2a49" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_56827f01-436a-4d44-b35c-c0d127805db8" xlink:to="loc_country_US_2e13c79e-494c-4aa8-8e5f-51c4e7da2a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_c9cf9e51-7747-4b5d-943a-318f407b1ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_96ea1ee0-b464-4d7c-a502-f17c1f4e7ccd" xlink:to="loc_us-gaap_ForeignPlanMember_c9cf9e51-7747-4b5d-943a-318f407b1ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f365a54d-347b-45d7-9d68-6e0a3af55fca" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_ee4bc80a-2208-4b20-b36f-8352231f84f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_ee4bc80a-2208-4b20-b36f-8352231f84f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_eb15f7b6-aa89-4c7f-a01a-9f35c6de3d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_eb15f7b6-aa89-4c7f-a01a-9f35c6de3d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3ff274bd-6898-4fed-99d9-6b59db05c755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_3ff274bd-6898-4fed-99d9-6b59db05c755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5e8aab20-b929-4a0f-bde8-819a7c158f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5e8aab20-b929-4a0f-bde8-819a7c158f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_4e34d583-a344-4e98-8477-9aafee032be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_4e34d583-a344-4e98-8477-9aafee032be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f021631d-47c0-4895-be93-3bc103db8193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f71619ea-3f79-4bcd-987a-b1c38dc5b2b6" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_f021631d-47c0-4895-be93-3bc103db8193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b69aeda1-01ff-4ba2-8959-6d108cb698ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b69aeda1-01ff-4ba2-8959-6d108cb698ad" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3434ff01-d4ce-4809-856f-8911569ca7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_us-gaap_PlanNameAxis_3434ff01-d4ce-4809-856f-8911569ca7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3434ff01-d4ce-4809-856f-8911569ca7c1" xlink:to="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_2e831132-de29-4561-8eb2-c9803042823f" xlink:href="bhc-20220930.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_2e831132-de29-4561-8eb2-c9803042823f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_c16d161a-5ac4-44e9-b89b-f41a49fc367c" xlink:href="bhc-20220930.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member_2e831132-de29-4561-8eb2-c9803042823f" xlink:to="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_c16d161a-5ac4-44e9-b89b-f41a49fc367c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember_854ea228-021a-4d56-8845-1e9b0ca2d489" xlink:href="bhc-20220930.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:to="loc_bhc_IPOFoundersGrantsMember_854ea228-021a-4d56-8845-1e9b0ca2d489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_fecaf2cf-1e74-4d02-9337-69a1141306b2" xlink:href="bhc-20220930.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8630371c-2f63-4dfd-9506-6ac8ddfb1d60" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_fecaf2cf-1e74-4d02-9337-69a1141306b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_675fbab0-e501-4407-bf02-49b3d51da14a" xlink:href="bhc-20220930.xsd#bhc_A2022OmnibusIncentivePlanRetentionProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_A2022OmnibusIncentivePlanMember_fecaf2cf-1e74-4d02-9337-69a1141306b2" xlink:to="loc_bhc_A2022OmnibusIncentivePlanRetentionProgramMember_675fbab0-e501-4407-bf02-49b3d51da14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_srt_TitleOfIndividualAxis_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_f0345521-a7d3-4a9b-8e60-a1c7cb696fb0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:href="bhc-20220930.xsd#bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_eaeb405f-9f2e-44bf-85f4-7b9feb818618" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:to="loc_srt_ExecutiveOfficerMember_eaeb405f-9f2e-44bf-85f4-7b9feb818618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_69bcb910-19f0-4927-9bbe-28a0f00a3bb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember_ea11bd65-698f-400e-a9f2-8e159fd5b9b0" xlink:to="loc_srt_ChiefExecutiveOfficerMember_69bcb910-19f0-4927-9bbe-28a0f00a3bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember_49ddc57f-c331-441c-a291-b4c3b54a818a" xlink:href="bhc-20220930.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_NonExecutiveEligibleRecipientsMember_49ddc57f-c331-441c-a291-b4c3b54a818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_6b6269d0-4069-4d67-8a3f-77f004d3b6e5" xlink:href="bhc-20220930.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_6b6269d0-4069-4d67-8a3f-77f004d3b6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_86554bfb-6ed3-434f-8d1b-c1180dd250ef" xlink:href="bhc-20220930.xsd#bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ba603652-a599-4321-bda4-4d0150ec83fd" xlink:to="loc_bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember_86554bfb-6ed3-434f-8d1b-c1180dd250ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9667210a-983d-4ee2-bd3a-a617a5cbca0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_us-gaap_AwardTypeAxis_9667210a-983d-4ee2-bd3a-a617a5cbca0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbd2bbb4-fa4d-48df-afa3-5bd76a1f3bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9667210a-983d-4ee2-bd3a-a617a5cbca0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbd2bbb4-fa4d-48df-afa3-5bd76a1f3bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:href="bhc-20220930.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cbd2bbb4-fa4d-48df-afa3-5bd76a1f3bbf" xlink:to="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5228fc68-8e9f-45f9-9c74-bc07cdede4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5228fc68-8e9f-45f9-9c74-bc07cdede4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f046a628-365a-40b4-b1b1-aa40e446592a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_2096d0f7-cfc7-49c0-ad6c-002e26baccf8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f046a628-365a-40b4-b1b1-aa40e446592a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_229d0e08-b3b6-46cb-a80b-a9d1bff3364a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_dei_LegalEntityAxis_229d0e08-b3b6-46cb-a80b-a9d1bff3364a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f9f0f0c6-faa7-4dc3-a8c4-a38725bc3c6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_229d0e08-b3b6-46cb-a80b-a9d1bff3364a" xlink:to="loc_dei_EntityDomain_f9f0f0c6-faa7-4dc3-a8c4-a38725bc3c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_333fa265-c58c-437d-886b-de857246e585" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f9f0f0c6-faa7-4dc3-a8c4-a38725bc3c6d" xlink:to="loc_bhc_BauschLombMember_333fa265-c58c-437d-886b-de857246e585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_0af2d4ea-268d-4f31-af19-85143107d17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_us-gaap_VestingAxis_0af2d4ea-268d-4f31-af19-85143107d17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_0af2d4ea-268d-4f31-af19-85143107d17d" xlink:to="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_360577a5-b6c4-4b83-b019-887378bf0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_360577a5-b6c4-4b83-b019-887378bf0f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7e847e0-4090-4ecc-8f70-14573eff6143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e7e847e0-4090-4ecc-8f70-14573eff6143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e680f984-db6d-4dd9-95d7-13f426acfb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_59431317-eb16-4169-89a3-c8129ec61194" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_e680f984-db6d-4dd9-95d7-13f426acfb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4830df1e-6f03-47b7-88dc-0b0c26d62bd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cf831b-9eb5-4922-93f9-47cb5348a31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_77cf831b-9eb5-4922-93f9-47cb5348a31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e39d922-9e2a-403b-844c-0afc0e13b293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e39d922-9e2a-403b-844c-0afc0e13b293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdfd3586-3c62-481f-9399-7de0a891e6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fdfd3586-3c62-481f-9399-7de0a891e6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c8f2870-10e4-45f4-ae2c-e768473f3272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3c8f2870-10e4-45f4-ae2c-e768473f3272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_892a9450-c3aa-42b8-9621-4c408038f6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_892a9450-c3aa-42b8-9621-4c408038f6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6cf9b8f6-884e-49df-a093-2fc232328589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6cf9b8f6-884e-49df-a093-2fc232328589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_783ff1b3-65b3-4bcd-9ceb-5aa68525962c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_783ff1b3-65b3-4bcd-9ceb-5aa68525962c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_940ae232-e75c-4d06-b2be-6886f41cf015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_940ae232-e75c-4d06-b2be-6886f41cf015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_4c7d40dd-83f3-4263-9f25-7bc1e4dfc576" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_4c7d40dd-83f3-4263-9f25-7bc1e4dfc576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_49e3710a-6b48-4fa9-a374-dca8bf3bc143" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_49e3710a-6b48-4fa9-a374-dca8bf3bc143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_24729f95-6884-4f40-844f-12860d6cef2e" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod_24729f95-6884-4f40-844f-12860d6cef2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_4b4911f0-138f-4960-a090-542d2d2803c7" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod_4b4911f0-138f-4960-a090-542d2d2803c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_74d1472c-e2af-4444-8ecd-a474efb949d9" xlink:href="bhc-20220930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod_74d1472c-e2af-4444-8ecd-a474efb949d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_860c6f32-2dee-424c-a381-67df8063f76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_860c6f32-2dee-424c-a381-67df8063f76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68f09b5b-be57-44c8-a69e-38530cf5a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f270ba-b320-4e7a-8480-190ed1209302" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_68f09b5b-be57-44c8-a69e-38530cf5a4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3669eb6e-a8fb-437a-89b5-d8146aa234ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3669eb6e-a8fb-437a-89b5-d8146aa234ed" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_44402c39-9d35-46c1-adbb-8f6aee3b97cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:to="loc_us-gaap_AwardTypeAxis_44402c39-9d35-46c1-adbb-8f6aee3b97cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_44402c39-9d35-46c1-adbb-8f6aee3b97cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80adf5b7-1f3e-4d81-a027-4741d3edfffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80adf5b7-1f3e-4d81-a027-4741d3edfffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aad87936-27f6-41cf-96f7-e6d683b4b8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d6719b3c-49aa-49e2-8eeb-8f79d2f26548" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aad87936-27f6-41cf-96f7-e6d683b4b8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f31f5465-724e-43c6-ac1a-acb19774f6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f31f5465-724e-43c6-ac1a-acb19774f6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f31f5465-724e-43c6-ac1a-acb19774f6d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a1f62489-8f83-478d-8a7b-e758d88ebc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a1f62489-8f83-478d-8a7b-e758d88ebc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d4e9d45-5f48-4a21-abc3-9edeffb15e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a79bc41a-0559-4972-a238-aef65a84d081" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d4e9d45-5f48-4a21-abc3-9edeffb15e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8fb58ae6-0e58-4d54-a183-192223e14271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d62af8ee-47fc-4917-a69d-bdfeed49e2b9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8fb58ae6-0e58-4d54-a183-192223e14271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_188c169b-5d3a-49f8-aa61-d866e9c3f535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8fb58ae6-0e58-4d54-a183-192223e14271" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_188c169b-5d3a-49f8-aa61-d866e9c3f535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d226a839-abc3-408f-b067-d964f2017b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d226a839-abc3-408f-b067-d964f2017b68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ed38b6df-eade-4a78-a6d3-3ace220a977d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:to="loc_us-gaap_AwardTypeAxis_ed38b6df-eade-4a78-a6d3-3ace220a977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ed38b6df-eade-4a78-a6d3-3ace220a977d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_418ed384-c1ae-4d15-8a19-61c6edd9acad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_418ed384-c1ae-4d15-8a19-61c6edd9acad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_c8914a64-3173-4699-83c4-aec9b3165806" xlink:href="bhc-20220930.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_TimeBasedRSUMember_c8914a64-3173-4699-83c4-aec9b3165806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5410ba07-b9a3-4b7b-861f-0c8ee0368838" xlink:href="bhc-20220930.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5410ba07-b9a3-4b7b-861f-0c8ee0368838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_efd0986e-6820-4996-8433-9192a35d8178" xlink:href="bhc-20220930.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_efd0986e-6820-4996-8433-9192a35d8178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_010a7fe6-6f2d-498f-8354-7951c3b12117" xlink:href="bhc-20220930.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c83a12d-113b-4bc7-bfa9-543e642ce82c" xlink:to="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_010a7fe6-6f2d-498f-8354-7951c3b12117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:to="loc_dei_LegalEntityAxis_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_58be9335-7a8d-4cf0-a7d3-2a08fa92af5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1545d8e3-4d6a-4a15-86e9-e2502d1ffaca" xlink:to="loc_dei_EntityDomain_58be9335-7a8d-4cf0-a7d3-2a08fa92af5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3d2f1a2e-459a-4249-ac65-7f5e4dcf825c" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_58be9335-7a8d-4cf0-a7d3-2a08fa92af5f" xlink:to="loc_bhc_BauschLombMember_3d2f1a2e-459a-4249-ac65-7f5e4dcf825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4d00507-9cd1-4cc8-aef1-590340547acd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68e0a973-ec7b-4021-b626-7320f6c10ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_68e0a973-ec7b-4021-b626-7320f6c10ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_44c0568a-0ffd-4af0-aef3-1387869be404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_44c0568a-0ffd-4af0-aef3-1387869be404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_065acdb1-1028-4c5d-9148-09a5750b282a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_c22a2388-c247-421e-97f2-2e524e3ec3ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_065acdb1-1028-4c5d-9148-09a5750b282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_563445ce-4671-4833-a80f-070e91440274" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c18b239e-cece-4079-8095-671e4abb4c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c18b239e-cece-4079-8095-671e4abb4c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a14c71e3-10e1-4180-ba81-0a73ecb0add1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1aaaa387-b52a-40b4-bfd8-d51ae49b7624" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a14c71e3-10e1-4180-ba81-0a73ecb0add1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_074a8f84-a427-48c8-84c4-4717d017a26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25894525-d31e-4261-bdf4-ecf27adbf71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_074a8f84-a427-48c8-84c4-4717d017a26f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25894525-d31e-4261-bdf4-ecf27adbf71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c8ac6fbf-0fda-4494-82d9-4e6681444772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25894525-d31e-4261-bdf4-ecf27adbf71f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c8ac6fbf-0fda-4494-82d9-4e6681444772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c8ac6fbf-0fda-4494-82d9-4e6681444772" xlink:to="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_901b0eeb-c691-4a71-97e0-47fb13536adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_901b0eeb-c691-4a71-97e0-47fb13536adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_059ba6d3-fd33-4cb0-9658-53cb356056e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_059ba6d3-fd33-4cb0-9658-53cb356056e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_502a7bb9-76ab-4b80-8484-6c43dade88d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2f5630ce-d267-413d-9ab1-1bbda64c4e7f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_502a7bb9-76ab-4b80-8484-6c43dade88d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d867af88-0a43-4947-82aa-8505a0fdc3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_25894525-d31e-4261-bdf4-ecf27adbf71f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d867af88-0a43-4947-82aa-8505a0fdc3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52663b99-3b78-4e03-8d09-197715e93982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d867af88-0a43-4947-82aa-8505a0fdc3d7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52663b99-3b78-4e03-8d09-197715e93982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7037b210-070d-495d-a813-288777655e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192b4bc0-35fa-43b2-9593-0756d5008af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7037b210-070d-495d-a813-288777655e59" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192b4bc0-35fa-43b2-9593-0756d5008af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_be40e5bf-1ad5-413a-ba6a-5718bb7780d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192b4bc0-35fa-43b2-9593-0756d5008af1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_be40e5bf-1ad5-413a-ba6a-5718bb7780d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a7cf9485-5d80-43f1-b4bd-fa1521b2effd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_be40e5bf-1ad5-413a-ba6a-5718bb7780d2" xlink:to="loc_us-gaap_EquityComponentDomain_a7cf9485-5d80-43f1-b4bd-fa1521b2effd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b086720b-c800-4bc3-b29f-731a378cb6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a7cf9485-5d80-43f1-b4bd-fa1521b2effd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b086720b-c800-4bc3-b29f-731a378cb6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5c30a765-a0c2-4d2b-9d97-9d0a189730f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192b4bc0-35fa-43b2-9593-0756d5008af1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5c30a765-a0c2-4d2b-9d97-9d0a189730f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc000e5b-a07d-4dfc-9f64-0f3eccc808b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5c30a765-a0c2-4d2b-9d97-9d0a189730f6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bc000e5b-a07d-4dfc-9f64-0f3eccc808b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_f1bbaa30-0807-4ed4-ab47-2f849ae1ba73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_5d5b35a0-d37e-45e8-ad82-5b1859c7d816" xlink:href="bhc-20220930.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_f1bbaa30-0807-4ed4-ab47-2f849ae1ba73" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_5d5b35a0-d37e-45e8-ad82-5b1859c7d816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_6490598b-3749-4b7f-8559-53a2a0d36e21" xlink:href="bhc-20220930.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_f1bbaa30-0807-4ed4-ab47-2f849ae1ba73" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_6490598b-3749-4b7f-8559-53a2a0d36e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_86c2b05d-00b1-4083-b72e-8e9e8d0abaff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_f1bbaa30-0807-4ed4-ab47-2f849ae1ba73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_86c2b05d-00b1-4083-b72e-8e9e8d0abaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_99519d83-4f38-47be-a6f1-a32cc99f442a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_bc715e55-69f8-4829-9527-086b340f9afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_99519d83-4f38-47be-a6f1-a32cc99f442a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_bc715e55-69f8-4829-9527-086b340f9afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c20a8327-2d72-4c6e-9000-937aaf3ae005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_99519d83-4f38-47be-a6f1-a32cc99f442a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c20a8327-2d72-4c6e-9000-937aaf3ae005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_7017d623-2d5d-4263-ad4d-29c6583163a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_99519d83-4f38-47be-a6f1-a32cc99f442a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_7017d623-2d5d-4263-ad4d-29c6583163a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_950f0395-e55f-44be-b850-069ef54545eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_99519d83-4f38-47be-a6f1-a32cc99f442a" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_950f0395-e55f-44be-b850-069ef54545eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_1b0a9a17-6fd7-4e81-a4ca-4ea1b0a0a1ee" xlink:href="bhc-20220930.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_99519d83-4f38-47be-a6f1-a32cc99f442a" xlink:to="loc_bhc_OtherIncomeExpenseNet_1b0a9a17-6fd7-4e81-a4ca-4ea1b0a0a1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c7163210-2999-4e3f-b15c-293440442b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_99519d83-4f38-47be-a6f1-a32cc99f442a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c7163210-2999-4e3f-b15c-293440442b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#OTHEREXPENSEINCOMENETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_2383c7aa-0ca1-4b6d-a5a0-158527d53fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_2383c7aa-0ca1-4b6d-a5a0-158527d53fbc" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fd82e71a-7c8c-467f-b8ea-8991843632fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fd82e71a-7c8c-467f-b8ea-8991843632fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48d474b1-f3a5-428a-a003-4d288ded2d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fd82e71a-7c8c-467f-b8ea-8991843632fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48d474b1-f3a5-428a-a003-4d288ded2d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_5eacf379-bfc5-4928-95e1-18b458d37c34" xlink:href="bhc-20220930.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_48d474b1-f3a5-428a-a003-4d288ded2d61" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_5eacf379-bfc5-4928-95e1-18b458d37c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0874bf19-3ddc-4a88-8b76-1cafb76e50ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0874bf19-3ddc-4a88-8b76-1cafb76e50ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c4891ece-a22a-471e-ab83-2636b2edcc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0874bf19-3ddc-4a88-8b76-1cafb76e50ab" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c4891ece-a22a-471e-ab83-2636b2edcc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_debf10fe-07c2-4bd7-8f3b-3dddc98e2a3c" xlink:href="bhc-20220930.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c4891ece-a22a-471e-ab83-2636b2edcc50" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_debf10fe-07c2-4bd7-8f3b-3dddc98e2a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_0f018350-421a-414c-854d-654e8a40284d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_0f018350-421a-414c-854d-654e8a40284d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f7fedfb4-14fe-46b3-8741-69ca90f509f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_0f018350-421a-414c-854d-654e8a40284d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f7fedfb4-14fe-46b3-8741-69ca90f509f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b1d83acc-459d-4ee6-853f-d62d0e1b841e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f7fedfb4-14fe-46b3-8741-69ca90f509f0" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b1d83acc-459d-4ee6-853f-d62d0e1b841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:href="bhc-20220930.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_346c8406-d35e-4890-922b-79c7b19d46ec" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_9a4f6831-03ba-4205-a484-544b0d6f4d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_9a4f6831-03ba-4205-a484-544b0d6f4d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_deca8663-7a57-4345-a7a4-0df05a42d5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_921c8eb9-aaf1-4546-9f11-16438f5e233f" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_deca8663-7a57-4345-a7a4-0df05a42d5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_96d54a54-f58f-4014-bfb2-2723f6f30513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_96d54a54-f58f-4014-bfb2-2723f6f30513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5611f9b0-5d83-446b-b411-3d39b510c274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5611f9b0-5d83-446b-b411-3d39b510c274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_8641a4b2-8951-4d6d-bcbb-12e7a9a8522e" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_8641a4b2-8951-4d6d-bcbb-12e7a9a8522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_092821f0-ef27-4c9f-96bf-99c7687c28e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_092821f0-ef27-4c9f-96bf-99c7687c28e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_492117fe-a88b-4b3c-99af-b97fb8e98b27" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_492117fe-a88b-4b3c-99af-b97fb8e98b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_bf5d6eab-151a-471c-a7a5-2eab6c589d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_bf5d6eab-151a-471c-a7a5-2eab6c589d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_db0e2bac-836d-4374-a7cb-f8789edc649b" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_db0e2bac-836d-4374-a7cb-f8789edc649b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_0f703d61-b641-4c49-a342-5dbdf0c48b5f" xlink:href="bhc-20220930.xsd#bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_0f703d61-b641-4c49-a342-5dbdf0c48b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_84813668-54d2-4555-81d4-bbe4f05df7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_84813668-54d2-4555-81d4-bbe4f05df7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_07fda959-1797-4c2b-a9c2-036ec94425eb" xlink:href="bhc-20220930.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_07fda959-1797-4c2b-a9c2-036ec94425eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2b0291a1-fb14-4785-ba98-309836cd8679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2b0291a1-fb14-4785-ba98-309836cd8679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_6658437e-a335-4680-b67e-c7eac47a18a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_6658437e-a335-4680-b67e-c7eac47a18a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2aa10575-8a1c-42ab-827e-b21c742c0655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_2aa10575-8a1c-42ab-827e-b21c742c0655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_c833120a-d97e-4644-a258-ee5abe8f41c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb64d7c3-aa5d-494d-a534-ca8843eb2ebc" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_c833120a-d97e-4644-a258-ee5abe8f41c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f694c798-e2e4-450a-8237-c41e69ce6922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15f9bae9-c7bb-4b63-88ff-c2219fbaa7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f694c798-e2e4-450a-8237-c41e69ce6922" xlink:to="loc_us-gaap_NetIncomeLoss_15f9bae9-c7bb-4b63-88ff-c2219fbaa7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa00ab92-319b-469a-a8ba-99019d4d69b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f694c798-e2e4-450a-8237-c41e69ce6922" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa00ab92-319b-469a-a8ba-99019d4d69b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aff1d6cf-fa6d-444e-b769-7c7a14fbc035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f694c798-e2e4-450a-8237-c41e69ce6922" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_aff1d6cf-fa6d-444e-b769-7c7a14fbc035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43cdab8b-ffd2-4350-9406-26aa896fe751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f694c798-e2e4-450a-8237-c41e69ce6922" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43cdab8b-ffd2-4350-9406-26aa896fe751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4468dbad-9722-46c1-bd36-23cd6fe44029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f694c798-e2e4-450a-8237-c41e69ce6922" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4468dbad-9722-46c1-bd36-23cd6fe44029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a3c2f443-3593-4bed-81ba-2a8f1da7de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4468dbad-9722-46c1-bd36-23cd6fe44029" xlink:to="loc_us-gaap_EarningsPerShareBasic_a3c2f443-3593-4bed-81ba-2a8f1da7de7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_aa7eacec-2e50-4823-bee6-4b7aac051db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4468dbad-9722-46c1-bd36-23cd6fe44029" xlink:to="loc_us-gaap_EarningsPerShareDiluted_aa7eacec-2e50-4823-bee6-4b7aac051db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#EARNINGSLOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6b2d20fe-284a-4263-bcb6-653d810cdc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_43d38b80-6522-4ee7-91b9-1ad89bfca940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6b2d20fe-284a-4263-bcb6-653d810cdc93" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_43d38b80-6522-4ee7-91b9-1ad89bfca940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15e3f0a1-c0d1-4947-97c8-737c686e07e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_43d38b80-6522-4ee7-91b9-1ad89bfca940" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15e3f0a1-c0d1-4947-97c8-737c686e07e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15e3f0a1-c0d1-4947-97c8-737c686e07e1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_bdd9d5f8-e600-47ef-be36-b4642ef1dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:to="loc_us-gaap_StockCompensationPlanMember_bdd9d5f8-e600-47ef-be36-b4642ef1dd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_2b216048-234b-4f88-9a8e-a65d900d56ee" xlink:href="bhc-20220930.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_2b216048-234b-4f88-9a8e-a65d900d56ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_dfaebdfa-b48c-411c-9ef8-acd8038404e2" xlink:href="bhc-20220930.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_890422a5-1e09-4f85-8337-53db0c1cda53" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_dfaebdfa-b48c-411c-9ef8-acd8038404e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_43d38b80-6522-4ee7-91b9-1ad89bfca940" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5186d28-f7cf-41a0-96c1-a837adc813a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c5186d28-f7cf-41a0-96c1-a837adc813a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_b3e0a438-5e86-4df2-a326-097565d453f5" xlink:href="bhc-20220930.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3c21ef-3253-4f6f-818d-ab70b6e488cf" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_b3e0a438-5e86-4df2-a326-097565d453f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8995748f-614e-415c-819a-9ec4d5e93e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_976778fe-df08-4246-9deb-cc003975e309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8995748f-614e-415c-819a-9ec4d5e93e81" xlink:to="loc_us-gaap_LitigationReserveCurrent_976778fe-df08-4246-9deb-cc003975e309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7bbe7f89-1196-44ee-8d06-c1fee59bcfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7bbe7f89-1196-44ee-8d06-c1fee59bcfb1" xlink:to="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5cc20951-c91a-4b30-870a-2f0f4da9bced" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_srt_LitigationCaseAxis_5cc20951-c91a-4b30-870a-2f0f4da9bced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_5cc20951-c91a-4b30-870a-2f0f4da9bced" xlink:to="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_de20d3dc-e720-4f2d-ae16-81792188b97c" xlink:href="bhc-20220930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_de20d3dc-e720-4f2d-ae16-81792188b97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_90067e69-f59a-44f3-9ea7-a7e7b5c08639" xlink:href="bhc-20220930.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_90067e69-f59a-44f3-9ea7-a7e7b5c08639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_6248978e-7618-425f-b218-cca4d3c32788" xlink:href="bhc-20220930.xsd#bhc_RICOClassActionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_RICOClassActionsMember_6248978e-7618-425f-b218-cca4d3c32788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_fc99278f-21f0-4954-bdc9-1f834af0b4e0" xlink:href="bhc-20220930.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_440d5f38-f070-46a6-9a68-818c1ff204dc" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_fc99278f-21f0-4954-bdc9-1f834af0b4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_acb65f7c-b40b-40e2-814e-0c238feb96c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_us-gaap_LitigationStatusAxis_acb65f7c-b40b-40e2-814e-0c238feb96c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_50a94d80-6d9f-4c4a-a1c7-14b3494b6d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_acb65f7c-b40b-40e2-814e-0c238feb96c3" xlink:to="loc_us-gaap_LitigationStatusDomain_50a94d80-6d9f-4c4a-a1c7-14b3494b6d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5c41e014-79fb-4ccb-a144-d994e83f315c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_50a94d80-6d9f-4c4a-a1c7-14b3494b6d15" xlink:to="loc_us-gaap_SettledLitigationMember_5c41e014-79fb-4ccb-a144-d994e83f315c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9491703b-35b3-4ba4-8c2c-db6d0554a2e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_srt_StatementGeographicalAxis_9491703b-35b3-4ba4-8c2c-db6d0554a2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9491703b-35b3-4ba4-8c2c-db6d0554a2e7" xlink:to="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_1027eeb2-ab31-474c-8e59-90fc79533ef0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:to="loc_stpr_NJ_1027eeb2-ab31-474c-8e59-90fc79533ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_7375c8aa-a7af-4085-9f47-6434066f87b4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4c1ab68f-051f-45ef-94c9-5995464c6669" xlink:to="loc_country_CA_7375c8aa-a7af-4085-9f47-6434066f87b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4e408215-f53b-4740-957e-725f8dcdb2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4e408215-f53b-4740-957e-725f8dcdb2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_4e408215-f53b-4740-957e-725f8dcdb2d5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_d6a1074c-602a-4447-b6a7-5562ced594a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_d6a1074c-602a-4447-b6a7-5562ced594a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_089b49aa-ac0f-41cd-902f-b5596a5b0eaf" xlink:href="bhc-20220930.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_9b6193a5-700a-4d95-ab21-191192ab8568" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_089b49aa-ac0f-41cd-902f-b5596a5b0eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bcdee3ff-4a2c-43e0-9afd-85e13d8d0a91" xlink:to="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b3210501-431b-4fe2-b302-e21e99ee3ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b3210501-431b-4fe2-b302-e21e99ee3ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_74383054-b875-4577-ad03-6605eb3ed817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_74383054-b875-4577-ad03-6605eb3ed817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_9d4f6339-4fd6-4ccd-a5c7-2b14b79e4d92" xlink:href="bhc-20220930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_9d4f6339-4fd6-4ccd-a5c7-2b14b79e4d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_782c4342-94fd-4765-805b-b5b2941a8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_782c4342-94fd-4765-805b-b5b2941a8b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_992a8cc1-6657-4987-bc42-3573e4395fff" xlink:href="bhc-20220930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_992a8cc1-6657-4987-bc42-3573e4395fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_8f25ab3d-e512-484c-ac54-bba1dce28f9a" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_8f25ab3d-e512-484c-ac54-bba1dce28f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_1b0631af-7d9c-4919-9c88-3415d11c45ec" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_1b0631af-7d9c-4919-9c88-3415d11c45ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_a97654db-ead9-432e-8c28-c8507728cf27" xlink:href="bhc-20220930.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_a97654db-ead9-432e-8c28-c8507728cf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_50514555-8f9d-49b9-b882-e9d661923f88" xlink:href="bhc-20220930.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_50514555-8f9d-49b9-b882-e9d661923f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_54f14f9b-a74a-4346-9585-ec91e43313e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1a5aaf8-cff2-4196-a0df-45761b759633" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_54f14f9b-a74a-4346-9585-ec91e43313e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_902d985b-1309-4832-b67e-1899b203c62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_902d985b-1309-4832-b67e-1899b203c62e" xlink:to="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_25c4a852-f27d-4839-a870-a713561da969" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:to="loc_srt_LitigationCaseAxis_25c4a852-f27d-4839-a870-a713561da969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_25c4a852-f27d-4839-a870-a713561da969" xlink:to="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_0a355667-1851-4ec4-93dd-0b4c6bfb9e1b" xlink:href="bhc-20220930.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_0a355667-1851-4ec4-93dd-0b4c6bfb9e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_2ca06102-2ee8-42af-b467-7e9893ec217b" xlink:href="bhc-20220930.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a626e01f-1ba1-47ff-9eea-75887f3373ad" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_2ca06102-2ee8-42af-b467-7e9893ec217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_38d99c62-9bad-40f5-9b32-e880b601bf55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:to="loc_srt_CounterpartyNameAxis_38d99c62-9bad-40f5-9b32-e880b601bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746e62e8-5691-4c23-85cb-54af454c2425" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_38d99c62-9bad-40f5-9b32-e880b601bf55" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746e62e8-5691-4c23-85cb-54af454c2425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_bdd105b1-5179-497a-b1a2-70288eee009a" xlink:href="bhc-20220930.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_746e62e8-5691-4c23-85cb-54af454c2425" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_bdd105b1-5179-497a-b1a2-70288eee009a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a049209c-d34e-43fb-81f5-d97e429a3f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:to="loc_us-gaap_LitigationStatusAxis_a049209c-d34e-43fb-81f5-d97e429a3f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_27c9279d-6546-4cbf-a811-2aa46b946e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_a049209c-d34e-43fb-81f5-d97e429a3f3f" xlink:to="loc_us-gaap_LitigationStatusDomain_27c9279d-6546-4cbf-a811-2aa46b946e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_4c1c3087-4cbb-4946-a845-685e0288275b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_27c9279d-6546-4cbf-a811-2aa46b946e7e" xlink:to="loc_us-gaap_PendingLitigationMember_4c1c3087-4cbb-4946-a845-685e0288275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d1c85d0b-e2bf-47b5-9a2e-98767ed7baf6" xlink:to="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f6498ffa-63a7-4008-a76d-8c2cbf511ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_f6498ffa-63a7-4008-a76d-8c2cbf511ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_132d109d-a6df-4c16-9c64-ac85d79a4121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c91ba71e-9eb9-4c86-9cf9-b03a48f1f96a" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_132d109d-a6df-4c16-9c64-ac85d79a4121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f51382f7-83be-4b88-bb4d-efbc6b321dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f51382f7-83be-4b88-bb4d-efbc6b321dfd" xlink:to="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_daf88d5a-4519-44ae-aa48-18ec514ca659" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_srt_LitigationCaseAxis_daf88d5a-4519-44ae-aa48-18ec514ca659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_daf88d5a-4519-44ae-aa48-18ec514ca659" xlink:to="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_504ec8da-69ea-4093-81eb-0a3fc8dc62dd" xlink:href="bhc-20220930.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_504ec8da-69ea-4093-81eb-0a3fc8dc62dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_1ea92f5f-082e-414b-9665-ceafe3bfd12c" xlink:href="bhc-20220930.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_1ea92f5f-082e-414b-9665-ceafe3bfd12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_72197a1d-3897-439f-9691-dd726a123d9f" xlink:href="bhc-20220930.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_72197a1d-3897-439f-9691-dd726a123d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_a285dcfa-cb06-4e26-85d6-498fb7a534ad" xlink:href="bhc-20220930.xsd#bhc_PadagisLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PadagisLitigationMember_a285dcfa-cb06-4e26-85d6-498fb7a534ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_c8a88b5c-6f43-496b-9577-2a6a8175e782" xlink:href="bhc-20220930.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_c8a88b5c-6f43-496b-9577-2a6a8175e782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_68eb091b-65e1-4bc2-80b2-448372b3ea61" xlink:href="bhc-20220930.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_68eb091b-65e1-4bc2-80b2-448372b3ea61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_b2bd2d60-1c45-423c-a412-72fd475f0a96" xlink:href="bhc-20220930.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_b2bd2d60-1c45-423c-a412-72fd475f0a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_7e425e31-f7e1-451a-b576-374a5a12f044" xlink:href="bhc-20220930.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_7e425e31-f7e1-451a-b576-374a5a12f044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember_377be25b-0eef-4be0-9645-576970f091cb" xlink:href="bhc-20220930.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_PatentInfringementLitigationMember_377be25b-0eef-4be0-9645-576970f091cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_90f13c2a-9dd8-4e0d-b258-9716e9ded47e" xlink:href="bhc-20220930.xsd#bhc_ApotexIncLitigationMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6a4e513a-aa7c-4997-bc8c-3a2bf137d895" xlink:to="loc_bhc_ApotexIncLitigationMember_90f13c2a-9dd8-4e0d-b258-9716e9ded47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e72f29b1-ae24-42d9-a800-95bd5468284f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_srt_StatementGeographicalAxis_e72f29b1-ae24-42d9-a800-95bd5468284f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_868ed576-a9d0-47ef-9274-6d93d1f56e1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e72f29b1-ae24-42d9-a800-95bd5468284f" xlink:to="loc_srt_SegmentGeographicalDomain_868ed576-a9d0-47ef-9274-6d93d1f56e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8dfdd5e3-e455-42a2-a5c7-4e4eb81ed3e7" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_868ed576-a9d0-47ef-9274-6d93d1f56e1c" xlink:to="loc_country_CA_8dfdd5e3-e455-42a2-a5c7-4e4eb81ed3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_059fe05b-3958-4bd1-aaad-a864a95254be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_us-gaap_LitigationStatusAxis_059fe05b-3958-4bd1-aaad-a864a95254be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_059fe05b-3958-4bd1-aaad-a864a95254be" xlink:to="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_f1994913-726b-4de4-957c-9e7d64018d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:to="loc_us-gaap_PendingLitigationMember_f1994913-726b-4de4-957c-9e7d64018d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_929dd660-1d63-4358-bee3-a29795bf2107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:to="loc_us-gaap_SettledLitigationMember_929dd660-1d63-4358-bee3-a29795bf2107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_acf126ca-ab96-4991-95af-1b600d9c8464" xlink:href="bhc-20220930.xsd#bhc_DefaultJudgementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_bd0f75a6-8b1a-4706-b84c-4a37acc25a1c" xlink:to="loc_bhc_DefaultJudgementMember_acf126ca-ab96-4991-95af-1b600d9c8464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ae0f5e11-b405-4b74-9df6-7af37eb77a9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_dei_LegalEntityAxis_ae0f5e11-b405-4b74-9df6-7af37eb77a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1e317357-11dc-451a-a768-ed3607494b0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ae0f5e11-b405-4b74-9df6-7af37eb77a9d" xlink:to="loc_dei_EntityDomain_1e317357-11dc-451a-a768-ed3607494b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_bd28c8cf-f53c-4b71-86e2-2d456126bb3c" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1e317357-11dc-451a-a768-ed3607494b0e" xlink:to="loc_bhc_BauschLombMember_bd28c8cf-f53c-4b71-86e2-2d456126bb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_180d5ad0-dfb4-464d-a787-c5a78bf69931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_180d5ad0-dfb4-464d-a787-c5a78bf69931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4fb7cb31-18f4-48cc-86fe-ab7db2eb3abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_180d5ad0-dfb4-464d-a787-c5a78bf69931" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4fb7cb31-18f4-48cc-86fe-ab7db2eb3abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_59ebb296-95bc-45c7-85fb-d49396781bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4fb7cb31-18f4-48cc-86fe-ab7db2eb3abb" xlink:to="loc_us-gaap_SubsequentEventMember_59ebb296-95bc-45c7-85fb-d49396781bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ca0437d5-8504-44d3-a113-798e05ec8b71" xlink:to="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_0af6b4dc-89d5-40fc-a3a0-7314bbc8cafc" xlink:href="bhc-20220930.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_0af6b4dc-89d5-40fc-a3a0-7314bbc8cafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_e87dfc58-7a0a-4f60-ad4f-267c2d3bb6ed" xlink:href="bhc-20220930.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_e87dfc58-7a0a-4f60-ad4f-267c2d3bb6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings_6fa743c4-6ac6-4863-84ee-d737ac500af9" xlink:href="bhc-20220930.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_bhc_GainContingencyNumberOfProceedings_6fa743c4-6ac6-4863-84ee-d737ac500af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_323ddfc0-1b69-4937-8634-ada54a6f6145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ca54d9ef-68f4-46a3-8243-ca73060f7be5" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_323ddfc0-1b69-4937-8634-ada54a6f6145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aeec0732-1614-436c-9765-29110324f5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aeec0732-1614-436c-9765-29110324f5f9" xlink:to="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:to="loc_srt_LitigationCaseAxis_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9ca96cd0-a1d0-4199-a56a-fc1d2495bf10" xlink:to="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_a776109e-3d3c-4a78-806b-efe5df97c6e2" xlink:href="bhc-20220930.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_a776109e-3d3c-4a78-806b-efe5df97c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_096f296a-6323-47cb-aa40-5a8ff5b67c7b" xlink:href="bhc-20220930.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_a776109e-3d3c-4a78-806b-efe5df97c6e2" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_096f296a-6323-47cb-aa40-5a8ff5b67c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_b56db4ea-8346-4952-9929-782cc3487243" xlink:href="bhc-20220930.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_86e7b9ed-a27a-4bb1-a4f3-c8600c9e120f" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_b56db4ea-8346-4952-9929-782cc3487243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f6250362-63d1-4d0f-9789-315da363e8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:to="loc_us-gaap_LitigationStatusAxis_f6250362-63d1-4d0f-9789-315da363e8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_27097455-e01b-483e-b3c6-b52dbd630a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_f6250362-63d1-4d0f-9789-315da363e8d1" xlink:to="loc_us-gaap_LitigationStatusDomain_27097455-e01b-483e-b3c6-b52dbd630a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_30a583f3-ef15-4847-b979-c8be83aabdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_27097455-e01b-483e-b3c6-b52dbd630a95" xlink:to="loc_us-gaap_PendingLitigationMember_30a583f3-ef15-4847-b979-c8be83aabdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_119d4fef-2ded-49c8-a76c-02ef7a0c5824" xlink:href="bhc-20220930.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PendingLitigationMember_30a583f3-ef15-4847-b979-c8be83aabdb2" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_119d4fef-2ded-49c8-a76c-02ef7a0c5824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4e40ecd8-aa17-43c9-b46b-09c160a9be25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:to="loc_srt_StatementGeographicalAxis_4e40ecd8-aa17-43c9-b46b-09c160a9be25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4e40ecd8-aa17-43c9-b46b-09c160a9be25" xlink:to="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e3960d3c-9b1b-48ad-a8f8-3e8351e8788a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:to="loc_country_CA_e3960d3c-9b1b-48ad-a8f8-3e8351e8788a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_e7443751-621f-4f66-934d-e809e3aa9395" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:to="loc_stpr_CA-BC_e7443751-621f-4f66-934d-e809e3aa9395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_fc8981b3-fcf9-486e-8611-34c62f119268" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5b11ce32-750d-4498-84a1-b3db2a3ac819" xlink:to="loc_stpr_CA-QC_fc8981b3-fcf9-486e-8611-34c62f119268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_bc485818-2d5d-4707-a51a-45b37339f104" xlink:to="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b3dde066-50ac-48a2-87e8-4d512d191ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b3dde066-50ac-48a2-87e8-4d512d191ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_c1632b2b-c9cf-48b3-b9f2-a0001666bed7" xlink:href="bhc-20220930.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_c1632b2b-c9cf-48b3-b9f2-a0001666bed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_b21bd05b-d77d-4dc7-afdd-3e5e7acf6277" xlink:href="bhc-20220930.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7864ff6b-21d4-4e18-85d0-42a4428efa3a" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_b21bd05b-d77d-4dc7-afdd-3e5e7acf6277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_075930d7-82a6-46b0-8668-334d7fb2905c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_88c5145e-8cfe-46a8-8b13-1f85a6888095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_075930d7-82a6-46b0-8668-334d7fb2905c" xlink:to="loc_us-gaap_LossContingenciesTable_88c5145e-8cfe-46a8-8b13-1f85a6888095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b329c0e4-b24d-4105-96fe-de5486391479" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_88c5145e-8cfe-46a8-8b13-1f85a6888095" xlink:to="loc_srt_LitigationCaseAxis_b329c0e4-b24d-4105-96fe-de5486391479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b329c0e4-b24d-4105-96fe-de5486391479" xlink:to="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_ad6f523a-f0e0-43a9-98f6-e45f196afe89" xlink:href="bhc-20220930.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_ad6f523a-f0e0-43a9-98f6-e45f196afe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_e7217311-5fc1-4b64-b3ef-f5e7ddf0be1b" xlink:href="bhc-20220930.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_aed1ebc9-67ef-4d0c-a6f5-721535efa4f6" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_e7217311-5fc1-4b64-b3ef-f5e7ddf0be1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d909ba83-6646-4a55-a476-49cf054cb27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_88c5145e-8cfe-46a8-8b13-1f85a6888095" xlink:to="loc_us-gaap_LossContingenciesLineItems_d909ba83-6646-4a55-a476-49cf054cb27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_c6ba9c59-6123-4f1e-bea1-372067da491b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d909ba83-6646-4a55-a476-49cf054cb27e" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_c6ba9c59-6123-4f1e-bea1-372067da491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e1880074-c3f0-47f6-91fa-9c95e445110a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e1880074-c3f0-47f6-91fa-9c95e445110a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_aa8e8a87-e095-4e4d-8d07-aa2be6d66f96" xlink:to="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_1e0c0fc9-4ff3-408c-bf35-f820ef13ef36" xlink:href="bhc-20220930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_1e0c0fc9-4ff3-408c-bf35-f820ef13ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_c9863faa-3eef-4151-8715-7de5a15e9b8b" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_caf8840a-2ea5-44aa-b852-36fced25e31f" xlink:to="loc_bhc_SalixSegmentMember_c9863faa-3eef-4151-8715-7de5a15e9b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df983ec2-e1ff-4459-aa8b-c5061971afbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_srt_ProductOrServiceAxis_df983ec2-e1ff-4459-aa8b-c5061971afbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d9c64158-8da2-4d7a-9942-b16581cd82bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_df983ec2-e1ff-4459-aa8b-c5061971afbb" xlink:to="loc_srt_ProductsAndServicesDomain_d9c64158-8da2-4d7a-9942-b16581cd82bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_dbfcd7b8-2b53-4757-a1e4-77b607c0111f" xlink:href="bhc-20220930.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9c64158-8da2-4d7a-9942-b16581cd82bd" xlink:to="loc_bhc_XifaxanBrandedProductsMember_dbfcd7b8-2b53-4757-a1e4-77b607c0111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a483a246-994d-45ee-946d-0ca85ee86acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a483a246-994d-45ee-946d-0ca85ee86acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93201bad-b8df-4211-be71-142d9012d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a483a246-994d-45ee-946d-0ca85ee86acb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93201bad-b8df-4211-be71-142d9012d4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_85d1488c-f9c8-43c8-b943-8aca240a66b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_93201bad-b8df-4211-be71-142d9012d4b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_85d1488c-f9c8-43c8-b943-8aca240a66b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9524787b-5c75-4dc3-911f-138b690a79ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9524787b-5c75-4dc3-911f-138b690a79ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_155ab678-9d35-416f-ae1b-c1b44d178431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9524787b-5c75-4dc3-911f-138b690a79ba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_155ab678-9d35-416f-ae1b-c1b44d178431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_d11abd77-80e1-4d77-abf4-fbfaec336409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_155ab678-9d35-416f-ae1b-c1b44d178431" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_d11abd77-80e1-4d77-abf4-fbfaec336409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d0092a76-1cde-4a2c-8692-afc09968e2ab" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_e2b026b3-c12e-4470-a89f-2a86be7c8f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:to="loc_us-gaap_NumberOfReportingUnits_e2b026b3-c12e-4470-a89f-2a86be7c8f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_598f21f2-2abe-48ed-9e46-b344132d0b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c2f81ad2-d89c-419c-a7de-61801d26b350" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_598f21f2-2abe-48ed-9e46-b344132d0b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3049b318-e12c-4de9-9720-dd66b2969b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3049b318-e12c-4de9-9720-dd66b2969b74" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_bbbac6c1-8de8-4fa8-bb7e-2036b245b071" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:to="loc_srt_ConsolidationItemsAxis_bbbac6c1-8de8-4fa8-bb7e-2036b245b071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_bbbac6c1-8de8-4fa8-bb7e-2036b245b071" xlink:to="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_3159f94c-626c-4c86-ad00-8d3b7c980d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:to="loc_us-gaap_OperatingSegmentsMember_3159f94c-626c-4c86-ad00-8d3b7c980d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_182ed762-c6ce-4809-9a5d-18ba13832b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_fe12e144-ffee-4a3b-ba90-2e350eb91078" xlink:to="loc_us-gaap_CorporateNonSegmentMember_182ed762-c6ce-4809-9a5d-18ba13832b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3d61d34c-397a-4e10-ba87-c2e372c7ed94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3d61d34c-397a-4e10-ba87-c2e372c7ed94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3d61d34c-397a-4e10-ba87-c2e372c7ed94" xlink:to="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_bf6d47cd-94a1-4574-9726-9d6ed1ffbd2c" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_SalixSegmentMember_bf6d47cd-94a1-4574-9726-9d6ed1ffbd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_6d4f02b2-1b5a-435d-9ae4-cb876a74ed1d" xlink:href="bhc-20220930.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_InternationalRxMember_6d4f02b2-1b5a-435d-9ae4-cb876a74ed1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_33631fda-271e-4b41-b3c3-789712008e36" xlink:href="bhc-20220930.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_SoltaMedicalSegmentMember_33631fda-271e-4b41-b3c3-789712008e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_7dc8ce20-b080-40d0-bcf9-f6ce12508c8a" xlink:href="bhc-20220930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_7dc8ce20-b080-40d0-bcf9-f6ce12508c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_5c390a9c-5adc-4940-b654-b929a55cb31a" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_24aedd5b-2ce7-460e-afcd-1f2f3a287313" xlink:to="loc_bhc_BauschLombMember_5c390a9c-5adc-4940-b654-b929a55cb31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_31095e93-2ae7-4e2e-a3a0-514fa5e89cd3" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fde1efce-e0fa-4876-9a50-d74c5694de69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fde1efce-e0fa-4876-9a50-d74c5694de69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_532fe166-27f0-4638-8972-ca7c3357b2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_OperatingIncomeLoss_532fe166-27f0-4638-8972-ca7c3357b2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_970dcfa6-a794-4d02-88e3-db0d37dd2e76" xlink:href="bhc-20220930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_970dcfa6-a794-4d02-88e3-db0d37dd2e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0ff9aede-873e-460b-87f0-c1c932a1fde1" xlink:href="bhc-20220930.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0ff9aede-873e-460b-87f0-c1c932a1fde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c26f0066-0c4f-4dc7-ace0-895eb13b73f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_AssetImpairmentCharges_c26f0066-0c4f-4dc7-ace0-895eb13b73f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_48dea98b-e058-41e6-9aa3-56b03dfdfe25" xlink:href="bhc-20220930.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_48dea98b-e058-41e6-9aa3-56b03dfdfe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8387009f-591a-4920-b2bc-eaf8fb034337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8387009f-591a-4920-b2bc-eaf8fb034337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_969ce13b-56ca-49ea-8c75-2ed61ad07cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_969ce13b-56ca-49ea-8c75-2ed61ad07cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3ccc7371-4a80-4cea-a3ad-f366b6ccbf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_InterestExpenseDebt_3ccc7371-4a80-4cea-a3ad-f366b6ccbf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_94658ede-58a7-46bf-b833-8658bfe2e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_94658ede-58a7-46bf-b833-8658bfe2e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e83550f0-0b8a-4d0c-a7e8-81e3ef6de6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e83550f0-0b8a-4d0c-a7e8-81e3ef6de6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5e3d82f-28e7-4dd3-b49a-a265b2e4bb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_204eab5e-68e8-42b0-aa3c-4fc368fcae6f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f5e3d82f-28e7-4dd3-b49a-a265b2e4bb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_92cdfa18-665a-445b-be72-efde613369cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_92cdfa18-665a-445b-be72-efde613369cd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_46cffc93-ddde-4304-b2b9-a9806c33509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_46cffc93-ddde-4304-b2b9-a9806c33509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_46cffc93-ddde-4304-b2b9-a9806c33509a" xlink:to="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_2ba0b15d-35df-4f8e-a9c5-40c01f6e122b" xlink:href="bhc-20220930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_SalixSegmentMember_2ba0b15d-35df-4f8e-a9c5-40c01f6e122b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_c3147002-ecf7-48d6-910e-d8bb428d858f" xlink:href="bhc-20220930.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_InternationalRxMember_c3147002-ecf7-48d6-910e-d8bb428d858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_99099ae2-1583-4aaf-a276-90b6d74326a7" xlink:href="bhc-20220930.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_SoltaMedicalSegmentMember_99099ae2-1583-4aaf-a276-90b6d74326a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_9a2ca8fb-1580-450a-80ff-679a35179d95" xlink:href="bhc-20220930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_9a2ca8fb-1580-450a-80ff-679a35179d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_47d10411-90ff-4d28-b47e-33bc4ca8ad23" xlink:href="bhc-20220930.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4c291e29-9352-4b0d-acc8-aea07f0c0c16" xlink:to="loc_bhc_BauschLombMember_47d10411-90ff-4d28-b47e-33bc4ca8ad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_238c6557-eb14-4cf4-8ffb-6beeee281770" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:to="loc_srt_ProductOrServiceAxis_238c6557-eb14-4cf4-8ffb-6beeee281770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_238c6557-eb14-4cf4-8ffb-6beeee281770" xlink:to="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_3474c4a2-498a-4f59-897a-d99f17b4d79a" xlink:href="bhc-20220930.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_PharmaceuticalProductsMember_3474c4a2-498a-4f59-897a-d99f17b4d79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_83a7b00c-1db0-4792-84de-ebfd1b652f6c" xlink:href="bhc-20220930.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_DeviceProductsMember_83a7b00c-1db0-4792-84de-ebfd1b652f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_22bb0647-061d-4f06-9d72-ef0c35b416bd" xlink:href="bhc-20220930.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_OvertheCounterProductsMember_22bb0647-061d-4f06-9d72-ef0c35b416bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_c0b20668-7134-4a1e-b97a-679d019817ff" xlink:href="bhc-20220930.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_c0b20668-7134-4a1e-b97a-679d019817ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_ef41631c-d894-413b-82cd-4b4633e398f3" xlink:href="bhc-20220930.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4add25a7-fdbc-4deb-ab8c-1970e7f7b8a0" xlink:to="loc_bhc_OtherRevenuesMember_ef41631c-d894-413b-82cd-4b4633e398f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b0a12c3a-ef04-4e30-b9f3-7906aec922ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5f7d70fb-094a-4947-8a80-eadbf9afbbcf" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b0a12c3a-ef04-4e30-b9f3-7906aec922ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2aa71afd-acdf-4a87-a1b2-f9691dce332e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b0a12c3a-ef04-4e30-b9f3-7906aec922ef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2aa71afd-acdf-4a87-a1b2-f9691dce332e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0b9c9dca-f8ce-4681-9ba5-950aff89a6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0b9c9dca-f8ce-4681-9ba5-950aff89a6b6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_df78a6e4-6fa9-4125-a55d-1b638d4bf539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ca7acb30-f8d0-4fd0-a7d7-4890c9f62adf" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_df78a6e4-6fa9-4125-a55d-1b638d4bf539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f843bcab-e4d7-4bd3-a15e-5496f3ab9f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_df78a6e4-6fa9-4125-a55d-1b638d4bf539" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f843bcab-e4d7-4bd3-a15e-5496f3ab9f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333e69ae-5117-4590-a3c3-80c9412b2f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d1271c64-d4fa-4ad4-9ed6-a164a9539dbb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333e69ae-5117-4590-a3c3-80c9412b2f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_fdbb21eb-d785-41e4-b130-380eccefc215" xlink:href="bhc-20220930.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_333e69ae-5117-4590-a3c3-80c9412b2f32" xlink:to="loc_bhc_RevenuesNetMember_fdbb21eb-d785-41e4-b130-380eccefc215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:to="loc_srt_MajorCustomersAxis_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_69a6bd0e-30f6-48b3-9c01-e4b29322b851" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d1a0d5ec-21bf-4afe-9c1a-9b2e4febf9de" xlink:to="loc_srt_NameOfMajorCustomerDomain_69a6bd0e-30f6-48b3-9c01-e4b29322b851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_59824f0d-b432-4ba9-ac21-c8cf96ff06eb" xlink:href="bhc-20220930.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_69a6bd0e-30f6-48b3-9c01-e4b29322b851" xlink:to="loc_bhc_CustomerTopTenProductsMember_59824f0d-b432-4ba9-ac21-c8cf96ff06eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d5a963e5-d110-4b96-944a-2a78bd0fddb6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_d8295fbf-c773-491a-abb8-ce5583937a7b" xlink:href="bhc-20220930.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_d8295fbf-c773-491a-abb8-ce5583937a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_204c5fc1-891d-4088-94b0-1054c7d89600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaccfcb1-f1ec-4093-ba49-4104c10a2a13" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_204c5fc1-891d-4088-94b0-1054c7d89600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f6f01c60-afdc-42f2-a9ee-81fe612e62b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_975fa236-8227-4ef0-beaa-8ceb40d12a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f6f01c60-afdc-42f2-a9ee-81fe612e62b4" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_975fa236-8227-4ef0-beaa-8ceb40d12a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eff4938c-2db0-499d-9f1c-33a3036df14a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_975fa236-8227-4ef0-beaa-8ceb40d12a0a" xlink:to="loc_srt_StatementGeographicalAxis_eff4938c-2db0-499d-9f1c-33a3036df14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_eff4938c-2db0-499d-9f1c-33a3036df14a" xlink:to="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_e6ad0c76-448f-4a42-b92c-8df62d8dde7c" xlink:href="bhc-20220930.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_e6ad0c76-448f-4a42-b92c-8df62d8dde7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_9376b69f-35fb-455d-977e-31a63d40d3cc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_CN_9376b69f-35fb-455d-977e-31a63d40d3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_fd5dde9c-dfde-4c01-8c2b-fe8fda8ed429" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_CA_fd5dde9c-dfde-4c01-8c2b-fe8fda8ed429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_52e37276-b6c3-416e-9379-390a381deb3c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_PL_52e37276-b6c3-416e-9379-390a381deb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_1abdddf5-28b2-4dde-9e92-3059625396cd" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_MX_1abdddf5-28b2-4dde-9e92-3059625396cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_14a0dbc6-99fe-4432-9c46-4f54b42ac631" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_FR_14a0dbc6-99fe-4432-9c46-4f54b42ac631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c6a86cc6-d08f-48f2-8a86-cb951f61d637" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_JP_c6a86cc6-d08f-48f2-8a86-cb951f61d637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_bcacd1fd-8ad6-48da-a591-e628aec0facc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_DE_bcacd1fd-8ad6-48da-a591-e628aec0facc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_289e1320-f53d-4eb1-b636-618fc64ee356" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_GB_289e1320-f53d-4eb1-b636-618fc64ee356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_ae96768b-5159-4552-8529-a9f9619bd3a4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_RU_ae96768b-5159-4552-8529-a9f9619bd3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_15d81012-8c9f-4709-8fdb-acf5b341b327" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_ES_15d81012-8c9f-4709-8fdb-acf5b341b327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_abf9b2ee-dd9a-46c6-9938-2c55d071a125" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_IT_abf9b2ee-dd9a-46c6-9938-2c55d071a125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_624a0f27-bdc3-4876-9782-510c2ff59ac2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_country_KR_624a0f27-bdc3-4876-9782-510c2ff59ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_b28b81d5-0272-47f5-9073-fea01b2bd39a" xlink:href="bhc-20220930.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f0f55fbc-dbc0-4b24-8bb6-3cd46c0eef15" xlink:to="loc_bhc_OtherCountriesMember_b28b81d5-0272-47f5-9073-fea01b2bd39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9b1f0e0-0b95-4526-b356-fb46ab571e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_975fa236-8227-4ef0-beaa-8ceb40d12a0a" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9b1f0e0-0b95-4526-b356-fb46ab571e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cf5c50b-f093-48b8-8e15-86cf1f83ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f9b1f0e0-0b95-4526-b356-fb46ab571e1d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cf5c50b-f093-48b8-8e15-86cf1f83ddc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220930.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_51d2cee4-627f-4be8-8c1e-0f4df69c0ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_51d2cee4-627f-4be8-8c1e-0f4df69c0ec5" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d3e7b7c-68d4-4108-891d-7ace8d634f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d3e7b7c-68d4-4108-891d-7ace8d634f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65eb7b52-dbb5-4447-bbe3-a0fee6f6d7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0d3e7b7c-68d4-4108-891d-7ace8d634f74" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65eb7b52-dbb5-4447-bbe3-a0fee6f6d7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_824f929f-7e74-47ef-bb9b-6b8ba14bd7f2" xlink:href="bhc-20220930.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65eb7b52-dbb5-4447-bbe3-a0fee6f6d7cd" xlink:to="loc_bhc_RevenuesNetMember_824f929f-7e74-47ef-bb9b-6b8ba14bd7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_dc9e41ea-cb0d-47be-a9ee-347f5781468e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_dc9e41ea-cb0d-47be-a9ee-347f5781468e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_da8d5b6d-dda2-4875-9c2b-7735b9e85680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_dc9e41ea-cb0d-47be-a9ee-347f5781468e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_da8d5b6d-dda2-4875-9c2b-7735b9e85680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4f088c54-24e4-4ffd-8dc4-e170d5661d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_da8d5b6d-dda2-4875-9c2b-7735b9e85680" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4f088c54-24e4-4ffd-8dc4-e170d5661d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_9b5ddf64-4e72-4f32-b618-c0add2984c8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:to="loc_srt_MajorCustomersAxis_9b5ddf64-4e72-4f32-b618-c0add2984c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9b5ddf64-4e72-4f32-b618-c0add2984c8c" xlink:to="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_97ae50ee-d2d8-4d7e-b155-171cb1fe125c" xlink:href="bhc-20220930.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_97ae50ee-d2d8-4d7e-b155-171cb1fe125c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_f51e9329-9c34-4c36-83e7-54020e603fae" xlink:href="bhc-20220930.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:to="loc_bhc_McKessonCorporationMember_f51e9329-9c34-4c36-83e7-54020e603fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_45b7d23e-fa57-4af5-948e-aa670edf95e4" xlink:href="bhc-20220930.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0b9b812d-ebcd-4c8f-8d24-8095b5cceabb" xlink:to="loc_bhc_CardinalHealthIncMember_45b7d23e-fa57-4af5-948e-aa670edf95e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ca58c8f0-a456-4694-85a3-151795b04f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f364ad6e-bc8f-4466-9afa-623bedac4210" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ca58c8f0-a456-4694-85a3-151795b04f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_623e29b8-2637-4993-b932-2c075e3e1467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_ca58c8f0-a456-4694-85a3-151795b04f16" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_623e29b8-2637-4993-b932-2c075e3e1467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678599120352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,868,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596479728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,739<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">1,056<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,010<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">6,024<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,044<span></span>
</td>
<td class="nump">12,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">2,372<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,298<span></span>
</td>
<td class="nump">29,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">2,934<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,831<span></span>
</td>
<td class="nump">5,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">20,804<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,865<span></span>
</td>
<td class="nump">29,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 361,781,292 and 359,405,748 issued and outstanding at September 30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">10,387<span></span>
</td>
<td class="nump">10,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,776)<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,265)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; deficit</a></td>
<td class="num">(525)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity (deficit)</a></td>
<td class="nump">433<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity (deficit)</a></td>
<td class="nump">$ 26,298<span></span>
</td>
<td class="nump">$ 29,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678599114592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
<td class="nump">361,781,292<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">361,781,292<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597361872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 6,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">653<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">902<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense (income), net</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">5,241<span></span>
</td>
<td class="nump">6,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(385)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
<td class="num">(1,157)<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">570<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(1,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Bausch Health Companies Inc.</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="num">$ (1,017)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to Bausch Health Companies Inc.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted-average common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">362.5<span></span>
</td>
<td class="nump">359.6<span></span>
</td>
<td class="nump">361.8<span></span>
</td>
<td class="nump">358.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">363.4<span></span>
</td>
<td class="nump">364.0<span></span>
</td>
<td class="nump">363.7<span></span>
</td>
<td class="nump">358.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,026<span></span>
</td>
<td class="nump">$ 2,088<span></span>
</td>
<td class="nump">$ 5,871<span></span>
</td>
<td class="nump">$ 6,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593679504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="num">$ (1,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(1,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Bausch Health Companies Inc.</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="num">$ (293)<span></span>
</td>
<td class="num">$ (1,147)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593319312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 10,227<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="num">$ (8,013)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Release of foreign currency translation losses upon disposal of assets held for sale</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,009)<span></span>
</td>
<td class="num">(1,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="nump">$ 10,312<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="num">(9,030)<span></span>
</td>
<td class="num">(1,923)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2021</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(687)<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="num">(9,218)<span></span>
</td>
<td class="num">(2,182)<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Release of foreign currency translation losses upon disposal of assets held for sale</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2021</a></td>
<td class="num">$ (135)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
<td class="nump">$ 10,312<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="num">(9,030)<span></span>
</td>
<td class="num">(1,923)<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from B+L initial public offering, net of costs (Note 2)</a></td>
<td class="nump">675<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">$ (459)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(478)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">361,781,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="nump">$ 10,387<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="num">(8,776)<span></span>
</td>
<td class="num">(2,265)<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2022</a></td>
<td class="nump">253<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="nump">$ 10,380<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="num">(9,175)<span></span>
</td>
<td class="num">(2,002)<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from B+L initial public offering, net of costs (Note 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">$ (244)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">361,781,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="num">$ (525)<span></span>
</td>
<td class="nump">$ 10,387<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="num">$ (8,776)<span></span>
</td>
<td class="num">$ (2,265)<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596506640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 198<span></span>
</td>
<td class="num">$ (1,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt premiums, discounts and issuance costs</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivable and inventories</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sale of assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Adjustments to accrued legal settlements</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(1,572)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign exchange (gain) loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on extinguishment of debt</a></td>
<td class="num">(683)<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities', window );">Third party fees paid in connection with the Exchange Offer</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities', window );">Payments of contingent consideration adjustments, including accretion</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(122)<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(1,203)<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(152)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for intangible and other assets</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of assets and businesses, net of costs to sell</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Interest settlements from cross-currency swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(167)<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">6,481<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(7,224)<span></span>
</td>
<td class="num">(3,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty', window );">Proceeds from B+L initial public offering, net of costs</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of employee withholding taxes related to share-based awards</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(1,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and other</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</a></td>
<td class="num">(1,622)<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 1,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600658144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its approximately 89% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately 100 countries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678683491504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health (the &#8220;B+L Separation&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health indirectly holds 310,449,643 Bausch + Lomb common shares, which represent approximately 89% of Bausch + Lomb&#8217;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million. The Company continues to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company which includes the Company&#8217;s Salix, International (formerly International Rx), Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical) products, and Solta aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than the effects of the B+L IPO described above, these unaudited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has had, and continues to have, an adverse impact on the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#8220;Solta&#8221; or &#8220;Solta Medical&#8221;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Salix, (ii) International Rx, (iii) Ortho </span></div>Dermatologics, (iv) Diversified Products and (v) Bausch + Lomb. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678683404768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2022 and 2021 were $84&#160;million and $94&#160;million, respectively, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21&#160;million and $28&#160;million for the three months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the nine months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,064)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $36&#160;million as of September 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $38 million and $32&#160;million as of September 30, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $1&#160;million during the nine months ended September 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2022 and 2021 is as follows.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602890016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND DIVESTITURE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock', window );">LICENSING AGREEMENTS AND DIVESTITURE</a></td>
<td class="text">LICENSING AGREEMENTS AND DIVESTITURE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International Rx segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $88&#160;million during the nine months ended September 30, 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during the three months ended September 30, 2021, included within Other (income) expense, net in the Combined Statements of Operations. Revenues associated with Amoun were $20&#160;million and $157&#160;million for the three and nine months ended September 30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678683324512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of September 30, 2022 was $13 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $28 million and $9&#160;million of restructuring and integration costs and made payments of $37&#160;million and $13&#160;million during the nine months ended September 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities relating to the B+L Separation. The Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the nine months ended September 30, 2022 and 2021 are separation and IPO costs of $30&#160;million and $20&#160;million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and expects to continue to incur with respect to the B+L Separation, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO including, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the nine months ended September 30, 2022 and 2021 are separation-related and IPO-related costs of $84&#160;million and $91&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities And Initial Public Offering Costs Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678683236560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of September 30, 2022 includes $297&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Restricted cash and other settlement deposits included $1,210&#160;million of payments into an escrow fund under the terms of the Securities Class Action Settlement (as defined in Note 18, &#8220;LEGAL PROCEEDINGS&#8221;), which was subject to one objector&#8217;s appeal of the final court approval of the agreement. The period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the Securities Class Action Settlement has become &#8220;final&#8221;, as no more appeals can be filed. As a result, the Company's rights to the funds in escrow were extinguished and the Company reduced Restricted cash and other settlement deposits with a corresponding reduction to liabilities for legal settlements, included in Accrued and other current liabilities on the Company's Consolidated Balance Sheets, by $1,210&#160;million in the three months ended September 30, 2022. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;U.S. Securities Litigation - Opt -Out Litigation&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for additional details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 assets or liabilities during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps, with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s cross-currency swaps qualify for and have been designated as a hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the periods presented. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with Bausch + Lomb&#8217;s cross-currency swaps as included in the Consolidated Balance Sheet as of September&#160;30, 2022 are as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021. As a result, there were no assets or liabilities related to the cross-currency swaps included in the Consolidated Balance Sheets as of December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest settlement of the 2022 cross-currency swaps occurs in January and July each year, with the first settlement in January 2023. Future settlements of the 2022 cross-currency swaps will be reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 and 2021, the Company received $0 and $23&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company's outstanding foreign currency exchange contracts had an aggregate notional amount of $394&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At September&#160;30, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at September&#160;30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:70.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of September&#160;30, 2022 and December&#160;31, 2021 was $13,450 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678603245344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678683304032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,945)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the nine months ended September 30, 2022 were $15&#160;million and include: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $5&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets included in the unaudited Consolidated Balance Sheets had a carrying value of $2,828&#160;million and an estimated remaining useful life of 63 months as of September 30, 2022. On August 10, 2022, a court held, that among other findings, that certain U.S. patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) were invalid (the &#8220;Norwich Legal Decision&#8221;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $1,216&#160;million and $1,194&#160;million for the nine months ended September 30, 2022 and 2021, respectively. As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets for potential impairment. The Company performed this assessment using a probability-weighted undiscounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. This assessment resulted in no impairment of the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets as of September&#160;30, 2022. The Company also determined that no change to the remaining useful lives of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets was required as of September&#160;30, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be material to the results of operations of the Company in the period or periods in which they were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the nine months ended September 30, 2021 were $213&#160;million and include: (i) $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an adjustment of $88&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $20&#160;million, in aggregate, related to the discontinuance of certain product lines. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets amounts to approximately $539&#160;million annually through 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 and the year ended December&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment of Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s latest discounted cash flow model for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate of 10%. The discount rate had increased 1% since the assessment performed at March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the time Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The decline in the equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which at June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized Bausch + Lomb&#8217;s most recent cash flow projections for each of the reporting units and utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, with the exception of the Ortho Dermatologics reporting unit and the reporting units of the Bausch + Lomb segment, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairment to those reporting units was recorded.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 30, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Based on the impairment of goodwill recognized in the second quarter of 2022 for the Ortho Dermatologics reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections which reflect current market conditions and current trends in business performance. The Company&#8217;s latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of 1% and the discount rate increased from 10.0% at June 30, 2022 to 10.5% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $119&#160;million for the three months ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues represent approximately 80% of the Salix reporting unit&#8217;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of 2.5% and discount rates of 9.75% and 10.0%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore no impairment was recorded as of September 30, 2022. However, as the Company&#8217;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix segment in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period of October 1, 2021 (the last time goodwill was tested for all other reporting units) through September&#160;30, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics and Salix reporting units and the reporting units of the Bausch + Lomb segment, might be below its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through September&#160;30, 2022 were $4,382 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678683304032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678599045824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the 9.00% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of September&#160;30, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $12,000&#160;million (although such availability is subject to the Company&#8217;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to seek to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#8220;Exchange Offer&#8221;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $5,594&#160;million as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) for $3,125&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $2,469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#8220;11.00% First Lien Secured Notes&#8221;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#8220;14.00% Second Lien Secured Notes&#8221; and, together with the 11.00% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#8220;9.00% Intermediate Holdco Secured Notes&#8221; and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00% Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25% Senior Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50% Senior Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Exchange Offer and following receipt of the requisite number of consents from noteholders, the Company and the applicable notes trustee, executed supplemental indentures to amend each of the indentures governing the 9.25% Senior Notes due 2026, 8.50% Senior Notes due 2027, 5.00% Senior Notes due 2028, 7.00% Senior Notes due 2028 and 7.25% Senior Notes due 2029, which amendments eliminate substantially all of the restrictive covenants as well as certain events of default and related provisions applicable to such series of notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the principal amount of the New Secured Notes and their carrying value as calculated above has been recorded as a premium and is included in long-term debt on the Company&#8217;s Consolidated Balance Sheet, which will be reduced as the Company makes stated interest payments on the New Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, the Company recorded a gain of $570&#160;million, net of third party fees of $25&#160;million, in connection with the Exchange Offer. As of September 30, 2022, the premium recorded on the New Secured Notes was $1,835&#160;million, which will be reduced as stated interest payments are made on the New Secured Notes. Further details of the New Secured Notes are discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of September&#160;30, 2022, the Company had drawn $450&#160;million on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September&#160;30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $531&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five-year revolving credit facility of $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of September&#160;30, 2022, the principal amount outstanding under the B+L Term Facility was $2,494&#160;million and $2,442&#160;million net of issuance costs. The B+L Revolving Credit Facility remained undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%. The stated rate of interest under the Term Facility at September&#160;30, 2022 was 6.10% per annum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, payable in quarterly installments. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of September&#160;30, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $113&#160;million through March 2027, with the remaining term loan balance being due in May 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture, the &#8220;April 2025 Unsecured Notes Indenture&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of 7.00% Senior Secured Notes due 2024 (the &#8220;March 2024 Secured Notes&#8221;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.125% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 11.00% First Lien Secured Notes mature on September 30, 2028, and accrue interest at 11.00% per year, payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 11.00% First Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 14.00% Second Lien Secured Notes mature on October 15, 2030, and accrue interest at 14.00% per year, payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.00% Intermediate Holdco Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and accrue interest at 9.00% per year, payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of September 30, 2022 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee certain of the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of the Company&#8217;s outstanding 9.00% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) conditioned upon the receipt of aggregate proceeds of at least $7,000&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of September&#160;30, 2022 and December&#160;31, 2021 was 7.24% and 5.88%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company completed the Exchange Offer and recorded a net gain of $570&#160;million as described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company repurchased and retired certain outstanding Senior Unsecured Notes with an aggregate par value of $481&#160;million in the open market, for an aggregate cost of $300&#160;million. In connection with these repurchases, the Company recognized a gain of $176&#160;million on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with (i) the repayment of the June 2025 Term Loan B Facility, November 2025 Term Loan B Facility and 2023 Revolving Credit Facility and (ii) the redemption of April 2025 Unsecured Notes, the Company incurred a loss on extinguishment of debt of $63&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678603245344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2022 and 2021 consists of: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678599103184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved Bausch Health&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced Bausch Health&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 18,328,000 common shares were available for future grants under the Amended and Restated 2014 Plan as of September&#160;30, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to retain and incentivize certain members of the Company&#8217;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#8220;Retention RSU Grant&#8221;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTA5OTUxMTYzODk0Ng_fd0ab737-0f9e-4702-b219-264d2a3842ea">three</span> anniversaries of the grant date based on continuous employment with Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to May 5, 2022, Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb participated in Bausch Health&#8217;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of 28,000,000 common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, in connection with the B+L IPO, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted certain awards to certain eligible recipients (the &#8220;IPO Founder Grants&#8221;). Eligible recipients are individuals employed by </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb or employed by an affiliate of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb. Approximately 3,900,000 IPO Founder Grants were issued to </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb executive officers and were awarded 50% in the form of stock options and 50% in the form of RSUs. Additionally, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted approximately 5,700,000 stock options and RSUs to non-executive eligible recipients, of which approximately 4,300,000 were B+L IPO Founder Grants. The IPO Founder options have a three-year graded vesting period and the IPO Founder RSUs vest 50% in the second year and 50% in the third year after the grant. With the exception of the separation agreement and retention program, as discussed below, vesting of the IPO Founder Grants are linked to the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb entered into a separation agreement in connection with the departure of its Chief Executive Officer (&#8220;CEO&#8221;). Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of RSUs will vest upon his termination of service date (pro rated based on his period of service relative to the original three-year vesting period associated with such grants), but the shares received upon settlement will remain fully restricted and nontransferable until the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer pursue a distribution, and the two-year anniversary of the CEO&#8217;s termination of service date. Under the terms of the separation agreement, the CEO&#8217;s IPO Founder Grants in the form of stock options will vest and become exercisable (pro-rated based on his period of service relative to the original three-year vesting period associated with such grants) upon the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pursue a distribution, and the two-year anniversary of the CEO&#8217;s termination of service date and remain exercisable for two years following this date. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Talent and Compensation Committee of the Bausch + Lomb Board of Directors approved a retention program that includes </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s named executive officers (other than the CEO) and certain other employees. This program provides the Executive Officers (other than the CEO), among other benefits, pro-rata vesting of the IPO Founder Grants previously issued to these named executives, subject to certain restrictions, in the event of an involuntary termination of employment by </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb without &#8220;cause&#8221; or the executive&#8217;s resignation for &#8220;good reason&#8221;, in each case through the one-year anniversary of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s appointment of the successor to the CEO (pro-rated based on the period of service relative to the original three-year vesting period associated with such grants). Additionally, these named executive officers (other than the CEO) and certain other employees were granted a one-time award of approximately 850,000 RSUs under the retention program pursuant to </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s 2022 Omnibus Incentive Plan. The retention grant will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5Mjg4MQ_d3858cff-cf89-4b94-8aea-b1ba58bb78da">three</span> anniversaries of the grant date based on continuous employment with </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 17,500,000 Bausch + Lomb common shares were available for future grants as of September&#160;30, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company's share-based compensation expenses related to stock options and RSUs for the three and nine months ended September 30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the nine months ended September 30, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,455,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,205,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $152 million, which will be amortized over a weighted-average period of 1.77 years.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $72&#160;million, which will be amortized over a weighted-average period of 1.64 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602644928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602636192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600664592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE (INCOME), NET</a></td>
<td class="text">OTHER EXPENSE (INCOME), NET<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Gain) loss on sale of assets, net for the nine months ended September 30, 2021, includes $25&#160;million related to the achievement of a milestone related to a certain product and a $26&#160;million loss upon completion of the Amoun Sale during the three months ended September 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600833040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes for the nine months ended September 30, 2022 was $30 million and included: (i) $42&#160;million of income tax expense for the Company&#8217;s ordinary income for the nine months ended September 30, 2022 and (ii) $9 million of net income tax benefit for discrete items, which includes: (a) $37&#160;million of net income tax benefit recognized for changes in uncertain tax positions, (b) a $22&#160;million tax provision associated with filing certain tax returns and (c) a $5&#160;million tax provision associated with stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the nine months ended September 30, 2021 was $36 million and included: (i) $34 million of income tax benefit for the Company&#8217;s ordinary loss for the nine months ended September 30, 2021 and (ii) $2&#160;million of net income tax provision for discrete items, which includes: (a) a $54&#160;million of net income tax benefit associated with certain legal settlements, (b) a $46&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (c) an $11&#160;million tax provision recognized for changes in uncertain tax provisions, (d) an $8&#160;million tax benefit related to a deduction for stock compensation and (e) a $3&#160;million tax provision associated with the filing of certain tax returns. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was $1,931 million and $2,222 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The decrease was primarily due to the utilization of net operating losses against debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forgiveness income in Canada associated with the Exchange Offer. The Company will continue to assess the need for a valuation allowance on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Some further guidance on the plan and rules has been published, with additional guidance expected to be published in 2023. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which it operates. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#8217;s liability for corporate taxes and the Company&#8217;s consolidated effective tax rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, President Biden signed the Inflation Reduction Act into law, which includes implementation of a new alternative minimum tax, an excise tax on stock buybacks, and significant tax incentives for energy and climate initiatives, among other provisions. The corporate alternative minimum tax (&#8220;CAMT&#8221;) imposes a minimum tax on the adjusted financial statement income (&#8220;AFSI&#8221;) for &#8220;applicable corporations&#8221; with average annual AFSI over a three-year period in excess of $1 billion. A corporation that is a member of a foreign-parented multinational group, as defined, must include the AFSI (with certain modifications) of all members of the group in applying the $1 billion test, but would only be subject to CAMT if the three-year average AFSI of its U.S. members, US trades or business of foreign group members that are not subsidiaries of U.S. members, and foreign subsidiaries of U.S. members exceeds $100 million. The Company currently does not believe this will have a significant impact on its tax results, but will continue to evaluate the law and its provisions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221;, during the three months ended September 30, 2022, the Company undertook a restructuring of its third-party debt resulting in extinguishment of debt income in the US and Canada for tax purposes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December&#160;31, 2021, the Company had $937 million and $927 million, respectively, of unrecognized tax benefits, which included $45 million and $41 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of September&#160;30, 2022, $164 million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at September&#160;30, 2022 could decrease by approximately $13 million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of September&#160;30, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 capital loss&#8221;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#8220;IRS&#8221;) is continuing its examination of the Company&#8217;s annual tax filings for 2015 and 2016 and the Company&#8217;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017. In 2021, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. The Company has been accepted into the IRS's fast track mediation program and mediation meetings are scheduled for early 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settled its audit with the Australian Taxation Office for various years beginning in 2011 through 2017 with no material adjustments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600944880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.6&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted effect of stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 1,906,000 and 5,221,000 common shares for the nine months ended September 30, 2022 and 2021, respectively.</span></div>During the three and nine months ended September 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 16,008,000 and 15,392,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately 3,103,000 and 3,453,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2022 and 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602652192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGSFrom time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the nine months ended September 30, 2022.<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of September 30, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $323 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts (Department of Justice), requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. In October 2022, the Company and the Department of Justice reached an agreement in principle to resolve the investigation as to the Company for an immaterial settlement payment plus payment of applicable interest and other related costs. Any final resolution would be subject to certain material contingencies, including, without limitation, the parties negotiating mutually satisfactory civil settlement documents and final approvals by the Department of Justice and the Company. While the Company has reached an agreement in principle with the Department of Justice, there can be no assurance that a settlement will be agreed to and finalized, nor the timing of any such potential resolution.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#8220;Securities Class Action Settlement&#8221;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the settlement agreement. The Company's rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above), Humana Inc. (&#8220;Humana&#8221;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. Trial is scheduled to begin on August 25, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022. On October 4, 2022, Defendants filed a motion to consolidate this action with the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Colazal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued the Norwich Legal Decision on August 10, 2022, finding that the U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D invalid. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal Circuit on August 16, 2022. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. A three-day trial commenced on October 4, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a 30-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion. A three-day trial commenced on October 4, 2022. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against 19 named defendants in 16 proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes Review Proceedings at the U.S. Patent and Trademark Office</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. On October 12, 2022, MSN filed a petition for IPR of U.S. Patent No. 7,041,786. The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-six (26) of such product liability suits currently remain pending. In three cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-five (25) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022, and a decision is pending. Further, pursuant to a court order dated March 18, 2022, the Bankruptcy Court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also ordered separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. The Bankruptcy Court extended LTL&#8217;s exclusive period to file a chapter 11 plan until November 17, 2022, and the talc claimants filed a motion to terminate LTL&#8217;s exclusivity. The parties have since consensually agreed to extend LTL&#8217;s exclusive period to December 13, 2022. On July 26, 2022, the Bankruptcy Court held a hearing to consider alternative paths to case resolution, and on July 28, 2022, authorized an abbreviated estimation process designed to determine the extent of LTL&#8217;s aggregate liability. Additionally, the Bankruptcy Court appointed an independent expert who will issue a report forecasting and estimating the volume and value of claims. The Bankruptcy Court has scheduled November 16, 2022 for a status update on the expert report and to discuss scheduling further formal mediation sessions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Bankruptcy Court also ruled that it would leave in place the stay and injunction enjoining talc product liability cases from proceeding until at least the completion of the estimation process. To the extent that any cases proceed </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the pendency of the bankruptcy case, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. As a result, the New Jersey Superior Court action is closed and the case is now pending in the District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion is fully briefed and pending. Other proceedings are in abeyance pending resolution of Plaintiffs&#8217; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the current stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and accordingly, asked the Ninth Circuit if Johnson &amp; Johnson could have until December 19, 2022, to provide the next status report while the stay remains in place in this action. They also indicated they will inform the court if the status of the bankruptcy stay changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on May 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the State of New Mexico from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction and noting it would be revisited during the December 2022 omnibus hearing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600833040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s previously announced plan to separate its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company had begun managing its operations in a manner which was consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s CEO, who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, the Company announced it was suspending plans for the Solta IPO; however, the Company is continuing to manage and operate the business in its current reportable segment structure. See Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues for each of the three and nine month periods ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,045)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:29.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top ten products for the nine months ended September 30, 2022 and 2021 represented 48% and 45% of total revenues for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591925440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2022 and 2021 were $84&#160;million and $94&#160;million, respectively, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21&#160;million and $28&#160;million for the three months ended September 30, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600835712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the nine months ended September 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,064)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $36&#160;million as of September 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the nine months ended September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2022 and 2021 is as follows.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596926000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with Bausch + Lomb&#8217;s cross-currency swaps as included in the Consolidated Balance Sheet as of September&#160;30, 2022 are as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.442%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock', window );">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2022 and 2021:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:70.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (a),(b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 55<br> -Paragraph 184<br> -URI https://asc.fasb.org/extlink&amp;oid=127000641&amp;loc=SL5634876-113961<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600825728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596409840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,945)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,945)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,945)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,024&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text">The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 and the year ended December&#160;31, 2021 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600775840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,934&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678599037312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock', window );">Schedule of aggregate principal amounts of debt validly tendered and subsequently accepted</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00% Senior Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25% Senior Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.50% Senior Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2028</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Senior Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Senior Notes due 2031</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of long-term debt maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,215&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of troubled debt restructuring which results when the debtor restructures the terms of its debt with a creditor due to the debtor's financial difficulties and the creditor grants certain concessions to obtain payment it might not otherwise receive. Includes a description of the principal changes in terms, the major features of settlement for each restructuring, the aggregate gain on restructuring and the related income tax effect, the per share amount of the total gain on restructuring, net of related income tax effect, and the total gain (loss) on transfers of assets recognized during the period. After the troubled debt restructuring has occurred debtors discuss the extent and amount to which amounts contingently payable are included in the carrying amount of restructured payables, and the conditions under which those amounts would become payable or would be forgiven when there is at least a reasonable possibility that a liability for contingent payments will be incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15765-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600761344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net periodic benefit cost</a></td>
<td class="text">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2022 and 2021 consists of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593127776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company's share-based compensation expenses related to stock options and RSUs for the three and nine months ended September 30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of share-based awards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the nine months ended September 30, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,455,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,205,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600768640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of Accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678598995504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs consist of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600655632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense (income), net</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600780560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of earnings (loss) per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.6&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted effect of stock options and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596503744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,045)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and product category</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:29.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenue attributed to a geographic region</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of customers that accounted for 10% or more of total revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597668240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="nump">89.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591954624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,781,292<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">310,449,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember', window );">IPO and Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares sold, net proceeds</a></td>
<td class="nump">$ 675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">B+L IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">4,550,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SaleOfStockOverAllotmentTerm', window );">Underwriters option to purchase additional shares, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Additional Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SaleOfStockOverAllotmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Over-Allotment, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SaleOfStockOverAllotmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678592283376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,145,000,000<span></span>
</td>
<td class="nump">$ 4,062,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 1,944,000,000<span></span>
</td>
<td class="nump">$ 1,951,000,000<span></span>
</td>
<td class="nump">1,944,000,000<span></span>
</td>
<td class="nump">1,951,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,863,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,813,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">2,046,000,000<span></span>
</td>
<td class="nump">2,111,000,000<span></span>
</td>
<td class="nump">5,931,000,000<span></span>
</td>
<td class="nump">6,238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000,000<span></span>
</td>
<td class="nump">94,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Reduction in variable consideration provision, adjustment</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">421,000,000<span></span>
</td>
<td class="nump">502,000,000<span></span>
</td>
<td class="nump">421,000,000<span></span>
</td>
<td class="nump">502,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596147264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(4,064)<span></span>
</td>
<td class="num">(3,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(452)<span></span>
</td>
<td class="num">(448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(145)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,911<span></span>
</td>
<td class="nump">1,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(1,847)<span></span>
</td>
<td class="num">(1,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,558<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(1,532)<span></span>
</td>
<td class="num">(1,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597365488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for expected credit losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs charged against the allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries of amounts previously written off</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596439088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Amoun - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds from divestiture</a></td>
<td class="nump">$ 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue associated with products for disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678592319600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">$ 1,959<span></span>
</td>
<td class="nump">$ 1,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities associated with restructuring, integration and separation costs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember', window );">Separation and IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration, separation, and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593604288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596875296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>appeal</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash and other settlement deposits</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LitigationSettlementNumberOfObjectorsAppeals', window );">Settlement, escrow fund included in restricted cash, number of objectors' appeals | appeal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent', window );">Decrease in restricted cash and other settlement deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent', window );">Decrease in accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LitigationSettlementNumberOfObjectorsAppeals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number of Objectors' Appeals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LitigationSettlementNumberOfObjectorsAppeals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602260144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details) - Net Investment Hedging - Cross-currency swaps - Designated as Hedging Instrument - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments or receipts in settlement of cross-currency swaps</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597400640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details) - Cross-currency swaps - Net Investment Hedging - Designated as Hedging Instrument - Bausch + Lomb<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678598947168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Net Investment Hedging - Cross-currency swaps - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain recognized in Other comprehensive loss</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600920688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 394,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678598945888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593689792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) related to changes in fair value</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597402208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details) - Recurring basis - Level&#160;3<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>rate</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678592330720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments/Settlements</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Foreign currency translation adjustment included in other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion included in Accrued and other current liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember', window );">Fair value adjustments due to changes in estimates of other future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600719664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring adjustment | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 13,450<span></span>
</td>
<td class="nump">$ 22,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593166640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Components of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Inventories</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596189328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,271<span></span>
</td>
<td class="nump">$ 25,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(20,945)<span></span>
</td>
<td class="num">(20,180)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,326<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">26,969<span></span>
</td>
<td class="nump">27,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">6,024<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Bausch + Lomb Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">20,748<span></span>
</td>
<td class="nump">20,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(16,902)<span></span>
</td>
<td class="num">(16,169)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,846<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(520)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">3,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,197)<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678587937744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 213,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,326,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,326,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,111,000,000<span></span>
</td>
<td class="nump">5,931,000,000<span></span>
</td>
<td class="nump">6,238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,382,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,382,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,000,000<span></span>
</td>
<td class="nump">$ 1,509,000,000<span></span>
</td>
<td class="nump">1,515,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember', window );">Reporting Units Excluding Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember', window );">Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,000,000<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, change in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember', window );">Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember', window );">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical and Ophthalmic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember', window );">Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember', window );">Xifaxan Branded Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,828,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,828,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,216,000,000<span></span>
</td>
<td class="nump">1,194,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AnnualAmortizationOfIntangibleAssets', window );">Finite lived intangible assets, annual amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember', window );">Xifaxan Branded Products | Salix | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,846,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,846,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,673,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AnnualAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Amortization Of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AnnualAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593530064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 4,326<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678592836880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,457,000,000<span></span>
</td>
<td class="nump">$ 13,044,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(202,000,000)<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,000,000)<span></span>
</td>
<td class="num">(118,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,044,000,000<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,704,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,395,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,000,000)<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,154,000,000<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">887,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99,000,000)<span></span>
</td>
<td class="num">(62,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726,000,000<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(798,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,000,000<span></span>
</td>
<td class="num">(578,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000,000<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,890,000,000<span></span>
</td>
<td class="nump">$ 2,357,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678590493088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">965<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">672<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 2,934<span></span>
</td>
<td class="nump">$ 4,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591467792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 19,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">21,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">20,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">2,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 2,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 2,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 5.50% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 6.125% Senior Notes Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 5.75% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 4.875% Senior Notes Due June 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 11.00% First Lien Senior Notes, Due September 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 2,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 14.00% Second Lien Senior Notes, Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 9.00% Intermediate Holdco Senior Notes, Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 9.00% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 9.25% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 8.50% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 6.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.00% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.25% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.25% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602928272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member', window );">9.00% Intermediate Holdco Senior Notes, Due January 2028 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember', window );">Senior Secured Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678587656512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Exchange Offer (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (63,000,000)<span></span>
</td>
<td class="num">$ (38,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="num">$ (12,000,000)<span></span>
</td>
<td class="nump">$ 683,000,000<span></span>
</td>
<td class="num">$ (62,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember', window );">Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ExtinguishmentOfDebtThirdPartyFees', window );">Third party fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember', window );">Exchange Offer | Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="nump">$ 176,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 9.25% Senior Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 9.25% Senior Notes due 2026 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 8.50% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 8.50% Senior Notes due 2027 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.25% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal', window );">Reduction of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt instrument, premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 11.00% First Lien Senior Notes, Due September 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 11.00% First Lien Senior Notes, Due September 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 14.00% Second Lien Senior Notes, Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 14.00% Second Lien Senior Notes, Due October 2030 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 9.00% Intermediate Holdco Senior Notes, Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 9.00% Intermediate Holdco Senior Notes, Due January 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ExtinguishmentOfDebtThirdPartyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment Of Debt, Third Party Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ExtinguishmentOfDebtThirdPartyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1375209BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1375209BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678587755600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details) - Existing Unsecured Senior Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 5,594,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member', window );">9.00% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member', window );">9.00% Senior Notes due 2025 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 541,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member', window );">9.25% Senior Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member', window );">9.25% Senior Notes due 2026 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member', window );">8.50% Senior Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member', window );">8.50% Senior Notes due 2027 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 1,099,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member', window );">7.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member', window );">7.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member', window );">5.00% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member', window );">5.00% Senior Notes due 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 710,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member', window );">7.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member', window );">7.25% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member', window );">6.25% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member', window );">6.25% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member', window );">5.00% Senior Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member', window );">5.00% Senior Notes due 2029 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 371,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member', window );">5.25% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member', window );">5.25% Senior Notes due 2030 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 332,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member', window );">5.25% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member', window );">5.25% Senior Notes due 2031 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Total</a></td>
<td class="nump">$ 336,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678588914560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 01, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,215,000,000<span></span>
</td>
<td class="nump">$ 22,654,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,574,000,000<span></span>
</td>
<td class="nump">22,870,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">Revolving Credit Facility Due June 2023 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,565,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,829,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">984,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">994,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member', window );">Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage', window );">Incremental borrowings interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,419,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="nump">$ 531,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember', window );">New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,442,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,494,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member', window );">Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.275%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember', window );">Base Rate Factor, SOFR | Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember', window );">Base Rate Factor, SOFR | Minimum | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds | Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR Rate | Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable', window );">Variable rate, if rate not ascertainable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR Rate | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR Rate | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR Rate | Minimum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR Rate | Minimum | Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR Rate | Maximum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember', window );">EURIBOR | Minimum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember', window );">U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember', window );">U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember', window );">U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember', window );">U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember', window );">U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember', window );">U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember', window );">U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate | Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate | Minimum | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember', window );">SOFR, CDOR and EURIBOR Rates | Minimum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember', window );">SOFR, CDOR and EURIBOR Rates | Maximum | Revolving Credit Facility Due February 2027 | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember', window );">SOFR, CDOR, EURIBOR and SONIA Rates | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember', window );">SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember', window );">SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember', window );">SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember', window );">SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Revolving Credit Facility Due May 2027 | Bausch + Lomb | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Credit Spread Adjustment on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591465760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,224,000,000<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (570,000,000)<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="num">$ (683,000,000)<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (570,000,000)<span></span>
</td>
<td class="num">$ (176,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member', window );">7.00% Senior Notes, Due March 2024 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member', window );">11.00% First Lien Senior Notes, Due September 2028 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member', window );">11.00% First Lien Senior Notes, Due September 2028 | Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes, Due October 2030 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes, Due October 2030 | Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes, Due October 2030 | Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member', window );">9.00% Intermediate Holdco Senior Notes, Due January 2028 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1375209BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1375209BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596195472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased debt, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 9.00% Senior Notes due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased debt, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet', window );">Debt covenant, redemption and discharge condition, amount, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678600726496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">7.24%<span></span>
</td>
<td class="nump">5.88%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593290720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (63,000,000)<span></span>
</td>
<td class="num">$ (38,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="num">$ (12,000,000)<span></span>
</td>
<td class="nump">$ 683,000,000<span></span>
</td>
<td class="num">$ (62,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,224,000,000<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 570,000,000<span></span>
</td>
<td class="nump">$ 176,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased debt, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591358400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">2,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">6,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt obligations</a></td>
<td class="nump">19,574<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized premiums, discounts and issuance costs</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 21,215<span></span>
</td>
<td class="nump">$ 22,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678587826448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | U.S. Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591469200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 05, 2022</div></th>
<th class="th"><div>Jul. 19, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember', window );">Non-Executive Eligible Recipients | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross', window );">Incentive stock plan, grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,328,000<span></span>
</td>
<td class="nump">18,328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer, Excluding The Chief Executive Officer | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod', window );">Involuntary termination, program criteria, if circumstances met, anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent', window );">Incentive stock plan, award type, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent', window );">Incentive stock plan, award type, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Chief Executive Officer | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod', window );">Involuntary termination, program criteria, if circumstances met, anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod', window );">Involuntary termination, program criteria, if circumstances met, exercisable period following the anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Chief Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod', window );">Involuntary termination, program criteria, if circumstances met, anniversary period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross', window );">Incentive stock plan, grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | RSUs | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | RSUs | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Incentive stock plan, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, one-time award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember', window );">2022 Omnibus Incentive Plan, Retention Program | Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanRetentionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597454944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591962848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 23.95<span></span>
</td>
<td class="nump">$ 32.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 11.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,151<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 11.76<span></span>
</td>
<td class="nump">$ 31.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-based RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 17.22<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember', window );">ROTC performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 9.40<span></span>
</td>
<td class="nump">$ 31.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember', window );">B+L Separation performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 28.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602093856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (135)<span></span>
</td>
<td class="num">$ (611)<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (2,265)<span></span>
</td>
<td class="num">$ (2,002)<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="num">$ (1,923)<span></span>
</td>
<td class="num">$ (2,182)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591947408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Adjustment to reflect change in ownership interest in Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Adjustment to reflect change in ownership interest in Bausch + Lomb</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596148112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597385360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (212)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">(Gain) loss on sale of assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_OtherIncomeExpenseNet', window );">Other, Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (183)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596896272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE (INCOME), NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember', window );">Amoun | Disposal Group, Disposed of by Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets classified as held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember', window );">Milestone Payment Related To Certain Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Other Income And Expenses [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfOtherIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591072096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) from income taxes</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) on ordinary income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount', window );">Income tax provision (benefit) for discrete items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Tax provisions (benefits) related to changes in uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount', window );">Provision related to filing certain tax returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax provision (benefit) related to stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount', window );">Income tax benefit for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount', window );">Provision related to withholding tax, intercompany dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">1,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits related to interest and penalties</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefit, amount possible to decrease in next twelve months</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Discrete Items, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Legal Settlements, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597453296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Bausch Health Companies Inc.</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="num">$ (1,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">362.5<span></span>
</td>
<td class="nump">359.6<span></span>
</td>
<td class="nump">361.8<span></span>
</td>
<td class="nump">358.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Diluted effect of stock options and RSUs (in shares)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">363.4<span></span>
</td>
<td class="nump">364.0<span></span>
</td>
<td class="nump">363.7<span></span>
</td>
<td class="nump">358.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings (loss) per share attributable to Bausch Health Companies Inc.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678602151024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">5,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Time-based RSUs, Performance-based RSUs and Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">16,008<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
<td class="nump">15,392<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount', window );">Excluded from computation of earnings per share, performance conditions not met (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678765031408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Current accrued loss contingencies</a></td>
<td class="nump">$ 323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593396320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($) </div>
<div>insured</div>
</th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>action </div>
<div>case </div>
<div>group</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>entity</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors filing action | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims dismissed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of suits filed but not yet served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action | entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Settled Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember', window );">RICO Class Actions | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers', window );">Settlement agreements, number of insurers | insured</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Aggregate amount to be received | $</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreements, Number Of Insurers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencySettlementAgreementsNumberOfInsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678590608784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Antitrust (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593007728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Intellectual Property (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>defendant</div>
</th>
<th class="th"><div>Jul. 21, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Mar. 26, 2020</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>defendant </div>
<div>proceeding</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>defendant</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>defendant </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember', window );">Norwich Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember', window );">Perrigo Israel Pharmaceuticals, Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember', window );">Taro Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember', window );">Padagis Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfProceedings', window );">Number of proceedings | proceeding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Pending Litigation | Bausch + Lomb | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Settled Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Default Judgement | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember', window );">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember', window );">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember', window );">Patent Infringement Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember', window );">Apotex Inc. Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of lawsuits pending | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyNumberOfProceedings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Proceedings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyNumberOfProceedings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PadagisLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593768512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Product Liability (Details) - case<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod', window );">Stay of approval, motion to extend, period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | BRITISH COLUMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | QUEBEC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation, Agreed Stipulations of Dismissal Submitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember', window );">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678590575296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - General Civil Actions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678597469008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - reporting_unit<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678593501824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 6,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="num">(902)<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
<td class="num">(1,157)<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(1,045)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">6,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">377<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (218)<span></span>
</td>
<td class="num">$ (186)<span></span>
</td>
<td class="num">$ (614)<span></span>
</td>
<td class="num">$ (566)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678591784336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 6,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="nump">2,670<span></span>
</td>
<td class="nump">2,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">395<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678596503872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - product<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenues | Customer, Top Ten Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678592390000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenue by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 6,238<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139678598993616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Revenues - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">McKesson Corporation (including McKesson Specialty)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>bhc-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20220930"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20220930.xsd" xlink:type="simple"/>
    <context id="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i57c4dbce9e34463bbe2a00df8262767d_I20221028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-10-28</instant>
        </period>
    </context>
    <context id="ib630580e79374684b3bc209e9e4a1fc3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if69ff7ae606c425c94a4c448e089a08c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59d79d42128d480b82421ffda65ff432_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i51b121d7e567435ea3af71bf428e3992_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iefd2719ffeb04494b5ee89c5d6c0a3a0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1d19e9379e0b46ff90d34e1fad8d4f3d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e24bce6ec5b4cebbd4550c104f4e7a0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1cd02a55811c46a28847d139aeb65d5d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cd1fe160b76486586dea1195d3717a4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4616ed6436e429cb0594228303a7f15_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8fe2e15021d740338238235057cd9b13_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i491b8b5f831e4808948911e15a6b2a0f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i07559fd94f9e408894b9f0c6aada463c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i76eac81be66b465e8aba6b3b5a572b56_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4460f5d13fa347f896eef94a4a28cf12_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i40be409bfc0e4dc099944810f89c820c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id510a93f2b0d4cf69f18a984bca524b0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ided2e9f46db04fda99ec75cd3415d325_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7d1740e6c15b4fbc806318e1936a2721_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf017ab13df548e2924759ee558786bd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i39bc9daea7904ebe939e366457a5979b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idd550841fc7c45b8af6c60f3fa0f8a34_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd39be4430f7409d935946ee25e5a791_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i59016e9a1d5d48dea6c8c26d31dd6af0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8095b42f3c3d46cfb8bfdef54101a414_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie97645899e0b4e1d91b3cd525dccb36d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5c1da51dbab44e64942a8f1d0b64b893_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6b9cc0087df7423bace5af792d04a89b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i70d26e27e7eb4667bc1c7dfa8dc72756_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i36852dd15708409995b804b93901ddf2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i59c4371c6a064973ac5404a53c264be7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0a588955016a4859baf6ff4894efc919_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3cffb35711eb46d0a03ca5bfcf9b95b1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6e25b288b94b4d6bba1d74ff8d01f12f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaab855eaea194ef4a3d9af3afceb50c7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idb174302e02b47c68127faa1d72aa6f2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i52ab05c36a284bfd9324f1075433acc0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12a385d9c0e3419ca8a25109e4234007_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3313fdc6f1694bb296ecbac5328fdb95_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c2b530ece41403e8f0fdbb413bee88f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id43076b85ac44e909d1c513b58c40e62_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id97b7fc5f8df45e9bcc906e84ddf8c0d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibfaf80fdae174541957b5feb3aae627a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifda2519ceb7a4fc5ad1fcf6edc583672_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie79d8ec7d74b44b3a63979eaf5bdd09b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id8819f6bc6184106ba285e6415d9d42a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i988f46577a7a4454b3957c277d8b04fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15e3ddf01146436a8b3c8b5d3de2420d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52176978c3e649dea74aeb5b1def24dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6be7f41bbca44db88e2eea447f357ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95f46d75206b485682e1e2267be9e2df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i025bf4b7665f402cbde028bef48f281f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iceb866bb408947579450eca5b5dfd24a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba83711893564f9c8987daf355043fdb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icdf4f32143d24f1fa87f639690b700e3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0a46937aff434e73aae5f0ed8b35218f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib5d21251ba2e4156877ad94aed58ea65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1e021ab77684430873b508aa3f19f9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6b28c3de4db4949bc89001e98278b7b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d5398ad231d43158c6f75706adfe6f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbe2379453e44861a0ed685834555c93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ief8fc54ee0cd4b3e9e5451b181dc7a62_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia798b021a554457c89afa7d9f4e59bf9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9acba15c5791474e88c007d6018e0579_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i488484ed6b0d4a8eb2d7c63599be0468_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i645aadc8462e4f0bb9c3992e508abc6d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib6d1b61008f54b72978ed1b60c02dd15_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i029ce1f6669d4d13bf48542871624ff7_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ie4ecb2729d3c48b5a5174645d3aea6b0_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i7976654304fe4df0800004afdc2d26a2_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id24bd8f4d8504fd09de88aa4e16a7666_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="if7a1d308f9414a5fa9f55e2a191cc9dc_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i400457a1387e48eaa2cf072d6caa4556_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i9385fd4916c644dcaffe698618f5a572_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="ie66b2900222448dca6ffb1983135533a_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bhc:IPOAndOverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="ia75431739df4487280446af7b19c22ac_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id13e6d60640d4848933c41324b30da24_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia2b64397f3134ccc856057d7d06cac18_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55bc36e507494e61b200544c3360e3d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7bba4a0408e47b6904cb9363a54d0c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64d25a700a694dd0bb04c6e978004998_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i588fb4f24bc44da9b20f9ba64cdce034_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5023261686ca407a90455d9077dc3871_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a74aed9df0544728bda592f48dc4d5c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12459cee3f4646d2966fb895ab93f2eb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1a39f472d42a4f5ebd126b085b5fe9e1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia09603225e8f46f9adf432aff5307061_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3f5cafad91a7439a8ee4e91276eddf07_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id6e2c1d055a04b8ca3b8229415cd198d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic54b70832a484dda991eba0bea3d37ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id913d7fd4ae340d99bf84a67735c6296_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i37dc4d41d03d46f296e6c60b958dba8d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf53ff30035f4469b7bf0b121a32dffd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7419cf53c79e45e3a1c6ffa5120da79d_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="id369b423b8504df5bb95a335c257add6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5c705f4ebe8f4e9caa8290ee18d7fa8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c2600d93b104798b8817d0bd816b754_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a5b868d47f54d2daecf77fbde9240da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67586450d7a94efeb4d4b4e98a992f51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i383189ddaae4494a9ead4886d08862ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54c5d4750d6b4c8ab87893cf4856f81b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i33ad1c289f4d477c9fa5a51190c9e7cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87ed4784134a476cac4779215bef619d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0b06a8025f5c4eb68a5b3de937057a18_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa59c5c6d2574133b660040dfd6f39d7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iae15cba69f554a19879bbd577f98cbc2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibf7ec2397c1c476d83c06887b07a46d3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i264f439282794b6795807f3ae1bb71b6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2965757201c94320abadce3840340f63_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i24db5cc85723404fb1251cfa00551475_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6131be55d52f42009c7700e15ebe45e7_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icf4245062a7b418a90b5c3eb455b38c7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i687a6d97c876442da5f14198d88e14b1_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2c0c9cf75bab4540be7e213a897e311f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f67a143f58b4616851d1f79883c3ce8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i83dd54e76be14e2b8cddedd0ad775700_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4bc7df085735496995eedc6a00cacc90_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c15779e38db4d9f960b2dbcddd1f4c7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i98ff32b9f66642d49d99b62aac6963ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iede60bc2c8b94524b78454391fd1f286_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib1b8d98ba0764e17812507d2898812ea_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6bf4d2916304721b590b0e9b170762c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i189881ec0c284dfcbb328b608d14d436_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5d6f4ef12df34897a610582fba7a5ca1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iddfccdfa38764f7ab26413e57457105b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib11917dc946040bfa50a896265fc544d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3856df3c34054e50b83aafeb6a21dfa8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59def28407a7463daf61067d0788531e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55579786a38243319015619aafa89fd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7cb0e3db56a4ea981bbab9943aa32d0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibdfbccb558174a2c8c0c09b05b34c8ef_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3c63ea1cea814379bfb6c3678f5a4b33_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5ec1e524d22a438c9c456e1b9c501f25_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i560fd028d7474fdd985f6a52302094c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b7c343d445f4dcc9a19e5d1ba15e4af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3102bdd26ddc4acc85720c1d44031b39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79f25ff584194105b7bc29f5d77efe7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2ad6947f6374ac48f3ac1e7694627ce_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if80389df867444889b10bc292d83780a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6cb7a659ca664b599f9e404ffbd842e7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i97ffb0132d5844cbb9a45d214fa9b29a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0d83aa84f0be438bac5f8d689a31f364_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02290af2908a48d9818fdaed17915266_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80540287663d42bebe1ebb76c28b9e75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cb8cfd06a6a49f8879cde7f8a7d98ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic0ef55f3a8f4410b942a22f1c9b01c26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3064f6af45484839a5e9e28044f57d64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i259cd2e6dab94c2ba09224dea2beb7c7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i172f1137c8f54eb5aee6b0e56da822a2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i664840dc517c429f8d7027d6465fdf0d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic1e5a6363fc74a07884d25a0f2217af6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i658a48e24ddb46329d8726eb2248580e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib700cf771af14037994bc18bd56d1eac_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifd5c6d1837094f3da3275340aac12543_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2c32f9e20d74e7ab62844bacfe8a06d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6ae5d31784454d4f9c64507a80288ac4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6f6d573695f9479a899bfc1140a6a312_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i82ebd628dcc84efa96e5a3f56fbb029b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9a33dade7514111bc4b73c39a7e80d8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i39777750e2f64ea99b3afe8746b25115_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04b46684430b436b80adda1d481b4307_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3c5a5a87413f4813b60dc909501166c4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0d13600b4ae84400ad2d966a20e8cc67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5f7fd33a30e4a169c5464ee3e62b2cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic008afd14a8e42b1b866d63b770b5fa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0491752f49af4e53b382633de1597dca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7c556fd4fe44909bc9174e88819eb06_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba36257072b246d29fda1803494bc0af_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6ed75df41237422bacb5217c299a7a89_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07c71f42a1544418b4d10d3fc382ee03_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i75b032ae3e214a648b569459dbab455d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9ae4a5ad398947318b5198492ce65b04_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i260c0d75915a4ca3ad834d641fa75343_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i48f2915dbf2941e5b52e80096e27bf1a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ae79b3262d842b1af103d3792958795_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifb7aaa35ab964b01b84dfe94e256903f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i63a5e3f00efb48b2b18db41abfecd3de_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i71e359c95d524712918710296eeeae37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11472c1bcca3473484bcfadfc7e303e1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id18a1afc3dcb4214ad64a89920a42e55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9613fcb5ca34578a0abf1ab147f9208_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3e063d61f8c44899a3f8978861d16697_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i602595f1880446f59ec15696e1d75c4a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6e873c909a3144db9339746a1a94254f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia86e90503a154ca4bb57d7823f5d7f75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iec524df231434a33b3b75a1f327b3a14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88feb25df1514be1b2bf7b05d2488070_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i96a1ed1bc1784b8db2b2d22151163626_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3d864a514bb45dca143ed3ab32eedb7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i397b0577878d4f30830c80e5e23ba904_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia8ea1f91a3ce42f0acfbb45e515ff2fe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i940f002456e444718203e05f909f5845_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4f554645c0484ce0ae9425488ca631d5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69a2ccee5a034061b928c4d52b49efe2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0129268431144c2283e8e4acc5441d56_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebbd566effed4fadb5896bab8a971143_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b8feee0c59f4701a4312e6c630644df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66ef4daf91aa4f8281c317fad068c66c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icee578c670ae4dc29125f5982e51a5c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ee081f26b684d829a12ac1265d3053c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28b49bc1d6794cc7856a6269ce445917_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied3da8eb119b435bbd381609ad532677_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7c7425072c141219aa1cdd573bd405a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i184f88c56dd24fc0a24d578d3cec1912_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i524914c3e77a431bb6e23bf2b8d68654_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c2a1f6e1e67469ca7b69557b895dc8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i054e43fb12054855a665b8a78721656b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e156c972764457f83682644cc5296a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0655cf22cd44bd085e0dfc3bd855124_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i041eda0c99c84e58bc1f197756109245_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4586553989374f86b0151f9e1dc47d44_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i28a9044c2815433dadfb6a1fbc0fc718_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i00e30d8a0b70472da327a5cd5d504e40_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3eb7d5760de84dbba93d5758373f7df3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifd3f217039214cc99ebb1a3146d44e2c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icaf04300c0b04203930e4017146b0a29_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i171290f4c16143278fe977553e53a298_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i361b8355ced14036903137406c65acd3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie32f67a7dcdc4304965f785c3401a61c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia6e12bdaebcc45a1b8c0c18938e51e4e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i734ba9baeab74604b0c7c558dc66e5be_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0c43778cbdf409ca15ed80687c13da5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec85868873634d7aaec5771a953c7224_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9ee0f7dd3ca94d9a813c20822f42b12e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia75d309fb9e24efe806b94be702f2683_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icf0b557c0f5743d4853cda063a55d5a1_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i64029e7dfd364587a73eb03edb488c6c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7be821d39f844c7c9e6f5db374b2d390_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icebcda21eb184f5596ae20266fcd05c5_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i807f651e453049d280b13aa13946098b_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i7e572145d9a7467baa36216af20a4a17_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iad592bdffaae43e9a655afeab7d37965_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9520dcf4eed94040af3402086c331516_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ieaabe709841d4ab5a8f48593d73a6236_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i29fa46a2016a4d6fbd35835aab2e7733_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0d23798ee6944435964f0ae2a74b0053_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib7cbe70ccd6a46a295e6b86c6ca5e603_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if06aa410016b4d3d9736289f10b1b949_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iabdffbd57d864d79afae07b110981771_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8161c31ec1444e4282b76d79a09434c1_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i34d55f72c27c47f6afb001ca411f5fa2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4339e12a380546a9b2b74237a9f3cff2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1130a33c0fde483fa1bae8711549f82b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibefdea46ac904b858f0d89701cc31d09_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i203a22f1210340a79695abcf5e8cbc84_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7a8a8be34dc47ba912bb7fad91b59d1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6e21f5810f55489593ecaa960423f5ab_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaf38a4e092a6474e82b48723b723f43e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4bad238d099849c8bbcf419abb996956_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i07b8f0ab2fbb4bb7b6a75eb4df909667_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie58467a391034c9cb187019aeffd9731_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59c61192e231431db2b0a3faccf31084_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5e23e6b1602e45c69f5e0263e4e91c1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41e0efdc5bd2442e86a6a489bf72fa7a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i20e089be5eb041cf9cce81981f011be7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96f39bda64df4253bfb97df28400bd07_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib4825754c7324c8182558e6ae17503ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief4424b9ece149c8ae2652648e9479fe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib60f32e20efe40bdafd03b20dcc4ea54_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2719dec24cd48aea9d17bcf664f412b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i658fec0dcb034795a01b1f1d2734dfe7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id923a0c7821d408eab60e2d1ebbdbec9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i17c72157e725454bae3d98331b48e1b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia4c8689541c04f66b5293904f3094a90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9736f916a62479d8d54ac9b1251c9c4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id34ba1093cad49c292458d52b08c823e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65627fa9869f456389b3882ce8b37654_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i847b6dcc9bf747ab946d8f1b08b3d71e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2824f9dc84c40c396db9edca43574e5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8bb6c1c4d20b44c3a7dd173a66fc96d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i202ff1947e264b19a06b70f0ffcc5c89_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i48ead96a008c4245b48958509368a215_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6770f439f6854fdf80d5b734c92a4554_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0837135263d44f058fe95a28f43c5e2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabd7119954044616a3233f093428ce2e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4849d9106bec4ca28083d112da7d7ad9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8a060f4700c410dbf92bd4bbab91133_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3d20de201c0e49b49c27d368b4cb4cb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i67496121616e45d98e1c3a401c8ad3e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i79ea118f8acc428ca2545966a39f9e19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6125e68618df43ada745dc4ed96c0b44_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1f48cc3094e8425dbf7cb547b1775c69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i624988cc531340da8809b18541e3ae0c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icb7f0a78f9524510a26d87340b762969_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec3a4af6ebd741b697f1f5228fc4b251_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i46824116217340c19c4097a996b6f0f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iffaec666689a4abf87b5f4f4e20a8005_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaed6c73971e144729fd723b401f24f72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i736c5fc93f2242fe9da805a6c5e69418_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib7da4ab69e9549eaa9e8488eb34481b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ad837f07b304b389bac2395b7bb644c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i05e0e09e5ca542869e0a304640beb346_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3431ac7fda8140f496bbf1281db492f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2386767ef8494039a45eedf4276380c7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1b58cc7f53b24512935c9762a50cc8ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28a31a3954134e40bc913cd1fb66abf3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ice079f38e9d1403daa063c880dace2d2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i74a12b5112bb435791910303cfa182e6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8728c63be96941459a588f3116991b8d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia6053ee47e754dcc8601ba99403a76b5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0cae089600e94389bc02d059bc908b54_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie79f3bd1f9bc4330bfa744f8b69c453d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if878061e7e8a4d5b87624e62ac22aa3a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie761f67bcaf44003906b0b905ba5b263_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i66a9533f0c874026af3f2ce11e610087_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f288fb4475b42e396cfd814e2d07cb9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9a8044c0008d4224a9252821ed90cab1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7e2c41e745e94aaca242b47db1e9da3a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i22f1e467a3104724bf0814979c3d7b24_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib64b46934a374f298609c8f8d6de0962_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie88308ccb55545679dce2acf47006522_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ideda0b3afeb94283b8b7495bc71f5cfa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i58945eb4f42545a2a975fa287df7030b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0f887978c4a542b19634fbdbca4dbd97_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i278988850934419e80acc9d963dac666_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="i00732fc9ff374b49b979455466cc8f7e_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="icdfc7e6315fd42efbda70b4c17cce33d_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i6365ee6027ab48f0a916168124555cb4_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ia532a9f771954ea39e670e6607d20d41_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ie52f1d3dd7b44370875bfbf01edce092_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iff4ef5de85bb4627a12cb69700bd7abe_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i829327ff659443278a6e3108a31e2416_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ifafb7519d3db4ba79da9149156c9be5b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ie2c63af1038a498d97b0707660dbeca4_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ie319941a51a34294bbdb2ae3718dec8e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i20cd5f0493f2487bbde5f2221db59a0c_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id3eed0b285dc42a99845525f57bc2eaf_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8a03fb030a0040cebef22c0f5654ea66_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id3e53d6553f64b7eae83fca240d210f8_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i15dd8f000b9941858060dedaf7e029d0_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id330da73af3e4586bf7d8a9ae96e9b1f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ifb86b03b3ac24b4e82d95decf997f3b8_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i06b38bcf16e54859a0dde3ac0bd30c5c_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3944f858836c472bb400b25d49c9a870_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id154aa3590224033afe021d4daefc439_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i02856360ad9c4499aa8ee226526b1aa5_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i36893810d2ab469aaa9b5e3e8bd9c2e4_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i3b91f50e40904c03b83e3484fe6eee31_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1be6df6cb851454f9afb224870173486_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i93f125d7ae474da9a0a4942295b43c0c_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i726749b95a30497288303bb51019c959_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i22e638cdad174145acfe1cb7ca9c3b06_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i85f9310875d34c5aab769c2612112be4_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i14b599cb18c944ee87759c867f11b854_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i2b8e5c5dac3f4de3a568fb4b1dc17504_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic15ff81720f140728bd400ed17b1d660_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3070a693a5854af3a22dfe66f3655e85_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i943999c56fff450aa77e708b60d39def_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic16b8fead453422ab2aa9fbbbcccf83c_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i297866a68ce24747b81d40a30c023bb4_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i13632d9de3844a9cbd798441522b1bc7_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i4d4c681d58b24f99b498d9e6a296937c_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic4b5207c38da4c0c9112b7da48cb7ce7_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i80f700a1b8cb457dbc050366a46232f1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia63c47b1828f4ae0b6b1dbab0bb42d98_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ifaa17fd0da484c67bc48038c0747623b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i53fbf53285954caeb0e7f050632c7597_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8d49f58bd8e741069f996a82897124ce_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ifebc6076ad5441fe9acf2610a82c6104_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic1f904c39c824f0cbed6373fc8027458_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="i61dd05e0e56948b8bcb9f052101aeaf6_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i9189a38171dd4ebaa45559422267b0ab_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="i797254cc60b049dcb744c873a7a119bb_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i35465fe55b7945e3b6f24aa54344fa38_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i2a503b3152c24a3aae993d9cca166b10_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="ic7cb7ba0199a427782c6e11d979cc908_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="i463a1df44c5e447c95a44b5652a58c27_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="ic986ed29a4b54c67b340f512dca91b23_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3cb285fdcf7346e4931be632a5d32554_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i08d9f7c4a1b54b0893e8a5c93f2b8b41_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1870e555a1fd4b21a7e5585f4d019a9f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i31cc3cc5d3ca41eaaeacd771a686a45e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7356824e0b3446aeb0703cbdc0f9101f_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="i4804f7e82ed3464d857db9b9aadf33f1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i7f730e3004c4467e93c8beedc0748d7b_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4afef88c6a4140829ef856906a21c44c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id98c05c2a0a14ddb8c06bf78beb4aad8_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i042059a75e2442fd999e415f9c25591a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i2717f1d183464ab1be432c601c1e94f8_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93eb31e461ac4db5ba4c0df1c70c52c7_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="i7e9c7cf1e63843dd9922d9993278a56a_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ic1d0f02ef63b4948ba4e261acdbbbfc2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iee6e1b627daa4dd5ab985eaf3d792732_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="i23da95982875422e85842884cfcf3c78_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="id7cc1e4c1e0e45c088cf0da8d3478561_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i879c2fd226954205b21a10810b667c13_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i40e0ab954b9546489a9ef90bab33b427_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i12e20cb0b43649a1a6d77f2a05f00d92_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="iba04e7a5f74b447488bf33d1bba8d3d1_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i4638c5e4165448498eae9d03caa89485_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i9e3179052a5e4e44b4b9793cfa4650a3_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i125d23605450450a9432058cc84577ab_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="if3ae116d5b71442d8c602ff3e0ff2420_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ie8dc48d6ec2b4113ad14034a1c76b675_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ib87da6b4d8544d5dade0efad5191c5c3_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="id7042d4e6e0d42a092deb71733fc7627_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i7e5a843db9464057940288007937dd58_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="i838762aec48a48bfaae871f10aa12c35_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c04f97f5c714af7a5e387b0d156bc8d_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="ia324b82ecfe4472a8eec915831a5f250_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8ae9beb58b9b44bcbb18d4e6cd9e9fbb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i80f371d3c6a04f48a82246f042826add_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i96b5c2e6a48345c0b538f3138c5ab5b2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia2a9ae3100a74f7ebf2929870b5083e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7c6a3ac703f94d4e8ba3718b45516087_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1c67b322920745f8ba3080e92c213cff_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf2bc07e5c9d48648d447ff5d3dfcfc8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4c782729eb2a4eaeae9a5f19119db3ef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2464c5727ff448ddb5ad8146c4b17152_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4675f7627ec5490496e997650085e455_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67d2d86b33a741058fda2e20bf9a30d4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d8cb01e461c43f0ba0ff2f3565c5ef5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie31113824bcf41b3885c724ca05e5ed5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i15c39c0bbcb54df291baffd09082d1d1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60fae9ccc16447a4bb6ce23208cd688c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5e8f2a27e6664bf9aca3e322fc1aa7ea_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2b865ebec004e23aa361ef3a12e65ac_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if73278e7a6654cec90d56f5d9e86109f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8ce14ad9dd241979ec43ff28ed9826c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i18c983dff3c34ced9a702d90c64a861a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65cd64412b1044dca3d7df190d03e1c1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0ff9b7bc0a6b4740af09323c44145b47_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa5726cb791047928df873284ca85f71_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i788020833e76460b8e095fa176b6d7ce_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i781d955207d8472f97604932ca86559d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67229cf570e341819da1a0f863e8fcb8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8fac2a0db25144f7bc4d94691e6afeaa_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="i68315b257d6e4c95b8a3e5c0005d0240_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="i206a35173cac452e80a9011a351123e0_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="ib0a224dcb25e4aa8bc91a4cef4a39b4d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id428743f89e44793bea4c8584a67335c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i677c4838f7c64a0fa4133f133bfaf2ce_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanRetentionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i71c67458cddf440fae3e9d2616d2822e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieb87d76e2584480b8c68e4b07d46150a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib82c90dfcfed4b258e3dfca87b481343_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i93570e5abb6e4069bba204d6409b97aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39bbe98ba2634efa8a0ac3f26b52da3d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id17555885c6b4ec5b2e98860a7c4cf48_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7b3c57844e57475ab663a9bb253a2e8e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icda04c31ebe54292bc90ace1f755d969_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3e9cb5876bfd4fbeb27c0c8d2d1847d7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iae4a35e3c4d845dea31eb0b4afb0fab0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b3fef19b7a044478c661e599645a697_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i177e13e488324255b69c74c8f05e9364_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia499047b1cbd4a05a81ffaa7a7ac8912_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib221baeee1504b62a9a00fd4bafa821d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2ed370dc33214c95b38faa3097c8e671_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieb3cf936e9a74f7ebf11fb503c9b7c72_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i5e3f5299561c4eebbd5248dec3a4060e_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idcb2e316fec14bdc856e971726c9f87e_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i99ebe24a04454b4091861650ed6bacb1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4fd9f0cc91de49dcb8c8cb33d395da0d_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="i29e2849b192f4aaba1d8952c944b6789_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="iaab8fb8a87cb4b22aebbfd8cc4b85230_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="iafd7324df4a84a149605aa327631d7ab_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="ia481a4b7a6514b33bd76b28c5e86f915_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="i048227f1aea14eb384517a325981bff1_I20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="i871383296da145e486609cb4113359a6_D20210720-20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="i0c6de1e6ea024ddbaff325eb35a50f24_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i49d2de7c0d8f4004960c2d05a237a525_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i8a53e2265c4140e89771283e17cbb465_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i2c3c58e3d67e4e9cad64210e49062a44_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i1d5f207d7cdc4819ab32038b7d6fb0c6_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="i6dbd8d94f94a4b9b9032e8124939d763_D20200326-20200326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-03-26</endDate>
        </period>
    </context>
    <context id="i99c90fbc7cb942fcad2237f660bb4d3b_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ie6951d2873de43869ddbd5c757e327b2_D20220721-20220721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-21</endDate>
        </period>
    </context>
    <context id="i74ea1630078d4e05a6bca37ee09dc60f_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="ie22ec902753448c8a53dab3d0449fdc3_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i53724202d602400c9250252097901776_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i845628c47166456bb97e0565f2c1bdc9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if47547b12409405d8d9c9257fea4a4ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibc621b0fe4dd43248d552d9e078f0955_D20221103-20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="i33c91c7c2a624d73a2b21e6f04607fd7_D20210910-20210910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="i3ea0bb7c52aa4fc2b812e3b4ce2644ba_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="ie5916243ff944d46aa17d2219e926c0e_D20180801-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PatentInfringementLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i332ac3fd809849fd83751e1cc812e29a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4136072a63394788a51d3aa4149f4df9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5d82fa052dd1452883203a200bf1217f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie3e10e59808e4d0092702cbb02aea06a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idb508c450eed40579b6ee442cc2907b7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i184af1e8e9cc401f9c92a4612adf20cc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4f33cd61e80f44d8b6fec68312c48113_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i92e33ca886304a7f8736aba94ba18b95_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="iafc41fcffae24dafb443704717376dce_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic05dba365c7149048c6b1a7245d1b247_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i88b4c08132f844779089399f6327cc37_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="i50b3dcad39c345c5ac603e17ed95fc3a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a48564554644fbf91499853e1132e1d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8bb4504aa6bf41d1a6be48aa2c1f175d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d031dd6d0d24cffa3eb903bb856d240_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if5656b3707db4122895e60ea240cf646_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib141aa7ca51144b7b474e3fc89019f7d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f6422ec5e814d71921b4040a843846b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d22d39c1ee04a7787dc2f60be8d5f7a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86d17424aa5a4db5a07016d40a84d937_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia1f9b74c57634e8c912801d8ecd437ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6378396c4e9a47e1bf78d4f23861e774_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i870c4afe29af49f3a2a7f8542ee2ccfb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7789d8fa68d94ab1832565529cc7b6dd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i961d5c068e19458eba50a317f05a809d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d87fac315ac4359b4ba48ecf9d3800a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3dc4fa0ce3094043b06c419d4f2739db_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12f4d42dc1e84b6ebb78a7f56a821a8e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6abdfe5c4694514950ade150231952d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icb2f85a36c4542b38c592e0acf6f1180_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idee32157246540168ca54485ea8c5d71_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic2502f43413f4cd480e2a0246b792a52_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id84aaf53830b474e8b82377c387fa23c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib58454b50b234f0cae6d889781bf1c3f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f1bff2464e6492f978876c9c6825fc3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26d876376e54400484f8385cdeda205d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibd45d6d098e940cea4a1d9a05d7a84d1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie4a9da148f254cccbc56ead023ff8e94_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id018a592918a4c7d92d36586e30b8b25_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e0df6736f2847b197e7b8bed8c689ca_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6e24b87e5d8f49d18b41d6f564417334_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i21fbd1b5e5b446a289edffe298fe2beb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if9903b8834174c129ab4fc958937b81c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if1abefd1a9ec41a0a822f596885e4972_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8eede7fabe3a4f2ba57b19bd82733d3d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i567d22541928427db55a03ad179a4ad1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3aae3e10a71b4f6a98a38090820fa000_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie53e184c5e4e4ea79e2591ec3164d59f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50af148aa25b49fbbfe10ca60b5ceceb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i947a6e91ffdc4fbe89b4ecb87866d600_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6813706915f4ea589187e4729d7e82d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i88458031f6ac47b59b944bfddbce8e54_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaa45dacdd3d94b9da782f49919c50c7c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5529206dd0354add818ec8ebc745ea99_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3b101667c39b43339df8dca9eb8a5c17_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i195b71e75a26477289ed617294657ed5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i586500eaabcf48daa510aef12cb36e94_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4547bdb61bec469cb232355667f60334_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d5528e4e03c4951891b8333a4918812_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1da9ab6b49674688a517da02ff148635_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8677733f10724b908cb5fa12e547a9cd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i99d18eaf8a344deabfb39b5d1d2f5244_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if4c7c1f563024eb885219d1cc73e2c03_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7e529afb54794cf0a4114a5202965a4d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i888846f7a8a24e6cac9459c35c333be9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idfcbd7bd0541403ba70a5c4a488abfad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib2366ec826494978b8848268dbd37f56_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5abfa18a5c8641a1819cda416997710d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia79e84fc1b29410e8ce4e71df86aa5b6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2c5421c9b35b4516a49077974d2e5949_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if27fc1e4a91e4d25a238da7b45796c0b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if4a4f9d43f164c9b99692b1912045740_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i66b3252a18104908b5a55f890c213286_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i425034548a5c4d40b9c2c34552bd6d3d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i34bd3f79386a444ea669a83657bf3167_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1418ca7566eb4be890fe201a00997650_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie60598e761b44eaaaceb643fb0d3f737_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib91c304c54df4d51a17ad1319b6cefd2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8153aeaa29c14cf78898a3e0430db0b3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3155b234cd454dcda100820d79b828e3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2478dd9d311e41849390cfdcaf83acb0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1b297ee44b024a5a84ce38bae85846c2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22473c0e99cb43b1bd4931030815e25a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic56c6ec263244270a0635f1fc010b8d1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i55c3b644d34948be9d9c18866f4a5d9a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f341155d9df46758157a2f5d967fcf5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib9c0d01651fa42ddb2726f307d78e1b1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i70e6f8d534264d698d9daaefe158ba7b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i43251ca627784927b25da791c21f44b4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3037fa5f424f4fcd91ed8575d90726cd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic136910890c64c788ae7b465e4125b6c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9b3ff051184a4834850b051a7d4eb1df_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i40c9b728ace2464d8f96d58ae572ebbc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6567a2441b6f405199585a4b83fe5bc8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if77a4befe17f484688509cd99dc3b12e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5aca7ca963b44994a71d3617c064d6fe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i422af7d7e455458c85d983e22cdac59a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i944bf2eea27245dfa96a85b44b8afebb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44102882489d45b8a65cbe80612eb503_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i629f1d9bd1a2455f855f4061c4ce4dfe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib508b0f79c104da081f95ec2beaff2c1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1e8b341226e741e6a61a9d17cbae03d0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e1c2ec3c04143fc919380f19acc7cd5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic90dad0cb3874aca84524b1022581f5a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8aa8cafb0fc44a99b36bcfc0892304b6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icda4a6e048d64e4c8a7245ff0c6385df_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23473ab81eaf45d8a36b3bf461716a8a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48494750e70944a6a8fe08c72a157c9d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a743c0619b545b2b9851ee1735cece3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26aec855e3534a57b91887cca0df636c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia8b64fc9195a481b99d8eba5eba2c499_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2020a325cfd844aeae55587fb97a9bde_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idc165abe9fd94612a2e9711f068afaa2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67b7b11900d04f5ab4a91815dc85a13f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7d594998be2c466a8ae3f74769b467f1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id14c76797d024f8a850f17d12da55d9b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d945399f7fb410484aeea7fa1086e9c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19757afbfd8c45fa860915adcb1688d8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib120955476934bcab3cfc8a57258b2df_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i54edda7460544fea9cde5c3172db7617_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1eb54743e79e418c8eeba61c5c9441e3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i755e8ef589a6417c85697fb2489e0997_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5e344425e326404fa4c3a5ceeb0a33ad_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie27be4668ecb485da4269a39bfa27526_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibcfc2d283efe4a7e834029578338109a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i599ad95889f140dd856c86816a0647de_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i75dbc41746a6477da43e97ab5cdea898_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4464cc778bb74ce498dcb23fed88c066_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i583e1c626b03403f87d3f3663e850328_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i35e34d06d4c144ab84ed676f2b1e7904_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9e97965210ba400a8aa5affa4e5e8dda_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9713e38b2cbc4a72bf04b0dea907a1e3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i579951261424471ebfa617bcad167deb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4241952b1e174e2b865fc979ca30a592_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50980e0088f041399e5e72f5cff6248c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib2de33d45cf94f6b9d2f33a3c2bba1cc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idc88c3d81b1c4955992d1247bfba1b8e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2811781ce7f642ca89c86c7f0de518bd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i791a2916a2aa4ab395ca981e61e7daf2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9826556f6d8947a69d81d512d9468782_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b2f39db7b954476bf2c8bb5f8ad798f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib54bd462ed1446b096e8f3df008338e2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36f9d93817ce485782bbbade2c8f8fab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i84ea63fc42464411a719b65e9cea618a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12376a48681c46099f3a4e9ecbf34c5f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2bb127d7bf284643bc5c01a24c9fc5b0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i58982e1d6ef14225a9ab3729ceaa6948_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i301b2caac8d446778085cc79b589a737_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2fe2a425b9245fca2bb47d15a250d6b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0dae99d75ed24ba5b1b8b1f3747dda78_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8c493f1eaa24d36a5056a2ca842a812_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad50b284a5ed4c6d86183cb2fe3fdb97_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i23f87201482142909a01e5261b00e554_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i905ce8cfd82b4f538a2dc187e9546dbf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id81d14aa32074f3ab7f08a1036ee0b8f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id20223e746334d6f82eca42140a4c935_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5755175f3f06430ab66277abd6454600_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia191f4ea8c4945b4906ab7f70a93deed_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ec8559c1ec940ef809744ef427103e5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i214a5e16df454787bd61853a8fb3b9f4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib03306f36d12454ab64e7ac8cdae92a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f14675214e546ad9d45a02682113cf2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0cbf185e217c4dc9a7593467145c745b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc95d6d82edd44fe9ed4f8dc335f7e42_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1fe643b692e4449fadb261eff5314a8a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37ecc27feb094b618ce6496fa054bc12_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b0115418e894ab6b82b70dc6e6d9531_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia407433f62b843baa034edc40f2c05c3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86d57f75bc2442e29fe1c7f8fa969c3b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie0e8eb0aeed843fba31c70ada9493305_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i072aaec2db174878954cb70bf860e758_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic0814d1f5f404ef9b9ce2c33efbb9cf5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46f1158b96e7498b8bfdd8ccc5ad9827_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i24af9b92680b4f0694745bf435e5472a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2d52656bf37d43cdb7e063c81480fb0d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6ed64d739418416f87bf91f8425ea391_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c17a5874a9e4075aaf8c4ce5d1a4e12_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e326ea2d1834500a5932fa3f6d1b28f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34a7b27f028d4f1b8e3316964ae4b6ed_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib8acc98b4a99485f8de664a8f1b2574b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7593d4411424499ea8071b2b1744ee40_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i81cef13fb1fe4cff88b12247a3647d2f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a1547713f2b44918264056f12b2d4a2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1cee586c236841fc9a104c883eb25025_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae1a9b9786b845c6826efe7b5650b900_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id94f8fad7b19469aa645f46052c57c3b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00ad1728e8924998803b5744ae677c7c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifbe3c58b4ffa463c91e47a7cb28199b4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id150c24526bc4303af49c01163da23dd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i38317d58388c4fdebeaa753429b54d9e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib445c562897042bdbd49b80e1286d65a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9e344dce62744d278e0b20e50c3fb0e3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3b0143ed82024e4ba05f759a4321dc0f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0197306db91e4812a3d4fa3b19135985_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i75298065a5bb4d7abc0cd5a872c8c23a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib0ed176248a7493d8af99f37e6e639a8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if9253db1500949fe906fc9a1f4fa1b38_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2b96a64aab504e74910b39ceb4520476_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia30d18d2c61649808a5f0ae632b41c66_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic5dc9560462546608eaecbaa48330ebf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59f4818ab24d4eef82fd27de079b7973_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i05f81890fdf044bcb330e157d04a97a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3eff41ef021547c6bd85e06df906d0fe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac7d036a10b44a9b80aec045229f3086_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic155d49fa70f4c1198d083cf8239e270_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icc467b3d64744017a93680acfc732aa9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iefbd58fa6bd147a482305292a074c257_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if0d0748800694d148893ade42e236442_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2c124d21acf42ce85f54a6eac7f7ba9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i56c7a4309c6b4558b2d3e9160a31980b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia8dbcf8ffc494fab8b9df1864aaf00a5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i11d0c319938f45b0a9419a9e53c66df5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3959030e4f5c4df99cf6dcf1ebede4d4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie1e5e8321bd646448a93cf036eae8e2b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc35d5603e0942dda30e190b9deb1627_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i11911151b9f54dabb034a5f6b1fe8839_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a95d34d1ea24fd586a885cd6b872083_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i89bbb02a54d240ef8ea4afba712e86a2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i52bf2297ad3d49449422ea1e9823e61f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if6f8127e8b0141fb9d4372bf3c182783_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7ada8553598f446f8ad09650f86726aa_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifbaea260f0344e5b94077f35b76e27eb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd4d24d726d04432a277be2e908a6abc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if6f382705cad4a4b84c68be25fa55777_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ec9bea2ce13443798c0a6d868c068d6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id7c5dedac9f749aa9c8913ab247f1fdc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic29b7b8ee29a431598793c1ba4520dc0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ee531f5d0b64027bae00dc04e77f297_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21fc561bc8064837bb579d9d55ae3b5a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieea6d886b69f47798e958d42e3654c2a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id3e2a5680cfc4b46b7891fc6f9830006_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1f8595d458c34e018a63a7863b77580f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i72d246b81e15499094a367cbe1d8db6d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i54794b3420624c9fb619461becb59f8f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd0d411b81984c788cc81aa73ab8f449_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i62a332bbaec540e481ed114e383e4dd0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a84613cff7f4368a54a708f8ba0ff04_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8bbda526e0454dffafc588718e72bdbf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="appeal">
        <measure>bhc:appeal</measure>
    </unit>
    <unit id="rate">
        <measure>bhc:rate</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bhc:reporting_unit</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="insured">
        <measure>bhc:insured</measure>
    </unit>
    <unit id="defendant">
        <measure>bhc:defendant</measure>
    </unit>
    <unit id="proceeding">
        <measure>bhc:proceeding</measure>
    </unit>
    <unit id="lawsuit">
        <measure>bhc:lawsuit</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV8zLTEtMS0xLTE0MzA2MQ_ad1debf5-f6d6-4f33-b6c9-19aeb36eafe1">0000885590</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV80LTEtMS0xLTE0MzA2MQ_4900a47c-062e-44b1-bba1-5cfa3a34e7e2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV81LTEtMS0xLTE0MzA2MQ_4099ea4b-8460-4ba0-925a-4569eab3e5b5">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV82LTEtMS0xLTE0MzA2MQ_bab46bc0-b1af-4b75-ade5-b683877710b6">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80L2ZyYWc6MDVkNDhhMTkxYzEwNDExMGIyNjg4Y2EyZTgyMDRjMjgvdGFibGU6ZjhjOWJjMjhlMjUyNDkxMDk0N2ZkNDhkZmI1ZGMyZWEvdGFibGVyYW5nZTpmOGM5YmMyOGUyNTI0OTEwOTQ3ZmQ0OGRmYjVkYzJlYV83LTEtMS0xLTE0MzA2MQ_d657b874-b1d8-445c-9606-4225b74e4896">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2717f1d183464ab1be432c601c1e94f8_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83MC9mcmFnOmI1Y2E2OWY5ODFhYzQ3NzA4YzAyYzNmMDAyOTEzMjRhL3RhYmxlOmE3NWZhNjc2ZjE1NTRkNzU5MmFjMWFkZmYxNWJjODAwL3RhYmxlcmFuZ2U6YTc1ZmE2NzZmMTU1NGQ3NTkyYWMxYWRmZjE1YmM4MDBfMC0xLTEtMS0xNDMwNjE_98af9c80-b158-4ccd-8997-a5cd3c1317fd"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iee6e1b627daa4dd5ab985eaf3d792732_D20220905-20220905"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTA5OTUxMTYzODk0Ng_fd0ab737-0f9e-4702-b219-264d2a3842ea">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia324b82ecfe4472a8eec915831a5f250_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5Mjg4MQ_d3858cff-cf89-4b94-8aea-b1ba58bb78da">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8fac2a0db25144f7bc4d94691e6afeaa_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwMDEy_e97cd2b1-3d30-484e-913a-aa54ff2af89e"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i68315b257d6e4c95b8a3e5c0005d0240_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwMDIx_bc9436ff-de88-4331-91d8-a9df8b7736b9"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i206a35173cac452e80a9011a351123e0_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwMDMw_30562d2b-c006-404e-812d-781fda3c08a9"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib0a224dcb25e4aa8bc91a4cef4a39b4d_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwNjc5_a46ac787-f630-4eca-a546-55d19a548b75"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id428743f89e44793bea4c8584a67335c_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwNjg3_a09f85e8-e9d5-479e-94f3-6c540031b33c"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i677c4838f7c64a0fa4133f133bfaf2ce_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xODg2L2ZyYWc6MzQ0NmZjMGNhNmViNGYxYWE5MWVlOTgxNjJhNzhkNTAvdGV4dHJlZ2lvbjozNDQ2ZmMwY2E2ZWI0ZjFhYTkxZWU5ODE2MmE3OGQ1MF8yNzQ4Nzc5MDcwNjk1_a39c23fa-c1bb-430a-976e-6abd42ad57f8"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTg0_7f38060f-e9a3-435e-871b-a0f48cf0352f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NDVhN2EyMDBlODAyNGI0NjgyNzc4M2E2ZWY2OGMyYjkvdGFibGVyYW5nZTo0NWE3YTIwMGU4MDI0YjQ2ODI3NzgzYTZlZjY4YzJiOV8wLTAtMS0xLTE0MzA2MQ_5d7f7bb5-97cd-4b40-8705-639c601fd42c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NDVhN2EyMDBlODAyNGI0NjgyNzc4M2E2ZWY2OGMyYjkvdGFibGVyYW5nZTo0NWE3YTIwMGU4MDI0YjQ2ODI3NzgzYTZlZjY4YzJiOV8xLTItMS0xLTE0MzA2MQ_11521d02-7009-49ae-b243-4ae7390852d0">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NDVhN2EyMDBlODAyNGI0NjgyNzc4M2E2ZWY2OGMyYjkvdGFibGVyYW5nZTo0NWE3YTIwMGU4MDI0YjQ2ODI3NzgzYTZlZjY4YzJiOV8zLTAtMS0xLTE0MzA2MQ_636972bf-b8be-4a61-8e81-e6c1e4b3bc28">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTg1_896c6609-6019-4088-b107-e6f49b6136a2">001-14956</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTg2_0bf463d4-ae34-4aa5-acdb-373c1f8c5ccc">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6MTI2YmNjYzAwODYxNDk5ZjhiZDljYTIxYzZlNTZjZDYvdGFibGVyYW5nZToxMjZiY2NjMDA4NjE0OTlmOGJkOWNhMjFjNmU1NmNkNl8wLTAtMS0xLTE0MzA2MQ_d2a6c7bf-c19f-4a77-8c55-155185087a40">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6MTI2YmNjYzAwODYxNDk5ZjhiZDljYTIxYzZlNTZjZDYvdGFibGVyYW5nZToxMjZiY2NjMDA4NjE0OTlmOGJkOWNhMjFjNmU1NmNkNl8wLTQtMS0xLTE0MzA2MQ_2cd7d047-8e44-4288-a19e-c1e492e27e9b">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6MTI2YmNjYzAwODYxNDk5ZjhiZDljYTIxYzZlNTZjZDYvdGFibGVyYW5nZToxMjZiY2NjMDA4NjE0OTlmOGJkOWNhMjFjNmU1NmNkNl8wLTctMS0xLTE0MzA2MQ_04a5bc82-7177-4815-bb13-4c038e4c2c78">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgw_c9446c84-c107-401a-a53f-1bbf36a46918">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgx_56abe654-f128-4123-ada1-f696939572e8">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgy_32122d9d-3690-46d0-a71b-e8e90aa48bdb">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc3_61090692-ae16-4319-ad2d-e8a6afe37e30">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc4_ab37f43f-9cb0-4e58-800b-837cbf21ba80">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc5_be748414-7cb2-45a4-bf0f-2b8bb57ad330">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc2_14b130c9-6992-471d-ab8b-e552a5710e0f">744-6792</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NmNmNDAzOGU3MjM4NGVmOGI0NTQwYWEwMzBhZWZiMjgvdGFibGVyYW5nZTo2Y2Y0MDM4ZTcyMzg0ZWY4YjQ1NDBhYTAzMGFlZmIyOF8xLTAtMS0xLTE0MzA2MQ_890f1185-77c2-42de-8bb8-1a7aafeda72a">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NmNmNDAzOGU3MjM4NGVmOGI0NTQwYWEwMzBhZWZiMjgvdGFibGVyYW5nZTo2Y2Y0MDM4ZTcyMzg0ZWY4YjQ1NDBhYTAzMGFlZmIyOF8xLTEtMS0xLTE0MzA2MQ_b5ca43f1-d0c1-4350-9f7f-1b35c8a9abed">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6NmNmNDAzOGU3MjM4NGVmOGI0NTQwYWEwMzBhZWZiMjgvdGFibGVyYW5nZTo2Y2Y0MDM4ZTcyMzg0ZWY4YjQ1NDBhYTAzMGFlZmIyOF8xLTItMS0xLTE0MzA2MQ_8d7ae362-fa2c-4d56-aa05-3591975879de">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTc0_66c46762-1c59-478c-9823-bc497e1238b5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTcz_c45f7cfb-6993-4100-a14c-f44808e5270c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6YmFhMDA1OTIzN2U1NDczODkwMjliZjljODA4OTZiYTMvdGFibGVyYW5nZTpiYWEwMDU5MjM3ZTU0NzM4OTAyOWJmOWM4MDg5NmJhM18wLTAtMS0xLTE0MzA2MQ_e3d71db3-1a2b-40f2-b748-11431f47ef9a">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6YmFhMDA1OTIzN2U1NDczODkwMjliZjljODA4OTZiYTMvdGFibGVyYW5nZTpiYWEwMDU5MjM3ZTU0NzM4OTAyOWJmOWM4MDg5NmJhM18wLTctMS0xLTE0MzA2MQ_64908284-e7bd-4107-9a56-b25b4617cd17">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGFibGU6YmFhMDA1OTIzN2U1NDczODkwMjliZjljODA4OTZiYTMvdGFibGVyYW5nZTpiYWEwMDU5MjM3ZTU0NzM4OTAyOWJmOWM4MDg5NmJhM18wLTktMS0xLTE0MzA2MQ_db341cde-4c1c-41d5-b969-b7f627f19540">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTgz_4b6684f2-090a-44ed-9abf-9adfeb412078">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i57c4dbce9e34463bbe2a00df8262767d_I20221028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8xL2ZyYWc6OWI5MmMzZWVjMDBjNDQyZjg2Y2RhNWJhZjkyMzgwY2IvdGV4dHJlZ2lvbjo5YjkyYzNlZWMwMGM0NDJmODZjZGE1YmFmOTIzODBjYl8xOTI5_738a12a3-7420-4c2a-862d-00b673022946"
      unitRef="shares">361868131</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMy0xLTEtMS0xNDMwNjE_34a0178d-6d3b-4b63-b816-8454cb107404"
      unitRef="usd">486000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMy0zLTEtMS0xNDMwNjE_13816750-86fe-4313-9cf3-4fd3ca721db3"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNC0xLTEtMS0xNDMwNjE_2c7d9fba-8e7e-4b2a-b88c-328a4ec9e3a7"
      unitRef="usd">11000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNC0zLTEtMS0xNDMwNjE_66246cba-c41b-47db-864a-7047dba821fa"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNS0xLTEtMS0xNDMwNjE_ac0c9f28-1abd-4768-b630-e372b78ff151"
      unitRef="usd">1739000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNS0zLTEtMS0xNDMwNjE_a920a054-7db0-4731-a6cc-2e2424c82cdf"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNi0xLTEtMS0xNDMwNjE_c95c80a1-bfd7-4631-a062-0af941019a49"
      unitRef="usd">1056000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNi0zLTEtMS0xNDMwNjE_dfd98fb4-7cad-4b77-a569-5a978b221ec5"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNy0xLTEtMS0xNDMwNjE_550aa195-91ff-440d-9770-21ae6cc140bc"
      unitRef="usd">718000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfNy0zLTEtMS0xNDMwNjE_faf6a28a-b9f9-43bd-9376-0a7c451fdb28"
      unitRef="usd">720000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOC0xLTEtMS0xNDMwNjE_c14a7ba4-7461-4a64-b042-46b722e2b449"
      unitRef="usd">4010000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOC0zLTEtMS0xNDMwNjE_72a82245-594b-468e-995f-26744c110cb0"
      unitRef="usd">5607000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOS0xLTEtMS0xNDMwNjE_652755e0-c495-43f7-8352-100a79af49cd"
      unitRef="usd">1507000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfOS0zLTEtMS0xNDMwNjE_9bf58513-6850-4c50-b9d9-a528e8dfc7fe"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTAtMS0xLTEtMTQzMDYx_f27f5263-7eb1-4104-812b-ec1636d2ce85"
      unitRef="usd">6024000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTAtMy0xLTEtMTQzMDYx_052a7fd2-896b-43de-a930-2534dd0b5ad0"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTEtMS0xLTEtMTQzMDYx_243b4eda-6384-42db-ba04-230746dc8c76"
      unitRef="usd">12044000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTEtMy0xLTEtMTQzMDYx_f3817632-2cbb-4fd1-b639-cf752649766b"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTItMS0xLTEtMTQzMDYx_54538867-7565-4218-b676-0eef7facc7b8"
      unitRef="usd">2372000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTItMy0xLTEtMTQzMDYx_0544ef01-cee2-4cd6-86ad-b002f6754b81"
      unitRef="usd">2252000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTMtMS0xLTEtMTQzMDYx_e052e142-e5eb-485b-bec2-13f6fa1cf9e9"
      unitRef="usd">341000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTMtMy0xLTEtMTQzMDYx_1347d26a-d43b-4e32-ae7e-eb2347af73d6"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTQtMS0xLTEtMTQzMDYx_cd455c78-7241-4ecd-834e-abb679eef6ca"
      unitRef="usd">26298000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTQtMy0xLTEtMTQzMDYx_2c2d3ed7-03c1-48b4-91f0-03351ca6bb0e"
      unitRef="usd">29202000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTctMS0xLTEtMTQzMDYx_3434b80e-647f-4aaa-b5ca-05b2935c2982"
      unitRef="usd">486000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTctMy0xLTEtMTQzMDYx_40a41124-2d59-4c7a-be7a-ad18500bef2e"
      unitRef="usd">407000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTgtMS0xLTEtMTQzMDYx_2d38df92-2695-4bca-ab56-cb6bece937d0"
      unitRef="usd">2934000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTgtMy0xLTEtMTQzMDYx_d6daac51-3b61-4b0e-863c-918d850dcfe4"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTktMS0xLTEtMTQzMDYx_a5c7896a-bd57-4faa-96ed-266f5abddfe2"
      unitRef="usd">411000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMTktMy0xLTEtMTQzMDYx_d56221b8-3833-4a14-a402-d2a525d187f0"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjAtMS0xLTEtMTQzMDYx_42bf85a6-51f2-4031-8ed9-ccbee1ecc794"
      unitRef="usd">3831000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjAtMy0xLTEtMTQzMDYx_d0ddf8bf-765e-4be4-b8c0-d3138077fbac"
      unitRef="usd">5198000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjEtMS0xLTEtMTQzMDYx_6e82ead0-4ffe-4f54-8f1b-8182108e7d14"
      unitRef="usd">189000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjEtMy0xLTEtMTQzMDYx_697a223e-6abe-4c8d-b962-ae34b675db9d"
      unitRef="usd">202000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjItMS0xLTEtMTQzMDYx_321154bc-e993-45e5-94e3-893a114f1a3a"
      unitRef="usd">20804000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjItMy0xLTEtMTQzMDYx_6d05c7c9-5d77-4a84-a217-64dddaf4a0b9"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjMtMS0xLTEtMTQzMDYx_fb6ca9b0-d333-4ce0-9bd3-4574550b6867"
      unitRef="usd">422000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjMtMy0xLTEtMTQzMDYx_200d35f5-0333-4cf7-97dc-f9d773b876c4"
      unitRef="usd">529000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjQtMS0xLTEtMTQzMDYx_07dbda16-d55a-4e5a-81fa-1aeb7d14bff9"
      unitRef="usd">619000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjQtMy0xLTEtMTQzMDYx_58d28982-2739-4c90-a072-c08e19f2ccb4"
      unitRef="usd">653000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjUtMS0xLTEtMTQzMDYx_8b869365-4647-4c0b-9e36-583c4ee96adb"
      unitRef="usd">25865000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjUtMy0xLTEtMTQzMDYx_eadd84cf-42ec-4007-8832-ada8c83d866a"
      unitRef="usd">29236000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjYtMS0xLTEtMTQzMDYx_3574f597-1e50-452e-b40b-4ff3fbb1045a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjYtMy0xLTEtMTQzMDYx_11478fb4-8ff8-475c-93fe-e3807cc2b777"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjI_3627a8a4-db6c-4bc2-820f-df46ccdbc530"
      unitRef="shares">361781292</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjI_f95d1ca6-3b69-4e35-82a6-988662fd41f7"
      unitRef="shares">361781292</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjk_5eb1d84d-715d-4e3f-98e6-1992152d6cd1"
      unitRef="shares">359405748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjUyNjgyMmJkN2ZlNDc5NjhkNjY5MjJiNWM4ZjQyNjhfNjk_6cb04e06-02fe-47c0-8048-c26b19aa6f41"
      unitRef="shares">359405748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMS0xLTEtMTQzMDYx_c568eec6-8efb-4a2e-837a-5abc69ced4c3"
      unitRef="usd">10387000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjgtMy0xLTEtMTQzMDYx_78af924b-4623-427d-a508-6e8600d2e82a"
      unitRef="usd">10317000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjktMS0xLTEtMTQzMDYx_208c1e03-132b-45ae-ae81-810341fc05f9"
      unitRef="usd">129000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMjktMy0xLTEtMTQzMDYx_fe17c273-eb92-4534-9eb1-81b3f649f7d7"
      unitRef="usd">462000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzAtMS0xLTEtMTQzMDYx_f9bd4acb-7022-49bc-8a8b-309243a0d502"
      unitRef="usd">-8776000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzAtMy0xLTEtMTQzMDYx_903a86ef-4628-434c-bc23-883aa5f76d1a"
      unitRef="usd">-8961000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzEtMS0xLTEtMTQzMDYx_a7f3ea5b-b26c-4b8a-82c7-4a873b70ad2d"
      unitRef="usd">-2265000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzEtMy0xLTEtMTQzMDYx_9470794f-332c-4215-84f8-1fe00e61f062"
      unitRef="usd">-1924000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzItMS0xLTEtMTQzMDYx_b3e7bc49-f306-4acc-8b6d-eb7bc9c8b7b6"
      unitRef="usd">-525000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzItMy0xLTEtMTQzMDYx_d73e062b-49be-432b-8fe0-c06af3531568"
      unitRef="usd">-106000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzMtMS0xLTEtMTQzMDYx_882ee015-8aa4-434f-936b-3f784e455c0c"
      unitRef="usd">958000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzMtMy0xLTEtMTQzMDYx_93a852dd-091b-438c-808a-f9c1d70a5f97"
      unitRef="usd">72000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzQtMS0xLTEtMTQzMDYx_f23c1da9-7363-4060-bf83-7954619669f6"
      unitRef="usd">433000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzQtMy0xLTEtMTQzMDYx_e690ce12-328f-40f0-bcd9-2b78e256c4bf"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzUtMS0xLTEtMTQzMDYx_922e64a2-72f4-4ff0-b2cf-f9c0e9ae8fbd"
      unitRef="usd">26298000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yMi9mcmFnOjU3NDEwMzU4NjdmZDRkZDRhYzkzOGJlMmEzZGE5OTc5L3RhYmxlOjJmYzRiMzQ5Zjc0MTQ5Yzk5NDczMzkyMzRhZjFkNWQ0L3RhYmxlcmFuZ2U6MmZjNGIzNDlmNzQxNDljOTk0NzMzOTIzNGFmMWQ1ZDRfMzUtMy0xLTEtMTQzMDYx_61d81d8a-b10e-4ca1-858f-f5a37ca3dd8a"
      unitRef="usd">29202000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59d79d42128d480b82421ffda65ff432_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy0xLTEtMS0xNDMwNjE_1aee8974-3563-4b80-80cd-7a6573662f89"
      unitRef="usd">2026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51b121d7e567435ea3af71bf428e3992_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy0zLTEtMS0xNDMwNjE_d5925af0-d58c-4038-9173-8c488f27c2c3"
      unitRef="usd">2088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefd2719ffeb04494b5ee89c5d6c0a3a0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy01LTEtMS0xNDMwNjE_3c61b20d-602a-477d-bbb6-02e749f8ae34"
      unitRef="usd">5871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d19e9379e0b46ff90d34e1fad8d4f3d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMy03LTEtMS0xNDMwNjE_30908725-f513-4718-aefd-c60caaeacff2"
      unitRef="usd">6167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e24bce6ec5b4cebbd4550c104f4e7a0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC0xLTEtMS0xNDMwNjE_7efac629-8075-4687-8102-2ca66cf6840c"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cd02a55811c46a28847d139aeb65d5d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC0zLTEtMS0xNDMwNjE_4476da3a-8a85-4d74-bef7-ab40e7847168"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cd1fe160b76486586dea1195d3717a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC01LTEtMS0xNDMwNjE_c1926737-0d89-4b75-ab2c-e5c2c217de97"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4616ed6436e429cb0594228303a7f15_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNC03LTEtMS0xNDMwNjE_958c2742-d5a1-4ce5-a960-32ed9ee2db98"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS0xLTEtMS0xNDMwNjE_6e9da6ac-4eb2-4990-b114-8167bda65c0d"
      unitRef="usd">2046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS0zLTEtMS0xNDMwNjE_de4eeb30-4a57-41a3-8a29-0cb9f2b900ed"
      unitRef="usd">2111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS01LTEtMS0xNDMwNjE_1bcefd04-f8f1-45b8-9019-cc4308ad0cbb"
      unitRef="usd">5931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNS03LTEtMS0xNDMwNjE_fa140726-da3b-42e3-adbf-667c5f9f67cc"
      unitRef="usd">6238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i59d79d42128d480b82421ffda65ff432_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy0xLTEtMS0xNDMwNjE_1536519a-ad68-46da-9dff-16f1d3a4035d"
      unitRef="usd">578000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i51b121d7e567435ea3af71bf428e3992_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy0zLTEtMS0xNDMwNjE_64117549-1776-4d29-ba1c-ba5e288fb716"
      unitRef="usd">574000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iefd2719ffeb04494b5ee89c5d6c0a3a0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy01LTEtMS0xNDMwNjE_fc17d89f-7a8b-40dc-8119-1e4f75d08f0a"
      unitRef="usd">1691000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1d19e9379e0b46ff90d34e1fad8d4f3d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfNy03LTEtMS0xNDMwNjE_41a4fa05-f98b-49ed-965a-566572c97ba0"
      unitRef="usd">1742000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9e24bce6ec5b4cebbd4550c104f4e7a0_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC0xLTEtMS0xNDMwNjE_7a8e196c-4b68-48e6-a2dd-ebd420af1abd"
      unitRef="usd">6000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1cd02a55811c46a28847d139aeb65d5d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC0zLTEtMS0xNDMwNjE_418ab3db-70b2-4cf7-b127-0c8668637d02"
      unitRef="usd">8000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7cd1fe160b76486586dea1195d3717a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC01LTEtMS0xNDMwNjE_6f9c3b0d-7896-421a-b034-692f0a4d6a77"
      unitRef="usd">21000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib4616ed6436e429cb0594228303a7f15_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOC03LTEtMS0xNDMwNjE_e20404d1-2caa-4268-b9aa-3c763fbb687d"
      unitRef="usd">26000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS0xLTEtMS0xNDMwNjE_b9ef45ff-1de6-48b1-a69d-797565a548df"
      unitRef="usd">661000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS0zLTEtMS0xNDMwNjE_3cca0754-dce6-420b-9fae-4ad30cb11016"
      unitRef="usd">653000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS01LTEtMS0xNDMwNjE_9d378969-b461-4133-abcf-6190b9e2326b"
      unitRef="usd">1959000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfOS03LTEtMS0xNDMwNjE_338edf76-c4b1-4739-aeb6-6b23e706fce3"
      unitRef="usd">1944000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtMS0xLTEtMTQzMDYx_e2469cb8-6509-4d61-a273-d49312d37ebd"
      unitRef="usd">133000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtMy0xLTEtMTQzMDYx_9d11b81d-ecde-4016-a58d-625e2113993a"
      unitRef="usd">121000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtNS0xLTEtMTQzMDYx_e9bcf1d6-f927-44fb-a0d1-b1266d4e6692"
      unitRef="usd">387000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTAtNy0xLTEtMTQzMDYx_d3b754cb-c4ce-4b07-b6b7-f5d9218c9e71"
      unitRef="usd">348000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtMS0xLTEtMTQzMDYx_a4e81901-d4f7-43fe-8855-fe80cd5a6cd3"
      unitRef="usd">290000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtMy0xLTEtMTQzMDYx_e58b8188-f517-42e1-a3f3-d0cdbdd76200"
      unitRef="usd">338000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtNS0xLTEtMTQzMDYx_6a56e1fc-53ab-4410-ad7d-efd1b4a05126"
      unitRef="usd">902000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTEtNy0xLTEtMTQzMDYx_051943e3-4b3c-4fcb-985d-48494e2e32b3"
      unitRef="usd">1055000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItMS0xLTEtMTQzMDYx_7db686ff-4b03-4222-992d-17188ae55e15"
      unitRef="usd">119000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItMy0xLTEtMTQzMDYx_47f7f12e-6128-4015-aa82-135db32db2f0"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItNS0xLTEtMTQzMDYx_54aeb270-6113-4d1f-885d-f39eaefef274"
      unitRef="usd">202000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTItNy0xLTEtMTQzMDYx_d5fbaf97-0fab-4c15-9586-ca64cd2d6a3e"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtMS0xLTEtMTQzMDYx_b011880c-3157-48e7-8fa6-de3abf3015b7"
      unitRef="usd">1000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtMy0xLTEtMTQzMDYx_3fb1f731-20ad-49af-9088-deadde64682d"
      unitRef="usd">18000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtNS0xLTEtMTQzMDYx_53576144-f858-4587-9f84-f2380bee12a1"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTMtNy0xLTEtMTQzMDYx_dabca78c-e0a5-44d4-937d-7dc57ad0ae3f"
      unitRef="usd">213000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtMS0xLTEtMTQzMDYx_aa92231d-8bcb-438f-bb18-8151dae512f9"
      unitRef="usd">10000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtMy0xLTEtMTQzMDYx_97f4518d-eb65-4e92-ac45-c858a0c77863"
      unitRef="usd">8000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtNS0xLTEtMTQzMDYx_b480e1e6-ee4f-45ed-ac10-afb2a2dd456d"
      unitRef="usd">58000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTQtNy0xLTEtMTQzMDYx_ed6bf435-0d91-4950-8491-abae387f70ca"
      unitRef="usd">29000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtMS0xLTEtMTQzMDYx_5d3fc0cc-1b15-4371-a0e7-6412775e612a"
      unitRef="usd">-4000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtMy0xLTEtMTQzMDYx_7d79482a-931a-4f7a-92a6-3936ee7013d9"
      unitRef="usd">183000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtNS0xLTEtMTQzMDYx_a795633f-4438-43ee-8633-f6f59003b1f8"
      unitRef="usd">-6000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTUtNy0xLTEtMTQzMDYx_fb0527c4-9828-4f0c-8863-41dfe00be639"
      unitRef="usd">-329000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtMS0xLTEtMTQzMDYx_4cbd206e-f299-47f5-ae8a-b5e0ea54b81c"
      unitRef="usd">1802000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtMy0xLTEtMTQzMDYx_22bd2834-7f3f-41a1-afc8-957069501ae1"
      unitRef="usd">1537000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtNS0xLTEtMTQzMDYx_0806ca5d-2a9e-45b8-b9fb-ff0d98ad9d22"
      unitRef="usd">5241000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTYtNy0xLTEtMTQzMDYx_5d8ae629-32e6-43a0-9428-67818c3d2f43"
      unitRef="usd">6155000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctMS0xLTEtMTQzMDYx_c652b240-cc1a-4b61-a96e-840d734ded81"
      unitRef="usd">244000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctMy0xLTEtMTQzMDYx_a1a52138-2aba-46ff-8fca-73407124bbb9"
      unitRef="usd">574000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctNS0xLTEtMTQzMDYx_98a24026-805b-44c4-a737-2032a1c63bdb"
      unitRef="usd">690000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTctNy0xLTEtMTQzMDYx_87e4dff5-99af-44bd-bcf8-c555cd3568ed"
      unitRef="usd">83000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtMS0xLTEtMTQzMDYx_7c14e528-82b9-46e1-b3b5-7aab7204e525"
      unitRef="usd">3000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtMy0xLTEtMTQzMDYx_9b7d5462-7a78-4d76-a86e-d5759a169c65"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtNS0xLTEtMTQzMDYx_44cc43e1-8168-4541-a481-325e2a9f11e5"
      unitRef="usd">8000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTgtNy0xLTEtMTQzMDYx_cc514f33-6dbb-464c-b580-63e954da75ea"
      unitRef="usd">6000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktMS0xLTEtMTQzMDYx_a35b9a37-6267-4df5-8f21-713b2177c80f"
      unitRef="usd">385000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktMy0xLTEtMTQzMDYx_962c0837-44e3-4cfd-904a-4f9022aa52e8"
      unitRef="usd">351000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktNS0xLTEtMTQzMDYx_ee234b8d-a1cc-4515-a52e-82e98ae17008"
      unitRef="usd">1157000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMTktNy0xLTEtMTQzMDYx_34356990-91a7-4875-abca-6a04c1eebb7a"
      unitRef="usd">1083000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtMS0xLTEtMTQzMDYx_3322aa28-d4c9-4bcb-af54-3bee85bfd2ca"
      unitRef="usd">570000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtMy0xLTEtMTQzMDYx_6014ee8d-f338-4ee4-95af-34c69ec798c5"
      unitRef="usd">-12000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtNS0xLTEtMTQzMDYx_284af2fc-2603-45de-adb1-02b34e306e5d"
      unitRef="usd">683000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjAtNy0xLTEtMTQzMDYx_e50eccaa-e46f-4aa7-af27-44408860dcbc"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtMS0xLTEtMTQzMDYx_6a6b205b-83b6-42c1-a4a3-5b2cddddadaa"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtMy0xLTEtMTQzMDYx_1d6ecf2c-c8c5-40fb-a623-bb82fd2c9220"
      unitRef="usd">3000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtNS0xLTEtMTQzMDYx_9353523f-6392-4108-9877-78a45fc38961"
      unitRef="usd">4000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjEtNy0xLTEtMTQzMDYx_f8fb37c1-0e8d-4be5-b7bf-9496af5ecfda"
      unitRef="usd">11000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItMS0xLTEtMTQzMDYx_eb23c674-7e2b-458e-a5a3-80776bb33bef"
      unitRef="usd">439000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItMy0xLTEtMTQzMDYx_4070fa03-b91c-47ee-a6ea-a211dbfcc870"
      unitRef="usd">216000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItNS0xLTEtMTQzMDYx_8b44bea0-a89c-4141-ab5b-d4f3c1b338dc"
      unitRef="usd">228000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjItNy0xLTEtMTQzMDYx_42302d2f-c5c3-4f3b-9b90-d01747d0fe97"
      unitRef="usd">-1045000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtMS0xLTEtMTQzMDYx_f273fad4-7593-40ae-b596-fb7d0dc3eec1"
      unitRef="usd">36000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtMy0xLTEtMTQzMDYx_785d6de3-3337-4383-a679-f52a7ebd8764"
      unitRef="usd">25000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtNS0xLTEtMTQzMDYx_de081cd2-35b4-4ddd-aced-95b33cbe6ccd"
      unitRef="usd">30000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjMtNy0xLTEtMTQzMDYx_97135b66-87c4-4caa-b357-9fb6f4044fcc"
      unitRef="usd">-36000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtMS0xLTEtMTQzMDYx_4d2b06f8-42a8-407c-a967-dd70af5c476f"
      unitRef="usd">403000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtMy0xLTEtMTQzMDYx_0ff7f9ef-a241-40b4-90e6-66025087f17d"
      unitRef="usd">191000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtNS0xLTEtMTQzMDYx_e2970937-48a1-4e1d-92bb-e06659edcb65"
      unitRef="usd">198000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjQtNy0xLTEtMTQzMDYx_578a9dcb-97ce-468e-ba3d-bc5e44ba6fe5"
      unitRef="usd">-1009000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtMS0xLTEtMTQzMDYx_f61a9283-556c-4ede-b958-325c6cc19d5d"
      unitRef="usd">4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtMy0xLTEtMTQzMDYx_4bcbd5d6-a3bb-48d4-9413-479d8d2a6574"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtNS0xLTEtMTQzMDYx_415ffba8-2917-4806-8ebe-193c824cfb27"
      unitRef="usd">13000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjUtNy0xLTEtMTQzMDYx_13aaf1b0-e2c2-47b2-abd9-80a31cc80e24"
      unitRef="usd">8000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtMS0xLTEtMTQzMDYx_1d6e841e-c79a-4e1b-8424-c0317b41e58b"
      unitRef="usd">399000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtMy0xLTEtMTQzMDYx_df65d569-281c-4a1c-b67c-121dac226f6b"
      unitRef="usd">188000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtNS0xLTEtMTQzMDYx_18754181-cc86-472f-8695-dd41c3859721"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMjYtNy0xLTEtMTQzMDYx_7d9b6870-a1a7-47f6-b1b5-274b5f275f51"
      unitRef="usd">-1017000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMS0xLTEtMTQ3MjM0_2e7a496a-b7e8-44f6-b921-0ac06951c873"
      unitRef="usdPerShare">1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMy0xLTEtMTQ3MjQ0_49fa1996-5163-4e1f-a08d-28eaf5bff4cf"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNS0xLTEtMTQ3MjQ5_2cc35c29-fdbb-4e6b-8eb2-8cfb7a303d35"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNy0xLTEtMTQ3MjQ5_d1a311c7-6533-43bb-b815-0dae4967d478"
      unitRef="usdPerShare">-2.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMS0xLTEtMTQzMDYx_5b9e8b4e-21ea-4cb7-a193-bb336639113f"
      unitRef="usdPerShare">1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtMy0xLTEtMTQzMDYx_317947e2-949c-48ec-b172-61c8df62bfd6"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNS0xLTEtMTQzMDYx_59078555-809d-4d4f-8170-2fdbf9894b40"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzAtNy0xLTEtMTQzMDYx_198d8b0c-4bd6-47df-aba8-ee3772aed201"
      unitRef="usdPerShare">-2.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtMS0xLTEtMTQ3MjI1_1544ce08-714a-4087-976e-a6e552df2516"
      unitRef="shares">362500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtMy0xLTEtMTQ3MjAw_74ee50c5-84a6-4050-8765-bd7facb33012"
      unitRef="shares">359600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtNS0xLTEtMTQ3MjEx_b29561b1-2230-4dcb-bd60-553a1b105aaa"
      unitRef="shares">361800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzUtNy0xLTEtMTQ3MjAz_662a735e-800d-4f56-9524-02f290a13eec"
      unitRef="shares">358500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtMS0xLTEtMTQzMDYx_c1874835-bc0b-47b3-9bee-6201f79daf72"
      unitRef="shares">363400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtMy0xLTEtMTQzMDYx_b2f9aff0-fae2-4f87-af1f-883d65fda68a"
      unitRef="shares">364000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtNS0xLTEtMTQzMDYx_9f556423-26c1-49bf-8057-e0bfe63b4a01"
      unitRef="shares">363700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yNS9mcmFnOmQ2MjY5ZDQwZjAyNzRjMzRiYzE5Yjk4YTZmOTE3MzBiL3RhYmxlOjkwYzRhYTk1YmFlMjQwMDZhOTczY2I3MGRiM2JlNzkzL3RhYmxlcmFuZ2U6OTBjNGFhOTViYWUyNDAwNmE5NzNjYjcwZGIzYmU3OTNfMzMtNy0xLTEtMTQzMDYx_5470d419-cf15-4f07-ad2f-de02d39a3f72"
      unitRef="shares">358500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi0xLTEtMS0xNDMwNjE_e43481fb-7748-4ece-b66f-7b5b3ca749ed"
      unitRef="usd">403000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi0zLTEtMS0xNDMwNjE_074d1996-99c4-4398-a2ff-f21fcb2ffbf6"
      unitRef="usd">191000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi01LTEtMS0xNDMwNjE_35422856-d03a-42c8-8780-63bcd6022eaa"
      unitRef="usd">198000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfMi03LTEtMS0xNDMwNjE_296421d9-7ac3-459f-90dc-2334f5a922ee"
      unitRef="usd">-1009000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC0xLTEtMS0xNDMwNjE_dabb653a-0267-420c-af15-f5342364bf41"
      unitRef="usd">-243000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC0zLTEtMS0xNDMwNjE_8c897e43-15a3-4986-aecf-1cf04d290ed4"
      unitRef="usd">-80000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC01LTEtMS0xNDMwNjE_460684af-d3f1-4905-b972-f2c409ac1223"
      unitRef="usd">-465000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNC03LTEtMS0xNDMwNjE_9035d1fe-1ea4-4b96-866b-92284fcd890f"
      unitRef="usd">-128000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS0xLTEtMS0xNDMwNjE_4e0d86ac-1073-4e1a-af3b-1941ad1cea79"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS0zLTEtMS0xNDMwNjE_8a54412c-6196-4e65-8d1c-cc7cd1b8a81a"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS01LTEtMS0xNDMwNjE_e64e4314-12f5-497e-a229-779b256c4199"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNS03LTEtMS0xNDMwNjE_69be4ea4-1693-484e-a691-6f08c8e0c398"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi0xLTEtMS0xNDMwNjE_410daa47-e3a6-4ab9-9166-663b87c5b11c"
      unitRef="usd">-244000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi0zLTEtMS0xNDMwNjE_f8024abe-9e0e-4306-ab77-c6998ddecb81"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi01LTEtMS0xNDMwNjE_63e12231-c79a-4a72-81dc-a43c809ae62f"
      unitRef="usd">-459000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNi03LTEtMS0xNDMwNjE_4ff32b5e-083d-4a93-bbf0-801f7dd35a5f"
      unitRef="usd">-129000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy0xLTEtMS0xNDMwNjE_bf6d90af-fb22-4828-8f19-b2070fff0c3a"
      unitRef="usd">159000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy0zLTEtMS0xNDMwNjE_342afb5e-8308-4663-9767-2851410ed14d"
      unitRef="usd">110000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy01LTEtMS0xNDMwNjE_02cec7fb-ae2c-498a-bb73-81cddee3a9b9"
      unitRef="usd">-261000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfNy03LTEtMS0xNDMwNjE_cdca795a-ffe4-44b9-a2ed-35cfcd1f0a54"
      unitRef="usd">-1138000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC0xLTEtMS0xNDMwNjE_1587875c-f8ba-4449-bcbf-95acaef5b170"
      unitRef="usd">23000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC0zLTEtMS0xNDMwNjE_fcfe6516-7287-47bc-bfa9-4afdd46209cb"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC01LTEtMS0xNDMwNjE_82a5e59f-24a3-4026-9fed-8d6f9e00ebaf"
      unitRef="usd">32000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOC03LTEtMS0xNDMwNjE_00149f90-530b-422f-859e-9aa7707538c8"
      unitRef="usd">9000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS0xLTEtMS0xNDMwNjE_afd2ee5e-b13f-4824-bbfe-e3fe6b93323f"
      unitRef="usd">136000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS0zLTEtMS0xNDMwNjE_a6edecca-5f8f-4702-8c9f-dfdb87535136"
      unitRef="usd">107000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS01LTEtMS0xNDMwNjE_3ed9638e-168d-4252-a09e-8ceff05302a9"
      unitRef="usd">-293000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8yOC9mcmFnOmQxNDk0ZjkyMjkzZDRiZjdiODE3MGViZmQyMmViOWU1L3RhYmxlOjY5NmJmNTI3ZGQyNjQ5NTg5ZDUzZTAxZmYzMmEwMDg1L3RhYmxlcmFuZ2U6Njk2YmY1MjdkZDI2NDk1ODlkNTNlMDFmZjMyYTAwODVfOS03LTEtMS0xNDMwNjE_729b5df6-7b4e-4892-8a7d-070a91b02b1f"
      unitRef="usd">-1147000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i491b8b5f831e4808948911e15a6b2a0f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0yLTEtMS0xNDMwNjE_9a2afb54-d475-4db1-9ca3-38da59bce168"
      unitRef="shares">361600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i491b8b5f831e4808948911e15a6b2a0f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC00LTEtMS0xNDMwNjE_5c7adc67-85bb-4c43-9cf5-6f9e94648cff"
      unitRef="usd">10380000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07559fd94f9e408894b9f0c6aada463c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC02LTEtMS0xNDMwNjE_8c5b032d-17aa-4796-9ad8-8a87b83e1eab"
      unitRef="usd">104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76eac81be66b465e8aba6b3b5a572b56_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC04LTEtMS0xNDMwNjE_7c57a50b-b96c-47f0-bcb6-0421ed6abae6"
      unitRef="usd">-9175000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4460f5d13fa347f896eef94a4a28cf12_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xMC0xLTEtMTQzMDYx_8b0aad78-ce23-4781-bfbc-0125ab03a4d6"
      unitRef="usd">-2002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40be409bfc0e4dc099944810f89c820c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xMi0xLTEtMTQzMDYx_1f954f08-f2b7-4d6f-9fac-7ec7d9a15b23"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id510a93f2b0d4cf69f18a984bca524b0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xNC0xLTEtMTQzMDYx_98f7c6f7-2487-4a9e-8ea1-30430cb108ac"
      unitRef="usd">946000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ided2e9f46db04fda99ec75cd3415d325_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNC0xNi0xLTEtMTQzMDYx_38655b02-da22-4d57-a4d0-2c999a22235d"
      unitRef="usd">253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7d1740e6c15b4fbc806318e1936a2721_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi0yLTEtMS0xNDMwNjE_8224913c-72e7-44d1-b5f3-03d4051a1d73"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7d1740e6c15b4fbc806318e1936a2721_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi00LTEtMS0xNDMwNjE_cae7686d-246a-49ed-83c9-80161c607469"
      unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi02LTEtMS0xNDMwNjE_290be743-52d4-461d-840c-ffabed7c443c"
      unitRef="usd">-7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi0xMi0xLTEtMTQzMDYx_a358e277-f212-4a92-a1e0-74caec37f368"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNi0xNi0xLTEtMTQzMDYx_12ca1712-80ad-49e0-965e-0f4e44d18edc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNy02LTEtMS0xNDMwNjE_bf02f1ca-60aa-4fa2-a1d9-269a825c2111"
      unitRef="usd">33000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNy0xMi0xLTEtMTQzMDYx_4091374f-88cd-4eae-8df9-a1a43a40575d"
      unitRef="usd">33000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNy0xNi0xLTEtMTQzMDYx_404d1e3f-c73c-4463-b0d1-19d044ed4914"
      unitRef="usd">33000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5e302d3466c6462ebcf97456bec5d248_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfOC02LTEtMS0xNDMwNjE_90bbe1df-5b74-4dcb-ad3a-0c85b1d43fd2"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfOC0xMi0xLTEtMTQzMDYx_73504058-7050-433f-a316-cb0e13795c9f"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfOC0xNi0xLTEtMTQzMDYx_7ec69e2d-8700-43e5-9e3f-984da28cc5c4"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibf017ab13df548e2924759ee558786bd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTAtMTQtMS0xLTE0MzA2MQ_637b4aa5-6e4f-4cfd-b0f8-f905837487c6"
      unitRef="usd">11000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTAtMTYtMS0xLTE0MzA2MQ_4e5b3256-9a50-4b53-b2b6-8f0730af3805"
      unitRef="usd">11000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i39bc9daea7904ebe939e366457a5979b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItOC0xLTEtMTQzMDYx_3f0b24a6-43ab-43f3-8731-7dba0af2555b"
      unitRef="usd">399000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItMTItMS0xLTE0MzA2MQ_8b1a6258-f57c-4988-a4e6-48e2dc1a9dbb"
      unitRef="usd">399000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibf017ab13df548e2924759ee558786bd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItMTQtMS0xLTE0MzA2MQ_b4b7f407-3685-4c0b-9750-270b912b1c56"
      unitRef="usd">4000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTItMTYtMS0xLTE0MzA2MQ_76d90ec0-fef6-4bca-b8a8-4a9cdbd210b7"
      unitRef="usd">403000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idd550841fc7c45b8af6c60f3fa0f8a34_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTAtMS0xLTE0MzA2MQ_a3398503-9d11-4536-85c6-4d124cddc4cf"
      unitRef="usd">-263000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f5f68452b704491904da94159b0a7b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTItMS0xLTE0MzA2MQ_d7f12ca8-3b9d-4294-93cf-88aa79081bed"
      unitRef="usd">-263000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibf017ab13df548e2924759ee558786bd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTQtMS0xLTE2MzAzNA_732e3a64-c03f-4b95-9b4b-61ed5a8edb06"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTMtMTYtMS0xLTE0MzA2MQ_e27a171b-336d-4bcc-81e8-5f208480f728"
      unitRef="usd">-244000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMi0xLTEtMTQzMDYx_4f6e082d-e221-47dd-8516-f08e8d7774e5"
      unitRef="shares">361800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtNC0xLTEtMTQzMDYx_716afc85-3bb4-4144-8bf4-84e297d42215"
      unitRef="usd">10387000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59016e9a1d5d48dea6c8c26d31dd6af0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtNi0xLTEtMTQzMDYx_32140b04-a03f-4d0f-b88a-4d518ceddbcf"
      unitRef="usd">129000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8095b42f3c3d46cfb8bfdef54101a414_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtOC0xLTEtMTQzMDYx_aa0f9748-4028-4fa4-81ea-c2ce194bee3b"
      unitRef="usd">-8776000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie97645899e0b4e1d91b3cd525dccb36d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTAtMS0xLTE0MzA2MQ_3b598cec-1468-43ae-82b8-c6476d4dda4c"
      unitRef="usd">-2265000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c1da51dbab44e64942a8f1d0b64b893_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTItMS0xLTE0MzA2MQ_060567d9-e6e8-4268-8cc3-606a65ebbb8e"
      unitRef="usd">-525000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b9cc0087df7423bace5af792d04a89b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTQtMS0xLTE0MzA2MQ_10ad975d-1e67-4b33-968b-7c1d18d5bbd5"
      unitRef="usd">958000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTQtMTYtMS0xLTE0MzA2MQ_3bf6dd6c-ae45-4786-9903-90934ff2afdd"
      unitRef="usd">433000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i70d26e27e7eb4667bc1c7dfa8dc72756_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMi0xLTEtMTQzMDYx_3f8b7ef5-5c87-477b-8158-1638ae7fff7f"
      unitRef="shares">358700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70d26e27e7eb4667bc1c7dfa8dc72756_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctNC0xLTEtMTQzMDYx_15c9d711-dd58-4669-97bd-ec1b569e1ba1"
      unitRef="usd">10300000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36852dd15708409995b804b93901ddf2_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctNi0xLTEtMTQzMDYx_4fe119d7-2e88-4b6d-a14d-5f32a49cb15c"
      unitRef="usd">413000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59c4371c6a064973ac5404a53c264be7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctOC0xLTEtMTQzMDYx_7c9b8877-150b-4044-bd65-266531106a23"
      unitRef="usd">-9218000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a588955016a4859baf6ff4894efc919_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTAtMS0xLTE0MzA2MQ_049866e3-147b-4158-b03b-729d595fcbf0"
      unitRef="usd">-2182000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cffb35711eb46d0a03ca5bfcf9b95b1_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTItMS0xLTE0MzA2MQ_bc47e962-87d1-4fec-b6b9-31c2557dca9a"
      unitRef="usd">-687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e25b288b94b4d6bba1d74ff8d01f12f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTQtMS0xLTE0MzA2MQ_4ac0a7bc-da5b-4311-93a2-1b5a91f5f0ab"
      unitRef="usd">76000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaab855eaea194ef4a3d9af3afceb50c7_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTctMTYtMS0xLTE0MzA2MQ_3a17cbd4-7bea-4f91-aaff-cdf1f9b4737e"
      unitRef="usd">-611000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="idb174302e02b47c68127faa1d72aa6f2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtMi0xLTEtMTQzMDYx_a0b14037-9e8c-4d59-a91b-882c29a35ec5"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idb174302e02b47c68127faa1d72aa6f2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtNC0xLTEtMTQzMDYx_92d71fff-c5dc-4d0f-bf98-5db6bf8d622a"
      unitRef="usd">12000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtNi0xLTEtMTQzMDYx_8eef0632-a182-4ea0-aec7-c6cc646a2e83"
      unitRef="usd">-6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtMTItMS0xLTE0MzA2MQ_f68af68b-d843-440d-b28c-ed08a9ed8113"
      unitRef="usd">6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTgtMTYtMS0xLTE0MzA2MQ_1d1d59bb-1764-4aa2-8abd-3fa17c780fa2"
      unitRef="usd">6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTktNi0xLTEtMTQzMDYx_0d5ed254-610e-4264-980e-59c336dcea2c"
      unitRef="usd">33000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTktMTItMS0xLTE0MzA2MQ_29eee240-32de-4f41-9a51-293846407271"
      unitRef="usd">33000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMTktMTYtMS0xLTE0MzA2MQ_c361b85d-0230-466c-b7de-84fa483c4fa8"
      unitRef="usd">33000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4e373e9fde464623bbb8a1ec989f0b6d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjAtNi0xLTEtMTQzMDYx_3a4dbbba-03c6-46d5-a74b-9ee1521a6cae"
      unitRef="usd">3000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjAtMTItMS0xLTE0MzA2MQ_830bdd7b-5912-4aa3-8b0e-911eec6dea3e"
      unitRef="usd">3000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjAtMTYtMS0xLTE0MzA2MQ_80611a6a-2b99-454a-b424-b2769a910819"
      unitRef="usd">3000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i52ab05c36a284bfd9324f1075433acc0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTAtMS0xLTE0NzM5Nw_6e37cba2-3d3d-45d8-a69c-837b1eedff66"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTItMS0xLTE0NzM5Nw_fd4e0dda-6cbb-4e12-976a-dca0bbc413b0"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTYtMS0xLTE0NzM5Nw_1834fa5f-c622-4a6d-85c3-094537822054"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i12a385d9c0e3419ca8a25109e4234007_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTQtMS0xLTE0MzA2MQ_1359a1c8-5653-4f82-98f3-78f8ceedfd86"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjEtMTYtMS0xLTE0MzA2MQ_de7fed96-aab0-4eaa-819c-5f5f3f23f1cd"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i3313fdc6f1694bb296ecbac5328fdb95_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItOC0xLTEtMTQzMDYx_e759e1ed-cde2-4818-b965-aada2854f717"
      unitRef="usd">188000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItMTItMS0xLTE0MzA2MQ_c56fe246-45e3-4dd6-bd4f-523147a67ad7"
      unitRef="usd">188000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12a385d9c0e3419ca8a25109e4234007_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItMTQtMS0xLTE0MzA2MQ_8ed51dc4-6bf7-4469-894a-5cad7483b774"
      unitRef="usd">3000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjItMTYtMS0xLTE0MzA2MQ_7b5ae678-8622-448c-b4ba-daa3fe84fd08"
      unitRef="usd">191000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i52ab05c36a284bfd9324f1075433acc0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjMtMTAtMS0xLTE0MzA2MQ_9ec5f866-d184-41a2-8866-7792665d5a86"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie3a1bbd546524796a29c631e96a22b31_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjMtMTItMS0xLTE0MzA2MQ_50f14369-8d4c-4375-b1fd-407b7f8a67d7"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjMtMTYtMS0xLTE0MzA2MQ_bfc7aa78-da33-41e1-aba2-92d4339888c8"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMi0xLTEtMTQzMDYx_c84c4e95-b723-4238-b408-56c143552494"
      unitRef="shares">359200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtNC0xLTEtMTQzMDYx_505dca01-bf9c-4fd3-8613-8524e46ab444"
      unitRef="usd">10312000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id43076b85ac44e909d1c513b58c40e62_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtNi0xLTEtMTQzMDYx_8ce8685c-71e6-4144-993c-519eb38498af"
      unitRef="usd">437000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id97b7fc5f8df45e9bcc906e84ddf8c0d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtOC0xLTEtMTQzMDYx_84171c59-07b7-43c2-9379-2ca30eaabef7"
      unitRef="usd">-9030000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfaf80fdae174541957b5feb3aae627a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTAtMS0xLTE0MzA2MQ_967c439e-b9b6-44f1-9a1f-2db58d197e5e"
      unitRef="usd">-1923000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifda2519ceb7a4fc5ad1fcf6edc583672_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTItMS0xLTE0MzA2MQ_ff9943f1-d6d4-45a9-92fb-7c8f3ad8733e"
      unitRef="usd">-204000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie79d8ec7d74b44b3a63979eaf5bdd09b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTQtMS0xLTE0MzA2MQ_14ef84bf-10e5-419b-9201-fb0af3538a19"
      unitRef="usd">69000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjQtMTYtMS0xLTE0MzA2MQ_17b19557-67af-4f73-8f2d-9d11437cacdf"
      unitRef="usd">-135000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i988f46577a7a4454b3957c277d8b04fe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMi0xLTEtMTQzMDYx_4901836f-edf9-48be-b2e8-587d339c5f9c"
      unitRef="shares">359400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i988f46577a7a4454b3957c277d8b04fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctNC0xLTEtMTQzMDYx_c17d492c-569b-482f-ab0c-83618609c050"
      unitRef="usd">10317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15e3ddf01146436a8b3c8b5d3de2420d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctNi0xLTEtMTQzMDYx_63084b6f-cf5f-4831-95ff-4509102efbdf"
      unitRef="usd">462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52176978c3e649dea74aeb5b1def24dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctOC0xLTEtMTQzMDYx_c3332639-d126-411d-8e70-f78f83ecfc6f"
      unitRef="usd">-8961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6be7f41bbca44db88e2eea447f357ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTAtMS0xLTE0MzA2MQ_684e3be5-3e93-46f2-9117-b4bc72ac0e3f"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95f46d75206b485682e1e2267be9e2df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTItMS0xLTE0MzA2MQ_e78aa44a-4ecb-45cd-b7fa-b5939bdb28ae"
      unitRef="usd">-106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i025bf4b7665f402cbde028bef48f281f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTQtMS0xLTE0MzA2MQ_006995fe-084c-4a30-b27e-d1d54c1ac6d1"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjctMTYtMS0xLTE0MzA2MQ_5e5c7954-b2aa-474a-a8ca-ea1188365b37"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtNi0xLTEtMTQzMDYx_6b761b49-d100-4beb-aa5a-9feaf6a79503"
      unitRef="usd">-327000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iceb866bb408947579450eca5b5dfd24a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTAtMS0xLTE0MzA2MQ_b9d75b8b-a7c4-46c4-b9c5-95cccef1c70e"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTItMS0xLTE0MzA2MQ_4104d726-64f3-4a8f-a4fa-1981d97f6567"
      unitRef="usd">-190000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTQtMS0xLTE0MzA2MQ_f6322f8e-bf4e-4799-bc53-30e22911ceba"
      unitRef="usd">865000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjgtMTYtMS0xLTE0MzA2MQ_09ee6806-81ce-4474-891f-846f9f69d017"
      unitRef="usd">675000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icdf4f32143d24f1fa87f639690b700e3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktMi0xLTEtMTQzMDYx_ffda2870-9aba-4578-ba07-ab4342773ad2"
      unitRef="shares">2400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icdf4f32143d24f1fa87f639690b700e3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktNC0xLTEtMTQzMDYx_e37a804c-fca2-4b9a-aad7-49b5e095bc4a"
      unitRef="usd">70000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktNi0xLTEtMTQzMDYx_92955f80-d6e6-47a2-9133-384546a1caa7"
      unitRef="usd">-67000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktMTItMS0xLTE0MzA2MQ_f28d44c9-e252-491c-8bc1-e549970b5ffd"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMjktMTYtMS0xLTE0MzA2MQ_caef58a8-f991-4190-9599-eab3ec678bd4"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzAtNi0xLTEtMTQzMDYx_a301f257-2c6a-4f0d-a3ea-c76659aab023"
      unitRef="usd">91000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzAtMTItMS0xLTE0MzA2MQ_d1f85021-92bb-4b0c-bb46-e523aaf70b17"
      unitRef="usd">91000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzAtMTYtMS0xLTE0MzA2MQ_26f45bf9-393b-4db2-9731-2c556faf9d17"
      unitRef="usd">91000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic914e9d2fa7a4666ab7d5bafa5deba3d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzEtNi0xLTEtMTQzMDYx_8ec0fcbe-4958-426c-9d59-7ff83385f0f4"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzEtMTItMS0xLTE0MzA2MQ_4ab72182-77e2-4906-b1e6-2a90878fae0d"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzEtMTYtMS0xLTE0MzA2MQ_59d9a25e-86ec-4226-bac6-dc1a7b384b7f"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzItMTQtMS0xLTE0MzA2MQ_7a6d793c-c226-4c92-8d70-622afd71f525"
      unitRef="usd">11000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzItMTYtMS0xLTE0MzA2MQ_c040b27a-df2d-4312-8546-8b41b5d68719"
      unitRef="usd">11000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i0a46937aff434e73aae5f0ed8b35218f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtOC0xLTEtMTQzMDYx_c2b28d4f-3c1b-4f46-a64b-c4b47e6f3e50"
      unitRef="usd">185000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtMTItMS0xLTE0MzA2MQ_95cfefa7-41e3-426d-b4f6-9278e53a719f"
      unitRef="usd">185000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtMTQtMS0xLTE0MzA2MQ_fca9b3ab-032b-4dff-bdfd-fe177a36495e"
      unitRef="usd">13000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzMtMTYtMS0xLTE0MzA2MQ_8477a188-0530-4ac0-b658-4858cdeda680"
      unitRef="usd">198000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iceb866bb408947579450eca5b5dfd24a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzQtMTAtMS0xLTE0MzA2MQ_e620daa2-b9bb-4459-b472-e37753cb9abd"
      unitRef="usd">-478000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib9b5ac6fc9634422944daa9e56b0384e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzQtMTItMS0xLTE0MzA2MQ_b752d9f4-0feb-415f-adb1-1e9718497a5f"
      unitRef="usd">-478000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iba83711893564f9c8987daf355043fdb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTQtMS0xLTE2MzA0Mg_189f3298-7cd7-4d6f-bca1-fec167536c3b"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzQtMTYtMS0xLTE0MzA2MQ_606d738d-9c80-4479-b1b9-7f315829b051"
      unitRef="usd">-459000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMi0xLTEtMTQzMDYx_43a297d9-d3f6-447d-8d7d-b8408fc7a477"
      unitRef="shares">361800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd39be4430f7409d935946ee25e5a791_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtNC0xLTEtMTQzMDYx_e2806944-490e-4ad6-beee-c427944ad304"
      unitRef="usd">10387000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59016e9a1d5d48dea6c8c26d31dd6af0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtNi0xLTEtMTQzMDYx_8167a52e-8b7c-416c-983f-34ae539c130b"
      unitRef="usd">129000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8095b42f3c3d46cfb8bfdef54101a414_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtOC0xLTEtMTQzMDYx_4c62c150-9aac-438c-b388-baa573d636a9"
      unitRef="usd">-8776000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie97645899e0b4e1d91b3cd525dccb36d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTAtMS0xLTE0MzA2MQ_48a2f797-4164-4c52-b608-ec193efe6bfd"
      unitRef="usd">-2265000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c1da51dbab44e64942a8f1d0b64b893_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTItMS0xLTE0MzA2MQ_33867f58-53b8-4b25-8d58-aa3329510382"
      unitRef="usd">-525000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b9cc0087df7423bace5af792d04a89b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTQtMS0xLTE0MzA2MQ_d7b60386-2e0d-4033-bc89-ee6a9940aeb8"
      unitRef="usd">958000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzUtMTYtMS0xLTE0MzA2MQ_24faa1ae-714f-4060-96e8-52f04982dba3"
      unitRef="usd">433000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib5d21251ba2e4156877ad94aed58ea65_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMi0xLTEtMTQzMDYx_4427d7bb-a242-4fd5-9555-95cc8ef94507"
      unitRef="shares">355400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5d21251ba2e4156877ad94aed58ea65_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtNC0xLTEtMTQzMDYx_7a92ae32-3c3f-4985-b24e-9582302b403a"
      unitRef="usd">10227000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1e021ab77684430873b508aa3f19f9a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtNi0xLTEtMTQzMDYx_33aae100-ddc3-478a-afeb-40a51b79532e"
      unitRef="usd">454000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6b28c3de4db4949bc89001e98278b7b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtOC0xLTEtMTQzMDYx_30a0f9bf-0a06-404f-a80b-110d10e6e362"
      unitRef="usd">-8013000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1d5398ad231d43158c6f75706adfe6f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTAtMS0xLTE0MzA2MQ_2a70fe01-bb8e-48d3-9f01-c6fdd27a3341"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbe2379453e44861a0ed685834555c93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTItMS0xLTE0MzA2MQ_c1f9d5d1-fc94-48e3-9b57-96e631014217"
      unitRef="usd">535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief8fc54ee0cd4b3e9e5451b181dc7a62_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTQtMS0xLTE0MzA2MQ_986c289d-f189-490a-a01c-6ee67635aa58"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzgtMTYtMS0xLTE0MzA2MQ_4a27fa72-eab6-4c8c-b385-c125d906bada"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9acba15c5791474e88c007d6018e0579_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktMi0xLTEtMTQzMDYx_ae4f761d-296b-45f1-a689-2f08b692fe5b"
      unitRef="shares">3800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9acba15c5791474e88c007d6018e0579_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktNC0xLTEtMTQzMDYx_d203006f-29e7-4277-8281-51697feb6fb7"
      unitRef="usd">85000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktNi0xLTEtMTQzMDYx_c03753a3-9d7c-4e4f-998b-7cfc2b9b5147"
      unitRef="usd">-64000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktMTItMS0xLTE0MzA2MQ_be0ff916-852d-4088-89a7-28dcdb3fc173"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfMzktMTYtMS0xLTE0MzA2MQ_2144a246-0624-4ac3-98e4-b8095f31a587"
      unitRef="usd">21000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDAtNi0xLTEtMTQzMDYx_eada50df-8b17-4fb6-b085-b0280c84598e"
      unitRef="usd">95000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDAtMTItMS0xLTE0MzA2MQ_f4d1af59-1349-46b2-a00c-0cbd4fa0933b"
      unitRef="usd">95000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDAtMTYtMS0xLTE0MzA2MQ_9765c0d9-5896-4bb8-b724-f2718fd3d2ec"
      unitRef="usd">95000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i45cb957289ec4d90826449400c24c9ae_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDEtNi0xLTEtMTQzMDYx_4f9bfd86-392e-4b3c-bb56-78ef963c4097"
      unitRef="usd">48000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDEtMTItMS0xLTE0MzA2MQ_f0713fe5-5e05-4ba5-a99f-d37648e7a8a1"
      unitRef="usd">48000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDEtMTYtMS0xLTE0MzA2MQ_1d53ac12-9b16-4292-a482-552cc889e631"
      unitRef="usd">48000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i488484ed6b0d4a8eb2d7c63599be0468_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTAtMS0xLTE0NzM5NQ_db1290b6-d5ab-4d6b-925e-4646926cb7ab"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTItMS0xLTE0NzM5NQ_d29d3ab2-c889-45c5-8fd8-93a85d75393d"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTYtMS0xLTE0NzM5NQ_883a04d7-797b-4d60-a5a8-8ca2021ee12f"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTQtMS0xLTE0NzM5Mw_6de4885e-1a3d-473f-a743-92704b93561c"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTYtMS0xLTE0NzM5MQ_2b86592a-233e-4640-bab6-01c314c9a6c9"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i645aadc8462e4f0bb9c3992e508abc6d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItOC0xLTEtMTQzMDYx_13ed6761-22a8-4143-aeb6-eefc8165f384"
      unitRef="usd">-1017000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItOC0xLTEtMTQzMDYx_39a1679d-3c77-49ad-ac3f-c71053ccd212"
      unitRef="usd">-1017000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItMTItMS0xLTE0MzA2MQ_45bf546f-bdc0-47ad-ab90-2237fd7352da"
      unitRef="usd">-1017000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItMTQtMS0xLTE0MzA2MQ_2ebcacbe-cb6a-440e-9e94-bf4ed3402776"
      unitRef="usd">8000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDItMTYtMS0xLTE0MzA2MQ_e3fdf8ec-bac1-4ad8-8bbf-39003eea0185"
      unitRef="usd">-1009000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i488484ed6b0d4a8eb2d7c63599be0468_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTAtMS0xLTE0MzA2MQ_229445af-57af-4f0e-8a99-1a51c9bf75c1"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if06de8f0d7b94e6e8e07388ea38138c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTItMS0xLTE0MzA2MQ_faa8782a-7f60-4c71-ab7b-0ff8ffb15745"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idc994a6d356547a9867d0ec8320e3006_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTQtMS0xLTE0MzA2MQ_1acc90ac-ddc5-405e-b110-445168d38ca9"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDMtMTYtMS0xLTE0MzA2MQ_32898338-cc2a-4f34-bb9b-5e42d89b5230"
      unitRef="usd">-129000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMi0xLTEtMTQzMDYx_b421657d-2f20-45f8-8b38-5ba5c8f263d8"
      unitRef="shares">359200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c2b530ece41403e8f0fdbb413bee88f_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtNC0xLTEtMTQzMDYx_5e0e7243-cc2d-4cbd-993e-3392ad6ea979"
      unitRef="usd">10312000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id43076b85ac44e909d1c513b58c40e62_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtNi0xLTEtMTQzMDYx_35c15fa8-b6a7-4d7c-8e1b-0433fec2af3a"
      unitRef="usd">437000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id97b7fc5f8df45e9bcc906e84ddf8c0d_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtOC0xLTEtMTQzMDYx_acfb74a1-8319-4699-89f4-2ea52adb3ebc"
      unitRef="usd">-9030000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfaf80fdae174541957b5feb3aae627a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTAtMS0xLTE0MzA2MQ_7fdde931-a006-4c36-9f72-7edf4e2bed1e"
      unitRef="usd">-1923000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifda2519ceb7a4fc5ad1fcf6edc583672_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTItMS0xLTE0MzA2MQ_5b947cba-d768-4699-8343-ed6d2843c939"
      unitRef="usd">-204000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie79d8ec7d74b44b3a63979eaf5bdd09b_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTQtMS0xLTE0MzA2MQ_5ddfd9fc-6bca-4062-b603-5f62d9301b7a"
      unitRef="usd">69000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zMS9mcmFnOjg3ZjI4YzkyNTQ1ZDRjZmU4YjBlN2RlZDAwNjA1YTAzL3RhYmxlOjcwZGQ3ZjE2ZTA4ODQyMmE4ZDkxMDQyYzJmZDAwODY1L3RhYmxlcmFuZ2U6NzBkZDdmMTZlMDg4NDIyYThkOTEwNDJjMmZkMDA4NjVfNDQtMTYtMS0xLTE0MzA2MQ_9809072c-4530-4fa8-8b4e-3ef96a6485cd"
      unitRef="usd">-135000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMy0xLTEtMS0xNDMwNjE_35422856-d03a-42c8-8780-63bcd6022eaa"
      unitRef="usd">198000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMy0zLTEtMS0xNDMwNjE_296421d9-7ac3-459f-90dc-2334f5a922ee"
      unitRef="usd">-1009000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNS0xLTEtMS0xNDMwNjE_48604e6a-6800-4a1a-ad7a-d0ae343f82e9"
      unitRef="usd">1034000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNS0zLTEtMS0xNDMwNjE_e47bc27f-74b0-4135-b0bd-168424653167"
      unitRef="usd">1189000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNi0xLTEtMS0xNDMwNjE_0c94560b-ed25-4e31-bb9d-4d5ca6e09ec5"
      unitRef="usd">86000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNi0zLTEtMS0xNDMwNjE_2b19ec32-d11f-4264-bd9f-9f570cacfbd2"
      unitRef="usd">42000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNy0xLTEtMS0xNDMwNjE_53576144-f858-4587-9f84-f2380bee12a1"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNy0zLTEtMS0xNDMwNjE_dabca78c-e0a5-44d4-937d-7dc57ad0ae3f"
      unitRef="usd">213000000</us-gaap:AssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOC0xLTEtMS0xNDMwNjE_54aeb270-6113-4d1f-885d-f39eaefef274"
      unitRef="usd">202000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOC0zLTEtMS0xNDMwNjE_d5fbaf97-0fab-4c15-9586-ca64cd2d6a3e"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOS0xLTEtMS0xNDMwNjE_82ea33f3-2d09-4af5-8789-299fcb02fd99"
      unitRef="usd">2000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfOS0zLTEtMS0xNDMwNjE_ccc3f4e1-0c62-40a4-9934-3004bd6a7ac8"
      unitRef="usd">8000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTAtMS0xLTEtMTQzMDYx_41d9df97-51a1-41a8-9297-4840fa70c086"
      unitRef="usd">36000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTAtMy0xLTEtMTQzMDYx_a6335d9f-8a49-4f11-8a5a-dfc52c3cc909"
      unitRef="usd">51000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTEtMS0xLTEtMTQzMDYx_1d18680d-762e-44f7-a9d8-b034da03a788"
      unitRef="usd">-195000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTEtMy0xLTEtMTQzMDYx_ef44d94c-14b1-4443-9ef1-28eaa1cb1db9"
      unitRef="usd">-137000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTItMS0xLTEtMTQzMDYx_8ccc7d29-4558-4ac4-bb82-c9ff541360d0"
      unitRef="usd">3000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTItMy0xLTEtMTQzMDYx_c0408b58-a72b-42d5-a92b-36683f36efdf"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets1>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTMtMS0xLTEtMTQzMDYx_5bec94af-6ff8-4775-b82d-158d6ee6c0ea"
      unitRef="usd">-7000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTMtMy0xLTEtMTQzMDYx_1b56421e-5118-42ed-84cd-bc1ddb1580e6"
      unitRef="usd">-534000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTQtMS0xLTEtMTQzMDYx_5481c0fc-64f5-412d-8402-428e1524c709"
      unitRef="usd">1572000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTQtMy0xLTEtMTQzMDYx_6f9301ae-70e2-4775-b3e0-99a4068f6ac2"
      unitRef="usd">144000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTUtMS0xLTEtMTQzMDYx_a77926be-b3e4-4e8d-bf87-c379ff8fe770"
      unitRef="usd">91000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTUtMy0xLTEtMTQzMDYx_7463e76b-1f66-4f1c-87ab-a88282e4d3a3"
      unitRef="usd">95000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTYtMS0xLTEtMTQzMDYx_128b0c71-7825-45e7-98a6-9ada4a92a4b5"
      unitRef="usd">1000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTYtMy0xLTEtMTQzMDYx_ed34aade-9658-41ef-a45a-6187dd549d81"
      unitRef="usd">-8000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <bhc:DerivativeGainExcludedComponent
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTctMS0xLTEtMTQzMDYx_300d9336-69ef-48f1-9159-471ae3891026"
      unitRef="usd">3000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTctMy0xLTEtMTQzMDYx_a469a13c-451f-4dfe-b7bc-b3f335792f61"
      unitRef="usd">17000000</bhc:DerivativeGainExcludedComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTgtMS0xLTEtMTQzMDYx_c23ac869-3e11-42bd-89fd-a5df0bc1785c"
      unitRef="usd">683000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTgtMy0xLTEtMTQzMDYx_ad5ad934-9a89-455e-a038-db7550a1614c"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMS0xLTEtMTY1NjMz_06da84a4-c859-4b8d-82a2-e4987fc4bf3b"
      unitRef="usd">31000000</bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities>
    <bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMy0xLTEtMTY1NjM1_13b40197-8cd4-4766-a24a-e0e29467711a"
      unitRef="usd">0</bhc:PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMS0xLTEtMTQzMDYx_335ebee3-6d09-4eef-aaa6-c825c3ce691b"
      unitRef="usd">1000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMTktMy0xLTEtMTQzMDYx_09b929ef-d887-4dd4-9386-4ad61d172112"
      unitRef="usd">16000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjAtMS0xLTEtMTQzMDYx_17b65f35-6cf6-486e-9052-905abd4e4ced"
      unitRef="usd">11000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjAtMy0xLTEtMTQzMDYx_bab2bc1c-6e52-4f34-a92f-5fc392f78524"
      unitRef="usd">33000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjItMS0xLTEtMTQzMDYx_44e9a9e4-c63e-4186-b957-da8209fe8562"
      unitRef="usd">26000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjItMy0xLTEtMTQzMDYx_b7278372-df80-4c27-b312-3229a137479f"
      unitRef="usd">177000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjMtMS0xLTEtMTQzMDYx_dc461697-e422-4aa0-8ca3-d0f23ebaf3bc"
      unitRef="usd">194000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjMtMy0xLTEtMTQzMDYx_7f4ba631-f3f7-4098-814d-4852590f5788"
      unitRef="usd">62000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjQtMS0xLTEtMTQzMDYx_67b46f64-c1f3-4a1a-bf2b-445fc424ad67"
      unitRef="usd">32000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjQtMy0xLTEtMTQzMDYx_4da1dfea-07b0-4ac5-b00f-689b35b87408"
      unitRef="usd">-37000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjUtMS0xLTEtMTQzMDYx_a1b48b93-854d-4c47-9d67-65cd14744521"
      unitRef="usd">-122000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjUtMy0xLTEtMTQzMDYx_1c5ab316-2c69-41b1-96b3-bc9d347d85c1"
      unitRef="usd">291000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjYtMS0xLTEtMTQzMDYx_09cb4e7e-2220-4698-9169-d2c8b96a2ab9"
      unitRef="usd">-1203000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjYtMy0xLTEtMTQzMDYx_0f916f48-0e40-43f3-a0e4-9797996a6c9f"
      unitRef="usd">1402000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjgtMS0xLTEtMTQzMDYx_c3aa8dc9-8724-4594-9e0c-b8966717514b"
      unitRef="usd">152000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjgtMy0xLTEtMTQzMDYx_44664b67-04fc-4402-a47f-ed87eaad097c"
      unitRef="usd">191000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjktMS0xLTEtMTQzMDYx_716005b9-196b-4092-8338-cb28182589c3"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMjktMy0xLTEtMTQzMDYx_200c4e31-5848-4b62-afe8-4b60f6367d3f"
      unitRef="usd">9000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzAtMS0xLTEtMTQzMDYx_2380941b-0a70-47c6-8e24-8da997b1cee2"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzAtMy0xLTEtMTQzMDYx_10b7955a-e28d-4773-ac8b-1daab5babd06"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzEtMS0xLTEtMTQzMDYx_bf976ba4-65e5-4df9-86df-515740174f4c"
      unitRef="usd">20000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzEtMy0xLTEtMTQzMDYx_334575f9-666a-4204-a677-030f70e5581b"
      unitRef="usd">11000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzItMS0xLTEtMTQzMDYx_14d9ebdc-117f-4a33-928a-496396684a57"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzItMy0xLTEtMTQzMDYx_030031e1-8ab4-49e8-907e-f48896a20888"
      unitRef="usd">669000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzMtMS0xLTEtMTQzMDYx_77b23f4e-ec77-4ca5-b8cb-ce24b14eb9fb"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzMtMy0xLTEtMTQzMDYx_0ac5e3da-75cc-41d1-9f9f-4fd034c21eb5"
      unitRef="usd">23000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzQtMS0xLTEtMTQzMDYx_b7516dde-e8fd-44a3-b6e1-b221686818b4"
      unitRef="usd">-167000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzQtMy0xLTEtMTQzMDYx_37fe0d6e-1eb7-4d09-a1e4-df7b8e5278fa"
      unitRef="usd">489000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzYtMS0xLTEtMTQzMDYx_741219c2-38a2-47bb-8d9a-7a60a43e77d9"
      unitRef="usd">6481000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzYtMy0xLTEtMTQzMDYx_3f44d946-a6b0-46e7-b7c5-d3ba01b37106"
      unitRef="usd">1576000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzctMS0xLTEtMTQzMDYx_fbd95540-2503-4832-b67d-bf8baaa7657a"
      unitRef="usd">7224000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfMzctMy0xLTEtMTQzMDYx_d1c9f135-f5b9-4860-bbf9-6e70330ae8a8"
      unitRef="usd">3200000000</us-gaap:RepaymentsOfLongTermDebt>
    <bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDAtMS0xLTEtMTQzMDYx_a3af3ed6-8642-4c20-b005-d4ed55feea6d"
      unitRef="usd">675000000</bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty>
    <bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDAtMy0xLTEtMTQzMDYx_144adb08-5b8c-4140-be79-2918be284dc4"
      unitRef="usd">0</bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDEtMS0xLTEtMTQzMDYx_22812969-309d-4e8a-86b2-062153b2ea14"
      unitRef="usd">30000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDEtMy0xLTEtMTQzMDYx_3c4f833f-4a8f-4682-a4d4-cd3563a6a81c"
      unitRef="usd">48000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDItMS0xLTEtMTQzMDYx_1acbdefb-2475-46e5-b83e-e3f9691f67bd"
      unitRef="usd">19000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDItMy0xLTEtMTQzMDYx_2b8d6bba-6033-4433-8290-6446ee3301f5"
      unitRef="usd">77000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDMtMS0xLTEtMTQzMDYx_75ba6e52-feb0-4a6e-aa79-08b461aa9b19"
      unitRef="usd">71000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDMtMy0xLTEtMTQzMDYx_0a9e67c0-164f-45db-a974-a854877c00d9"
      unitRef="usd">48000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDQtMS0xLTEtMTQzMDYx_d2435bf5-aab4-4ab7-a13c-a350c0d60287"
      unitRef="usd">-10000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDQtMy0xLTEtMTQzMDYx_1bb5f13d-8cd9-44c4-94de-1a782c9351e5"
      unitRef="usd">9000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDUtMS0xLTEtMTQzMDYx_81d4f8a3-8689-4774-ad32-a1f19b64b72c"
      unitRef="usd">-198000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDUtMy0xLTEtMTQzMDYx_5c0f923a-81a6-41b8-99a7-b2e3abeab6b9"
      unitRef="usd">-1788000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDYtMS0xLTEtMTQzMDYx_a82b3e9b-9669-42ff-b2fb-6d4b679f74f6"
      unitRef="usd">-54000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDYtMy0xLTEtMTQzMDYx_6b1cc7db-b5c1-4261-b7d6-0cfede33418d"
      unitRef="usd">-15000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDctMS0xLTEtMTQzMDYx_6875ed3f-76a3-494e-905d-82cae03844fc"
      unitRef="usd">-1622000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDctMy0xLTEtMTQzMDYx_ce20655d-9b44-4540-85d5-9025a6211f69"
      unitRef="usd">88000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDgtMS0xLTEtMTQzMDYx_26c976b7-e6f9-4b05-a5c6-c66565344b44"
      unitRef="usd">2119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDgtMy0xLTEtMTQzMDYx_27a79cfe-ca86-432b-92ed-71f54d65f248"
      unitRef="usd">1816000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDktMS0xLTEtMTQzMDYx_cded048f-a2a0-4315-9c3c-bfba1a631a3e"
      unitRef="usd">497000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNDktMy0xLTEtMTQzMDYx_544e07d3-5839-4693-80ed-d244d0d7a57b"
      unitRef="usd">1904000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTAtMS0xLTEtMTQzMDYx_303e0163-3166-4c1e-aee3-a3773822944b"
      unitRef="usd">486000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTAtMy0xLTEtMTQzMDYx_2577d89f-46b9-4db5-a3b4-f88a25603f4d"
      unitRef="usd">690000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTEtMS0xLTEtMTQzMDYx_6bbcf930-67f1-48dd-b74b-c9d19983eb05"
      unitRef="usd">11000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTEtMy0xLTEtMTQzMDYx_fa1d8b9c-55d4-4ddc-bbec-8391a309e7e6"
      unitRef="usd">1214000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTMtMS0xLTEtMTQzMDYx_21744c2d-43ce-417b-9849-8ee378336806"
      unitRef="usd">497000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF8zNC9mcmFnOjRiODg2YTBkOGVkYzQ0ZTI5ZWJlZTYzMmJkYWFiZDE4L3RhYmxlOjYzMzU0M2NhNzAzNTQ2MTRiZDJjZjQ0NmY5MTUzZDk0L3RhYmxlcmFuZ2U6NjMzNTQzY2E3MDM1NDYxNGJkMmNmNDQ2ZjkxNTNkOTRfNTMtMy0xLTEtMTQzMDYx_81f1faec-2670-4427-aabe-89c09190d9d2"
      unitRef="usd">1904000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80MC9mcmFnOjMyYTI4YjNjN2Q5ODQwMTdhMjUyZTE5MWI0OWE3MDc0L3RleHRyZWdpb246MzJhMjhiM2M3ZDk4NDAxN2EyNTJlMTkxYjQ5YTcwNzRfNzg5_48ca1d71-b024-4460-8472-690cdf9dcee5">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#x201c;Company&#x201d; or &#x201c;Bausch Health&#x201d;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#x201c;GI&#x201d;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and medical aesthetic devices and, through its approximately 89% ownership of Bausch + Lomb Corporation (&#x201c;Bausch + Lomb&#x201d;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company&#x2019;s products are marketed directly or indirectly in approximately 100 countries.</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ib6d1b61008f54b72978ed1b60c02dd15_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80MC9mcmFnOjMyYTI4YjNjN2Q5ODQwMTdhMjUyZTE5MWI0OWE3MDc0L3RleHRyZWdpb246MzJhMjhiM2M3ZDk4NDAxN2EyNTJlMTkxYjQ5YTcwNzRfMTA5OTUxMTYyODU3Mw_b4119140-e597-4467-bba5-42cd22f534d3"
      unitRef="number">0.89</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80MC9mcmFnOjMyYTI4YjNjN2Q5ODQwMTdhMjUyZTE5MWI0OWE3MDc0L3RleHRyZWdpb246MzJhMjhiM2M3ZDk4NDAxN2EyNTJlMTkxYjQ5YTcwNzRfNzc2_48d9d1fd-7a45-439f-b4d0-da4de24aac0d"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTEyMQ_8a013838-1d33-4e6c-b63a-86398203883c">SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the &#x201c;CSA&#x201d;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye Health Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health (the &#x201c;B+L Separation&#x201d;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#x201c;IPO&#x201d;) of Bausch + Lomb (the &#x201c;B+L IPO&#x201d;) was declared effective on May 5, 2022, and Bausch + Lomb&#x2019;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#x201c;BLCO&#x201d; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#x201c;Selling Shareholder&#x201d;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health indirectly holds 310,449,643 Bausch + Lomb common shares, which represent approximately 89% of Bausch + Lomb&#x2019;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million. The Company continues to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x201d; of Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d;) on the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company which includes the Company&#x2019;s Salix, International (formerly International Rx), Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical) products, and Solta aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;than the effects of the B+L IPO described above, these unaudited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impacts of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has had, and continues to have, an adverse impact on the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which these events may continue to impact the Company&#x2019;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#x2019;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#x2019;s business, financial condition, cash flows and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Initial Public Offering of Solta Medical Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#x201c;Solta IPO&#x201d;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#x201c;Solta&#x201d; or &#x201c;Solta Medical&#x201d;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Salix, (ii) International Rx, (iii) Ortho &lt;/span&gt;&lt;/div&gt;Dermatologics, (iv) Diversified Products and (v) Bausch + Lomb. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTEwNg_25011561-2e94-463a-b7d8-8c9cc5ca71f7">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the &#x201c;CSA&#x201d;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i029ce1f6669d4d13bf48542871624ff7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjM2MA_9e8f4294-5447-4205-919b-4657efec1796"
      unitRef="shares">35000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie4ecb2729d3c48b5a5174645d3aea6b0_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjQxOQ_de0416c3-362b-4d22-8e3a-f0cb7f7df762"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <bhc:SaleOfStockOverAllotmentTerm
      contextRef="i7976654304fe4df0800004afdc2d26a2_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjU0Ng_e0870265-4b25-4742-8dfe-a279ea6668c9">P30D</bhc:SaleOfStockOverAllotmentTerm>
    <bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance
      contextRef="i7976654304fe4df0800004afdc2d26a2_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjYxMA_5c4842f0-3855-4294-a24d-e38671e2e20f"
      unitRef="shares">5250000</bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id24bd8f4d8504fd09de88aa4e16a7666_D20220601-20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjg4MA_4976f7a3-296d-46ec-8e5c-bfe45579fbd5"
      unitRef="shares">4550357</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if7a1d308f9414a5fa9f55e2a191cc9dc_I20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMjkzOA_7ff8a8d4-7cce-45f5-8049-2baf4f769b8a"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i400457a1387e48eaa2cf072d6caa4556_I20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMzIyNQ_0f4f64b6-0f3c-4eb5-8329-6af748742c16"
      unitRef="shares">310449643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i9385fd4916c644dcaffe698618f5a572_D20220601-20220601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMzI4Nw_11f8726a-5d96-4bda-8f65-224e79086aa5"
      unitRef="number">0.89</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie66b2900222448dca6ffb1983135533a_D20220601-20220601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfMzUxNQ_3e63daf3-c182-4e15-9e6b-2560d490b539"
      unitRef="usd">675000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:UseOfEstimates
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTA5Mw_b7f3ffcc-d5cc-4375-91a2-7895104a79cd">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTA4OQ_8fa33b87-468a-4ede-b4e0-637d22ddc206">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80My9mcmFnOjA1NDk4MTkyMmQwODQxMGU4NGQ3NjU5ZDRkMzRhOTAwL3RleHRyZWdpb246MDU0OTgxOTIyZDA4NDEwZTg0ZDc2NTlkNGQzNGE5MDBfOTExNg_1df640c1-fd82-4c2e-8765-ab352bd86e77">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTY5NA_756ce900-e2ac-42cd-b529-9f8715da9970">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2022 and 2021 were $84&#160;million and $94&#160;million, respectively, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21&#160;million and $28&#160;million for the three months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTcyMA_8897fe79-70bf-408d-b699-1385992a5072">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2022 and 2021 were $84&#160;million and $94&#160;million, respectively, and include reductions in variable consideration for sales return provisions related to past sales of approximately $21&#160;million and $28&#160;million for the three months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $36&#160;million as of September 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $38 million and $32&#160;million as of September 30, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $1&#160;million during the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2022 and 2021 is as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs charged against the allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries of amounts previously written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ia75431739df4487280446af7b19c22ac_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfMzg0ODI5MDcwNTY0MA_cadd8561-a02f-4317-be4a-2e7f329e64bb"
      unitRef="usd">84000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTQ5NzU1ODIxMjQ4_43d44e02-da31-4cde-b5fc-357c7919734d"
      unitRef="usd">94000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="id13e6d60640d4848933c41324b30da24_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTQ5NzU1ODIyMTYx_2305e3e7-16cf-44af-acfa-571f597da38c"
      unitRef="usd">21000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ia2b64397f3134ccc856057d7d06cac18_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTQ5NzU1ODIxMjYx_0938ac8c-e4c8-4298-b4a0-c6302cdd5a27"
      unitRef="usd">28000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTcxOA_3c7e6673-07ba-48d8-92ad-06ca17ab57c9">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $36&#160;million as of September 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i55bc36e507494e61b200544c3360e3d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi0yLTEtMS0xNDMwNjE_22468879-c940-47fa-9da6-30e104f1ebec"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie7bba4a0408e47b6904cb9363a54d0c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi00LTEtMS0xNDMwNjE_3ef87621-d37c-4258-984d-dc1dcdc057c4"
      unitRef="usd">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i64d25a700a694dd0bb04c6e978004998_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi02LTEtMS0xNDMwNjE_61273537-c8d9-4497-9b05-70ee1378db18"
      unitRef="usd">944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i588fb4f24bc44da9b20f9ba64cdce034_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi04LTEtMS0xNDMwNjE_bfc4fabd-a128-4cf0-840e-fb6d57cc8e5d"
      unitRef="usd">170000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5023261686ca407a90455d9077dc3871_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi0xMC0xLTEtMTQzMDYx_4c259f23-f13d-4296-ac75-d9e674cdd3c7"
      unitRef="usd">45000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMi0xMi0xLTEtMTQzMDYx_34baad09-1c23-486a-aa47-61d588b682b0"
      unitRef="usd">1863000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i9a74aed9df0544728bda592f48dc4d5c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy0yLTEtMS0xNDMwNjE_d0cea854-6265-499b-af89-a3e9ae19ff71"
      unitRef="usd">427000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ia75431739df4487280446af7b19c22ac_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy00LTEtMS0xNDMwNjE_8a17f6e4-bf10-4762-b133-aee0806e57f4"
      unitRef="usd">84000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i12459cee3f4646d2966fb895ab93f2eb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy02LTEtMS0xNDMwNjE_f2bcca6c-28cd-4594-be25-8cd3ebf2682d"
      unitRef="usd">1911000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i1a39f472d42a4f5ebd126b085b5fe9e1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy04LTEtMS0xNDMwNjE_1a91dbb4-5f6e-4000-95c0-ba30a4c32710"
      unitRef="usd">1558000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ia09603225e8f46f9adf432aff5307061_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy0xMC0xLTEtMTQzMDYx_6f47bab8-b7f6-43b3-a3f9-c951f9de725f"
      unitRef="usd">165000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfMy0xMi0xLTEtMTQzMDYx_3aa7154f-1d35-440b-af21-284e83915ec6"
      unitRef="usd">4145000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9a74aed9df0544728bda592f48dc4d5c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC0yLTEtMS0xNDMwNjE_d35908be-fccf-4e7d-80d8-68fc41a564b0"
      unitRef="usd">452000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia75431739df4487280446af7b19c22ac_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC00LTEtMS0xNDMwNjE_03c4e681-b710-4409-b00a-cd0dcd5b322a"
      unitRef="usd">145000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i12459cee3f4646d2966fb895ab93f2eb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC02LTEtMS0xNDMwNjE_69937037-e69e-4ff5-8a30-59959c92dbe5"
      unitRef="usd">1847000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1a39f472d42a4f5ebd126b085b5fe9e1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC04LTEtMS0xNDMwNjE_567a3f6f-4ede-4400-9c1c-96d778b397d7"
      unitRef="usd">1532000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ia09603225e8f46f9adf432aff5307061_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC0xMC0xLTEtMTQzMDYx_fa9b027e-ad9f-406b-a370-de9d1ae18196"
      unitRef="usd">88000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNC0xMi0xLTEtMTQzMDYx_c08ca8ed-c950-435c-892d-379de20eb8c6"
      unitRef="usd">4064000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3f5cafad91a7439a8ee4e91276eddf07_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS0yLTEtMS0xNDMwNjE_d1843a86-17c1-43e4-9996-b594a4ad6ad5"
      unitRef="usd">197000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id6e2c1d055a04b8ca3b8229415cd198d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS00LTEtMS0xNDMwNjE_44480c1b-1165-4db3-ad8f-2653fe15b023"
      unitRef="usd">421000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic54b70832a484dda991eba0bea3d37ba_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS02LTEtMS0xNDMwNjE_2d0a477a-6ea8-4274-b550-f83fb358e725"
      unitRef="usd">1008000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id913d7fd4ae340d99bf84a67735c6296_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS04LTEtMS0xNDMwNjE_b2dddb0f-2971-4837-b209-6aa81b09e4c7"
      unitRef="usd">196000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i37dc4d41d03d46f296e6c60b958dba8d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS0xMC0xLTEtMTQzMDYx_1c2fcf5b-5f9c-416a-952d-2470cbece27e"
      unitRef="usd">122000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOjRmNWFlYzE2OGEyZjRmYzlhN2I3OTQzN2Y5MzlhZTRjL3RhYmxlcmFuZ2U6NGY1YWVjMTY4YTJmNGZjOWE3Yjc5NDM3ZjkzOWFlNGNfNS0xMi0xLTEtMTQzMDYx_afdca43c-6fd1-4077-b684-61014e34fa0b"
      unitRef="usd">1944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibf53ff30035f4469b7bf0b121a32dffd_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDEwOA_bcde2efe-1331-48ba-a29c-88720cd28346"
      unitRef="usd">43000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7419cf53c79e45e3a1c6ffa5120da79d_I20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDExNQ_efbbcf43-41e2-412f-897f-e06f4c42035d"
      unitRef="usd">36000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id369b423b8504df5bb95a335c257add6_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDI2NA_3c653040-e6e5-4984-bc9e-e30181f9a89f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5c705f4ebe8f4e9caa8290ee18d7fa8c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi0yLTEtMS0xNDMwNjE_31897c38-ea52-43ed-b2fd-c26df6a0dcf8"
      unitRef="usd">190000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0c2600d93b104798b8817d0bd816b754_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi00LTEtMS0xNDMwNjE_09f8e64f-10df-445b-ac45-4f348bcd45dc"
      unitRef="usd">575000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5a5b868d47f54d2daecf77fbde9240da_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi02LTEtMS0xNDMwNjE_79133b6f-6afc-45a1-bf8d-bfede30f8594"
      unitRef="usd">779000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i67586450d7a94efeb4d4b4e98a992f51_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi04LTEtMS0xNDMwNjE_055f4c14-ea8c-4e7f-838a-3252f603a0eb"
      unitRef="usd">184000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i383189ddaae4494a9ead4886d08862ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi0xMC0xLTEtMTQzMDYx_8d4a163e-9edf-466b-831b-a3b2336c846d"
      unitRef="usd">85000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMi0xMi0xLTEtMTQzMDYx_3457fb82-fc79-4a9c-8a6e-069b9a6d0521"
      unitRef="usd">1813000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i54c5d4750d6b4c8ab87893cf4856f81b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy0yLTEtMS0xNDMwNjE_828f619f-4eab-46a9-bf5d-f4e2e12f6a4d"
      unitRef="usd">472000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy00LTEtMS0xNDMwNjE_1948c4c6-46ae-486c-9448-c2131d68bac4"
      unitRef="usd">94000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i33ad1c289f4d477c9fa5a51190c9e7cb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy02LTEtMS0xNDMwNjE_00267a57-9ad7-4777-a6b4-61cb6a8c304a"
      unitRef="usd">1842000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i87ed4784134a476cac4779215bef619d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy04LTEtMS0xNDMwNjE_d5e51cc1-a678-4cfb-ae31-fc8b10225afb"
      unitRef="usd">1487000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i0b06a8025f5c4eb68a5b3de937057a18_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy0xMC0xLTEtMTQzMDYx_89ab61c2-5c6f-4cda-9179-8b76366a4cf8"
      unitRef="usd">167000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfMy0xMi0xLTEtMTQzMDYx_39f61079-f7c8-415f-ba63-a189c078a58d"
      unitRef="usd">4062000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i54c5d4750d6b4c8ab87893cf4856f81b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC0yLTEtMS0xNDMwNjE_387fd979-c00b-4f8a-af58-0043a99ce5fc"
      unitRef="usd">448000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i7bce3dd69b024bc791ce131d90acd234_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC00LTEtMS0xNDMwNjE_0b2cb2e2-1dfd-435f-b8fc-7aaaf7e03e4b"
      unitRef="usd">167000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i33ad1c289f4d477c9fa5a51190c9e7cb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC02LTEtMS0xNDMwNjE_51fd1cb8-6b96-48a0-b0d5-017bdc6dae3f"
      unitRef="usd">1619000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i87ed4784134a476cac4779215bef619d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC04LTEtMS0xNDMwNjE_85977555-988f-4180-8b92-b0f827de1699"
      unitRef="usd">1524000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0b06a8025f5c4eb68a5b3de937057a18_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC0xMC0xLTEtMTQzMDYx_361c3e32-efe3-455f-9cf8-fed8257a2d80"
      unitRef="usd">166000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNC0xMi0xLTEtMTQzMDYx_feeab653-52b3-4bf3-8ed8-d86b67c03d2a"
      unitRef="usd">3924000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifa59c5c6d2574133b660040dfd6f39d7_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS0yLTEtMS0xNDMwNjE_19bb8f1e-2215-439d-a53b-79efaa3e098b"
      unitRef="usd">214000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iae15cba69f554a19879bbd577f98cbc2_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS00LTEtMS0xNDMwNjE_f3b85513-78d6-401a-8f21-a40ab58b6f71"
      unitRef="usd">502000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibf7ec2397c1c476d83c06887b07a46d3_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS02LTEtMS0xNDMwNjE_c6ad771a-e1fd-4864-b83c-634ed1fc16b2"
      unitRef="usd">1002000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i264f439282794b6795807f3ae1bb71b6_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS04LTEtMS0xNDMwNjE_c234be4b-3b9e-490c-85db-66c81e0c0282"
      unitRef="usd">147000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2965757201c94320abadce3840340f63_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS0xMC0xLTEtMTQzMDYx_73f561b4-3b73-4b27-815e-6237a25193a0"
      unitRef="usd">86000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmUyOTU2MjdjMDZkNTQ0MmFiMzRiMDU2NmZmZDkyZWZjL3RhYmxlcmFuZ2U6ZTI5NTYyN2MwNmQ1NDQyYWIzNGIwNTY2ZmZkOTJlZmNfNS0xMi0xLTEtMTQzMDYx_d28ae144-6ee4-4355-b41d-82a18d5d447d"
      unitRef="usd">1951000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i24db5cc85723404fb1251cfa00551475_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDQyMA_4e4b144f-d8a3-44ff-9297-ae4b3db95a58"
      unitRef="usd">38000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6131be55d52f42009c7700e15ebe45e7_I20210101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDQyNw_5598d81f-c91e-44fd-90cd-9435f60393b8"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf4245062a7b418a90b5c3eb455b38c7_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNDU4MA_e32d99f6-7673-4c49-a46d-fb533b27a963"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RleHRyZWdpb246NzNlNWJkMWIzMGNmNDNkMzhkNWFmZTVhMTZhNzk4ODZfNTcxMw_bcf95550-643b-4a5a-b856-5177265be791">The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2022 and 2021 is as follows.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs charged against the allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries of amounts previously written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMS0xLTEtMS0xNDMwNjE_db269abb-fe41-434f-ad29-c15d5382025d"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMS0zLTEtMS0xNDMwNjE_b81d3435-95df-4119-85ab-6545b9bd1d51"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMi0xLTEtMS0xNDMwNjE_57db6dbf-002c-44a9-85d1-302abbaa4b5e"
      unitRef="usd">-2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMi0zLTEtMS0xNDMwNjE_afb86df4-8e34-4b3d-a83c-1666e0b3b403"
      unitRef="usd">-1000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMy0xLTEtMS0xNDMwNjE_99576590-7b12-4edd-8ce5-f57745b0428f"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfMy0zLTEtMS0xNDMwNjE_0ea6b793-b522-4c5e-b0d4-7b71d9f5baa5"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNC0xLTEtMS0xNDMwNjE_78e93c68-5a50-44eb-92ba-d76240f17a8a"
      unitRef="usd">4000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNC0zLTEtMS0xNDMwNjE_7e7502ad-25eb-4e1e-82e9-f070f8816ec9"
      unitRef="usd">2000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNS0xLTEtMS0xNDMwNjE_99263c9f-4735-4269-964f-e3cdf91d0e2d"
      unitRef="usd">3000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNS0zLTEtMS0xNDMwNjE_ecfaa2eb-e1f4-4a05-a635-15fda743ee29"
      unitRef="usd">0</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNi0xLTEtMS0xNDMwNjE_7ca3e068-263b-4393-904f-5c0e4a542ccf"
      unitRef="usd">34000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80Ni9mcmFnOjczZTViZDFiMzBjZjQzZDM4ZDVhZmU1YTE2YTc5ODg2L3RhYmxlOmEwOGI2MGUyNzdhOTRiOGI5N2YyNzRjNGE4MWMwOWZjL3RhYmxlcmFuZ2U6YTA4YjYwZTI3N2E5NGI4Yjk3ZjI3NGM0YTgxYzA5ZmNfNi0zLTEtMS0xNDMwNjE_7008fcb8-1d47-4df1-934b-0575926d29ce"
      unitRef="usd">37000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjUwMA_e7a928ca-5eaf-486a-b98c-0a9b1bb78f4f">LICENSING AGREEMENTS AND DIVESTITURE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Amoun Pharmaceutical Company S.A.E. (&#x201c;Amoun&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#x201c;Amoun Sale&#x201d;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International Rx segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $88&#160;million during the nine months ended September 30, 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during the three months ended September 30, 2021, included within Other (income) expense, net in the Combined Statements of Operations. Revenues associated with Amoun were $20&#160;million and $157&#160;million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i687a6d97c876442da5f14198d88e14b1_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMTI0OQ_32a84388-ea3b-49b8-a29c-eb15b0b60b58"
      unitRef="usd">740000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i2c0c9cf75bab4540be7e213a897e311f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjIwMA_b392da48-6937-4e09-882a-436462c4ff2c"
      unitRef="usd">88000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i0f67a143f58b4616851d1f79883c3ce8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMTA5OTUxMTYzMDYxOA_cfc4f074-cb10-41b5-8304-4ffbb8e907d9"
      unitRef="usd">26000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i83dd54e76be14e2b8cddedd0ad775700_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjQyNg_93e7f51a-e675-4609-afd4-60c65d25e4ac"
      unitRef="usd">20000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i4bc7df085735496995eedc6a00cacc90_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF80OS9mcmFnOjMxN2I0MTViODQ2MDRmMTg5NTg5OWFjZmUxYTI0YjhmL3RleHRyZWdpb246MzE3YjQxNWI4NDYwNGYxODk1ODk5YWNmZTFhMjRiOGZfMjc0ODc3OTA3MjMzOQ_0652c010-5db2-43bb-b315-78163bdd7517"
      unitRef="usd">157000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMjczMQ_0980ee2c-ac9e-48e3-bf43-2ff62c98682d">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and Integration Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of September 30, 2022 was $13 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $28 million and $9&#160;million of restructuring and integration costs and made payments of $37&#160;million and $13&#160;million during the nine months ended September 30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and expects to continue to incur costs associated with activities relating to the B+L Separation. The Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the nine months ended September 30, 2022 and 2021 are separation and IPO costs of $30&#160;million and $20&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also incurred, and expects to continue to incur with respect to the B+L Separation, separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO including, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the nine months ended September 30, 2022 and 2021 are separation-related and IPO-related costs of $84&#160;million and $91&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i5c15779e38db4d9f960b2dbcddd1f4c7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfNzA4_eb5fc6fa-fdad-42ab-8c8e-d213894d63b3"
      unitRef="usd">13000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i98ff32b9f66642d49d99b62aac6963ff_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfNzMz_ff57779e-ac23-47d5-b5b0-054a09d01796"
      unitRef="usd">28000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iede60bc2c8b94524b78454391fd1f286_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfNzQw_7f390438-2bcb-4f17-964b-3d3c21357612"
      unitRef="usd">9000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i98ff32b9f66642d49d99b62aac6963ff_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfODAz_9492096d-cd0e-4eba-a029-e9776bd3467f"
      unitRef="usd">37000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="iede60bc2c8b94524b78454391fd1f286_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfODEw_a1548621-af63-45e0-bdd1-70c1bc3d2270"
      unitRef="usd">13000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="ib1b8d98ba0764e17812507d2898812ea_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMTkzMQ_b1c63252-d3a1-410f-9842-debca74f32fc"
      unitRef="usd">30000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id6bf4d2916304721b590b0e9b170762c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMTkzOA_0c891e6a-d097-4901-a073-c6cce00b865d"
      unitRef="usd">20000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib1b8d98ba0764e17812507d2898812ea_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMjU0Mg_84db55c5-8a4b-4c7f-baf2-fda2c7b18f5b"
      unitRef="usd">84000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id6bf4d2916304721b590b0e9b170762c_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81Mi9mcmFnOmE1MTc2Mzc2MmJiNjRmZDNiNjQ3ZTRkODBlMzk3ZTg3L3RleHRyZWdpb246YTUxNzYzNzYyYmI2NGZkM2I2NDdlNGQ4MGUzOTdlODdfMjU0OQ_ddff2195-6098-4340-9119-675638ce048a"
      unitRef="usd">91000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAxOQ_516cbc17-5c0a-4c68-8582-4f05d9394495">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of September 30, 2022 includes $297&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#x2019;s shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, Restricted cash and other settlement deposits included $1,210&#160;million of payments into an escrow fund under the terms of the Securities Class Action Settlement (as defined in Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d;), which was subject to one objector&#x2019;s appeal of the final court approval of the agreement. The period to file a petition for an appeal with the U.S. Supreme Court expired on August 10, 2022 and the objector did not file such a petition. The expiration of this deadline means the Securities Class Action Settlement has become &#x201c;final&#x201d;, as no more appeals can be filed. As a result, the Company's rights to the funds in escrow were extinguished and the Company reduced Restricted cash and other settlement deposits with a corresponding reduction to liabilities for legal settlements, included in Accrued and other current liabilities on the Company's Consolidated Balance Sheets, by $1,210&#160;million in the three months ended September 30, 2022. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;U.S. Securities Litigation - Opt -Out Litigation&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d; for additional details. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 assets or liabilities during the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps, with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#x2019;s investment in certain Bausch + Lomb euro-denominated subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb&#x2019;s cross-currency swaps qualify for and have been designated as a hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the periods presented. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with Bausch + Lomb&#x2019;s cross-currency swaps as included in the Consolidated Balance Sheet as of September&#160;30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#x2019;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021. As a result, there were no assets or liabilities related to the cross-currency swaps included in the Consolidated Balance Sheets as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest settlement of the 2022 cross-currency swaps occurs in January and July each year, with the first settlement in January 2023. Future settlements of the 2022 cross-currency swaps will be reported as investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2022 and 2021, the Company received $0 and $23&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company's outstanding foreign currency exchange contracts had an aggregate notional amount of $394&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#x2019;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#x2019;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#x2019;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At September&#160;30, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#x2019;s relative fair value at September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of September&#160;30, 2022 and December&#160;31, 2021 was $13,450 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAyMg_4bbc918a-b612-4f4e-957d-7f43127894ad">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i189881ec0c284dfcbb328b608d14d436_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0yLTEtMS0xNDMwNjE_271e9333-ac9c-4bf1-a87d-55efbab2c5a8"
      unitRef="usd">24000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5d6f4ef12df34897a610582fba7a5ca1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy00LTEtMS0xNDMwNjE_15e053da-5f2f-4d88-8791-e752673e0d4e"
      unitRef="usd">13000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy02LTEtMS0xNDMwNjE_35ee2cb8-551a-4ac7-9393-c0538afe07fe"
      unitRef="usd">11000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iddfccdfa38764f7ab26413e57457105b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy04LTEtMS0xNDMwNjE_f8c1f7ed-8ee5-4276-b131-5f4bf7cf3bd4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib11917dc946040bfa50a896265fc544d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xMC0xLTEtMTQzMDYx_02d38be8-9605-490b-96a3-1465014b8cd5"
      unitRef="usd">76000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3856df3c34054e50b83aafeb6a21dfa8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xMi0xLTEtMTQzMDYx_6617c031-0116-4dc1-a740-2c00b34ea3ef"
      unitRef="usd">58000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i59def28407a7463daf61067d0788531e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xNC0xLTEtMTQzMDYx_d38ef7ad-4a8f-402d-8998-f0be810fc402"
      unitRef="usd">18000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i55579786a38243319015619aafa89fd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfMy0xNi0xLTEtMTQzMDYx_2af09d06-3c53-4de0-84ae-b9857ba38ead"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i189881ec0c284dfcbb328b608d14d436_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0yLTEtMS0xNDMwNjE_f29ef554-ed6e-473d-a390-7e0fb02068a7"
      unitRef="usd">11000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i5d6f4ef12df34897a610582fba7a5ca1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC00LTEtMS0xNDMwNjE_ea2adeee-5c3a-406e-a565-59dbb8b80fe8"
      unitRef="usd">11000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC02LTEtMS0xNDMwNjE_3c8b04a0-9162-4e8b-8c76-4ecd71fd2045"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="iddfccdfa38764f7ab26413e57457105b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC04LTEtMS0xNDMwNjE_cab8ed32-e8ee-4e00-9346-b013bb09c0d7"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ib11917dc946040bfa50a896265fc544d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xMC0xLTEtMTQzMDYx_02bcd4ae-999c-4726-9147-292ac0a60be7"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i3856df3c34054e50b83aafeb6a21dfa8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xMi0xLTEtMTQzMDYx_3bd1321d-87b4-4e16-9581-7f8850339276"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i59def28407a7463daf61067d0788531e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xNC0xLTEtMTQzMDYx_0a78d637-58c0-436c-8ed0-1000672b4bf3"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i55579786a38243319015619aafa89fd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNC0xNi0xLTEtMTQzMDYx_7cb5270f-184e-4f7b-8586-60859497fa76"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="ib7cb0e3db56a4ea981bbab9943aa32d0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0yLTEtMS0xNDMwNjE_72ec095a-dc37-4bbe-a6c9-1556fbc74081"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibdfbccb558174a2c8c0c09b05b34c8ef_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS00LTEtMS0xNDMwNjE_e542a916-6bcc-476e-8031-efa0cafceaeb"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3c63ea1cea814379bfb6c3678f5a4b33_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS02LTEtMS0xNDMwNjE_786253ac-0477-4f55-8101-976a092330d9"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5ec1e524d22a438c9c456e1b9c501f25_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS04LTEtMS0xNDMwNjE_946f9702-fc14-422c-8f12-b2bd294118b1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i560fd028d7474fdd985f6a52302094c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xMC0xLTEtMTQzMDYx_5f71557a-3367-44b4-9d4e-3a812bb74f77"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3b7c343d445f4dcc9a19e5d1ba15e4af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xMi0xLTEtMTQzMDYx_8de5d699-2918-4bba-b222-60b6633e9fa5"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i3102bdd26ddc4acc85720c1d44031b39_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xNC0xLTEtMTQzMDYx_38c9baff-559b-47ab-b96a-9a23a5c63bbb"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i79f25ff584194105b7bc29f5d77efe7f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNS0xNi0xLTEtMTQzMDYx_fd33f3de-6343-47f0-9f5f-6ca5b97afa7e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie2ad6947f6374ac48f3ac1e7694627ce_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0yLTEtMS0xNDc1MTY_29dd0b29-d6f3-4c05-9e7a-7ad4ab69e501"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if80389df867444889b10bc292d83780a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi00LTEtMS0xNDc1MTY_5f6e38b1-ba7b-467c-a78f-801a841b4dbc"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6cb7a659ca664b599f9e404ffbd842e7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi02LTEtMS0xNDc1MTY_1bc2c794-f6a5-4e34-9f53-1770d1a08c96"
      unitRef="usd">14000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i97ffb0132d5844cbb9a45d214fa9b29a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi04LTEtMS0xNDc1MTY_7909a100-1e39-4ded-8bb8-2e8e89d5a5b7"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0d83aa84f0be438bac5f8d689a31f364_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xMC0xLTEtMTQ3NTE2_f0199044-ce51-4311-9ab1-e06623396ec5"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i02290af2908a48d9818fdaed17915266_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xMi0xLTEtMTQ3NTE2_aea1cdf5-6bff-4052-b0d0-811e4987e0c9"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i80540287663d42bebe1ebb76c28b9e75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xNC0xLTEtMTQ3NTE2_ce9c69c1-8a05-42f2-b9f1-90ae6ebcc8dc"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9cb8cfd06a6a49f8879cde7f8a7d98ee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNi0xNi0xLTEtMTQ3NTE2_7eb5646f-a49c-47c0-a6aa-ad7f43c2cde6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i189881ec0c284dfcbb328b608d14d436_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0yLTEtMS0xNDMwNjE_f259206a-1f2d-4928-b6b9-845bad02d786"
      unitRef="usd">224000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i5d6f4ef12df34897a610582fba7a5ca1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy00LTEtMS0xNDMwNjE_7b71f75f-46bf-4365-b992-ef395fa4dfd0"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ib4687e77ce8b420395f7c2c6f8ddb66b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy02LTEtMS0xNDMwNjE_841acfc2-55c9-4e72-b5d7-6c0a3828fd0e"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="iddfccdfa38764f7ab26413e57457105b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy04LTEtMS0xNDMwNjE_3e5fe08b-e902-4323-9a01-39bbff553b33"
      unitRef="usd">224000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ib11917dc946040bfa50a896265fc544d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xMC0xLTEtMTQzMDYx_2bf25644-431d-4668-b40c-3bcb9f506707"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i3856df3c34054e50b83aafeb6a21dfa8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xMi0xLTEtMTQzMDYx_21e8c4cb-3907-4ef4-8534-8984cc19b2d8"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i59def28407a7463daf61067d0788531e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xNC0xLTEtMTQzMDYx_f6d61fad-320d-4915-9d13-9ebbc9f2e0da"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i55579786a38243319015619aafa89fd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfNy0xNi0xLTEtMTQzMDYx_3bfe8131-c82f-4017-b6f2-6f229b7f7bb2"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ib7cb0e3db56a4ea981bbab9943aa32d0_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0yLTEtMS0xNDMwNjE_38a3098c-1252-4f9d-a8ec-a18f9eec081a"
      unitRef="usd">6000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ibdfbccb558174a2c8c0c09b05b34c8ef_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC00LTEtMS0xNDMwNjE_569e8f16-2689-48a0-b9c5-05b6383342df"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3c63ea1cea814379bfb6c3678f5a4b33_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC02LTEtMS0xNDMwNjE_625e2700-b57c-4fc4-af56-434f0d185a0e"
      unitRef="usd">6000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5ec1e524d22a438c9c456e1b9c501f25_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC04LTEtMS0xNDMwNjE_e44ff201-e744-47d6-a189-8c0187e69a87"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i560fd028d7474fdd985f6a52302094c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xMC0xLTEtMTQzMDYx_bd02469a-bc85-402a-be2c-16c99df6d3eb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3b7c343d445f4dcc9a19e5d1ba15e4af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xMi0xLTEtMTQzMDYx_ed4d35a6-ed2c-4250-b520-535c3ebdd066"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3102bdd26ddc4acc85720c1d44031b39_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xNC0xLTEtMTQzMDYx_ac687f53-4b58-4840-9637-14f5167506e9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i79f25ff584194105b7bc29f5d77efe7f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjIzMzBmMGEwYzBlYjQ4M2FhYTU3YTJkNTk1ZDRlNTgwL3RhYmxlcmFuZ2U6MjMzMGYwYTBjMGViNDgzYWFhNTdhMmQ1OTVkNGU1ODBfOC0xNi0xLTEtMTQzMDYx_b6f53747-bc9b-4295-b8fb-1d11caf8105b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMTQyOA_24d038a1-b487-4eaf-8edd-47508afdb945">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMTczMA_dbadd6b0-eba4-4f52-bb5a-b992994eba7d"
      unitRef="usd">297000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic0ef55f3a8f4410b942a22f1c9b01c26_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjU0MA_92fc8385-bb65-4db8-bfce-203ad1eebf41"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LitigationSettlementNumberOfObjectorsAppeals
      contextRef="i3064f6af45484839a5e9e28044f57d64_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjcwNA_9a8057e1-0ec6-4de0-b48e-015a4f394c60"
      unitRef="appeal">1</bhc:LitigationSettlementNumberOfObjectorsAppeals>
    <bhc:IncreaseDecreaseInAccruedLiabilitiesCurrent
      contextRef="i259cd2e6dab94c2ba09224dea2beb7c7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjc0ODc3OTA4MTk0OA_7f2b8c6c-b57b-471d-90fd-f0c374664664"
      unitRef="usd">-1210000000</bhc:IncreaseDecreaseInAccruedLiabilitiesCurrent>
    <bhc:IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i259cd2e6dab94c2ba09224dea2beb7c7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjc0ODc3OTA4MTk0OA_ad1df5c8-d6c8-4087-a0af-6607862f87ba"
      unitRef="usd">-1210000000</bhc:IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i172f1137c8f54eb5aee6b0e56da822a2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMTA5OTUxMTYzODE1OQ_948dab73-f25e-408a-aabe-b6048bf28169"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMjc0ODc3OTA4MDIzMQ_68b4bde9-3816-4e4a-a79d-b2a13307a03a">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with Bausch + Lomb&#x2019;s cross-currency swaps as included in the Consolidated Balance Sheet as of September&#160;30, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i664840dc517c429f8d7027d6465fdf0d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmEyMmNiMTkyZGZkZTQxYzc5NjQ1OTE3Y2NkZjM1Zjg2L3RhYmxlcmFuZ2U6YTIyY2IxOTJkZmRlNDFjNzk2NDU5MTdjY2RmMzVmODZfMS0yLTEtMS0xNDc1Mzc_bdef57bb-aa03-4558-9e3a-e84a50ebad50"
      unitRef="usd">11000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="ic1e5a6363fc74a07884d25a0f2217af6_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmEyMmNiMTkyZGZkZTQxYzc5NjQ1OTE3Y2NkZjM1Zjg2L3RhYmxlcmFuZ2U6YTIyY2IxOTJkZmRlNDFjNzk2NDU5MTdjY2RmMzVmODZfMi0yLTEtMS0xNDc1Mzc_3621ec9e-1bee-40ad-bf1a-b75a3c78abab"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i172f1137c8f54eb5aee6b0e56da822a2_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmEyMmNiMTkyZGZkZTQxYzc5NjQ1OTE3Y2NkZjM1Zjg2L3RhYmxlcmFuZ2U6YTIyY2IxOTJkZmRlNDFjNzk2NDU5MTdjY2RmMzVmODZfMy0yLTEtMS0xNDc1Mzc_2ebb9ba6-1799-455f-9dc9-cb5ab0344e4d"
      unitRef="usd">14000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i658a48e24ddb46329d8726eb2248580e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfMzIyNg_7d39239d-3b8a-4362-a846-0ef9a107335e"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAyNA_cb221e9b-9f8a-4def-8a36-71593d55b27f">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib700cf771af14037994bc18bd56d1eac_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi0yLTEtMS0xNDMwNjE_7af03ed5-98b2-4ce8-b5e1-6c064fd069da"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ifd5c6d1837094f3da3275340aac12543_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi00LTEtMS0xNDMwNjE_6b4f7712-cdfb-4fb8-a793-783c98205208"
      unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ie2c32f9e20d74e7ab62844bacfe8a06d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi01LTEtMS0xNDMwNjE_2de95f30-0a91-4201-b802-a2ff114f4ff4"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6ae5d31784454d4f9c64507a80288ac4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMi03LTEtMS0xNDMwNjE_6bcba301-3a7c-440e-a1e8-810f6938ea1b"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i6f6d573695f9479a899bfc1140a6a312_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy0yLTEtMS0xNDMwNjE_b954365e-5497-4809-ab3b-989740727ef4"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i82ebd628dcc84efa96e5a3f56fbb029b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy00LTEtMS0xNDMwNjE_3cb7e069-3a65-4e01-a626-411382c1bd52"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="if9a33dade7514111bc4b73c39a7e80d8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy01LTEtMS0xNDMwNjE_007c7124-f827-45f9-97d3-0a0b6d24e587"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i39777750e2f64ea99b3afe8746b25115_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOmRkNzQzZDQyN2U5YzQ3NmY5ZDU2MWNmMGY4MTJiNzEwL3RhYmxlcmFuZ2U6ZGQ3NDNkNDI3ZTljNDc2ZjlkNTYxY2YwZjgxMmI3MTBfMy03LTEtMS0xNDMwNjE_eee68cce-65bc-4107-9a61-3c29fc8f60c5"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="ie2c32f9e20d74e7ab62844bacfe8a06d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNDA0Nw_4872ffd9-bd05-4343-99f2-cfbaef438270"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i6ae5d31784454d4f9c64507a80288ac4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNDA1NA_5cbf7e92-d4a0-4364-9aa9-1a7bea784cc4"
      unitRef="usd">23000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i04b46684430b436b80adda1d481b4307_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNDM3Mw_b16d766f-c45b-43a8-9dc8-bc317e47ef9b"
      unitRef="usd">394000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i3c5a5a87413f4813b60dc909501166c4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMS0xLTEtMS0xNDMwNjE_d663d5a3-cae4-4898-9d16-1eac09654183"
      unitRef="usd">-6000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i0d13600b4ae84400ad2d966a20e8cc67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMS0zLTEtMS0xNDMwNjE_db629e9a-c270-4cfe-b4bb-3a5ce85ae399"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="if5f7fd33a30e4a169c5464ee3e62b2cb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMi0xLTEtMS0xNDMwNjE_c7a5395e-f95b-4395-8b28-8e6d94ddb77f"
      unitRef="usd">-3000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="ic008afd14a8e42b1b866d63b770b5fa0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMi0zLTEtMS0xNDMwNjE_2c72222a-d2ab-412d-a5c4-84b306135cea"
      unitRef="usd">-1000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i04b46684430b436b80adda1d481b4307_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMy0xLTEtMS0xNDMwNjE_27a007a9-e6f9-4aa3-95b8-18026d075f50"
      unitRef="usd">-3000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i0491752f49af4e53b382633de1597dca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjgyNWJmNjA0Yzg0YTQ0ODJhN2RiNzgxN2E0ZmFjNWU0L3RhYmxlcmFuZ2U6ODI1YmY2MDRjODRhNDQ4MmE3ZGI3ODE3YTRmYWM1ZTRfMy0zLTEtMS0xNDMwNjE_5028d612-969b-4d4e-88d0-8b4b036607c7"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAxMw_fa1606f1-1077-4fa6-9f97-d1a533df67ef">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi0xLTEtMS0xNDMwNjE_69d69049-1907-4dd0-b687-8d4e16b43480"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="id7c556fd4fe44909bc9174e88819eb06_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi0zLTEtMS0xNDMwNjE_7445cbbe-eed1-4de6-a0ec-32f2a4d4f904"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="iba36257072b246d29fda1803494bc0af_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi01LTEtMS0xNDMwNjE_f382dcdf-0a09-4836-aec1-b3e97df52043"
      unitRef="usd">-3000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i6ed75df41237422bacb5217c299a7a89_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMi03LTEtMS0xNDMwNjE_54d59b60-462d-4a8f-a8fd-8b4ccd52e628"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy0xLTEtMS0xNDMwNjE_c56d30b8-dfff-490b-900e-2a170391a11e"
      unitRef="usd">18000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="id7c556fd4fe44909bc9174e88819eb06_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy0zLTEtMS0xNDMwNjE_a4f3bf76-8794-4348-bb61-8e863d0ec21e"
      unitRef="usd">5000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="iba36257072b246d29fda1803494bc0af_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy01LTEtMS0xNDMwNjE_69b74c84-346b-41ec-924b-bf52a4fa99ac"
      unitRef="usd">21000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i6ed75df41237422bacb5217c299a7a89_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjUxOWIyZGJlODlkZjQ3Njc5ZDczM2NjZDE2NjFkZmIwL3RhYmxlcmFuZ2U6NTE5YjJkYmU4OWRmNDc2NzlkNzMzY2NkMTY2MWRmYjBfMy03LTEtMS0xNDMwNjE_51d7cb25-4583-4fe0-bdf7-6a4e54524ade"
      unitRef="usd">14000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i07c71f42a1544418b4d10d3fc382ee03_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjQzMQ_10a7d873-2b41-48ae-8e64-295503ab27dd"
      unitRef="rate">0.06</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i75b032ae3e214a648b569459dbab455d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjQzNw_1ca51df9-03b1-4167-8581-18913c3805af"
      unitRef="rate">0.18</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i9ae4a5ad398947318b5198492ce65b04_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjQ5NQ_24b39baa-894a-4558-928f-6fb49e795906"
      unitRef="rate">0.07</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNzAyNw_af2b69ae-1e60-4d05-913f-972c0433d0d6">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMS00LTEtMS0xNDMwNjE_07d0df5e-c039-46f8-bf20-5099f1b9e384"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMS04LTEtMS0xNDMwNjE_abea0037-2df8-42aa-9819-29d2ef6e168a"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i260c0d75915a4ca3ad834d641fa75343_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMy0yLTEtMS0xNDMwNjE_ebb4faa3-4fc5-4380-8ec8-b7291f6f79c6"
      unitRef="usd">12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i48f2915dbf2941e5b52e80096e27bf1a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMy02LTEtMS0xNDMwNjE_c1786361-71fc-4dcd-99e8-04388ba82112"
      unitRef="usd">12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5ae79b3262d842b1af103d3792958795_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNC0yLTEtMS0xNDMwNjE_5e0d5073-9e97-429a-89c9-501091c19b7e"
      unitRef="usd">-10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifb7aaa35ab964b01b84dfe94e256903f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNC02LTEtMS0xNDMwNjE_8e785d40-33a2-4949-bcbb-a74471542692"
      unitRef="usd">-4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNS00LTEtMS0xNDMwNjE_21b2a73b-634a-445b-8ef7-8771b1f0b8f0"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNS04LTEtMS0xNDMwNjE_ea097f52-a039-446f-8edf-ac6498c82489"
      unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNi00LTEtMS0xNDMwNjE_2e615764-325b-4a35-b152-49c9c29269a3"
      unitRef="usd">19000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNi04LTEtMS0xNDMwNjE_2934f5b1-82ec-41f5-bf99-3896f6b8ba52"
      unitRef="usd">93000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNy00LTEtMS0xNDMwNjE_54f5a5fb-8ed6-41b0-9ca2-f05eaa7b7467"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfNy04LTEtMS0xNDMwNjE_b3efc8fd-6a0e-4b84-b59e-1890a71130a1"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfOS00LTEtMS0xNDMwNjE_a6d4524e-ec84-499e-95a3-37aa8ead2889"
      unitRef="usd">224000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfOS04LTEtMS0xNDMwNjE_aec3c327-37b2-40de-b1ca-32675960431b"
      unitRef="usd">244000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTAtNC0xLTEtMTQzMDYx_54c61132-111e-40c7-bc64-12454e1522df"
      unitRef="usd">35000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTAtOC0xLTEtMTQzMDYx_2e32c4b4-31af-49e4-b732-129e2580508f"
      unitRef="usd">37000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTEtNC0xLTEtMTQzMDYx_9a6d61a4-15d8-49c7-afd8-c9e880f62c86"
      unitRef="usd">189000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id8819f6bc6184106ba285e6415d9d42a_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RhYmxlOjBkMDk0OGM2ZDFkYjQ1YjZiMjMyODZkMDI3ZmFmM2FiL3RhYmxlcmFuZ2U6MGQwOTQ4YzZkMWRiNDViNmIyMzI4NmQwMjdmYWYzYWJfMTEtOC0xLTEtMTQzMDYx_8290049c-1fbf-4186-939c-d4633e156593"
      unitRef="usd">207000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i63a5e3f00efb48b2b18db41abfecd3de_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjg4MA_fa21f526-8db6-4883-bfab-c0052b83dfd2"
      unitRef="usd">13450000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i71e359c95d524712918710296eeeae37_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81NS9mcmFnOjI0NTdlNzRjYjZhYzRjOTNhMzcwN2EwYTM1MzNjNGY4L3RleHRyZWdpb246MjQ1N2U3NGNiNmFjNGM5M2EzNzA3YTBhMzUzM2M0ZjhfNjg4Nw_13237079-af11-460a-ab94-92de1d31a971"
      unitRef="usd">22689000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RleHRyZWdpb246MTk3N2VlNDk3YzEyNDRiYWI4MmY3NDMwYmYwYTBkMjdfNTk_2dc1291e-1382-4bb0-b0af-a528bb62cb39">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RleHRyZWdpb246MTk3N2VlNDk3YzEyNDRiYWI4MmY3NDMwYmYwYTBkMjdfNTU_633ab699-8d9d-4a02-bab5-8734728c8a0e">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMS0yLTEtMS0xNDMwNjE_f8a5092f-1188-47b3-a6c5-0ee4128e8b1d"
      unitRef="usd">302000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMS00LTEtMS0xNDMwNjE_45103006-8c88-45f4-b2b1-cf6f3ece5557"
      unitRef="usd">279000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMi0yLTEtMS0xNDMwNjE_d2f0b45e-0cd6-4178-a072-21872d904bc0"
      unitRef="usd">120000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMi00LTEtMS0xNDMwNjE_c88012b4-002a-45f7-8851-b5e051bf4ce3"
      unitRef="usd">112000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMy0yLTEtMS0xNDMwNjE_c3c54576-d220-4081-957c-63a03271438f"
      unitRef="usd">634000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfMy00LTEtMS0xNDMwNjE_55473472-7107-4dee-943f-8d05ef95b8b2"
      unitRef="usd">602000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfNC0yLTEtMS0xNDMwNjE_91ac43e3-f91b-42b2-8ad0-55e720e1e9b1"
      unitRef="usd">1056000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF81OC9mcmFnOjE5NzdlZTQ5N2MxMjQ0YmFiODJmNzQzMGJmMGEwZDI3L3RhYmxlOjMwMjIxZTYyMmJjMTRlZWZhMzlkYWFhOWQ5MmQyNWUxL3RhYmxlcmFuZ2U6MzAyMjFlNjIyYmMxNGVlZmEzOWRhYWE5ZDkyZDI1ZTFfNC00LTEtMS0xNDMwNjE_47c17942-830a-41fb-8157-1ad45178c3e9"
      unitRef="usd">993000000</us-gaap:InventoryGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5NjI_39f0d0c3-2e97-469a-9f8e-ad45045fd38a">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale, for the nine months ended September 30, 2022 were $15&#160;million and include: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $5&#160;million, in aggregate, related to the discontinuance of certain product lines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets included in the unaudited Consolidated Balance Sheets had a carrying value of $2,828&#160;million and an estimated remaining useful life of 63 months as of September 30, 2022. On August 10, 2022, a court held, that among other findings, that certain U.S. patents protecting the composition and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating inflammatory bowel syndrome with diarrhea (&#x201c;IBS-D&#x201d;) were invalid (the &#x201c;Norwich Legal Decision&#x201d;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intellectual property. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d; for details of this litigation matter and the Company&#x2019;s response. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues were $1,216&#160;million and $1,194&#160;million for the nine months ended September 30, 2022 and 2021, respectively. As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, could impact the timing and extent of future revenues and cash flows associated with Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determined that the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets for potential impairment. The Company performed this assessment using a probability-weighted undiscounted cash flow analysis, with a base case representing the Company&#x2019;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if they are able to launch one at all. This assessment resulted in no impairment of the carrying value of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets as of September&#160;30, 2022. The Company also determined that no change to the remaining useful lives of its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets was required as of September&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; could be material to the results of operations of the Company in the period or periods in which they were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale, for the nine months ended September 30, 2021 were $213&#160;million and include: (i) $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an adjustment of $88&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $20&#160;million, in aggregate, related to the discontinuance of certain product lines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets amounts to approximately $539&#160;million annually through 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 and the year ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#x2019;s terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To forecast a reporting unit&#x2019;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#x2019;s and a market participant&#x2019;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#x2019;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2021 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#x2019;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Interim Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2022 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2022 Interim Assessment of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 30, 2022 Interim Assessment of Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#x2019;s latest discounted cash flow model for the Ortho Dermatologics reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rate of 10%. The discount rate had increased 1% since the assessment performed at March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period May 6, 2022 (the time Bausch + Lomb&#x2019;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The decline in the equity markets negatively impacted the market price for Bausch + Lomb&#x2019;s common stock which at June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value tests utilized Bausch + Lomb&#x2019;s most recent cash flow projections for each of the reporting units and utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2022, with the exception of the Ortho Dermatologics reporting unit and the reporting units of the Bausch + Lomb segment, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairment to those reporting units was recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;September 30, 2022 Interim Assessment of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ortho Dermatologics &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Ortho Dermatologics reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at June 30, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Based on the impairment of goodwill recognized in the second quarter of 2022 for the Ortho Dermatologics reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections which reflect current market conditions and current trends in business performance. The Company&#x2019;s latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of 1% and the discount rate increased from 10.0% at June 30, 2022 to 10.5% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $119&#160;million for the three months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salix &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intellectual property. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d; for details of this litigation matter and the Company&#x2019;s response.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues represent approximately 80% of the Salix reporting unit&#x2019;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, could impact the timing and extent of future revenues and cash flows associated with Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues are indicators that the Salix reporting unit&#x2019;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#x2019;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of 2.5% and discount rates of 9.75% and 10.0%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#x2019;s probability-weighted discount valuation model and therefore no impairment was recorded as of September 30, 2022. However, as the Company&#x2019;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that the Norwich Legal Decision and other potential future developments may adversely impact the estimated fair value of the Salix segment in one or more future periods. Any such impairment could be material to the Company&#x2019;s results of operations in the period in which it were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other events occurred or circumstances changed during the period of October 1, 2021 (the last time goodwill was tested for all other reporting units) through September&#160;30, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics and Salix reporting units and the reporting units of the Bausch + Lomb segment, might be below its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through September&#160;30, 2022 were $4,382 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5NjQ_ff948247-4539-4392-a5b7-a79666a419ca">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5OTY_6a5662f1-0217-47d6-8a1b-3d229cb08e05">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i11472c1bcca3473484bcfadfc7e303e1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy0yLTEtMS0xNDMwNjE_d46774ab-8480-488b-894f-183bbd59563b"
      unitRef="usd">20748000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i11472c1bcca3473484bcfadfc7e303e1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy00LTEtMS0xNDMwNjE_1d29082c-a95c-4960-9394-bf2ff9aa3d3e"
      unitRef="usd">16902000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i11472c1bcca3473484bcfadfc7e303e1_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy02LTEtMS0xNDMwNjE_fa8afd22-0094-4140-afc8-5c820799e529"
      unitRef="usd">3846000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id18a1afc3dcb4214ad64a89920a42e55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy04LTEtMS0xNDMwNjE_1aef4626-5cbd-43f9-bf25-f6c0ee5c1363"
      unitRef="usd">20842000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id18a1afc3dcb4214ad64a89920a42e55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy0xMC0xLTEtMTQzMDYx_29839fb3-af00-4d7e-9c28-df4cab71c45c"
      unitRef="usd">16169000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id18a1afc3dcb4214ad64a89920a42e55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMy0xMi0xLTEtMTQzMDYx_23e27a10-2e36-4f3c-ae2e-f8d86bb46021"
      unitRef="usd">4673000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic9613fcb5ca34578a0abf1ab147f9208_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC0yLTEtMS0xNDMwNjE_71413593-0c8d-485c-b4fd-aca5c334baeb"
      unitRef="usd">892000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic9613fcb5ca34578a0abf1ab147f9208_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC00LTEtMS0xNDMwNjE_5b87d61e-1f42-4f23-ada6-5d25715ba0c3"
      unitRef="usd">520000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic9613fcb5ca34578a0abf1ab147f9208_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC02LTEtMS0xNDMwNjE_f022ebcf-5640-4f9f-a4aa-5f65e8708dd7"
      unitRef="usd">372000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3e063d61f8c44899a3f8978861d16697_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC04LTEtMS0xNDMwNjE_1932abf1-d38f-4b18-a633-7ca1e9d22c81"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3e063d61f8c44899a3f8978861d16697_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC0xMC0xLTEtMTQzMDYx_3d7e3278-7177-4908-a51a-6d4e1136b09f"
      unitRef="usd">473000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3e063d61f8c44899a3f8978861d16697_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNC0xMi0xLTEtMTQzMDYx_de27f238-b396-4d8d-9283-cd8f052a760f"
      unitRef="usd">429000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i602595f1880446f59ec15696e1d75c4a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS0yLTEtMS0xNDMwNjE_d5984271-2eab-4eb2-90ed-01796f5fc414"
      unitRef="usd">3305000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i602595f1880446f59ec15696e1d75c4a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS00LTEtMS0xNDMwNjE_5b00e597-8e38-4901-998d-d60fe71b3d16"
      unitRef="usd">3197000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i602595f1880446f59ec15696e1d75c4a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS02LTEtMS0xNDMwNjE_dc82a742-918e-46b1-b150-7bd5252e3e99"
      unitRef="usd">108000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6e873c909a3144db9339746a1a94254f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS04LTEtMS0xNDMwNjE_9b242258-4b78-480d-a048-803aadf32fae"
      unitRef="usd">3321000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6e873c909a3144db9339746a1a94254f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS0xMC0xLTEtMTQzMDYx_fb3b1814-0659-43d7-9638-385e411740b2"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6e873c909a3144db9339746a1a94254f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNS0xMi0xLTEtMTQzMDYx_24ae3f32-40a3-4afd-840b-6f6fcd386895"
      unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi0yLTEtMS0xNDMwNjE_46503b47-0fe6-4e3f-8d21-931292bbe401"
      unitRef="usd">135000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi00LTEtMS0xNDMwNjE_3d7e548e-a7e8-4b3a-9e92-316b85f44447"
      unitRef="usd">135000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebb5b1d88b6d4ea49c0e843c4821eb6e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi02LTEtMS0xNDMwNjE_32f654ec-c261-41ac-8ebc-2d2e1d7a0959"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia86e90503a154ca4bb57d7823f5d7f75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi04LTEtMS0xNDMwNjE_626c0b81-e59e-49af-9897-dbcbdf49edeb"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia86e90503a154ca4bb57d7823f5d7f75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi0xMC0xLTEtMTQzMDYx_986bf0e4-adb1-481a-ab00-225eaa296072"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia86e90503a154ca4bb57d7823f5d7f75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNi0xMi0xLTEtMTQzMDYx_dbab492e-fef5-4470-a321-87e57a328077"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy0yLTEtMS0xNDMwNjE_58ab0085-3bfe-4687-b33f-4f35b1a3e652"
      unitRef="usd">191000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy00LTEtMS0xNDMwNjE_5d7dea9d-6f55-4acf-8652-001a7c3099d3"
      unitRef="usd">191000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i27fc2b9412b548fcb902b2cacf2f7f8c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy02LTEtMS0xNDMwNjE_d9dbda62-38b4-45d1-9d3f-3bfbc4dff827"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iec524df231434a33b3b75a1f327b3a14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy04LTEtMS0xNDMwNjE_8c277b59-0321-4346-a095-7d38dd78735d"
      unitRef="usd">207000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iec524df231434a33b3b75a1f327b3a14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy0xMC0xLTEtMTQzMDYx_75475671-88b1-4344-a26a-7fc403aac5aa"
      unitRef="usd">206000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iec524df231434a33b3b75a1f327b3a14_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfNy0xMi0xLTEtMTQzMDYx_f38401b8-c9b3-4f63-8d49-3ecdc519dcf2"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC0yLTEtMS0xNDMwNjE_9596e5f3-6cd5-4b8e-b708-1ff5489f92c8"
      unitRef="usd">25271000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC00LTEtMS0xNDMwNjE_4450b5c7-a908-40a3-89a3-a3a905971f09"
      unitRef="usd">20945000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC02LTEtMS0xNDMwNjE_8e72f995-f0e5-48d9-aa8c-2277202de5dd"
      unitRef="usd">4326000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC04LTEtMS0xNDMwNjE_28df14b8-c113-4630-be6c-a6ced4804e3d"
      unitRef="usd">25430000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC0xMC0xLTEtMTQzMDYx_f5339114-349d-47f1-958f-09267cd407cb"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOC0xMi0xLTEtMTQzMDYx_638ebbec-44a6-429b-b3f1-a7fa9dc8ff4d"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i88feb25df1514be1b2bf7b05d2488070_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS0yLTEtMS0xNDMwNjE_b429093b-03bf-4769-9720-b88d1f670b04"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i88feb25df1514be1b2bf7b05d2488070_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS02LTEtMS0xNDMwNjE_61ebc2e2-9e50-4b17-838c-1fb904b9b8bc"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i96a1ed1bc1784b8db2b2d22151163626_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS04LTEtMS0xNDMwNjE_3b6a5525-a8d0-4003-a2d6-6833d847503e"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i96a1ed1bc1784b8db2b2d22151163626_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfOS0xMi0xLTEtMTQzMDYx_1cc5de08-5e45-45fa-8faf-642d387c0c1d"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtMi0xLTEtMTQzMDYx_3ad6e52e-433d-4a5d-a9df-0b37ebb451b7"
      unitRef="usd">26969000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtNC0xLTEtMTQzMDYx_3dc083df-6802-487e-8e1d-3d05d02fbc59"
      unitRef="usd">20945000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtNi0xLTEtMTQzMDYx_e1978be1-d42f-4a6d-8b06-e0fffe0b1d23"
      unitRef="usd">6024000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtOC0xLTEtMTQzMDYx_c3c48259-678a-4237-99ad-f1d7a0a298ad"
      unitRef="usd">27128000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtMTAtMS0xLTE0MzA2MQ_370e4176-b130-48ab-a209-25a5c39882c5"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjc5YWIzMWEzYTVkZTRhZDdiYTE1MmYzNDkwZDk5YjhiL3RhYmxlcmFuZ2U6NzlhYjMxYTNhNWRlNGFkN2JhMTUyZjM0OTBkOTliOGJfMTAtMTItMS0xLTE0MzA2MQ_84936794-756e-4bd1-a6c6-7560bf51c744"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODkwNjY4_53576144-f858-4587-9f84-f2380bee12a1"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ib3d864a514bb45dca143ed3ab32eedb7_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzA0_31611b36-f383-406e-bb8a-5b718814c7d5"
      unitRef="usd">10000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i397b0577878d4f30830c80e5e23ba904_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODA4_98c70142-c193-4611-ad7b-9562837cfaf1"
      unitRef="usd">5000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia8ea1f91a3ce42f0acfbb45e515ff2fe_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2MzExNQ_33fd9752-3724-4d5c-a2e4-299cefd85777"
      unitRef="usd">2828000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2MzE0MA_138ec543-1d61-4cda-8f77-2463c9074cfe">P63M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODg2MTY1_ba1ec995-fb9f-4d9a-828f-bbd588b21a3b"
      unitRef="usd">1216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f554645c0484ce0ae9425488ca631d5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODg2MTgz_f60ad7b7-88a0-4906-a7cb-2d9782ea6cc4"
      unitRef="usd">1194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2NzIyMw_d9308d91-8e1f-40a0-93d5-2aad6308f034"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfOTU3_1ad201cf-5dbc-4f27-8d6b-064334853e9e"
      unitRef="usd">213000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i69a2ccee5a034061b928c4d52b49efe2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfOTc3_25a827e5-16a7-46f7-b724-60b250788ecb"
      unitRef="usd">105000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i4bc7df085735496995eedc6a00cacc90_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA4MA_cb894826-f98a-4a6f-bfa7-f060f5b2ebc6"
      unitRef="usd">88000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i0129268431144c2283e8e4acc5441d56_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTE4Mg_0445adac-802b-4ff8-b0e7-823607e212f9"
      unitRef="usd">20000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5OTc_ab3c2e2c-67f7-41e8-9263-6ecafa9263de">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0yLTEtMS0xNDMwNjE_8f0c6042-4e1c-4e1c-972a-ad22d81a00f8"
      unitRef="usd">274000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS00LTEtMS0xNDMwNjE_a7adb653-453a-4325-8ef3-7d35a553fa91"
      unitRef="usd">1018000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS02LTEtMS0xNDMwNjE_aff9cf30-bc98-4fd4-83ce-d3199e1943ad"
      unitRef="usd">897000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS04LTEtMS0xNDMwNjE_dbc04233-961a-44c5-8dea-37991a075500"
      unitRef="usd">792000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xMC0xLTEtMTQzMDYx_bcf94400-b360-4ca9-a24d-4cd96684b0b0"
      unitRef="usd">664000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xMi0xLTEtMTQzMDYx_6f4f6087-3cb9-4bfb-92f5-8369a53cf89f"
      unitRef="usd">627000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xNC0xLTEtMTQzMDYx_d583201a-d496-451e-9e48-ea5d830ddf9a"
      unitRef="usd">54000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOmZmYjJlNzZlYmM1MzQzYTI4NzcyN2ZiNGJjY2ZkYWIxL3RhYmxlcmFuZ2U6ZmZiMmU3NmViYzUzNDNhMjg3NzI3ZmI0YmNjZmRhYjFfMS0xNi0xLTEtMTQzMDYx_9a2b2b35-00d0-45aa-a9b3-43d4ceff1f3c"
      unitRef="usd">4326000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <bhc:AnnualAmortizationOfIntangibleAssets
      contextRef="i940f002456e444718203e05f909f5845_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMzg0ODI5MDc2MzY0Mg_e1c685d3-8d89-493a-9237-e5e45816d18e"
      unitRef="usd">539000000</bhc:AnnualAmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjE5Njg_129cb3b8-80f5-4f9a-9bbf-76a5055f3c5f">The changes in the carrying amounts of goodwill during the nine months ended September 30, 2022 and the year ended December&#160;31, 2021 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="iebbd566effed4fadb5896bab8a971143_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0yLTEtMS0xNDMwNjE_b7fb324d-d6ab-4cdf-830a-3d3b6202c8f6"
      unitRef="usd">5704000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8b8feee0c59f4701a4312e6c630644df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS00LTEtMS0xNDMwNjE_ccaaa89c-20b4-4a27-b268-3e5d03e2ee70"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i66ef4daf91aa4f8281c317fad068c66c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS02LTEtMS0xNDMwNjE_262ad717-4eea-4598-b642-d6a0755c64c7"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icee578c670ae4dc29125f5982e51a5c9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS04LTEtMS0xNDMwNjE_9beabc63-5413-4aba-9547-5eadc58eeaff"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3ee081f26b684d829a12ac1265d3053c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xMC0xLTEtMTQzMDYx_eb1d4d63-2106-47a1-b558-b8778b4f0673"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i28b49bc1d6794cc7856a6269ce445917_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xMi0xLTEtMTQzMDYx_c9636b96-1a77-4fed-84f3-93de12229f82"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ied3da8eb119b435bbd381609ad532677_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xNC0xLTEtMTQzMDYx_5871de61-f7a4-4e44-8b6e-518d5ae76ded"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia798b021a554457c89afa7d9f4e59bf9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMS0xNi0xLTEtMTQzMDYx_71d5db4b-1202-48ab-92b9-7941b8892134"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0yLTEtMS0xNDMwNjE_fbef9ba5-14c8-4157-8c94-8e7466297e55"
      unitRef="usd">-5704000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi00LTEtMS0xNDMwNjE_30b53fe8-1e6d-48d3-b05a-cfc1afa37521"
      unitRef="usd">5395000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi02LTEtMS0xNDMwNjE_44d49ae3-f032-4dc7-a9a8-7e805f933cea"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi04LTEtMS0xNDMwNjE_c7fa3a04-7893-4e5d-8382-a6a03acbb655"
      unitRef="usd">887000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xMC0xLTEtMTQzMDYx_ffc7d027-1f6b-4669-b298-68d1e2396220"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xMi0xLTEtMTQzMDYx_7bddffac-b297-452b-a000-0f36d7e1846a"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xNC0xLTEtMTQzMDYx_361c45f6-d766-4ba6-bab2-9ddf6549ea23"
      unitRef="usd">-578000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMi0xNi0xLTEtMTQzMDYx_71e9c2af-51b8-4018-9320-ecbb00a9014d"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0yLTEtMS0xNDMwNjE_af5b03eb-e701-42e3-bb1a-482000d8004d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy00LTEtMS0xNDMwNjE_846c6fee-ff3f-4916-ab71-8674356b4be6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy02LTEtMS0xNDMwNjE_4a04ddb4-e2ed-4be8-b9bd-a6952d6319ec"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy04LTEtMS0xNDMwNjE_fc19827e-875d-4990-a900-11bec60a75e6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xMC0xLTEtMTQzMDYx_57966609-3551-4c6e-87e8-56e7fec0f4be"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xMi0xLTEtMTQzMDYx_9ea7ec0a-5270-4fcf-a49c-014eaf3ab7d8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xNC0xLTEtMTQzMDYx_f8a2154d-37ec-493a-8939-1f37bbd3b9f2"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfMy0xNi0xLTEtMTQzMDYx_7637ab82-5470-4044-b0af-7f83f863c509"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib520411e8d8341d7b289cb06f57a74a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0yLTEtMS0xNDMwNjE_69542c61-e4e4-443a-81e1-eba1812a6005"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i57bdbb36023f4c8a8627d6144d83a952_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC00LTEtMS0xNDMwNjE_339fd1e8-6090-4022-9b3c-821c05eed1c9"
      unitRef="usd">77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i958ab726999c4c0fa8ca01cc6e81625f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC02LTEtMS0xNDMwNjE_c37e917f-6c4f-4d5e-87a1-120e3a06a087"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id277eda06925418fb8fb9de6fa24a4d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC04LTEtMS0xNDMwNjE_5b89bc0b-f2ab-4257-b274-1ffc1ee6bb5b"
      unitRef="usd">62000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib419fd2fd1b341018bc5617ec6ba1725_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xMC0xLTEtMTQzMDYx_a9cfd1be-a8d2-41a7-91c2-17cfa32c3929"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i524a50c7d22c43ccbe8bc666be77d1a5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xMi0xLTEtMTQzMDYx_dc9e5eeb-29aa-4fb0-bc32-76ef06a89a40"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i0105a67a840741599b8ec39b7ff8978e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xNC0xLTEtMTQzMDYx_e2d0ee40-f476-49a0-bd02-d97ad8593d92"
      unitRef="usd">-21000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i79b3052510244cf0ba47748c52dd8afe_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNC0xNi0xLTEtMTQzMDYx_6f7bdeb1-34db-43c2-92c9-dc740432d5bc"
      unitRef="usd">118000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ie7c7425072c141219aa1cdd573bd405a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0yLTEtMS0xNDMwNjE_889d3290-42ff-4d66-988c-6e898ec9bab2"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i184f88c56dd24fc0a24d578d3cec1912_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS00LTEtMS0xNDMwNjE_ef937ef7-73ed-478e-8902-b0193c3eeaf3"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i524914c3e77a431bb6e23bf2b8d68654_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS02LTEtMS0xNDMwNjE_cc390d7b-d15f-462f-92d3-93ad53813181"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5c2a1f6e1e67469ca7b69557b895dc8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS04LTEtMS0xNDMwNjE_614eb1e3-bca7-4a89-8b0e-bafbb6af6f22"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i054e43fb12054855a665b8a78721656b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xMC0xLTEtMTQzMDYx_1f7a3fe4-3167-4ced-936a-9bbf1c20b978"
      unitRef="usd">798000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5e156c972764457f83682644cc5296a4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xMi0xLTEtMTQzMDYx_08a74d10-0205-4ef8-b4bb-0824eebfff2f"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id0655cf22cd44bd085e0dfc3bd855124_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xNC0xLTEtMTQzMDYx_e7542ecb-ef01-42ff-8680-3ec1252bfc26"
      unitRef="usd">2357000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNS0xNi0xLTEtMTQzMDYx_d7cac102-39b8-491f-b226-1cce1b5512e0"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0yLTEtMS0xNDMwNjE_b8597f76-6fa0-4af3-82a5-c8b57a57d335"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi00LTEtMS0xNDMwNjE_6777d22d-f019-4dea-afca-6dada7070f23"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi02LTEtMS0xNDMwNjE_73a78fce-25f0-4259-939c-0e8152504d24"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi04LTEtMS0xNDMwNjE_96404b5f-1fc5-4e2a-bdcb-8e510ac4bbd9"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xMC0xLTEtMTQzMDYx_f24079af-e78a-49cd-8f1c-0ccf26f91c93"
      unitRef="usd">-798000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xMi0xLTEtMTQzMDYx_2f172447-e494-49e0-be64-d2adccd1e7bb"
      unitRef="usd">115000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xNC0xLTEtMTQzMDYx_d680251f-feb9-432c-be4c-c0d88868be6c"
      unitRef="usd">683000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNi0xNi0xLTEtMTQzMDYx_28dd2565-c205-41c6-99cd-d7ffed625613"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0yLTEtMS0xNDMwNjE_4f5fc81b-9403-48e2-9611-bb8d6599cd7b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy00LTEtMS0xNDMwNjE_16b3b3fb-7087-423a-8dbd-a56c70479bff"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy02LTEtMS0xNDMwNjE_f70d8138-0976-4614-8f7a-0e9594c0c537"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy04LTEtMS0xNDMwNjE_46e4dc92-5263-4ad8-bc4c-e7abb6bb0940"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xMC0xLTEtMTQzMDYx_1e367968-8010-4f1e-8ee8-974a686a889b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xMi0xLTEtMTQzMDYx_0a4936c0-3331-408d-b5d2-71b3707aec4d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xNC0xLTEtMTQzMDYx_4baf43b5-54da-4434-a089-b89546b0efe6"
      unitRef="usd">202000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfNy0xNi0xLTEtMTQzMDYx_61075e65-4f22-41c5-bc78-9e0062f73b92"
      unitRef="usd">202000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ic87150d0c071444c9b2838e9025542cc_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0yLTEtMS0xNDMwNjE_a9ea3cc4-8866-43d0-a0dd-8038ab25e87e"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC00LTEtMS0xNDMwNjE_4f469167-665e-49a5-ae6f-cfe516c58160"
      unitRef="usd">164000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC02LTEtMS0xNDMwNjE_88e785dc-65ab-4f17-98d2-9ca5cc03bf9e"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC04LTEtMS0xNDMwNjE_a32f6e83-2c21-49b4-a12a-8e248ccd8884"
      unitRef="usd">99000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xMC0xLTEtMTQzMDYx_757bee70-60a6-4fd7-af84-638a11145850"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xMi0xLTEtMTQzMDYx_2e17aae7-8b73-4619-8f24-137ed0f5e805"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xNC0xLTEtMTQzMDYx_d18893a3-05d0-49d5-a249-cf1d2def4144"
      unitRef="usd">-52000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOC0xNi0xLTEtMTQzMDYx_fbe88739-145a-4ffb-b2d4-13eef1cedace"
      unitRef="usd">211000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i4586553989374f86b0151f9e1dc47d44_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0yLTEtMS0xNDMwNjE_7fc7263f-f4fa-4aee-ab0e-981536cdb89b"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i28a9044c2815433dadfb6a1fbc0fc718_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS00LTEtMS0xNDMwNjE_27f4e8f3-8f71-481a-a824-459272b32c5c"
      unitRef="usd">5154000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i00e30d8a0b70472da327a5cd5d504e40_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS02LTEtMS0xNDMwNjE_81c1d981-9eb5-4d8a-8ba1-36321787ad19"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3eb7d5760de84dbba93d5758373f7df3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS04LTEtMS0xNDMwNjE_275f5884-c351-4466-8366-2412903b3975"
      unitRef="usd">726000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ifd3f217039214cc99ebb1a3146d44e2c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xMC0xLTEtMTQzMDYx_6f5a58f7-c9c1-4752-84c5-1a8edbe99ad7"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icaf04300c0b04203930e4017146b0a29_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xMi0xLTEtMTQzMDYx_2f79529e-e208-4e7c-af00-f699aa3c944a"
      unitRef="usd">115000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i171290f4c16143278fe977553e53a298_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xNC0xLTEtMTQzMDYx_c2e720a0-a4f6-4410-8570-f0241dc5eda3"
      unitRef="usd">2890000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RhYmxlOjgzOTAyYTE0ZTBiYzRjNGE5ZmEyNWE5NmZkZmZmM2Y0L3RhYmxlcmFuZ2U6ODM5MDJhMTRlMGJjNGM0YTlmYTI1YTk2ZmRmZmYzZjRfOS0xNi0xLTEtMTQzMDYx_d136499b-31ea-4040-8232-6bf601ee3030"
      unitRef="usd">12044000000</us-gaap:Goodwill>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i361b8355ced14036903137406c65acd3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzc4MA_7f86be98-9984-4189-bbaa-988c186b5ea8"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ie32f67a7dcdc4304965f785c3401a61c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzc4Ng_248192d6-4443-4772-a098-eeca58913842"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i361b8355ced14036903137406c65acd3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzgyNw_6914d4ea-be05-48d5-969f-4a8bf7a18716"
      unitRef="number">0.110</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ie32f67a7dcdc4304965f785c3401a61c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNzgzNA_95bb6826-70fc-4d1f-9fe9-aa3956ae2ce6"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ia6e12bdaebcc45a1b8c0c18938e51e4e_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODAxMw_1b41f052-6484-4200-8a6f-68d6d678f2f0"
      unitRef="number">0.40</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i734ba9baeab74604b0c7c558dc66e5be_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODA0Mw_e2486b88-10f7-41bf-b820-024b16fad090"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if0c43778cbdf409ca15ed80687c13da5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfODk2Ng_c8711b0e-0cf4-4231-a959-67e1be1b1859"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="iec85868873634d7aaec5771a953c7224_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA1ODQ_92166582-492b-4a6e-b00c-68d978aa5d71"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i9ee0f7dd3ca94d9a813c20822f42b12e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA2MjU_857cb2c0-ade8-4a75-8b1c-08eab66ffd5b"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ia75d309fb9e24efe806b94be702f2683_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA2MzI_942853ac-10d8-4b8e-bd4e-031d87e00168"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icf0b557c0f5743d4853cda063a55d5a1_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA4MzU_d5940295-cbad-414e-8463-90a39554bb0d"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i64029e7dfd364587a73eb03edb488c6c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI4ODI_2284189d-a30f-472a-944e-23d89fe489e8"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i7be821d39f844c7c9e6f5db374b2d390_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI4ODk_e7c47439-215e-4dc0-b709-7b9224f49010"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i64029e7dfd364587a73eb03edb488c6c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5MzA_58b290a0-b949-4a7e-8018-4c7256cfa783"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i64029e7dfd364587a73eb03edb488c6c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5MzA_93f0d3c0-0a23-4387-80ca-465a3ad9e2a0"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i7be821d39f844c7c9e6f5db374b2d390_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5Mzc_1901ddc8-e2d0-4976-8209-7ffcb1f6c1bd"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i7be821d39f844c7c9e6f5db374b2d390_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTI5Mzc_77e11b24-d122-49ce-afbf-29debfa5d799"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="iaab855eaea194ef4a3d9af3afceb50c7_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTMxMTY_7fa5473d-ffbb-4995-b5d9-7bb1e5fe5699"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="iaab855eaea194ef4a3d9af3afceb50c7_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTMxMTY_bda18d06-d8ee-4d2d-907c-b6f64fff771a"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icebcda21eb184f5596ae20266fcd05c5_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTMxNDY_e3b95092-cb2a-43a3-9743-dd75b86678f6"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i807f651e453049d280b13aa13946098b_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ2MDA_ad3318f8-bab6-4baf-9c44-39bea9a75ffd"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i807f651e453049d280b13aa13946098b_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ2MjY_a0a1f2be-9131-4ea6-b624-ca9c59cbef7c"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i807f651e453049d280b13aa13946098b_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ4MDQ_33a58c98-70a4-45b1-91a4-6019a8011910"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i7e572145d9a7467baa36216af20a4a17_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTQ4NjU_aaf536f2-a15c-4018-9505-6cfa69ba8d48"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="iad592bdffaae43e9a655afeab7d37965_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTU3ODQ_d0fe07c8-5aa0-4a4a-8cba-f967df385d0f"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i9520dcf4eed94040af3402086c331516_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTY4NzU_1dff4f26-245c-4e14-ac94-a377e97d730f"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i9520dcf4eed94040af3402086c331516_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTY5MDE_5ab490f8-7028-4341-8722-1fdc2446c5f3"
      unitRef="number">0.09</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i9520dcf4eed94040af3402086c331516_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTcyOTI_1b883fd4-5d28-459f-a335-72f063f65f0f"
      unitRef="number">0.02</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ieaabe709841d4ab5a8f48593d73a6236_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTczNTM_fa901669-7d39-4581-9cc9-dff611247bbf"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTg4NzY_5810e0b2-2a1f-40d0-bd6e-e98198a60df0"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTg5MDI_6a536fb4-5fbf-4235-9b98-51fa12c849b4"
      unitRef="number">0.10</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate
      contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTg5Mzg_466756da-0ce7-42ee-8993-81618f872da0"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i29fa46a2016a4d6fbd35835aab2e7733_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTkzMzg_9af4c7b6-933b-42b8-ba28-0015a30e328a"
      unitRef="usd">83000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="i0d23798ee6944435964f0ae2a74b0053_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjAwMzk_15574e27-f365-442c-8b70-881e6ee1a7ba"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ib7cbe70ccd6a46a295e6b86c6ca5e603_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA0NjE_5736e1e5-f32f-4e6b-9d09-a9c7d71388dc"
      unitRef="number">0.02</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="if06aa410016b4d3d9736289f10b1b949_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA0Njg_68616f0b-8658-45eb-b09f-0f07208b6a51"
      unitRef="number">0.03</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ib7cbe70ccd6a46a295e6b86c6ca5e603_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA0OTM_4a558cfa-47cd-4f69-a70c-388f04e222b3"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="if06aa410016b4d3d9736289f10b1b949_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA1MDA_aeb2e925-f0de-44c2-9e8f-84cf6a57f874"
      unitRef="number">0.115</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="iabdffbd57d864d79afae07b110981771_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA2Mzc_d1877980-f666-43b2-aacb-9c4c8a63c711"
      unitRef="number">0.25</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8161c31ec1444e4282b76d79a09434c1_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjA2Njc_582e81e3-517f-428d-92dd-b645f533b24b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i34d55f72c27c47f6afb001ca411f5fa2_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjEwMDc_8fcb2217-0de2-4946-aa51-be04e0fd1df2"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i4339e12a380546a9b2b74237a9f3cff2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTA5NjIwOQ_efacf78b-ba47-4c45-87df-aa47089d643b"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ic1a494d22e0741aca0c0ee31ff3d3765_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTA5NjIxMw_41ce841d-63d1-4af3-a321-5210fee211c3"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i4339e12a380546a9b2b74237a9f3cff2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTA5NjIyMA_6fbf815b-c5f3-414d-8f1d-703c48cb7238"
      unitRef="number">0.105</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1130a33c0fde483fa1bae8711549f82b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMTA5OTUxMTcwNDk3Ng_8ebb5360-6b22-4983-abd6-7d7f2d72f08f"
      unitRef="usd">119000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibefdea46ac904b858f0d89701cc31d09_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODkwNjQ4_55bddcd0-22e3-43d0-8247-5ae7e288b8bd"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i203a22f1210340a79695abcf5e8cbc84_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfNTQ5NzU1ODkwNjQ4_fd5b7fd8-c824-4511-bf98-6fadce5b2205"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ic7a8a8be34dc47ba912bb7fad91b59d1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0NjYxMw_c87939fb-5567-4bef-a252-3008acb294d4"
      unitRef="number">0.025</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i6e21f5810f55489593ecaa960423f5ab_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0NjYxOQ_1309f3a6-28f4-40d0-b9bd-65c6779f83b7"
      unitRef="number">0.0975</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="iaf38a4e092a6474e82b48723b723f43e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0NjYyNg_80277a99-8d71-4dea-a4ab-a987c4b54803"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4bad238d099849c8bbcf419abb996956_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0ODkzNQ_e1af756c-c873-4a4a-a4ee-49421aa7371c"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ic7a8a8be34dc47ba912bb7fad91b59d1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjc0ODc3OTE0ODk0NA_b11ee74d-95df-4571-b1d5-407dc21253e2"
      unitRef="number">0.05</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82MS9mcmFnOjdiZDcxZmE0YzkwYjQ4MjI5Yzc1MWUyMGZmZWM5MTU1L3RleHRyZWdpb246N2JkNzFmYTRjOTBiNDgyMjljNzUxZTIwZmZlYzkxNTVfMjExMTc_3234dd2a-877a-410a-b745-38914c2dcfd6"
      unitRef="usd">4382000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RleHRyZWdpb246ZGFjMWVlMjUwNjhlNDdlNWE2NmMwZmZkZGJmZDI5NDBfMTAw_a430af61-aef5-419b-a246-17f0facdaf56">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RleHRyZWdpb246ZGFjMWVlMjUwNjhlNDdlNWE2NmMwZmZkZGJmZDI5NDBfOTk_a17eb9a7-71ca-4b4f-b226-1e58c83ab08b">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMS0yLTEtMS0xNDMwNjE_a9174373-fa3c-44d3-b029-7c977eda74ed"
      unitRef="usd">323000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMS00LTEtMS0xNDMwNjE_02f44f04-c297-4953-b328-36460f1e7795"
      unitRef="usd">1890000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:AccruedProductRebateCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMi0yLTEtMS0xNDMwNjE_2e25370b-0b70-4447-82dd-862bb661996d"
      unitRef="usd">965000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMi00LTEtMS0xNDMwNjE_e85b85e2-0c9e-4e3f-b1be-0b75cc35f6dc"
      unitRef="usd">908000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMy0yLTEtMS0xNDMwNjE_fabd5283-c0c0-4889-b645-769c00097714"
      unitRef="usd">421000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfMy00LTEtMS0xNDMwNjE_7710a605-f20f-4120-aabe-cb5ec7dbf92c"
      unitRef="usd">482000000</bhc:AccruedProductReturnCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNC0yLTEtMS0xNDMwNjE_633dbf2e-2461-4a3b-bd31-ccb73d3d00c0"
      unitRef="usd">208000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNC00LTEtMS0xNDMwNjE_e48f6ff5-0e60-4032-b119-5e291aa58b78"
      unitRef="usd">328000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNS0yLTEtMS0xNDMwNjE_08893894-2f63-4790-a580-4f3f2e6e3004"
      unitRef="usd">279000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNS00LTEtMS0xNDMwNjE_4c65bdab-c093-4965-a9c0-a9e57310ce84"
      unitRef="usd">336000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNi0yLTEtMS0xNDMwNjE_026aa796-449f-43f3-b52a-0106a1d1b341"
      unitRef="usd">66000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNi00LTEtMS0xNDMwNjE_160a7bcd-eede-4242-aa8b-57aff49c6e98"
      unitRef="usd">98000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNy0yLTEtMS0xNDMwNjE_c2f7a305-9a1c-4bc2-b99d-376a701aa055"
      unitRef="usd">672000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfNy00LTEtMS0xNDMwNjE_67af27fc-c348-4aaf-b482-2c996bba8855"
      unitRef="usd">749000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfOC0yLTEtMS0xNDMwNjE_1af8e54c-58a6-443b-8825-0779a529e157"
      unitRef="usd">2934000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82NC9mcmFnOmRhYzFlZTI1MDY4ZTQ3ZTVhNjZjMGZmZGRiZmQyOTQwL3RhYmxlOjZiODNjMGI4Zjc3YzQ2ODdhODRlODllNzIxYWM4YjYxL3RhYmxlcmFuZ2U6NmI4M2MwYjhmNzdjNDY4N2E4NGU4OWU3MjFhYzhiNjFfOC00LTEtMS0xNDMwNjE_24ae09db-3adf-460c-8501-28200e798889"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg4OTY_10c8247f-2f4d-4702-bb56-f2df1fe39220">FINANCING ARRANGEMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.00% First Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.00% Second Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.00% Intermediate Holdco Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the 9.00% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of September&#160;30, 2022, the amount available for restricted payments under the &#x201c;builder basket&#x201d; in the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $12,000&#160;million (although such availability is subject to the Company&#x2019;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to improve its operating results to seek to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#x201c;Exchange Offer&#x201d;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $5,594&#160;million as set forth in the table below (collectively, the &#x201c;Existing Unsecured Senior Notes&#x201d;) for $3,125&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $2,469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#x201c;11.00% First Lien Secured Notes&#x201d;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#x201c;14.00% Second Lien Secured Notes&#x201d; and, together with the 11.00% First Lien Secured Notes, the &#x201c;New BHC Secured Notes&#x201d;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#x201c;9.00% Intermediate Holdco Secured Notes&#x201d; and, together with the New BHC Secured Notes, the &#x201c;New Secured Notes&#x201d;) issued by 1375209 B.C. Ltd. (&#x201c;Intermediate Holdco&#x201d;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25% Senior Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50% Senior Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Exchange Offer and following receipt of the requisite number of consents from noteholders, the Company and the applicable notes trustee, executed supplemental indentures to amend each of the indentures governing the 9.25% Senior Notes due 2026, 8.50% Senior Notes due 2027, 5.00% Senior Notes due 2028, 7.00% Senior Notes due 2028 and 7.25% Senior Notes due 2029, which amendments eliminate substantially all of the restrictive covenants as well as certain events of default and related provisions applicable to such series of notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the principal amount of the New Secured Notes and their carrying value as calculated above has been recorded as a premium and is included in long-term debt on the Company&#x2019;s Consolidated Balance Sheet, which will be reduced as the Company makes stated interest payments on the New Secured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September 30, 2022, the Company recorded a gain of $570&#160;million, net of third party fees of $25&#160;million, in connection with the Exchange Offer. As of September 30, 2022, the premium recorded on the New Secured Notes was $1,835&#160;million, which will be reduced as stated interest payments are made on the New Secured Notes. Further details of the New Secured Notes are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#x201c;Senior Secured Credit Facilities&#x201d; under the Company&#x2019;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#x201c;2018 Restated Credit Agreement&#x201d;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#x201c;BHA&#x201d;) in an aggregate principal amount in excess of $1,000 million (the &#x201c;2023 Revolving Credit Facility&#x201d;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#x201c;June 2025 Term Loan B Facility&#x201d;) and November 2025 (the &#x201c;November 2025 Term Loan B Facility&#x201d;), respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#x201c;Second Amendment&#x201d;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#x201c;2022 Amended Credit Agreement&#x201d;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#x201c;2027 Term Loan B Facility&#x201d;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#x201c;2027 Revolving Credit Facility&#x201d;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#x201c;Credit Agreement Refinancing&#x201d;), along with certain of the Company&#x2019;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of September&#160;30, 2022, the Company had drawn $450&#160;million on the 2027 Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#x201c;term SOFR rate&#x201d;) for the interest period relevant to such borrowing&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a Canadian dollar offer rate or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#x201c;EURIBOR&#x201d;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September&#160;30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $531&#160;million through December 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#x201c;restricted&#x201d; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#x201c;unrestricted&#x201d; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the B+L Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#x201c;B+L Credit Agreement&#x201d;, and the credit facilities thereunder, the &#x201c;B+L Credit Facilities&#x201d;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#x201c;B+L Term Facility&#x201d;) and a five-year revolving credit facility of $500&#160;million (the &#x201c;B+L Revolving Credit Facility&#x201d; and such financing, the &#x201c;B+L Debt Financing&#x201d;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of September&#160;30, 2022, the principal amount outstanding under the B+L Term Facility was $2,494&#160;million and $2,442&#160;million net of issuance costs. The B+L Revolving Credit Facility remained undrawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#x2019;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) a term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) a Canadian Dollar Offered Rate (&#x201c;CDOR&#x201d;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#x201c;SONIA&#x201d;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#x2019;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#x2019;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;amp;P, Moody&#x2019;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#x201c;IG Trigger&#x201d;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#x2019;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#x2019;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%. The stated rate of interest under the Term Facility at September&#160;30, 2022 was 6.10% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, payable in quarterly installments. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of September&#160;30, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $113&#160;million through March 2027, with the remaining term loan balance being due in May 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). In connection with the closing of the B+L IPO, the redemption of the Company&#x2019;s 6.125% Senior Unsecured Notes due 2025 (the &#x201c;April 2025 Unsecured Notes&#x201d; and the related indenture, the &#x201c;April 2025 Unsecured Notes Indenture&#x201d;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#x201c;June 2028 Secured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of 7.00% Senior Secured Notes due 2024 (the &#x201c;March 2024 Secured Notes&#x201d;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;June 2021 Refinancing Transactions&#x201d;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.125% Senior Secured Notes due 2027 - February 2022 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#x201c;February 2027 Secured Notes&#x201d;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;New BHC Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 11.00% First Lien Secured Notes mature on September 30, 2028, and accrue interest at 11.00% per year, payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#x201c;make-whole&#x201d; premium as described in the 11.00% First Lien Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 14.00% Second Lien Secured Notes mature on October 15, 2030, and accrue interest at 14.00% per year, payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#x201c;make-whole&#x201d; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.00% Intermediate Holdco Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and accrue interest at 9.00% per year, payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of September 30, 2022 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#x2019;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee certain of the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Redemption of April 2025 Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of the Company&#x2019;s outstanding 9.00% Senior Unsecured Notes due 2025 (the &#x201c;December 2025 Unsecured Notes&#x201d;) conditioned upon the receipt of aggregate proceeds of at least $7,000&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The weighted average stated rate of interest for the Company&#x2019;s outstanding debt obligations as of September&#160;30, 2022 and December&#160;31, 2021 was 7.24% and 5.88%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#x2019;s financial statements in future periods will not be representative of the weighted average stated rate of interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on Extinguishment of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Company completed the Exchange Offer and recorded a net gain of $570&#160;million as described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company repurchased and retired certain outstanding Senior Unsecured Notes with an aggregate par value of $481&#160;million in the open market, for an aggregate cost of $300&#160;million. In connection with these repurchases, the Company recognized a gain of $176&#160;million on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with (i) the repayment of the June 2025 Term Loan B Facility, November 2025 Term Loan B Facility and 2023 Revolving Credit Facility and (ii) the redemption of April 2025 Unsecured Notes, the Company incurred a loss on extinguishment of debt of $63&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg5MDU_2a30bf46-e112-4be7-9a47-12d5e9c40a69">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.00% First Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.00% Second Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.00% Intermediate Holdco Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i07b8f0ab2fbb4bb7b6a75eb4df909667_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC00LTEtMS0xNDMwNjE_e89cc100-d9aa-4c65-a23e-0c91dd069804"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i07b8f0ab2fbb4bb7b6a75eb4df909667_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC02LTEtMS0xNDMwNjE_b0a5bcdb-1a35-44ac-8f86-14ae98b42f1c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie58467a391034c9cb187019aeffd9731_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC04LTEtMS0xNDMwNjE_9b7e24a0-6643-4e96-9a90-776c608b5a46"
      unitRef="usd">285000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ie58467a391034c9cb187019aeffd9731_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNC0xMC0xLTEtMTQzMDYx_0453e577-6d5b-4405-abcb-7b2c820017d3"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59c61192e231431db2b0a3faccf31084_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS00LTEtMS0xNDMwNjE_dccffd04-7cd5-43f4-945b-5e4f8afef1df"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i59c61192e231431db2b0a3faccf31084_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS02LTEtMS0xNDMwNjE_281799fe-655b-4ae1-998c-3079f1ef73cc"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5e23e6b1602e45c69f5e0263e4e91c1f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS04LTEtMS0xNDMwNjE_ba5db6f9-8a86-4124-a3dd-e8073abd0128"
      unitRef="usd">2829000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5e23e6b1602e45c69f5e0263e4e91c1f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNS0xMC0xLTEtMTQzMDYx_bf1b3d0c-bb7d-49b7-a696-f5ce99d03426"
      unitRef="usd">2772000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i41e0efdc5bd2442e86a6a489bf72fa7a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi00LTEtMS0xNDMwNjE_30d66993-b5ea-45a9-8613-2524c166b148"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i41e0efdc5bd2442e86a6a489bf72fa7a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi02LTEtMS0xNDMwNjE_f7c1c064-be61-4685-85e5-da9ec26ff994"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i20e089be5eb041cf9cce81981f011be7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi04LTEtMS0xNDMwNjE_cbcc4f28-734c-4e1b-b521-4fd90ee0c202"
      unitRef="usd">994000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i20e089be5eb041cf9cce81981f011be7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfNi0xMC0xLTEtMTQzMDYx_3566a632-af78-4bf5-a8cf-076ccd311181"
      unitRef="usd">984000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i96f39bda64df4253bfb97df28400bd07_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC00LTEtMS0xNDMwNjE_6340978a-a85d-4912-a7a2-b396b7f65501"
      unitRef="usd">450000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i96f39bda64df4253bfb97df28400bd07_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC02LTEtMS0xNDMwNjE_94b7045d-250d-42d4-9315-c847c9228975"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib4825754c7324c8182558e6ae17503ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC04LTEtMS0xNDMwNjE_5ad10557-892f-45a4-812d-4b6afc293b40"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib4825754c7324c8182558e6ae17503ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOC0xMC0xLTEtMTQzMDYx_57ac6314-f7f9-4a5e-90d2-f8f371433b58"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ief4424b9ece149c8ae2652648e9479fe_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS00LTEtMS0xNDMwNjE_e0ed11c7-fc7d-4978-82f0-cb2d793e2edb"
      unitRef="usd">2469000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ief4424b9ece149c8ae2652648e9479fe_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS02LTEtMS0xNDMwNjE_715bbd13-6f8a-4091-ae23-88f4d05b1170"
      unitRef="usd">2419000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib60f32e20efe40bdafd03b20dcc4ea54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS04LTEtMS0xNDMwNjE_54fd6584-830d-45d3-bc55-3d2569697796"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib60f32e20efe40bdafd03b20dcc4ea54_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfOS0xMC0xLTEtMTQzMDYx_bf057957-143c-4957-a219-25d80d872061"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib2719dec24cd48aea9d17bcf664f412b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtNC0xLTEtMTQzMDYx_2d86744a-d52f-4bcb-8574-ef25fac6e189"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib2719dec24cd48aea9d17bcf664f412b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtNi0xLTEtMTQzMDYx_da9c5729-05b1-4b85-8975-4857a4fd51bf"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i658fec0dcb034795a01b1f1d2734dfe7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtOC0xLTEtMTQzMDYx_d16e0761-0a3c-4410-bd54-498a8138d4e5"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i658fec0dcb034795a01b1f1d2734dfe7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTEtMTAtMS0xLTE0MzA2MQ_07926b3d-a5d4-4109-82e5-0fc1527c6c4d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItNC0xLTEtMTQzMDYx_e958c7e6-8474-4e80-a63a-a2cd6d860f20"
      unitRef="usd">2494000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItNi0xLTEtMTQzMDYx_1e6bf392-d5fd-41a5-9643-08cc3d98aa0d"
      unitRef="usd">2442000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i17c72157e725454bae3d98331b48e1b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItOC0xLTEtMTQzMDYx_542343da-748f-4e27-aff3-bb4338d94bf5"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i17c72157e725454bae3d98331b48e1b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTItMTAtMS0xLTE0MzA2MQ_3795ad6a-babe-48fb-bdf9-5d64395d216e"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NWU4MTNjN2ZjOWI1NDI2ZGFiNzc0OWUyOWQyNGIyZDBfNA_41f62df0-c592-4edf-8710-07ee72c68647"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtNC0xLTEtMTQzMDYx_3f728565-3b44-48a9-a8ef-266d23f3216f"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtNi0xLTEtMTQzMDYx_f1cb2696-dc55-46b6-9481-e037d05a0cd2"
      unitRef="usd">1741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia4c8689541c04f66b5293904f3094a90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtOC0xLTEtMTQzMDYx_bbd020c4-84db-49d4-aeb2-217711e0b9ad"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia4c8689541c04f66b5293904f3094a90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTQtMTAtMS0xLTE0MzA2MQ_80ad0a8b-adae-41ce-95c2-00ba04d724c9"
      unitRef="usd">1739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic9736f916a62479d8d54ac9b1251c9c4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NWVjZDZhOTAxMDJiNDVkYjlhZTY5NzYxNDVlZDIyMTdfNA_888513ac-6e16-438b-8136-7593eb813a86"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic9736f916a62479d8d54ac9b1251c9c4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtNC0xLTEtMTQzMDYx_bf561fba-25d2-4990-b63c-27b3dbde52af"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic9736f916a62479d8d54ac9b1251c9c4_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtNi0xLTEtMTQzMDYx_18e114aa-3f0f-418f-9d9b-620add493ae5"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id34ba1093cad49c292458d52b08c823e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtOC0xLTEtMTQzMDYx_24897fa8-cd79-4a7f-9f24-57d739ac4e64"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id34ba1093cad49c292458d52b08c823e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTUtMTAtMS0xLTE0MzA2MQ_0ef06ef6-d462-45f9-910c-3683c778a38c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65627fa9869f456389b3882ce8b37654_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MjAwMTE3ZjU2ZDQ3NDRhNGE0MWE0NjQyZjY5MDRmYWJfNA_cb47dd77-0f91-45d9-93fa-f25430a4681e"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i65627fa9869f456389b3882ce8b37654_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtNC0xLTEtMTQzMDYx_20d99bec-888f-442e-a7b7-15cf9fdca442"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i65627fa9869f456389b3882ce8b37654_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtNi0xLTEtMTQzMDYx_75df2572-ee1a-4dae-99b1-d56a3a6a87b2"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i847b6dcc9bf747ab946d8f1b08b3d71e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtOC0xLTEtMTQzMDYx_22eccc90-d7de-43b5-8e65-6f70a2ec7ba1"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i847b6dcc9bf747ab946d8f1b08b3d71e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTYtMTAtMS0xLTE0MzA2MQ_26f6f798-8ae2-411c-9a71-1ca44b9a27ee"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia2824f9dc84c40c396db9edca43574e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctMC0xLTEtMTQzMDYxL3RleHRyZWdpb246OWQ0MDBkOWFjM2NmNDM5MmI4YTNiNDc0NTg5NzViOGNfNA_e89bac14-5a61-4092-9ef9-51315bf02e73"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia2824f9dc84c40c396db9edca43574e5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctNC0xLTEtMTQzMDYx_ce713418-489b-436f-9301-24c32ee8eea9"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia2824f9dc84c40c396db9edca43574e5_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctNi0xLTEtMTQzMDYx_67839575-5c0f-4e3d-a3cf-fdb17f9d4773"
      unitRef="usd">1582000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8bb6c1c4d20b44c3a7dd173a66fc96d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctOC0xLTEtMTQzMDYx_0b2e42fd-385f-4aa4-b2cd-7adec61888ce"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8bb6c1c4d20b44c3a7dd173a66fc96d4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTctMTAtMS0xLTE0MzA2MQ_c29cb46b-925e-4e06-9d6f-1cf992fffffb"
      unitRef="usd">1580000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMC0xLTEtMTQ5NTE4L3RleHRyZWdpb246OTM2ZjliOThhMTQzNDUwZTg5NzAyNTY0N2Q2ZjQwZDlfNTQ5NzU1ODEzOTI5_9dcc4884-e42b-4418-90e5-b436386c1941"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNC0xLTEtMTQ5NTI1_be5334f6-ebd2-433b-8f62-54a8cb30cca3"
      unitRef="usd">1774000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNi0xLTEtMTQ5NTI1_0b1ba91f-930a-4eba-a042-ca443b912126"
      unitRef="usd">2826000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i48ead96a008c4245b48958509368a215_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktOC0xLTEtMTQ5NTI1_371404df-c509-411a-9b71-a31441ca8bfb"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i48ead96a008c4245b48958509368a215_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMTAtMS0xLTE0OTUyNQ_4453e455-8060-4882-a96b-8d60011ec2d1"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMC0xLTEtMTQ5NTE4L3RleHRyZWdpb246NDY4YjUzODJkNzg1NGJlNjhmNmZhZWNkOTdmNWQyMDNfNTQ5NzU1ODEzOTMw_51f3eb8c-b7d5-4b1e-9ef4-676861a7da93"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNC0xLTEtMTQ5NTI1_f17d78da-50bf-46b1-8677-7e7ba46473cc"
      unitRef="usd">352000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNi0xLTEtMTQ5NTI1_fa911e80-6a27-4688-bc77-1b00be21ee6e"
      unitRef="usd">711000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0837135263d44f058fe95a28f43c5e2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtOC0xLTEtMTQ5NTI1_d9ccde47-a763-42c8-95c5-57f1a55cfd2a"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0837135263d44f058fe95a28f43c5e2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMTAtMS0xLTE0OTUyNQ_dd6b9f28-e27f-47b0-9356-f684407e0e7f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMC0xLTEtMTUxMjM4L3RleHRyZWdpb246MjZmM2RjYmJmZDU0NGY1MjhjNzM3Zjg0ZmJhZjhhOTlfNTQ5NzU1ODEzOTM2_1ac71bb1-ce37-4e1f-bcac-73cab2354eef"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNC0xLTEtMTUxMjM4_54e86c50-c110-41a4-b433-459869ac7cff"
      unitRef="usd">999000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNi0xLTEtMTUxMjM4_88b7e0c1-aeab-43c3-a3dd-7a5a6981d841"
      unitRef="usd">1423000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4849d9106bec4ca28083d112da7d7ad9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItOC0xLTEtMTUxMjM4_ae145d9b-c9e9-484d-bfe5-21f98c33d131"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4849d9106bec4ca28083d112da7d7ad9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMTAtMS0xLTE1MTIzOA_ea65b95f-5416-4fed-a902-a876f39cbd3f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMC0xLTEtMTQzMDYxL3RleHRyZWdpb246ZjRlN2YyNzg1NTEwNGI0MDgxNDJlMTkxNzVkNTgxNDVfNA_0e827e85-f3cc-4c94-a203-c9b75ffb8122"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNC0xLTEtMTQzMDYx_cd66fbf8-a61b-4470-a8ce-d459fe9bbebc"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktNi0xLTEtMTQzMDYx_36f4b6d4-efa0-457a-8d2e-2de2bda643d5"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3d20de201c0e49b49c27d368b4cb4cb3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktOC0xLTEtMTQzMDYx_76de95ae-fa8f-4d0c-8091-b08fdce44512"
      unitRef="usd">2650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3d20de201c0e49b49c27d368b4cb4cb3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMTktMTAtMS0xLTE0MzA2MQ_25d56557-d095-49cf-acd5-980939fe1629"
      unitRef="usd">2640000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246N2I1ZWZjYmU3YzQ3NGQ3YzgzMTU1MGJjZmMxY2Y5ZjVfNA_a99e52ac-5dcf-44c9-b916-86f26939094f"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNC0xLTEtMTQzMDYx_6e992740-9208-4c68-8190-b3f155f0c06c"
      unitRef="usd">959000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0939a50aa4194dcfb21d73fc1bf8b86a_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtNi0xLTEtMTQzMDYx_420f3d98-c658-413f-bdba-9c844ef7fa33"
      unitRef="usd">950000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i67496121616e45d98e1c3a401c8ad3e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtOC0xLTEtMTQzMDYx_2589fb37-56d5-482a-b90f-40084ca0b1fd"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i67496121616e45d98e1c3a401c8ad3e6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjAtMTAtMS0xLTE0MzA2MQ_203de56b-d5d7-41ae-b437-5d024c2f2c1b"
      unitRef="usd">1482000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NGZkZDY2MTJkYmEwNGJlNWIyNjYwNTk5NzU0YWYyZDBfNA_f96683da-a87f-48a8-8945-6021db7374a7"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtNC0xLTEtMTQzMDYx_e198c077-bed5-4d07-aead-f7847e52b8a6"
      unitRef="usd">748000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia734f817ecef4a7cbac3c4b912ad3c8b_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtNi0xLTEtMTQzMDYx_718c82c5-a5cb-499a-948c-4d33fa3755bb"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i79ea118f8acc428ca2545966a39f9e19_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtOC0xLTEtMTQzMDYx_06209e61-8176-46da-89ea-06712f04923c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i79ea118f8acc428ca2545966a39f9e19_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjEtMTAtMS0xLTE0MzA2MQ_acd0accd-575e-4359-90b3-66c5109f54cf"
      unitRef="usd">1489000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6125e68618df43ada745dc4ed96c0b44_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMC0xLTEtMTQzMDYxL3RleHRyZWdpb246MDRmZWE3ZjZjMDYyNGRlYWIyNTYyOGE2ZTQwODYwZTlfNA_279a66f0-4a37-4681-8e34-1bc59809f956"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6125e68618df43ada745dc4ed96c0b44_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNC0xLTEtMTQzMDYx_9eefdf49-54f3-4374-9f66-8e0a44efc54f"
      unitRef="usd">651000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6125e68618df43ada745dc4ed96c0b44_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItNi0xLTEtMTQzMDYx_2619b6e5-cd28-4701-b145-15c927e6ddb3"
      unitRef="usd">652000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1f48cc3094e8425dbf7cb547b1775c69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItOC0xLTEtMTQzMDYx_ee1cc719-d01b-4ae3-bc6b-7baa8421dfc4"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1f48cc3094e8425dbf7cb547b1775c69_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjItMTAtMS0xLTE0MzA2MQ_66d175c8-0d28-4c66-9e16-8e69396656b4"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i624988cc531340da8809b18541e3ae0c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NjczYjNjNDE5MzNhNDhjZTk5OTUwN2I3NTUzNmZlMTVfNA_ed44f234-b5f9-4ffc-b1c3-4cb11fea98d0"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i624988cc531340da8809b18541e3ae0c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtNC0xLTEtMTQzMDYx_6a7d1aae-b7b2-4141-8373-b0c8e6fe2ae6"
      unitRef="usd">208000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i624988cc531340da8809b18541e3ae0c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtNi0xLTEtMTQzMDYx_b02412bc-3492-4e43-a703-61a34710284a"
      unitRef="usd">207000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icb7f0a78f9524510a26d87340b762969_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtOC0xLTEtMTQzMDYx_289b58a3-a554-4404-9fc5-c2adca799e87"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="icb7f0a78f9524510a26d87340b762969_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjMtMTAtMS0xLTE0MzA2MQ_af115aaa-045f-46fb-8935-1463ac4f32eb"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iec3a4af6ebd741b697f1f5228fc4b251_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NDU0YmMxNmEyMTZjNDliMGI4ZTc3ZDAzYTQ5MmVlN2VfNA_8c65228b-f129-4250-98e1-a1288d4aa844"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iec3a4af6ebd741b697f1f5228fc4b251_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtNC0xLTEtMTQzMDYx_1d288116-167f-4928-a997-99c687b6cdc9"
      unitRef="usd">466000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iec3a4af6ebd741b697f1f5228fc4b251_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtNi0xLTEtMTQzMDYx_e6e66c82-2f6c-4340-ba6c-d82a44b9fb1c"
      unitRef="usd">462000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i46824116217340c19c4097a996b6f0f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtOC0xLTEtMTQzMDYx_07e40298-2293-4f41-a404-ae9bf23d6efb"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i46824116217340c19c4097a996b6f0f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjQtMTAtMS0xLTE0MzA2MQ_97086d13-1992-400b-947c-81e6dc5ec20c"
      unitRef="usd">1238000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246NzAxMTQzMjRlZGQ1NGJlNTgwYmUxODQwZDE4NGVhNmNfNA_2256c272-ec3c-447b-8970-8af95dc80453"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtNC0xLTEtMTQzMDYx_2ad5133c-511f-4253-ba24-ba601bb53ba7"
      unitRef="usd">866000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib486a5725ceb4e8ba5452f31c2ba4380_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtNi0xLTEtMTQzMDYx_84c1b632-1086-41a8-b1c1-2345423fc600"
      unitRef="usd">857000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iffaec666689a4abf87b5f4f4e20a8005_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtOC0xLTEtMTQzMDYx_18b4a37a-0644-4dd8-9681-51fd3420344b"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iffaec666689a4abf87b5f4f4e20a8005_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjUtMTAtMS0xLTE0MzA2MQ_056ae5d0-ca53-4693-8c07-606a006de39d"
      unitRef="usd">1483000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtMC0xLTEtMTQzMDYx_761edc8c-3320-4de5-abcd-47822a23f25a"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtNC0xLTEtMTQzMDYx_c8fc643f-5b53-46b7-b115-0e618ea61807"
      unitRef="usd">463000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i65c98d7e313b4a7d9a7469cc03ffb2c8_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtNi0xLTEtMTQzMDYx_f22dc069-09b6-429d-9bbc-0f73c1d67f31"
      unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaed6c73971e144729fd723b401f24f72_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtOC0xLTEtMTQzMDYx_46778c1d-40e1-43bf-8c6e-866bbc5e553a"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iaed6c73971e144729fd723b401f24f72_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjYtMTAtMS0xLTE0MzA2MQ_2afa0c5d-4e6e-4b10-9f0d-2e525eb6ef1d"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i736c5fc93f2242fe9da805a6c5e69418_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctMC0xLTEtMTQzMDYxL3RleHRyZWdpb246ZjBjYTI5Zjk3YmEwNGQ1Y2E4ZDFhOTU2OWRhNjc5MTlfNA_262367d2-e649-40a2-af46-1828f0b51ccf"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i736c5fc93f2242fe9da805a6c5e69418_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctNC0xLTEtMTQzMDYx_d3b516dd-8901-454d-ad2b-958620aef6dd"
      unitRef="usd">372000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i736c5fc93f2242fe9da805a6c5e69418_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctNi0xLTEtMTQzMDYx_eb3a1f18-cb0c-47be-b6c2-a1b299d607ea"
      unitRef="usd">369000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib7da4ab69e9549eaa9e8488eb34481b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctOC0xLTEtMTQzMDYx_6b13f328-bc24-48f0-8f0e-cfe2cbbfc794"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib7da4ab69e9549eaa9e8488eb34481b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjctMTAtMS0xLTE0MzA2MQ_da2c679d-904a-4f3f-8dd3-796f68a9c7af"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7ad837f07b304b389bac2395b7bb644c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtMC0xLTEtMTQzMDYxL3RleHRyZWdpb246Njc5ZjVjMmVhYTI2NDI1ZTg1YjlmN2Y2ZTY5MzIxNWRfNA_2c7be1e9-44e3-4128-9583-f03902f8b349"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7ad837f07b304b389bac2395b7bb644c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtNC0xLTEtMTQzMDYx_59a92555-1ec7-4314-ac07-fd8c1891cc47"
      unitRef="usd">869000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7ad837f07b304b389bac2395b7bb644c_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtNi0xLTEtMTQzMDYx_b0966cb1-a5c8-4ea6-8998-c6f443e80c48"
      unitRef="usd">861000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i05e0e09e5ca542869e0a304640beb346_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtOC0xLTEtMTQzMDYx_f6444f5d-4e8f-45fb-a90f-8d28db6d5ebd"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i05e0e09e5ca542869e0a304640beb346_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjgtMTAtMS0xLTE0MzA2MQ_d95d2b92-b448-4ee1-9c4d-e39155864f66"
      unitRef="usd">1237000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktMC0xLTEtMTQzMDYx_a015c81a-286e-49db-9225-484f7986e8c3"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktNC0xLTEtMTQzMDYx_11322ee9-d414-40b9-815f-79f5adc4405f"
      unitRef="usd">572000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="idd89bfc3628a4bec9f4e663c6e2a8a06_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktNi0xLTEtMTQzMDYx_908d0cfe-bec5-43ee-b6a1-867d39de0a96"
      unitRef="usd">567000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3431ac7fda8140f496bbf1281db492f8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktOC0xLTEtMTQzMDYx_f87e5ac7-3ccd-4c51-a667-dbb316e935a0"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3431ac7fda8140f496bbf1281db492f8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMjktMTAtMS0xLTE0MzA2MQ_3a63b8fe-8dbb-4968-a1b0-33167415f076"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2386767ef8494039a45eedf4276380c7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtNC0xLTEtMTQzMDYx_d2b0afb1-cb6a-4a80-ab42-c6fd0eb21abf"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2386767ef8494039a45eedf4276380c7_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtNi0xLTEtMTQzMDYx_9e86a08d-b4e8-4e1e-9fe5-d8503dee57c8"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b58cc7f53b24512935c9762a50cc8ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtOC0xLTEtMTQzMDYx_dfef9f6b-6ef2-4cc6-9fd1-8dd5ccf26e21"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1b58cc7f53b24512935c9762a50cc8ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzAtMTAtMS0xLTE0MzA2MQ_c38aff11-ca18-47cf-9c2b-655dfda8ffec"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtNC0xLTEtMTQzMDYx_3c6c3729-b1ac-48f3-951b-595bd0f0c3db"
      unitRef="usd">19574000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtNC0xLTEtMTQzMDYx_d1b50fe3-d39b-4fec-bf7e-ca8ae8d73507"
      unitRef="usd">19574000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtNi0xLTEtMTQzMDYx_89f44626-7384-455a-bd71-77dd229151d8"
      unitRef="usd">21215000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtOC0xLTEtMTQzMDYx_5e1e0a05-70d7-4d8b-9613-241a150f630f"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzEtMTAtMS0xLTE0MzA2MQ_bded3c9c-1c36-41cf-95ab-dc5ad9ac6ec0"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzItNi0xLTEtMTQzMDYx_a5c7896a-bd57-4faa-96ed-266f5abddfe2"
      unitRef="usd">411000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzItMTAtMS0xLTE0MzA2MQ_d56221b8-3833-4a14-a402-d2a525d187f0"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzMtNi0xLTEtMTQzMDYx_1359b7ea-5125-47e7-a066-f5b374f14115"
      unitRef="usd">20804000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOmExNDM4OTNjZWIwZjQ3ZTBiYjk2ZTllNmQyMGY0NTg0L3RhYmxlcmFuZ2U6YTE0Mzg5M2NlYjBmNDdlMGJiOTZlOWU2ZDIwZjQ1ODRfMzMtMTAtMS0xLTE0MzA2MQ_e29c07a5-df51-44c2-b016-9e32546688bb"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTYwMQ_a51a7a44-bf8f-4b71-b38d-265a78a29344"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments
      contextRef="i28a31a3954134e40bc913cd1fb66abf3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTMzOQ_6cd1e034-ce04-454d-9052-2f973a22bc66"
      unitRef="usd">12000000000</bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio
      contextRef="ice079f38e9d1403daa063c880dace2d2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQxNg_a4e43ecc-e4c0-4fc1-8342-9d0ec08a72f7"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="ice079f38e9d1403daa063c880dace2d2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTY0Ng_f1cd59a0-0045-4888-985a-fb824192b500"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i74a12b5112bb435791910303cfa182e6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2Njk2MA_5d5be041-2ca4-420e-9db3-e0c5c7fe1d7b"
      unitRef="usd">5594000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTcyNjMzNA_50f8dd17-9155-4262-a1f8-6d7398c3212a"
      unitRef="usd">3125000000</us-gaap:DebtInstrumentFaceAmount>
    <bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal
      contextRef="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTk0Nw_c96b5d05-fb14-4645-a389-2d6496257909"
      unitRef="usd">2469000000</bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8728c63be96941459a588f3116991b8d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2Njk3Ng_33b0535d-008e-485c-bf5f-e2b5572993c6"
      unitRef="usd">1774000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8728c63be96941459a588f3116991b8d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2Njk5Mg_39775e25-d5df-425f-9901-a45d303ed861"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8728c63be96941459a588f3116991b8d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAwMA_f7f26343-53fc-4dd7-af68-f53941b5c16f"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia6053ee47e754dcc8601ba99403a76b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAwOA_02e988cc-ad2e-4030-8e02-5996a3522270"
      unitRef="usd">352000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia6053ee47e754dcc8601ba99403a76b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAyMg_3d6d604d-1bb0-43f3-9215-178b62cc2dfc"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia6053ee47e754dcc8601ba99403a76b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAzMA_ed857ad6-be07-4a0b-89f4-d5f00e5817c7"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8728c63be96941459a588f3116991b8d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzAzOA_c3599c20-4906-440b-8962-426ff7a8bb82"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0cae089600e94389bc02d059bc908b54_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA0Ng_68d610c5-f7b2-4725-a892-548d31103e27"
      unitRef="usd">999000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0cae089600e94389bc02d059bc908b54_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA2MA_15f025b2-4f0f-4bb5-bde7-e30883e0805f"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0cae089600e94389bc02d059bc908b54_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA2Nw_06bbc837-d6fa-47ef-8cd0-37d191f3cb22"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ie79f3bd1f9bc4330bfa744f8b69c453d_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA3NA_edd66f23-56be-4b66-98cb-ced92fc0c6b2"
      unitRef="number">0.386</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE0OTI3MQ_963a11f2-0fc8-489b-b8ab-5bf84ecdfa3a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate principal amounts of the Existing Unsecured Senior Notes that were validly tendered and accepted by the Company in the Exchange Offer are set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25% Senior Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.50% Senior Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Senior Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if878061e7e8a4d5b87624e62ac22aa3a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMS0wLTEtMS0xNDgxNTQvdGV4dHJlZ2lvbjplZDY3OWVlYTQwYTM0YmEwYjgwNmY0NzYxNjdjNzZkM181NDk3NTU4MTM4OTE2_ff0888a9-253d-4806-aaa8-3babfd7370ca"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="if878061e7e8a4d5b87624e62ac22aa3a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMS0yLTEtMS0xNTI3Mzg_595d47d5-586e-418d-9b6e-7e58e0bf8f34"
      unitRef="usd">541000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie761f67bcaf44003906b0b905ba5b263_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMi0wLTEtMS0xNTI4NDAvdGV4dHJlZ2lvbjoxNzcxYTU5NWRjNTA0OTQ5OTMwY2M0OGMxZDdiYjVkM181NDk3NTU4MTM4OTE2_f281094f-e385-4f85-af2e-09aafe3d9f44"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ie761f67bcaf44003906b0b905ba5b263_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMi0yLTEtMS0xNTI3Mzg_9ac18b87-03e9-41a2-a9d4-d147c6dfe68e"
      unitRef="usd">752000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i66a9533f0c874026af3f2ce11e610087_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMy0wLTEtMS0xNTI4NDIvdGV4dHJlZ2lvbjphNjA1MTk5Y2IzOTA0OTczYjE3NWFmNWZjOGVjM2ExMl81NDk3NTU4MTM4OTE2_ce911d19-dab0-4e42-9932-baa8e290b064"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i66a9533f0c874026af3f2ce11e610087_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMy0yLTEtMS0xNTI3Mzg_9e740247-ae22-4be2-8741-b229d22fda64"
      unitRef="usd">1099000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f288fb4475b42e396cfd814e2d07cb9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNC0wLTEtMS0xNTI4NDQvdGV4dHJlZ2lvbjowZjI1MmU1MjcxYTM0MWI2OGY3YTMzMmU3MjEyNmI2MF81NDk3NTU4MTM4OTE2_92a4e2a0-bdd1-4f3d-8572-3327c845abc4"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i8f288fb4475b42e396cfd814e2d07cb9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNC0yLTEtMS0xNTI3Mzg_bb07f1d4-9fed-4919-aebc-f2fbe3461446"
      unitRef="usd">540000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a8044c0008d4224a9252821ed90cab1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNS0wLTEtMS0xNTI4NDYvdGV4dHJlZ2lvbjowOGY0NGI4MjQzNjE0NDliODM5OGRjNmNhMmM3OTZmNl81NDk3NTU4MTM4OTE3_e67eeb03-bdf3-4b60-a78b-6b34cfa0b764"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i9a8044c0008d4224a9252821ed90cab1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNS0yLTEtMS0xNTI3Mzg_a891bf29-11df-4da4-820d-04c657fa0840"
      unitRef="usd">710000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e2c41e745e94aaca242b47db1e9da3a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNi0wLTEtMS0xNTI4NDgvdGV4dHJlZ2lvbjpiMDRkMGE1ZTZlY2Y0OTc4YWYyYWMwYzFiYWM4Nzg3Ml81NDk3NTU4MTM4OTE2_fde20288-d5ba-42c7-bc0b-a2a381cd9769"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i7e2c41e745e94aaca242b47db1e9da3a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNi0yLTEtMS0xNTI3Mzg_b52987a4-ecca-4fce-898c-83dd8a576a61"
      unitRef="usd">373000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i22f1e467a3104724bf0814979c3d7b24_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNy0wLTEtMS0xNTI4NTAvdGV4dHJlZ2lvbjo5YTI0NDkxYjI3ZGQ0YzZiOWUyMmFjZWE1NGEzNWU1NV81NDk3NTU4MTM4OTE2_15fe57bf-8f9a-44b0-8871-5e25e4784226"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i22f1e467a3104724bf0814979c3d7b24_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfNy0yLTEtMS0xNTI3Mzg_422f9a4e-2bd6-42b1-ae5b-6211d7c5777c"
      unitRef="usd">540000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib64b46934a374f298609c8f8d6de0962_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOC0wLTEtMS0xNTI4MzYvdGV4dHJlZ2lvbjozNmE5OGZjZDQ4MmY0Y2FiOTRkZjQ4MWI1ODU0MDBkMV81NDk3NTU4MTM4OTE2_d45abf8c-2be3-4acc-be3e-09776b60b68a"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ib64b46934a374f298609c8f8d6de0962_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOC0yLTEtMS0xNTI3Mzg_df7d8e1f-bc23-4a2a-9fb9-b4bf55b3a1c4"
      unitRef="usd">371000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie88308ccb55545679dce2acf47006522_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOS0wLTEtMS0xNTI4MzQvdGV4dHJlZ2lvbjo4OTRkMzcyOGExZTk0NGU0OTUzOGNkNzc0NjYwM2I3MF81NDk3NTU4MTM4OTE2_121e9edd-d4a6-4e45-a308-b66070552875"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ie88308ccb55545679dce2acf47006522_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfOS0yLTEtMS0xNTI3Mzg_0062246f-46be-49bb-8b81-75cf500c6a08"
      unitRef="usd">332000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ideda0b3afeb94283b8b7495bc71f5cfa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMTAtMC0xLTEtMTUyODMyL3RleHRyZWdpb246ZmM0YTI0NTY3ZjY0NDI5ZWE0MzMwZjNjYTQwODBiNjBfNTQ5NzU1ODEzODkxNg_00318007-4a3a-4857-b45e-432c2a4d31d4"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ideda0b3afeb94283b8b7495bc71f5cfa_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMTAtMi0xLTEtMTUyNzM4_0fa37f81-e876-4535-a0b5-c3b591fbd318"
      unitRef="usd">336000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i74a12b5112bb435791910303cfa182e6_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjYxZWJlMTY2N2E4ODRkOTk4YWM5ZDNiNDUwZjNjYWY3L3RhYmxlcmFuZ2U6NjFlYmUxNjY3YTg4NGQ5OThhYzlkM2I0NTBmM2NhZjdfMTEtMi0xLTEtMTUyNzM4_2e7f9a04-38bf-4699-94e1-3b32ba44c1bf"
      unitRef="usd">5594000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie761f67bcaf44003906b0b905ba5b263_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4Nzg5OA_704bc108-a098-4e28-8595-082efedd113e"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i66a9533f0c874026af3f2ce11e610087_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkwNQ_8d4b8b98-0731-4398-81a6-5cd1f91729ef"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a8044c0008d4224a9252821ed90cab1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkxMg_e2aada53-f571-4a0d-8802-c1b6c1429888"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8f288fb4475b42e396cfd814e2d07cb9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkxOQ_bbc2f005-e184-4228-b90e-a11e9a8706a1"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7e2c41e745e94aaca242b47db1e9da3a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NzkyNg_193d05b7-1b30-49f5-90ba-469c824c823d"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i58945eb4f42545a2a975fa287df7030b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTkwNA_b030b7cb-fb38-4f08-a1ea-c05503879260"
      unitRef="usd">570000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:ExtinguishmentOfDebtThirdPartyFees
      contextRef="i58945eb4f42545a2a975fa287df7030b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTkxOA_cd2dfc5f-630a-4af7-9a9e-0f8a8ca88a77"
      unitRef="usd">25000000</bhc:ExtinguishmentOfDebtThirdPartyFees>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="ia6b7ffdcf51b43589f6d8696bb978c91_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NTkzMQ_b6e6c90e-82cf-4e26-a2aa-b683b6d4a955"
      unitRef="usd">1835000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0f887978c4a542b19634fbdbca4dbd97_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzIzOQ_617610f4-678e-4893-9025-98386ca7fa96"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i278988850934419e80acc9d963dac666_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzMwNA_2274dd2e-4246-484b-9bb5-4af526dfd41f">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="i0f887978c4a542b19634fbdbca4dbd97_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzQ5MA_338c189d-5a5d-4d52-93b6-8d00bb570ff9"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i00732fc9ff374b49b979455466cc8f7e_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzU5MA_30237722-ba63-492a-9087-e88308859398"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icdfc7e6315fd42efbda70b4c17cce33d_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzU5Nw_05a73282-a424-4cbc-9dae-62b10d632bde"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i6365ee6027ab48f0a916168124555cb4_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDE5NA_15a74b8e-3679-4d9a-ba12-905b7a03608f"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDI5OQ_ec5bae8d-e880-4c18-a7e9-136f644991c5"
      unitRef="usd">975000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="ie52f1d3dd7b44370875bfbf01edce092_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDQxNA_5ea35fbf-5c13-42e9-bf18-1b4d8ff5c818">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNDU2Nw_2752cfd3-1c1d-49c7-988d-98d725c8c4bb"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:LongTermDebt
      contextRef="i96f39bda64df4253bfb97df28400bd07_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTE2Ng_2ee413ce-0f36-4675-be60-1e27d4119494"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iff4ef5de85bb4627a12cb69700bd7abe_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTgwOQ_43ff6199-4033-483b-abc6-a8b53c67c1d4"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable
      contextRef="i829327ff659443278a6e3108a31e2416_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTg1Nw_103b194f-5ccb-438b-b2f2-b3142d4207fb"
      unitRef="number">0.0150</bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifafb7519d3db4ba79da9149156c9be5b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTk4MQ_f003b4c9-671d-4803-8f39-fb1a0f363e77"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie2c63af1038a498d97b0707660dbeca4_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNjMzNQ_26dc7c20-0a2a-4959-8859-9b9fedb9b06e"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie319941a51a34294bbdb2ae3718dec8e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzY0OQ_46d69282-ec6c-4288-8106-8c5be9ab4d8e"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="ie2c63af1038a498d97b0707660dbeca4_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzc4MA_81486f5a-1f70-4ea8-81b7-858a8f64cb5e"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i20cd5f0493f2487bbde5f2221db59a0c_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzc4Mw_975caa4f-df87-4dcf-8c98-da0fea84ee55"
      unitRef="number">0.0025</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i829327ff659443278a6e3108a31e2416_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzg3Nw_1cb07f7f-2157-4217-a56f-d93f160671b9"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id3eed0b285dc42a99845525f57bc2eaf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNzkwOQ_6fe6a68d-a50a-47af-8e43-0b23ce4aeef7"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8a03fb030a0040cebef22c0f5654ea66_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODA0OQ_7c0fbd5f-f721-449a-9a2b-2646e86226f3"
      unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id3e53d6553f64b7eae83fca240d210f8_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODA1NQ_36d32131-b0db-4cdd-b3ea-9fe05c76ac4f"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i15dd8f000b9941858060dedaf7e029d0_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODEyMA_7a67d167-95bd-4482-9d0e-903e8f6c5b1e"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id330da73af3e4586bf7d8a9ae96e9b1f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODEyNg_7ebcbd8b-6ea8-4ec5-8270-e438651d3124"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ifb86b03b3ac24b4e82d95decf997f3b8_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODI1NQ_4665f200-612b-478b-ac7d-879d9cc27a0f"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i06b38bcf16e54859a0dde3ac0bd30c5c_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfODI1OA_e6240b5a-c0e1-4038-b874-57875c21032a"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTA0OA_75361f2d-9ce6-4ced-8334-e51f44770954"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTIxMg_278b94bc-0321-4a57-8b4b-c1faec499d2b"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTM1Mw_b161e7fb-442f-4c32-af7d-a8ea42f7d3a9"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="ib19ad7492e1e410387009d745cc6f590_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTUxNA_b37172d7-99f4-437b-b4bc-e14a23d4c37e"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i6365ee6027ab48f0a916168124555cb4_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTc1MA_3f4c3e57-a61c-4ca0-97f5-1e84c8636d81"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="i3944f858836c472bb400b25d49c9a870_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfOTc2Nw_13c6b640-04be-4fba-aaf9-c30c7090acd9"
      unitRef="usd">125000000</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="id154aa3590224033afe021d4daefc439_D20220630-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTAwNTc_1810bca9-da73-40bf-939d-b2bf2ccff5a3"
      unitRef="usd">531000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTAyMDM_d9fda4ae-cdb0-4aee-b32e-c6be83de339d"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage
      contextRef="ie52f1d3dd7b44370875bfbf01edce092_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTAyMTA_52a7c554-4f50-44e5-b729-ff94c1a296ee"
      unitRef="number">0.40</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i02856360ad9c4499aa8ee226526b1aa5_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA1MTU_e519fcb8-484f-41df-8d52-6cd002c4ab5d"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="i36893810d2ab469aaa9b5e3e8bd9c2e4_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA2MTA_a638f431-0a79-4255-add9-903c88e1543b"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="ia532a9f771954ea39e670e6607d20d41_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA2NjU_26408ecc-d991-427f-9967-cf911386d33b"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentCovenantTotalLeverageRatio
      contextRef="i3b91f50e40904c03b83e3484fe6eee31_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTEzNzI_f75ca1ca-896b-418c-bae6-27e5318d74aa"
      unitRef="number">7.60</bhc:DebtInstrumentCovenantTotalLeverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1be6df6cb851454f9afb224870173486_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTE3NDk_bc5633ef-ccbe-44c8-b6cc-219e260f80f4"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i93f125d7ae474da9a0a4942295b43c0c_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg5MDc_a68d2b34-4dd2-407f-8007-693197b903ba">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg5MTA_0ea4e220-daba-4548-9c9e-44dbd5f9bc00">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i726749b95a30497288303bb51019c959_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTE4NTM_2fb7e1e9-292b-480d-8bc3-9bb4809c4193"
      unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODQ5MDU2_20a5b292-de72-4f5f-ac42-61d924fbce90"
      unitRef="usd">2494000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODQ5MTUz_0852705a-030e-4e70-a05f-736e4ce6b796"
      unitRef="usd">2442000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i22e638cdad174145acfe1cb7ca9c3b06_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTEwNDE3MA_08dad638-ffe1-463f-a726-a5fed9329d18"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i85f9310875d34c5aab769c2612112be4_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY1OTMzMA_cb2c897f-8ed9-455f-bdf9-f57ad5a3b5be"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i14b599cb18c944ee87759c867f11b854_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY1OTMzOA_2ef2122f-d844-4cd7-b9d0-73819c1ba335"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2b8e5c5dac3f4de3a568fb4b1dc17504_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ4Nzk_7b609be8-60d8-4021-9e95-d99508078ee4"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic15ff81720f140728bd400ed17b1d660_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ4ODU_6ebf9b3b-232d-4804-8c8e-27c0ba2c7010"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3070a693a5854af3a22dfe66f3655e85_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ5Nzk_72efb4be-be86-4466-90cc-a9719417578b"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i943999c56fff450aa77e708b60d39def_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTQ5ODU_8aab4805-6968-4ea8-b3d9-4ec1bfc090ac"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic16b8fead453422ab2aa9fbbbcccf83c_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTUzOTc_0893e939-37ee-4682-9919-15f7b4cbcf61"
      unitRef="number">0.00015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i297866a68ce24747b81d40a30c023bb4_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU0MDM_eed7d323-bd8b-420c-a64d-e403a46fa358"
      unitRef="number">0.00475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i13632d9de3844a9cbd798441522b1bc7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU0OTc_38b43446-e2ca-44cd-8d2e-06d6c19c1e3e"
      unitRef="number">0.01015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4d4c681d58b24f99b498d9e6a296937c_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU1MDM_0bd7d985-b3b6-412b-9024-af5e034e600f"
      unitRef="number">0.01475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU2Nzg_368d3880-4bd5-42b8-ba1a-360b2a1576a9"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ic4b5207c38da4c0c9112b7da48cb7ce7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU4NTA_b085fdb4-8a54-4705-835f-0d73238b0b69"
      unitRef="number">0.00110</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i80f700a1b8cb457dbc050366a46232f1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTU4NTY_682e2429-6e21-4e02-ae29-c2409fde7cef"
      unitRef="number">0.00275</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia63c47b1828f4ae0b6b1dbab0bb42d98_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU2MA_7abb4b9e-fe5f-4567-9063-6ba9d716725a"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifaa17fd0da484c67bc48038c0747623b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU2Mg_5b1ef72c-65ab-44f3-a3b5-ae28d5bc1812"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i53fbf53285954caeb0e7f050632c7597_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU3MA_f6cec17e-aad1-497f-b550-778fc940e657"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8d49f58bd8e741069f996a82897124ce_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU4NQ_3510fcaf-98fe-4773-8f22-c3de28f48731"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="ia63c47b1828f4ae0b6b1dbab0bb42d98_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU5Mg_7a0dab72-3c97-4efb-b5cf-de021480fade"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id923a0c7821d408eab60e2d1ebbdbec9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTA5OTUxMTY2MDU3Nw_84b31bb6-6d35-4f22-9091-eef471f15ffb"
      unitRef="number">0.0610</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc0OTI_b30f3150-1ac3-40ea-bceb-452e2fc37f77"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc2ODk_5f25226a-e99b-4ca5-970e-117275f662ee"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc4MjE_f6cefbc7-9ca8-46f8-a576-2dae99bef35d"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="if517388cf1e2455f8c722c3f75b6681d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTc5NzM_156c44f2-29b1-4b76-bd8c-7db39f56a27a"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i1be6df6cb851454f9afb224870173486_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTgyMzM_91a45858-07a9-4bf0-bc80-6d07939979a9"
      unitRef="number">0.0100</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="i93f125d7ae474da9a0a4942295b43c0c_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTgyNTA_b0ee8f11-92ee-4dbf-b728-892329b5bb8e"
      unitRef="usd">25000000</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="ifebc6076ad5441fe9acf2610a82c6104_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTg1MzQ_0ad466fd-6e04-4923-8c40-a2d9644a3093"
      unitRef="usd">113000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8a060f4700c410dbf92bd4bbab91133_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMTg4Njc_9ccdf8ce-33fd-4423-8312-77016de33703"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjEwMTE_5cccd8f1-29c6-4a3f-ad3b-189d1246ec31"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic1f904c39c824f0cbed6373fc8027458_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjEwODA_431dca51-9728-4436-b033-6893c46b4820"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic1f904c39c824f0cbed6373fc8027458_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjExODY_38a1f11d-d287-436f-b187-12362abd42df"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic1f904c39c824f0cbed6373fc8027458_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjEyMTk_431dca51-9728-4436-b033-6893c46b4820"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i61dd05e0e56948b8bcb9f052101aeaf6_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjE0MTA_7cf63adf-be4a-47f3-93be-a86ffbccf532"
      unitRef="usd">1600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9189a38171dd4ebaa45559422267b0ab_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjE0MTY_c3d9de7e-a60d-4e83-9c4b-d7aed3d6704b"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i797254cc60b049dcb744c873a7a119bb_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjE4NDg_a816b21c-dff9-403c-80a0-f9caf25836a1"
      unitRef="usd">-38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i35465fe55b7945e3b6f24aa54344fa38_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI0MDM_72109c5a-9c1f-478e-99ac-649fba09c82c"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i2a503b3152c24a3aae993d9cca166b10_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI2Mjg_70133c16-33a4-42a7-b2ba-e054ba1c4ece"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI4MjM_6880c1aa-898d-4807-bf52-75d635a5fc1f"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI5MjM_398cedb9-1a32-48de-965e-c5439b040d1a"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjI5NTY_7adb45e8-0104-4670-8240-d9426f7a2dc5"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3b31c1096fa41628dbf2c0ff7c7a2c3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjMzNTg_7adb45e8-0104-4670-8240-d9426f7a2dc5"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ic7cb7ba0199a427782c6e11d979cc908_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjM3Mzc_b9b70f99-22cc-4676-855d-9ed3051b9c64"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i463a1df44c5e447c95a44b5652a58c27_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjM4NTQ_fb7337ef-9107-4523-8bcc-2f4b92dab2ed"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzI4_53f19781-169e-45b6-bf7b-0fb7d722d7e6"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzM4_08129b26-faef-4113-bf54-6cc2e2ef9353"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzg0_9f582f25-2e29-41f6-9152-5a06d4ec34e0"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ic986ed29a4b54c67b340f512dca91b23_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDA1_7c0d91a7-7537-4f23-b9a6-7e791aa96b26"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i202ff1947e264b19a06b70f0ffcc5c89_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzU0_029caf7d-9947-4d7c-b479-fb616d0496cb"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzMz_fc6ba770-e1de-480d-aad3-8de40db5678c"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzQ2_8e7bc046-6b4e-4fa2-ac9d-f75459490f64"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzY5_7f343c68-25d1-49e6-b144-f94f259e8033"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDAw_e54e2e57-b14e-4382-8ddc-8c0ecb483247"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzc0_5c674a1d-f6ef-4686-b92d-1693c411a239"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i3cb285fdcf7346e4931be632a5d32554_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzg5_6dba2095-be54-43ed-ac6f-7858b01fb315"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzU5_d76647a4-ceea-4fc6-a44b-1d614cd114d7"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i08d9f7c4a1b54b0893e8a5c93f2b8b41_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzk1_1d96f9af-55e6-4630-b27f-ea20eb0f7e8f"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzY0_147a706d-b739-43e8-9bcc-c5c099dfe52f"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6770f439f6854fdf80d5b734c92a4554_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwMzc5_37f843bc-2f49-4cb8-b4f9-d511568310ba"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDEx_0b697979-f7b3-496a-a9c7-e606051f2a14"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDE1_afd4e92a-b83a-4f37-a438-9109f4197bfe"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDE5_f5d2f5ca-23b3-4d9f-8588-5d1c57016e6b"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDIz_bc419a9d-42be-4aba-9f87-ff93183dc84e"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDI3_e4d9adba-8c03-493c-8b69-9df7f8289dee"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDMx_4c0fb4f9-9de8-406a-8ee1-2ea86e30c95a"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i1870e555a1fd4b21a7e5585f4d019a9f_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE4NjE1OQ_f5cc6232-4954-4b48-9b24-079852c52062"
      unitRef="number">0.386</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfNTQ5NzU1ODkwNDM1_49b3c8f6-8c3d-4321-a97d-288af82a0259"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzg0ODI5MDgxMzA2OQ_4c0fb4f9-9de8-406a-8ee1-2ea86e30c95a"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iabd7119954044616a3233f093428ce2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMzg0ODI5MDgxMzEyMg_4c0fb4f9-9de8-406a-8ee1-2ea86e30c95a"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i31cc3cc5d3ca41eaaeacd771a686a45e_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjUyMjA_e543ab50-d0c8-48d6-ae72-6eafa354275a"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i7356824e0b3446aeb0703cbdc0f9101f_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjU1Nzk_7b8991c1-5506-440c-9f45-d7bd3cc6d885"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7356824e0b3446aeb0703cbdc0f9101f_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjU2NDE_418303fb-4775-4be1-a78d-ed40cb951490"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet
      contextRef="i7356824e0b3446aeb0703cbdc0f9101f_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjU3Nzc_8f8a09fc-da0b-4768-be05-03671b338db9"
      unitRef="usd">7000000000</bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i4804f7e82ed3464d857db9b9aadf33f1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjY0Nzk_cba4dc97-afd2-4e90-8bc8-58472548d2a9"
      unitRef="number">1.01021</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc1ODk_f612d778-16af-470f-af15-77dcc68b0320"
      unitRef="number">0.0724</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc1OTY_9ab9e655-4057-4b65-8863-64c5f4579d67"
      unitRef="number">0.0588</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7f730e3004c4467e93c8beedc0748d7b_D20220901-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc0ODc3OTE2NzA4Mg_c7177483-07c1-47dd-9f5f-591074c05d8d"
      unitRef="usd">570000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i4afef88c6a4140829ef856906a21c44c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc4MDA_3055e2a2-8582-441c-ae35-cf8c7c1bc576"
      unitRef="usd">481000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id98c05c2a0a14ddb8c06bf78beb4aad8_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc4NDg_c2b15d21-2a8e-4b4c-9e7f-e9aa9d1a12aa"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id98c05c2a0a14ddb8c06bf78beb4aad8_D20220601-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjc5MjM_a820e6ec-8975-4e5d-825a-ea6adb70164c"
      unitRef="usd">176000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i042059a75e2442fd999e415f9c25591a_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjgzMjU_b8d89087-bfa1-474c-943d-a52d2bbaf845"
      unitRef="usd">-63000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RleHRyZWdpb246MTliYjAzYzA1OGE2NDlkOWEwNGY5NDgzMDQzMDA4ZDVfMjg4OTQ_33748b9e-3687-48e8-9f2b-bc33f224bf1e">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMS0xLTEtMS0xNDMwNjE_a16695a5-fe64-4e79-8985-f4503831aecd"
      unitRef="usd">38000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMi0xLTEtMS0xNDMwNjE_8a1cee05-0f43-4add-ab85-29d6c8c8f87e"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMy0xLTEtMS0xNDMwNjE_817dcbd2-36e1-40d6-9baa-6f26209b2f90"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNC0xLTEtMS0xNDMwNjE_02e48968-e27e-4de4-9c73-40614c54a2fd"
      unitRef="usd">2859000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNS0xLTEtMS0xNDMwNjE_6dc6694e-6fc1-404a-bf54-f49feb3cef48"
      unitRef="usd">898000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNi0xLTEtMS0xNDMwNjE_0da4201b-c36f-4e48-814b-71533370c8dc"
      unitRef="usd">6926000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfNy0xLTEtMS0xNDMwNjE_566c398d-cfa4-4544-8f78-0f914cacd3bf"
      unitRef="usd">8553000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfOC0xLTEtMS0xNDMwNjE_26f52e99-5a25-426a-9eba-5bc274b1f73a"
      unitRef="usd">19574000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfOS0xLTEtMS0xNDMwNjE_677bb556-2f95-44ff-b4fe-be2729f65720"
      unitRef="usd">-1641000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF82Ny9mcmFnOjE5YmIwM2MwNThhNjQ5ZDlhMDRmOTQ4MzA0MzAwOGQ1L3RhYmxlOjczODI3NWYzYTgzODRjMWNiNDBhNGNmM2NlYjg3ZDRjL3RhYmxlcmFuZ2U6NzM4Mjc1ZjNhODM4NGMxY2I0MGE0Y2YzY2ViODdkNGNfMTAtMS0xLTEtMTQzMDYx_7ee7bb7f-0175-4684-a3b8-c3e7cc109b9c"
      unitRef="usd">21215000000</us-gaap:LongTermDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RleHRyZWdpb246ODk2Mjc1OTY1MjcxNDE2ZGI4ZjU3NDExMWY5NDYwZjNfNDAx_eefd187a-41a8-4f0e-bc8c-dc7b9bdfaf9e">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2022 and 2021 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RleHRyZWdpb246ODk2Mjc1OTY1MjcxNDE2ZGI4ZjU3NDExMWY5NDYwZjNfMzk3_d61bdbfb-80e9-4713-a2ae-a6d35ac5c983">Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2022 and 2021 consists of: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy0yLTEtMS0xNDMwNjE_2f46b296-8940-45b5-9420-a4bb2c435f02"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy00LTEtMS0xNDMwNjE_8037585e-2821-44a8-bb8d-1b1105026e0b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy02LTEtMS0xNDMwNjE_f238fc75-52ac-4f28-ae3d-03ad511ea1bb"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy04LTEtMS0xNDMwNjE_7bcb9d43-c8ad-4e03-abb1-a684ad521328"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy0xMC0xLTEtMTQzMDYx_6811e4e8-83d2-49ac-aec6-bc389f2de9e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfMy0xMi0xLTEtMTQzMDYx_828297cc-2805-446f-8fe5-78ac32b69ef6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC0yLTEtMS0xNDMwNjE_89c961a3-7e75-4287-b58e-ebf1cd6ffd9d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC00LTEtMS0xNDMwNjE_6bcf092c-6847-4981-8cb7-25433ac4f790"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC02LTEtMS0xNDMwNjE_55cf03d8-d311-4f01-9457-0887b9c4562d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC04LTEtMS0xNDMwNjE_717b9823-5516-45d7-98d6-1216e935ccf0"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC0xMC0xLTEtMTQzMDYx_d8bd8106-d0f2-465a-ab25-9655aab91aa6"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNC0xMi0xLTEtMTQzMDYx_c61fb3b2-8079-4eff-be82-3057c0037695"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS0yLTEtMS0xNDMwNjE_251f518d-1697-4417-8279-777299695d31"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS00LTEtMS0xNDMwNjE_df057853-8a5e-4658-af07-be7ec8bfe060"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS02LTEtMS0xNDMwNjE_db2989d1-72e4-4de9-8520-fc4328b14576"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS04LTEtMS0xNDMwNjE_dd97a1b0-e1a9-4782-8ade-86f3f33cd6a1"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS0xMC0xLTEtMTQzMDYx_02ba54a8-7486-4f82-9381-2c4da6b2cef5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNS0xMi0xLTEtMTQzMDYx_98200266-5dc7-4caf-9fd0-aa88eebf9500"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi0yLTEtMS0xNDMwNjE_8e2c08d4-7fdc-4196-962f-67482d6df7cf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi00LTEtMS0xNDMwNjE_f2e6d7b7-1189-44c9-848a-6622505042f6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi02LTEtMS0xNDMwNjE_b76cf389-20ea-4f15-b107-46753cc2b66e"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi04LTEtMS0xNDMwNjE_469321f8-b190-482d-ba7c-4f89d3d64468"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi0xMC0xLTEtMTQzMDYx_1d5a5e60-1d6f-4ff4-9452-2bd06f7cab49"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNi0xMi0xLTEtMTQzMDYx_8d95a826-c8d1-4980-975d-7365069981d8"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy0yLTEtMS0xNDMwNjE_76db2ffe-27c1-4432-990b-d60fd1e623c0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy00LTEtMS0xNDMwNjE_d479caf0-88f5-4ca4-baef-167033dc39a1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy02LTEtMS0xNDMwNjE_fbb0389f-5273-420a-a140-e0ac6d1b8694"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy04LTEtMS0xNDMwNjE_4a850ffb-3658-424b-85ee-4291d3853d09"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy0xMC0xLTEtMTQzMDYx_06fd92e2-a1c1-4abf-805a-7d74480ad0b3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfNy0xMi0xLTEtMTQzMDYx_8b20e282-c01d-4cdd-8a02-73316c33dc1b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC0yLTEtMS0xNDMwNjE_0734d40e-d10c-40ae-91e1-f509fb1c8db3"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ifc1b3f62b8e84196a918499e5f264520_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC00LTEtMS0xNDMwNjE_985e249d-5681-4e78-b2c4-532a36de407f"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib90af40e2c8e498f847a737c3843a639_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC02LTEtMS0xNDMwNjE_dedefe5e-204d-47a5-8a5e-e1822c1b4a4f"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib8a9f52e9a394b3eacee770a8e7ed771_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC04LTEtMS0xNDMwNjE_8857f2b1-d7ca-42f6-aa09-c6ac9504634f"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i37a26177aceb40adbe206fb0891149a4_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC0xMC0xLTEtMTQzMDYx_20321e7b-596d-417b-bc9b-b9a95b7e79a2"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8bbf7d7ab6cf4663be64949582839eb3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83My9mcmFnOjg5NjI3NTk2NTI3MTQxNmRiOGY1NzQxMTFmOTQ2MGYzL3RhYmxlOjA3MWE3ZTJlNmZiNDQ4ODE5N2ZiZmU3MTQxYTc0OTk5L3RhYmxlcmFuZ2U6MDcxYTdlMmU2ZmI0NDg4MTk3ZmJmZTcxNDFhNzQ5OTlfOC0xMi0xLTEtMTQzMDYx_57cb3668-cab0-4990-9756-b10693d6c544"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMg_e81cc71e-42c0-4572-9134-0030d020705c">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch Health&#x2019;s Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, shareholders approved Bausch Health&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;) which replaced Bausch Health&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#x201c;Amended and Restated 2014 Plan&#x201d;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 18,328,000 common shares were available for future grants under the Amended and Restated 2014 Plan as of September&#160;30, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#x201c;RSUs&#x201d;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;), (ii) vest upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to retain and incentivize certain members of the Company&#x2019;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#x201c;Retention RSU Grant&#x201d;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTA5OTUxMTYzODk0Ng_fd0ab737-0f9e-4702-b219-264d2a3842ea"&gt;three&lt;/span&gt; anniversaries of the grant date based on continuous employment with Bausch Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch + Lomb Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to May 5, 2022, Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb participated in Bausch Health&#x2019;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#x201c;B+L Plan&#x201d;). A total of 28,000,000 common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2022, in connection with the B+L IPO, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb granted certain awards to certain eligible recipients (the &#x201c;IPO Founder Grants&#x201d;). Eligible recipients are individuals employed by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb or employed by an affiliate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb. Approximately 3,900,000 IPO Founder Grants were issued to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb executive officers and were awarded 50% in the form of stock options and 50% in the form of RSUs. Additionally, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb granted approximately 5,700,000 stock options and RSUs to non-executive eligible recipients, of which approximately 4,300,000 were B+L IPO Founder Grants. The IPO Founder options have a three-year graded vesting period and the IPO Founder RSUs vest 50% in the second year and 50% in the third year after the grant. With the exception of the separation agreement and retention program, as discussed below, vesting of the IPO Founder Grants are linked to the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb entered into a separation agreement in connection with the departure of its Chief Executive Officer (&#x201c;CEO&#x201d;). Under the terms of the separation agreement, the CEO&#x2019;s IPO Founder Grants in the form of RSUs will vest upon his termination of service date (pro rated based on his period of service relative to the original three-year vesting period associated with such grants), but the shares received upon settlement will remain fully restricted and nontransferable until the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer pursue a distribution, and the two-year anniversary of the CEO&#x2019;s termination of service date. Under the terms of the separation agreement, the CEO&#x2019;s IPO Founder Grants in the form of stock options will vest and become exercisable (pro-rated based on his period of service relative to the original three-year vesting period associated with such grants) upon the earliest to occur of the distribution date, a change in control, the date the Board determines that Bausch Health will no longer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pursue a distribution, and the two-year anniversary of the CEO&#x2019;s termination of service date and remain exercisable for two years following this date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, the Talent and Compensation Committee of the Bausch + Lomb Board of Directors approved a retention program that includes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s named executive officers (other than the CEO) and certain other employees. This program provides the Executive Officers (other than the CEO), among other benefits, pro-rata vesting of the IPO Founder Grants previously issued to these named executives, subject to certain restrictions, in the event of an involuntary termination of employment by &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb without &#x201c;cause&#x201d; or the executive&#x2019;s resignation for &#x201c;good reason&#x201d;, in each case through the one-year anniversary of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s appointment of the successor to the CEO (pro-rated based on the period of service relative to the original three-year vesting period associated with such grants). Additionally, these named executive officers (other than the CEO) and certain other employees were granted a one-time award of approximately 850,000 RSUs under the retention program pursuant to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s 2022 Omnibus Incentive Plan. The retention grant will generally vest in 1/3 installments on each of the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5Mjg4MQ_d3858cff-cf89-4b94-8aea-b1ba58bb78da"&gt;three&lt;/span&gt; anniversaries of the grant date based on continuous employment with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 17,500,000 Bausch + Lomb common shares were available for future grants as of September&#160;30, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of the Company's share-based compensation expenses related to stock options and RSUs for the three and nine months ended September 30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the nine months ended September 30, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch Health Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,151,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B+L Separation performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch+ Lomb Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,455,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,205,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $152 million, which will be amortized over a weighted-average period of 1.77 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $72&#160;million, which will be amortized over a weighted-average period of 1.64 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i93eb31e461ac4db5ba4c0df1c70c52c7_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDg1_f6a62d10-6683-4c0f-995a-7dbf72d055a7"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i93eb31e461ac4db5ba4c0df1c70c52c7_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfODQ1_72c60f1c-5db9-481c-9093-c8151392665f"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i7e9c7cf1e63843dd9922d9993278a56a_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTM5NQ_e9121c57-eb3a-4958-85d6-1e4ec128ef9f"
      unitRef="shares">11500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic1d0f02ef63b4948ba4e261acdbbbfc2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMTQ0Nw_d09735cd-6851-46ae-850e-01f9a3d0cb84"
      unitRef="shares">18328000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i23da95982875422e85842884cfcf3c78_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjg2Mg_fecc6a05-64bc-430a-bfb6-386e5343a26f"
      unitRef="shares">28000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="id7cc1e4c1e0e45c088cf0da8d3478561_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzI4NA_a34b260e-cdbe-4fff-833d-3b7b5735f70d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id7cc1e4c1e0e45c088cf0da8d3478561_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMw_ef1ff35d-1a83-4850-8390-2fb8db673f89">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i879c2fd226954205b21a10810b667c13_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzYxNA_220286e3-16e3-47e2-a343-323335edbfc4"
      unitRef="shares">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent
      contextRef="i40e0ab954b9546489a9ef90bab33b427_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzcwMQ_cd4de13e-f943-439c-a993-92a809a4b301"
      unitRef="number">0.50</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent
      contextRef="i12e20cb0b43649a1a6d77f2a05f00d92_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzczNw_e2ab4e29-7a78-4984-b7b6-8f75c096fdb5"
      unitRef="number">0.50</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross
      contextRef="iba04e7a5f74b447488bf33d1bba8d3d1_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzgxMQ_973d2ac3-c544-4964-a664-e4031ebe6987"
      unitRef="shares">5700000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross
      contextRef="i4638c5e4165448498eae9d03caa89485_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzg5OA_04ae0860-07b8-4f32-a433-d62ee89f3538"
      unitRef="shares">4300000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9e3179052a5e4e44b4b9793cfa4650a3_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIwNQ_2a299e91-c5d9-48b9-aa19-1c97555746d9">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i125d23605450450a9432058cc84577ab_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMzk5Mw_55b21155-f9ad-45e2-bc4c-89bdc9c940bc"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="if3ae116d5b71442d8c602ff3e0ff2420_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDAxOQ_393bfb3e-0df4-42be-af56-a1e53ddc7bc9"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie8dc48d6ec2b4113ad14034a1c76b675_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzYxMg_03b2c250-504e-48c7-997b-df70889d00ef">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod
      contextRef="ib87da6b4d8544d5dade0efad5191c5c3_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzYyMg_fe65804b-8f18-463e-83bd-0468d6c7d4dc">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id7042d4e6e0d42a092deb71733fc7627_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzYzMw_e56734c6-76c3-42e0-afac-9610fb117cc6">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod
      contextRef="i7e5a843db9464057940288007937dd58_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzY0Mw_4a8470cd-d378-4607-ba3a-6f59432215df">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod
      contextRef="i7e5a843db9464057940288007937dd58_D20220719-20220719"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5NzY0NA_481f4f05-392c-4d42-895c-c0d88adb4126">P2Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod
      contextRef="i838762aec48a48bfaae871f10aa12c35_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA3Njk3NQ_2417b719-5d29-49c2-a146-5e310819f53b">P1Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9c04f97f5c714af7a5e387b0d156bc8d_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA3Njk5Nw_1a4b0d6c-6dd3-4082-9a75-97aa09da5d10">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia324b82ecfe4472a8eec915831a5f250_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfMjc0ODc3OTA5Mjg3Mw_05656e03-b6a6-46d3-9598-710c86c81b40"
      unitRef="shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDIzMg_481a2064-b8d9-4617-8bfe-dd80e3828e6a"
      unitRef="shares">17500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMA_d167bbb3-83e2-45d9-9a6d-b52b355476f5">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of the Company's share-based compensation expenses related to stock options and RSUs for the three and nine months ended September 30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ae9beb58b9b44bcbb18d4e6cd9e9fbb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi0yLTEtMS0xNDMwNjE_cfc2299d-8094-449b-8fc7-54aba323dd3e"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80f371d3c6a04f48a82246f042826add_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi00LTEtMS0xNDMwNjE_bab6fe75-f38e-4cbc-9c05-52e937a9ff4a"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi02LTEtMS0xNDMwNjE_e478b6f9-6600-49eb-b824-70b75c9c4db2"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMi04LTEtMS0xNDMwNjE_689731c4-1ebb-400a-a812-c5bc164dc62f"
      unitRef="usd">11000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96b5c2e6a48345c0b538f3138c5ab5b2_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy0yLTEtMS0xNDMwNjE_6b93ef4d-c647-4e8c-83ae-d0f45f4e14a8"
      unitRef="usd">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia2a9ae3100a74f7ebf2929870b5083e9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy00LTEtMS0xNDMwNjE_4bb378ba-739f-4f0f-9875-1f504d750fde"
      unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c6a3ac703f94d4e8ba3718b45516087_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy02LTEtMS0xNDMwNjE_7bdf60bd-8739-4786-b63a-908cd898eb17"
      unitRef="usd">81000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c67b322920745f8ba3080e92c213cff_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfMy04LTEtMS0xNDMwNjE_0114b6a7-bfb1-47fa-8faa-2a0a6deb323e"
      unitRef="usd">84000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC0yLTEtMS0xNDMwNjE_b816eadd-1c6f-4115-8aef-242473d24f9a"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC00LTEtMS0xNDMwNjE_ecef509d-631e-43d1-8e7e-49c8eda5aeaf"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC02LTEtMS0xNDMwNjE_3dc67b52-90b7-48e6-bbf0-05e316cefc1d"
      unitRef="usd">91000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNC04LTEtMS0xNDMwNjE_9a3b0fd7-32dd-43d9-9f86-c6c47d0437b9"
      unitRef="usd">95000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf2bc07e5c9d48648d447ff5d3dfcfc8_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi0yLTEtMS0xNDMwNjE_45bce321-d70a-492c-9cbc-ec792f5e711e"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c782729eb2a4eaeae9a5f19119db3ef_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi00LTEtMS0xNDMwNjE_697f2285-b281-46c8-8156-47119febb4a1"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2464c5727ff448ddb5ad8146c4b17152_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi02LTEtMS0xNDMwNjE_75a69aca-6dba-4b97-ad57-eb3e6e984f1e"
      unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4675f7627ec5490496e997650085e455_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNi04LTEtMS0xNDMwNjE_a97e760b-ba01-4aa4-925b-4329128765e9"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67d2d86b33a741058fda2e20bf9a30d4_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy0yLTEtMS0xNDMwNjE_0552d146-2c63-4cdf-a935-e7058953035b"
      unitRef="usd">30000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d8cb01e461c43f0ba0ff2f3565c5ef5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy00LTEtMS0xNDMwNjE_d42dae95-10cf-4c29-9a71-9f103b3c9d1f"
      unitRef="usd">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie31113824bcf41b3885c724ca05e5ed5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy02LTEtMS0xNDMwNjE_7564e350-738d-45af-98f2-a5c29724ae14"
      unitRef="usd">82000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15c39c0bbcb54df291baffd09082d1d1_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfNy04LTEtMS0xNDMwNjE_81024a32-4e7d-49d5-b942-bbb877e4e4b5"
      unitRef="usd">88000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC0yLTEtMS0xNDMwNjE_aa3b202a-39d1-4d03-a267-eee15b415092"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC00LTEtMS0xNDMwNjE_f42206ac-8a2a-4a46-9328-b83556c9ec5c"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC02LTEtMS0xNDMwNjE_ae5280be-9827-4713-9c19-9299297332b7"
      unitRef="usd">91000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOmU5NzE0MmQ2NDVlNzQwYTk5ZjkzODk5ODg4NmFmMjExL3RhYmxlcmFuZ2U6ZTk3MTQyZDY0NWU3NDBhOTlmOTM4OTk4ODg2YWYyMTFfOC04LTEtMS0xNDMwNjE_8e6d611a-cd47-43eb-ba0d-945861787aef"
      unitRef="usd">95000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTIxMQ_6c248912-e6a3-47df-b1f7-f93e8dda3e7f">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the nine months ended September 30, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch Health Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,151,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B+L Separation performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch+ Lomb Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,455,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,205,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMy0xLTEtMS0xNDMwNjE_d5d321c6-7084-4351-bf52-19712b557e14"
      unitRef="shares">2570000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMy0zLTEtMS0xNDMwNjE_cf591f1b-1119-4168-a771-ca82bd2d8e9c"
      unitRef="shares">1497000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNC0xLTEtMS0xNDMwNjE_e0e17cd7-5b6a-4980-895b-bbb5802acc15"
      unitRef="usdPerShare">23.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNC0zLTEtMS0xNDMwNjE_71921fa5-b51c-4688-8410-1878af73e9cc"
      unitRef="usdPerShare">32.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNS0xLTEtMS0xNDMwNjE_598d8174-f750-4e97-bea7-f6da689e2c8d"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if164ed55ef26426fb2ea77441982e9ba_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNS0zLTEtMS0xNDMwNjE_cedf8731-f312-4b41-8ee2-263a64cde79c"
      unitRef="usdPerShare">11.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i60fae9ccc16447a4bb6ce23208cd688c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNy0xLTEtMS0xNDMwNjE_941d4512-cc06-4590-ad14-fee949f9a41d"
      unitRef="shares">6151000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5e8f2a27e6664bf9aca3e322fc1aa7ea_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfNy0zLTEtMS0xNDMwNjE_986060ab-148d-4267-950a-c1ee46f498f0"
      unitRef="shares">3119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i60fae9ccc16447a4bb6ce23208cd688c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfOC0xLTEtMS0xNDMwNjE_fcb65796-0442-4874-9154-e485830d0630"
      unitRef="usdPerShare">11.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5e8f2a27e6664bf9aca3e322fc1aa7ea_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfOC0zLTEtMS0xNDMwNjE_0333acb8-841c-43cd-a1da-49dfdefb09b7"
      unitRef="usdPerShare">31.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib2b865ebec004e23aa361ef3a12e65ac_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTAtMS0xLTEtMTQzMDYx_28d6c26f-0cf9-4d59-bee8-a37f7d080edb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if73278e7a6654cec90d56f5d9e86109f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTAtMy0xLTEtMTQzMDYx_1ff00dbb-4e87-4b38-878b-0d077b586f45"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib2b865ebec004e23aa361ef3a12e65ac_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTEtMS0xLTEtMTQzMDYx_637c3012-b66e-4c6a-bf98-2ab13407efb3"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if73278e7a6654cec90d56f5d9e86109f_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTEtMy0xLTEtMTQzMDYx_6b142dff-4ca4-4562-8b4d-2b2073ca5ceb"
      unitRef="usdPerShare">56.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib8ce14ad9dd241979ec43ff28ed9826c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTMtMS0xLTEtMTQzMDYx_9646f748-a7ce-4b26-9176-8d9a93da126e"
      unitRef="shares">369000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i18c983dff3c34ced9a702d90c64a861a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTMtMy0xLTEtMTQzMDYx_bf1ce5d6-1d73-4070-a546-b7717aedb9f5"
      unitRef="shares">413000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib8ce14ad9dd241979ec43ff28ed9826c_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTQtMS0xLTEtMTQzMDYx_0728d811-ca0f-4ad5-bd89-f45be4d269d8"
      unitRef="usdPerShare">9.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i18c983dff3c34ced9a702d90c64a861a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTQtMy0xLTEtMTQzMDYx_2994e750-784e-4638-9228-d0a3e4ba3a5c"
      unitRef="usdPerShare">31.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i65cd64412b1044dca3d7df190d03e1c1_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTYtMS0xLTEtMTQzMDYx_648a186c-64ad-4b15-a667-9573822cc2af"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0ff9b7bc0a6b4740af09323c44145b47_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTYtMy0xLTEtMTQzMDYx_6453b81c-7080-4d74-a382-b91f19d4fcc1"
      unitRef="shares">222000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i65cd64412b1044dca3d7df190d03e1c1_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTctMS0xLTEtMTQzMDYx_57222237-6a7c-472d-9de4-068f82dd7ff7"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0ff9b7bc0a6b4740af09323c44145b47_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMTctMy0xLTEtMTQzMDYx_241d459e-7dd1-4793-954d-d968f8bd7551"
      unitRef="usdPerShare">28.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ifa5726cb791047928df873284ca85f71_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjAtMS0xLTEtMTQzMDYx_a00f4b88-1e48-4cb3-ae3b-6bce750e0395"
      unitRef="shares">6455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjAtMy0xLTEtMTQzMDYx_74dfef3b-b923-4871-9c5f-2f509bc5c632"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ifa5726cb791047928df873284ca85f71_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjEtMS0xLTEtMTQzMDYx_49c7228c-a4d2-43b8-ab19-d291c6cede68"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjEtMy0xLTEtMTQzMDYx_6b91bbbd-0dde-44c2-ab9c-daadffae17d5"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifa5726cb791047928df873284ca85f71_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjItMS0xLTEtMTQzMDYx_94759f25-c841-45c4-b7c8-6ecf020b21f5"
      unitRef="usdPerShare">4.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5fdd215aa0fe4611b2f46a729fa41166_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjItMy0xLTEtMTQzMDYx_fd95ec5f-54a0-44de-b658-2f16c6180d1d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i788020833e76460b8e095fa176b6d7ce_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjQtMS0xLTEtMTQzMDYx_90c1edfd-225c-457f-b582-66a3e838c988"
      unitRef="shares">4205000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i781d955207d8472f97604932ca86559d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjQtMy0xLTEtMTQzMDYx_4c5ec8c7-4731-4ebe-b907-beeeb02b4ead"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i788020833e76460b8e095fa176b6d7ce_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjUtMS0xLTEtMTQzMDYx_dcbdd885-67d1-4ea7-9b98-2af1da322a59"
      unitRef="usdPerShare">17.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i781d955207d8472f97604932ca86559d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RhYmxlOjQ3YmY0ZTBkN2E5OTRiNzJiMGZhOWE1YWE1ZGIxODgyL3RhYmxlcmFuZ2U6NDdiZjRlMGQ3YTk5NGI3MmIwZmE5YTVhYTVkYjE4ODJfMjUtMy0xLTEtMTQzMDYx_494f1b41-41c3-49c9-8fc1-2bcb452ba8b7"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDg3NA_54015417-5f71-470b-8d90-df073f82eb5e"
      unitRef="usd">152000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNDkzNg_1745aa2e-6861-4388-b6d9-f1616d20d958">P1Y9M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie375bf8481ea4297bae9bbd4ab9babeb_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTEzMg_12749228-556f-42c6-928e-7563e61c6163"
      unitRef="usd">72000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i67229cf570e341819da1a0f863e8fcb8_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83Ni9mcmFnOjJjNjU2YTM4OTY0NDQyYjQ4YWRjNmQ4NTA1NjUxODRiL3RleHRyZWdpb246MmM2NTZhMzg5NjQ0NDJiNDhhZGM2ZDg1MDU2NTE4NGJfNTE5NA_2adfffd9-4387-450e-90c3-0d362f9f8ca5">P1Y7M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RleHRyZWdpb246MWE3ZDk3YjNlNjNiNDRhYWFjMDAwYjJiN2ZlODUzYWNfNzcy_94840f08-0cde-4b45-894f-b0e5a3a74744">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in the Company&#x2019;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RleHRyZWdpb246MWE3ZDk3YjNlNjNiNDRhYWFjMDAwYjJiN2ZlODUzYWNfNzYz_4a184c52-1ef6-4346-957d-bedd763ce0c1">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71c67458cddf440fae3e9d2616d2822e_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMS0yLTEtMS0xNDMwNjE_7969a93f-cb45-4da9-bcad-472ae3634037"
      unitRef="usd">-2252000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb87d76e2584480b8c68e4b07d46150a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMS00LTEtMS0xNDMwNjE_519043ca-2f67-401d-8682-520e2a79e50c"
      unitRef="usd">-1905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib82c90dfcfed4b258e3dfca87b481343_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMy0yLTEtMS0xNDMwNjE_e4cfce8d-786c-4615-8ff8-7a0726552644"
      unitRef="usd">-13000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93570e5abb6e4069bba204d6409b97aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfMy00LTEtMS0xNDMwNjE_4ff19f08-dc7a-44aa-b122-186932bdccba"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie97645899e0b4e1d91b3cd525dccb36d_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfNC0yLTEtMS0xNDMwNjE_d7e1f1ac-b29c-4bd6-8dad-493b54ab8d98"
      unitRef="usd">-2265000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie6be7f41bbca44db88e2eea447f357ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RhYmxlOjNjYjExODQyMzVlZTRiODhiMTVmMWNlNGZlNjA5ODdiL3RhYmxlcmFuZ2U6M2NiMTE4NDIzNWVlNGI4OGIxNWYxY2U0ZmU2MDk4N2JfNC00LTEtMS0xNDMwNjE_5b1a3c3f-37c3-4d01-8f1f-6e94c4f92931"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idd550841fc7c45b8af6c60f3fa0f8a34_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF83OS9mcmFnOjFhN2Q5N2IzZTYzYjQ0YWFhYzAwMGIyYjdmZTg1M2FjL3RleHRyZWdpb246MWE3ZDk3YjNlNjNiNDRhYWFjMDAwYjJiN2ZlODUzYWNfNzIz_7cc5ade2-8b44-4095-b189-b0376d7bde77"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RleHRyZWdpb246MGZkMWU4MmZjZGMyNDNmM2JmMDc0NDc5NjdkNGUzNTdfMjM4_c72cd873-3dcb-493f-a54c-1690749fc6e5">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RleHRyZWdpb246MGZkMWU4MmZjZGMyNDNmM2JmMDc0NDc5NjdkNGUzNTdfMjM3_04dddc88-5a62-4bd5-a9ce-c17cc8f4dfcc">Research and development costs consist of:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi0yLTEtMS0xNDMwNjE_f948a297-a478-40ef-8e5a-ec2735618b23"
      unitRef="usd">125000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi00LTEtMS0xNDMwNjE_ee55b204-4d90-4460-9b7a-1ff869281e12"
      unitRef="usd">114000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi02LTEtMS0xNDMwNjE_30fbb371-66b1-4eaa-92fe-40ee20e06799"
      unitRef="usd">366000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMi04LTEtMS0xNDMwNjE_6c9dfca1-91c7-46c9-ad59-1ceabff9811f"
      unitRef="usd">328000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy0yLTEtMS0xNDMwNjE_05cac056-96e2-44b3-964b-09b49be4d79f"
      unitRef="usd">8000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy00LTEtMS0xNDMwNjE_cc3dab25-67e7-4f4e-ac97-a0e2cbc2a4f5"
      unitRef="usd">7000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy02LTEtMS0xNDMwNjE_a8fea922-08fe-40c0-a15a-4aaa4400f8d6"
      unitRef="usd">21000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfMy04LTEtMS0xNDMwNjE_e78fc6a2-5b64-41d4-aaec-66bc6cb1cc74"
      unitRef="usd">20000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC0yLTEtMS0xNDMwNjE_94f0a7c6-3440-45c9-bb2a-85153763f989"
      unitRef="usd">133000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC00LTEtMS0xNDMwNjE_44c86581-00e6-4423-a9a2-6a1ee7d2e8b7"
      unitRef="usd">121000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC02LTEtMS0xNDMwNjE_2586bc46-0525-4ab4-a1b1-69d65c84c512"
      unitRef="usd">387000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84Mi9mcmFnOjBmZDFlODJmY2RjMjQzZjNiZjA3NDQ3OTY3ZDRlMzU3L3RhYmxlOmZiZWVmMGE5NWViMDRiNmY4NTgxOTg5YWUwYzViNGQ4L3RhYmxlcmFuZ2U6ZmJlZWYwYTk1ZWIwNGI2Zjg1ODE5ODlhZTBjNWI0ZDhfNC04LTEtMS0xNDMwNjE_2111beff-3197-48a3-a891-3d69701a04f3"
      unitRef="usd">348000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfMTg3_5f0aed97-3acf-48ad-ae7e-93b7e4cd45d6">OTHER EXPENSE (INCOME), NET&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense (income), net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Gain) loss on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Gain) loss on sale of assets, net for the nine months ended September 30, 2021, includes $25&#160;million related to the achievement of a milestone related to a certain product and a $26&#160;million loss upon completion of the Amoun Sale during the three months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfMTkw_c9f40383-602a-431d-a981-ed346a18e088">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense (income), net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Gain) loss on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi0yLTEtMS0xNDMwNjE_cb057985-0fb7-42b1-ba82-4f6043a0283a"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi00LTEtMS0xNDMwNjE_d4e143ea-8f23-4aa8-b290-723230a0d957"
      unitRef="usd">212000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi02LTEtMS0xNDMwNjE_b9b82b19-8c10-4b0b-8dac-18b7b50de253"
      unitRef="usd">-7000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMi04LTEtMS0xNDMwNjE_d11b2d7c-2d33-452a-9d0b-7a0e0c4ba173"
      unitRef="usd">-320000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy0yLTEtMS0xNDMwNjE_c5b381f8-813e-417e-8eae-9815de79f30b"
      unitRef="usd">4000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy00LTEtMS0xNDMwNjE_7eea5012-d13e-46fe-84c0-a29fb3c11745"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy02LTEtMS0xNDMwNjE_2fccd0b0-109b-4c65-a548-6fd1ab1acd85"
      unitRef="usd">2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfMy04LTEtMS0xNDMwNjE_24743bb8-698f-4959-88cc-430fef71e394"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC0yLTEtMS0xNDMwNjE_34bffbf7-41bc-401d-87bb-788ec27747e4"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC00LTEtMS0xNDMwNjE_83db9f38-8649-450b-9719-a0c41218045b"
      unitRef="usd">-21000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC02LTEtMS0xNDMwNjE_20546e94-c35f-42d9-b5fc-4fd935a83007"
      unitRef="usd">3000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNC04LTEtMS0xNDMwNjE_41902a11-014f-45aa-875b-b67019cabacf"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS0yLTEtMS0xNDMwNjE_95f36a22-5a88-46d1-a34b-f422e090a936"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS00LTEtMS0xNDMwNjE_6be2f193-c116-4557-9a3a-84b19e77943d"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS02LTEtMS0xNDMwNjE_9911885d-9576-405a-8999-d4ee560e0880"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNS04LTEtMS0xNDMwNjE_69616e87-6685-4e47-b9c8-ba4a2c475b25"
      unitRef="usd">3000000</us-gaap:ResearchAndDevelopmentInProcess>
    <bhc:OtherIncomeExpenseNet
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi0yLTEtMS0xNDMwNjE_00a0da3c-da85-4281-934a-8799c5a2facd"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi00LTEtMS0xNDMwNjE_b65e6c27-c543-4dd0-8378-d3939abb8088"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi02LTEtMS0xNDMwNjE_23299581-6222-4d8c-b224-5b6e80afd11f"
      unitRef="usd">-1000000</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNi04LTEtMS0xNDMwNjE_b6f49d95-abbd-4bfc-980f-a98580dd9d26"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy0yLTEtMS0xNDMwNjE_c08558dc-71fd-4e52-86c8-788fc5e5b2cf"
      unitRef="usd">-4000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy00LTEtMS0xNDMwNjE_c26b4a87-5fb7-46a4-8f5e-b3a29f601e86"
      unitRef="usd">183000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy02LTEtMS0xNDMwNjE_fc96aa62-0e27-4e47-8eb3-35c805077a65"
      unitRef="usd">-6000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RhYmxlOjM3MzIxMDI4NjhiZTRhMGE5ODExMzBlODdlNTJlMzA1L3RhYmxlcmFuZ2U6MzczMjEwMjg2OGJlNGEwYTk4MTEzMGU4N2U1MmUzMDVfNy04LTEtMS0xNDMwNjE_c3fc1efe-20e5-4165-afef-2983f7e1cb27"
      unitRef="usd">-329000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i39bbe98ba2634efa8a0ac3f26b52da3d_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfMTEx_4514c622-499c-4d5a-a425-4b547a887f8d"
      unitRef="usd">25000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i83dd54e76be14e2b8cddedd0ad775700_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84NS9mcmFnOmExMjVmNWI1YjEzNjQ1MjliMTVjODI0NjQxMDNhMjc4L3RleHRyZWdpb246YTEyNWY1YjViMTM2NDUyOWIxNWM4MjQ2NDEwM2EyNzhfNTQ5NzU1ODE0Mjk1_7ba25497-aa62-46b0-9362-6aebb1a0ff73"
      unitRef="usd">26000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNzQyNA_a8a5d4a4-098b-4e32-a9af-e9c787a5e678">INCOME TAXES&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#x2019;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#x2019;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#x2019;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes for the nine months ended September 30, 2022 was $30 million and included: (i) $42&#160;million of income tax expense for the Company&#x2019;s ordinary income for the nine months ended September 30, 2022 and (ii) $9 million of net income tax benefit for discrete items, which includes: (a) $37&#160;million of net income tax benefit recognized for changes in uncertain tax positions, (b) a $22&#160;million tax provision associated with filing certain tax returns and (c) a $5&#160;million tax provision associated with stock compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefit from income taxes for the nine months ended September 30, 2021 was $36 million and included: (i) $34 million of income tax benefit for the Company&#x2019;s ordinary loss for the nine months ended September 30, 2021 and (ii) $2&#160;million of net income tax provision for discrete items, which includes: (a) a $54&#160;million of net income tax benefit associated with certain legal settlements, (b) a $46&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (c) an $11&#160;million tax provision recognized for changes in uncertain tax provisions, (d) an $8&#160;million tax benefit related to a deduction for stock compensation and (e) a $3&#160;million tax provision associated with the filing of certain tax returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was $1,931 million and $2,222 million as of September&#160;30, 2022 and December&#160;31, 2021, respectively. The decrease was primarily due to the utilization of net operating losses against debt &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forgiveness income in Canada associated with the Exchange Offer. The Company will continue to assess the need for a valuation allowance on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8, 2021, the Organisation for Economic Co-operation and Development (&#x201c;OECD&#x201d;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#x201c;Inclusive Framework&#x201d;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#x20ac;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#x20ac;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Some further guidance on the plan and rules has been published, with additional guidance expected to be published in 2023. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which it operates. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#x2019;s liability for corporate taxes and the Company&#x2019;s consolidated effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2022, President Biden signed the Inflation Reduction Act into law, which includes implementation of a new alternative minimum tax, an excise tax on stock buybacks, and significant tax incentives for energy and climate initiatives, among other provisions. The corporate alternative minimum tax (&#x201c;CAMT&#x201d;) imposes a minimum tax on the adjusted financial statement income (&#x201c;AFSI&#x201d;) for &#x201c;applicable corporations&#x201d; with average annual AFSI over a three-year period in excess of $1 billion. A corporation that is a member of a foreign-parented multinational group, as defined, must include the AFSI (with certain modifications) of all members of the group in applying the $1 billion test, but would only be subject to CAMT if the three-year average AFSI of its U.S. members, US trades or business of foreign group members that are not subsidiaries of U.S. members, and foreign subsidiaries of U.S. members exceeds $100 million. The Company currently does not believe this will have a significant impact on its tax results, but will continue to evaluate the law and its provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As detailed in Note 10, &#x201c;FINANCING ARRANGEMENTS&#x201d;, during the three months ended September 30, 2022, the Company undertook a restructuring of its third-party debt resulting in extinguishment of debt income in the US and Canada for tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December&#160;31, 2021, the Company had $937 million and $927 million, respectively, of unrecognized tax benefits, which included $45 million and $41 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of September&#160;30, 2022, $164 million would reduce the Company&#x2019;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at September&#160;30, 2022 could decrease by approximately $13 million in the next 12 months as a result of the resolution of certain tax audits and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to be under examination by the Canada Revenue Agency. The Company&#x2019;s position as of September&#160;30, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#x201c;2017 capital loss&#x201d;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#x201c;IRS&#x201d;) is continuing its examination of the Company&#x2019;s annual tax filings for 2015 and 2016 and the Company&#x2019;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#x2019;s internal restructuring efforts during 2017. In 2021, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#x2019;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. The Company has been accepted into the IRS's fast track mediation program and mediation meetings are scheduled for early 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company settled its audit with the Australian Taxation Office for various years beginning in 2011 through 2017 with no material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNzA3_de081cd2-35b4-4ddd-aced-95b33cbe6ccd"
      unitRef="usd">30000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNzI4_a880b04e-c68e-4f03-94dd-deac69a54055"
      unitRef="usd">42000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfODA1_70a2006b-0b76-49f6-84ee-ae9f85c4b44d"
      unitRef="usd">-9000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfODc0_1e9eee3a-be4d-4196-97ea-d11264ef5e63"
      unitRef="usd">-37000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfOTYz_cb8976a4-e0b6-439e-83b6-e4d037910828"
      unitRef="usd">22000000</bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNTQ5NzU1ODI3MDc3_9764e9ae-92d6-4235-a0f0-f057bd3e18a6"
      unitRef="usd">5000000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTA1NQ_97135b66-87c4-4caa-b357-9fb6f4044fcc"
      unitRef="usd">-36000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTA3Ng_da87282e-ab56-44c2-ab5d-2c1d9268b310"
      unitRef="usd">-34000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTE4MQ_e1f9fcf5-f63e-4cb2-8f92-f5151f56d9c7"
      unitRef="usd">2000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTI1NA_f1dca7c8-3947-47a3-a6da-224acaf08024"
      unitRef="usd">-54000000</bhc:EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTMzMg_84c2f286-8f47-4393-8493-e9d579819be3"
      unitRef="usd">46000000</bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTQzNA_99b75660-7498-45e0-a099-cc2909429d9a"
      unitRef="usd">11000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNTQ5NzU1ODIxNjY0_951e76ef-13c7-4891-b5a9-6e61ccfe49d8"
      unitRef="usd">-8000000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMTUwNQ_da7e5b67-e974-43b6-b0ba-8273d87c6ccb"
      unitRef="usd">3000000</bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMjAxOA_92d40822-6bf7-4775-9e07-84617323e9ef"
      unitRef="usd">1931000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfMjAyNQ_d0f4e97f-13b9-4df5-b37b-523c5cdab8e8"
      unitRef="usd">2222000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDIyMg_94f7008a-9d51-43bc-ae75-f753fae29a3b"
      unitRef="usd">937000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDIyOQ_cdee07bd-2014-4c97-8724-63248a4b18c7"
      unitRef="usd">927000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDI3Nw_e42ab867-618a-45ff-a793-cc8f3585d586"
      unitRef="usd">45000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="if69ff7ae606c425c94a4c448e089a08c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDI4NA_01fcd8e0-f645-4657-9cb2-24e2d5d4a483"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDM3Nw_abc93fae-25a0-4c32-a4b9-e62d70f22476"
      unitRef="usd">164000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNDU4Mw_be68e96c-1979-40ad-94dd-6727a05082a8"
      unitRef="usd">13000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF84OC9mcmFnOjAyYjg2YmE4MDAyZDQ5ZjliZjI3NTYyOGQ3OTg5MDRkL3RleHRyZWdpb246MDJiODZiYTgwMDJkNDlmOWJmMjc1NjI4ZDc5ODkwNGRfNjE3Nw_5c9ab5f0-35e7-4325-9f8f-149051288437"
      unitRef="usd">2100000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTM5NA_03688a22-8fac-4dfb-b375-9760fa1ab9b2">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted effect of stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 1,906,000 and 5,221,000 common shares for the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;During the three and nine months ended September 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 16,008,000 and 15,392,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately 3,103,000 and 3,453,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2022 and 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTQwMQ_ca4f8125-2f47-4922-9fb5-86ae2ad10329">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted effect of stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi0xLTEtMS0xNDMwNjE_edf23bb6-5281-4429-a02d-09119e3a2ab0"
      unitRef="usd">399000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi0zLTEtMS0xNDMwNjE_d07d8088-ab6d-422b-b929-debab82fced9"
      unitRef="usd">188000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi01LTEtMS0xNDMwNjE_03fb66b7-4164-4592-abb2-77a1cff3f280"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMi03LTEtMS0xNDMwNjE_ea02ae06-b451-4e7c-b5ce-5bf22f5d1c23"
      unitRef="usd">-1017000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy0xLTEtMS0xNDMwNjE_1544ce08-714a-4087-976e-a6e552df2516"
      unitRef="shares">362500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy0zLTEtMS0xNDMwNjE_74ee50c5-84a6-4050-8765-bd7facb33012"
      unitRef="shares">359600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy01LTEtMS0xNDMwNjE_b29561b1-2230-4dcb-bd60-553a1b105aaa"
      unitRef="shares">361800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfMy03LTEtMS0xNDMwNjE_662a735e-800d-4f56-9524-02f290a13eec"
      unitRef="shares">358500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC0xLTEtMS0xNDMwNjE_b7dd587c-7c5b-4446-83df-5209a62e20b9"
      unitRef="shares">900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC0zLTEtMS0xNDMwNjE_5892456a-f41f-4156-bb33-086c521da95b"
      unitRef="shares">4400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC01LTEtMS0xNDMwNjE_aa367248-5722-4199-ab7f-114d3a7ab214"
      unitRef="shares">1900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNC03LTEtMS0xNDMwNjE_f123fe96-fea7-492c-9f77-6707c99982a1"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS0xLTEtMS0xNDMwNjE_987ae857-fbf8-4553-bbaf-c0ec999c99b7"
      unitRef="shares">363400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS0zLTEtMS0xNDMwNjE_83c7fe85-4ea1-409f-b9ee-10c9e9bd454f"
      unitRef="shares">364000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS01LTEtMS0xNDMwNjE_6f20019a-f994-46df-b539-18a6ace7172e"
      unitRef="shares">363700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNS03LTEtMS0xNDMwNjE_a318103d-ea1c-454d-b488-b737c37dc0bb"
      unitRef="shares">358500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0xLTEtMS0xNDcyOTI_2e7a496a-b7e8-44f6-b921-0ac06951c873"
      unitRef="usdPerShare">1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0zLTEtMS0xNDcyOTI_49fa1996-5163-4e1f-a08d-28eaf5bff4cf"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy01LTEtMS0xNDcyOTI_2cc35c29-fdbb-4e6b-8eb2-8cfb7a303d35"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy03LTEtMS0xNDcyOTI_d1a311c7-6533-43bb-b815-0dae4967d478"
      unitRef="usdPerShare">-2.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0xLTEtMS0xNDMwNjE_5b9e8b4e-21ea-4cb7-a193-bb336639113f"
      unitRef="usdPerShare">1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy0zLTEtMS0xNDMwNjE_317947e2-949c-48ec-b172-61c8df62bfd6"
      unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy01LTEtMS0xNDMwNjE_59078555-809d-4d4f-8170-2fdbf9894b40"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RhYmxlOmJlMGEwNmIzNTg4YTRkMzk4MGE0NzJkNWQwYjRiNDY1L3RhYmxlcmFuZ2U6YmUwYTA2YjM1ODhhNGQzOTgwYTQ3MmQ1ZDBiNGI0NjVfNy03LTEtMS0xNDMwNjE_198d8b0c-4bd6-47df-aba8-ee3772aed201"
      unitRef="usdPerShare">-2.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id17555885c6b4ec5b2e98860a7c4cf48_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNTA5_f57260a4-0ea3-4032-8f45-cd0c24ef9bb8"
      unitRef="shares">1906000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b3c57844e57475ab663a9bb253a2e8e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNTE2_5730e8d9-a27d-47a2-999b-18b62387e29c"
      unitRef="shares">5221000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icda04c31ebe54292bc90ace1f755d969_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNjk2_69d04318-89ce-45de-8784-98e7b8256d2a"
      unitRef="shares">16008000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3e9cb5876bfd4fbeb27c0c8d2d1847d7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfNzAz_8291b74d-55de-43ce-bd15-aa707d3522b1"
      unitRef="shares">15392000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iae4a35e3c4d845dea31eb0b4afb0fab0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTAyMQ_44ec8df7-584c-4883-84ff-d740c4106722"
      unitRef="shares">3103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8b3fef19b7a044478c661e599645a697_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTAyOA_c1ea4de2-b622-4e2e-bdc5-38178e1f8094"
      unitRef="shares">3453000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="i177e13e488324255b69c74c8f05e9364_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_27eefd50-5114-4bbb-be5b-0224d6fcd5e8"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="ia499047b1cbd4a05a81ffaa7a7ac8912_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_b998454b-9498-4761-a0b8-b07a207d7e0a"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="ib221baeee1504b62a9a00fd4bafa821d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_bc54a751-cb44-4b0d-865c-7f41b5723eef"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="i2ed370dc33214c95b38faa3097c8e671_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85MS9mcmFnOjZhZmU2OWQ1ZDBkNTQ4YTVhN2RkODBhMTI4ZjJiZDU0L3RleHRyZWdpb246NmFmZTY5ZDVkMGQ1NDhhNWE3ZGQ4MGExMjhmMmJkNTRfMTIzOA_cbdb3a2f-76a8-4df3-9f14-a4d2718fac67"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNjE2MDA_d7211030-88de-45fa-9c7f-ea56e017370d">LEGAL PROCEEDINGSFrom time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the nine months ended September 30, 2022.&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of September 30, 2022, the Company&#x2019;s Consolidated Balance Sheets includes accrued current loss contingencies of $323 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Governmental and Regulatory Inquiries&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney&#x2019;s Office for the District of Massachusetts - re OraPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a subpoena from the U.S. Attorney&#x2019;s Office for the District of Massachusetts (Department of Justice), requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including related support services, and other matters. In October 2022, the Company and the Department of Justice reached an agreement in principle to resolve the investigation as to the Company for an immaterial settlement payment plus payment of applicable interest and other related costs. Any final resolution would be subject to certain material contingencies, including, without limitation, the parties negotiating mutually satisfactory civil settlement documents and final approvals by the Department of Justice and the Company. While the Company has reached an agreement in principle with the Department of Justice, there can be no assurance that a settlement will be agreed to and finalized, nor the timing of any such potential resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - Opt-Out Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#x201c;Securities Class Action Settlement&#x201d;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#x201c;Timber Hill&#x201d;) filed a notice of appeal of the Court&#x2019;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#x2019;s final approval order, which overruled her objections as to the attorneys&#x2019; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#x2019;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#x2019;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor Rx Services, LLC (&#x201c;Philidor&#x201d;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the settlement agreement. The Company's rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#x201c;Aly&#x201d;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#x2019; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#x2019; Retirement System (&#x201c;CalSTRS&#x201d;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2021, the Quebec Superior Court granted the Company&#x2019;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Securities and RICO Class Actions and Related Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#x2019;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#x201c;Allergan Securities Litigation&#x201d;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#x201c;Complete or Inactive Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#x201c;Governmental and Regulatory Inquiries&#x201d; and &#x201c;Complete or Inactive Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#x2019;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#x2019;s motion to dismiss as to the insurer plaintiff&#x2019;s direct claims but dismissed the insurer plaintiff&#x2019;s indirect claims. On February 2, 2021, the insurer plaintiff&#x2019;s motion for leave to amend its complaint was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions were consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;) (discussed in further detail below, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;see Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#x2019; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#x2019; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#x2019; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this paragraph, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#x201c;Company&#x201d;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These lawsuits cover products of both Bausch + Lomb and the Company&#x2019;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff from the federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (discussed in further detail above), Humana Inc. (&#x201c;Humana&#x201d;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#x2019;s direct opt-out claims from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, discussed above, were deemed asserted in the State Court Action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#x2019; answers were filed on February 3, 2022. Trial is scheduled to begin on August 25, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#x2019; answers were filed on June 17, 2022. On October 4, 2022, Defendants filed a motion to consolidate this action with the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims and intends to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 550mg, Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Relistor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Injection, Arazlo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Nuvessa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Colazal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Canada, or other similar suits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A. (&#x201c;Alfasigma&#x201d;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 26 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued the Norwich Legal Decision on August 10, 2022, finding that the U.S. Patents protecting the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#x201c;HE&#x201d;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating IBS-D invalid. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal Circuit on August 16, 2022. The Company remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#x201c;Padagis&#x201d;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#x2019; ANDA for generic Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion. A three-day trial commenced on October 4, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#x201c;Taro&#x201d;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#x2019;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and triggering a 30-month stay of the approval of the Taro ANDA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#x2019; ANDA for generic Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion. A three-day trial commenced on October 4, 2022. The Company remains confident in the strength of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#x201c;MSN&#x201d;) and Mylan Pharmaceuticals Inc., (&#x201c;Mylan&#x201d;) alleging patent infringement by MSN&#x2019;s and Mylan&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; AREDS Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#x201c;AMD&#x201d;). The PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp;amp; Lomb Incorporated (&#x201c;B&amp;amp;L Inc.&#x201d;) has filed patent infringement proceedings against 19 named defendants in 16 proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation against Certain Ocuvite and PreserVision &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2021, ZeaVision, LLC (&#x201c;ZeaVision&#x201d;) filed a complaint for patent infringement against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#x2019;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2021, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#x201c;Slayback&#x201d;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#x2019;s generic drops, for which an ANDA has been filed by Slayback. B&amp;amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#x201c;Eye Therapies&#x201d;). On September 10, 2021, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2022, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#x201c;Lupin&#x201d;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#x2019;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;B&amp;amp;L Inc. remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and B&amp;amp;L Inc. intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inter Partes Review Proceedings at the U.S. Patent and Trademark Office&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company&#x2019;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#x201c;IPR&#x201d;) at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#x2019;s branded pharmaceutical products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board (&#x201c;PTAB&#x201d;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (U.S. Patent No. 7,214,506 (the &#x201c;&#x2018;506 Patent&#x201d;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#x2018;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in U.S. regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been settled. In Canada, two lawsuits remain pending against Apotex Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. On October 12, 2022, MSN filed a petition for IPR of U.S. Patent No. 7,041,786. The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, twenty-six (26) of such product liability suits currently remain pending. In three cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Twenty-five (25) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and at this time no appeal of that judgment has been filed. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2021, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp;amp; Johnson Consumer, Inc. (&#x201c;JJCI&#x201d;). LTL Management, LLC (&#x201c;LTL&#x201d;), the resulting entity of the divisional merger, assumed JJCI&#x2019;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#x201c;Bankruptcy Court&#x201d;), and substantially all cases related to Johnson &amp;amp; Johnson&#x2019;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#x2019;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp;amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#x2019;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp;amp; Johnson&#x2019;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022, and a decision is pending. Further, pursuant to a court order dated March 18, 2022, the Bankruptcy Court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also ordered separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. The Bankruptcy Court extended LTL&#x2019;s exclusive period to file a chapter 11 plan until November 17, 2022, and the talc claimants filed a motion to terminate LTL&#x2019;s exclusivity. The parties have since consensually agreed to extend LTL&#x2019;s exclusive period to December 13, 2022. On July 26, 2022, the Bankruptcy Court held a hearing to consider alternative paths to case resolution, and on July 28, 2022, authorized an abbreviated estimation process designed to determine the extent of LTL&#x2019;s aggregate liability. Additionally, the Bankruptcy Court appointed an independent expert who will issue a report forecasting and estimating the volume and value of claims. The Bankruptcy Court has scheduled November 16, 2022 for a status update on the expert report and to discuss scheduling further formal mediation sessions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 28, 2022, the Bankruptcy Court also ruled that it would leave in place the stay and injunction enjoining talc product liability cases from proceeding until at least the completion of the estimation process. To the extent that any cases proceed &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the pendency of the bankruptcy case, it is the Company&#x2019;s expectation that Johnson &amp;amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;it&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#x2019;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#x2019;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#x2019; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#x2019;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. As a result, the New Jersey Superior Court action is closed and the case is now pending in the District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion is fully briefed and pending. Other proceedings are in abeyance pending resolution of Plaintiffs&#x2019; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#x2019; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#x2019; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp;amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the current stay. Johnson &amp;amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and accordingly, asked the Ninth Circuit if Johnson &amp;amp; Johnson could have until December 19, 2022, to provide the next status report while the stay remains in place in this action. They also indicated they will inform the court if the status of the bankruptcy stay changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp;amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on May 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the State of New Mexico from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction and noting it would be revisited during the December 2022 omnibus hearing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended September 30, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#x201c;General Civil Actions&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#x2019;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="ib630580e79374684b3bc209e9e4a1fc3_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTM2Ng_bda77d35-24ae-4f7a-9aab-da36fce6ebef"
      unitRef="usd">323000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ieb3cf936e9a74f7ebf11fb503c9b7c72_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQzNg_f1cc61af-23d2-4b96-80de-aa74d24a17c2"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ieb3cf936e9a74f7ebf11fb503c9b7c72_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNTAwNw_d2822bd8-d70c-4908-a5f2-12fe023003fa"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i5e3f5299561c4eebbd5248dec3a4060e_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNTMwNw_b2e1bc3f-8e0f-42d6-aaaf-efc91771adfa"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNzgyNA_e7424e47-94cf-4fa7-aeb5-fe09ac27d315"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfODI3Nw_1ae34cba-2765-48ea-9d7e-eeb02ee5d9a1"
      unitRef="case">16</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfODI4Nw_e7424e47-94cf-4fa7-aeb5-fe09ac27d315"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfODQxOA_26921de2-634a-4ce6-9258-5cf7b653ed3b"
      unitRef="group">21</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="idcb2e316fec14bdc856e971726c9f87e_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTExMzM_eeb60f76-c5bc-41eb-8161-41de715660a2"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="i99ebe24a04454b4091861650ed6bacb1_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTEzNTE_d41c4f91-0973-4638-970e-86ce2aeea902"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i4fd9f0cc91de49dcb8c8cb33d395da0d_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTI5MTQ_825fa4ff-9be8-4810-9cef-42666843972c"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i29e2849b192f4aaba1d8952c944b6789_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTQzMzg_915588e2-13ce-4a89-ad57-bd841a0fdd28"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="iaab8fb8a87cb4b22aebbfd8cc4b85230_I20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTYzMjQ_3817af16-8e7d-4a82-8e46-d20fa3a84dd5"
      unitRef="entity">4</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iafd7324df4a84a149605aa327631d7ab_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTc2MzA_87d33821-4634-43d1-94cb-68c4703f771f"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="ia481a4b7a6514b33bd76b28c5e86f915_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMTk2MjI_d30e6dd8-3ec5-46c1-af9d-0080e69803b4"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i048227f1aea14eb384517a325981bff1_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjE1OTI_7d46a21f-cf57-42f5-8def-952b684bd762"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i048227f1aea14eb384517a325981bff1_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjE3MDg_4ae0f607-2bb4-42de-abf0-c016fa3d028d"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i871383296da145e486609cb4113359a6_D20210720-20210720"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjE5NDU_d39065c7-7688-4de2-aacd-15d2b540e78b"
      unitRef="usd">213000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i0c6de1e6ea024ddbaff325eb35a50f24_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjI2Njk_08926a0d-f77d-412e-b58f-06a22624ce02"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i49d2de7c0d8f4004960c2d05a237a525_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjI3MTM_ca4f72aa-e301-46a2-96de-dd90ee8872c2"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i8a53e2265c4140e89771283e17cbb465_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjI5OTI_07091453-e78c-48ab-84f3-80c334c959ab"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i2c3c58e3d67e4e9cad64210e49062a44_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjM0MDE_97181fdf-c9ac-4aef-a3e1-58da639bbb4d"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i1d5f207d7cdc4819ab32038b7d6fb0c6_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjUxNTA_fcfa3461-ff01-4ae1-8efc-28224aaf6ecf"
      unitRef="usd">300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i6dbd8d94f94a4b9b9032e8124939d763_D20200326-20200326"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzMxNzg_b5c118b6-36a9-47b7-9aeb-f1706215bee5">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i99c90fbc7cb942fcad2237f660bb4d3b_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzQ4MDg_14823161-5c84-48c2-bdbb-83b625909af0">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="ie6951d2873de43869ddbd5c757e327b2_D20220721-20220721"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzU3NzA_f4e4c526-e162-491b-98c1-efed26a3617f">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i74ea1630078d4e05a6bca37ee09dc60f_D20200501-20200501"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzY2MjI_ba2a9397-a59e-49dd-98ec-2209ccab7497">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="ie22ec902753448c8a53dab3d0449fdc3_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzc4NjA_f82d7958-818b-4c89-8380-b8b9114233fd">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i53724202d602400c9250252097901776_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjc0ODc3OTE1NjQ5NQ_9de20cf2-3856-4a25-89ab-2a0088dd9072"
      unitRef="defendant">19</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfProceedings
      contextRef="i53724202d602400c9250252097901776_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjc0ODc3OTE1NjQ5OQ_5911ec75-7c65-494b-a85d-38a28bc698cb"
      unitRef="proceeding">16</bhc:GainContingencyNumberOfProceedings>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i845628c47166456bb97e0565f2c1bdc9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzg2ODE_c4c9e1ba-e392-4d43-9c98-e4a646c5ef00"
      unitRef="defendant">12</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="if47547b12409405d8d9c9257fea4a4ff_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzg3MzI_021c6b61-8197-4ba6-96a0-bd073313f744"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="ibc621b0fe4dd43248d552d9e078f0955_D20221103-20221103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMzg5OTM_7547e4be-9bed-482f-b768-58493b5fb618"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i33c91c7c2a624d73a2b21e6f04607fd7_D20210910-20210910"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDEzMDA_367c3b74-8dfc-4030-a68e-04dbd6b639d5">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i3ea0bb7c52aa4fc2b812e3b4ce2644ba_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDIwODQ_5500b176-49f9-470a-8f34-ff9db0270c27">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="ie5916243ff944d46aa17d2219e926c0e_D20180801-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQwMDY_ead12dd2-af8d-46a0-9477-dbf879121a62"
      unitRef="defendant">4</bhc:GainContingencyNumberOfDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i332ac3fd809849fd83751e1cc812e29a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQwOTY_0163ee5a-d1a3-407e-8939-bd50dfd472ec"
      unitRef="lawsuit">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4136072a63394788a51d3aa4149f4df9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDQ4NTk_5b74786e-18ed-48ac-b158-3be066d97b6c"
      unitRef="case">26</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5d82fa052dd1452883203a200bf1217f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfMjc0ODc3OTE1NDE0Nw_3013dddc-0344-4a76-96c6-0de7ef998cfe"
      unitRef="case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie3e10e59808e4d0092702cbb02aea06a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDU0MDE_863e6c8b-13b4-44f7-820f-a8235af90fea"
      unitRef="case">25</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="idb508c450eed40579b6ee442cc2907b7_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDYyNDg_965aaf49-a295-49f6-85e2-d7809d1f1320"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i184af1e8e9cc401f9c92a4612adf20cc_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDYzNjA_95a12951-72d8-4411-9cc0-cf32a28cc3db"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4f33cd61e80f44d8b6fec68312c48113_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDY0MDg_0bddd973-29fe-488f-b451-d5446e59a1bf"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i92e33ca886304a7f8736aba94ba18b95_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDgwOTM_67347915-ca8c-4eb9-88af-e1dcf605c3cf">P60D</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriod
      contextRef="iafc41fcffae24dafb443704717376dce_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNDg4NzI_d55edf51-b813-4263-beb6-c69fc32a5f0c">P60D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ic05dba365c7149048c6b1a7245d1b247_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNTk5NDU_f934cb8f-2869-47b2-b9e6-b8934106e123"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i88b4c08132f844779089399f6327cc37_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85NC9mcmFnOjA4MzM1N2VjMTA1NjQwNTRiNzFiNDUyZGM5YjNkZTM2L3RleHRyZWdpb246MDgzMzU3ZWMxMDU2NDA1NGI3MWI0NTJkYzliM2RlMzZfNjA4NzQ_37a04844-af68-4e47-ad7d-3526c079c1fd"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY3Mg_b9c8025f-9364-407a-b144-2eb382644264">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s previously announced plan to separate its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company had begun managing its operations in a manner which was consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#x2019;s CEO, who is the Company&#x2019;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#x2019;s historical segment structure. This realignment is consistent with how the Company&#x2019;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Solta Medical, (iv) Diversified Products and (v) Bausch + Lomb. The new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2022, the Company announced it was suspending plans for the Solta IPO; however, the Company is continuing to manage and operate the business in its current reportable segment structure. See Note 2, &#x201c;SIGNIFICANT ACCOUNTING POLICIES&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales in the U.S. of GI products. Sales of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product line represented approximately 80% of the Salix segment&#x2019;s revenues for each of the three and nine month periods ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The International segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Solta Medical segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Solta aesthetic medical devices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Diversified Products segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Bausch + Lomb segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Segment and Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The top ten products for the nine months ended September 30, 2022 and 2021 represented 48% and 45% of total revenues for the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made and are reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i11db7ac9a59a4c8d8b94f2a57e2697fe_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfMTMwMg_8480efee-e389-422e-bd1a-b3f6a144a5c1"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibefdea46ac904b858f0d89701cc31d09_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfMjEyNw_55bddcd0-22e3-43d0-8247-5ae7e288b8bd"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i203a22f1210340a79695abcf5e8cbc84_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfMjEyNw_fd5b7fd8-c824-4511-bf98-6fadce5b2205"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY1MQ_c225e2de-d0ea-4af6-994f-0712fc77fa9d">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,045)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50b3dcad39c345c5ac603e17ed95fc3a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy0xLTEtMS0xNDMwNjE_430532be-6734-4098-8a41-b93368f233f2"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a48564554644fbf91499853e1132e1d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy0zLTEtMS0xNDMwNjE_6b5eb4ca-b9f3-4895-af3e-c4965a0fecbc"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bb4504aa6bf41d1a6be48aa2c1f175d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy01LTEtMS0xNDMwNjE_a4155c4f-ffcd-4fb2-bb2e-08ed9d66a178"
      unitRef="usd">1509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d031dd6d0d24cffa3eb903bb856d240_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMy03LTEtMS0xNDMwNjE_f4eebb77-8380-4677-85b6-32de5e061c00"
      unitRef="usd">1515000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5656b3707db4122895e60ea240cf646_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC0xLTEtMS0xNDMwNjE_85ade8db-757f-41dd-9f04-54d8e286fdf8"
      unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib141aa7ca51144b7b474e3fc89019f7d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC0zLTEtMS0xNDMwNjE_ba2a83c1-47b6-4679-9a8d-72bf3a433db3"
      unitRef="usd">271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f6422ec5e814d71921b4040a843846b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC01LTEtMS0xNDMwNjE_ecbdd68f-c7be-4ce5-a7be-29fffca2f2b2"
      unitRef="usd">727000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d22d39c1ee04a7787dc2f60be8d5f7a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNC03LTEtMS0xNDMwNjE_f675e869-6ede-4625-b093-89af779855a6"
      unitRef="usd">890000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86d17424aa5a4db5a07016d40a84d937_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0xLTEtMS0xNjc5NDY_e8a42e82-44d5-4b14-8cfd-1f351a2da4ea"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1f9b74c57634e8c912801d8ecd437ff_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0zLTEtMS0xNjc5NDY_6c3974ca-a86c-456f-8669-bf7159a892b3"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6378396c4e9a47e1bf78d4f23861e774_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS01LTEtMS0xNjc5NDY_cd2f56fe-15dc-44e6-aff1-321c02584464"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i870c4afe29af49f3a2a7f8542ee2ccfb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS03LTEtMS0xNjc5NDY_e4d60e50-96aa-48e4-8082-d1303c66aa88"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7789d8fa68d94ab1832565529cc7b6dd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0xLTEtMS0xNDMwNjE_c59a736b-a6f6-4e33-8c27-be337f5130d0"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i961d5c068e19458eba50a317f05a809d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS0zLTEtMS0xNDMwNjE_a28d05a0-66fc-4036-b2df-fb3bb6ce3f4c"
      unitRef="usd">290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d87fac315ac4359b4ba48ecf9d3800a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS01LTEtMS0xNDMwNjE_3aa8ad50-2c98-4e5b-a005-2f455ccebe70"
      unitRef="usd">722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dc4fa0ce3094043b06c419d4f2739db_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNS03LTEtMS0xNDMwNjE_9ef2189c-4550-4e0d-9b57-8fdfddb048cc"
      unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12f4d42dc1e84b6ebb78a7f56a821a8e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy0xLTEtMS0xNDMwNjE_2ec516fc-7f62-4c04-a671-9b1fda13fb71"
      unitRef="usd">942000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6abdfe5c4694514950ade150231952d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy0zLTEtMS0xNDMwNjE_73fc35ce-73b1-43bf-842e-aac18f6d3402"
      unitRef="usd">949000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb2f85a36c4542b38c592e0acf6f1180_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy01LTEtMS0xNDMwNjE_1032cae8-a89d-4f87-bc80-6dc63a1a3359"
      unitRef="usd">2772000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idee32157246540168ca54485ea8c5d71_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfNy03LTEtMS0xNDMwNjE_898209ce-9a3b-4484-ad59-5b8ada01527b"
      unitRef="usd">2764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2502f43413f4cd480e2a0246b792a52_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC0xLTEtMS0xNDMwNjE_47a05a51-940d-4c8c-99ca-fe7eb56f09ab"
      unitRef="usd">2046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id84aaf53830b474e8b82377c387fa23c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC0zLTEtMS0xNDMwNjE_e94b35ba-c6a6-4417-bf29-68d4648e2cc0"
      unitRef="usd">2111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib58454b50b234f0cae6d889781bf1c3f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC01LTEtMS0xNDMwNjE_45b38a6a-2afb-409c-8a63-d36f9c2bc927"
      unitRef="usd">5931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f1bff2464e6492f978876c9c6825fc3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfOC03LTEtMS0xNDMwNjE_912c4b1f-2d41-4a75-8470-99d7eeda37dd"
      unitRef="usd">6238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50b3dcad39c345c5ac603e17ed95fc3a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtMS0xLTEtMTQzMDYx_74ea4f5b-a15f-4f5f-adfa-c2c7b32a61a2"
      unitRef="usd">391000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6a48564554644fbf91499853e1132e1d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtMy0xLTEtMTQzMDYx_0b3e89a2-ed8c-4229-9741-712e9e87d456"
      unitRef="usd">377000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8bb4504aa6bf41d1a6be48aa2c1f175d_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtNS0xLTEtMTQzMDYx_fa3b40fa-0baf-4bf4-a87f-09a81f0b6be5"
      unitRef="usd">1067000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2d031dd6d0d24cffa3eb903bb856d240_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTAtNy0xLTEtMTQzMDYx_6817d61b-34c7-49b4-b200-ea86139b4ee9"
      unitRef="usd">1074000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if5656b3707db4122895e60ea240cf646_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtMS0xLTEtMTQzMDYx_500a39f5-6d69-4f58-b2ed-56eccef8911d"
      unitRef="usd">85000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib141aa7ca51144b7b474e3fc89019f7d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtMy0xLTEtMTQzMDYx_f3889194-bfb9-449d-8a57-b236bdedfdd5"
      unitRef="usd">92000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7f6422ec5e814d71921b4040a843846b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtNS0xLTEtMTQzMDYx_eb79cef0-bd0d-4df8-a4c4-dfb3db7f130b"
      unitRef="usd">242000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5d22d39c1ee04a7787dc2f60be8d5f7a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTEtNy0xLTEtMTQzMDYx_7a58d165-26ad-4d11-bc04-d367f39b5ee4"
      unitRef="usd">304000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i86d17424aa5a4db5a07016d40a84d937_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMS0xLTEtMTY3OTYx_1fca8bc6-a57f-418b-a457-fe907d929b3c"
      unitRef="usd">33000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia1f9b74c57634e8c912801d8ecd437ff_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMy0xLTEtMTY3OTYx_d4865963-b221-4a3f-b6fe-19b10a39ad21"
      unitRef="usd">40000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6378396c4e9a47e1bf78d4f23861e774_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNS0xLTEtMTY3OTYx_32f9b508-ff21-49c8-8b35-49247834b473"
      unitRef="usd">88000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i870c4afe29af49f3a2a7f8542ee2ccfb_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNy0xLTEtMTY3OTYx_558766e5-b65c-4308-9e27-1774e00120c5"
      unitRef="usd">120000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7789d8fa68d94ab1832565529cc7b6dd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMS0xLTEtMTQzMDYx_48824f87-fccb-473b-a66c-83443c088d39"
      unitRef="usd">151000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i961d5c068e19458eba50a317f05a809d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItMy0xLTEtMTQzMDYx_14556271-b5ad-41e6-acda-b889213037b6"
      unitRef="usd">185000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0d87fac315ac4359b4ba48ecf9d3800a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNS0xLTEtMTQzMDYx_8b3cadcc-31f9-49b3-a3b4-25bed206d19f"
      unitRef="usd">450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3dc4fa0ce3094043b06c419d4f2739db_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTItNy0xLTEtMTQzMDYx_457eab78-8258-42e7-b4e1-d9ba515cd14c"
      unitRef="usd">547000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12f4d42dc1e84b6ebb78a7f56a821a8e_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtMS0xLTEtMTQzMDYx_18112fb7-3d07-41c8-ab5f-9590ba920dfd"
      unitRef="usd">226000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia6abdfe5c4694514950ade150231952d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtMy0xLTEtMTQzMDYx_c14a8908-330b-4fc9-8902-9747eee1346e"
      unitRef="usd">247000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb2f85a36c4542b38c592e0acf6f1180_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtNS0xLTEtMTQzMDYx_90dd772f-4f97-4f0a-9096-09d2419e4db1"
      unitRef="usd">640000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idee32157246540168ca54485ea8c5d71_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTQtNy0xLTEtMTQzMDYx_532357e0-82ac-4b49-a6cf-e1e9a56734a5"
      unitRef="usd">699000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic2502f43413f4cd480e2a0246b792a52_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtMS0xLTEtMTQzMDYx_5fa7cfb4-8a7d-415f-8422-3a8b681dae2b"
      unitRef="usd">886000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id84aaf53830b474e8b82377c387fa23c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtMy0xLTEtMTQzMDYx_4bd90882-ee64-4969-b8dc-1f772b3f2755"
      unitRef="usd">941000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib58454b50b234f0cae6d889781bf1c3f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtNS0xLTEtMTQzMDYx_55c52ba9-8151-4950-8d41-7bb6a355b09d"
      unitRef="usd">2487000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6f1bff2464e6492f978876c9c6825fc3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTUtNy0xLTEtMTQzMDYx_c86e4ecf-668f-4288-bf28-abb2e9fed543"
      unitRef="usd">2744000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i26d876376e54400484f8385cdeda205d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtMS0xLTEtMTQzMDYx_b019b7d2-c9c9-409f-8ef7-01d170a054d5"
      unitRef="usd">-218000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibd45d6d098e940cea4a1d9a05d7a84d1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtMy0xLTEtMTQzMDYx_cd8dace4-2904-4756-9e22-2da0f2989e96"
      unitRef="usd">-186000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4a9da148f254cccbc56ead023ff8e94_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtNS0xLTEtMTQzMDYx_256b399b-60b7-401a-bf7e-8a6d0b20ac4c"
      unitRef="usd">-614000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id018a592918a4c7d92d36586e30b8b25_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTYtNy0xLTEtMTQzMDYx_68a55808-1947-4e4c-a80a-c064e8e2101d"
      unitRef="usd">-566000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctMS0xLTEtMTQzMDYx_3dd47d6d-1868-48a4-9f2b-8aafd8d7c761"
      unitRef="usd">290000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctMy0xLTEtMTQzMDYx_71df02dc-bd64-4932-90c4-6aefb84597f3"
      unitRef="usd">338000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctNS0xLTEtMTQzMDYx_ba1c286e-4283-433f-9c5a-e37756ce7532"
      unitRef="usd">902000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTctNy0xLTEtMTQzMDYx_6c1ef00f-c8fe-46a5-9c36-5bc9f48b355e"
      unitRef="usd">1055000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtMS0xLTEtMTQzMDYx_5e328c17-7afc-4f1a-8b89-820e11357532"
      unitRef="usd">119000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtMy0xLTEtMTQzMDYx_a376b834-af7b-4df3-a9db-36800cb11741"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtNS0xLTEtMTQzMDYx_8a398dec-fe1a-4e3a-a6a5-e4285f64cf46"
      unitRef="usd">202000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTgtNy0xLTEtMTQzMDYx_061bce0a-1e74-4a1e-8afd-8dea4889497e"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktMS0xLTEtMTQzMDYx_78228e0a-181f-45e0-b0a2-516b4086dce0"
      unitRef="usd">1000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktMy0xLTEtMTQzMDYx_a3f2ec8d-341c-435f-8b11-49fdce462ac7"
      unitRef="usd">18000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktNS0xLTEtMTQzMDYx_2d54f675-0631-4e95-98f1-7e7ff4235e94"
      unitRef="usd">15000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMTktNy0xLTEtMTQzMDYx_c7e1cbca-0e03-4703-9c5e-edb56a3cdd1b"
      unitRef="usd">213000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtMS0xLTEtMTQzMDYx_05ea8fb3-d884-49c0-8290-e9a1e27bf33d"
      unitRef="usd">10000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtMy0xLTEtMTQzMDYx_c63db402-b48f-4082-9f46-085c88e9d38e"
      unitRef="usd">8000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtNS0xLTEtMTQzMDYx_aab0bf52-e4be-45a8-aa4b-d99d2d8157a8"
      unitRef="usd">58000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjAtNy0xLTEtMTQzMDYx_50d218d4-0b1e-4d37-a154-6f2c724e8b6a"
      unitRef="usd">29000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtMS0xLTEtMTQzMDYx_8f37e401-e506-42de-ad02-21642f239f76"
      unitRef="usd">-4000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtMy0xLTEtMTQzMDYx_8c394ef7-d256-43c2-b5ea-b9050f3af075"
      unitRef="usd">183000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtNS0xLTEtMTQzMDYx_1cd821c8-8802-482a-9234-40d9c5b4fe97"
      unitRef="usd">-6000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjEtNy0xLTEtMTQzMDYx_c44bbe15-f19f-40d4-95e8-0f7c8fa37494"
      unitRef="usd">-329000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItMS0xLTEtMTQzMDYx_99045aa2-6bf5-4bb5-8627-2c6bddae4d45"
      unitRef="usd">244000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItMy0xLTEtMTQzMDYx_b7cebfbb-e079-4954-87eb-9fc9a633d58a"
      unitRef="usd">574000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItNS0xLTEtMTQzMDYx_ccb8596b-8314-40fa-ba8e-07201c6707f5"
      unitRef="usd">690000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjItNy0xLTEtMTQzMDYx_8eeb0f76-0b70-469d-b07c-f315459e15e0"
      unitRef="usd">83000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtMS0xLTEtMTQzMDYx_146c1892-b53a-47bc-be29-db2b7935e1e9"
      unitRef="usd">3000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtMy0xLTEtMTQzMDYx_21f9a4b5-b970-44a8-8ca5-f22c18178516"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtNS0xLTEtMTQzMDYx_78bfcc1a-a74c-49c8-bee4-27b8bdcfeff7"
      unitRef="usd">8000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjMtNy0xLTEtMTQzMDYx_7d7a1cdc-20bc-4308-a6f4-b4a12ceca7b4"
      unitRef="usd">6000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtMS0xLTEtMTQzMDYx_0ec7c617-9a38-44e7-9b67-179efdd432df"
      unitRef="usd">385000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtMy0xLTEtMTQzMDYx_f2a67a54-77fe-4961-a80e-3cdd0e95ce5c"
      unitRef="usd">351000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtNS0xLTEtMTQzMDYx_b9b9b62e-8b73-47f5-968e-8e5c45dc93f1"
      unitRef="usd">1157000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjQtNy0xLTEtMTQzMDYx_ac4cf34c-8667-4575-b25d-c15213cfdf5c"
      unitRef="usd">1083000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtMS0xLTEtMTQzMDYx_fa3c062b-a0da-4fe1-8a0a-412e637facc6"
      unitRef="usd">570000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtMy0xLTEtMTQzMDYx_a8ff5c07-e33a-4436-bd67-bf6853249596"
      unitRef="usd">-12000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtNS0xLTEtMTQzMDYx_27527a54-9e8e-45ca-9743-80f595f829da"
      unitRef="usd">683000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjUtNy0xLTEtMTQzMDYx_163a52c3-41e1-4778-9b74-81df0f1a0b87"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtMS0xLTEtMTQzMDYx_0c225ad0-0fdc-4394-b747-5ad10f58d78f"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtMy0xLTEtMTQzMDYx_9a5cd991-470b-448d-9a89-13bf061b1eae"
      unitRef="usd">3000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtNS0xLTEtMTQzMDYx_ca73fc32-2913-45b4-891c-3a90cbf0cd1e"
      unitRef="usd">4000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjYtNy0xLTEtMTQzMDYx_33c21daa-e591-4129-a739-a7b1e397efd2"
      unitRef="usd">11000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctMS0xLTEtMTQzMDYx_365f7c72-d87f-4eb6-b0c7-245b36fdde5b"
      unitRef="usd">439000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctMy0xLTEtMTQzMDYx_2344df24-99ae-42fd-8f5b-078bba3271d6"
      unitRef="usd">216000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctNS0xLTEtMTQzMDYx_8a945bc7-da1f-4f7d-aed7-c5f190f91708"
      unitRef="usd">228000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjk2YTJjMzkxMTU1YjQ5Nzk5NWU3M2VhOWQwYjAxMGVjL3RhYmxlcmFuZ2U6OTZhMmMzOTExNTViNDk3OTk1ZTczZWE5ZDBiMDEwZWNfMjctNy0xLTEtMTQzMDYx_b33d3fd4-3f7f-4728-b84a-3169c8cc4e8e"
      unitRef="usd">-1045000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY1Mg_8b4d8f2d-4faa-4ef1-a0cd-b60bfb1825ee">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e0df6736f2847b197e7b8bed8c689ca_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi0xLTEtMS0xNDMwNjE_f6ae3e3f-6d1b-468a-af23-61952ff7f228"
      unitRef="usd">543000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e24b87e5d8f49d18b41d6f564417334_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi0zLTEtMS0xNDMwNjE_061e963f-f3cb-4e1a-92e1-74732127b46e"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21fbd1b5e5b446a289edffe298fe2beb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi01LTEtMS0xNjc5ODM_2d4824b8-33f4-4604-a698-ee48cd5aa03b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9903b8834174c129ab4fc958937b81c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi03LTEtMS0xNDMwNjE_75f36d33-6a74-42ff-8eb6-1dd6116213b6"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1abefd1a9ec41a0a822f596885e4972_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi05LTEtMS0xNDMwNjE_4d628386-34d5-49fa-a1aa-75af8b40fe33"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eede7fabe3a4f2ba57b19bd82733d3d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMi0xMS0xLTEtMTQzMDYx_4e8e59e2-ae7e-4617-ab88-4cac9b0c9130"
      unitRef="usd">942000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i567d22541928427db55a03ad179a4ad1_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy0xLTEtMS0xNDMwNjE_b89da1ef-1c90-40dd-8137-c4d439eaba58"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3aae3e10a71b4f6a98a38090820fa000_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy0zLTEtMS0xNDMwNjE_5e3a195b-3802-4709-84dd-cb9ab9d95782"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie53e184c5e4e4ea79e2591ec3164d59f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy01LTEtMS0xNjc5ODM_554eff9f-efb2-444c-bf57-35e47ae0855a"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50af148aa25b49fbbfe10ca60b5ceceb_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy03LTEtMS0xNDMwNjE_b4571ca2-90e0-41fe-81d5-c1b728cd40a5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i947a6e91ffdc4fbe89b4ecb87866d600_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy05LTEtMS0xNDMwNjE_cf7f0a88-02f9-4db9-8680-879a9d437f24"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6813706915f4ea589187e4729d7e82d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMy0xMS0xLTEtMTQzMDYx_06729d9a-f52d-4f3c-9697-1cef6df2fa7e"
      unitRef="usd">462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88458031f6ac47b59b944bfddbce8e54_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC0xLTEtMS0xNDMwNjE_869ffe61-4188-4691-bf2f-3ad6c6ec33cd"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa45dacdd3d94b9da782f49919c50c7c_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC0zLTEtMS0xNDMwNjE_0c5f5a1c-a48c-43d8-a7e8-76c6a5aa6914"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5529206dd0354add818ec8ebc745ea99_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC01LTEtMS0xNjc5ODM_d88ba5ec-b651-474a-9181-97ea5b3917fb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b101667c39b43339df8dca9eb8a5c17_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC03LTEtMS0xNDMwNjE_cf0f12a2-0dd9-4b6d-a350-37e844c742d8"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i195b71e75a26477289ed617294657ed5_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC05LTEtMS0xNDMwNjE_999bc769-9e92-4a11-b0d3-d1fea086418e"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i586500eaabcf48daa510aef12cb36e94_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNC0xMS0xLTEtMTQzMDYx_a9c9c6f2-8876-4601-9dbe-51eb1c77158a"
      unitRef="usd">402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4547bdb61bec469cb232355667f60334_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS0xLTEtMS0xNDMwNjE_cbd8b1a0-b44b-4464-876b-86c47fcdab9b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d5528e4e03c4951891b8333a4918812_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS0zLTEtMS0xNDMwNjE_abbed9d9-a6c5-4a27-89d5-6cdb0c37b194"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1da9ab6b49674688a517da02ff148635_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS01LTEtMS0xNjc5ODM_62c5645a-324f-4a9a-b16c-5f6082127e28"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8677733f10724b908cb5fa12e547a9cd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS03LTEtMS0xNDMwNjE_6bcd572b-681e-41e3-89f6-48cde3c3f974"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99d18eaf8a344deabfb39b5d1d2f5244_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS05LTEtMS0xNDMwNjE_10d21907-f7bf-411d-8d92-3a21951aefc7"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c7c1f563024eb885219d1cc73e2c03_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNS0xMS0xLTEtMTQzMDYx_8f1f28aa-d7e0-4ed3-a304-b8413d564f64"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e529afb54794cf0a4114a5202965a4d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi0xLTEtMS0xNDMwNjE_0ef7dd13-5583-4d4b-b691-b888438afe2b"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i888846f7a8a24e6cac9459c35c333be9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi0zLTEtMS0xNDMwNjE_da203cac-9107-4a78-8c2e-af8632e686a5"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfcbd7bd0541403ba70a5c4a488abfad_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi01LTEtMS0xNjc5ODM_eed6350f-b29c-463c-ad34-fb0d6519db96"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2366ec826494978b8848268dbd37f56_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi03LTEtMS0xNDMwNjE_1c4aaa59-4195-45f4-bbf6-a857c292b3ec"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5abfa18a5c8641a1819cda416997710d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi05LTEtMS0xNDMwNjE_eed25414-62ce-49dd-a3ce-8e7b79592d34"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia79e84fc1b29410e8ce4e71df86aa5b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNi0xMS0xLTEtMTQzMDYx_8749de7e-19fb-4532-81cb-a9611af4b049"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c5421c9b35b4516a49077974d2e5949_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy0xLTEtMS0xNDMwNjE_31dc81c6-62cc-4212-b674-9fff49a1f4ed"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if27fc1e4a91e4d25a238da7b45796c0b_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy0zLTEtMS0xNDMwNjE_fca294d3-bbb8-45c8-ae85-ef93fcf06c61"
      unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4a4f9d43f164c9b99692b1912045740_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy01LTEtMS0xNjc5ODM_2ea22d66-11a9-4e73-b449-b8c900358949"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66b3252a18104908b5a55f890c213286_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy03LTEtMS0xNDMwNjE_328f5eb4-c25c-4e61-b5fe-7d926a77d240"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i425034548a5c4d40b9c2c34552bd6d3d_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy05LTEtMS0xNDMwNjE_3b2530ed-69c2-4399-b534-bd0d9b809c49"
      unitRef="usd">942000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfNy0xMS0xLTEtMTQzMDYx_6e97eea2-9d08-49df-b78e-2a49e49917e5"
      unitRef="usd">2046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34bd3f79386a444ea669a83657bf3167_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtMS0xLTEtMTQzMDYx_00566f34-5f05-4d2a-890f-f3b40fab42a9"
      unitRef="usd">525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1418ca7566eb4be890fe201a00997650_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtMy0xLTEtMTQzMDYx_f856fc41-ebaa-4ada-9051-c08bcb0dd57d"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie60598e761b44eaaaceb643fb0d3f737_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtNS0xLTEtMTY3OTgz_48b95b4b-8f9d-4b74-b770-db2506a44f3a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib91c304c54df4d51a17ad1319b6cefd2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtNy0xLTEtMTQzMDYx_6ae71e58-04c5-430f-aebe-baf39f09af04"
      unitRef="usd">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8153aeaa29c14cf78898a3e0430db0b3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtOS0xLTEtMTQzMDYx_fa4f57b1-bbaa-4cd6-8c93-71d55167180a"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3155b234cd454dcda100820d79b828e3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTAtMTEtMS0xLTE0MzA2MQ_64019404-7d11-4f07-8e8c-1343446bcf03"
      unitRef="usd">941000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2478dd9d311e41849390cfdcaf83acb0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtMS0xLTEtMTQzMDYx_0e53e830-498b-4c3d-a11f-e14b08eb85cb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b297ee44b024a5a84ce38bae85846c2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtMy0xLTEtMTQzMDYx_2287b3da-9d70-4f6e-8415-43cda08ae05d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22473c0e99cb43b1bd4931030815e25a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtNS0xLTEtMTY3OTgz_2a02e432-8c5f-4a99-b2ec-8231e4ea2b8e"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic56c6ec263244270a0635f1fc010b8d1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtNy0xLTEtMTQzMDYx_983301a9-78b6-44b9-ad6a-2b1b8878409c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55c3b644d34948be9d9c18866f4a5d9a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtOS0xLTEtMTQzMDYx_1acfa27b-0338-44e2-aae5-6ea5b0eee644"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f341155d9df46758157a2f5d967fcf5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTEtMTEtMS0xLTE0MzA2MQ_b1ea01db-4c95-4c61-8a5d-31823ebc8952"
      unitRef="usd">469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9c0d01651fa42ddb2726f307d78e1b1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItMS0xLTEtMTQzMDYx_c5585d12-d9b3-4f26-8cff-141af8d32737"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e6f8d534264d698d9daaefe158ba7b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItMy0xLTEtMTQzMDYx_eaef294e-f4ce-4a35-89de-f6bd532a421e"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43251ca627784927b25da791c21f44b4_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItNS0xLTEtMTY3OTgz_63a07426-0269-4441-9a17-496cf545426a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3037fa5f424f4fcd91ed8575d90726cd_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItNy0xLTEtMTQzMDYx_3e3c3996-3010-4b74-a32e-53948c872a6d"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic136910890c64c788ae7b465e4125b6c_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItOS0xLTEtMTQzMDYx_60e99367-c766-4c51-a1a9-0ae7988107a9"
      unitRef="usd">365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b3ff051184a4834850b051a7d4eb1df_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTItMTEtMS0xLTE0MzA2MQ_3a0f7d44-e95d-42da-9ab3-28fd7bc70340"
      unitRef="usd">409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40c9b728ace2464d8f96d58ae572ebbc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtMS0xLTEtMTQzMDYx_4d67cbe1-e819-4f5b-bb40-2a1bc2d49080"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6567a2441b6f405199585a4b83fe5bc8_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtMy0xLTEtMTQzMDYx_bb13e48e-3597-4ccc-884a-ec88492a6bf8"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if77a4befe17f484688509cd99dc3b12e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtNS0xLTEtMTY3OTgz_96453d38-f714-4833-854d-4a5eb2c52534"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aca7ca963b44994a71d3617c064d6fe_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtNy0xLTEtMTQzMDYx_dbb7920c-820e-401a-90c2-e970583dd994"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i422af7d7e455458c85d983e22cdac59a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtOS0xLTEtMTQzMDYx_f57001d2-90b1-4ea1-b411-be4c540331e9"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i944bf2eea27245dfa96a85b44b8afebb_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTMtMTEtMS0xLTE0MzA2MQ_c6725d79-afef-436a-af1d-49a70e7869df"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44102882489d45b8a65cbe80612eb503_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtMS0xLTEtMTQzMDYx_128df98d-3431-448f-8301-f2b869f84812"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i629f1d9bd1a2455f855f4061c4ce4dfe_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtMy0xLTEtMTQzMDYx_7feb0283-8af1-4082-ba3a-b5e4842cfa19"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib508b0f79c104da081f95ec2beaff2c1_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtNS0xLTEtMTY3OTgz_f81a3035-add9-4683-a248-ce70ef9f644c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e8b341226e741e6a61a9d17cbae03d0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtNy0xLTEtMTQzMDYx_62ef6778-67cb-4e15-b6d5-26e490ca3f38"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e1c2ec3c04143fc919380f19acc7cd5_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtOS0xLTEtMTQzMDYx_d090b31e-8ab2-4c2b-a071-fe252ef709df"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic90dad0cb3874aca84524b1022581f5a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTQtMTEtMS0xLTE0MzA2MQ_cf064f37-ed45-4084-be73-fce20e3c471f"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aa8cafb0fc44a99b36bcfc0892304b6_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtMS0xLTEtMTQzMDYx_9eddb412-c17b-4d2b-ac6c-8b2f5dd41eb1"
      unitRef="usd">527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icda4a6e048d64e4c8a7245ff0c6385df_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtMy0xLTEtMTQzMDYx_e7fbac54-190d-4cd5-a728-7d3d213b92f4"
      unitRef="usd">271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23473ab81eaf45d8a36b3bf461716a8a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtNS0xLTEtMTY3OTgz_7bd59405-b99b-4796-af8d-afbf06bf933b"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48494750e70944a6a8fe08c72a157c9d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtNy0xLTEtMTQzMDYx_faf9dda4-45b4-4cb7-a439-53c5aca132e9"
      unitRef="usd">290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a743c0619b545b2b9851ee1735cece3_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtOS0xLTEtMTQzMDYx_8ea9f441-7747-494a-9ccd-7bc66f1ccfbc"
      unitRef="usd">949000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTUtMTEtMS0xLTE0MzA2MQ_b05cdf07-fe72-4cb4-8a19-2f89bf823971"
      unitRef="usd">2111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26aec855e3534a57b91887cca0df636c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtMS0xLTEtMTQzMDYx_0cde31be-7370-4cec-ab71-18b8f074924a"
      unitRef="usd">1508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8b64fc9195a481b99d8eba5eba2c499_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtMy0xLTEtMTQzMDYx_860927db-3507-40ea-ab06-02b58aca51fc"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2020a325cfd844aeae55587fb97a9bde_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtNS0xLTEtMTY3OTgz_9e0d0a9c-541f-462f-ac81-c0c797b29fb8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc165abe9fd94612a2e9711f068afaa2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtNy0xLTEtMTQzMDYx_78320feb-2f5e-40db-b6bc-05c2a65336ab"
      unitRef="usd">608000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67b7b11900d04f5ab4a91815dc85a13f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtOS0xLTEtMTQzMDYx_0c3c3772-0010-4bcd-b430-03b0295bfb3c"
      unitRef="usd">348000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d594998be2c466a8ae3f74769b467f1_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTgtMTEtMS0xLTE0MzA2MQ_d2fbc5b1-1585-4d14-abb3-885531b2dac9"
      unitRef="usd">2670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id14c76797d024f8a850f17d12da55d9b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktMS0xLTEtMTQzMDYx_c014e12a-b30a-4bcc-98ed-15e18ec354d6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d945399f7fb410484aeea7fa1086e9c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktMy0xLTEtMTQzMDYx_fc1d1db5-4a88-4089-967d-0d56450718ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19757afbfd8c45fa860915adcb1688d8_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktNS0xLTEtMTY3OTgz_8b36edf7-a59d-474c-8ced-fd023a67c659"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib120955476934bcab3cfc8a57258b2df_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktNy0xLTEtMTQzMDYx_d031db20-b1a4-469b-936d-1b6a956eb16a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54edda7460544fea9cde5c3172db7617_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktOS0xLTEtMTQzMDYx_34b2c5e8-5f70-4ba9-bec2-962962d19f9e"
      unitRef="usd">1168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1eb54743e79e418c8eeba61c5c9441e3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMTktMTEtMS0xLTE0MzA2MQ_1b608c9c-d3ea-431a-9572-b6a4b00925b0"
      unitRef="usd">1369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i755e8ef589a6417c85697fb2489e0997_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtMS0xLTEtMTQzMDYx_a3bed599-dd02-48c2-9339-0478cc273278"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e344425e326404fa4c3a5ceeb0a33ad_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtMy0xLTEtMTQzMDYx_31a5b618-5510-4683-90a7-efa1b0aa07f2"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie27be4668ecb485da4269a39bfa27526_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtNS0xLTEtMTY3OTgz_1b2d3517-b0c7-4094-a7ec-b76e78a2eb97"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcfc2d283efe4a7e834029578338109a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtNy0xLTEtMTQzMDYx_cc4eef19-b531-4133-a875-2840555aac5c"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i599ad95889f140dd856c86816a0647de_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtOS0xLTEtMTQzMDYx_88d94db7-eb55-4ed2-a341-120c5cc9a43e"
      unitRef="usd">1061000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75dbc41746a6477da43e97ab5cdea898_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjAtMTEtMS0xLTE0MzA2MQ_6fda2693-bb41-4e2c-ba91-7230bc3b1ec2"
      unitRef="usd">1177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4464cc778bb74ce498dcb23fed88c066_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtMS0xLTEtMTQzMDYx_4155e26e-b038-40ec-828e-5a3d356f0cf2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i583e1c626b03403f87d3f3663e850328_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtMy0xLTEtMTQzMDYx_1a4181aa-6bde-4544-b850-9a1ff501514b"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35e34d06d4c144ab84ed676f2b1e7904_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtNS0xLTEtMTY3OTgz_aceb7af7-2444-456c-bc55-bb8d8cafaf43"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e97965210ba400a8aa5affa4e5e8dda_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtNy0xLTEtMTQzMDYx_5dc604f0-d800-4185-9bd2-77ebc0da4209"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9713e38b2cbc4a72bf04b0dea907a1e3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtOS0xLTEtMTQzMDYx_fe82dff1-0a0f-4aaa-b6bd-51b217852c7a"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i579951261424471ebfa617bcad167deb_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjEtMTEtMS0xLTE0MzA2MQ_17b1841a-d74b-4086-966d-ebad1aa875f6"
      unitRef="usd">655000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4241952b1e174e2b865fc979ca30a592_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItMS0xLTEtMTQzMDYx_2bf2e605-d7f5-4fcf-9648-af4bb15c2a71"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50980e0088f041399e5e72f5cff6248c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItMy0xLTEtMTQzMDYx_7720ae27-8ad6-43ef-af26-65ac5ddb2c5e"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2de33d45cf94f6b9d2f33a3c2bba1cc_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItNS0xLTEtMTY3OTgz_85d6db5f-cf57-445d-97c5-df8e54d1909c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc88c3d81b1c4955992d1247bfba1b8e_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItNy0xLTEtMTQzMDYx_d82d0c30-7905-4bd2-8718-5bba0b7378ed"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2811781ce7f642ca89c86c7f0de518bd_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItOS0xLTEtMTQzMDYx_7d972b20-5c29-44a2-be6d-69bcaf0a0675"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i791a2916a2aa4ab395ca981e61e7daf2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjItMTEtMS0xLTE0MzA2MQ_03d5e446-6d38-440e-b970-690a5b1cf1bf"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b2bf72a6d8f4db79a9735c15481911b_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtMS0xLTEtMTQzMDYx_ba2862f3-221b-40fc-86f2-a006d3263897"
      unitRef="usd">1509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44d82915bab14054a1f24995a7bd4ea3_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtMy0xLTEtMTQzMDYx_1a894e0b-7380-43fb-92b4-d1c55932ce0f"
      unitRef="usd">727000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i041eda0c99c84e58bc1f197756109245_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtNS0xLTEtMTY3OTgz_2a786c38-25b2-4552-ada6-a40ddd5f135c"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifac4e559a19f4355ab8fca0156543f04_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtNy0xLTEtMTQzMDYx_5f869b5b-4499-4c6d-93a1-8a4364eaeba1"
      unitRef="usd">722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b0c9489a5944525a7beaf699e925064_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtOS0xLTEtMTQzMDYx_ef23aa61-2683-4c23-8f63-43f689248945"
      unitRef="usd">2772000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjMtMTEtMS0xLTE0MzA2MQ_906f87b5-398c-4a5e-863d-c4c7084ec24e"
      unitRef="usd">5931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9826556f6d8947a69d81d512d9468782_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtMS0xLTEtMTQzMDYx_c213757e-21ce-462a-a567-7ac4a24a809b"
      unitRef="usd">1509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b2f39db7b954476bf2c8bb5f8ad798f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtMy0xLTEtMTQzMDYx_ba766093-52e6-4cd3-9b35-156d49975bc0"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54bd462ed1446b096e8f3df008338e2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtNS0xLTEtMTY3OTgz_caeeaf5e-99ae-4519-94e1-89f1bc653972"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36f9d93817ce485782bbbade2c8f8fab_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtNy0xLTEtMTQzMDYx_b67a7cd5-9c6c-44f0-86e1-5690b19e39f8"
      unitRef="usd">699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84ea63fc42464411a719b65e9cea618a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtOS0xLTEtMTQzMDYx_321ae192-d9d5-4e8f-a2f0-fe4a9c91e41b"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12376a48681c46099f3a4e9ecbf34c5f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjYtMTEtMS0xLTE0MzA2MQ_0330aa76-264e-40f9-9938-3686aaa6feec"
      unitRef="usd">2775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bb127d7bf284643bc5c01a24c9fc5b0_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctMS0xLTEtMTQzMDYx_1e4d56ef-ada6-4153-aedc-90cdc59e4445"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58982e1d6ef14225a9ab3729ceaa6948_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctMy0xLTEtMTQzMDYx_dcd8477b-31e8-4492-a3eb-8bb88507cc61"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i301b2caac8d446778085cc79b589a737_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctNS0xLTEtMTY3OTgz_e5dcf530-6e74-4f35-b633-32b18dc9a7f3"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2fe2a425b9245fca2bb47d15a250d6b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctNy0xLTEtMTQzMDYx_2c17c9e3-f8e5-49a0-91d6-0cce9495f976"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dae99d75ed24ba5b1b8b1f3747dda78_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctOS0xLTEtMTQzMDYx_e5373ea7-640b-4ab8-a8ac-079db3aca7f0"
      unitRef="usd">1174000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8c493f1eaa24d36a5056a2ca842a812_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjctMTEtMS0xLTE0MzA2MQ_2a11e4bf-dec0-49f3-8fb8-1f8daffd99cc"
      unitRef="usd">1393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad50b284a5ed4c6d86183cb2fe3fdb97_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtMS0xLTEtMTQzMDYx_aa6ac760-fc8a-446d-a892-080d9fb7f35c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23f87201482142909a01e5261b00e554_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtMy0xLTEtMTQzMDYx_04281dc8-d577-4c4c-a202-8472027fadfd"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i905ce8cfd82b4f538a2dc187e9546dbf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtNS0xLTEtMTY3OTgz_6708354b-9a2e-46f8-8a93-1b6571021948"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id81d14aa32074f3ab7f08a1036ee0b8f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtNy0xLTEtMTQzMDYx_65847d6e-914d-4c5c-98b4-af9c56824377"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id20223e746334d6f82eca42140a4c935_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtOS0xLTEtMTQzMDYx_0366466b-46c7-4010-91f5-660c0ce9d71e"
      unitRef="usd">1010000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5755175f3f06430ab66277abd6454600_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjgtMTEtMS0xLTE0MzA2MQ_3db2e087-3ab1-4b3d-9328-ff68b3de9159"
      unitRef="usd">1115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia191f4ea8c4945b4906ab7f70a93deed_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktMS0xLTEtMTQzMDYx_496f7001-c5e0-4c37-a333-2ad996c81941"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ec8559c1ec940ef809744ef427103e5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktMy0xLTEtMTQzMDYx_82844c05-3b3c-4e46-bbce-90371fd641ec"
      unitRef="usd">579000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i214a5e16df454787bd61853a8fb3b9f4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktNS0xLTEtMTY3OTgz_0b1e7bd6-f0ef-4214-b7b0-d46b3550251b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib03306f36d12454ab64e7ac8cdae92a6_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktNy0xLTEtMTQzMDYx_70dc7876-783e-466e-86c4-f89f4be961a5"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f14675214e546ad9d45a02682113cf2_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktOS0xLTEtMTQzMDYx_5803d258-7bf0-4cec-b703-3b7814b3c35f"
      unitRef="usd">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cbf185e217c4dc9a7593467145c745b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMjktMTEtMS0xLTE0MzA2MQ_974ddcd0-66fd-4813-aede-57721226f10e"
      unitRef="usd">884000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc95d6d82edd44fe9ed4f8dc335f7e42_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtMS0xLTEtMTQzMDYx_efc8ef54-b681-432e-9d70-36db15afc022"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fe643b692e4449fadb261eff5314a8a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtMy0xLTEtMTQzMDYx_9c5be941-c071-42df-a1ff-f24f104d85e6"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37ecc27feb094b618ce6496fa054bc12_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtNS0xLTEtMTY3OTgz_c2b9c9b4-5a8c-4b48-8484-5bcf5c770f42"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b0115418e894ab6b82b70dc6e6d9531_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtNy0xLTEtMTQzMDYx_d898793c-42d3-40f7-9d21-5680fc4aa57c"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia407433f62b843baa034edc40f2c05c3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtOS0xLTEtMTQzMDYx_b246e2f9-4a62-4de0-bc92-864cb9479de2"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86d57f75bc2442e29fe1c7f8fa969c3b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzAtMTEtMS0xLTE0MzA2MQ_b5442712-d3d9-4658-9c00-ddfa41057174"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0e8eb0aeed843fba31c70ada9493305_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtMS0xLTEtMTQzMDYx_6b795e4d-b6e9-4f1d-8807-c9458ebb2e12"
      unitRef="usd">1515000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i072aaec2db174878954cb70bf860e758_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtMy0xLTEtMTQzMDYx_1ee3f6b8-2c16-4e75-a61d-2daea9b40e0c"
      unitRef="usd">890000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0814d1f5f404ef9b9ce2c33efbb9cf5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtNS0xLTEtMTY3OTgz_03a727a1-420e-4dc6-ab64-2643e1478947"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46f1158b96e7498b8bfdd8ccc5ad9827_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtNy0xLTEtMTQzMDYx_7e9571d6-0447-4fa5-8d9f-c166060a65ae"
      unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24af9b92680b4f0694745bf435e5472a_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtOS0xLTEtMTQzMDYx_ec0517ac-4c9c-414b-8fe8-ce124a6ebd14"
      unitRef="usd">2764000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOmI1ZmJlNmNhOWY3YTRiZThhZWEzMTc1OGNjZWRmYzMxL3RhYmxlcmFuZ2U6YjVmYmU2Y2E5ZjdhNGJlOGFlYTMxNzU4Y2NlZGZjMzFfMzEtMTEtMS0xLTE0MzA2MQ_530ebee7-2788-4338-9650-0f888bd6a4f1"
      unitRef="usd">6238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDIzNw_50d139a3-be39-4606-8391-abf02aceec5d"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDIzNw_87e8c58f-71fa-43e1-ad80-d089883ba428"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d52656bf37d43cdb7e063c81480fb0d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDI3Mg_90085ee7-9402-405e-8cd6-cb4fc17e043e"
      unitRef="number">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6ed64d739418416f87bf91f8425ea391_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDI3OQ_17c205ce-a618-494a-a256-21f838f74cc4"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY1OA_8269a742-f130-4535-8542-98a2609e53f7">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c17a5874a9e4075aaf8c4ce5d1a4e12_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi0xLTEtMS0xNDMwNjE_7b6fff45-b1c7-4ac4-ae39-abb1d7f1b8ca"
      unitRef="usd">1219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e326ea2d1834500a5932fa3f6d1b28f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi0zLTEtMS0xNDMwNjE_5c5402f0-61fb-4ec4-967e-0e473567b934"
      unitRef="usd">1251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34a7b27f028d4f1b8e3316964ae4b6ed_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi01LTEtMS0xNDMwNjE_ebe8e2ff-30b4-43ab-a5d5-66f6ad8adfa9"
      unitRef="usd">3524000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8acc98b4a99485f8de664a8f1b2574b_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMi03LTEtMS0xNDMwNjE_ef68291b-3bfb-4f0a-a4f3-87ae44e226c4"
      unitRef="usd">3629000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7593d4411424499ea8071b2b1744ee40_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy0xLTEtMS0xNDMwNjE_6f30a9eb-4e7b-4dac-b1d0-fa76a610ff53"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81cef13fb1fe4cff88b12247a3647d2f_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy0zLTEtMS0xNDMwNjE_53d81ac7-dbd9-4004-9246-3596ed5a1639"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a1547713f2b44918264056f12b2d4a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy01LTEtMS0xNDMwNjE_fe51ca5d-619b-45b7-8473-e58059d68b81"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cee586c236841fc9a104c883eb25025_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMy03LTEtMS0xNDMwNjE_6ca14ed9-d903-4c61-9863-ef70cab098a1"
      unitRef="usd">350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae1a9b9786b845c6826efe7b5650b900_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC0xLTEtMS0xNDMwNjE_9bc37c73-763a-4a61-9272-259f1b570bf5"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id94f8fad7b19469aa645f46052c57c3b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC0zLTEtMS0xNDMwNjE_90586c8a-30fb-4876-b1a4-641ffe4a152a"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00ad1728e8924998803b5744ae677c7c_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC01LTEtMS0xNDMwNjE_2b378557-21be-4fac-9dac-c5a9803b6933"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbe3c58b4ffa463c91e47a7cb28199b4_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNC03LTEtMS0xNDMwNjE_ba804fa8-1066-42ac-8128-f64996dfa3f8"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id150c24526bc4303af49c01163da23dd_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS0xLTEtMS0xNDMwNjE_d29efab3-77ce-4fbf-a8c9-be3e91fa33df"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38317d58388c4fdebeaa753429b54d9e_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS0zLTEtMS0xNDMwNjE_d18c9cbc-11db-492b-919c-d2c51d934a4b"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib445c562897042bdbd49b80e1286d65a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS01LTEtMS0xNDMwNjE_ebe2b6c1-ef9b-4137-a629-047e019c0b4b"
      unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e344dce62744d278e0b20e50c3fb0e3_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNS03LTEtMS0xNDMwNjE_6e742d67-04dd-42bc-8fe8-669afaac56b6"
      unitRef="usd">203000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b0143ed82024e4ba05f759a4321dc0f_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi0xLTEtMS0xNDMwNjE_09f68e45-2aeb-4c8c-83ef-2b60d7e09db2"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0197306db91e4812a3d4fa3b19135985_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi0zLTEtMS0xNDMwNjE_65140fa1-c679-41de-b04d-c75daf7dd468"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75298065a5bb4d7abc0cd5a872c8c23a_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi01LTEtMS0xNDMwNjE_f106bd36-83bd-4e24-8057-1e0642376b5b"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0ed176248a7493d8af99f37e6e639a8_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNi03LTEtMS0xNDMwNjE_5fae71c5-1b0c-4bcb-bda2-d87d0ef79db9"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9253db1500949fe906fc9a1f4fa1b38_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy0xLTEtMS0xNDMwNjE_3c9b9f8e-212e-43bb-a97d-b3d6ce2fd05c"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b96a64aab504e74910b39ceb4520476_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy0zLTEtMS0xNDMwNjE_b2094d49-5079-4846-ae00-b6e2ef4ca802"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia30d18d2c61649808a5f0ae632b41c66_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy01LTEtMS0xNDMwNjE_cbdd4a9f-d974-404c-9501-de7eefb1d9ba"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5dc9560462546608eaecbaa48330ebf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfNy03LTEtMS0xNDMwNjE_cf8dc1fe-cc08-44b9-9c8f-0f6166a1c059"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59f4818ab24d4eef82fd27de079b7973_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC0xLTEtMS0xNDMwNjE_cf309f40-7c24-4ee5-b85d-2f73ea988d21"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05f81890fdf044bcb330e157d04a97a0_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC0zLTEtMS0xNDMwNjE_90b2b515-8efb-440d-8e14-81d20361470c"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3eff41ef021547c6bd85e06df906d0fe_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC01LTEtMS0xNDMwNjE_72d5ce26-164a-4d34-9789-3b4d8d57a321"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac7d036a10b44a9b80aec045229f3086_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOC03LTEtMS0xNDMwNjE_9cf6b42f-92fb-48ae-8fbf-c1912a0ba338"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic155d49fa70f4c1198d083cf8239e270_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS0xLTEtMS0xNDMwNjE_1f74c8f1-6bd3-47bd-a66b-0bdba5f985f7"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc467b3d64744017a93680acfc732aa9_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS0zLTEtMS0xNDMwNjE_739d086a-597a-44f9-b65e-bc0d051f665a"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefbd58fa6bd147a482305292a074c257_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS01LTEtMS0xNDMwNjE_a9586a63-7f42-439c-a9ca-4dc7cfa76604"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0d0748800694d148893ade42e236442_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfOS03LTEtMS0xNDMwNjE_d4c64302-e3d2-4e85-abe6-f2d1c8ce8c50"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2c124d21acf42ce85f54a6eac7f7ba9_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtMS0xLTEtMTQzMDYx_9b76e0d6-d642-430f-ab14-14b47e5aa392"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56c7a4309c6b4558b2d3e9160a31980b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtMy0xLTEtMTQzMDYx_4c37bce3-c6a1-4d64-8ddb-3dfdbc8656cd"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8dbcf8ffc494fab8b9df1864aaf00a5_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtNS0xLTEtMTQzMDYx_f6573837-3bc3-45cf-bd7a-8672b46b8b5d"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11d0c319938f45b0a9419a9e53c66df5_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTAtNy0xLTEtMTQzMDYx_f3d66b57-df5b-4d3e-9d5e-49abc9f39587"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3959030e4f5c4df99cf6dcf1ebede4d4_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtMS0xLTEtMTQzMDYx_530a0a1f-3205-4b9a-bfc3-14596d6fed74"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1e5e8321bd646448a93cf036eae8e2b_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtMy0xLTEtMTQzMDYx_100299f3-c014-4e52-afed-891752f01c9f"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc35d5603e0942dda30e190b9deb1627_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtNS0xLTEtMTQzMDYx_5e1e75f9-7ff8-4594-bc4c-ec09fe03bed7"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11911151b9f54dabb034a5f6b1fe8839_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTEtNy0xLTEtMTQzMDYx_1f66fa47-b2b7-4835-acc7-2ac08e9cc0a9"
      unitRef="usd">106000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a95d34d1ea24fd586a885cd6b872083_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItMS0xLTEtMTQzMDYx_8f3cfd0c-33f0-47f0-bad3-655366cda396"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89bbb02a54d240ef8ea4afba712e86a2_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItMy0xLTEtMTQzMDYx_ff7419f3-f2df-4f11-909d-fb3fbd9e5909"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52bf2297ad3d49449422ea1e9823e61f_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItNS0xLTEtMTQzMDYx_4b9bee2f-10b8-4597-bd23-1dbac1c10aa9"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6f8127e8b0141fb9d4372bf3c182783_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTItNy0xLTEtMTQzMDYx_85b94591-0b4d-4d66-ac2a-3bd4cb0d19b6"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ada8553598f446f8ad09650f86726aa_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtMS0xLTEtMTQzMDYx_891cd2b1-49a3-4cca-8612-b452e0bf463d"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbaea260f0344e5b94077f35b76e27eb_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtMy0xLTEtMTQzMDYx_362fdcc2-fe61-4753-8332-1f6f1138df78"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd4d24d726d04432a277be2e908a6abc_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtNS0xLTEtMTQzMDYx_e2769516-7b0a-4a8b-bd20-c8a59c3ea82c"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6f382705cad4a4b84c68be25fa55777_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTMtNy0xLTEtMTQzMDYx_92767da5-23e5-42d0-a740-319ac37edd59"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ec9bea2ce13443798c0a6d868c068d6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtMS0xLTEtMTQzMDYx_eee43507-95fe-4aff-b9ac-4072f092bd61"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7c5dedac9f749aa9c8913ab247f1fdc_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtMy0xLTEtMTQzMDYx_0c547f40-65de-47cc-8e88-185f9823fa59"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic29b7b8ee29a431598793c1ba4520dc0_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtNS0xLTEtMTQzMDYx_101a1003-5eea-445f-94f9-acdcb80d8165"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ee531f5d0b64027bae00dc04e77f297_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTQtNy0xLTEtMTQzMDYx_746c454b-6264-4306-aa71-3c9ae3b47abd"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21fc561bc8064837bb579d9d55ae3b5a_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtMS0xLTEtMTQzMDYx_edbe8bab-dd42-48e5-89f7-f7dd9b261678"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieea6d886b69f47798e958d42e3654c2a_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtMy0xLTEtMTQzMDYx_ebc4bcc5-4c84-4430-9f49-89693154d599"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3e2a5680cfc4b46b7891fc6f9830006_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtNS0xLTEtMTQzMDYx_6da16d04-b6bf-4af4-9e37-ad73ae41759f"
      unitRef="usd">647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f8595d458c34e018a63a7863b77580f_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTUtNy0xLTEtMTQzMDYx_aa76eac0-ca10-4e11-adf3-2e92a0257871"
      unitRef="usd">803000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe2e15021d740338238235057cd9b13_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtMS0xLTEtMTQzMDYx_96923222-7c05-46bb-9300-b4df5c758c1f"
      unitRef="usd">2046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9299e3c9e7664fd88e27a87f2692f637_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtMy0xLTEtMTQzMDYx_f39534ff-9e93-4b7a-82ef-8e6c891533cc"
      unitRef="usd">2111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtNS0xLTEtMTQzMDYx_a6e97476-02ca-4e0f-b760-2aa9e3701af8"
      unitRef="usd">5931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjllYjI5MTBjZDM5NjRmNTFhNGJlNWI1Zjk2ZGI0Y2E1L3RhYmxlcmFuZ2U6OWViMjkxMGNkMzk2NGY1MWE0YmU1YjVmOTZkYjRjYTVfMTYtNy0xLTEtMTQzMDYx_4868d98d-ae70-4f1e-9b82-e2739750f12a"
      unitRef="usd">6238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RleHRyZWdpb246ZmYyMzUzNWVmNjE0NDM4MTkzMmI4ZTQ5NzU0ZmZhYmNfNDY3MQ_2686087a-4c51-48f6-9418-cba93aa983bf">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i72d246b81e15499094a367cbe1d8db6d_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMi0xLTEtMS0xNDMwNjE_a77d2a59-5355-42d4-b874-9b73c8b762e3"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i54794b3420624c9fb619461becb59f8f_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMi0zLTEtMS0xNDMwNjE_dca2d213-cac9-45fe-b1a7-b08c84a5f01c"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icd0d411b81984c788cc81aa73ab8f449_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMy0xLTEtMS0xNDMwNjE_7752dd92-514c-4486-853a-589b6c9eb216"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i62a332bbaec540e481ed114e383e4dd0_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfMy0zLTEtMS0xNDMwNjE_7074498d-408d-4c64-a6f9-4bd2d20f1dc9"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5a84613cff7f4368a54a708f8ba0ff04_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfNC0xLTEtMS0xNDMwNjE_f0df8f33-7976-48ae-944b-9c55436f8d86"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8bbda526e0454dffafc588718e72bdbf_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyNjliNjFmMDEwNTRiNjY5OGIzNTc5OWMyMTgzM2JkL3NlYzowMjY5YjYxZjAxMDU0YjY2OThiMzU3OTljMjE4MzNiZF85Ny9mcmFnOmZmMjM1MzVlZjYxNDQzODE5MzJiOGU0OTc1NGZmYWJjL3RhYmxlOjA0ZTVhYmUzODA3OTQ3NjliNTg5OGU0M2FlN2ZmNzZmL3RhYmxlcmFuZ2U6MDRlNWFiZTM4MDc5NDc2OWI1ODk4ZTQzYWU3ZmY3NmZfNC0zLTEtMS0xNDMwNjE_833d0b9e-9641-4a3b-84f2-9c16a02ecb81"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M965T,BYX;6RMF6USFS@0Q[^*QNUTVAD[1N(Y33R3.+EK9MHT4[=WKQ508J:
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M^QV'-F#W0;TW:=Z3+?X%4$L#!!0    ( %*&8U4BZAMA8 (  -T%   8
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MSU5E@NF/)S[C>5Y9TL_QY];H8'_/:N#A]YWU3S5Y3>:!23X3^>]9JI87@VB
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MQQ,=WGF^2?6<1KF0$E52O(XR6O(\1;JQ0)+EX*3>WNO(&88K((@9<@@3&,X
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M(ZT"(VX%]H7O"O8V 4"BMN;Q/;-R R \,8L:"#*##8!TL+T.T4%:E47<*NN
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MS^@!,(66;.HE5S^WEGHE1"5*))C\-Y%V8CB:3:/9QW%P_QP&('J6CTDX?8[
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MT;1.$-LDA(,4KZ4KY[8C-Y,5?6 Q$'2;-SH+*F3;E+_&LG?&3 'D_VM*Q>M
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ME=:+]WG%+0+>.[JZ,NA/M%.CT.[$F:HYF6L_F%609*F>0@U1?4: 3T>]\F"
MT=3W.F:;5F)TS1+CLR5 S7X'ST.HA\Y=7;LCX$4&JML0%2U"16-8:#(-3PZ>
MFY5*U RH"^RE5&>6LR:!:SSYW? #$-]\;:Y 50]1T1@6FASV5F9TS3+CD!2H
MJXMBFMC8PR8P5VGP<G'>8XCJ,4)%8UAH,@%:5=(UJY*8*5 7$-[4&_-Y'Z/
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M8($2*^;<Y%\!2% =FY*8,Q[2/T!)_T YCBBF-0EN(Y9^,M:09XP?9P1%2N+
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M!^(Z/)ZQ[C9NS&$$Z!>E:4H38)O$D&6D5:PW K^.Y(08P&\W8-55+5K$?-G
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MTAD2+ G@_M(87[^0@^;_!^/_ 5!+ P04    " !2AF-5*CR%3% 0  !E-@
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M%3,RX7X EXC4,V%N726UN%8CT2'' !%QOZBI5BD *(HPV#)09VCXM$;X6 =
M"L0%Y,V\D%/#4C)4E\KC.EB-7X;V[F-'YJ'$5,]]$ BNNIPS0UWC#@C>=S/J
MNI=G=(OU*VK1!!]7UQ^(&:41!AD5P5YH#)3SP"02!3=(6_KL><P25^-TOQ=U
M8\(-\GO_O4Z;ZV5+6(&%MFZVLIY2@[('I4.)+Y;0 R*9D+%1-('WDHT"3YE)
MSDW(+E!^UW@)>/U80\0X E6AW:?\@PUFWQ4O*CT&3)#"W.[5NKVY_X9 H[HJ
M;G(H"=:MXE!#;3>*2HA0H?A:<3/80F,0P2\C"V&$46/9>RW!!]6$^X79KYJ$
M"(Y+E):]T.:+&HZ[H=.Q%WIG3-[5G;297%8I]T+LZKU-@@EA#&F]X%@&\18+
MDG 1(AH+@C-B:K),VAZH!7*: [X+$Y>:"B&0OF_B3!<!O@:-0"2!9#5(:/<[
MT:D"%@L:^"C3"6_7=S<MQ9*EER2I,7"/U=H1K=.:V)Q#4Y:-IFWLCYHW 1$4
M!O1"#F9XDS/$VWV/R7MQF%OK0G 2SX)5I;^5P>X"B ->XZNI6OI7!>.QXLY]
M+]2F]&8Q@*9R5F;>O3MYH7B/4DO7D=K)T#''Z RFYGN^K69X\\BW+%K]P#JM
M0.2W)DZP7G,=0F;D H.N=L'*+&K$'U7Y*Y& >K\>8[,M^MXU.RP@CG-UJ&T$
ME./V*A%*2"JK*V'@"K#\;U4##!B\1Z%U\>W)5_W:%G%A[J/:J\(5G=O&LC>5
M-U IGK,G;A\P0]+N[K+BM@$HH?D,H)X00654>7Y'5X4,,WX)U>[2?F2#RTV^
M7\7ZL!%N?WZ"TU'A'<3B.E!_/7PH;E6KD\P]R !$!T?]YZV"Z,<ASL')_Q!Q
MMA3PKD:<=_]EQ$GU?%>3OQMP;@$Q*RV4^<*4OM!T&Z)"@ .W<"@V+.J@K!>Z
M4>'37==4'>00.KNC_-;F[H*]K_5V#E;>L72\3O%Q(L:J,> RWY=+ZJ)]&Z15
MQ5=?YM+<;4H^'DA[O<!>:6)\1$'<$H76G;;#,P5^7=-\^YFLI@T7?5Q(6EOE
M7!M>BPS.JV\G9WY^.SRW0W-'] \O/$[#__X9(F+S1LNG]W%#M'X'UL3JZQ"K
M-]^(&B(A[_&>.VW/($5SK2[^+G,4R_[E[M]+Y%G&,TM%^*GN:8VU;2\03<0B
M0X!ZWRZ.&^6/,K& FGP+N,$Z4<.V:=%N@7BH>'E'(?\@[@8\R<#:$1L&HJ"\
M5#P[XA'/!L,F\%)WR2LW6_8X6JXKP54O*NP/WV$%W*XJ>5Y7(?>J?GUTN2%#
MKC;J## X0%8:X.RCKZ6F,N6NYZ9$Q7EJ^/RX$E8K C?O:[=8Z8?6-.L'$<#"
M@KKQG*5ZD;+6CV?X2J6'FCLK-(!^T]!?V?SW;18AB;)8PG"WBM9Q-53/:\K$
M)@]N>#/.EID$HQ[YK%*78+%:[WDWG45K'C=I0G<@Q'[(WH3C#^TR9U4#WUW4
M1)FDHX:I15-CMH.HU>TV26=[._P?<A[*J6;%4.M_3\AX FA_2$Y=XODC2&9#
M&%X_9?$PGF^3:<W>KG/_3.R>[D4OS)]6 M!)A;4R8'>XQP^>@,R>*/''05ML
M<8]CM,9._G]AM-V,46:$I:,(WY(Y'4L9U+(G<.5:&#S.RAC5/Z=ANR?\.>CS
MO_[Q7N<9D*OF#,A5ZPS(QU$6WJJXU7[9RM&JC<=(3$0"Y8I/2X0G1Y2B"#8B
M<(_"V377V8:;6S/RYKS<7_#!9CSJ/&.WVJ$K\_4>W? I/;KFJ&C(_&QJ>L;M
MOS%Q]IM*6CRXJ"47,5Z_>4VF&FS$"'8LZ:7H+JR 6_O5H;Y:HHC8]8&X=K>.
MVG3[OHD52<0W *O#>\$=@]96N&K$V?"/G!*=J8-$+#2MN/I+575!;=H\;,HT
M,B24" _TFD_XC("O*'U?-SJL1]D?2]/[*\OG^^P&XT)A6FR$>-U3V.'E4\XZ
M<:&[AIX>$"\\#UY:V_+I3R3J_OE/X020J.4*R&'EY&%5@=NSGWSZ>M(\ZB$
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M3I6$F=( /!\;;#-<T +U+\M>_P=02P,$%     @ 4H9C57 W!,)I @  004
M !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULA51=3]LP%/TK5]DT;5)%
MODJA71N) M-X@*%V@X=I#VYRVU@X=F:[!/[]KITTZZ32O<2^SCW'Y]KW>-HH
M_61*1 LOE9!F%I36UI,P-'F)%3,GJD9)?]9*5\Q2J#>AJ36RPH,J$291- HK
MQF603?W:O<ZF:FL%EWBOP6RKBNG7.0K5S((XV"TL^*:T;B',IC7;X!+MC_I>
M4Q3V+ 6O4!JN)&A<SX*+>#(?NGR?\,"Q,7MS<)6LE'IRP4TQ"R(G" 7FUC$P
M&I[Q$H5P1"3C=\<9]%LZX/Y\Q_[%UTZUK)C!2R4>>6'+67 >0(%KMA5VH9JO
MV-5SZOAR)8S_0M/FIDD ^=98575@4E!QV8[LI3N'/<!Y] 8@Z0")U]UNY%5>
M,<NRJ58-:)=-;&[B2_5H$L>ENY2EU?27$\YF-W</UW??ORUNKI?3T!*A6P[S
M#CQOP<D;X#'<*FE+ ]>RP.)??$A">C7)3LT\.4JXQ/H$TF@ 290D1_C2OKK4
M\Z5O52>?45JE7^&*FUPHL]4(/R]6QFIJAU^'*FX)AX<)G44FIF8YS@+R@$']
MC$'VX5T\BCX?D3OLY0Z/L?_O,HZ"#TO;8X3=87 T Y#D]UR1MXP%M9[ 1RZI
MO80@IYA/0/=@L5JA]I=QA7D7Q -8L(;ZSZ+F3!AX3PD)?9.S,3R2_8!H:JUR
M- ;B)((X3N +EYP:M("-4H6!43J$D0?%@^AT1.-XG,*ATPOWVKI"O?'F-21[
M*VW;X?UJ_SY<M+;XF]X^+K=,;[@T('!-T.CD[#0 W1JV#:RJO4E6RI+E_+2D
M-PZU2Z#_:Z7L+G ;]*]F]@=02P,$%     @ 4H9C59].=)5B'0  -7P  !D
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL[5WK<]M&DO]7IK1.2JJ%)8*D
M1,I.7"4_XM66;?DL)[FJJ_L  4,2,8AA,*!H[5]_W3T/S  #DI(=[^8J7_3
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MYT5>WY&9PSP[= 45#WDL:8CN^1;C\YGAIZB4)VG.X9K)B9;U<7?!D>8'\KU
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M9C6>!9\)T1Q*R6Z@[,SB:C>H *]@#M)O':^K=:$L<AOW,(&%]:]Q&G1/F!@
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MS-D0CYR."<="W.8BQ#%'$+OC"LJ\ID( :H=*?"91@%-]=#HZ=]0<I(@AM%Y
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MM DS-[E) Y":[IC=7@M1RIX H31%>S1=&]HG/<P5.N:3CP?KR"HAEKI!T%\
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MF>6D0C3-P['H!H<.!6AEN?=I#PD%[,Z^2WO_QNMGDWR5D.RV^0&MMMT@[B!
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MXP4-6F=/)Z/1V=-UG.8'KU[09Q_*5R^*IL[27'XH1=6LUW'Y<"VSXO[EP?A
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MO@"Y#<SU/JD+GNET)$YG$W$^'G<9FB:YS6N@'Y ?A%C\4F2+I&AO+<XU&B]
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M?2YDOH08&#EG+<NE+)$JR=^;M$H-MO.JR-*%0XQX'6?+>,V?/!<0S>35'2Q
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M!K,L=X('&O4&'9Y!CJ4N_#76G>L"5@#592L"'$^P@%CL[IABT9M)TC)IUL@
M"88=MJ\399Z9;8QZ6:V& 0F% 28JH< 5_%+"K&II7LAUSL5Q&[S@J8826V"Y
MYY,Z^0%X+/%[%J&4]K"!*-$AKM11$"<4PEI'17U+VET<!M*$3G0<@PV?/NU[
MJ(^0H&JA<Q>U;@@@U[5U%F8'YQ7 F3$T;SCNOD%@WE*;YK[>L&O"%A)/B(!F
M-!4ZO\6]:I]_B2VBC#8@-O]J$=:#+*9/%6??21Y]LB?,PZJCOJF8VRO8174'
MHM=0\@5 +NOT'\1)RLXYGUBW?@=CZ[D6$3+@D[&;V];JA0\+&0T#<I%E#.I<
M@HK+57ZJ&_7ZRGM-YW2H+8]B 7?/<Z4ZU9;IO(:[+?,@:M1RP6I>YXFVA=VV
M$\ BW&XHO,YV%%*&Y,GL=&SB=Z P'3=Q#VB>[91N) FK L*8.J6<=FK/M2,;
M;8#T28YN7IZ\)V9OKRY[13X?_/+F^O;SZRMQF!?Y\<]75Q^.'A.FN@?-O+,;
MYFC'0I]Y<EJHNAOWSH/MA .[<J2!3>BDUYUIG$;]%5'#._^]PV&84W" Z#!,
MQ$VOK9EM3SO/S9$.ZA@^&+I]@3.] !F W+JJ_KDB/=;&NA/_F,Z."6V2/*]#
M5874(""J]PUE42?V;,.LKF0Z?;.M$U1,965NAL$Q?721F#<U.+@ &>Y.6?D6
M@#"_/2B(D[M'478LCNPKALYA*D!;NJ0>01^LF"(OA2BWMSB JEU+.&0U"FJO
MD.4@@MWSF< PO("I9!*982+J271;$M-*'Z=1B2U*[//9&S9RI'SUGK7BH.5[
M6/HCJ=>D>(0=I\55(LF3BO.3,RT5Y/E"U$U7%+'GJ^S*0-+9GB%S^BYY4VQB
ME ;A\@1G?L%\Q*6RJWO4Y)P#T0.E.)]U6N4U[6W;PI>36P_-KSC,]C/Y>C&5
M+E=XF?K@\6V3N&#^(4^7,H.VZ-4M9*GB_EWZ51X_8"*&'B;W7)5OVKOP[L+P
MRJKN-,.UK+Y2VN"5'<ZQ!6;O<!6CF_[W:X;AH^_<2\]\,G_H[R/F8[J= P+<
M^4!N'_7E9I%_:$%'^!'E B+QNJG1.<(K:<JT6GE%W"ATSMM&9KP+2],412(O
MUN:H<ZMJA8L$@]5^$NE6(RJ#V2"[,S7E[\##+"BS5J$GAM-Y*0WU\/8.J7;-
MU8G=?3'U+V.AABF^B,7K'^!;6?1'JMO+O]/(\L- FHC4HL1C)Y1=V&5,BFUW
M5=&4[ 1AWE$+8YAIO!)^D6,[P=6\TCVARILE?\H<D3==8463+2CWX25!"5=%
M7%(]X#6YZT79P[:;.*7&=K0%U%#N/6+2P'0TQAQ*Z,:?PSA!^4(3X:5L$#/L
M"O#Y47(H.0C3?&1M =T-9QI*O&Z8GKS_%BK]@+1_&%/AA#GGCY2*>6]*8K9(
M^9&J ;H=X_U;DXD^YJ#8SZW_D56 ?;9EUGK-L% _)$#K[>;FM9-7WU(>,/MX
M3(% IV--+J"MF_:8ZY,>8XEU"[SU35PIW\G2ZMVM;;OJ%LVB0-7,H6DD$#V1
M!SM-J7SZN21GTBF/>2$_;0)]7%U;P77"&6?3-]V+^)XEQ_U+/JJ8H7:_;S6#
M$MKCT6[5BZJ_-+!55;%FT#W;(YW1'],O[>QY&->P]@":';#(/JN5QGJE27 E
M1)WADT@Q"2X$_.-.:9)H84'F$"!PCX0YF!!C.PL@X=M1GS'H'@;/CYENQS)?
M<;<)-8H0QV_K_Z$#<E^IX=VYD 6""71 U,T"G+M#F/'VA?J>HI9/?XK7F^<?
M(O%;42R<JVQ@(V]3[6(=/ASU. ].RSQ90:PG-11&<^+0]4UO?Q:?RW2YM&?D
M(X=#1F,FW.AD^H?SB%YK'%[K!W$)GQLCW+?*4+X+L4<ARM$@=-:'05:>]=8"
MU*#4#I=1!)YSRV@62T8=LVAF % =@HY!SS!!)XAD?><)B8[C.5M(T2/CD]24
M\R7IP-^B/1"M_+&A0EH'^51-:U/@?VT5C0IHCU#*CRF=N:<[O[N YI7.>MU-
M7[W\ 6X7&::XQX_H-;VXEU.20'2^2,/W.9"#<TQHCKT]G%Y'9O9(1\;K77(.
M1([[9SSZT>Z'ZGTN]14_FLR6(7QF %@"-^5B^'J&DUJH?U!E-I1QVJ*[]R_)
M=GG^WZ\&&^U8?0S7 ?_I5=H071]3G W.\V]0D_U.<OVSJK9=R4BK=AS%U=J]
MBK5M!^#?LAP;R.)1&78\/NV487^+2X";KY0PIR_MXC8/JJ]NFDLZ+=X0$O55
MS9U: )]M_-SM*K&''DVUBC)J[FT9[0Y)_VI,=4XBMB=Q]BH<R6T'U/6-/?Z5
M//"=/GQ3E)5->??<5X+7AE'MZ,Y0Y/;#>TU:T+ ;?;E5:,/F,NH@A.:&&3=\
M<BY';CWOYO5Y^<Q<VDEWDG@;[9^'LC,TP.9B4.WY9U>/.NM@/V=,]U*V0Y+A
M$X<,EN&2RKLH1'6R/]AB'O#0#MG?+A#!4Q1])V;4@0_:D+K*+\S?"@<.].9N
M1"PYH3:GB@B-;;]?P"F6>,4*:[WX>E?OM!H9.?=N6I6FIKL'^7Y+.DE$]TC2
M<+Z:D-8)-R;O7T!VGO/JL'M=;[PG7N/\"_OY')Z0%<-UC:9613A;9.K<S)OS
M_"T!A^^<0XB642AOSA:KR7OOP67KS9OHN3UUMW754KT+?3\;FN,1@,$-R G\
M@'BM_UI'/>WC<.8AR:D)QB$N-9=)F),M2O2'KL<F->_L:3L5?M!NM&TR>3O7
M)?>43=_5&T5I)G%0\[>&GB:Q]?/!K3M.%(-[-VY8U 7:G7NML[[/B,3*XSV\
MFYJB9!"H+.6[@E75"%7ESC9\47"?C]>TTDM/CJK[YR=_/H Z55"F;W21S,7(
M[QO%847B=58)=?\$WT]1ET46<O+WTFL0132Y"L_=8VYXDD^628HV% T6:S"^
M=Q74JJNYC''2]Y%&0I4,]1-!!*(7J[N&6GT[SFW?Y,'R= :MZDPA;!?K[912
M37.ZSR/BA(L9#6(+J#,9JO%H;.*U3O&9E ]\R<F0)"GUE8%-KO+$'.R?V#=E
M#-W1>&R.<XZ]]I;/[D6M^IZ+"WYC3KMWFFZ_>L)OVS"%[L$CR]M L^_S"!VC
MO^B[X9$[>=*O?% M3IS&+!-ND>%WCE2R7Z*B*I9.AZZQ>1<">U#$5-;-7YA&
M2'?O\,GYUNLQI][63"@Q#>^-KI;'MS!Q@M /-+;>:HN/]ZU@-00F9U%>[K3#
MJ&Z6"EZ#ANK399'^FW"W\Y??!+,#/Q+)NA?+82H*T=.DU4IGQ<P%R![+<J8#
M4^R8AQ%%[T@D[NF%H6R'"#W7*"E.)X&DZZ;K.I/:V*AU3")% =?YQMX4[UVP
M=,*WJ-+A3UZM1RY0F^N@O9+K]!@#>^WJZ>I#H0PBWR5"P)CNXK%/D/;T<2F5
M1/"+*FK5+Q&(S@:TH,ZJXIB2JWONQ293<_;/"?U(7P;RBKV(T*:FVR^N1+HJ
MU@2:8R_Z)C-W"KA0*H7>UN.CK7H\VJK(*06/3:QH?HU+Q"*F+W%OXX>FU *(
MJ=-C0KX.9]6=3RV?QJ5&<).^WG>PQ]WA4[O;8>T_A%T^@:\SE6ZNU:2;U0WF
M*'A<@0SSQZ/8P\\>!!7W.=A,]]U!$Z=/YKU[B4;P9+ZUEJ.=K>4VH/Q7;;EF
MQ?\F:%E:YM%D@P>&>A<MA+NM3,+&/]Y@(X; 30AMRQQYIMDUO@.)%J/JAWIW
MNZD7QL+ GI6$ADIFED*8/<46TVAWO6N61,#YO6<[P/*':5YWU;U4[Z-4[- >
MC0;R0'JTGMU=)WX(+OPC==_0MJW^^[&ZSZ%/\!)UHMJV"_GM]3R=U/L%=_,&
MI&1L*PM[R@:[K*<C;CMS5CS9"5I?2G80A'^M#=_??@=K<-NPTA+4K2\VL#37
MKS4<SR*ZH;R?XM/'4IP5^WA&,]OU=@35N89R=Z*[VL_?(5@7)5Y.P\$.JG K
MG X)/ <LH"%W(,^#W;)<6+49VLO_ >[> [=7(7^VC9;H,0I\;ZJ8=/"/=VKW
MP<C02SAZ2I"[OOO0J@G]2LRMAN'RL5K"KD!3_Z7)'HQ1V!7>;2Y48(;MRF0?
MAVE70%OZ>I_]+66NLOY$7.TH>^_9"NY4U5],(CA8 CM\9'7M".FXPR&F( 74
M^Q5ZRO_V"OZ2,L+86O;=+U@!IZ_<%*736;$S#? ,5?B-,EPD),R$2X6&[$YR
MG)+,N2$O:EN/EO0*Q0V^F,DI+$3>:S"1G)XKVVZ[HC/"NE*0EFX)Q[[>4;W$
MTA8EW#XA@^@RM'D5;U9%QC?5-V5E,ABM=/RN:+9(VX<P.R YK02^O4.]E:]/
M3E)Z60=RK>GD: >E3I&Q_57/FYEZRLJ=WO90^?MO!6C9[$$),78?H8PY+$ -
MJYVIJ&_5;2?IOEGU\>TC)[OA /L$G.)^>)\HH/C<#]JNA_=\T;]]E\D!@*/O
MP\=;4YIVSM<%.R<BO!R/1-6X%;8OTI8 6S=>AG']J*8;S)7PJTC5M[LTNOQ_
MZF6Y]9_"N@FL@GVEH6)H-Y70HBGUNM*1:+RWSB\TNN^Z>?&T?O7B:5K!CP3^
M+XM[^%GAVP]>QW7\Z@6]"OA&9AD>R0?W]>7!^,#Y%*^C>WEP-7YV-3EX"B/M
MXZ]>;.*E_$V=5<KD'0S%DT8'7%_5?]3%!J<4\Z*NBS7]NI(Q\#\^ -_?%8!#
M]0<N<%^47PB\5_\#4$L#!!0    ( %*&8U6!<I$P@P,  $D(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;*U6;6_B.!#^*Z-LM:+2'H% M[T6D*";
MU2%M:03LG4ZG^V#"0*Q-[*QM2GN__L9V$M@NY=,*.7Z;>9Z9\7C,8"_5-YTA
M&G@N<J&'069,>1N&.LVP8+HM2Q2TLY&J8(:F:AOJ4B%;.Z4B#Z-.YV-8,"Z"
MT<"M)6HTD#N3<X&) KTK"J9>)IC+_3#H!O7"G&\S8Q?"T:!D6UR@^5HFBF9A
M@[+F!0K-I0"%FV$P[MY.^E;>"?S)<:^/QF ]64GYS4ZFZV'0L09ACJFQ"(RZ
M)[S'/+= 9,;W"C-H**WB\;A&_^Q\)U]63..]S/_B:Y,-@YL UKAAN]S,Y?X/
MK/RYLGBIS+7[PM[+7G4"2'?:R*)2)@L*+GS/GJLX'"G<O*4050J1L]L3.2L_
M,<-& R7WH*PTH=F!<]5IDW%<V$-9&$6[G/3,*(EGB^GC#,:S3Y \+I;S>#F=
MQP_Q; GQ0_+E\>\XADD\BS]/EY!\&<\6@] 0K54.TXIBXBFB-RA^AP<I3*8A
M%FM<_Z@?DKF-S5%M\R0Z"[C L@V]S@>(.E%T!J_7Q*#G\'IOX,W1<(64:08F
M*'##C89_QBMM%.7,OZ<<]GC]TWCV'MWJDJ4X#.BB:%1/&(S>O^M^[-R=L;;?
M6-L_A_YK3NP74\ R0[B71<G$"^A2"BV5MI>#@->P\D&%,F=" Q-K8% R97C*
M2V:D>OE94E+P#Z=2X)JG+'>J.=\@<*%WBHD4'>8'V&<\S2"53TBT*2I#U0B^
MMA=MP*+,Y0NBYSW,:+^6DR9#1<H[811'W889U<(2%9?$"JW*IDN2T :H#((Y
M./O^W4W4O;X[X6M5MPX^O_+I."@-JB ,*/QM07M;@'+=8+$B ^N$=V TZ))!
MQ*$I6>7F%I**L,I@2!QQ\B.I"XG=@9D4OS4S#2V*0\'SG!#TI:=Q%*=&"TIH
M3J%W\;B +C47ANB.1KVJ'5;JT508I-M@O%ZO^G6;_?BYI$I-+I.].T7'XH,'
M3&LD'UO7E]"ZH=;WK5:K^W$A*:/^8Z[6RPV4='[T^-2V*DHAXT+GC_NU>JM[
MZ5ODVVLX03F12ZU_4NP>N5#WYQ+H EJ]2_N]LM^H:I;ZPA*?*A#A47DO4&W=
M(Z9]QOI*WZPV[^38/P\'<?_(/C"UI<L#.6Y(M=.^O@I ^8?+3XPLW6.QDH:>
M'C?,Z*U'905H?R.EJ2>6H/GW,/H?4$L#!!0    ( %*&8U7;'EBV. T  &8K
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;.5:6W/;-A;^*Q@WVTVG
MM"Q1DB^YS=B.VZ;3U![;W3[L[ -$01(V)*&"I!WUU^]W#@"*E"C%R;:[L[,/
M3D02.#B7[US)5X_&?B@62I7B8Y;FQ>N#15DN7QP=%<E"9;+HF:7*\61F;"9+
M7-KY4;&T2DYY4Y8>Q?W^\5$F=7[PYA7?N[%O7IFJ3'6N;JPHJBR3=G6A4O/X
M^F!P$&[<ZOFBI!M';UXMY5S=J?*7Y8W%U5%-9:HSE1?:Y,*JV>N#\\&+BQ&M
MYP5_T^JQ:/P6),G$F ]T\6[Z^J!/#*E4)251D/CO05VJ-"5"8.,W3_.@/I(V
M-G\'ZM^Q[)!E(@MU:=)?];1<O#XX/1!3-9-56MZ:QQ^4EV=,]!*3%ORO>'1K
M1\,#D51%:3*_&1QD.G?_RX]>#XT-I_T=&V*_(6:^W4',Y5M9RC>OK'D4EE:#
M&OU@47DWF-,Y&>6NM'BJL:]\<_?#^>W5X<7YW=5;<7G]_N;JY[OS^W?7/[\Z
M*D&=UAPEGM*%HQ3OH'0FWIN\7!3B*I^J:7O_$;BJ68L#:Q?Q7H)W:MD3PWXD
MXGX<[Z$WK$4=,KWA+GH+:=7A!4PX%3=R!625XMQ:F<\5__[[^:0H+6#RCR[A
M'>U1-VURG1?%4B;J]0%\HU#V01V\^?JKP7'_Y1[.1S7GHWW4/\M(7T9)7,@*
M#B]^4#(M%U]_=1H/3EX6XB>3SP_OE<W$NSR!CN! XB:5.2[%>[F"90:C2!2D
MV(5)I\H60BZ7UCQ Q=T4:8>XSG(]J8I-HL_+A1*T,NZ_Y'5TEZ\'+[\1CPL-
M<E8M4ZAY#_G!$\D/VN01W\2L*BNKA/JMTN5*R$=IIX68 R$E#IRL!!&X--E2
MYJN>N%]?", F+V;*6JRC18G),H0<5@Q4\B!U*B>I$A5<P_**F@%1FG##">PH
MP\5U5F4BK[()MIC9!LUR(4LL6HF)$KHH*CK8B*6TI4XT>"J+]F&.MGB4!8DG
M4UH].(WZ_3[]M8E'8IE6!>_<=7R7(![WT%158H'G2N93D9O2[4A7.I\+Y(:B
MQ'WZ[95,J_:=-U&XYO6U+LE@5E6%$G)68D^@! /B$HLEK!;1LIG2_#.1 $2:
MTD_U,5F0XT^%H0P%PQ%[N.P2+##GK=T 6_]$7#FPT#.D*LFI9FW& !"KYKHH
M^82XWZUU%HB41EQV&<]1;-M29L2XTS)HE"2S4+.9XF0GSI=6ISZ&#DYYE;L5
MGW)8[0,&$8@8L@H.HQ.A92! YPER/)2[SRJR*A?&ZM]QYJ>9OZJY^K'*\63@
M GO4]F3XH&5&.B5KD03C!6PW*0!H^'FZZM[3=/OSQH+;L& KU/3$706&F!IG
MA@8]O@[*V8_93VMG/SL4<0A]TZDF5,%G!X-HW.VPVR;LP=*(Q(@BH K=P-F'
M\6D'[!Z!R@VW\G&0(U_Q='YA#B@!:1MJ(HV$W-UV!7ALL8X51*J.%1LAS@CR
MIV*V$AILF$FJY^Q?@26ZRVL/)VR,I.F#2!,YE- &UX)<1J24U2A&D"%]AH"J
M(&Z&Z@O+2%8S^:>'*V22.#JG\$-/FD=NY AB6>4:*LQD+GU=49/<C!\S@P)/
M@%>=4<XD^B020N-<DRD2N=0ES%X5(,6:DFEJ$B<?TF%*:4+G)?YH;P>YTM#^
M1GZ&XF':7"!#.Y/6NG!&VB-;@($N]BHP@7T0ZDAK):IW3PMU;/)!F"6;+VH^
M(;^R.J$3^'!" Y3PW'OL[=TO19VC205+9;D5P<&> BWIB9O.^YP."!=6TRTR
MI9.*\N<+\5Q_(Q[ @*B6W"$LM'IP1B-O5I94Z]D"!?@N53<JT<X$$-6YID_'
MM,P=;?+=J@^2W=_=!L$B,-+FI*23-QEIB Z0V+DJ.P_N0%JP>KX-KEK1U_>7
M+46#I<#3K$H108!JKB\D7>QA<VYDVF ,)>@'YQK$V<6W/U&$D)95V*-"TE@&
MEB$N:3\='G"%Z%G3S3BJ<(SIDM$[7HK.%*L6>HDR0&81";T.2>.0=(C"O4Q#
M=&^E;UQDNBR5"D==&&"&+MYJ6+\TS3)7$MO$*\4<[P,40P/7ZJ-**A]'9H"0
M=<6."]4-D=9\]\0O=<3=HAW]&X1=J _^+*$9=4B>Z'R"UC:=D3W6.V,CA=[6
M',&_Q/=$K(;-4S.%BS4=E)"-=)J*N<J599@Q_"#LX&B(_T G30EN'.84_#58
M:*8M%I8+"Z/YD/\MNI=LLKN%N;$$%\".&IGQ1C'B-]?U-+$/-KJ;CCWAL%GV
M[#F'-(3TAC;>E13MIY?&+HUS&-[]E :'_*Q=TYS[D 2-Q3L*?WK6/IH<N%''
MK T<Z#M3ABO!B6?JBUE:QV@CN@\2^J:N8K5T!_E #)6E%;<"%*\CC[M6G+4T
M6:D?U4ED.Q,TFHE$%@M_W?0G5S?2+[B/39 4?&"O&4+IBY_Y"O]33"E#2'6"
M3($$ID^M%[4U:+]257"X<^MF4E/VMQ^P]4&FE2(^?0YA4M)1Z8GO \HW)$.5
M HM*[F(8WRH7*R6]?TN'\D.ZP^Y!JL,1VJ"M035,50NA.M69YF;@8Z(<W9ZX
MSML@U)S#<C\@J^L4LN:[F^M-D(; $0)0R*1F'9)0)G%R(=LM-3MJ$Y0@*KXS
M#D3.W]?PO.K82SK3R+& 5$4Y167+U*Q<+][F#6AK/J1B%$$QU62N35!O5L;#
MZ,P[PS9_+F2N&^P-M^T.P:ZB)NU@T[C_%](S0\,X@[:M33LZ%KFJYKPN_@DF
MW?:0+6G&T8F79OL8KH@@16[RPS7O'5:+B ,W<&E3'T5#3YV%]$C94)J+"<W[
MF\A>(QA"D);:0*X[[B8-9I[S04-;A:(BC-UC4Y&H5&UXP@."VHM[XM< ]=H[
M0B(IZMI$R#FX;/1_6YD8S<14%RBZ*?9,:+X=U8)X<AV(VJZ)J#Y-59.+=I7$
MYZN/5*"PD0QZ$>^Q2)83-8?$.<G)8E-"[R3#_O]C1;W@V8XTE+L1!7H* S-U
MZF)'S)C26NX:<3;5#)>HI6?BJD;9M?.0NMZ\O+I>._\Z0%/0*_89PT5OOYO3
M;X>..WS)*6M=8E,?$^9$7O/4DE(NX"#_'&86EA-_75K3'H_0QG*K4LDB>G,B
M5\(B-&+;%:B!G,)0=@-9UF!!\P;7;J,9H/E9W6A2\9XH3:4F\XV45*:AL81$
M5E$/Z$OT1OWFYFYYF$SZ\6.I4X=[:5--N@#/)DDJ&U0.0(,".""=D"( <^%F
M9=[TI36I,P+K:5T?3Y739YA.MEMO9C8W7"S!4,O*(J:"=O/ J';\\M$<>J?.
M(;LMI%W5A7_#]GLL^*>CJAU?U_ B&7A>61<9K'P"U.%_ U .-_\G5O>Q.O,=
M4JU]KD<?C2^D9B9%M'8#'9C P>5M9<.(Q^6.WRJ$-#?9^Y*FL15:/[>%9%VZ
MVAB:;=&JU9#+C N\K2+D>1@$^IH4NG,]?2C4W'-?,2E.V(1$?W9=Q-/>K0C>
M3;X]@IR@M)UIJB,\Z.43$B,J_@=J$1#'U@47UB+I;4A:M"K=(%0(?JX[\,ZJ
M'OQT KSJ_,&DB(&$J@T(.55P5-VJ+<FA#$*R3UP)'BJ?NH3O<FK.&A.70L\]
M?<*>WSPWAN I"Q,Z,^:46]G$C=NMJ>9^!)FK3G?H1@/@9)"XPS2&(UV5)&A.
M7)OK+=49A^C9GQZ'-JO93M-^.8@_/=UHE[*G8U?(<G%0[9ZXN*!%S=]F_=]X
M$;2S*7>U\)JH:R/_Z"G'UK#_I'Y1T,;R9X[^=TWT.P<![9/^LV/^>\[+=5!G
M<=QW)OIW'\AH&S#!8A&*4F!5 VNR67C[H>)?]YSH"_'"N8<?^G>W6F$(XBS&
M%1D2I<C<=Q)N0M:A7%J('X,7$(LV-K^K$#\3A=:=YS0;!:#H[&\<!=K=^'77
M8N^9&.)OA+]!G_X9.&:'?1&?B=.!.*5'PV'XYVQ _XQIC >'IXXPIZS_@'YG
MR<&F5H@C'--R_)U -#"5SZ. =#>_F"+N4O9WH:7>C..'.#L6IZ>=Q]_M?C,1
MU/Q9RFV\J'C14%6[?&E^,G+N#FWK\GO/0AR-3YR_#:+1V0G_^I6_"%+30S2]
MEM[@;(R<H*IA#Y)!T+@W&FVO;XR<>*KDQDG/Q''OV!FN!]O=KU^EL!D#1\?1
M8#Q@/H;1  U?)T>[3@#IDV-B;- [&XK[N]L=KUWJTS@4QB_%R$>=)Y\4-CX3
MX^->?R3H-<2G#AL>.W%&@^'G'7;6&_6=5"?Q9H_]1 %CU(%?*&!\VAN=>8#Y
M(/ED?!U'H_&8#P[T/HVNP6FOWV]P\&261[WQN+%O%\)&4=S_!$\[\772B^/&
M$><[\DSD4W+F7W%6N1]__/Z4J(PTVOK6A,9>E&KWOH]T;PUWOFBD,K<*[WJ?
M#<9Q"+V1GY?YF0RMLR7SR>]:)9+MAG+6!1?P>.(ZD][_DBJVBX"V=D[^(.4<
MC[QRNCZE.VI\^Y@I.^<O/ MH!'RXSR#KN_5'I.?NV\GU<O<%ZGMI4=\6(E4S
M;.WW3L8'[MU#N"C-DK^DG)BR-!G_7/#;-5J YS-CRG!!!]2?UK[Y%U!+ P04
M    " !2AF-51(X<YML#  "["   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6RE5EMO&CL0_BNC;54%'<3"0JX%)$*H$BEI4$AZ'H[.@]D=6+=>>VM[
MN?S[,[872JHDK7H> %]FOOGFYJ&_5OJ;R1$M; HAS2#*K2TOXMBD.1;,M%2)
MDFX62A?,TE8O8U-J9)E7*D2<M-LG<<&XC(9]?S;5P[ZJK. 2IQI,511,;R]1
MJ/4@ZD2[@P>^S*T[B(?]DBUQAO:IG&K:Q7N4C!<H#5<2-"X&T:AS<=ES\E[@
M"\>U.5B#\V2NU#>WN<D&4=L10H&I=0B,?E8X1B$<$-'X7F-&>Y-.\7"]0__D
M?2=?YLS@6(F_>6;S0706088+5@G[H-;76/MS[/!2)8S_AG60/3V.(*V,546M
M3 P*+L,OV]1Q.% X:[^BD-0*B><=#'F65\RR85^K-6@G36ANX5WUVD2.2Y>4
MF=5TRTG/#D?C\=/=T^WH<7(%]X_7DP<8W]]-'R;7D\^SFR\3N+V?S?JQ)4M.
M/DYKU,N FKR">@YW2MK<P$1FF#W7CXGAGF:RHWF9O DXP[(%W783DG:2O('7
MW;O=]7C=5_#&JJ :SEUQK1!N9*H*A*-;94RC"9^I%]0"'MFF"2-K-9]7ELT%
M@E4P91JEA7]&<V,UE=2_+P4GV.Z];-NUV84I68J#B#@8U"N,AA_>=4[:']_P
MK+?WK/<6^A\G]/^CPBA-JZ(2S&(&RN:H(7T69D'AI2/:&&LHPA=PQ"45M1#4
MGZ8!E&2+Q9ST7*:O,*TWG290!U)_2>H(3?%/MT#!EX9,^<[.OE*C%"XO[^$H
M:2;'2<.M.LWS]G$#IO43PF0&I:*TH>4:O?@<)2ZXA5*P0QC3!!EJ@(?*L&R#
MA@"[#?HZ;]1F3HYW9I)>8U=$092J!*0B8*U6G%H Z/ETG]]QPFESP^42Z)C"
M^$R,.+DC5[],;C^\.TLZIQ\IF"5J+V @9RNGRV!12?_R,?'#8DB+S5E ?FK-
M6I I(9AN FY22H K<G>%&^LBY.R]PE)C2'6M\#,E"C/-!+I'IB4Q,L]B\+4B
M'S.>!LY4!NN<I_DA$'#C0^@+)D,=+,T1R-6"2:(@MF2$RQ4:HM&"$06.#@R]
MQ[LPI>3H$AW\BT%;2]0FYR4)6#)@K).\9!6-/O@+;E4Q;P88IO76![5050@*
M^T6MUX6S9J:.6:!/(\?-HQ?(_089DM.J6N;D9JHHH:94,G.T4@H.][3>=[JG
MNXYR]O![Q>T6V$^OV$$T6B^].?'!0"E0+_W8=+U+WH?9LC_=3^91&$@_Q,-8
MOV-ZR2G% A>DVFZY0:C#J P;JTH_GN;*TK#SRYS^7:!V G2_4,KN-L[ _O_*
M\#]02P,$%     @ 4H9C58@[QQ#) @  @08  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&ULE551;]HP$/XKIVR:-FDB(:&4,4""EJF5UHY!USU,>S#)
MD41U[-1VH/WW.SN0@09(>[G8Y_L^?W>V+X.-5$\Z0S3P4G"AAUYF3-GW?1UG
M6##=DB4*6EE)53!#4Y7ZNE3($@<JN!\&0=<O6"Z\T<#Y9FHTD)7AN<"9 ET5
M!5.O$^1R,_3:WLXQS]/,6(<_&I0LQ06:'^5,T<QO6)*\0*%S*4#A:NB-V_U)
MQ\:[@,<<-WIO##:3I91/=G*;#+W "D*.L;$,C#YKO$+.+1')>-YR>LV6%K@_
MWK%_<;E3+DNF\4KRGWEBLJ'7\R#!%:NXF<O-#6[SN;!\L>3:6=C4L5'7@[C2
M1A9;,"DH<E%_V<NV#GN 7G "$&X!H=-=;^147C/#1@,E-Z!L-+'9@4O5H4E<
M+NRA+(RBU9QP9C2?+J;C^=4-C.^OX7KZ./WZ;78WO7\8^(;8;8P?;YDF-5-X
M@ND3W$EA,@U3D6!RB/=)52,MW$F;A&<)%UBV( H^0AB$X1F^J$DU<GS1J511
M(U-Q!DPD<(UKNI E72\#O\9+;13=C]_'LJY).\=)[9OIZY+%./3H46A4:_1&
M[]ZTN\'G,Y([C>3..?;_.IVS3,=UGJ*'6Q'SBDX1<@$'94OVRL840BRUT?0X
M.3,4;2242B95; X#"?A<,9Z;5V!:5XJ)&&UDJEBA6_#]GS5+;;(=?2[B2JF:
MO["-"M>2KW.1;A\(*K>%PK0B'5*]@C;D8"HA\I/R:^Y84G_1!N2J#P^90CRX
MQ7!/93STO*>2%#GGU%+T!W<UK6GOC6;;$NRJHDXI> OM\,+:=H=LU.U:&_:.
MU*,'E^#VL-%1Y)!M&]V[M+;3@V.7S=]K"U2DU#4_FW(E3-TA&F_37\=U6_D;
M7C?G.Z;27&C@N")HT+J\\$#5#:^>&%FZ)K.4AD[$#3/Z1Z"R ;2^DM+L)G:#
MYJ\S^@-02P,$%     @ 4H9C56FXS<-1 P  <P<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&ULG57;;MLX$/V5@5H4-I!&-R=Q4]N D[IM@"8-XG1W
M@44?:&EL$:5(A:3B].\[)"VM R39[CY(O(ASYIP9SFBR5?J'J1 M/-1"FFE4
M6=N<QK$I*JR9.50-2OJR5KIFEI9Z$YM&(RN]42WB+$F.XYIQ&<TF?N]:SR:J
MM8)+O-9@VKIF^N<9"K6=1FG4;=SP367=1CR;-&R#2[3?FFM-J[A'*7F-TG E
M0>-Z&LW3T[.1.^\/_,%Q:_;FX)2LE/KA%A?E-$H<(1186(? :+C'<Q3" 1&-
MNQUFU+MTAOOS#OVCUTY:5LS@N1)_\M)6TV@<08EKU@I[H[:?<:?GR.$52AC_
MAFTXFY]$4+3&JGIG3 QJ+L/('G9QV#,8)\\89#N#S/,.CCS+#\RRV42K+6AW
MFM#<Q$OUUD2.2Y>4I=7TE9.=G7V]_;RX@<5?UXNKY0(&%U?G7R\7PP.X6MQ.
M8DL.W+&XV(&=!;#L&;!W<*FDK0PL9(GE8_N8B/7LLH[=6?8BX!*;0\B3 \B2
M+'L!+^_5YAXO?TZMK5##A2Q4C<!D"8L'NMT&#?P]7QFKZ8Y\?TIV0!T]C>KJ
MYM0TK,!I1(5A4-]C-'OS*CU.WK_ >=1S'KV$_E\S]+_!( 0'0T1@P'V4Z)ND
MUE H*D-C#:CU*=Q6&O%1JN&*_#S>(7NZKT)0Z9FASY][I7NS+]SR#0NU2:E0
MWCW5F45MX#6\>37.TNP]S08T#FD\H2?/$I@7=RTWW%F^U2B8)7=$T'*Y0;GC
M6J(.T",80T;/X!-UJ"$(94B$!,,$DAA@QJ U063GD;@-\B&Y'097FO"Y?-MH
M52!9NQ0S752>=8GWU-B:.CAV$>I0NC&%/(26HKSGI!L'Z7!/ZLC)3<>YDWOL
MY;[['>;4G(%<@'1IJ$,:T*>!*LABO:+([LHH/2 MA6A+NO2OLZ,N1] %TBJ/
MQ(J*DS2ORSESYY"Z$>'OG610H+9$#R@X95M8'Q-&P,<]L.?=-C2C^]0(]%DA
M2.=E7JM6PM(I*EM-^?.[UM^O?Y%Q^%1IQ7N-L$:]\>W>D.-6VM 3^]W^CS(/
MC?2?X^%W=,GTADL# M=DFAR>'$6@0XL/"ZL:WU97RE*3]M.*_HJHW0'ZOE;*
M=@OGH/_/SGX!4$L#!!0    ( %*&8U47G>I&+ \  ,<J   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;,U:VVX;.1+]%<*;F74 Q;9DQ[D'4!PGZP42
M!W:RL\!B'ZAN2N*DNZDAN^UHOGY/59%]423'F:=]L:466:SKJ0O[Y:WS7\/2
MF%I]*XLJO-I;UO7J^>%AR):FU.' K4R%7^;.E[K&5[\X#"MO=,Z;RN)P<G1T
M>EAJ6^V]?LG//OG7+UU3%[8RG[P*35EJOWYC"G?[:F^\EQY<V<6RI@>'KU^N
M],)<F_K+ZI/'M\.62FY+4P7K*N7-_-7>=/S\S0FMYP7_LN8V]#XKDF3FW%?Z
M<I&_VCLBADQALIHH:/R[,6>F*(@0V/@CTMQKCZ2-_<^)^CN6';+,=#!GKOC-
MYO7RU=[3/96;N6Z*^LK=_L-$>1X3O<P5@?^J6UE[?+RGLB;4KHR;P4%I*_FO
MOT4]]#8\/=JQ81(W3)AO.8BY?*MK_?JE=[?*TVI0HP\L*N\&<[8BHUS7'K]:
M[*M?7WP\N_QPKCY/_WU^_?*P!D5Z?IC%W6]D]V3'[F?J@ZOJ95#G56[RX?Y#
M<-*R,TGLO)G<2?#:K [4\=%(38XFDSOH';?B'3.]XUWB59DKC?JLOZFW-F2%
M"XTWZC_36:@]'.*_VT06BB?;*5*0/ \KG9E7>XB"8/R-V7O]Z]_&IT<O[N#W
MI.7WY"[J/S3'_7<K.*VR56V\+=7<5KK*K"Y4J'5M$%2U6C5^Y8()(_7EX/I
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MT,GC(>&3\7 P!_@S=$> WU9(JM +@>>P5[Z,0>1JA/W.LW<VY".X\6DW0).
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M1N4 D;I+8:+&-!4(0YK<E+>Z*I"6%H!*W[2Y:LIJA9#JNC$W"N4=YJ\TW #
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M=8'2(E\!OY*PL?K1,IMF$)TUZ4*$\$K: I5[U1(IT8,C[B"^M3H1M$0Y41)
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M^FL@U^:N07MCT1U1&DBQCZ00R+UU<OF+Y\ZE:LJ&V)/FAM$@O@8LD8!UAED
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M'BC.-W$^"AN.0#I!OP ^<DI7N#1.X+K;2!#N8C4-?[X'A1564$X"=QX@"/#
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MB;5Q=?"!T\MF'SX[MJ\::'WV;?5 QVW>C*X)=^"!WWO@XD/\JX/D!VO+K_B
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M%.^W9J"W+5Y[48>LC[+@MB^$,9<5XJ^P\=M-_.,L^Z/%^D&[%3B?Z?P"/L/
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MJY$LQNRNTD7%81$2![84HO& PP2\8XH8.>-YH5.;9_UGEBAHO"=S#_C.0K,
MQ@^UN?,<DO,F#\X('Z$1'</G]P\CI[;8!ORU2,F/]/#+B+V#RKJ0*XE(N-,J
MA4MKD#!8)_C?V:]JNR0W"X3._NL(8*F"%;F"XV$9$#OD:-WR>Y53M"ZKLHF9
MHDW<IY/J<+2VL5M=(L'>":KX*E-KF12M,OL-L@.93:NVUD2XN)GY^$0R.SL@
M:T1QFR-.01YM)M2Q>1BH9G,"K*.4)UO50FF\4)EX.ESO0\ .'-0(1]AIJ32E
M@%0I,U4M+VU<8VVC JJ R"MAG=<\!.6M") -Z&\I!+5J"2],_"(_"=4ZE%LS
M.W&-DKT\O\W9SU4NF!<[!\*YJSZPBMB[J JJ*R9_48\*<N.0>2^(%J"X'DJR
M]('=*T.#RE*B,*;523,DQYH &R.^3I^^%0LAV(V"".A/T>F[%XOYQYOYA_G5
M)<KRY=75[>>;3_.;C^SN]M?YU?S]PLSR+HS^/$UEG5HRMXTWOMGDZ!)84D%9
M:J)\\$RBY:[QUZ'4Z'+<[!1?&&DFUUL#:CXU*5'PK&.-S^/%F!Y^G).[35R.
M::UHL^>?<L4?4.C1!DW"BV86H[Z$H+(!195@AZ$'"8L$:&3JOF@$##3I)70=
M<02+X""*I@)OM+#.RFF++?6?=?@6C!J-%#[8E6*[1$XWG>1X8/N0PXYBX'1M
M@7A(1 MRT9@_8+ 6'Z.;#4(N"JPN9=(CC2\R(=$X)A4R%1W(M.JN$AH!>2\3
M1?*7FAM[=AN.2$A$51H9S49..V$MT-E@ER,3C>S;3U<]%PY"X1 Q#.!89VI)
M0XWAW[%N*/Z;W/:]P+.%Z9A=]5P.IC<2<E%I2\AD<0(PT4\RA3F&&C3?&1$L
MR4P74)>Z%KT65UO1#A6$L[3WE6>C(<:FZ%&K"Y/TXQ&XAU'S'+B'*WZSG=T5
MK';8HM)&$>OBW:;<\&P+6^X&B!7]Y!VP-W$)G6U3:GRZCDCFZ!@![*JTR#&1
M29Q!V[H@*8.2FE#1S><%-P<)8(>E665H>2G*/96%H?J&9HU'&F(:LZO:4XDJ
M"/ZBPG1X]')+5>+/_JYHB"0Q+_F/IE[2IVD,I*Z[T(]*I7N99<.G]Z(A::CF
M& /6]GC@- V]>5< [5 ZK"865*/KF45D!"9 U2F ?"[0S<,'MC,Q1E-QLA&Y
M14#6IX9AM73(+EMPS%,0"RTLZHY/@K?L<<5TJ:9"UNM7@#]/)(5_UZX".J51
MCLPA+.]$U;.A9JF-*H].FP[$R%P3PK .&2LRM6LT!"1;@%7R!S.:B37VZQVD
MCI28IE36#0(T02_;;EA#!KEK?+53,F5F:Y&98T+=)R@P!1KK/D##'9LS1H-[
MW87W)!AOM:6["['Y(4S[C3]IU1Z..I.=OC)M)TJGXEZO:J-QS#Y4FO9'V )Y
MSDR34]<,Y*/XT68:Y0T L0'7'&; *^:XE+3^I!!$;$I2SK#<%@V0 <3D1XTJ
ML\?K@O*W3L@?]U18^K9!GJ5 ;L/SR-%GQ2B=":&NM^D(X[[? ][5O=_B4(/8
M-(9[V$3Q;CL7-""?3.WNOS)Z4JMOJ*1_8QQIR+;(;?+,R%1VNGB]NT;+EW5?
M<<JB,*2K/\'5<R)W9C^]Z$D?X$<N\R<>FV#F=.8^*8L3GTU";(&]O-GAFN8'
M4^9CX02Z3"%LR'NST,?_&?K""63A&I-:ON.&L?GT/(_4=&8!?<8.21MR=<^F
M8$:3@HFUR8WK3V@XM&D:L1DVP]:!&SZQ* A8Z++IE'F^>]@@+_*8!Q$AC(G"
MR1.#4- @><)B2(EG,TB*82#P<<+IA P$[AT[G?G>=,3.O&F,:^R%N$8Q[K_+
M\5@Y<S$["&C]S/5)BN-&T>@@TV/0FXU,P?7\"RPV"\(8SP[4BJY8$2&9P[_=
M=".RU+2>5(0ATZA.%VP+4X+1_U90SCPRA01%=/&AE:TO=<$]J[-Z9.H+]![!
M 0$ (P#,[*<EV@?*$?P>(_ PT[@?FC7# 4,LLKA[WM#&63 E4X+(F.9XT<3B
M.H5I'XFUSPB1$4$B'FC#2A:;AI%3L2RQJXL50#<V&N+F W@/!VXJ:N;-1:_6
M3Z!)R!#B\]I0*WTI@+%HE$79 8.<LC"@'/4]DQC^%%?2+(Q&'0?A++[H'8_K
MD$53!"\HM%[]B?US=',\29J)7W'4D&)LP@V3:IA&!S-GF"F?5(F)WR4_0V)/
M&S?BKP!7<,9I&]6 Q25P/)]H@)CEG>V\VQG-)Y8UMP$B)(Q]<Q!HGTW;6U $
M!D/79V_K4T77_7RT'7(GW@-)M0L1?!'\Y-:3VU+@L5D[*69$GBT;$]?6-A'/
M61L:-GP.4-XAH/R(F-,; A6$/:"\XT"%/:! >?%L %38V1L *$Q '7D.4'&W
MD+@2]$B2AT!1BG9 @3N#MF!103HEY4Y-:3DU):0I%]^KED<"BHK@M(VA#JK8
M/ U",^;$2.]C8%$9;"UTO!@UQ F>($8*-O>1*5(>S47)>@9L 6I)<X]2YTW
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M KPT5%1B&Q7R-4 :P8UL5->B$$H"#XK:3Q<C42H",FOL/(2TNE=BH:1I%Z.
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MG?<#T+6AZ\"JRIMHJ2Q9TD\+>@-1NP3:7REE=X$KT+ZJZ1]02P,$%     @
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M=QU@+F-'Y/FMY[Z5YW]'WI64^:8H2^!U#M>UX?6B0%]AK+4P&BX*G952KY6
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M%O37H78.M)XK94\#MT'W>R[^!5!+ P04    " !2AF-56J2;.;0'  #<$P
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MTE#GJH<9_2I0V0.TGTIIGB>V?;4_G^ W4$L#!!0    ( %*&8U7,+*K( @4
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M8-Y3\A*1B/@\1V#QLR,&B:*<),KQ7P7MU3%SQ^/C5[I=5%Y4YAFGQ*#17V'
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M-"X.-P2+KZ'<0-Q?4\I?3_( ]:;NQ?]02P,$%     @ 4H9C599$=C)^!0
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M<#ZD-.FJ.5<#JXJROSTJ2]VR?,SH>P:U,Z#WJ5)V/W +U%](T0]02P,$%
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M./Z2)/SMC7P\H7@<I?L;4$L#!!0    ( %*&8U6'TRBC\P0  *@<   9
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MK>N3*-K@8J)XFC>&>ZYTFYD/C_K+ 84QT/</G*O'B=F@^A:9_ =02P,$%
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M]]@'[=,^N&YR7I_-^:BQ9#P'?+8]C+!65WES_+\QSD)_HU@W3>$W/Y4Q;GX
MU]N&Z^UW&N/VJP]$YS^^"(\:H/N7F#%M6P.!P+6-:5U>6U?INC_7$Z-*WQ-7
MRM@.ZX=;^TN#VAVP^VNES,O$M=GF)RG^!U!+ P04    " !2AF-5W;MH9X\#
M  #-#   &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6RU5VUSXC80_BL[
M[DTGF<G%8-ZN*3!#L--C)G 9.*X?.OV@F 5KSI8X24"NO_Y6MN/RXI"T=;^
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MPBRM;YE@,D98.*4&WH[0,B[,NSVZ.-<:9?P%\(4WKGG/8*8LC-!08,''#'S
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MX:IVX>JW:NJK4QIW(K(#XZYKXZY_L:FO__^6;@CY]IKV]^8D-Z-.F:8)PH#
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MI7UR=+STR^>&*J-R8W8/;HHQD6M[@58 (.4ZN^L43XM+^M!>34O/;\WEW=Y
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M7ND-Y[,>7%Y<P070#,:4,9T LN4JK=^H<.-2:Z?0ZI_1.L/\%@+O&GS/]T_
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M[_0,O<FJDU83+0K;C.9"8VNSPQ7^?$": -Q?"*'?)Z:_-;^S^"]02P,$%
M  @ 4H9C561Z)6D^!0  )A\  !D   !X;"]W;W)K<VAE971S+W-H965T-C N
M>&ULM5EA<YLX$/TK&JYST\Y= I(PV#G;,X[=YCR3I)DZO7Z6;=GF"H@3<MS<
MKS^!"3(@.&>J?+$![S[>+KN\E34\,/X]W5$JP(\HC-.1M1,BN;+M=+6C$4DO
M64)C^<N&\8@(><JW=IIP2M:Y4Q3:R'$\.R)!;(V'^;4'/AZRO0B#F#YPD.ZC
MB/#G:QJRP\B"ULN%+\%V)[(+]GB8D"U=4/$U>>#RS"Y1UD%$XS1@,>!T,[(F
M\&J*O<PAM_@KH(?TY!ADH2P9^YZ=S-<CR\D8T9"N1 9!Y-<3G=(PS) DCW\*
M4*N\9^9X>OR"_BD/7@:S)"F=LO!;L!:[D=6WP)INR#X47]CA3UH$U,OP5BQ,
M\T]P*&P="ZSVJ6!1X2P91$%\_"8_BD2<.$"WQ0$5#NA<!UPXX#S0([,\K!D1
M9#SD[ !X9BW1LH,\-[FWC":(L\>X$%S^&D@_,9[?/T[N;^;7MQ_!9+'X^+@
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M\]<^4+;N&K;Q=N.>S!=2WS"#3HKG, 'YF-YQ-3-+EXC$D C"$L1AUC5Z]L7
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M-T6ZKI=YNT^+(EW5+Y<BG(NL"BA__Y"FQ<N;Z@MV:Q%._@=02P,$%     @
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MZQXF+:LO@VJ@15$VUY70V*K+RQU^38$T ?A\(X1^&9A^W7R?)?\#4$L#!!0
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M\?;AG%6C\5DU@K(J5"V%JC&4FE@LSJK1J*P:Z>^KE"BH:MX-ZQ) 416E)I:
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MG5*P+AMZ.;$J*YKH0EEJR<5P33]!J-T">K]4U#=V$]>7J]^JP0]02P,$%
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M.S4T6NQR[T3K.J+2#*7%*$V@-(G2%$K3%,W^,3#2+.Q$FH6H-$-I$4J+49I
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MY=>OLG):KC[9!MQE^1^[AWGQ?U!+ P04    " !2AF-5:77,\J@'  "42@
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MS.KOY#4Z@Y;^; NPQ&J;V>P_=O@4C<LW/=94:GHPMAC--I'N2I4J!D1J>@R
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MG+I.+5U^;.F:X"D./,7Q*XKU:Q^5'0I7:YRE)CB* T?QP$BEDMX$1J6FQP!
MC!L%,:5^8)T GT-;CT!A'*<P),>/:T^D6$:EIC\Y UCF&\$RGQ3+J-3T& "6
M^3B6U3\_9%?\!ZKZIG1\%VTM '+Y.'*=6+=*_4#=XG-HZQ%(RL>O&/(ZK'2M
M2D^D!$6EIGL'@O(](V5*>L<7E9H> T PWRB"^=4(QO<0#)]&6YM;#S,>0K#:
M-#^J/>'RC8^Y"2;S@<E\(TSFDS(9E9H> V R'V>R^O;4VV]/;O5-Z?@NVEH
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M*$ZQ.(WAK!'4,G@1O,PV8CT=BHM9G&)Q&L-9:;<\700OLY5Y[FGW+[/M^<A
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MG;L%C;PKS5Y8]>\O_*G^[!X$0U^"0#6):@K5-*H92K.;HD[:!^P]I=U<YRY
M4_=!A]0=K2Q03:*:0C6-:H;2[,E?I^X#=^K^U-5V(KG,;N+L6[FC<=1J1P/-
MTU$M1+4(U02J2513J*91S5":W3=UGCY@\_0!FJ>C6HAJ$:H)5).HIE!-HYJA
M-+L]ZCQ]X,[37[JC@6;KE?;\)5XA6C=J75>@=67KN@JMJUO7-51=>W;6L??
M'7NW.;?6372>@B?[Z_)^\[H\1"M'J"903:*:0C6-:H;2[-\A5N?/0_?5S]^U
MRG_9^;7N5]2U?U M1+4(U02J2513J*91S5":W6%UA#UD[],]1#-J5 M1+4(U
M@6H2U12J:50SE&:W1QUF#]UA]G><7^L6.W=(L!</[(0!(5HP0C6!:A+5%*II
M5#.49D_[.HX>NN_W_2/77<^>8^M^;9T;",VV42U"-8%J$M44JFE4,Y1F]]JC
M7Y0\9%=@:)B-:B&J1:@F4$VBFD(UC6J&TNSVJ%/NH3OEAL^Q=5?KW#W[=YS>
M.RLV1$M&J"903:*:0C6-:H;2[*:HT^^A._WV_>U)MF*>;7+O_3Q9-9QO>Y&L
MBVW(99*UOLV4NVCGWD"C<%2+4$V@FD0UA6H:U0REV4U41^%#-@H?HE$XJH6H
M%J&:0#6):@K5-*H92K/;HX["AS\T"G?KG;L%O<P<U:+A_D7K_0-_YRB=0&O*
M5C456E.WJFFHFO:LK2/RH3LB?_G*Z(7Q(1J_HUJ(:A&J"523J*903:.:H32K
MW49U0#]B+Q ?H>DZJH6H%J&:0#6):@K5-*H92K/;HT[71_B]S]UBYPY! W94
MBU!-H)I$-85J>K1_*?[N(HPJ:$_[.C4?N5-S?UA= SY)5].G5F&_3O+T;@TV
MZ+<Y.N6NV;DQT"O"42U"-8%J$M44JFE4,Y1F]U =P8_8*\)':&J.:B&J1:@F
M4$VBFD(UC6J&TNSVJ%/SD3-V?.G1*;?>N5O0$!W5HDK;.6JSDU$*M*9L55.A
M-76KFH:J:<_:.LP>N</L%R^,7G9PROWJ.L]Z] IP5(M03:":1#6%:AK5#*79
MW5:GY*,QNX1"\V]4"U$M0C6!:A+5%*II5#.49K='G7^/W+^-^WL.3J$1.*J%
MJ!:AFD UB6H*U72E.0]._8A<>U3GVB-WKOW_6H,]>YZ[^W5V;B8T(4>U"-4$
MJDE44ZBF4<U0FMUW=3(_8G_1]PA-TE$M1+4(U02J2513J*91S5":U1[C.DD?
MNR]UA\]S=U?KVCVH%J):A&H"U22J*533E>:\=L%0)>VFJ//SL3L_/]DNU71Y
MD+>8Y_/R&*]*%]-)VK!D,_'J_M+$5F>[NTMW[A T:$>U"-4$JDE44ZBF4<U0
MFMU*=28_#M#EUQB-VU$M1+4(U02J2513J*91S5":W1YUW#YV7_'^PCS1K7?N
M%C1]1[6HTG;N5WVRDR>B-66KF@JMJ5O5-%3-NUE[N)DE21[&>7Q^MDRRZ^1=
MLEALO$FY\B^+/'JT6/Q?%;/:/WT3] [W'H_\4^$W/"[]4]7TN/9/S?;QP[KL
M^=FZV GY$&?7\]7&6R17Q4OH'QR->EXVOYX]?)*GZ]>]8M-VF>9YNMQ^.$OB
M:9*53RC^_RHM%F#5)V6!VS3[??LVS_\'4$L#!!0    ( %*&8U5<8-6$GP0
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M!,W*S37!"\)4@#R^I/)%L-Y1"9K%P>F_4$L#!!0    ( %.&8U7F!L5Y5P,
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M-E$Q0&R,'.I54%J(T@1*DRA-H31=T1Y'KM?Q1LZJD^ZA[B2:S>*R)XX6?S"
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MOS_Y_IU^\=]?JA1?[F3,QY6I33(J85!:B-($2I,H3:$T3='<=%M3TQL<>R2
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MJ4[@JQN&2WG$_(@9P[F\3!",$1$&_/D:8W:X$1TTWT&\_P!02P,$%     @
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M82I /E]1*EX+ZA"C.GB;_@M02P,$%     @ 4X9C5?<3R[C3 @  %PD  !D
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MM84 *#5$.HUO):=536F A^T]^^=<N]:RPA("3K^02,5]ZX.%(ECCC*HYW]U
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MS@3359PQE,!2A#*NKD5G:'5YJ :<Y.7IN"!<G+7EXUK<MX!*@'B_)(3O!C)
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M#30$:2K@^Z40^NW!.,BOL&?_ %!+ P04    " !3AF-5\C2P!0($   ;#P
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M/&ZA>R5< >#]FC%Y&"@'=3\\^1=02P,$%     @ 4X9C59<)8W+< P  ,Q,
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M<Z5X:A]72!(49H+^ON!<O0Z,@[IS-?D;4$L#!!0    ( %.&8U4A<A#9<PH
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M6Z,A*E3S4,U'M0#50E23J!:A6HQJBM*Z3P!MB,K&0U0V&J)"-1?5/%3S42U
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M=V]R:W-H965T<R]S:&5E=#DR+GAM;*V676_:,!2&_\I15DVMU)&0\+4.(M'
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MUPMGN/H[54")U'*JD!#-N5JF0X@6[M!IN[3#N-D.^QSOR]6&_8W]*]_>D1&
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M!/7?[_.\>GG3;.#XK*FK_P-02P,$%     @ 4X9C53_&1YO[#   ))<  !D
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M1+]$LA)]8LH&^;P->LD#'=4%?O3@!08M7T%I$D73^XJ48PO<B7)  +5T4)J
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M"9K?WY1E_?)@]P)/9?7[?CKG_P=02P,$%     @ 4X9C564@%-K7 @  BP@
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MC1YVF\A'7[Y1/#738\457@"SW.#7 @CM@,_7G*O]1@<HOS^\WU!+ P04
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M*^$S_O]TMX).,W>Z:?!:1_"&RB@B6,(#& %? 56N\9BEGI7950FG'^\+$>,
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M=$ML^KI7F+2?GF*^(E2@$)8*TFETU-N?IRUJ.I$L-EW>(Y/J^LUPK=IZX#I
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M1S 'X %#DJ1Y#^Z]C^+U>RK>_(=N]!M02P,$%     @ 4X9C59>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !3AF-5
M,#E8F2T'  #G0   #P   'AL+W=O<FMB;V]K+GAM;,6<T7.:2A2'_Y4=G]*9
MYAH1$3I-9PAN##,*#FC:MPS1C7*KD %,>_O7WT63VT.+O[DOISX9D9#/L\M^
M9W</^?@M+[X^YOE7\7VWS<KKSJ:JGC]TN^5RHW9)^5?^K#+]R5->[))*ORW6
MW?*Y4,FJW"A5[;9=X^K*ZNZ2-.M\^OAVK5G1I6_R2BVK-,_TP?K ?:J^E3\_
MK]^*E[1,']-M6OUSW3G\O%4=L4NS=)?^4*OKSE5'E)O\VUU>I#_RK$JV\;+(
MM]OK3N_XP;TJJG3YV^&XAIPGC^7A2)4\1HD&N>Y85_J"3VE15H<S#M=/-..+
MTB<?W^VK_#;=5JH8)94:%_G^.<W6]67TM^B2KW&(P]OK,8@?BO\3QOSI*5VJ
M4;[<[U16'>-8J&T-F)6;]+GLB"S9J>O.VRDBR59"9I4.DO"SXZ7TN?4WU7_:
M7QV_=:5Q20R+#ZG^H/!7!W ^2"\,XG#BC]RY'(D;=^(&GA3QG93SF  : - X
M&Z"XF"4$L@\@^W\0,I[KEZD,-&!X*\*9C BD"2#-LT%ZX71&( < <G VR/C.
MI9&T *1UODBZ\1V!' +((2_D2,9>Y,_F?AC48#>+V ]D3.]J&\#9O'"Q/P[\
M6]]S@[EP/2]<!',_&(N9CJKG2PKI $B'%S*2]S)82!%)+]2X=23IH'V%1NTK
M7C0=)AG$=<C<<21?NY\;C,3(OY?QG&)"N3#;)=(LT<*;+R*-^E[XP5R.([<.
MY'L12SKD])!B>LR.N77]2-R[$]W64^G&BX@$]-9O-#J23(_9,GZ@^^,\C)HW
M2 \II<?L%-VB;C#V;R92N'$L7V,V#L/19W\RH93(*3UFJ>@1)EKHH;IF"^=W
M,A+>(HIT+,7$=V]\BHFLTF/6BNYJ.KLYW-11I,-Z[(64#NFDQ^R363W@:)?4
M09R%^KZ6<_]XHP@YG37:&HFEQVT6G27(RQLWUNU=IS6:VOUUY$9.Z3%+1??%
MQ70Q.:0.KWU14T;RK@[OO:1)-Q*,P2P8/7)+-_+NCE+1(IR$L[JM*1\RB\%L
MEF/HY)>Z?:6X\ ,=1?GNO0AD Q%.7)BM<F02<_=+8[PVD$(,9H7H-@WT *.G
M3I,PCM\)/3DYY-6-?H>$8C +92+'[D3,HM"3<E234C#D$(/9(;$<'\8Z/[@-
MH^FO0XJ!O&$P>P,FTP\&Q40",9@%TI).BXMYHB'*=Y01V<-@M@?,!)NA1!(Q
MF"5",L&V$/:1.?K,YL IH:"82"!]9H' G+#1TGTDD3[WU*0U)VQM=+C^Q>P5
MF!PVHXGLTF>VRZGD\#6>%!.YIL\_7SF=(S:CB;S39_;.J1RQ)9K(.WUF[X!4
ML2:EF$@]?6;UG$S-CN&DF$@]?6;UM.1!;:.1B11D,BOHQ-*GN!1!4A2TQ4VD
M()-903AOZU-,I""364%M>=MK).N=-XJ)%&0R*Z@=\SXITKISTKS#A)LPS IJ
MQW3K3<QZ@Y!B(@69S J""\P-!9E(02:_@DXO,#<QD8),9@7A:47C3D<*,L\Z
M^S$I)E*0R:P@C#F@&YG(0@-F"V%,BV(B"PV8+80QAQ0366APSCV:!YMB(@L-
MF"V$,1V*B2PT8+80PGPX[&S^APF+ 9@MA#%[%!-9:,"]<0,QJ84&R$*#,UKH
MH4<M-$ 6&C!;B"YN70HOWSWGF?Z-4N1/PL]>*":RT(!]#0ZL<S52#PM9R#KG
M<EPC];"0A2QF"V%,FGI8R$(6^YX.PJ2IAX4L9#%;""]N-AH=6<CBME#[XN:E
MB/>[75)03&0AB]M"IS"]_$5E=#G!@D5I9RD?T)CR^W*3T'I3"UG(XK80:O3F
MN(DL9''/A4YBJBS-&WT36<CBG@LAS$8TA\A"0^ZY$,2D ](066C(/1<ZA?E9
MI>M-13&1A8;GV12Z%.,DS<0%Q406&G+/A4YANNMUH=84$UEHR&PAO'?5Z)O(
M0D/N H13>U?'M5B*B2PTY"Y&.(U9#_ 4$Q9',UL(8C;'362A(;.%\$Y@HV\B
M"PW/6=36R-YM9"'[3$5MO_=-&UG(/E]M6TU*,9&%;&8+84Q:'64C"]GL5=,_
MR_#HOI6X&*DJ22DFLI#-;*'3V[^ZR9<;BHDL9#-;"&$&C2F;C2QD,UOHMS)"
MC3=1ZV0K9D6^I'N6-K*0S6RA-LQ8+?=%6J6JI)N!-GQ8A]E";9AN_4!CL2^K
M1KYI(PO9S!9JP_2S2FVW:EGMZ3S=019RN)_=:<'4O7*U7U9BDC8PD84<9@NU
M88Y5I@I]$WDI789UD(4<9@NUU:.T5R<XR$(.LX7:,6.U/CPA3)]K=)"%'.X"
MN5;,45HFOT[9'&0AY\\78_]L]$;V[B +.=QSH5;,2+VH;*_$(\5$%G*XYT*M
MF-/D[[P0WKZDF,A"SL%"W</)Y:>/*_649FH5Z#]1ZN/+9+N<%:)^J:_4,\Q!
M_1S.TWZ[]?2Q,)ODR>KM.?VW_S'PZ5]02P,$%     @ 4X9C5:.T-3') @
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M]78">COJ[03T=I/-$@&]'?5V GH[ZNT$]';4VPGH[:BW$]#;46\GH+>CWDY
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !2AF-5 '8TY>X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !2AF-5
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( %*&8U7[?OCY^04  ,X?   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !2AF-5
MPXDL1(@&   S&P  &               @($\#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ 4H9C52+J&V%@ @  W04  !@
M     ("!^A0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M %*&8U6W#"3H4P@  "\O   8              " @9 7  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !2AF-57ZL\H1H$  "9#P  &
M            @($9(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ 4H9C5?;/4"@\#   \W$  !@              ("!:20  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %*&8U5RBL[&0 D  #DJ
M   8              " @=LP  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !2AF-5UBI=0*(#   B"   &               @(%1.@
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 4H9C57^,8M!6
M#P  R2H  !@              ("!*3X  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( %*&8U6>M)++V@P  !LC   9              "
M@;5-  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 4H9C
M53EAPVC?!@  H@\  !D              ("!QEH  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !2AF-5L(3S2^,%  !+$   &0
M        @('<80  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( %*&8U4J/(5,4!   &4V   9              " @?9G  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 4H9C57 W!,)I @  004
M !D              ("!?7@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !2AF-5GTYTE6(=   U?   &0              @($=>P
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %*&8U4^$<\P
MW@(  "4&   9              " @;:8  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ 4H9C5=@BNOFG(   -H@  !D
M ("!RYL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !2
MAF-5@7*1,(,#  !)"   &0              @(&IO   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %*&8U7;'EBV. T  &8K   9
M          " @6/   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#
M%     @ 4H9C542.'.;; P  NP@  !D              ("!TLT  'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !2AF-5B#O'$,D"  "!
M!@  &0              @('DT0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+ 0(4 Q0    ( %*&8U5IN,W#40,  ','   9              " @>34
M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 4H9C51>=
MZD8L#P  QRH  !D              ("!;-@  'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " !2AF-5IW)%*-0#  !/"0  &0
M    @('/YP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M %*&8U6!'F!^<R4  (^'   9              " @=KK  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ 4H9C51 3+"V$#0  42,  !D
M             ("!A!$! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !2AF-5HSBKKS(-  #8)   &0              @($_'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %*&8U55G/,?_ 0
M %(,   9              " @:@L 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ 4H9C5<)C/_2$!@  M14  !D              ("!
MVS$! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !2AF-5
ME0">)8,"  !A!0  &0              @(&6. $ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( %*&8U468KD]P04  +<1   9
M      " @5 [ 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ 4H9C52?*UBOK @  % 8  !D              ("!2$$! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !2AF-53+-.L6 &  "Y$0
M&0              @(%J1 $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( %*&8U5V)MN-0 ,  $D'   9              " @0%+ 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 4H9C508NR%\Y
M!   9 L  !D              ("!>$X! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !2AF-5A@K-(MP"   $!@  &0
M@('H4@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %*&
M8U5_:+DVAP(  +$%   9              " @?M5 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ 4H9C50SKSY+O @  :@8  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( %*&8U5\B0;?H@4  . M   9
M  " @6UO 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M4H9C599$=C)^!0  BA\  !D              ("!1G4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !2AF-5K[MO2$<#   M"0  &0
M            @('[>@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( %*&8U5I+_@$X0,  !\1   9              " @7E^ 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 4H9C58_=I,XN!
M>Q4  !D              ("!D8(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " !2AF-5]-,^(]H&  ":,@  &0              @('V
MA@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( %*&8U6'
MTRBC\P0  *@<   9              " @0>. 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ 4H9C58%2D4Z  P  EPP  !D
M     ("!,9,! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %*&8U7BKL _;0,  -H)   9              "
M@4BD 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 4H9C
M5;TQVO0B P  BPH  !D              ("![*<! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " !2AF-5_>7#OW$$  #>$   &0
M        @(%%JP$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( %*&8U4'$SSWN@(  ,X&   9              " @>VO 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 4H9C5=HE(*:6 @  V@8
M !D              ("!WK(! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " !2AF-59'HE:3X%   F'P  &0              @(&KM0$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( %*&8U55ZC.,
M+A0  !)) 0 9              " @2"[ 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ 4H9C5:4#.K , P  50H  !D
M ("!A<\! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !2
MAF-5"S#>-G0(  "74   &0              @('(T@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( %*&8U5D0!^140,  *L)   9
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M970V."YX;6Q02P$"% ,4    " !2AF-5Y<5F[:$6  #+1P$ &0
M    @(%G"0( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M %*&8U4G&Q6L-@T  $S"   9              " @3\@ @!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ 4H9C55Q@U82?!   71P  !D
M             ("!K"T" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " !2AF-5IAJZ2C\"   M!0  &0              @(&",@( >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( %.&8U7-2Y@H1 0
M "@<   9              " @?@T @!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ 4X9C5>8&Q7E7 P  W@L  !D              ("!
M<SD" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !3AF-5
MWG8Z>I4$  #Y%0  &0              @($!/0( >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( %.&8U4G9;!G;P\  'K?   9
M      " @<U! @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ 4X9C55\IAH8A!   $QD  !D              ("!<U$" 'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " !3AF-5ROSNK"(%  #<'
M&0              @('+50( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( %.&8U7]3%:#-@0  (0;   9              " @21; @!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ 4X9C5?<3R[C3
M @  %PD  !D              ("!D5\" 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    " !3AF-5_)[HA <#  #-"0  &0
M@(&;8@( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( %.&
M8U7JU>$FJ0,  )(,   9              " @=EE @!X;"]W;W)K<VAE971S
M+W-H965T.#(N>&UL4$L! A0#%     @ 4X9C58#:WQ[? P  X!$  !D
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M=#@W+GAM;%!+ 0(4 Q0    ( %.&8U6Y^"7\M@D  %!\   9
M  " @9!^ @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @
M4X9C53F#?":W P  Q1(  !D              ("!?8@" 'AL+W=O<FMS:&5E
M=',O<VAE970X.2YX;6Q02P$"% ,4    " !3AF-5(7(0V7,*   FG0  &0
M            @(%KC ( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4
M Q0    ( %.&8U58PW;YN 0  /@@   9              " @167 @!X;"]W
M;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ 4X9C559"KT?; @
M?PD  !D              ("!!)P" 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX
M;6Q02P$"% ,4    " !3AF-50]3++2\#   (#   &0              @($6
MGP( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( %.&8U6<
MQ$G;Z@H  '=J   9              " @7RB @!X;"]W;W)K<VAE971S+W-H
M965T.30N>&UL4$L! A0#%     @ 4X9C53_&1YO[#   ))<  !D
M     ("!G:T" 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4
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M  "N$P  #0              @ &KR ( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( %.&8U67BKL<P    !,"   +              "  0S, @!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( %.&8U4P.5B9+0<  .=    /              "
M ?7, @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !3AF-5H[0U,<D"  ">
M.0  &@              @ %/U ( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !3AF-58=MXD5$"  "P-P  $P              @ %0
LUP( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     :@!J !T=  #2V0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>767</ContextCount>
  <ElementCount>386</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>205</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>19</UnitCount>
  <MyReports>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE</Role>
      <ShortName>LICENSING AGREEMENTS AND DIVESTITURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - OTHER EXPENSE (INCOME), NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/REVENUERECOGNITION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails</Role>
      <ShortName>REVENUE RECOGNITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails</Role>
      <ShortName>REVENUE RECOGNITION - Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails</Role>
      <ShortName>LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - INVENTORIES - Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails</Role>
      <ShortName>INVENTORIES - Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Exchange Offer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails</Role>
      <ShortName>OTHER EXPENSE (INCOME), NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Antitrust (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Intellectual Property (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Product Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - General Civil Actions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenue by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="bhc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentBasisSpreadOnVariableRate1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  bhc-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="bhc-20220930.htm">bhc-20220930.htm</File>
    <File>bhc-20220930.xsd</File>
    <File>bhc-20220930_cal.xml</File>
    <File>bhc-20220930_def.xml</File>
    <File>bhc-20220930_lab.xml</File>
    <File>bhc-20220930_pre.xml</File>
    <File>exhibit104supplementalinde.htm</File>
    <File>exhibit105supplementalinde.htm</File>
    <File>exhibit106supplementalinde.htm</File>
    <File>exhibit107supplementalinde.htm</File>
    <File>exhibit108supplementalinde.htm</File>
    <File>exhibit311q32022.htm</File>
    <File>exhibit312q32022.htm</File>
    <File>exhibit321q32022.htm</File>
    <File>exhibit322q32022.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1611">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>121
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20220930.htm": {
   "axisCustom": 1,
   "axisStandard": 46,
   "contextCount": 767,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 785,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 14
   },
   "keyCustom": 84,
   "keyStandard": 302,
   "memberCustom": 124,
   "memberStandard": 79,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - REVENUE RECOGNITION",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE",
     "shortName": "LICENSING AGREEMENTS AND DIVESTITURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - INVENTORIES",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - FINANCING ARRANGEMENTS",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - RESEARCH AND DEVELOPMENT",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - OTHER EXPENSE (INCOME), NET",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET",
     "shortName": "OTHER EXPENSE (INCOME), NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - INCOME TAXES",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - LEGAL PROCEEDINGS",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - REVENUE RECOGNITION (Tables)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - OTHER EXPENSE (INCOME), NET (Tables)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables",
     "shortName": "OTHER EXPENSE (INCOME), NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i400457a1387e48eaa2cf072d6caa4556_I20220601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - REVENUE RECOGNITION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
     "shortName": "REVENUE RECOGNITION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "id369b423b8504df5bb95a335c257add6_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "if69ff7ae606c425c94a4c448e089a08c_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails",
     "shortName": "REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "if69ff7ae606c425c94a4c448e089a08c_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails",
     "shortName": "REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "if69ff7ae606c425c94a4c448e089a08c_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i687a6d97c876442da5f14198d88e14b1_D20210331-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
     "shortName": "LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i687a6d97c876442da5f14198d88e14b1_D20210331-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i98ff32b9f66642d49d99b62aac6963ff_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i189881ec0c284dfcbb328b608d14d436_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i189881ec0c284dfcbb328b608d14d436_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i658a48e24ddb46329d8726eb2248580e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i658a48e24ddb46329d8726eb2248580e_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i172f1137c8f54eb5aee6b0e56da822a2_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i172f1137c8f54eb5aee6b0e56da822a2_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib700cf771af14037994bc18bd56d1eac_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib700cf771af14037994bc18bd56d1eac_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i04b46684430b436b80adda1d481b4307_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i04b46684430b436b80adda1d481b4307_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i04b46684430b436b80adda1d481b4307_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i04b46684430b436b80adda1d481b4307_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i5ecd34cbf70047d581aacda69e14f631_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i07c71f42a1544418b4d10d3fc382ee03_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i07c71f42a1544418b4d10d3fc382ee03_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "if69ff7ae606c425c94a4c448e089a08c_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "if69ff7ae606c425c94a4c448e089a08c_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i63a5e3f00efb48b2b18db41abfecd3de_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i63a5e3f00efb48b2b18db41abfecd3de_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - INVENTORIES - Components of Inventories (Details)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails",
     "shortName": "INVENTORIES - Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib5d21251ba2e4156877ad94aed58ea65_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib5d21251ba2e4156877ad94aed58ea65_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i0e5e1db69fcc44599f220cf73306bacf_D20210101-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "if69ff7ae606c425c94a4c448e089a08c_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ia798b021a554457c89afa7d9f4e59bf9_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ide6282cbd6934b8d9a2d10f3b7cc0544_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "iabd7119954044616a3233f093428ce2e_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i28a31a3954134e40bc913cd1fb66abf3_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i042059a75e2442fd999e415f9c25591a_D20220510-20220510",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
     "shortName": "FINANCING ARRANGEMENTS - Exchange Offer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i58945eb4f42545a2a975fa287df7030b_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i4afef88c6a4140829ef856906a21c44c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Aggregate Principal Amounts Validly Tendered and Accepted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "if878061e7e8a4d5b87624e62ac22aa3a_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i0f887978c4a542b19634fbdbca4dbd97_I20180601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1f904c39c824f0cbed6373fc8027458_I20210608",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i7356824e0b3446aeb0703cbdc0f9101f_I20220118",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i042059a75e2442fd999e415f9c25591a_D20220510-20220510",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i2298c61bc25a4158b0e7b2effac5d67a_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i638f574f114f4eab8f9dd23192032e2e_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i71c67458cddf440fae3e9d2616d2822e_I20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails",
     "shortName": "OTHER EXPENSE (INCOME), NET - Summary of Other Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - OTHER EXPENSE (INCOME), NET - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails",
     "shortName": "OTHER EXPENSE (INCOME), NET - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i39bbe98ba2634efa8a0ac3f26b52da3d_D20210101-20210930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "id17555885c6b4ec5b2e98860a7c4cf48_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "id17555885c6b4ec5b2e98860a7c4cf48_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails",
     "shortName": "LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ib630580e79374684b3bc209e9e4a1fc3_I20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
     "shortName": "LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i382068ec3e7d4fd2abe8a991e682aa28_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i0c6de1e6ea024ddbaff325eb35a50f24_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
     "shortName": "LEGAL PROCEEDINGS - Antitrust (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i0c6de1e6ea024ddbaff325eb35a50f24_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i6dbd8d94f94a4b9b9032e8124939d763_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:GainContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
     "shortName": "LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i6dbd8d94f94a4b9b9032e8124939d763_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:GainContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i92e33ca886304a7f8736aba94ba18b95_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
     "shortName": "LEGAL PROCEEDINGS - Product Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i92e33ca886304a7f8736aba94ba18b95_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic05dba365c7149048c6b1a7245d1b247_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
     "shortName": "LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic05dba365c7149048c6b1a7245d1b247_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "iad592bdffaae43e9a655afeab7d37965_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic2502f43413f4cd480e2a0246b792a52_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8eede7fabe3a4f2ba57b19bd82733d3d_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "ic1fcfc437dd34982941e112b9e7153a2_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i8fe2e15021d740338238235057cd9b13_D20220701-20220930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
     "shortName": "SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i5c17a5874a9e4075aaf8c4ce5d1a4e12_D20220701-20220930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i72d246b81e15499094a367cbe1d8db6d_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220930.htm",
      "contextRef": "i72d246b81e15499094a367cbe1d8db6d_D20220101-20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 205,
   "tag": {
    "bhc_A1375209BCLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1375209 B.C. Ltd.",
        "label": "1375209 B.C. Ltd. [Member]",
        "terseLabel": "Intermediate Holdco"
       }
      }
     },
     "localname": "A1375209BCLtdMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A2022OmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Omnibus Incentive Plan",
        "label": "2022 Omnibus Incentive Plan [Member]",
        "terseLabel": "2022 Omnibus Incentive Plan"
       }
      }
     },
     "localname": "A2022OmnibusIncentivePlanMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A2022OmnibusIncentivePlanRetentionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Omnibus Incentive Plan, Retention Program",
        "label": "2022 Omnibus Incentive Plan, Retention Program [Member]",
        "terseLabel": "2022 Omnibus Incentive Plan, Retention Program"
       }
      }
     },
     "localname": "A2022OmnibusIncentivePlanRetentionProgramMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.00SeniorNotesdueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "9.00% Senior Notes due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes due December 2025"
       }
      }
     },
     "localname": "A9.00SeniorNotesdueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued And Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "label": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "terseLabel": "LICENSING AGREEMENTS AND DIVESTITURE"
       }
      }
     },
     "localname": "AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic",
        "label": "All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic [Member]",
        "terseLabel": "All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical and Ophthalmic"
       }
      }
     },
     "localname": "AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivable and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmounPharmaceuticalCompanySAEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amoun Pharmaceutical Company S.A.E",
        "label": "Amoun Pharmaceutical Company S.A.E [Member]",
        "terseLabel": "Amoun"
       }
      }
     },
     "localname": "AmounPharmaceuticalCompanySAEMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AnnualAmortizationOfIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Amortization Of Intangible Assets",
        "label": "Annual Amortization Of Intangible Assets",
        "terseLabel": "Finite lived intangible assets, annual amortization expense"
       }
      }
     },
     "localname": "AnnualAmortizationOfIntangibleAssets",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ApotexIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc. Litigation",
        "label": "Apotex Inc. Litigation [Member]",
        "terseLabel": "Apotex Inc. Litigation"
       }
      }
     },
     "localname": "ApotexIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetImpairmentChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges",
        "label": "Asset Impairment Charges [Member]",
        "terseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentChargesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
        "label": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Base Rate Factor, SOFR"
       }
      }
     },
     "localname": "BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch Lomb/International [Member]",
        "label": "Bausch + Lomb/International [Member]",
        "terseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BauschLombInternationalMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb",
        "label": "Bausch + Lomb [Member]",
        "terseLabel": "Bausch + Lomb"
       }
      }
     },
     "localname": "BauschLombMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CanadianSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Securities Litigation",
        "label": "Canadian Securities Litigation [Member]",
        "terseLabel": "Canadian Securities Litigation"
       }
      }
     },
     "localname": "CanadianSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Executive Officers And Other Members Of Leadership",
        "label": "Certain Executive Officers And Other Members Of Leadership [Member]",
        "terseLabel": "Certain Executive Officers and Other Members of Leadership"
       }
      }
     },
     "localname": "CertainExecutiveOfficersAndOtherMembersOfLeadershipMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_CustomerTopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer, Top Ten Products",
        "label": "Customer, Top Ten Products [Member]",
        "terseLabel": "Customer, Top Ten Products"
       }
      }
     },
     "localname": "CustomerTopTenProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "label": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "terseLabel": "Variable rate, if rate not ascertainable (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "terseLabel": "Debt covenant, redemption and discharge condition, amount, if circumstances met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio",
        "terseLabel": "Total leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "label": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "terseLabel": "Credit spread adjustment (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentCreditSpreadAdjustmentOnVariableRate",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "terseLabel": "Quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "terseLabel": "Remaining quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal",
        "label": "Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal",
        "terseLabel": "Reduction of outstanding principal"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DefaultJudgementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Default Judgement",
        "label": "Default Judgement [Member]",
        "terseLabel": "Default Judgement"
       }
      }
     },
     "localname": "DefaultJudgementMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiversifiedProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diversified Products Segment [Member]",
        "label": "Diversified Products Segment [Member]",
        "terseLabel": "Diversified Products"
       }
      }
     },
     "localname": "DiversifiedProductsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "terseLabel": "Income tax provision (benefit) for discrete items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "terseLabel": "Provision related to filing certain tax returns"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Legal Settlements, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Legal Settlements, Amount",
        "negatedTerseLabel": "Income tax benefit for legal settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount",
        "terseLabel": "Provision related to withholding tax, intercompany dividends"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Time-based RSUs, Performance-based RSUs and Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EuropeInterbankOfferedRateEURIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe Interbank Offered Rate (EURIBOR)",
        "label": "Europe Interbank Offered Rate (EURIBOR) [Member]",
        "terseLabel": "EURIBOR"
       }
      }
     },
     "localname": "EuropeInterbankOfferedRateEURIBORMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExchangeOfferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Offer",
        "label": "Exchange Offer [Member]",
        "terseLabel": "Exchange Offer"
       }
      }
     },
     "localname": "ExchangeOfferMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer",
        "label": "Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer [Member]",
        "terseLabel": "Executive Officer And Certain Other Employees, Excluding The Chief Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerAndCertainOtherEmployeesExcludingTheChiefExecutiveOfficerMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officer, Excluding The Chief Executive Officer",
        "label": "Executive Officer, Excluding The Chief Executive Officer [Member]",
        "terseLabel": "Executive Officer, Excluding The Chief Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerExcludingTheChiefExecutiveOfficerMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExtinguishmentOfDebtThirdPartyFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extinguishment Of Debt, Third Party Fees",
        "label": "Extinguishment Of Debt, Third Party Fees",
        "terseLabel": "Third party fees"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtThirdPartyFees",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "label": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "terseLabel": "Fair value adjustments due to changes in estimates of other future payments"
       }
      }
     },
     "localname": "FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Finite Lived and Indefinite Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_GainContingencyNumberOfDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Defendants",
        "label": "Gain Contingency, Number Of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberOfDefendants",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_GainContingencyNumberOfProceedings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Proceedings",
        "label": "Gain Contingency, Number Of Proceedings",
        "terseLabel": "Number of proceedings"
       }
      }
     },
     "localname": "GainContingencyNumberOfProceedings",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_GainContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Stay Of Approval, Period",
        "label": "Gain Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "GainContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedLabel": "Adjustments to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "label": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "negatedTerseLabel": "Goodwill impairments",
        "terseLabel": "Goodwill impairments",
        "verboseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_IPOAndOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO And Over-Allotment Option",
        "label": "IPO And Over-Allotment Option [Member]",
        "terseLabel": "IPO and Over-Allotment Option"
       }
      }
     },
     "localname": "IPOAndOverAllotmentOptionMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_IPOFoundersGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO Founders Grants",
        "label": "IPO Founders Grants [Member]",
        "terseLabel": "IPO Founders Grants"
       }
      }
     },
     "localname": "IPOFoundersGrantsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_IncreaseDecreaseInAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Liabilities, Current",
        "label": "Increase (Decrease) In Accrued Liabilities, Current",
        "negatedTerseLabel": "Decrease in accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesCurrent",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current",
        "label": "Increase (Decrease) In Restricted Cash And Other Settlement Deposits, Current",
        "negatedTerseLabel": "Decrease in restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Interest settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InternationalRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Rx",
        "label": "International Rx [Member]",
        "terseLabel": "International",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "InternationalRxMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_Legalsettlementsandrelatedfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements and related fees",
        "label": "Legal settlements and related fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "Legalsettlementsandrelatedfees",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.",
        "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of annual excess cash flow"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments",
        "terseLabel": "Percentage of cash proceeds from incurrence of debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Threshold for incremental borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "label": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "terseLabel": "Incremental borrowings interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationSettlementNumberOfObjectorsAppeals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number of Objectors' Appeals",
        "label": "Litigation Settlement, Number of Objectors' Appeals",
        "terseLabel": "Settlement, escrow fund included in restricted cash, number of objectors' appeals"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfObjectorsAppeals",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of suits filed but not yet served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors filing action"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencySettlementAgreementsNumberOfInsurers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "label": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "terseLabel": "Settlement agreements, number of insurers"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementsNumberOfInsurers",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "terseLabel": "Stay of approval, motion to extend, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriod",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Period",
        "label": "Loss Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsLupinANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsSlaybackANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MSNLaboratoriesPrivateLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MSN Laboratories Private Ltd. Litigation",
        "label": "MSN Laboratories Private Ltd. Litigation [Member]",
        "terseLabel": "MSN Laboratories Private Ltd. Litigation"
       }
      }
     },
     "localname": "MSNLaboratoriesPrivateLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation (including McKesson Specialty)"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted Average Risk-Adjusted Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MilestonePaymentRelatedToCertainProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Related To Certain Product [Member]",
        "label": "Milestone Payment Related To Certain Product [Member]",
        "terseLabel": "Milestone Payment Related To Certain Product"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToCertainProductMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Restated Credit Agreement",
        "label": "New Restated Credit Agreement [Member]",
        "terseLabel": "New Restated Credit Agreement"
       }
      }
     },
     "localname": "NewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonExecutiveEligibleRecipientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Executive Eligible Recipients",
        "label": "Non-Executive Eligible Recipients [Member]",
        "terseLabel": "Non-Executive Eligible Recipients"
       }
      }
     },
     "localname": "NonExecutiveEligibleRecipientsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NorwichPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwich Pharmaceuticals Inc. Litigation",
        "label": "Norwich Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Norwich Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "NorwichPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014, Retention RSU Grant",
        "label": "Omnibus Incentive Plan 2014, Retention RSU Grant [Member]",
        "terseLabel": "2014 Plan, Retention RSU Grant"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014RetentionRSUGrantMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Reporting Unit [Member]",
        "label": "Ortho Dermatologics Reporting Unit [Member]",
        "terseLabel": "Ortho Dermatologics Reporting Unit"
       }
      }
     },
     "localname": "OrthoDermatologicsReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Segment [Member]",
        "label": "Ortho Dermatologics Segment [Member]",
        "verboseLabel": "Ortho Dermatologics"
       }
      }
     },
     "localname": "OrthoDermatologicsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense), Net",
        "label": "Other Income (Expense), Net",
        "terseLabel": "Other, Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNet",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PadagisLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Padagis Litigation",
        "label": "Padagis Litigation [Member]",
        "terseLabel": "Padagis Litigation"
       }
      }
     },
     "localname": "PadagisLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PatentInfringementLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement Litigation",
        "label": "Patent Infringement Litigation [Member]",
        "terseLabel": "Patent Infringement Litigation"
       }
      }
     },
     "localname": "PatentInfringementLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "label": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "negatedLabel": "Payments of contingent consideration adjustments, including accretion"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities",
        "label": "Payment For Debt Extinguishment Or Debt Prepayment Cost, Operating Activities",
        "negatedTerseLabel": "Third party fees paid in connection with the Exchange Offer"
       }
      }
     },
     "localname": "PaymentForDebtExtinguishmentOrDebtPrepaymentCostOperatingActivities",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted",
        "label": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]",
        "terseLabel": "Pending Litigation, Agreed Stipulations of Dismissal Submitted"
       }
      }
     },
     "localname": "PendingLitigationAgreedStipulationsOfDismissalSubmittedMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units",
        "label": "Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perrigo Israel Pharmaceuticals, Ltd. Litigation",
        "label": "Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]",
        "terseLabel": "Perrigo Israel Pharmaceuticals, Ltd. Litigation"
       }
      }
     },
     "localname": "PerrigoIsraelPharmaceuticalsLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PreserVisionAREDSPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PreserVision\u00ae AREDS Patent Litigation",
        "label": "PreserVision\u00ae AREDS Patent Litigation [Member]",
        "terseLabel": "PreserVision\u00ae AREDS Patent Litigation"
       }
      }
     },
     "localname": "PreserVisionAREDSPatentLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party",
        "label": "Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party",
        "terseLabel": "Proceeds from B+L initial public offering, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RICOClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RICO Class Actions",
        "label": "RICO Class Actions [Member]",
        "terseLabel": "RICO Class Actions"
       }
      }
     },
     "localname": "RICOClassActionsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ROTC Performance-Based Restricted Stock Units [Member]",
        "label": "ROTC Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "ROTC performance-based RSUs"
       }
      }
     },
     "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, change in discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitsExcludingOrthoDermatologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Units Excluding Ortho Dermatologics",
        "label": "Reporting Units Excluding Ortho Dermatologics [Member]",
        "terseLabel": "Reporting Units Excluding Ortho Dermatologics"
       }
      }
     },
     "localname": "ReportingUnitsExcludingOrthoDermatologicsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current",
        "terseLabel": "Restricted cash and other settlement deposits",
        "verboseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure",
        "label": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_RestructuringChargesAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Initial Public Offering Costs",
        "label": "Restructuring Charges And Initial Public Offering Costs",
        "negatedTerseLabel": "Restructuring, integration, separation and IPO costs",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringChargesAndInitialPublicOfferingCosts",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due February 2027",
        "label": "Revolving Credit Facility Due February 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due February 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due May 2027",
        "label": "Revolving Credit Facility Due May 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due May 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDORAndEURIBORRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR and EURIBOR Rates",
        "label": "SOFR, CDOR and EURIBOR Rates [Member]",
        "terseLabel": "SOFR, CDOR and EURIBOR Rates"
       }
      }
     },
     "localname": "SOFRCDORAndEURIBORRatesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDOREURIBORAndSONIARatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR, EURIBOR and SONIA Rates",
        "label": "SOFR, CDOR, EURIBOR and SONIA Rates [Member]",
        "terseLabel": "SOFR, CDOR, EURIBOR and SONIA Rates"
       }
      }
     },
     "localname": "SOFRCDOREURIBORAndSONIARatesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Additional Shares Available For Issuance",
        "label": "Sale Of Stock, Number Of Additional Shares Available For Issuance",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfAdditionalSharesAvailableForIssuance",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_SaleOfStockOverAllotmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Over-Allotment, Term",
        "label": "Sale of Stock, Over-Allotment, Term",
        "terseLabel": "Underwriters option to purchase additional shares, term"
       }
      }
     },
     "localname": "SaleOfStockOverAllotmentTerm",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_SalixReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Reporting Unit",
        "label": "Salix Reporting Unit [Member]",
        "terseLabel": "Salix Reporting Unit"
       }
      }
     },
     "localname": "SalixReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Line Items]",
        "terseLabel": "Schedule Of Other Income And Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesLineItems",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Table]",
        "terseLabel": "Schedule Of Other Income And Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesTable",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "label": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "terseLabel": "Excluded from computation of earnings per share, performance conditions not met (in shares)"
       }
      }
     },
     "localname": "SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_SeniorNotes500DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.00%, Due February 2029",
        "label": "Senior Notes, 5.00%, Due February 2029 [Member]",
        "terseLabel": "5.00% Senior Notes due 2029"
       }
      }
     },
     "localname": "SeniorNotes500DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.25%, Due February 2031",
        "label": "Senior Notes, 5.25%, Due February 2031 [Member]",
        "terseLabel": "5.25% Senior Notes due 2031"
       }
      }
     },
     "localname": "SeniorNotes525DueFebruary2031Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Notes due 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "terseLabel": "6.25% Senior Notes due 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "terseLabel": "7.00% Senior Notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 7.00%, Due March 2024",
        "label": "Senior Notes, 7.00%, Due March 2024 [Member]",
        "terseLabel": "7.00% Senior Notes, Due March 2024"
       }
      }
     },
     "localname": "SeniorNotes700DueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "terseLabel": "7.25% Senior Notes due 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Notes due 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "terseLabel": "9.25% Senior Notes due 2026",
        "verboseLabel": "9.25% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 11.00% Notes, First Lien, Due September 2028",
        "label": "Senior Secured 11.00% Notes, First Lien, Due September 2028 [Member]",
        "terseLabel": "11.00% First Lien Senior Notes, Due September 2028"
       }
      }
     },
     "localname": "SeniorSecured1100NotesFirstLienDueSeptember2028Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 14.00% Notes, Second Lien, Due October 2030",
        "label": "Senior Secured 14.00% Notes, Second Lien, Due October 2030 [Member]",
        "terseLabel": "14.00% Second Lien Senior Notes, Due October 2030"
       }
      }
     },
     "localname": "SeniorSecured1400NotesSecondLienDueOctober2030Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured4875NotesDueJune2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 4.875% Notes Due June 2028",
        "label": "Senior Secured 4.875% Notes Due June 2028 [Member]",
        "terseLabel": "4.875% Senior Notes Due June 2028"
       }
      }
     },
     "localname": "SeniorSecured4875NotesDueJune2028Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.50% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.75% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured6125NotesDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 6.125% Notes Due February 2027",
        "label": "Senior Secured 6.125% Notes Due February 2027 [Member]",
        "terseLabel": "6.125% Senior Notes Due February 2027"
       }
      }
     },
     "localname": "SeniorSecured6125NotesDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028",
        "label": "Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 [Member]",
        "terseLabel": "9.00% Intermediate Holdco Senior Notes, Due January 2028"
       }
      }
     },
     "localname": "SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facility",
        "label": "Senior Secured Credit Facility [Member]",
        "terseLabel": "Senior Secured Credit Facility"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationAndInitialPublicOfferingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation And Initial Public Offering Costs",
        "label": "Separation And Initial Public Offering Costs [Member]",
        "terseLabel": "Separation and IPO Costs"
       }
      }
     },
     "localname": "SeparationAndInitialPublicOfferingCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation Performance-Based Restricted Stock Units",
        "label": "Separation Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "B+L Separation performance-based RSUs"
       }
      }
     },
     "localname": "SeparationPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Anniversary Period",
        "terseLabel": "Involuntary termination, program criteria, if circumstances met, anniversary period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetAnniversaryPeriod",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Exercisable Period Following Anniversary Period",
        "terseLabel": "Involuntary termination, program criteria, if circumstances met, exercisable period following the anniversary period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetExercisablePeriodFollowingAnniversaryPeriod",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Involuntary Termination Program Criteria, If Circumstances Met, Period",
        "terseLabel": "Involuntary termination, program criteria, if circumstances met, anniversary period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInvoluntaryTerminationProgramCriteriaIfCircumstancesMetPeriod",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent",
        "terseLabel": "Incentive stock plan, award type, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross",
        "terseLabel": "Incentive stock plan, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs",
        "label": "Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs [Member]",
        "terseLabel": "Options and RSUs"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer",
        "label": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower To Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SoltaMedicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solta Medical Segment",
        "label": "Solta Medical Segment [Member]",
        "terseLabel": "Solta Medical"
       }
      }
     },
     "localname": "SoltaMedicalSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaroPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taro Pharmaceuticals Inc. Litigation",
        "label": "Taro Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Taro Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "TaroPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Facility Due May 2027",
        "label": "Term Facility Due May 2027 [Member]",
        "terseLabel": "Term Facility Due May 2027"
       }
      }
     },
     "localname": "TermFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due February 2027",
        "label": "Term Loan B Facility Due February 2027 [Member]",
        "terseLabel": "Term Loan B Facility Due February 2027"
       }
      }
     },
     "localname": "TermLoanBFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TroubledDebtRestructuringDebtorTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Troubled Debt Restructuring, Debtor, Type",
        "label": "Troubled Debt Restructuring, Debtor, Type [Axis]",
        "terseLabel": "Troubled Debt Restructuring, Debtor, Type [Axis]"
       }
      }
     },
     "localname": "TroubledDebtRestructuringDebtorTypeAxis",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_TroubledDebtRestructuringDebtorTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Troubled Debt Restructuring, Debtor, Type [Domain]",
        "label": "Troubled Debt Restructuring, Debtor, Type [Domain]",
        "terseLabel": "Troubled Debt Restructuring, Debtor, Type [Domain]"
       }
      }
     },
     "localname": "TroubledDebtRestructuringDebtorTypeDomain",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate",
        "label": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]",
        "terseLabel": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate"
       }
      }
     },
     "localname": "USDollarBaseRateAndCanadianDollarPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision Care, Surgical And Ophthalmic Reporting Units",
        "label": "Vision Care, Surgical And Ophthalmic Reporting Units [Member]",
        "terseLabel": "Vision Care, Surgical And Ophthalmic Reporting Units"
       }
      }
     },
     "localname": "VisionCareSurgicalAndOphthalmicReportingUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_XifaxanBrandedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xifaxan Branded Products",
        "label": "Xifaxan Branded Products [Member]",
        "terseLabel": "Xifaxan Branded Products"
       }
      }
     },
     "localname": "XifaxanBrandedProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Plan"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r121",
      "r177",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r197",
      "r201",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r292",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r121",
      "r177",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r197",
      "r201",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r292",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r53",
      "r55",
      "r119",
      "r120",
      "r301",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r208",
      "r364",
      "r368",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r339",
      "r459",
      "r464",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r689",
      "r693",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r339",
      "r459",
      "r464",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r689",
      "r693",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r208",
      "r364",
      "r368",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r204",
      "r273",
      "r274",
      "r364",
      "r366",
      "r646",
      "r688",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r204",
      "r273",
      "r274",
      "r364",
      "r366",
      "r646",
      "r688",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r258",
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r339",
      "r400",
      "r459",
      "r464",
      "r496",
      "r497",
      "r498",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r689",
      "r693",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r258",
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r339",
      "r400",
      "r459",
      "r464",
      "r496",
      "r497",
      "r498",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r689",
      "r693",
      "r713",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r54",
      "r55",
      "r119",
      "r120",
      "r301",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r364",
      "r367",
      "r691",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r364",
      "r367",
      "r691",
      "r702",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r210",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-BC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRITISH COLUMBIA",
        "terseLabel": "BRITISH COLUMBIA"
       }
      }
     },
     "localname": "CA-BC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "QUEBEC"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "NEW JERSEY",
        "verboseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r634"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r18",
      "r653",
      "r671"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r59",
      "r64",
      "r71",
      "r72",
      "r73",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r62",
      "r63",
      "r64",
      "r673",
      "r698",
      "r699"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r61",
      "r64",
      "r71",
      "r72",
      "r73",
      "r130",
      "r131",
      "r132",
      "r558",
      "r630",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r57",
      "r64",
      "r71",
      "r72",
      "r73",
      "r558",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r507",
      "r508",
      "r509",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r467",
      "r511",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r28",
      "r211",
      "r216",
      "r217",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries of amounts previously written off"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs charged against the allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r107",
      "r320",
      "r331",
      "r332",
      "r627"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive effect of potential common shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive shares not included in the computation of diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r107",
      "r251"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments, including loss on assets held for sale",
        "terseLabel": "Asset impairments, including loss on assets held for sale",
        "verboseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r16",
      "r116",
      "r185",
      "r192",
      "r199",
      "r214",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r551",
      "r560",
      "r611",
      "r632",
      "r634",
      "r651",
      "r670"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r36",
      "r116",
      "r214",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r551",
      "r560",
      "r611",
      "r632",
      "r634"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r570",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r106",
      "r544"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r542",
      "r543"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion included in Accrued and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r542",
      "r543"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r12",
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r103",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period",
        "totalLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r103",
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r657",
      "r679"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r634"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value, unlimited shares authorized, 361,781,292 and 359,405,748 issued and outstanding at September 30, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r81",
      "r663",
      "r684"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r69",
      "r80",
      "r549",
      "r550",
      "r564",
      "r662",
      "r683"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r69",
      "r79",
      "r548",
      "r564",
      "r661",
      "r682"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r78",
      "r91",
      "r660",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r167",
      "r168",
      "r208",
      "r609",
      "r610",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r208",
      "r609",
      "r610",
      "r700",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r167",
      "r168",
      "r208",
      "r609",
      "r610",
      "r700",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r167",
      "r168",
      "r208",
      "r609",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r167",
      "r168",
      "r208",
      "r609",
      "r610",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r559",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r86",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Cross-currency swaps"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r165",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r314",
      "r321",
      "r322",
      "r324",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r115",
      "r121",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r329",
      "r330",
      "r331",
      "r332",
      "r628",
      "r652",
      "r654",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r19",
      "r325",
      "r654",
      "r669"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total debt obligations",
        "verboseLabel": "Principal amount outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r297",
      "r329",
      "r330",
      "r626",
      "r628",
      "r629"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Aggregate principal amount issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r115",
      "r121",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r329",
      "r330",
      "r331",
      "r332",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "netLabel": "Aggregate principal amount of debt exchanged",
        "terseLabel": "Total",
        "verboseLabel": "Repurchased debt, aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r115",
      "r121",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r329",
      "r330",
      "r331",
      "r332",
      "r342",
      "r343",
      "r344",
      "r345",
      "r625",
      "r626",
      "r628",
      "r629",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r310",
      "r326",
      "r329",
      "r330",
      "r627"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r310",
      "r625",
      "r629"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt instrument, premium"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Unrecognized tax benefit, amount possible to decrease in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r378",
      "r416",
      "r443",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Amortization of net loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r378",
      "r417",
      "r444",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit and other"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r378",
      "r415",
      "r442",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r378",
      "r382",
      "r414",
      "r441",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r412",
      "r439",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r380",
      "r413",
      "r440",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r107",
      "r253"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r51",
      "r52",
      "r55",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.",
        "label": "Derivative, Fair Value, Net",
        "terseLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r55",
      "r571",
      "r572",
      "r578",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r569",
      "r571",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r569",
      "r571",
      "r578",
      "r584",
      "r585",
      "r587",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r577",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) related to changes in fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r577",
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "negatedTerseLabel": "Loss related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r51",
      "r52",
      "r55",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r470",
      "r471",
      "r502",
      "r503",
      "r505",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r252",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r4",
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue associated with products for disposal"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r455",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r454",
      "r458",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r82",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r145",
      "r150",
      "r151",
      "r152",
      "r156",
      "r157",
      "r593",
      "r594",
      "r664",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings (loss) per share attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]",
        "terseLabel": "Weighted-average common shares"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r82",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r145",
      "r150",
      "r151",
      "r152",
      "r156",
      "r157",
      "r593",
      "r594",
      "r664",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and other"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r513",
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "verboseLabel": "Tax provision (benefit) related to stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average service period over which compensation cost is expected to be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r71",
      "r72",
      "r73",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r159",
      "r215",
      "r341",
      "r346",
      "r507",
      "r508",
      "r509",
      "r528",
      "r529",
      "r592",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r630",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Extinguishment of Debt [Line Items]",
        "terseLabel": "Extinguishment of Debt [Line Items]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r595",
      "r596",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r449",
      "r596",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r595",
      "r596",
      "r598",
      "r599",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r312",
      "r401",
      "r403",
      "r408",
      "r449",
      "r596",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r401",
      "r403",
      "r408",
      "r449",
      "r596",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r449",
      "r596",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "verboseLabel": "Reconciliation of contingent payment obligations measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r600",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r600",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "verboseLabel": "Foreign currency translation adjustment included in other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments/Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r600"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r449",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r595",
      "r596",
      "r598",
      "r599",
      "r604",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r605",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite lived intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r14",
      "r243"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r238",
      "r240",
      "r243",
      "r246",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r243",
      "r648"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r243",
      "r647"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r108",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign exchange (gain) loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r55",
      "r401",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r454",
      "r458",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Non-U.S. Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Net gain on sale of assets",
        "negatedTerseLabel": "(Gain) loss on sale of assets, net",
        "verboseLabel": "Milestone achievement, included in net (loss) gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r107",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r13",
      "r223",
      "r225",
      "r232",
      "r236",
      "r634",
      "r650"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r225",
      "r232",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r107",
      "r224",
      "r229",
      "r235",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairments",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Realignment of segment goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r569",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "B+L IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r107",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r107",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of long-lived assets classified as held for sale",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r185",
      "r191",
      "r195",
      "r198",
      "r201",
      "r649",
      "r658",
      "r665",
      "r686"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r455",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r255",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r521",
      "r525",
      "r527",
      "r530",
      "r532",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss, income tax examination (up to)"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r118",
      "r141",
      "r142",
      "r183",
      "r519",
      "r531",
      "r533",
      "r687"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "(Provision for) benefit from income taxes",
        "terseLabel": "Provision (benefit) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax expense (benefit) on ordinary income (loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Tax provisions (benefits) related to changes in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r152",
      "r469"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Diluted effect of stock options and RSUs (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r245"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r237",
      "r241"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r89",
      "r318",
      "r328",
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r35",
      "r634"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r88",
      "r178"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r116",
      "r193",
      "r214",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r552",
      "r560",
      "r561",
      "r611",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r116",
      "r214",
      "r611",
      "r634",
      "r656",
      "r676"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r42",
      "r116",
      "r214",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r552",
      "r560",
      "r561",
      "r611",
      "r632",
      "r633",
      "r634"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Facility fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r46",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Current accrued loss contingencies"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Aggregate amount to be received"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement, agreed to pay",
        "verboseLabel": "Settlement, escrow fund included in restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r311",
      "r327",
      "r329",
      "r330",
      "r654",
      "r672"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total long-term debt",
        "verboseLabel": "Amount drawn under credit facility"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Less: Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r121",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r121",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r121",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r121",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r121",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r121",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r269",
      "r270",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of suits filed",
        "verboseLabel": "Number of putative antitrust class actions filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r116",
      "r214",
      "r282",
      "r287",
      "r288",
      "r289",
      "r295",
      "r296",
      "r611",
      "r655",
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage by parent",
        "verboseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r160",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r103",
      "r105",
      "r108"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r65",
      "r68",
      "r73",
      "r77",
      "r108",
      "r116",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r149",
      "r185",
      "r191",
      "r195",
      "r198",
      "r201",
      "r214",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r594",
      "r611",
      "r659",
      "r680"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to Bausch Health Companies Inc.",
        "totalLabel": "Net income (loss) attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r68",
      "r73",
      "r141",
      "r142",
      "r555",
      "r563"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r346",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r185",
      "r191",
      "r195",
      "r198",
      "r201"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r60",
      "r62",
      "r548",
      "r557"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r548",
      "r549",
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Release of foreign currency translation losses upon disposal of assets held for sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r58",
      "r62",
      "r576",
      "r581",
      "r590"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r66",
      "r69",
      "r71",
      "r72",
      "r74",
      "r78",
      "r341",
      "r617",
      "r622",
      "r623",
      "r660",
      "r681"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive (loss) income",
        "totalLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r374",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE (INCOME), NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTotalLabel": "Other expense (income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other operating income (expense).",
        "label": "Other Operating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense (income), net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r427",
      "r430",
      "r434",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefit Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders\u2019 Deficit"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedTerseLabel": "Payments of accrued legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "terseLabel": "Payments or receipts in settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r101",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payments of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Payments for intangible and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r400",
      "r402",
      "r408",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r449",
      "r451",
      "r452",
      "r453",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r375",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r427",
      "r430",
      "r434",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash proceeds from divestiture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r95",
      "r100"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r65",
      "r68",
      "r73",
      "r102",
      "r116",
      "r133",
      "r141",
      "r142",
      "r185",
      "r191",
      "r195",
      "r198",
      "r201",
      "r214",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r548",
      "r554",
      "r556",
      "r563",
      "r564",
      "r594",
      "r611",
      "r665"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r254",
      "r634",
      "r666",
      "r678"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r83",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for expected credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r634",
      "r677",
      "r701"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Fair value of reporting value, greater than its carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r260",
      "r263",
      "r266",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r107",
      "r259",
      "r264",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, integration, separation, and IPO costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Liabilities associated with restructuring, integration and separation costs"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r346",
      "r634",
      "r674",
      "r697",
      "r699"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r215",
      "r507",
      "r508",
      "r509",
      "r528",
      "r529",
      "r592",
      "r694",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r430",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r454",
      "r458",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r430",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r454",
      "r458",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r427",
      "r430",
      "r434",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r427",
      "r430",
      "r434",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r176",
      "r177",
      "r190",
      "r196",
      "r197",
      "r204",
      "r205",
      "r208",
      "r363",
      "r364",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Price appreciation credits"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified business segment for satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Segment Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer, Segment Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerSegmentBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r365",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Shares sold, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Percentage of shares held"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r64",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r433",
      "r434",
      "r437",
      "r438",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock": {
     "auth_ref": [
      "r586",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.",
        "label": "Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]",
        "terseLabel": "Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of earnings (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r500",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExtinguishmentOfDebtTable": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to debt extinguished, including the amount of gain (loss) on the debt extinguished, the income tax effect on the gain (loss), and the amount of gain (loss), net of the related income tax.",
        "label": "Schedule of Extinguishment of Debt [Table]",
        "terseLabel": "Schedule of Extinguishment of Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfExtinguishmentOfDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r245",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories, net"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense (income), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of customers that accounted for 10% or more of total revenue"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r85",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenue attributed to a geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r75",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r185",
      "r188",
      "r194",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r185",
      "r188",
      "r194",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r482",
      "r489",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of share-based awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r466",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Notes"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r173",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r208",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r263",
      "r268",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r185",
      "r189",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Separation and IPO-related costs included in selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Incentive stock plan, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Granted, one-time award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting Period One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Vesting Period Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting Period Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Incentive stock plan, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r3",
      "r173",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r208",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r236",
      "r256",
      "r263",
      "r268",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r48",
      "r71",
      "r72",
      "r73",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r159",
      "r215",
      "r341",
      "r346",
      "r507",
      "r508",
      "r509",
      "r528",
      "r529",
      "r592",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r630",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r159",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock Options and RSUs"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r341",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r341",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from B+L initial public offering, net of costs (Note 2)",
        "verboseLabel": "Adjustment to reflect change in ownership interest in Bausch + Lomb"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r346",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r116",
      "r212",
      "r214",
      "r611",
      "r634"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r72",
      "r116",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r214",
      "r215",
      "r346",
      "r507",
      "r508",
      "r509",
      "r528",
      "r529",
      "r546",
      "r547",
      "r562",
      "r592",
      "r611",
      "r617",
      "r618",
      "r623",
      "r630",
      "r695",
      "r696"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total equity (deficit)",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r624",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r624",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r624",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock": {
     "auth_ref": [
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of troubled debt restructuring which results when the debtor restructures the terms of its debt with a creditor due to the debtor's financial difficulties and the creditor grants certain concessions to obtain payment it might not otherwise receive. Includes a description of the principal changes in terms, the major features of settlement for each restructuring, the aggregate gain on restructuring and the related income tax effect, the per share amount of the total gain on restructuring, net of related income tax effect, and the total gain (loss) on transfers of assets recognized during the period. After the troubled debt restructuring has occurred debtors discuss the extent and amount to which amounts contingently payable are included in the carrying amount of restructured payables, and the conditions under which those amounts would become payable or would be forgiven when there is at least a reasonable possibility that a liability for contingent payments will be incurred.",
        "label": "Summary of Troubled Debt Restructuring Note, Debtor [Table Text Block]",
        "terseLabel": "Schedule of aggregate principal amounts of debt validly tendered and subsequently accepted"
       }
      }
     },
     "localname": "SummaryOfTroubledDebtRestructuringNoteDebtorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Bausch + Lomb Trademark"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSEINCOMENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits related to interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "netLabel": "Existing Unsecured Senior Notes",
        "terseLabel": "Unsecured Notes",
        "verboseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofAggregatePrincipalAmountsValidlyTenderedandAcceptedDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "terseLabel": "Reduction in variable consideration provision, adjustment"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r122",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Reserve ending balance",
        "periodStartLabel": "Reserve beginning balance",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Current period provisions",
        "verboseLabel": "Sales return provisions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r143",
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 19
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15765-112638"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5634876-113961"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926"
  },
  "r716": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r717": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r718": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r719": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r720": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r721": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>122
<FILENAME>0000885590-22-000061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-22-000061-xbrl.zip
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MJ_WN:Y[\VJI!2C[MF%8T@DNJWLG9LN,B5(<^@Q/\^KL?_:._X_O1.Z#LA)L
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M3Y^MSYRF!^ZZ-FAMP%!SA@P:J_7:ZYB%7$T<?2B%Q$#,T\-R\XLP&P&Z<BF
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MD9Y6Z"B"+ZGIF O,G$,T(=54C8:O;/.("IZ- >/-5*8,Q#Y*, GZ(K8E9TP
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M^V1]<-%7@&;Z>FP)&IPJ9SA<-B^=@ /YLOBQ0IU"*E%M*0$,0+01O?.^J;\
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MM]OAUKE<)HY!-0P$*8#(Z, 1I$JV9[4/6<2,AHV33IY>'1.=:U8@)O360')
MS>@875)A7Q.Y <\L;G0?WC#,8'ITI @$O;<D^@3-E1Q-X=QRC55,B0/.\1@&
M([9;SE8[NY.S-YF90@@08BJ5Q2$O:_#&X+9TW&YD6",;JU0TY+$)%7#94Z8$
M)1 GVP*W;=2XS9I?)QU#+JI?"!KTTI'HL*30T.546U([IE]O+>F8C-WY(GGY
M"3@I%O/%+5S(!5)IQ[S.:GYS[/4SK&^=^C:HET<^)=.@Y9QZAA[TS7-D2_30
MJ!(C5*IE.8=LLXEF=%GP?Y)@^Z:1FE^5J0\LS=?F'1/?(M+GJ,642\[+%ED
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MKGB76HNAJ$=3T8A1O#5];[4XL''+O,]@WCL;!/Z$;R=M_N7PK6&C%&S1092
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MZ4LS@<W[ZQQ:Z5N,4Z@>."!2BH5=M+UE-\FT-\YM'?<V6>/SU#Q0*(7)9BX
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M1+(91/*I<F=0WH$N/M09/T%'8M6NN_JB=5J;U +EWJA6YU6K$_SXYI7;.I?
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MFU8D>C<E:1]UYVAP&J.7' Z R1Y9/74L8*63%GT;#.QFB, G"TT> C@CR(G
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M#I+SE\<?S&BY#9N\9I"<4IMS+K&4:[O$+^U;=G\\FA.D>9[Y7[@V)]8[G-0
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MO\D]O##0FC)0DB8E9:/$TG,JO.&6>\YUQ-I8K'W%0(101@H#/3@#?9UE(,*
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MT>%@O-_/%);MH16E??_\Y:D=?HBCPD<+\=%^W<B@8"_2,J5L%052HI0B8VA
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MFRS+H+;4O+(,;=H#?QT,X<]^QU\,A['O+SOC(=PMN__!?FC#QXO1./L1/K/
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M;%01_HQC&#?$:2>29B1RC;7AVA 2B;#248O3G_N5/ZV<\0<3<]S S@;]X_'
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MB!=R8YL7B*XQ1!L_-BD070*BM8,/)8/!T6.48H+=TWF+G+8ZIYCWP05*L%,
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M#UP29_$WY6)I+1W!\[BQ=?>JD!7WE9^KG:J=UM=.CQG\K.MHQ];1!:%2[@"
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M4,ZS:(G22A"9+2?.9D&,S3:6+8ID]<86F_=T:W[HTT#WRJ-=%=T="&3-T)W
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MAB>5(T$:3D 8HT0,SH>TL27-O/:N&5A/ \,KB#)7##\DAN<"T<$HGER6A&9
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M;&RQN^QSU%!#9U.L[O5L3\7O/>!W+M<B!)692,3&Y(B441(G$Q#FC>71"<5
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MY\WIL4>_*L)9*Y3;<.X)I/;W!'_V8A&*[=>A;/0ELOLG](>GX\T&)^LLHPN
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MG4HJ)"5SX*-^O(D2CC-2YE7< M$Q&D\MB)8:"6M)4&1D]K#F&RKYN %J.@?
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M8)N P-DZ/;#XTO,..2JPR 4;QMEV^%QR#G\$3]+V.%-IM6WYW*!FHY7\U#H
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M<;\[_4 9%I%%A8CT@%S<)F1]LD@HDH110*S:/WI"R0TCEZ5.<F8 '0GCWGL
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MM)*4H,!4KJP@-#*:!Q0\"3YX+)3GCYYPW<):"VL_-:Q)'JBP8&%9:7@(V#G
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M*5I.O@HGKYT::DM4DI$CET@.AI 4.<(8LA$T42RC4(E_I5Y%R\@/GY$)Y<*
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MA6S-&T%^&&0MX0O_*CW69T?VU=2ZTR-@'G_YMN_LO+;O-\K!!%_$PC2S\,[
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MV,]9J_(NN ^(?/@YAWQ5(=!'A?)SO.'G'#G6/UL,8OK)?!?W7_68;UX+3%<
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M!UP\C.5A>^UR13$; X CRS7ZC<8N*:P<B]2&1_>W-,ZY">B;V7_&!9TY&_P
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MR"%7W]R(S1%'YF^/UO5_T39!< W:%:B=61!ZP,ZV!H*]$2)<?PA%YYU!WF?
MGIBA9OQP>6F_=6PWY#ON-KJP"9WN[!Y5"ZVN#8!6@P>Q^?EN?*52Z-6O/< S
MV);33C/$;F_K2I&OE(]GJ6SL5-NQ&_T(&TF%C?#GAP6@&+;[K--K *>,H#0L
M!:4>QR1$8E8G#B8P2#=J*4T$+"M,/)65DD'&2L8"MO"?0$8G%1U^O%KC3@LL
MJO[..5!!#(>=@_P(?]EN_Z)@ZUQL_?(W!FPU-'G--!BW3@K$@]/()1_A')@-
M)$:7.-G8)IMP/#]&US-[,13<C3;P%=!X[/ENY[Q238$^@)4J3LV<6U%C?O$Q
M^K&J^GO3 N_O#,GI^F!K/P$2A)@J9@<MH-[IQQK1F[7,JQ3_^N>;=SM_UO[Z
M</#[FS>[>_5W'ZOWR:__&NLOY_#[WL!] 53(_'XKX8*>$S-%W/0F8\F3M(D+
M#KH ,U9$$ZG&'.20"K<-.-VKOYU4D^?1*VARP(@'Z:!:&,#53G7[WJRV#"1[
MI2V/J!6_.FJ%ZP&U6HV%B@3AZ"50:\19@XX($V%Y8H9[B3>VP2J:H=5:9[3-
M5P _/.TQ&6;QU823'X"@J_3=?ZX_LR>@A^<CVZH=PLNSRJC)E)0:("$MO-&O
M2A[SP66J'UVYLL3R[__>^KA5^S@ 5;:5]==\"Q#4(*4 :-NUG<$)"(8:&2NK
M&7\K43M:,(C 4 GEZFZ]05;(KVXY7%%UM8J\ADMN9'ZQ(0N!6BN"T%B4T\!\
M .'J.[#.$7-5^S)BJ,TLDML=L$A 81@^)-BL\, N5HL+6[6=++-!DQHT^YLC
M=;T%PN[B_^O5*M]5;V0P#*W5S,TCB#B/W?P<69T8-'JG,5SMP^@*<-4P\/#^
M<O*J.@0+!]N%59UUVI7.45VJ>G983?/:FUH=X%!5F3!#-J^%'JQWQ_ON8+2\
MX6V'%7W]&Q?JM*>>_CN&UV;68)81IU08'VB4 4P1[JFSV%"P**/-LP:55R.;
M7=VPV6^*TQXH)/"O28S::_MN!/,15(3J[[WVZ%$GW,V_#Q^U2-1;, H?['I8
MQP[?/_R*P<Y7B3KMI<^)T ZL>Q*0P2F@A#U37,K\WU+!A,<Z^FLF&YFOE3IU
MC12[(_XJ!+$<08!.%9+P&@4)?W"L%;+8)B0E5EK2I)6SMZE;/]"_1OZ12:<1
M&%P9M68](B".X$MCJ^:!S)'JBK\T^F#]^ 4,E)' &0K+:U%UK3K54.W@K%]#
M!X/^Q+LCV?3 S_+=E6>ANZA2.M010JBD-\B9D$WT9F^K]@),3%!%0(A7DART
MA'X7+I7 >AY: _#8G4'EVOXS_A.;-0;*1!XE63DR)R1G@(,'$9U)N5WI+S^@
MY)O[EEED.*)E8$=,,[V?HR4S"<]4@1A\[9=JO$OCG_CK>2/T3\=!WHE?C;8?
M7__$.A#H@_[M/YDX%Y]=F-W1L6S_K^O^O'WK>=_VL\<^34*FMG;BS]/N>#5G
M]B0B!U+C*[()%ON+;9[;B][&SS=I&,AU<M^GM^R)^+96F_>(-TZ]"T8KNKF@
MT9M#>*N4NO%;P\?"6SC??QS,9;)Z71-\^/?4ZZ'XGZ39H9",5A!NI3%6<4Z$
MTBQ:[$PRU@/=>[<Q&D4$"MI.EKN*.Q.QX%DUX#IQIXD..%E.>>)>VXVE0.7A
M:.Y6J:#FQ\BZG5X/737-^'ANSWHO "IWKU$.S+5NJ/UG8+O /AD?,ZQMSOIK
M8[<R0 !*_<T]Z>4]&07^[ G8JB 8,P*/)(RM_&*5OV49(X,HF@AARNLD>'3"
MQB@=C@+H"P29I?/#'Q-^C]F\E?IH24-/7=$9YX<\=L3!X=_?]@^/+@]VWY"#
M]Y\-U\#3BJ%$1<PZHT76.D!=B;EVB6HB3=89@6*_KR)N9G.W-=2<P )O@@T\
M1IRA[C@,ZP&AV%KV^(_\"=F,CH-N!\ZFW0$DKTS8=NQ/1*7S!1JC /:5E3N*
M"&1CN@]O##V#5;ACZM97G7"Z.<(X<FG\X(8N9OXYC>$D<T7O%B?^S17ZV,WQ
MD&G6FKY3;^!ZC="PW49\,7I9S7J?F2YO6M9 AQO>&Q_\1%"W.OUPQ;/P#; $
M!V.G2LQ>&SBU\]-8^3[RCR>^,?0?Q39\-9N9U79F1PF@6[.1JGA3#NYT^\/;
MY.,;^F.:PZ#2:>-LZ%@9V3(79]6"YGUOJ_8V^\;F+;0W__958!ON/[[:Q ^&
MOJK9#VJM[)JKPDWC"V[67(ZQUP9GHT7&;V=5&[,;)+DYC%Y-[&OU_BCTF)J=
M\_$;V1P8_OO*%3G;*6ITAVK39CG/7OWD*CSWW=W)SL3)'?K.EIQD?LD:.DB<
MS&;=Z#LG;:"]^?'XC]>,#FL]N H63FKU8W?9T(WZ$D)K\[%GGI0>4^+(4QR
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M>WZ2=I6(,PQ(WAHW73S"T1N%.&:*DY\HA@A2^;J7R?_E0^M=T\1D #%V*PR
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M@CFFJ60L1"*,"MZNTJU7<&<9W)G1W 2F.DA"D9$&-+? (](Z8# BN<-,RMQ
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M(1%<JG*%A!,T:HR-C%2Y1.S2-5<%5=<45>E,RPVBM&22($621SSX@(R)&F$
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MF9@$ ML6(\LH01JL8 7_TEBI=5287U>2_&'TIVVXU<E%S;9#K=,_C=V2(O^
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M'5$'DT ^9YU>(W_MEVX$LQA6_NMY(_1/QQKFQ*]&E(ZO?V(=[.>@?_M/)EC
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M#;"AL*L2>]ISL&X2XGKS$N7AAUF6@K[3ZL J1HL!!;/1"1/99/DYKF_5.^V
M[I:9=9H9"Y*NF!G'IWT^-+?;PZ3 K-->5=R#N7T6V]7I3IW?5FT' !:4U=,;
MI-$='^!(_:V<-U,'60[Q[H<XY$PP%S*#=S,^7 FQS$'5_G:NRF3&)S"6AR,K
M:7B$^;#&S @?#&FA4HJK( !<M^/]H/L2<O(>)S6?+!\]R9FO)#AIDO><"V,2
M:/\^*<:P=-:GI1WC)1WV/NFPAW^SS\0&L,1\0B(XCWBB"ND@'<*2,\:U8-$
M%%#"EDW07X8NI+$TUW0+"\8'EL09JCT/@CIN8HJTT,7CTH5GGZFPFJHH$)%6
M(2Z30BZG(DKLJ,!*ZY@G^!*\9*+TO5+R-X<:5*[5#!EAQ^K94K$YYU5(6 O%
M!#?2&!%C\-)B[*WW!A=2>U3_Q.$.W]_Y[)TV7%.)DLFMSJQ,R"4@NX0E3L+1
MZ+S<V-8_2G4=$5>67]^3<E6%<*?='OI5KPR#VDZK,VC7/N9OC+3U^Q5_8$(-
ME9HS0CCWE&H6=>1 98)S$H0LI/:XI ;W/OF,0>^PP7JD,74@[Y)&#D<0>I1)
MK"(E-%4]GQ^E_F/*YO]._O6=BAIO4L]'?QK#H!D[Z3LY^F\KJV>R"]F;H4ET
MF-W&A[">WYH=__6UT<Z7-P*DXF?K6!XIZ)%4( _A"#0"#F=(@OQ*-O\SQ(U:
M! X[RP7CW4%\KM6];ZZ<*G/MXQR/_GY;@735DR![&\-U>&H8UK8Y\C"TUA)<
M81@&JG(2:Q?1=BNC([_8C7[264;&N7V@/>2J]EH5KQA^F#K-[//Y9<4&7-6)
M8[;NO&G/>O&7\3]^'7?R:+2KO:Q^].O-&\ZQM:L;#C^^+KW?PL/R^U&[F-&=
M1Q]O51]--4@:?D;)EB#FUH_Q%KGC9R"N[O3+[RU6;6FJRUK+6LM:RUJ?SUH9
M6_2JJVD,-M6F[FF:8>KEJPZ&779!WQWIR[V9;JDKG;&YQ#7F[.2PF\\C[^5H
MY]3<G?LPK325W9O;@'3^[L&&L;)ARVT8+QNVW(:)LF'+;9@L&[;<AJFR84N(
MS,,KGT#9MB7H[+ #VMP".W8'W?6'K>6?08?W24?HG>AJ-=WT7WF__%?4$?\Q
M9HW..O>O[(V#]+:1XT-'T7:?>Z1HV!._==PZ^O)'LWYYW#QJ[9/]R_>71X=[
MO'[I+^KTN%%_]P?<^?CKT:>];],]\>%JC?W6WZS>^G?CZ/+OR_IN_73_RPFK
M7^ZQX]8>/FK5OQRWX#=?WJ;]C_BBFM[T$7^K[^Z?U[^\^:P3]A)SBG@D?OB'
M4=0B&R@-FEB,D\X#G%8\$.^EC! IH%= [R%!KP[W/SR/S7_B?I7G]J+#YH\-
MAG@:#*VRP4G!$!?,(LZH0#HFAE1@P@K!DC6Y#^PF)BN>#E+@<*U@H<#AFL)A
M5OD.SSL%Z)8#.CH#="D9GQA&SAN-> H<:>8C"HP8$XGA+(_MU$85F"LP5V#N
M26#NM!MC ;KE@(Y/ UUP'HQ;QI"1!#0Z[D&C"]$BIHP!XU8)@?'&MC*T %T!
MN@)T3P%T;SN#XL9;$N>^[4\/8G<^&0Y4@!R3&'%O#;*4A]R"V<A\GM@!T$E9
M_'@%Z K0/0W0P7<+T"T+=(TIH).))XFU0LP[@[A+#AF:0*UCTEC!?-(F =#1
M8KH6H"M ]^A MY.S6PK:W1'MZM-J71":40RF:^!&(BY(1'!^&D4K@F8XA&3L
MQK8H6ET!NP)V#PMV+WTRU..#W;1J9RQUU#&!, Y@PPIKD36.(<X"]T#7)#&_
ML<TW&;VM&?HSP;L[CE1_ED6Z._-*<R=*T4OGJ94V8LSM(?K5>")[=M;M?*L*
MI)L73S,_PIWZ7W;:[8%M3E+!;%^(%XVK*QJO=H3W3SY'XJ46@2$=-!B_AEDP
M?IE"440N-)&!:*!,P<P/&R'E0P&RZ)\"+)Z<YOHM];RZBLVDBE<L\:[3";E[
M\[-ZE/G<_4B=-@[2>,]><^.,^I>3SX0:#WJC1AHG@3A85L@XEY"25F A0/D0
M:8B4C?8@AIT,5XD&@Y.EG ?.X5_.NVB\-8EXJP@CTXTV<B?<8:?;WKCSWU5_
MXC%V=U+M9'0DM3#HCGNQ+SRS(W\Y]Z<8?6NZ.\5D7SR;>V",.U),:1LW."A_
M..X64^')+&>-B)=)H.Y9B7K5.>*_;W8;&3$BOOZ)=:"&#?JW_V2F5F7$H-O_
MZ[H_;]_*^;?][+'YFHBIK9WX\[1[751]$I'K1OL5505#O]CFN;WH;?Q\$\T
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M>":>KKGT,L6(4F()<4,DLDX1I*7B3$C'792%CU\^'S]81+WP\4/P\6PHW8+
M#8ZC2&%+@6LU<L8%9"6 <)",F.@+'[]\/GZP4'KAXX?@XYG8>O+$:*HBTDH
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MS8XGNR&];AO^S6KXV&:K%0;7KY\=-$@']O7JYVP:PQ"RHO''K?@UST/6:>>
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MAV:YW\7W'(UPT@V<L3CO<#HPF#4F85IK8[W;^66(H_]<ML+Y\? 8;>); PG
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M>&_OZ<[6YJ$-C!&=-'+62<2=3<AXSA$S+EICE4@IW)RC,=UO9^T6O?#*-PC
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ME#]'M<_5@)BM)3'5L*\?SVR%UILLK8&BFJ??)P+]7XTC]:O<AG%L_[UZ5;R
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M$\/$ Y5<FSM5<LEY-H>,@K46J$5:*8LXP18YQ05BVA#N:? IR(TW_!73\Z5
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M(?;/J^X? ^VT>=2+54'RF<.O5:0=E6N4:ZSB&DLR+>H8*38'XZ<S,Z[#,66
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M-J"D-%=14*>MW'BCN%ZCP[R"U/5$:N'<'H/,6<Y-$>TU]0)9X1WBQEADN/:
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M]W=>P=J]2GL'[\3>Y0>PC5]?[N]\SDV;,69$XU*_FMG<8D6!ABX +!CUU/+
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M,49 ',/1L#JDR099]PL\,B\WC*%3NID#P/TU:QIGX3=9JZOO+0Z7$%,YQB@
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MO(TL7D-G/IA7YG(@497V.$=)=6#'H&Q:RX;,W.6TI6^[QYGPRF'(8ZE\BYZ
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MY$A['1%5'CM+O<*PV"!\E^[TU2)_R[4Y0(]K%+D98"GG3'?""H85MM( 1H
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M*%W:82<+@9)EYP#KRT:-D\+8$@=[S84*SF.!&>C67%)&TQIYN,W>WW/O#X_
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MV8YSU_:!DG-7UZTJ]GF>$J=U4IWM% ^)B_GS,"ILE4OFYWM_+/U"+7>GSO=
MV.L-X^"'FM9JM6G9U,IYVZ1C3BDM6&J&U/Z$NK7--$]PMI!A <=2"[%^0(GK
MNWWSFOBU7=4!K ?V89)]6 WM^;!W7*(&YRH3Y^]:?XQ?.)B6)7[;S4C6C17$
M3:C8=WJ#TK\F32#R[5_[8ZP-\;1XRE=->,V 9FVQQ(D#:7E.,(@L0UW@SEF7
M.TRQYE3H8;&0[WWR1\;[ +9Y1(P!('*>L9 1BA1H[#(W3U68E:.@I5$Q*V@O
M(QOLE9A+&=T^Z[<[U<=7KI^MJET15J>N(QU@F^"Z.1)>_9Q2H:S<,*U'EITF
M[8$?#;*!YV*G=_[+PGO@9[$N%],#0%3KUOM8'Y8NGO&4=L)C_J^LT/%#R\BR
M$C%I%07H<(L"IXN#F'!ZG6?<+7.=9[GRK%?_WJY4EGI"X<<2*>MB;[V+,^L_
M7OO2!B9[LTI%]7+O;">S$G4[+;8^5^Q\ZLD%-75\!%@?L54.W^GYX-:XENP
MX*>5VOU!5G?A;7G;J]L+RE?O68J0=VBP-G/=7)^R";<,6L>]4K0OZQXK5N])
M1!JO11JV^[F***YBN8MK*2_=Q#RIN[Y,Z^Q?W:O\U"7R$[X;<VS[RPRWEOJ\
ME1MIU 4*ZQ7WXQC7)@4 B@.VFD0=WGZW]]:O6OFB*NSC/IP44ZK>!2LXII[O
MH2G7LY=G )U@SPT&HPV/Z_I:N1.M:=D.YL_O1CUSY#+3(,(N@YQQ*H;/(86
M#[932Z)KP*#2)V=V]V9ZO&8V3;7I356;%DVUZ4>L-GUC]>@KU::!:;DE/!HF
M.0^)NY"LT-D3+K2(DO^HU:;70:NQD3LIC3,;F#2GVRZW)(I/>OR0&>C[-"I7
M%QUKOE3G&+1@M>HPU_S7%]L9Q6E#US$T7DDC7XV/6;"".>EAAD6!F).RPUX5
M7I55AT[;NG$_G]R1H'MQ>V= Z%7=TN<Z\*[$ZRI[9?7S2R#"DJ6KNP>5;\9M
M!V96Y FHA1_.:AG8\[-!&[;E3VSWN)AYF5/[O<ZR,_6UU.A?MH"TZ^2.J2V6
M"RG%K['OV]GHS!9>I6V6X\T 6ORLECFQYFPKSS?3?-U&8GS%4A+(;O9Q$^<K
M;91!HQWU8:Z#6+G8J\=-"*-;,19,-[>'*E5;VMD;WA]N56EXD[M!L8"EFZ1>
MKEO7*?GD.5,A,&XT-9S$G*%NHB*"67J#*_S:(\'W$\_37WF(4W_.[V6'V]W?
MJ_W]B=T[GUZ?[QZ\/A+>^Z 3K+'Q$G&;*V\'YA#1)A!X9O0E]P"3U5%1"QVQ
MBDT 7U89<M[W0>(52!IUZ[IAE</M!\&2!VL O#9_Y![:S'A-><+>Q2"98LEK
M3!47NG@["998-][.!V&'_9WM(\Y(\%80E/LW(LZ91 XSAJ0VS'/IN*;XV4O^
M0B]-U5\*Q+6O4[=0ZW]&W?([F6NB?0#2?% ]XRF<A>QWJWGJ<NQ*MN:D3\YV
MC^NU0-L0'S1-DV_DB*_[.X='3%N2" DH4*T0,$1"CL!OA#))K0N<AESI:4O>
MV$33'A_WXW%)X5_HH;ANLED#CM^6%&"\GS<%CF-4U'.G0=-/_UYR%/1+*;>1
M">E+(:@.<'/>P,J).0GR*\[Y'%L(!'62_RBG'W4L7V64S2C#\+P<(5&W::PU
M\>E1?1UNL@YV21("%A%'(0W73COO3,("*)/8:%/57J:0*5I&KXM]'-]/8F7V
M4]/3\1:$BW.+:.639#8 <D5N$5>)(<-<1%;+E)SW.8/^=ABV-E 94*0MTT0!
M)?#HK.5"B!P$1Z5RV+H&J!Y\OP^//,L50',ZOL0!\:AAOSUW*(<B!A:DPMP]
M>ZF6QSM>I\3Q.8B:A/7PY1BUE<$%=BE697_F@WYF:QM-Y>$X *@VK5:]8>K@
MR267LK,@C8^7X]>SV,WI4G8PZ/EV<4"-SQVR]VM&V6P]SWZ=L5-_[@S]9DUU
MOF'US==7T O68!;X,*94TKMR 17@%;AXU!Z<C!//JQR9<8NFL>I89=CDXG@Y
M(2Q#^HH[U^W;#N),<.\E=IB;X)WBW&O%K+*$&.=N =(#4+OAMZL\^P?L]:!*
M.MSOOIX;;)6RU<#V"C;F\-F1U40Z2CP**1G$,?-(8XM1,MXF*C23ECQ[R?0-
MF+W A*%=NO!5@7959<5A%?>>=='BHLC1IW$X[,2QK[C>NDD"5TV<"]],O&B^
M;K1=N9:S([E.H*]]CROTF^R,'8?4#N)I&]D2W3Y?-[)7^[/+,T@9S$[T)>:U
M17X0K\J-!_>K%LCV8ZV;E46J*^STEL697>/$')=9R??TJPK^]7(6LY5OC1\\
M$\16W)U+TKM7;N784UQAY!C(*L]L42X'O=,RM!EW[ZJ'E4/<3)>SHZS]L?=Q
MPS+!I4A1"*<,%Y$YF2BW5N1*S@DTEQO0[T9-9:4K]F=64]Z6DNL*EM-X84$Y
M(0G44AV1,=8CR4UR%F?;UM^0D;K*][IUH_.UU,USHV$YWYF<N55*0*B+?ERE
M__+(L8J0*Q2@PESC\#R V=/VZ/3*H=DLMRTEXGD/T0QWC,[NT$+ "LP<(X)Z
M(&-F<R8E:(/>6R*E(WACY+R?_AKO1>56>E\F$<-/3>=T]]/QD<*$,4\D8LQR
MQ*E5R%%G4<2".TL\!]GU["6_ALRO=QU=!YNCP5CJSV7_Y0J;XW(>_SLJ93ZS
M3E U'U@._'?!_1]#%#_2 4?(?.H! F6RG$BJ@TO4XY245Y;Z<3@W7;/H6&,:
MK^!%OOMI]TAJC3VQ%FFC2S<VX,4D*%(B2":L2""*;@SG7FH;JQ9JO8FN/\JE
M<$J ZJ1Y]X_!!C>=:DPF1^8RRNYQM+$A#FB.-F[D!9%Y@1GM8W &$<LH\$(
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M>4'D!=>6:.D1:#0!<4<$LK+,D59,4^H]M:F.QWT=\(!3,DXYCZUT7'%L$R
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M1PP*U! O?0Q1ZK5-HC=6*K.E=I77T':C,L3WTT6?%MIJ/74YD#=?M,(0YUQ
M.(2(./<4(,]X%*P-*=E(5!"KN#_XVAQO=3I?G=:R"NIJW>WS"?%[=T')!JZ$
M250@KSE!7'B.G/(:R>@3IMA14J9C;PBQ0DZ&.FFO1K>5U%B7C6ZUUKH<U)O5
M6E,P(F9WJN 6@]8*JJN30B.:B/22:!QRO\B7[5U=]0" 9;0YKD, 5F]=ZQ"
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M[?;>\_!/Y.$%4U]&H8D4BXD*>4"XUCY)@C@A.DB#5$B98-7IGH<?*0_?<SS
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M[G&ICU=/7?]K?[M^*DZF_+[,=45^JX:(@RXO+4$-]0U0VLL<57R4TQ2$*^]
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M4/@@U+#8')<I,1'3L9\QQF/L;!%=D/+EK.%6N-="D:L%%Y>M7M7L9=?,K*/
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M=5-0-F;#:1V$W%7Z@"GQ) J4^Z(9&$"%NDA15,WYF6@TGNHI5<3Q<B5.S@K
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MOLQ4[:Z_]UPX^ZBZ%C:CLHN:DWD;2/#"NO^=6(1G_V<&VGY6NN&7N=YMA4#
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MT%,Z&QD'YC09(/Q7#H#.V4;M&WP@-G]>C6Q0&10PM+GS@H'W;>TZ!L; ,RB
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ME NK5=G9H$A9I#F^1"5E&NU?H8;& %6J,LT&_BJ7 "V-VCR1EAS=BZJXMU*
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MD/S!)7I+]G/T(#/X)]S@PZCO$IA@<ZT,&CL_V6;W_P:= \_=^Z?^R:OXD[J
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M1GWSNJP@L]32K:J+IA:PT< O?US=)W+2 D?6%X_U<!% H\(F:<]'3H@@U1)
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M9%40)RPNI">*"^F-%E@S4@8LM,2J2^_O(">OI/<UE0[."Z.B". I8%8@0UU
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MO<<*KR*W=SQ^+W@<>^&),X4*UG*0Z6#%46Q#R1@N8$_"I9/ZM\?C747 %@7
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M23AO5&VWW$*,J'HRA@(V7N50O9)1A:0+N>9P:_NRW60'D&\1D!V;8KFXHL&
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MB_-0P^@_,E5LNIK NY1:;!F,!@1BIMC(: R<;B"=8F#SP[&YL0^HF&IJ%K^
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M JY6D0.CC-6"[Y((W#(&K\/PS.\PTJ.ON8")$$B0'6L?]A0I^U*9,%U3)LI
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MM,7$DMBI7E)802*MDOA!2HO,39!\2S$,VSA5;.I*G%*-GJN%W"OE9<RFN2@
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MG+XWZX.[+*W743R;\ZLYRY <R.<NG%![R[$]JWJJM\&'W&1&@2LU1];!%32
MNF5=WS&?[%F[OS&CON-Y?X&>LSF>,,I^?C/&/7K^GZ0U^FZ $VBK0'M66&I0
M101G,?+D91)M;<.F]?W+<J@O-[*!:X :G3 $@@D-8V[)- 3KF82'WF$)QLB^
M]\@^^?X_)A;;^SWT95!QK1*0(NN#LO+ ';8(8HUE9#>S/?XRVV]BYP]H]WA#
M](=QP#WY_N(5RU%_X]TW]X\]M6./J$^.G;U#6C/0\O6W/*.U\^&">">O]A<[
M_6-?S'F7^@'_\7JG'KPXDA5O?6OM2.F3KU 6!^_PX.*OO.5A]>DC\W;E8&W_
M5Y[_??OT=;_'UZ[;+^OH//5HW_KY8GXBOY^SRG.F7Q4UN=@O:/<UO5EL_?VT
M-RJ.Y]O/_>PCNYD[G,UFY]WBJ5%?>O2G+VC]XO(C7RR=_*.75K>E[^M^_B.?
MWX7EWS,/JW_/_+URC-Z>LRM>*14+9&-,2@XLV=0;,4;/VM4J"D5O3=[=C^<^
M]&]X__F<7KW8*;-O]U8^E]SSZ7$X)6NNP"T\S>]/RPNNA[O\I*VU^Z*+]X>_
MR^S=H]TCX;[X<J_^S_[>\_\15JA=O!\LOGIS<O&T^Z5,^L6S+L>>R=5]M;M?
M?OWL3,)/YLF7_T$;$D6PJAFG%7CG%7KY,R'9H!-[U^+6C,5PONKT-C_DZ<_=
M\PGC:+[,:,XS.CB8[^3#[HD>[,]H]OQD8L_Y><=QIH6\*;]T&R?S8X7N;@;E
M[[*>9TN[]IK[ 1>KV$/;W]W=?[WXXD(+\=;C\1<]GF6<8)/&=NG5@K\X^N4?
M=6?Q:I?>?+&SM[S9Y9?^<7H\^AG.Q"66)UR]?<+D0F9+-E]GCZ_/O'[[_O*M
M,\&4U7L^W(\8+GQ;WS<7OO=GA\7[&"]^]\^.^N?O>8!QK;?H6NU['?4#]ST<
M?S2]3^'ZE3=W0X'S#6.L5[&W.?/LT<KS?KCI>5]8LN@S>#:/NRAYST=S&[H9
MI*.[7CFN.Z+$=LI[+*[\=6=O)N?9%=NU^-M[3(@+H^#G!,)O:@JD]YH!W8&\
MJAN^$!YW],&9JZ".._ILQJ2ZDDEUZ0J";?F_6U5!\,?[3^\O%<)WAW)5^[,?
M=LK^>V\,7=_O>T^!6Y[G\/'W?V>R''PQD3Q&H,2@HR=J6*"PKX: S5&4)%ZP
MV#&R'-XOR^&7W=V??OG6/WKVU2\_/WCD'__RP\O'S_ZYS%AX_.]OS<^__&I_
M_N9;_9-]:,YF.3SY][]V'OWRZ^^/OGG\ZZ,_?K6/O_G)//KW0_W3RQ]-SX!X
M\NSG7W_ZY8=??GKVK_9H9YW>]53+=3UZ_?B7A_^).<C<!J^RZ1W^J("BOOI*
M.9L:F\E8J&^\O'SR_D?#Z%,7DCA#XQ<E?@TZ''1X5%&#G0U,MAITX+4FGYQM
MY%JH)MOCUL5Q)'W=$CK\XRP=^N)!VZ95,"TK8*'#%"(KS1"=#S$G!TLZ]!]=
M;F/0X:##VTV'#BAF&YNV6*&["NR<"2D ,>3 [TJ%&70X-3HT9^F0,R/;UI33
M&10XRHI\[?V?6Z"*5!NEK6UWS]O+YO\/.AQT>,?H,".5DC"+6$Z OF'E(%R(
MPHS61[BF>FN##J^,#MT&';: -IFL7.[>8=.D")I3&,7B 5L;>M*:NQ?LK1'+
MGT/[E*]?[.S1Z)IR89,T4;$5P!BP "DQH8Y"6;W>$#"#OIX@WZ"F]Z>F-YMQ
MO-"<IL1=LT;Y4:FH;*J6R14#!:-[ZPP1KF8T6[C#2$93N!G7LFD,I37$;*R%
M2"Y K/::XE,#R9=!\F8(RE4T5**JN9=[U1I4LA"4\TDTM2<37.K=1J=4[W4@
M^8J1',AXB%&P;+,898,V@/:A&9MMA7?N6AM(O@$D;T1/&GM3R%<53!*;['-4
M"-$I]JA]J@$SFJUMF]Q \MU%LIAD&>]0K L(II5$1D-!=)QM;]\^:D!-#\D;
MPC\4,L!BCFO23D$)1B4,@N06=:&L$Y(@V5VZ!-0-UF"_$VE-7],>U0^3]N?<
M[=TC'V)#*:>((2/X$L2-X"8"T0>O<])#VD^-?!Y_O2GM4RXN%O$;8G#4&[H(
M^=AHE?6IF>Q[+6B_M9WL%84<)[3(,H!\!.2:H#=NJ3&;!"$1!? -@O:V^'C2
MRV4H^PD!>4/9)]T=023E=%\^P!A4-@0JB%_8&$3R6=K:OFP3]0'DVP1DK:F:
M:'N?1 LI(6HG% Y '**0?!G"?GI WA#V-KN(WD=E3>9>$;:HU"/NQ5/J QJ2
M<R+L_66K@@TDWR(DM\RN>,S0&D%P)1F&2+%DBR:E#$/83P_)&\(^$VK!+RJC
M0U!@!<1H+*H6A)Q#[;F]*$B&."$D?PY+]M_M[])>'6OV%^H!XW6QX&W(!9QV
MU" 5;4QPE:RK=0C[J9'/TTUA7VWB1EF$?2S=C<A-$9;4RQ]R,L(]KK:M[7#9
MCF=C>> 6 =FA,[%Z=(@%6N7,1-$[L"E[J(F'L)\>D#>$?34"VY*+,J:*L$\V
MJV124=46;VIR0)"WMN.45@<&D*\Z^Q? %Q\LIJC!YIHKI(R:Q9L,-7@:PGYZ
M0#YOOX/-H1C56Y$I,"XJ"C8I#9&U(%KG#F2K/SI$-Y \720G=@"U<+!1_K41
M66>K61QNU[)F-X3]])"\N6+/$6P-4:!;JPA[,<[+SB4A)&I$PM0Y="1/*??F
M<UBQ?\2_GU-Z9$05C_5 U@8<5Q1J 89,VK?H$X&SIA;=AK"?&OF<4U1#IQ:0
MP2M+/2._H)"/XZ;$M]!5/(E4L[T*/3"6!Z8+9'$7H].AYKXN@,:2J]#(99.,
M\PG]$/;3 _*&L _>@&YD5 DQB1ZHK+(X%*I$7ZG%6B'@UG;XZ$TU \C3!7+T
M-J$6!>]SAAHI%UVJ)XQ6>-VZ(>PG".3-5'RC0ZZN-Q3*(@?8@D+MHS*L U@7
M0_9+83],\AU&LHCW:F*P@!0AN8K44FHN<N#@$N$0]M-#\H:P]XTXFN*5R;HH
MR"6K7,FJBK%J;E%\Z[X]+EU5?::Q8O]^.)3'O%=XK-A?F"Z4K'<U&Z]U@M0X
MZ;#<#-1$%9CL< C[J9'/.;OL74DY-61EC64%+F=%*5:570V%;:O:EZUM&,L#
M=QC(-J=  8BRU\#B2!B=72J<P5L-,0QA/ST@;PC[+ 0+%9+RN@M[A*"(M58Y
ML.4&A5#;K>U)[><;0+[JS7%.5X/5EF "B,1'\DV32 &;P900AK"?'I WA'W)
MM0*EIFJ*H$!#4<G+B%6.,H6SJ2GW^M7^HPMR#21/%\G%UY)\T!"LAQ T,G')
M1("N=W!_5P_O@>0;0/*&L"\-:S&-52D:%4!.*A5L2C?AYT"F:-^%?9B23?X<
M5NS_7Y*3C@7["UMDI 9HD+(5?U(F%HH*M+&R^)4YINB&KI\8]SPY9XM]:4[+
M.&H5BQ4O@MFKC+XJVZ)C2BA>HA%=/Z5=0&-UX*H7['T3'"?=:M/0X\K==S ^
M5BW^920]=/WT@'S.%OMLLS=>(?<M]J"K_&9 H:E6NV @ZB*Z?@#Y#@/9B7<'
MAIN U$,L(5?TK$-M27[HQD/73P_(&[H^VNH+VZ!, %)0':@4,2F7H6+UD5RW
MR ;&%OL[C&0J8GV=:#^=08QP1BVZ7H.W-HG#AF'H^NDA>4/7I])"!MM4LLNJ
M-\0*^U;78I*QI#,YAX+D.*7Z59_#@OTW/)=CO!DK]A=&%8WW%5*CJ!L48Q)6
MC:Z(PG>);1S%\R;'/N?LL3<M0L%F5$__4Q!S511"5CK73+XE]"V*(!A[[.\R
MD N$V%,T((HB-)&2"^)*E%:BLT1I*/OI 7E#V4>7A'X#*9^B" )H2>7@6>6B
MJ_:FA>!I:SN,U)L[#&1NN7IL)%QN(!*()=;>)O$BA>2MCT/93P_(&\J>DA<8
M!Z=B ZO I:(HE:[Q2RR]74W0O<6J^6@],) \720W(>T(B%J'! )FQ.2H,EBV
M+@#8H>RGA^0-95^A!'#:*G95D,SH%64.JMEJ"A;&XO74>DY]#BOV/PKNN,[^
M6ZZW[K\<2_<7[@>RQ5BHUH@4 "OSU3</%)A*;#&O=<$0^-,AH4?/OEP2T)*(
MGGW_QZ,'/_W^GY1C8%V#$GW7_0G=A(4,* ,9(GLBE^S6MIU2>'$L%%QU$DXH
M(@><3B5D\!ZSK;V$8M#D3$(]RN-/$LEOSB 9BHNYL%,ED!$]$$!AK5FYVFHN
M&&24:]_:-Y!\=Y%,*$/=L+4""1IES*DV@WV_3=.:_)#X$T3RX[,VN04?';JH
M7"Y.@2]-Y1I)88@V0Y!1]8)D_.BH^T#R=)%L3-5%S&]RV,!G30E,HL3>E1!J
M&XWO)HGDLS:YN1I"]E')B/6^THY5JIX5),HE-9<\1D'R1Y?1&XOWE\+A#X>+
MQ<[H:7]Q#F#R23O-T'R!VE)/0JFE&<Y<&2H,:3\Y\GFX*>V]TZ3)-.6L]@IR
M(I6;.!0&? HU-*X1MK9AK!3<822S8<_HK,FB!P, 4G*E:1>8&-D.:3])))]U
M(V38;:^UI(HV?8.-MXH$O@J3B=XV;<27V-IV4UHI&$B^\C0<YZL/VK%.8&NE
MOK\F:1'XG$VP8_5^BDC>D/9>"#GZEE1L#47:)U"Y0%%<=&JLG3A8(@C,Q\?;
M!Y2G"V5CDC'&FYR:ATHY:P?D6\BF,:)+0]M/$<H;1KF%T BBRC9'!>B\HE*B
MLE0T<BI%4]]QKZ=DE3^']?NGKVAG[+B_N#\')5\=5,-DH=6>38;H2PT9H]4X
M=MQ/CWR^W=3VV$3&55V4<TTKB/(C4W4J>.]"*.(=IM"W!4THL#B6"*X8R9BR
MN Z6Q(>PH+DA$U#+%(UE0;4=VGZ*2-Y8(F@13-?VS=:FH!FCDDY5M>Q:KHF]
M_-5K:P\DWUTD>YN;M2D*@U=((/]9RV0XH74<3!O:?H)(WM#VD%-FMDT9G9?:
M7J1!M4Z9*M/:%*.I"X(PI=+: \E7G9D?&AH;&7LC*M-RJN"BH-L5@S;BZ'XW
M222?M<GH<Q+\&J4SU)Y*%T3:6U(N5RA95Y-Z^[LPI:38SV'9_ML#VAT[[B]N
MM4.54/2?3]@ A(BHZA2\;CUO+! -93\Y[GETCK)/IE2;3<\1<@I*Z7E_QJI>
M()UU;A!<O0IE/Q8(IHMD$?%,-NBF'0!W8Z1C;,[WO1KB7(Q5^TDB^:P7X8)M
MM12KFF@X!=$[A<Y99<1)-,9A;1&O0MD/)$\7R;7VX%P5^ULU@+-D8\QL.6FD
M0+D,93]!)&\H>R'=D+P)*F9-"@A[URRK54'RJ3@FM$7TP$#R'4:RD+83":]]
MH0H$&:$$%"C[1M['&(>RGR*2S]KD)$B.E;RRCKT"6[6B"%HYDZBXR+7V,OG^
MH^MBCC7[RZW9[Q\>O)C]]_Z</RPK_[.(+2*7E$47%#8B"UQ,6#2%BD'^#5C#
MT/>38Z#O-_4],X/S.JKD&XLOT9K*PCU*))YM.ME<@QG;=.\VDFLLOG*EDEJ$
M1)0*)N-Z$XS8C&C&H>^GB.2SOH0N7L9+G(<@@RGZOA2%C*@,]LJ8UHECV!,
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M6B.5-M$IZ^-O7DKC^AU)T.$/C50Z83$B;$_E>J8U@EL,I'#BQK/BW<*G]#+
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MU6;X4_:E?M>^Y<K%QE?RE@Z6K-OP%_2MY--]QW[["_(7Y"_(7Y"_(']!C^4
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MSB8XA1^Y*QFQ=-6#".4F[TR#2>DB_8'Y.B3%4F<RL#NVVW>2_1VZ@+%2.$6
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MU$?)1&!']!C5B!(7HVD)5C;LW[@G%\<7UC'YDQ F&VL_V"),N;,WEQLG;KX
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MS!CCAR8N-? W^H@\:_Q%J1)D.9G5U.J%:&8WN 4Z'.'OXC'NHB6YDG*N.8W
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MPG$GZ&&M/6PA) &@H0QG9OY9_,_<J*K0J"H9 (3QW@2[[4UM*=D<():RM@G
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MR5TNN].0W*PA+-6[!E?NZ,U.$Y1-)%DY"@8(/D9#4-*8)NC$!*:#?=S$6(B
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MS2"/>S/85#$#!]5%!6?'!: 87#".)N;V1*8JJ1)NVBN,$A>+#\9M]IS$,YV
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MX4843S)ER(Z@#I (!L"2N1FT3<O0#PFO<N!6,)6XU/:Z4<PTI8_!YL.APL_
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M42)(UL:.6R2!.O*JO"KSK3'F$Y\N"-*7$?M9/0?BF)FK;(OU9JYN9[2=B_:
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MVP%=S(_@?V#!N0 JT'0CQS60O@.U/$V!-3K&+[/G;]EY2Q39W42\36*42?)
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MUY_0!<9<8;C:<\=#!9QL1N,YM,8:L=WMI[^P^>+BDC+)<)_+^M![@\\7KO_
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MZ183G+14@B7@:A99?Q ,2. ]*H*=D1*)KI1<N5IQOT/>2*)36?48#)66*:;
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MA/4#] / NF$',(IGC!]RPP#D/(X[@8W]%]8+SUL ,QJ^/4J'+QM',\W63 ,
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MXU:#5+%+?*@^H_AS$N]?<N%*?.UQ0C%Q))ED_"+3J"]4SY G6.06R1B]3)5
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M YEEPZBIUL.&K(>-M1ZF6&16HQCB/)S?<3Z2./D_]V&IWV$RF0X=''C_$-Y
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MEU2FZ9LEH<X7R\RHFNS5L?;W9L;?BR$;UD$Y,UBZA%#UHPV42R8+39Y@F/(
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MUJT^T"G,RVZ$^;*O)CN47:M5OS;N&1[H?[NLGCAWDNM]).G5!8,4>VBU9(/
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M3L1B'.:5[F+8:8'_C8UL\XB74X)2E8BL12973DB'V P=OIO $$,14],IY[+
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MJJ0%8"K 5'E4&?2=8XDZKZE&%!L LNI%:J["UOAXD='%%DU2SPR)OI,F8S
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MXAH(QVNW?$Z@1#J.O'\6(]FZ12J)I:63]C<-96=-M]_S1" :^M!#%\T,IIK
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MFRH..$95 E2.OB,9K>N-Y"/X0G!K<"PKD0A59\EF;_-F];UWZ26L+*/56FT
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M3OP;_#V*$3EV#Y\,NY<P.B@:P1/)V'?-3:9/TPI7$6*++GO-)\*$F'CZ]KP
MEYKB@:Q+[XT7J=O @_.7B+=.HXSF B=@2BF\\)G@KA.NM")FD-L$7X7'Y:=P
MV'X4>TUCZD+"9-F&?O&Y-!>HM(T&"UQ!QB#E2Z_#7F"E$1+CYW7C%1):;QFN
MF+!EN%B.QH^2VQLYO]0 O0[>.J,]]B32S3"Q=Y9\TG5@V.9,! %!"^7.G[K4
MWM@3%"]+31,V-X^5+$L=F(;?B1W0Y":B=+&K2553/U(VHA&5,9"$767--)@+
M(!Y[$A>\[T68(CR:;.J_EZQ:DG:Z!LAV?#ZQ)=/&/"UQ. /SBN%Q=N4/ G^$
MJ?_#@'M!%/]#<=6\274HO[%K+<K!C4[\88IQE(A;V.O2-KK.9]A+P8)OH6FU
M<7!(;)+R-AK,Y+BB)+H58MN[B]>KB3T,IC8SQ8O6H&Q]*NQ)S_>BTH&8Y+8N
M#IWO2U=3PU3UUL?>UT8T\2=NI21?1BG)'<8Q-55D)(_Q1>JER$FN=*-0G9@&
MLZ0)\ESE)4!*3B2R9CIT[?.[BXN4B\C"PCYF#(+DHK5B8PVZN:5[-^]N0MT#
ME>O##%3K;"42&G1Y1)]<^PD][5NY$R++&K,&/LI"\8K-M>YJXNNLW]\\&CIT
M>C!II9S]X9&9XDG.A&U4>-P4LH.K4M&AXSL%E24=+/BU!AW!@<4QQNN&6#LO
M &/1'3'3+>^1M)D&7=LYUH"PZ\&LN5IQ]PDLP/)"%$IMW[QJQ,YE-1OL>P<0
M01=<?(B[(VMO" )A5#1*]K&B)W_772?,(<>+M,PQV4I<=8-CPB:W3?6:W&MP
M?O/131D5GT70JKGBS(85^(-RL*N@G7Z30R&#9$@=3)(]8$[*AN);IZ9LI?S!
MMC,5U#NT4JI@;CL=D"ZI&S*VR7I*S#\.58>DG)X&@Z&:(7*8/!.-.GXKZOWU
MW.54U,\)PWG$EI4<*6VD0;=@^S I[LO49&&$4EC.L@I*I8TTZ%:?/J,!+#)$
MA&S-.:=4[KB7M].@<]E+]8/9;KBIV&NKU%A3SUW:,A#Y\^IN#J6F&H";9)17
M"2_>KL,ZHWA&FNPF2.8GK.])_@!#9?E?%FMT8P93$1JM%\YLSV84KV?13>D!
M3/@:8<4%//V'=[PPBSW)</8D&7O[D-1TYO3=Y"92VV8"6N@06S$JO6.MUE:#
MN=-^0>,Y8-Y"5%B9X2%KLF \C$=TRNXYJ#35%-I4=M96A1D\2ZJD=.4T>O.C
MX^/XS@41>%RS#5:H%G&(Q8@3?@$FR)+*:[Y5IZ.#&BLL/[\Q?X''?%!:^%Y8
MEV9X2^6./3$+#H:'6.0J<-%U<H1O&@\VCV@WMQ[1CNYIB3UM0E_\6QLF1/&D
MJ47L%37*C[DHK1+L12EY)>^7&LR*%N&@A\3^)DJN@])*KM\6_5R#KG0=#UB(
MY/XP6MPCSUX@.W7)6FG0,5@5*/?8C"45TY543MY.@\Z)B J(%J!=*DQFG\YY
ME-;K26,TBJWUZ&CQZK9)]Q&)'B5W-RK0T'3O4-DA,8>14S],[3S CIM+3]?Q
M>3%%KKI( RK7_MR?:J#JF7LUFPOY:H7^REMJT$%Q7R5^<DOAA8C=G^K0A4PR
M[=;%L*J9N+F-->CF'9V1P/;_%EAS!4=ET:\UZ(BL!E>?^EN9A8X9/F5!PU/W
MZQ3^VH^I#FE\L(TRDZJEK.;_5@/=0/="U22F\C8:=*J]7-GNFM+0FQ+>"TPN
MP.3DX6#"Q]Y)/Z_-58.!W4Z2"+-&F!G=U!Q1) +K^-]AV_4IM]?IH(9BXD5%
MFIH:8B7))#OI(7'^R%X)*G*:FF;_QZZ_Y$:^:L!:I:4&$P9OY.1<1,'BS+"M
ME>V?"BW?.LED-Z5L$WO9Q&B]6&SA*J'J]5_4:+WQ'9T?_;93=&T)>QPNDQT7
M:W@)]X4C'#9 4)(&J+7,;Q[E&+NV3QY@P3,QE*CBFBUNH,GJ@Q,K\NM,W+SJ
M4O?X>%WI,J1*0M=[AN$K%K@S<NG;%_F_U0#+K7RET8O,,YW[8PVZL;EKW+3^
M%7A^JL""UW7B(C)>5+VO$X A0Z-52 +< 0AK,#Q)_N6(3N5/[13^7(.N-,VP
MU.2(FI0]B<-\7'$2Y(7_IVSNQ&[(N 9KV=W6.M0T/1]L5S-4<R&4M]$ \*VK
M7!\NKV[BJUSJUX4JD="@RTDM:SR=[:2LB,\2KQ4&E>K5R=Z#MJY;\A ?N.9A
M,>KFJ'TW'A)\W$ZYOKIJ<PUT)$DY5DU-UDCX^(VSB;N:4$=MH2IOHT&GX@?J
ML)Q8^$;=2/U5NX)&&G1K0KB[\]9 US%5IY1J:PTZNNT)&]%5P&'?A_-J!V0/
M76!QT<%!X.-9%/.E-DXR10];#;J:>MEVZX*@I5BUELA6&TW[N<D&PW- Z-=P
MK+\'Q&:S=?B*A# AJ^:65:.F1W)900&<3<;2T+69&?E=E)UR,BIO[8]4?@1#
M=JBJ2$:#);&D,FO/=>;HL0-NS_ZB;GW7/"H:%-:L5)'V\#5NM:MH&UU 316&
M1O>Y-?;9*HC>S1O,0.HE\SQBCX/IDOG0(=EK1GL1U6)ZA$DT?2KQY^;\4 /Q
M4ZE-GVZV7RE1.E"7M]2@@_>N:SV#&,E\PZT'Q Z?@,+K3_F%2(O]UO4I:NHS
M*HV3'S#D_I\5:4\2)G!1%K=)O 46B7XB-@T?NA&NP"18<0<+O <;>Y5:F@?F
M4M]^?LVAG  A$,I"[=A*CL8/7(Z-[\1\+CQ"JA/08,U)WC_JN!P7!^H-G!PW
M,V:&PZ8 '2CSUM6DINFL&M,5X?&9)[?"H$*"?44B&JB$@@(W7UAA^6'EYH>Y
MJFLQ$-Z+XMKUKNJFS(,/.Z\87'U6MBR*FVJ :29$UK2P?"CS-D7)O"'N<S+_
M6'4Z&G0^5?O9"Y^=1<_%)J,&7X$3]06^4?'J']Y!3?8I3^XC.1A]/;PF:9V^
MW"ITI%[+H*BA#MJP @%?*OB$2QIHT!TPJRC82(_CZMF#2DTUZ.+N';4H"R>)
M\)7NK,E4D\_D5^"DQYS>O!T,ZP]F8PMC?#![ %M(\E2W2DL-="3[SE+FM%)P
M-I'%  Y 65/[]AN;+^QUC\'N987%V\)$H"AQ6I)#J=CZ[;,94S?B1(6=6M9=
M<5,-E#^_\+=(?P-8MEYJ>6 .6P;%!3CJD'K+MU]VY!4F:/BR8I(!M_W&HFK7
ME4CI< -KIWCTQTVZ4#.8@]@5\XW*"6B@[+LOEV]"4Y,%;2T8G>W^0'8%N"8Y
M#8;B4%O<*VQH;^&Z*ZR)/Z*8%Y4DZM<LK5]$1@--V)K"[S\E4_AO@4,K/I]0
MUER'KF8N9B37-L+[AL)PS]X@'(T?9;ZZ0Y#68(CNW/"!;-NF?+X&PWT9V*37
M:ZD>#-7;:]#9YN7UQYNKB\^WK9XO">'F_E2#+I16)7]PD=O$;;_ ZF/M4]\\
MG]*;&^@E[PU&*])>S]\4TWE+NS5QI(815ZRNK'S-(:>)!EJ<.2TE47:E[:>\
MI08=W/]R_'_81?>\ZA6;Z]3XHBZZ1K %L6]=SL6%1B\I;U&I*D8ENCH<NV[!
M-+"H12)K^9XZP-Y42PY7:ZN!!B1U>86@884H3/X.*V:I%O4M;:Q-R=X'2M!Y
MBY]UG57@_T;Q241J-<-=(YWF5@YO#4(:8)V_?X89W^EWM)-%:R@K?[,/24W3
MJPLJ$J0>2ZA:S&"KZ5MG#S>7P,IS U@$;\'XIR P7[E<)4RFT%(#+1=E1"M4
MZBK^O0:=V8I71:E[I2$JM<B7&B5-HQIH\/=<XMS6>JI-M;4&X">91?L;IO5H
M:3 ([8"[*RKB$U/B_"%4%(2&G36ZGR;Q_JHVUZ"KI;5+Q94<?]WTHDLI]2J@
M9JEH.LF35ZCN&*<FOELM+JEQV0%,VDX#H(5]B&9"<O4,3TRRXGJ25AIT3*$:
M(@8@TA411>849DQY>-F0670@ZF?S=0LL#0_:W 8>]M)[M?J,KR61#F?8?/M\
M1"VZC-W=J%;"' #+U1(Y;J'YGBUR5/$44)N+GL&GK1#*MD)5B+WD-]1@ZCXP
M&Q_W<^BF)&%4":E%N0\4HA5'<BZN1D2#;@^)1>9,.:.N\.<:=$6ES'=D!G3@
M;_&TQHC"@< Y1 %Q"65=S0Q14*/KS/#8([Y2UP1Y2PV4HOAEZBCR>RV]*:C8
M7H/.IL(,'T5Z<EBS5ST)++>5!AW;O:%.GUM@YRX]F&W4N@U\$/X?8+-@],@*
MO4[*E]U52+VUS^H[<\,+N.XL+H@*.\D3%J3 >H2;W&8*2[.MDA==FYX&NC 9
MC_9W!U0DHD&W:U?TC$I48UCBST \81T;JIZ(6DP6Q(E^<\^QXFS7"2/GY14C
MWTR>5YJ,'@KKU<G#CFJHQ,_HPL2IGG%=0D-3R^%'5YC5M_:MCA5N=R(QVVDR
MDO%3:OOF/:SHV$B5L\%[W7 (I\L-OAO7QQ"=I=Q?#[AP@H07?'^(X^7UY-/!
M#?/H<#@LS1WV;S@,DY=;ZM 9PY4]2D6.T^^;F+7E$+NT8F(]8II&6\L?A-[D
M:J=_AG?0S="M$-<Q$84A9U@,8USVML#K,--T@]I-:\=I%7IAA)D1/^/A'3B]
M?F\V&MB:L8,7]L]IM MN-@0?_H5.X5"$OAL]Z./'ILNZ4/OVI*KI!,Z+I_;=
M)P&F_$:Q:FL-E*+O\F=F+NJ7GJQ 0(/N/HS[/3+%] Y1PV/(V1,L@SW?4NUN
M!0(:='>W*&8<N@"Q39K8+6&I]= ^Y*YZC4U5<CH8*PD^S\Q?X.4 RD623*L]
M*(=<I:4&6-_;@(K_;]*$Q1>$\)1]O@H-?VCW?CF'WGGF@B[)KW_Y/U!+ P04
M    " !3AF-5*2$N="(H  #%A $ %    &)H8RTR,#(R,#DS,%]C86PN>&UL
MY7U9<UO)L>:[?X6FYW7*JGUQV+X!25 W(RB20[*[?9\069N(:Q#0Q:+E_OK)
M.@#W15CJ@$<:1YLB01"5E?F=K,RL7/[^'U\O1Z\^I^EL.!G_XQ?V5_K+JS0.
MDS@<?_S'+[^?OR?VE__XYU_^\O?_1<B_WIP>OGHW"8O+-)Z_>CM-,$_QU9?A
M_.+5GS'-_OTJ3R>7K_Z<3/\]_ R$_+/YH[>33]^FPX\7\U><<G[_M]._&6VX
MIRD2H:@@4FE.?+"<&!!"6R>TL^+_?/R;X2K*: 11.5HB@V?$:P4$@$O%J0V)
MN^9#1\/QO_]6OGB8I5>XN?&L^?$?OUS,YY_^]OKUER]?_OK53T=_G4P_ON:4
MBM=7[_YE]?:O#][_133O9LZYU\UOK]\Z&S[V1OQ8]OI?'P[/PD6Z!#(<S^8P
M#F6!V?!OL^;%PTF ></S[]+UZLEWE)_(U=M(>8DP3@3[Z]=9_.6??WGU:LF.
MZ6243E-^5?[]_?3@SI(>%DC018+1_.*O87+YNKSI]=OCH[/CPX-WO?/^NS>]
MP][1V_[9;_W^^1ENH?G(^;=/Z1^_S(:7GT;IZK6+:<K_^,5?!%)$39V@A8[_
M_?1GO;XA,< H+$8-1P[QY]4G%EKJ49N^SM,XIB5GKA8>3<*=-XV*7";3J[\<
M@4^CYM7!8D8^ GP:' [!#T?#^3#-WBZF4WP6!E0&&FF0),;,B90Q$2\\)]HE
MEB$ 54G<Y5+9TPPWU<@SP\PW0ETM\;KP[W4:S6=7KS0<;;CY-!5+=FZ_KUX(
MD\5X/CN!;^!'Z6IOR5)CM9!$&(T/J#...,XT43K$K"@(+V7EO3U.R=W]W0),
M;QI>3:8Q35%__?+J2RK:9J7*EF3!-#Q TMT':?6.U[/%Y67SF60X3Y=7?U_T
M6E4,S"?56;^4,NZC @RFBQ0?V6$(H&WPB60F#9%<9%35C!$7,R1C(C* U4?"
MX\2L P;^PX*A@@"JX>%P,OYXGJ:7[Y*?7Q%BLDJ1!4N 1XV'MHG$*9UQMT9$
M*8#%7%W?/21C'0R('Q,#NS*]GC:8S=)\-D!@\20,)\SSC,CSFK@0'<DF4@FH
MI$#&VH]^LW(=^J]8F'GV$GPDEO-B;')%O-- +)-:4,&M -K*-CIXA&TAV0>:
M:FOF5L/GR73R*4WGWTY&,)[WQK'_WXOAI^*?'*7Y(#((BB9+5-*>2!H, 0VX
M52Y<5MD[$VJC]CEZNG1F59!^-=97 \/!&-VLCT.TH);;0T+Z7\-H49S97R>3
M^&4X&@V$X"Q('0E70I5#5!%K3$*M:DUDV2EE7&50K$-7EPZS"N"H+HIJ(+E>
M784@#( GQA9K*@E.'$U 7,$F-U0P!96!L(FPY8\C[*U86DV@[U).> +%@W&8
M7*9S^'J-N(%14ML4.:&)HA9R41&PE!)IDXL S'GK*XOX:6K6$;KZ<81>B>W5
M8' \OTC3%0V3<5@9)=H;PU*6Q":;B(QH+SNI)$F*YD2U]-37-@$>)60=X>L?
M1_B[,[N:W,_FD_#OB\D(63@K)LC\VR"*Q*35EE G+)&,40+%\U(\)*ITT)35
M#ED]I&+7?;V=7%Y.QLWG_@&C11I(&K5A4A$C#2-2..2S9HIDQD2.%+S.O/*N
M[M/0)?]E1[G?1_1.[*[G;L<X+'N'T0D,4;6^A4_#.8QN$3=0SF?OI<;]V4!D
MQN]<V;/@W$F-CR"/M<^T[U/5)=>F,C JBZ0:5$[3'(;C%/LP':-1/>N%L+@L
M7$\1C^9A&,X'3D8G*0-BDG?%OD8(<Z00%3R5S+LDO*T,E>]3U25'IS)4*HND
M9DC_BH[FX$;L?IJFBS2>#3^GI?UV.)D5T^TXHR$W<%PJI@,G  IYX"Q#'BBT
MW\ PK;) 'RW4#_1O0F*7'*C:^J9%8=6[%+@)=P]LD-X)EPDW.1+IM28>I" *
M')-!,'"\=E#UUO(5=W(5R'2@A%)*H/$*:,:&$L/4CA$4'4@KT9AUM0,#VUUP
MO<!MYT;2?G"KL1NO=T:OOPB#-XL9JNC9#!\K/QPWNW\[&<]172,Y^-ULB*QM
M7KYQ;*[H_C8(S$0PU!"#1B"1Y5K6<<Z(S_B00^:&\7LGZH-TB)V)Z)*MM2LR
M]BN15NY$;_F_$G4^\TD28U'92R58B6=FHG1"KU@$FIQJ\5ITLVC#"]R,[J8\
M=N=Y>R''6YLL 3#MI$C9>2*B584H0RQSQ2LP+'H S9UI.^YXEZ0N&4RU$%%3
M"G7#D+<)N8%J=#J#2)IH)AF>=5$0"YZ1J+75TJ8<8^T SM/4="D:70L0E7C?
MAI7<&\='_ 0-)C&-N(R1!B(C: (4.!'&6HG*"ZFK[6A]CZ::G@%J7^0L^B)<
M(:NE]X: ,NB:9"$X35:K6#L.^Z1GT!D+>G<D/&-6;\3R%D/PJ)*7=[TGDVG#
M\OE\.O2+><EN/)^4YQ(M/.0@?N+'@_$\3=-L/N *S7U>7-=0KHTT1.("YR0Q
MM/"X4Z@8=.MA^VTH[ZA%7A]I+R#H:B M =OAO.2G%,9<>QBA/#4N0O#1"R*X
M#N70R<@3A88#SR[:B*>%K!U3?X:<CEKO]>%42R25LQVO8A/<NV1E",1D5*,2
M;$)=JB5Q$'W0,28I:^NC9[(%MT \S"X*7_&?(JS/,&HX/7\+T^DWY/3RGDL'
MEYT&2U(NF5H>!>@@ Q%.4V&1W09J7Q*L15B7CN_M<?$ \M5E4B4J=HIJ>3H,
M\Q17!#:F]%F:ST>I/)_OTJ?);'C# E<JG((3Q FCB:0R$K34$PG9R&31EO;V
M>V5!6RS;I7-V=TBTS?>*-XTA(5+Q1"]N]74Q@E!:N!0)]Q(Q:A)NV3O<O&$N
M"N'1QZJM'1\EI$NG93T]L3O/*V;5?L:U)]-O):;"T+V0&9>$H#*13N!V$'A$
M14TUNMB^?O;![?6[%,:J)^RM.5PQC3Y]@F'L?_V4QK-TI8?N[K!@##=1#B4G
MBT7&"'"G"7-X/DGJ?1"UO?DUR.I2'*L>(FK+HVNN?C1.Z\@385F@&Z@HH"*+
M@6B@7F7OC;>UD_#;</6K9"NRP"T$'HE.(J$<,WK#Z$R1+!E/*5J>9>W+@N^%
M_;J6V=<ZQKX?Z-A(3-4>MP_#\63:,&"U*:4,1>4A20RX'PGX^'M!-3%1IIA\
M9CG6KL&]3T.7K/ .0&4G$=T#RM]?W^?I(?Y<JY'#V3E^_= _.C\[?G]\TC_M
MG1_@;^^2LG%'AR<^M(W6#NO07ZG'PTV>U7O$W#(RM4#$'']:I2+,WJ0\F:;K
MJ\<TZW^=3P'A/QS#]-L!HG;V!-A80/N..X4^'$,##Y(@P*0@.9N$+X>D4ZYN
M0K>VG9WO2Y<DE ^\HG% .=4RRT""8+(DLAGB8Q;H]6B3(C4LY]H)6(^0T:4C
ML2MX?'#CNJ/TJCJILR:4O*3DYJXAJ0C&2Q*B0FU<DH2<$HYH!]:&R"*EM;,3
MGZ*E2P=G5P%518XU"XJ;U5=^6$D]&G##<P+*"6<E8]'*5(K;%,F"6[06J-%0
MN_?%(V1L&/4B_Y^":3?QU:LYAN%X5OB39L=CW#IN<#&<7128'^>&+*^4\#9G
M0KE.Y;;>$^N4)#EX*J-#</O:#O%WB>I2L*VK$*LKV6J >X^L&'X<+T-%X=OY
M%,8S"(5/A>!"[Y)=I8# 1,B>H9>B Y[2D@57JI<<"90:P"]:\]II:1N0UZ7X
M7E=!V):TJ\'Q*,UO&8A:,,,C!'P.'"?2<4VL-IXP&8P3PF<J:I^@=PBHT',F
M#^?-5L#GTGM+$.<U6B7!9.)93,A2JZRT3/M4^]FY6;U+#LKV$GZDK<PVW&T'
MJVM%C\ F86P&0JVQ1$H3"63<MV9H700JL@FU;T(W)G)#WZ-=>[$>6-H55KVD
M\$?<Y!BBMU18DE1IEL"X)-YD1FBPSB*545?O3?+=(,<VN0&?TWB1KL[#*1X[
M?P[G%V\7LSFN,+WN^5.NKO"_V%0LND0CTV@":2AM#&G G2='>+(YI9S17JH=
MWMF"S"YIUUWQ\S"[H%VI54S:G#6Y@2L/#G>M0@B))J)D*?>)T1(K/&Y=*)X8
M.*=M]6RU>S1T2I761L9.#&]/[)H)W P:QHR#(U*4*B_% KKN(6;)--6\?H+N
M<V+?;D_'N;3*:C)IT_3S,*39V604!TD*'Q2WA!N'NZ->$)]9),EP2$VN0 OI
MQT]1TR6]MQ,.'H-V!0'42Z5(C67R:QKC(SQ"DGKQ<C@>SN;E@?Z<5GL>!.ZD
MB\R1Y-!&DN = 733"#5<:D69#Z&VB[$>95T*9U<%2@N"J9B+.4OX,255]!T>
MXJ-)TW%S1=+-N1W^>S%L*B/1FPI-;74)H7L?A6*2")$BNE.2EUK[1%*VEADF
M)9>U+QYW(+=+>9U5X;4O$59)#.]=EC2*_VF8=)SO=_6\H?;6VWJCYB/1:IRL
M[,S9C>IMU*WG*J#5:$ADUI6N@(:46"@R4^D<@1H=[CD CV:/MT%;EV+>55#7
M"2%6@>)5E]&#RT\PG)9GINF#,YDO4W[*H])LZ.;W;R]@^K'4$F7%.&7HY/NH
MRO"8TD,=214^"8-,RSRS-?"V-0%=BF%7 ]5^Q%&WM.LA+4F!ICD)PD4HW9.0
M!=Y0BZ"60L60 JM^[[8]1O;5(+3J<5>!\?5*G!9AOIBBJEM1@7L\& _G0QB=
M+/QH&(YS3LVO"P,&KN1IZZR(EP']:,I4*5/-! Q8Y2@DH'(-M;'QPNM P?Q(
M4&B?_77;=]P+JJSV7HHS,G69V0#$6%8F\EA;&EP+0L&E9+SWX&LW;'B>HG6P
M8O<5C*JJ-RI*HN:TB>N[J3*.R>*NJ"KIX-D#[HKCX^^Y"SY)FJN7OSUU\]>M
M]%:3N'":1Y)80L7. R=.H)Q\S D]8N5MJ!VAW5MZZ\M&P[9$W\.LJ&X(OV*6
MWHK0E7IXD\8)&36@0F0G)! \2(KV,8)8XS.)4F<:6=8AU7Y$GR"E4U<&56&T
M&]=?K/SA[?&'D]/^;_VCLX,_^@='^&/_\/BL9BW$4RNT71BQULXJ54D\TIKV
MNBTMC:;@21-J)9[/$G6"TR&0X+QB.2#H5&W'ZAER*C2/>>JCMRHX,LPQ(:4D
M&F3 AZ1P1^I +'>&TBQBUFE_W&FKY]'^KHGJX/"1_C0O)O6:?8^>VL1ZS9JD
MM%R83"Q+>$:DY(D#8XG7U+#2I!=/^OU!]8?+=7H!;%87ZSZPN-4#!5S3I+,F
M0D5>BD(4 :\EH=Z%Y'V08'XH-;J31\H%M4#1Q9:0R_2=7#(UM"6*:>M-9&"K
MM^;H9B[J2Z+LF6S63>13-Y[UO1$"5*ELDLL$G(FH"Q@O[:;*6#XN4Z8\)%&[
M;W6M(0_[2S#H#J:JRW2_:%/<&I6R*9'_3-#^B<0&*PDP$33',RBIVA69FZ.M
M[MZ?+M#HC6/STPK8\;\6R^K':VYYEXV@Q3N'$E&1@1(7*;),@C<0<F*FE8AS
M]9UTZ82HCM--'M$]@:'UA[J,-!JGN(K[E"G LX<D/ZH33V Y(%U'D75T)%E5
M#D1KB!>,$>&IX"&8Z%@KLQE;V$NG7(X70_=>$?%RL</>V6_O#X__K!HMO/[,
MUN.#CU-?*2)8>A7"[ *MWL]#_+0WWWZ?E420ZVN\'NJYS\M.Y9Z!4HP%DHV4
M: $I1SQ#+Q3MXI0@:D]][;S6]:FKZ)9)@?9^0;+VOO06DA%-,G0 @F8<HO=>
MBMI9E]UTRUK"QC,>UR:LKS@;!M5B&,+J0+^=5#=01E*TNQ4Q/.*^M* EZ06_
M>)HL,._0-J^,A6?(Z9)_M2=PU!).O;2T.ZF9[X=C&(>K#)B2(#R<A<EB/)\-
M+ \JEI)M =GAT:@".HQ2$YH%A:05U:'Z3,8U:>M2IO:><-2*V-K.=51.*>>"
M)3GJ,M&8,V*==$2#<!Z\C=E4GQR\=:[COI*L]P68W47RPDG4W "7(!EQ@N-A
M:HO;*1PE/ 7.!>?H4/#O6+\_31)URZ#9GZ#V/%*S-YT"OMI,_$!R\5O<Q671
ME,?YJ3\IFRS,'EAT28UQB3!\*DJ? $5\5I(D"$PRFB7 .NFX^Z&V2^G<>T!K
M!R%0I_QI-)I\P;,]E:C=59NG7E@>[C<]^IM$YF4/]\)%&;BEB4D" *673];$
M42X),YY;(V1)>5\#J5LMWJ7D\3T KWT!5<'1@U&5Y5JHS("YFSOGF$ZR-&>*
M%HT F0H7H SZ8(IRJK(4]^^S'P7.>JMMF#K^HR.E!1%4[0]8P'L\1L^AF?C2
M^!7+^CPV\*!L\,(C2)TN8S\8@9+P+B65,DA-7?6J@^<I6@<Z;H_=A/9AP5>4
M41U+?D7/:1HMZS0/D:*/#<-NY@?].BUQ,*N4B4&@$RJX*'VT2H<EKW';PH#5
M"/3[TQ8>-]W77G&ML"/]20#2HC#J%:[ M\;B*H=D^@BC&Z)F QI\YB45P:62
ML*UL)!!%1JJ$HM3$9.^7N>T>H'Z:G+6@PWX2Z-063[W>).A+IC> FRW7?'@^
M+D.D+&JPH#Q*5)6Y=$:5A$5/<@#C(]!D4^W.78]3LA9*?K+8=069[+&_[._C
M:8+1\']2'.2<:(R,$CP%D4)7JDQ49$0Y[YTV12'6-E\VH6\M+.VME_:>P-2:
M "NY2U/TVTJSG4+-LD'%$O:3\7(.'A71&T%*E1+J1.>(->7'F)@5QM DUXE%
M?F>9M8 A?Q)@U&;['GNG1T@9-%>$ E-(5D[$9CPP;<A6>D1K8+43"JOT3F?J
M)\%..Z*JHDE6EA6JN[+^/9J:UYI1>\V;F@8WC[#$^&Q-Z7>I;!D9$!@2[;(A
M@M/H VH_L&H-;5.!E+50I7\25+V$^"IC[HF ]M50]9MA9;T0IJD)*#RR@2B8
MC DT"6CK$QD#6GBLI.J5MMA)Z^B3V A_5<A:"XOFI\3B_L5:-YEW%?F\TU-C
MP*0R63A)DBUS*IBCQ ,$ L**'*FBN7X_ZJ>(60M;>VMKLJ?3LXYH:G950 >@
M3,U9_GOPR+7*@%L6N8Z"!,HSD50+XH,71#N&V_6:45F[RGL=NM;"S\\6H*XN
ML!:A=/LR+J%)2'F,)$ LF>A(ETM*$^<=@+>R9,*TCJ$-;U#YSQ*\KB^B%E&S
MFHI]=9/WZ'3L07"1FAP"^A3<(,(#)3921M##8&682/*N=E7)=I2NA;.?+=*]
M!Z'NX01$4W"555 LO$6*5Z;?L&EZ9H3*H11=EF)?ZP1QUE#"G'7H=V1PKG:X
M<SM*UP+@3Q9$WX-,ZW5+0'Z4_Y?!UI]AE)J3?#:?#L,\Q?(+I/7N"[?>>9*F
MPTE\N-V59]+_&IKDJU.8IW[.*<P'-!@;>8[$.]R>S!$(E#&NFC(G-$+.I>K-
M%/:ZPPJ3H=:%:&:FR1<ADCO45[;TKE1<$LTD17M+*\YK'T+;%C>]<*^&[F+\
MD5E3;8B_YN"RQ^A;3M2]2Q\XK2'H2)2)942]*\,&G2?.@8J1:N"\=L.']:GK
M4EG2CP_/7<7?-CRO:V=N'_ :SUH5/:%,EEIWEX@SBI(0,]7!&I-U[9+)]:GK
M4K73CP_/7<5?#9[++1[GV]L^'N_$X$'*"KPI::2FI'IY8TB9WT%"N7D [3UG
MM0>=MK"-+E5K_4" ?VE O81=(9T2--A J,RJM&QO9H)8DD ;RRE26!WPV]H5
MV^=0GD]6LWEP3;3]YM]*HXMY:7N.KS:S? 96F^P3'K FTD!D=)HXF1S^:"P>
MM#896GTL\-K4;6C^OTC8:5=P/95@65EVU?-SK^F[/Z1G8**BJ@S9H65*AO1)
M$F]9&>,-U@4;M;B?PUT?4O>)ZE37FY="TDZ2:@] 'V#Z[]1TUSE+83%=;IR%
M;&-TD;#&.95"$)>M)93+0)W.P&SU7B3K$+:A3?US FEGB=4<<Q%2BLU\@#-H
M8J(?H$QNF7\[SH^22964R B.VV<:37:.2C/03(3E3@0?;\_PKM?D9C,BNV3'
M[@MCK0JR%;R]&S8L0"+3<;XJ*T[+OF6%9<O?ISB(W(+5VA*.)G&QA=%*#R(2
M&F-@+!B:374;:PLZ?X"V!6VBKA5Q5LG2NVK%>E-K@]Y9J="ZRHD_^P*?9@./
M3I^0M RQR*B P5+B52Q]5,%;\"*D^]?)CR;?K;?:#] UH!986A+!2X0KE=*1
M.O3%!<A(9&:) (1 C$D)?7)GHM^3U_O=<.5NNOE@-EN46OOC?#@9?SQ/T\ME
M4K?F7$H'1#N.^Y=6$:M5+$/GE:><"9]:Z'#W':JZ=,G5$I:>T[L51%5Q9O4J
M0WMVCYJ<\-'&_Q'C/;K:G$EB00)1"<HL IE-]<ROIVCY$5S9VGBI(I<Z&?./
M(/?1R9!+NZ%T65M56I_ =/YMH%SD+,J,%):R$F%+,UO&B$)"J11<:J[7.*1W
M)*-+-T,M0VC?0JL>)[DNU#^'KW\.YQ<7DU&Y W@_F3Y19JNU$B*!)S:9TM4!
M+57GA20EF59$2BE05ON0VY+6#1W=GT*7[46NM5&X1BG)HWP2-'-\0 A#U5QZ
M2GKB8QDHA3M(C&<.NB4H;D?PAB[PSX3'/4BXNFI<EFI>:?3E+&:-JR:C.'KG
MMB2 XU,")0&<)V9=9B!"J)W/]@PY&[K)/Q.@=I9.*T&[6_U+FJSMQS:?<G):
M946HSJ6)@-7$(K\(38E'):3(T*:7N :)/T#KO#9=QMI"[$8>]( 9$-1)/-L9
MPX<CZ4R0*9YDCWQ+GIE<?<I(Q72;[;B%GW_O4WL(I^GT&TKS#Q@MTL!H8RE-
MC@@+L0PC8V7R'Y"LC.404TBN=LQJ+<*Z%+;9'^X>#'>L+L,J;OJ#W3=ZXB9Z
M^RXU??%6X=LY$JB\EMH1[6/"<RF),@W<$N$8U89[2=,ZC1,V7/:GR1_>"D)M
MRZGUL3OO>P>G?_0.?^]_Z/?.?C]=SJWI';U[?W#4.WI[T#L\.#H[/_U]^7*Y
M.5]V8IPN';\GK.UC/UJUXRO%L!,\UD;+(1"3IYH.W_J+=VD.P]'L+@?6&O?3
MW;W4&C/4W1W>D5:E\4;O83AM=.^'!+/%M'F82I3A]_'$S]*T*;$^&']:S._1
M77[$9PT)?P.SX>S:]UOJ\9"=XXE:XK071)HR$5JB(>\=9T'QA 9:[=2N5C:R
MJ^6R?A/QZW6O-!BS2C&N-6&YC-G0#%DH#"6616="T"!][>85VU/;)1OGY1%]
MW_;9$PJJ>2=;T%N:?*Q(YIQ'':PC,:/_+DO\&QTJ0510+('/QE2OQ-J)X"X9
M5S\%=K?$0NMFV,'1'WAF'Y\>],^N&P#.)OE65XCMS:+U/[N6F;+E;BJ9#5?+
M?%MV@#8!((B4B,NE.A0T1W#E4B(:+.=9:UF].N N!;LW1EA]VBE\^8!VW'0(
M(_16'&-4"D/0F6B:A#CBLP2"CHIT2B7-=?V^!X\0TJ7C=0?)/^Q<L"O3*S;&
M6)'RYV3Z[]+!8Q)0Z0TT4U(": *) 9'<,.(3<)(U>.E*76GU>ZG'*>G2(=4&
M K9G>WT(O!^.A[.+%,N\JME 1(@VJDR,2V6L/<>-!ID(@I-"PKTK;=J"P!U*
MNI2+T08$MF?['BR'\][1KP=O#ON]L[-^$PWX]?CXW9\'AX<?X+\FT[L'\-WB
MF5ULBMU7K6=M5.9 -3OD[EH-'I=MGM%$O9HX-TA&0H@1B.&  ,T@"&272?9,
M1*D\<U"[G_)ZE.W<M1X?FGDZ''XN5VF/+#BP(CNT\SWAD5+<.7ZQ^*B2"(89
MFI*$7/N.\GLT=<N:J8Z?!WWI:XJHXFD7RVC[IRA[R (7N#(^HV:WTI<$#D.<
M12>R5),K8[R@L;9;ORF-W3*26@=6JR*L-U?C:0J/TGQ@K*(Z1SSG?2KMT[T@
MGJ+)3VD EIQ/3-76S,]3U+I&#E9;%M">H=)J(A.*W)6&(! \",84AU#[0?J1
M-')%O&RLB3<1S3X>D%X(B\M%<Z]T9ZY[BMH%E3W1!DF4I86R,Q!(5(E*+U22
MO'9?N\VI[%3]P<N@JH;\*I[X#_;]\(@P@DN(N'/N4R!2,H.G@V1X/&DJ5 R:
MY?K=K[]/5^V]/W$:2TL#!:.(I:7JCR,6'#<2:<XZA("JP=@.N G=,IEWQM%#
MNZ:ZL%Y268-0AB4\5(3/C$@6(_%1(5-HC-X%PV3]66$_MK)N'6$M2_$EXU&W
MB5XUGFXE O7,.GN(.:V[RUI),L];#]GG&%Q W]W3DK5H. &-/IW77B<EK-&J
M]BW!B_DPCW#^-%W"$+D\/<[OAS,4^7\FF YBN?MECA'4R9E(4<SH2&VY"?8V
M14:#VJ?:6Y/L+AVT%5&WB0)L0\![.7\?$GZ$S__YES3ZG#Y,QO.+TG>!<\6E
M)2:6O@MEI+5SKG O4:&=%9SO,=JP!L5="FEU!H\[B?6%H%@>F?,ODX&+)JJ,
MSTK4I1N1,)8X$+$8L1F)98;YVJ.IMR*T2[>-G0'>-D)\2;PA@-(@2$=-%I9X
M4^8C><J)M4X2HX43.CD.4/L">TM2N]3.K%N8VUB0+XBZ]Y/%=""-0YW+!1(G
M!?*GW-PK8TAF(5&F93;WVU>\ .@*I5UJ9M8IS&TLQI>$'+YW8+6UDCI.HM!E
MH!(^'L# $4$5,DUX(?S+VG97E':I)5JW(+>I&%\(<KT\3]-K@GGPV4JCB14E
MQSE+2L Z((H9ETP,P=':+9]V(+=+%>&= =_V FT]U-=[^_;T]_Z[WM&[X_/?
M^J=O?S\][1^='Q[TWAP<'IP?],_."K.GWR9Y->,+5K61JPJ26R._MH\#MD!$
MK2!AV_RI%$%\.(#MJL+'@DI>:B!<R-(814<$>'3$94VA%/C(4-M2>I*872JI
M#]-'&,VN"W)GR.=5261.S?RHS'B(G!@E2@]ZD7&':,LR?*C0RL!?BW4*IY]?
MI4O1NSH2OUT#79'#56KG5SL\F4[B(LQ/DT=2KNO6/"IGARZQ-!%/<660F.@$
MB9!-=HP:H]81]S-+="DR5E_6M7C;BJ#GB^GXID"1 PK-$YXUHDY V9NWA":-
MY[.D1J9UF@D_LT27(E'M"WI;WM9,$VDZ&*^&AU[1(K337M% ;!D2*I5"3Y 5
M#$8G0P8N4W7OZG%*NA0DJ@N'BA*HAH;5#OMH)$Z^I?0FC5.^W68#(2I+(!2@
M:9X42U&I1:/9"*":"9E42\;+$Q1U*9S3#CHJ2J0V2@[&:):G<_AZLU-G%(\N
M)A*M**7'"8BSPA"0I:#=^.!<[?*#)XGI4MRE56SL*(=JL%B..W]RIYHQ)9C%
M_;&24N,I*K04#(F2,AD3_EK4#IP\3U&78B/M *2B1-KOFK3LMW/T:^_TM'?T
MZ[(/S[4W7UH/3$;#6-R?TNE[ONKTO4-GHYW6J]9]J-ZN*X4N[O11!Y-\#AX(
M50E]#XWF""AN4:T$+A*#I&SMKC1/][3?;2_75G9FFCE'\9P4>&*B/B2N-"=C
MU&GP0<5H:G=3?(2,+H4NMI;X?76S*[NKG42W";G5GL2IG*U !RL":T(FGN!>
M U$!W:P@/#A>.]_[<4JZ%,QH1?I;,OUE#IG>QX_3]!%U[&JR&)Z0DSOC)"H?
M,FNOU^HAL]VN*QTR30?H\6P^7930YE53T-[E9(&(R9%3%IDA*<J2;E.41\DT
M]!"]2J"C5+5SIIZCIZ8RNN'U[=$E)]/A. P_P>CQS$N;T=1+)I( WA9^9 *A
M!(=HU$P9([)H4VUM0W.7CK=J6'M.X;4NV%;.QN]0?3!^F'HIE4*W0.)QKF5I
MZ&J)XXD1;ZTQWHH89.V"L9T([M))VP4@[BC2ET'A51ZF54EP 4# <$!_-7H"
MW&:B'57*9F/1>'E)\'4PE[8;F-M&@"\(M2;]4I51<@QI%2%D=%R21EJI(9D'
MSJ.*U$/M'G?;4=JE&Y(.P6UC(;X<X)K<R^P<@$+OR,5<6IA[4])]2\VX,)Z#
M<BFV&6I9F] N7;ET!VX;B_ %T5:2WG0(#H3,A/M2S65*;YC@#$$:'0_:A\QJ
M=R79BM N7>)T"&V;BO ET'8ORY(*Y9P,)"1;6FYP5]JL)!*\U%2@F>G3"SH.
MG<V9[0+FMA=D*[ ;1)Z4MS23#.6FVP$G/@E&6*3*>4FSJ]YAH>:EQ/,B90JR
MU)P8ZO"AANB(EQ'P&0_>6&I-CK6KM]:/?77HFF(3#-R'?C4!5(/W78I^'\,R
M9SW%=\-9*&2=3-/E<''9&\<'L_-*ZKP50BO-&>$@D1L^:-0!9:R2 !NU3!1"
M[5E8.Y+<J08D+2&K73FV?E=RTC\Z.S@^ZAV].SD^.S_MGQ\LA^/T/YP<'O]G
MO_^F?]1_?W!^<M@[NM.2'C=RDJ;#21R&5;92V=_V=RCMT%'K;F4/7*IVYY*'
MXQ17JYV,8/PX#0-TF#-WR1!TC\M8ZP $($;"@"6C30Q>U[YO6)>VW17M_77.
MTO3S</D(#H+./*>B\:%,4C9"$6]"*J/$F,DBX_>U#8MG">K2Z=L*>A[JSUKB
MJ7@TWR?I*E^WH4F 8XKGHK*L(3(HM(:C9^B$"4A)22NJ%SX_3U&W+CQ>!#-;
M"ZA%T)3*PS+.<)GQ?SPNKRWK$P<R&,]%"D2+%-&A"G19 9NRU5( E=*W#Z&G
MZ=OP-J-=2^V%$%5)>BWBZW:5:^.Z3Z:W5.?;:8I#?!:X<0Z]&**B8T3F+(GU
M(I,HA=/<0M:V?:2M0VFWKC1>!'+5!;HW\/T*P_'L<(*/QVQ0>G5JBSSQ'@"/
M;$CH3:/V!0"M.-."Q?8MJB?)V_ JXZ=4;75DU[HS>MH_Z_=.W_Z&?M:[_A_]
MP^.3)HGM*E'Z-,T2KGX!Q;'^G$:33\LIP=OZG#LM5\NUK+?G2A[DU8J].RNN
MFBI<MVQMAN1.2UG*:KY3@UJN0@Q6*6)3"6THU%=6:$$"2"-+S .?F<J:8 =R
M=YPQ_O2RUX6?32'W@(,1@@MDB*0!%;@H/9[0K\E14A\TQ0?0?P>J&R[9)9]R
M7WBZ-UF\%>G4&D__-''_=P%EW";:G8MIB1H.&"BA(F@2/)=$.H6NL+*" !JD
MPCGJ&1.[@N?^HEUR+SL'GYTDU/H1VC1,Z?^K!"S[!T=OC_$PZ=^<)DVIV'7#
MS1V.SJV6J75D[K['2D=EL]319#SYU(S+'7]<%FFN%A^H+"C3EA/'!262@B4V
MZDRLX9!S])'KVK?ASU.TJU-0#,=B-ZY4Y_GD<#A?S;,_NVYA,E#4Q2R"((F5
M*7_4:>**)>M"BB$$RB34SCI9B[ N'8H5D7/?^J\OI!>80=Z;HF[]N&R)\_:B
M?'LP7M[='N?OC:IF@])'S#M%"6>EFM9)17P$/->%""[8,HJV=@AD3UOKU(UJ
MBR#N(E*J/0973^CQ^-UP]FDR&R[=\F6LD0T"YYH#9VA%Q.+Z&T]<"I%D[BR%
MG)*H7L#X/$5=2G7?@^*L()9J4'G<$KT9JFREU[29IUS&6TG/,G' )(DZN<BX
M,^!JYZ]_AZ0-H[H_K(:J*9DJ;F6SUSO[*\DFD%V@:+83+TKPN,E6UEP0K:/W
MRN68U?=L_2<_O%.1U19$78>KK;M\_=[IT<'1KV>'QV=G)_W3L]]ZI_VS<)'B
M8I0F^>W-0I/<A^D863,[2=.S"YCN,$6HPJ*UW,':^Z_D'/[9P#[%WF<$Y,=T
MM+CTI3+TW7"TP%>;Y6?'B_EL#N,2P1APB>=*S$"4T6B1@^?$2V#$&,[ 6TM%
MK'WL;TCBKH?9$\L]6.<-S(9A %P$&2@^HE:7ECAHGS5/6\Y<)T5ICKIVJ<Q&
M!';)G6P3:_</OO:D6+'=89@V'@&,T(&X1,>W(:XWGT^'?C$O#?C.)\UK2&2*
M)\ML^-N>Q !/9R5C\D0SU.M2 ?K'21HB+3,IR>B-J&U8[4YUE^*V^X3DGN6]
MYHF^>KU\\;CL/__R_P!02P,$%     @ 4X9C58(9?_.4U@  IVD) !0   !B
M:&,M,C R,C Y,S!?9&5F+GAM;.R]67=;1[(F^GY^A:_[]48YYZ'6J=.+FER\
M2Q;5DES5_<250Z2$4Q2@ D#9ZE]_(P%.(@D2&\B] 9*J\I(IDL;^,K[8F1&1
M,?SG__SS\\E/7W$Z&TW&?_N9_X7]_!..TR2/QA__]O/O'UZ!^_E__M=__,=_
M_C\ __O9N]<_O9BDT\\XGO_T?(IACOFG/T;S3S_],^/L7S^5Z>3S3_^<3/\U
M^AH _FOQ'SV??/DV'7W\-/]),"&N_W3Z5VNLB PS2,TD*&T$Q.0$V""E<5X:
M[^3_^_&O5NBLLI6@2W:@4N00C0X0@E!:,)=0^,6'GHS&__IK_2.&&?Y$BQO/
M%G_]V\^?YO,O?_WEES_^^.,O?\;IR5\FTX^_",;D+^>__?/9K_]YX_?_D(O?
MYM[[7Q8_O?C5V>BV7Z2/Y;_\[]]>OT^?\'. T7@V#^-T^0!Z?)Y?_(=7T>A?
MEC^D7YV-_CI;_/>O)RG,%_3<NX2?5OY&_1N<_QK4;P$7(/E?_ISEG__K/W[Z
M:2FY,$W3R0F^P_+3V9>_OSN\B70TGO^21Y]_.?N=7\+)"2%>?,+\VQ?\V\^S
MT><O)WC^O4]3+"O1GR^Y@M(5SO^HG_;+UI@^$9!I.HT(]%T<5P5OB/&V3]\>
M\\5G0<823D_F#1'?_.RF>">?PZBE@&]\= .TBP^"S_@YXK0EU.\^]PK.<Y#7
M$=:/C.&47N]/&$[FG_Z2)I]_64!\?O3F_='KPQ<''UZ^>/^!_OSMY9L/[X]>
M';U]^>[@PR']]'[<\5."NMDR+]D"WQH?>@4T:<=H/*H;SFOZZ]DG5W ]P,<_
MYSC.F'_^:93_]O,H,Q^91!E\DBKI0 O 4%!EF3**I(_7^/RZD/.EG$S2=X\[
MJ3OIY(+ZDQ#Q9/'=X],9? SAR_'[.1UJ]7RCM>,A?3D[-D[R(*V%'!4#%2.#
MJ#VGOX: .H@H,=Q4G-FY(I8PBPO5.7O$+Y6:7_!D/CO_SH*L!5&K42P)VGQ=
M[_ KCD]Q=A!G\VE(\V/GDBDZ:U RT(&:C0%G!(-BN%=2A) T;[RJZQB^7].E
MVAU,SU=W]N)N^&97<Z0IN_-)0Z$NF:,%_/S39)IQ^K>?62.27]&ZGT_&"TC_
M).OL^>EL/OF,TY=_II/3:M@=S&9(_^0/X<]C)R-F)A($C(1;H0$?BP*RMFCI
MT6<5;MD66^A!%YC#J\IVW-ZN*+T1<U.7^+:Z]'PRF\\.QOGEGU_H&+XB!QZ9
M+R8C:-JA0?%"N'AQ0&]1=%)EIYANK#"KL#SX#:2)D'LB_ZC\.IGDBNX]3K^.
M$L[>3T[RL<A)EI@B)&4B*.$07' :;-9:%>,TZ6T/]-^.9G@%:,/8+6K00-P]
M*,)[/*$???P5QS@-)P3N('\F&=<UST=?\4P*QX)[5BTVT%H+4$5[<%@86)M1
M118LYM9[PGK('HF"]$##3641VYL?,Z0/_$3X7M"!=S+Y4G?*,W"79USZ]^EH
MBOEP_'8Z(36?58D=*VND9KI T<*"2D* 4U(!(_VV= *2]K<W0S:&^TC4:BC"
M;NJ:W%37R+<]/O@\F<Y'_W<1$SLJA^-Y&'\<Q1.LUM-\=HG[RJ\=G"P^DBRK
MR;EA=[GI+C9:@Z4$SQ04;S,H[Q'("[7@.'FA#K5V[MH6=L/-[@O; ]>VO:#L
MI@JJ;52P8OAC=')R^/E+&$T7!N%D-GLSF1^.ZU+JR[)8VN7/GW\*TX\X.Q;,
M,>,SO3><SG(5,X=@9 06750I:6N,6$//-@;P")1I&.'?U!B][0&Y E6*QCC'
M28\=[:=*THD=T"H(ROF(Q7&6?>.S[U'J1D,QWR3?;+-=T$$[GYZF^>F4-KDS
M/+3JPRK></+V-)Z,TE$IN/AQ%<FQ]")EHPP86?<V)LGN9Y9#21BTD-DZ<U_4
M=Z,'/W 5Z%_8-S7#;KLM',T_X?3H"U9C?OR1-K')YW.3_@W.C[/C$8TJ8)BR
M-<!@(&KNR04,)A(TK6SK[>%N1 ]<1WH0^TVE<*WC;\?%*RT9\\"8H:7:HL%I
M+X"C$-'(3-M8ZCGN]DB(WTJT-ZGV6[__W^M@-6:.>7*<)V- T9E%MBV9M3[6
MS >7-;H255:N]4M_$\:##[!N*]H>HB2'XZ]T0-4E+C&1,X13^LZQUN3&E"0!
M!1(:P6C#*2I SHJ4TV3#>>M]?A66!\][$R$W#%M<XEKB.-MZ7F"<']N<A4CD
MA0B;2"E+(+LT,P<L,9.29YALZYO86V \ LJW$VW#",$YI%])#+.ZY^#L:/SR
MS[H/G8YFG^J:C\H"($8AO P%G)0"5!:T%QD9 &WBW!26<VC]SM\+ZL%K0ENQ
M]Q '>#69XNCC^/GI=(KC].W#-(QG9-20C"OTBOP9%OJ=Q35P2;1Z4N%B!">O
M%0/0VG/EU=!.QB6JUAK2 =Z#UY6^J&@80+C<X,Y-F/,\@M'XE'3[S,:9C,^@
M+G^/ ..,E'\:Z/FC<9A^6PCKS81^.IZ3Q$\65M'9L9B$MRZP1*^!IHW2F@#!
ME0S,*F-C2+1UJN9G4&_+>?!:N2]4]Q#LN(!\=DX_PS'Q,S]F9':7*B3'Z ]E
MBH2@K2> T8F<1,&2>]' &U >B?9L)^(>(AIOIQ-"L7#!/#U-.=(\Z>OSU2(*
M2XLU*J0DL!3#6I-]^?0'S^^&@NPA<O$&YY=;U<%\/AW%TWF()_AALF+W89P3
M8&L@I4B 12FT^W@%Y(.AXAB-E*PQ\YU!/G@%Z9>66]*,MLY<_0[Q,;<Q!:XD
ME.)I[<(*\%XA*7DJ@@MCBFT=ZOP.P.-2@$[BO(7<K9/(7H;IF)1M]A:G[S^%
M*5X)X@I/)X\##%K2$DU-;I,:-'ID*8H@;&G,\RHL#Y[R)D*^A?VMXYW7@3T+
MLU$Z3CZCS$)#*I9\J2(R>!YIPXD^1R^9IC]ZIGX!9'C>VQ!U#_O=A=Q#\NAU
M4"]&)Z=SS#5US%LN& 1&SK2J5_+!:0XL)C3>91F#Z9G[,RB/E/U-!-W#3<>M
M2KFX=7TQFJ63R>QT>N5&CUEM%2-TN9#UH2SS$*.38(517/O$>;%#[ BK #ZZ
M$Z(=';?L'5O?E/P3:]$XYH.O. T?\<UIE=5162"?'9W.:T5U31E<[G1>,R^1
M98BB!OH).$0R92$6@SKFXFQH7970">#N-YJ&;$^&8JJ',VD%V+,=\P;F8Z=5
M<H5V3T]^$*CL''A9 B"]A%(E0_)J':GH"/$)JE83MGHX\"XV[ _5V3XVAHY9
M81($R0F-XAZ<8 DRBZID)8UO'E3_'D%#U;C2X*'W@VH+,=ZV8_RT+-?_:]5,
MS'_[>3X]Q<MO3L9S_'/^\F3QP+_]/,./]8M--6$VG=?P7#Y-\Z/I62'7P9^C
MV7'T!54)$5AP) \MD>1!+X6QTOMB:YG76OD\]( K>D!_N]2!5<]NJ 5WM-2X
M0RLVH''24)P-3Y$K>*Y6ZKU8[)MK@3J^UM=C>ZYO FEY(JSJ1W))=QN.;A+>
M2,"#L:^<%SF@@U+=-A4+@B\L0K:QL.PYVKQ6T'*_6/^NJ\M.2.\BUQX,QC-@
MORULHF.C'18?Q:)BA,#H#"YE <H7;UW1M$#1^$C_#L!PQEY#4FY>7VTHT1Y:
M9IR!N5SAPHX]PY:UB4+& IZL2E+F0$>6]!J8MBQ8@61IMHY/WX7G$9&_O;Q7
MONK_^<LU\9!1^J\^6C*]__O!NY=_/WK]XN6[]R__U^^''_[/BY>O#I\??O@>
MXE8=FE8_H^>&36LN[EK_)K+BHI3)):^,PF2CERE[&QEY?*J@7]F_:?7CFK=S
M2CR10VH%:6]MYB*LK^%1"]$5@U8H'9N'BMJW<SH<IRF&FN6Z_/?A^/U\DO[U
M:7)"K\+LY;]/1_-O[R8G)Z\FTS_"-!_;XKF(QD(IL6:Z&TF[+#,$-7O,TAE4
MK4/N'2'N17BUBV[<DG73&R4]''S/)Y\_3Y80EW&4P]GL%/-Q$*S4GIQ@)-;4
M6,L@).8@2I52*D5GW[Z]SZU0AM>(7BF\482TO?S[:/AR8\'+HNK1^./;6IM/
MXE\GG\0RIT5T%E1P@?X@&?E$%@-&2:=!RD7P]IML"^2/6^EVP&XO859:Q?)U
M>;$H\GV+T]$D_R.<G.(;_&/QDUKN3<ZFH<V;#%()BMD 0<8,UG&;C;&*3-8^
M5/ ^8$] PYIRTT,5U@J0RWWX_$H#,VW1-7]VD7!]K%7Q16D/0A;R4YE!B$(E
M* IU,+2"X%I?3V\ \TDJ5S/>>B@!N^M]6(%8!5NB+HFL3DF[JW,U4$ZPE3>9
M%1XU-F\'TAWEDU2T5JSUT5HF__?ILN!U]F%RD/."C'#R-HSRX?AY^#*:AY,%
M\G@=^3LDT<U&<SP+R"R7^@[3Y..2TL6JCZ.54ECI(!BG0$67://6&0IR^G[4
M)C:/A?6]IL>MPWNE$3V4PUU9WSL\638*^Q#^K'UUJSSII24IKCH41%A4^@,F
M7D 9(2"BUR"B<"SI$A.V#N-O ??)Z&FO//;5N*<"FN*G>F'V]:P@;W51Z<$X
M+_YVLFQQ=['T-S@_*K3J6[VPM[3V\?RXA)!%*!ZB9K181B]=J''RP$V0267&
MFZ>3#+K QZWF^ZLK/93Z_38:3Z:+Z,(R8G NX%K-^J*VK:V :QGKJA##WY<4
M'"=M(TJRJI(1B20>(T2RLD ;+,J$R*5L[76UPOZXU7DG#/=0P7BEEE):[H+0
M!KSUOC;X=^ T5Y"++IKEDHIN'?G>95'JD-JRH93[J#1<M0\O6HB>[:S'-BD>
M0S3 $#6HQ +XZ",D(4Q2DG&!K9V==7 ];B5ISDP?M8RKKFUB=,A=IA/6%PD*
M3:AC["0PDH>0*O+"6M<UKW5MMK,;(,Z%2R9S*#I4@3"R0)A&0#28A67"E-:O
M4!\W0-LG@4>TJ40)V:?:;<XJB,QXR&@\ESI)55IW]]J;)/!MKM.W$..ND\!O
M+&&IC'5KFXRKG[O(E+2T32JC<LV41!*.J1GR#*%>GV%-A]:IM^J VP#M2YIX
M%Z)7Z<S6 N^C&O9[3&>Y=.N ZI(SWD$;;@4T;.YX#\1=+WIL)O7!5"*1-\1D
MDA#095#!DJV<0VTSEKRUCDG>OC1^.%58D5"^*TWH(NP^LLL7X9JS]%=:76W"
M$FJ4AM'65Z<3"%_CZSH[)HJ-Z]4(=7% KSQ_!X6$VU-RW='<5)[]9MB= RJJ
M8(D!:'6U6U-($*SD8.E0$\6E*'EK6_ &B.%9WIR3U2ES&PBTA[=WQ:W:&3CR
M :W-SM#:R$M5:)$L&2Y!\I(M\SZ0B]S\DND.0 ^8^7:"[F7LV9R$@?F\+/J\
MF($>JQ Y)*UI&^,^@-.E#@W5(<O$6&:MZ;\=R0/FO8%H>T@?.TCI]//IXJIR
M5<SJ#*@WTM6]"#BO,R2\TN QU2;4)9 D(N;0>L-?&]P#5HM^".@A^^OV"-,9
MMB*2\ H+J%1CI2G1!B:T NY]1%Z,=:EU$L)=>!Z#^==,WL-5E[UX^?[YN\.W
M=7;]T:MGO[\_?//R_?LW8;J<[/FB;H GLPTJRM;[W$959!LLXEKEV*+Q<!8F
MJE"4M2)HM-Y)4H1H7!3V>+U';&NQCV>3DU%>7+B_QMGLPZ<P_N<GTJ9O1W_0
M,?3^-,Y&>12FWY9;6?WF=/9I].5B]D IF.:SH_*<_L./6*\M+J.A,=A"VU$$
M:9FIBIU)_XH$#,79'#,SO/7[WNN"6B<)7#S\+4X3@0D?\=D9KN/(<HS!>]#:
M<%"L((2@#0A-<HN.9!=;)_-W@+>+N4C[HJGW)0:T8K47![V]$)=![,QKMKF/
M8)0@XT:12QJ*UQ"MK/.DR/C(K6W_WA8SU/W1_JKT?NC)KF^U:D^ BY4MHK$*
MI?0!$SG:GE[?9,AZEX$#CRDK'F32;JT#[9Z.)]\]=%>W5'NB Y,67#1NB7,!
MY+P]Q!I0&K9!NO;XX9L?;4'$;71N(<6>B=422\[D3#-OR8%BO"9QQ0">?&DC
MO,A1KW5CO0^$WM'7J!\^NPBO(8]U(.ZSA<_V>O(YG@=,M0\B, 8Z25N'9]H:
M-B<7V]%)&&/,(H9[W,O;/G?8_C1;"7C22#HKK=+F<8+WA[^^.7QU^/S@S8>#
MY\^/?G_SX?#-KV^/7A\^/WS9(E[0[?,;Q0VV6-2U^('F04==+X&%4X%YQQ2W
MB:52 @;K['&W1VV9^'-A#+P/)WA4%E=6E[9H]@(+B@B88@)%6@6QH >.M A3
M6+2A=:[@W8BV3G2Z_,SON_\N,Q(/QU>J&HZ#HO?3T?O$7:D-+@R]HMPRR!*9
MC,(Z;-Y@I N^'?2A::<M-Q*B^B*F!V_\"M:WTV75X0(K[<<IFMH'!4NM9:'7
M&P@J X$\"5$<":AY/?0*+(]5.387>&-3Y0JFHZ\X/3@YF2QJGC[@]/,QT:1\
MTKQ>\>8ZO;D>S-J!\(;KG%T)6JYAMMSUC$=!<%-!-KPPOX;K?$>ZO-Q?[DT'
M7^D(KJ[QJ\FT[E-AG/!8"*&M2 FPUM@KK!=YAJN:3NX0BU7B>O#\/NZ[//XQ
MJD5OXN_AQOU&J</5IN]>"J6RE)"9CN2AT4X5E"!LTD2,LCA^W9MI7WJQTW[\
M/9X1S03?1VN5*^?7Q=W"4;ETW\L<IU<-'!&DE5S0/F<L"8)S#4XM<@/JA#0=
MC2NMQ\IUQ?BHE*=7@GKHH7(%;PWWCO+9L-UWF)!\PWSTG;GL/5H7 X)8E+K5
MFM48D:PD(UE6&257V)\VW0_PL:I28VIZZ$QR*8>CZ3+'Y3><?YJ0N_459W/$
M*XMY]NWF+Y__VO)Z@#D6BV<2;!)DC'/MP3.RU;RB__DD@O'-^XXUQ#]8]5F/
MNK<K.G=]XW>G;!?!<6VUY:7V_ GU C\'\A2%RY!%%%$[&[QI7L.V"LS.ZM=V
MIAXK]70;FOKH*7O%Z0B?Z<LK>_5Y\'X-A#V5P=V/;D<U<6WHO",BV)"+W6B-
M"CDS)1 *A@RJ-GB,HG!P)MNLG+.V?8O7'6G+?65SNU*6+A0TCA4>OCTZ&.?O
MHEM'7RJTLWL\14>]=N246L_IS"^(Y)X&#ZGX$H4J7IMKEM.M(:-['K,#,[LQ
M*Y-^1-K#%0'!.P,B) ]%JUKIQ12H5!@$*3,P,N48I^_IU+I&]N+APS'>G)+K
M(PLVDF</>_WJY07%K%"UP4LNY,J%.APF*P5HF3/2:B%%ZYC-'KSJ?1/?1MX-
MKP9NYMWDB*ZVU 5?YPO1GE7 16FASK/./FH1Y%JE4P\AN7#G+L1VXN]+#\X.
MLW6@/-Y\PDY$W)%_MHD4>\XG-+2QT+,3[6"U9Y8RM5UE]K27&>-#- GMX\LG
M;,5G%^'UG4_(M.9.)06.&TUKXF1I>CJ/A/2&3J)2LC9K6-K[E4_82<!WY1-V
MD<YP^83O7O[CY9O?7[Y[^?SHUS>'M:RN01+A&A_:*'.P*_QKZ8),,2,S1Z^S
M58(IGXLV6DKD&.D%U,=K?/[F&V'MGQ[.6OS^K]-P,BK?1N./!RE-3L?SV>40
M]2OQZ^B812G!UWI8E5& KT9Z#,YA+M+RT*+4HC.P;0W_RP>2-?I'336H\R;?
MX0RG9-,\_Q2F'VL_\$65]SF,8V6S]X),W1P9UO%#"KRP&IPH22CFO!2MJ^HW
MP3GL]M6O3EUW('KGK8?HP=V8K[2A/TZQU$X2M$6CH!W;D),5C1,@N>'%\:Q<
M\Q&1:X-[NEJU*4,]Q"ON!OHLG"R2ID*40ENM@8X6$D6Q H(F7]HZ5B+!)ZBM
M$U?7 O9T56@39GKI&/05QZ>+7NG/:[N*D.9UW,5S4N_)9YR^_/.L:^W!;(;T
M3ZZ-CV.T/%LO(99$D&VN[6Z*!13*"69LM*9].Z'.,!^S:O7-6L.\R2["64:-
M8HI"22$@14T^CL= D*T'G5DRSM?IVVNEF30R, ?)'1E.A?KE8U_R1.[>>S_0
MIRPB("%8;JR/@!CJ;)*8:N,V#XZ%PGARJC0/Z:^';.CP;\]:T>EDW(B=P2VK
ML]#,.AA[RA99!]]N\D7ZX+>3"FU!SJX4">F%\24+R%K$VD_80O2,]G+ZTBLO
MI.3#6N@[3"'9%_WIPDGCP/89DE>3Z;E1]P[GI]/Q>=])3DZ"(;,-,@L$K61/
M1[]9##70RF>KY?4A'[?&N>]YS/ 9)>UYF?0CU(91H>^AO<,8YC7$\!6G\]&,
MCN#G4\RC^>QL<,@9UH1:1JXC>*'J^<LTQ$RVGP_&>XR6(;\O1+[)<Q^M1O0@
M]L9WEF^GDWR:YD?3LUFHRSW0Q2 ]EY"-<>0"U!D5SFDP,2=A2HH\F ;.TFW/
M?IPV:A-)-TY#.,-3]?X,T86%LP:HA@D)*X$,GYJP/4<W"6\DX'[>^UO .<^9
MS"E#2G4"F8\%'/<2G.'!6R6C-&MU[]@OUN_(7QB(]"YR;6SW+=H?''SY,L4T
M6FQTRU/H[/1Q66F6ZS:&0H*2J8YV4PS($+9.6JVD3VL<^G<^9-BX:2,2)GU(
M<)<9$/\(TU$]P[XK,21A?1W5EV36,B]BS4?UEBVQR5*OY5!X:U1@FA&WD0SU
MX(5CSFB9,69.9_\M.11K/G70S IK(IFJ 6R)IOJS&GR.9+@D&XQ-M>E!BSS3
MP3,K?IM\741W#\=WV_)7IW?Z.ERMF% ;@:B:_!O(K><%C#:"RUB8XZT;4VT
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M45I7&C4#/U16P_Z<>+OA?5^2(RY6_^S;V5KKI[Z:XK]/<9R^+>[L"N/>2N=
M"$\NA(@&8BSTBA;E&-FM1:76J7UKP-I5DL2.]&65UC;BK8>#]0+B;0#/;H76
M@=A30L4:\':36M&<VE6JTYB7':E0%$D[J24@\NHY(QDB7G+(B4=&KFZRH;>K
MAJ%5YY[DBWW0G"YT#*0QLXN]^.R6V,7 9$V/9(E)4"P1QJ@<\,RU+[4+F],#
MJ,QU7#N,.[0B= V%V8J-'NY5KKPT%U_^?43^ZC1]^O8:O^+),G&)HT^%6?#<
MDQB$BF1BFNKO%#JGM3/6MLX270_9#SNH,7M]^I97WX.;>,^S'-< .Z!1M!+H
MSLVC9HROLVTUI6NHDV\EZ.@L2A\38'*YEI!Y<-S5.7J1I9@]4VF0(W!8W5K?
M?MH/U>K"4I\J=3C^<CJ?+23 STYM=,&%.O7>8 T"!J7!N9 A"<P:6738O%+^
M#CC[83HU(G*5RFS)0I^VTQ5HX@R:UB@D2QQ"S?543A9P,D3@7A2FC2VT\@$4
M1#Q-!=F$A8%V$'D&C:D<M/4"LDC5_V2DNUHK\BXT>AU5T<UK)>Z \]049!,6
M>LT/.1S7I/$JA'>CV;^675*5%%%(2]B"JU-@$P3.$@B;I9$:E2FM?:Z[\#QM
M3ZL94SUDG%QBJ_?.]7ZR%B*<-[9: UM?/;OOP+6C02W-6%RI'HTHZ/6J_Q:,
MQ91<N$W D?9697P GZ0"SE%FR04+HG73V>'5X[ZQ+#O1CBZ2[\-&F4QQ]''\
M\L_T*8P_7@ \.Q^#T#KYH$%FH4#YK" 2.BCHN18Y8\S-XWYW =I!\^IFW%TW
M2YH)OH]T^]I]:9R^O?\C?#E#9"UY]]7;UT)S4"IE<"44\(8QS*F@%+*Q*MQ$
M\8CXWU+$/6P%?\?\L98LXHST\K(S+A97DC=D% ?):FM, B1(*;-A6?$8%8K6
M8W)O1_*T+= &[/30T>8FJK-78QU</=F=JS#MQN9LP=N]JK"%T ?92,Y;I0ME
MHHH18B!?7B6.$"/M<I$A"\H%+4QK<V)89;C'PAQ2%[K(N@<=H!TPGV'"?-XI
M6SK+BLT@0ZW'P& @Z!C(LA&8 S=*V=9IQ;? &-Z&:,/1I*V >[ :7US@.9B=
MK?G2DSJ/V2L6C8X61"1#:1F2]70BEH@94XCD1K6V)M: ]4ATHC4!O48A+I'-
M?J6%OY[,9L^^G:%>=-RJ@UX^C;XLMLA<"T2Y+5 R(],X*K*TI8R+C!RNI5,:
MFP_NV@CITS92!V#WID[J1O;*55AG+^,ZP/JU8F^"VI_0:6MF;S=M&M'2GYU[
M"T"1D1L1L.:9FGI?I0E@3F"Y]98K+SRV3LL=6%\VB*7N3%VZL-&'*8SSP_%7
MG,VK$,Y0GAML6JC@.)GZ5GE0,C'P2FA@N22K"W,YMKX%7HUF9T;0MI1=MXS;
MR+NA@9QQ=/P:/X:3E^/Y:+Y,17<N*B:*H7,UDAV6M06RRS)@'8X9Z/]DIMU!
M_0S37SY.OOY"'[UDG;ZX)/N6!SY-PV1;R=]4 K.-$BQ1G.GX.CC6,"[NUX2K
M3QW6>MA:_).&LFNXM=_ 8YBMN8\*F"2-5,87"-(R",HX*731">]*"-P'#E><
MZ+U1V$5DK;LH+/KJO9Y\CF?G@D3N37(!= J2[ Z9P1M5( KGK%).N.M1B=L;
M(US[W.%.U.VD.VDDFI5'YH-L*ME@Y-E.8#Z@-I/=!JP)E6U6*# K93A&$P4:
M^I\6W GI!NDWV7@N6]M. #+9S(L.4$>9@N+<@>/<0.)2!$=O<A*EL3NQ%XTG
MZ\;U]]''3R??7H_^?3K*E^;_[+=0&_'.O[TEAW22CU4PJ&6T()WW-?HIP!<E
M('/I1.3:*[U.!YRU'O;0.REUT::K1TA[)@9K*'DP?T[O]S>2Q4*,QSX8ZQ6K
M)07651%X\#XD,#%8% :-C*V[=*T%["FJ5G_,]1#S>4UR^;@(:EPV*CSX/#FE
M/_\(](S\8;)H8_@V3.??CB4=8BYD!I9@@\(Z?#J8 C)S]%DE+V7K2[%. )^R
MNO7'9,."@KKMW@;TS6D5\U$YBO^-B?[3V<&7+V3FS8Z5*%%9)\EUMZ;V#$K@
MD9-]KR2/7C!E/5_C'.SRS*>H1+WRTK"4H.(\'*<IR80,V^6_#\<W>K&NZ+RZ
M3&6<'X=B7="H0<14Z_%TJOU].60O"G?2&I'#&DJU-9"GJFG#,M@PF_!V\ <I
M34_QJB3/87IA")66I#O.UFLB!5'G#,Y;)CWZ%-,Z39@[//*'2K5EI8=;_'87
M#;X$:7VD33A%0:Z))]?$"@LUH(;.:32I=:K[$V]AN(V!MAO>=]W"<#:=7[$L
M:'=?3AAC)B&+R"#E%$ 9[< 'LB20.V&S2UR7M1H3T,=?45OZVZ7*WO[DAW^]
MV(G]23,6&CJ?-]%<J559!U.75*9.&K*KPL\6_*RD>DOA#D4\9SF78B2@<@X4
MRQ&"K55%2@L1@XC&KM7L9J\(7W%9.13?763:^.Z2-CL,X_GO[]_7/6RQS5W"
M/+NS2XJ)E(P'&VM[ZB@-1$'[J0A:BVR0V;6BW&L\:CB[N!T?D_Z$V4.@^DKX
M8![FI[-E-;(3KLZS ,FTJ1.O)00>'%A'<H@Q!*5:MY>Y#<?3//2;,=-#1Y'K
MF,Y;$*R!JJ<\YML1[2:)>7O&[E&!+<3=[R7$572EH%1)T@[&+3E;21CPCK2?
M<V&#+>AD:-W1?$@EN"<S>2@=Z"+E'KA?QOCRC=,LVQSHS*KW8D6!LB:#S\6"
M$TPYF80PI76*P HHNQCNL3U3D_9B;F@T5".IKFT18_@5)Q^GX<NG40K+UHU<
M*,FM<> (!&FY$1 RB\"+LMQS[KQ?JXCJ'D]@)8"G:2ZTXZ3AA<\"U#("=172
MN3F]!JB&L8*50(8/%C0B:M*7E!L'#5:#*YI9I9T"L:B42)PV,(P<I%2.2QLE
M-VMEONP7]7>$#89DOHMP6S(^_S(]?O/_'1O%!3?D'LOH:EO,XB$P7D!$C9$.
M/'*D[_(>SY/5Z\<MN:U?7>%U^9AA0P.-A#W97%(]UPL5+^B(D;:FRM5! 8*!
MLXQ!]BZ099$+YKL,MR=8+[3)8;VMY!M>BM](Z5\'QR.L%^HD_E7%)IO(KL]Z
M(<=8+384$!,=)VK1HSA(#RP96S3GADZ6/>>P0[U0$PJ[B*SO>J'HF*QE"'2(
M1#H7M [@9(E0<E#>9EKL]1#*OM<+=9+N7?5"742SG_5"SZ>3V2Q=:<\W="70
M&@!V4./352S7JG>B#%D8E7*L-=@</6?).9<PD]8Y&3M5[ZR!9??)1*\OTENT
MX4[5VZ,8?:YCQS*0.!*0%:D]2S%H_BCK<FYV@W@SJ8I*CM4B@_K8!N-\YK1%
MU)S7VO@((F,<K& ITX8416@MF%58'GJ&7Q<=6]VV9PM^>KC[?!N^+><"3*9O
MIY.$F&>O2(RUIP,N*XNJ6!(!7\CLF""I;"6KGGIMI&<0O'$:3 ID@CA=Y)U5
MV)NH4T>(3UG+^F2SS^D=6SNB3(N /!G(,=82:A*:<\P (D;)I$:O[FKU\2.?
M=% UW0WON\XGW;)QDQ(N::LL>/1D]=,;"D$*3P=%\8Q^EEF/\P.>5G^^3EK5
MIC]?%W8'[;.V#K ?_?E:,;MVP[5-:!E4;[@*0A47H#"9:T*H@L#]XI P(;/:
MT[]UW[5'T9^O'W7IPL:P_?FLQ=IS, *K)H02A3RAXAB0+4H_\3R8YO-/'D9_
MODZ4K=^?KXN\>VE@?<<$(*6-4YEG8,IS4#K36Z!HR:R07YQ]L27]F,>V2T-F
M(Z9ZG>IWR\B8=;#]F,?6F<4N$[<VH6#H>6S66Y3(D#94GD IH\ )'\'9F(*6
M7*]9Q[?7ZK'-/+;>M*.+Y'O0BEO&0@6T$2/SX"339'315U%HA*23I1W4N[O3
M=1[EY*U.+-T_>:N+B'NP.U;-A;%9B9P0I+&Q#H$C:X@L;$@N>U'+CE3LJ8OX
MHYN\M8VMT8"=AIF[JU&=#X%: ]>3GKS5A;>U)V]M(/0A)V\YZ1Q'7Y/?")J2
M/-2I@AFL5E[I@"F7UBTM'L3DK3YTH8NL>[$K[Q\"I+6OZ8\)<J[9/BI(\(AR
M,;V2:\\**ZZY>?F0IC!UXG"#*4Q=".@YL3@;TGLI!>BD=*UO%F1%60.<W@RK
M$$71=UW=/,'$XDV,B6TEWV=B\3HX'F%B<2?QK\I*W41V_0XBX+PD<F*,SX7P
MD$_D:RO!+(J71143^79C1?8JL;@)A5U$UG=B,>TH(ECNZA10#ZIX#\'6OEA.
M,*=*82Y>*]'<]\3B3M*]*[&XBV@>2F+QX3B=G&;,H_'SR7@V.1GE:C8\"R=A
MG/#])Z1S:E<IQQV@[44R\J:BO):F++W@)@E2KY*5BC9ZF[DPW.58C.)LRS3E
M#BAWG[WV^B*?*L5@LJ^I5%;0/IM+HG<O%LB&K%@CDXFZ=8/J/4U@OH!U5*YD
MS>+\&(4BFS[3460CJRT, P2I"F R#G7)A6S&WB+VJU ]]'33+GJW.LK?A+,>
MPK[M/!*'#HL3!3@*!.64@J"L!<^8"LEDYG+K\;A//,-T&\W<#>_[DF%Z];![
M77_[/!BGC+;>*0/&H@65HH:@>:SCKQEZ)Z*0K?L2K<+R\&,4G31CT@-#/40V
M;\-U?J>_!K*>+CU6H]K-M4<;]M90B2U$/ZQR^."%=BD#<Q6AJ T\C$K ?922
MI6(*MKY 'UHI[KG^&%HGNDB\!UU83#F@C7'I>LV_VT,7L025!.<L$#Z3Z/36
MDDYO;Q.XZ',P48F(K8WU^S -;ZJWXF_2H_#[*"J<XI<PRB___$(O#\[.AV*<
M33%8'KSG(:?@G926@XXU+<080EIO"Z.S]'98:3"VOB9;']VC49B>".DU9>^6
MC#0KL@M.>$#)%2C4"AQG'H)PB4F3H^<_\H.',F&;,35T?O ZV'[D!W=FL5,&
MZ 84#)T?S'3QF-"#=3S7VF@)7FL'J$5@6'R09JVF_GNM'MOD!_>F'5TD/TQ^
M,+*@%SV5D"5#AV+.M$4Z#4PG&WF*,;#6::)[GQ_<B:7[\X.[B'B@NJ0UJO6$
M29)[1H!=J$5:)H S$D$6Z;)PD:O8VN]]JD79K6V5QNSVEW]\2VW@.L!^%&6W
M8G;M*MM-:!FT*#L*%9G)%H1@Y$-Z[\&KHH!V6XS*E&Q"ZTOF1U&4W8^Z=&%C
MV*)L+Y+(14C05M0B]%S :2U!";1:%<VX;9W+_C"*LCM1MGY1=A=Y#U<<E5PA
MQ8\1 J\]18LO$*5EX'WV6>H<2FA]Y?U8BZ.V,5X:L-,PM?G>O/YU<#WEXJA.
MO*U;$+.)T(<LC@H8D1<7@5FAZM1K \'X.O#-J%)<\#*V+K9^",51O>A"%UGO
MJ#BJ<)&CMI*.4>M!:2[ *:;JY >9C-%TW+7O9?:0BJ,Z<;A!<507 GHNCN(8
M<O#60%2>W@&>(T%1#$))+J&-Q.1=.4E/L#AJ$V-B6\G?5(*-I\G?J%]8!\<C
M+([J)/Y5E36;R*[/XBAKA>'H%>A0Q\2&6B[$R;&1B-PQKHR4=T7*]X'##L51
M32CL(K*^BZ,*5PI%YI!JH;:*DDP3U *R+B&P;*-2U[KV[7MQ5"?IWE4<U44T
M#Z4XZF4IF.:3<L-,F$W&KT;C,$ZC<'+EN[NJE-H4YUZ43341\O4:JF!1LE 4
M+U&1O>9B)--0I^BSCDGG+6NH-H7<XQW<ZXNZ !^4%-H%T(Z3^4,O-P0I/7!Z
M!Z7@FF?6W\7\7<B:Y%0^GWS^,L5/]3"J3R,=Q/J0&\%#O(A:8YE,:==()V$V
M&Y716>KI.'\(?QY'))7@/(%A]8"J31"<=YG,_L(=9G(L]%HS!KMF839=Q2XO
MOIMIXJTYG+LCNX<H\ETKNA3HRS^7Y9GU%R=C6A_]TI2\'WR!RW\OEWB0__MT
MN?[9V>J,]BZ9.CZ8%U%C)9E<XAA!9^]\,3EQ;#W(I-\5/3FU'E@)!LI.O?OZ
M\-FWY?HO9I^>9_4^^[8JN6KIY&- KS4*8+&.YO#)@=<ETIJ+,M9*+5WK_MG#
MK6ZH@L0!%'Y/56)?2A$WO7#/*=$_'D0NN2[0D=>&G#PNXRTS(4KUM(==[*O:
M-4J\ZD#_H DTZP#[D7C5BMGU$Z\VH&50O2DF\."L RYL((!<0A360O!,T/<#
M6M&Z<N5Q)%[UHBY=V!@V\8HL6F:E81 YYZ"D)!=.&0VT!Z-QZ+).K0OT'T;B
M52?*UD^\ZB+OH:=AA&1=9!(A,4E+3J3[P1# 9&G!Q467U%.H=GO ELY&5 Y=
M#K<.MA_E<)U9[%+PM D%0Y?#%9Y<TK0U9E-3H*TVX(TOD$ODS*>@HFT]8?-A
ME</UIAU=)#],.5Q)D<MD.<0<'2@G/83D%7@E6=#6"RE:Z\+>E\-U8NG^<K@N
M(AXN(UQBX*C10<[:TB)=G4F6"@@,29@<,);689G]R@A_(,9( _J&G*>Q#JZG
MG#+>B;=UTX0W$?J0*>-8ATA+B\"-\*!J@E44@=[2K H*S8VV_5>?[%_*>"^Z
MT$76.TH9=UIG'6JEN?6U&Z3/X#$8<$6HR.GH#;%UZ>+#2AGOQ.$&*>-=".C!
M(EEQBB[>":T$4XD5\'52KG*)C*7BR0CG3B7NB@ZA=17^'7!^V"9WVB:MB.RA
MIFT%M+,7;!UP/5DI=P+;C:G2C,;UU&,+#GHXL.X&*95FWB<+T0=).Z4,=$0+
M.J*M9BQE99AI[27M0$'N,5]VHQ]=1-^+7LQQBK/Y6:.]\Y';1D;&R'G/P2A0
M#!,M/'!@+-.!75C(S2?-W@ID>&.E(5DWU&!;2>]GCOZKR13)%#N/"+W\,WT*
MXX\7 :?9FS"=+H[E85+Q.\/90<;]=B*[EEB?(Y9DE7'U3V'0R4 .E^=>&'*N
M5.F46-\9V>Z'';R^2(JS2?*,-H&2@?YP@MY3:P1HP3EW.5EK6N]:>SJ0Y,VD
M*G$X.?@\.1W/C\GK<4*3.'2LH5FF4^T!0M)Q41OZEA>JO_J#[[$\].$C771L
M]9W)%OSL]<@1X8-.0BN0N99F)^N #*, R6*)2(>;:Y[Q_L1'CFRCC[OA?5_R
M?%=$*T-)I7C/P>O:V(@S!)]8'024G>;1,,5;9['OUX71CK1BO?N@+NP,VBUF
M#5Q/^3ZH$V]KMXW90.A#*@7SJ L*":9&#I3C#'SP%I 9HSTS4NB>4FCW^CZH
M%UWH(NL^$F0GY)&=WTB<N?9&Z,(T2BC%6%#!:' Z)Y V::&])B&TO@Z\!<8>
MW?=TXNAZ1NR6 AXZ%1:9X\6J#+;46>XFU5;C,I-Q3\L6+FMI6EO"^Y@*NQ_&
M1#.FALYT70?;CTS7SBQVR67<A(*A,UT]8[;.-0>^'#Y94L5HH61Z*UA*R'J,
M[SR$3-?>M*.+Y'O0BK-P[?4P[=GY&)PI#&,DR\J3>242!Z>X 6Z+9LBC8+9Y
M//0N0'N6_]J)N^NADV:"W^M+G1OQ_[V93=\ X.XN?IJ)]=I5D"4#21M7;"Y"
M,8E!&,N1L4A6M\L8-KD*V@;K[L/2EX'29%FV*12(&.C%Q"#I*TP0B]&!);1%
MM1Z(LZ>70RLGGVO:J1PI"MBL0VT\5\A%EPIT0E\X<UXV'XEZ/ZJ'?F'41>\V
MF%;?A;.]OCHJ'(/S+( UO@Z=-04"UQRP9,9X\4R5UF,UG_C5T3::N1O>]^7J
M:.7DY!(MEQ@E6,_)\,/(P)E@@6<G97!%:-DZXOMXI]5WTHQUI]5W8:@'A^V.
M:;GK('OJT^H[L;?^9/)-1#^L<M33W1M1AV(C(0R"@4_9@#0Y<^%S3+%UEXV'
M,JV^)YWH(O'&/:X/4J)#+%^;>7US9KHL-JBD.)0D>1VYX"#6LEL1"^V/Q43%
M]3TN=X?'[=5H\4[L3/H5;0]F=8?IY](SIY0MP# )4(I.:2]+ FXL?=<E'IKG
MJSS0<?2;Z$S/A S4\/.RXX,VF17AP7!TH"(!#"(Q((81@_9>\]97TH_[5G(;
M&[494X/WWUD#VX];R<XL=NJ_LP$%0]]*VI QR.C!1WHM57:*SE#G0 =,R(WG
M4K6O?WY(MY*]:4<7R0]^*YE4Y%YQ!R*9!$J(NFI)Z^?!1J9]\:YUC.0AW4IV
MXJ[3K607P0_7H$=GID4P"$;9VB^3C.R8M(;LLK/6>:/O'+_T(]^ZC3'2@)TA
M^^^L@^LIYUMWXFW='-M-A#YDOK6V7G(7$SB;R<$SZ,$9I+]&XZSRM82[=9.W
MAY!OW8\N=)#U0/G6DBNMDT4ZWVAUBMMZLY4C)&>99]:K'%L;%ON=;]V)HS7R
MK;L(^&&F-4V^RVFYZ (PFY0C.M&776C".*_ZI>=A]NG5R>2//<F!:KV:/4R8
MZI6PZQ/L!,M1>LM3*$K)$D),:%WTB7F1I&F:7=5Z8;M/\WA]D7B@M6<%N2<?
MI(Y$BL%!<%% $E:1;+W(O'6>T9ZF8EUI>_5F,K^SI]E%7ZR:]5/0!=0\ "D?
M2= R 9XE0U_9DF,=_X-#Q'$[@7[HB5Q=M':MH3*],3Y0K=/]"ZC@CP.O->HJ
M0@RA5FEI6D/P&EP*7"A-YJ<0>Z&K%>T/)>V=XSX"CLU"*%[PD)B(P$2J5692
M0E1,@_2:#GD5;4JMIX\^\2S$;31V-[SO2Q;BG7<+W@7'I-,D1T%OI,Z!W#Y5
M (,TV7J!9,'^N.GM2T.ZW/1V86KPPL(UL/VXZ>W,8J<*PPTH&%Q-R/HL7B$H
M5E3%F,%E1."E9,YYSJC[VVP>PDUO?]K10?*#W_1Z]([7*666O!3R5&2L4_ T
M%/J*6Y45M\U+.A[036\G[CK=]'81_' WO<YIQZR2P'CB9.E%!K'>/V?'I0K,
MZ/8YS(_UIG<;8Z0!.STDG*V\Q%@'UU.^Z>W$V[JW>YL(?<B;7IMR8BDH*%R1
MYRA- 9]K/F]TQ05T(NO6W74>PDUO+[K01=8#W?2B=L9GZR 9S,O&3Z%@I),N
ML!B\82ZWSBS<[YO>3ARM<=/;1<#[>=-[D/Y].IHM'CNM\T.P7I7-27ADEM=+
MLU$^NT4[BB>CC\O[M($[E3>!N(,[V?:BO7;1RCWIK; F%I84<AV"# %YD-X(
M&:SL=-':!&VC\/3=YM["OOM]/(DSG'ZM9M[A^,OIG'X\&2?ZK\(9LV=Q4V);
M)FMKH#22"2@3O>U8!$0CN?8JH4NM?>X^UK%US>3IC#YJ-GL^^1Q'RSUQ!;_G
MH+^=0:X.^@+9<<G!)!(9:%E%*4J B))!8CY8[84POO7TDP:P=WA5M2L]OE&^
M.3#Y?3;0V%ZF2]?0(@M):P^AUJ I)C5$[R2$8 K/-CB7>QN"T&@-@U]D[8L^
M[U09]N5:ZT((SZZ^K*^F^._3.I)D.5)28(J6<1 8:R=972 ZLD]-]7%8*L7R
MWIHYK8:U\[C23M1FE0XWHJ_/=('; )Y/>EH#8D]AIS7@[28"U9S:5:K3F)<=
MJ9##9)(0$6SV=!(@O45!DT\=(V.HL^>V^?S7G:G./?&J?="<+G0,I#&SB[WY
M+.ZBC,"B-(<4:O$?1MJ":\:^Y$E+J3(/J74%RSJX=NAJM")T#879BHT>7(/K
MKDJ].EP6]*3L!5.T7),UJ&CJ\2P2^2T.O1%%E]+:^EF%Y8?)TXJH'N[4;L-U
M7AJT!K*>S)O5J'9CU;1A;PV5V$+T/9Q'=R T,CNAC8$B=+U&LAZ<-@581($V
M(8;8.F-[:*6XQUX96B>Z2'P 77@QFJ4ZF/!=F)_/J25]9"[02IU,DJPS1PC+
MHJK0V"225SFUCI'>CVIXNZ05A_>HQI8$-#1&:M.TZ^C^B:./GVHYP%><AH]X
M"U@K,QVFW-#Q61*HHA+XY#3XD+6W-AN\'E&_M3-=YP<_>(7H7]Q]NC;/OEU\
M^?<1@9VF3]]>XU<\63IX0>OD/8)-*A!*8\'%>JDLDXE:!!N;CT1:#]D/([8?
M$GMH"'*KWW83[WFP: VP P;Q5@+=>3BO&>/KN-E-Z1HJ4K,2="K2!E%# US5
M@4)"@LL"(7B><Y8Q:];;KK8[W5H_WK<?JM6%I3Y5:K%USQ82D!>&7?&TX C)
M! =*1X+F"5\2-MFHF7>NMPO;FW#V(]37B,A5*K,E"PW-Z]ET?ORN9O O\S<-
MG=02!43-8VT=R\![<C$-QN *"H]F+<>;/O6*&M#?+E7@NP<^:<-G<]'?Y%]M
MS?^9&JX#HXO%LHXFM'_Q[[=!MA#^=?JVD%S#G?XZ'!&++N2$@6&UV;3*#CQG
MF?:3K%C02FFYUN7?K@E<<="WYZ^+P!KS]AM)ZO/IYS,@T6BK(VT>F&J[M%J;
M%;67$*WFSOA41%CK#NX>YKY[Z'"G[E9BG[206>/3\[?PYQ4@)2@ZL8N!'!-9
ME!')HA3( 8-52OD2M5G+F+J/O*L/?8#D;2RSE6_>@TOV_]Z,F)3[_XO]K0K8
M?"T/I'R@$5G7Z@Q,]BB2]&@C*BN%-TBO#\?:(I/)HGJO,]A\67N3=/SZ(O$5
MLS$I1O*@L'I0E@7RH,B9+]ZHA-;X]EGT^UB0T!#3\W"23D\67[Z;G)R\FDS_
M"--\3%(VW@<&#J.@PY9Q^LIDL#YH73?LHEI/?.E]48^DF*'+.]!C\G<#Q>FS
MU.%*H.>?H_FG&XNYMB_.WEUK'756RK'XK&.E2Y#ULLM(@Z"T$N3U9PTE(!-!
MYJC%$"ES6R_D0;\!+11NC?CNL-HRT-7".HM:L:;S!I'G36,/QR_#=$R_-CL6
MR11=AUW%R#FHY!!\M)&,^FQ<0*LTVY?7HO/B?KPJ#T&K>DAH;+S0]SB?+XN7
MZ.3&I(75&IA7$I3,M7DEK9$G@=EJQ]#V5E'4?#4_7I"]U)N!\B&:OOK+,8>3
MSU^F^*G&A&M[,W+[\=@FK;BW'EA>+-Q[<+6"UB<AK;$V*M:Z!?7.%OOC?7J(
M6M?PFJY?HU2R.K"81<C>$Q4NDM<HA84B$>F,K?,&6N=;#^#"=)?N!N7\9P-8
MCZV3MIAD(7FO065FH);U WG<0@?+T; ]:.%PAO;'=K(3WF_N!V8'&ON&9'D&
MWJ<@'",A><5JEZ60P!627BR"H=*&B=RZA<M6@'_H[:[8OZFZ=H_BU,L<G!"X
M"LEEB$;4R\ADP-LB(6)$(8PQ<I_C_P^_\<B>Q)Z[*\.^-!Y9\>X^^W91_959
MD-F& %QF3J\LIU>6##00B952@B$KM'5#XWM!/9H<ODXJ,^F3NAX"ORL 7JD6
M6@=@3[4*]X+;37U"8U+74YDM&=F)ZA1ELV9\,=LS+SMG^,@E<*]UEN09HV\]
M3VU'*G-/V<&N-:8+$0TUI18-'J0TQ0J'#-L/)+#%UGQ4?IN,\=OY^$YRAU1V
M!4@ BR$$#H(DRS<+D8I1GHMR34UN+<J\_TG#^PF-J9GT)M?&E;F7'>7S?Y_.
MYHN0]//%1(#9X?CE;#[Z'.8X.RJ+>-JKTSD=SF_#M\6OG8$/7A5C:A6%%I$<
M:(G@K#=0DLT8O4TIZ#648FL@CTEGAF5E3U,R%R,.PJTC#B;C\.9Z,)A^\T)L
MD_)Z,OXXQ^GG%QCG0W=E[@_X+I(M!Z+A6F:EP!)9DLF@*XI%$P(S*L8<(M?:
M*M\ML[*_->Q^[."E_YX9$]G0"8+*T3M?- >7G0#28ZY\0-2RMX;.^S$5-\XO
M1R==0#M.*:)BTD#2FN12ITQZ8S-8+#Y8SDIN?M&X LI#'P[:1<-N3J':GIT^
M<PJW'ZEC$_=,T$%;SUWE<H8H+ )+PDO/57%L'U^_!SSY<QMUW WO^Q*I7*>=
MIK72"&5<G06C:T\844U(!M)YP;DRQ6!OW4?WN$7RL/JR06_D+KSMJ+'M.A!_
M]$;>DMH-.MQNPLNNVFMGZUV6$5+P"11SF=ZGXL$JS-K(+*UL';)\R+V1^]:<
M+G0,U7'GZOY[7N^*C,P$R2%(13#1\]J'44(,0EHOHPUIB([:MT#;C[8I6]&Z
M3G^=+3GITP&XN]-0%L:'X"VP4@O4$TH(ON@Z](6$D9@SS=M7/I#><_MB$+5B
M;Z"R@]4=BM8!^Z/I7$O&M^H,M@E=.V\ZYX3FTJL"@HL"RD:R!\AC!BS11YM0
MY3B$^?0@F\X-IUI=6!JHZ9PX/[5UR2P9 \+4@?3,(W@7.)CDF=),F11Z.P]O
MPMD/ZZD1D6LTG=N$A>'&K!Z^^7#PYM?#9Z]?'KQ__W)Q+?/KT=&+?QZ^?OU;
M^._)HBYC,JX"FY3#\3R,/X[(#EC:$9O?T;5X:J,+MN8"N'8[)NM09F.Y%SJK
M$M%I;J,V3C$9BU'JN 6 +9(*JN#P]>@K9K+Z#L=GHEQ^Y_KC+L.YZ+V-%GV=
M1,] 2:L@>EN["HE@4DF.VW"/#FS^]*WWRM7/>(/S@SB;3T.:'XLD"ODS'$2H
M]:^V9BM*[< '3HMW,?'F":#K(1MN!QU(0VYLH^T)ZL,;78WRU^ED-CO6F!VZ
MK(%93CM^YB0"7AOG%:>B=)QYV[QJ\AY,.SA\>^!R?77I3D0?MMEJ? <IG7X^
M7720.O@\F<Y'_W>1EW2L90BNI  \24'BT 9\*0Z$C:5D)Z/3S6W^SBB?FC*U
M(*N/B,6=0CDV@:42E(9D2J"-.-12$>^!Z5@B00LV-[?^[T3TU-2F*PD]= ZX
MY]1^^6>MQ1Z-/_XZF>0_1B<GER()S$D6- 1EZH#CPB$4+\'XQ!TF[7)N;0-M
MBO716T6#D-C#\=<5][$V,N9B Q3&'2@1+'BM+;V,],XXY)F[UNV,NF(<?@\;
MAOTM5:X3=;VHVHVM=[5@D-'N;ER$*@A07A3P%G6M0;-9""Y"<_^N"[XGL)_U
M1%8/-M:M?L5-]6<8LRN(]'*A) M"E652OXN(MHZK,+YOE;H=V2[VJ[[8O4>-
M&E"SHYWI6#.6%;<,$K>U8,T4>J]R A.B$\Y9:<HN=J0GI#Q;T])P[ZG;\OOT
M"?/I"1Z5+AOTLV_+R/%)F)W=VR?IG,[20"F1_ ^C+)#+X4#J@&B,+^CX&O':
M1G#Z3F$>^$#;%5%[DZ&\6K!7%[BXD#7TQF"VMH;B,B@N$SB>+"!&741P2JH!
M@^K7X0V=H+,SS5D_>K$5@\,&4R^!O@F?+P:SK@&WKPR=;E!WE*/3%_7KJU@S
MWO9 W= YYF)&T):9I;?ME4+@+$7&-7->Z,>H9O>EZ^RIEG6AJW$3A[?323Y-
M\V?3,,[GI>#&:-JHBR5SH\[(Y"S0'EYS>*V.+ DG/*HUS+1;/GJO@N[;4S%I
M)\<>;H8_3$/&NK1S/%%B9L61WRE2;?_&)/A,+@I*;ZWT4F;6>E>XCN%Q*D 3
MB??4QZ<ZIZ?AY%T=Z'X.RX84LDB:?,?:ZR'2+N?J&+T49$DE2J:;YW*N@/*X
M]:&%_!N[\F_#=#[&Z3M<]J6<?1I]N4"E24&939"PU&Y^44'(08%$S:)77%DC
MU]GV5S[A<9+=4*H-[UPKJJ/3^>M1(ML(\P=,G\:3D\G'\PY"GM3/BJS Q:!I
M9TH+%51@<F:<[)OD<UF#[#L>\7C9;B77'KJ%WQ-ANF'E(EFQQD1/^#0#I5."
M& I"SD0U-\)&;-V"H"/$IQH,Z9/)7JZF[H1[^_NW!N2>@B(;P-U-8*17->BF
M<LTX'#Z[XU;HJ2B7#!8HUIDZRM9#S#Y#(M-<IN*,XJU3TO9&[>X)E.R[UG6A
MK@=M6_AYG\/T7^=&GM29.UVO_+@2H&IBB\O&@%%,>Z_0*=9ZG,9U#'N7"[0]
M<;=YUYM*?2]JF1KT%>SRZ?W7)G7JT$>,8"RR:,.9RFB#P,+('\J!&Z*2W56#
MU+B-WOFE^N6-:\Y1LZ!US1&K W%L;2> '&Q TM20"V.Y\1M\ \2VV]+BO3O\
M_"6,IO5"]?FG,/V(M#0O,$O,H$4H4-\-\))6ZDJN361%,7JM ?4=EG8[DN&W
MJ.UXOKX!-9!O#V'>2T!'-RKSEN[+2=V>CZ63G@4,(&HZ@3+D!M5.F6""UX;V
MWQ*;UP&M">VAZT4?# Q[B5B+ ^CP95:BA.0Y'<TL"?"B*!"162Y**/QZ1.C1
M56BT58N&\AZT7N?W&993DD'!8Z=9S 85L) 0R%KSX'1A0&JLC>4611RN:N<2
MU^/5C UEWT.QSCO\BN-3?$6B.+_&J-/ZGI_.YI//.+W(3ZRP9S42&OX\-K'J
M;6903"#(CA<(42;Z:U&FQKI#\R*O#6 ^=.WIFYF&8>G%.(/Q^#2<7"U5O'E*
M'@N1?1+<@:YEL2I;A%A;_$8I4!*X5&*^QS-:]UD/E?Y>9'F3:[T-U^_P2X4V
M_O@[R?32+/J LWEMBOX!IY]_G4[^F']Z%^:TPUDE4L((TM8AI'0<DCUD/"A,
M%E60P>AU2._TT(?,?G_2;3BG\AZ@Y[,H\O,P^_3J9/+'[,5HEB:GX_D"M*9-
M*F>>P6#1H&P1$+DRD)FP3!<I(U_G6G)C (]4/1I*O8>YD-\!?XO31*C#QWK[
M=MG(B$XU.LR.RO,PG7ZKA]OGBO[8IQ0R[7,@N&&DY)81<E:@QIJ"SDZ1:]7<
MXM@4[4-5KH%YNJEA;EL-.Y?#Y5M1AW^3,*P@9\M X(MKB^# ^\1(&)*,(^Y,
MSJVUYW8D#UTS&LCW)NM^6];?G%89')7O]'9V3-I7Y^S6]K&<;&%6%UJ\)L=;
M:9Z0:6E;%W_<CN2AL]Y OK>$N;::3M;I##P<IRF&&;[ Y;\/Q]^?B@*115MJ
M;UFS%(VW9%;3>9A,(NLI7D^BW]X6N1O20U6873)SBX:UR*NM9]]R>MN[T>Q?
MEX<A/TX>O?*!P/'_G[TW:VXK2=)$_TI;OWM5[(O9S .EE+(UIA1U)67WG2=:
M+!X2[E" !@"5J?[UUP,D*!($B7. .  (55:5BHL2\86[1_@2OF2RMF/-^:U-
M7)P@3SM+[J3&QM?+4WB>J\PTI_4:0=@YB'I?[V&^TYMI1146:8WGD0.++($J
MM7HW60]:T@Y*+!C34.^+&\$]=Q$9A@MKY&7GH.K/Q,(EYNM$02M"DLHFL+5(
M1-74T>!K5GC0@KE0S:?6;W./0-G77*>V$M""KL^QCIG;K+Q$#3X7!<J3X^X$
M]W5<J.*1"2V;YQT=<1US4VG8H3:Y#U>.H%BT"]Q_U28/P/H=JT:WX=L1B%M(
M5NI@'!V[3#I8ETBGL$[PP,!LB)*VU;JOVE&(6</:Y'U*61]V[:$VF4L18LX(
M DL&A29!+$D#ZJ(,TYP;9%V*U)YC;7(O5FRH3>Y#Q\83Y!>N?!V$?H7Y!EJU
M I?(',?,(UE_C >R X,VM-]"F\9HO#7)8G0=./ST*J?+[(;4;7B<9]/Y4@S/
MIQ]Q^GV4<'&5R<PE*LF!)^] 91W >[1@:HD4T\ZZR+MH UK@CB:@[WYJ@<?6
M/@7SM E=&V:7W<%3!WS=()K=#H?;#*J/I=F-Z0^![->.;,.CAPQO1.!A3OD:
M<)QQ[5S4X&SM/ET3'J.I83N#W.7 I5.=LL..B^N/F'5[9'H?NC:VT/[?40E_
MA_'"LKA5-TM5HVR,3'$#7F=5@[,%O$P*I!;&*".]<%WZ"3RUQO[4>$,63 :@
MWP!U!61(?)O,PN7OT\G5MX5U,BJCM C#+P19:2?4(K7(%0ZJU&;R)10HGI?H
MG-%*MHX];8!T"@I]".H/D!W\!+R;(]$%X$!1I8W@#A-':LK2[N*R S\&B!9M
M!FI<S#KF #QK2T"C!&](0=KBT+/"Z9_6[Z<'$I@-$:'#RDL?-@PM)]??8#XO
M+WY\#)?X;C*_Z^:>TUU]W7=G61@L6'0\T^6-H<XY$37YN5I;3/M0!#K>O+WK
M+GCW'XQHS/ZGA&M(WC6T>JI]]R&,/U\;Z:XV6A:,3A7F#$K(VK1)6F RB,AJ
M"V;>J2W.!E?E=L%3L%RVIV##@I-;$,MP5P<8#2,.=Y;>?XQA2^*OLF\'RC4.
M)=R%4UOK(_T:N(BUAD'5%'4;H+K,J2@FT'=Z-3HT Y\(%[3E7Q^"->;;'T2I
MKU=?;X"P')1(W)-=0K>ZTID<VMKQ4-/>>-"AH.N49+V!<_<6W6]<8&NR3UK0
MK+$2_"/\?0>(]2P;)S+P5"2H9#7X.L,\RT36@3')EDY._B;FW5WT&3)O:YH-
MT@HK3;[BQWF8+_*27H3+,$[X\0OB_&R<SW)>$#-<5BOL<E(GD<]>_+AGLM7T
MV^L2TO66VN*.LEB(7 '!"T6TDM+15]&!+FC(1HLVJ=:U$_O9V2G88D<L"PTK
M3M?Z&YL WWEB[0)['R&J[I /U8/P^*3H*9=S8!$8.MK1 [Y*16CA2VTNK^EN
M,!R<9Z2UHDM9"^N,9Z<LN1O;&)ZLX/;A?.-'OT5)Y_LO8?HU)+R:CU*X?#GY
M^BV,?WP\>[6T@5+DI>0 )7AR8[)S$(S14#-:)/.&%;.ITUW'I0X</!N*99/A
MZ#W 6^&]XJ[KCJ 9,2BL<^XC&<&E(&U6UR) $3Q3SI;<>L3  Q"G9,GM1N&&
M_1W6 EHV ^X :2"#:@V<PQA+.S+J*;;O0.4!;)9UT+(L)3C& ;DB:%Q'""Y&
ML"%KZ3.+B(.>^@/:&L/SO0]Q&ZO\^Q7>MQVFSJ?S+Y/?D!33O,Y &*7E(T[.
MR1L? F"6O XX81 X>I"&I^Q0,V^[9&GW7';_IL#.;'JL0+HQC1MG<#_$= _\
M\B4O<\:%+9!2;3OD60:OL@7M;1*HDHLF=A""3HL];]:WIV?C\_^?HWH'O@Q3
M_'@U_5PM4/*?SK]]F7\)EU]'Z;[H+B>AI) ,"@O"J$S7GS#@HK: 7A?'E"QQ
MM0Y^+?NW6/IY"\/0M&X\4.KL\K+SS;5A:\N\1_*&0D'RCIQ&4$J+6M2OH%@9
M, FRDKWOXCNV!O:\Q>JP?&H\V>ICN!S]O>Z.]"$QSFP&EP,CPZLH\#HF,%$E
M4H@"R>GJ(#N/??[S%H$F5!M@:-7/ -W5K)8JS3Y>5])?1]>*Y)R)8"$I26(6
MN(%8C ";HU8\(R,J-/8IG@1T2E&%=I0?H"W@#98;H>\"9J#8PCT@AXDJ-&34
MJ@CL3.4!8@OW07&+KEA7P#M30&EE(2KRIFTLWB=G3"ZMGYKWP/(-\81]<;P/
M<1M[%0\-CQMHRZ V1Z4Y3U"4)H?'B@+1^D W&].2K%TN9>J@S#<LLW^=O@,#
MGG0:MZ=>X_C PM"XCT9*JTNPAFP*35K*UWSBD T(1>8&EU9%)[H:9B?!OAUI
MU/ H9AQ=O,7/X?+5>#Z:_[A^TDQ<*2L58*P%!CYQ""PGD((QI6W0\<GBKAFF
M?WR>?/\G??3U;4M?_+QDURQX"D;5KG1LV/>V0KE&L<QSZ("C@_6TF:]W5]VO
MJ;0S^2<-:=?X>-[#XR*CBR(RP)IDJ*(AV8R>'$'GLM99!?-D=<LQ\/ 1VV<P
M%O8A66,CY\5BIM[;R==X<\L'QX,(9*M%+*Q.B*XM/E* 8(-5WCBZ]KN$MU8_
M=W]Z<#?J3AJ19H LA@>M1E_\>('C]*7.G%S(8DC<H$H,G'*I#O!*$.K 21>M
M\$Z0J/+6K:LV83H%Q3D(_0?H)_X0WQ+=;<^>S?@&BE%LPG:8L$5;CFX4EP;L
M&""8L1&G<DSP1"Z$BO7,!$W77A$)'$I#-K^1:%O'-PXC+AM"'H>5ECY<&"2=
MYLFI7C>>XBWH&XT9DRP!"64IDC1F3 H\T0(X(T_2A%1<<]'9"NC^O?2V_.XW
M@JT!L_9CWGRB?_4Z5XEIFV-FX*-PH+ @6=E)0&%86V8+IINW)W\"SHD;-5M1
MO>6DC$>Q563++,,.V/9ER_R$=31FS'8\W"0;.])_'\;+'8@A1\-]U*"MI?M,
M.%+,.I%B5LBRH,M4E-;C/O<N&OU-EL$EHP_9!Y"(FRYE#Q N&\O6,:-<:%#2
M>5*KA=QWK0L4*Q+Y]RGRYIKD:41'8'ILR[S)8)1_U+SX'_]<(=-;^G;QB\7/
M*QD^8/FW^O]_?GAS2[*__OKK'W$1SOF"X7+^Y1]I\O6?"YJ]>??I[-WO;UZ\
M?77V\>.K3Q_/WOWV^_GY;__UYNW;EU]J[?5L-+X_+&YRJWU_PWD87<[N@YZ-
MOGZ[W)0YV&+5?_[<]GURW"Q]3V;V2 #\>XZU7>"__]LH_\]_'P7)C4E:YBBL
M4I8%B<(S'J24CB63+UH :#,FY^WML(\08_)6!Y#1AYH@3W8W<Q*DPLR%<#*4
MUDD]#T"T&O[S87)Y^7HR_2M,\X4M2'X%69M%10/*VYJ:57P]B)GYVB(R#+6O
M.S".8:!/'PX_-M!G6\H.X#PM(5TPR9FB P=%,[IEL^+@0Q00I;1!T\Z\+0-Q
M^'!LW9H1CS"V%Q4'L&&6.,[G7W"Z.FRN/CGYF"R""/45(Y.S'H2O+5@2,G1.
M6C_4(5X+Z'3XOCN]&V:OKX);F17F&!-)%@TE<[+4I-'@A(B0K#.B!"-U;-W?
M]MB&P[9F_PX4'J"'[1(5[1!'G\<OKZ93'*<?GZ9A/+M<&->_$[$62+G&$+R*
MD$WMAB@2K]T0%Q>7"$4+$4+K^6S=T9V.?#3FQ "IZC\5F';>9[JS4HF*9)<K
MB+539E(&+8DN8W*H>8Y##2%,=!@3+0J65__1!P$^%3+;#/W8LZ2$:IYH?VQ#
M"'>Q6EO0]5B&$#Z=?1RQ&*6< RV0@W*ZD/56N]7)$ W61Q76ND7SLRK)Z,7Q
M7B49?2@_>%Y^%S"_:DE&+T8]F:"_#94'9[UDL2B7;:T3(S7L:_V!"Q9"BJYP
M48>9M#:.C[TDHQW'^Q!WL&S%-Z17IN-PW2!K62?H.>9:9JP$63[*U=DD&#3(
M$I)Q4NH2NE3T/[G(H?/Y>Q%_;3+CKI1K7(SQ(,NR*,8MAII;*:KA3-HIN&2
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MQ)'U/S1[-YGC;+T%$HL75<R 8)':<89N'Q\9F$A>:_:68^RBV7LL>0*,'XK
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M^\DXWT ^3_/) K!DRZB%EH8[%" BLW2G60%!UP"6")+[%$O:0DJZK7UR0C(
MR=?(R$Y!PWN _0W>16GR5_)SPQS_8W*9TZ3>?V%\8P#=7H',:,=D-7_KC'=A
M"T0?,J3@+5H3HK>];8M^$$Y-8@9DP!K!V2G$>(U[@;;:R=4\^C8=7=Y] TD"
M40D&VA(QE.82G-0"HN).":Z3,5W>$C<N=#)"T(J8:UB]6T>CG^A(0 G<;Y@>
MO'MD<H90,\A<UEK&3*)H@X.LK6/:JO"@*>\F9C^VU&FQNPE!US!\ITCB77SW
MI-$L1V6;X+PRGC:>Z\QM9."]BY ]":(BW65UI[: &]8Y,5;O3,HU?&X05ER
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M<_X438RT%R@197W!D.0%DJ7D8\P\V*+)26PL',?=G+\77S<WY^]#W[WU9>^
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MT,28I$3!P$DF:K(SN>VIUAXIU"+YXIWCC77(?03/EOD-"-IZ'A39PB]_._]
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M72^.=9M=M@VY]W )W* C+XJAL0R<*I)D/N;:_LZ#Y4)*%CB=A-9)O,<^OVX
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M=O[7&*>S+Z-O/[&_^/$^3+$.*3)2&:,,<.V)3BX5B();X)F[@)KI*%I7E/>
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MI74;WP&W\\O)\K&(Q@#QTU;JXSM9@C7:3,?Z=_IWYQ<RN2*<)0(S5+59FX*
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M<DY.2<;:!E<;3EYX%)"\8Y(IX81<\577AFF>7F7_EO(N])\,0KR&54E/(?N
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M:\$AV$SR'TA].*ROACS9%(TW)78ROVF%.Z8W???3['YT\5_3 6_#BX9WQEI
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MR*+TXQKA[+R\Q5!#<D29I>A&(XS/)+7,^#I3G/RY( M82X*KLHP&=0?1V!K
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M$)A;>*<M,-MQX2 WS"?B_5*ZT3A6O%.0HZ&+-6</7F<+7!8E3$@ER@.(S$^
M)RXT6W+BT?C<GJ;\?KSZ^C5,?TS*^BD3K_ZN7S8? =QOU4'G ^] @)7AP9*\
M2"Z]#\1V1?+D7>9"<V:4TIK<E$>&!_<#L(<F;&>7ES<SL,_+:I>LVC]K]O:V
MYY$K4;N !A@YT+54F5QS3FJ5>R&$1*Z$;=VLI_$6=D[#NEX)\WH@-]R[X,XE
MNG$BZ/I6KGQQ$(+AD)TQZ),L6K:>2-(-V?YOY4/*X(/$K?;<&\)PO(V=M*'=
M=1PE&Q&*J[T@;4FT*=*,P?@,,1?$K#R*V'R2V1 ;V5>+N&.2V\-+Q+'TCKN?
MG*248B))LK>RU#6DSX&T<22KW01$&;U-K6.K1Y8&>S!Y>#(EM@]?GDM*89<]
M_2LEME=*;"\QV4=NX38\?B[RFXWE/LIZL.M45CK-0&>][LWZ+(HP6G4JBSU)
MN>V5$GMT8MN'M0.(Z^,I;XZ%7'2TP(LDM9(=48H)2PI&\2PQEU(&Z\I]N#3$
MX^%UY]S$/HP:P.-Y.O\MA.RLEP:$+362EPIX4RR@R<;)J*)+K9/YCR0W\6@E
MJ1W#!KB/WHS3Y"L).3GZE0YO;VS?ZZXJDA>MC 8KZDAGF0R$Q /]$;FW5A6"
MV%B6GH#S+_^A-<\:YK]N@+9,6>H ;B"WX$E@A['OF[&QFWCLP(/]W3LW((/U
M,2E"Q;3V=#JL@""D@X#%Z.!49JYU[/P  K+!D#Z,?/0A_3"5%T@?^(54\&_X
M'2\GWRK&FV#S4F7R8H1RGK2OJUEN+H,+-M;AU"X[AS'YU-[&V01K_Y9.0T8^
M-%F:<F&(P#]>TJ\^_XYCG(9+ GJ6OQ+%R=0*BS8KUUB7!2<L*_19:="E3J<-
MM55<3!(\$J-*Y!I-\ZGW?0">DO ,QYE'[YN#) 2LSWDX2[3)FJ4]:%I M[7W
MF!RP!3%64@30>)-M=*36@F*\Q%249DHJ5"H$X3NE"'2#,7#$<?,\)&VD4KK.
MKB"_$I23-7>?%6"6H><U9&9;9[KNCGKP2.V&R>3WIXZ_P_EY>3V9%AS-KZ8X
M.XOU@DGSBR1$O:H<)*$L*,$1O"T"!&JRE20F^N^QT+;7SHXPE-)6TGO'?_<O
M,/M+?=UREQ?&(0O>2L!$QAC1ET/M"096"E9,XBRDYI9.TQT\(S$?4,X&/0J]
MA.2HWNS6;N>_</3Y2YUK^9T,SL]X,_X;WT]'"2^42DP;1Y9L*9GLR\*J$2OK
MO&_KC(^HV-Y5;;OM_>NP-'TW'%:\!HBWMN7&RDX7O_R-',37833]SW!YA1>,
MO+^4(P?.!'EK26<@+>Z ^:"M9E&XYJTO]KS%?YVHP=5/6S$;HDU@?:=[,YM=
M8?[M:CH:?[[&O=CB;.4Y;['-1XG. _U#5P%$+9;M2$IVD#4/J'RT1C37/JW
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MEQGT2D7V@6.TO%,7H7[U5&0OX#HEH/;1^F@F 2Z5H+UAAAQ7^@**8/1%9%9
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M;ZA_[R4W=!))<>^J1+&.2+,DEC;,>H/U=)+.Q,;@/R#*T73)]4)JVE[-#WH
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M)HW;P=XK.]Q'_8.G"+L(\ZMFAWL!M357N(^6AX<^R2!0!A:4D12,\WK>)<\
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MV5R$[F26.SS]!P5X?(+TX0U@VAJ(QG'@3=OL79%NW.4N0C7, 3PHR/@Y@$9
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M QNJZ>IL;B2SD17(- /BQZ-@>B?",L&3 BS5N(C<CFXZH38CFJ$ ')EB&I'
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MV@V:LF1[2^HQ2_E:63)EV"*OU;3T&-B/CZ$S8534Q_8SU,*#4OH3L)$?M!4
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M8"N\&2]9H=]-2V-A.O8.W@S.PP$G_7'E=>;!\G>3X_NB]W\ G(U7@#Z 50N
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M9URMXJM"7"9/.BM)H;Z1A"Y%U>EOY+_2[&Q)\OR+^I3J6,[("6(2^@%TPR"
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MT,P;,?VPC&RB[RJI?0(V2H%:JS=5ME\JMJF -&:M[6.0'JTN=R^AWKF&]S%
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M%'AA;%QM[6!W<Z,$_V?D_S.HY :EX("O!= "6Q2Q.HSR86?9L-B-S!%MP$Y
M">()4#*#6N@2P![>,@,D+8IW#8KH1)ZR'1^D/:YVU;",8>JJ776XD>DJ31DK
M]*(NE/E;_4RQ&UU\\2+/UX)_6F?*TJNJ<Y;WPW87I5H$KN=C3@4,HDB9:<B3
MD$0L@"%FB#N82LZM-ICV(LR-KY5L#\HP*>NKJ.UFJ0I8KWA3<P72LO@<:Q>I
MT_4N+5UH/<;*S/H;=P3&9OT*]4K\^O+IR>ZB?]MR:B> 2)T,Z'.:29$4ZVS
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MK+K\BRB:"[I.[,=N['B*61!2NV7*(=%WH*4(D'0XEPZU2@FULY>YD<MM1K@
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M*X?D_9X&[CC5?L!P#$S/;8V,/5CK!+9*38!6JZG%;!0SI6* 40VT= -_&NU
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MG 9,,UB4$1@H90ZRI( T0!&4:<)(@F4H8SFM'('W*[I<V=E_)\GD\IV_EVQ
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M%$R49-I&$Q$D$:%0,"5#0I-8"J=2\([]GQN';,0O,UCONR3=M[ZGZ\#8,<Z
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MTS*2KH8E%CR(64C,-B_6UEJH((VC$-(L4%3CHB0.IS_DDBT& *;=[H#0R+_
M?Y@A>'6#IIL->Z@[,--9? +VH81OM>M(,6J>K-C*_-0*'JQ;&"=D\*VXFT#!
M=[\^-3SPNUQ]EG.I\E59XZ0,M6G=<0\QCS/"(&%"0H03"G&01!!'D;99D$1<
MJ'Y1@9W]GAL3F>CHQ;Q)]#27J[KD2,X!JY0H:SSU#?WK'@,["V8 9 >>V^U
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MG@E[BMIOS-:3&G)?;K3M^RWGID"D>)#\:;Z8+1Z;9'M)$"<J#214/$(0"1Y
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M!V?@!:==.Z+2!E3J@+8^)IMY.8+&RWRU&<(C<=X>K_CXP]S3<N%!H%%7 G\
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M+EWTKZ#VJ3F3KBWTY@6\G?/)<9Q^73N)4XY[IF;W!Q5NM#FO+'I(RHGGUQ\
M)"7*LB@ (FGV>6LFG=@DL-8#XL$"L"[&*NY[?)F_;D']MLO0]?HY7VW$)UJ\
MW/'B,5O7V3:+_+[ CY=%)D@XP]?I95:(3[FL9&'7\BNOKG[Q@F:EW/#4F3D_
MY[+NJXQS7Z^S9\'<HL$FBVZ $RJ6EA2RE'@0<>1#' 0A#+F7.LQUW9 1[:5F
MOGK.;6GK:*R2*#<J+\!3K32@C=8JT3WM*@X>>;4 ?*<[>%(J@K357N6_QSL(
MF@<,>'R^ ZFS-,]7^CF9 CI[L8^]>['N1]P!##2(@<OM-WR=@CW4P%?Y#7>
M:[)0@RUTH(/=J135?ZOOU\#NF:\6<[2S_O_S/9L9>?/_2OJ,RAE+/YT1.V,0
MWC*:_P;B6A>8X^*EAXLU^\2?^2I_DK)?_9)*\JM?=+5A*EG4?VTRL5^X7JO<
M4F4IHT*6KN/&.'42B!,W@BB,7)AXH0>=((T)#A$)8FI8=\Y6EKD9NZTJRM.&
M[90Q+CMG/3@(X=3C80@ID:$U"660Q#2$*<9!$CA>[#K!4B4MG=?@;"6:?G
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MKIOX'H<^BR*('#>""7$22!E./.E'FQ C=S*3SN?&R(V<@+2" MI(:FA@F@R
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M>0Q1X%.('3>&V"/,B9GCT$@KK?H;;<^-N)1XH);/*)/*6[CU4\^9:(QMKAH
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M2B<P2G*3@? =:J]^IC33[NJ'@>Y@_S]0LW8D?5&6O"J77L P(A&2#H>>K(!
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M#/N?&]]<W-\77,@O^$4)+9F%<%!PRH59I9G'RW8L]/AE1(3'/L_;2@YVHB]
M+3QHI*]+?=7['J7 @)$%=L@-%5)@V/NTL01VT!P$$5@V8Y\4=A>E]:?X]/*B
MROZ;L^\%?\PVCTL<\3#P?!>FKA<+JREA$.,T@A%"+(F1Z[N^<7;8O@[GQF8J
M!6JV%7@!GFHYS1/%]L*LQUM#@C?VI:?$[;J#6T=:\/T$AE8I9'6 &3"7;&]W
MDR>5U5'^K>RR6N]9GG2LJXQEJXU,OJ 2::EHJ*M?=+5I6$SN,#;U'<M-^MJ8
M^_CR=@-U98P@BF3>:DA26<Z7R<*^OG2L\D+,N!=%/C(JQ3:BK',CM*ZD8">J
M57[\,8=8\^AG'@,W]GF2W9B9GS.-C^90AU<C2CKMB=CXD!\<LTW0I;GWS1TN
M\N^B_4<Q!43+%*_*ZS7=6<.M#VV<I"EU"71BY$#D^ %,0L^!&,6$89IB&FG5
M1-+O<FX$+J4&K\161W1@)[F^RX8F[/UL/ Z8(Y.J#HX6:6LU =5W>!D>V(F\
M6\[Z4(V\5\P@ZG%5T6QH,K\4,\6Z3BB&;Y[K<;)7WTI%":MK55GIJKX_75*?
MA!%-(X@)$<3M<47<!/I.P",'8_%K+1])B[[GQN!=3X7]:FUU2'SMMZ#D;WP3
M3.M6&8R+GIT]$MHC4_R00)_A^:$-V>!>'J=[?B>/#FU(CGMOZ#=A1VX[!Y#:
M))8.?1O1U<T3KRM#EQ]YFA>-H\@=_B5MZ*K HH]LC8L7%4WV30 CWA0@B9[N
MKYL _&60\,3A@@Q)F,C2.C+-MR=++W@I]2,2)<AC)NX?(\HZ-Y^2UG6KOLPF
M2BV0U3^LI&)F5#GF*.M1ZTS&;F0JWO>X4Q=4.U7!3M=V1)OGE;H+L*\>:/4;
MCJPG&(2!R'U,22==#": _/7B,467EI9T7>>Q3=?E8!>Q-(5A@!A$,2,0TS"%
M*&0A8['KN=3H>'NO]=E9P]O"HU:9MO:1T[1F;?$8VU[5AL+<&GU+Y:'LS;VV
MI[4HWU+KP&9\\Z%SM[Q_Y#G[F:U6]38J=GT61SZ%)&!BRF+'AP01#CE+W A%
MF*:AT3WYD7YF-WD[.ZQ6T'/WK/O FNY/K>&:<"^JC=09F\XW<1A\@[G?RSMM
M)M]4]?C&\>W'+2^YZSOSYJKDL[ 2UK2I\"Z3Y<GBK=)UIUQR/W933Z;Y"625
M99;Z,&9A# GW:$(]UW="9G1CK=GQW BC*[<ZA?E99!6'>9K*B<&DUTCC82/,
M?M9JH9[,RG(CLQ "*I4TO*G6'2?-:^<1T!_[#KD+O("Z=M!I(:W/P"3*6]D'
MO%8V1&NH.V+=;J>]\#4$X^#VUO3]8<(H=G&%D1,S\0J!/G:0V)*XLEZ\,'PH
M]FF">1SZ9@?Y1WN:&W5=7=Q^N_[VQP_PX<O-CQ^_@>]7M^#'/RYNK\Z+C3"-
MV!P$KY')YJWHB%'"*T^",5* Q#N%1)Y4]U2(Q%!AC()FGO(2KU0H>_T/SF[2
MCR\_\(I_RU75^OIX1?QX>[K2W'TG2<BP8 \8I3Z'B#(?8AH$X@^6Q YV&(F,
M\J"=(\S<2*;5I<[YL "M.G+))B] :B2/0RO05:IS?FKHEWS.,.K1U52#,S*C
MG3LN(R1W&P+9H1RBSQ%E6F?I 4 [<*0>HDT['GXC9/T;KV[2._Q+_&NUD6E%
MODN#,5]?=*(][_(C5U;$ISQ 7@0=*C-92<=J3%WIJA'1R'.#!)'(Y&)R8/GF
M=AFYGU4BZUY-FA'QT..HQ\WO.#HCTW5/N@]!T[R2M"VT7("MGJ!1%%R\BHH>
M_>YQI%$8B-J'EFY2MA\)VM<+P%C=6%Y1G"K?5AZKWZ;^N!.]7JS9=S&?OHD9
MUERLQ4'@NG'B0(9E87H2$>F[PJ ?N]A-PRA*/;/D4",(.3=;7DD*I*BV=YMC
MC*3FA<H[C\_8IZ$&0V-^"3,B=D/=X(PAXK37/R."?'!W-&9?=B3_AVBBE/8,
M+V_65[]DLL%-5C[(CF]2>;:_3 C'4>@)BL9A")&/&(S=$,&8T2A&*/&0KU5,
M7+O'N=&O%+CU$Q1V'=\3N;UM,B/DTZC[$4M)F 9BRKDR&8@GU\G(AQ'ECA>F
MV$-!N%RK_!AL2MR3&O=NS^,A_T'*_)O*>3@A\DX4AFF40A2DRFF*PQCY 71\
MG$:8.8D?1"WR=U-_]OOPWTWP]7^9%'P]HV)0"AG90JC9XTO+'E<','[J@]'8
M9M"&9B #X'1_DZ[FVNJ_7IKU7[2- I!%(O+BY7.V%NUR)KU'RB7G/L)!$D,O
M#CE$:>I!PH( IAY%R"=NF%"M\@[]W<QM16V% _=2.E-'^S>!U"..\^$9F2VV
M B[ %B0EXP*HVN9#>JKW03&8D_F;G4SL']ZGZ*%K=^_3YO'H/_@ZRXMO><7+
MT L^;?AG3HH-+EX$6$ES ^;@* I([-8AZ,A-$22!2Z#'4HIC%G'D8=U@=(W^
MYD8'X>]>\"^@%APHR0';<" %UH^7UL&YGR1&0&]DMNA"M@ *Q@400H-6:H6A
M1?"Y#ICZD><#@SI1V+D>N,,$GAL@U!-UKM/*9"'G!BIUX\U-7K.SQ+[QJBZ8
M(+^A?W!V+TR]YI-V>> ''#MBKQ?)6TN<P)B'*:1^BF(G8*'#C)SOCW<U-PJ6
M5UD[44$CJYEEU@.LGG4V#%PC<^[;2(W@EG$:C8&,M)Z.)C743BO\VEC3>,/"
M8#LX@-V=S]X\J0-;5;V^*C):<?:CRND__UQG57G[X\_6I2F@+H]D?@K/#85!
M1SF&B?@?Y%'@8P<[<>IK9Q<:0)ZYL4TM=NTG+J4T,$P&&!P-*W!:R,>V$J4V
M4*D#&GU 1Z$%J%4"%RJ71:L44%H!I98:)!LS<H#1,C SIQVUJ<S0849O(#MU
M.(C[[-@!>IG.SAT.DCT[>,!FS=? O9PHET*4>RZ#0JY%!QE>?=^0549OTI07
M;<3(,J*)QZGG0R\)0HB(CR"A:0H1CWV/IA'!6/L(P[CWN:UO>PHL0+:N^'WM
MK;D )7_"Q2YL[?K[C4D<FMW@! 'F<<QBZ/N(0.1P'V*/)# 08^5X-$I<EQM<
M:8TW1M-?;\UMJ$X;)Z/.CI%-D?WD68WP:NEJQ >U_*!5H XH'!-P??MB5. G
MLB:&'@ CZ\$:P!Y;P;S-R2P#:W6[=H!](V:KO@KV+%Z6E]^6ONLZ*>)B <=8
M;%YCAT#B)QC&L>?[$0W#@&MEC=DU.;?U^?(A6V,]4NG@TD_-=MJ.S+>7_[C^
M=G'^Y#W4K:<@?/-P??+4_&-WZ-1I:I*)>"AZ.[O>^(VYH?Q)3+QG+!-82P>"
M-O?U95O2=9F@%'DH%I/'CP.(*(X@3L(4ABYQ(HP8CA/7T/(ZT>5,[2SE!L,;
M8>N\;0^<W7/ !7E1J<V:ZU:VU0'^M!TU!(Y3U4!I)5T *>L"M-*"K;C#(:=O
M$ V(X$3FSUE(&MDZFMCT6#:G6IC,CM%4I6NUZ+YB3K@7E!8;65HF9\(JNN7"
M,%I?;HI"?KE^&,9!Y,G8$LXA\BF'<>(3&&'B,T+"-'*TXL%/]#,W:Z:1$11*
M2 ,.[</R-'\.A-#(W-E("5J0:CE!(^@P6.DSYD"83<26E[@H7N0>\!FO-AS@
MLBU93_!*9?LI'SBO ),U&L5O<K$7N6^BU+,UE6HQ\7B1;^X?Q']Q\Z0\2GG"
M+RHL,LT+\+3_^?X._I1'W54N?I"NA&F@>J0U2."I":YL!%EEF&2KNHC-!^DS
M]#.KA&T/!,N %XX+02OMC^3CZ[QX%%O<O(Z=%HK1%RJDR%*PRM?WO/CM>'E:
M(_+7&.8>XN][>S+2UU"A2_@ZCUL&J#19UC[G!<_NFT;IRUV!U^5*?6URB9&>
MNTN?4S\A:0S]-$Z$L1U%D"#'@52%J02^PWUDX[FO+<%,;>]&<&E^/\@[!#4%
M<UGZT=!]7W\H^I>/D9"=R*&_$7H!6EQ;N4%'<-#Q^Q_0N]\8L*'<_/4[GM;?
MWQB0 \=_\Q8L4SQ2L6AO5&V!3N,7[#\WM?]*<]\=TR"D<1#"E$>Q(#%!9SC"
M(0S"V'=]SXVY7F$JLV[G9M.V4XNV4ZOJ3"V\%=XP>:/>".AQU_"XCF\)MP(?
M,M=.[H.\%=^QLKR&=W S0W"H9(YZG4Z;RM$(B(-$CF9OFY$7X]GR:EUEU<L%
M8^)K+"_%7V^*N_SG>ADEJ8LCQ"#F@6 JGX4P\9@/'2*3.7#NA7KUZGOZF!LM
MU6*"1LX%D)+*/8:458^+^@#M)YZ!8!J99:P0TJ8.#0QZ;B;$VS5%B+_LF*&O
MS4EH0$.I=L[K/&I^IB:-F[J(Q;U<#+[QGY<KG#V6G[,59Q\WU;>\^@]>_>#%
M,V??-FJ-I'Z<1!&/8.BY2,8M.I!0'\F=5X@)BV,G(KI';>;=SXT6:JGDH42Y
MD0YWJ90<B#44K/,*O/ *E$IZ_>,FBR$Y?6(W+M C$XN*0^](#X3XH)8?* 6
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M"6("$?7$YA E#N0!BX,(8X]%6L6V3G<U-ZI0TH)'7*GL S(E>2,L2(VRNYP
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M/ NFUV1X7F-V;'?+I=L 9U>X6 NB;1V-$@?%2>KY,,)I!)$8&4AP2&',O#3
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MPKB77DP0=J-(+@0,(D8QC(F+(:<X25(2Q Z.#=)X&W5NX5<T1>KNG:B[I-U
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MD&(_A(1'./7#4&#?,K/_Y)Q3$V?H=T7JVPS_,J-:4ZT3JK%M;OIIU$^;Q ;
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M[9614:7>$_-,36R4I((MK: FUCRFLPO3;CGA$*F!1<01D$XW(;2*]S3 XHS
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M.P5U-.EN JXK@6Z,4*?\/CW*B.+:F*6WTMG\M9Y5#;?YE]]T>_H?HG;KS7&
M4X\G!$J,M<.-8H@33^GSS,>AB")"D57TZ[&)IB9^&T\R82S?*'5%ER$!;%M:
MS+I4_%& S<SJ+F ;6.Y>%>OLF6C5KI4?W31I>YTUOGF'I?).8.*J/MZQ:<8M
MBG>"V7>5\$X]WS/\\^ZV/NF\1,0>#A/HI4+JB[X2##2@ZA^42DD"CS"CP)QW
M(T]-$N@;O"+.,@QPBY/9_N[%_< ;6M'DT-A]E%-7$7C;<<>-L-MGYUT$W;L'
M^NV\LM_,K;Q@I6U/G4)WJT7&7JM_=YD00FU"&3,&$R\.=-AO#%/&?(A0) @)
M6<RHD4?+;MK)[=FR =-*@CLU:J,5V^U@0[S-MK=[% ?>^UL =R3/0$4N^*O^
M[R#Y)'9(.9(=AI..*ECL@-B7.I9O]Q-)5U(*MKZ55[_8D_KRE-VO;G4!ER?]
M_U?_M<E^D(4.!]K9D/0?+I;\[0>M)^<X)#0-@Q R$>B:*[BLON+!T,.8)S[S
MTL2H--F -$Y-V%4LZLTJ:B:KGHW5SX5NN*V[8,VJ7EABQTB9IK?2!1;L1.,0
MZVXF1S]X-8>^06T7LN&OZA-8U9E2"UAVV6K1/FL;U*M'])+N??CVC:H\]D:'
MD=YNRV6XD]\#KI C83\$A:.># -"O'^,##E57T/5MNO[!553$+:>AS@2'HX9
MC+U05]T(0T@BS*",0^I%F$91:M7*ZL <4Y/Y+1)M[5#O\3,U09V%RL"RLT4=
M^*NASZ%>VL&],SO3^QE&-C$=9?&]=>GXHSTS/G)=O&G]>J=6=:WDAY88+]JA
M<2/6<\GC%"6$0B\.)4325QL<ZTNMB&DD$DQBLS!-D\FFMM,;6F?@15-;'O"B
MH7<&EL*RQ$(GT&:2P!5\ XN$'7)W6^2N=LC=="!GGQ5B (FKS)"NJ<;-#C%@
M^EV&B,D[]@$%C8)RJQ26;7 WCSTB4 QIC$.(.&$0^TIT".Y)$>HNE\0X%.W
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M-E1%HT6+R(.H=>\O%U@,;D;[47H!FAN2?6+305S,4YG.Q6>DY"5KG*PRE+I
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MM<PJB0:\S9J=X'*VHF8B;M0%&NDJ^791&D)GH.&M2C9ZPYU.!3[R'J@Y="=
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M[%'1]CA.%O4-7> U5@W#0[@YJDQX"H:NZH-'WQVOPN I\M]4$3SYL+W@J^M
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M(B1I&F&&I8%OY/L[FH1QX@&'IL$=^'JKH2- '2]V=Y(=5:G4Y6+1Y-DTPL_
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M4=N] *E.4R5\KTOZ??OKG4Y *34#6[7 3J]QI\HDI#'JE(T6\QACZ@Q#)-:
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M'!/I=98)5O=5:F=.B@B4C'NE80!9@58GL%5J_QY[VZY.8;?6_<"F;"/W2W
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MP_O8IPH'EKA 04A@BLC<1,$0Q##G)&%FS5KG9!?L;$18#5C:"P#CMK71(<3
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M]_:/QW<.XH>LB^/Q*+>  4;@J^D E#+O2OV8.GC@^'L_GWC0(!+LQM$B[KD
M2RH-HI)P);E72;R(P%868.U%1#6;UUY>\V%U48.-6C*S2UDI+J7@47DDM<L'
M]X0BC:5"E.:NA"0J8DI7Y*^FI)J]K4PPMK^T*\#,J]SWDIAR APGJH,#S%O-
M0$*.:61$TU8@X>1<<'IM)[ B)P[/2:IFQRN"HI+RKP!.35Y\F86GA6%<HCR
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MU&TM&%W-D"(\28>M(*3T2?]+&KK-+K4$E;T$7:5= 5LYOU!TD6=X@')FL\G
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M]0"K\"5(X"[O">?IK7^2!905UJ<6W'I-&0HX@7^C"('UZTP>9!8PB\1$&38
M]F&H[;:BNJI54"$\.O0ILD2.AL/Q7^ ;Q3RH)"LC3L]'1W[N'(&ZXN!K/GH
ME^ED]!4X'D] #WTC0-+) T>.@DU@+->A,W":=!06=C,5,-\ _SN]O-L"Z:K@
MW+[R.D;GQ\4KY\*]MM_R 1@(M_<ME\G&Q;"0/F4NF6ABKA2(B ?ND340>)*4
MF#*6<NG%!G#<[&W=%B]7A;\6U%-!B/79#D99CN<CB!*_C*>#>0S9F/<IZ4N=
M_]\D)( \Q(U-R 983<YPC .-0O+2H=9ZBKJM$:X&D"VHK],Q08W7ON#E\>[
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M'6GNC6_^K)!UGTMJ'.4<,9I[*Q#@U)%< >(-#2&IH$1+Y]"[$5QE4K%E$!]
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MGPR^Y _[V,8H<IO!9#$LEMQZ4$>PK Y3HJU*TK'2.=9M:>QVVFI+H&M5414
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MR.>F39QKABPQ)+=9XA'S%$@H76>T(ZD_TCB.;="VSOJUI<D*HH^EM/+&+-+
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M]A=I0(Q24\2()$F3P+4M?4MX8^+J]^L/@<E=M56]P?Q@ATUUDG6,"B4$$E*
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MOR?P#SON]?(</UVZJYM==]4%&X.A_47;SI%?K)@4X*2P8*Q4V0CA@Q[8&7C
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M%*'K.Z'UX+0IP"(*M DQQ-975P]3,^^!UD;; R"T@^@[!%$-QFHGS??A_&K
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M(F3O27DN4I MA84B$<DIX"F4UHT8YHO@CB%AM:--U@XY>T9P+Y=YKC36%R0
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M[&,PV4'*,QNG'\C_7K#S[NS\\^H7I&/SO#:/7*2KF]:<DZ_CM &SY+4C+8/
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MJV97$XMY9NA\)$O]9A66S^]RHZ_Z\.@2-(L1LJ[U1PP3!,88I"*B+$EZ+L(
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M!H_MQKF9;/M!BMG8TAL/+_YJW)\/.DM1()7,:J_Q #X;"W%3"R10A3AD NZ
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M"^\-9H7<M>YZ.)RZGAHW[ B'1R'63#,=HNY%.#O[MEA^>O9E=5&G$Z%4*=>
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M&JJH0>JQLA%,K*A >KZ<GWTXN4^-1Y-+:,X)==(C-3(2N[A8<Y"(_ C6F2V
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M%A(-O?+<[ PW)!IIT0B,UHM=X?)TM99B+CU!9D\6-WLUW6M$N.ZG31-XB\X
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M2+YXY??<GQ1E,"9JHKE.)> ()- 0B4[&"L.-3*%+]>YVJW;#Y5&\+?7,\J;
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MG%Z-+D>A)"?$T?<1W(4_I$LI*I-)%*)X)>A*>^Y0I\LH@I(>#T@7;[#+6L,
MZ)!W7'6.#XR@MS"=(S\>'X79R3@M6@LL*2I#LL"7P!IR<GU,@N;:)3PA5+LR
MIQ3]'"\R,08/B4PB:% =8+7S!H8)4AT2:X>136/&/!*WHGM!X^GU]ZO)3X!9
MUQO!:J70 @A$0_&7A$1C()7Q[HQ9FA)73SJ1=#+R]]S6,*G.0QK_AY1C \D"
MRP#0NCN5T]IP1CUQ5I0I!<"1B<(3KYGQ*H:(ED3E7($'&VBE?'+(U)/=)=(
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M(441$R(#F7)4YM%PSU>*HPZW]TY'R/UB1^@H@-),T6!__'FH:'Z;3F:S"^E
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M:9<>)D\_^1=\:=\%/Q78/C1HOGS^!-,\F5Z7$K@E'1O2!M;C?B6CP:/U$LJ
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M8@7Z@*B7 HTL)J]J7X6O[6G@=M>M@*<3J'>49 /(_#*?Q/^\7U;SZ<J/USW
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M,  ^C-$D7X9CEZ5\'_V?LYO1?$5)CL[A;C-9='N73DD24D2+/5LA?:9! NT
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M"U:26>GI$%0QTYX((=-V,"IX+30Y2]/E\_5=+[//@=),V!T"YG+7Q,R*U<&
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M;&D;<:V!6YXB+\B%'E)E^/!(/;)=C5+E<C*YSHR2W]+?<;U>WK&(HCEZ69L
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MK:D-);#6Q#9/UI>K=&DWL<>O[1]73VK3+]>J]:G79DU;?YMI%UCM+D%"00,
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M3%38EA_9-(XE)$%C^^GCW BB4L41289JD$8X8/N>4G[H^,U(PGF,^EM%]E/
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M5' 29O-%(9=HW!)6"O#$R7 Q6#4"0-==A&!V$_Q67A78&GIDX#'*@@"; 1L
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MA^_?6I][T5EY<XMNZ]]IG$AGI'Z2O@V[)+0N::/=@8S9E702 0L9L$X:AJY
M4N8N:]/JTDA4F$VG@\<L<%A'A(GP>B)BC:.*.A+;"0[S\<-1HU$[-7#Y^=M1
M0+6%%40<^<-)"CN(\*ZML^D[6]Y:M\X(7/733Q76&S'NVZPGDB&@@7WA:6P-
MV+7@+J#D(O!"[DN8M^U;U0KC#+87ZAW"9S^1?HJL"_?*DH%@+A\2HO#S?10\
M2M\2^/U+!%PSQA'=U.M)CF@3JXTUM?G1:J )<=0%B'WA_@/"$R?X$X0!^RI<
M-_ K>#Z2",ZW$&Q[I<':5:M\Y\71B"<2#IRT%@?T,G']J7"*,A[!(N&(*((C
ME@1P1MU@6'T=ZU^J1/O1[MZV.IU6]_KCA_VCTU]">/VX;GUKG7<J3'#@EYKC
M:99!IQ6_]U,."F,21#$+>92,\,=( "H'<%S51R< +(LG8:4DY>!!6[CR46B<
MXRCZQ,!G#MJBB!(N?2:G"\BO?,0:312-]6.V#;]Q$#NVL"LLSH00?AMRF,-F
M0<0"7--0QH)Y@2T=";^&D80+>G8<G=8:.!6V\DQ[Q:1K)%Q8(JCU&IB:0/"&
M^N%IS ZKC?W:;Z#6^ CQVR"!1=BI0,WF> U$)"UX%2 -?.7XE/U:C"5,HS@%
M[H&TTQ$6J5S'U8;A-04->1KK,4R# WOA:3(((E@#L13-;(J\AI$./5U-Q4=R
MWH$<@WA'QHA"U/)B6%P\L3+F!$J>P59",(5C%HL$?P35$CF*!+UE*.$+W@/:
M9$P3J$&N Q?(C,;DS./_AO4#_Z3Y0*>4(2R1>T&:/Q"D29S GO"T$5W^ZC2!
MFVX]60/N]P6[<T!/()1>:#AV E!]0 $BNNG OX2_LK0X3_NP4=:LY;;4BG.<
M^;M;!594/HXHZ&.U5H"ZIO&8.5'@%4D<'U'<'Q!+(GOL)/')L[,&V#K'G2!B
M5DA(P!GYM7C"7^>40*6/&0/.]<X<>^:7@LP!@D0)H!3&WHA=5J^J[ \<\N.'
MYM$I'(!J17L-X(2.*9*$B5\+"]QU48KZ_9CYPA)QS*,1@LWC#V*N>.7L$78&
M'+D?"25BD8L7).XX[!6V>NBML0-?_#JPO+W[46%=!.C5W;=6!4D8:5("=2L^
MK^D73:9^@*2&D'*,#</Z0: L* !HRGNN*#^N&',$R)$AG87A0(+I)I4EAGXP
MZ\$/AJZP^V@AS5.JO#1) >$CF.!1^%SCC#"8Z3SB/RF>//@=IJ?5](0O'#E-
MP\G9/QPK)W#!SH_GF\HAM_'\[I"W_62G?C3-W"\A%F]9$F+/OW7;%S<MUEZ0
M3.N-E7%>S)-N[+)UU;YM=]MWMYU7[DR?P"7AQ5@5]6K]XX?Z0>UT\N\JN>GF
MX>(23I8/DJ@K(F^IRD:5L>^^"_R_X%BQ]>*D/T\2 ,O!Q9?O+NF \'\:PQ6M
M_Z'+5W_4S\QV#H[QB^;!RIRP GOXQ?C#^=?6[25&[SJL>U>(WRVVR:-5Y!2-
M]><4JV&3 )MX.YT-3_.2"&.;?YI%$.=@'5B@]K3_F46D+K2Z%!N3;-)E5%#'
M,L]UX K0M<A3%(DX!%HT2C$I317\9@M7@'U1],8K10KUQ%B1;XP\58(Y W/)
M2"2DV%4,H[5X3*%*&B).\8^F^M@,3S<#I!)\QI4B50Q8SQ<.(AQ"[_7CA^/Z
M:1L8DZ_216 '=YY,8!"XTCS5$%A,RW.%HQ,P2AI=L[J_-,33^@^6Z7<H :=^
M5#T@8!A.M5=M$B;J]5/V381!E)_W#9C?$LQ[&9C16G(EQXC_A7(-6+P0']B
M_2W!OI^!_2J-R/QM^W$2I<I?@V;GN;4A^?>!_5&!LP#,I85.LWL^*FD5$R O
MYM&%@<HB/%$!PD<Q,[-.:P&U_!'> X&8)K,?F:49G[T@<ZQ6K2E_@7)=9(N)
M0(_: 32X/(S%B?EP:LLX=/GH1/H$3'KHM#PBP/#T$=F"Q5V].EJHNIQOIEI3
M&TI@K8EM9M:7JW1I-[$GKS6/JL>UV9=KU?K,:_.&K;_/L"]8[2Y!0D$# !Z'
MW/]]J[DU=I)/:JQ."#/CS;FU$3[AS46U$DE] CU!N#6;:32JAXC2LF&I?UP!
MVXR 6Q]+ GT>-"4H$N1WB9BG')@7'+/BWT&4S]D7.[U(\(<=[L#S)]P=\E&\
M]989N#,7LY$%;R,+CC-9T/:M-(J$3GA$BZ8'<L%'5Q"*XW:,D5MU\3Y+Z^HD
M@?6PD=+O@9EZ/4/-C13^1A=Z'R@W,BA?RD=I8^@:R?V.=%*M%&5Z$AGAYXZ#
MCX-=7E"?.FDOEK;DD=Q8#.^$J=P@IC(6KBZ06P50(L%TVUAK[P7[W$H^CS&1
MH\/=#:S?"=:Y:7P.=RKO&WD*V3]4/J[8@/Z=0'^8@?X+EK.A[G,.%Q\!"W-@
M/B/P,0WF+[%A9P1;5\9UWGO6=9Y[SK^*J"^B"F7W!:ZT=4)$1(R$4OF0K;RU
M7QWN)L<W93 /T T TOI!^ Q!R+8!AN3BRV*5,8S- # ^YB+&8TYX\<2]T!7D
M\69SB-AQ?F[$3GDL!E&0]@=;9Z4M+K<>A')*Z, 1)%7D =.SWA'XS=X>V"U+
M"9>6]K=DR!>S+:GLYB6%*\1W2JQR/-R^&L'<_:4%<U])(0LRP>7&=5\0UEV$
M1LK2JKY$]6.;?Z(21),4%P\PY]$/,*=<1D!3($L %\B7U#?%;+;KGR@/3R$,
M,T<][O;A#^AC<+N'.%4RB![&_&=?Y?/=BR@&_&X/!X*^PW6X4DK,DXK/Q6GT
M"$H&\+E"?>HG?&"[\0F.LNMBPFH,8*VP!&T?!\D(5O4H1N4:*'1D!RH.C+N#
M:S$8I@DHC9)"N/2C#O=&08@.4X!P@!P726]:(1@&G&<8NK :CK(&Z[38< #R
MF*+1@:] $U !H$M,/LE--A7P+D.IPE+*.BHS^)?2X.&*:TSR$YO%L80D:&P_
M?5J80%0^.!+)2#VD"0[8OJ>2F@G]YDFB>4P+L(KLIT#/FAD11<.@TM%YJ<F
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MKH7B04657>BB*>PV$1<+664QUAS!^9:1"D[":+XH)!M-6L)* 9XZ&"X&RTH
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MC9*"N/2C#OA&08@N4X!P@!P746]:N1>&G&<8NK :CK(&J['8< #RF.+1@:]
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M )G1F)RY_-^P?F"B-!\HEC* )7+73[('_"2.8M@3GC:BRX].$[CIUJ,UY-Y
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M_Y?EP=3??U.#&Q[F,RQ7D_F"HGBHDLTH8J8ZSKJJ #YK9"*1/<5*RJ*!1UJ
MEM5QF"@==X!-)Y%CF?2&O@3N@5PK'Y&=<*Z:'DL3#9Q4/-@1 TX)':B9*J\@
M\0]LVPIFXUBS1.GJV!UEHZ1YD88%SFGKY4^V<\Z'ODG7T)M7-]+'5)-95LE8
MT\-3>^^'YQ_HUR#GR"4?E9B(K16?H^X"2DN/RX!637):Z1_9^<%N01;LU*:(
M :I2I:E\CX[)NS -YM\Y%=;?.Q5V!'K7>M*1\4I?10#TU_94,Y0B!UO<SRHC
M3.E1RE&)@4EF>&[B"=3_+(%\5Q$CW01[+2G.+%4W%I;>1X PU HL&EBE#E09
M.R1-0"2"A[6.^)BL2/*B*NDBW8"3'R(VV>_4;K%@4N96KARP*'M\STES+@!I
M.C9/3^H-TMKU'FFIA6W2\M_YF6J\]S.%CFKRA&EK/Z56Y0F>0\FH3!7N7O%Q
M;#U:(HC1.9%+12JX*4K3Q1YX),C:)?TE(H\Z66E:5* ^I;^9="9J2%?*^]'P
M:N[ F69'ZL"H,XD3]1/X2G2OCC =HJ7D&-F$G-Z9,*/3^=,%*NC.PW%,RW$E
M"9&3CMF0M$$2<:KM;?8:!G@*OZD(./9+1QU5%5,47\R0LH:>#V1EG$*,\J#3
M]J#\7F"^("P1L8,;-7D (QYBO=F8ZC'\ MM3B07HNI5@LH^?4##+R^D$*?M:
M!G8\U04H10 ((HHS'P) H@<:QG(36[X+0 VH]>IRDQ-[30*=HQ#H,N'IX%2Q
M)>QD+HAJH3CA1'A!G_1E=DD)H7CJ2LKC01CD#E'08J]B+O"EW>+/;?>?ZY9/
MW<E2":=I?).SL<G9V.1LK-QA1L"M;W(VGIVSL5;Z+RH'N2;[)E%Q?Y_5/G]J
M'!S7?UO4;E\7!*#XIPQPW1->92&8UJ-:A*2:J18D].V=VPQ[[]UF.$M(^="O
MS#E%W(J0%-1K('+I<6?5;M8N:4RJ\LP%DQ<S1DD'\1(JJ0%*M/R ZM*>4"K9
MM2?H<7I;24"%+\+#( X2+JHT"]]F\(2*[RIS/'WGF9Q>90K<*'N_FLZ)];,'
M4_V6XUE12"BQ7A+GRO$PM#10=8*I'I[E1*7U%66"GC *X@2HQ-S7-F %49]
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MQ2@SDOLUZ:1&*<KT)#+"3_M]' YV>4%]ZJ2]6+J21W)C,;P2IG*#F*I'N+Y
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MB*6UVU/N&/XW3'SO\_\!4$L#!!0    ( %.&8U5"*ONVE0@  %DG   4
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MHVH$T:$T1L;HAVC>9&3J[B$?RL1 +X5U_$^_W,JBAM^8,HW$*&F[K>=#B^Y
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M_X1K[:<I:S_JRJ_^4S3W4=SA_P!02P,$%     @ 4X9C54V-&U@V!@  H1D
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M-MZ-E_TYI=4;$S+#PWTN-YL\_GU@XX7EQB\&^:_YSJ&_N!S\ U!+ 0(4 Q0
M   ( %.&8U54;:%VEB@% )XM.@ 0              "  0    !B:&,M,C R
M,C Y,S N:'1M4$L! A0#%     @ 4X9C58^!#P=,)0  %)P! !
M     ( !Q"@% &)H8RTR,#(R,#DS,"YX<V102P$"% ,4    " !3AF-5*2$N
M="(H  #%A $ %               @ $^3@4 8FAC+3(P,C(P.3,P7V-A;"YX
M;6Q02P$"% ,4    " !3AF-5@AE_\Y36  "G:0D %               @ &2
M=@4 8FAC+3(P,C(P.3,P7V1E9BYX;6Q02P$"% ,4    " !3AF-5!BL\_">/
M 0"AXP\ %               @ %8308 8FAC+3(P,C(P.3,P7VQA8BYX;6Q0
M2P$"% ,4    " !3AF-5/>B-66L5 0#P0PP %               @ &QW <
M8FAC+3(P,C(P.3,P7W!R92YX;6Q02P$"% ,4    " !3AF-5CHDTI'X6  !T
MI   '@              @ %.\@@ 97AH:6)I=#$P-'-U<'!L96UE;G1A;&EN
M9&4N:'1M4$L! A0#%     @ 4X9C5>J%)HZ]%@  +J@  !X
M ( !" D) &5X:&EB:70Q,#5S=7!P;&5M96YT86QI;F1E+FAT;5!+ 0(4 Q0
M   ( %.&8U6_1R8/H!8  (>D   >              "  0$@"0!E>&AI8FET
M,3 V<W5P<&QE;65N=&%L:6YD92YH=&U02P$"% ,4    " !3AF-588U&,X<6
M   0I0  '@              @ '=-@D 97AH:6)I=#$P-W-U<'!L96UE;G1A
M;&EN9&4N:'1M4$L! A0#%     @ 4X9C540XWN.)%@  OJ,  !X
M     ( !H$T) &5X:&EB:70Q,#AS=7!P;&5M96YT86QI;F1E+FAT;5!+ 0(4
M Q0    ( %.&8U5"*ONVE0@  %DG   4              "  65D"0!E>&AI
M8FET,S$Q<3,R,#(R+FAT;5!+ 0(4 Q0    ( %.&8U6IUT#KH @  &\G   4
M              "  2QM"0!E>&AI8FET,S$R<3,R,#(R+FAT;5!+ 0(4 Q0
M   ( %.&8U5-C1M8-@8  *$9   4              "  ?YU"0!E>&AI8FET
M,S(Q<3,R,#(R+FAT;5!+ 0(4 Q0    ( %.&8U7@['X!3 8  ,P9   4
M          "  69\"0!E>&AI8FET,S(R<3,R,#(R+FAT;5!+!08     #P /
+  @$  #D@@D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
